2021”N“x –k—˘‘ĺŠwˆăŠw•”E‘ĺŠw•a‰@Œ¤‹†‹ĆŃW(HTML”Ĺ)


i’FŒ´–{‚ĹŒäŠm”F‰ş‚ł‚˘j



‰đ–UŠw (Źě’PˆĘ)

[Šwp˜_•ś]

110001. [Œ´’˜] An analysis of the demographic history of the risk allele R4810K in RNF213 of moyamoya disease. Koganebuchi K1, Sato K2, Fujii K2, Kumabe T2, Haneji K, Toma T, Ishida H, Joh K, Soejima H, Mano S, Ogawa M3, Oota H3: Ann Hum Genet 2021/9; 85 (5): 166-77. (Ź‹ŕŸş‰Ŕ]1, ˛“ĄŒör2, “Ąˆä´F2, ŒG•”rG2, ŹěŒł”V3, ‘ž“c”ŽŽ÷3: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2”]ŠO, 3‰đ–U)

[Šw‰ďEŒ¤‹†‰ď“™]

712001. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) An approach to understand the phenotypic diversity of human populations using local medaka populations as a model. Katsumura T1: The 2nd AsiaEvo Conference (2021/8/18), WebŠJĂ. (Ÿ‘şŒ[Žj1: 1‰đ–U)

722001. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒRƒƒi‰Đ‚É‚¨‚Ż‚é‰đ–UŠw‹łˆç‚Ö‚Ě‚Ć‚č‚­‚݁|–k—˘‘ĺŠwˆăŠw•”‚É‚¨‚Ż‚éˆę—á|. Vˆä—Y‘ž1, ŹěŒł”V1 (1‰đ–U): ‘ć127‰ń“ú–{‰đ–UŠw‰ď‘‰ďE‘S‘ŠwpW‰ď (2022/3/29), WebŠJĂ.

723001. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ApoE KOƒƒ_ƒJ‚̍쐬‚Ć‚ť‚̍s“Ž‰đÍ. –Ř‘ş•śş1, Ÿ‘şŒ[Žj1, ‘ž“c”ŽŽ÷1, ŹěŒł”V1, ’|“ŕG–ž (1‰đ–U): “ú–{i‰ťŠw‰ď‘ć23‰ń“Œ‹ž‘ĺ‰ď (2021/8/19), WebŠJĂ.

723002. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “ę•śl•łÎ‚đ—p‚˘‚˝ƒ}ƒCƒNƒƒoƒCƒI[ƒ€‰đÍ. ź‘ş—Ú‰Ŕ, ’J–쏲—E1, Ÿ‘şŒ[Žj1, Ź‹ŕŸş‰Ŕ]2, ˜a‹v‘ĺ‰î, ŒF’J^•F, ™–{—ł‘ž, ‘ž“c”ŽŽ÷1, ˆäƒmăˆí˜N (1‰đ–U, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): “ú–{i‰ťŠw‰ď‘ć23‰ń“Œ‹ž‘ĺ‰ď (2021/8/19), WebŠJĂ.

723003. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŤŒoŒą‚Ě‚Č‚˘ƒIƒXƒƒ_ƒJ‚͏‰‚߂Ă̐Ť“Iƒp[ƒgƒi[‚ɑ΂ľ‚Ä”z‹ôŽŇ‘IDŤ‚đŽŚ‚ˇ. ‘ĺ–叫Š°, ˆŔâV@ŒŤ, Ÿ‘şŒ[Žj1, â–{_—˛, ’|“ŕG–ž (1‰đ–U): ‘ć40‰ń“ú–{“Ž•¨s“ŽŠw‰ď‘ĺ‰ď (2021/9/22), WebŠJĂ.

723004. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) X‚Ɛě‚Ě‚Â‚Č‚Ş‚č‚ŞˆŰŽ‚ˇ‚éƒAƒ}ƒS‚̐śŠˆŽj‘˝—lŤ: –ěŠO‘€ěŽŔŒą‚ĆƒQƒmƒ€‰đÍ‚Ě—Z‡‚Ö. ă“c‚邢, ‹ŕŠâ@–Ť, Ćˆä@Œd, ‘ë–{@Šx, •“‡O•F, Ÿ‘şŒ[Žj1, ‹´ŒűN”V, ŽRé@—j, ˛“Ą‘ńĆ (1‰đ–U), ‘ć69‰ń“ú–{ś‘ÔŠw‰ď‘ĺ‰ď, (2022/3/17), WebŠJĂ.

723005. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰đ–UŽŔKŽž‚É‚¨‚Ż‚邲ˆâ‘Ě‚Ěƒzƒ‹ƒ€ƒAƒ‹ƒfƒqƒh”Z“x•Ď‰ť‚Ć”÷ś•¨ (‹Ű—Ţ) ‚Ě”­ś. ŽO‰Ył–ž1, Vˆä—Y‘ž1, Ÿ‘şŒ[Žj1, ŹěŒł”V1 (1‰đ–U): ‘ć127‰ń“ú–{‰đ–UŠw‰ď‘‰ďE‘S‘ŠwpW‰ď (2022/3/27), WebŠJĂ.

723006. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ApoE KOƒƒ_ƒJ‚̍s“Ž‰đÍ‚Ćƒƒ_ƒJ‚̐VŠďŤ’Ç‹‚ÉŠÖ˜A‚ˇ‚éƒQƒmƒ€—Ěˆć‚Ě’Tő. –Ř‘ş•śş1, ‘ž“c”ŽŽ÷1, ŹěŒł”V1, ’|“ŕG–ž, Ÿ‘şŒ[Žj1 (1‰đ–U): ‘ć127‰ń“ú–{‰đ–UŠw‰ď‘‰ďE‘S‘ŠwpW‰ď (2022/3/28), WebŠJĂ.

723007. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒTƒP (Oncorhynchus keta) ‚É‚¨‚Ż‚郁ƒX‰ťŠç–e‚𔺂¤¸‘ƒ–Ô“ű“ޏóůN–EüŽî‚Ěˆę—á. źę r”V1,2, Ź‰ęŒú“ż, ç—t—m–ž, ´…ŒbŽq, ’ˇâ„Žu, ´…—Eˆę, Ÿ‘şŒ[Žj2, ŹěŒł”V2 (1Œ`‘ÔŒn, 2‰đ–U): ‘ć127‰ń“ú–{‰đ–UŠw‰ď‘‰ďE‘S‘ŠwpW‰ď (2022/3/28), WebŠJĂ.

732001. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) ƒƒ_ƒJW’c‚ĹƒqƒgW’c‚Ě‘˝—lŤ‚̐i‰ť‚đ’T‚é. Ÿ‘şŒ[Žj (‰đ–U): ‘ć11‰ń’č—ጤ‹†‰ď: ŽĐ‰ďŤ‚Ě‹NŒ´‚Ɛi‰ť (2021/10/2), WebŠJĂ.

732002. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) ƒƒ_ƒJ’nˆćW’c‚ĹŒŠ‚ç‚ę‚éVŠďŤ’Ç‹‚Ěˆá‚˘‚Ć‚ť‚ę‚ÉŠÖ˜A‚ˇ‚éˆâ“`Žq‚Ě’Tő. Ÿ‘şŒ[Žj (‰đ–U): ‘ć3‰ńB03”ÇŒ¤‹†‰ď (2021/10/30), WebŠJĂ.


‰đ–UŠw (ăă’PˆĘ)

[Šwp˜_•ś]

110002. [Œ´’˜] Attenuated ƒŔ-adrenergic response in calcium/calmodulin-dependent protein kinase IV-knockout mice. Murakami M, Murakami AM, Matsuzaki Y, Sawamura D, Ohba T, Miyoshi I, Itagaki S, Sakagami H1: PLoS One 2021/4; 16 (4): e0249932. (ăă—ms1: 1‰đ–U)

110003. [Œ´’˜] GluA2 overexpression in oligodendrocyte progenitors promotes postinjury oligodendrocyte regeneration. Khawaja RR, Agarwal A, Fukaya M1, Jeong HK, Gross S, Gonzalez-Fernandez E, Soboloff J, Bergles DE, Kang SH: Cell Rep 2021/5; 35 (7): 109147. ([’JšO1: 1‰đ–U)

110004. [Œ´’˜] Telencephalon-specific Alkbh1 conditional knockout mice display hippocampal atrophy and impaired learning. Kawarada L, Fukaya M1, Saito R, Kassai H, Sakagami H1, Aiba A: FEBS Lett 2021/6; 595 (12): 1671-80. ([’JšO1, ăă—ms1: 1‰đ–U)

110005. [Œ´’˜] Phospholipase D and phosphatidylinositol-4-phosphate 5-kinase 1 are involved in the regulation of oligodendrocyte morphological differentiation. Kato Y, Ochiai A, Seki Y, Morimoto T, Oizumi H, Ohbuchi K, Mizoguchi K, Yamamoto M, Sakagami H1, Miyamoto Y, Yamauchi J: Exp Cell Res 2021/8; 405 (1): 112654. (ăă—ms1: 1‰đ–U)

110006. [Œ´’˜] Localization of phosphatidylinositol 4-phosphate 5-kinase (PIP5K) ƒż confined to the surface of lipid droplets and adjacent narrow cytoplasm in progesterone-producing cells of in situ ovaries of adult mice. Sirisin J, Kamnate A, Polsan Y, Somintara S, Chomphoo S, Sakagami H1, Kondo H, Hipkaeo W: Acta Histochem 2021/10; 123 (7): 151794. (ăă—ms1: 1‰đ–U)

110007. [Œ´’˜] Cytohesin-2 mediates group I metabotropic glutamate receptor-dependent mechanical allodynia through the activation of ADP ribosylation factor 6 in the spinal cord. Ito A1, Fukaya M2, Sugawara T2, Hara Y2, Okamoto H1, Yamauchi J, Sakagami H2: Neurobiol Dis 2021/11; 159: 105466. (ˆÉ“Ą—@Žq1, [’JšO2, ›Œ´Œ’”V2, Œ´@–FL2, ‰Ş–{_Žk1, ăă—ms2: 1–ƒŒ, 2‰đ–U)

110008. [Œ´’˜] Localization of PIP5KƒÁ selectively in proprioceptive peripheral fields and also in sensory ganglionic satellite cells as well as neuronal cell membranes and their central terminals. Chomphoo S, Sakagami H1, Kondo H, Hipkaeo W: J Anat 2021/11; 239 (5): 1196-206. (ăă—ms1: 1‰đ–U)

110009. [Œ´’˜] Oligomerization of Ca2+/calmodulin-dependent protein kinase kinase. Fukumoto Y, Harada Y, Ohtsuka S, Kanayama N, Magari M, Hatano N, Sakagami H1, Tokumitsu H: Biochem Biophys Res Commun 2022/1; 587: 160-5. (ăă—ms1: 1‰đ–U)

[Šw‰ďEŒ¤‹†‰ď“™]

723008. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) The cytohesin-2-Arf6 signaling pathway mediates group I mGluR-dependent mechanical allodynia in the mouse spinal cord. [’JšO1, ‰Ş–{_Žk2, ăă—ms1 (1‰đ–U, 2–ƒŒ): ‘ć44‰ń“ú–{_Œo‰ČŠw‘ĺ‰ďE‘ć1‰ńCJK‘Ű‰ď‹c (2021/7/31), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).


ś—Šw (ěă’PˆĘ)


ś—Šw (‚‹´’PˆĘ)

[Šwp˜_•ś]

110010. [Œ´’˜] Regulation of Rhcg, an ammonia transporter, by aldosterone in the kidney. Eguchi K, Izumi Y, Yasuoka Y1, Nakagawa T, Ono M, Maruyama K, Matsuo N, Hiramatsu A, Inoue H, Nakayama Y, Nonoguchi H2, Lee HW, Weiner ID, Kakizoe Y, Kuwabara T, Mukoyama M: J Endocrinol 2021/5; 249 (2): 95-112. (ˆŔ‰Ş—L‹IŽq1, –ěXŒű”ŽŽj2: 1ś—, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

110011. [Œ´’˜] Effects of Angiotensin II on Erythropoietin Production in the Kidney and Liver. Yasuoka Y1, Izumi Y, Fukuyama T2, Inoue H, Oshima T3, Shimada Y2,4, Nagaba Y2,4, Mukoyama M, Sato Y5, Sands JM, Kawahara K, Nonoguchi H2: Molecules 2021/9; 26 (17): 5399. (ˆŔ‰Ş—L‹IŽq1, •ŸŽR@—˛2, ‘ĺ“ˆ—F”ü3, “‡“c–F—˛2,4, ’ˇę@‘×2,4, ˛“Ą—Yˆę5, –ěXŒű”ŽŽj2: 1ś—, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3ś•¨•¨—Œn, 4t‘Ÿ“ŕ, 5ˆă—ÉqśŠw•”)

110012. [Œ´’˜] Mechanical actions of dendritic-spine enlargement on presynaptic exocytosis. Ucar H, Watanabe S, Noguchi J, Morimoto Y, Iino Y, Yagishita S, Takahashi N1, Kasai H: Nature 2021/12; 600 (7890): 686-9. (‚‹´—ĎŽq1: 1ś—)

110013. [Œ´’˜] Effects of Roxadustat on Erythropoietin Production in the Rat Body. Yasuoka Y1, Izumi Y, Fukuyama T2, Omiya H, Pham TD, Inoue H, Oshima T3, Yamazaki T2, Uematsu T2, Kobayashi N2, Shimada Y2,4, Nagaba Y2,4, Yamashita T, Mukoyama M, Sato Y5, Wall SM, Sands JM, Takahashi N1, Kawahara K, Nonoguchi H2: Molecules 2022/2; 27 (3): 1119. (ˆŔ‰Ş—L‹IŽq1, •ŸŽR@—˛2, ‘ĺ“ˆ—F”ü3, ŽRč‘ĺ‰ę2, Aź’”V2, Ź—ŃŒ›’‰2, “‡“c–F—˛4, ’ˇę@‘×4, ˛“Ą—Yˆę5, ‚‹´—ĎŽq1, –ěXŒű”ŽŽj2: 1ś—, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3ś•¨•¨—Œn, 4t‘Ÿ“ŕ, 5ˆă—ÉqśŠw•”)

110014. [Œ´’˜] Three live-imaging techniques for comprehensively understanding the initial trigger for insulin-responsive intracellular GLUT4 trafficking. Hatakeyama, H1. Kobayashi, K. Kanzaki, M: iScience 2022/3; 25 (4): 104164. (”ŠŽR—TN1: 1ś—)

522001. [uŔ]y‹łˆçu‰‰z3. ×–E‹@”\‚̉Ž‹‰ť. ‚‹´—ĎŽq (ś—): ”ĺ”AŠíŠO‰Č 2021/6; 34 (—ŐŽž‘Š§): 666-7.

540001. [‚ť‚Ě‘ź (Œ¤‹†•ńW)] Œőƒvƒ[ƒu‚đŠˆ—p‚ľ‚˝ƒCƒ“ƒXƒ“ƒŠƒ“•Ş”ĺ‹@\‚̉đ–ž. ‚‹´—ĎŽq (ś—): ƒAƒXƒeƒ‰ƒX•a‘Ô‘ăŽÓŒ¤‹†‰ďu•˝Ź29”N“x•ŹŒ¤‹†•ńWv2021/5.

540002. [‚ť‚Ě‘ź] w‰ČŠw§—ă‹ŕEŒ¤‹†•Ź‚Ě‘Ą’ć‚đŽó‚Ż‚āx“ŕ•Ş”ĺŒ¤‹†‚̐V‚˝‚Č’n•˝‚đ‹‚ß‚Ä. ‚‹´—ĎŽq (ś—): “ŕ“Ą‹L”O‰ČŠwU‹ťŕ’cŽž•ń 2021/9; 108: p.51.

[’˜@‘]

620001. [Šwp‘ (•Ş’SŽˇ•M)]y…E“d‰đŽż‚đ‰ČŠw‚ˇ‚é (t‚Ć“§Í2021”N5ŒŽ‘‘ĺ†)z[ś—Šw“IŠî‘b] ‘˜_@×–EŠO‰t‚ĚƒzƒƒIƒXƒ^ƒVƒX‚É‚¨‚Ż‚ét‘Ÿ‚Ě–đŠ„, p.641-7. ‰ÍŒ´Ž‰ë, ˆŔ‰Ş—L‹IŽq1 (1ś—), “Œ‹žˆăŠwŽĐ, “Œ‹ž, 2021/5”­s.

620002. [Šwp‘ (•Ş’SŽˇ•M)]y— ‚Ă‚ŻE‚‚Ȃ°E—‰đ‚ˇ‚é!@•a‘Ԑś—‚Š‚ç‚Đ‚ŕ‚Ć‚­…E“d‰đŽżˆŮí (ŠĹŒě‹Zp2021”N10ŒŽ‘Š§†)z‘ć1Í ‰đ–Uś—‘‚´‚炢@2. ‘̉t—Ę‚ĆƒiƒgƒŠƒEƒ€, p.18-21. ˆŔ‰Ş—L‹IŽq (ś—), •Ň: •—ŠÔˆí˜Y, ƒƒaƒJƒ‹ƒtƒŒƒ“ƒhŽĐ, “Œ‹ž, 2021/10”­s.

620003. [Šwp‘ (•Ş’SŽˇ•M)]y— ‚Ă‚ŻE‚‚Ȃ°E—‰đ‚ˇ‚é!@•a‘Ԑś—‚Š‚ç‚Đ‚ŕ‚Ć‚­…E“d‰đŽżˆŮí (ŠĹŒě‹Zp2021”N10ŒŽ‘Š§†)z‘ć2Í …E“d‰đŽżˆŮí‚Ě•a‘Ԑś—@1. ‘̉t—Ę’˛ß‚ĚƒƒJƒjƒYƒ€, p.35-9. ˆŔ‰Ş—L‹IŽq (ś—), •Ň: •—ŠÔˆí˜Y, ƒƒaƒJƒ‹ƒtƒŒƒ“ƒhŽĐ, “Œ‹ž, 2021/10”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

722002. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Imaging analysis of granule dynamics within insulin-secreting cells. ”ŠŽR—TN1, ‘ĺ“ˆ—F”ü2, ‚‹´—ĎŽq1 (1ś—, 2ś•¨•¨—Œn): ‘ć64‰ń“ú–{“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (2021/5/20), WebŠJĂ.

722003. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Roles of MEK/ERK signaling in pancreatic b cells under insulin resistant status. ś“‡–FŽq, ˆžŕVŒł°, Ź—Ń’źŽ÷, ’x–ěˆäË, z–K“ŕ_Đ, Žç–{—Sˆę, “Y“cŒő‘ž˜Y, ‘Ť—§@~, ‘ş’J‹§Žj, …ă_Ć, ‚‹´—ĎŽq1, A–؍_“ń˜Y (1ś—): ‘ć64‰ń“ú–{“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (2021/5/20), WebŠJĂ.

723009. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Presynaptic terminals can sense spine enlargement and mechanical pressure to provide stronger synaptic transmission. Ucar H, Noguchi J, Watanabe S, Morimoto Y, Yagishita S, ‚‹´—ĎŽq1, Kasai H (1ś—): ‘ć44‰ń“ú–{_Œo‰ČŠw‘ĺ‰ďE‘ć1‰ńCJK‘Ű‰ď‹c (2021/7/30), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723010. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) FilGAP‚̓|ƒhƒTƒCƒg‚É‚¨‚˘‚čזE|ECMŠÔ‚̐ڒ…‚đ§Œä‚ˇ‚é. äoěłŽĄ, Ä“ĄN“ń, ”ŠŽR—TN1, ‚‹´—ĎŽq1, ŒIŒ´G„, ‘ž“cˆŔ—˛ (1ś—): ‘ć44‰ń“ú–{•ŞŽqś•¨Šw‰ď”N‰ď (2021/12/1), ‰Ą•l.

723011. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Single-molecule analysis for cytoskeletal dependence of intracellular insulin granule behavior. ”ŠŽR—TN1, ‘ĺ“ˆ—F”ü2, Ź–ěVˆę˜Y, ‚‹´—ĎŽq1 (1ś—, 2ś•¨•¨—Œn): ‘ć99‰ń“ú–{ś—Šw‰ď‘ĺ‰ď (2022/3/16), ĺ‘ä (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733001. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‰ČŒ¤”ď\ż‚ɂ܂‚í‚éƒGƒgƒZƒgƒ‰. ”ŠŽR—TN (ś—): –k—˘‘ĺŠwˆăŠw•”‰ČŒ¤”ďŠl“žƒtƒH[ƒ‰ƒ€ (2021/8/4), WebŠJĂ.

733002. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒCƒ“ƒXƒŠƒ“•Ş”ĺč÷—ą‚Ě×–E“ŕ‹““Ž‚̉Ž‹‰ťŒv‘Ş. ”ŠŽR—TN1, ‘ĺ“ˆ—F”ü2, ‚‹´—ĎŽq1 (1ś—, 2ś•¨•¨—Œn): ‘ć251‰ńś—Šw“Œ‹ž’k˜b‰ď (2021/10/16), WebŠJĂ.

733003. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) –{ˆçŹƒvƒƒOƒ‰ƒ€‚Ĺ“ž‚˝‚ą‚Ć‚ĆŤ—ˆ“W–]. ”ŠŽR—TN (ś—): ŽŸ˘‘ăŒ¤‹†ŽŇƒVƒ“ƒ|ƒWƒEƒ€2021 (2021/10/27), WebŠJĂ.

733004. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ×–E“ŕˆę•ŞŽqŒv‘Ş‚ÉŠî‚Ă‚­ś—‹@”\‚Ě—‰đ‚đ–ÚŽw‚ľ‚Ä. ”ŠŽR—TN (ś—): ŽŸ˘‘ăŒ¤‹†ŽŇƒVƒ“ƒ|ƒWƒEƒ€2021 (2021/10/27), WebŠJĂ.


ś‰ťŠw (ä’PˆĘ)

[Šwp˜_•ś]

110015. [Œ´’˜] Highly accurate and precise quantification strategy using stable isotope dimethyl labeling coupled with GeLC-MS/MS. Konno R, Matsui T, Ito H, Kawashima, Y Itakura M1, Kodera Y: Biochem Biophys Res Commun 2021/4; 550: 37-42. (”‘q@˝1: 1ś‰ť)

110016. [Œ´’˜] LC-MS peak assignment based on unanimous selection by six machine learning algorithms. Ito H, Matsui T, Konno R, Itakura M1, Kodera Y: Sci Rep 2021/12; 11 (1): 23411. (”‘q@˝1: 1ś‰ť)

110017. [Œ´’˜] D1 Receptor Mediated Dopaminergic Neurotransmission Facilitates Remote Memory of Contextual Fear Conditioning. Saito N, Itakura M1, Sasaoka T: Front Behav Neurosci 2022/2; 16: 751053. (”‘q@˝1: 1ś‰ť)

[Šw‰ďEŒ¤‹†‰ď“™]

723012. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) MYCN‘•Œ^_Œo‰čŽî×–E‚ŞŽŚ‚ˇƒ`ƒ~ƒWƒ‹Ž_‡Źy‘f‘jŠQÜ‚Ö‚Ě‚Š´ŽóŤ‚Ć‚ť‚ĚƒƒJƒjƒYƒ€. ´ŹMˆę1, ä@—˛ˆę1, –叼Œ’ŽĄ (1ś‰ť): ‘ć80‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď (2021/10/2), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).


ś‰ťŠw (äݑă’PˆĘ)

[Šw‰ďEŒ¤‹†‰ď“™]

723013. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒPƒ^ƒ~ƒ“‚Ě”]“ŕ‘ăŽÓŽY•¨‚É‚ć‚éR‚¤‚ě—p‹@\. “V–ěŽj–Ť1, ‰Ş“c‘ĺ•1,2, äݑ㌤“ń1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ś‰ť): ‘ć94‰ń“ú–{ś‰ťŠw‰ď‘ĺ‰ď (2021/11/3-5), WebŠJĂ.

723014. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒŠƒ“ƒNƒXˆâ“`Žq•ĎˆŮ‚É‚ć‚éˆâ“`ŤŽžŠł‚Ě”­Ç‹@\‚̉đ–ž. ‹M“c‘ĺ’q1, ŠŰ”ö’m•F1,2, ›’J’Ă‹MŽq2, äݑ㌤“ń1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ś‰ť): ‘ć94‰ń“ú–{ś‰ťŠw‰ď‘ĺ‰ď (2021/11/3-5), WebŠJĂ.

723015. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) PSD-95Œ‹‡•ŞŽqƒ}ƒMƒ“‚Í‹ť•ąŤƒVƒiƒvƒX‚ɋǍ݂ˇ‚é. ‚‹´‰“TŽé1, ŠŰ”ö’m•F1,2, ›’J’Ă‹MŽq2, äݑ㌤“ń1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ś‰ť): ‘ć94‰ń“ú–{ś‰ťŠw‰ď‘ĺ‰ď (2021/11/3-5), WebŠJĂ.

723016. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒ}ƒEƒX‚Ě”]‚É‚¨‚Ż‚éƒAƒtƒ@ƒfƒBƒ“‚ĚƒXƒvƒ‰ƒCƒVƒ“ƒOƒoƒŠƒAƒ“ƒg‚Ě‹ÇÝ. ‘OâŒő‹P1, ŠŰ”ö’m•F1,2, ›’J’Ă‹MŽq2, äݑ㌤“ń1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ś‰ť): ‘ć94‰ń“ú–{ś‰ťŠw‰ď‘ĺ‰ď (2021/11/3-5), WebŠJĂ.


•ŞŽqˆâ“`Šw

[Šwp˜_•ś]

110018. [Œ´’˜] Dynamic Spatiotemporal Expression Changes in Connexins of the Developing Primate's Cochlea. Hosoya M, Fujioka M1, Murayama AY, Ogawa K, Okano H, Ozawa H: Genes (Basel) 2021/7; 12 (7): 1082. (“Ą‰Şłl1: 1•ŞŽqˆâ“`)

110019. [Œ´’˜] Three cases of otitis media caused by Mycobacterium abscessus subsp. abscessus: Importance of medical treatment and efficacy of surgery. Nishiyama Y, Nishiyama T, Kanzaki S, Oishi N, Fujioka M1, Yamada H, Ebisuno C, Kaiho M, Uwamino Y, Fukano H, Hoshino Y, Hasegawa N, Ogawa K: J Infect Chemother 2021/8; 27 (8): 1251-7. (“Ą‰Şłl1: 1•ŞŽqˆâ“`)

110020. [Œ´’˜] Investigation of the hearing levels of siblings affected by a single GJB2 variant: Possibility of genetic modifiers. Hosoya M, Fujioka M1, Nara K, Morimoto N, Masuda S, Sugiuchi T, Katsunuma S, Takagi A, Morita N,?Ogawa K, Kaga K, Matsunaga T: Int J Pediatr Otorhinolaryngol 2021/10; 149: 110840. (“Ą‰Şłl1: 1•ŞŽqˆâ“`)

110021. [Œ´’˜] Neuronal development in the cochlea of a nonhuman primate model, the common marmoset. Hosoya M, Fujioka M1, Murayama AY, Ozawa H, Okano H, Ogawa K. Dev Neurobiol 2021/11; 81 (8): 905-38. (“Ą‰Şłl1: 1•ŞŽqˆâ“`)

110022. [Œ´’˜] Multicenter phase III trial of regenerative treatment for chronic tympanic membrane perforation. Kanemaru S, Kanai R, Omori K, Yamamoto N, Okano T, Kishimoto I, Ogawa K, Kanzaki S, Fujioka M1, Oishi N, Naito Y, Kakehata S, Nakamura H, Yamada S, Omae K, Kawamoto A, Fukushima M: Auris Nasus Larynx 2021/12; 48 (6): 1054-60. (“Ą‰Şłl1: 11•ŞŽqˆâ“`)

110023. [Œ´’˜] Analysis of conductive olfactory dysfunction using computational fluid dynamics. Asama Y, Furutani A, Fujioka M1, Ozawa H, Takei S, Shibata S, Ogawa K: PLoS One 2022/1; 17 (1): e0262579. (“Ą‰Şłl1: 1•ŞŽqˆâ“`)

110024. [Œ´’˜] Transcanal endoscopic ear surgery for management of ossicular malformation: clinical outcomes of 17 cases. Yoshida A, Hosoya M, Kanzaki S, Fujioka M1, Ozawa H: Acta Otolaryngol 2022/2; 142 (2): 154-60. (“Ą‰Şłl1: 1•ŞŽqˆâ“`)

110025. [Œ´’˜] Otic Organoids Containing Spiral Ganglion Neuron-like Cells Derived from Human-induced Pluripotent Stem Cells as a Model of Drug-induced Neuropathy. Kurihara S, Fujioka M1, Hirabayashi M, Yoshida T, Hosoya M, Nagase M, Kato F, Ogawa K, Okano H, Kojima H, Okano HJ:@Stem Cells Transl Med 2022/3; 11 (3): 282-96. (“Ą‰Şłl1: 1•ŞŽqˆâ“`)

120001. [Œ´’˜] ŠOŽ¨“šŠŕÇ—á22Ž¨‚ĚŒŸ“˘. —é–ؐŹŽ, ‘ĺÎ’źŽ÷, ŹŕVG”V, _č@ť, “Ą‰Şłl1, źŽR’Œo, –ěŒű@Ÿ, ×’J@˝, ŠÖ…^—Žq, Ö“Ą@^, Źě@ˆč (1•ŞŽqˆâ“`): “ú–{Ž¨•@ˆôA‰ČŠw‰ď‰ď•ń 2021/3;124(3):197-204.

310001. [Ç—á•ń] Complete Removal of Stage II Congenital Cholesteatoma Destroying Temporomandibular Joints Using Transcanal Endoscopic Ear Surgery With a Mirror Technique: A Case Report. Ogawa S, Hosoya M, Fujioka M1, Ogawa K: J Int Adv Otol 2022/1; 18 (1): 88-91. (“Ą‰Şłl1: 1•ŞŽqˆâ“`)

310002. [Ç—á•ń] A Case Report of a Middle Ear Mass Originated From Cartilage-like Tissue Treated With Transcanal Endoscopic Ear Surgery. Suda S, Kitamura M, Kawaida M, Fujioka M1, Ozawa H:@Ear Nose Throat J 2021/12: 1455613211065510. (“Ą‰Şłl1: 1•ŞŽqˆâ“`)

520001. [‘ŕ] iPS×–E‘n–ň‚ĚŽŔŰ: PendredÇŒóŒQ‚ɑ΂ˇ‚éƒVƒƒŠƒ€ƒX­—Ę—Ă–@. “Ą‰Şłl1, ×’J@˝ (1•ŞŽqˆâ“`): “ú–{Ž¨•@ˆôA‰Č“Şčň•”ŠO‰ČŠw‰ď‰ď•ń2021/10; 124 (10): 1331-40.

522002. [uŔ]yŽ¨–E“ď’Ž‚Ö‚ĚŒř‰Ę“IƒAƒvƒ[ƒ`zŠ´‰š“ď’ŽŽĄ—Ă‚Ě‹ß–˘—ˆ. “Ą‰Şłl1, ŽR–ě糋`°, ×’J@˝ (1•ŞŽqˆâ“`): ENTONI 2021/5; 258: 63-8.

522003. [uŔ]yƒgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ˆĎˆő‰ďŠé‰ć@ƒe[ƒ}: PendredÇŒóŒQ‚ĚŽĄ—Áz‚ ‚˝‚ç‚ľ‚˘‘n–ň‚Ě‚Š‚˝‚żě‚č: ŽžŠł“Ž•¨ƒ‚ƒfƒ‹‚đ—p‚˘‚Č‚˘”ń—Տ°POCŒ¤‹† (iPS×–E‘n–ň). “Ą‰Şłl1, źŽRŒ‹”ü, HŽR‘ôŒČ (1•ŞŽqˆâ“`): Otology Japan 2021/12; 31 (4): 425-34.

522004. [uŔ]yBIOLOGY TOPICSzŹŒ^—ě’ˇ—ŢƒRƒ‚ƒ“ƒ}[ƒ‚ƒZƒbƒg‚đ—p‚˘‚˝’ŽŠoŒ¤‹†. ŒIŒ´@Â, ‰Ş–ěƒWƒFƒCƒ€ƒX—mŽ, “Ą‰Şłl1 (1•ŞŽqˆâ“`): BIO Clinica 2022/2;37 (2): 207-9.

[Šw‰ďEŒ¤‹†‰ď“™]

712002. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) DRUG DISCOVERY AND DEVELOPMENT FOR THE HEARING LOSS USING PATIENT-DERIVED IPSCS: A PHASE I/IIA CLINICAL TRIAL FOR PENDRED SYNDROME/DFNB4. Fujioka M1: The 7th East Asian Symposium on Otology (EASO 2022) (2022/3/24-26), Tokyo Japan (ƒnƒCƒuƒŠƒbƒhŠJĂ). (“Ą‰Şłl1: 1•ŞŽqˆâ“`)

713001. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Beyond the borders: Current status and challenges of the hiPSC-based medicine for inner ear disorders. Fujioka M1: Korean Otologic Society Annual Meeting (2021/4/3), WebŠJĂ. (“Ą‰Şłl1: 1•ŞŽqˆâ“`)

713002. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) DRUG DISCOVERY AND DEVELOPMENT FOR THE HEARING LOSS USING PATIENT-DERIVED IPSCS: A PHASE I/IIA CLINICAL TRIAL FOR PENDRED SYNDROME/DFNB4. Fujioka M1: ISSCR/JSRM 2021 Tokyo International Symposium (2021/10/27-29), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ). (“Ą‰Şłl1: 1•ŞŽqˆâ“`)

713003. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Induced marginal cells of inner ear from human iPS cells as the disease models for hearing loss. Saegusa C1, Ozawa H, Okano H, Fujioka M1: ISSCR/JSRM 2021 Tokyo International Symposium (2021/10/27-29), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ). (ŽOŽ}’q1, “Ą‰Şłl1: 1•ŞŽqˆâ“`)

722004. [Šw‰ď (‘S‘)] (ƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€) Š´Šoă”ç‚Ć“ŕƒŠƒ“ƒpůN‚̖ƉuŠw“IƒNƒƒXƒg[ƒN: T×–EˆË‘śŤŠ´Šoă”ç“ÁˆŮ“IŽŠŒČ–ƉuŤ“ď’Žƒgƒ‰ƒ“ƒXƒWƒFƒjƒbƒNƒ}ƒEƒX‚ŞŽŚ‚ˇ‚ą‚Ć. “Ą‰Şłl1, …‘Ť–M—Y, ŽOŽ}’q1, _č@ť (1•ŞŽqˆâ“`): ‘ć1‰ń“ú–{Ž¨•@ˆôA‰Č–ƉuƒAƒŒƒ‹ƒM[Š´őÇŠw‰ď‘‰ďEŠwpu‰‰‰ď (2021/6/30-7/2), ‹ŕ‘ň.

722005. [Šw‰ď (‘S‘)] (ŠwpƒZƒ~ƒi[) “ŕŽ‹‹ž‰şŽ¨‰ČŽčp‚É‚¨‚Ż‚é“d“ŽŽŽœŽčpŠíŠB (’´‰š”gœíŠJŽčp‹@Ší) ‚ĚŽg—pŒoŒą. “Ą‰Şłl (•ŞŽqˆâ“`): ‘ć122‰ń“ú–{Ž¨•@ˆôA‰ČŠw‰ď‘‰ďEŠwpu‰‰‰ď (2021/5/12-15), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722006. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Ž¨‰ČŠw‚É‚¨‚Ż‚éƒxƒ“ƒ`ƒƒ[Šé‹Ć‚Ě“ŽŒü: “ú–{‰‚ĚŽ¨‰ČŠÖ˜Aƒxƒ“ƒ`ƒƒ[Šé‹ĆuŠ”ŽŽ‰ďŽĐƒIƒgƒŠƒ“ƒN (Otolink Inc.)v. Źě@ˆč, V“c´ˆę, “Ą‰Şłl1, ×’J@˝, źč˛‰hŽq (1•ŞŽqˆâ“`): ‘ć31‰ń“ú–{Ž¨‰ČŠw‰ď‘‰ďEŠwpu‰‰‰ď (2021/10/13-16), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722007. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yŠî‘b‚Ć—Ő°‚̉˂Ż‹´ziPS×–E‘n–ň‚ĚŽŔŰ: PendredÇŒóŒQ‚Ě•a‘Ô‰đÍ‚ĆƒVƒƒŠƒ€ƒX­—Ę—Ă–@‚Ě‘no. “Ą‰Şłl1 (1•ŞŽqˆâ“`): ‘ć64‰ń“ú–{bó‘BŠw‰ďŠwpW‰ď (2021/11/18-20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722008. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “நáŠQ‚ɑ΂ˇ‚éiPS×–E‘n–ň: PendredÇŒóŒQ‚ɑ΂ˇ‚éƒVƒƒŠƒ€ƒX—Ă–@‚Ě‘ćI/II‘ŠˆăŽtŽĺ“ąŽĄŒą (PENDLRAŽŽŒą). “Ą‰Şłl (•ŞŽqˆâ“`): ‘ć21‰ń“ú–{Äśˆă—ĂŠw‰ď‘‰ď (2022/3/17-19), WebŠJĂ.

723017. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œcœä‹`m‘ĺŠw—Տ°ˆâ“`ŠwƒZƒ“ƒ^[“ď’Žˆâ“`ŠO—ˆ‚Ě“ŽŒü|“ď’Ž‚É‚¨‚Ż‚é—Տ°ˆâ“`Šw‚ĚŒ[”­‚ƐV‹Kˆă—Ă‚Ö‚Ě“W–]|. ŽR–ě糋`°, “Ą‰Şłl1, ‹g•lŒ\—S, ×’J@˝, Źě@ˆč, ź‰i’B—Y (1•ŞŽqˆâ“`): ‘ć122‰ń“ú–{Ž¨•@ˆôA‰ČŠw‰ď‘‰ďEŠwpu‰‰‰ď (2021/5/12-15), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723018. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒJƒ_ƒo[‚đ—p‚˘‚˝Ž¨‰ČŽčp‹łˆçƒZƒ~ƒi[‚ɂ‚˘‚Ä. ˜a˛–ě_ˆę˜Y, ‘ĺÎ’źŽ÷, “Ą‰Şłl1, “ěCŽi˜Y, •˝‰ę—Ç•F, źŽR’Œo, r–؍N’q, Źě@ˆč (1•ŞŽqˆâ“`): ‘ć122‰ń“ú–{Ž¨•@ˆôA‰ČŠw‰ď‘‰ďEŠwpu‰‰‰ď (2021/5/12-15), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723019. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰Č‚É‚¨‚Ż‚éZAOSONiC‚đ—p‚˘‚˝Ž¨‰ČŽčp‚ĚŒoŒą. {“cŒĺŽj, –k‘ş@[, ’ˇ’J•”‰ÄŠó, “s’zL‰Ŕ, ×’J@˝, ‘ĺÎ’źŽ÷, Źě@ˆč, “Ą‰Şłl1, _č@ť (1•ŞŽqˆâ“`): ‘ć122‰ń“ú–{Ž¨•@ˆôA‰ČŠw‰ď‘‰ďEŠwpu‰‰‰ď (2021/5/12-15), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723020. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œă–Ŕ˜H–@‚É‚ć‚é’Ž_ŒoŽîᇎčp‚É‚ć‚č’Ž—͉ˇ‘ś‚ľ“ž‚˝Ç—á‚Ě’Ž—Í—\Œă‚ĚŒŸ“˘. ×’J@˝, ‘ĺÎ’źŽ÷, “s’zL‰Ŕ, –k‘ş@[, ’ˇ’J•”‰ÄŠó, “Ą‰Şłl1, _č@ť, Źě@ˆč (1•ŞŽqˆâ“`): ‘ć122‰ń“ú–{Ž¨•@ˆôA‰ČŠw‰ď‘‰ďEŠwpu‰‰‰ď (2021/5/12-15), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723021. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) bFGF‚đ—p‚˘‚˝ŒŰ–ŒúE•Â˝p‚ĚŽĄ—ÐŹŃ‚ÉŠÖ‚ˇ‚錟“˘. _č@ť, “Ą‰Şłl1, ‘ĺÎ’źŽ÷, Źě@ˆč (1•ŞŽqˆâ“`): ‘ć122‰ń“ú–{Ž¨•@ˆôA‰ČŠw‰ď‘‰ďEŠwpu‰‰‰ď (2021/5/12-15), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723022. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚ß‚Ü‚˘‚đ”ş‚ˇ‚é––˝ŤŠç–ʐ_Œo–ƒáƒ‚đ’ć‚ľ‘˝”­Ťd‰ťÇ‚Ş‹^‚í‚ę‚˝1—á. ‹g“c—Lť, “s’zL‰Ŕ, _č@ť, “Ą‰Şłl1, ‘ĺÎ’źŽ÷, Źě@ˆč (1•ŞŽqˆâ“`): ‘ć83‰ńŽ¨•@ˆôA‰Č—Տ°Šw‰ď‘‰ďEŠwpu‰‰‰ď (2021/6/26-27), ŽD–y (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723023. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒAƒpƒ^ƒCƒglHŽ¨Źœ‚đ—p‚˘‚˝Ž¨d‰ťÇŽčp‚̏pŒă’ˇŠúŹŃ. ŽR–ě糋`°, “Ą‰Şłl1, _č@ť, ‘ĺÎ’źŽ÷, “s’zL‰Ŕ, Źě@ˆč (1•ŞŽqˆâ“`): ‘ć83‰ńŽ¨•@ˆôA‰Č—Տ°Šw‰ď‘‰ďEŠwpu‰‰‰ď (2021/6/26-27), ŽD–y (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723024. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰Č‚É‚¨‚Ż‚éBell–ƒáƒ, HuntÇŒóŒQ‚ɑ΂ˇ‚éŠç–ʐ_ŒoŒ¸‰×p‚ĚŽĄ—ÐŹŃ. {“cŒĺŽj, “s’zL‰Ŕ, “Ą‰Şłl1, _č@ť, ‘ĺÎ’źŽ÷, ŹŕVG”V (1•ŞŽqˆâ“`): ‘ć31‰ń“ú–{Ž¨‰ČŠw‰ď‘‰ďEŠwpu‰‰‰ď (2021/10/13-16), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723025. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) p‘OƒXƒP[ƒ‹ƒAƒEƒg‚Š‚ç’˜–ž‚ɏpŒă’Ž—͉ń•œ‚đ”F‚ß‚˝’Ž_ŒoŽîᇎčp—á. ĺ@—I—C, ×’J@˝, ‘ĺÎ’źŽ÷, źŽR’Œo, “s’zL‰Ŕ, Žá—с@‹B, “ě@—˛“ń, “Ą‰Şłl1, _č@ť, ŹŕVG”V (1•ŞŽqˆâ“`): ‘ć31‰ń“ú–{Ž¨‰ČŠw‰ď‘‰ďEŠwpu‰‰‰ď (2021/10/13-16), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723026. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŒÇ”­Ť’Ž_ŒoŽîᇂ̈â“`Žqƒvƒƒtƒ@ƒCƒ‹‚ÉŠî‚Ă‚˘‚˝—Տ°“I“Á’Ľ‚ÉŠÖ‚ˇ‚錟“˘. Žá—с@‹B, ˜a˛–ě_ˆę˜Y, ‘ĺÎ’źŽ÷, ×’J@˝, “s’zL‰Ŕ, –k‘ş@[, ’ˇ’J•”‰ÄŠó, “ě@—˛“ń, źŽR’Œo, “Ą‰Şłl1, ŹŕVG”V (1•ŞŽqˆâ“`): ‘ć31‰ń“ú–{Ž¨‰ČŠw‰ď‘‰ďEŠwpu‰‰‰ď (2021/10/13-16), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723027. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒqƒg‘˝”\ŤŠ˛×–E‚Š‚ç‚ĚŒŒŠÇđ•Ó‰×–E•Ş‰ť—U“ąŒn‚ĚŒŸ“˘. ŽOŽ}’q1, ×’J@˝, “Ą‰Şłl1, ŹŕVG”V (1•ŞŽqˆâ“`): ‘ć31‰ń“ú–{Ž¨‰ČŠw‰ď‘‰ďEŠwpu‰‰‰ď (2021/10/13-16), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723028. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆę‘¤ŤŠOŽ¨“š•Â˝Ç—á‚ɑ΂ľ““`“ą•â’ŽŠí‘•—p‚ŞŽG‰š‰ş’ŽŽć‚É—^‚Ś‚é‰e‹ż. źŽR’Œo, ‘ĺÎ’źŽ÷, V“c´ˆę, —é–Ř‘ĺ‰î, “Ą‰Şłl1, ×’J@˝, “s’zL‰Ŕ, Žá—с@‹B, “ě@—˛“ń (1•ŞŽqˆâ“`): ‘ć66‰ń“ú–{’ŽŠoˆăŠw‰ď‘‰ďEŠwpu‰‰‰ď (2021/10/20-22), “Œ‹ž.

723029. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒ‰š’Ž—ÍŒŸ¸‚Ĺ‚Ě3000Hz‘Ş’č‚ĚˆÓ‹`. “ě@—˛“ń, ‘ĺÎ’źŽ÷, –x@–ž”ü, œŤ“c‚Š‚¨‚č, “Ą‰Şłl1, źŽR’Œo, ×’J@˝, “s’zL‰Ŕ, Žá—с@‹B (1•ŞŽqˆâ“`): ‘ć66‰ń“ú–{’ŽŠoˆăŠw‰ď‘‰ďEŠwpu‰‰‰ď (2021/10/20-22), “Œ‹ž.

723030. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒRƒ‚ƒ“ƒ}[ƒ‚ƒZƒbƒg‚Ě“ď’Žƒ‚ƒfƒ‹‚É‚¨‚Ż‚é”]Voxel Based Analysis‚¨‚ć‚эs“Ž‰đÍ. •˝—ŃŒšŠó, ŒIŒ´@Â, –앐KŽq, —Í•šŒŽ, “Ą‰Şłl1, ŽR–{@—T, Ź“‡”ŽŒČ (1•ŞŽqˆâ“`): ‘ć66‰ń“ú–{’ŽŠoˆăŠw‰ď‘‰ďEŠwpu‰‰‰ď (2021/10/20-22), “Œ‹ž.

723031. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰Č‚É‚¨‚Ż‚é嗓d}ŒŸ¸‚̍H•v. –x@–ž”ü, ×’J@˝, ‘ĺÎ’źŽ÷, ŽR–ě糋`°, “Ą‰Şłl1, œŤ“c‚Š‚¨‚č, źŽR’Œo, “s’zL‰Ŕ, Žá—с@‹B, “ě@—˛“ń (1•ŞŽqˆâ“`): ‘ć66‰ń“ú–{’ŽŠoˆăŠw‰ď‘‰ďEŠwpu‰‰‰ď (2021/10/20-22), “Œ‹ž.

723032. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰)ˆę‰ßŤ‚ÉFT3‚’l‚đ’ć‚ľ‚˝PendredÇŒóŒQ‚Ěˆę—á. ‚‹´—˜“Ţ, ŒIŒ´@ŒM, Ź—э˛‹IŽq, ‹{‰ş˜a‹G, ‰Ą“cŒ’ˆę, ™“cŠG—˘“ß, “ú•@@‰l, “Ą‰Şłl1, ˆÉ“Ą@—T (1•ŞŽqˆâ“`)F‘ć94‰ń“ú–{“ŕ•Ş”ĺŠw‰ďŠwp‘‰ď ( 2021/4/22-24), WebŠJĂ.

723033. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚Ě“ď’Žˆâ“`ŠO—ˆ‚É‚¨‚Ż‚éŠî‘bE—Տ°ˆę‘ĚŒ^Œ¤‹†. “Ą‰Şłl1, ŽR–ě糋`°, ‹g•lŒ\—S, ×’J@˝, ŽOŽ}’q1, ŹŕVG”V, ŹčŒ’ŽŸ˜Y, ź‰i’B—Y (1•ŞŽqˆâ“`): “ú–{l—Ţˆâ“`Šw‰ď‘ć66‰ń‘ĺ‰ď/‘ć28‰ń“ú–{ˆâ“`Žqf—ĂŠw‰ď‘ĺ‰ď‡“ŻŠJĂ (2021/10/13-16), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

732003. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) –{‹C‚Łu—Տ°‚đ•Ď‚Ś‚éƒgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒ“v‚đ–ÚŽw‚ˇl‚ސSŠ|‚Ż‚é‚ׂŤŠî‘bŒ¤‹†‚Ěƒ|ƒCƒ“ƒg. “Ą‰Şłl (•ŞŽqˆâ“`): ‘ć1‰ńŽ¨ƒIƒ“ƒ‰ƒCƒ“Œ¤‹†‰ď (2021/4/1), WebŠJĂ.

733005. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ’á—p—ĘƒVƒƒŠƒ€ƒX—Ă–@‚É‚¨‚Ż‚é—LŠQŽ–Ű: PendredÇŒóŒQ/DFNB4‚đ‘ÎŰ‚É. ŽR–ě糋`°, “Ą‰Şłl1, źŽRŒ‹”ü (1•ŞŽqˆâ“`): ‘ć2‰ńƒVƒƒŠƒ€ƒXVě—pŒ¤‹†‰ď (JASMINŒ¤‹†‰ď) (2021/10/23), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733006. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) PendredÇŒóŒQ/DFNB4‚ɑ΂ˇ‚éCƒI[ƒgƒtƒ@ƒW[‘Łi‚đě—p‹@˜‚Ć‚ľ‚˝ƒVƒƒŠƒ€ƒX­—Ę—Ă–@‚Ě’PŽ{Ý“ńd–ÓŒŸ•ŔsŒQŠÔ”äŠr‘ćI/IIa‘ŠˆăŽtŽĺ“ąŽĄŒą (PENDLRAŽŽŒą). “Ą‰Şłl1, ×’J@˝, ŽR–ě糋`° (1•ŞŽqˆâ“`): ‘ć2‰ńƒVƒƒŠƒ€ƒXVě—pŒ¤‹†‰ď (JASMINŒ¤‹†‰ď) (2021/10/23), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-110001. [Œ´’˜] Deficiency of large tumor suppressor kinase 1 causes congenital hearing loss associated with cochlear abnormalities in mice. Nishiyama T, Fujioka M1, Saegusa C1, Oishi N, Harada T, Hosoya M, Saya H, Ogawa K: Biochem Biophys Res Commun 2021/1; 534: 921-6. (“Ą‰Şłl1, ŽOŽ}’q1: 1•ŞŽqˆâ“`)

'20-110002. [Œ´’˜] The common marmoset as suitable nonhuman alternative for the analysis of primate cochlear development. Hosoya M, Fujioka M1, Murayama AY, Okano H, Ogawa K: FEBS J 2021/1; 288 (1): 325-53. (“Ą‰Şłl1: 1•ŞŽqˆâ“`j

'20-110003. [Œ´’˜] Hydroxyapatite Prostheses in Endoscopic Transcanal Stapes Surgery for Otosclerosis Cases. Hosoya M, Fujioka M1, Ogawa K: Ear Nose Throat J 2021/2: 145561321989143. (“Ą‰Şłl1: 1•ŞŽqˆâ“`)


–ň—Šw

[Šwp˜_•ś]

110026. [Œ´’˜] Roles of Thromboxane Receptor Signaling in Enhancement of Lipopolysaccharide-Induced Lymphangiogenesis and Lymphatic Drainage Function in Diaphragm. Matsuda H1, Ito Y2, Hosono K2, Tsuru S1, Inoue T3, Nakamoto S4, Kurashige C1, Hirashima M, Narumiya S, Okamoto H1, Majima M2: Arterioscler Thromb Vasc Biol 2021/4; 41 (4): 1390-407. (ź“cO”ü1, ˆÉ“Ą‹`–ç2, ×–ě‰Á“ŢŽq2, ’Ă—Ż˘—˘1, ˆäă’qm3, ’†–{CŽi4, ĺUdçŠG1, ‰Ş–{_Žk1, ”n“ˆł—˛2: 1–ƒŒ, 2–ň—, 3Á‰ťŠí“ŕ, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO)

110027. [Œ´’˜] Macrophages contribute to liver repair after monocrotaline-induced liver injury via SDF-1/CXCR4. Otaka F1, Ito Y2, Nakamoto S3, Nishizawa N3, Hyodo, T4, Hosono K2, Majima M2, Koizumi W1, Amano H2: Exp Ther Med 2021/7; 22 (1): 668. (‘ĺ‚Žjš1, ˆÉ“Ą‹`–ç2, ’†–{CŽi3, źŕVL‹ą3, •ş“Ą“O–ç4, ×–ě‰Á“ŢŽq2, ”n“ˆł—˛2, Źň˜aŽO˜Y1, “V–ě‰pŽ÷2: 1Á‰ťŠí“ŕ, 2–ň—, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110028. [Œ´’˜] Recovery of Liver Sinusoidal Endothelial Cells Following Monocrotaline-induced Liver Injury. Otaka F1, Ito Y2, Goto T3, Kojo K4, Tanabe M3, Hosono K2, Majima M2, Koizumi W1, Amano H2: In Vivo 2021/9-10; 35 (5): 2577-87. (‘ĺ‚Žjš1, ˆÉ“Ą‹`–ç2, Œă“Ą‘ě–ç3, ŒĂé@Œ›4, “c糔ü“Ţ3, ×–ě‰Á“ŢŽq2, ”n“ˆł—˛2, Źň˜aŽO˜Y1, “V–ě‰pŽ÷2: 1Á‰ťŠí“ŕ, 2–ň—, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4‰ş•”Á‰ťŠÇŠO)

110029. [Œ´’˜] Activation of iNKT Cells Facilitates Liver Repair After Hepatic Ischemia Reperfusion Injury Through Acceleration of Macrophage Polarization. Goto T1, Ito Y2, Satoh M3, Nakamoto S4, Nishizawa N4, Hosono K2, Naitoh T5, Eshima K3, Iwabuchi K3, Hiki N6, Amano H2: Front Immunol 2021/10; 12: 754106. (Œă“Ą‘ě–ç1, ˆÉ“Ą‹`–ç2, ˛“Ą@‰ë3, ’†–{CŽi4, źŕVL‹ą4, ×–ě‰Á“ŢŽq2, “ŕ“Ą@„5, ]“‡k“ń3, ŠâŸş˜a–ç3, ”äŠé’źŽ÷6, “V–ě‰pŽ÷2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3–Ɖu, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 5‰ş•”Á‰ťŠÇŠO, 6ă•”Á‰ťŠÇŠO)

110030. [Œ´’˜] The role of thromboxane prostanoid receptor signaling in gastric ulcer healing. Yamane S1, Amano H2, Ito Y2, Betto T1, Matsui Y3, Koizumi W1, Narumiya S, Majima M2: .Int J Exp Pathol 2022/2; 103 (1): 4-12. (ŽRŞ‘‹IŽq1, “V–ě‰pŽ÷2, ˆÉ“Ą‹`–ç2, •Ęác•üL1, źˆäŒ[•v3, Źň˜aŽO˜Y1, ”n“ˆł—˛2: 1Á‰ťŠí“ŕ, 2–ň—, 3ŒÄ‹zŠíŠO)

510001. [‘ŕ] VEGFR1-tyrosine kinase signaling in pulmonary fibrosis. Amano H1, Matsui Y2, Hatanaka K1, Hosono K1, Ito Y1: Inflamm Regen 2021/6; 41 (1): 16. (“V–ě‰pŽ÷1, źˆäŒ[•v2, ”¨’†@Œö1, ×–ě‰Á“ŢŽq1, ˆÉ“Ą‹`–ç1: 1–ň—, 2ŒÄ‹zŠíŠO)

520002. [‘ŕ] ŠĚƒ}ƒNƒƒtƒ@[ƒW‚Ě‘˝—lŤ. ˆÉ“Ą‹`–ç (–ň—): –k—˘ˆăŠw 2021/12; 51 (2): 73-81.

[Šw‰ďEŒ¤‹†‰ď“™]

723034. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠĚ‹•ŒŒÄŸó—ŹáŠQŒă‚̩̏C•œ‚É‚¨‚Ż‚éiNKT×–E‚Ě–đŠ„. Œă“Ą‘ě–ç1, ˆÉ“Ą‹`–ç2, ˛“Ą@‰ë3, ’†–{CŽi4, ×–ě‰Á“ŢŽq2, ”¨’†@Œö2, ”n“ˆł—˛2, “V–ě‰pŽ÷2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3–Ɖu, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć42‰ń“ú–{‰ŠÇĽÄśˆăŠw‰ď (2021/7/7), WebŠJĂ.

723035. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “÷‰č‘gDŒ`Ź‚É‚¨‚Ż‚émPGES-1/PGE2 axis‚Ě‹@˜‚̉đÍ. •ş“Ş“O–ç, “V–ě‰pŽ÷1, ˆÉ“Ą‹`–ç1, ×–ě‰Á“ŢŽq1, ”¨’†@Œö1, ]“‡k“ń2, —с@@ň, Aź@’q, R—ǐÒj, •“c@Œ[3, ”n“ˆł—˛1 (1–ň—, 2–Ɖu, 3Œ`ŹE”üŠO): ‘ć42‰ń“ú–{‰ŠÇĽÄśˆăŠw‰ď (2021/7/7), WebŠJĂ.

723036. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) 2ŽŸŤƒŠƒ“ƒp•‚Žî‚É‚¨‚Ż‚é“ŕˆöŤƒgƒƒ“ƒ{ƒLƒTƒ“‚Ě–đŠ„. ×–ě‰Á“ŢŽq1, ”ü“‡—˜ş2, ˆÉ“Ą‹`–ç1, ”¨’†@Œö1, ‹{’n@ŠÓ2, ”n“ˆł—˛1, Ź‹{@Žü, “V–ě‰pŽ÷1 (1–ň—, 2S‘ŸŒŒŠÇŠO): ‘ć42‰ń“ú–{‰ŠÇĽÄśˆăŠw‰ď (2021/7/7), WebŠJĂ.

723037. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠˆŤ‰ťNKT×–E‚̓}ƒNƒƒtƒ@[ƒW‹ÉŤ•ĎŠˇ‚đ‰Á‘Ź‚ł‚š‚ĩ̏C•œ‚𑣐i‚ˇ‚é (Activated iNKT cells promote liver repair by acceleration of macrophage polarization). ˆÉ“Ą‹`–ç1, Œă“Ą‘ě–ç2, ˛“Ą@‰ë3, ŽR‰ş@“Ö2, ’ˇ“c^—RŽq4, “c糔ü“Ţ2, ”¨’†@Œö1, ×–ě‰Á“ŢŽq1, “V–ě‰pŽ÷1 (1–ň—, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3–Ɖu, 4‹~–˝): ‘ć95‰ń“ú–{–ň—Šw‰ď”N‰ď (2022/3/8), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723038. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “÷‰č‘gDŒ`Ź‚𑣐i‚ˇ‚émPGES-1/PGE2Œo˜H‚ĚƒƒJƒjƒYƒ€‚Ɛ§ŒäŤT×–E‚Ć‚ĚŠÖ˜AŤ‚̉đÍ (Analysis of microsomal Prostaglandin E syntase-1 (mPGEs-1)/PGE2 axis mechanism and relationship between regulatory T cells (Tregs) in promoting granulation formation). •ş“Ş“O–ç, “V–ě‰pŽ÷1, ˆÉ“Ą‹`–ç1, ×–ě‰Á“ŢŽq1, ”¨’†@Œö1, ]“‡k“ń2, —с@@ň, Aź@’q, R—ǐÒj, •“c@Œ[3, ”n“ˆł—˛1 (1–ň—, 2–Ɖu, 3Œ`ŹE”üŠO): ‘ć95‰ń“ú–{–ň—Šw‰ď”N‰ď (2022/3/8), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723039. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) mPGES-1/PGE2/EP4Œo˜H‚Í‹•ŒŒ‰ü‘P‚𑣐i‚ˇ‚é (The microsomal prostaglandin E synthase-1/PGE2 /EP4 axis induces blood flow recovery via recruitment of regulatory T cells). “V–ě‰pŽ÷1, ]“‡k“ń2, ˆÉ“Ą‹`–ç1, ×–ě‰Á“ŢŽq1, ”¨’†@Œö1, Ź‹{@Žü, R—ǐ×Y, ”n“ˆł—˛1 (1–ň—, 2–Ɖu): ‘ć95‰ń“ú–{–ň—Šw‰ď”N‰ď (2022/3/8), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723040. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒgƒƒ“ƒ{ƒLƒTƒ“A2Žó—e‘ĚƒVƒOƒiƒ‹‚Í, ƒŠƒ“ƒpŠÇVś‚đ§Œä‚ľ‘ą”­ŤƒŠƒ“ƒp•‚Žî‚đ‰ü‘P‚ˇ‚é (Thromboxane A 2 receptor signaling improves secondary lymphedema and promotes lymphangiogenesis). ×–ě‰Á“ŢŽq1, ”ü“‡—˜ş2, ˆÉ“Ą‹`–ç1, ”¨’†@Œö1, ‹{’n@ŠÓ2, ”n“ˆł—˛1, Ź‹{@Žü, “V–ě‰pŽ÷1 (1–ň—, 2S‘ŸŒŒŠÇŠO): ‘ć95‰ń“ú–{–ň—Šw‰ď”N‰ď (2022/3/9), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733007. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “÷‰č‘gDŒ`Ź‚É‚¨‚Ż‚émPGES-1/PGE2 axis‚Ě–đŠ„‚ĚŒŸ“˘. •ş“Ş“O–ç, “V–ě‰pŽ÷1, ˆÉ“Ą‹`–ç1, ×–ě‰Á“ŢŽq1, ”¨’†@Œö1, ]“‡k“ń2, —с@@ň, Aź@’q, R—ǐÒj, •“c@Œ[3, ”n“ˆł—˛1 (1–ň—, 2–Ɖu, 3Œ`ŹE”üŠO): ‘ć144‰ń“ú–{–ň—Šw‰ďŠÖ“Œ•”‰ď (2021/6/5), WebŠJĂ.

733008. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) §ŒäŤT×–E‚ĚmPGES-1/PGE2 axis‚É‚ć‚é“÷‰č‘gDŒ`Ź‚Ě–đŠ„. •ş“Ş“O–ç, “V–ě‰pŽ÷1, ˆÉ“Ą‹`–ç1, ×–ě‰Á“ŢŽq1, ”¨’†@Œö1, ]“‡k“ń2, —с@@ň, Aź@’q, R—ǐÒj, •“c@Œ[3, ”n“ˆł—˛1 (1–ň—, 2–Ɖu, 3Œ`ŹE”üŠO): ‘ć145‰ń“ú–{–ň—Šw‰ďŠÖ“Œ•”‰ď (2021/10/9), WebŠJĂ.

733009. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) 2ŽŸŤƒŠƒ“ƒp•‚Žî‚É‚¨‚Ż‚郊ƒ“ƒpŠÇVś‚đ§Œä‚ˇ‚éƒgƒƒ“ƒ{ƒLƒTƒ“A2Žó—e‘ĚƒVƒOƒiƒ‹‚Ě–đŠ„. ×–ě‰Á“ŢŽq1, ”ü“‡—˜ş2, ˆÉ“Ą‹`–ç1, ”¨’†@Œö1, ‹{’n@ŠÓ2, ”n“ˆł—˛1, Ź‹{@Žü, “V–ě‰pŽ÷1 (1–ň—, 2S‘ŸŒŒŠÇŠO): ‘ć145‰ń“ú–{–ň—Šw‰ďŠÖ“Œ•”‰ď (2021/10/9), WebŠJĂ.

733010. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Role of IFN-ƒÁ produced by iNKT cells in liver repair after hepatic ischemiareperfusion injury in mice. Œă“Ą‘ě–ç1, ˆÉ“Ą‹`–ç2, ˛“Ą@‰ë3, ’†–{CŽi4, ×–ě‰Á“ŢŽq2, ”¨’†@Œö2, “V–ě‰pŽ÷2, ”n“ˆł—˛2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3–Ɖu, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć145‰ń“ú–{–ň—Šw‰ďŠÖ“Œ•”‰ď (2021/10/9), WebŠJĂ.

733011. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) RAMP1ƒVƒOƒiƒ‹‚ĚŽ‰–bŠĚ“ŕ‰ŠÇ—}§Œř‰Ę. ˆÉ“Ą‹`–ç1, ×–ě‰Á“ŢŽq1, Œă“Ą‘ě–ç2, “c粔ü“Ţ2, ŽR‰ş@“Ö2, ’ˇ“c^—RŽq3, ”¨’†@Œö1, ”n“ˆł—˛1, “V–ě‰pŽ÷1 (1–ň—, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‹~–˝): ‘ć145‰ń“ú–{–ň—Šw‰ďŠÖ“Œ•”‰ď (2021/10/9), WebŠJĂ.


”÷ś•¨Šw

[Šwp˜_•ś]

110031. [Œ´’˜] Efficacy and safety of 0.0584% hydrocortisone aceponate topical spray and systemic oclacitinib combination therapy in dogs with atopic dermatitis: a randomized, double-blinded, placebo-controlled trial. Takahashi J, Kanda S, IImanishi I1, Hisano T, Fukamachi T, Taguchi N, Momiyama S, Nishiyama S, Motegi T, Iyori K: Vet Dermatol 2021/4; 32 (2): 119-e25. (ĄźŽs˜N1: 1”÷ś•¨)

110032. [Œ´’˜] Influence of hospital size on antimicrobial resistance and advantages of restricting antimicrobial use based on cumulative antibiograms in dogs with Staphylococcus pseudintermedius infections in Japan. Iyori K, Shishikura T, Shimoike K, Minoshima K, Imanishi I1, Toyoda Y: Vet Dermatol 2021/5; 32 (6): 668-e178. (ĄźŽs˜N1: 1”÷ś•¨)

110033. [Œ´’˜] Anaphylaxis after rabies vaccination for dogs in Japan. Yoshida M, Mizukami K, Hisasue M, Imanishi I1, Kurata K, Ochiai M, Itoh M, Nasukawa T, Uchiyama J, Tsujimoto H, Sakaguchi M: J Vet Med Sci 2021/8; 83 (8): 1202-5. (ĄźŽs˜N1: 1”÷ś•¨)

110034. [Œ´’˜] IgE reactivity to milk components in dogs with cutaneous adverse food reactions. Shimakura H, Nasukawa T, Uchiyama J, Sugimoto R, Imanishi I1, Oota S, Mizukami K, Fujimura M, Sakaguchi M: J Vet Med Sci 2021/10; 83 (10): 1509-12. (ĄźŽs˜N1: 1”÷ś•¨)

310003. [Ç—á•ń] Fecal microbiota transplantation as therapy for recurrent Clostridioides difficile infection is associated with amelioration of delirium and accompanied by changes in fecal microbiota and the metabolome. Gotoh K, Sakaguchi Y1, Kato H, Osaki H, Jodai Y, Wakuda M, Take A1, Hayashi S1, Morita E, Sugie T, Ito Y, Ohmiya N: Anaerobe 2022/2; 73: 102502. (ăŒű‹`•F1, •@@W1, —с@rŽĄ1: 1”÷ś•¨)

510002. [‘ŕ] Epithelial-immune crosstalk with the skin microbiota in homeostasis and atopic dermatitis - a mini review. Kobayashi T, Imanishi I1: Vet Dermatol 2021/12; 32 (6): 533-e147. (ĄźŽs˜N1: 1”÷ś•¨)

520003. [‘ŕ] 2020”NŒă”ź‚¨‚ć‚Ń2021”N‚ɏł”F‚ł‚ę‚˝Helicobacter‘Ž‚̐V‹ŰŽí‚ĚĐ‰î|•ń˜_•ś‚ć‚č|. —с@rŽĄ (”÷ś•¨): Helicobacter Research 2022/1; 26 (1): 116-9.

521001. [‰đŕ] —Տ°ˆă‚É’m‚Á‚Ä‚Ů‚ľ‚˘•\ÝŤ”^”çÇ. ĄźŽs˜N (”÷ś•¨): bˆă—Տ°”畆‰Č 2021/4; 27 (1): 44569.
522005. [uŔ] H‚ĚˆŔ‘SEˆŔS‰ČŠw|H•iť‘˘ŒťęEH•i‚É‚Š‚Š‚í‚é”÷ś•¨‰˜ő‚Ć‚ť‚Ě‘Îô|[5] H•iť‘˘Œťę‚É‚¨‚Ż‚é‰č–EŒ`Ź×‹Ű. ăŒű‹`•F (”÷ś•¨): “ú–{–h‹Ű–hꀊw‰ďŽ 2021/5; 49 (5): 223-8.

540003. [‚ť‚Ě‘ź (Œ¤‹†•ń‘)]y‰ČŠwŒ¤‹†”ď•â•‹ŕEŽáŽčŒ¤‹†uƒoƒNƒeƒŠƒIƒtƒ@[ƒW—n‹Űy‘f‚đ—p‚˘‚˝ƒfƒBƒtƒBƒVƒ‹‹Ű×–E•Ç‚̍\‘˘‰đÍ‚Ć‚ť‚̉ž—p (Œ¤‹†ŠúŠÔ: 2020”N“x`2021”N“x)vzŒ¤‹†‘ă•\ŽŇ: •@@W1 (1”÷ś•¨):uƒoƒNƒeƒŠƒIƒtƒ@[ƒW—n‹Űy‘f‚đ—p‚˘‚˝ƒfƒBƒtƒBƒVƒ‹‹Ű×–E•Ç‚̍\‘˘‰đÍ‚Ć‚ť‚̉ž—pv2020”N“xŽŔŽ{ó‹ľ•ń‘ 2021/5; https://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-20K16250/20K162502020hokoku/.

540004. [‚ť‚Ě‘ź (Œ¤‹†•ń‘)]y‰ČŠwŒ¤‹†”ď•â•‹ŕEŠî”ŐŒ¤‹† (C)uƒfƒBƒtƒBƒVƒ‹‹ŰƒoƒNƒeƒŠƒIƒtƒ@[ƒW‚̏hŽĺ”FŽŻ‹@\‚̉𖞋y‚ŃŽĄ—Ă‚Ć—\–h‚ւ̉ž—p (Œ¤‹†ŠúŠÔ: 2019”N“x`2021”N“x)vzŒ¤‹†‘ă•\ŽŇ: ăŒű‹`•F1, Œ¤‹†•Ş’SŽŇ: ‰Á“Ą‚Í‚é, ‘ĺ‹{’ź–Ř, “ŕŽR~•˝, Œă“Ą˜a‹`, –…”ö[•q, —с@rŽĄ1 (1”÷ś•¨):uƒfƒBƒtƒBƒVƒ‹‹ŰƒoƒNƒeƒŠƒIƒtƒ@[ƒW‚̏hŽĺ”FŽŻ‹@\‚̉𖞋y‚ŃŽĄ—Ă‚Ć—\–h‚ւ̉ž—pv2020”N“xŽŔŽ{ó‹ľ•ń‘ 2021/5; https://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-19K07560/19K075602020hokoku/.

540005. [‚ť‚Ě‘ź (Œ¤‹†•ń‘)]y‰ČŠwŒ¤‹†”ď•â•‹ŕEŠî”ŐŒ¤‹† (C)uƒtƒ@[ƒW“ŕÝ‰ť‚É‚ć‚éƒsƒƒŠ‹Ű‚ĚŽ‘ąŠ´ő‹@\‚ĚŒŸŘ (Œ¤‹†ŠúŠÔ: 2018”N“x`2020”N“x)vzŒ¤‹†‘ă•\ŽŇ: “ŕŽR~•˝, Œ¤‹†•Ş’SŽŇ: źč–ΓW, —с@rŽĄ1, ăŒű‹`•F1, ŽOŽşm”ü (1”÷ś•¨)uƒtƒ@[ƒW“ŕÝ‰ť‚É‚ć‚éƒsƒƒŠ‹Ű‚ĚŽ‘ąŠ´ő‹@\‚ĚŒŸŘv2020”N“xŽŔŃ•ń‘ 2021/5; https://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-18K07127/18K071272020jisseki/.

540006. [‚ť‚Ě‘ź (Œ¤‹†•ń‘)]y‰ČŠwŒ¤‹†”ď•â•‹ŕEŠî”ŐŒ¤‹† (C)uƒtƒ@[ƒW“ŕÝ‰ť‚É‚ć‚éƒsƒƒŠ‹Ű‚ĚŽ‘ąŠ´ő‹@\‚ĚŒŸŘ (Œ¤‹†ŠúŠÔ: 2018”N“x`2020”N“x)vzŒ¤‹†‘ă•\ŽŇ: “ŕŽR~•˝, Œ¤‹†•Ş’SŽŇ: źč–ΓW, —с@rŽĄ1, ăŒű‹`•F1, ŽOŽşm”ü (1”÷ś•¨):uƒtƒ@[ƒW“ŕÝ‰ť‚É‚ć‚éƒsƒƒŠ‹Ű‚ĚŽ‘ąŠ´ő‹@\‚ĚŒŸŘv2018”N“x`2020”N“xŒ¤‹†Ź‰Ę•ń‘ 2021/5; https://kaken.nii.ac.jp/ja/file/KAKENHI-PROJECT-18K07127/18K07127seika.pdf.

540007. [‚ť‚Ě‘ź (Œ¤‹†•ń‘)]yŒö‰vŕ’c–@l •ZˆăŠwŒ¤‹†V‹ťŕ’cE2019”N“x (‘ć27‰ń) Œ¤‹†•Ź‹ŕuƒoƒNƒeƒŠƒIƒtƒ@[ƒW‚Ě”ö•”‹z’…•ŞŽq‚đ—˜—p‚ľ‚˝ƒfƒBƒtƒBƒVƒ‹‹ŰŠ”‚̐V‹Kv‘ŹŒŸo–@‚ĚŠJ”­ (Œ¤‹†ŠúŠÔ: 2019”N10ŒŽ`2020”N9ŒŽ)vzŒ¤‹†‘ă•\ŽŇ: ăŒű‹`•F1, ‹Ś—ÍŒ¤‹†ŽŇ: ‰Á“Ą‚Í‚é, –…”ö[•q, Œă“Ą˜a‹`, “ŕŽR~•˝, •@@W1, ăŒű­´ (1”÷ś•¨):uƒoƒNƒeƒŠƒIƒtƒ@[ƒW‚Ě”ö•”‹z’…•ŞŽq‚đ—˜—p‚ľ‚˝ƒfƒBƒtƒBƒVƒ‹‹ŰŠ”‚̐V‹Kv‘ŹŒŸo–@‚ĚŠJ”­v2019”N“x•ń‘ 2021/6.

540008. [‚ť‚Ě‘ź (Œ¤‹†•ńW)]y‚₸‚âH‚ĆŒ’NŒ¤‹†ŠE2019”N“xŒ¤‹†•ŹŒ¤‹†uH•¨‚Ş‚ŕ‚˝‚炡Œ’N‚Ć‚ĚŠÖ˜A|—L—pŤ•úü‹Ű‚Ě’°“ŕ‚É‚¨‚Ż‚é–đŠ„|(Œ¤‹†ŠúŠÔ: 2019”N11ŒŽ`2021”N11ŒŽ)vzŒ¤‹†‘ă•\ŽŇ: •@@W1, Žw“ąŽŇ: ăŒű‹`•F1, ‹¤“ŻŒ¤‹†ŽŇ: ‰Á“Ą‚Í‚é, —с@rŽĄ1 (1”÷ś•¨):uH•¨‚Ş‚ŕ‚˝‚炡Œ’N‚Ć‚ĚŠÖ˜A|—L—pŤ•úü‹Ű‚Ě’°“ŕ‚É‚¨‚Ż‚é–đŠ„|v2019”N“xŒ¤‹†Ź‰Ę•ń‘ 2022/1.

[Šw‰ďEŒ¤‹†‰ď“™]

722009. [Šw‰ď (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) The panel of antibiotic-resistant strains of Helicobacter pylori. —с@rŽĄ1, Yokota K, Osaki T, Yokota S, Takeuchi H, Rimbara E (1”÷ś•¨): ‘ć27‰ń“ú–{ƒwƒŠƒRƒoƒNƒ^[Šw‰ďŠwpW‰ď (2021/9/25), WebŠJĂ.

722010. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) CŒ^‚ĆDŒ^ƒ{ƒcƒŠƒkƒX“Ĺ‘f‚đŽx”z‚ˇ‚éƒoƒNƒeƒŠƒIƒtƒ@[ƒW‚Ě—nŒ´‰ť‹@\‚̉đÍ. ăŒű‹`•F1, •@@W1, Œă“Ą˜a‹`, ŽR–{—R–íŽq, K“c’mŽq, Œü–{‰ëˆč, ŹčrŽi, —с@rŽĄ1, —с@“N–ç, ŹŒFœ¨“ń (1”÷ś•¨): ‘ć95‰ń“ú–{×‹ŰŠw‰ď‘‰ď (2022/3/29), WebŠJĂ.

723041. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”^áo]‚ĚŽŠ‘R”­Ç“Ž•¨ƒ‚ƒfƒ‹ (ƒCƒk•\ÝŤ”^”çÇ) ‚ɑ΂ˇ‚éƒtƒ@[ƒW—R—ˆy‘fƒGƒ“ƒhƒ‰ƒCƒVƒ“‚ĚŒŸ“˘. ĄźŽs˜N1, ź“ĄŒöŽi, ’Š”ä“Ţ—Ç‘ž, —с@rŽĄ1, ’Ă‹vˆä—˜L, “ŕŽR~•˝ (1”÷ś•¨): 95‰ń“ú–{Š´őÇŠw‰ďŠwpu‰‰‰ď^‘ć69‰ń“ú–{‰ťŠw—Ă–@Šw‰ď‘‰ď‡“ŻŠw‰ď (2021/5/7), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723042. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Ş–ěŘ‚Š‚ç‚Ě•úü‹Ű‚Ě•Ş—Ł‚Ć‚ť‚Ě’°“ŕŠÂ‹Ťś‘ś”\‚Ě•]‰ż. •@@W1, ăŒű‹`•F1, ˆî‹´—C‹N, Œă“Ą˜a‹`, —с@rŽĄ1, ‰Á“Ą‚Í‚é, ‘ĺ‹{’ź–Ř (1”÷ś•¨): ‘ć35‰ń“ú–{•úü‹ŰŠw‰ď‘ĺ‰ď (2021/9/18), WebŠJĂ.

723043. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠĹŒěŽt‚ŞŽg—p‚ˇ‚é‘ŹŠŁŤŽCŽŽŽčŽwÁ“Ĺ–ň‚đ“ü‚ę‚éŒg‘Ń—pƒ|[ƒ`‚Ě×‹Ű‰˜ő‚ĆŠÇ—ó‹ľ‚ĚŒŸ“˘. ˆÉ“Ą“šŽq, “ń‹{@ˆŠ, Îˆä˜aŽq, ^“c–ƒ”ü, “‡“c–žŒb, ‘ĺ–ě“TŽq, ‹ŕŽR“֍G, —с@rŽĄ1 (1”÷ś•¨): ‘ć36‰ń“ú–{ŠÂ‹ŤŠ´őŠw‰ď‘‰ďEŠwpW‰ď (2021/9/20), –źŒĂ‰Ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723044. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚š‚ń–ς𔺂¤Ä”­ŤClostridioides difficileŠ´őÇ‚ɑ΂ˇ‚é•ł•Ö”÷ś•¨ˆÚA—Ă–@`Ä”­—\–hŒř‰Ę‚đŽŚ‚ľ‚˝Ç—á‚Ě’°“ŕ”÷ś•¨‘p‹y‚Ń‚ť‚Ě‘ăŽÓŽY•¨‚̉đÍ`. ăŒű‹`•F1, Œă“Ą˜a‹`, •@@W1, ”öé”šl, é‘ăN‹M, ˜a‹v“cŒő‹B, —с@rŽĄ1, ‰Á“Ą‚Í‚é, ‘ĺ‹{’ź–Ř (1”÷ś•¨): “ú–{–ňŠw‰ď‘ć142”N‰ď (2022/3/25), WebŠJĂ.

723045. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) H•¨‚¨‚ć‚Ńƒqƒg•ł•Ö‚Š‚ç•Ş—Ł‚ľ‚˝•úü‹Ű‚̐lHÁ‰ť‰t‚ł̐śŽcŤ. •@@W1, ăŒű‹`•F1, ˆî‹´—C‹N, Œă“Ą˜a‹`, —с@rŽĄ1, ‰Á“Ą‚Í‚é, ‘ĺ‹{’ź–Ř (1”÷ś•¨): ‘ć95‰ń“ú–{×‹ŰŠw‰ď‘‰ď (2022/3/29), WebŠJĂ.

731001. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ƒqƒg‚ĆƒCƒk‚É‚¨‚Ż‚éƒAƒŒƒ‹ƒM[‚Ě‹““Ž‚Ěˆá‚˘`ƒuƒhƒE‹…‹Ű‚Ě‰ßč‘B`. ĄźŽs˜N (”÷ś•¨): ‘ć20‰ń–ƉuƒAƒŒƒ‹ƒM[Terakoya•×‹­‰ď (2021/6/25), WebŠJĂ.

732004. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) Ä”­ŤƒNƒƒXƒgƒŠƒWƒEƒ€EƒfƒBƒtƒBƒVƒ‹Š´őÇ‚ɑ΂ˇ‚éV‘N•ÖEƒoƒ“ƒNƒhƒi[“€Œ‹•Ö‚É‚ć‚éD‹C“I•ł•ÖˆÚA. ‘ĺ‹{’ź–Ř, ăŒű‹`•F1, ‰Á“Ą‚Í‚é (1”÷ś•¨): “ú–{Á‰ťŠí•aŠw‰ď“ŒŠCŽx•”‘ć135‰ń—á‰ď (2021/12/11), –źŒĂ‰Ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).


Šńś’ŽŠwE”M‘ŃˆăŠw

[Šwp˜_•ś]

110035. [Œ´’˜] Venestatin from parasitic helminths interferes with receptor for advanced glycation end products (RAGE)-mediated immune responses to promote larval migration. Tsubokawa D1, Kikuchi T, Lee JM, Kusakabe T, Yamamoto Y, Maruyama H: PLoS Pathog 2021/6; 17 (6): e1009649. (’ؐě‘ĺŒĺ1: 1Šńś’ŽE”M‘ŃˆăŠw)

110036. [Œ´’˜] Mitochondria as a Potential Target for the Development of Prophylactic and Therapeutic Drugs against Schistosoma mansoni Infection. Talaam K, Inaoka DK, Hatta T1, Tsubokawa D1, Tsuji N1, Wada M, Saimoto H, Kita K, Hamano S: Antimicrob Agents Chemother 2021/9; 65 (10): e0041821. (”Ş“cŠxŽm1, ’ؐě‘ĺŒĺ1, ’ҁ@Ž—˜1: 1Šńś’ŽE”M‘ŃˆăŠw)

510003. [‘ŕ] The antiviral immunity of ticks against transmitted viral pathogens. Talactac MR, Hernandez EP, Hatta T1, Yoshii K, Kusakisako K, Tsuji N1, TanakaT: Dev Comp Immunol 2021/6; 119: 104012. (”Ş“cŠxŽm1, ’ҁ@Ž—˜1: 1Šńś’ŽE”M‘ŃˆăŠw)

520004. [‘ŕ]yĹć’[ˆă—Ă‚ĚĄzÁ‰ťŠÇŠńśĺž’Ž‚Ş—L‚ˇ‚éƒJƒ‹ƒVƒEƒ€Œ‹‡ƒ^ƒ“ƒpƒNŽż‚̍R‰ŠÇ‹@”\. ’ؐě‘ĺŒĺ (Šńś’ŽE”M‘ŃˆăŠw): Medical Science Digest 2022/3; 48 (3): 36-8.

[Šw‰ďEŒ¤‹†‰ď“™]

723046. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Šńśĺž’ŽS100—l•ŞŽq‚̏I––“œ‰ťŽY•¨Žó—e‘Ě (RAGE) ‚đ‰î‚ˇ‚鉊Ç‰ž“š‚Ö‚Ěě—p. ’ؐě‘ĺŒĺ1, ˛“Ą@‰ë2 (1Šńś’ŽE”M‘ŃˆăŠw, 2–Ɖu): ‘ć44‰ń“ú–{•ŞŽqś•¨Šw‰ď”N‰ď (2021/12/1), ‰Ą•l.


•a—Šw (‘ş‰_’PˆĘ)

[Šwp˜_•ś]

110037. [Œ´’˜] Prognostic values of L-type amino acid transporter 1 and CD98hc expression in breast cancer. Ichinoe M1, Mikami T, Yanagisawa N, Yoshida T1,2, Hana K, Endou H, Okayasu I1, Sengoku N, Ogata H, Saegusa M1, Shibuya K, Murakumo Y1: J Clin Pathol 2021/9; 74 (9): 589-95. (ˆęŒËš–ž1, ‹g“c@Œ÷1,2, ‰ŞˆŔ@ŒM1, ŽOŽ}@M1, ‘ş‰_–FŽ÷1: 1•a—, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

110038. [Œ´’˜] CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer. Adachi K1, Sakurai Y2, Ichinoe M2, Tadehara M1, Tamaki A1, Kesen Y2, Kato T2, Mii S, Enomoto A, Takahashi M, Koizumi W3, Murakumo Y2: Virchows Arch 2022/4; 480 (4): 819-29. doi: 10.1007/s00428-021-03230-2. Epub 2021 Nov 11. (ˆŔ’B@‰ő1, ŸNˆä–ő‚2, ˆęŒËš–ž2, äřŒ´Ť—Ç1, ‹Ę’u–žŠ°1, Ÿ†ĺ—T—œ2, ‰Á“Ą‘ôĆ2, Źň˜aŽO˜Y3, ‘ş‰_–FŽ÷2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2•a—, 3Á‰ťŠí“ŕ)

110039. [Œ´’˜] Upregulation of REV7 correlates with progression of malignant melanoma. Hoshino A1, Nakayama C1, Jiang SX1, Sakurai Y1, Kato T1, Numata Y2, Umezawa A2, Ichinoe M1, Murakumo Y1: Pathol Int 2022/1; 72 (1): 14-24. (Ż–쏺–F1, ’†ŽR ’m‰Ŕ1, Ó@˘ˆŽ1, ŸNˆä–ő‚1, ‰Á“Ą‘ôĆ1, Ŕ“c‰ęŽq2, ”~‘ň“ÖŽq2, ˆęŒËš–ž1, ‘ş‰_–FŽ÷1: 1•a—, 2Œ`‘ÔŒn)

110040. [Œ´’˜] Clinicopathological Significance of BRCAness in Resectable Pancreatic Ductal Adenocarcinoma and Its Association With Anticancer Drug Sensitivity in Pancreatic Cancer Cells. Tadehara M1, Kato T2, Adachi K1, Tamaki A1, Kesen Y2, Sakurai Y2, Ichinoe M2, Koizumi W3, Murakumo Y2: Pancreas 2022/2; 51 (2): 183-9. (äřŒ´Ť—Ç1, ‰Á“Ą‘ôĆ2, ˆŔ’B@‰ő1, ‹Ę’u–žŠ°1, Ÿ†ĺ—T—œ2, ŸNˆä–ő‚2, ˆęŒËš–ž2, Źň˜aŽO˜Y3, ‘ş‰_–FŽ÷2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2•a—, 3Á‰ťŠí“ŕ)

[Šw‰ďEŒ¤‹†‰ď“™]

723047. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) äX‘Ě•”‚É”­ś‚ľ‚˝Pancreatic hamartoma‚Ě1—á. Ÿ†ĺ—T—œ1, ‘ş‰_–FŽ÷1, ˆęŒËš–ž1 (1•a—): ‘ć110‰ń“ú–{•a—Šw‰ď‘‰ď (2021/4/22), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723048. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) äX‘ŸŠŕ‚É‚¨‚Ż‚éCD109”­Œť‚Ě—Ő°“I, ×–Eś•¨Šw“IˆÓ‹`‚̉đÍ. ˆŔ’B@‰ő1, ŸNˆä–ő‚2, ‰Á“Ą‘ôĆ2, ˆęŒËš–ž2, ‘ş‰_–FŽ÷2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2•a—): ‘ć80‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď (2021/9/30), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723049. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) äXŠŕ‚É‚¨‚Ż‚éBRCAness‚Ě—Ő°•a—Šw“I“ÁŤ‚¨‚ć‚ŃäXŠŕ×–EŠ”‚É‚¨‚Ż‚éRŠŕÜŠ´ŽóŤ. äřŒ´Ť—Ç1, ‰Á“Ą‘ôĆ2, ˆŔ’B@‰ő1, ŸNˆä–ő‚2, ˆęŒËš–ž2, ‘ş‰_–FŽ÷2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2•a—): ‘ć80‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď (2021/9/30), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-110004. [Œ´’˜] Increased expression of REV7 in small cell lung carcinomas and its association with tumor cell survival and proliferation. Sanoyama I1, Sakurai Y1, Ichinoe M1, Hoshino A1, Kesen Y1, Kato T1, Numata Y2, Umezawa A2, Jiang SX1, Murakumo Y1: Pathol Int 2021/1; 71 (1): 15-23. (áÁŽR@“ž1, ŸNˆä–ő‚1, ˆęŒËš–ž1, Ż–쏺–F1, Ÿ†ĺ—T—œ1, ‰Á“Ą‘ôĆ1, Ŕ“c‰ęŽq2, ”~‘ň“ÖŽq2, Ó@˘ˆŽ1, ‘ş‰_–FŽ÷1: 1•a—, 2Œ`‘ÔŒn)

[Šw‰ďEŒ¤‹†‰ď“™]

'20-723001. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Ź×–E”xŠŕ‚É‚¨‚Ż‚éREV7”­Œť‚ĚˆÓ‹`‚̉đÍ. áÁŽR@“ž1, ‘ş‰_–FŽ÷1, ˆęŒËš–ž1, ”~‘ň“ÖŽq2 (1•a—, 2Œ`‘ÔŒn): ‘ć109‰ń“ú–{•a—Šw‰ď‘‰ď (2020/7/1-31), WebŠJĂ.


•a—Šw (ŽOŽ}’PˆĘ)

[Šwp˜_•ś]

110041. [Œ´’˜] Anaplastic Lymphoma Kinase Overexpression Is Associated with Aggressive Phenotypic Characteristics of Ovarian High-Grade Serous Carcinoma. Matsumoto T1, Oda Y, Hasegawa Y, Hashimura M2, Oguri Y2, Inoue H1, Yokoi A3, Tochimoto M3, Nakagawa M, Jiang Z, Saegusa M1: Am J Pathol 2021/10; 191 (10): 1837-50. (ź–{r‰p1, ‹´‘ş”ü‹I2, ŹŒINŽq2, ˆäă‹vŽq1, ‰Ąˆäˆ¤3, “Č–{šF3, ŽOŽ}@M1: 1•a—, 2Œ`‘ÔŒn, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110042. [Œ´’˜] Therapeutic inhibition of USP9x-mediated Notch signaling in triple-negative breast cancer. Jaiswal A, Murakami K, Elia A, Shibahara Y1, Done SJ, Wood SA, Donato NJ, Ohashi PS, Michael Reedijk M: Proc Natl Acad Sci U S A 2021/9; 118 (38): e2101592118. (ŽÄŒ´—T‹IŽq1: 1•a—)

110043. [Œ´’˜] Prognostic Impact of CXCR7 and CXCL12 Expression in Patients with Esophageal Adenocarcinoma. Goto M, Shibahara Y1, Baciu C, Allison F, Yeung JC, Darling GE, Liu M: Ann Surg Oncol 2021/9; 28 (9): 4943-51. (ŽÄŒ´—T‹IŽq1: 1•a—)

110044. [Œ´’˜] Cytoplasmic EBP50 and elevated PARP1 are unfavorable prognostic factors in ovarian clear cell carcinoma. Matsumoto T1, Yoki A2, Konno R, Oguri Y3, Hashimura M3, Tochimoto M2, Nakagawa M, Jiang Z, Ishibashi Y, Ito T, Kodera Y, Saegusa M1: Carcinogenesis 2021/10; 42 (9): 1162-70. (ź–{r‰p1, ‰Ąˆäˆ¤2, ŹŒINŽq3, ‹´‘ş”ü‹I3, “Č–{šF2, ŽOŽ}@M1: 1•a—, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3Œ`‘ÔŒn)

110045. [Œ´’˜] Intestinal Stem Cell Marker ASCL2 is a Novel Prognostic Predictor in Esophageal Adenocarcinoma. Shibahara Y1, Espin-Garcia O, Conner J, Weiss J, Derouet M, Allen J, Allison F, Kalimuthu S, Yeung JC, Darling GE: Cureus 2022/1; 14 (1): e21021. (ŽÄŒ´—T‹IŽq1: 1•a—)

[Šw‰ďEŒ¤‹†‰ď“™]

722011. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŽŸ˘‘ă‚Ě×–EŒŸ¸Žm‚Ě‹łˆç‚Ć“­‚Ť•ű: –k—˘‘ĺŠw‚É‚¨‚Ż‚鎟˘‘ă‚Ě×–EŒŸ¸Žm‹łˆç. ź‘ş—R—˘1, ˆ˘•”’ź–ç1, ŽRéhŽj2, ŽR‰ş˜a–ç3, ‚‹´”Ž”V1, ŽOŽ}@M4, ˛“Ą”Vr5, ŒĂ“c—ćŽq1 (1ˆă—ÉqśŠw•”, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3•a—•”, 4•a—, 5ŒÄ‹zŠíŠO): ‘ć62‰ń“ú–{—Տ°×–EŠw‰ď‘‰ďtŠú‘ĺ‰ď (2021/6/5), ç—t (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723050. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —‘‘ƒŠŕ‚̐V‹K—\ŒăˆöŽq‚Ě“Ż’č, ‹@”\‰đÍ, ‚ť‚ľ‚Ä—Ő°‰ž—p‚ÉŠÖ‚ˇ‚錤‹†. ‰Ąˆäˆ¤1, ź–{r‰p2, ‹´‘ş”ü‹I3, ŹŒINŽq3, “n•Ó@‹, ’ˇ’Jě‰Ă‘Ľ, ŽOŽ}@M1 (1•a—, 2ˆă—ÉqŻŠw•”, 3Œ`‘ÔŒn): ‘ć110‰ń“ú–{•a—Šw‰ď‘‰ď (2021/4/22), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723051. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) äP‰čŽî‚É‚¨‚Ż‚éS100A4/ƒ~ƒIƒVƒ“9 axis‚Ě‹@”\‰đÍ. Î’ËŒ‹Šě1, Œ˘Ž”@‰~2, ź–{r‰p3, ŽOŽ}@M4 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2”]ŠO, 3ˆă—ÉqśŠw•”, 4•a—): ‘ć110‰ń“ú–{•a—Šw‰ď‘‰ď (2021/4/22), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723052. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —‘‘ƒ–ž×–EŠŕ‚É‚¨‚˘‚ÄEBP50/PARP-1 axis‚͍RŠŕÜ‘ϐŤ”\Šl“ž‚ÉŠń—^‚ˇ‚é. ź–{r‰p1, ‰Ąˆäˆ¤2, Ž–ě@—ş, ŹŽ›‹`’j, ŽOŽ}@M2 (1ˆă—ÉqśŠw•”, 2•a—): ‘ć110‰ń“ú–{•a—Šw‰ď‘‰ď (2021/4/23), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723053. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Žq‹{“ŕ–ŒŠŕ‚ĚEBP50/ƒŔ-ƒJƒeƒjƒ“/PTENŒn‚É‚ć‚émorule•Ş‰ť—U“ą‹@\. “ě–ƒ—˘“Ţ1, ‰Ąˆäˆ¤2, ‹´‘ş”ü‹I3, “Č–{š—˛2, ’†ě䝗S2, M‘žşŽq2, ŽOŽ}@M2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2•a—, 3Œ`‘ÔŒn): ‘ć110‰ń“ú–{•a—Šw‰ď‘‰ď (2021/4/24), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723054. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”xG•˝ă”çŠŕ‚Ě’źÚ“h–•‚Ɖtó‰ťŒŸ‘Ě×–Ef•W–{‚Ĺ‚ĚOGDőG•˝ă”çŠŕ×–E”‚̍ˇˆŮ. ŽRř“hŽj1, ź”ö—R‹IŽq2, ŽR‰ş˜a–ç3, ź‘ş—R—˘4, ˆ˘•”’ź–ç4, ‹g“c@Œ÷5, ŽOŽ}@M5, ˛“Ą”Vr6, ŒĂ“c—ćŽq4 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2•a‘ԁEf—ĂŒn, 3•a—•”, 4ˆă—ÉqśŠw•”, 5•a—, 6ŒÄ‹zŠíŠO): ‘ć60‰ń“ú–{—Տ°×–EŠw‰ďHŠú‘ĺ‰ď (2021/11/21), •ÄŽq.


‰qśŠw

[Šwp˜_•ś]

110046. [Œ´’˜] Influence of the position of the palatal bar on brain activity during speech. Kataoka K, Tamaki K, Ono Y, Hoshi K1, Ikuta R, Fujiwara M: Ann Jpn Prosthodont Soc 2021/4; 13 (2): 135-45. (Ż@‰Ŕ–F1: 1‰qś)

110047. [Œ´’˜] The progress of medication-related osteonecrosis of the jaw with conservative initial treatment: A 12-year retrospective study of 129 patients. Kaibuchi N, Hoshi K1, Yamazaki A, Miyamoto-Sangu N, Akagi Y, Okamoto T: Bone Rep 2021/4; 14: 101072. (Ż@‰Ŕ–F1: 1‰qś)

110048. [Œ´’˜] National Data Analysis and Systematic Review for Human Resources for Cervical Cancer Screening in Japan. Hamashima C, Sasaki S, Hosono S, Hoshi K1, Katayama T, Terasawa T: Asian Pac J Cancer Prev 2021/6; 22 (6): 1695-702. (Ż@‰Ŕ–F1: 1‰qś)

110049. [Œ´’˜] Modified Creatinine Index and Clinical Outcomes of Hemodialysis Patients: An Indicator of Sarcopenia? Yamamoto S, Matsuzawa R, Hoshi K1, Suzuki Y, Harada M, Watanabe T, Isobe Y, Imamura K, Osada S, Yoshida A, Kamiya K2, Matsunaga A2: J Ren Nutr 2021/7; 31 (4): 370-9. (Ż@‰Ŕ–F1, _’JŒ’‘ž˜Y2, ź‰i“Ä•F2: 1‰qś, 2ˆă—ÉqśŠw•”)

110050. [Œ´’˜] Increased Prevalence of Atopic Dermatitis in Children Aged 0-3 Years Highly Exposed to Parabens. Arafune J, Tsujiguchi H, Hara A, Shimizu Y, Hori D, Nguyen TTT, Suzuki F, Hamagishi T, Yamada Y, Nakamura H, Yoshikawa T, Hayashi K, Shibata A, Fukutomi Y, Ohya Y, Yamamoto-Hanada K, Muto G1, Hirota R, Konoshita T, Kambayashi Y, Nakamura H: Int J Environ Res Public Health 2021/11; 18 (21):11657. (•“Ą@„1: 1‰qś)

110051. [Œ´’˜] Overview of Legal Measures for Managing Workplace COVID-19 Infection Risk in Several Asia-Pacific Countries. Derek M, Tsai FJ, Kim J, Tejamaya M, Putri V, Muto G1, Reginald A, Phanprasit W, Granadillos N, Bt Zainal Farid M, Capule CQ, Lin YW, Park J, Chen RY, Lee KH, Park J, Hashimoto H, Yoon C, Padungtod C, Park DU: Saf Health Work 2021/12; 12 (4): 530-5. (•“Ą@„1: 1‰qś)

110052. [Œ´’˜] A case control study of occupation and cardiovascular disease risk in Japanese men and women. Fukai K, Furuya Y, Nakazawa S, Kojimahara N, Hoshi K1, Toyota A, Tatemichi M: Sci Rep 2021/12; 11 (1): 23983. (Ż@‰Ŕ–F1: 1‰qś)

110053. [Œ´’˜] Depressive and anxiety symptoms among Japanese cancer survivors: Japan cancer survivorship research project. Endo M, Matsui K, Akaho R, Mitsui K, Yan Y, Imai Y, Ueda Y, Muto G1, Deshpande GA, Terao Y, Takeda S, Saito M, Hayashi K, Nishimura K, Tanigawa T: BMC Cancer 2022/2; 22 (1): 134. (•“Ą@„1: 1‰qś)

110054. [Œ´’˜] Occupational physical activity differentially affects the risk for developing later-onset Crohn's disease and ulcerative colitis among middle-aged and older populations. Furuya Y, Fukai K, Nakazawa S, Kojimahara N, Hoshi K1, Toyota A, Tatemichi M: Scand J Gastroenterol 2022/2; 57 (2): 206-13. (Ż@‰Ŕ–F1: 1‰qś)

110055. [Œ´’˜] Mortality risk in older Japanese people based on self-reported dyslipidemia treatment and socioeconomic status: The JAGES cohort study. Katsuyama Y, Kondo K, Kojima M, Kamiji K, Ide K, Iizuka G, Muto G1, Uehara T, Noda K, Ikusaka M: Prev Med Rep 2022/3; 27: 101779. (•“Ą@„1: 1‰qś)

110056. [Œ´’˜] 2-mercaptobenzothiazole generates ƒÁ-H2AX via CYP2E1-dependent production of reactive oxygen species in urothelial cells. Qi Y1, Toyooka T, Horiguchi H2, Koda S, Wang RS: J Biochem Mol Toxicol 2022/6; 36 (6): e23043. doi: 10.1002/jbt.23043. Epub 2022 Mar 13. (Yonggang Qi1, –xŒű•ş„2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‰qś)

120002. [Œ´’˜] Œłż|‰şż\‘˘ (ż•‰E‹Ć–ąˆĎ‘ő) ‚É‹Nˆö‚ˇ‚é‘ć3ŽŸŽY‹Ć‚Ě˜J“­ˆŔ‘S‰qś‚̉ۑč‚Ć‰đŒˆ‚ÖŒü‚Ż‚˝“W–]|IT‚¨‚ć‚Ńˆă—Ă‹Ć‚É‚¨‚Ż‚éŽŔ‘Ô’˛¸. •“Ą@„1, Ź“ˆŒ’ˆę, ŽRč—Fä, ‰““ĄŒšŽ÷, Îˆä—“Ţ, •Ÿ“c@—m, ‘ĺX—R‹I1, ‰ĄŽR˜am (1‰qś): ŽY‹ĆˆăŠwƒWƒƒ[ƒiƒ‹ 2021/5; 44 (3): 90-7.

220001. [€Œ´’˜] Œ’fŒăŽó—Ís“Ž—\‘ރ‚ƒfƒ‹‚ĚŠJ”­|Œ’fEƒŒƒZƒvƒgƒrƒbƒOƒf[ƒ^‚ÉAI ‚đ“K—p‚ˇ‚鎎‚݁|. •“Ą@„1, •Đ‰Ş—ČŽq, ‘ĺ–î‚ß‚Ž‚Ý, Œă“Ą@‰ˇ, •Ÿ“c@—m, ‰““ĄŒšŽ÷, ‰ĄŽR˜am (1‰qś): ŽY‹ĆˆăŠwƒWƒƒ[ƒiƒ‹ 2021/7; 44 (4): 64-8.

522006. [uŔ]y˜AÚ: Eˆć‚ŐVŒ^ƒRƒƒiƒEƒCƒ‹ƒX‚ÉŒü‚Ť‡‚¤…IzEˆćŽş“ŕ‹óŠÔ‚̐VŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´őÇƒNƒ‰ƒXƒ^[‘jŽ~‚đ–Ú“I‚Ć‚ľ‚˝3–§’č—ʉť‚ƉŽ‹‰ť‚ĚŽŽ‚݁|Žş“ŕCO2”Z“x‚𐄒股‚銡‹CƒVƒ~ƒ…ƒŒ[ƒ^[‚̍\’z‚ĆŽŔŘ|. ꎓĄG”V, •“Ą@„1, ‰Ô—˘^“š, ‹´–{°’j (1‰qś): ŽY‹ĆˆăŠwƒWƒƒ[ƒiƒ‹ 2021/5; 44 (3): 35-41.

522007. [uŔ]y“ÁW: ‚Ş‚ńŠłŽŇ‚̏A˜JŒp‘ą`With-cancer, Post-cancer`zŽY‹Ćˆă‚Ć‚ľ‚Ä‚Ç‚¤ŠÖ‚í‚é‚Š: ŽĺŽĄˆă‚Ć‚Ě˜AŒg‚ÉŒü‚Ż‚˝Eę‚Ă‚­‚č. •“Ą@„ (‰qś): ŒŽŠ§•Ű’c˜A 2021/6; 1347: 29-35.

522008. [uŔ]y˜AÚ: <Œ’N> ‘ć1‰ń ‚Ç‚¤i‚ß‚é?—ź—§Žx‰‡z—ź—§Žx‰‡‚đ“­‚­l‚ĚŒ’NŠë‹@ŠÇ—‚Ć‚ľ‚Ä‘¨‚Ś, ŽŔ‘H‚ˇ‚鍑“ŕŠO‚Ě“ŽŒü. •“Ą@„ (‰qś): ˆŔ‘S‚ĆŒ’N 2022/1; (1ŒŽ): 40-2.

522009. [uŔ]y˜AÚ: <Œ’N> ‘ć2‰ń ‚Ç‚¤i‚ß‚é?—ź—§Žx‰‡z‚Ş‚ńƒŠƒeƒ‰ƒV[‚ĆŠé‹ĆŠˆ“Ž‚ĚŽ‘ą‰Â”\Ť‚đ‚‚ß‚é. •“Ą@„ (‰qś): ˆŔ‘S‚ĆŒ’N 2022/2; (2ŒŽ): 35-7.

522010. [uŔ]y˜AÚ: <Œ’N> ‘ć3‰ń ‚Ç‚¤i‚ß‚é?—ź—§Žx‰‡z—ź—§Žx‰‡‚đŽx‚Ś‚é‚˝‚ß‚ĚŽĐ“ŕŠO‚ĚƒŠƒ\[ƒXŠˆ—p. •“Ą@„ (‰qś): ˆŔ‘S‚ĆŒ’N 2022/3; (3ŒŽ): 46-8.

540009. [‚ť‚Ě‘ź (Plain language summary–|–ó)] ‹Ö‰ŒŽĄ—Ă‚É‚Š‚Š‚é”ď—p‚đŒ¸Šz‚ˇ‚é‰î“ü‚Í, ‹Ö‰Œ—Ś, ‹Ö‰Œ‚ĚŽŽ‚Ý, ŽĄ—Ă‚Ě—˜—p‚đ‘‰Á‚ł‚š‚é‚Š? (Healthcare financing systems for increasing the use of tobacco dependence treatment). –|–ó: Ż@‰Ŕ–F (‰qś), ŠÄ–ó: ´Œ´N‰î: Cochrane Database of Systematic Reviews 2017, Issue 9. Art. No.: CD004305. DOI: 10.1002/14651858.CD004305.pub5. 2021/6; https://www.cochrane.org/ja/CD004305/TOBACCO_jin-yan-zhi-liao-nikakarufei-yong-wojian-e-surujie-ru-hajin-yan-lu-jin-yan-noshi-mizhi-liao-noli[2021.06.27
540010. [‚ť‚Ě‘ź (Plain language summary–|–ó)] Â”NŠú‚Ě‹Ö‰Œ‚đŽx‰‡‚ˇ‚é‹Ö‰ŒƒvƒƒOƒ‰ƒ€‚Í‚ ‚é‚Š? (Tobacco cessation interventions for young people [Fanshawe TR, Halliwell W, Lindson N, Aveyard P, Livingstone-Banks J, Hartmann-Boyce J]). –|–ó: Ż@‰Ŕ–F (‰qś), ŠÄ–ó: ´Œ´N‰î, 2021/6/29.

540011. [‚ť‚Ě‘ź (Plain language summary–|–ó)] ‹Ö‰Œ‚đƒTƒ|[ƒg‚ˇ‚é–ň: ƒŒƒrƒ…[‚ĚŠT—v (Pharmacological interventions for smoking cessation: an overview and network meta]analysis). –|–ó: Ż@‰Ŕ–F (‰qś), ŠÄ–ó: ´Œ´N‰î: Cochrane Database Syst Rev. 2013 May 31;(5):CD009329. DOI: 10.1002/14651858.CD009329.pub2. 2021/7; https://www.cochrane.org/ja/CD009329/TOBACCO_jin-yan-wosapotosuruyao-rebiyunogai-yao.

540012. [‚ť‚Ě‘ź (Plain language summary–|–ó)] ƒ}ƒXƒƒfƒBƒA‚É‚ć‚éƒLƒƒƒ“ƒy[ƒ“ (ƒeƒŒƒr, ƒ‰ƒWƒI, V•ˇ, ŠĹ”Â, ŹűŽq) ‚Í, ŽáŽŇ‚ރ^ƒoƒR‚đ‹z‚˘Žn‚ß‚é‚Ě‚đ—}Ž~‚Ĺ‚Ť‚é‚Š? (Mass media interventions for preventing smoking in young people). –|–ó: Ż@‰Ŕ–F (‰qś), ŠÄ–ó: ´Œ´N‰î: Cochrane Database of Systematic Reviews 2017, Issue 6. Art. No.: CD001006.DOI: 10.1002/14651858.CD001006.pub3. 2021/7; https://www.cochrane.org/ja/CD001006/TOBACCO_masumedeianiyorukiyanpenterebirazioxin-wen-kan-ban-xiao-ce-zi-haruo-zhe-gatabakowoxi-ishi-merunowoyi.

540013. [‚ť‚Ě‘ź (Plain language summary–|–ó)] ‹i‰ŒŽŇ‚Ş, ƒ^ƒoƒR‚đ‹z‚¤–{”‚đŒ¸‚ç‚ľ‚˝‚č, ˆŮ‚Č‚éƒ^ƒoƒRť•i‚đŽg—p‚ˇ‚é‚ą‚Ć‚Ĺ, ƒ^ƒoƒR‚ĚŠQ‚đŒ¸‚ç‚ˇ‚ą‚Ć‚Ş‚Ĺ‚Ť‚é‚Š? (Interventions to reduce harm from continued tobacco use). –|–ó: Ż@‰Ŕ–F (‰qś), ŠÄ–ó: ´Œ´N‰î: Cochrane Database of Systematic Reviews 2016, Issue 10. Art. No.: CD005231.DOI: 10.1002/14651858.CD005231.pub3. 2021/7; https://www.cochrane.org/ja/CD005231/TOBACCO_chi-yan-zhe-gatabakowoxi-uben-shu-wojian-rasitariyi-narutabakozhi-pin-woshi-yong.

540014. [‚ť‚Ě‘ź (Œ¤‹†•ń‘)]y—ߘa3”N“xŽY‹ĆˆăŠw’˛¸Œ¤‹†•ŹzVŒ^ƒRƒƒiƒEƒCƒ‹ƒX“™‚̐ś•¨Šw“I”˜˜I‘΍ô‚Ć‚ľ‚Ä‚Ě, ‚ƒŠƒXƒNEˆć (ˆă—ÁEˆůHE‹ťs‹Ć) ‚̍ě‹ĆŠÂ‹ŤŠÇ—‚É‚¨‚Ż‚é, Žş“ŕCO2”Z“x‚đŠî‘b‚Ć‚ˇ‚éŽw•W‚Ě’ńŒžE‘Ă“–ŤŒŸŘ‚Č‚ç‚Ń‚É‘ÎôŽŔ‘H‚É‚ˇ‚éƒ}ƒlƒWƒƒ“ƒgƒVƒXƒeƒ€‚̍\’z. •“Ą@„ (‰qś): —ߘa3”N“xŽY‹ĆˆăŠw’˛¸Œ¤‹†•ŹŒ¤‹†•ń‘ 2022/3.

540015. [‚ť‚Ě‘ź (Œ¤‹†•ń‘)]y˜JĐŽž•a—Տ°Œ¤‹†Ž–‹Ć”ď•â•‹ŕzŽ––ąŠ‰qśŠî€‹K‘Ľ‚ÉŠÖ‚ˇ‚錤‹†|‘Ă“–Ť‚ƍ‘ŰŠî€‚Ć‚Ě’˛˜a|. •“Ą@„1, ‰Ô—˘^“š, ‹´–{°’j, ꎓĄG”V, ’†‘ş—T”V, ‰ĄŽR˜am, ź•˝@_, ‰““ĄŒšŽ÷ (1‰qś):y˜JĐŽž•a—Տ°Œ¤‹†Ž–‹Ć”ď•â•‹ŕz—ߘa3”N“x‘Š‡E•Ş’SŒ¤‹†•ń‘ 2022/3.

540016. [‚ť‚Ě‘ź (Œ¤‹†•ń‘)]y˜JĐŽž•a—Տ°Œ¤‹†Ž–‹Ć”ď•â•‹ŕzŽ––ąŠ‰qśŠî€‹K‘Ľ‚ÉŠÖ‚ˇ‚錤‹†|‘Ă“–Ť‚ƍ‘ŰŠî€‚Ć‚Ě’˛˜a|. •“Ą@„1, ‰Ô—˘^“š, ‹´–{°’j, ꎓĄG”V, ’†‘ş—T”V, ‰ĄŽR˜am, ź•˝@_, ‰““ĄŒšŽ÷ (1‰qś):y˜JĐŽž•a—Տ°Œ¤‹†Ž–‹Ć”ď•â•‹ŕz—ߘaŒł”N-3”N“x‘‡Œ¤‹†•ń‘ 2022/3.

[’˜@‘]

620004. [Šwp‘ (•Ş’SŽˇ•M)]yƒvƒ‰ƒCƒ}ƒŠEƒPƒA‚Ě—˜_‚ĆŽŔ‘Hz‘ć12Í ŽĄ—Ă‚ĆŽdŽ–‚Ě—ź—§Žx‰‡@65. ŠłŽŇ‚ĚŽĄ—Ă‚ĆŽdŽ–‚Ě—ź—§Žx‰‡ (‘˜_E‘O•Ň)@ŽdŽ–‚âEę‚đl—ś‚ľ‚˝ŽĄ—Ă‚Ě’ńŽŚ‚Í, “­‚­ŠłŽŇ‚ւ̎Љď“Iˆ•űⳂƂȂé, p.130-1. •“Ą@„ (‰qś), ŠÄC: “ú–{ƒvƒ‰ƒCƒ}ƒŠEƒPƒA˜A‡Šw‰ď, •Ň: ‰Á“ĄŒőŽ÷, ŠěŁŽçl, ’ˇ—ä—RˆßŽq, •ŸˆäŒc‘ž˜Y, ŽO‰Y‘ž˜Y, ‹{’nƒˆę˜Y, ŽR–{@—S, ˆăŽ–V•ńŽĐ, “Œ‹ž, 2021/10”­s.

620005. [Šwp‘ (•Ş’SŽˇ•M)]yƒvƒ‰ƒCƒ}ƒŠEƒPƒA‚Ě—˜_‚ĆŽŔ‘Hz‘ć12Í ŽĄ—Ă‚ĆŽdŽ–‚Ě—ź—§Žx‰‡@66. ŠłŽŇ‚ĚŽĄ—Ă‚ĆŽdŽ–‚Ě—ź—§Žx‰‡ (‘˜_EŒă•Ň)@ˆă—Ă—pŒę‚đŽdŽ–‚̍ě‹Ć‚ĚŒž—t‚É–|–ó‚ľ‚˝ŽĺŽĄˆăˆÓŒŠ‘‚ŞŒŽ. ƒvƒ‰ƒCƒ}ƒŠEƒPƒA‚Ě—˜_‚ĆŽŔ‘H, p1.32-3. •“Ą@„ (‰qś), ŠÄC: “ú–{ƒvƒ‰ƒCƒ}ƒŠEƒPƒA˜A‡Šw‰ď, •Ň: ‰Á“ĄŒőŽ÷, ŠěŁŽçl, ’ˇ—ä—RˆßŽq, •ŸˆäŒc‘ž˜Y, ŽO‰Y‘ž˜Y, ‹{’nƒˆę˜Y, ŽR–{@—S, ˆăŽ–V•ńŽĐ, “Œ‹ž, 2021/10”­s.

620006. [Šwp‘ (•Ş’SŽˇ•M)]yĄ“ú‚ĚŽĄ—ĂŽwj2022”N”Ł@Ž„‚Í‚ą‚¤ŽĄ—Ă‚ľ‚Ä‚˘‚éz‘˜_@2 ’†“ŐŤŽžŠł@ƒJƒhƒ~ƒEƒ€’†“Ĺ, p.1120-1. –xŒű•ş„ (‰qś), ‘•ŇW: •ŸˆäŽŸ–î, ‚–؁@˝, ŹŽşˆęŹ, ˆăŠw‘‰@, “Œ‹ž, 2022/1”­s.

620007. [Šwp‘ (•Ş’SŽˇ•M)]y‘–Ż‚̉h—{”’‘ 2021”N“x”Ł@“ú–{‚̐H‚Ɖh—{‚Ş‘n‚éVŽž‘ă‚ĚŒ’NzĄ‘ć2•” “ú–{l‚đŽć‚芪‚­HŠÂ‹Ť@‘ć1Í HŽ–ŠÂ‹Ť‚É‚¨‚Ż‚é—ǍD‚ČŠˇ‹C‚Ƃ́|ƒGƒAƒƒ]ƒ‹Š´ő‚Ě—\–h‚Ć, ˆŔ‘SEˆŔS‚ȉďH‚ĚŽŔŒť‚ÉŒü‚Ż‚ā|, p.49-64. •“Ą@„ (‰qś), ŠÄC: ’†‘ş’šŽŸ, “ú–{ˆă—ĂŠé‰ć, “Œ‹ž, 2022/1”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713004. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Current guidelines and strategies against COVID-19 clusters at workplaces in Japan - a model for evaluating 3Cs using indoor exhaled CO2 prediction system. Muto G1: The 12th IOHA International Scientific Conference (2021/9/11-15), WebŠJĂ. (•“Ą@„1: 1‰qś)

722012. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) “ű‚Ş‚ńŠłŽŇ‚ւ́uŽĐ‰ď“Iˆ•űⳁv‚̍‘“ŕŠO‚Ě“ŽŒü|A˜JˆÓŒŠ‘ěŹŽx‰‡ƒ\ƒtƒg‚É‚ć‚é, ˆăŽt‹Ć–ąŒyŒ¸‚Əˆ•űƒXƒLƒ‹‚Ě•W€‰ť|. •“Ą@„ (‰qś): ‘ć29‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2021/7/1-3), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722013. [Šw‰ď (‘S‘)] (‹¤ĂƒZƒ~ƒi[) ŒÄ‹zŠíƒAƒŒƒ‹ƒM[‚⊴őÇ‚đ—\–h‚ˇ‚銡‹C: 3–§•]‰żƒZƒ~ƒi[. •“Ą@„1, O“c—Ę“ń (1‰qś): ‘ć32‰ń“ú–{‰uŠw‰ďŠwp‘‰ď (2022/1/26-28), WebŠJĂ.

722014. [Šw‰ď (‘S‘)] (YIAƒZƒbƒVƒ‡ƒ“) “œ”A•aŠłŽŇ‚É‚¨‚Ż‚ét‘Ÿ‚Ě”­Ç—\–h‚đ–Ú“I‚Ć‚ľ‚˝śŠˆKŠľ‰î“ü”ď—p‘ÎŒř‰Ę•ŞÍ. —é–Ř—T‘ž1, Ż@‰Ŕ–F2, ”’Šâ@Œ’, •Ÿ“c@Œh (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‰qś): ‘ć12‰ń“ú–{t‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ďŠwpW‰ď (2022/3/26-27), ‰ŞŽR (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723055. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚—î‚ĚŠÖßƒŠƒEƒ}ƒ`ŠłŽŇ‚ĚŒ’NŽő–˝‰„L‚đ‚ß‚´‚ľ‚˝, ŽĐ‰ďŽQ‰Á‚ĚŽŔ‘Ô‚Ć, ”F’m‹@”\’ቺ/‚¤‚ÂŒXŒü‚Ć‚ĚŠÖ˜A•ŞÍ. •“Ą@„1, •‘ň”ü’qŽq, Ź“ˆr‹v, ‰i’J—SŽq, Ź“ˆ‰ë‘ă (1‰qś): ‘ć65‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď‘‰ďEŠwpW‰ď (2021/4/26-28), WebŠJĂ.

723056. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŒÄ‹CCO2‚ĆŽş“ŕ—ąŽq“Ž‘Ô—\‘Ş‚É‚ć‚é3–§‚̉Ž‹‰ť]COVID-19ƒNƒ‰ƒXƒ^[ƒŠƒXƒN•]‰ż. •“Ą@„1, ‹´–{°’j, ˜a“ckŽĄ, ‰ĄŽR˜am, ‰““ĄŒšŽ÷, ‘ĺX—R‹I1, –xŒű•ş„1, ‰Ô—˘^“š (1‰qś): ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2021/5/18-21), ź–{ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723057. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —LŠQ‹Ć–ą‚Ö‚Ě]Ž–ŠúŠÔ‚Ć‚Ş‚ńœëŠł‚ĚŠÖ˜A|‘S‘˜JĐ•a‰@•aE—đ’˛¸ƒf[ƒ^ƒx[ƒX‚ć‚č|. [ˆäq‘ž, ŒĂ‰Ž—CŽq, ’†ŕVËŽq, Ź“‡Œ´“TŽq, Ż@‰Ŕ–F1, –L“cÍG, —§“ššK (1‰qś): ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2021/5/18-21), ź–{ (ƒnƒCƒuƒŠƒbƒhŠJĂ), ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ďu‰‰W ŽY‹Ć‰qśŠwŽGŽ 2021/4; 63 (—ŐŽž‘Š§†): 335.

723058. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “œ”A•aŠłŽŇ‚É‚¨‚Ż‚é“œ”A•a‡•šÇ‚ĚœëŠł‚ƐE‹Ć—đ‚Ć‚ĚŠÖ˜A|‘S‘˜JĐ•a‰@•aE—đƒf[ƒ^ƒx[ƒX‚ć‚č|. ’†ŕVËŽq, [ˆäq‘ž, ŒĂ‰Ž—CŽq, Ź“‡Œ´“TŽq, Ż@‰Ŕ–F1, —§“ššK, –L“cÍG (1‰qś): ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2021/5/18-21), ź–{ (ƒnƒCƒuƒŠƒbƒhŠJĂ), ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ďu‰‰W ŽY‹Ć‰qśŠwŽGŽ 2021/4; 63 (—ŐŽž‘Š§†): 458.

723059. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’×ᇐŤ‘ĺ’°‰Š‚̐E‹Ć—đ‚É‚¨‚Ż‚é”­ÇƒŠƒXƒN‚ĚŒŸ“˘|‘S‘˜JĐ•a‰@•aE—đƒf[ƒ^ƒx[ƒX‚ć‚č|. ŒĂ‰Ž—CŽq, [ˆäq‘ž, ’†ŕVËŽq, Ź“‡Œ´“TŽq, Ż@‰Ŕ–F1, –L“cÍG, —§“ššK (1‰qś): ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2021/5/18-21), ź–{ (ƒnƒCƒuƒŠƒbƒhŠJĂ), ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ďu‰‰W ŽY‹Ć‰qśŠwŽGŽ 2021/4; 63 (—ŐŽž‘Š§†): 460.

723060. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽY‹Ć‰qś‹Zp•”‰ďŒ¤C‰ď: ƒVƒ~ƒ…ƒŒ[ƒ^[‚đ—p‚˘‚˝ŽŔ—á. ŽR“ŕ•‹I, ꎓĄG”V, ŽR–ě—DŽq, •“Ą@„1, ‹MŽuF—m, ’†Œ´_•F, ’†‘ş@C, ”Ń“c—T‹MŽq, ‹´–{°’j (1‰qś): ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2021/5/18-21), ź–{ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723061. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ĺŠw•a‰@—ź—§Žx‰‡ŠO—ˆ‚ĚŠJÝ]‚Ş‚ńE“ď•aEzŠÂŠí‚Ě‘˝EŽí˜AŒg‚É‚ć‚éŽć‚č‘g‚Ý (‘ć2•ń). ‘ĺX—R‹I1, •“Ą@„1, ‘â—R”üŽq2, ś‰E“c“N2, –xŒű•ş„1, ’ç@–žƒ3 (1‰qś, 2ƒg[ƒ^ƒ‹ƒTƒ|[ƒgƒZ, 3ŒöO‰qś): ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2021/5/18-21), ź–{ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723062. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) COVID-19‘΍ô‚ÉŠˆ—p‰Â”\‚ČŠˇ‹CƒVƒ~ƒ…ƒŒ[ƒ^[‚ĚŠJ”­ (‘ćˆę•ń) Šî–{“I‚ȍl‚Ś•ű. ‹MŽuF—m, ’†Œ´_•F, ’†‘ş@C, ŽR“ŕ•‹I, •“Ą@„1, ”Ń“c—T‹MŽq, ꎓĄG”V, ŽR“cŒ›ˆę, ŽR–ě—DŽq, ‹´–{°’j (1‰qś): ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2021/5/18-21), ź–{ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723063. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) COVID-19‘΍ô‚ÉŠˆ—p‰Â”\‚ČŠˇ‹CƒVƒ~ƒ…ƒŒ[ƒ^[‚ĚŠJ”­ (‘ć“ń•ń) ŽŔ‘Ş’l‚Ě”äŠr. ꎓĄG”V, ŽR“ŕ•‹I, •“Ą@„1, ‹MŽuF—m, ’†Œ´_•F, ’†‘ş@C, ”Ń“c—T‹MŽq, ŽR–ě—DŽq, ‹´–{°’j (1‰qś): ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2021/5/18-21), ź–{ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723064. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Eˆć‚ĚCOVID-19—\–h‘΍ôƒRƒ“ƒTƒ‹ƒe[ƒVƒ‡ƒ“-s­EŽY‹Ć•ŰŒ’EŠÂ‹Ť‰qś‚̐V‚˝‚Č˜AŒg. Î‹´÷Žq, •“Ą@„1, ‰ĄŽR˜am, ‰““ĄŒšŽ÷, Îˆä—“Ţ, ‘ĺ–î‚ß‚Ž‚Ý, ‘ĺX—R‹I1, ’†‘ň@–L, Œü]—F—C, ‹´–{°’j, ˜a“ckŽĄ (1‰qś): ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2021/5/18-21), ź–{ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723065. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –F‘°ƒAƒ~ƒ“—ŢMOCA‚Ě•ĎˆŮ‘Ě×–EŠ”ŒQDT40‚đ—p‚˘‚˝DNAC•œŒo˜H‚Ě’Tő. Ź—эš•ä, ŒV@‰i„1, –L‰Ş’BŽm, ‰¤@ś, •“crˆę, b“c–ÎŽ÷ (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2021/5/18-21), ź–{ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723066. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) CPX (S”x‰^“Ž•‰‰×ŽŽŒą) Ž{sŽž‚Ě“–‰@‚Ĺ‚ĚŠ´ő—\–h‘΍ô. ’†‘ş“ލ÷, Ż@Œ¤ˆę, ŽRŠÝ‰ÄŽq, Ź“cŒúŽq, ŽR“c”ü’qŽĄ, ‚‹´@–L, –Ń“ŕŠ°Žq, •“Ą@„1, ‹´–{°’j (1‰qś): ‘ć27‰ń“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ďŠwpW‰ď (2021/6/19-20), –‹’Ł (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723067. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒIƒ‹ƒgƒtƒFƒjƒŒƒ“ƒWƒAƒ~ƒ“‚ĚŽOŽŸŒł”畆’~ĎŤ‚Ćin vitroˆâ“`“ŐŤ‚ÉŠÖ‚ˇ‚錤‹†. ŒV@‰i„1, –L‰Ş’BŽm, ”–Ř—T˜CŽ÷, ‰¤@ś, b“c–ÎŽ÷, –xŒű•ş„2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‰qś): ‘ć48‰ń“ú–{“ŐŤŠw‰ďŠwp”N‰ď (2021/7/7-9), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723068. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒIƒ‹ƒgƒtƒFƒjƒŒƒ“ƒWƒAƒ~ƒ“‚̔畆’~ĎŤ‚Ćˆâ“`“ŐŤ‚ÉŠÖ‚ˇ‚錤‹†. ŒV@‰i„1, –L‰Ş’BŽm, ”–Ř—T˜CŽ÷, ‰¤@ś, b“c–ÎŽ÷, –xŒű•ş„2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‰qś): “ú–{ŠÂ‹Ť•ĎˆŮŒ´ƒQƒmƒ€Šw‰ď‘ć50‰ń‹L”O‘ĺ‰ď (2021/11/1-2), ‰Ą{‰ę (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723069. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒƒ^EƒAƒiƒŠƒVƒX‚É‚ć‚éFITƒJƒbƒgƒIƒt’l‚ĚŒŸ“˘. ‘ü–ě•q_, Ž›ŕVW•F, ˛X–ؐ´Žő, •ĐŽR‹M•ś, ×–ěŠo‘ă, Ż@‰Ŕ–F1, ˆ˘•”_ˆę˜Y, ŕ_“‡‚ż‚ł‚Ć (1‰qś): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/4-7), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{Á‰ťŠí‚Ş‚ńŒŸfŠw‰ďŽGŽ 2021/10; 59 (Suppl 2): 665.

723070. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) VŒ^ƒRƒƒiƒEƒBƒ‹ƒXŠ´ő—\–h‘΍ôƒRƒ“ƒTƒ‹ƒe[ƒVƒ‡ƒ“˜AŒg: Žş“ŕƒNƒ‰ƒXƒ^[‰ť‚Ě‘jŽ~ •“Ą@„1, ‰Ô—˘^“š, ‰ĄŽR˜am, ‰““ĄŒšŽ÷, •‘ň”ü’qŽq, ‘ĺX—R‹I1, ˜a“ckŽĄ (1‰qś): ‘ć80‰ń“ú–{ŒöO‰qśŠw‰ď‘‰ď (2021/12/21), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723071. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “ď•a–@Ž{s‘OŒă‚Ěƒx[ƒ`ƒFƒbƒg•aˆă—Î󋋎҉uŠw‘œ‚̕ωť. •‘ň”ü’qŽq, ˆî—t@—T, •“Ą@„1, ‰ĄŽR˜am (1‰qś): ‘ć80‰ń“ú–{ŒöO‰qśŠw‰ď‘‰ď (2021/12/21-23), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723072. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œ’NŒo‰c‚Í, Œ’fŒăŽó—Ís“Ž‚𑣐i‚ˇ‚é: ‹@ŠBŠwK‚đ—p‚˘‚˝, Eˆć50–œls“Ž—\‘ރ‚ƒfƒ‹. •“Ą@„1, •Đ‹Ë—ČŽq (1‰qś): ‘ć32‰ń“ú–{‰uŠw‰ďŠwp‘‰ď (2022/1/26-28), WebŠJĂ.

723073. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽŠ—§‚—îŽŇ‚É‚¨‚Ż‚éŠÖßƒŠƒEƒ}ƒ`‚̐f’f‚ĆƒtƒŒƒCƒ‹, ŽĐ‰ď“I”wŒi‚ÉŠÖ‚ˇ‚錟“˘: JAGES‰Ą’fŒ¤‹†. Ź“ˆ‰ë‘ă, “n糗Ǒž, ˆŔ‰ŞŽŔ‰ŔŽq, ’|“ŕŒ¤Žž, Ö“Ą@–Ż, Ž›•”Œ’Ć, Ź“ˆr‹v, ”ö“‡r”V, •“Ą@„1, ‘ĺŠÖšˆË, ‹ß“ĄŽ‘Ľ (1‰qś): ‘ć32‰ń“ú–{‰uŠw‰ďŠwp‘‰ď (2022/1/26-28), WebŠJĂ.

723074. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “ď•a–@Ž{s‘OŒă‚Ě“Vávገă—Î󋋎҉uŠw‘œ‚̕ωť. •‘ň”ü’qŽq, “V’J‰ës, ŽRă@~, ’r“cŽu›|, HŽR^Žu, •“Ą@„1, ‰ĄŽR˜am (1‰qś): ‘ć32‰ń“ú–{‰uŠw‰ďŠwp‘‰ď (2022/1/26-28), WebŠJĂ.

723075. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’á”Z“x‰””˜˜I‚É‚ć‚é—Ł“űŒă‚ĚŽeƒ‰ƒbƒg‚Ě’ˆÓ—͒ቺ‚ĆŠC”n’†D,L-ƒZƒŠƒ“‚ւ̉e‹ż ‘ĺX—R‹I1, ăŒE—T“ń, ŠÖŞłŒb, ™’J‘PM, źěŠx‹v, Ź—Ń“Žq2, •“Ą@„1, ‰ĄŽR˜am, Šp“cłŽj, •ĐŞ^Ÿ, âV“ĄNş, ‹{–{“N–ç, ‰Á“Ą‚­‚ÝŽq, –{ŠÔ@_, –xŒű•ş„1 (1‰qś, 2—\–hˆăŠwŒn): ‘ć92‰ń“ú–{‰qśŠw‰ďŠwp‘‰ď (2022/3/21), WebŠJĂ.

723076. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽŠ‰ĆŽY•ÄŰŽć‚É‚ć‚čƒJƒhƒ~ƒEƒ€ŒoŒű”˜˜I‚đŽó‚Ż‚˝”_‹Ć]Ž–ŽŇ‚Ě11”NŠÔ‚̒ǐՒ˛¸ –xŒű•ş„1, ŹŒF‰xŽq, ‘ĺX—R‹I1, Ź—Ń“Žq2, ‘ĺ–ě’qŽq (1‰qś, 2—\–hˆăŠwŒn): ‘ć92‰ń“ú–{‰qśŠw‰ďŠwp‘‰ď (2022/3/21), WebŠJĂ.

723077. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘S‘˜JĐ•a‰@•aE—đƒf[ƒ^ƒx[ƒX‚É‚¨‚Ż‚éE‹ĆŤg‘ĚŠˆ“Ž|SŒŒŠÇŽžŠł•Ň (‰ď‹c˜^). ŒĂ‰Ž—CŽq, [ˆäq‘ž, ’†ŕVËŽq, Ź“‡Œ´“TŽq, Ż@‰Ŕ–F1, –L“cÍG, —§“ššK (1‰qś): ‘ć92‰ń“ú–{‰qśŠw‰ďŠwp‘‰ď (2022/3/21-23), WebŠJĂ, “ú–{‰qśŠwŽGŽ 2022/3; 77 (Suppl): S212.

723078. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘S‘˜JĐ•a‰@•aE—đƒf[ƒ^ƒx[ƒX‚É‚¨‚Ż‚éE‹ĆŤg‘ĚŠˆ“Ž|‚Ş‚ń•Ň (‰ď‹c˜^). [ˆäq‘ž, ŒĂ‰Ž—CŽq, ’†ŕVËŽq, Ź“‡Œ´“TŽq, Ż@‰Ŕ–F1, –L“cÍG, —§“ššK (1‰qś): ‘ć92‰ń“ú–{‰qśŠw‰ďŠwp‘‰ď (2022/3/21-23), WebŠJĂ, “ú–{‰qśŠwŽGŽ 2022/3; 77 (Suppl): S 213.

732005. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) H“cŒ§‚ĚƒJƒhƒ~ƒEƒ€‰˜ő’nˆć‚É‚¨‚Ż‚é•Äě”_‰Ć‚ĚŒoŒűƒJƒhƒ~ƒEƒ€”˜˜I‚Ć‚ť‚ĚŒ’N‰e‹ż. –xŒű•ş„ (‰qś): ƒƒ^ƒ‹ƒoƒCƒIƒTƒCƒGƒ“ƒXŒ¤‹†‰ď2021 (2021/10/27), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733012. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ’nˆćƒNƒŠƒjƒbƒN”­”MŠO—ˆ‚Ĺ‚Ěƒhƒ‰ƒCƒuƒXƒ‹[PCRf—Ă‚É‚¨‚Ż‚銈—p. •“Ą@„ (‰qś): ‘ć1‰ń’Žfƒf[ƒ^Œ¤‹†‰ď (2021/4/9), WebŠJĂ.

733013. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) –F‘°ƒAƒ~ƒ“—Ţ‚É‚ć‚éDNA‘š‚ɂ‚˘‚Ä. ‰¤@ś, –öę—RŠG, ŒV@‰i„1, –L‰Ş’BŽm (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć48‰ńŽY‹Ć’†“ŁEś•¨Šw“Iƒ‚ƒjƒ^ƒŠƒ“ƒOŒ¤‹†‰ď (2021/10/2), WebŠJĂ.

733014. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ’á”Z“x‰””˜˜I‚É‚ć‚é—Ł“űŒă‚ĚŽeƒ‰ƒbƒg‚Ě’ˆÓ—͒ቺ‚ւ̉e‹ż. ‘ĺX—R‹I1, ăŒE—T“ń, ™’J‘PM, źěŠx‹v, Ź—Ń“Žq2, •“Ą@„1, ‰ĄŽR˜am, Šp“cłŽj, –xŒű•ş„1 (1‰qś, 2—\–hˆăŠwŒn): ƒƒ^ƒ‹ƒoƒCƒIƒTƒCƒGƒ“ƒXŒ¤‹†‰ď2021 (2021/10/28), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733015. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) UHC‘Ű“WŠJ‚ÉŒü‚Ż‚˝, Œ’NŒo‰c‚É‚ć‚鍑–ŻŠF•ŰŒŻ§“x‚Ě—LŒřŠˆ—pŠî”Ս\’z‚Ě•]‰ż‰đÍ: Beyond next health policy|a prediction model for maximizing UHC utizliation through healthy companies movement against NCDs in Japan. •“Ą@„1, ‰““ĄŒšŽ÷ (1‰qś): ‘ć28‰ńƒtƒ@ƒCƒU[ƒwƒ‹ƒXƒŠƒT[ƒ`ƒtƒH[ƒ‰ƒ€ (2021/12/11-12), WebŠJĂ.

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-110005. [Œ´’˜] Relationship between personal-sampled air lead and blood lead in low-lead-exposure workers in Japan to apply multiple regression models determining permissible air lead concentration. Ono A, Horiguchi H1: J Occup Health 2021/1; 63 (1): e12264. (–xŒű•ş„1: 1‰qś)

[Šw‰ďEŒ¤‹†‰ď“™]

'20-733001. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒVƒXƒeƒ}ƒeƒBƒbƒNƒŒƒrƒ…[/ƒƒ^ƒAƒiƒŠƒVƒX‚̍ě‚ç‚ę•ű. Ż@‰Ŕ–F (‰qś): NPO–@l“ú–{ˆăŠw}‘ŠŮ‹Ś‰ď (JMLA) 2020”N“x•a‰@•”‰ďŽĺĂŒ¤C‰ď (2021/3/6), WebŠJĂ, ‚mPO–@l“ú–{ˆăŠw}‘ŠŮ‹Ś‰ď 2020”N“x•a‰@•”‰ďŽĺĂŒ¤C‰ďuƒKƒCƒhƒ‰ƒCƒ“‚đ’m‚낤v´˜^W 2021/3; p.1.


ŒöO‰qśŠw

[Šwp˜_•ś]

110057. [Œ´’˜] Development and validation of the Japanese version of the team job crafting scale for nurses. Iida M, Watanabe K1, Imamura K, Sakuraya A, Asaoka H, Sato N, Nozawa K, Kawakami N: Res Nurs Health 2021/4; 44 (2): 329-43. (“n•Ó˜aL1: 1ŒöO‰qś)

110058. [Œ´’˜] Effect of smartphone-based stress management programs on depression and anxiety of hospital nurses in Vietnam: a three-arm randomized controlled trial. Imamura K, Tran TTT, Nguyen HT, Sasaki N, Kuribayashi K, Sakuraya A, Nguyen AQ, Bui TM, Nguyen QT, Nguyen NT, Nguyen KT, Nguyen GTH, Tran XTN, Truong TQ, Zhang MW, Minas H, Sekiya Y, Watanabe K1, Tsutsumi A1, Kawakami N: Sci Rep 2021/5; 11 (1): 11353. (“n•Ó˜aL1, ’ç@–žƒ1: 1ŒöO‰qś)

110059. [Œ´’˜] Adolescent Work Values and Drug Use in Adulthood: A Longitudinal Prospective Cohort Study. Takano A, Fukasawa M, Watanabe K1, Nishi S, Kawakami N: Subst Use Misuse 2021/6; 56 (10): 1483-92. (“n•Ó˜aL1: 1ŒöO‰qś)

110060. [Œ´’˜] Associations Between Personal Values and Work Engagement: A Cross-Sectional Study Using A Representative Community Sample. Sato N, Watanabe K1, Nishi D, Kawakami N: J Occup Environ Med 2021/6; 63 (6): e335-40. (“n•Ó˜aL1: 1ŒöO‰qś)

110061. [Œ´’˜] Associations between work-related stressors and QALY in a general working population in Japan: a cross-sectional study. Hidaka Y, Imamura K, Watanabe K1, Tsutsumi A1, Shimazu A, Inoue A, Hiro H, Odagiri Y, Asai Y, Yoshikawa T, Yoshikawa E, Kawakami N: Int Arch Occup Environ Health 2021/8; 94 (6): 1375-83. (“n•Ó˜aL1, ’ç@–žƒ1: 1ŒöO‰qś)

110062. [Œ´’˜] Association Between Adaptation of Management Philosophy and Mission Statement, and Work Engagement Among Japanese Workers: A 1-year Prospective Cohort Study in a Japanese Company. Eguchi H1, Inoue A1, Kachi Y1, Tsutsumi A1: J Occup Environ Med 2021/9; 63 (9): e601-4. (]Œű@Ž1, ˆäă˛b1, ‰Â’m—IŽq1, ’ç@–žƒ1: 1ŒöO‰qś)

110063. [Œ´’˜] Association between Urban Upbringing and Compulsive Internet Use in Japan: A Cross-Sectional, Multilevel Study with Retrospective Recall. Yasuma N, Nishi D, Watanabe K1, Ishikawa H, Tachimori H, Takeshima T, Umeda M, Kawakami N: Int J Environ Res Public Health 2021/9; 18 (18): 9890. (“n•Ó˜aL1: 1ŒöO‰qś)

110064. [Œ´’˜] Effectiveness of an Internet-Based Machine-Guided Stress Management Program Based on Cognitive Behavioral Therapy for Improving Depression Among Workers: Protocol for a Randomized Controlled Trial. Kawakami N, Imamura K, Watanabe K1, Sekiya Y, Sasaki N, Sato N, SMART-CBT Project Team: JMIR Res Protoc 2021/9; 10 (9): e30305. (“n•Ó˜aL1: 1ŒöO‰qś)

110065. [Œ´’˜] The Effect of Perceived Gratitude From Others on Work Engagement: A Cross-Sectional Study. Komase Y, Watanabe K1, Sasaki N, Kawakami N: J Occup Environ Med 2021/9; 63 (9): e592-5. (“n•Ó˜aL1: 1ŒöO‰qś)

110066. [Œ´’˜] Heterogeneity in cognitive disability after a major disaster: A natural experiment study. Shiba K, Daoud A, Hikichi H1, Yazawa A, Aida J, Kondo K, Kawachi I: Sci Adv 2021/10; 7 (40): eabj2610. (ˆř’n”Ž”V1: 1ŒöO‰qś)

110067. [Œ´’˜] Predictors associated with the mental health of Japanese male registered nurses: focusing on environments with many female registered nurses and female patients' refusal to accept nursing services from male registered nurses. Kudo Y, Toyoda T, Sugimoto N, Tsutsumi A1: J Rural Med 2021/10; 16 (4): 191-9. (’ç@–žƒ1: 1ŒöO‰qś)

110068. [Œ´’˜] Organizational Justice and Cognitive Failures in Japanese Employees: A Cross-Sectional Study. Inoue A, Eguchi H, Kachi Y1, Tsutsumi A1: J Occup Environ Med 2021/10; 63 (10): 901-6. (‰Â’m—IŽq1, ’ç@–žƒ1: 1ŒöO‰qś)

110069. [Œ´’˜] WORK-LIFE BALANCE IN THE CURRENT JAPANESE CONTEXT. Tsutsumi A1: International Journal of Person Centered Medicine 2021/10; 9 (4): 57-64. (’ç@–žƒ1: 1ŒöO‰qś)

110070. [Œ´’˜] Association of child's disability status with father's health outcomes in Japan. Dhungel B, Tsuguhiko K, Ochi M, Gilmour S, Kachi Y1, Takehara K: SSM Popul Health 2021/10; 16: 100951. (‰Â’m—IŽq1: 1ŒöO‰qś)

110071. [Œ´’˜] Association between sitting time at work and the onset of major depressive episode: a 1-year prospective cohort study using the Bayesian regression. Watanabe K1, Kawakami N: BMC Public Health 2021/10; 21 (1): 1960. (“n•Ó˜aL1: 1ŒöO‰qś)

110072. [Œ´’˜] Reliability and validity of the Chinese version of the New Brief Job Stress Questionnaire (New BJSQ) among workers in China. Hidaka Y, Watanabe K1, Imamura K, Tatha O, Kawakami N: Ind Health 2022/10; 60 (5): 407-19. doi: 10.2486/indhealth.2021-0027. Epub 2021 Nov 1. (“n•Ó˜aL1: 1ŒöO‰qś)

110073. [Œ´’˜] Prevalence of and associated factors for psychological distress among single fathers in Japan. Dhungel B, Kato T, Kachi Y1, Ochi M, Gilmour S, Takehara K: J Epidemiol 2021/10. doi: 10.2188/jea.JE20210273. Online ahead of print. (‰Â’m—IŽq1: 1ŒöO‰qś)

110074. [Œ´’˜] Reliability and Validity of the Japanese Version of the 12-Item Psychosocial Safety Climate Scale (PSC-12J). Inoue A, Eguchi H, Kachi Y1, McLinton SS, Dollard MF, Tsutsumi A1: Int J Environ Res Public Health 2021/12; 18 (24): 12954. (‰Â’m—IŽq1, ’ç@–žƒ1: 1ŒöO‰qś)

110075. [Œ´’˜] Determining whether periodic health checkups have any preventive effect on deterioration in health among middle-aged adults: A hazards model analysis in Japan. Oshio T, Tsutsumi A1, Inoue A: J Occup Health 2021/11; 63 (1): e12291. (’ç@–žƒ1: 1ŒöO‰qś)

110076. [Œ´’˜] Factors related to parenting stress among fathers of preschool children in Japan. Kachi Y1, Ochi M, Kato T, Otsuka M, Takehara K: Pediatr Int 2022/1; 64 (1): e15132. (‰Â’m—IŽq1: 1ŒöO‰qś)

110077. [Œ´’˜] Suggestions for new organizational-level item pools for the national Stress Check Program from management philosophy and mission statement: A qualitative study using unsupervised learning. Watanabe K1, Inoue A, Eguchi H, Iwata N, Odagiri Y, Tsutsumi A1: J Occup Health 2022/1; 64 (1): e12335. (“n•Ó˜aL1, ’ç@–žƒ1: 1ŒöO‰qś)

110078. [Œ´’˜] The Effect of the Imacoco Care Psychoeducation Website on Improving Psychological Distress Among Workers During the COVID-19 Pandemic: Randomized Controlled Trial. Imamura K, Sasaki N, Sekiya Y, Watanabe K1, Sakuraya A, Matsuyama Y, Nishi D, Kawakami N: JMIR Form Res 2022/3; 6 (3): e33883. (“n•Ó˜aL1: 1ŒöO‰qś)

110079. [Œ´’˜] Association between working overtime and psychological stress reactions in elementary and junior high school teachers in Japan: a large-scale cross-sectional study. Furihata R, Kuwabara M, Oba K, Watanabe K1, Takano N, Nagamine N, Maruyama Y, Ito N, Watanabe I, Tsubono K, Ikeda C, Sakamoto J: Ind Health 2022/3; 60 (2): 133-45. (“n•Ó˜aL1: 1ŒöO‰qś)

120003. [Œ´’˜]y“Á•Ę˜_•śzƒƒ“ƒ^ƒ‹ƒwƒ‹ƒX‘΍ô: Eˆć‚Ć’nˆć‚Ě˜AŒg‚ĚƒMƒƒƒbƒv‚đ–„‚ß‚é‚˝‚ß‚É. œAě‹ó”ü, XŒűŽŸ˜Y, Ň”ö‘ĺ‰ë, –ě‘ş—mŽq, –ě‘ş‹ąŽq, ‘ĺ•˝“N–ç, ˆÉ“ĄOl, ˆäă˛b, ’ç@–žƒ1 (1ŒöO‰qś): “ú–{ŒöO‰qśŽGŽ 2021/5; 68 (5): 311-9.

120004. [Œ´’˜] ‰ä‚ލ‘‚Ě˜J“­ŽŇ‚̐VŒ^ƒRƒƒiƒƒNƒ`ƒ“‚ɑ΂ˇ‚éˆÓŽŻ‚ƐVŒ^ƒRƒƒiƒƒNƒ`ƒ“‚đÚŽí‚ˇ‚é“Ž‹@‚Ă‚Ż‚Ć‚ĚŠÖ˜AŤ. H“ĄˆŔŽj, Œă“Ą—R‹I, Š`Œ´‰Á‘ăŽq, ‹g“c˜aŽ}, ‰|–{Šě•F, X@’qŽq, ‰Í–ěŒ[Žq, ’ç@–žƒ1 (1ŒöO‰qś): ˜J“­ˆŔ‘S‰qśŒ¤‹† 2021/9; 14 (2): 129-39.

120005. [Œ´’˜] “ú–{l—Ť˜J“­ŽŇ‚̏A˜Jă‰Ű‘č‚ƂȂ鐜•¨S—ŽĐ‰ď“I‚Č—vˆö, §“x—˜—pó‹ľ, Šú‘Ň‚ˇ‚éEę‚Ĺ‚ĚŒ¤‹†ƒe[ƒ}‚Ěƒj[ƒY: ŠłŽŇEŽs–ŻŽQ‰ć (PPI: Patient and Public Involvement) ‚Ě˜g‘g‚Ý‚đ—p‚˘‚˝ƒCƒ“ƒ^[ƒlƒbƒg’˛¸‚É‚ć‚鉥’fŒ¤‹†. ˛X–Ř“ß’Ă, ’Ă–ě“Ţ”ü, “ú‚Œ‹ˆß, ˆŔ“ĄŠG”üŽq, óˆä—T”ü, ŸN’J‚ ‚ˇ‚Š, “ú–ěˆŸ–íŽq, ˆäă—äŽq1, Ą‘şK‘ž˜Y, “n•Ó˜aL1, ’ç@–žƒ1, ěăŒ›l (1ŒöO‰qś): ŽY‹Ć‰qśŠwŽGŽ 2021/11; 63 (6): 275-90.

120006. [Œ´’˜] ‚í‚Ş‘‚Ě˜J“­ŽŇ‚É‚¨‚Ż‚éVŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´őÇ‚ĚŒŸ¸‚đŽó‚Ż‚é“Ž‹@‚Ă‚Ż‚ÉŠÖ˜A‚ˇ‚éˆöŽq. H“ĄˆŔŽj, Œă“Ą—R‹I, Š`Œ´‰Á‘ăŽq, ‹g“c˜aŽ}, ‰|–{Šě•F, X@’qŽq, ‰Í–ěŒ[Žq, ’ç@–žƒ1 (1ŒöO‰qś): Œúś‚ĚŽw•W 2021/12; 68 (15): 1-8.

510004. [‘ŕ] Review on the influence of paternal involvement in childcare on mothers, children, and fathers. Kato T, Ochi M, Kachi Y1, Suto M, Otsuka M, Takehara K: Nihon Koshu Eisei Zasshi 2022/5; 69 (5): 321-37. doi: 10.11236/jph.21-040. Epub 2022 Mar 16. (‰Â’m—IŽq1: 1ŒöO‰qś)

520005. [‘ŕ] (zŠÂŠí•a—\–h‘ŕƒVƒŠ[ƒY28: —vˆö•Ň13) ¸_ŽžŠł‚ƏzŠÂŠíŽžŠł. ’ç@–žƒ (ŒöO‰qś): “ú–{zŠÂŠí•a—\–hŠw‰ďŽ 2021/11; 56 (3): 212-25.

520006. [‘ŕ] ƒŠ[ƒ_[ƒVƒbƒv‚Ě—˜_‚ĆŽY‹Ć•ŰŒ’ę–ĺE‚ĚƒŠ[ƒ_[ƒVƒbƒv‚ւ̉ž—p; •śŒŁƒŒƒrƒ…[. Ź—Ń—R‰Ŕ, ˆäă˛b, ’Ă–ě“Ţ”ü, ŸN’J‚ ‚ˇ‚Š, ‘ĺ’ˑאł, ]Œű@Ž, “n•Ó˜aL1 (1ŒöO‰qś): ŽY‹ĆˆăŠwƒŒƒrƒ…[ 2021; 33 (3): 225-50.

521002. [‰đŕ]y ‘“ŕŠO‚ĚŽY‹ĆˆăŠw‚ÉŠÖ‚ˇ‚é•śŒŁĐ‰îzŮ—Ę˜J“­§‚É”ş‚¤Œ’NŠÖ˜A—vˆö. ’ç@–žƒ (ŒöO‰qś): ŽY‹ĆˆăŠwƒWƒƒ[ƒiƒ‹ 2022/3; 45 (2): 95-101.

522011. [uŔ]y“ÁW: Eę‚É‚¨‚Ż‚ég‘ĚŠˆ“ŽE‰^“ŽEŔˆĘs“Ž‚Ćƒƒ“ƒ^ƒ‹ƒwƒ‹ƒXzg‘ĚŠˆ“ŽE‰^“Ž‚𑣐i‚ˇ‚éEęŠÂ‹Ť. “n•Ó˜aL (ŒöO‰qś): ŽY‹ĆƒXƒgƒŒƒXŒ¤‹† 2021/4; 28 (2): 249-53.

522012. [uŔ]y“ÁW: ¸_‰Č‚Ş‹ß‚­‚É‚Č‚˘’nˆć‚É‚¨‚Ż‚鑍‡ˆă‚Ě‚˝‚߂̐¸_‰Čf—ÁzˆăŽtEˆă—ĂŽŇ‚Ěƒƒ“ƒ^ƒ‹ƒwƒ‹ƒX. ’ç@–žƒ (ŒöO‰qś): ŒŽŠ§’nˆćˆăŠw 2021/5; 31 (5): 440-4.

522013. [uŔ]yƒƒCƒ“ƒe[ƒ}: ƒXƒgƒŒƒX‚Ɛ_ŒoŒnzA. ƒXƒgƒŒƒX‘˜_@ƒXƒgƒŒƒX‚ĚŠT”O‚Ć•Ş—Ţ. ’ç@–žƒ (ŒöO‰qś): Clinical Neuroscience 2021/6; 39 (6): 688-92.

522014. [uŔ]y“ÁW: ƒpƒ[ƒnƒ‰ƒXƒƒ“ƒg‚đ‚Č‚­‚ˇ‚˝‚߂Ɂz3. ƒpƒ[ƒnƒ‰ƒXƒƒ“ƒg‚Ćƒƒ“ƒ^ƒ‹ƒwƒ‹ƒX. ’ç@–žƒ (ŒöO‰qś): ˜J“­’˛¸ 2021/6; 608: 17-22.

522015. [uŔ]y“ÁW: ‚ť‚ĚŒă‚ĚŽŠŽE‘΍ôII|—Տ°‚ɐś‚Š‚ˇŽŠŽE‘΍ô‚Ě“WŠJ|zˆăŠw‹łˆç‚ÉŽŠŽE—\–h‚đŽć‚č“ü‚ę‚é. ’ç@–žƒ (ŒöO‰qś): ¸_‰ČŽĄ—ĂŠw 2021/9; 36 (9): 1041-5.

522016. [uŔ]yBOOK ReviewzŠî‘b‚Š‚çŠw‚ÔŠy‚ľ‚˘‰uŠw@‘ć4”Ĺ. ’ç@–žƒ (ŒöO‰qś): •a‰@ 2021/9; 80 (9): 819.

522017. [uŔ]y“ÁW: ˆăŽt‚Ě“­‚Ť•ű‰üŠvzˆăŽt‚Ě“­‚Ť•ű‰üŠv@ŒöO‰qś‚Ě—§ę‚Š‚ç. ’ç@–žƒ (ŒöO‰qś): “ú–{¸_‰Č•a‰@‹Ś‰ďŽGŽ 2021/11; 40 (11): 65-71.

522018. [uŔ]y“ÁW: ‘ć28‰ń“ú–{ŽY‹ĆƒXƒgƒŒƒXŠw‰ď“ÁW†z[ƒVƒ“ƒ|ƒWƒEƒ€] ƒXƒgƒŒƒXƒ`ƒFƒbƒN§“x‚ĚŒťó‚ƍĄŒă‚Ě“W–]. ’ç@–žƒ (ŒöO‰qś): ŽY‹ĆƒXƒgƒŒƒXŒ¤‹† 2021/11; 28 (4): 413-6.

522019. [uŔ]yƒRƒƒ“ƒg: ĹVŒ¤‹†‚Ĺ•Ş‚Š‚Á‚˝u–˝‚ĚŠiˇvŽ€‚É‹ß‚Ă‚­E‹Ćz‘Ě‚ÉˆŤ‚˘ŽdŽ–|u‰ß˜JŽ€ƒ‰ƒCƒ“v‚Ě4”{‚đ’´‚Ś‚錎327ŽžŠÔ‚ĚŽc‹Ć. ’ç@–žƒ (ŒöO‰qś): —ŤƒZƒuƒ“ 2022/1; 60 (3): 56-7.

522020. [uŔ]y“ÁW: COVID-19‚đ’´‚Ś‚Ä-‚ą‚ę‚Š‚ç‚̐¸_ˆăŠw‚đ‚ß‚Ž‚éŠÂ‹ŤzŽY‹Ć¸_•ŰŒ’‚É‚¨‚Ż‚éV‚˝‚ȉۑč‚Ć‚ľ‚Ä‚ĚƒeƒŒƒ[ƒN. ’ç@–žƒ (ŒöO‰qś): —Տ°¸_ˆăŠw 2022/3; 51 (3): 281-5.

540017. [‚ť‚Ě‘ź (Œ¤‹†•ń‘)]yƒAƒŒƒ‹ƒM[EŠÖßƒŠƒEƒ}ƒ`‚ÉœëŠł‚ľ‚˝˜J“­ŽŇ‚ĆŠłŽŇ‚Ě—{ˆçŽŇ‚ɑ΂ˇ‚鎥—Ă‚ĆA˜J‚Ě—ź—§Žx‰‡ƒ}ƒjƒ…ƒAƒ‹zIV Eę‚Ĺ‚Ě—ź—§Žx‰‡‚̐i‚ß•ű. ’ç@–žƒ1,2, ăŒ´—˘’ö2 (1ŒöO‰qś, 2ƒAƒŒƒ‹ƒM[ŽžŠł‚ĚŠłŽŇ‚¨‚ć‚Ń—ĂˆçŽŇ‚̏A˜JEAŠwŽx‰‡‚𐄐i‚ˇ‚é‚˝‚ß‚ĚŒ¤‹†”Ç): ƒAƒŒƒ‹ƒM[EŠÖßƒŠƒEƒ}ƒ`‚ÉœëŠł‚ľ‚˝˜J“­ŽŇ‚ĆŠłŽŇ‚Ě—{ˆçŽŇ‚ɑ΂ˇ‚鎥—Ă‚ĆA˜J‚Ě—ź—§Žx‰‡ƒ}ƒjƒ…ƒAƒ‹Œ¤‹†•ń‘ 2021/4; p.9-11.

540018. [‚ť‚Ě‘ź (Œ¤‹†•ń‘)]yƒAƒŒƒ‹ƒM[EŠÖßƒŠƒEƒ}ƒ`‚ÉœëŠł‚ľ‚˝˜J“­ŽŇ‚ĆŠłŽŇ‚Ě—{ˆçŽŇ‚ɑ΂ˇ‚鎥—Ă‚ĆA˜J‚Ě—ź—§Žx‰‡ƒ}ƒjƒ…ƒAƒ‹zVI ŽĐ‰ďŽ‘Œš‚ĚŠˆ—pE˜J“­ŠÖŒW–@—ß‚Ě’mŽŻ. ’ç@–žƒ1,2, ăŒ´—˘’ö2 (1ŒöO‰qś, 2ƒAƒŒƒ‹ƒM[ŽžŠł‚ĚŠłŽŇ‚¨‚ć‚Ń—ĂˆçŽŇ‚̏A˜JEAŠwŽx‰‡‚𐄐i‚ˇ‚é‚˝‚ß‚ĚŒ¤‹†”Ç): ƒAƒŒƒ‹ƒM[EŠÖßƒŠƒEƒ}ƒ`‚ÉœëŠł‚ľ‚˝˜J“­ŽŇ‚ĆŠłŽŇ‚Ě—{ˆçŽŇ‚ɑ΂ˇ‚鎥—Ă‚ĆA˜J‚Ě—ź—§Žx‰‡ƒ}ƒjƒ…ƒAƒ‹Œ¤‹†•ń‘ 2021/4; p.17-20.

540019. [‚ť‚Ě‘ź (CURRENT REPORT)] ‘ć36‰ń“ú–{ƒXƒgƒŒƒXŠw‰ďŠwp‘‰ď ŠJĂ•ń ƒ‰ƒCƒtƒR[ƒX‚ĚŽ‹“_‚Š‚猊‚˝ƒXƒgƒŒƒX‰ČŠw. ’ç@–žƒ (ŒöO‰qś): Œ’NŠJ”­ 2021/6; 25 (4): 75-7.

540020. [‚ť‚Ě‘ź (Œ¤‹†•ń‘)]yŒúś˜J“­Č ˜JĐŽž•a—Տ°Œ¤‹†•â•‹ŕŽ–‹ĆzŽ–‹Ćę‚É‚¨‚˘‚ÄŽĄ—Ă‚ĆŽdŽ–‚Ě—ź—§Žx‰‡‚đ‚ˇ‚é‚˝‚ß‚Ě”z—ś‚Ć‚ť‚ĚŒˆ’čƒvƒƒZƒX‚ÉŠÖ‚ˇ‚錤‹†. ]Œű@Ž (Œ¤‹†‘ă•\ŽŇ), ’ç@–žƒ1, ˛X–ŘŽĄˆę˜Y, {‰ę–œ’q, “n•Ó@“N, ŽR–ě‰Ă‹v, Ä“Ą@‘, ŒĂ‰Ž”Žs, X“c“N–ç, Š–ؔɔV, –k‹@–ž, X‰i—Y‘ž, •“Ą@„2, ˆäă˛b (1ŒöO‰qś, 2‰qś):yŒúś˜J“­Č ˜JĐŽž•a—Տ°Œ¤‹†•â•‹ŕŽ–‹Ćz—ߘa3”N“x‘Š‡E•Ş’SŒ¤‹†•ń‘ 2022/3.

[’˜@‘]

620008. [Šwp‘ (•Ş’SŽˇ•M)]yŽY‹Ć•ŰŒ’ƒ}ƒjƒ…ƒAƒ‹ ‰ü’ů8”Łz10 Œ’NŠÇ—, p.167-229. Îˆä‹`ăů, ň@”Ž”V, ŠâčŽl, Š–ؔɔV, âV“ĄŒőł, •—с@‹œ, ’JŒű‰”ü, ’ç@–žƒ1, œA@Ž“T, •Ű—˜@ˆę, –x]ł’m, X@WŽ˘, ‹gě@“O (1ŒöO‰qś), ‘•ŇW: X@WŽ˘, “ěŽR“°, “Œ‹ž, 2021/6”­s.

620009. [Šwp‘ (•Ş’SŽˇ•M)]yEę‚Ěƒƒ“ƒ^ƒ‹ƒwƒ‹ƒX•s’˛@˘“—á‚ւ̑Ήž—Í‚Ş‚Ž‚ń‚Ž‚ńă‚Ş‚éSOAP‹L˜^pzp,178-94. “n•Ó˜aL (ŒöO‰qś): •Ň: ěăŒ›l, “ď”gŽs, Ź—Ń—R‰Ŕ, ˝M‘–[, “Œ‹ž, 2021/6”­s.

620010. [Šwp‘ (•Ş’SŽˇ•M)]yƒƒ“ƒ^ƒ‹ƒwƒ‹ƒXEƒ}ƒlƒWƒƒ“ƒgŒŸ’莎ŒąŒöŽŽƒeƒLƒXƒg@IŽíƒ}ƒXƒ^[ƒR[ƒX (‘ć5”Ĺ)z‘ć8Í2ß ŠÇ—ŠÄ“ÂŽŇ‚Ö‚Ě‹łˆçŒ¤C, p.341-8. ’ç@–žƒ (ŒöO‰qś), •Ň: ‘ĺă¤H‰ď‹cŠ, ’†‰›ŒoĎŽĐ, “Œ‹ž, 2021/7”­s.

620011. [Šwp‘ (•Ş’SŽˇ•M)]yŽĐ‰ďEŠÂ‹Ť‚ĆŒ’N ŒöO‰qśŠw 2022”N”ŁzCHAPTER 9 ¸_ŽžŠł, p.97-102. ’ç@–žƒ (ŒöO‰qś), •ŇW‘ă•\: –öě@—m, •Ň’˜: ”ö“‡r”V, ˆăŽ•–ňo”Ĺ, “Œ‹ž, 2022/1”­s.

620012. [Šwp‘ (•Ş’SŽˇ•M)]yŽĐ‰ďEŠÂ‹Ť‚ĆŒ’N ŒöO‰qśŠw 2022”N”ŁzCHAPTER 10 ŽŠŽE, •s—ś‚ĚŽ–ŒĚ, ‹s‘Ň, –\—Í, p.103-6. ’ç@–žƒ (ŒöO‰qś), •ŇW‘ă•\: –öě@—m, •Ň’˜: ”ö“‡r”V, ˆăŽ•–ňo”Ĺ, “Œ‹ž, 2022/1”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

711001. [Šw‰ď (‘Ű)] (“Á•Ęu‰‰) Long working hours and the consequences: health problems and work-life balance. Tsutsumi A1: 2nd Conference of the Asia Pacific Academy for Psychosocial Factors at Work (2021/7/30), WebŠJĂ. (’ç@–žƒ1: 1ŒöO‰qś)

712003. [Šw‰ď (‘Ű)] Association of long working hours and ischemic stroke among Japanese workers. Tsutsumi A1: 16th International Congress of Behavioral Medicine (ICBM) (2021/6/7-12), Glasgow, UK (WebŠJĂ), International Journal of Behavioral Medicine 2021/6; 28 (SUPPL 1): S130. (’ç@–žƒ1: 1ŒöO‰qś)

712004. [Šw‰ď (‘Ű)] (SEMI-PLENARY) Preventing overwork related disorders "Karoshi". Tsutsumi A1: 33rd International Congress on Occupational Health (ICOH 2022) (2022/2/9), WebŠJĂ. (’ç@–žƒ1: 1ŒöO‰qś)

713005. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Association of long working hours and ischemic stroke among Japanese workers. Tsutsumi A1: 16th International Congress of Behavioural Medicine (ICBM) (2021/6/7), WebŠJĂ. (’ç@–žƒ1: 1ŒöO‰qś)

722015. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‘S‚Ă̐l‚ÉŽY‹Ć•ŰŒ’‚ĚŒő‚đ|‘˝—l‚Č”wŒi‚É‚ć‚č“­‚Ť‚É‚­‚ł‚đ•ř‚Ś‚é˜J“­ŽŇ‚Ɂ|. ’ç@–žƒ (ŒöO‰qś): ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2021/5/21), ’ˇ–ě (ƒnƒCƒuƒŠƒbƒhŠJĂ), ŽY‹Ć‰qśŠwŽGŽ ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ďu‰‰W 2021; 63 (—ŐŽž‘nŠ§): 145.

722016. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) AIŽž‘ă‚ĚŒ’Nˆă—Ăƒf[ƒ^Šˆ—p‚Ć‚ť‚̉ۑč. ’ç@–žƒ (ŒöO‰qś): ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2021/5/19), ’ˇ–ě (ƒnƒCƒuƒŠƒbƒhŠJĂ), ŽY‹Ć‰qśŠwŽGŽ ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ďu‰‰W 2021; 63 (—ŐŽž‘nŠ§): 183.

722017. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) International Symposium. ’ç@–žƒ (ŒöO‰qś): ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2021/5/20), ’ˇ–ě (ƒnƒCƒuƒŠƒbƒhŠJĂ), ŽY‹Ć‰qśŠwŽGŽ ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ďu‰‰W 2021; 63 (—ŐŽž‘nŠ§): 305.

722018. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Œ’N‚̎Љď“IŒˆ’č—vˆö‚ɑ΂ˇ‚éƒAƒvƒ[ƒ`. ’ç@–žƒ (ŒöO‰qś): ‘ć62‰ń“ú–{SgˆăŠw‰ď‘‰ď‚Č‚ç‚Ń‚ÉŠwpu‰‰‰ď (2021/7/10), ě (ƒnƒCƒuƒŠƒbƒhŠJĂ), SgˆăŠw 2021; 61 (5): 18.

722019. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒRƒƒi‰Đ‚É‚¨‚Ż‚é˜J“­ŽŇ‚̐g‘ĚŠˆ“Ž‚̕ωť‚Ćƒƒ“ƒ^ƒ‹ƒwƒ‹ƒX. “n•Ó˜aL (ŒöO‰qś): “ú–{S—Šw‰ď‘ć85‰ń‘ĺ‰ď (2021/9/1-8), WebŠJĂ.

722020. [Šw‰ď (‘S‘)] (ŽŠ—RW‰ď) “ú ˆľ‚¤ŽĐ“ŕƒf[ƒ^‚Š‚çŒťę‚É–đ—§‚ÂƒŠƒT[ƒ`ƒNƒGƒXƒ`ƒ‡ƒ“‚đl‚Ś‚悤. “n•Ó˜aL1, ‹ŕX@Œĺ, ‰Â’m—IŽq1, [ˆäq‘ž (1ŒöO‰qś): ‘ć31‰ń“ú–{ŽY‹Ć‰qśŠw‰ď‘S‘‹Ś‹c‰ď (2021/12/3), ŽOd (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722021. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ˆă—ËΖąŠÂ‹Ť‰ü‘P‚É‚ć‚éˆăŽt‚Ě“­‚Ť•ű‰üŠv|ˆăŽt‚Ć‚ľ‚Ăǂ̂悤‚É“­‚Ť‚˝‚˘‚Š|‘ĺŠw‹Î–ą“™‚Ě˜J“­ŠÂ‹Ť‚̉ü‘P‚ÉŒü‚Ż‚Ä‚Ě’˛¸•ń. ’ç@–žƒ (ŒöO‰qś): ‘ć159‰ń“ú–{ˆăŠw‰ďƒVƒ“ƒ|ƒWƒEƒ€ (2021/12/25), “Œ‹ž, “ú–{ˆăŽt‰ďŽGŽ 2022/3; 150 (12): 2225.

722022. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‚ƒXƒgƒŒƒXŽŇ–ĘÚŒ¤C‚Ě‚˝‚ß‚Ěƒ}ƒjƒ…ƒAƒ‹‚Ć“Ž‰ć: ‚ƒXƒgƒŒƒXŽŇ–ʐڂ̂ ‚é‚ׂŤ•űŒüŤ. ’ç@–žƒ (ŒöO‰qś): ‘ć28‰ń“ú–{ŽY‹Ć¸_•ŰŒ’Šw‰ď (2021/11/20-2022/1/10), WebŠJĂ, ŽY‹Ć¸_•ŰŒ’‘ć28‰ń“ú–{ŽY‹Ć¸_•ŰŒ’Šw‰ď´˜^W 2021/11; 29 (‘Š§†): 80-1.

722023. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‚ƒXƒgƒŒƒXŽŇ–ʐڂ̂ ‚é‚ׂŤ•űŒüŤ. ’ç@–žƒ1, HŽR@„ (1ŒöO‰qś): ‘ć28‰ń“ú–{ŽY‹Ć¸_•ŰŒ’Šw‰ď (2021/11/20-2022/1/10), WebŠJĂ, ŽY‹Ć¸_•ŰŒ’Šw‰ďŽGŽ 2021; 30 (2): 167-70.

722024. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Ž¸”s‚Š‚çŠw‚ÔŽY‹ĆƒXƒgƒŒƒX: ŽŠŽE‘΍ô‹łˆç‚Ě“WŠJ. ’ç@–žƒ (ŒöO‰qś): ‘ć29‰ń“ú–{ŽY‹ĆƒXƒgƒŒƒXŠw‰ď (2022/3/25-26), ˆ¤’m (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722025. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒ|ƒXƒgƒRƒƒi‚đŒŠ˜‚Ś‚˝ƒZƒ‹ƒtƒ}ƒlƒWƒƒ“ƒgug‘ĚŠˆ“Žv. “n•Ó˜aL (ŒöO‰qś): ‘ć29‰ń“ú–{ŽY‹ĆƒXƒgƒŒƒXŠw‰ď (2022/3/26), ˆ¤’m (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723079. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ˜J“­ŽŇ‚ĚŽĺŠĎ“IƒEƒFƒ‹ƒr[ƒCƒ“ƒOŒüă‚Ě‚˝‚ß‚Ě–łěˆ×‰ť”äŠrŽŽŒą‚Ěƒƒ^•ŞÍ. ŸN’J‚ ‚ˇ‚Š, Ą‘şK‘ž˜Y, ’ç@–žƒ1, “‡’Ă–žl, ěăŒ›l (1ŒöO‰qś): ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2021/5/20), ’ˇ–ě (ƒnƒCƒuƒŠƒbƒhŠJĂ), ŽY‹Ć‰qśŠwŽGŽ ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ďu‰‰W 2021; 63 (—ŐŽž‘nŠ§): 336.

723080. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒ}ƒ^ƒjƒeƒBƒnƒ‰ƒXƒƒ“ƒg‚ĆŠÖ˜A‚ˇ‚éEęŠÂ‹Ť—vˆö: VŒ^ƒRƒƒiƒEƒCƒ‹ƒX—Źs‰ş‚Ĺ‚ĚŒŸ“˘. ‰Â’m—IŽq1, ]Œű@Ž, ˆäă˛b, “ĄŒ´•’j, ”nęKŽq, ‘ž“c@Š°1, ’ç@–žƒ1 (1ŒöO‰qś): ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2021/5/19), ’ˇ–ě (ƒnƒCƒuƒŠƒbƒhŠJĂ), ŽY‹Ć‰qśŠwŽGŽ ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ďu‰‰W 2021; 63 (—ŐŽž‘nŠ§): 364.

723081. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ’Pg‚ĆƒeƒŒƒ[ƒNŽŔŽ{‚É”ş‚¤¸_“IŒ’N‚ĚˆŤ‰ť‚ɑ΂ˇ‚éƒIƒ“ƒ‰ƒCƒ“Œđ—ŹŽQ‰Á‚ĚŠÉŐŒř‰Ę. ˆäă˛b, ˛X–Ř“ß’Ă, Ą‘şK‘ž˜Y, Ąˆä“S•˝, ]Œű@Ž, Ź—Ń—R‰Ŕ, ‚ŽR”ŽŒő, ’ç@–žƒ1 (1ŒöO‰qś): ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2021/5/24-6/25), ’ˇ–ě (ƒnƒCƒuƒŠƒbƒhŠJĂ), ŽY‹Ć‰qśŠwŽGŽ ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ďu‰‰W 2021; 63 (—ŐŽž‘nŠ§): 480.

723082. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŽŠŽĄ‘̐Eę‚É‚¨‚Ż‚éOSHMS’č’…‚ĆˆŔ‘S‰qśŽw•W‚⊈“Ž‚ւ̉e‹ż•]‰ż‘ć27•ń. “n•Ó—TW, b“c–ÎŽ÷ ,˛X–Ř‹B, ź—tŽjŽq, ˆÉ“ĄşD, Œ´@–M•v, ’ç@–žƒ1, ŠŰŽRłŽĄ, ŽRŒűGŽ÷ (1ŒöO‰qś): ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ď (2021/5/24-6/25), ’ˇ–ě (ƒnƒCƒuƒŠƒbƒhŠJĂ), ŽY‹Ć‰qśŠwŽGŽ ‘ć94‰ń“ú–{ŽY‹Ć‰qśŠw‰ďu‰‰W 2021; 63 (—ŐŽž‘nŠ§): 559.

723083. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ăŽiE“Ż—ť‚ĚŽx‰‡‚ƐS—“IƒfƒBƒXƒgƒŒƒX‚̉ü‘P‚Ć‚ĚŠÖ˜A: 1”NŠÔ‚̏c’fŒ¤‹†. ˆäă—äŽq1, ˆř’n”Ž”V1, ‰Â’m—IŽq1, “n•Ó˜aL1, rˆä—L”ü1, Šâ“c@¸, ’ç@–žƒ1 (1ŒöO‰qś): ‘ć31‰ń“ú–{ŽY‹Ć‰qśŠw‰ď‘S‘‹Ś‹c‰ď (2021/12/3-2022/1/10), ŽOd (ƒnƒCƒuƒŠƒbƒhŠJĂ), ‘ć31‰ń“ú–{ŽY‹Ć‰qśŠw‰ď‘S‘‹Ś‹c‰ďu‰‰W 2021; p.253.

723084. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Ź‹K–ÍŽ–‹ĆŠ‚̐EęŠÂ‹Ť‰ü‘P‚ÉŠÖ‚ˇ‚éƒCƒ“ƒ^ƒrƒ…[’˛¸Œ‹‰Ę‚Ć•ŞÍ. ’†“ˆ’mŒb, XŒűŽŸ˜Y, “ŕ“c—z”V, …–{łŽu, ˛–ě—F”ü, Ź“‡Œšˆę, ‹gě‰xŽq, ‹gě@“O, ’ç@–žƒ1 (1ŒöO‰qś): ‘ć31‰ń“ú–{ŽY‹Ć‰qśŠw‰ď‘S‘‹Ś‹c‰ď (2021/12/3-2022/1/10), ŽOd (ƒnƒCƒuƒŠƒbƒhŠJĂ), ‘ć31‰ń“ú–{ŽY‹Ć‰qśŠw‰ď‘S‘‹Ś‹c‰ďu‰‰W 2021; p.272.

723085. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) •ƒe‚ĚˆçŽ™•p“x‚Ć—cŽ™‚Ě’ˇŽžŠÔ‚ĚƒeƒŒƒrŽ‹’Ž‚Ć‚ĚŠÖ˜A: 21˘‹IośŽ™c’f’˛¸‚ć‚č. ‰Â’m—IŽq1, ‰Á“Ął•F, ‰z’q^“Ţ”ü, ‰i‹g^Žq, ’|Œ´Œ’“ń (1ŒöO‰qś), ‘ć80‰ń“ú–{ŒöO‰qśŠw‰ď‘‰ď (2021/12/21-2022/3/14), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{ŒöO‰qśŠw‰ď‘‰ď´˜^W 2021/11; 80: 236.

723086. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ––Žq‚Ş–˘AŠwŽ™‚ĚŽq‚Ç‚ŕ‚đŽ‚Â•ƒe‚̐śŠˆŽžŠÔ. ‘ĺ’Ë”ü–ëŽq, ’|Œ´Œ’“ń, ‰Á“Ął•F, ‰z’q^“Ţ”ü, ‰Â’m—IŽq1 (1ŒöO‰qś), ‘ć80‰ń“ú–{ŒöO‰qśŠw‰ď‘‰ď (2021/12/21-2022/3/14), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{ŒöO‰qśŠw‰ď‘‰ď´˜^W 2021/11; 80: 236.

723087. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‚—îŽŇ•ŰŒ’‚ť‚Ě‘ź. ’ç@–žƒ (ŒöO‰qś): ‘ć32‰ń“ú–{‰uŠw‰ďŠwp‘‰ď (2022/1/26-28), WebŠJĂ, ‘ć32‰ń“ú–{‰uŠw‰ďŠwp‘‰ďu‰‰W 2022; p.26.

732006. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) “Œ“ú–{‘ĺkĐ”íĐ’n‚É‚¨‚Ż‚郌ƒWƒŠƒGƒ“ƒX‚Ćƒ\[ƒVƒƒƒ‹EƒLƒƒƒsƒ^ƒ‹. ˆř’n”Ž”V (ŒöO‰qś): JAGES‹@\Ý—§3Žü”N‹L”OƒVƒ“ƒ|ƒWƒEƒ€uŒ’NŠë‹@‚Ö‚ĚƒŒƒWƒŠƒGƒ“ƒX‚ƐVŽž‘ă‚Ö‚Ě’E”ç|Š´őÇEŽŠ‘RĐŠQ‚đ—á‚Ɂ|v(2021/5/14), WebŠJĂ.

732007. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) ˆăŽt‚Ě“­‚Ť•ű‰üŠv Workstyle reform for Japanese doctors. ’ç@–žƒ (ŒöO‰qś): “ú–{–ƒŒ‰ČŠw‰ď2021”N“xŽx•”ŠwpW‰ď–kŠC“šE“Œ–kŽx•”‘ć11‰ńŠwpW‰ď (2021/9/4-10/4), WebŠJĂ.

732008. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) Eę‚Ě‘˝—l‚ČŠO‘oglŢ‚ĚƒCƒ“ƒNƒ‹[ƒWƒ‡ƒ“‚Ě•ű–@`‘˝•ś‰ťŠÔ¸_ˆăŠw‰ď‚ĚŽ‹“_‚Š‚ç. ’ç@–žƒ (ŒöO‰qś): ‘ć62‰ńŽY‹Ć¸_‰qśŒ¤‹†‰ď (2022/2/12), WebŠJĂ.

732009. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (Šî’˛u‰‰) Eę‚Ě‘˝—l‚ČŠO‘oglŢ‚ĚƒCƒ“ƒNƒ‹[ƒWƒ‡ƒ“‚̐„i. ’ç@–žƒ (ŒöO‰qś): ‘ć62‰ńŽY‹Ć¸_‰qśŒ¤‹†‰ď (2022/2/12), WebŠJĂ.

733016. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ’nˆćŽY‹Ć•ŰŒ’ƒZƒ“ƒ^[‚̏Ź‹K–ÍŽ–‹Ćę‚Ěƒƒ“ƒ^ƒ‹ƒwƒ‹ƒXŠˆ“Ž‚ĚŽx‰‡‚ĚŒťó. ]Œű@Ž, “ú–ěˆŸ–íŽq, ’ç@–žƒ1 (1ŒöO‰qś): ‘ć62‰ńŽY‹Ć¸_‰qśŒ¤‹†‰ď (2022/2/12), WebŠJĂ.

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-110006. [Œ´’˜] Role ambiguity as an amplifier of the association between job stressors and workers' psychological ill-being: Evidence from an occupational survey in Japan. Oshio T, Inoue A, Tsutsumi A1: J Occup Health 2021/1; 63 (1): e12310. (’ç@–žƒ1: 1ŒöO‰qś)

'20-110007. [Œ´’˜] Internet-based acceptance and commitment therapy programme 'Happiness Mom' for well-being: a protocol for a randomised controlled trial. Sasaki N, Imamura K, Nishi D, Watanabe K1, Sekiya Y, Tsuno K, Kobayashi Y, Kawakami N: BMJ Open 2021/2; 11 (2): e042167. (“n•Ó˜aL1: 1ŒöO‰qś)

'20-110008. [Œ´’˜] Association between energy drink consumption and substance use in adolescence: A systematic review of prospective cohort studies. Yasuma N, Imamura K, Watanabe K1, Nishi D, Kawakami N, Takano A: Drug Alcohol Depend 2021/2; 219: 108470. (“n•Ó˜aL1: 1ŒöO‰qś)


–@ˆăŠw

[Šwp˜_•ś]

110080. [Œ´’˜] Y chromosome analysis for common surnames in the Japanese male population. Ochiai E1, Osawa M, Satoh S, Tamura T, Nakatome M, Kaneko Y, Kakimoto Y, Minaguchi K: J Hum Genet 2021/7; 66 (7): 731-8. (—Ž‡Œb—Žq1: 1–@ˆă)

110081. [Œ´’˜] A survey of solitary death by heat stroke in Yokohama City. Kakiuchi Y, Nagao R, Ochiai E1, Kakimoto Y, Osawa M: Journal of Public Health 2021/10; 29: 1055-9. (—Ž‡Œb—Žq1: 1–@ˆă)

310004. [Ç—á•ń] Rare primary peritoneal mucinous adenocarcinoma in a 69-year-old man. Satoh F1, Tsutsumi Y: Clin Case Rep 2021/9; 9 (9): e04820. (˛“Ą•śŽq1: 1–@ˆă)

[Šw‰ďEŒ¤‹†‰ď“™]

713006. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Relation between sudden death during bathing and age-related changes in the heart. Satoh F1, Irie W1, Sasaki C1, Ochiai E1, Inoue H2, Saito J2, Kondo M2, Nakamaru N3, Sakamoto M3, Nagato J3: 100. Jahrestagung der Deutschen Gesellschaft fŸr Rechtsmedizin (2021/9/15), Munich, Germany (Web), Abstracts 2021/7; p.364. (˛“Ą•śŽq1, “ü]@Â1, ˛X–ؐçŽőŽq1, —Ž‡Œb—Žq1, ˆäă“úŘŽq2, âV“Ą€ˆę˜Y2, ‹ß“Ą^”ż2, ’†ŠŰŽ”ü3, ă–{“Žq3, ’ˇ–ĺƒ•˝3: 1–@ˆă, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3Œ`‘ÔŒn)

723088. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) DSMSƒvƒƒWƒFƒNƒg‚É‚¨‚Ż‚é–ň•¨•ŞÍ‚Ě•iŽżŠÇ—‚ÉŒü‚Ż‚˝ƒuƒ‰ƒCƒ“ƒhƒeƒXƒgŽŔŽ{•ń (2020”N). ˛X–ؐçŽőŽq1, ˛“Ą•śŽq1 (1–@ˆă): ‘ć105ŽŸ“ú–{–@ˆăŠw‰ďŠwp‘S‘W‰ď (2021/10/4-31), WebŠJĂ, u‰‰—vŽ|W 2021/5; p.41.

723089. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) RapidHIT IDƒVƒXƒeƒ€‚đ—p‚˘‚˝Touch DNA‰đÍ. —Ž‡Œb—Žq1,2, ź“‡@—T2, Š_–{—R•z2, ‘ĺŕVŽ‘Ž÷2 (1–@ˆă, 2“ŒŠC‘ĺŠwˆăŠw•”Šî”Րf—ĂŠwŒn–@ˆăŠw): ‘ć105ŽŸ“ú–{–@ˆăŠw‰ďŠwp‘S‘W‰ď (2021/10/4-31), WebŠJĂ, u‰‰—vŽ|W 2021/5; p.49.

723090. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Œđ’ĘŽ€–SŽ–ŒĚ‚É‚¨‚Ż‚éˆÓ}“I‚ČŽÔ—źŐ“Ë‚ĚŠÖ—^. ‘ĺŕVŽ‘Ž÷1, ‘ĺ˜a“cK‰„1, VŔ‘ńŠC1, Š_–{—R•z1, ’ŘˆäH’j1, —Ž‡Œb—Žq1,2, ˛“Ą•śŽq2 (1“ŒŠC‘ĺŠwˆăŠw•”Šî”Րf—ĂŠwŒn–@ˆăŠw, 2–@ˆă): ‘ć105ŽŸ“ú–{–@ˆăŠw‰ďŠwp‘S‘W‰ď (2021/10/4-31), WebŠJĂ, u‰‰—vŽ|W 2021/5; p.52.

723091. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ‹C“š‚Ö‚Ě”•Đ‹zˆř‚đ”F‚ß‚˝‚ŞŒŒ’†CO-Hb–O˜a“x‚̏㏸‚đ”F‚ß‚Č‚Š‚Á‚˝1–UŒŸ—á. “ü]@Â1, ˛X–ؐçŽőŽq1, ’†ŠŰŽ”ü2, ă–{“Žq2, ’ˇ–ĺƒ•˝2, ˆäă“úŘŽq3, ˛“Ą•śŽq1 (1–@ˆă, 2Œ`‘ÔŒn, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć105ŽŸ“ú–{–@ˆăŠw‰ďŠwp‘S‘W‰ď (2021/10/4-31), WebŠJĂ, u‰‰—vŽ|W 2021/5; p.57.

723092. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒQƒmƒ€ƒf[ƒ^‚ĚŽ‚ŒlŽŻ•ĘŤ. “c‘ş—F‹I1,2, —Ž‡Œb—Žq2,3, ŽRčˆęŽ÷1, ‘ĺŕVŽ‘Ž÷2 (1_“ŢěŒ§ŒxŽ@‰ČŠw‘{¸Œ¤‹†Š, 2“ŒŠC‘ĺŠwˆăŠw•”Šî”Րf—ĂŠwŒn–@ˆăŠw, 3–@ˆă): “ú–{–@‰ČŠw‹ZpŠw‰ď‘ć27‰ńŠwpW‰ď (2021/11/11-12), WebŠJĂ, “ú–{–@‰ČŠw‹ZpŠw‰ďŽ 2021/10; 26(Suppl): 31.

723093. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒxƒbƒh‚Š‚ç“]—ŽŒă‚É‹}•Ď‚ľ, ”sŒŒÇ‚É‚ć‚莀–S‚ľ‚˝VśŽ™–UŒŸ—á. ˛“Ą•śŽq1, “ü]@Â1, ˛X–ؐçŽőŽq1, —Ž‡Œb—Žq1, ’†ŠŰŽ”ü2, ă–{“Žq2, ’ˇ–ĺƒ•˝2, ˆäă“úŘŽq3, âV“Ą€ˆę˜Y3 (1–@ˆă, 2Œ`‘ÔŒn, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć27‰ń“ú–{SIDSE“ű—cŽ™“Ë‘RŽ€—\–hŠw‰ď (2022/2/19-20), WebŠJĂ, ƒvƒƒOƒ‰ƒ€E´˜^W 2021/2; p24.

723094. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) “ű—cŽ™“Ë‘RŽ€—á‚ĹŒŸo‚ł‚ę‚˝PHOX2Bˆâ“`Žq‚Ě”ńƒ|ƒŠƒAƒ‰ƒjƒ“ƒŠƒs[ƒg•ĎˆŮ. ‘ĺŕVŽ‘Ž÷1, ă“c@“Ä1, “ŕ“ĄtŒ°1, —Ž‡Œb—Žq2, Š_–{—R•z1, ˛“Ą•śŽq2 (1“ŒŠC‘ĺŠwˆăŠw•”Šî”Րf—ĂŠwŒn–@ˆăŠw, 2–@ˆă): ‘ć27‰ń“ú–{SIDSE“ű—cŽ™“Ë‘RŽ€—\–hŠw‰ď (2022/2/19-20), WebŠJĂ, ƒvƒƒOƒ‰ƒ€E´˜^W 2021/2; p.30.

733017. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) “ü—’†‹}Ž€‚É‚¨‚Ż‚é”]_Œo×–E‚Ě‹•ŒŒŤ•Ď‰ť‚ɂ‚˘‚Ä‚ĚŒŸ“˘. ˆäă“úŘŽq1, ˛“Ą•śŽq2, “ü]@Â2, ˛X–ؐçŽőŽq2, —Ž‡Œb—Žq2, ’†ŠŰŽ”ü3, ă–{“Žq3, ’ˇ–ĺƒ•˝3, âV“Ą€ˆę˜Y1 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–@ˆă, 3Œ`‘ÔŒn): ‘ć90‰ń“ú–{–@ˆăŠw‰ďŠwpŠÖ“Œ’n•űW‰ď (2021/10/9), WebŠJĂ, u‰‰—vŽ|W 2021/10; p.22.

733018. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) –@ˆăŒŸ‘Ě‚Ě–ň•¨•ŞÍ‚ĚŽŔŰ‚Ć’ˆÓ“_‚ɂ‚˘‚ā`–k—˘‘ĺŠw‚ĚŒťó`. ˛X–ؐçŽőŽq (–@ˆă): ‘ć6‰ń“ú–{ˆă—pƒ}ƒXƒXƒyƒNƒgƒ‹Šw‰ď“Œ•”‰ď (2021/11/6), WebŠJĂ, JSBMS Letters 2021/6; 46 (2): 27.


ŽŔŒą“Ž•¨Šw

[Šwp˜_•ś]

110082. [Œ´’˜] A highly efficient method for extracting peptides from a single mouse hypothalamus. Nakagawa Y, Matsui T, Konno R, Kawashima Y, Sato T1, Itakura M2, Kodera Y: Biochem Biophys Res Commun 2021/4; 548: 155-60. (˛“ĄrĆ1, ”‘q@˝2: 1ŽŔ“Ž, 2ś‰ť)

110083. [Œ´’˜] Candesartan prevents arteriopathy progression in cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy model. Kato T, Manabe R, Igarashi H, Kametani F, Hirokawa S, Sekine Y, Fujita N, Saito S, Kawashima Y, Hatano Y, Ando S, Nozaki H, Sugai A, Uemura M, Fukunaga M, Sato T1, Koyama A, Saito R, Sugie A, Toyoshima Y, Kawata H, Murayama S, Matsumoto M, Kakita A, Hasegawa M, Ihara M, Kanazawa M, Nishizawa M, Tsuji S, Onodera O: J Clin Invest 2021/11; 131 (22): e140555. (˛“ĄrĆ1: 1ŽŔ“Ž)

[’˜@‘]

620013. [Šwp‘ (•Ş’SŽˇ•M)]yƒqƒg‚Ě•ŞŽqˆâ“`Šw ‘ć5”Łz21Í ƒ‚ƒfƒ‹ś•¨‚ĆŽžŠł‚Ěƒ‚ƒfƒ‹‰ť, p.735-76 ˛“ĄrĆ (ŽŔ“Ž), ŠÄ–ó: ŒË“c’BŽj, ˆäă@‘, ź–{’ź’Ę, ƒƒfƒBƒJƒ‹EƒTƒCƒGƒ“ƒXEƒCƒ“ƒ^[ƒiƒVƒ‡ƒiƒ‹, “Œ‹ž, 2021/10”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

733019. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ALSŒ´ˆöˆâ“`ŽqŽY•¨TDP-43‚̉đÍ. ˛“ĄrĆ (ŽŔ“Ž): 2021”N“x”]Œ¤‹†Š‹¤“Ż—˜—p‹¤“ŻŒ¤‹† (ů‰Ş”Ç) (2022/2/9), WebŠJĂ.


–ƉuŠw

[Šwp˜_•ś]

110084. [Œ´’˜] Natural Killer Cell Group 7 Sequence in Cytotoxic Cells Optimizes Exocytosis of Lytic Granules Essential for the Perforin-Dependent, but Not Fas Ligand-Dependent, Cytolytic Pathway. Morikawa Y, Murakami M, Kondo H1, Nemoto N, Iwabuchi K2, Eshima K2: Immunohorizons 2021/4; 5 (4): 234-45. (‹ß“Ą@‹Ď1, ŠâŸş˜a–ç2, ]“‡k“ń2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–Ɖu)

110085. [Œ´’˜] Activation of Invariant Natural Killer T Cells by ƒż-Galactosylceramide Attenuates the Development of Angiotensin II-Mediated Abdominal Aortic Aneurysm in Obese ob/ob Mice. Saito A, Ishimori N, Tokuhara S, Homma T, Nishikawa M, Iwabuchi K1, Tsutsui H: Front Cardiovasc Med 2021/5; 8: 659418. (ŠâŸş˜a–ç1: 1–Ɖu)

110086. [Œ´’˜] A new approach to analysis of intracellular proteins and subcellular localization using cellprofiler and imageJ in combination. Hattori A1, Ohta E2, Nagai M3, Iwabuchi K4, Okano E: Methods 2021/4; S1046-2023 (21) 00111-0. doi: 10.1016/j.ymeth.2021.04.019. Online ahead of print. (•ž•”¸l1, ‘ž“c‰x˜N2, ‰iˆä^‹MŽq3, ŠâŸş˜a–ç4: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3”]_Œo“ŕ, 4–Ɖu)

110087. [Œ´’˜] Natural Killer T Cells Are Involved in Atherosclerotic Plaque Instability in Apolipoprotein-E Knockout Mice. Ohmura Y, Ishimori N, Saito A, Yokota T, Horii S, Tokuhara S, Iwabuchi K4, Tsutsui H: Int J Mol Sci 2021/11; 22 (22): 12451. (ŠâŸş˜a–ç4: 4–Ɖu)

110088. [Œ´’˜] Development of an immunochromatographic test for the detection of Mycoplasma pneumoniae GroES antigen. Matsui H, Sugimura M, Inoue-Tsuda M, Iwabuchi K4, Hanaki H: J Microbiol Methods 2021/12; 191: 106359. (ŠâŸş˜a–ç4: 4–Ɖu)

110089. [Œ´’˜] Adipose invariant NKT cells interact with CD1d-expressing macrophages to regulate obesity-related inflammation. Satoh M1, Iizuka M2, Majima M3, Ohwa C, Hattori A, Van Kaer L, Iwabuchi K1: Immunology 2022/4; 165 (4): 414-27. doi: 10.1111/imm.13447. Epub 2022 Feb 28. (˛“Ą@‰ë1, ”Ń’Ë‚Ý‚ł‚đ2, ”n“ˆł—˛3, ŠâŸş˜a–ç1: 1–Ɖu, 2—\–hˆăŠwŒn, 3–ň—)

522021. [uŔ]yŠO‘Ž—v——zŽŔŒą“IŽŠŒČ–ƉuŤ‚Ô‚Ç‚¤–Œ–Ô–Œ‰Š‚ĚÄ”­‚É‚¨‚Ż‚éƒCƒ“ƒoƒŠƒAƒ“ƒgƒiƒ`ƒ…ƒ‰ƒ‹ƒLƒ‰[T×–E‚Ě–hŒě“I–đŠ„. “cK‰ÄŠC, ‰Á“Ą‘žŠě, ˛“Ą@‰ë1, ”Ń’Ë‚Ý‚ł‚đ2, ’JŒű@Ž, –kŽsL‹`, ŠâŸş˜a–ç1 (1–Ɖu, 2—\–hˆăŠwŒn)F“ú–{Šá‰ČŠw‰ďŽ 2021/5; 125 (5): 558.

522022. [uŔ]y“ÁW1qBasic Sciencer: ŽŠ‘R–ƉuŒ^T×–E‚̐V“WŠJzŽŠ‘RT×–EŒ¤‹†‚̐i“W. ŠâŸş˜a–ç (–Ɖu): ‰ŠÇ‚ƖƉu 2021/6; 29 (4): 283-7.

522023. [uŔ]y“ÁW: ƒx[ƒ`ƒFƒbƒg•a|Šî‘b‚Ć—Ő°‚̍ŐV’mŒŠ|zII. Šî‘bŒ¤‹†@5. ŽŔŒą“IŽŠŒČ–ƉuŤ‚Ô‚Ç‚¤–Œ‰Šƒ‚ƒfƒ‹‚̉ŠÇ§Œä. ŠâŸş˜a–ç1, “cK‰ÄŠC, ‰Á“Ą‘žŠě, ť“œ@‰ë (1–Ɖu): “ú–{—Őଠ2021/6; 79 (6): 843-9.

[Šw‰ďEŒ¤‹†‰ď“™]

722026. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€jś‘Ě–hŒäŒ¤‹†‚ĚŒťó‚Ć“W–]: ŽŠ‘RT×–E‚đ‰î‚ľ‚˝ŽžŠł§Œä‚ĚŽŽ‚Ý. ŠâŸş˜a–ç (–Ɖu): ‘ć32‰ń“ú–{ś‘Ě–hŒäŠw‰ďŠwp‘‰ď (2021/9/8), WebŠJĂ.

723095. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰)y20ƒŠƒ“ƒpß‚QE‘˘ŒŒŠíEäB‘ŸzŽŔŒą“IŽŠŒČ–ƉuŤ‚Ô‚Ç‚¤–Œ‰ŠÄ”­ƒ‚ƒfƒ‹‚ĚNKT×–E‚É‚ć‚鐧Œä. ŠâŸş˜a–ç (–Ɖu): ‘ć110‰ń“ú–{•a—Šw‰ď‘‰ď (2021/4/24), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723096. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Ž‰–b‘gDNKT×–E‚Ćƒ}ƒNƒƒtƒ@[ƒW‚Ě‘ŠŒÝě—p‚É‚ć‚閝Ť‰ŠÇ‚̐§Œä. ˛“Ą@‰ë1, ŠâŸş˜a–ç1 (1–Ɖu): ‘ć30‰ńKyoto T Cell Conference (2021/10/8), WebŠJĂ.

723097. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠQč÷—ą–Œ•ŞŽqNkg7‚É‚ć‚éč÷—ą•úo§Œä‹y‚Ń×–EŠQ‹@”\‘Łi. ]“‡k“ń1, Xě—DŽ÷, ‹ß“Ą@‹Ď2, ‘şă@“ě, ‚źšŽq1, Ş–{“TŽq, ŠâŸş˜a–ç1 (1–Ɖu, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć30‰ńKyoto T Cell Conference (2021/10/9), WebŠJĂ.

723098. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) U1 RNP can induce NETosis to isolated mouse neutrophils through NOX2 independent pathway. ’|“ŕŒb”üŽq1, ‘ĺ’Á@^2, ’|“ŕN—Y3, ŠâŸş˜a–ç1 (1–Ɖu, 2—AŒŒE×–EˆÚA, 3t‘Ÿ“ŕ): ‘ć50‰ń“ú–{–ƉuŠw‰ďŠwpW‰ď (2021/12/10), “Ţ—Ç (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723099. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Eomesodermin in CD8+ CTLs induces the expression of Nkg7 which specifically promotes perforin/granzyme-pathway of cytolysis by optimizing exocytosis of lytic granules. ]“‡k“ń1, ŠâŸş˜a–ç1, Xě—DŽ÷, ‹ß“Ą@‹Ď2, Ş–{“TŽq (1–Ɖu, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć50‰ń“ú–{–ƉuŠw‰ďŠwpW‰ď (2021/12/10), “Ţ—Ç (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723100. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Analyses of cross-reactivity of T cells specific for murine tumor cell lines. ‹ß“Ą@‹Ď1, ]“‡k“ń2, ‰–ŒŠ@˜a3, ŠâŸş˜a–ç2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–Ɖu, 3ŒÄ‹zŠíŠO): ‘ć50‰ń“ú–{–ƉuŠw‰ďŠwpW‰ď (2021/12/10), “Ţ—Ç (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723101. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Adipose iNKT cell interacting with macrophage regulates obesity-associated inflammation. ˛“Ą@‰ë1, ŠâŸş˜a–ç1 (1–Ɖu): ‘ć50‰ń“ú–{–ƉuŠw‰ďŠwpW‰ď (2021/12/10), “Ţ—Ç (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723102. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Recurrence of experimental autoimmune uveoretinitis (EAU) induced by administration of Staphylococcal Enterotoxin B was ameliorated by NKT-cell activation. ‘ĺ˜aç’ß1, ˛“Ą@‰ë2, ŠâŸş˜a–ç2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–Ɖu): ‘ć50‰ń“ú–{–ƉuŠw‰ďŠwpW‰ď (2021/12/10), “Ţ—Ç (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733020. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‹š‘B”玿ă”ç×–E‚Ě‹@”\‚É‚¨‚Ż‚éNF-şB-inducing kinase‚ĚŠń—^‚ɂ‚˘‚Ä. ]“‡k“ń1, ŽOŕV‰Ŕ“Ţ, ŠâŸş˜a–ç1 (1–Ɖu): ‘ć40‰ń“ú–{‹š‘BŒ¤‹†‰ď (2021/2/6), WebŠJĂ.


’nˆćŽ™“ś¸_‰Čˆă—ĂŠw


Äśˆă—ĂŒ`ŹŠO‰ČŠw


’nˆć‘‡ˆă—ĂŠw


‰ŠÇŤ’°ŽžŠł‹łˆçE—Տ°Œ¤‹†Šw


Á‰ťŠí“ŕ‰ČŠw

[Šwp˜_•ś]

110090. [Œ´’˜] Randomized study of prevention of gastrointestinal toxicities by nutritional support using an amino acid-rich elemental diet during chemotherapy in patients with esophageal cancer (KDOG 1101). Katada C1, Fukazawa S2, Sugawara M3, Sakamoto Y, Takahashi K, Takahashi A4, Watanabe A1, Wada T1, Ishido K1, Furue Y1, Harada H5, Hosoda K5, Yamashita K5,6, Hiki N5, Sato T7, Ichikawa T8, Shichiri M9, Tanabe S1,10, Koizumi W1: Esophagus 2021/4; 18 (2): 296-305. (Œ˜“ce—˜1, [‘ň˛ŒbŽq2, ›Œ´[L3, ‚‹´ˆŸ‹IŽq4, “n糍WŽŻ1, ˜a“c‘ń–ç1, ÎŒËŒŞŽŸ1, ŒĂ]N–ž1, Œ´“cG‹P5, ×“c@Œj5, ŽR‰şŒpŽj5,6, ”äŠé’źŽ÷5, ˛“Ą•˜Y7, Žsě‘¸•ś8, Žľ—˘áÁ‹`9, “c糁@‘1,10, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2‰h—{•”, 3–ňÜ•”, 4ŠĹŒě•”, 5ă•”Á‰ťŠÇŠO, 6V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 7ˆă—Ă‹Zp‹łˆç, 8ˆă—ÉqśŠw•”, 9“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 10V˘‹Iˆă—ÁEć’[ˆă—Ă)

110091. [Œ´’˜] Determinant Factors on Differences in Survival for Gastric Cancer Between the United States and Japan Using Nationwide Databases. Ito Y, Miyashiro I, Ishikawa T, Akazawa K, Fukui K, Katai H, Nunobe S, Oda I, Isobe Y, Tsujitani S, Ono H, Tanabe S1,2, Fukagawa T, Suzuki S, Kakeji Y, Sasako M, Bilchik A, Fujita M: J Epidemiol 2021/4; 31 (4): 241-8. (“c糁@‘1,2: 1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2Á‰ťŠí“ŕ)

110092. [Œ´’˜] Clinicopathological Features of Autoimmune Hepatitis with IgG4-Positive Plasma Cell Infiltration. Arase Y, Matsumoto K, Anzai K, Tsuruya K, Sugiyama S, Yoshihara S, Hirose S, Uojima H1, Hidaka H1, Nakazawa T1, Deguchi R, Kojima S, Takashimizu S, Shiraishi K, Shirai T, Kagawa T: Dig Dis 2021/5; 39 (3): 225-33. (‹›“ˆ°‹I1, “ú‚@‰›1, ’†ŕV‹MG1: 1Á‰ťŠí“ŕ)

110093. [Œ´’˜] Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease. Wada N1, Uojima H1, Satoh T2, Okina S3, Iwasaki S1, Shao X4, Takiguchi H, Arase Y, Itokawa N, Atsukawa M, Miyazaki K5, Hidaka H1, Kako M, Kagawa T, Iwakiri K, Horie R2, Suzuki T3, Koizumi W1: Dig Dis 2021/5; 39 (3): 234-42. (˜a“cŽ‹v1, ‹›“ˆ°‹I1, ˛“Ą—˛Ži2, ‰Ľ@‘c˝3, ŠâčGˆę˜Y1, Ó@ŕV“4, ‹{ř“_“ń5, “ú‚@‰›1, –x]—Lję2, —é–Ř—˛_3, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2ˆă—ÉqśŠw•”, 3ŒŒ‰t“ŕ, 4‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 5—AŒŒE×–EˆÚA)

110094. [Œ´’˜] Usefulness of endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma in elderly patients: a single-center retrospective cohort study. Ishido K1, Tanabe S1,2, Katada C1, Kubota Y1, Furue Y1, Wada T1, Watanabe A1, Koizumi W1: Jpn J Clin Oncol 2021/5; 51 (6): 895-904. (ÎŒËŒŞŽŸ1, “c糁@‘1,2, Œ˜“ce—˜1, ‹v•Ű“c—z1, ŒĂ]N–ž1, ˜a“c‘ń–ç1, “n糍WŽŻ1, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă)

110095. [Œ´’˜] Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma. Tsujie M, Iwai T1, Kubo S, Ura T, Hatano E, Sakai D, Takeda Y, Kaibori M, Kobayashi T, Katanuma A, Katayose Y, Fukase K: Jpn J Clin Oncol 2021/5; 51 (6): 911-7. (Šâˆä’m‹v1: 1Á‰ťŠí“ŕ)

110096. [Œ´’˜] Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response. Toyoda H, Hiraoka A, Uojima H1, Nozaki A, Shimada N, Takaguchi K, Abe H, Atsukawa M, Matsuura K, Ishikawa T, Mikami S, Watanabe T, Itobayashi E, Tsuji K, Arai T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Okubo T, Ehira T, Kumada T, Tanaka J: Hepatol Commun 2021/5; 5 (7): 1290-9. (‹›“ˆ°‹I1: 1Á‰ťŠí“ŕ)

110097. [Œ´’˜] Surgically treated gastric cancer in Japan: 2011 annual report of the national clinical database gastric cancer registry. Suzuki S, Takahashi A, Ishikawa T, Akazawa K, Katai H, Isobe Y, Miyashiro I, Ono H, Tanabe S1,2, Fukagawa T, Muro K, Nunobe S, Kadowaki S, Suzuki H, Irino T, Usune S, Miyata H, Kakeji Y, Registration Committee of the Japanese Gastric Cancer Association: Gastric Cancer 2021/5; 24 (3): 545-66. (“c糁@‘1,2: 1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2Á‰ťŠí“ŕ)

110098. [Œ´’˜] Confirming Whether Fine Needle Biopsy Device Shortens the Learning Curve of Endoscopic Ultrasound-Guided Tissue Acquisition Without Rapid Onsite Evaluation. Lin MY, Wu CL, Kida M1, Chang WL,Sheu BS: Clin Endosc 2021/5; 54 (3): 420-7. (–Ř“cŒőL1: 1Á‰ťŠí“ŕ)

110099. [Œ´’˜] Clinicopathological Features of Autoimmune Hepatitis with IgG4-Positive Plasma Cell Infiltration. Arase Y, Matsumoto K, Anzai K, Tsuruya K, Sugiyama S, Yoshihara S, Hirose S, Uojima H1, Hidaka H1, Nakazawa T1, Deguchi R, Kojima S, Takashimizu S, Shiraishi K, Shirai T, Kagawa T: Dig Dis 2021/5; 39 (3): 225-33. (‹›“ˆ°‹I1, “ú‚@‰›1, ’†ŕV‹MG1: 1Á‰ťŠí“ŕ)

110100. [Œ´’˜] New image-processing technology for endoscopic ultrasound-guided fine-needle aspiration biopsy specimen evaluation in patients with pancreatic cancer. Okuwaki K1, Imaizumi H1, Kida M1, Masutani H1, Watanabe M1, Adachi K2, Tadehara M2, Tamaki A2, Iwai T1, Yamauchi H1, Hasegawa R1, Kaneko T1, Kurosu T1, Koizumi W1: DEN open 2021/6; 2 (1): e21. (‰œ˜e‹ť‰î1, Ąň@O1, –Ř“cŒőL1, Ą’JŠ°ˆČ1, “n•Ó^ˆč1, ˆŔ’B@‰ő2, äřŒ´Ť—Ç2, ‹Ę’u–žŠ°2, Šâˆä’m‹v1, ŽR“ŕ_Žj1, ’ˇ’Jě—Í–ç1, ‹ŕŽq@‹œ1, •{‹M_1, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110101. [Œ´’˜] Transoral surgery for superficial head and neck cancer: National Multi-Center Survey in Japan. Katada C1, Muto M, Fujii S, Yokoyama T, Yano T, Watanabe A, Iizuka T, Yoshinaga S, Tateya I, Mitani H, Shimizu Y, Takahashi A, Kamijo T, Hanaoka N, Abe M, Shiotani A, Kano K2, Asada Y, Matsuhashi T, Umeno H, Okami K, Goda K, Hori S, Ono Y, Terai S, Nagami Y, Takemura K, Kawada K, Ando M, Shimeno N, Arai A, Sakamoto Y, Ichinoe M3, Nemoto T, Fujita M, Watanabe H, Shimoda T, Ochiai A, Kato T, Hayashi R: Cancer Med 2021/6; 10 (12): 3848-61. (Œ˜“ce—˜1, ‰Á”[Fˆę2 ˆęŒËš–ž3: 1Á‰ťŠí“ŕ, 2Ž¨•@ˆôAE“Şčň•”ŠO, 3•a—)

110102. [Œ´’˜] Defining the endoscopic ultrasound features of chronic pancreatitis in Asians: a multicenter validation study. Koh CJ, Lakhtakia S, Kida M1, Lesmana CRA, Ang TL, Vu CKF, Aye TT, Park SH, Almadi MA, Chong CC, Tang RSY, Wu X, Hilmi I, Dhir V, Pausawasdi N, Basha J, Jin ZD, Yang AM, Teoh AYB, Seo DW, Wang HP, Ho KY: Endoscop. 2021/6; 53 (6): 595-602. (–Ř“cŒőL1: 1Á‰ťŠí“ŕ)

110103. [Œ´’˜] Histopathological comparison of aspiration and biopsy needles in endoscopic ultrasound-guided tissue acquisition in patients with subepithelial lesions. Watanabe M1, Okuwaki K1, Kida M1, Tadehara M2, Adachi K2, Masutani H1, Tamaki A2, Imaizumi H1, Iwai T1, Yamauchi H1, Kaneko T1, Hasegawa R1, Kurosu T1, Koizumi W1: Diagn Cytopathol 2021/7; 49 (7): 856-63. (“n粐^ˆč1, ‰œ˜e‹ť‰î1, –Ř“cŒőL1, äřŒ´Ť—Ç2, ˆŔ’B@‰ő2, Ą’JŠ°ˆČ1, ‹Ę’u–žŠ°2, Ąň@O1, Šâˆä’m‹v1, ŽR“ŕ_Žj1, ‹ŕŽq@‹œ1, ’ˇ’Jě—Í–ç1, •{‹M_1, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110104. [Œ´’˜] Cholecystitis after Placement of Covered Self-Expandable Metallic Stents in Patients with Distal Malignant Biliary Obstructions. Watanabe M1, Okuwaki K1, Woo J2, Kida M1, Imaizumi H1, Iwai T1, Yamauchi H1, Kaneko T1, Hasegawa R1, Kurosu T1, Minato N1, Haradome H3, Koizumi W1: Clin Endosc 2021/7; 54 (4): 589-95. (“n粐^ˆč1, ‰œ˜e‹ť‰î1, âZ@@2, –Ř“cŒőL1, Ąň@O1, Šâˆä’m‹v1, ŽR“ŕ_Žj1, ‹ŕŽq@‹œ1, ’ˇ’Jě—Í–ç1, •{‹M_1, –Š@Ž‹M1, Œ´—ŻOŽ÷3, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2•úŽËü (‰ć‘œ), 3V˘‹Iˆă—ÁEć’[ˆă—Ă)

110027. [Œ´’˜] Macrophages contribute to liver repair after monocrotaline-induced liver injury via SDF-1/CXCR4. Otaka F1, Ito Y2, Nakamoto S3, Nishizawa N3, Hyodo T4, Hosono K2, Majima M2, Koizumi W1, Amano H2: Exp Ther Med 2021/7; 22 (1): 668. (‘ĺ‚Žjš1, ˆÉ“Ą‹`–ç2, ’†–{CŽi3, źŕVL‹ą3, •ş“Ş“O–ç4, ×–ě‰Á“ŢŽq2, ”n“ˆł—˛2, Źň˜aŽO˜Y1, “V–ě‰pŽ÷2: 1Á‰ťŠí“ŕ, 2–ň—, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4Œ`ŹE”ü—eŠO)

110105. [Œ´’˜] Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice. Toyoda H, Leong J, Landis C, Atsukawa M, Watanabe T, Huang DQ, Liu J, Quek SXZ, Ishikawa T, Arai T, Yokohama K, Chuma M, Takaguchi K, Uojima H1, Senoo T, Dang H, Maeda M, Hoang J, Le RH, Yasuda S, Thin KN, Tran S, Chien N, Henry L, Asai A, Fukunishi S, Cheung R, Lim SG, Trinh HN, Nguyen MH: Hepatology 2021/8; 74 (2): 656-66. (‹›“ˆ°‹I1: 1Á‰ťŠí“ŕ)

110106. [Œ´’˜] The Diagnosis of Drug-induced Liver Injury: Current Diagnostic Ability and Future Challenges of the Digestive Disease Week-Japan 2004 Scale 15 Years after Its Proposal. Watanabe M1, Shibuya A2, Yokomori H3, Koizumi W1: Intern Med 2021/8; 60 (16): 2557-68. (“n粐^˛1, a’J–ž—˛2, ‰ĄXOş3, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2ˆă—ĂˆŔ‘SEŠÇ—, 3–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

110107. [Œ´’˜] Diagnostic Ability of High-definition Imaging Using Ultraslim Endoscopes in Early Gastric Cancer. Sugita T, Suzuki S, Ichijima R, Ogura K, Kusano C1, Ikehara H, Gotoda T, Moriyama M: J Gastric Cancer 2021/9; 21 (3): 246-57. (‘–ě@‰›1: 1Á‰ťŠí“ŕ)

110108. [Œ´’˜] Prospective study for an independent predictor of prognosis in liver cirrhosis based on the new sarcopenia criteria produced by the Japan Society of Hepatology. Kikuchi N, Uojima H1, Hidaka H1, Iwasaki S1, Wada N1, Kubota K1, Nakazawa T1, Shibuya A2, Fujikawa T, Kako M, Sato T3, Koizumi W1: Hepatol Res 2021/9; 51 (9): 968-78. (‹›“ˆ°‹I1, “ú‚@‰›1, ŠâčGˆę˜Y1, ˜a“cŽ‹v1, ŒE“cK‰î1, ’†ŕV‹MG1, a’J–ž—˛2, ˛“ĄĆŽq3, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2ˆă—ĂˆŔ‘SEŠÇ—, 3‰h—{•”)

110028. [Œ´’˜] Recovery of Liver Sinusoidal Endothelial Cells Following Monocrotaline-induced Liver Injury. Otaka F1, Ito Y2, Goto T1, Kojo K3, Tanabe M1, Hosono K2, Majima M2, Koizumi W1, Amano H2: In Vivo 2021/9-10; 35 (5): 2577-87. (‘ĺ‚Žjš1, ˆÉ“Ą‹`–ç2, Œă“Ą‘ě–ç1, ŒĂé@Œ›3, “c糔ü“Ţ1, ×–ě‰Á“ŢŽq2, ”n“ˆł—˛2, Źň˜aŽO˜Y1, “V–ě‰pŽ÷2: 1Á‰ťŠí“ŕ, 2–ň—, 3‰ş•”Á‰ťŠÇŠO)

110109. [Œ´’˜] Safety and feasibility of laparoscopic and endoscopic cooperative surgery for duodenal neoplasm: a retrospective multicenter study. Nunobe S1, Ri M1, Yamazaki K1, Uraoka M1, Ohata K1, Kitazono I1, Terashima M1, Yamagata Y1, Tanabe S1,2,3, Abe N1, Tsuji T1, Niimi K1, Kawakubo H1, Tsukada T1, Kitashiro S1, Ishizuka N1, Hiki N1,4 (1Society for the Study of Laparoscopic Endoscopic Cooperative Surgery): Endoscopy 2021/10; 53 (10): 1065-8. (“c糁@‘1,2,3, ”äŠé’źŽ÷1,4: 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3Á‰ťŠí“ŕ, 4ă•”Á‰ťŠÇŠO)

110110. [Œ´’˜] A prospective multicenter study of endoscopic ultrasound-guided fine needle biopsy using a 22-gauge Franseen needle for pancreatic solid lesions. Ishigaki K1, Nakai Y1, Sasahira N1, Sugimori K1, Kitamura K1, Iwai T1,2, Matsubara S1, Shimura K1, Itoi T1, Ryozawa S1, Ushio J1, Doi S1, Imazu H1, Maetani I1, Isayama H1 (1Acquire Study Group): J Gastroenterol Hepatol 2021/10; 36 (10): 2754-61. (Šâˆä’m‹v1,2: 2Á‰ťŠí“ŕ)

110111. [Œ´’˜] Direct oral anticoagulants increase bleeding risk after endoscopic sphincterotomy: a retrospective study. Masuda S, Koizumi K, Nishino T, Tazawa T, Kimura K, Tasaki J, Ichita C, Sasaki A, Kako M, Uojima H1, Sugitani A: BMC Gastroenterol 2021/10; 24; 21 (1): 401. (‹›“ˆ°‹I1: 1Á‰ťŠí“ŕ)

110112. [Œ´’˜] Efficacy and safety of oral sulfate solution for bowel preparation in Japanese patients undergoing colonoscopy: Noninferiority-based, randomized, controlled study. Saito Y, Oka S, Tamai N, Kudo T, Kuniyoshi N, Shirakura T, Omae Y, Hamahata Y, Arai T, Tanaka S, Uedo N, Shimizu S, Fukuzawa M, Uraoka T, Ichinose S, Ogata H, Kobayashi K1,2, Saito S, Tajiri H: Dig Endosc 2021/11; 33 (7): 1131-8. (Ź—ѐ´“T1,2: 1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2Á‰ťŠí“ŕ)

110113. [Œ´’˜] Identifying Bleeding Etiologies by Endoscopy Affected Outcomes in 10,342 Cases With Hematochezia: CODE BLUE-J Study. Nagata N, Kobayashi K, Yamauchi A, Yamada A, Omori J, Ikeya T, Aoyama T, Tominaga N, Sato Y, Kishino T, Ishii N, Sawada T, Murata M, Takao A, Mizukami K, Kinjo K, Fujimori S, Uotani T, Fujita M, Sato H, Suzuki S, Narasaka T, Hayasaka J, Funabiki T, Kinjo Y, Mizuki A, Kiyotoki S, Mikami T, Gushima R, Fujii H, Fuyuno Y, Gunji N, Toya Y, Narimatsu K, Manabe N, Nagaike K, Kinjo T, Sumida Y, Funakoshi S, Kawagishi K1, Matsuhashi T, Komaki Y, Miki K, Watanabe K, Fukuzawa M, Itoi T, Uemura N, Kawai T, Kaise M: Am J Gastroenterol 2021/11; 116 (11): 2222-34. (ěŠÝ‰Á“Ţ1: 1Á‰ťŠí“ŕ)

110114. [Œ´’˜] Dietary intake of vegetables, fruit, and antioxidants and risk of ulcerative colitis: A case-control study in Japan. Miyake Y1, Tanaka K1, Nagata C1, Furukawa S1, Andoh A1, Yokoyama T1, Yoshimura N1, Mori K1, Ninomiya T1, Yamamoto Y1, Takeshita E1, Ikeda Y1, Saito M1, Ohashi K1, Imaeda H1, Kakimoto K1, Higuchi K1, Nunoi H1, Mizukami Y1, Suzuki S1, Hiraoka S1, Okada H1, Kawasaki K1, Higashiyama M1, Hokari R1, Miura H1, Miyake T1, Kumagi T1, Kato H1, Hato N1, Sayama K1, Hiasa Y1; 1Japan Ulcerative Colitis Study Group (Collaborators: Yokoyama K2, et al): Nutrition 2021/11-12; 91-92: 111378. (‰ĄŽR@ŒO2: 2Á‰ťŠí“ŕ)

110115. [Œ´’˜] Nafamostat Mesylate is Not Effective in Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis. Matsumoto T1, Okuwaki K1, Imaizumi H1, Kida M1, Iwai T1, Yamauchi H1, Kaneko T1, Hasegawa R1, Masutani H1, Tadehara M2, Adachi K2, Watanabe M1, Kurosu T1, Tamaki A2, Kikuchi H1, Ohno T1, Koizumi W1: Dig Dis Sci 2021/12; 66 (12): 4475-84. (ź–{‚–ž1, ‰œ˜e‹ť‰î1, Ąň@O1, –Ř“cŒőL1, Šâˆä’m‹v1, ŽR“ŕ_Žj1, ‹ŕŽq@‹œ1, ’ˇ’Jě—Í–ç1, Ą’JŠ°ˆČ1, äřŒ´Ť—Ç2, ˆŔ’B@‰ő2, “n•Ó^ˆč1, •{‹M_1, ‹Ę’u–žŠ°2, ‹e’nG•F1, ‘ĺ–ě@—˛1, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110116. [Œ´’˜] Factors for unsuccessful endoscopic hemostasis in patients with severe peptic ulcer bleeding. Kubota Y1, Yamauchi H1, Nakatani K2, Iwai T1, Ishido K1, Masuda T2, Maruhashi T2, Tanabe S1,3: Scand J Gastroenterol 2021/12; 56 (12): 1396-405. (‹v•Ű“c—z1, ŽR“ŕ_Žj1, ’†’JŒ’“l2, Šâˆä’m‹v1, ÎŒËŒŞŽŸ1, ‘“c’qŹ2, ŠŰ‹´Fş2, “c糁@‘1,3: 1Á‰ťŠí“ŕ, 2‹~–˝, 3V˘‹Iˆă—ÁEć’[ˆă—Ă)

110117. [Œ´’˜] Predictive Significance of Promoter DNA Methylation of Cysteine Dioxygenase Type 1 (CDO1) in Metachronous Gastric Cancer. Kubota Y1, Tanabe S1,2, Azuma M1, Horio K3, Fujiyama Y4, Soeno T4, Furue Y1, Wada T1, Watanabe A1, Ishido K1, Katada C1, Yamashita K5, Koizumi W1, Kusano C1: J Gastric Cancer 2021/12; 21 (4): 379-91. (‹v•Ű“c—z1, “c糁@‘1,2, “Œ@’q1, –x”ö˜aŽőŒb3, “ĄŽR–FŽ÷4, “Y–ěF•ś4, ŒĂ]N–ž1, ˜a“c‘ń–ç1, “n糍WŽŻ1, ÎŒËŒŞŽŸ1, Œ˜“ce—˜1, ŽR‰şŒpŽj5, Źň˜aŽO˜Y1, ‘–ě@‰›1: 1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3•a‘ԁEf—ĂŒn, 4‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 5V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

110118. [Œ´’˜] A genome-wide association study identifying SVEP1 variant as a predictor of response to tolvaptan for cirrhotic ascites. Kawaratani H, Sawai H, Onishi M, Kogiso T, Shimada N, Uojima H1, Nakajima T, Matsumoto N, Ikejima K, Ishikawa T, Terai S, Motoyama H, Komori A, Hirashima N, Saito S, Eguchi Y, Nojima M, Kawai Y, Tateyama M, Yoshiji H, Tanaka Y: Liver Int 2021/12; 41 (12): 2944-53. (‹›“ˆ°‹I1: 1Á‰ťŠí“ŕ)

110119. [Œ´’˜] Comparative study between sorafenib and lenvatinib as the first-line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real-world setting. Fukushima T, Morimoto M, Ueno M, Kubota K1, Uojima H1, Hidaka H1, Chuma M, Numata K, Tsuruya K, Hirose S, Kagawa T, Hattori N, Watanabe T, Matsunaga K, Yamamoto K, Tanaka K, Maeda S: JGH Open 2021/12; 6 (1): 29-35. (ŒE“cK‰î1, ‹›“ˆ°‹I1, “ú‚@‰›1: 1Á‰ťŠí“ŕ)

110120. [Œ´’˜] Long term impact of vonoprazan-based Helicobacter pylori treatment on gut microbiota and its relation to post-treatment body weight changes. Suzuki S, Gotoda T, Takano C, Horii T, Sugita T, Ogura K, Ichijima R, Kusano C1, Ikehara H: Helicobacter 2021/12; 26 (6): e12851. (‘–ě@‰›1: 1Á‰ťŠí“ŕ)

110121. [Œ´’˜] The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113. Yamada I1, Morizane C1, Okusaka T1, Mizusawa J1, Kataoka T1, Ueno M1, Ikeda M1, Okano N1, Todaka A1, Shimizu S1, Mizuno N1, Sekimoto M1, Tobimatsu K1, Yamaguchi H1, Nishina T1, Shirakawa H1, Kojima Y1, Oono T1, Kawamoto Y1, Furukawa M1, Iwai T1,2, Sudo K1, Okamura K1, Yamashita T1, Kato N1, Shioji K1, Shimizu K1, Nakagohri T1, Kamata K1, Ishii H1, FuruseJ1 (1JCOG-HBPOG): Sci Rep 2022/1; 12 (1): 987. (Šâˆä’m‹v1,2: 2Á‰ťŠí“ŕ)

110122. [Œ´’˜] Current status of diagnostic and therapeutic colonoscopy in Japan: The Japan Endoscopic Database Project. Saito Y1, Kodashima S1, Matsuda T1, Matsuda K1, Fujishiro M1, Tanaka K1, Kobayashi K1,3, Katada C1,3, Horimatsu T1, Muto M1, Ohtsuka K1, Oda I1, Kato M1, Kida M1,3, Hoteya S1, Yamamoto H1, Ryozawa S1, Iwakiri R2, Kutsumi H2, Kato M2, Haruma K2, Fujimoto K2, Iishi H2, Ogata H2, Uemura N2, Kaminishi M2, Tajiri H2, Inoue H2 (1MSED-J (Minimal Standard Endoscopic Database) Creation Subcommittee, Japan Gastroenterological Endoscopy Society, 2JED (Japan Endoscopy Database) Project Committee, Japan Gastroenterological Endoscopy Society): Dig Endosc 2022/1; 34 (1): 144-52. (Ź—ѐ´“T1,3, Œ˜“ce—˜1,3, –Ř“cŒőL1,3: 3Á‰ťŠí“ŕ)

110123. [Œ´’˜] Efficacy and factors affecting procedure results of short-type single-balloon enteroscopy-assisted ERCP for altered anatomy: a multicenter cohort in Japan. Tanisaka Y, Ryozawa S, Itoi T, Yamauchi H1, Katanuma A, Okabe Y, Irisawa A, Nakahara K, Iwasaki E, Ishii K, Kin T, Terabe H, Izawa N, Morita R, Minami K, Araki R, Fujita A, Ogawa T, Mizuide M, Kida M1: Gastrointest Endosc 2022/2; 95 (2): 310-8.e1. (ŽR“ŕ_Žj1, –Ř“cŒőL1: 1Á‰ťŠí“ŕ)

110030. [Œ´’˜] The role of thromboxane prostanoid receptor signaling in gastric ulcer healing. Yamane S1, Amano H2, Ito Y2, Betto T1, Matsui Y3, Koizumi W1, Narumiya S, Majima M2: Int J Exp Pathol 2022/2; 103 (1): 4-12. (ŽRŞ‘‹IŽq1, “V–ě‰pŽ÷2, ˆÉ“Ą‹`–ç2, •Ęác•üL1, źˆäŒ[•v3, Źň˜aŽO˜Y1, ”n“ˆł—˛2: 1Á‰ťŠí“ŕ, 2–ň—, 3ŒÄ‹zŠíŠO)

110124. [Œ´’˜] Endoscopic direct clipping versus indirect clipping for colonic diverticular bleeding: A large multicenter cohort study. Kishino T, Nagata N, Kobayashi K, Yamauchi A, Yamada A, Omori J, Ikeya T, Aoyama T, Tominaga N, Sato Y, Ishii N, Sawada T, Murata M, Takao A, Mizukami K, Kinjo K, Fujimori S, Uotani T, Fujita M, Sato H, Suzuki S, Narasaka T, Hayasaka J, Funabiki T, Kinjo Y, Mizuki A, Kiyotoki S, Mikami T, Gushima R, Fujii H, Fuyuno Y, Gunji N, Toya Y, Narimatsu K, Manabe N, Nagaike K, Kinjo T, Sumida Y, Funakoshi S, Kawagishi K1, Matsuhashi T, Komaki Y, Miki K, Watanabe K, Kaise M: United European Gastroenterol J 2022/2; 10 (1): 93-103. (ěŠÝ‰Á“Ţ1: 1Á‰ťŠí“ŕ)

110125. [Œ´’˜] Multicenter prospective study of the efficacy of stereomicroscopic on-site evaluation in endoscopic ultrasound-guided tissue acquisition in patients with pancreatic cancer. Watanabe M1, Okuwaki K1, Kida M1, Imaizumi H1, Matsumoto T1, Iwai T1, Hasegawa R1, Masutani H1, Kurosu T11, Minato N1, Tamaki A2, Ishizaki J, Kusano C1: Pancreatology 2022/3; 22 (2): 311-6. (“n•Ó^ˆč1, ‰œ˜e‹ť‰î1, –Ř“cŒőL1, Ąň@O1, ź–{‚–ž1, Šâˆä’m‹v1, ’ˇ’Jě—Í–ç1, Ą’JŠ°ˆČ1, •{‹M_1, –Š@Ž‹M1, ‹Ę’u–žŠ°2, ‘–ě@‰›1: 1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110126. [Œ´’˜] Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis. Atsukawa M1, Tsubota A1, Kondo C1, Toyoda H1, Nakamuta M1, Takaguchi K1, Watanabe T1, Hiraoka A1, Uojima H1,2, Ishikawa T1, Iwasa M1, Tada T1, Nozaki A1, Chuma M1, Fukunishi S1, Asano T1, Ogawa C1, Abe H1, Kato K1, Hotta N1, Shima T1, Matsuura K1, Mikami S1, Tachi Y1, Fujioka S1, Okubo H1, Shimada N1, Tani J1, Morishita A1, Hidaka I1, Moriya A1, Tsuji K1, Akahane T1, Okubo T1, Arai T1, Kitamura M1, Morita K1, Kawata K1, Tanaka Y1, Kumada T1, Iwakiri K1 (1KTK49 Liver Study Group): Hepatol Res 2022/3; 52 (3): 235-46. (‹›“ˆ°‹I1,2: 2Á‰ťŠí“ŕ)

110127. [Œ´’˜] Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis. Chuma M, Uojima H1, Hattori N, Arase Y, Fukushima T, Hirose S, Kobayashi S, Ueno M, Tezuka S, Iwasaki S1, Wada N1, Kubota K1, Tsuruya K, Shimma Y, Ikeda H, Ehira T, Tokoro C, Iwase S, Miura Y, Moriya S, Watanabe T, Hidaka H1, Morimoto M, Numata K, Kusano C1, Kagawa T, Maeda S: Hepatol Res 2022/3; 52 (3): 269-80. (‹›“ˆ°‹I1, ŠâčGˆę˜Y1, ˜a“cŽ‹v1, ŒE“cK‰î1, “ú‚@‰›1, ‘–ě@‰›1: 1Á‰ťŠí“ŕ)

110038. [Œ´’˜] CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer. Adachi K1, Sakurai Y2, Ichinoe M2, Tadehara M1, Tamaki A1, Kesen Y2, Kato T2, Mii S, Enomoto A, Takahashi M, Koizumi W3, Murakumo Y2: Virchows Arch 2022/3; 480 (4): 819-29. doi: 10.1007/s00428-021-03230-2. Epub 2021 Nov 11. (ˆŔ’B@‰ő1, ŸNˆä–ő‚2, ˆęŒËš–ž2, äřŒ´Ť—Ç1, ‹Ę’u–žŠ°1, Ÿ†ĺ—T—œ2, ‰Á“Ą‘ôĆ2, Źň˜aŽO˜Y3, ‘ş‰_–FŽ÷2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2•a—, 3Á‰ťŠí“ŕ)

310005. [Ç—á•ń] The First Case of Metastatic Pancreatic Leiomyosarcoma Derived from the Urinary Bladder Diagnosed Using an Endoscopic Ultrasound-guided Fine-needle Biopsy. Ishizaki A1, Okuwaki K1, Kida M1, Imaizumi H1, Iwai T1, Yamauchi H1, Kaneko T1, Hasegawa R1, Masutani H1, Tadehara M2, Adachi K2, Watanabe M1, Kurosu T1, Tamaki A2, Koizumi W1: Intern Med 2021/5; 60 (9): 1377-81. (Îč‚ ‚â“ß1, ‰œ˜e‹ť‰î1, –Ř“cŒőL1, Ąň@O1, Šâˆä’m‹v1, ŽR“ŕ_Žj1, ‹ŕŽq@‹œ1, ’ˇ’Jě—Í–ç1, Ą’JŠ°ˆČ1, äřŒ´Ť—Ç2, ˆŔ’B@‰ő2, “n•Ó^ˆč1, •{‹M_1, ‹Ę’u–žŠ°2, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

310006. [Ç—á•ń] Pancreatic Schwannoma Diagnosed by Endoscopic Ultrasound-guided Fine-needle Aspiration. Hanaoka T1, Okuwaki K1, Imaizumi H1, Imawari Y1, Iwai T1, Yamauchi H1, Hasegawa R1, Adachi K2, Tadehara M2, Kurosu T1, Watanabe M1, Tamaki A2, Kida M1, Koizumi W1: Intern Med 2021/5; 60 (9): 1389-95. (‰Ô‰Ş‘ž˜Y1, ‰œ˜e‹ť‰î1, Ąň@O1, ˆä‰ô—C‰î1, Šâˆä’m‹v1, ŽR“ŕ_Žj1, ’ˇ’Jě—Í–ç1, ˆŔ’B@‰ő2, äřŒ´Ť—Ç2, •{‹M_1, “n•Ó^ˆč1, ‹Ę’u–žŠ°2, –Ř“cŒőL1, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

310007. [Ç—á•ń] A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma. Iwasaki S1, Hidaka H1, Uojima H1, Hashimura M2, Nabeta T2, Sanoyama I3, Wada N1, Kubota K1, Nakazawa T1, Shibuya A4, Koizumi W1: Clin J Gastroenterol 2021/8; 14 (4): 1233-9. (ŠâčGˆę˜Y1, “ú‚@‰›1, ‹›“ˆ°‹I1, ‹´‘ş”ü•Ű2, “ç“c@Œ’2, áÁŽR@“ž3, ˜a“cŽ‹v1, ŒE“cK‰î1, ’†ŕV‹MG1, a’J–ž—˛4, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2zŠÂŠí“ŕ, 3•a—, 4ˆă—ĂˆŔ‘SEŠÇ—)

310008. [Ç—á•ń] Endoscopic submucosal dissection of cervical esophageal cancer with hypopharyngeal invasion using a curved laryngoscope. Furue Y1, Katada C1, Kano K2, Yoshida T3, Yamashita T2: VideoGIE 2021/9; 6(12): 533-5. (ŒĂ]N–ž1, Œ˜“ce—˜1, ‰Á”[Fˆę2, ‹g“c@Œ÷3, ŽR‰ş@‘ń2: 1Á‰ťŠí“ŕ, 2Ž¨•@ˆôAE“Şčň•”ŠO, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

310009. [Ç—á•ń] A case of pancreatic neuroendocrine carcinoma with a favorable clinical response to pembrolizumab. Kogami T1, Iwai T1, Kida M1, Okuwaki K1, Hasegawa R1, Kurosu T1, Watanabe M1, Matsushita M1, Imawari K1, Adachi K2, Tadehara M2, Tamaki A2, Imaizumi H1, Koizumi W1: Clin J Gastroenterol 2021/12; 14 (6): 1804-10. (ƒă‘ž˜Y1, Šâˆä’m‹v1, –Ř“cŒőL1, ‰œ˜e‹ť‰î1, ’ˇ’Jě—Í–ç1, •{‹M_1, “n•Ó^ˆč1, ź‰şš—T1, ˆä‰ô‰ŔŘ1, ˆŔ’B@‰ő2, äřŒ´Ť—Ç2, ‹Ę’u–žŠ°2, Ąň@O1, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

310010. [Ç—á•ń] Cartilage-hair Hypoplasia Complicated with Liver Cirrhosis Due to Chronic Intrahepatic Cholestasis. Kogami T1, Uojima H1, Ebato T2, Bando Y2, Hoshino A3, Saegusa M3, Ohbu M, Iwasaki S1, Wada N1, Kubota K1, Tanaka Y1, Hidaka H1, Nakazawa T1, Shibuya A4, Koizumi W1: Intern Med 2021/11; 60 (21): 3427-33. (ƒă‘ž˜Y1, ‹›“ˆ°‹I1, ]”gŒËF•ă2, â“Œ—R‹I2, Ż–쏺–F3, ŽOŽ}@M3, ŠâčGˆę˜Y1, ˜a“cŽ‹v1, ŒE“cK‰î1, “c’†ŒŤ–ž1, “ú‚@‰›1, ’†ŕV‹MG1, a’J–ž—˛4, Źň˜aŽO˜Y1: 1Á‰ťŠí“ŕ, 2ŹŽ™, 3•a—, 4ˆă—ĂˆŔ‘SEŠÇ—)

320001. [Ç—á•ń] p‘Of’f‚މ”\‚Ĺ‚ ‚Á‚˝ƒNƒ[ƒ“•a‡•š‘ŠúŹ’°Šŕ‚Ě1—á. ’†”ö‰rˆę, ’C–¤Œ’Žu, •–Ř”Ž‰î, “ń–؁@—š, Ź‹ŕˆäˆę—˛, ™“c@ş, —с@Gs, ‰ĄŽR@ŒO1 (1Á‰ťŠí“ŕ): “ú–{Á‰ťŠí•aŠw‰ďŽGŽ 2021/7: 118 (7): 645-51.

510005. [‘ŕ] Is There an Increasing Incidence of Gastroesophageal Junctional Adenocarcinoma and Barrett Esophagus in Asia? A Review of Diagnostic Conundrums. Tan PO, Soh AYS, Kusano C1, Lee YY, Gotoda T: Digestion 2022/1; 103 (1): 37-44. (‘–ě@‰›1: 1Á‰ťŠí“ŕ)

510006. [‘ŕ] The Ideal Helicobacter pylori Treatment for the Present and the Future. Suzuki S, Kusano C1, Horii T, Ichijima R, Ikehara H: Digestion 2022/1; 103 (1): 62-8. (‘–ě@‰›1: 1Á‰ťŠí“ŕ)

522024. [uŔ]y“ÁW: ‹Ů‹}“ŕŽ‹‹ž‚̍Ąz[Še˜_] II. Ź’°‘ĺ’°‚Ě‹Ů‹}“ŕŽ‹‹ž@‘ĺ’°oŒŒ. Ź—ѐ´“T1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2Á‰ťŠí“ŕ): Á‰ťŠí“ŕŽ‹‹ž 2021/4; 33 (4): 740-5.

522025. [uŔ]y“ÁW: äXŽžŠł‚ɑ΂ˇ‚é“ŕŽ‹‹žŽĄ—Ă‚Ě‚ˇ‚ׂāz[Še˜_] I. äXŽžŠł‚ɑ΂ˇ‚é“ŕŽ‹‹žf’f@äXŽîᇂɑ΂ˇ‚éEUS-FNA‚É‚¨‚Ż‚éH•v‚Ć–â‘č“_, ĄŒă‚Ě“W–]. ‰œ˜e‹ť‰î1, –Ř“cŒőL1, Šâˆä’m‹v1, ’ˇ’Jě—Í–ç1, Ą’JŠ°ˆČ1, ˆŔ’B@‰ő2, äřŒ´Ť—Ç2, •{‹M_1, “n•Ó^ˆč1, ‹Ę’u–žŠ°2, Ąň@O1 (1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): Á‰ťŠí“ŕŽ‹‹ž 2021/9; 33 (9): 1411-7.

522026. [uŔ]y“ÁW: –ĺ–Źˆł˜´iÇ‚ɑ΂ˇ‚éf—Áz3-8. –ĺ–Źˆł˜´iÇ‚Ě‚¨‚ŕ‚ȍ‡•šÇ|f—Ă‚ĚŽŔŰ@(8) –ĺ–ŹŒŒđÇ. “ú‚@‰›1, ‹›“ˆ°‹I1 (1Á‰ťŠí“ŕ), —ŐଏÁ‰ťŠí“ŕ‰Č 2021/10; 36 (12): 1546-53.

522027. [uŔ] “ÁW: ŠĚ‘Ÿf—Ă2021@ƒAƒeƒ]ƒŠƒYƒ}ƒu+ƒxƒoƒVƒYƒ}ƒu“oęŒă‚Ě“WŠJz9) ƒAƒeƒ]ƒŠƒYƒ}ƒu‚ĆƒxƒoƒVƒYƒ}ƒuŽĄ—Ă“ą“ü‘O‚¨‚ć‚ŃŽĄ—Ă’†‚Ě–ĺ–Źˆł˜´iÇ‚Ěƒ}ƒlƒWƒƒ“ƒg|H“šˆÝĂ–ŹáŽ‚𒆐S‚Ɂ|. “ú‚@‰›1, Œ´@—E•ă1, ‹›“ˆ°‹I1 (1Á‰ťŠí“ŕ): ŠĚ‘ŸƒNƒŠƒjƒJƒ‹ƒAƒbƒvƒf[ƒg 2021/10; 7 (1): 63-6.

522028. [uŔ]y‘ĺ’°“ŕŽ‹‹žƒXƒLƒ‹ƒAƒbƒv|‘}“ü‚Š‚çf’f‚܂Łz[Še˜_] III ŠÔˆá‚˘‚Ě‚Č‚˘Characterization (Žż“If’f`[’B“xf’f) ‚đ–ÚŽw‚ľ‚ā@ EUS‚đ‹É‚ß‚é. Ź—ѐ´“T1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2Á‰ťŠí“ŕ): Á‰ťŠí“ŕŽ‹‹ž 2021/10; 33 (10): 1629-33.

522029. [uŔ]y“ÁW: Ź’°“ŕŽ‹‹ž‚Ş”ƒ‚Ś‚˝ŽžŠłƒ}ƒl[ƒWƒƒ“ƒgz[Še˜_] B. f’f”\‚Ş‘ĺ‚Ť‚­Œüă‚ľ‚˝•a‘ԁ@‰ŠÇŤŽžŠł. ‰ĄŽR@ŒO1, Œ´“c—m•˝1, ˆÉ“Ą—˛Žm2, ‹ŕŕV@1, •Ęác•üL1, ěŠÝ‰Á“Ţ1, ˛“c”ü˜a1, Ź—ѐ´“T1,3, ‘–ě@‰›1 (1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă) Á‰ťŠí“ŕŽ‹‹ž 2021/12; 33 (12): 1874-86.

522030. [uŔ] Ă–ŹáŽŽĄ—Ă‚ĆŒŒŠÇ“஡—Ă, –ĺ–ŹŒŒđŽĄ—Ă “ú‚@‰›1, ‹›“ˆ°‹I1, ’†ŕV‹MG1 (1Á‰ťŠí“ŕ): “ú–{“ŕ‰ČŠw‰ďŽGŽ 2021/1; 111 (1): 66-73.

522031. [uŔ]y“ÁW: ŠĚd•ĎÇ‚̐f’fŽĄ—Ă‚ĚĹV’mŒŠzĂ–ŹáŽŽĄ—Ă‚ĆŒŒŠÇ“஡—Ă, –ĺ–ŹŒŒđŽĄ—Ă. “ú‚@‰›1, ‹›“ˆ°‹I1, ’†ŕV‹MG1 (1Á‰ťŠí“ŕ): “ú–{“ŕ‰ČŠw‰ďŽGŽ 2022/1; 111 (1): 66-73.

522032. [uŔ]yŠŕ“ŕŽ‹‹žf’f‚̍ŐVƒ€[ƒuƒƒ“ƒg|H. pylori‰AŤˆÝŠŕ‚Ě‚ˇ‚ׂāz[‘˜_] H. pylori‰AŤˆÝŠŕ‚Ƃ͉˝‚Š?|Ą‚Ü‚Ĺ‚Ć‚ą‚ę‚Š‚ç. ‘–ě@‰›1, ’rŒ´‹v’Š, Œă“Ą“c‘ěŽu (1Á‰ťŠí“ŕ): Á‰ťŠí“ŕŽ‹‹ž 2022/2; 34 (2): 142-50.

522033. [uŔ]y‚ą‚ń‚Č‚Ć‚Ť‚Ç‚¤‚ˇ‚éz[Še˜_] IV ‘ĺ’°@[f’f] SD junction‚މz‚Ś‚ç‚ę‚Č‚˘. Ź—ѐ´“T1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2Á‰ťŠí“ŕ): Á‰ťŠí“ŕŽ‹‹ž 2022/3; 34 (3): 406-7.

530001. [‚ť‚Ě‘ź (Clinical Practice Guidelines)] Evidence-based clinical practice guidelines for liver cirrhosis 2020. Yoshiji H1,2, Nagoshi S1,2, Akahane T1,2, Asaoka Y1,2, Ueno Y1,2, Ogawa K1,2, Kawaguchi T1,2, Kurosaki M1,2, Sakaida I1,2, Shimizu M1,2, Taniai M1,2, Terai S1,2, Nishikawa H1,2, Hiasa Y1,2, Hidaka H1,2,3, Miwa H1,2, Chayama K2, Enomoto N1,2, Shimosegawa T1,2, Takehara T2, Koike K1,2 (1Guidelines Committee for Creating and Evaluating the Evidence-Based Clinical Practice Guidelines for Liver Cirrhosis, The Japanese Society of Gastroenterology, 2The Japan Society of hepatology): Hepatol Res 2021/7; 51 (7): 725-49. (“ú‚@‰›1,2,3: 3Á‰ťŠí“ŕ)

530002. [‚ť‚Ě‘ź (Clinical Practice Guidelines)] Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. Yoshiji H1,2, Nagoshi S1,2, Akahane T1,2, Asaoka Y1,2, Ueno Y1,2, Ogawa K1,2, Kawaguchi T1,2, Kurosaki M1,2, Sakaida I1,2, Shimizu M1,2, Taniai M1,2, Terai S1,2, Nishikawa H1,2, Hiasa Y1,2, Hidaka H1,2,3, Miwa H1,2, Chayama K2, Enomoto N1,2, Shimosegawa T1,2, Takehara T2, Koike 1,2 (1Guidelines Committee for Creating and Evaluating the Evidence-Based Clinical Practice Guidelines for Liver Cirrhosis, The Japanese Society of Gastroenterology, 2The Japan Society of hepatology): J Gastroenterol 2021/7; 56 (7): 593-619. (“ú‚@‰›1,2,3: 3Á‰ťŠí“ŕ)

530003. [‚ť‚Ě‘ź (Comment)] Endoscopic Closure After Endoscopic Resection for Superficial Non-Ampullary Duodenal Tumors. Tanabe S1,2, Wada T2: Clin Endosc 2021/7; 54 (4): 453-4. “c糁@‘1,2, ˜a“c‘ń–ç2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2Á‰ťŠí“ŕ)

530004. [‚ť‚Ě‘ź (Editorial)] Can we find a precise timing for endoscopic intervention in gastrointestinal bleeding? Kusano C1: Dig Endosc 2022/2; 34 (4): 750-2. (‘–ě@‰›1: 1Á‰ťŠí“ŕ)

[’˜@‘]

620014. [Šwp‘ (•Ş’SŽˇ•M)]yÁ‰ťŠÇf’fEŽĄ—ĂŽč‹Z‚Ě‚ˇ‚ׂÄ2021 (ˆÝ‚Ć’°2021”N5ŒŽ†‘Š§†)zˆôA“Ş: f’f@’ʏí“ŕŽ‹‹ž (ŒoŒű), p.532-3. ŒĂ]N–ž1, Œ˜“ce—˜1 (1Á‰ťŠí“ŕ), ˆăŠw‘‰@, “Œ‹ž, 2021/5”­s.

620015. [Šwp‘ (•Ş’SŽˇ•M)]yÁ‰ťŠÇf’fEŽĄ—ĂŽč‹Z‚Ě‚ˇ‚ׂÄ2021 (ˆÝ‚Ć’°2021”N5ŒŽ†‘Š§†)zˆÝ: ŽĄ—Á@ESDâ‰‘ĚŒn (Itknife, ITknife2), p.630-1. “c糁@‘1,2, ˜a“c‘ń–ç2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2Á‰ťŠí“ŕ), ˆăŠw‘‰@, “Œ‹ž, 2021/5”­s.

620016. [Šwp‘ (•Ş’SŽˇ•M)]yÁ‰ťŠÇf’fEŽĄ—ĂŽč‹Z‚Ě‚ˇ‚ׂÄ2021 (ˆÝ‚Ć’°2021”N5ŒŽ†‘Š§†)zˆÝ: ŽĄ—Á@ÄŽÜp: GAVE‚ɑ΂ˇ‚éAPCÄŽÜŽĄ—Ă, p.652. “c糁@‘1,2, ÎŒËŒŞŽŸ2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2Á‰ťŠí“ŕ), ˆăŠw‘‰@, “Œ‹ž, 2021/5”­s.

620017. [Šwp‘ (•Ş’SŽˇ•M)]yH“šEˆÝĂ–ŹáŽ ‰ü’ů‘ć4”Łz‘ćV•” H“šĂ–ŹáŽŽĄ—Ă‚ĚŽŔŰ@II. ‘ŇŠúE—\–h—á‚ւ̑Ήž@2. ŠeŽíŽĄ—Ă–@@a. –ň•¨—Ă–@, p.178-81. “ú‚@‰›1, ‹›“ˆ°‹I1 (1Á‰ťŠí“ŕ), ŠÄC: ŹŒ´Ÿ•q, ‹ßX•ś•v, •Ň: “üŕV“ÄŽu, ‰—•Ű˜a•F, ’†‘ş^ˆę, “ú–{ƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, “Œ‹ž, 2021/6”­s.

620018. [Šwp‘ (•Ş’SŽˇ•M)]yäX‘ŸÇŒóŒQ (‘ć3”Ĺ)|‚ť‚Ě‘ź‚ĚäX‘ŸŽžŠł‚đŠÜ‚߂ā| (•Ęű“ú–{—Őଠ—Ěˆć•ĘÇŒóŒQƒVƒŠ[ƒY No.16)zVII. äX‰Š@4. äX‰źŤ”X–EEWON‚Ě•a‘Ô‚ĆŽĄ—Ă, p.294-303. –Ř“cŒőL1, “n•Ó^ˆč1, •{‹M_1, ăŒ´ˆę”ż1, ’ˇ’Jě—Í–ç1, ‹ŕŽq@‹œ1, ‰œ˜e‹ť‰î1, Šâˆä’m‹v1, Ąň@O1 (1Á‰ťŠí“ŕ), “ú–{—Ő଎Đ, “Œ‹ž, 2021/6”­s.

620019. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ę‚ž‚Ż‚Í“Ç‚ń‚Ĺ‚¨‚Ť‚˝‚˘! Á‰ťŠí“ŕŽ‹‹žˆă‚Ě‚˝‚ß‚Ěd—v˜_•ś200•Ń <’_EäX•Ň>zäXŽîᇁ@23-Q023. äXŠŕ‚̉“Šu“]ˆÚ‚Í—\–h‰Â”\‚Š?, p.24. 25-Q025. ‰“Šu“]ˆÚ‚đ—L‚ˇ‚éäXŠŕ‚ɑ΂ľ‚ÄFOLFIRINOX—Ă–@‚Ígemcitabine—Ă–@‚ć‚č—LŒř‚Š?, p.26. 26-Q026. “]ˆÚŤäXŠŕ‚ɑ΂ľ‚Ägemcitabine‚Énab-paclitaxel‚đ•š—p‚ˇ‚é‚ą‚Ć‚Í—LŒř‚Š?. Šâˆä’m‹v (Á‰ťŠí“ŕ), •Ň: Ž…ˆä—˛•v, “üŕV“ÄŽu, ŠƒŔ˜Nś, ˆŔ“cˆę˜N, —Ç‘ňş–Á, ƒV[ƒr[ƒA[ƒ‹, “Œ‹ž, 2021/7”­s.

620020. [Šwp‘ (•Ş’SŽˇ•M)]yÁ‰ťŠÇ“ŕŽ‹‹žŽĄ—Á|Šî–{‚Š‚獂“ď“x‚Ü‚Ĺ (Á‰ťŠí“ŕŽ‹‹ž2021”N33ŠŞ‘Š§†)z[Še˜_] I. Á‰ťŠÇoŒŒ‚ɑ΂ˇ‚é“ŕŽ‹‹ž“IŽ~ŒŒp@[”ńĂ–ŹáŽŤoŒŒ] oŒŒŤˆÝ\“ńŽw’°’×á‡, p.43-8. “c糁@‘1,2, ‹v•Ű“c—z1, “c糔ü“Ţ1, –kŒ´@Œž1, ŒĂ]N–ž1, “n糍WŽŻ1, ˜a“c‘ń–ç1, ÎŒËŒŞŽŸ1, Œ˜“ce—˜1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ), “Œ‹žˆăŠwŽĐ, “Œ‹ž, 2021/10”­s.

620021. [Šwp‘ (•Ş’SŽˇ•M)]yÁ‰ťŠÇ“ŕŽ‹‹žŽĄ—Á|Šî–{‚Š‚獂“ď“x‚Ü‚Ĺ (Á‰ťŠí“ŕŽ‹‹ž2021”N33ŠŞ‘Š§†)z[Še˜_] I. Á‰ťŠÇoŒŒ‚ɑ΂ˇ‚é“ŕŽ‹‹ž“IŽ~ŒŒp@[”ńĂ–ŹáŽŤoŒŒ] oŒŒŤˆÝ\“ńŽw’°’×ᇂɑ΂ˇ‚éOTSCҖ@, p.53-6. ‹v•Ű“c—z1. ŽR“ŕ_Žj1, ’†’JŒ¤“l2, ˜a“c‘ń–ç1, “c糁@‘1,3 (1Á‰ťŠí“ŕ, 2‹~–˝, 3V˘‹Iˆă—ÁEć’[ˆă—Ă), “Œ‹žˆăŠwŽĐ, “Œ‹ž, 2021/10”­s.

620022. [Šwp‘ (•Ş’SŽˇ•M)]yÁ‰ťŠÇ“ŕŽ‹‹žŽĄ—Á|Šî–{‚Š‚獂“ď“x‚Ü‚Ĺ (Á‰ťŠí“ŕŽ‹‹ž2021”N33ŠŞ‘Š§†)z[Še˜_] I. Á‰ťŠÇoŒŒ‚ɑ΂ˇ‚é“ŕŽ‹‹ž“IŽ~ŒŒp@[”ńĂ–ŹáŽŤoŒŒ] ‘ĺ’°oŒŒ (ŒeŽş‚đœ‚­), p.78-83. ˛“c”ü˜a1, Ź—ѐ´“T1,2 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), “Œ‹žˆăŠwŽĐ, “Œ‹ž, 2021/10”­s.

620023. [Šwp‘ (•Ş’SŽˇ•M)]yę–ĺˆă‚Ě‚˝‚ß‚ĚÁ‰ťŠí•aŠw ‘ć3”ŁzVI ŠĚ‘Ÿ@‚ł‚Ü‚´‚Ü‚Č•a‘Ô‚ĆŽĄ—Á@–ĺ–Źˆł˜´iÇ, p468-72. “ú‚@‰›1, ‹›“ˆ°‹I1 (1Á‰ťŠí“ŕ), ŠÄC: ‰şŁě“O, “n•Ó@Žç, •Ň: –؉ş–Fˆę, ‹ŕŽqŽüˆę, Š~“c”ŽŽj, ‘şă˜aŹ, ˆŔ“Ą@˜N, Ž…ˆä—˛•v, ˆăŠw‘‰@, “Œ‹ž, 2021/11”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713007. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Bilateral metallic stent placement for malignant hilar biliary obstruction. Iwai T1: Japan-Korea joint web meeting (2021/9/29), WebŠJĂ. (Šâˆä’m‹v1: 1Á‰ťŠí“ŕ)

713008. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Management of early gastric cancer Kusano C1: ASEAN GASTRO 2021 (2021/11/4-6), BangKok, Thailand (ƒnƒCƒuƒŠƒbƒhŠJĂ). (‘–ě@‰›1: 1Á‰ťŠí“ŕ)

721001. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ’×ᇐŤ‘ĺ’°‰Š‚É‚¨‚Ż‚鎥—Ă‘I‘đ‚̍L‚Ş‚č. ‰ĄŽR@ŒO (Á‰ťŠí“ŕ): ‘ć107‰ń“ú–{Á‰ťŠí•aŠw‰ď‘‰ď (2021/4/16), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

721002. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ŠĚd•Ď‡•šÇŽĄ—Ă‚Ěƒ}ƒl[ƒWƒƒ“ƒg. ‹›“ˆ°‹I (Á‰ťŠí“ŕ): ‘ć107‰ń“ú–{Á‰ťŠí•aŠw‰ď‘‰ď (2021/4/16), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

721003. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ‚ą‚ę‚Š‚ç‚Ě–ĺ–Źˆł˜´iÇ`ŠĚd•Ďf—ĂƒKƒCƒhƒ‰ƒCƒ“2020‚Š‚猊‚Ś‚Ä‚­‚é‚ŕ‚́`. “ú‚@‰› (Á‰ťŠí“ŕ): ‘ć107‰ń“ú–{Á‰ťŠí•aŠw‰ď‘‰ď (2021/4/17), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

721004. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) –ĺ–ŹŒŒđÇ‚ɑ΂ˇ‚鎥—Ă‚Ěƒ|ƒCƒ“ƒg`‘ŠúŽĄ—Ă‚Ěd—vŤ‚ŕŠÜ‚߂ā`. “ú‚@‰› (Á‰ťŠí“ŕ): ‘ć57‰ń“ú–{ŠĚ‘ŸŠw‰ď‘‰ď (2021/6/17), –kŠC“š (ƒnƒCƒuƒŠƒbƒhŠJĂ).

721005. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) CŒ^ŠĚ‰ŠŽĄ—Ă‚ĚˆÓ‹`‚Ć‚ľ‚Ä‚ĚŠĚd•Ď‚É‚¨‚Ż‚éPoint of No Return. ‹›“ˆ°‹I (Á‰ťŠí“ŕ): ‘ć28‰ń“ú–{–ĺ–Źˆł˜´iÇŠw‰ď‘‰ď (2021/9/16), WebŠJĂ.

721006. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ”ń‘㏾ŤŠĚd•Ď‚̐f’fEŽĄ—Ă‚Ěup to date. “ú‚@‰› (Á‰ťŠí“ŕ): ‘ć28‰ń“ú–{–ĺ–Źˆł˜´iÇŠw‰ď‘‰ď (2021/9/17), WebŠJĂ.

722027. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) ’_“š‹ˇóÇ—á‚ɑ΂ˇ‚éV‹KƒKƒCƒhƒƒCƒ„[—U“ąŽŽƒuƒ‰ƒV‚đ—p‚˘‚˝’_`ƒZƒ‹ƒuƒƒbƒN–@. äřŒ´Ť—Ç1, ‰œ˜e‹ť‰î2, –Ř“cŒőL2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2Á‰ťŠí“ŕ): ‘ć107‰ń“ú–{Á‰ťŠí•aŠw‰ď‘‰ď (2021/4/15), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722028. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‚—î”­Ç’×ᇐŤ‘ĺ’°‰Š‚Ć”ń‚—î”­Ç—á‚Ě“ü‰@—á‚É‚¨‚Ż‚鎥—Ă‘I‘đ‚ɂ‚˘‚Ä. ˆÉ“Ą—˛Žm1, ‰ĄŽR@ŒO2, Ź—ѐ´“T2,3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2Á‰ťŠí“ŕ, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć107‰ń“ú–{Á‰ťŠí•aŠw‰ď‘‰ď (2021/4/16), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722029. [Šw‰ď (‘S‘)] (Šî’˛u‰‰) –ĺ–Źˆł˜´iÇ‚̐f’f‚ĆŽĄ—Ă‚ĚĹ‘Oü, ĄŒă‚ÉŽc‚ł‚ę‚˝‰Ű‘č‚ŕŠÜ‚ß. “ú‚@‰› (Á‰ťŠí“ŕ): ‘ć107‰ń“ú–{Á‰ťŠí•aŠw‰ď‘‰ď (2021/4/16), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722030. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) VƒKƒCƒhƒ‰ƒCƒ“‚É‚¨‚˘‚Ä, ŠĚŤ”]ÇŽĄ—Ă‚É•]‰ż‚ł‚ę‚˝ƒŒƒ{ƒJƒ‹ƒjƒ`ƒ“‚ĆƒŠƒtƒ@ƒLƒVƒ~ƒ“‚ĚŽg—p‚ÉŠÖ‚ˇ‚élŽ@. ‹›“ˆ°‹I1, “ú‚@‰›1 (1Á‰ťŠí“ŕ): ‘ć107‰ń“ú–{Á‰ťŠí•aŠw‰ď‘‰ď (2021/4/17), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722031. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) ƒNƒ[ƒ“•a‚ɍ‡•š‚ľ‚˝‰ş•”Á‰ťŠÇŠŕ‚Ě7—á. “c糔ü“Ţ1, Ź—ѐ´“T2,3, ‹v•Ű“c (˛“c) ”ü˜a3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3Á‰ťŠí“ŕ): ‘ć107‰ń“ú–{Á‰ťŠí•aŠw‰ď‘‰ď (2021/4/17), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722032. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “Şčň•”•\ÝŠŕ‚ɑ΂ˇ‚é“ŕŽ‹‹žf’f|AI“ŕŽ‹‹žf’f\’z‚ĚŽŽ‚Ý. Œ˜“ce—˜1, ŒĂ]N–ž1, “c糁@‘1,2, ‰Á”[Fˆę3, ×–ě_Žj3, ŽR‰ş@‘ń3, ˆęŒËš–ž4, ‹g“c@Œ÷4, ‘ş‰_–FŽ÷4, ŽOŽ}@M4 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3Ž¨•@ˆôAE“Şčň•”, 4•a—): ‘ć110‰ń“ú–{•a—Šw‰ď‘‰ď (2021/4/22), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722033. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‘ĺ’°T1Šŕ‚̐[’B“xf’f‚É‚¨‚Ż‚éEUS‚Ě—L—pŤ‚ɂ‚˘‚Ä‚ĚŒŸ“˘. •Ęác•üL1, Ź—ѐ´“T1,2, ‹v•Ű“c (˛“c) ”ü˜a1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć101‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2021/5/14), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722034. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) pŒă’_ŠÇ‹ó’°•Ť‡•”‹ˇó‚É‚¨‚Ż‚éƒoƒ‹[ƒ“Ź’°‹ž‰şERCP˘“ď—á‚ɑ΂ˇ‚é“–‰@‚̍H•v. •{‹M_1, –Ř“cŒőL1, Šâˆä’m‹v1 (1Á‰ťŠí“ŕ): ‘ć101‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2021/5/15), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722035. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŽĄ—Ă“K‰žÁ‰ťŠÇĂ–ŹáŽ‚Ě—\‘ވöŽq‚Ć‚ľ‚Ä‚ĚƒAƒ‹ƒuƒ~ƒ“EƒrƒŠƒ‹ƒrƒ“EŒŒŹ”Â’l (ABP criteria) ‚Ě—L—pŤ. ‹›“ˆ°‹I1, “ú‚@‰›1, ŠâčGˆę˜Y1 (1Á‰ťŠí“ŕ): ‘ć57‰ń“ú–{ŠĚ‘ŸŠw‰ď‘‰ď (2021/6/17), –kŠC“š (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722036. [Šw‰ď (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ŠĚƒTƒ‹ƒRƒyƒjƒAf’fŠî€‚Ě—L—pŤ‚ÉŠÖ‚ˇ‚é‘˝Ž{Ý‘OŒü‚ŤŒŸ“˘. ‹›“ˆ°‹I1, “ú‚@‰›1 (1Á‰ťŠí“ŕ): ‘ć57‰ń“ú–{ŠĚ‘ŸŠw‰ď‘‰ď (2021/6/17), –kŠC“š (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722037. [Šw‰ď (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ƒAƒ‹ƒR[ƒ‹ŤŠĚáŠQ‚ɑ΂ˇ‚éHarm reduction“ą“üŒă‚Ědrinking risk level‚̕ωť‚ĆŽĄ—ĂŒř‰Ę‚ÉŠÖ‚ˇ‚錟“˘. ‹›“ˆ°‹I1, “ú‚@‰›1 (1Á‰ťŠí“ŕ): ‘ć57‰ń“ú–{ŠĚ‘ŸŠw‰ď‘‰ď (2021/6/17), –kŠC“š (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722038. [Šw‰ď (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) PNPLA3ˆâ“`Žq‘˝Œ^‚ŞŠĚd•Ď‡•šÇ”­ś‚É—^‚Ś‚é‰e‹ż. ‹›“ˆ°‹I1, “ú‚@‰›1, ˆä‰ô‰ŔŘ1 (1Á‰ťŠí“ŕ): ‘ć57‰ń“ú–{ŠĚ‘ŸŠw‰ď‘‰ď (2021/6/18), –kŠC“š (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722039. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) äXSolid pseudopapillary neoplasm‚Ě—Ő°“I“Á’Ľ‚ĆEUSŠŒŠ‚ĚŒŸ“˘. “n•Ó^ˆč1, –Ř“cŒőL1, Šâˆä’m‹v1, ‰œ˜e‹ť‰î1, ’ˇ’Jě—Í–ç1, ˆŔ’B@‰ő2, äřŒ´Ť—Ç2, •{‹M_1, ‹Ę’u–žŠ°2, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć52‰ń“ú–{äX‘ŸŠw‰ď‘ĺ‰ď (2021/9/23), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722040. [Šw‰ď (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) “–‰@‚Ĺ‚ĚŒÂ•Ę‰ťˆă—Ă‚đŒŠ˜‚Ś‚˝äXŠŕ‚ɑ΂ˇ‚éEUS-TA‚É‚¨‚Ż‚éH•v. ‰œ˜e‹ť‰î1, “n•Ó^ˆč1, –Ř“cŒőL1, Ąň@O2, Šâˆä’m‹v1, ŽR“ŕ_Žj1, ’ˇ’Jě—Í–ç1, ź–{‚–ž1, Ą’JŠ°ˆČ1, ˆŔ’B@‰ő3, äřŒ´Ť—Ç3, ’†’JŞŒá1, •{‹M_1, –Š@Ž‹M1, ‹Ę’u–žŠ°3, Îčƒ˜Y1, ‰Ô‰Ş‘ž˜Y1, áÁ•”—Dě1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2JCHO‘Š–Í–ě•a‰@, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć52‰ń“ú–{äX‘ŸŠw‰ď‘ĺ‰ď (2021/9/23), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722041. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) ˆÝŠŕ—\–h‚đ–Ú“I‚Ć‚ľ‚˝Žá”NŽŇH. pyloriŠ´őŒŸ¸, œ‹ŰŽ–‹Ć‚ĚŠm—§‚đ–ÚŽw‚ľ‚Ä. ‘–ě@‰›1, –xˆä•qŠě, Žs“‡—Č“ń, —é–؁@ăÄ, ’rŒ´‹v’Š, Œă“Ą“c‘ěŽu (1Á‰ťŠí“ŕ): ‘ć27‰ń“ú–{ƒwƒŠƒRƒoƒNƒ^[Šw‰ďŠwpW‰ď (2021/9/25), WebŠJĂ.

722042. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) —ǐŤ’_ŠÇ‹ˇó‚ɑ΂ˇ‚é‹ŕ‘ŽƒXƒeƒ“ƒg‚Ě—L—pŤ. Šâˆä’m‹v1, –Ř“cŒőL1, ‘–ě@‰›1 (1Á‰ťŠí“ŕ): ‘ć57‰ń“ú–{’_“šŠw‰ďŠwpW‰ď (2021/10/8), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722043. [Šw‰ď (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) “–‰@‚É‚¨‚Ż‚éäXŽüˆÍ‰t‘Ě’™—Ż‚ɑ΂ˇ‚é“ŕŽ‹‹ž“IŽĄ—Ă‚ĚŒťó‚Ć‹ô”­Ç. •{‹M_1, Šâˆä’m‹v1, –Ř“cŒőL1 (1Á‰ťŠí“ŕ): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/4), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722044. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) ŠĚŤ”]Ç‚ɑ΂ˇ‚éBRTOŽĄ—ĂŒă, –ĺ–ŹŒa•Ď‰ť‚Ş—\Œă‚É—^‚Ś‚é‰e‹ż‚ÉŠÖ‚ˇ‚錟“˘. ŠâčGˆę˜Y1, ‹›“ˆ°‹I1, ŒE“cK‰î1 (1Á‰ťŠí“ŕ): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/4), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722045. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) DDW-J2004ƒ[ƒNƒVƒ‡ƒbƒv–ň•¨ŤŠĚáŠQf’fŠî€‚É‹‚ß‚ç‚ę‚é‹ß”N‚Ě–ň•¨ŤŠĚáŠQ‚ւ̑Ήž. “n粐^˛1,2, ‘ĺ’ˏr˜a1,2 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Á‰ťŠí“ŕ): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/4), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722046. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‘Šú‘ĺ’°Šŕ‚ɑ΂ˇ‚é‘ĺ’°ESD‚ɂ‚˘‚Ä: ‚—îŽŇŒQ‚Ć”ń‚—îŽŇŒQ‚Ě”äŠr. ěŠÝ‰Á“Ţ1, Ź—ѐ´“T1,2 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć76‰ń“ú–{‘ĺ’°ăč–ĺ•aŠw‰ďŠwpW‰ď (2021/11/12), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722047. [Šw‰ď (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ƒ^ƒNƒƒŠƒ€ƒX‚Ě’ZŠúŽĄ—ÐŹŃ‚Š‚çl‚Ś‚é’×ᇐŤ‘ĺ’°‰Š“ü‰@—á‚É‚¨‚Ż‚鎥—ĂŒř‰Ę”ť’č‚Ěƒ^ƒCƒ~ƒ“ƒO. ‹ŕŕV@1, ‰ĄŽR@ŒO1, •Ęác•üL1, ěŠÝ‰Á“Ţ1, ‹v•Ű“c (˛“c) ”ü˜a1, Ź—ѐ´“T1,2 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć76‰ń“ú–{‘ĺ’°ăč–ĺ•aŠw‰ďŠwpW‰ď (2021/11/12), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722048. [Šw‰ď (‘S‘)] (ƒvƒŒƒiƒŠ[ƒZƒbƒVƒ‡ƒ“) V‚ľ‚˘‹K–ńô’č‚ÉŒü‚Ż‚˝Žć‚č‘g‚Ý: “ŕŽ‹‹ž—Ěˆć‚É‚¨‚Ż‚éŒťó‚Ɖۑč. ‘–ě@‰› (Á‰ťŠí“ŕ): ‘ć94‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2022/3/2-4), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723103. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Crohn•a‚̏Ź’°•a•Ďf’f‚É‚¨‚Ż‚éMR enterography‚Ě—L—pŤ‚ɂ‚˘‚Ä‚ĚŒŸ“˘. ‹ŕŕV@1, ‰ĄŽR@ŒO1, •Ęác•üL1, ěŠÝ‰Á“Ţ1, Œ´—ŻOŽ÷2, ‹v•Ű“c (˛“c) ”ü˜a1, Ź—ѐ´“T1,3, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć107‰ń“ú–{Á‰ťŠí•aŠw‰ď‘‰ď (2021/4/15), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723104. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) —ǐŤ’_ŠÇ‹ˇó‚ɑ΂ˇ‚é‹ŕ‘ŽƒXƒeƒ“ƒg‚Ě—L—pŤ. Šâˆä’m‹v1, –Ř“cŒőL1, ‰œ˜e‹ť‰î1, ’ˇ’Jě—Í–ç1, ‹ŕŽq@‹œ1, “n•Ó^ˆč1, •{‹M_1, ˆŔ’B@‰ő2, äřŒ´Ť—Ç2, ŽR“ŕ_Žj1, Ąň@O3, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‘Š–Í–ě•a‰@): ‘ć101‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2021/5/15), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723105. [Šw‰ď (‘S‘)] (Žĺ‘艉‘č) ŠĚŤ”]Ç‚ɑ΂ˇ‚éBRTOŽĄ—ĂŒă, –ĺ–Źˆł˜´iÇ‚Ş—\Œă‚É—^‚Ś‚é‰e‹ż‚ÉŠÖ‚ˇ‚錟“˘. ‹›“ˆ°‹I1, “ú‚@‰›1 (1Á‰ťŠí“ŕ): ‘ć28‰ń“ú–{–ĺ–Źˆł˜´iÇŠw‰ď‘‰ď (2021/9/16-17), WebŠJĂ.

723106. [Šw‰ď (‘S‘)] (Žĺ‘艉‘č) “ŕŽ‹‹ž“IŽĄ—Ă“K‰žÁ‰ťŠÇĂ–ŹáŽ‚Ě—\‘ވöŽq‚Ć‚ľ‚Ä‚ĚŒŒŹ””/äB‘ŸŒa”ä‚Ě—L—pŤ. ‹›“ˆ°‹I1, “ú‚@‰›1 (1Á‰ťŠí“ŕ): ‘ć28‰ń“ú–{–ĺ–Źˆł˜´iÇŠw‰ď‘‰ď (2021/9/16-17), WebŠJĂ.

723107. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ALBI grade‚ĆŠĚƒTƒ‹ƒRƒyƒjƒA‚ŞŠĚd•ĎŠłŽŇ‚Ě—\Œă‚É—^‚Ś‚é‰e‹ż. ‹›“ˆ°‹I1, “ú‚@‰›1 (1Á‰ťŠí“ŕ): ‘ć28‰ń“ú–{–ĺ–Źˆł˜´iÇŠw‰ď‘‰ď (2021/9/16-17), WebŠJĂ.

723108. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Œo”çŒoŠĚĂ–ŹáŽÇđp‚Ş‘tŒ÷‚ľ‚˝lHăč–ĺĂ–ŹáŽoŒŒ‚Ě1—á. ź‰şš—T1, “ú‚@‰›1, “Ąˆä@Š]2, ŠâčGˆę˜Y1, ˜a“cŽ‹v1, ŒE“cK‰î1, ‹›“ˆ°‹I1, ’†ŕV‹MG1, a’J–ž—˛3, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2•úŽËü (‰ć‘œ), 3ˆă—ĂˆŔ‘SEŠÇ—): ‘ć28‰ń“ú–{–ĺ–Źˆł˜´iÇŠw‰ď‘‰ď (2021/9/16-17), WebŠJĂ.

723109. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) d“Ä‚Č‡•šÇ‚đ”­Ç‚ľ‚˝“Ť‹t—ŹŤH“š‰Š‚Ě1—á. ˛–ě’BĆ1, “c糁@‘1,2, X’JGŒő3, ‹v•Ű“c—z4, ŒĂ]N–ž1, “n粍WŽŻ1, ˜a“c‘ń–ç1, ÎŒËŒŞŽŸ1, Œ˜“ce—˜1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3ă•”Á‰ťŠÇŠO, 4‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć75‰ń“ú–{H“šŠw‰ďŠwpW‰ď (2021/9/23), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723110. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ˆŤŤ’_“š‹ˇó‚ɑ΂ˇ‚éBONASTENT; M-Intraductal‚Ě—LŒřŤ‚ĆˆŔ‘SŤ‚ÉŠÖ‚ˇ‚錟“˘. ˛–ě’BĆ1, ’ˇ’Jě—Í–ç1, ‹Ę’u–žŠ°2, “n•Ó^ˆč1, •{‹M_1, äřŒ´Ť—Ç2, ˆŔ’B@‰ő2, ‰œ˜e‹ť‰î1, Šâˆä’m‹v1, Ąň@O3, –Ř“cŒőL1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3JCHO‘Š–Í–ě•a‰@): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/4), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723111. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ŽŠŒČ–ƉuŤäX‰Š‚̐f’f‚É‚¨‚Ż‚éEUS-TA‚Ě—L—pŤ‚ĚŒŸŘ. ‰Ô‰Ş‘ž˜Y1, ‰œ˜e‹ť‰î1, –Ř“cŒőL1, Šâˆä’m‹v1, ’ˇ’Jě—Í–ç1, ˆŔ’B@‰ő2, äřŒ´Ť—Ç2, •{‹M_1, “n•Ó^ˆč1, ‹Ę’u–žŠ°2, Ąň@O3, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3JCHO‘Š–Í–ě•a‰@): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/4), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723112. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ’†‹K–Í•a‰@‚É‚¨‚Ż‚éäXŽîᇂɑ΂ˇ‚éŽŔ‘ĚŒ°”÷‹ž‰şv‘ŹŒŸ‘Ě•]‰ż‚đ—p‚˘‚˝EUS-TA“ą“ü‰Šú‚̐f’f”\‚ĚŒŸŘ. Îčƒ˜Y1,2, Ąň@O2, •˝ˆä“N•F1,2, ‹ŕ@–ž“N2, ŽOŽ}—zˆę2, ˆä‰ô—C‰î1, ‹Ę’u–žŠ°3, “n•Ó^ˆč1, Ą’JŠ°ˆČ1, ‰œ˜e‹ť‰î1, –Ř“cŒőL1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2JCHO‘Š–Í–ě•a‰@, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/4), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723113. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) CŒ^ŠĚ‰Š‚ɑ΂ˇ‚é’źÚě—pŒ^RƒEƒCƒ‹ƒX–ň‚Ĺ‚ĚŽĄ—ĂŒă48T‚É‚¨‚Ż‚éRGPIIb/IIIaR‘ĚŽYśB×–E‚̕ωť‚ÉŠÖ‚ˇ‚錟“˘. ˜a“cŽ‹v1, ‹›“ˆ°‹I1, ŠâčGˆę˜Y1, ŒE“cK‰î1, “ú‚@‰›1, ’†ŕV‹MG1, a’J–ž—˛2, ˛“Ą—˛Ži3 (1Á‰ťŠí“ŕ, 2ˆă—ĂˆŔ‘SEŠÇ—, 3ˆă—ÉqśŠw•”): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/4), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723114. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Řœ•s”\äXŠŕ‚É‚¨‚Ż‚éƒTƒ‹ƒRƒyƒjƒA‚Ě—Ő°“IˆÓ‹`‚ÉŠÖ‚ˇ‚錟“˘. Îč‚ ‚â“ß1, ‰œ˜e‹ť‰î1, –Ř“cŒőL1, Šâˆä’m‹v1, ŽR“ŕ_Žj1, ’ˇ’Jě—Í–ç1, ˆŔ’B@‰ő2, äřŒ´Ť—Ç2, •{‹M_1, “n•Ó^ˆč1, ‹Ę’u–žŠ°2, Ąň@O3, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3JCHO‘Š–Í–ě•a‰@): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/5), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723115. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ‰ŠÇŤ’°ŽžŠł (IBD) ”ń“TŒ^—á‚Š‚çMEFVˆâ“`ŽqŠÖ˜A’°‰Š‚̐f’f‚đ‚Ś‚˝3—á. Œ´“c—m•˝1, ‰ĄŽR@ŒO1, ‹ŕŕV@1, •Ęác•üG1, ěŠÝ‰Á“Ţ1, ‹v•Ű“c (˛“c) ”ü˜a1, Ź—ѐ´“T1,2, Źň˜aŽO˜Y1, ‚‹´”Ž”V3 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3ˆă—ÉqśŠw•”): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/5), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723116. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚É‚¨‚Ż‚é“ŕŽ‹‹ž“IäXŠÇƒhƒŒƒi[ƒW‚ĚƒXƒgƒ‰ƒeƒW[‚Ć‚ť‚̐ŹŃ‚ĚŒŸŘ. áÁ•”—Dě1, “n•Ó^ˆč1, ‰œ˜e‹ť‰î1, –Ř“cŒőL1, Šâˆä’m‹v1, ’ˇ’Jě—Í–ç1, Ą’JŠ°ˆČ1, ˆŔ’B@‰ő2, äřŒ´Ť—Ç2, •{‹M_1, ‹Ę’u–žŠ°2, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/5), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723117. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ŠĚd•ĎŠłŽŇ‚Ě—\Œă‚ÉŠÖ‚ˇ‚éŠĚƒTƒ‹ƒRƒyƒjƒAf’fŠî€‚Ě—L—pŤ‚ÉŠÖ‚ˇ‚é‘˝Ž{Ý‘OŒü‚ŤŒŸ“˘. ‰Ą‘qqˆę1, ‹›“ˆ°‹I1, “ú‚@‰›1 (1Á‰ťŠí“ŕ): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/5), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723118. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Helicobacter pylori‘΂ˇ‚éƒ{ƒmƒvƒ‰ƒUƒ“2Ü—Ă–@‚Ć3Ü—Ă–@Œă‚Ě’°“ŕ×‹Ű‘p‚̕ωť‚ÉŠÖ‚ˇ‚é’ˇŠúŠĎŽ@Œ¤‹†. —é–؁@ăÄ, –xˆä•qŠě, ‚–ě’qŒ\, ™“c’mŽŔ, Ź–¸‰Á“ŢŽq, Žs“‡—Č“ń, ‘–ě@‰›1, ’rŒ´‹v’Š, Œă“Ą“c‘ěŽu (1Á‰ťŠí“ŕ): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/5), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723119. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚É‚¨‚Ż‚é‹}Ť’_ůN‰Š‚ɑ΂ˇ‚é“ŕŽ‹‹ž“IŒo“ű“Ş“I’_ůNƒhƒŒƒi[ƒW‚ĚŽĄ—ÐŹŃ. ź‰şš—T1, “n•Ó^ˆč1, ‰œ˜e‹ť‰î1, Šâˆä’m‹v1, ’ˇ’Jě—Í–ç1, Ą’JŠ°ˆČ1, ˆŔ’B@‰ő2, äřŒ´Ť—Ç2, •{‹M_1, ‹Ę’u–žŠ°2, –Ř“cŒőL1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/6), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723120. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ’×ᇐŤ‘ĺ’°‰Š‚É‚¨‚Ż‚鐜•¨Šw“IťÜćs•i‚Š‚çŒă‘ą•i‚ւ̐؂č‘Ö‚Ś‚É”ş‚¤ŽĄ—ÐŹŃ‚ĆˆŔ‘SŤ‚ɂ‚˘‚Ä‚ĚŒŸ“˘. Œ´“c—m•˝1, ‰ĄŽR@ŒO1, ‹ŕŕV@1, •Ęác•üL1, ěŠÝ‰Á“Ţ1, ‹v•Ű“c (˛“c) ”ü˜a1, Ź—ѐ´“T1,2 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć76‰ń“ú–{‘ĺ’°ăč–ĺ•aŠw‰ďŠwpW‰ď (2021/11/12), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723121. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ˆŮŽžŤˆÝŠŕ‚É‚¨‚Ż‚éCDO1ˆâ“`ŽqDNAƒƒ`ƒ‹‰ť‚Ě—\‘Ş“IˆÓ‹`. ‹v•Ű“c—z1, “c糁@‘2,3, “Œ@’q2, Î‹´@˜Đ1, ŒĂ]N–ž2, ˜a“c‘ń–ç2, “n•ÓWŽŻ2, ÎŒËŒŞŽŸ2, Œ˜“ce—˜2, ŽR‰şŒpŽj4,5, ‘–ě@‰›2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2Á‰ťŠí“ŕ, 3V˘‹Iˆă—ÁEć’[ˆă—Ă, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 5ă•”Á‰ťŠÇŠO): ‘ć94‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2022/3/2-4), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723122. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) 2‰ń‚ĚESDŽ{s—đ‚Ş‚ ‚čH. pyloriœ‹ŰŒăŒo‰ßŠĎŽ@’†‚ɐisˆÝŠŕ‚đ”F‚ß‚˝1—á. Î‹´@˜Đ1, “c糁@‘2,3, ‹v•Ű“c—z1, ŒĂ]N–ž3, “n粍WŽŻ3, ˜a“c‘ń–ç3, ÎŒËŒŞŽŸ3, Œ˜“ce—˜3, ‘–ě@‰›3, ˜h”ö^—ˆ¤4, ”äŠé’źŽ÷4 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3Á‰ťŠí“ŕ, 4ă•”Á‰ťŠÇŠO): ‘ć94‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2022/3/2-4), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{ˆÝŠŕŠw‰ď‘‰ď‹LŽ– 2022/3; 94: 474.

731002. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ’×ᇐŤ‘ĺ’°‰Š‚Ě•a‘Ô‚Ć“ŕ‰ČŽĄ—Ă‚ĚĹVî•ń|’nˆć˜AŒg‚đŠÜ‚ß‚Ä. Ź—ѐ´“T1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2Á‰ťŠí“ŕ): ‘Š–ÍŒ´IBDŽĄ—ĂWEBƒZƒ~ƒi[ (2021/4/22), WebŠJĂ (‘Š–ÍŒ´).

731003. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) —Ď—R¸ˆĎˆő‰ďˆĎˆő’ˇu‰‰. Ź—ѐ´“T1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2Á‰ťŠí“ŕ): “ú–{‘ĺ’°ăč–ĺ•aŠw‰ď‘ć30‰ń‹łˆçƒZƒ~ƒi[ (2021/5/7-13), WebŠJĂ.

731004. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ’×ᇐŤ‘ĺ’°‰Š‚Ě•a‘Ô‚Ć“ŕ‰ČŽĄ—Ă‚ĚĹVî•ń. Ź—ѐ´“T1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2Á‰ťŠí“ŕ): Ź“cŒ´ƒGƒŠƒAUCŽĄ—ĂƒZƒ~ƒi[ (2021/10/7), WebŠJĂ (Ź“cŒ´).

732010. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) äXŠŕ‚ɑ΂ˇ‚éEUS-FNAB‚É‚¨‚Ż‚éf’fŹŃŒüă‚Ě‚˝‚ß‚ĚŒŸ‘̏ˆ—•ű–@‚̍H•v|SIPS‚Š‚çSOSE‚ց|. “n•Ó^ˆč1, ‰œ˜e‹ť‰î1, Šâˆä’m‹v1, –Ř“cŒőL1, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ): ‘ć112‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2021/6/12-13), WebŠJĂ.

732011. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ[ƒNƒVƒ‡ƒbƒv) ‘ź‘ŸŠíŠŕ‚ĚƒŠƒ“ƒpß“]ˆÚ‚É‚ć‚éˆŤŤH“š‹ˇó‚ɑ΂ˇ‚éOTCS‚đ•š—p‚ľ‚˝H“šƒXƒeƒ“ƒg—Ż’up‚ĚŽŔŽ{‰Â”\Ť. ˜a“c‘ń–ç1, Œ˜“ce—˜1, “c糁@‘1,2 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć112‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2021/6/12-13), WebŠJĂ.

732012. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ[ƒNƒVƒ‡ƒbƒv) ‚‚Š‚Ý’ź‚ľ‹@”\‚đ—L‚ˇ‚éƒNƒŠƒbƒv‚ŞŽ~ŒŒ‚É—LŒř‚Ĺ‚ ‚Á‚˝’ź’°Dieulafoy’×ᇂĚ1—á. ‹ŕŕV@1, Ź—ѐ´“T1,2 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć112‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2021/6/12-13), WebŠJĂ.

732013. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (Ç—áƒZƒbƒVƒ‡ƒ“) ‰ťŠw•úŽËü—Ă–@ (CRT) Œă‹ÇŠˆâŽcÄ”­H“šŠŕ‚É‹~Ď“ŕŽ‹‹žŽĄ—Ă, ‹~ĎŽčp‚đŽ{s‚ľ‚˝1—á. ŒĂ]N–ž1, Œ˜“ce—˜1, VŒ´ł‘ĺ2, “c糁@‘1,3, Źň˜aŽO˜Y1 (1Á‰ťŠí“ŕ, 2ă•”Á‰ťŠÇŠO, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć112‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2021/6/12-13), WebŠJĂ.

732014. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) Á‰ťŠÇă”琍Žîᇂɑ΂ˇ‚é“ŕŽ‹‹žŽĄ—Ă‚ĚH•v‚ĆƒRƒc: ‰ŠwŽŇ‚Ĺ‚ŕŽ{s‰Â”\‚ČU—Ěˆć‚É‚¨‚Ż‚éˆÝESD‚̍H•v Ź–¸‰Á“ŢŽq, ’rŒ´‹v’Š, —é–؁@ăÄ, ‘–ě@‰›1, Œă“Ą“c‘ěŽu (1Á‰ťŠí“ŕ): ‘ć112‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2021/6/13), WebŠJĂ.

732015. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰) “–‰@‚É‚¨‚Ż‚éˆÝŠŕ‚ɑ΂ˇ‚éNivolumab‚ĚŽg—pŒoŒą. ŒĂ]N–ž (Á‰ťŠí“ŕ): Step Up Web Seminar (2021/6/25), “Œ‹ž.

732016. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒrƒfƒIƒ[ƒNƒVƒ‡ƒbƒv) Á‰ťŠÇoŒŒ‚ɑ΂ˇ‚鎥—Ă‚ĚH•v@‚‚Š‚Ý’ź‚ľ‹@”\‚đ—L‚ˇ‚éƒNƒŠƒbƒv‚ŞŽ~ŒŒ‚É—LŒř‚Ĺ‚ ‚Á‚˝’ź’°Dieulafoy’×ᇂĚ1—á. ‹ŕŕV@1, Ź—ѐ´“T1,2 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ú–{Á‰ťŠí•aŠw‰ďŠÖ“ŒŽx•”‘ć365‰ń—á‰ď (2021/7/10), WebŠJĂ.

732017. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ[ƒNƒVƒ‡ƒbƒv) ‚—îŽŇ‚É‚¨‚Ż‚鉝Šw•úŽËü—Ă–@‚Ü‚˝‚Í•úŽËüŽĄ—ĂŒă‚Ě‹ÇŠˆâŽcÄ”­H“šŠŕ‚ɑ΂ˇ‚éŒőü—ÍŠw“I—Ă–@‚Ě‘k‹y“IŒŸ“˘. [ěŘ‰›”ü1, ŒĂ]N–ž1, ˜a“c‘ń–ç1, “n糍WŽŻ1, ÎŒËŒŞŽŸ1, Œ˜“ce—˜1, “c糁@‘1,2, ‘–ě@‰›1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć53‰ń_“ŢěŒ§Á‰ťŠí•aˆăŠw‰ď‘‰ď (2021/10/30), WebŠJĂ.

732018. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ[ƒNƒVƒ‡ƒbƒv) ‚—î”­Ç’×ᇐŤ‘ĺ’°‰Š‚Ě”­ÇŒă‘Šú‚ĚŠˆ“ŽŤ‚ĆŽĄ—Ă‘I‘đ‚ɂ‚˘‚Ä. ˆÉ“Ą—˛Žm1, ‰ĄŽR@ŒO2, Ź—ѐ´“T2,3, ‘–ě@‰›2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2Á‰ťŠí“ŕ, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć53‰ń_“ŢěŒ§Á‰ťŠí•aˆăŠw‰ď‘‰ď (2021/10/30), WebŠJĂ.

732019. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ[ƒNƒVƒ‡ƒbƒv) ŽĄ–üŘœ•s”\‚—îäXŠŕŠłŽŇ‚ɑ΂ˇ‚égemcitabine + nab-paclitaxel—Ă–@‚Ě”E—eŤ‚Ć—LŒřŤ‚ĚŒŸŘ. Źě‘ĺ•ă1, ’ˇ’Jě—Í–ç1, •{‹M_1, ‹Ę’u–žŠ°2, “n•Ó^ˆč1, ˆŔ’B@‰ő2, äřŒ´Ť—Ç2, ‰œ˜e‹ť‰î1, Šâˆä’m‹v1, Ąň@O3, –Ř“cŒőL1 (1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3JCHO‘Š–Í–ě•a‰@): ‘ć53‰ń_“ŢěŒ§Á‰ťŠí•aˆăŠw‰ď‘‰ď (2021/10/30), WebŠJĂ.

732020. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ[ƒNƒVƒ‡ƒbƒv) –ĺ–ŹŒŒđÇ‚ɑ΂ˇ‚éR‹ĂŒĹ—Ă–@‚ĚŒŸ“˘`ƒ[ƒtƒ@ƒŠƒ“‚ĆƒGƒhƒLƒTƒoƒ“‚Ě”äŠr`. Œ´@—E•ă1, ‹›“ˆ°‹I1, “ú‚@‰›1, ŠâčGˆę˜Y1, ˜a“cŽ‹v1, ŒE“cK1, “c糁@‘1,2, ‘–ě@‰›1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć53‰ń_“ŢěŒ§Á‰ťŠí•aˆăŠw‰ď‘‰ď (2021/10/30), WebŠJĂ.

732021. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒoƒCƒIƒ}[ƒJ[‚đ—p‚˘‚˝ŒÂ•Ę‰ťf—Ă‚ĚŽŔŰ. Šâˆä’m‹v1, ’Ă‘şGN2, ŒĂěł‹`3 (1Á‰ťŠí“ŕ, 2”ĺ”AŠí, 3•wl): HBOC Seminar-‘ŸŠí‰Ą’f‚ÉŒÂ•Ę‰ťŽĄ—Ă‚đl‚Ś‚é- (2021/11/18), WebŠJĂ.

733021. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) Œo”çŒoŠĚĂ–ŹáŽÇđp‚Ş‘tŒ÷‚ľ‚˝lHăč–ĺĂ–ŹáŽoŒŒ‚Ě1—á. ź‰şš—T1, “ú‚@‰›1, ‹›“ˆ°‹I1, ŒE“cK‰î1, ˜a“cŽ‹v1, ŠâčGˆę˜Y1 (1Á‰ťŠí“ŕ): “ú–{Á‰ťŠí•aŠw‰ď
ŠÖ“ŒŽx•”‘ć364‰ń—á‰ď (2021/4/24), WebŠJĂ.

733022. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ęCˆăƒZƒbƒVƒ‡ƒ“) ‹}‘Ź‚É”­ˆç‚ľ‚˝‚ƍl‚Ś‚ç‚ę‚é’×ᇐŤ‘ĺ’°‰ŠŠÖ˜A‘ĺ’°Šŕ‚Ě1—á. Œ´“c—m•˝1, Ź—ѐ´“T1,2, ‹ŕŕV@1, •Ęác•üG1, ěŠÝ‰Á“Ţ1, ‰ĄŽR@ŒO1, ‹v•Ű“c (˛“c) ”ü˜a1, Źň˜aŽO˜Y1, ‚‹´”Ž”V3 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3ˆă—ÉqśŠw•”): ‘ć112‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2021/6/12-13), WebŠJĂ.

733023. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ęCˆăƒZƒbƒVƒ‡ƒ“) ˆÝvanishing tumor‚đ’ć‚ľ‚˝ˆÝƒAƒjƒTƒLƒXÇ‚Ěˆę—á. Źě‘ĺ•ă1, “n•Ó^ˆč1, ‹Ę’u–žŠ°2, •{‹M_1, ˆŔ’B@‰ő2, äřŒ´Ť—Ç2, ’ˇ’Jě—Í–ç1, ‰œ˜e‹ť‰î1, Šâˆä’m‹v1, –Ř“cŒőL1 (1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): “ú–{Á‰ťŠí•aŠw‰ďŠÖ“ŒŽx•”‘ć365‰ń—á‰ď (2021/7/10), WebŠJĂ.

733024. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ęCˆăƒZƒbƒVƒ‡ƒ“) ‰ťŠw—Ă–@‚Ĺ•a¨ƒRƒ“ƒgƒ[ƒ‹‚đ“ž‚ç‚ę‚˝• –Œ’†”çŽî‚Ě1—á. ˆî—t‹IŽq1, “n糍WŽŻ1, ŒĂ]N–ž1, ˜a“c‘ń–ç1, ÎŒËŒŞŽŸ1, Œ˜“ce—˜1, “c糁@‘1,2 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): “ú–{Á‰ťŠí•aŠw‰ďŠÖ“ŒŽx•”‘ć366‰ń—á‰ď (2021/9/18), WebŠJĂ.

733025. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ’ź’°äSá‘‚đ‡•š‚ľ‚˝’×ᇐŤ‘ĺ’°‰Š‚Ěˆę—á. “ŕ“ĄŽj–ž1, ‰ĄŽR@ŒO1, ‹ŕŕV@1, ěŠÝ‰Á“Ţ1, •Ęác•üL1, ‹v•Ű“c (˛“c) ”ü˜a1, Ź—ѐ´“T1,2 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ú–{Á‰ťŠí•aŠw‰ďŠÖ“ŒŽx•”‘ć366‰ń—á‰ď (2021/9/18), WebŠJĂ.

733026. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) EUS-FNAB‚Őf’f‚ľ“ž‚˝AFPŽYś’_ůNŠŕ‚Ě1—á. •˝ˆä“N•F1,2 (1Á‰ťŠí“ŕ, 2JCHO‘Š–Í–ě•a‰@): “ú–{“ŕ‰ČŠw‰ď‘ć671‰ńŠÖ“Œ’n•ű‰ď (2021/9/12), WebŠJĂ.

733027. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) p‘O‚ɐf’f‚ľ“ž‚˝—LŒsŤ•ÇŠO”­ˆçŒ^GIST‚Ě1—á. –kě”Ž”V1, ”Ń“c~‹M1, ”ä—ŻŠÔ’q‹I1, źŽR@—ł1 (1Á‰ťŠí“ŕ): “ú–{’´‰š”gˆăŠw‰ď‘ć33‰ńŠÖ“ŒbM‰z’n•ű‰ďŠwpW‰ď (2021/10/16), ’ˇ–ě (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733028. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) f’f‚ލ˘“ď‚Ĺ‚ ‚Á‚˝–Ó’°Œ´”­MALTƒŠƒ“ƒpŽî‚Ě1Řœ—á. –kě”Ž”V1, ”Ń“c~‹M1, ”ä—ŻŠÔ’q‹I1, źŽR@—ł1 (1Á‰ťŠí“ŕ): “ú–{’´‰š”gˆăŠw‰ď‘ć33‰ńŠÖ“ŒbM‰z’n•ű‰ďŠwpW‰ď (2021/10/16), ’ˇ–ě (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733029. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (JGES-Kanto Cup) äX“ޏ\“ńŽw’°ŘœpŒă‚Ě‹“ă‹ó’°‚Š‚ç‚̐֬ᮏoŒŒ‚ɑ΂ľ‚čd‰ť—Ă–@‚Ş‘tŒ÷‚ľ‚˝1—á. ˆä‰ô‰ŔŘ1, Šâˆä’m‹v1, –Ř“cŒőL1, “ú‚@‰›1, ‘–ě@‰›1 (1Á‰ťŠí“ŕ): ‘ć113‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2021/12/4-5), WebŠJĂ.

733030. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (JGES-Kanto Cup) A case of successful endoscopic injection sclerotherapy for hemorrhagic anastomotic varices after pancreatic duodenectomy. ˆä‰ô‰ŔŘ1, Šâˆä’m‹v1, ‘–ě@‰›1 (1Á‰ťŠí“ŕ): ‘ć113‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2021/12/4-5), WebŠJĂ.

733031. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (Žĺ‘艉‘č) “–‰@‚É‚¨‚Ż‚épŒă’_ŠÇ‹ó’°•Ť‡•”‹ˇó‚ɑ΂ˇ‚é“ŕŽ‹‹žƒhƒŒƒi[ƒWí—Ş. âV“ĄŒöĆ1, •{‹M_1, Šâˆä’m‹v1, –Ř“cŒőL1, ‘–ě@‰›1 (1Á‰ťŠí“ŕ): ‘ć113‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2021/12/4-5), WebŠJĂ.

733032. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (Žĺ‘艉‘č) Crohn•a (CD) ‚É‚¨‚Ż‚鏬’°‚Ě‹ˇó•a•Ď•]‰ż‚É—L—p‚Čƒ‚ƒ_ƒŠƒeƒB‚Ě’Tő. ‹ŕŕV@1, ‰ĄŽR@ŒO1, Ź—ѐ´“T1,2, ‘–ě@‰›1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć113‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2021/12/4-5), WebŠJĂ.

733033. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (Žĺ‘艉‘č) H“šĂ–ŹáŽŽĄ—ĂŒă‚ÉPPI’ˇŠú“Š—^‚Ş•K—v‚ČÇ—á‚đŒŠ‹É‚ß‚é`ŽĄ—Ă‘OŒă‚Ě24ŽžŠÔpHƒ‚ƒjƒ^ƒŠƒ“ƒO‚ÉŠî‚Ă‚­ŒŸ“˘`. “ú‚@‰›1, ‹›“ˆ°‹I1, š •Ş–ΔŽ2, ‘–ě@‰›1 (1Á‰ťŠí“ŕ, 2V•S‡ƒ–‹u‘‡•a‰@): ‘ć113‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2021/12/4-5), WebŠJĂ.

733034. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (Žĺ‘艉‘č) RŒŒđ–ň•ž—pŠłŽŇ‚ɑ΂ˇ‚éÁ‰ťŠí“ŕŽ‹‹žf—ĂƒKƒCƒhƒ‰ƒCƒ“‰ü’č‘OŒă‚É‚¨‚Ż‚éˆÝESDŒăoŒŒ‚ĚŒŸ“˘. ˆä‰ô—C‰î1, ˜a“c‘ń–ç1, “c糁@‘1,2, ‘–ě@‰›1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć113‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2021/12/4-5), WebŠJĂ.

733035. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ęCˆăƒZƒbƒVƒ‡ƒ“) oŒŒ‚đ’ć‚ľLECS‚É‚ÄŘœ‚ľ‚˝‹‘ĺ‚Č‰ßŒ`Źƒ|ƒŠ[ƒv‚Ě1—á. ›ŕV@G1, “c糁@‘1,2, ŒĂ]N–ž1, ˜a“c‘ń–ç1, “n糍WŽŻ1, ÎŒËŒŞŽŸ1, Œ˜“ce—˜1, ‘–ě@‰›1, ˜h”ö^—ˆ¤3, ”äŠé’źŽ÷3 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3ă•”Á‰ťŠÇŠO): ‘ć113‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2021/12/4-5), WebŠJĂ.

733036. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ęCˆăƒZƒbƒVƒ‡ƒ“) Ź’°“ŕˆŮ•¨‚đ“ŕŽ‹‹ž“I‚ɏœ‹Ž‚ľ“ž‚˝Crohn•a‚Ě1—á. ˛–ě’BĆ1, Ź—ѐ´“T1,2, ˆÉ“Ą—˛Žm3, ‹ŕŕV@1, •Ęác•üL1, ěŠÝ‰Á“Ţ1, ‰ĄŽR@ŒO1, ‹v•Ű“c (˛“c) ”ü˜a1, ‘–ě@‰›1 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć113‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2021/12/4-5), WebŠJĂ.

733037. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ˆÝ”S–Œ‰şŽîᇂɑ΂ˇ‚éŽŔ‘ĚŒ°”÷‹ž‰şv‘ŹŒŸ‘Ě•]‰ż‚đ—p‚˘‚˝EUS-TA‚̐f’f”\‚ĚŒŸ“˘|EUS-TA“ą“ü‰ŠúŽ{Ý‚É‚¨‚Ż‚鐏Ń|. •˝ˆä“N•F1,2 (1Á‰ťŠí“ŕ, 2JCHO‘Š–Í–ě•a‰@): ‘ć113‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2021/12/4-5), WebŠJĂ.

733038. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ęCˆăƒZƒbƒVƒ‡ƒ“) Crohn•a‚ɍ‡•š‚ľ‚˝’ź’°Šŕ‚Ěˆę—á. Źě‘ĺ•ă1, •Ęác•üL1, ˆÉ“Ą—˛Žm2, ‹ŕŕV@1, ěŠÝ‰Á“Ţ1, ‰ĄŽR@ŒO1, ‹v•Ű“c (˛“c) ”ü˜a1, Ź—ѐ´“T1,3, ‘–ě@‰›1, “ŕ“Ą@„4, ŽOŽ}@M5 (1Á‰ťŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4‰ş•”Á‰ťŠÇŠO, 5•a—): “ú–{Á‰ťŠí•aŠw‰ďŠÖ“ŒŽx•”‘ć367‰ń—á‰ď (2021/12/11), WebŠJĂ.

733039. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ęCˆăƒZƒbƒVƒ‡ƒ“) ’°ŠÇƒx[ƒ`ƒFƒbƒg•aŽĄ—Ă’†‚É”­Ç‚ľ‚˝”x‹y‚ŃŠĚäB”^ᇂ𔺂Á‚˝ƒmƒJƒ‹ƒWƒA”sŒŒÇ‚Ěˆę—á. {“Ą—˛Žq1, •Ęác•üL1, ‹ŕŕV@1, ěŠÝ‰Á“Ţ1, ‰ĄŽR@ŒO1, ‹v•Ű“c (˛“c) ”ü˜a1, ‘–ě@‰›1, Ź—ѐ´“T1,2 (1Á‰ťŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă—): “ú–{Á‰ťŠí•aŠw‰ďŠÖ“ŒŽx•”‘ć368‰ń—á‰ď (2022/2/5), WebŠJĂ.

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-110009. [Œ´’˜] Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial. Naganuma M1, Yokoyama Y1, Motoya S1, Watanabe K1, Sawada K1, Hirai F1, Yamamoto T1, Hanai H1, Omori T1, Kanai T1, Hibi T1; 1CAPTAIN study Group (Collaborators: Yokoyama K2, et al): J Gastroenterol 2020/4; 55 (4): 390-400. (‰ĄŽR@ŒO2: 2Á‰ťŠí“ŕ)

'20-522001. [uŔ] y“ÁW: ˆôA“ށEčň•”H“šŠŕ‚đŒŠ“Ś‚ˇ‚ȁ|E‚˘ă‚°‚Š‚玥—Â܂Łz[‘˜_] ˆô“ށEH“šŠŕ‚̍‚ƒŠƒXƒNŒQ‚̍i‚荾‚Ý‚Ć‚ť‚̉ž—p–@. ŒĂ]N–ž (Á‰ťŠí“ŕ): Á‰ťŠí“ŕŽ‹‹ž 2020/12; 32 (12): 1790-7.

[’˜@‘]

'20-620001. [Šwp‘ (•Ş’SŽˇ•M)]y’×ᇐŤ‘ĺ’°‰Š‚̐f—ĂƒKƒCƒh ‘ć4”Łz‘ć11Í@HŽ–‚¨‚ć‚ѐśŠˆŽw“ą, p.98-103. Ź—ѐ´“T1,2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2Á‰ťŠí“ŕ), •Ň: NPO–@l“ú–{‰ŠÇŤ’°ŽžŠł‹Ś‰ď, •śŒő“°, “Œ‹ž, 2021/1”­s.

‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č@Á‰ťŠí“ŕ‰ČŠw
Šń•uŔu‰ŠÇŤ’°ŽžŠł—Տ°Œ¤‹†uŔv

[Šwp˜_•ś]

110128. [Œ´’˜] Does anti-tumor necrosis factor alpha prevent the recurrence of Crohn's disease? Systematic review and meta-analysis. Uchino M, Ikeuchi H, Hata K, Minagawa T, Horio Y, Kuwahara R, Nakamura S, Watanabe K, Saruta M, Fujii T, Kobayashi T1,2, Sugimoto K, Hirai F, Esaki M, Hiraoka S, Matsuoka K, Shinzaki S, Matsuura M, Inoue N, Nakase H, Watanabe M: J Gastroenterol Hepatol 2021/4; 36 (4): 864-72. (Ź—с@‘ń1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

110129. [Œ´’˜] Determining the usefulness of Capsule Scoring of Ulcerative Colitis in predicting relapse of inactive ulcerative colitis. Matsubayashi M, Kobayashi T1,2, Okabayashi S, Nakano M2, Sagami S2, Ozaki R, Kiyohara H, Morikubo H, Asonuma K, Miyatani Y2, Maeda S, Hibi T1,2: J Gastroenterol Hepatol 2021/4; 36 (4): 943-50. (Ź—с@‘ń1,2, ’†–ě@‰ë2, ˛ăW‘ž˜Y2, ‹{’J˜Đ—C2, “ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

110130. [Œ´’˜] Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. Sagami S1, Kobayashi T1,2, Miyatani Y1, Okabayashi S, Yamazaki H, Takada T, Kinoshita K, Alocca M, Kunisaki R, Ramaswamy PK, Shiraki M, Hibi T1,2, Kataoka Y: Clin Gastroenterol Hepatol 2021/5; 19 (5): 908-21.e6. (˛ăW‘ž˜Y1, Ź—с@‘ń1,2, ‹{’J˜Đ—C1, “ú”ä‹I•ś1,2: 1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110131. [Œ´’˜] International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases D'Amico F, Rubin DT, Kotze PG, Magro F, Siegmund B,_Kobayashi T1,2, Olivera PA, Bossuyt P, Pouillon L, Louis E, DomŽnech E, Ghosh S, Danese S, Peyrin-Biroulet L: United European Gastroenterol J 2021/5; 9 (4): 451-60. (Ź—с@‘ń1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

110132. [Œ´’˜] Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. Shinzaki S, Matsuoka K, Tanaka H, Takeshima F, Kato S, Torisu T, Ohta Y, Watanabe K, Nakamura S, Yoshimura N, Kobayashi T1,2, Shiotani A, Fumihito Hirai F, Hiraoka S, Watanabe M, Matsuura M, Nishimoto S, Mizuno S, Iijima H, Takehara T, Naka T, Kanai T, Matsumoto T: J Gastroenterol 2021/6; 56 (6): 560-9. (Ź—с@‘ń1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

110133. [Œ´’˜] Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group Shen B, Kochhar GS, Navaneethan U, Cross RK, Farraye FA, Iacucci M, Schwartz DA, Gonzalez-Lama Y, Schairer J, Kiran RP, Kotze PG, Kobayashi T1,2, Bortlik M, Liu X, Levy AN, Gonzalez Su‡rez B, Tang SJ, Coelho-Prabhu N, Lukas M, Bruining DH, El-Hachem S, Charles RJ, Chen Y, Sood A, Mao R, Loras C, Dulai PS, Picoraro JA, Chiorean M, Lukas M, Shergill A, Silverberg MS, Sandborn WJ, Bernstein CN: Lancet Gastroenterol Hepatol 2021/6; 6 (6): 482-97. (Ź—с@‘ń1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

110134. [Œ´’˜] Evidence-based clinical practice guidelines for inflammatory bowel disease 2020 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T1,2, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K: J Gastroenterol 2021/6; 56 (6): 489-526. (Ź—с@‘ń1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

110135. [Œ´’˜] Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. Kobayashi T1,2, Motoya S, Nakamura S, Yamamoto T, Nagahori M, Tanaka S, Hisamatsu T, Hirai F, Nakase H, Watanabe K, Matsumoto T, Tanaka M, Abe T, Suzuki Y, Watanabe M, Hibi T1,2, on behalf of the HAYABUSA Study Group: Lancet Gastroenterol Hepatol 2021/6; 6 (6): 429-37. (Ź—с@‘ń1,2, “ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

110136. [Œ´’˜] Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Feagan BG, Danese S, Loftus Jr EV , Vermeire S, Schreiber S, Ritter T, Fogel R , Mehta R, Nijhawan S, KempiŤnski R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T1,2, Peyrin-Biroulet L: Lancet 2021/6; 397 (10292): 2372-84. (“ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

110137. [Œ´’˜] Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis. Yoshihara T, Shinzaki S, Amano T, Iijima H, Takehara T, Inoue N, Uchino M, Esaki M, Kobayashi T1,2, Saruta M, Sugimoto K, Nakamura S, Hata K, Hirai F, Hiraoka S, Fujii T, Matsuura M, Matsuoka K, Watanabe K, Nakase H, Watanabe M: J Gastroenterol Hepatol 2021/7; 36 (7): 1744-53. (Ź—с@‘ń1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

110138. [Œ´’˜] Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine S-methyltransferase inhibition. Morikubo H, Kobayashi T1,2, Ozaki R, Okabayashi S, Kuronuma S, Takeuchi O, Shiba T, Kiyohara H, Matsubayashi M, Sagami S2, Nakano M2, Ikezaki O, Hisamatsu T, Tanaka Y, Hibi T1,2: J Gastroenterol Hepatol 2021/8; 36 (8): 2116-24. (Ź—с@‘ń1,2, ˛ăW‘ž˜Y2, ’†–ě@‰ë2, “ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

110139. [Œ´’˜] Stopping Anti-TNF in CD Remitters: Cons. Kobayashi T1,2: Inflamm Intest Dis 2021/8; 7 (1): 59-63. (Ź—с@‘ń1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

110140. [Œ´’˜] Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis. Kobayashi T1,2, Ito H, Ashida T, Yokoyama T, Nagahori M, Inaba T, Shikamura M, Yamaguchi T, Hori T, Pinton P, Watanabe M, Hibi T1,2: Intest Res 2021/10; 19 (4): 448-60. (Ź—с@‘ń1,2, “ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

110141. [Œ´’˜] Increased DNA-incorporated thiopurine metabolite as a possible mechanism for leukocytopenia through cell apoptosis in inflammatory bowel disease patients with NUDT15 mutation Toyonaga T, Kobayashi T1,2, Kuronuma S, Ueno A, Kiyohara H, Okabayashi S, Takeuchi O, Redfern CPF, Terai H, Ozaki R, Sagami S2, Nakano M2, Coulthard SA, Tanaka Y, Hibi T1,2: J Gastroenterol 2021/11; 56 (11): 999-1007. (Ź—с@‘ń1,2, ˛ăW‘ž˜Y2, ’†–ě@‰ë2, “ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

110142. [Œ´’˜] International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Olivera P, Zuily S, Kotze PG, Regnault V, Al Awadhi S, Bossuyt P, Gearry RB, Ghosh S, Kobayashi T1,2, Lacolley P, Louis E, Magro F, Ng SC, Papa A, Raine T, Teixeira FV, Rubin D, Danese S, and Peyrin-Biroulet L: Nat Rev Gastroenterol Hepatol 2021/12; 18 (12): 857-73. (Ź—с@‘ń1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

110143. [Œ´’˜] Genetic Background of Mesalamine-induced Fever and Diarrhea in Japanese Patients with Inflammatory Bowel Disease. Suzuki K, Kakuta Y, Naito T, Takagawa T, Hanai H, Araki H , Sasaki Y, Sakuraba H, Sasaki M , Hisamatsu H, Motoya S, Matsumoto T, Onodera M, Ishiguro Y, Nakase H, Andoh A, Hiraoka S, Shinozaki M, Fujii T, Katsurada T, Kobayashi T1,2, Fujiya M, Otsuka T, Oshima N, Suzuki Y, Sato Y , Hokari R , Noguchi M, Ohta Y, Matsuura M, Kawai Y, Tokunaga K, Nagasaki M , Kudo H, Minegishi N, Okamoto D , Shimoyama Y , Moroi R , Kuroha M , Shiga H, Li D, McGovern DPB, Kinouchi Y, Masamune A, MENDEL study group: Inflamm Bowel Dis 2022/1; 28 (1): 21-31. (Ź—с@‘ń1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

110144. [Œ´’˜] Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. Vermeire S, D'Haens G, Baert F, Danese S, Kobayashi T1,2, Loftus EV, Bhatia S, Agboton C, Rosario M, Chen C, Zhang W, Kisfalvi K, Sandborn WJ: J Crohns Colitis 2022/1; 16 (1): 27-38. (Ź—с@‘ń1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

110145. [Œ´’˜] Residual Short-Segment Distal Inflammation Has No Significant Impact on the Major Relapse of Extensive Ulcerative Colitis Asonuma K, Kobayashi T1,2, Nakano M2, Sagami S2, Kiyohara H, Matsubayashi M, Morikubo H, Miyatani Y2, Okabayashi S, Yamazaki H, Kuroki Y, Hibi T1,2: Inflamm Bowel Dis 2022/2; 28 (2): 200-7. (Ź—с@‘ń1,2, ’†–ě@‰ë2, ˛ăW‘ž˜Y2, ‹{’J˜Đ—C2, “ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

110146. [Œ´’˜] Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials. Ben-Horin S, Novack L, Mao R, Guo J, Zhao Y, Sergienko R, Zhang J, Kobayashi T1,2, Hibi T1,2, Chowers Y, Peyrin-Biroulet L, Colombel JF, Kaplan GG, Chen MH: Gastroenterology 2022/2; 162 (2): 482-94. (Ź—с@‘ń1,2, “ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

110147. [Œ´’˜] Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis. Sagami S1, Kobayashi T1,2, Aihara K, Umeda M, Odajima K, Morikubo H, Asonuma K, Miyatani Y1, Fukuda T, Matsubayashi M, Kiyohara H, Nakano M1, Hibi T1,2: Aliment Pharmacol Ther 2022/5; 55 (10): 1320-9. doi: 10.1111/apt.16817. Epub 2022 Feb 25. (˛ăW‘ž˜Y1, Ź—с@‘ń1,2, ‹{’J˜Đ—C1, ’†–ě@‰ë1, “ú”ä‹I•ś1,2: 1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110148. [Œ´’˜] Lower effectiveness of intravenous steroid treatment for moderate-to-severe ulcerative colitis in hospitalised patients with older onset: a multicentre cohort study Okabayashi S, Yamazaki H, Tominaga K, Miura M, Sagami S1, Matsuoka K, Yamaguchi Y, Noake T, Ozeki K, Miyazaki R, Kamano T, Fukuda T, Yoshioka K, Ando K, Fukuzawa M, Andoh A, Yamamoto Y, Hibi T1,2, Kobayashi T1,2, IBD Terakoya Group: Aliment Pharmacol Ther 2022/6; 55 (12): 1569-80. doi: 10.1111/apt.16865. Epub 2022 Mar 11. (˛ăW‘ž˜Y1, Ź—с@‘ń1,2, “ú”ä‹I•ś1,2: 1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110149. [Œ´’˜] Lack of Increased Risk of Lymphoma with Thiopurine Therapy Regardless of Dose and Duration of Treatment in Japanese Patients with Inflammatory Bowel Diseases. Kobayashi T1,2, Udagawa E, Hibi T1,2: Digestion 2022; 103 (2): 169-73. (Ź—с@‘ń1,2, “ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

510007. [‘ŕ] Perspectives on Subcutaneous Infliximab for Rheuatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Schreiber S, Ben-Horin S, Alten R, Westhovens R, Peyrin-Biroulet L, Danese S, Hibi T1,2, Takeuchi K, Magro F, An Y, Kim DH, Yoon S, Reinisch W: Adv Ther 2022/6; 39 (6): 2342-64. doi: 10.1007/s12325-021-01990-6. Epub 2022 Jan 6. (“ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

520007. [‘ŕ]y‰ŠÇŤ’°ŽžŠł‚É‚¨‚Ż‚éTreat to Target‚ĚƒGƒrƒfƒ“ƒXz‰ŠÇŤ’°ŽžŠł ‚Ěƒ‚ƒjƒ^ƒŠƒ“ƒO|”ńNPŤƒoƒCƒIƒ}[ƒJ[. Ź—с@‘ń1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): “ú–{Á‰ťŠí•aŠw‰ďŽGŽ 2021/3; 118 (3): 229-34.

522034. [uŔ]y“ÁW: ‰ŠÇŤ’°ŽžŠł‚Ě•ŞŽq•W“IŽĄ—Ă‚đ‘Š‡‚ˇ‚éz2. ś•¨Šw“IťÜE’á•ŞŽq‰ť‡•¨‚̍ě—p‹@˜. Ź—с@‘ń1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): INTESTINE 2021/9; 25 (3): 255-8.

522035. [uŔ]y˜AÚ7-1zŠ°‰đŠú’×ᇐŤ‘ĺ’°‰ŠŠłŽŇ‚É‚¨‚Ż‚éƒCƒ“ƒtƒŠƒLƒVƒ}ƒu‚Ě‹x–ň‚ɂ‚˘‚Ä‚Ě‘˝Ž{Ý‹¤“Ż”ń–ÓŒŸƒ‰ƒ“ƒ_ƒ€‰ť”äŠrŽŽŒą (HAYABUSA). Ź—с@‘ń1,2, –{’J@‘, ’†‘şŽu˜Y, ŽR–{—˛s, ’ˇ–xł˜a, “c’†MŽĄ, ‹vź—ˆę, •˝ˆäˆčm, ’‡Ł—TŽu, “n•ÓŒ›ŽĄ, ź–{Žĺ”V, “c’†ł‘Ľ, ˆ˘•”‹Ms, —é–؍N•v, “n•Ó@Žç, “ú”ä‹I•ś1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): INTESTINE 2021/12; 25 (4): 441-4.

522036. [uŔ]yŽĺ‘č: ‰ŠÇŤ’°ŽžŠł‚Ě”S–ŒŽĄ–ü‚đÄl‚ˇ‚ézCrohn•a‚É‚¨‚Ż‚é‘S‘wŤ‰ŠÇ•]‰ż‚ĚˆÓ‹`[MRE‚Ě—§ę‚Š‚ç. ˛ăW‘ž˜Y1, —é–Ř•qŽi, Ź—с@‘ń1,2 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ˆÝ‚Ć’° 2022/2; 57 (2): 191-200.

522037. [uŔ]yDiagnosisz’×ᇐŤ‘ĺ’°‰Š‚É‚¨‚Ż‚é•Ö’†ƒoƒCƒIƒ}[ƒJ[‘Ş’č‚Ě—Ő°“I—L—pŤ. •Ÿ–{—SŽq, “y‹—m‰î, ŽR–{—˛s, ‰şŽR‹MŠ°, ‹vź—ˆę, ŸN’돲l, ź‰ŞŽ‘P, “ĄˆärŒő, –{—Ń–ƒˆßŽq, ’|’†Œ’l, ‘ĺ’˘a˜N, “n•Ó@Žç, Ź—с@‘ń1,2, “ú”ä‹I•ś1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): ˆăŠw‚Ć–ňŠw 2022/3; 79 (4): 575-84.

522038. [uŔ]y“ÁW: ‰ŠÇŤ’°ŽžŠłupdate|f’fEŽĄ—Ă‚ĚĹV’mŒŠ|zV. “Á˜_@2. ŽĄ—Ă–Ú•W‚Ć‚ľ‚Ä‚Ě‘gDŠw“IŽĄ–ü. Ź—с@‘ń1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): “ú–{—Őଠ2022/ 80 (3): 520-3.

[Šw‰ďEŒ¤‹†‰ď“™]

713009. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Usefulness of colestimide for postoperative refractory diarrhea in patients with Crohn's disease. Hojo A1: The 9th annual meeting of Asian Organization for Crohn's and Colitis (AOCC 2021) (2021/10/14-16), Guangzhou, Chaina. (–kžŠ@–ä1: 1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

713010. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Predicting risk factors of steroid dependence after initial steroid therapy in ulcerative colitis. Miyatani Y1: The 9th annual meeting of Asian Organization for Crohn's and Colitis (AOCC 2021) (2021/10/14-16), Guangzhou, Chaina. (‹{’J˜Đ—C1: 1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

713011. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) IL-1R-mediated mechanisms of IL-10 production by gut macrophages. Hibi T1,2: The 9th annual meeting of Asian Organization for Crohn's and Colitis (AOCC 2021) (2021/10/14-16), Guangzhou, Chaina. (“ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

713012. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Recommendations on abdominal ultrasound in inflammatory bowel disease (20-min pre-recorded presentation video). Kobayashi T1,2: The 9th annual meeting of Asian Organization for Crohn's and Colitis (AOCC 2021) (2021/10/14-16), Guangzhou, Chaina. (Ź—с@‘ń1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

713013. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Challenge case III (20-min pre-recorded presentation video). Kobayashi T1,2: The 9th annual meeting of Asian Organization for Crohn's and Colitis (AOCC 2021) (2021/10/14-16), Guangzhou, Chaina. (Ź—с@‘ń1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

713014. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Corticosteroid-free remission of Ulcerative Colitis with filgotinib maintenance therapy:Post hoc analysis of the phase 2b/3 SELECTION study. Hibi T1,2: The 15th IGICS (International Gastrointestinal Consensus Symposium) (2022/2/12), Tokyo, Japan. (“ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

721007. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰)yŽi‰ďz’°‚Š‚çƒqƒg‘Sg‚đㆂ­V‚ľ‚˘Žž‘ă‚Ě“ž—ˆ New Era for clarifying whole fuman body through the view of intestine. “ú”ä‹I•ś1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): ‘ć76‰ń“ú–{‘ĺ’°ăč–ĺ•aŠw‰ďŠwpW‰ď (2021/11/12-13), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722049. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) ƒNƒ[ƒ“•aŹ’°•a•Ď‚Ěƒ‚ƒjƒ^ƒŠƒ“ƒO‚É•Ö’†ƒJƒ‹ƒvƒƒeƒNƒ`ƒ“‚Í•K{‚Š?`LRG, CRP‚Ć‚Ě”äŠr`. ˆ˘‘]Ŕ–M‰›1, Ź—с@‘ń1,2, “ú”ä‹I•ś1,2 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć107‰ń“ú–{Á‰ťŠí•aŠw‰ď‘‰ď (2021/4/15-/17), Vh (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722050. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Šˆ“ŽŠú’×ᇐŤ‘ĺ’°‰Š‚ĚŠ°‰đ“ą“ü—\Œă—\‘Ş‚É‚¨‚Ż‚éĹ“K‚Čƒ‚ƒjƒ^ƒŠƒ“ƒO–@ (Çó?ƒoƒCƒIƒ}[ƒJ[?’°ŠÇƒGƒR[?). ˛ăW‘ž˜Y1, Ź—с@‘ń1,2, “Ą‹g‰Ŕ“ߎq1, ’š‘ƒ”üç1, Ź“c“‡ˆęO1, “ú”ä‹I•ś1,2 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć39‰ń“ú–{‘ĺ’°ŒŸ¸Šw‰ď‘‰ď (2021/10/1), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722051. [Šw‰ď (‘S‘)] (ƒTƒeƒ‰ƒCƒgƒVƒ“ƒ|ƒWƒEƒ€)yŔ’ˇzIBDf—Ă‚É‚¨‚Ż‚éShared Decision Making. “ú”ä‹I•ś1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/4), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722052. [Šw‰ď (‘S‘)] (ƒTƒeƒ‰ƒCƒgƒVƒ“ƒ|ƒWƒEƒ€) ‰ŠÇŤ’°ŽžŠł‚Ě“úíf—Ă‚É‚¨‚˘‚Ä’°ŠÇƒGƒR[‚đ“ą“ü‚ˇ‚éˆÓ‹`uŽŔ—Տ°‚Ĺ’°ŠÇƒGƒR[‚đ‚Ç‚¤Šˆ—p‚ˇ‚é‚Šv. Ź—с@‘ń1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/6), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722053. [Šw‰ď (‘S‘)] (ƒuƒŒƒbƒNƒtƒ@[ƒXƒgƒZƒ~ƒi[) yŔ’ˇz–Ť•Ö”éÇf—Ă‚Ěƒ|ƒCƒ“ƒg|‚قǂ悢”r•Ö‚ĆŠłŽŇ‚̏Ωç|. “ú”ä‹I•ś1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/6), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722054. [Šw‰ď (‘S‘)] (ƒAƒtƒ^ƒk[ƒ“ƒZƒ~ƒi[)yŽi‰ďzƒAƒtƒ^ƒk[ƒ“ƒZƒ~ƒi[2: ”S–ŒŽĄ–ü‚Š‚çl‚Ś‚éˆŰŽ—ĂŽĄ|ƒ‚ƒjƒ^ƒŠƒ“ƒO‚đŠÜ‚߂ā|. “ú”ä‹I•ś1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): ‘ć12‰ń“ú–{‰ŠÇŤ’°ŽžŠłŠw‰ďŠwpW‰ď (2021/11/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722055. [Šw‰ď (‘S‘)] (ƒAƒtƒ^ƒk[ƒ“ƒZƒ~ƒi[) Š°‰đˆŰŽ—Ă–@‚Ć‚ľ‚Ä‚ĚGMA `X‚Ȃ銳ŽŇ‚ł‚ń‚Ö‚ĚvŒŁ`. “ú”ä‹I•ś1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): ‘ć12‰ń“ú–{‰ŠÇŤ’°ŽžŠłŠw‰ďŠwpW‰ď (2021/11/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722056. [Šw‰ď (‘S‘)] (‡“ŻƒVƒ“ƒ|ƒWƒEƒ€) ’×ᇐŤ‘ĺ’°‰ŠŠłŽŇ‚É‚¨‚Ż‚éƒ~ƒŠƒLƒYƒ}ƒu‚̍RTNFƒżR‘̑ϐŤŠÖ˜A‹y‚ŃŽžŠłŠˆ“ŽŤŠÖ˜Aˆâ“`Žq”­Œť‚ւ̉e‹ż. Ź—с@‘ń1,2, Steere Boyd, Higgs Richard, Gottlieb Klaus, Sands Bruce E, Î’Ë’qŽq, Krishnan Venkatesh, “ú”ä‹I•ś1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): ‘ć12‰ń“ú–{‰ŠÇŤ’°ŽžŠłŠw‰ďŠwpW‰ď (2021/11/27), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722057. [Šw‰ď (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ’×ᇐŤ‘ĺ’°‰ŠŠłŽŇ‚ɑ΂ˇ‚éƒCƒ“ƒtƒŠƒLƒVƒ}ƒu‹x–ň‚ÉŠÖ‚ˇ‚郉ƒ“ƒ_ƒ€‰ť”äŠrŒ¤‹† (HAYABUSAŽŽŒą). Ź—с@‘ń1,2, –{’J@‘, ’†‘şŽu˜Y, ŽR–{—˛s, ’ˇ–xł˜a, “c’†MŽĄ, ‹vź—ˆę, •˝ˆäˆčm, ’‡Ł—TŽu, “n•ÓŒ›ŽĄ, ź–{Žĺ”V, —é–؍N•v, “n•Ó@Žç, “ú”ä‹I•ś1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): ‘ć12‰ń“ú–{‰ŠÇŤ’°ŽžŠłŠw‰ďŠwpW‰ď (2021/11/27), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722058. [Šw‰ď (‘S‘)] (‡“ŻƒVƒ“ƒ|ƒWƒEƒ€) ƒNƒ[ƒ“•aŹ’°•a•Ď‚ɑ΂ˇ‚éƒoƒCƒIƒ}[ƒJ[‚Ě—L—pŤ”äŠr. ˆ˘‘]Ŕ–M‰›1, Ź—с@‘ń1,2, ‹{’J˜Đ—C1, X‹v•Ű‘ń1, –kžŠ@–ä1, •Ÿ“c’mG, ˛ăW‘ž˜Y1, ’†–ě@‰ë1, “ú”ä‹I•ś1 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć12‰ń“ú–{‰ŠÇŤ’°ŽžŠłŠw‰ďŠwpW‰ď (2021/11/27), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722059. [Šw‰ď (‘S‘)] (ƒAƒtƒ^ƒk[ƒ“ƒZƒ~ƒi[) AYA˘‘ă‚ĚIBDŠłŽŇ‚ɑ΂ˇ‚éŠÖ‚í‚č•ű`f—ÉȂ𒴂Ś‚ă`[ƒ€ƒAƒvƒ[ƒ`‚đŠw‚ԁ`. “ú”ä‹I•ś1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): ‘ć12‰ń“ú–{‰ŠÇŤ’°ŽžŠłŠw‰ďŠwpW‰ď (2021/11/27), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722060. [Šw‰ď (‘S‘)] (ƒvƒŒƒiƒŠ[ƒZƒbƒVƒ‡ƒ“) ’×ᇐŤ‘ĺ’°‰Š‚Ě’ź’°ŠŒŠ‚𔽉f‚ˇ‚éŒo‰ď‰A’´‰š”gƒpƒ‰ƒ[ƒ^‚ĚŒŸő. –kžŠ@–ä1, Ź—с@‘ń1,2, ˛ăW‘ž˜Y1, X‹v•Ű‘ń1, “Ą‹g‰Ŕ“ߎq1, ”~“c”üç1, Ź“c“‡ˆęO1, ‹{’J˜Đ—C1, •Ÿ“c’mG, ˆ˘‘]Ŕ–M‰›1, ’†–ě@‰ë1, ŒÜ\—’—Ç“T, “ú”ä‹I•ś1,2 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć12‰ń“ú–{‰ŠÇŤ’°ŽžŠłŠw‰ďŠwpW‰ď (2021/11/27), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722061. [Šw‰ď (‘S‘)] (‡“ŻƒVƒ“ƒ|ƒWƒEƒ€) ƒNƒ[ƒ“•aŹ’°•a•Ď‚ɑ΂ˇ‚éƒoƒCƒIƒ}[ƒJ[‚Ě—L—pŤ”äŠr. ˆ˘‘]Ŕ–M‰›1, Ź—с@‘ń1,2, ‹{’J˜Đ—C1, X‹v•Ű‘ń1, –kžŠ@–ä1, •Ÿ“c’mL1, ˛ăW‘ž˜Y1, ’†–ě@‰ë1, “ú”ä‹I•ś1,2 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć59‰ń“ú–{Ź’°Šw‰ďŠwpW‰ď (2021/11/27), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722062. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ‰ŠÇŤ’°ŽžŠł‚É‚¨‚Ż‚éƒqƒ…ƒ~ƒ‰‚ĚˆĘ’u•t‚Ż‚đ‚ ‚ç‚˝‚߂čl‚Ś‚é. Ź—с@‘ń1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): ‘ć18‰ń“ú–{Á‰ťŠÇŠw‰ď‘‰ďŠwpW‰ď (2022/2/11-12), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723123. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ’†“™“x‚Š‚çd“x‚ĚŠˆ“ŽŠúUCŠłŽŇ‚ɑ΂ˇ‚éfilgotinib‚Ě—LŒřŤ‚ĆˆŔ‘SŤ (Š°‰đ“ą“ü—Ă–@): ‘ć2b/3‘ŠSELECTIONŽŽŒą. “ú”ä‹I•ś1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): ‘ć107‰ń“ú–{Á‰ťŠí•aŠw‰ď‘‰ď (2021/4/15-/17), Vh (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723124. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ’†“™“x‚Š‚çd“x‚ĚŠˆ“ŽŠúUCŠłŽŇ‚ɑ΂ˇ‚éfilgotinib‚Ě—LŒřŤ‚ĆˆŔ‘SŤ (Š°‰đˆŰŽ—Ă–@): ‘ć2b/3‘ŠSELECTIONŽŽŒą. “ú”ä‹I•ś1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): ‘ć107‰ń“ú–{Á‰ťŠí•aŠw‰ď‘‰ď (2021/4/15-/17), Vh (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723125. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒNƒ[ƒ“•aŠłŽŇ‚̏pŒă“Ť‰ş—Ÿ‚ɑ΂ˇ‚éƒRƒŒƒXƒ`ƒ~ƒh‚Ě—L—pŤ (ÁP-18). –kžŠ@–ä (–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/4), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723126. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “Ť’×ᇐŤ‘ĺ’°‰Š‚ɑ΂ˇ‚éƒEƒXƒeƒLƒkƒ}ƒu‚ĚŒř‰Ę“I‚ČÇ—á‘I‘đ‚ĚŒŸ“˘ (ÁP-62). ŽR–źŕôŽq (–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/4), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723127. [Šw‰ď (‘S‘)] (ƒfƒWƒ^ƒ‹ƒ|ƒXƒ^[ƒZƒbƒVƒ‡ƒ“) yŔ’ˇz‘ĺ’° (’×ᇐŤ‘ĺ’°‰Š) ƒfƒWƒ^ƒ‹ƒ|ƒXƒ^[ƒZƒbƒVƒ‡ƒ““ŕ10. Ź—с@‘ń1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/4), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723128. [Šw‰ď (‘S‘)] (ƒfƒWƒ^ƒ‹ƒ|ƒXƒ^[ƒZƒbƒVƒ‡ƒ“) ƒ`ƒIƒvƒŠƒ“ťÜ‚̍‚—p—Ę“Š—^‰Â”Ű—\‘Ş‚É‚¨‚Ż‚é“Š—^‰ŠúMCV/WBC”ä‚Ě—L—pŤ. •Ÿ“c’mL (–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/5), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723129. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’°ŠÇƒGƒR[‚ÍŠ°‰đŠú’×ᇐŤ‘ĺ’°‰Š‚ĚÄ”R‚đ—\‘Ş‚Ĺ‚Ť‚é‚Š? “c“‡–G–˛ (–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/5), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723130. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’×ᇐŤ‘ĺ’°‰Š‚É‚¨‚Ż‚銰‰đ“ą“ü1TŒă’°ŠÇƒGƒR[‚Ě’ZŠú—\Œă—\‘Ş”\. ˛ăW‘ž˜Y1, Ź—с@‘ń1,2, “ú”ä‹I•ś1,2 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/6), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723131. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “ŕŽ‹‹ž“IŠ°‰đ‚Ě’×ᇐŤ‘ĺ’°‰ŠŠłŽŇ‚É‚¨‚Ż‚é1”NˆČ“ŕ‚ĚƒXƒeƒƒCƒh“Š—^—đ‚ĆÄ”R‚ĚŒŸ“˘ (ƒvƒƒgƒRƒ‹). •Ÿ“c’mL1, ŕV“c‚‚ȋR, ŕF’JŽŠó, •Ÿś—L‰Ř, ‹{’J˜Đ—C1, ŽRč@‘ĺ, ź‰ŞŽ‘P (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): ‘ć12‰ń“ú–{‰ŠÇŤ’°ŽžŠłŠw‰ďŠwpW‰ď (2021/11/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723132. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ’†“™Ç`dÇŠˆ“ŽŠúUCŠłŽŇ‚ĚŠ°‰đ“ą“ü—Ă–@‚Ć‚ľ‚Ä‚Ěfilgotinib‚Ě—LŒřŤ‚ĆˆŔ‘SŤ (“ú–{“o˜^W’c). “ú”ä‹I•ś1,2, –{’J@‘, ‹vź—ˆę, •˝ˆäˆčm, “n•ÓŒ›ŽĄ, ź‰ŞŽ‘P, ‰Ž“c‰ë”V, Ź—с@‘ń1,2, Brain G Feagan, Chantal Tasset, Robin Besuyen, Chohee Yun, Gerald Crans, Jie Zhang, ‹ß“Ą@—z, “n•Ó@Žç (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): ‘ć12‰ń“ú–{‰ŠÇŤ’°ŽžŠłŠw‰ďŠwpW‰ď (2021/11/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723133. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’†“™Ç`dÇŠˆ“ŽŠúUCŠłŽŇ‚ĚŠ°‰đˆŰŽ—Ă–@‚Ć‚ľ‚Ä‚Ěfilgotinib‚Ě—LŒřŤ‚ĆˆŔ‘SŤ (“ú–{“o˜^W’c). “ú”ä‹I•ś1,2, –{’J@‘, ‹vź—ˆę, •˝ˆäˆčm, “n•ÓŒ›ŽĄ, ź‰ŞŽ‘P, ‰Ž“c‰ë”V, Ź—с@‘ń1,2, Brain G Feagan, Chantal Tasset, Robin Besuyen, Chohee Yun, Gerald Crans, Jie Zhang, ‹ß“Ą@—z, “n•Ó@Žç (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): ‘ć12‰ń“ú–{‰ŠÇŤ’°ŽžŠłŠw‰ďŠwpW‰ď (2021/11/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723134. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’×ᇐŤ‘ĺ’°‰Š‚ɑ΂ˇ‚éƒuƒfƒ]ƒjƒh’’°ƒtƒH[ƒ€‚Ě’ZŠú—LŒřŤ‚Ě—\‘ވöŽq‚ĚŒŸ“˘. h“‡@—É1, Ź—с@‘ń1,2, ź—ѐ^‰›, –kžŠ@–ä1, ‹{’J˜Đ—C1, ˛ăW‘ž˜Y1, ’†–ě@‰ë1, ŒÜ\—’—Ç“T, “ú”ä‹I•ś1,2 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‰ŠÇŤ’°ŽžŠł): ‘ć12‰ń“ú–{‰ŠÇŤ’°ŽžŠłŠw‰ďŠwpW‰ď (2021/11/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723135. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’°ŠÇ‚ĚShear wave elastography‚Í’×ᇐŤ‘ĺ’°‰Š‚̉ŠÇ‚𔽉f‚ˇ‚é. X‹v•Ű‘ń1, Ź—с@‘ń1,2, ˛ăW‘ž˜Y1, ‘ŠŒ´‰Ŕ“ߎq1, ”~“c”üç1, Ź“c“‡ˆęO1, ‹{’J˜Đ—C1, –kžŠ@–ä1, •Ÿ“c’mG, ˆ˘‘]Ŕ–M‰›1, ’†–ě@‰ë1, “ú”ä‹I•ś1,2 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‰ŠÇŤ’°ŽžŠł): ‘ć12‰ń“ú–{‰ŠÇŤ’°ŽžŠłŠw‰ďŠwpW‰ď (2021/11/27), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723136. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’×ᇐŤ‘ĺ’°‰ŠŠłŽŇ‚ɑ΂ˇ‚鎞ŠłŠÇ—ƒAƒvƒŠƒP[ƒVƒ‡ƒ“‚Ě—L—pŤ‚Č‚ç‚Ń‚ÉŽŔŒť‰Â”\Ť. ‹{’J˜Đ—C1, Ź—с@‘ń1,2, X‹v•Ű‘ń1, •Ÿ“c’mL1, ˆ˘‘]Ŕ–M‰›1, ˛ăW‘ž˜Y1, ’†–ě@‰ë1, “ú”ä‹I•ś1,2 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć12‰ń“ú–{‰ŠÇŤ’°ŽžŠłŠw‰ďŠwpW‰ď (2021/11/27), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

731005. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) IBD—Տ°Œ¤‹†‚Ě5W1H. Ź—с@‘ń1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@): “ú–{Á‰ťŠí•aŠw‰ďŠÖ“ŒŽx•”‘ć368‰ń—á‰ď (2022/2/5), WebŠJĂ.

733040. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ˆÝ”S–Œ‰ş‚É“ÁˆŮ‚ČŒ`‘Ô‚Ě‘˝–[Ť‚Ě”^ᇂđŒ`Ź‚ľ, \“ńŽw’°’×ᇂ̐ú”j‚Ş‹^‚í‚ę‚˝1—á. ‹vŒ´ÍO1, ź‘ş@ŒŤ1,2, ‹{’J˜Đ—C1, “ú”ä‹I•ś1, Ź—с@‘ń1,3, •l–ěˆč”ü1, ‰€“cŒ[‘ž1, ’|‘ş—S‰î1, ”—@—T”V1, —Ž‡‘ĺŽ÷1, Îˆä—ǍK1,4, ˛ăW‘ž˜Y1, h“‡@—É1, –kžŠ@–ä1, ’†–ě@‰ë1 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2Á‰ťŠí“ŕ, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4‰ş•”Á‰ťŠÇŠO): “ú–{Á‰ťŠí•aŠw‰ďŠÖ“ŒŽx•”‘ć366‰ń—á‰ď (2021/9/18), WebŠJĂ.

733041. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ’°ƒŠƒ“ƒpŠÇŠg’ŁÇ‚É‚ć‚é’`”’˜RoŤˆÝ’°Ç‚đ—ˆ‚ľ‚˝’×ᇐŤ‘ĺ’°‰Š‘ĺ’°‘S“EpŒă‚Ě1—á. —é–؁@‘á1, ź‘ş@ŒŤ1,2, ‹{’J˜Đ—C1, h“‡@—É1, –kžŠ@–ä1, ˛ăW‘ž˜Y1, ˆ˘‘]Ŕ–M‰›1, ’†–ě@‰ë1, Ź—с@‘ń1,3, “ú”ä‹I•ś1,3 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2Á‰ťŠí“ŕ, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): “ú–{Á‰ťŠí•aŠw‰ďŠÖ“ŒŽx•”‘ć368‰ń—á‰ď (2022/2/5), WebŠJĂ.

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-110010. [Œ´’˜] Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial. Kita T, Ashizuka S, Ohmiya N, Yamamoto T, Kanai T, Motoya S, Hirai F, Nakase H, Moriyama T, Nakamura M, Suzuki Y, Kanmura S, Kobayashi T1,2, Ohi H, Nozaki R, Mitsuyama K. Yamamoto S, Inatsu H, Watanbe K, Hibi T1,2, Kitamura K: J Gastroenterol 2021/2; 56 (2): 147-57. (Ź—с@‘ń1,2, “ú”ä‹I•ś1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)

'20-110011. [Œ´’˜] The dietary practices and beliefs of people living with inactive ulcerative colitis. Crooks B, McLaughlin J, Matsuoka K, Kobayashi T1,2, Yamazaki H, Limdi JK: Eur J Gastroenterol Hepatol 2021/3; 33 (3): 372-9. (Ź—с@‘ń1,2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@)


zŠÂŠí“ŕ‰ČŠw

[Šwp˜_•ś]

110150. [Œ´’˜] Clinical outcomes of ablation versus non-ablation therapy for atrial fibrillation in Japan: analysis of pooled data from the AF Frontier Ablation Registry and SAKURA AF Registry. Iso K, Nagashima K, Arai M, Watanabe R, Yokoyama K, Matsumoto N, Otsuka T, Suzuki S, Hirata A, Murakami M, Takami M, Kimura M, Fukaya H1, Nakahara S, Kato T, Hayashi H, Iwasaki Y, Shimizu W, Nakajima I, Harada T, Koyama J, Okumura K, Tokuda M, Yamane T, Tanimoto K, Momiyama Y, Nonoguchi N, Soejima K, Ejima K, Hagiwara N, Harada M, Sonoda K, Inoue M, Kumagai K, Hayashi H, Yazaki Y, Satomi K, Watari Y, Okumura Y, AF Ablation Frontier Registry investigators: Heart Vessels 2021/4; 36 (4): 549-60. ([’J‰p•˝1: 1zŠÂŠí“ŕ)

110151. [Œ´’˜] Optimized lesion size index (o-LSI): A novel predictor for sufficient ablation of pulmonary vein isolation. Matsuura G1, Kishihara J2, Fukaya H2, Oikawa J2, Ishizue N2, Saito D1, Sato T2, Arakawa Y2, Kobayashi S2, Shirakawa Y2, Nishinarita R2, Horiguchi A2, Niwano S2, Ako J2: J Arrhythm 2021/4; 37 (3): 558-65. (ź‰Y@Œł1, ŠÝŒ´@~2, [’J‰p•˝2, ‹yě@~2, Î––ŹĆ2, Ö“Ą‘ĺŽ÷1, ˛“Ą“N˜Y2, rě—Y‹I2, Ź—ŃŽü•˝2, ”’ě—TŠî2, źŹ“c—ş2, –xŒű@ˆ¤2, ’ë–ěTˆę2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ)

110152. [Œ´’˜] Efficacy and safety of esaxerenone in patients with hypertension and concomitant heart failure. Naruke T1, Maemura K1, Oki T1, Yazaki M1, Fujita T1, Ikeda Y1, Nabeta T1, Ishii S1, Minami Y1, Fukaya H1, Yuge M, Shimohama T1, Kawaguchi T, Ako J1: Hypertens Res 2021/5; 44 (5): 601-3. (Ź–с@’1, ‘O‘şŒ’ŽĄ1 , ‘ĺ–Ř‘ě–¤1, –îč–ƒ—R1, “Ą“c“S•˝1, ’r“c—S‹B1, “ç“c@Œ’1, Îˆär•ă1, “ě@ŽŒŤ1, [’J‰p•˝1, ‰ş•lF˜Y1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110153. [Œ´’˜] Long-Term Clinical Impact of Cardiogenic Shock and Heart Failure on Admission for Acute Myocardial Infarction. Wada H, Ogita M, Suwa S, Nakao K, Ozaki Y, Kimura K, Ako J1, Noguchi T, Yasuda S, Fujimoto K, Nakama Y, Morita T, Shimizu W, Saito Y, Hirohata A, Morita Y, Inoue T, Okamura A , Mano T,Wake M, Tanabe K, Shibata Y, Owa M, Tsujita K, Funayama H, Kokubu N, Kozuma K, Uemura S, Tobaru T, Saku K, Oshima S, Nishimura K, Miyamoto Y, Ogawa H, Ishihara M, J-MINUET investigators: Int Heart J 2021/5; 62 (3): 520-7. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110154. [Œ´’˜] Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. Schwartz GG, Szarek M, Bittner VA, Bhatt DL, Diaz R, Goodman SG, Jukema JW, Loy M, Manvelian G, Pordy R, White HD, Steg PG, ODYSSEY OUTCOMES Committees and Investigators (Collaborators: Ako J1): Diabetes Care 2021/5; 44 (5): 1219-27. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110155. [Œ´’˜] Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis. Akao M, Yasuda S, Kaikita K, Ako J1, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H: Am Heart J 2021/6; 236: 59-68. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110156. [Œ´’˜] Clinical valuables related to resolution of complete or advanced atrioventricular block after steroid therapy in patients with cardiac sarcoidosis. Nabeta T1, Hara M, Naruke T1, Maemura K1, Oki T1, Yazaki M1, Fujita T1, Ikeda Y1, Ishii S1, Koitabashi T1, Ako J1: J Arrhythm 2021/6; 37 (4): 1093-100. (“ç“c@Œ’1, Ź–с@’1, ‘O‘şŒ’ŽĄ1, ‘ĺ–Ř‘ě–¤1, –îč–ƒ—R1, “Ą“c“S•˝1, ’r“c—S‹B1, Îˆär•ă1, Ź”‹´r”ü1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110157. [Œ´’˜] Association between acute myocardial infarction-to-cardiac rupture time and in-hospital mortality risk: a retrospective analysis of multicenter registry data from the Cardiovascular Research Consortium-8 Universities (CIRC-8U). Yoneyama K, Ishibashi Y, Koeda Y, Itoh T, Morino Y, Shimohama T1, Ako J1, Ilari Y, Yoshioka K, Kunishima T, Inami S, Ishikawa T, Sugimura H, Kozuma K, Sugi K, Yoshino H, Akashi YJ: Heart Vessels 2021/6; 36 (6): 782-9. (‰ş•lF˜Y1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110158. [Œ´’˜] Transcatheter Aortic Valve Replacement in Patients With a Small Annulus - From the Japanese Nationwide Registry (J-TVT). Meguro K1, Kumamaru H, Kohsaka S, Hashimoto T1, Kakizaki R1, Kitamura T2, Shimizu H, Ako J1: Circ J 2021/6; 85 (7): 967-76. (–ڍ•Œ’‘ž˜Y1, ‹´‰ş‘ń–í1, Š`č—Ç‘ž1, –k‘ş@—Ľ2, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2S‘ŸŒŒŠÇŠO)

110159. [Œ´’˜] Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial. Lam CSP, Giczewska A, Sliwa K, Edelmann F, Refsgaard J, Bocchi E, Ezekowitz JA, Hernandez AF, O'Connor CM, Roessig L, Patel MJ, Pieske B, Anstrom KJ, Armstrong PW, VICTORIA Study Group (Collaborators: Ako J1): JAMA Cardiol. 2021/6; 6 (6): 706-12. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110160. [Œ´’˜] JCS/JHRS 2019 Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias. Nogami A, Kurita T, Abe H, Ando K, Ishikawa T, Imai K, Usui A, Okishige K, Kusano K, Kumagai K, Goya M, Kobayashi Y, Shimizu A, Shimizu W, Shoda M, Sumitomo N, Seo Y, Takahashi A, Tada H, Naito S, Nakazato Y, Nishimura T, Nitta T, Niwano S1, Hagiwara N, Murakawa Y, Yamane T, Aiba T, Inoue K, Iwasaki Y, Inden Y, Uno K, Ogano M, Kimura M, Sakamoto S, Sasaki S, Satomi K, Shiga T, Suzuki T, Sekiguchi Y, Soejima K, Takagi M, Chinushi M, Nishi N, Noda T, Hachiya H, Mitsuno M, Mitsuhashi T, Miyauchi Y, Miyazaki A, Morimoto T, Yamasaki H, Aizawa Y, Ohe T, Kimura T, Tanemoto K, Tsutsui H, Mitamura H, JCS/JHRS Joint Working Group: Circ J. 2021/6; 85 (7): 1104-244. (’ë–ěTˆę1: 1zŠÂŠí“ŕ)

110161. [Œ´’˜] JCS/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias. Nogami A, Kurita T, Abe H, Ando K, Ishikawa T, Imai K, Usui A, Okishige K, Kusano K, Kumagai K, Goya M, Kobayashi Y, Shimizu A, Shimizu W, Shoda M, Sumitomo N, Seo Y, Takahashi A, Tada H, Naito S, Nakazato Y, Nishimura T, Nitta T, Niwano S1, Hagiwara N, Murakawa Y, Yamane T, Aiba T, Inoue K, Iwasaki Y, Inden Y, Uno K, Ogano M, Kimura M, Sakamoto S, Sasaki S, Satomi K, Shiga T, Suzuki T, Sekiguchi Y, Soejima K, Takagi M, Chinushi M, Nishi N, Noda T, Hachiya H, Mitsuno M, Mitsuhashi T, Miyauchi Y, Miyazaki A, Morimoto T, Yamasaki H, Aizawa Y, Ohe T, Kimura T, Tanemoto K, Tsutsui H, Mitamura H, JCS/JHRS Joint Working Group: J Arrhythm 2021/6; 37 (4): 709-870. (’ë–ěTˆę1: 1zŠÂŠí“ŕ)

110162. [Œ´’˜] Clinical valuables related to resolution of complete or advanced atrioventricular block after steroid therapy in patients with cardiac sarcoidosis. Nabeta T1, Hara M, Naruke T1, Maemura K1, Oki T1, Yazaki M1, Fujita T1, Ikeda Y1, Ishii S1, Koitabashi T1, Ako J1: J Arrhythm 2021/6; 37 (4): 1093-100. (“ç“c@Œ’1, Ź–с@’1, ‘O‘şŒ’ŽĄ1, ‘ĺ–Ř‘ě–¤1, –îč–ƒ—R1, “Ą“c “S•˝1, ’r“c—S‹B1, Îˆär•ă1, Ź”‹´r”ü1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110163. [Œ´’˜] Aspartate aminotransferase to alanine aminotransferase ratio is associated with frailty and mortality in older patients with heart failure. Maeda D, Kagiyama N, Jujo K, Saito K, Kamiya K1, Saito H, Ogasahara Y, Maekawa E2, Konishi M, Kitai T, Iwata K, Wada H, Hiki M, Dotare T, Sunayama T, Kasai T, Nagamatsu H, Ozawa T, Izawa K, Yamamoto S, Aizawa N, Yonezawa R, Oka K, Momomura S, Matsue Y: Sci Rep 2021/7; 11 (1): 11957. (_’JŒ’‘ž˜Y1, ‘OěŒb”ü2: 1ˆă—ÉqśŠw•”, 2zŠÂŠí“ŕ)

110164. [Œ´’˜] Glucose-dependent diuresis in relation to improvements in renal-tubular markers of sodium-glucose cotransporter-2 inhibitors in hospitalized heart failure patients with diabetes. Ikeda Y1, Ishii S1, Maemura K1, Oki T1, Yazaki M1, Fujita T1, Nabeta T1, Maekawa E1, Koitabashi T1, Ako J1: Heart Vessels 2021/7; 36 (7): 978-85. (’r“c—S‹B1, Îˆär•ă1, ‘O‘şŒ’ŽĄ1, ‘ĺ–Ř‘ě–¤1, –îč–ƒ—R1, “Ą“c“S•˝1, “ç“c@Œ’1, ‘OěŒb”ü1, “ç“c@Œ’1, Ź”‹´r”ü1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110165. [Œ´’˜] Clinical outcomes according to dose reduction criteria of apixaban in Japanese elderly patients with atrial fibrillation: J-ELD AF Registry subanalysis. Akao M, Yamashita T, Suzuki S, Okumura K, J-ELD AF Investigators (Collaborators: Ako J1): Heart Vessels 2021/7; 36 (7): 1035-46. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110166. [Œ´’˜] Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure. Nabeta T1, Kida K, Ishida M1, Shiono T1, Suzuki N, Doi S, Tsukahara M, Ohta Y, Kimura T, Yamaguchi K, Takita A, Matsumoto N, Akashi Y, Ako J1, Inomata T1: Clin Pharmacokinet 2021/8; 60 (8): 1061-71. (“ç“c@Œ’1, Î“cŽO˜a1, ‰––ě•ű–ž1, ˆ˘ŒĂĆ1, ’––“FŒł1: 1zŠÂŠí“ŕ)

110167. [Œ´’˜] Impact of sarcopenia on prognosis in patients with heart failure with reduced and preserved ejection fraction. Konishi M, Kagiyama N, Kamiya K1, Saito H, Saito K, Ogasahara Y, Maekawa E2, Misumi T, Kitai T, Iwata K, Jujo K, Wada H, Kasai T, Nagamatsu H, Ozawa T, Izawa K, Yamamoto S, Aizawa N, Makino A, Oka K, Momomura S, Matsue Y: Eur J Prev Cardiol 2021/8; 28 (9): 1022-9. (_’JŒ’‘ž˜Y1, ‘OěŒb”ü2: 1ˆă—ÉqśŠw•”, 2zŠÂŠí“ŕ))

110168. [Œ´’˜] Ischemic/bleeding event after short dual-antiplatelet therapy in patients with high bleeding risk: Sub-analysis of the MODEL U-SES study. Hioki H1, Kozuma K, Kinoshita Y, Nanasato M, Ito Y, Yamaguchi J, Shiode N, Hibi K, Tanabe K, Ako J1, Morino Y, Hirohata A, Sonoda S, Nakagawa Y, Okada H, Nakagami T, Takamisawa I, Ando K, Abe M, Ikari Y: J Cardiol 2021/8; 78 (2): 107-13. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110169. [Œ´’˜] Clinical significance of ischemia-like electrocardiographic finding during heart failure treatment on left ventricular recovery in patients with non-ischemic dilated cardiomyopathy. Maemura K1, Ikeda Y1, Oki T1, Yazaki M1, Fujita T1, Nabeta T1, Ishii S1, Maekawa E1, Naruke T1, Koitabashi T1, Inomata T1, Ako J1: J Cardiol 2021/8; 78 (2): 142-9. (‘O‘şŒ’ŽĄ1, ’r“c—S‹B1, ‘ĺ–Ř‘ě–¤1, –îč–ƒ—R1, “Ą“c“S•˝1, “ç“c@Œ’1, Îˆär•ă1, ‘OěŒb”ü1, Ź–с@’1, Ź”‹´r”ü1, ’––“FŒł1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110170. [Œ´’˜] The optimal ablation setting for a local impedance guided catheter in an in vitro experimental model. Kawano D, Mori H, Kato R, Tsutsui K, Ikeda Y, Sumitomo N, Fukaya H1, Iwanaga S, Nakano S, Muramatsu T, Matsumoto K: J Cardiovasc Electrophysiol 2021/8; 32 (8): 2069-76. ([’J‰p•˝1: 1zŠÂŠí“ŕ)

110171. [Œ´’˜] Characteristics of carotid atherosclerosis in patients with plaque erosion. Kato A1, Minami Y1, Asakura K2, Katamine M2, Katsura A1, Muramatsu Y1, Sato T1, Kakizaki R1, Hashimoto T1, Meguro K1, Shimohama T1, Ako J1: J Thromb Thrombolysis 2021/8; 52 (2): 620-7. (‰Á“ĄĘ”ü1, “ě@ŽŒŤ1, ’Š‘q´Žj2, •Đ•ô łáŠ2, Œj@—L’q1, ‘şź—T‰î1, ˛“Ąrˆň1, Š`č—Ç‘ž1, ‹´–{‘ń–í1, –ڍ•Œ’‘ž˜Y1, ‰ş•lF˜Y1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110172. [Œ´’˜] Predictors of Rapid Plaque Progression: An Optical Coherence Tomography Study. Araki M, Yonetsu T, Kurihara O, Nakajima A, Lee H, Soeda T, Minami Y1, McNulty I, Uemura S, Kakuta T, Jang IK: JACC Cardiovasc Imaging 2021/8; 14 (8): 1628-38. (“ě@ŽŒŤ1: 1zŠÂŠí“ŕ)

110173. [Œ´’˜] Novel Predictor for New-Onset Atrial High-Rate Episode in Patients With a Dual-Chamber Pacemaker. Nishinarita R1, Niwano S1, Oikawa J1, Saito D2, Sato T1, Matsuura G2, Arakawa Y1, Kobayashi S1, Shirakawa Y1, Horiguchi A1, Nakamura H1, Ishizue N1, Kishihara J1, Fukaya H1, Ako J1: Circ Rep 2021/8; 3 (9): 497-503. (źŹ“c—ş1, ’ë–ěTˆę1, ‹yě@~1, Ö“Ą‘ĺŽ÷2, ˛“Ą“N˜Y1, ź‰Y@Œł2, rě—Y‹I1, Ź—ŃŽü•˝1, ”’ě—TŠî1, –xŒű@ˆ¤1, ’†‘ş—m”Í1, Î––ŹĆ1, ŠÝŒ´@~1, [’J‰p•˝1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110174. [Œ´’˜] Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, L—pez-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg PG, ODYSSEY Outcomes Committees and Investigators (Collaborators: Ako J1): J Am Coll Cardiol. 2021/8; 78 (5): 421-33. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110175. [Œ´’˜] Impact of Chronic Kidney Disease on In-Hospital and 3-Year Clinical Outcomes in Patients With Acute Myocardial Infarction Treated by Contemporary Percutaneous Coronary Intervention and Optimal Medical Therapy - Insights From the J-MINUET Study. Hashimoto Y, Ozaki Y, Kan S, Nakao K, Kimura K, Ako J1, Noguchi T, Suwa S, Fujimoto K, Dai K, Morita T, Shimizu W, Saito Y, Hirohata A, Morita Y, Inoue T, Okamura A, Mano T, Wake M, Tanabe K, Shibata Y, Owa M, Tsujita K, Funayama H, Kokubu N, Kozuma K, Uemura S, Tobaru T, Saku K, Oshima S, Yasuda S, Ismail TF, Muramatsu T, Izawa H, Takahashi H, Nishimura K, Miyamoto Y, Ogawa H, Ishihara M, J-MINUET Investigators: Circ J 2021/9; 85 (10): 1710-8. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110176. [Œ´’˜] Gender Differences in the Circadian and Seasonal Variations in Patients with Takotsubo Syndrome: A Multicenter Registry at Eight University Hospitals in East Japan. Yoshizawa M, Itoh T, Morino Y, Taniai S, Ishibashi Y, Komatsu T, Taguchi I, Nishinari M1, Ako J1, Kyono H, Furukawa T, Murakami T, Ikari Y, Kato R, Matsumoto K, Sakuma M, Sugimura H, Akashi YJ, Yoshino H, CIRC-8U study group: Intern Med 2021/9; 60 (17): 2749-55. (źŹ^‹Ő1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110177. [Œ´’˜] Impact of Social Frailty in Hospitalized Elderly Patients With Heart Failure: A FRAGILE-HF Registry Subanalysis. Jujo K, Kagiyama N, Saito K, Kamiya K, Saito H, Ogasahara Y, Maekawa E1, Konishi M, Kitai T, Iwata K, Wada H, Kasai T, Nagamatsu H, Ozawa T, Izawa K, Yamamoto S, Aizawa N, Yonezawa R, Oka K, Makizako H, Momomura S, Matsue Y: J Am Heart Asso 2021/9; 10 (17): e019954. (‘OěŒb”ü1: 1zŠÂŠí“ŕ)

110178. [Œ´’˜] Intravascular ultrasound predictors of long-term outcomes following ABSORB bioresorbable scaffold implantation: A pooled analysis of the ABSORB III and ABSORB Japan trials. Nishi T, Okada k, Kitahara H, Kameda R1, Ikutomi M, Imura S, Hollak MB, Yock PG, Popma JJ, Kusano H, Cheong WF, Sudhir K, Fitzgerald PJ, Ellis GS, Kereiakes DJ, Stone GW, Honda Y, Kimura T, ABSORB III and ABSORB Japan Investigators: J Cardiol 2021/9; 78 (3): 224-9. (‹T“c@—Ç1: 1zŠÂŠí“ŕ)

110179. [Œ´’˜] The impact of pre-hospital 12-lead electrocardiogram and first contact by cardiologist in patients with ST-elevation myocardial infarction in Kanagawa, Japan. Mori H, Maeda A, Akashi Y, Ako J1, Ikari Y, Ebina T, Tamura K, Namiki A, Fukui K, Michishita I, Kimura K, Suzuki H: J Cardiol 2021/9; 78 (3): 183-92. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110180. [Œ´’˜] Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2. Watanabe H, Morimoto T, Ogita M, Suwa S, Natsuaki M, Suematsu N, Koeda Y, Morino Y, Nikaido A, Hata Y, Doi M, Hibi K, Kimura K, Yoda S, Kaneko T, Nishida K, Kawai K, Yamaguchi K, Wakatsuki T, Tonoike N, Yamamoto M, Shimizu S, Shimohama T1, Ako J1, Kimura T, STOPDAPT-2 Investigators: Cardiovasc Interv Ther 2021/10; 36 (4): 403-15. (‰ş•lF˜Y1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110181. [Œ´’˜] Clinical significance of prehospital 12-lead electrocardiography in patients with ST-segment elevation myocardial infarction presenting with syncope: from a multicenter observational registry (K-ACTIVE study). Sato N1, Minami Y1, Ako J1, Maeda A, Akashi Y, Ikari Y, Ebina T, Tamura K, Namiki A, Fukui K, Michishita I, Kimura K, Suzuki H: Heart Vessels 2021/10; 36 (10): 1466-73. (˛“ĄL—m1, “ě@ŽŒŤ1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110182. [Œ´’˜] Impact of Chronic Kidney Disease on In-Hospital and 3-Year Clinical Outcomes in Patients With Acute Myocardial Infarction Treated by Contemporary Percutaneous Coronary Intervention and Optimal Medical Therapy - Insights From the J-MINUET Study. Hashimoto Y, Ozaki Y, Kan S, Nakao K, Kimura K, Ako J1, Noguchi T, Suwa S, Fujimoto K, Dai K, Morita T, Shimizu W, Saito Y, Hirohata A, Morita Y, Inoue T, Okamura A, Mano T, Wake M, Tanabe K, Shibata Y, Owa M, Tsujita K, Funayama H, Kokubu N, Kozuma K, Uemura S, Tobaru T, Saku K, Oshima S, Yasuda S, Ismail TF, Muramatsu T, Izawa H, Takahashi H, Nishimura K, Miyamoto Y, Ogawa H, Ishihara M, J-MINUET Investigators: Circ J 2021/9; 85 (10): 1710-8. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110183. [Œ´’˜] Clinical and procedure characteristics in patients treated with polytetrafluoroethylene-covered stents after coronary perforation: a CIRC-8U multicenter registry and literature review. Itoh T, Kimura T, Kudo A, Morino Y, Ikari Y, Yoshioka K, Nakano M, Natsumeda M, Sakuma M, Inami S, Ako J1, Nishinari M1, Shimohama T1, Komatsu T, Ishikawa T, Taguchi I, Sugimura H, Mitarai T, Akashi Y, Suzuki N, Sugi K, Matsumoto K, Kohshoh H, Yoshino H, CIRC-8U Study Group: Cardiovasc Interv Ther 2021/10; 36 (4): 418-28. (ˆ˘ŒĂĆ1, źŹ^‹Ő1, ‰ş•lF˜Y1: 1zŠÂŠí“ŕ)

110184. [Œ´’˜] Impact of hemodialysis on clinical and angiographic outcomes in in-stent restenotic lesions following optical coherence tomography-guided drug-coated balloon treatment. Aoki J, Nakazawa G, Ando K, Nakamura S, Tobaru T, Sakurada M, Okada H, Hibi K, Zen K, Ikuta A, Fujii K, Habara M, Ako J1, Asano T, Ozaki S, Fusazaki T, Kozuma K, ELEGANT investigators: Cardiovasc Interv Ther 2021/10; 36 (4): 429-35. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110185. [Œ´’˜] Clinical Outcomes of Rivaroxaban Monotherapy in Heart Failure Patients With Atrial Fibrillation and Stable Coronary Disease: Insights From the AFIRE Trial. Yazaki Y, Nakamura M, Iijima R, Yasuda S, Kaikita K, Akao M, Ako J1, Matoba T, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K , Ogawa H, AFIRE Investigators: Circulation 2021/10; 144 (17): 1449-51. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110186. [Œ´’˜] Association between intestinal oedema and oral loop diuretic resistance in hospitalized patients with acute heart failure. Ikeda Y1, Ishii S1, Maemura K1, Oki T1, Yazaki M1, Fujita T1, Nabeta T1, Maekawa E1, Koitabashi T1, Ako J1: ESC Heart Fail 2021/10; 8 (5): 4067-76. (’r“c—S‹B1, Îˆär•ă1, ‘O‘şŒ’ŽĄ1, ‘ĺ–Ř‘ě–¤1, –îč–ƒ—R1, “Ą“c“S•˝1, “ç“c@Œ’1, ‘OěŒb”ü1, Ź”‹´r”ü1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110187. [Œ´’˜] Validation of the atherothrombotic risk score for secondary prevention in patients with acute myocardial infarction: the J-MINUET study. Hashimoto T1, Minami Y1, Ako J1, Nakao K, Ozaki Y, Kimura K, Noguchi T, Suwa S, Fujimoto K, Nakama Y, Morita T, Shimizu W, Saito Y, Hirohata A, Morita Y, Inoue T, Okamura A, Mano T, Hirata K, Tanabe K, Shibata Y, Owa M, Tsujita K, Funayama H, Kokubu N, Kozuma K, Uemura S, Tobaru T, Saku K, Oshima S, Nishimura K, Miyamoto Y, Ogawa H, Ishihara M, J-MINUET Investigators: Heart Vessels 202/10; 36 (10): 1506-13. (‹´–{‘ń–í1, “ě@ŽŒŤ1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110188. [Œ´’˜] Age and Phenotype of Patients With Plaque Erosion. Araki M, Yonetsu T, Kurihara O, Nakajima A, Lee H, Soeda T, Minami Y1, Higuma T, Kimura S, Takano M, Yan BP, Adriaenssens T, Boeder NF, Nef HM, Kim CJ, McNulty I, Crea F, Kakuta T, Jang IK: J Am Heart Assoc 2021/10; 10 (19): e020691. (“ě@ŽŒŤ1: 1zŠÂŠí“ŕ)

110189. [Œ´’˜] Optimal interlesion distance in ablation index-guided pulmonary vein isolation for atrial fibrillation. Kobayashi S1, Fukaya H1, Oikawa J1, Saito D2, Sato T1, Matsuura G2, Arakawa Y1, Shirakawa Y1, Nishinarita R1, Horiguchi A1, Ishizue N1, Kishihara J1, Niwano S1, Ako J1: J Interv Card Electrophysiol 2021/10; 62 (1): 123-31. (Ź—ŃŽü•˝1, [’J‰p•˝1, ‹yě@~1, Ö“Ą‘ĺŽ÷2, ˛“Ą“N˜Y1, ź‰Y@Œł2, rě—Y‹I1, ”’ě—TŠî1, źŹ“c—ş1, –xŒű@ˆ¤1, Î––ŹĆ1, ŠÝŒ´@~1, ’ë–ěTˆę1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110190. [Œ´’˜] Impact of Diastolic Vessel Restriction on Quality of Life in Symptomatic Myocardial Bridging Patients Treated With Surgical Unroofing: Preoperative Assessments With Intravascular Ultrasound and Coronary Computed Tomography Angiography. Hashikata T1, Honda Y, Wang H, Pargaonkar VS, Nishi T, Brooke Hollak M, Rogers IS, Nieman K, Yock PG, Fitzgerald PJ, Schnittger I, Boyd JH, Tremmel JA: Circ Cardiovasc Interv 2021/10; 14 (10): e011062. (”˘•űŒ’G1: 1zŠÂŠí“ŕ)

110191. [Œ´’˜] Bleeding and Subsequent Cardiovascular Events and Death in Atrial Fibrillation With Stable Coronary Artery Disease: Insights From the AFIRE Trial. Kaikita K, Yasuda S, Akao M, Ako J1, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H: Circ Cardiovasc Interv 2021/11; 14 (11): e010476. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110192. [Œ´’˜] Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations. Tan JWC, Chew DP, Tsui KL, Tan D, Duplyakov D, Hammoudeh A, Zhang B, Li Y, Xu K, Ong PJ, Firman D, Gamra H, Almahmeed W, Dalal J, Tam LW, Steg G, Nguyen QN, Ako J1, Suwaidi JA, Chan M, Sobhy M, Shehab A, Buddhari W, Wang Z, Fong AYY, Karadag B, Kim BK, Baber U, Chin CT, Han YL: Eur Cardiol 2021/11; 16: e43. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110193. [Œ´’˜] Coronary plaque and clinical characteristics of South Asian (Indian) patients with acute coronary syndromes: An optical coherence tomography study. Nakajima A, Subban V, Russo M, Bryniarski KL, Kurihara O, Araki M, Minami Y1, Soeda T, Yonetsu T, Crea F, Takano M, Higuma T, Kakuta T, Adriaenssens T, Boeder NF, Nef HM, Raffel OC, McNulty I, Lee H, Nakamura S, Abdullakutty J, Mathew R, Sankardas MA, Jang IK: Int J Cardiol 2021/11; 343: 171-9. (“ě@ŽŒŤ1: 1zŠÂŠí“ŕ)

110194. [Œ´’˜] Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting: Insights From the AFIRE Trial. Matoba T, Yasuda S, Kaikita K, Akao M, Ako J1, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H, AFIRE Investigators: JACC Cardiovasc Interv 2021/11; 14 (21): 2330-40. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110195. [Œ´’˜] Antithrombotic Therapy for Atrial Fibrillation and Coronary Artery Disease in Patients With Prior Atherothrombotic Disease: A Post Hoc Analysis of the AFIRE Trial. Matsuzawa Y, Kimura K, Yasuda S, Kaikita K, Akao M, Ako J1, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Hirayama A, Matsui K, Ogawa H, AFIRE Investigators: J Am Heart Assoc 2021/11; 10 (21): e020907. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110196. [Œ´’˜] Aspirin versus P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation. Fukaya H1, Ako J1, Yasuda S, Kaikita K, Akao M, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H: Heart 2021/11; 107 (21): 1731-8. ([’J‰p•˝1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110197. [Œ´’˜] Fibrillation cycle length predicts cardiovascular events in patients with long-standing persistent atrial fibrillation. Nakamura H1, Niwano S1, Fukaya H1, Kishihara J1, Satoh A1, Oikawa J1, Yoshizawa T1, Ishizue N1, Igarashi T1, Fujiishi T1, Nishinarita R1, Horiguchi A1, Ako J1: Heart Vessels 2022/6; 37 (6): 1027-33. doi: 10.1007/s00380-021-01993-x. Epub 2021 Nov 19. (’†‘ş—m”Í1, ’ë–ěTˆę1, [’J‰p•˝1, ŠÝŒ´@~1, ˛“Ą@—z1, ‹yě@~1, ‹gŕV’qŽĄ1, Î––ŹĆ1, ŒÜ\—’Œ’1, “ĄÎŽě”ü1, źŹ“c—ş1, –xŒű@ˆ¤1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110198. [Œ´’˜] Randomised controlled trial to investigate optimal antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: a study protocol of the OPTIMA-AF trial. Sotomi Y, Kozuma K, Kashiwabara K, Higuchi Y, Ando K, Morino Y, Ako J1, Tanabe K, Muramatsu T, Nakazawa G , Hikoso S, Sakata Y, OPTIMA-AF Investigators: BMJ Open 2021/12; 11 (12): e048354. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110199. [Œ´’˜] Impact of physical performance on exercise capacity in older patients with heart failure with reduced and preserved ejection fraction. Saka K, Konishi M, Kagiyama N, Kamiya K1, Saito H, Saito K, Ogasahara Y, Maekawa E2, Misumi T, Kitai T, Iwata K, Jujo K, Wada H, Kasai T, Nagamatsu H, Ozawa T, Izawa K, Yamamoto S, Aizawa N, Makino A, Oka K, Kimura K, Tamura K, Momomura S, Matsue Y: Exp Gerontol 2021/12; 156: 111626. (_’JŒ’‘ž˜Y1, ‘OěŒb”ü2: 1ˆă—ÉqśŠw•”, 2zŠÂŠí“ŕ)

110200. [Œ´’˜] Moderate potassium lowering effect of exogenous atrial natriuretic peptide in patients with acute heart failure. Konishi M, Akiyama E, Shibata A, Kida K, Ishii S1, Ikari Y, Kimura K, Tamura K, Matsumoto S: J Cardiol 2021/12; 78 (6): 558-63. (Îˆär•ă1: 1zŠÂŠí“ŕ)

110201. [Œ´’˜] Characteristics and optimal ablation settings of a novel, contact-force sensing and local impedance-enabled catheter in an ex vivo perfused swine ventricle model. Tsutsui K, Kawano D, Mori H, Kato R, Ikeda Y, Sumitomo N, Fukaya H1, Iwanaga S, Nakano S, Muramatsu T, Matsumoto K: J Cardiovasc Electrophysiol 2021/12; 32 (12): 3187-94. ([’J‰p•˝1: 1zŠÂŠí“ŕ)

110202. [Œ´’˜] Lipid Management and 2-Year Clinical Outcomes in Japanese Patients with Acute Coronary Syndrome: EXPLORE-J. Nakamura M, Ako J1, Arai H, Hirayama A, Nohara A, Murakami Y, Ozaki A, Harada-Shiba M: J Atheroscler Thromb 2021/12; 28 (12): 1307-22. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110203. [Œ´’˜] Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study. Kusunose K, Yoshida H, Tanaka A, Teragawa H, Akasaki Y, Fukumoto Y, Eguchi K, Kamiya H, Kario K, Yamada H, Sata M, Node K, PRIZE Study Investigators (Collaborators: Ako J1): Hypertens Res 2022/1; 45 (1):106-15. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110204. [Œ´’˜] Different Determinants of the Recurrence of Atrial Fibrillation and Adverse Clinical Events in the Mid-Term Period After Atrial Fibrillation Ablation. Watanabe R, Nagashima K, Wakamatsu Y, Otsuka N, Yokoyama K, Matsumoto N, Otsuka T, Suzuki S, Hirata A, Murakami M, Takami M, Kimura M, Fukaya H1, Nakahara S, Kato T, Hayashi H, Iwasaki Y, Shimizu W, Nakajima I, Harada T, Koyama J, Okumura K, Tokuda M, Yamane T, Tanimoto K, Momiyama Y, Nonoguchi N, Soejima K, Ejima K, Hagiwara N, Harada M, Sonoda K, Inoue M, Kumagai K, Hayashi H, Yazaki Y, Satomi K, Watari Y, Okumura Y, AF Ablation Frontier Registry Investigators: Circ J 2022/1; 86 (2): 233-42. ([’J‰p•˝1: 1zŠÂŠí“ŕ)

110205. [Œ´’˜] Risk for Proteinuria in Newly Defined Hypertensive People Based on the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline. Suzuki Y, Kaneko H, Okada A, Itoh H, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yamaguchi S, Yano Y, Kamiya K1, Matsunaga A1, Ako J2, Fukui A, Yokoo T, Nishiyama A, Node K, Yamauchi T, Nangaku M, Yasunaga H, Komuro I: Am J Cardiol 2022/4; 168: 83-9. doi: 10.1016/j.amjcard.2021.12.023. Epub 2022 Jan 19. (_’JŒ’‘ž˜Y1, ź‰i“Ä•F1, ˆ˘ŒĂĆ2: 1ˆă—ÉqśŠw•”, 2zŠÂŠí“ŕ)

110206. [Œ´’˜] Lower levels of low-density lipoprotein cholesterol are associated with a lower prevalence of thin-cap fibroatheroma in statin-treated patients with coronary artery disease. Hashimoto T1, Minami Y1, Asakura K1, Katamine M2, Kato A1, Katsura A1, Sato T1, Muramatsu Y1, Kameda R1, Meguro K1, Shimohama T1, Ako J1: J Clin Lipidol 2022/1-2; 16 (1): 104-11. (‹´‰ş‘ń–í1, “ě@ŽŒŤ1, ’Š‘q´Žj1, •Đ•ôłáŠ2, ‰Á“ĄĘ”ü1, Œj@—L’q1, ˛“Ąr[1, ‘şź—T‰î1, ‹T“c@—Ç1, –ڍ•Œ’‘ž˜Y1, ‰ş•lF˜Y1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒ¤‹†‰Č)

110207. [Œ´’˜] Impact of triglyceride levels on plaque characteristics in patients with coronary artery disease. Asakura K1, Minami Y1, Kinoshita D1, Katamine M2, Kato A1, Katsura A1, Sato T1, Muramatsu Y1, Hashimoto T1, Kameda R1, Meguro K1, Shimohama T1, Ako J1: Int J Cardiol 2022/2; 348: 134-9. (’Š‘q´Žj1, “ě@ŽŒŤ1, –؉ş‘厑1, •Đ•ôłáŠ2, ‰Á“ĄĘ”ü1, Œj@—L’q1, ˛“Ąr[1, ‘şź—T‰î1, ‹´‰ş‘ń–í1, ‹T“c@—Ç1, –ڍ•Œ’‘ž˜Y1, ‰ş•lF˜Y1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒ¤‹†‰Č)

110208. [Œ´’˜] Layered Plaque Characteristics and Layer Burden in Acute Coronary Syndromes. Nakajima A, Araki M, Minami Y1, Soeda T, Yonetsu T, McNulty I, Lee H, Nakamura S, Jang IK: Am J Cardiol 2022/2; 164: 27-33. (“ě@ŽŒŤ1: 1zŠÂŠí“ŕ)

110209. [Œ´’˜] The impact of kidney function in patients on antithrombotic therapy: a post hoc subgroup analysis focusing on recurrent bleeding events from the AFIRE trial. Matsui K, Yasuda S, Kaikita K, Akao M, Ako J1, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Ogawa H: BMC Med 2022/2; 20 (1): 69. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110210. [Œ´’˜] Impact of sinus rhythm maintenance on major adverse cardiac and cerebrovascular events after catheter ablation of atrial fibrillation: insights from AF frontier ablation registry. Usuda K, Kato T, Tsuda T, Tada H, Niwa S, Usui S, Sakata K, Hayashi K, Furusho H, Kawashiri M, Takamura M, Otsuka T, Suzuki S, Hirata A, Murakami M, Takami M, Kimura M, Fukaya H1, Nakahara S, Shimizu W, Iwasaki Y, Hayashi H, Harada T, Nakajima I, Okumura K, Koyama J, Tokuda M, Yamane T, Momiyama Y, Tanimoto K, Soejima K, Nonoguchi N, Ejima K, Hagiwara N, Harada M, Sonoda K, Inoue M, Kumagai K, Hayashi H, Satomi K, Yazaki Y, Watari Y, Arai M, Watanabe R, Yokoyama K, Matsumoto N, Nagashima K, Okumura Y, on behalf of the AF Ablation Frontier Registry: Heart Vessels 2022/2; 37 (2): 327-36. ([’J‰p•˝1: 1zŠÂŠí“ŕ)

110211. [Œ´’˜] Impact of atrial fibrillation and the clinical outcomes in patients with acute myocardial infarction from the K-ACTIVE registry. Mori H, Fukui K, Maeda A, Akashi Y, Ako J1, Ikari Y, Ebina T, Tamura K, Namiki A, Michishita I, Kimura K, Suzuki H: J Cardiol 2022/6; 79 (6): 768-75. doi: 10.1016/j.jjcc.2022.02.007. Epub 2022 Feb 23. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110212. [Œ´’˜] Impact of Glucose Tolerance and Its Change on Incident Proteinuria: Analysis of a Nationwide Population-Based Dataset. Suzuki Y, Kaneko H, Okada A, Itoh H, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yamaguchi S, Kamiya K1, Matsunaga A1, Ako J2, Node K, Yamauchi T, Nangaku M, Yasunaga H, Komuro I: Am J Nephrol 2022/2; 53 (4): 307-15. (_’JŒ’‘ž˜Y1, ź‰i“Ä•F1, ˆ˘ŒĂĆ2: 1ˆă—ÉqśŠw•”, 2zŠÂŠí“ŕ)

110213. [Œ´’˜] Re-worsening left ventricular ejection fraction after response to cardiac resynchronization therapy. Oki T1, Ishii S1, Takigami Y1, Eda Y1, Maemura K1, Yazaki M1, Fujita T1, Ikeda Y1, Nabeta T1, Maekawa E1, Koitabashi T1, Ako J1: J Cardiol 2022/3; 79 (3): 358-64. (‘ĺ–Ř‘ě–¤1, Îˆär•ă1, ‘ëă@—I1, ]“c—DŽq1, ‘O‘şŒ’ŽĄ1, –îč–ƒ—R1, “Ą“c“S•˝1, ’r“c—S‹B1, “ç“c@Œ’1, ‘OěŒb”ü1, Ź”‹´r”ü1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

110214. [Œ´’˜] Re-worsening left ventricular ejection fraction after response to cardiac resynchronization therapy. Oki T1, Ishii S1, Takigami Y2, Eda Y2, Maemura K1, Yazaki M1, Fujita T1, Ikeda Y1, Nabeta T1, Maekawa E1, Koitabashi T1, Ako J1: J Cardiol 2022/3; 79 (3): 358-64. (‘ĺ–Ř‘ě–¤1, Îˆär•ă1, ‘ëă@—I2, ]“c—DŽq2, ‘O‘şŒ’ŽĄ1, –îč–ƒ—R1, “Ą“c “S•˝1, ’r“c—S‹B1, “ç“c@Œ’1, ‘OěŒb”ü1, Ź”‹´r”ü1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110215. [Œ´’˜] Catheter contact angle influences local impedance drop during radiofrequency catheter ablation: Insight from a porcine experimental study with 2 different LI-sensing catheters. Matsuura G1, Fukaya H2, Ogawa E, Kawakami S, Mori H, Saito D1, Sato T2, Nakamura H2, Ishizue N2, Oikawa J2, Kishihara J2, Niwano S2, Ako J2: J Cardiovasc Electrophysiol 2022/3; 33 (3): 380-8. (ź‰Y@Œł1, [’J‰p•˝2, Ö“Ą‘ĺŽ÷1, ˛“Ą“N˜Y2, ’†‘ş—m”Í2, Î–– ŹĆ2, ‹yě@~2, ŠÝŒ´@~2, ’ë–ěTˆę2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ)

110216. [Œ´’˜] Change in Cardiovascular Health Metrics and Risk for Proteinuria Development: Analysis of a Nationwide Population-Based Database. Suzuki Y, Kaneko H, Okada A, Itoh H, Morita K, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yamaguchi S, Kamiya K1, Matsunaga A1, Ako J2, Fukui A, Nishiyama A, Yokoo T, Node K, Yamauchi T, Nangaku M, Yasunaga H, Komuro I: Am J Nephrol 2022; 53 (2-3): 240-8. doi: 10.1159/000522147. Epub 2022 Mar 8. (_’JŒ’‘ž˜Y1, ź‰i“Ä•F1, ˆ˘ŒĂĆ2: 1ˆă—ÉqśŠw•”, 2zŠÂŠí“ŕ)

210001. [€Œ´’˜] Efficacy and safety of esaxerenone in patients with hypertension and concomitant heart failure. Naruke T1, Maemura K1, Oki T1, Yazaki M1, Fujita T1, Ikeda Y1, Nabeta T1, Ishii S1, Minami Y1, Fukaya H1, Yuge M, Shimohama T1, Kawaguchi T, Ako J1: Hypertens Res 2021/5; 44 (5): 601-3. doi: 10.1038/s41440-020-00606-w. Epub 2021 Jan 8. (Ź–с@’1, ‘O‘şŒ’ŽĄ1, ‘ĺ–Ř‘ě–¤1, –îč–ƒ—R1, “Ą“c“S•˝1, ’r“c—S‹B1, “ç“c@Œ’1, Îˆär•ă1, “ě@ŽŒŤ1, [’J‰p•˝1, ‰ş•lF˜Y1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

310011. [Ç—á•ń] Unique feature of novel activation mapping to identify the successful ablation site of atrial tachycardia. Kishihara J1, Fukaya H1, Oikawa J1, Ako J1: Heart Rhythm 2021/4; 18 (4): 653-4. (ŠÝŒ´@~1, [’J‰p•˝1, ‹yě@~1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

310012. [Ç—á•ń] Successful Retrieval of Entrapped Guide Extension Catheter in the Right Coronary Artery with Heavy Calcifications. Imura S, Hashikata T1, Ando M, Hosaka F: Int Heart J 2021/5; 62 (3): 682-6. (”˘•űŒ’G1: 1zŠÂŠí“ŕ)

310013. [Ç—á•ń] Multiple Vasculopathies and Heart Failure in Patient With ACTA-2 Mutation. Saito D1, Nabeta T2, Inoue N3, Ishizue N2, Ako J2: Circ J 2021/8; 85 (9): 1588. (Ö“Ą‘ĺŽ÷1, “ç“c@Œ’2, ˆäăMK3, Î––ŹĆ2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ, 3S‘ŸŒŒŠÇŠO)

310014. [Ç—á•ń] Atrial flutter with an epicardial and endocardial breakthrough in the cavotricuspid isthmus. Kobayashi S1, Fukaya H1, Saito D2, Sato T1, Matsuura G2, Arakawa Y1, Shirakawa Y1, Nishinarita R1, Horiguchi A1, Ishizue N1, Oikawa J1, Kishihara J1, Niwano S1, Ako J1: J Arrhythm 2021/12; 38 (1): 160-2. (Ź—ŃŽü•˝1, [’J‰p•˝1, Ö“Ą‘ĺŽ÷2, ˛“Ą“N˜Y1, ź‰Y@Œł2, rě—Y‹I1, ”’ě—TŠî1, źŹ“c—ş1, –xŒű@ˆ¤1, Î––ŹĆ1, ŠÝŒ´@~1, ’ë–ěTˆę1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

310015. [Ç—á•ń] Cardiac sarcoidosis accompanied by a tumor-like blush on coronary angiography. Asakura K1, Minami Y2, Nagata T1, Koitabashi T2, Ako J2: J Cardiol Cases 2022/2; 26 (1): 21-3. (’Š‘q´Žj1, “ě@ŽŒŤ2, ‰i“c‹MŽq1, Ź”‹´r”ü2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ)

510008. [‘ŕ] Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes. Tan JWC, Sim D, Ako J1, Almahmeed W, Cooper ME, Dalal JJ, Deerochanawong C, Huang DWC, Johar S, Kaul U, Kim SG, Koh N, Kong APS, Krittayaphong R, Kwok B, Matawaran BJ, Nguyen QN, Ong LM, Park JJ, Peng Y, Quek DK, Suastika K, Sukor N, Teo BW, Teoh CK, Zhang J, Reyes EB, Su Goh Y: Eur Cardiol 2021/4; 16: e14. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

510009. [‘ŕ] Cardiovascular Disease Prevention in the COVID-19 Era. Yokoyama M, Kamide N, Tojo T1, Yamaoka-Tojo M2: Austin J Cardiovasc Dis Atherosclerosis 2021/4; 8 (1): 1042. (“ŒžŠ‘ĺ‹P1, “ŒžŠ”ü“ŢŽq2: 1zŠÂŠí“ŕ, 2ˆă—ÉqśŠw•”)

510010. [‘ŕ] 2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-risk Chronic Coronary Syndrome. Tan JWC, Chew DP, Brieger D, Eikelboom J, Montalescot G, Ako J1, Kim BK, Quek DK, Aitken SJ, Chow CK, Chour S, Tse HF, Kaul U, Firdaus I, Kubo T, Liew BW, Chong TT, Sin KY, Yeh HI, Buddhari W, Chunhamaneewat N, Hasan F, Fox KA , Nguyen QN, Lo ST: Eur Cardiol 2021/6; 16: e26. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

510011. [‘ŕ] Wearable cardioverter-defibrillators after myocardial infarction: a review of its clinical utility and unmet needs in current clinical practice. Hioki H, Kozuma K, Kobayashi Y, Ando K, Morino Y, Kishihara J1, Ako J1, Ikari Y: Cardiovasc Interv Ther 2021/7. doi: 10.1007/s12928-021-00788-1. Online ahead of print. (ŠÝŒ´@~1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

510012. [‘ŕ] Optical Coherence Tomography of Coronary Plaque Progression and Destabilization: JACC Focus Seminar Part 3/3. Adriaenssens T, Allard-Ratick MP, Thondapu V, Sugiyama T, Raffel OC, Barlis P, Poon EKW, Araki M, Nakajima A, Minami Y1, Takano M, Kurihara O, Fuster V, Kakuta T, Jang IK: J Am Coll Cardiol 2021/9; 78 (12): 1275-87. (“ě@ŽŒŤ1: 1zŠÂŠí“ŕ)

510013. [‘ŕ] 2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations. Tan JWC, Chew DP, Tsui KL, Tan D, Duplyakov D, Hammoudeh A, Zhang B, Li Y, Xu K, Ong PJ, Firman D, Gamra H, Almahmeed W, Dalal J, Tam LW, Steg G, Nguyen QN, Ako J1, Suwaidi JA, Chan M, Sobhy M, Shehab A, Buddhari W, Wang Z, Fong AYY, Karadag B, Kim BK, Baber U, Chin CT, Han YL: Eur Cardiol 2021/11; 16: e43. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

510014. [‘ŕ] Asian Pacific Society of Cardiology Consensus Recommendations on Dyslipidaemia. Koh N, Ference BA, Nicholls SJ, Navar AM, Chew DP, Kostner K, He B, Tse HF, Dalal J, Santoso A, Ako J1, Tada H, Park JJ, Ong ML, Lim E, Subramaniam T, Li YH, Phrommintikul A, Iyengar SS, Ray S, Park KW, Tan HC, Chunhamaneewat N, Yeo KK, Tan JWC: Eur Cardiol 2021/12; 16: e54. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

510015. [‘ŕ] CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) update 2022. Ozaki Y, Hara H, Onuma Y, Katagiri Y, Amano T, Kobayashi Y, Muramatsu T, Ishii H, Kozuma K, Tanaka N, Matsuo H, Uemura S, Kadota K, Hikichi Y, Tsujita K, Ako J1, Nakagawa Y, Morino Y, Hamanaka I, Shiode N, Shite J, Honye J, Matsubara T, Kawai K, Igarashi Y, Okamura A, Ogawa T, Shibata Y, Tsuji T, Yajima J, Iwabuchi K, Komatsu N, Sugano T, Yamaki M, Yamada S, Hirase H, Miyashita Y, Yoshimachi F, Kobayashi M, Aoki J, Oda H, Katahira Y, Ueda K, Nishino M, Nakao K, Michishita I, Ueno T, Inohara T, Kohsaka S, Ismail TF, Serruys PW, Nakamura M, Yokoi H, Ikari Y, Task Force on Primary Percutaneous Coronary Intervention (PCI) of the Japanese Cardiovascular Interventional Therapeutics (CVIT): Cardiovasc Interv Ther 2022/1; 37 (1): 1-34. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

522039. [uŔ]y“ÁW: •Ů–ŒÇ (SHD) ‚—îŽĐ‰ď‚Ĺ•Ď‚í‚Á‚Ä‚Ť‚˝ŽĄ—Ă“K‰žz<ƒZƒ~ƒi[^ŽŔ’nˆă‰Ć‚ŞŽŔ‘H‚ˇ‚ׂŤf—Ă‚ĚƒvƒƒZƒX>@Š´őŤS“ŕ–Œ‰Š‚̐f’f‚ĆƒŠƒXƒN. Ź”‹´r”ü (zŠÂŠí“ŕ): Medical Practice 2021/4; 38 (4): 541-6.

522040. [uŔ]y“ÁW: S•s‘SW’†uŔ@‘˝—l‰ť‚ˇ‚éS•s‘S‚đ‚Ç‚¤f‚Ä‚Ç‚¤‘Ώˆ‚ˇ‚é‚ŠzŽŻ‚é@7 S-ICD‚âWCD‚đ“Ľ‚Ü‚Ś‚˝S•s‘S—á‚Ě“Ë‘RŽ€‘΍ô. ŠÝŒ´@~ (zŠÂŠí“ŕ): Heart View 2021/5; 25 (6): 45-50.

522041. [uŔ]y“ÁW: ƒGƒLƒXƒp[ƒg‚ÉŠw‚ԁ@’m‚Á‚Ä‚¨‚Ť‚˝‚˘S“d}f’f‚ĚƒRƒc‚Ć—Ž‚Ć‚ľŒŠzĄ’m‚Á‚Ä‚¨‚Ť‚˝‚˘S“d}ˆŮí@“d‰đŽżˆŮí. ’ë–ěTˆę (zŠÂŠí“ŕ): zŠÂŠíƒWƒƒ[ƒiƒ‹ 2021/5; 69 (2): 306-11.

522042. [uŔ]y“ÁW: •sŽ–Ź–ň•¨ŽĄ—Ă‚đl‚Ś‚é|ƒKƒCƒhƒ‰ƒCƒ“‰ü’č‚đ“Ľ‚Ü‚Ś‚ā|zŽĄ‚ˇ@11 [Expertise] •š‘śŽžŠł‡•šS–[×“ŽŠłŽŇ‚É‚¨‚Ż‚éR‹ĂŒĹ—Ă–@. [’J‰p•˝ (zŠÂŠí“ŕ): Heart View 2021/6; 25 (7).

522043. [uŔ]y“ÁW: ƒy[ƒXƒ[ƒJŠO—ˆ‚ć‚ë‚Ă‘Š’kzf‚é@5 [Expertise] ’…—pŒ^ŽŠ“Žœ×“ŽŠí (WCD) ŠłŽŇ‚ĚŠO—ˆƒtƒHƒ[‚Ć’ˆÓ“_. ’ë–ěTˆę1, ŠÝŒ´@~1, •“cÍ”2 (1zŠÂŠí“ŕ, 2MEƒZ): Heat View 2021/8; 25 (9): 823-8.

522044. [uŔ]y“ÁW: ‚—îŽŇ‚Ě–ň•¨—Ă–@|‚—îŽŇ‚ĚˆŔ‘S‚Č–ň•¨—Ă–@ƒKƒCƒhƒ‰ƒCƒ“‚̉ü’ů‚đŒŠ˜‚Ś‚āz7.uŒ¸‚炡ƒGƒrƒfƒ“ƒXv‚Ě‘no|RŒŒđ–ň‚đ—á‚Ɂ|. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): Geriatric Medicine 2021/9; 59 (9): 891-4.

522045. [uŔ]y“ÁW: SƒGƒR[ƒ‰ƒ{•KŒg! Źlć“VŤSŽžŠł‚ĚŠî–{uŔzSŽş’†ŠuŒ‡‘š‚ĚƒtƒHƒ[ƒAƒbƒv‚̐SƒGƒR[‚ĚƒRƒc. Ź”‹´r”ü (zŠÂŠí“ŕ): SƒGƒR[ 2021/10; 22 (10): 908-17.

522046. [uŔ] ˜b‘č: COVID-19‚Ć‘SgŤ‰ŠÇ”˝‰žŤ”÷ŹŒŒŠÇ“ŕ”çÇ (SIRME). “ŒžŠ‘ĺ‹P1, “ŒžŠ”ü“ŢŽq2 (1zŠÂŠí“ŕ, 2ˆă—ÉqśŠw•”): ŒÄ‹zŠí“ŕ‰Č 2021/10; 40 (4): 407-16.

522047. [uŔ]y“ÁW: zŠÂŠí—Ěˆć‚̍RŒŒđ—Ă–@‚Ě‚ł‚ç‚Č‚éi‰ťzŔ’k‰ď: oŒŒƒŠƒXƒN‚đˆÓŽŻ‚ľ‚˝RŒŒđ—Ă–@‚ĚŽž‘ă‚Ö. ˆ˘ŒĂĆ1, ’†ě‹`‹v, ˆŔ“c@‘, [’J‰p•˝1 (1zŠÂŠí“ŕ): Cardiac Practice 2021/10; 32 (1): 61-7.

522048. [uŔ]y“ÁW: SƒGƒR[ƒ‰ƒ{•KŒg! Źlć“VŤSŽžŠł‚ĚŠî–{uŔzSŽş’†ŠuŒ‡‘š‚ĚƒtƒHƒ[ƒAƒbƒv‚̐SƒGƒR[‚ĚƒRƒc. Ź”‹´r”ü (zŠÂŠí“ŕ): SƒGƒR[ 2021/10; 22 (10): 908-17.

522049. [uŔ] “ÁW: Žčp^ˆ’u‘O‚ĚˆŔ‘S‚ȍR‹ĂŒĹ–ňERŒŒŹ”–ň‚Ě‹x–ň. [’J‰p•˝ (zŠÂŠí“ŕ): “ú–{ˆăŽ–V•ń 2021/12; 5093: 18-29.

522050. [uŔ]y“ÁW: ‘SgŤŽžŠł‚đSƒGƒR[‚Őf‚é@‚ą‚ę‚ž‚Ż‚Í’m‚Á‚Ä‚¨‚Ť‚˝‚˘SƒGƒR[ŠŒŠzäPŒ´•a‚̐S‡•šÇ‚đSƒGƒR[‚Őf‚é. Ź”‹´r”ü (zŠÂŠí“ŕ): SƒGƒR[ 2022/1; 23 (1): 26-43.

522051. [uŔ]y“ÁW: “úíf—Ă‚Ĺ‘˜‹ö‚ˇ‚é‰ESŽžŠłz‰ES‹@”\|S‹ŘÇ. Ź”‹´r”ü (zŠÂŠí“ŕ): SƒGƒR[ 2022/2; 23 (3): 240-50.

522052. [uŔ]y“ÁW: zŠÂŠíŽžŠł‡•š”DP@ŠłŽŇ‚̕ωť‚đŒŠ“Ś‚ł‚Č‚˘, ”DP‚Š‚çŽYŒăŠÇ—‚܂Łz[f‚é]@4. ”DP’†‚̏zŠÂŠíŒŸ¸. Ź”‹´r”ü (zŠÂŠí“ŕ): Heart View 2022/3; 26 (3): 20-4.

530005. [‚ť‚Ě‘ź (Comment)] Response to letter to the editor entitled ""Association between left atrial sphericity index and clinical outcomes in patients with systolic heart failure"". Yazaki M1, Nabeta T1, Ako J1: Clin Cardiol 2021/4; 44 (4): 444-5. (–îč–ƒ—R1, “ç“c@Œ’1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

530006. [‚ť‚Ě‘ź (Editorial)] Atrial High-Rate Episodes Are a Comprehensive Surrogate Marker for Thromboembolic and Bleeding Events. Fukaya H1: Circ J 2021/7; 85 (8): 1338-40. ([’J‰p•˝1: 1zŠÂŠí“ŕ)

530007. [‚ť‚Ě‘ź (Published Erratum)] CORRIGENDUM: JCS/JHRS 2019 Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias. Nogami A, Kurita T, Abe H, Ando K, Ishikawa T, Imai K, Usui A, Okishige K, Kusano K, Kumagai K, Goya M, Kobayashi Y, Shimizu A, Shimizu W, Shoda M, Sumitomo N, Seo Y, Takahashi A, Tada H, Naito S, Nakazato Y, Nishimura T, Nitta T, Niwano S1, Hagiwara N, Murakawa Y, Yamane T, Aiba T, Inoue K, Iwasaki Y, Inden Y, Uno K, Ogano M, Kimura M, Sakamoto S, Sasaki S, Satomi K, Shiga T, Suzuki T, Sekiguchi Y, Soejima K, Takagi M, Chinushi M, Nishi N, Noda T, Hachiya H, Mitsuno M, Mitsuhashi T, Miyauchi Y, Miyazaki A, Morimoto T, Yamasaki H, Aizawa Y, Ohe T, Kimura T, Tanemoto K, Tsutsui H, Mitamura H, JCS/JHRS Joint Working Group: Circ J 2021/9; 85 (9): 1692-700. (’ë–ěTˆę1: 1zŠÂŠí“ŕ)

530008. [‚ť‚Ě‘ź (Guideline)] JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease. Nakamura M, Yaku H, Ako J1, Arai H, Asai T, Chikamori T, Daida H, Doi K, Fukui T, Ito T, Kadota K, Kobayashi J, Komiya T, Kozuma K, Nakagawa Y, Nakao K, Niinami H, Ohno T, Ozaki Y, Sata M, Takanashi S, Takemura H, Ueno T, Yasuda S, Yokoyama H, Fujita T, Kasai T, Kohsaka S, Kubo T, Manabe S, Matsumoto N, Miyagawa S, Mizuno T, Motomura N, Numata S, Nakajima H, Oda H, Otake H, Otsuka F, Sasaki K, Shimada K, Shimokawa T, Shinke T, Suzuki T, Takahashi M, Tanaka N, Tsuneyoshi H, Tojo T1, Une D, Wakasa S, Yamaguchi K, Akasaka T, Hirayama A, Kimura K, Kimura T, Matsui Y, Miyazaki S, Okamura Y, Ono M, Shiomi H, Tanemoto K, Japanese Circulation Society Joint Working Group: Circ J 2022/2; 86 (3): 477-588. (ˆ˘ŒĂĆ1, “ŒžŠ‘ĺ‹P1: 1zŠÂŠí“ŕ)

540021. [‚ť‚Ě‘ź (Editorial Commentl)] Š|‹´˜_•ś‚ɑ΂ˇ‚éEditorial Comment. ŠÝŒ´@~ (zŠÂŠí“ŕ): S‘Ÿ 2021/4; 53 (4):379.

540022. [‚ť‚Ě‘ź (Editorial Commentl)] ‘ĺ“ˆ˜_•ś‚ɑ΂ˇ‚éEditorial Comment. Ź”‹´r”ü (zŠÂŠí“ŕ): S‘Ÿ 2021/4; 53 (4): 408-9.

540023. [‚ť‚Ě‘ź (Editorial Commentl)] ‰ĄŽR˜_•ś‚ɑ΂ˇ‚éEditorial Comment. Ź”‹´r”ü (zŠÂŠí“ŕ): S‘Ÿ 2021/12; 53 (12): 1340-1.

[’˜@‘]

620024. [Šwp‘ (•Ş’SŽˇ•M)]y‚í‚Š‚é! ‚Ĺ‚Ť‚é! t‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Q&AzI. t‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚đŽŔŽ{‚ˇ‚é‚˝‚ß‚ĚŠî‘b’mŽŻ@5. ‰^“Ž‚ˇ‚é‚ĆŒŒŸ÷pH‚ÍŽ_Ť‰ť‚ľ‚Ü‚ˇ‚Š?, p.26-7. ‰ÍŒ´Ž‰ë, ‰ş•lF˜Y1 (1zŠÂŠí“ŕ), •Ň: ŽRăp–MO, Ż–ěƒˆę, ź‰i“Ä•F, ˆăŽ•–ňo”Ĺ, “Œ‹ž, 2021/5”­s.

620025. [Šwp‘ (•Ş’SŽˇ•M)]y“ŻŽíE“ŻŒř–ň‚ĚŽg‚˘•Ş‚Ż@ŽžŠł~Šî–{–ň‚ĚƒGƒrƒfƒ“ƒX‚𐎗‚ˇ‚é (ŒŽŠÔ–ňŽ–5ŒŽ—ŐŽž‘Š§†)z‘ć1Í zŠÂŠíŒn‚ĚŠî–{–ň‚ĚŽg‚˘•Ş‚Ż@2. S•s‘S‚Ö‚ĚƒŔŽŐ’f–ň‚Í‚Ç‚¤‘I‚Ô, p.24-31. “ç“c@Œ’ (zŠÂŠí“ŕ), •Ň: Žu‰ę@„, ‚ś‚Ů‚¤, “Œ‹ž, 2021/5”­s.

620026. [Šwp‘ (•Ş’SŽˇ•M)]yĄ‚ą‚ťŠw‚Ń’ź‚ˇ! ś—ŠwE‰đ–UŠw@‚ ‚Ě‚Ć‚ŤŠw‚ń‚ž’mŽŻ‚Ć—Ő°ŒoŒą‚đ‚‚Ȃ˘‚Ĺ, ”[“ž‚ľ‚Ä“Ž‚­! (ƒŒƒWƒfƒ“ƒgƒm[ƒg‘Š§Vol.23 No.8)z‘ć1Í zŠÂŠíŒn@3. ‹•ŒŒŤSŽžŠł, p.29-36. ‹´–{‘ń–í1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ), •Ň: ”‹•˝@“N, —r“yŽĐ, “Œ‹ž, 2021/7”­s.

620027. [Šwp‘ (•Ş’SŽˇ•M)]yS•s‘Sf—Ăƒp[ƒtƒFƒNƒg@ƒVƒ`ƒ…ƒG[ƒVƒ‡ƒ“•Ę‚̍l‚Ś•űE“Ž‚Ť•ű‚đg‚ɂ‚Ż‚ĐS•s‘Sƒpƒ“ƒfƒ~ƒbƒN‚É—§‚żŒü‚Š‚¤ (ƒŒƒWƒfƒ“ƒgƒm[ƒg‘Š§Vol.23 No.11)z‘ć1Í ‹~‹}ŠO—ˆ‚ł̐S•s‘S@3. ‹}ŤS•s‘S‚ĚƒZƒJƒ“ƒhƒ^ƒbƒ`‚Š‚çICU/CCU“üŽş‚Ü‚Ĺ‚Él‚Ś‚é‚ą‚Ć, ‚â‚é‚ׂŤ‚ą‚Ć, p.39-48. “ç“c@Œ’ (zŠÂŠí“ŕ), •Ň: –Ř“cŒ\—ş, —r“yŽĐ, “Œ‹ž, 2021/9”­s.

620028. [Šwp‘ (•Ş’SŽˇ•M)]ySƒGƒR[ Œv‘Ş/•`o‚ĚƒRƒc, g‚ɂ‚Ż‚˝‚˘l‚Ś•ű/i‚ß•ű (Heart View 2021”N11ŒŽ‘Š§†)zII g‚ɂ‚Ż‚˝‚˘l‚Ś•ű/i‚ß•ű@3 •a‹C‚đŽŻ‚é, •a‹C‚đf‚é@i. ‚˝‚ą‚‚ڐS‹ŘÇ (‚˝‚ą‚‚ڏnjóŒQ)@…@SƒTƒ‹ƒRƒCƒh[ƒVƒXESƒAƒ~ƒƒCƒh[ƒVƒX, p.164-9. Ź”‹´r”ü (zŠÂŠí“ŕ), ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, “Œ‹ž, 2021/10”­s.

620029. [Šwp‘ (•Ş’SŽˇ•M)]yV PCIEƒJƒe[ƒeƒ‹Žş‚Ěƒsƒ“ƒ`‚Š‚ç‚Ě’Eo–@@’Bl‚Ş‹ł‚Ś‚é119‚ĚƒeƒNƒjƒbƒNzXII PCIŒă—Ă–@‚ŕ‚¤‚Ü‚­‚â‚é!@115 ƒXƒeƒ“ƒgÄ‹ˇó—á‚ĚŠO‰Č“K‰ž‚Ěƒ^ƒCƒ~ƒ“ƒO‚Í?, p.489-93. “ě@ŽŒŤ (zŠÂŠí“ŕ), •Ň: ‘şźrĆ, “ě]“°, “Œ‹ž, 2021/12”­s.

620030. [Šwp‘ (•Ş’SŽˇ•M)]y“úíf—Ă‚ÉŠˆ‚Š‚ˇf—ĂƒKƒCƒhƒ‰ƒCƒ“UP-TO-DATE 2022-2023zIII. zŠÂŠíŽžŠł@3 ‹ˇSÇ, p.158-62. •Đ•ôłáŠ1, ‰ş•lF˜Y1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ), ŠÄC: –ĺ˜e@F, ŹŽşˆęŹ, ‹{’n—ÇŽ÷, ƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽĐ, ‘ĺă, 2022/2”­s.

620031. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŠî‘b•Ň@1) RŒŒđ–ň@1 ŠTŕ, p.10-7. ‰ş•lF˜Y1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620032. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŠî‘b•Ň@1) RŒŒđ–ň@2 RŒŒŹ”–ň, p.18-23. ‹T“c@—Ç1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620033. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŠî‘b•Ň@1) RŒŒđ–ň@3 R‹ĂŒĹ–ň, p.24-31. [’J‰p•˝1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620034. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŠî‘b•Ň@2) R‹ˇSÇ–ň@1 ŠTŕ, p.32-35. 2 ÉŽ_–ň, CahR–ň, ƒjƒRƒ‰ƒ“ƒWƒ‹, p.36-43. –k—˘—œŽŃ1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620035. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŠî‘b•Ň@3) S•s‘SŽĄ—Ă–ň@1 ŠTŕ, p.44-50. Ź”‹´r”ü1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620036. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŠî‘b•Ň@3) S•s‘SŽĄ—Ă–ň@2 ACE‘jŠQ–ň/ARB, MRA, ARNI, p.51-61. “ç“c@Œ’1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620037. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŠî‘b•Ň@3) S•s‘SŽĄ—Ă–ň@3 ƒŔŽŐ’f–ň, p.62-7. ”Ń“c—Sˆę˜Y1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620038. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŠî‘b•Ň@3) S•s‘SŽĄ—Ă–ň@4 ƒCƒoƒuƒ‰ƒWƒ“, p.68-72. “Ą“c“S•˝1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620039. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŠî‘b•Ň@4) ‹­S–ň, ¸ˆł–ň@1 ŠTŕ, p.88-91. 2 Ă’‹­S–ň, “ŕ•ž‹­S–ň, p.92-7. ˛“ĄL—m1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620040. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŠî‘b•Ň@5) R•sŽ–Ź–ň@1 ŠTŕ, p.98-105. ’ë–ěTˆę1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620041. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŠî‘b•Ň@5) R•sŽ–Ź–ň@2 IŒQ–ň, …ĄŒQ–ň, p.106-11. ŠÝŒ´@~1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620042. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŠî‘b•Ň@5) R•sŽ–Ź–ň@3 IVŒQ–ň, ƒWƒMƒ^ƒŠƒXťÜ, p.112-8. Î––ŹĆ1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620043. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŠî‘b•Ň@6) ~ˆł–ň@2 ƒŔŽŐ’f–ň, CahR–ň, ARB, ACE‘jŠQ–ň, p.131-6. ‘OěŒb”ü1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż1, •Ň: ˆ˘ŒĂĆ, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620044. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŠî‘b•Ň@7) ”x‚ŒŒˆłÇŽĄ—Ă–ň@1 ŠTŕ, p.137-42. 2 ƒvƒƒXƒ^ƒTƒCƒNƒŠƒ“ťÜ, p.143-6. 3 ƒGƒ“ƒhƒZƒŠƒ“Žó—e‘̝hR–ň, p.147-9. 4@PDE-5‘jŠQ–ň‚ĆsGCŽhŒƒ–ň, p.150-3. Îˆär•ă1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620045. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŠî‘b•Ň@8) Ž‰ŽżˆŮíÇŽĄ—Ă–ň@1 ŠTŕ, p.154-6. 2 ƒXƒ^ƒ`ƒ“, ƒGƒ[ƒ`ƒ~ƒu, p.157-9. 3 PCSK9‘jŠQ–ň, p.160-2. 4 ‚ť‚Ě‘ź‚Ě–ňÜ, p.163-7. “ě@ŽŒŤ1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620046. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŽŔ‘H•Ň@1 –éŠÔAQ’†‚Ě“Ë‘R‚Ě‹š’É, p.168-73. –ڍ•Œ’‘ž˜Y1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620047. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŽŔ‘H•Ň@2 1ƒJŒŽ‘O‚Š‚ç‚Ě˜JěŽž‹š•”ˆł”—Š´‚Ć–éŠÔ‚̗⊞‚𔺂¤‘O‹š•”’É, p.174-7. 3 isˆÝŠŕ‚đ”F‚ß‚˝˜JěŤ‹ˇSÇŠłŽŇ, p.178-9. ‹´–{‘ń–í1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620048. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŽŔ‘H•Ň@4 Ĺ‹ß•p“x‚Ş‘‚Ś‚Ä‚Ť‚˝“Žœ§, p.180-4. ’†‘ş—m”Í1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620049. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŽŔ‘H•Ň@5 “ú’†‹N—§Žž‚Ě“Ë‘R‚ĚŒÄ‹z˘“ď, p.185-90. –؉ş‘厑1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620050. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŽŔ‘H•Ň@6 ‘’Š‚ĚŽ¸_‚𔺂¤‹š’É, p.191-63. Œj@—L’q1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620051. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŽŔ‘H•Ň@7 Ž‘ą‚ˇ‚é‹š’ɂɈř‚Ť‘ą‚˘‚ďoŒť‚ľ‚˝“Ë‘R‚ĚŒÄ‹z˘“ď, p.197-204. Ź”‹´r”ü1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620052. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŽŔ‘H•Ň@8 1TŠÔ‘O‚Š‚ç‚ĚŠPšu‚Ć–éŠÔ”­ěŤŒÄ‹z˘“ď, p.205-11. ’r“c—S‹B1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620053. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŽŔ‘H•Ň@9 ‰ş‘Ú•‚Žî‚𔺂¤–éŠÔ”­ěŤŒÄ‹z˘“ď, p.212-8. ”Ń“c—Sˆę˜Y1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620054. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŽŔ‘H•Ň@10 Šg’ŁŒ^S‹ŘÇ‚ĚŠů‰‚Ɖş‘Ú•‚Žî‚𔺂¤˜JěŽžŒÄ‹z˘“ď, p.219-24. “Ą“c“S•˝1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620055. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŽŔ‘H•Ň@11 2TŠÔ‘O‚Š‚ç‚Ě˜JěŽžŒÄ‹z˘“ď, p.225-8. –îč–ƒ—R1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620056. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŽŔ‘H•Ň@12 Š´–`Œă‚ĚŒÄ‹z‹ę, p.229-32. ˛“ĄL—m1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620057. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŽŔ‘H•Ň@13 –ž‚Ż•ű‚Ě“Žœ§, p.233-8. ‹yě@~1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

620058. [Šwp‘ (•Ş’SŽˇ•M)]yzŠÂŠí–ňƒhƒŠƒ‹zŽŔ‘H•Ň@14 ™X‚É‘ˆŤ‚ľ‚˝‘§Ř‚ę, p.239-41. Îˆär•ă1 (1zŠÂŠí“ŕ), ŠÄC: ’r“c—˛“ż, •Ň: ˆ˘ŒĂĆ1, —r“yŽĐ, “Œ‹ž, 2022/3”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

712005. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Optimal Strategies for the Treatment of Severe Calcified Lesions Under OCT Guidance. Minami Y1: the 19th Gwangju International Interventional Cardiology Symposium (GICS 2021) (2021/6/11), Gwangju, Korea. (“ě@ŽŒŤ1: 1zŠÂŠí“ŕ)

712006. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) New Lipid Guidelines: what is new and important? Ako J1: APSC 2021 (2021/10/3), WebŠJĂ. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

712007. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Role of Wearable Cardioverter Defibrillator (WCD) in Acute Phase Care of Patients at High SCD Risk. Niwano S1: 14th Asia Pacific Heart Rhythm Society Scientific Session (APHRS 2021) (2021/11/13), Suzhou, China & Online. (’ë–ěTˆę1: 1zŠÂŠí“ŕ)

713015. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Higher triglyceride level is associated with higher frequency of plaque with macrophage accumulation in coronary plaques among patients with low low-density lipoprotein cholesterol level. Asakura K1, Minami Y2, Katamine M1, Kato A2, Katsura A2, Hashimoto T2, Kinoshita D2, Ako J2: American College Cardiology (ACC) 2021 Scientific Session (2021/5/15-17), WebŠJĂ. (’Š‘q´Žj1, “ě@ŽŒŤ2, •Đ•ôłáŠ1, ‰Á“ĄĘ”ü2, Œj@—L’q2, ‹´–{‘ń–í2, –؉ş‘厑2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ)

713016. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Anti-thrombotic Therapy Decision-making in a Stable Patient Six Months After Complex PCI. Ako J1: American College Cardiology (ACC) 2021 Scientific Session (2021/5/15-17), WebŠJĂ. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

713017. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Higher Red Cell Distribution Width is Associated with the Presence of Calcification in Coronary Plaque. Kato A1, Minami Y2, Nagata T1, Asakura K1, Katamine M1, Katsura A2, Kinoshita D3, Hashimoto T2, Ako J2: American College Cardiology (ACC) 2021 Scientific Session (2021/5/15-17), WebŠJĂ. (‰Á“ĄĘ”ü1, “ě@ŽŒŤ2, ‰i“c‹MŽq1, ’Š‘q´Žj1, •Đ•ôłáŠ1, Œj@—L’q2, –؉ş‘厑3, ‹´–{‘ń–í2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ, 3‹~–˝)

713018. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Plaque Phenotype and Clinical Characteristics of South Asian (Indian) Patients with Acute Coronary Syndromes: An Optical Coherence Tomography Study. Nakajima A, Subban V, Russo M, Bryniarski K, Kurihara O, Araki M, Minami Y1, Soeda T, Yonetsu T, Crea F, Takano M, Higuma T, Kakuta T, Adriaenssens T, Boeder N, Nef H, Raffel OC, McNulty I, Lee H, Nakamura S, Abdullakutty J, Mathew R, Sankardas AM, Jang IK: American College Cardiology (ACC) 2021 Scientific Session (2021/5/15-17), WebŠJĂ. (“ě@ŽŒŤ1: 1zŠÂŠí“ŕ)

713019. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Severe Coronary Calcification is Associated with Higher Incidence of Device-oriented Clinical Events after Percutaneous Coronary Intervention. Nagata T1, Minami Y2, Asakura K1, Katamine M1, Kinoshita D3, Ako J2: American College Cardiology (ACC) 2021 Scientific Session (2021/5/15-17), WebŠJĂ. (‰i“c‹MŽq1, “ě@ŽŒŤ2, ’Š‘q´Žj1, •Đ•ôłáŠ1, –؉ş‘厑3, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ, 3‹~–˝)

713020. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Higher Lipoprotein a Level is Associated with Vulnerable Characteristics in Nonculprit Plaque in Patients with Plaque Erosion. Kato A1, Kinoshita D2, Nagata T1, Asakura K1, Katamine M1, Katsura A3, Hashimoto T3, Minami Y3, Ako J3: American College Cardiology (ACC) 2021 Scientific Session (2021/5/15-17), WebŠJĂ. (‰Á“ĄĘ”ü1, –؉ş‘厑2, ‰i“c‹MŽq1, ’Š‘q´Žj1, •Đ•ôłáŠ1, Œj@—L’q3, ‹´–{‘ń–í3, “ě@ŽŒŤ3, ˆ˘ŒĂĆ3: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‹~–˝, 3zŠÂŠí“ŕ)

713021. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) What does real world data show us? Ako J1: Atherosclerosis Imaging Symposium (2021/6/26), WebŠJĂ. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

713022. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Association between lowering heart rate during IMPELLA support and favorable short-term outcome in patients with cardiogenic shock. Maemura K1, Ikeda Y2, Eda Y1, Oki T1, Yazaki M3, Fujita T3, Iida Y3, Koriyama K4, Nabeta T3, Ishii S3, Maekawa E3, Koitabashi T3, Ako J3: European society of cardiology (ESC) congress 2021 (2021/8/27-30), WebŠJĂ. (‘O‘şŒ’ŽĄ1, ’r“c—S‹B2, ]“c—DŽq1, ‘ĺ–Ř‘ě–¤1, –îč–ƒ—R3, “Ą“c“S•˝3, ”Ń“c—Sˆę˜Y3, ŒSŽRŒbŽq4, “ç“c@Œ’3, Îˆär•ă3, ‘OěŒb”ü3, Ź”‹´r”ü3, ˆ˘ŒĂĆ3: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‹~–˝, 3zŠÂŠí“ŕ, 4‘‡f—Ă)

713023. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Prognostic impact of atrial fibrillation under oral anticoagulation therapy in patients with type B acute aortic dissection. Ishizue N1, Fukaya H1, Saito D2, Matsuura G2, Sato T2, Kobayashi S1, Shirakawa Y1, Arakawa Y1, Oikawa J1, Kishihara J1, Niwano S1, Ako J1: European society of cardiology (ESC) congress 2021 (2021/8/27-30), WebŠJĂ. (Î––ŹĆ1, [’J‰p•˝1, âV“Ą‘ĺŽ÷2, ź‰Y@Œł2, ˛“Ą“N˜Y2, Ź—ŃŽü•˝1, ”’ě—TŠî1, rě—Y‹I1, ‹yě@~1, ŠÝŒ´@~1, ’ë–ěTˆę1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

713024. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Catheter contact angle influences local impedance drop during radiofrequency catheter ablation: Insight from a porcine experimental studyCatheter contact angle influences local impedance drop during radiofrequency catheter ablation: Insight from a porcine experimental study. Matsuura G1, Fukaya H2, Ogawa E3, Kawakami S1, Saito D1, Sato T1, Arakawa Y2, Kobayashi S2, Shirakawa Y2, Ishizue N2, Oikawa J2, Kishihara J2, Niwano S2, Ako J2: European society of cardiology (ESC) congress 2021 (2021/8/27-30), WebŠJĂ. (ź‰Y@Œł1, [’J‰p•˝2, ŹěŒb”ü—I3, ěă‘‘ž1, âV“Ą‘ĺŽ÷1, ˛“Ą“N˜Y1, rě—Y‹I2, Ź—ŃŽü•˝2, ”’ě—TŠî2, Î––ŹĆ2, ‹yě@~2, ŠÝŒ´@~2, ’ë–ěTˆę2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ, 3ˆă—ÉqśŠw•”)

713025. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Rivaroxaban inhibits the vascular endothelial glycocalyx shedding under oxidative stress. Kitasato L1, Tojo M2, Ako J1: The 19th International Symposium of Atherosclerosis (ISA2021) (2021/10/24-27), Kyoto, Japan (ƒnƒCƒuƒŠƒbƒhŠJĂ). (–k—˘—œŽŃ1, “ŒžŠ”ü“ŢŽq2, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ, 2ˆă—ÉqśŠw•”)

713026. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) High Bleeding Risk is Associated with a Higher Prevalence of Severe Calcified Plaque in Patients Requiring Percutaneous Coronary Intervention. Nagata T1, Minami Y2, Muramatsu Y2, Nakata T2, Asakura K1, Katamine M1, Kinoshita D2, Ako J2: American Heart Association (AHA) 2021 Scientific Session (2021/11/13-15), WebŠJĂ. (‰i“c‹MŽq1, “ě@ŽŒŤ2, ‘şź—T‰î2, ’†“c Ć2, ’Š‘q´Žj1, •Đ•ôłáŠ1, –؉ş‘厑2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ)

713027. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Lower EPA/AA ratio is associated with a higher prevalence of vulnerable characteristics in non-culprit coronary plaques in statin-treated patients with coronary artery disease. Asakura K1, Minami Y2, Kinoshita D2, Nagata T1, Katamine M1, Katsura A1, Hashimoto T2, Kameda R2, Meguro K2, Shimohama T2, Ako J2: American Heart Association (AHA) 2021 Scientific Session (2021/11/13-15), WebŠJĂ. (’Š‘q´Žj1, “ě@ŽŒŤ2, –؉ş‘厑2, ‰i“c‹MŽq1 •Đ•ôłáŠ1, Œj@—L’q2, ‹´–{‘ń–í2, ‹T“c@—Ç2, –ڍ•Œ’‘ž˜Y2, ‰ş•lF˜Y2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ)

713028. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Higher body mass index is associated with a higher prevalence of thin-cap fibroatheroma in younger patients with type 2 diabetes mellitus. Katamine M1, Minami Y2, Asakura K1, Kato A2, Katsura A2, Sato T2, Muramatu Y2, Hashimoto T2, Kameda R2, Meguro K2, Shimohama T2, Ako J2: American Heart Association (AHA) 2021 Scientific Session (2021/11/13-15), WebŠJĂ. (•Đ•ôłáŠ1, “ě@ŽŒŤ2, ’Š‘q´Žj1, ‰Á“ĄĘ”ü2, Œj@—L’q2, ˛“Ąr[2, ‘şź—T‰î2, ‹´–{‘ń–í2, ‹T“c@—Ç2, –ڍ•Œ’‘ž˜Y2, ‰ş•lF˜Y2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ)

713029. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Impact of catheter contact angle on local impedance drop and lesion size using the INTELLANAV STABLEPOINT ablation catheter: Insight from a porcine experimental study. Matsuura G1, Fukaya H2, Ogawa E3, Kawakami S1, Mori H, Saito D1, Sato T1, Nakamura H2, Ishizue N2, Oikawa J2, Kishihara J2, Niwano S2, Ako J2: American Heart Association (AHA) 2021 Scientific Session (2021/11/13-15), WebŠJĂ. (ź‰Y@Œł1, [’J‰p•˝2, ŹěŒb”ü—I3, ěă‘‘ž1, âV“Ą‘ĺŽ÷1, ˛“Ą“N˜Y1, ’†‘ş—m”Í2, Î––ŹĆ2, ‹yě@~2, ŠÝŒ´@~2, ’ë–ěTˆę2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ, 3ˆă—ÉqśŠw•”)

713030. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Is an Induction Test Necessary While Catheter Ablation of Atrial Fibrillation? Sato T1, Oikawa J2, Fukaya H2, Mitani Y1, Murayama Y1, Saito D1, Matsuura G1, Ishizue N2, Kishihara J2, Niwano S2, Ako J2: American Heart Association (AHA) 2021 Scientific Session (2021/11/13-15), WebŠJĂ. (˛“Ą“N˜Y1, ‹yě@~2, [’J‰p•˝2, ŽO’J—D‘ž˜N1, ‘şŽR—F‰î1, âV“Ą‘ĺŽ÷1, ź‰Y@Œł1, Î––ŹĆ2, ŠÝŒ´@~2, ’ë–ěTˆę2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ)

713031. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Sex Differences in Culprit Plaque Characteristics in Acute Coronary Syndromes. Araki M, Nakajima A, Yonetsu T, Soeda T, Kurihara O, Higuma T, Kimura S, Minami Y1, Ako J1, Adriaenssens T, Nef H, Lee H, McNulty I, Sugiyama T, Kakuta T, Jang IK: American Heart Association (AHA) 2021 Scientific Session (2021/11/13-15), WebŠJĂ. (“ě@ŽŒŤ1, ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

713032. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) High sensitivity C-reactive protein is associated with vulnerable characteristics in non-culprit plaques in patients with ST-segment elevation myocardial infarction. Katamine M1, Minami Y2, Asakura K1, Katsura A2, Hashimoto T2, Ako J2: ESC Asia 2021with APSC & AFC (2021/12/2-4), WebŠJĂ. (•Đ•ôłáŠ1, “ě@ŽŒŤ2, ’Š‘q´Žj1, Œj@—L’q2, ‹´–{‘ń–í2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ)

713033. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Management of diabetes mellitus in patients with cardiovascular disease. Ako J1: ESC Asia 2021with APSC & AFC (2021/12/2-4), WebŠJĂ. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

713034. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) The burden of diabetes mellitus in Asia. Ako J1: ESC Asia 2021with APSC & AFC (2021/12/2-4), WebŠJĂ. (ˆ˘ŒĂĆ1: 1zŠÂŠí“ŕ)

721008. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) The Clinical Outcomes of DP-EES vs. BP-SES in a Real-world Cohort Study. “ě@ŽŒŤ (zŠÂŠí“ŕ): Complex Cardiovasculr Therapeutics (CCT) 2021 Annual Meeting (2021/10/29), WebŠJĂ.

722063. [Šw‰ď (‘S‘)] (‹łˆçˆĎˆő‰ďŠé‰ć) SƒGƒR[}‚ĹŒŠ‹É‚ß‚é‚ׂŤ‹}ŤS•s‘S‚ĚŒ´ˆöŽžŠł. Ź”‹´r”ü1, ‘ëă@—I2, ]“c—DŽq2, ‘O‘şŒ’ŽĄ2, ‘ĺ–Ř‘ě–¤2, “Ą“c“S•˝1, –îč–ƒ—R1, “ç“c@Œ’1, ’r“c—S‹B3, Îˆär•ă1, ŒSŽRŒbŽq4, ‘OěŒb”ü1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‹~–˝, 4‘‡f—Ă): “ú–{SƒGƒR[}Šw‰ď‘ć32‰ńŠwpW‰ď (2021/4/23-25), WebŠJĂ.

722064. [Šw‰ď (‘S‘)] (‹łˆçƒZƒbƒVƒ‡ƒ“) Ç—á‚Š‚çŠw‚Ô!SƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ě‘˝—lŤ‚đŽŻ‚é. Ź”‹´r”ü1, ‘ëă@—I2, ]“c—DŽq2, ‘O‘şŒ’ŽĄ2, ‘ĺ–Ř‘ě–¤2, “Ą“c“S•˝1, –îč–ƒ—R1, “ç“c@Œ’1, ’r“c—S‹B3, Îˆär•ă1, ŒSŽRŒbŽq4, ‘OěŒb”ü1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‹~–˝, 4‘‡f—Ă): “ú–{SƒGƒR[}Šw‰ď‘ć32‰ńŠwpW‰ď (2021/4/23-25), WebŠJĂ.

722065. [Šw‰ď (‘S‘)] (‹łˆçƒZƒbƒVƒ‡ƒ“) śŽş•Ç”ěŒú: ‚ą‚̐S‘Ÿ‚͐¸¸‚Ş•K—v? ŒSŽRŒbŽq1, Ź”‹´r”ü2, “Ą“c“S•˝2, “ç“c@Œ’2, ’r“c—S‹B3, Îˆär•ă2, ‘OěŒb”ü2, ˆ˘ŒĂĆ2 (1‘‡f—Ă, 2zŠÂŠí“ŕ, 3‹~–˝): “ú–{SƒGƒR[}Šw‰ď‘ć32‰ńŠwpW‰ď (2021/4/23-25), WebŠJĂ.

722066. [Šw‰ď (‘S‘)] (‹łˆçƒZƒ~ƒi[) ŠĽ“Ž–ŹŽžŠł‚Ě–ň•¨—Ă–@. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ‘ć6‰ń“ú–{SŒŒŠÇ‹Ś‰ďŠwpW‰ď (2021/4/25), WebŠJĂ.

722067. [Šw‰ď (‘S‘)] (Pro/Con) ECMO‚đ“ą“ü‚ˇ‚é‚ŕ‹~–˝‚Ĺ‚Ť‚Č‚Š‚Á‚˝”x‚ŒŒˆł‡•š”D•w‚Ěˆę—á. “Ą“c“S•˝ (zŠÂŠí“ŕ): ‘ć6‰ń“ú–{”x‚ŒŒˆłE”xzŠÂŠw‰ďŠwpW‰ď (2021/5/6-8), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722068. [Šw‰ď (‘S‘)] (ƒWƒ‡ƒCƒ“ƒgƒZƒbƒVƒ‡ƒ“) ƒfƒBƒx[ƒg‚Š‚çS•s‘S‰h—{‚̉ۑč‚đl‚Ś‚é. ‘OěŒb”ü (zŠÂŠí“ŕ): ‘ć27‰ń“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ďŠwpW‰ď (2021/6/19-20), ç—t (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722069. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Role of Wearable Cardioverter Defibrillator (WCD) in Patients with Reduced EF and Heart Failure. ’ë–ěTˆę (zŠÂŠí“ŕ): ‘ć67‰ń“ú–{•sŽ–ŹS“dŠw‰ďŠwp‘ĺ‰ď (2021/7/2), WebŠJĂ.

722070. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Smart PCI‚Ě’ńˆÄ`OCT‚Š‚ç“ǂ݉đ‚­ACS—vˆö‚Ě“Á’č‚Ć—\ŒăŠÇ—`. “ě@ŽŒŤ (zŠÂŠí“ŕ): Tokyo Percutaneous cardiovascular Intervention Conference (TOPIC) 2021 (2021/7/9-10), WebŠJĂ.

722071. [Šw‰ď (‘S‘)] (‹łˆçu‰‰) SƒAƒ~ƒƒCƒh[ƒVƒX‚Ě—Ő°: ‰ć‘œ‚Š‚炢‚Š‚É‹^‚¤‚Š. Ź”‹´r”ü (zŠÂŠí“ŕ): ‘ć69‰ń“ú–{S‘Ÿ•aŠw‰ďŠwpW‰ď (2021/9/17-19), ’šŽć (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722072. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Antithrombotic therapy after LMT bifurcation PCI. When should we stop DAPT? ˆ˘ŒĂĆ (zŠÂŠí“ŕ): Tokyo Percutaneous cardiovascular Intervention Conference (TOPIC) 2021 (2021/7/9-10), WebŠJĂ.

722073. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) –ŤŠĽ“Ž–ŹÇŒóŒQ|ĄŒă‚Ě“WŠJ|. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ‘ć69‰ń“ú–{S‘Ÿ•aŠw‰ďŠwpW‰ď (2021/9/17-19), ’šŽć (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722074. [Šw‰ď (‘S‘)] (—Տ°E‚Š‚Š‚č‚‚ŻˆăƒZƒbƒVƒ‡ƒ“) Ĺ‹ßƒtƒHƒ[‚ľ‚Ä‚˘‚Č‚Š‚Á‚˝zŠÂŠí‚Ě˜b: ŠĽ“Ž–ŹŽžŠł‚ĚŽĄ—Á|ƒKƒCƒhƒ‰ƒCƒ“‚Ěƒ|ƒCƒ“ƒg|. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ‘ć69‰ń“ú–{S‘Ÿ•aŠw‰ďŠwpW‰ď (2021/9/17-19), ’šŽć (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722075. [Šw‰ď (‘S‘)] (ƒXƒ|ƒ“ƒT[ƒhƒZƒ~ƒi[) uŒ¸‚炡ƒGƒrƒfƒ“ƒXv‚ĚŽŔ‘H|AFIREX‚Č‚éŘ‚čŒű|. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘ĺ‰ď2021 (2021/9/23-25), WebŠJĂ.

722076. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Protective roles of rivaroxaban on H202-induced oxidative stress injury in vascular endothelial glycocalyx through the PI3K/IQGAP1 pathway. –k—˘—œš1, “ŒžŠ”ü“ŢŽq2, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2ˆă—ÉqśŠw•”): CVMW2021SŒŒŠÇ‘ăŽÓTŠÔ (‘ć38‰ń‘ŰS‘ŸŒ¤‹†Šw‰ď“ú–{•”‰ď‘‰ď) (2021/12/10-11), WebŠJĂ.

722077. [Šw‰ď (‘S‘)] (—DG‰‰‘čÜŒó•âƒZƒbƒVƒ‡ƒ“) ŠĽ“Ž–Ź‘˘‰e‚Ĺ’Z—ŒŒ—Ź‚𔺂¤Žîᎏó”Ző‘œ‚đ”F‚ß‚˝SƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ěˆę—á. ’Š‘q´Žj1, “ě@ŽŒŤ2, ‰i“c‹MŽq1, ‹T“c@—Ç2, Ź”‹´r”ü2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ): ‘ć35‰ń“ú–{ŠĽŽžŠłŠw‰ďŠwpW‰ď (2021/12/17-18), WebŠJĂ.

723137. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) S‹ŘÇ`overview`. Ź”‹´r”ü1, ‘ëă@—I2, ]“c—DŽq2, ‘O‘şŒ’ŽĄ2, ‘ĺ–Ř‘ě–¤2, “Ą“c“S•˝1, –îč–ƒ—R1, “ç“c@Œ’1, ’r“c—S‹B3, Îˆär•ă1, ŒSŽRŒbŽq4, ‘OěŒb”ü1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‹~–˝, 4‘‡f—Ă): “ú–{SƒGƒR[}Šw‰ď‘ć32‰ńŠwpW‰ď (2021/4/23-25), WebŠJĂ.

723138. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Pulmonary artery pulsatility index‚ĆMitraClipŒă‚ĚŽOë•Ů‹t—ŹÇ‚¨‚ć‚Ń—\Œă‚Ć‚ĚŠÖŒW. “Ą“c“S•˝1, Ź”‹´r”ü1, ‹´‘ş”ü•Ű1, ‘ëă@—I2, ŒSŽRŒbŽq3, ‘OěŒb”ü1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‘‡f—Ă): “ú–{SƒGƒR[}Šw‰ď‘ć32‰ńŠwpW‰ď (2021/4/23-25), WebŠJĂ.

723139. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œ’f‚đŒ_‹@‚ɐf’f‚ł‚ę‚˝S‘ŸŽîᇗá‚É‚¨‚Ż‚éSƒGƒR[}‚Ě–đŠ„‚ĆŽĄ—Ð헪. ‰i“c‹MŽq1, ’r“c—S‹B2, ]“c—DŽq1, “Ą“c“S•˝3, ŒSŽRŒbŽq4, ‘OěŒb”ü3, Ź”‹´r”ü3, ˆ˘ŒĂĆ3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‹~–˝, 3zŠÂŠí“ŕ, 4‘‡f—Ă): “ú–{SƒGƒR[}Šw‰ď‘ć32‰ńŠwpW‰ď (2021/4/23-25), WebŠJĂ.

723140. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”xŒŒŠÇŠg’Ł–ň‚É‚ć‚Á‚ĐS“ŕC•œp‚މ”\‚Ć‚Č‚Á‚˝SŽş’†ŠuŒ‡‘šÇ‡•š‰EŽşƒjoÇ‚Ěˆę—á. “Ą“c“S•˝1, ‘ĺ–؁@‘ě, ’r“c—S‹B2, Î––ŹĆ1, Ź”‹´r”ü1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‹~–˝): ‘ć6‰ń“ú–{”x‚ŒŒˆłE”xzŠÂŠw‰ďŠwpW‰ď (2021/5/6-8), “Œ‹ž.

723141. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) zŠÂŠíˆă‚ĚŽ‹“_‚Š‚ç‚ą‚ę‚Š‚ç‚Ě“œ”A•aŽĄ—Ă‚đlŽ@‚ˇ‚é. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): Slender Club Japan Live Demonstration & Annual Meeting 2021 in TOKYO (2021/5/28-30), WebŠJĂ.

723142. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) FRAGILE-HF research group: ‚—îS•s‘SŠłŽŇ‚É‚¨‚Ż‚éˆŤ‰tŽż‚Ě—L•a—Ś‚Ć—\Œă‚ւ̉e‹ż|FRAGILE HFƒŒƒWƒXƒgƒŠ[‚Š‚ç. ‘OěŒb”ü (zŠÂŠí“ŕ): ‘ć27‰ń“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ďŠwpW‰ď (2021/6/19-20), ç—t (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723143. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Time from diagnosis and atrial size are associated with the recurrence of atrial fibrillation after catheter ablation. ‹yě@~1, [’J‰p•˝1, âV“Ą‘ĺŽ÷2, ˛“Ą“N˜Y2, ź‰Y@Œł2, rě—Y‹I1, Ź—ŃŽü•˝1, ”’ě—TŠî1, –xŒű@ˆ¤1, źŹ“c—ş1, Î––ŹĆ1, ŠÝŒ´@~1, ˛“Ą@—z1, ’ë–ěTˆę1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć67‰ń“ú–{•sŽ–ŹS“dŠw‰ďŠwp‘ĺ‰ď (2021/7/1-4), WebŠJĂ.

723144. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Right Ventricular Apex Pacing Increases the Left Ventricular Flow Energy Loss. rě—Y‹I1, [’J‰p•˝1, âV“Ą‘ĺŽ÷2, ˛“Ą“N˜Y2, ź‰Y@Œł2, Ź—ŃŽü•˝1, ”’ě—TŠî1, –xŒű@ˆ¤1, źŹ“c—ş1, Î––ŹĆ1, ‹yě@~1, ŠÝŒ´@~1, ’ë–ěTˆę1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć67‰ń“ú–{•sŽ–ŹS“dŠw‰ďŠwp‘ĺ‰ď (2021/7/1-4), WebŠJĂ.

723145. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Comorbidity with asymptomatic sinus bradycardia is an additional risk of permanent pacemaker implantation after catheter ablation for the patients with tachycardia-bradycardia syndrome. źŹ“c—ş1, ’ë–ěTˆę1, ‹yě@~1, âV“Ą‘ĺŽ÷2, ˛“Ą“N˜Y2, ź‰Y@Œł2, rě—Y‹I1, Ź—ŃŽü•˝1, ”’ě—TŠî1, –xŒű@ˆ¤1, ’†‘ş—m”Í1, Î––ŹĆ1, ŠÝŒ´@~1, [’J‰p•˝1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć67‰ń“ú–{•sŽ–ŹS“dŠw‰ďŠwp‘ĺ‰ď (2021/7/1-4), WebŠJĂ.

723146. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •ďŠ‡“IŠO—ˆS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚É‚ć‚čI––“œ‰ťŽY•¨‚¨‚ć‚щ^“Ž‹@”\, ‰^“Ž‘Ď—e”\‚މü‘P‚ľ‚˝’áS‹@”\‚̐S•s‘SÇ—á. •˝ˆä’q–ç, “Ą‹g˜a”Ž1, d“c@‹Ĺ, ź–{‘ě–ç, ‹e’rŽq, Î“cO‹B1, Î“cŽO˜a1, ‘ş‰ŞD, “ŒžŠ‘ĺ‹P1 (1zŠÂŠí“ŕ): ‘ć5‰ń“ú–{zŠÂŠí—Šw—Ă–@Šw‰ďŠwp‘ĺ‰ď (2021/8/28), WebŠJĂ.

723147. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒRƒƒi‰Đ‚É‚¨‚Ż‚éS‘ŸƒJƒe[ƒeƒ‹Žş‚Ĺ‚Ě•úŽËü”í‚΂­ŠÇ—‚ɂ‚˘‚Ä‚ĚŒŸ“˘. “Ą‹g˜a”Ž1, Î“cO‹B1, Î“cŽO˜a1, ˆ˘ŒĂĆ1, “ŒžŠ‘ĺ‹P1 (1zŠÂŠí“ŕ): ‘ć69‰ń“ú–{S‘Ÿ•aŠw‰ďŠwpW‰ď (2021/9/17), ’šŽć (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723148. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) IMPELLA 5.0‚¨‚ć‚яWŠw“IS•s‘SŽĄ—Ă‚É‚ć‚čĂ’‹­S–ňˆË‘ś‚Š‚ç’E‹p‚Ĺ‚Ť‚˝Ž‘ąŤS–[×“Ž‡•šŠg’ŁŒ^S‹ŘÇ‚Ěˆę—á. ‘O‘şŒ’ŽĄ1, ’r“c—S‹B2, ]“c—DŽq1, ‘ĺ–Ř‘ě–¤1, –îč–ƒ—R3, “Ą“c“S•˝3, ”Ń“c—Sˆę˜Y3, “ç“c@Œ’3, Îˆär•ă3, ŒSŽRŒbŽq4, ‘OěŒb”ü3, Ź”‹´r”ü3, ˆ˘ŒĂĆ3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‹~–˝, 3zŠÂŠí“ŕ, 4‘‡f—Ă): ‘ć69‰ń“ú–{S‘Ÿ•aŠw‰ďŠwpW‰ď (2021/9/17-19), ’šŽć (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723149. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ””NŠÔŒ´ˆö•s–ž‚Ĺ‚ ‚Á‚˝ŔˆĘ‚É‚Ä’áŽ_‘fŒŒÇ‚đ’悡‚éPlatypnea-orthodeoxiasyndrome‚Ě1—á. ‹gŕV’qŽĄ1, ’ë–ěTˆę1, Îč—S–í, “yˆäËŽq, rě—Y‹I1, Š`č—Ç‘ž1, “c‹{ÂŽ , ™–{“Ä•F, Šąę‘אŹ, ˆäŠÖŽĄ˜a, ‹yě@~1, [’J‰p•˝1, Ą–Ř—˛‘ž, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ): ‘ć69‰ń“ú–{S‘Ÿ•aŠw‰ďŠwpW‰ď (2021/9/17-19), ’šŽć (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723150. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Ă’‹­S–ňˆË‘śó‘Ô‚Ě–ŤS•s‘S‚Ö‚ĚCRT‚Ě—LŒřŤ. ‘ĺ–Ř‘ě–¤1, ’r“c—S‹B2, ]“c—DŽq1, ‘O‘şŒ’ŽĄ1, –îč–ƒ—R3, “Ą“c“S•˝3, ”Ń“c—Sˆę˜Y3, “ç“c@Œ’3, Îˆär•ă3, ŒSŽRŒbŽq4, ‘OěŒb”ü3, Ź”‹´r”ü3, ˆ˘ŒĂĆ3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‹~–˝, 3zŠÂŠí“ŕ, 4‘‡f—Ă): ‘ć69‰ń“ú–{S‘Ÿ•aŠw‰ďŠwpW‰ď (2021/9/17-19), ’šŽć (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723151. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) •Ą”‚Ě•â•zŠÂƒfƒoƒCƒX‚É‚ć‚錌ŠÇƒAƒNƒZƒX§ŒŔ‰ş‚ɐSŽş•p”ƒAƒuƒŒ[ƒVƒ‡ƒ“‚đŽ{s‚ľ, ’áS”o‚đ—Ł’E‚ľ“ž‚˝‹•ŒŒŤS‹ŘÇ‚Ěˆę—á. ź‰Y@Œł1, [’J‰p•˝2, “Ą“c“S•˝2, ”Ń‘q‘‰fŽq2, âV“Ą‘ĺŽ÷1, ˛“Ą“N˜Y1, Î––ŹĆ2, ŠÝŒ´@~2, ’ë–ěTˆę2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ): ‘ć69‰ń“ú–{S‘Ÿ•aŠw‰ďŠwpW‰ď (2021/9/17-19), ’šŽć (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723152. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) S–[×“Ž‚ĚƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Žž‚Ě•sŽ–Ź—U”­ŽŽŒą‚Ě•K—vŤ‚ɂ‚˘‚Ä. ˛“Ą“N˜Y1, ‹yě@~2, [’J‰p•˝2, ŽO’J—D‘ž˜N1, ‘şŽR—F‰î1, âV“Ą‘ĺŽ÷1, ź‰Y@Œł1, ’†‘ş—m”Í2, Î––ŹĆ2, ŠÝŒ´@~2, ’ë–ěTˆę2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ): ‘ć69‰ń“ú–{S‘Ÿ•aŠw‰ďŠwpW‰ď (2021/9/17-19), ’šŽć (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723153. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ’…—pŒ^ŽŠ“Žœ×“ŽŠí (WCD) ‚̉@ŠOě“Ž‚É‚ć‚č‹~–˝‚ľ“ž‚˝“Á”­ŤSŽş×“Ž‚Ěˆę—á. âV“Ą‘ĺŽ÷1, ŠÝŒ´@~2, [’J‰p•˝2, ˛“Ą“N˜Y1, ź‰Y@Œł1, rě—Y‹I2, ”’ě—TŠî2, Ź—ŃŽü•˝2, Î––ŹĆ2, ‹yě@~2, ’ë–ěTˆę2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ): ‘ć69‰ń“ú–{S‘Ÿ•aŠw‰ďŠwpW‰ď (2021/9/17-19), ’šŽć (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723154. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) S•s‘S‚đ”­Ç‚ľf’f‚ނ‚˘‚˝Žűk”\‚Ş•Ű‚˝‚ę‚˝ŹlśŽşS‹Řăk–§‰ťáŠQ‚Ěˆę—á. ‘şŽR—F‰î1, Ą–Ř—˛‘ž, ‹gŕV’qŽĄ2, Š`č—Ç‘ž2, ŽO’J—D‘ž˜N1, âV“Ą‘ĺŽ÷1, ˛“Ą“N˜Y1, ź‰Y@Œł1, ’†‘ş—m”Í2, Î––ŹĆ2, ŠÝŒ´@~2, [’J‰p•˝2, ’ë–ěTˆę2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ): ‘ć69‰ń“ú–{S‘Ÿ•aŠw‰ďŠwpW‰ď (2021/9/17-19), ’šŽć (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723155. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ĚŠOŽŽ–ŒŒ^lH”x‚đ“ą“ü‚ˇ‚é‚ŕ‹~–˝‚ľ“ž‚ç‚ę‚Č‚Š‚Á‚˝”x‚ŒŒˆłÇ‡•š”D•w‚Ěˆę—á. “Ą“c“S•˝1, ’r“c—S‹B2, “ç“c@Œ’1, ‹´–{‘ń–í1, Îˆär•ă1, ŒSŽRŒbŽq3, ‘OěŒb”ü1, –ڍ•Œ’‘ž˜Y1, Ź”‹´r”ü1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‹~–˝, 3‘‡f—Ă): ‘ć69‰ń“ú–{S‘Ÿ•aŠw‰ďŠwpW‰ď (2021/9/17-19), ’šŽć (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723156. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘OŽşŠÔĂ–Ź‹ß–T‚đ‹NŒš‚Ć‚ˇ‚éSŽşŠúŠOŽűk‚ɑ΂ľ‚ÄBipolar ablation‚Ş—LŒř‚Ĺ‚ ‚Á‚˝ˆę—á. Î––ŹĆ1, [’J‰p•˝1, ŽO’J—D‘ž˜N2, ‘şŽR—F‰î2, âV“Ą‘ĺŽ÷2, ź‰Y@Œł2, ˛“Ą“N˜Y2, ’†‘ş—m”Í1, ŠÝŒ´@~1, ’ë–ěTˆę1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘ĺ‰ď2021 (2021/9/23-25), WebŠJĂ.

723157. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) SŽş’†Šu‹NŒš‚̐SŽş•p”‚ɑ΂ľ‚ÄBipolar ablation‚Ş—LŒř‚Ĺ‚ ‚Á‚˝ˆę—á. ’†‘ş—m”Í1, [’J‰p•˝1, Ź—ŃŽü•˝1, rě—Y‹I1, ˛“Ą“N˜Y2, ź‰Y@Œł2, Î––ŹĆ1, ‹yě@~1, ŠÝŒ´@~1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘ĺ‰ď2021 (2021/9/23-25), WebŠJĂ.

723158. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) S“ŕC•œp–˘Ž{s‚̐ŹlŠú’PSŽşÇ‚ɍ‡•š‚ľ‚˝•Ą”‚Ě–ňÜ’ďRŤS–[•p”‚ɑ΂ľ‚Ä, ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚đs‚Á‚˝ˆę—á. ź‰Y@Œł1, [’J‰p•˝2, “Ą“c“S•˝2, âV“Ą‘ĺŽ÷1, ˛“Ą“N˜Y1, rě—Y‹I2, ”’ě—TŠî2, Ź—ŃŽü•˝2, ’†‘ş—m”Í2, Î––ŹĆ2, ‹yě@~2, ŠÝŒ´@~2, ’ë–ěTˆę2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ): ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘ĺ‰ď2021 (2021/9/23-25), WebŠJĂ.

723159. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) S–[×“Ž‚̒ljÁƒAƒuƒŒ[ƒVƒ‡ƒ“‚ĹCARTO Finder҂ɂć‚édriver‚ւ̉î“ü‚Ş—L—p‚Ĺ‚ ‚Á‚˝‚ƍl‚Ś‚ç‚ę‚˝ˆę—á. ˛“Ą“N˜Y1, Î––ŹĆ2, [’J‰p•˝2, ŽO’J—D‘ž˜N1, ‘şŽR—F‰î1, âV“Ą‘ĺŽ÷1, ź‰Y@Œł1, ’†‘ş—m”Í2, ŠÝŒ´@~2, ’ë–ěTˆę2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ): ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘ĺ‰ď2021 (2021/9/23-25), WebŠJĂ.

723160. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) S“ŕ–Œ‘¤‚Ě‚Ý‚Ěˆę•űŒüŤƒuƒƒbƒN‚đ”F‚ß‚˝ŽOë•Ů—Ö‰ş‘ĺĂ–Ź‹Ź•”ˆË‘śŒ^S–[‘e“Ž‚Ěˆę—á. âV“Ą‘ĺŽ÷1, [’J‰p•˝2, ˛“Ą“N˜Y1, ź‰Y@Œł1, rě—Y‹I2, ”’ě—TŠî2, Ź—ŃŽü•˝2, Î––ŹĆ2, ‹yě@~2, ŠÝŒ´@~2, ’ë–ěTˆę2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ): ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘ĺ‰ď2021 (2021/9/23-25), WebŠJĂ.

723161. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰EŽş‘O“ű“Ş‹ŘŠî•”‚đ‹NŒš‚Ć‚ˇ‚éSŽşŠúŠOŽűk‚ɑ΂ľ‚ĐS‹ŘÄŽÜp‚Ş—LŒř‚Ĺ‚ ‚Á‚˝ˆę—á. ‘şŽR—F‰î1, Î––ŹĆ2, [’J‰p•˝2, ŽO’J—D‘ž˜N1, âV“Ą‘ĺŽ÷1, ˛“Ą“N˜Y1, ź‰Y@Œł1, ’†‘ş—m”Í2, ŠÝŒ´@~2, ’ë–ěTˆę2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ): ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ŠÖ˜AH‹G‘ĺ‰ď2021 (2021/9/23-25), WebŠJĂ.

723162. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) uŒ¸‚炡ƒGƒrƒfƒ“ƒXv‚ĚŽŔ‘H|AFIREX‚Č‚éŘ‚čŒű|. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ADATARA Live Demonstration 2021 (2021/9/30-10/1), WebŠJĂ.

723163. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Multicenter retrospective registry of cardiac sarcoidosis in Japan: a preliminary report from ILLUMINATE-CS. “ç“c@Œ’1, Naruse Y, Taniguchi T, Kitani T, Yoshida K, Tanaka H, Okumura T, Baba Y, Kida K, Tamaki H, Sato K, Kitano D, Matsumoto S, Toma Y, Watanabe N, Miyazaki K, Saito H, Sato H, Kikuchi A, Ishihara S, Fukunaga M, Okabe T, Oyama K, Hidaka T, Yamaguchi T, Abe M, Ito M, Kato S, Ise T, Tamura Y, Ishida M, Matsue Y (1zŠÂŠí“ŕ): ‘ć25‰ń“ú–{S•s‘SŠw‰ďŠwpW‰ď (2021/10/1-3), WebŠJĂ.

723164. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Relationship between ischemia-like electrocardiographic finding and myocardial scar in patients with non-ischemic cardiomyopathy. ‘O‘şŒ’ŽĄ1, ’r“c—S‹B2, ]“c—DŽq1, ‘ĺ–Ř‘ě–¤1, –îč–ƒ—R3, “Ą“c“S•˝3, ”Ń“c—Sˆę˜Y3, ŒSŽRŒbŽq4, “ç“c@Œ’3, Îˆär•ă3, ‘OěŒb”ü3, Ź”‹´r”ü3, ˆ˘ŒĂĆ3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‹~–˝, 3zŠÂŠí“ŕ, 4‘‡f—Ă): ‘ć25‰ń“ú–{S•s‘SŠw‰ďŠwpW‰ď (2021/10/1-3), WebŠJĂ.

723165. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) SƒTƒ‹ƒRƒCƒh[ƒVƒX. “ç“c@Œ’ (zŠÂŠí“ŕ): ‘ć25‰ń“ú–{S•s‘SŠw‰ďŠwpW‰ď (2021/10/1-3), WebŠJĂ.

723166. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Native T1 mapping and recovery of left ventricular ejection fraction in patients with newly diagnosed dilated cardiomyopathy. –îč–ƒ—R1, “ç“c@Œ’1, ]“c—DŽq2, ‘O‘şŒ’ŽĄ2, ‘ĺ–Ř‘ě–¤2, “Ą“c“S•˝1, ”Ń“c—Sˆę˜Y1, ŒSŽRŒbŽq3, ’r“c—S‹B4, Îˆär•ă1, ‘OěŒb”ü1, Ź”‹´r”ü1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‘‡f—Ă, 4‹~–˝): ‘ć25‰ń“ú–{S•s‘SŠw‰ďŠwpW‰ď (2021/10/1-3), WebŠJĂ.

723167. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –łÇŒóŤŽOë•Ů‹t—Ź‚É”ş‚¤‰E–[Šg‘ĺ‚ƐöÝ“I‰e‹ż‚ɂ‚˘‚Ä‚ĚŒŸ“˘. ŒSŽRŒbŽq1, Ź”‹´r”ü2, ]“c—DŽq3, ‘O‘şŒ’“ń3, ‘ĺ–Ř‘ě–¤3, –îč–ƒ—R2, “Ą“c“S•˝2, ”Ń“c—Cˆę˜Y2, ’r“c—S‹B4, “ç“c@Œ’2, Îˆär•ă2, ‘OěŒb”ü2, ˆ˘ŒĂĆ2 (1‘‡f—Ă, 2zŠÂŠí“ŕ, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4‹~–˝): ‘ć25‰ń“ú–{S•s‘SŠw‰ďŠwpW‰ď (2021/10/1-3), WebŠJĂ.

723168. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Reappearing left ventricular mechanical dyssynchrony after MitraClip implantation: a case report. ‘ĺ–Ř‘ě–¤1, Îˆär•ă2, ‘ëă@—I1, ]“c—DŽq1, –îč–ƒ—R2, ‘O‘şŒ’“ń1, “Ą“c“S•˝2, ’r“c—S‹B3, “ç“c@Œ’2, ‘OěŒb”ü2, Ź”‹´r”ü2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ, 3‹~–˝): ‘ć25‰ń“ú–{S•s‘SŠw‰ďŠwpW‰ď (2021/10/1-3), WebŠJĂ.

723169. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) A Case of Fulminant Myocarditis Introduced ƒŔ-blocker in Acute Phase with Veno-Arterial Extracorporeal Membrane Oxygenation and ImpellaTM CP. ]“c—DŽq1, ’r“c—S‹B2, ‘O‘şŒ’“ń1, ‘ĺ–Ř‘ě–¤1, –îč–ƒ—R3, “Ą“c“S•˝3, ”Ń“c—Cˆę˜Y3, ŒSŽRŒbŽq4, “ç“c@Œ’3, Îˆär•ă3, ‘OěŒb”ü3, Ź”‹´r”ü3, ˆ˘ŒĂĆ3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‹~–˝, 3zŠÂŠí“ŕ, 4‘‡f—Ă): ‘ć25‰ń“ú–{S•s‘SŠw‰ďŠwpW‰ď (2021/10/1-3), WebŠJĂ.

723170. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒn[ƒgƒ`[ƒ€‚Ĺdeep discussion‚đ‚ľ‚˝Ç—á. –ڍ•Œ’‘ž˜Y (zŠÂŠí“ŕ): Structure Club Japan Live Demonstration 2021 (2021/11/5-6), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723171. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) oŒŒƒnƒCƒŠƒXƒNŠłŽŇ‚̍RŒŒđ—Ă–@‚đÄl‚ˇ‚é. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): Complex Peripheral Angioplasty Conference (CPAC) 2021 (2021/11/26-27), WebŠJĂ.

723172. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) The Big Change: S‘Ÿf—Ă‚ĚƒOƒ[ƒuƒŒƒ{ƒŠƒ…[ƒVƒ‡ƒ“ ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ‘ć86‰ń“ú–{zŠÂŠíŠw‰ďŠwpW‰ď (JCS2022) (2022/3/11), WebŠJĂ.

723173. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Continuous positive alveolar pressure therapy is associated with a lower prevalence of coronary macrophage in patients with sleep apnea syndrome. “Ą‹g˜a”Ž1, Î“cO‹B1, Î“cŽO˜a1, •˝ˆä’q–ç, ź–{‘ě–ç, ‹e’rŽq, ˆ˘ŒĂĆ1, “ŒžŠ‘ĺ‹P1 (1zŠÂŠí“ŕ): ‘ć86‰ń“ú–{zŠÂŠíŠw‰ďŠwpW‰ď (JCS2022) (2022/3/11), WebŠJĂ.

723174. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Ă’‹­S–ň‚Š‚ç’ˇŠúŠÔ—Ł’E˘“ď‚Ĺ‚ ‚Á‚˝dÇS•s‘SÇ—á‚ɑ΂ˇ‚éSƒŠƒn‚ĚŒoŒą. ź–{‘ě–ç, •˝ˆä’q–ç, ‹e’rŽq, d“c@‹Ĺ, “Ą‹g˜a”Ž1, Î“cŽO˜a1, Î“cO‹B1, “ŒžŠ‘ĺ‹P1 (1zŠÂŠí“ŕ): ‘ć86‰ń“ú–{zŠÂŠíŠw‰ďŠwpW‰ď (JCS2022) (2022/3/11), WebŠJĂ.

723175. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) SŒŒŠÇŽžŠł‚ĚŽc—]ƒŠƒXƒN‚É‚¨‚Ż‚鉊Ç‚̏d—vŤ`ƒRƒŒƒXƒgƒ[ƒ‹Œ‹ť‚ĚŠÖ˜A`. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ‘ć86‰ń“ú–{zŠÂŠíŠw‰ďŠwpW‰ď (JCS2022) (2022/3/12), WebŠJĂ.

723176. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ƒZƒ“ƒ^[ŠJÝ‚ÉŽŠ‚éŠO—ˆS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ˆÚs—Ś‚̕ωť. ‹e’rŽq, “Ą‹g˜a”Ž1, ź–{‘ě–ç, •˝ˆä’q–ç, Î“cŽO˜a1, Î“cO‹B1, “ŒžŠ‘ĺ‹P1 (1zŠÂŠí“ŕ): ‘ć86‰ń“ú–{zŠÂŠíŠw‰ďŠwpW‰ď (JCS2022) (2022/3/12), WebŠJĂ.•Ş

723177. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •ďŠ‡“IŠO—ˆS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚͍ŏI“œ‰ťŽY•¨‚đ‰ü‘P‚ˇ‚é. •˝ˆä’q–ç, ź–{‘ě–ç, “Ą‹g˜a”Ž1, ‹e’rŽq, Î“cO‹B1, Î“cŽO˜a1, d“c@‹Ĺ, “ŒžŠ‘ĺ‹P1 (1zŠÂŠí“ŕ): ‘ć86‰ń“ú–{zŠÂŠíŠw‰ďŠwpW‰ď (JCS2022) (2022/3/12), WebŠJĂ.

723178. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) S•s‘SŽĄ—Ă‚Ě•Ď‘J`‚ƒJƒŠƒEƒ€ŒŒÇ‚Ě˜b‘č‚ŕŠÜ‚߂ā`. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ‘ć86‰ń“ú–{zŠÂŠíŠw‰ďŠwpW‰ď (JCS2022) (2022/3/13), WebŠJĂ.

732022. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‰ď’ˇŠé‰ć) S•s‘SŽĄ—Ă‚É‚¨‚Ż‚éƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ˆă‚̐V‚˝‚Č‚é—§‚żˆĘ’u. –ڍ•Œ’‘ž˜Y (zŠÂŠí“ŕ): ‘ć57‰ń“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ŽĄ—ĂŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/5/8), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

732023. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‰ď’ˇŠé‰ć) COVID-19‚ƐSŒŒŠÇŽžŠł. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ‘ć57‰ń“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ŽĄ—ĂŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/5/8), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

732024. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ACS‚É‚¨‚Ż‚鎉ŽżŠÇ—‚ĚTisp & Tricks. “ě@ŽŒŤ (zŠÂŠí“ŕ): ‘ć57‰ń“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ŽĄ—ĂŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/5/8), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

732025. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) S–[×“Ž‚̍RŒŒđŽĄ—Ă-‚—îŽĐ‰ď‚É‹‚ß‚ç‚ę‚Ä‚˘‚éDOAC‚Ě‚ ‚č•ű-. ’ë–ěTˆę (zŠÂŠí“ŕ): CadiOvascular MeICine in Sagamihara The 4th Night (2021/5/21), ‘Š–ÍŒ´.

732026. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ACS‚É‚¨‚Ż‚鎉ŽżŠÇ—‚ĚTisp & Tricks. “ě@ŽŒŤ (zŠÂŠí“ŕ): ‘ć52‰ń“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ŽĄ—ĂŠw‰ď–kŠC“š’n•ű‰ď (2021/5/22), WebŠJĂ.

732027. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒXƒ|ƒ“ƒT[ƒhƒZƒ~ƒi[) ĹVƒKƒCƒhƒ‰ƒCƒ“‚ÉŠî‚Ă‚­GDMT‚̏d—vŤ‚Ć+ƒż‚Ěˆă—Éî“ü. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ‘ć261‰ń“ú–{zŠÂŠíŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/9/12), WebŠJĂ.

732028. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•ĘƒZƒ~ƒi[) oŒŒƒnƒCƒŠƒXƒNŠłŽŇ‚̍RŒŒđ—Ă–@‚đÄl‚ˇ‚é. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ‘ć37‰ń“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ŽĄ—ĂŠw‰ď‹ß‹E’n•ű‰ď (2021/10/9), WebŠJĂ.

732029. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) Œť‘ă‚É‚¨‚Ż‚é•sŽ–Ź–ň•¨ŽĄ—Ă‚ĚˆĘ’u‚Ă‚Ż-ƒAƒ~ƒIƒ_ƒƒ“‚ĆƒŔŽŐ’f–ň‚Ć‚ť‚ę‚Š‚ç?-. ’ë–ěTˆę (zŠÂŠí“ŕ): ‘ć10‰ńVŠƒ•sŽ–ŹŽĄ—ĂƒJƒ“ƒtƒ@ƒ‰ƒ“ƒX (2021/10/16), VŠƒ.

732030. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‰ď’ˇŠé‰ć) S•s‘SŽĄ—Ă‚É‚¨‚Ż‚é–ň•¨—Ă–@‚ĆdeviceŽĄ—Ă. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ‘ć58‰ń“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ŽĄ—ĂŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/10/16), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

732031. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒAƒtƒ^ƒk[ƒ“ƒZƒ~ƒi[) ˆę•ŕć‚ĚSMART PCI‚ĚƒXƒXƒ. “ě@ŽŒŤ (zŠÂŠí“ŕ): ‘ć58‰ń“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ŽĄ—ĂŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/10/16), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

732032. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (AwardƒZƒbƒVƒ‡ƒ“) SŒ´ŤƒVƒ‡ƒbƒNŠłŽŇ‚É‚¨‚Ż‚éImpella•â•‰ş‚̐S””„ˆÚ‚Ć—Ő°“]‹@‚ĚŠÖŒW. ‘O‘şŒ’ŽĄ1, ’r“c—S‹B2, ]“c—DŽq1, ‘ĺ–Ř‘ě–¤1, –îč–ƒ—R3, “Ą“c“S•˝3, ”Ń“c—Sˆę˜Y3, “ç“c@Œ’3, Îˆär•ă3, ŒSŽRŒbŽq4, ‘OěŒb”ü3, Ź”‹´r”ü3, ˆ˘ŒĂĆ3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‹~–˝, 3zŠÂŠí“ŕ, 4‘‡f—Ă): ‘ć261‰ń“ú–{zŠÂŠíŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/9/6-12), WebŠJĂ.

732033. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) S–[’†ŠuŒ‡‘š`pŒă‚ɐf‚é‚ׂŤƒ|ƒCƒ“ƒg‚Ć‚Í. Ź”‹´r”ü (zŠÂŠí“ŕ): “ú–{’´‰š”gˆăŠw‰ď‘ć33‰ńŠÖ“ŒbM‰z’n•ű‰ďŠwpW‰ď (2021/10/16-17), ’ˇ–ě (ƒnƒCƒuƒŠƒbƒhŠJĂ).

732034. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) S–[×“Ž‚̍RŒŒđŽĄ—Á|VƒKƒCƒhƒ‰ƒCƒ“‚ƍ‚—îŽĐ‰ď‚É‹‚ß‚ç‚ę‚éDOAC‘I‘đ|. ’ë–ěTˆę (zŠÂŠí“ŕ): ’Ź“cŽsSŽžŠłƒvƒ‰ƒCƒ}ƒŠƒPƒAƒtƒH[ƒ‰ƒ€ (2021/12/20), ’Ź“c.

733042. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Šg’ŁŒ^S‹ŘÇŠłŽŇ‚É‚¨‚Ż‚éNative T1 mapping‚ƍśŽş‹ěo—Ś‰ü‘P‚ĚŠÖ˜A. –îé–ƒ—R1, “ç“c@Œ’1, ‘O‘şŒ’ŽĄ2, ‘ĺ–Ř‘ě–¤2, “Ą“c“S•˝1, ’r“c—S‹B3, Îˆär•ă1, ‘OěŒb”ü1, Ź”‹´r”ü1, ’––”FŒł1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‹~–˝): ‘ć7‰ń“ú–{S‹ŘÇŒ¤‹†‰ď (2021/4/17), WebŠJĂ.

733043. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) —‘‰~EŠJ‘ś‚É‚ć‚éPlatypnea orthodeoxia syndrome‚ÉŒo”ç“I—‘‰~E•Â˝p‚đs‚˘‰ü‘P‚đ”F‚ß‚˝1—á. ”Ń‘q‘‰fŽq1, –ڍ•Œ’‘ž˜Y1, ‹´–{‘ń–í1, ‘OěŒb”ü1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ): ‘ć57‰ń“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ŽĄ—ĂŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/5/8), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733044. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) •â•zŠÂ—pƒ|ƒ“ƒvƒJƒe[ƒeƒ‹‚đ—p‚˘‹~–˝‚ľ‚˝‰EŠĽ“Ž–Ź‚đÓ”CŒŒŠÇ‚Ć‚ˇ‚é‹}ŤŠĽÇŒóŒQ‚Ě2—á. ”Ń‘q‘‰fŽq1, ’r“c—S‹B2, –؉ş‘厑1, ‹´–{‘ń–í1, ˛“ĄL—m2, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‹~–˝): ‘ć260‰ń“ú–{zŠÂŠíŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/6/19), WebŠJĂ.

733045. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) f’f‚É‹ę—ś‚ľ‚˝ATTRv‚ĆALƒAƒ~ƒƒCƒh[ƒVƒX‚̍‡•š—á. ]“c—DŽq1, Îˆär•ă2, ‰Á“ĄC–ž, ‘ĺ–Ř‘ě–¤1, ‘O‘şŒ’ŽĄ1, –îč–ƒ—R2, “Ą“c“S•˝2, ’r“c—S‹B3, “ç“c@Œ’2, ŒSŽRŒbŽq4, Ź”‹´r”ü2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ, 3‹~–˝, 4‘‡f—Ă): ‘ć42‰ńS‹ŘśŒŸŒ¤‹†‰ďŠwpW‰ď (2021/6/21), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733046. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Hippo effector Yap1‚đ‰î‚ľ‚˝Amotl1‚̐S‹Ř×–E‘B‚Ö‚Ě–đŠ„. –k—˘—œŽŃ (zŠÂŠí“ŕ): ‘ć21‰ńŠÖ“ŒSEŒŒŠÇƒtƒH[ƒ‰ƒ€ (2021/7/10), “Œ‹ž (WebŠJĂ).

733047. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‘O—§‘BŠŕŠłŽŇ‚ɑ΂ˇ‚éƒzƒ‹ƒ‚ƒ“—Ă–@‚ŞŠ´őŤS“ŕ–Œ‰Š‚Ě”­Ç‚ĚƒŠƒXƒN‚đ‚‚ß‚˝‚ƍl‚Ś‚ç‚ę‚˝ˆę—á. —é–؁@‘á, “Ą‹g˜a”Ž1, Î“cŽO˜a1, Î“cO‹B1, ˆ˘ŒĂĆ1, “ŒžŠ‘ĺ‹P1 (1zŠÂŠí“ŕ): ‘ć261‰ń“ú–{zŠÂŠíŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/9/6), WebŠJĂ.

733048. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) SŒŒŠÇƒCƒxƒ“ƒg—\–h‚Ěƒpƒ‰ƒ_ƒCƒ€ƒVƒtƒg`“œ”A•aŽĄ—Ă–ň‚̐V‚˝‚Č“WŠJ`. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ‘ć31‰ń“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ŽĄ—ĂŠw‰ď (CVIT) ‹ăBE‰Ť“ę’n•ű‰ď (2021/10/2), –k‹ăB.

733049. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ‹}ŤAŒ^‘ĺ“Ž–Ź‰đ—Ł‚É”ş‚¤‹}Ť‰ş•ÇS‹Ř[Ç‚ɉEŠĽ“Ž–ŹƒXƒeƒ“ƒgŽĄ—Ă‚ľśŠĽ“Ž–Ź‚ւ̉𗣂̔g‹y‚ŕ”ť–ž‚ľŠO‰ČÄŒšp‚đs‚Á‚˝ˆęÇ—á. źŹ“c—ş1, r”öŒ›Ži˜Y, Š}Œ´@‘ě, ™čŒ’ˆę, ŽR‰ş‹M‘ĺ, ˘‘ň•ś‰š, ŠÔŁ‘ěŒ° (1zŠÂŠí“ŕ): ‘ć58‰ń“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ŽĄ—ĂŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/10/15-16), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733050. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŠĹŒěŽtŽĺ“ąŒ^‚̕“IS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ““ą“ü‚É‚ć‚čÄ“ü‰@ŠúŠÔ‚đ‰„’ˇ‚Ĺ‚Ť‚˝dÇS•s‘S‚Ěˆę—á. ‹e’rŽq, “Ą‹g˜a”Ž1, ź–{‘ě–ç, •˝ˆä’q–ç, Î“cŽO˜a1, Î“cO‹B1, “ŒžŠ‘ĺ‹P1 (1zŠÂŠí“ŕ): “ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ď‘ć6‰ńŠÖ“ŒbM‰zŽx•”’n•ű‰ď (2021/10/16), WebŠJĂ.

733051. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŽĄ—Ă‘OŒă‚̐SƒGƒR[`Žčp‚ĆƒJƒe\ƒeƒ‹ŽĄ—Ă‚É”ş‚¤SƒGƒR[‚đl‚Ś‚é`ć“VŤSŽžŠł|S–[’†ŠuŒ‡‘š|. Ź”‹´r”ü (zŠÂŠí“ŕ): M”Z’ŹSƒGƒR[ƒJƒ“ƒtƒ@ƒŒƒ“ƒXwebuK‰ď (2021/11/13), WebŠJĂ.

733052. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ”­Ç‚ɐS‹Ř‰Ë‹´‚ŞŠÖ—^‚ľ‚Ä‚˘‚˝‚ƍl‚Ś‚ç‚ę‚˝‹}ŤS‹Ř[Ç‚Ěˆę—á. ”Ń‘q‘‰fŽq1, ’r“c—S‹B2, ‹´–{‘ń–í1, ‹T“c@—Ç1, ˛“ĄL—m2, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‹~–˝): ‘ć262‰ń“ú–{zŠÂŠíŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/12/4), WebŠJĂ.

733053. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰)yStudent Award FinalistzƒAƒ“ƒWƒIƒeƒ“ƒVƒ“Žó—e‘ĚƒlƒvƒŠƒ‰ƒCƒVƒ“‘jŠQ–ň“ą“üŽž‚É’áS”o—ĘÇŒóŒQ‚Ć‚Č‚čS•s‘SƒoƒCƒIƒ}[ƒJ[‚̉đŽß‚É“ďa‚ľ‚˝Šg’ŁŒ^S‹ŘÇ‚Ěˆę—á. ‹{é—C‹K, “Ą‹g˜a”Ž1, —é–؁@‘á, Î“cŽO˜a1, Î“cO‹B1, ˆ˘ŒĂĆ1, “ŒžŠ‘ĺ‹P1 (1zŠÂŠí“ŕ): ‘ć262‰ń“ú–{zŠÂŠíŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/12/4), WebŠJĂ.

733054. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‹•ŒŒŤSŽžŠłŠłŽŇ‚̍RŒŒđ—Ă–@‚̐i•ŕ. ˆ˘ŒĂĆ (zŠÂŠí“ŕ): ‘ć46‰ń“ú–{S‘Ÿ•aŠw‰ď‹łˆçƒZƒ~ƒi[ƒAƒhƒoƒ“ƒXƒR[ƒX (2022/2/27), WebŠJĂ.

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-110012. [Œ´’˜] Worries and concerns among healthcare workers during the coronavirus 2019 pandemic: A web-based cross-sectional survey. Sahashi Y, Endo H, Sugimoto T, Nabeta T1, Nishizaki K, Kikuchi A, Matsumoto S, Sato H, Goto T, Hasegawa K, Matsue Y: J Public Health Res 2020/11; 9 (4): 1936. (“ç“c@Œ’1: 1zŠÂŠí“ŕ)

'20-110013. [Œ´’˜] Optical Coherence Tomography Predictors for a Favorable Vascular Response to Statin Therapy. Nakajima A, Minami Y1, Araki M, Kurihara O, Soeda T, Yonetsu T, Wang Z, McNulty I, Lee H, Nakamura S, Jang IK: J Am Heart Assoc 2021/1; 10 (1): e018205. (“ě@ŽŒŤ1: 1zŠÂŠí“ŕ)

'20-110014. [Œ´’˜] Familial hypercholesterolemia and vulnerability of coronary plaque in patients with coronary artery disease. Katamine M1, Minami Y2, Hashimoto T2, Ako J2: Pract Lab Med 2021/1; 24: e00202. (•Đ•ôłáŠ1, “ě@ŽŒŤ2, ‹´–{‘ń–í2, ˆ˘ŒĂĆ2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ)

'20-110015. [Œ´’˜] Predictors for Rapid Progression of Coronary Calcification: An Optical Coherence Tomography Study. Nakajima A, Araki M, Kurihara O, Minami Y1, Soeda T, Yonetsu T, Higuma T, Kakuta T, McNulty I, Lee H, Malhotra R, Nakamura S, Jang IK: J Am Heart Assoc 2021/2; 10 (3): e019235. (“ě@ŽŒŤ1: 1zŠÂŠí“ŕ)

'20-522002. [uŔ]y‘ć39‰ń“Œ‹žCCUŒ¤‹†‰ďƒVƒ“ƒ|ƒWƒEƒ€zS-4. CCU/ICU‚É‚¨‚Ż‚éS‘Ÿ“Ë‘RŽ€ƒŠƒXƒN•]‰ż‚Ć—\–h–@|WCD‚É‚ć‚é“Ë‘RŽ€—\–h‚̍l‚Ś•ű‚đŠÜ‚߂ā|. ’ë–ěTˆę (zŠÂŠí“ŕ): ICU‚ĆCCU 2020; 44 (•Ęű): S99-S103.

'20-522003. [uŔ]y“ÁW: COVID-19z[˘ŠE‚ĚˆăŠwŽ‚Š‚ç] 19 śŽşŽűk”\’ቺ‚̐S•s‘SŠłŽŇ@SGLT2‘jŠQ–ň‚ŐSŒŒŠÇŽ€ƒŠƒXƒN14%’ቺ|Lancet. [’J‰p•˝ (zŠÂŠí“ŕ): MMJ 2021/2; 2E3ŒŽ†: 42-6.

21-540001. [‚ť‚Ě‘ź (Editorial Commentl)] ’†“‡˜_•ś‚ɑ΂ˇ‚éEditorial Comment. “ç“c Œ’ (zŠÂŠí“ŕ): S‘Ÿ 2021/3; 53 (3): 265.

[Šw‰ďEŒ¤‹†‰ď“™]

'20-722001. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Confronting the Diversity of Cardiac Sarcoidosis. Ź”‹´r”ü (zŠÂŠí“ŕ): ‘ć85‰ń“ú–{zŠÂŠíŠw‰ďŠwpW‰ď (2021/3/26-28), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-723002. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Řœ•s‰Â”\‚ȐS‘ŸŽîᇂɊ֘A‚ľ‚˝–ňÜ’ďRŤSŽş•p”‚ɑ΂ľ‚Ä, ŒoĂ–ŹAž‚ÝŒ^œ×“ŽŠí—Ż’up‚đŽ{s‚ľ‚˝ˆę—á. ź‰Y@Œł1, ŠÝŒ´@~2, ’r“c—S‹B3, ‰i“c‹MŽq1, âV“Ą‘ĺŽ÷1, ˛“Ą“N˜Y1, rě—Y‹I2, ”’ě—TŠî2, Ź—ŃŽü•˝2, Î––ŹĆ2, ‹yě@~2, [’J‰p•˝2, ’ë–ěTˆę2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ, 3‹~–˝): ‘ć13‰ńAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘ĺ‰ď (2021/2/5-7), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-723003. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚É‚¨‚Ż‚éŒoƒJƒe[ƒeƒ‹“I‘ĺ“Ž–Ź•Ů’uŠˇpŒăP‹v“Iƒy[ƒXƒ[ƒJAž‚ݏp‚̐ŹŃ. ˛“Ą“N˜Y1, ŠÝŒ´@~2, –ڍ•Œ’‘ž˜Y2, âV“Ą‘ĺŽ÷1, ź‰Y@Œł1, rě—Y‹I2, Ź—ŃŽü•˝2, ”’ě—TŠî2, Î––ŹĆ2, ‹yě@~2, [’J‰p•˝2, ’ë–ěTˆę2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ–˝): ‘ć13‰ńAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘ĺ‰ď (2021/2/5-7), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-723004. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚É‚¨‚Ż‚éA‚Śž‚ÝŒ^ƒ‹[ƒvƒŒƒR[ƒ_[ (ILR) ‚Ě—L—pŤ‚ĚŒŸ“˘. âV“Ą‘ĺŽ÷1, ŠÝŒ´@~2, [’J‰p•˝2, •“cÍ”3, ˛“Ą“N˜Y1, ź‰Y@Œł1, rě—Y‹I2, ”’ě—TŠî2, Ź—ŃŽü•˝2, Î––ŹĆ2, ‹yě@~2, ’ë–ěTˆę2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ, 3ME•”): ‘ć13‰ńAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘ĺ‰ď (2021/2/5-7), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-723005. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) SelectSecureţ‚É‚ć‚é‰EŽş‚ˆĘ’†Šuƒy[ƒVƒ“ƒO‚ލśŽş“ŕŒŒ—Ź‚É‹y‚Ú‚ˇ‰e‹ż‚ĚŒŸ“˘. rě—Y‹I1, [’J‰p•˝1, ŠÝŒ´@~1, âV“Ą‘ĺŽ÷2, ˛“Ą“N˜Y2, ź‰Y@Œł2, Ź—ŃŽü•˝1, ”’ě—TŠî1, Î––ŹĆ1, ‹yě@~1, ’ë–ěTˆę1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć13‰ńAž‚݃fƒoƒCƒXŠÖ˜A“~‹G‘ĺ‰ď (2021/2/5-7), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-723006. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Źlć“VŤSŽžŠłcaseƒJƒ“ƒtƒ@: Źlć“VŤSŽžŠłcase3 (PDA). Ź”‹´r”ü (zŠÂŠí“ŕ): ‘ć23‰ńƒGƒR[ƒEƒBƒ“ƒ^[ƒZƒ~ƒi[ (2021/2/14), WebŠJĂ.

'20-723007. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Reduction of Intraventricular Flow Energy Loss per Stroke Work is Associated with Ventricular Recovery after Cardiac Resynchronization Therapy. ‘O‘şŒ’ŽĄ1, ’r“c—S‹B2, Š`č—Ç‘ž3, ‘ĺ–Ř‘ě–¤1, –îč–ƒ—R3, “Ą“c“S•˝3, “ç“c@Œ’3, Îˆär•ă3, ‘OěŒb”ü3, Ź”‹´r”ü3, ˆ˘ŒĂĆ3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‹~–˝, 3zŠÂŠí“ŕ): ‘ć85‰ń“ú–{zŠÂŠíŠw‰ďŠwpW‰ď (2021/3/26-28), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-723008. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Comparison Study Between Hypokinetic Non-Dilated Cardiomyopathy and Dilated Cardiomyopathy on Cardiac Outcomes. ]“c—DŽq1, “ç“c@Œ’2, ‘ëă@—I1, ‘O‘şŒ’ŽĄ1, ‘ĺ–Ř‘ě–¤1, –îč–ƒ—R2, “Ą“c“S•˝2, ’r“c—S‹B3, Îˆär•ă2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ, 3‹~–˝): ‘ć85‰ń“ú–{zŠÂŠíŠw‰ďŠwpW‰ď (2021/3/26-28), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-723009. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Multicenter Pharmacokinetic and Pharmacodynamic Study of Oral Factor Xa Inhibitor Edoxaban in Non-valvular Atrial Fibrillation Patients with Acute Heart Failure. “ç“c@Œ’1, Kida K, Î“cŽO˜a1, Shiono T, Suzuki N, Doi S, Tsukahara M, Akashi Y, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ): ‘ć85‰ń“ú–{zŠÂŠíŠw‰ďŠwpW‰ď (2021/3/26-28), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-723010. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Clinical Effects of Re-worsening Left Ventricular Function after Response to Cardiac Resynchronization Therapy. ‘ĺ–Ř‘ě–¤1, Îˆär•ă2, ‘O‘şŒ’ŽĄ1, –îč–ƒ—R2, “Ą“c“S•˝2, ’r“c—S‹B3, “ç“c@Œ’2, ŒSŽRŒbŽq4, ‘OěŒb”ü2, Ź”‹´r”ü2, ’––”FŒł2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ, 3‹~–˝, 4‘‡f—Ă): ‘ć85‰ń“ú–{zŠÂŠíŠw‰ďŠwpW‰ď (2021/3/26-28), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-723011. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Concomitance with vascular disease is associated with stroke and bleeding complication in patients with atrial fibrillation after catheter ablation. [’J‰p•˝1, ‹yě@~1, Otsuka T, Suzuki S, Nagashima K, Arai M, Watanabe R, Yokoyama K, Matsumoto N, Hirata A, Murakami M, Takami M, Kimura M, Nakahara S, Kato T, Iwasaki Y, Shimizu W, Harada T, Nakajima E, Okumura K, Koyama J, Yamane T, Tokuda M, Momiyama Y, Tanimoto K, Soejima K, Nonoguchi N, Hagiwara N, Ejima K, Harada M, Sonoda K, Inoue M, Kumagai K, Hayashi H, Satomi K, Yazaki Y, Watari Y, Okumura Y (1zŠÂŠí“ŕ): ‘ć85‰ń“ú–{zŠÂŠíŠw‰ďŠwpW‰ď (2021/3/26-28), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-723012. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Novel predict or of new-onset heart failure in patients with pacemaker. ”’ě—TŠî1, ‹yě@~1, âV“Ą‘ĺŽ÷2, ˛“Ą“N˜Y2, ź‰Y@Œł2, rě—Y‹I1, Ź—ŃŽü•˝1, Î––ŹĆ1, ŠÝŒ´@~1, [’J‰p•˝1, ’ë–ěTˆę1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć85‰ń“ú–{zŠÂŠíŠw‰ďŠwpW‰ď (2021/3/26-28), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-723013. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Different effects of catheter ablation on the exercise tolerance, leg strength, and quality of life: Paroxysmal vs. Persistent atrial fibrillation. ź‰Y@Œł1, [’J‰p•˝2, ‹yě@~2, âV“Ą‘ĺŽ÷1, ˛“Ą“N˜Y1, rě—Y‹I2, Ź—ŃŽü•˝2, ”’ě—TŠî2, Î––ŹĆ2, ŠÝŒ´@~2, ’ë–ěTˆę2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ): ‘ć85‰ń“ú–{zŠÂŠíŠw‰ďŠwpW‰ď (2021/3/26-28), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-723014. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Esaxerenone Suppresses Electrical Remodeling in the Isoproterenol Induced Myocardial Injury Model. ˛“Ą“N˜Y1, ’ë–ěTˆę2, ’ë–ě—TŒb, ‹yě@~2, âV“Ą‘ĺŽ÷1, ź‰Y@Œł1, rě—Y‹I2, Ź—ŃŽü•˝2, ”’ě—TŠî2, źŹ“c—ş2, –xŒű@ˆ¤2, Î––ŹĆ2, ŠÝŒ´@~2, [’J‰p•˝2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ): ‘ć85‰ń“ú–{zŠÂŠíŠw‰ďŠwpW‰ď (2021/3/26-28), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-723015. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Atrial Late Potentials are Associated with Recurrence of Atrial Fibrillation after Catheter Ablation. âV“Ą‘ĺŽ÷1, [’J‰p•˝2, ‹yě@~2, ˛“Ą“N˜Y1, ź‰Y@Œł1, rě—Y‹I2, Ź—ŃŽü•˝2, ”’ě—TŠî2, Î––ŹĆ2, ŠÝŒ´@~2, ’ë–ěTˆę2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ): ‘ć85‰ń“ú–{zŠÂŠíŠw‰ďŠwpW‰ď (2021/3/26-28), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-732001. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‚—îŽĐ‰ď‚É‚¨‚Ż‚éS–[×“Ž‚Ěƒg[ƒ^ƒ‹ƒPƒA|•sŽ–Ź–ň•¨ŽĄ—ĂƒKƒCƒhƒ‰ƒCƒ“‰ü’ů‚đ“Ľ‚Ü‚Ś‚ā|. ’ë–ěTˆę (zŠÂŠí“ŕ): S–[×“ŽŽĄ—Ă Up to Date in ‘O‹´ (2020/12/19), ‘O‹´

'20-732002. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‚—îŽĐ‰ď‚É‚¨‚Ż‚éS–[×“Ž‚Ěƒg[ƒ^ƒ‹ƒPƒA|•sŽ–Ź–ň•¨ŽĄ—ĂƒKƒCƒhƒ‰ƒCƒ“‰ü’ů‚đ“Ľ‚Ü‚Ś‚ā|. ’ë–ěTˆę (zŠÂŠí“ŕ): ƒGƒŠƒLƒ…[ƒX_“ސě WebƒVƒ“ƒ|ƒWƒEƒ€`‚—îŽŇ‚̍RŒŒđ—Ă–@‚đl‚Ś‚é` (2021/1/19), ‘Š–ÍŒ´.

'20-732003. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‚—îŽĐ‰ď‚É‚¨‚Ż‚éS–[×“Ž‚Ěƒg[ƒ^ƒ‹ƒPƒA|•sŽ–Ź–ň•¨ŽĄ—ĂƒKƒCƒhƒ‰ƒCƒ“‰ü’ů‚đ“Ľ‚Ü‚Ś‚ā|. ’ë–ěTˆę (zŠÂŠí“ŕ): ‘ć15‰ń‚ł‚Ş‚Ý“ŕ‰ČƒZƒ~ƒi[ (2021/2/26), ‘Š–ÍŒ´.

'20-733002. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‰EŽşSë•”ƒy[ƒVƒ“ƒO‚ƉEŽş‚ˆĘ’†Šuƒy[ƒVƒ“ƒO‚ލśŽş“ŕŒŒ—Ź‚É‹y‚Ú‚ˇ‰e‹ż‚ĚŒŸ“˘. rě—Y‹I1, [’J‰p•˝1, ŠÝŒ´@~1, Î––ŹĆ1, Š`č—Ç‘ž1, âV“Ą‘ĺŽ÷2, ˛“Ą“N˜Y2, ź‰Y@Œł2, Ź—ŃŽü•˝1, ”’ě—TŠî1, ‹yě@~1, ’ë–ěTˆę1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć1‰ń“ú–{•sŽ–ŹS“dŠw‰ďŠÖ“ŒbM‰zŽx•”’n•ű‰ď (2021/1/30), WebŠJĂ.

'20-733003. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‰E’†”xĂ–Ź‚ƉE–[‚Ě“d‹C“IŒ‹‡‚É‚ć‚č”xĂ–ŹŠu—Ł‚É“ďa‚ľ‚˝”­ěŤS–[×“Ž‚Ěˆę—á. ”’ě—TŠî1, [’J‰p•˝1, âV“Ą‘ĺŽ÷2, ˛“Ą“N˜Y2, ź‰Y@Œł2, rě—Y‹I1, Ź—ŃŽü•˝1, źŹ“c—ş1, –xŒű@ˆ¤1, Î––ŹĆ1, ‹yě@~1, ŠÝŒ´@~1, ’ë–ěTˆę1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć1‰ń“ú–{•sŽ–ŹS“dŠw‰ďŠÖ“ŒbM‰zŽx•”’n•ű‰ď (2021/1/30), WebŠJĂ.

'20-733004. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ć“VŤSŽžŠłpŒăS–[‘e“Ž‚É‚¨‚˘‚ÄAdvisorTMHD grid‚Ĺ“ž‚ç‚ę‚˝“dˆĘ‚Ş‹łŒP“I‚ž‚Á‚˝ˆę—á. Ź—ŃŽü•˝1, ŠÝŒ´@~1, [’J‰p•˝1, âV“Ą‘ĺŽ÷2, ˛“Ą“N˜Y2, ź‰Y@Œł2, rě—Y‹I1, ”’ě—TŠî1, Î––ŹĆ1, ‹yě@~1, ’ë–ěTˆę1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć1‰ń“ú–{•sŽ–ŹS“dŠw‰ďŠÖ“ŒbM‰zŽx•”’n•ű‰ď (2021/1/30), WebŠJĂ.

'20-733005. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒGƒ“ƒgƒŒƒCƒ“ƒƒ“ƒgƒy[ƒVƒ“ƒO‚ɂĐS“ŕ–Œ-ŠO–Œ‘¤ŠÔ‚Ěbreakthrough‚đŘ–ž‚ľ“ž‚˝perimitral AT‚Ě1—á. źŹ“c—ş1, ‹yě@~1, [’J‰p•˝1, âV“Ą‘ĺŽ÷2, ˛“Ą“N˜Y2, ź‰Y@Œł2, rě—Y‹I1, Ź—ŃŽü•˝1, ”’ě—TŠî1, –xŒű@ˆ¤1, ’†‘ş—m”Í1, Î––ŹĆ1, ŠÝŒ´@~1, ’ë–ěTˆę1, ˆ˘ŒĂĆ1 (1zŠÂŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć1‰ń“ú–{•sŽ–ŹS“dŠw‰ďŠÖ“ŒbM‰zŽx•”’n•ű‰ď (2021/1/30), WebŠJĂ.

'20-733006. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ”xŒŒŠÇŠg’Ł–ň‚É‚ć‚Á‚ĐS“ŕC•œp‚މ”\‚Ć‚Č‚Á‚˝SŽş’†ŠuŒ‡‘šÇ‡•š‰EŽş“ńoÇ‚Ěˆę—á. Ź–Ř‘]ăÄ1, “Ą“c“S•˝2, ‰i“c‹MŽq1, •yˆä‘ĺ“ń˜Y2, ‘OěŒb”ü2, Ź”‹´r”ü2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ): ‘ć259‰ń“ú–{zŠÂŠíŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/2/13-15), WebŠJĂ.

'20-733007. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) S–Œ‰Š‚É‚ć‚éS‘ŠŤáŠQ‚̏oŒť‚đŒ_‹@‚ɏdÇ‰ť‚ľ‚˝‘m–X•Ů‚¨‚ć‚ŃŽOë•Ů‹t—ŹÇ‚Ě1—á. Ź–Ř‘]ăÄ1, “Ą“c“S•˝2, ‰i“c‹MŽq1, •yˆä‘ĺ“ń˜Y2, ‘OěŒb”ü2, Ź”‹´r”ü2, ˆ˘ŒĂĆ2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2zŠÂŠí“ŕ): ‘ć259‰ń“ú–{zŠÂŠíŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/2/13-15), WebŠJĂ.

'20-733008. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) S•s‘S `HFpEF/HFrEF ‚΂Š‚č‚ŞS•s‘S‚ś‚á‚Č‚˘` ć“VŤSŽžŠł‚̐S•s‘S. Ź”‹´r”ü (zŠÂŠí“ŕ): M”Z’ŹSƒGƒR[ƒJƒ“ƒtƒ@ƒŒƒ“ƒXwebu‰‰‰ď (2021/3/6), WebŠJĂ.


”]_Œo“ŕ‰ČŠw

[Šwp˜_•ś]

110217. [Œ´’˜] Asymptomatic acute ischemic lesions in intracerebral hemorrhage: Its frequency, MRI features, and risk factors. Kitamura E1, Iizuka T1, Mamorita N2, Nagai T1, Usui R1, Yanagida A, Nakamura M1, Ishima D1, Kaneko J1, Akutsu T1, Kanazawa N3, Nishiyama K1: J Neurol Sci 2021/7; 426: 117472. (–k‘ş‰p“ń1, ”Ń’Ë‚_1, Žç“cŒ›’2, ‰iˆärs1, ‰Oˆä@—É1, ’†‘şŠ˛ş1, ˆä“‡‘ĺ•ă1, ‹ŕŽq~‘ž˜Y1, ˆ˘‹v’Ă“ń•v1, ‹ŕŕV’ź”ü3, źŽR˜a—˜1: 1”]_Œo“ŕ, 2ˆă—ÉqśŠw•”, 3•a‘ԁEf—ĂŒn)

110218. [Œ´’˜] The influence of right-left error in the placement of the Cc electrode in tibial nerve somatosensory evoked potentials (SEPs). Takahashi K1, Oishi C, Hamada Y, Nishiyama K1, Sonoo M: Clin Neurophysiol Pract 2021/7; 6: 215-8. (‚‹´˜aš1, źŽR˜a—˜1: 1”]_Œo“ŕ)

110219. [Œ´’˜] Thymoma and Autoimmune Encephalitis: Clinical Manifestations and Antibodies. Guasp M, Landa J, Martinez-Hernandez E, Sabater L, Iizuka T1, Simabukuro M, Nakamura M, Kinoshita M, Kurihara M, Kaida K, Bruna J, Kapetanovic S, S‡nchez P, Ruiz-Garc’a R, Naranjo L, Planagumˆ J, Munoz-Lopetegi A, Bataller L, Saiz A, Dalmau J, Graus F: Neurol Neuroimmunol Neuroinflamm 2021/7; 8 (5): e1053. (”Ń’Ë‚_1: 1”]_Œo“ŕ)

110220. [Œ´’˜] Status epilepticus suspected autoimmune: Neuronal surface antibodies and main clinical features. Suga H, Yanagida A, Kanazawa N1, Ohara H, Kitagawa T, Hayashi M, Onozawa Y, Nagata N, Kaneko J1, Kitamura E1, Nishiyama K1, Iizuka T1: Epilepsia 2021/11; 62 (11): 2719-31. (‹ŕŕV’ź”ü1, ‹ŕŽq~‘ž˜Y1, –k‘ş‰p“ń1, źŽR˜a—˜1, ”Ń’Ë‚_1: 1”]_Œo“ŕ)

110221. [Œ´’˜] Cholesterol crystal embolism-related cerebral infarction: Magnetic resonance imaging and clinical characteristics. Kondo Y1, Kanzaki M1, Ishima D1, Usui R1, Kimura A1, Usui K1, Amoh Y2, Takeuchi Y3, Kumabe T4, Ako J5, Miyaji K6, Nishiyama K1, Akutsu T1: eNeurologicalSci 2021/12; 25: 100388. (‹ß“Ą—TŽq1, _č^ŽŔ1, ˆä“‡‘ĺ•ă1,‰Oˆä@—É1, –Ř‘ş•śŤ1, ‰Pˆäk‘ž˜Y1, “V‰HN”V2, ’|“ŕN—Y3, ŒG•”rG4, ˆ˘ŒĂĆ5, ‹{’n@ŠÓ6, źŽR˜a—˜1, ˆ˘‹v’Ă“ń•v1: 1”]_Œo“ŕ, 2”畆, 3t‘Ÿ“ŕ, 4”]ŠO, 5zŠÂ‹@“ŕ, 6S‘ŸŒŒŠÇŠO)

110222. [Œ´’˜] Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis. Aizawa H, Kato H, Oba K, Kawahara T, Okubo Y, Saito T, Naito M, Urushitani M, Tamaoka A, Nakamagoe K, Ishii K, Kanda T, Masahisa Katsuno M , Atsuta N, Maeda Y, Nagai M1, Nishiyama K1, Ishiura H, Toda T, Kawata A, Abe K, Yabe I, Takahashi-Iwata I, Sasaki H, Warita H, Aoki M, Sobue G, Mizusawa H, Matsuyama Y, Haga T, Shin Kwak S: J Neurol 2022/2; 269 (2): 885-96. (‰iˆä^‹MŽq1, źŽR˜a—˜1: 1”]_Œo“ŕ)

310016. [Ç—á•ń] Gerstmann's Syndrome in a Patient Double-positive for Antibodies against the N-methyl-D-aspartate Receptor and NH2-terminal of ƒż-enolase. Sugiyama A, Suzuki M, Suichi T, Uchida T, Iizuka T1, Tanaka K, Yoneda M, Kuwabara S: Intern Med 2021/5; 60 (9): 1463-8. (”Ń’Ë‚_1: 1”]_Œo“ŕ)

310017. [Ç—á•ń] Case Report: Dexmedetomidine for Intractable Clusters of Myoclonic Jerks and Paroxysmal Sympathetic Hyperactivity in Progressive Encephalomyelitis With Rigidity and Myoclonus. Fujino Y, Shiga K, Hori M, Tamura A, Iizuka T1: Front Neurol 2021/7; 12: 703050. (”Ń’Ë‚_1: 1”]_Œo“ŕ)

310018. [Ç—á•ń] Paraneoplastic Polymyositis Due to Renal Cell Carcinoma in a Patient with Autosomal Dominant Polycystic Kidney Disease. Noda-Narita S, Kanzaki M1, Uesaka Y, Suwabe T, Kinowaki K, Marui Y, Hoshino J, Sawa N, Ubara Y: Intern Med 2021/11; 60 (22): 3577-80. (_č^ŽŔ1: 1”]_Œo“ŕ)

310019. [Ç—á•ń] Severe dysautonomia in glycine receptor antibody-positive progressive encephalomyelitis with rigidity and myoclonus (PERM): A case report. Mizutani Y, Adachi S, Nakano S, Hayashi K, Higashi A, Kikuchi K, Maeda T, Murate K, Shima S, Iizuka T1, Ueda A, Ito M, Watanabe H: Auton Neurosci 2022/1; 237: 102910. (”Ń’Ë‚_1: 1”]_Œo“ŕ)

522053. [uŔ]y“ÁW: ˆę•ŕi‚ń‚žŠÇ—E—\–hEŽĄ—Ă‚đŽŔ‘H! ”]‘˛’†‚Ě–ň‚ĚŽg‚˘•űz’´‹}ŤŠú”]‘˛’†‚Ě‘SgŠÇ—. Ź’Jş”Ž, źŽR˜a—˜1 (1”]_Œo“ŕ): ŒŽŠ§–ňŽ– 2021/12; 63 (16): 34-9.

522054. [uŔ]y“ÁW: “ޒɐf—ĂupdatezIII. “Ş’É‚Ěf’f‚ĆŽĄ—Á@1. ”˝•œŤ•Đ“Ş’É. –k‘ş‰p“ń (”]_Œo“ŕ): “ú–{—Őଠ2022/2; 80 (2): 249-55.

[’˜@‘]

620059. [Šwp‘ (•Ş’SŽˇ•M)]yĹVƒKƒCƒhƒ‰ƒCƒ“‚ÉŠî‚Ă‚­ _ŒoŽžŠł f—ĂŽwj 2021-'22z10. ‹ŘŽžŠł@ƒ~ƒgƒRƒ“ƒhƒŠƒA•a, p,386-94. ”Ń’Ë‚_ (”]_Œo“ŕ), •Ň: —é–Ř‘ĽG, ‘‡ˆăŠwŽĐ, “Œ‹ž, 2021/5”­s.

620060. [Šwp‘ (•Ş’SŽˇ•M)]yAnnual Review _Œo 2021zIII. Clinical Topics@7. ’E‘E–ƉuŤŽžŠł@1 ŽŠŒČ–Ɖu‰îÝŤ”]‰Š‚ĚƒXƒyƒNƒgƒ‰ƒ€, p.271-82. ”Ń’Ë‚_1, ‹ŕŕV’ź”ü2 (1”]_Œo“ŕ, 2•a‘ԁEf—ĂŒn), •Ň: —é–Ř‘ĽG, r–ؐM•v, ‰Fě‹`ˆę, ŒKŒ´@‘, ‰–ě–Fş, ’†ŠOˆăŠwŽĐ, “Œ‹ž, 2021/5”­s.

620061. [Šwp‘ (•Ş’SŽˇ•M)]y’†•_Œo‚ĚŽŠŒČ–ƉuŤE‰ŠÇŤŽžŠłƒnƒ“ƒhƒuƒbƒN (Brain and Nerve 2021”N‘‘ĺ†)zĄ‘ć2Í ŽžŠłŠe˜_@RNMDAŽó—e‘Ě”]‰Š, p,595-604. ”Ń’Ë‚_1, ‹ŕŕV’ź”ü2, –ö“c“ÖŽq3 (1”]_Œo“ŕ, 2•a‘ԁEf—ĂŒn, 3Œ`‘ÔŒn), ˆăŠw‘‰@, “Œ‹ž, 2021/5”­s.

620062. [Šwp‘ (•Ş’SŽˇ•M)]y“Ş’É‚Ěf—ĂƒKƒCƒhƒ‰ƒCƒ“2021zII •Đ“ޒɁ@3. —\–h—Ă–@@CQ II-3-4 •Ą”‚Ě—\–h—Ă–@‚đ‚ǂ̂悤‚ÉŽg‚˘•Ş‚Ż‚é‚Š, p.207. CQ II-3-13 •Đ“Ş’É‚ť‚Ě‘ź‚Ě—\–h—Ă–@‚Í—LŒř‚Š, p.235. V ‚ť‚Ě‘ź‚ĚˆęŽŸŤ“ޒɁ@•Đ“Ş’É, ‹Ů’ŁŒ^“Ş’É, ŒQ”­“Ş’ÉˆČŠO‚Ě1ŽŸŤ“Ş’É‚É‚Í‚Ç‚Ě‚ć‚¤‚Č‚ŕ‚Ě‚Ş‚ ‚é‚Š, p.326. –k‘ş‰p“ń (”]_Œo“ŕ), ŠÄC: “ú–{_ŒoŠw‰ď, “ú–{“Ş’ÉŠw‰ď, “ú–{_ŒoŽĄ—ĂŠw‰ď, •Ň:u“Ş’É‚Ěf—ĂƒKƒCƒhƒ‰ƒCƒ“věŹˆĎˆő‰ď, ˆăŠw‘‰@, “Œ‹ž, 2021/10”­s.

620063. [Šwp‘ (•Ş’SŽˇ•M)]yĹV—Տ°”]‘˛’†Šw (‘ć2”Ĺ) ‰ş|ĹV‚̐f’f‚ĆŽĄ—Á| (“ú–{—ŐŕŹ80ŠŞ‘Š§†2)zXV. ”][Ç‘˜_@4. ‹}ŤŠúŽĄ—Á@(4) ”]•ŰŒě—Ă–@, p.55-9. ˆ˘‹v’Ă“ń•v (”]_Œo“ŕ), “ú–{—Ő଎Đ, “Œ‹ž, 2022/2”­s.

620064. [Šwp‘ (•Ş’SŽˇ•M)]yĄ“ú‚ĚŽĄ—ĂŽwj2022”N”Ł@Ž„‚Í‚ą‚¤ŽĄ—Ă‚ľ‚Ä‚˘‚éz15 _ŒoE‹ŘŽžŠł@–łÇŒóŤ”]ŒŒŠÇáŠQ (–˘”j—ô”]“Ž–ŹáŽ‚đœ‚­), p,949-51. źŽR˜a—˜ (”]_Œo“ŕ), ‘•ŇW: •ŸˆäŽŸ–î, ‚–؁@˝, ŹŽşˆęŹ, ˆăŠw‘‰@, “Œ‹ž, 2022/1”­s.

620065. [Šwp‘ (•Ş’SŽˇ•M)]y”­“W‚ˇ‚é”]‘˛’†f—Ă‚ĚĹ‘Oü (ˆăŠw‚Ě‚ ‚ä‚Ý3ŒŽ‘ć1“y—j“ÁW)zŠŞ“ŞŒž, p.969. źŽR˜a—˜ (”]_Œo“ŕ), ˆăŽ•–ňo”Ĺ, “Œ‹ž, 2022/3”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

722078. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ”]‰ŠE‘–Œ‰ŠŽ•ž‚ÉŒü‚Ż‚˝f—ĂƒAƒ‹ƒSƒŠƒYƒ€‚̍\’z: u_ŒoŠ´őÇ‚ĆŽŠŒČ–ƉuŤ”]‰Š‚ĚƒNƒƒXƒg[ƒNv‚É‚¨‚Ż‚éuŽŠŒČ–ƉuŤ”]‰Š‚É‚¨‚Ż‚éf’fƒAƒ‹ƒSƒŠƒYƒ€‚Ć—Ő°ƒXƒyƒNƒgƒ‰ƒ€‚ĚŠg‚Ş‚čv. ”Ń’Ë‚_ (”]_Œo“ŕ): ‘ć62‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2021/5/21), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722079. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) —Տ°ˆă•”‰ďÝ’u€”őˆĎˆő‰ď‚Š‚ç‚ĚŠˆ“Ž•ń. źŽR˜a—˜ (”]_Œo“ŕ): ‘ć62‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2021/5/22), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722080. [Šw‰ď (‘S‘)] (ƒ}ƒ‰ƒ\ƒ“ƒŒƒNƒ`ƒƒ[) ŽŠŒČ–ƉuŤ”]‰Š‚¨‚ć‚Ń‚ť‚̗މŽžŠł‚É‚¨‚Ż‚é‹}ŤÇŒóŤ”­ě ÇŒó‚Ć•a‘Ô). ”Ń’Ë‚_ (”]_Œo“ŕ): ‘ć54‰ń“ú–{‚Ä‚ń‚Š‚ńŠw‰ďŠwpW‰ď (2021/9/25), –źŒĂ‰Ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722081. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) RNMDAŽó—e‘Ě”]‰Š‚ĆŽŠ—Ľ_ŒoáŠQ. ”Ń’Ë‚_ (”]_Œo“ŕ): ‘ć74‰ń“ú–{ŽŠ—Ľ_ŒoŠw‰ď‘‰ď (2021/10/24), WebŠJĂ.

722082. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‰ŠÇŤ”]ŽžŠłf—Ă‚É‚¨‚Ż‚é”]_Œo“ŕ‰Čˆă‚ĚŠˆ–ô (ŽŠŒČ–ƉuŤ”]‰Š‚⌴ˆö•s–ž‚Ě‚Ä‚ń‚Š‚ńdĎó‘Ô‚đŠÜ‚Ţ). ”Ń’Ë‚_ (”]_Œo“ŕ): ‘ć39‰ń“ú–{_ŒoŽĄ—ĂŠw‰ďŠwpW‰ď (2021/10/29), ŽOd (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722083. [Šw‰ď (‘S‘)] (‹łˆçƒZƒ~ƒi[) •Đ“Ş’É‘O’›‚Ć“Ş’É”­ěŽž‚Ě”]ŒŒ—Ź•Ď‰ť: 2‘ŠŤ_ŒoŒŒŠÇ•Ď‰ť. ”Ń’Ë‚_ (”]_Œo“ŕ): ‘ć49‰ń“ú–{“Ş’ÉŠw‰ď‘‰ď (2021/11/19), Ă‰Ş.

722084. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‹CŰ•Ď‰ť‚͔玿Šg‰„Ť—}§‚ɉe‹ż‚đ‹y‚Ú‚ˇ‚Š. –k‘ş‰p“ń (”]_Œo“ŕ): “ú–{“Ş’ÉŠw‰ď (2021/11/20), Ă‰Ş.

723179. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Combined technique‚đ—p‚˘‚˝‹@ŠB“IŒŒđ‰ńŽű—Ă–@‚Ĺ‹zˆřƒJƒe[ƒeƒ‹‚ĚŒŒđˆł’…‚Í•K{‚Š? ‰Oˆä@—É1, ˆä“‡‘ĺ•ă1, –Ř‘ş•śŤ1, ‰Pˆäk‘ž˜Y1, {‰ę—TŽ÷1, ‰iˆärs1, ŒI“c‰l—˘Žq1, ‹ŕŽq~‘ž˜Y1, –k‘ş‰p“ń1, _č^ŽŔ1, m–؁@~2, ŽR–{‘ĺ•ă2, ˆ˘‹v’Ă“ń•v1, źŽR˜a—˜1 (1”]_Œo“ŕ, 2”]ŠO): ‘ć62‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2021/5/19), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723180. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒRƒŒƒXƒeƒ[ƒ‹ÇđÇ‚É‚¨‚Ż‚éčň“Ž–Ź‹ˇó‚ɂ‚˘‚Ä‚ĚŒŸ“˘. ˆ˘‹v’Ă“ń•v1, ‹ß“Ą—TŽq2, ‰Pˆäk‘ž˜Y1, –Ř‘ş•śŤ1, ‰Oˆä@—É1, ˆä“‡‘ĺ•ă1, _č^ŽŔ1, ”Ń’Ë‚_1, źŽR˜a—˜1 (1”]_Œo“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć62‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2021/5/19), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723181. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ĺ”]Šî’ęŠjŽžŠł‚É‚¨‚Ż‚é‹ť•ą—}§ƒoƒ‰ƒ“ƒX‚ĚŒŸ“˘. •yŠ~Ž•F1, ŕ_“c@‰ë, ‘ă“c—Iˆę˜Y, ŒË“c’BŽj, źŽR˜a—˜1, ’ˇ’JěˆęŽq (1”]_Œo“ŕ): ‘ć62‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2021/5/21), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723182. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Clinico-immunological investigations in suspected autoimmune encephalitis or its related disorders. ”Ń’Ë‚_1, –ö“c“ÖŽq, ‹ŕŕV’ź”ü2, ŠâŁ—ČŽq1, ’ˇ“c“ޏ”ü3, {‰ę—TŽ÷1, ‹ŕŽq~‘ž˜Y1, –k‘ş‰p“ń1, źŽR˜a—˜1 (1”]_Œo“ŕ, 2•a‘ԁEf—ĂŒn, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć62‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2021/5/21), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723183. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Clinical and immunological investigations in autoimmune encephalitis and its related disorders. ”Ń’Ë‚_1, –ö“c“ÖŽq, ‹ŕŕV’ź”ü2, ŠâŁ—ČŽq1, ’ˇ“c“ޏ”ü3, {‰ę—TŽ÷1, ‹ŕŽq~‘ž˜Y1, –k‘ş‰p“ń1, źŽR˜a—˜1 (1”]_Œo“ŕ, 2•a‘ԁEf—ĂŒn, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć62‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2021/5/21), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723184. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Immunostaining pattern of neuronal surface antibodies with in-house IHC and commercial IHC. –ö“c“ÖŽq, ”Ń’Ë‚_1, ‹ŕŕV’ź”ü2, –k‘ş‰p“ń1, {‰ę—TŽ÷1, ‹ŕŽq~‘ž˜Y1, źŽR˜a—˜1 (1”]_Œo“ŕ, 2•a‘ԁEf—ĂŒn): ‘ć62‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2021/5/21), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723185. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Effect of blue light on cortical spreading depression. –k‘ş‰p“ń1, ‹ŕŕV’ź”ü2, ”Ń’Ë‚_1, źŽR˜a—˜1 (1”]_Œo“ŕ, 2•a‘ԁEf—ĂŒn): ‘ć62‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2021/5/21), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723186. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Ž‹_ŒoŇ‘‰Š‚ĚÄ”­Žž‚ɍRGluN1R‘Ě‚Ş‘‰t‚Š‚猟o‚ł‚ę‚˝39Î—Ť. ‹ŕŽq~‘ž˜Y1, ‹ŕŕV’ź”ü2, ”Ń’Ë‚_1, ’ˇ“c“ޏ”ü3, {‰ę—TŽ÷1, –ö“c“ÖŽq, źŽR˜a—˜1 (1”]_Œo“ŕ, 2•a‘ԁEf—ĂŒn, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć33‰ń“ú–{_Œo–ƉuŠw‰ďŠwpW‰ď (2021/10/21), WebŠJĂ.

723187. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒ‰ƒbƒg”]–Ɖu‘gD‰ťŠwă‚Ě“Á’Ľ“IőFƒpƒ^[ƒ“‚ÉŠî‚Ă‚˘‚˝_Œo•\–ʍRŒ´‚Ě—\‘Ş: —\”ő“IŒ¤‹†. ’ˇ“c“ޏ”ü1, ”Ń’Ë‚_2, ‹ŕŕV’ź”ü3, –ö“c“ÖŽq, {‰ę—TŽ÷2, ‹ŕŽq~‘ž˜Y2, –k‘ş‰p“ń2, źŽR˜a—˜2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2”]_Œo“ŕ, 3•a‘ԁEf—ĂŒn): ‘ć33‰ń“ú–{_Œo–ƉuŠw‰ďŠwpW‰ď (2021/10/22), WebŠJĂ.

723188. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”’FŒő‚Şcortical spreading depression‚É—^‚Ś‚é‰e‹ż. –k‘ş‰p“ń1, ‹ŕŕV’ź”ü2, ”Ń’Ë‚_1, źŽR˜a—˜1 (1”]_Œo“ŕ, 2•a‘ԁEf—ĂŒn): “ú–{“Ş’ÉŠw‰ď (2021/11/21), Ă‰Ş.

723189. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰ß‰^“Ž”­ě‚̓•”•Ş‚Ä‚ń‚Š‚ń‚̏p‘O•]‰ż‚É‚¨‚Ż‚éd–ŒŠO“d‹É‚Ě“Á•Ę‚Č—L—pŤ‚ĚŒŸ“˘. ‰iˆärs (”]_Œo“ŕ): ‘ć51‰ń“ú–{—Տ°_Œoś—Šw‰ďŠwp‘ĺ‰ď (2021/12/18), ĺ‘ä (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723190. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŒyÇ‚Š‚ç’†“™Ç‚Ě”]’ę“Ž–Ź•ÂÇÇ‚Í•Đ–ƒáƒ‚đ’悡‚é. ˆ˘‹v’Ă“ń•v1, źŽR˜a—˜1, –Ř‘ş•śŤ1, ‰Oˆä@—É1, ˆä“‡‘ĺ•ă1, ‹ŕŽq~‘ž˜Y1, ŽR–{‘ĺ•ă2, –Ř‹–‘ń”n1, ’ˇ“‡@˝1, {‰ę—TŽ÷1, ’†‘şŠ˛ş1, ”Ń’Ë‚_1, –k‘ş‰p“ń1, _č^ŽŔ1 (1”]_Œo“ŕ, 2”]ŠO): STROKE 2022 (2022/3/17), ‘ĺâ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733055. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ”˝•œŤ‚Ě–ł‹ŰŤ‘–Œ‰Š‚ƝG“‰Š‚đŒ_‹@‚ɉƑ°Ť’n’†ŠC”M‚Ɛf’f‚ľ‚˝46Î’jŤ ’†‘şŠ˛ş1, ‰iˆärs1, ˆŔ’B’q”ü1, –Ř‹–‘ń”n1, ‹ŕŽq~‘ž˜Y1, _é^ŽŔ1, ]”gŒËF•ă2, źŽR˜a—˜1 (1”]_Œo“ŕ, 2ŹŽ™): ‘ć237‰ń“ú–{_ŒoŠw‰ďŠÖ“ŒEbM‰z’n•ű‰ď (2021/6/5), WebŠJĂ.

733056. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ”­ěŽž“Ş”ç”]”gŠJŽn‘O‚ÉDC“dˆĘ‚đ”F‚ß‚˝‘e‘ĺ•a•Ď‚̓ś‘¤“Ş—t‚Ä‚ń‚Š‚ń‚Ěˆę—á. ‰iˆärs (”]_Œo“ŕ): ‘ć17‰ń“ú–{‚Ä‚ń‚Š‚ńŠw‰ď‹ß‹E’n•ű‰ď (2021/7/18), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733057. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Ž‹_ŒoŇ‘‰Š‚ĚÄ”­‚Ć“ŻŽž‚ɍRNMDAŽó—e‘Ě”]‰Š‚đ”­Ç‚ľ‚˝39Î—Ť—á. •űŒ’—ş1, ‹ŕŽq~‘ž˜Y1, ‹ŕŕV’ź”ü2, ”Ń’Ë‚_1, •˝ŽRŒ’ŽŸ1, “ż“c@ăÄ1, ˆŔ’B’q”ü1, ˆ˘‹v’Ă“ń•v1, źŽR˜a—˜1 (1”]_Œo“ŕ, 2•a‘ԁEf—ĂŒn): ‘ć238‰ń“ú–{_ŒoŠw‰ďŠÖ“ŒEbM‰z’n•ű‰ď (2021/9/4), “Œ‹ž.

733058. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) dÇ‹Ř–ł—͏ǎĄ—Ă’†‚É”­Ç‚ľ‚˝Ň‘d–ŒŠOŽ‰–bŽî‚Ěˆę—á. ˆŔ’B’q”ü1, ‰Oˆä@—É1, ‹ŕŽq~‘ž˜Y1, ˆ˘‹v’Ă“ń•v1, ”Ń’Ë‚_1, źŽR˜a—˜1 (1”]_Œo“ŕ): ‘ć239‰ń“ú–{_ŒoŠw‰ďŠÖ“ŒEbM‰z’n•ű‰ď (2021/12/4), WebŠJĂ.

733059. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ázŤ‘Ζƒáƒ‚Ĺ”­Ç‚ľCSF1Rˆâ“`Žq‚̐V‹K•ĎˆŮ‚đ”F‚ß‚˝_ŒoŽ˛őƒXƒtƒFƒƒCƒhŒ`Ź‚𔺂¤ˆâ“`Ť‚Ń‚Ü‚ńŤ”’Žż”]Ç (HDLS) ‚Ě50Î’jŤ—á. Ź’Jş”Ž1, ‰iˆä^‹MŽq1, ŠâŁ—ČŽq1, •˝ŽRŒ’ŽŸ1, ‘ĺŔšD, Î‰Y_”V, ’ҁ@ČŽŸ, ‚@‹IM, ‘ëŽR‰Ă‹v, źŽR˜a—˜1 (1”]_Œo“ŕ): ‘ć240‰ń“ú–{_ŒoŠw‰ďŠÖ“ŒEbM‰z’n•ű‰ď (2022/3/5), “Œ‹ž.

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-110016. [Œ´’˜] Clinically based score predicting cryptogenic NORSE at the early stage of status epilepticus. Yanagida A, Kanazawa N1, Kaneko J2, Kaneko A2, Iwase R2, Suga H, Nonoda Y3, Onozawa Y4, Kitamura E2, Nishiyama K2, Iizuka T2: Neurol Neuroimmunol Neuroinflamm 2020/7; 7 (5): e849. (‹ŕŕV’ź”ü1, ‹ŕŽq~‘ž˜Y2, ‹ŕŽq@Œú2, ŠâŁ—ČŽq2, –ěX“c–L3, Ź–ěŕV—T–ç4, –k‘ş‰p“ń2, źŽR˜a—˜2, ”Ń’Ë‚_2: 1•a‘ԁEf—ĂŒn, 2”]_Œo“ŕ, 3ŹŽ™, 4—ŐŒŸ•”)


ŒŒ‰t“ŕ‰ČŠw

[Šwp˜_•ś]

110223. [Œ´’˜] Real-world assessment of myelodysplastic syndrome: Japanese claims data analysis . Tsutsue S, Suzuki T1, Kim H, Crawford B : Future Oncol 2022/1; 18 (1): 93-104. (—é–Ř—˛_1: 1ŒŒ‰t“ŕ)

521003. [‰đŕ] ƒGƒŠƒXƒƒ|ƒGƒ`ƒ“•s‰žŤMDS‚ɑ΂ˇ‚郌ƒiƒŠƒhƒ~ƒhEƒGƒŠƒXƒƒ|ƒGƒ`ƒ“•š—p—Ă–@‚Ě—Ő°Œř‰Ę. —é–Ř—˛_: ŒŒ‰t“ŕ‰Č2021/9; 83 (3): 416-20.

522055. [uŔ]y‘ĺ‚Ť‚­i•ŕ‚ľ‚˝‘˘ŒŒŠíŽîᇂ̐f’f‚ĆŽĄ—Ázœ‘ˆŮŒ`ŹÇŒóŒQ. ‰ĄŽR^Šě1, —é–Ř—˛_1 (1ŒŒ‰t“ŕ): f’f‚ĆŽĄ—Ă 2021/6; 109 (6): 761-5.

[’˜@‘]

620066. [Šwp‘ (•Ş’SŽˇ•M)]yV—Տ°Žîᇊw ‚Ş‚ń–ň•¨—Ă–@ę–ĺˆă‚Ě‚˝‚ß‚É ‰ü’ů‘ć6”Łzœ‘ˆŮŒ`ŹÇŒóŒQ (MDS), p. 598-602. —é–Ř—˛_ (ŒŒ‰t“ŕ), “ě]“°, “Œ‹ž, 2021/5”­s.

620067. [Šwp‘ (•Ş’SŽˇ•M)]yę–ĺˆă‚Ě‚˝‚ß‚ĚŒŒ‰t•aŠwzVI ŽĄ—Ă‘˜_@3 ŽxŽ—Ă–@@1) ƒTƒCƒgƒJƒCƒ“—Ă–@, p,370-5. ‰Ľ@‘c˝ (ŒŒ‰t“ŕ), •Ň: —é–Ř—˛_, ’|’†Ž“l, ’r“Y—˛”V, ˆăŠw‘‰@, “Œ‹ž, 2022/3”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713035. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Emerging strategies for myelodysplastic syndromes. Suzuki T1: The 12th JSH International Symposium 2021 in Kamakura (2021/5/14-15), Kamakura, Japan. (—é–Ř—˛_1: 1ŒŒ‰t“ŕ)

721009. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) œ‘•s‘SÇ‚ĚŠÓ•Ę‚ĆŽĄ—Ă. —é–Ř—˛_ (ŒŒ‰t“ŕ): ‘ć22‰ń“ú–{ŒŸ¸ŒŒ‰tŠw‰ďŠwpW‰ď (2021/9/12), _“ސě (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723191. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) CD45‰AŤƒAƒOƒŒƒbƒVƒuNK×–E”’ŒŒ•a‚Ěˆę—á. “š‰ş—Y‰î1, ‰Ľ@‘c˝1, Š™“c_–Ť1, “cŽ›”͍s1, –x•Ä—Cˆę1, ‰ĄŽR^Šě1, ‰HŽRŒdˆČ2, ‹{ř“_“ń3, —é–Ř—˛_1 (1ŒŒ‰t“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3—AŒŒE×–EˆÚA): ‘ć83‰ń“ú–{ŒŒ‰tŠw‰ďŠwpW‰ď (2021/9/23-25), WebŠJĂ.

723192. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘˘ŒŒŠíŽžŠł‚É‚¨‚Ż‚鍜‘ŠÂó“S‰č‹…‚đŠÜ‚ŢˆŮŒ`Ź‚ÉŠÖ‚ˇ‚é’PŽ{ÝÇ—áWĎŒ¤‹†. ‰HŽRŒdˆČ1, Š™“c_–Ť2, ˆ˘•”—L3, ŸNˆäŒcŽO3, ‘şă”ޏdŽq4, Žë–ě—Lě5, —é–Ř—˛_2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŒŒ‰t“ŕ, 3—ŐŒŸ•”, 4Œ`‘ÔŒn, 5—ŐŒŸŠw): ‘ć83‰ń“ú–{ŒŒ‰tŠw‰ďŠwpW‰ď (2021/9/23-25), WebŠJĂ.

732035. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (’nˆćˆă—ĂƒVƒ“ƒ|ƒWƒEƒ€) ŒŒ‰t–K–âf—Ă‚É‚¨‚Ż‚éƒ^[ƒ~ƒiƒ‹ƒPƒA‚ĆÝ‘î—AŒŒ‚̉”\Ť. ‰Ľ@‘c˝ (ŒŒ‰t“ŕ): ‘ć15‰ń“ú–{ŒŒ‰tŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/7/10), ” Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

732036. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€)yŒŒ‰t“ŕ‰Čf—Ă‚Ěˆă—Ă˜AŒgzŒŒ‰t–K–âf—Â̐f‚Š‚˝: Ý‘î—AŒŒ‚ɂ‚˘‚Ä. ‰Ľ@‘c˝ (ŒŒ‰t“ŕ): ‘ć15‰ń“ú–{ŒŒ‰tŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/7/10), ” Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733060. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) –Ťœ‘Ť”’ŒŒ•aŠłŽŇ‚É‚¨‚Ż‚éƒ`ƒƒVƒ“ƒLƒi[ƒ[‘jŠQ–ň‚Ě’ˇŠúŽg—p‚ÉŠÖ˜A‚ľ‚˝„’莅‹…‘Ěŕh‰ß—Ś‚̕ωť. ŹźG–ž1, Š™“c_–Ť1, –{‹´’m”ü1, “š‰ş—Y‰î1, –x•Ä—Cˆę1, “cŽ›”͍s1, ‰Ľ@‘c˝1, —é–Ř—˛_1 (1ŒŒ‰t“ŕ): ‘ć15‰ń“ú–{ŒŒ‰tŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/7/10), ” Ş.

733061. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) PNH‡•š”DP‚Œ鉤ŘŠJ‚É‚Ä•Ş•Ř‚ľŽY‰Č“I‡•šÇ‚đ—ˆ‚ľ‚˝ˆę—á. ]”¨Wˆę1, ‰Ľ@‘c˝1, Š™“c_–Ť1, “cŽ›”͍s1, –x•Ä—Cˆę1, “š‰ş—Y‰î1, ‰ĄŽR^Šě1, ‹{ř“_“ń2, —é–Ř—˛_1 (1ŒŒ‰t“ŕ, 2—AŒŒE×–EˆÚA): ‘ć16‰ń“ú–{ŒŒ‰tŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2022/3/19), “Œ‹ž.


ŒÄ‹zŠí“ŕ‰ČŠw

[Šwp˜_•ś]

110224. [Œ´’˜] Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320). Otani S1, Sasaki J2, Nakahara Y1, Fukui T1, Igawa S1, Naoki K1, Bessho A, Hosokawa S, Fukamatsu N, Nakamura Y, Kasai T, Sugiyama T, Tokito T, Seki N, Hamada A, Okamoto H, Masuda N: Invest New Drugs 2021/4; 39 (2): 530-6. (‘ĺ’JçŽq1, ˛X–ŘŽĄˆę˜Y2, ’†Œ´‘P˜N1, •Ÿˆä•ü–ç1, ˆäě@‘1, —P–؍Ž•F1: 1ŒÄ‹zŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

110225. [Œ´’˜] Examination of endobronchial ultrasound-guided transbronchial needle aspiration using a puncture needle with a side trap. Miyazaki K, Hirasawa Y, Aga M, Aiko N, Hamakawa Y, Taniguchi Y, Misumi Y, Agemi Y, Shimokawa T, Hayashi H, Naoki K1, Okamoto H: Sci Rep 2021/5; 11 (1): 9789. (—P–؍Ž•F1: 1ŒÄ‹zŠí“ŕ)

110226. [Œ´’˜] Trends of concerns from diagnosis in patients with advanced lung cancer and their family caregivers: A 2-year longitudinal study. Sato T1, Fujisawa D, Arai D, Nakachi I, Takeuchi M, Nukaga S, Kobayashi K, Ikemura S, Terai H, Yasuda H, Kawada I, Sato Y, Satomi R, Takahashi S, Haraguchi-Hashiguchi M, Nakamura M, Oyamada Y, Terashima T, Sayama K, Saito F, Sakamaki F, Inoue T, Naoki K1, Fukunaga K, Soejima K: Palliat Med 2021/5; 35 (5): 943-51. (˛“Ą@’1, —P–؍Ž•F1: 1ŒÄ‹zŠí“ŕ)

110227. [Œ´’˜] Prognostic significance of galectin-3 expression in patients with resected NSCLC treated with platinum-based adjuvant chemotherapy. Kusuhara S1, Igawa S1, Ichinoe M2, Nagashio R3, Kuchitsu Y3, Hiyoshi Y1, Shiomi K4, Murakumo Y2, Saegusa M2, Satoh Y4, Sato Y3, Naoki K1: Thorac Cancer 2021/5; 12 (10): 1570-8. (“팴­ˆę˜Y1, ˆäě@‘1, ˆęŒËš–ž2, ’ˇ‰–@—ş3, ‹€’Ă—L‹I3, “ú‹gNO1, ‰–ŒŠ@˜a4, ‘ş‰_–FŽ÷2, ŽOŽ}@M2, ˛“Ą”Vr4, ˛“Ą—Yˆę3, —P–؍Ž•F1: 1ŒÄ‹zŠí“ŕ, 2•a—, 3ˆă—ÉqśŠw•”, 4ŒÄ‹zŠíŠO)

110228. [Œ´’˜] Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis. Horiuchi K, Sato T1, Kuno T, Takagi H, Hirsch FR, Powell CA, Fukunaga K: Lung Cancer 2021/6; 156: 59-67. (˛“Ą@’1: 1ŒÄ‹zŠí“ŕ)

110229. [Œ´’˜] Implementation of clinical sequencing for molecular profiling in patients with advanced cancer. Fukui T1, Sakai K, Sasaki J2, Ishihara-Kakegawa M1, Igawa S1, Mitsufuji H3, Takeda M, Takahama T, Nakagawa K, Nishio K, Naoki K1: Cancer Biomark 2021/6; 31 (2): 119-26. (•Ÿˆä•ü–ç1, ˛X–ŘŽĄˆę˜Y2, Š|ě–˘ŠóŽq1, ˆäě@‘1, ŽO“Ą@‹v3, —P–؍Ž•F1: 1ŒÄ‹zŠí“ŕ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3ŠĹŒěŠw•”)

110230. [Œ´’˜] Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. Ishioka K, Yasuda H, Hamamoto J, Terai H, Emoto K, Kim TJ, Hirose S, Kamatani T, Mimaki S, Arai D, Ohgino K, Tani T, Masuzawa K, Manabe T, Shinozaki T, Mitsuishi A, Ebisudani T, Fukushima T, Ozaki M, Ikemura S, Kawada I, Naoki K1, Nakamura M, Ohtsuka T, Asamura H, Tsuchihara K, Hayashi Y, Hegab AE, Kobayashi S, Kohno T, Watanabe H, Ornitz DM, Betsuyaku T, Soejima K, Fukunaga K: Cancer Res 2021/7; 81 (14): 3916-29. (—P–؍Ž•F1: 1ŒÄ‹zŠí“ŕ)

110231. [Œ´’˜] Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer. Fukuda K, Otani S1, Takeuchi S, Arai S, Nanjo S, Tanimoto A, Nishiyama A, Naoki K1, Yano S: Cancer Sci 2021/9; 112 (9): 3784-95. (‘ĺ’JçŽq1, —P–؍Ž•F1: 1ŒÄ‹zŠí“ŕ)

110232. [Œ´’˜] A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer. Igawa S1, Kasajima M1, Ono T1, Ozawa T1, Kakegawa M1, Kusuhara S1, Sato T1, Nakahara Y1, Fukui T1, Yokoba M2, Kubota M2, Mitsufuji H3, Sasaki J4, Naoki K1: Cancer Manag Res 2021/11; 13: 8695-705. (ˆäě@‘1, Š}“‡^Žu1, Ź–ě‘ו˝1, ŹŕV‹M—T1, Š|ě–˘ŠóŽq1, “팴­ˆę˜Y1, ˛“Ą@’1, ’†Œ´‘P˜N1, •Ÿˆä•ü–ç1, ‰Ąęł“T2, ‹v•Ű“cŸ2, ŽO“Ą@‹v3, ˛X–ŘŽĄˆę˜Y4, —P–؍Ž•F1: 1ŒÄ‹zŠí“ŕ, 2ˆă—ÉqśŠw•”, 3ŠĹŒěŠw•”, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

110233. [Œ´’˜] Longitudinal Assessment of Prognostic Understanding in Patients with Advanced Lung Cancer and Its Association with Their Psychological Distress. Arai D, Sato T1, Nakachi I, Fujisawa D, Takeuchi M, Sato Y, Kawada I, Yasuda H, Ikemura S, Terai S, Nukaga S, Inoue T, Nakamura M, Oyamada Y, Terashima T, Sayama K, Saito F, Sakamaki F, Naoki K1, Fukunaga K, Soejima K: Oncologist 2021/12; 26 (12): e2265-e2273. (˛“Ą@’1, —P–؍Ž•F1: 1ŒÄ‹zŠí“ŕ)

110234. [Œ´’˜] Early-Stage Lung Adenocarcinoma MDM2 Genomic Amplification Predicts Clinical Outcome and Response to Targeted Therapy. Sinha A, Zou Y, Patel AS, Yoo S, Jiang F, Sato T1, Kong R, Watanabe H, Zhu J, Massion PP, Borczuk AC, Powell CA: Cancers (Basel) 2022/1; 14 (3): 708. (˛“Ą@’1: 1ŒÄ‹zŠí“ŕ)

110235. [Œ´’˜] Real-world evaluation of second line chemotherapy for patients with advanced non-small cell lung cancer harboring preexisting interstitial lung disease. Igawa S1, Yokoba M2, Takakura A, Hosotani S1, Nakahara Y1, Sato T1, Mitsufuji H3, Sasaki J4, Naoki K1: Invest New Drugs 2022/2; 40 (1): 182-9. (ˆäě@‘1, ‰Ąęł“T2, ×’J^Ži1, ’†Œ´‘P˜N1, ˛“Ą@’1, ŽO“Ą@‹v3, ˛X–ŘŽĄˆę˜Y4, —P–؍Ž•F1: 1ŒÄ‹zŠí“ŕ, 2ˆă—ÉqśŠw•”, 3ŠĹŒěŠw•”, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

310020. [Ç—á•ń] A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib. Haraguchi-Hashiguchi M, Sato T1, Watanabe R, Kagyo J, Matsuzaki T, Domoto H, Kato T, Nakahara Y1, Yokose T, Hiroshima Y, Shiomi T: Thorac Cancer 2021/9; 12 (18): 2504-7. (˛“Ą@’1, ’†Œ´‘P˜N1: 1ŒÄ‹zŠí“ŕ)

310021. [Ç—á•ń] Standard therapy-resistant small cell lung cancer showing dynamic transition of neuroendocrine fate during the cancer trajectory: A case report. Ito F, Sato T1, Emoto K, Kaizuka N1, Yagi K, Watanabe R, Haraguchi-Hashiguchi M, Ninomiya H, Ikematsu Y, Tanaka K, Domoto H, Shiomi T: Mol Clin Oncol 2021/12; 15 (6): 261. (˛“Ą@’1, ŠL’Ë‹XŽ÷1: 1ŒÄ‹zŠí“ŕ)

310022. [Ç—á•ń] Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation: Case Report. Haraguchi-Hashiguchi M, Sato T1, Yamamoto H1, Watanabe R, Kagyo J, Domoto H, Shiomi T: JTO Clin Res Rep 2021/12; 3 (2): 100271. (˛“Ą@’1, ŽR–{_‹M1: 1ŒÄ‹zŠí“ŕ)

[’˜@‘]

620068. [Šwp‘ (•Ş’SŽˇ•M)]y‚Ş‚ń–ƉuƒyƒfƒBƒA@ŽîᇖƉuŠwE‚Ş‚ń–Ɖu—Ă–@‚Ě‘S‚Ä‚đ‚܂邲‚Ć—‰đ!z—Տ°•Ň,@1Í ‚Ş‚ń–Ɖu—Ă–@@–Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQÜ…@ (RPD-1R‘Ě), p.24-6. —P–؍Ž•F (ŒÄ‹zŠí“ŕ), •Ň: ‹g‘ş@´, —r“yŽĐ, “Œ‹ž, 2022/2”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713036. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Platinum-Doublets as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Sato T1, Horiuchi K, Kuno T, Takagi H, Fred R Hirsch, Charles A Powell, Fukunaga K: IASLC 2021 World Conference on Lung Cancer (2021/9/13), WebŠJĂ. (˛“Ą@’1: 1ŒÄ‹zŠí“ŕ)

713037. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Clinical impact of post-progression survival on overall survival in NSCLC patients with pre-existing interstitial lung disease. Igawa S1, Yokoba M2, Takakura A, Hosotani S1, Nakahara Y1, Sato T1, Mitsufuji H3, Kubota M2, Sasaki J1,4, Naoki K1: The 25th congress of the Asian Pacific Society of Respirology (2021/11/20), Kyoto, Japan. (ˆäě@‘1, ‰Ąęł“T2, ×’J^Ži1, ’†Œ´‘P˜N1, ˛“Ą@’1, ŽO“Ą@‹v3, ‹v•Ű“cŸ2, ˛X–ŘŽĄˆę˜Y1,4, —P–؍Ž•F1: 1ŒÄ‹zŠí“ŕ, 2ˆă—ÉqśŠw•”, 3ŠĹŒěŠw•”, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

713038. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Utility of thoracoscopy under local anesthesia in the diagnosis of tuberculous pleurisy and drug susceptibility testing for tuberculosis. Manaka H1, Sato T1, Ozawa T1, Akazawa Y1, Nakano M1, Oguri A1, Sone H1, Hosotani S1, Ono T1, Harada S2, Kusuhara S1, Kasajima M1, Kakegawa M1, Nakahara Y1, Igawa S1, Yokoba M3, Sasaki J1,4, Kubota M3, Mitsufuji H5, Naoki K1: The 25th Congress of the Asian Pacific Society of Respirology (APSR 2021) (2021/11/20-21), Kyoto, Japan (ƒnƒCƒuƒŠƒbƒhŠJĂ). (ŠÔ’†”Ž–ç1, ˛“Ą@’1, ŹŕV‹M—T1, ÔŕV—IŠó1, ’†–ě^śl1, ŹŒI–žl1, ‘]Ş‰p”V1, ×’J^Ži1, Ź–ě‘ו˝1, Œ´“c^–ç2, “팴­ˆę˜Y1, Š}“‡^Žu1, Š|ě–˘ŠóŽq1, ’†Œ´‘P˜N1, ˆäě@‘1, ‰Ąęł“T3, ˛X–ŘŽĄˆę˜Y1,4, ‹v•Ű“cŸ3, ŽO“Ą@‹v5, —P–؍Ž•F1: 1ŒÄ‹zŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ÉqśŠw•”, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 5ŠĹŒěŠw•”)

713039. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Evaluation of atezolizumab monotherapy for chemotherapy-refractory patients with non-small cell lung cancer in clinical practice. Kasajima M1, Igawa S1, Katagiri M2, Kubota M2, Sasaki J1,3, Mitsuhuji H4, Yokoba M2, Sato T1, Nakahara Y1, Kakegawa M1, Kusuhara S1, Harada S5, Ozawa T1, Ono T1, Kurata T1, Naoki K1: The 25th Congress of the Asian Pacific Society of Respirology (APSR 2021) (2021/11/20-21), Kyoto, Japan (ƒnƒCƒuƒŠƒbƒhŠJĂ). (Š}“‡^Žu1, ˆäě@‘1, •Đ‹Ë^l2, ‹v•Ű“cŸ2, ˛X–ŘŽĄˆę˜Y1,3, ŽO“Ą@‹v4, ‰Ąęł“T2, ˛“Ą@’1, ’†Œ´‘P˜N1, Š|ě–˘ŠóŽq1, “팴­ˆę˜Y1, Œ´“c^–ç5, ŹŕV‹M—T1, Ź–ě‘ו˝1, ‘q“c‘ń“l1, —P–؍Ž•F1: 1ŒÄ‹zŠí“ŕ, 2ˆă—ÉqśŠw•”, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4ŠĹŒěŠw•”, 5‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

721010. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ”ńŹ×–E”x‚Ş‚ń‚Ě•ŞŽq•W“IŽĄ—ÂƖƉu—Ă–@. —P–؍Ž•F (ŒÄ‹zŠí“ŕ): ‘ć22‰ń“ú–{ŠŕŽĄ—ĂŠw‰ďƒAƒbƒvƒf[ƒg‹łˆçƒR[ƒX (2021/6/19), WebŠJĂ.

722085. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) With Corona‘OŒă‚Ĺ‚Ě“–‰@‹CŠÇŽx‹žŒŸ¸‚̕ωť. •Ÿˆä•ü–ç1, ŽR“cŒO—œ1, ŹŒI–žl1, ‹T“c–ƒĘŽŔ1, ”ޏă—L—˘1, ‘]Ş‰p”V1, ™“cŒi—C, Ź–ě‘ו˝1, ŹŕV‹M—T1, “팴­ˆę˜Y1, Š|ě–˘ŠóŽq1, Š}“‡^Žu1, ˆäě@‘1, ‰Ąęł“T2, ŽO“Ą@‹v3, ‹v•Ű“cŸ2, —P–؍Ž•F1 (1ŒÄ‹zŠí“ŕ, 2ˆă—ÉqśŠw•”, 3ŠĹŒěŠw•”): ‘ć44‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ďŠwpW‰ď (2021/6/24), –źŒĂ‰Ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723193. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) EGFRˆâ“`Žq•ĎˆŮ—zŤ”ńŹ×–E”xŠŕŠłŽŇ‚Ö‚ĚƒAƒtƒ@ƒ`ƒjƒuŽĄ—Âɂ‚˘‚Ä‚ĚŒŸ“˘. ”ޏă—L—1, ˆäě@‘1, Ź–ě‘ו˝1, Š|ě–˘ŠóŽq1, Š}“‡^Žu1, •Ÿˆä•ü–ç1, ŽO“Ą@‹v2, ‹v•Ű“cŸ3, ˛X–ŘŽĄˆę˜Y1,4, —P–؍Ž•F1 (1ŒÄ‹zŠí“ŕ, 2ŠĹŒěŠw•”, 3ˆă—ÉqśŠw•”, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć61‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď (2021/4/23), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723194. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠÔŽżŤ”x‰Š‚ސćs‚ľ‚˝RSignal recognition particle (SRP) R‘Ě—zŤ‰óŽ€Ť‹Ř‰Š‚Ěˆę—á. “í–{—ł–ç, ‰ŞX@Œd, ‘ŕVŒ[‘ž, ’Š‘q’“ż, m‰Č@’ź, ’†”Ťł‘ž˜Y, Îˆä@˝, —P–؍Ž•F1, •Ÿ‰i‹ťˆë (1ŒÄ‹zŠí“ŕ): ‘ć61‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď (2021/4/23), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723195. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”xŠŕ‚É‚¨‚Ż‚éƒtƒRƒVƒ‹‰ť‚̐§Œä‹@\‹y‚Ń‹@”\‰đÍ. ‘ŕVŒ[‘ž, ˆŔ“c_”V, ™‰Y—I‹B, ź“cŒúŽu, ]–{@Œj, Ž›ˆäGŽ÷, •l–{ƒŽq, ‰ÁěŽu’ĂŽq, rˆä‘ĺ•ă, ˛“Ą@’1, â–{‹œ‰F, ––ź@˝, •›“‡Œ¤‘˘, •Ÿ‰i‹ťˆë (1ŒÄ‹zŠí“ŕ): ‘ć61‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď (2021/4/23), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723196. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Ä”­Ź×–E”xŠŕ‚ɑ΂ˇ‚é“ńŽŸŽĄ—Ă‚É‚¨‚Ż‚éƒvƒ‰ƒ`ƒi•š—p‰ťŠw—Ă–@‚Ě—LŒřŤ‚ĚŒŸ“˘: ƒƒ^‰đÍ‚ĆƒVƒXƒeƒ}ƒeƒBƒbƒNEƒŒƒrƒ…[. –x“ŕN•˝, ˛“Ą@’1, H–ěrŽ÷, ‚–ŘŽől, ‰Ş“c^•F, âV“ĄĘ‰Ä, •Ÿ“‡‹M‘ĺ, ŽÂč‘ž˜Y, ŒÓ’JrŽ÷, ŒőÎ•jŽj, ™Œ´@‰ő, ’|Œ´•üG, ’r‘ş’C”V‰î, Ž›ˆäGŽ÷, ˆŔ“c_”V, ě“cˆę˜Y, Charles A Powell, •Ÿ‰i‹ťˆë, •›“‡Œ¤‘˘ (1ŒÄ‹zŠí“ŕ): ‘ć61‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď (2021/4/23), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723197. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚Ĺ‚ĚROS1—Z‡ˆâ“`Žq—zŤ”xŠŕ‚ĚŒoŒą. ‰Ş“c^•F, ’r‘ş’C”V‰î, ˛“Ą@’1, ’†ěŒ´ŒŤ—ş, ‹´Œű…—t, âV“ĄĘ‰Ä, •Ÿ“‡‹M‘ĺ, ŽÂč‘ž˜Y, –x“ŕN•˝, ™Œ´@‰ő, ŒőÎ•jŽj, ŒÓ’JrŽ÷, ’|Œ´•üG, Ž›ˆäGŽ÷, ˆŔ“c_”V, ě“cˆę˜Y, •›“‡Œ¤‘˘, •Ÿ‰i‹ťˆë (1ŒÄ‹zŠí“ŕ): ‘ć61‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď (2021/4/25), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723198. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) f’f‚¨‚ć‚ŃŠ´ŽóŤŒŸ¸–Ú“I‚ɋǏŠ–ƒŒ‰ş‹šo‹žŒŸ¸‚đs‚Á‚˝Œ‹ŠjŤ‹š–Œ‰Š‚Ě—Ő°“IŒŸ“˘. ŹŒI–žl1, ŹŕV‹M—T1, ŽO“Ą@‹v2, ŽR“cŒO—œ1, ‹T“c–ƒĘ”ü1, ”ޏă—L—˘1, “팴­ˆę˜Y1, Œ´“c^–ç3, •Ÿˆä•ü–ç1, ˆäě@‘1, ‰Ąęł“T4, •Đ‹Ë^l4, —P–؍Ž•F1 (1ŒÄ‹zŠí“ŕ, 2ŠĹŒěŠw•”, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4ˆă—ÉqśŠw•”): ‘ć61‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠwpu‰‰‰ď (2021/4/25), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723199. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) isäXŠŕ‚Ěáu’ɂɑ΂ľ‚ÄŽ{ÝŠÔ˜AŒg‚É‚ć‚č• o_Œo‘pƒuƒƒbƒN‚đs‚Á‚Äáu’ɃRƒ“ƒgƒ[ƒ‹‚đ“ž‚˝ˆę—á. ˆé–ě‰iˆË, ěč—R‰Ř, ˛“Ą@’1, ‚‹´‚Ý‚Č‚Ý, ŹŕV—L‹P, ŠO‰€–퐜, •‚“cšŽq, —с@–€–ë (1ŒÄ‹zŠí“ŕ): ‘ć26‰ń“ú–{ŠÉ˜aˆă—ĂŠw‰ďŠwp‘ĺ‰ď (2021/6/18), ‰Ą•l.

723200. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) is”x‚Ş‚ńŠłŽŇ‹y‚щƑ°‚Ş•ř‚Ś‚é–â‘č‚ɑ΂ˇ‚éƒXƒNƒŠ[ƒjƒ“ƒO‚ĆŠÉ˜aƒPƒA‚ĚŽć‚č‘g‚Ý. •‚“cšŽq, ˛“Ą@’1, ‘ě’źŽq, ŠL’Ë‹XŽ÷1, ˆÉ“ĄO‹I1, ‰Ás~Žq, ‰–ŒŠ“N–ç, ‹´Œű…—t, ‚‹´‚Ý‚Č‚Ý, ěč—R‰Ř, ŹŕV—L‹P, ˆé–ě‰iˆË (1ŒÄ‹zŠí“ŕ): ‘ć26‰ń“ú–{ŠÉ˜aˆă—ĂŠw‰ďŠwp‘ĺ‰ď (2021/6/18), ‰Ą•l.

723201. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹CŠÇŽx‹žŒŸ¸‚ĹCPPA‹y‚ŃABPA‚̐f’f‚ÉŽŠ‚Á‚˝ˆę—á. ‘]Ş‰p”V1, ŽO“Ą@‹v2, Ź–ě‘ו˝1, ’†–ě^śl1, ÔŕV—IŠó1, ŹŒI–žl1, ŽR“cŒO—œ1, ‹T“c–ƒĘŽŔ1, ™“cŒi—C, ŹŕV‹M—T1, Œ´“c^–ç3, “팴­ˆę˜Y1, Š|ě–˘ŠóŽq1, Š}“‡^Žu1, •Ÿˆä•ü–ç1, ˆäě@‘1, ‹v•Ű“cŸ4, —P–؍Ž•F1 (1ŒÄ‹zŠí“ŕ, 2ŠĹŒěŠw•”, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4ˆă—ÉqśŠw•”): ‘ć44‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ďŠwpW‰ď (2021/6/24-7/30) –źŒĂ‰Ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723202. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘Šú”x‘BŠŕŠłŽŇ‚É‚¨‚Ż‚éNAP1L1”­Œť‚Ě—\Œă—\‘ރ}[ƒJ[‚Ć‚ľ‚Ä‚Ě—L—pŤ‚ɂ‚˘‚Ä. ’ˇ‰–@—ş1, ‹€’Ă—L‹I1, ˆäě@‘2, “팴­ˆę˜Y2, —P–؍Ž•F2, ˛“Ą”Vr3, ˆęŒËš–ž4, ‘ş‰_–FŽ÷4, ŽOŽ}@M4, ˛“Ą—Yˆę1 (1ˆă—ÉqśŠw•”, 2ŒÄ‹zŠí“ŕ, 3ŒÄ‹zŠíŠO, 4•a—): ‘ć72‰ń“ú–{“d‹C‰j“ŽŠw‰ď‘‰ď (2021/7/15), WebŠJĂ.

723203. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”ńŹ×–E”x‚Ş‚ń‚É‚¨‚Ż‚épŒă•â•‰ťŠw—Ă–@Œř‰Ę—\‘ރ}[ƒJ[‚Ć‚ľ‚Ä‚ĚTRAP1‚Ě—L—pŤ‚ɂ‚˘‚Ä. ‹€’Ă—L‹I1, ˆäě@‘2, “팴­ˆę˜Y2, —P–؍Ž•F2, “y‰Žg1, ˛“Ą”Vr3, ˆęŒËš–ž4, ‘ş‰_–FŽ÷4, ŽOŽ}@M4, ˛“Ą—Yˆę1, ’ˇ‰–@—ş1 (1ˆă—ÉqśŠw•”, 2ŒÄ‹zŠí“ŕ, 3ŒÄ‹zŠíŠO, 4•a—)‘ć72‰ń“ú–{“d‹C‰j“ŽŠw‰ď‘‰ď (2021/7/16), WebŠJĂ.

723204. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”x‘BŠŕ‚̏Ź×–EŠŕ“]‰ť‚ÉFGF9‚ŞŠÖ—^‚ˇ‚é. •l–{ƒŽq, ˆŔ“c_”V, Î‰ŞG‘ž, Ž›ˆäGŽ÷, ]–{@Œj, ŽO–qK‘ă, rˆä‘ĺ•ă, ‘ŕVŒ[‘ž, ě“cˆę˜Y, —P–؍Ž•F1, “yŒ´ˆęĆ, Ź—с@i, ‰Í–ě—˛Žu, •›“‡Œ¤‘˘ (1ŒÄ‹zŠí“ŕ): ‘ć80‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď (2021/10/1), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723205. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠÔŽżŤ”x‰Š‡•šis”ńŹ×–E”xŠŕŠłŽŇ‚ɑ΂ˇ‚é2ŽŸ‰ťŠw—Ă–@‚ɂ‚˘‚Ä‚ĚŒŸ“˘. ×’J^Ži1, ˆäě@‘1, ‚‘q@W, ŽR“cŒO—œ1, ‹T“c–ƒĘ”ü1, ‘]Ş‰p”V1, Ź–ě‘ו˝1, ŹŕV‹M—T1, Œ´“c^–ç2, “팴­ˆę˜Y1, Š}“‡^Žu1, Š|ě–˘ŠóŽq1, ’†Œ´‘P˜N1, ˛“Ą@’1, ŽO“Ą@‹v3, ‰Ąęł“T4, ‹v•Ű“cŸ4, •Đ‹Ë^l, ˛X–ŘŽĄˆę˜Y1,5, —P–؍Ž•F1 (1ŒÄ‹zŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ŠĹŒěŠw•”, 4ˆă—ÉqśŠw•”, 5V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć62‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ď (2021/11/26), ‰Ą•l.

723206. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) EchoTip ProCore (Ecotip) ‚¨‚ć‚Ńmodified slow-pull–@ (MSP) ‚đ—p‚˘‚˝EBUS-TBNA‚ĚŒŸ“˘: ĹI•ń. ‹{č˜al, ŽÄ@@ˆť, ˆ˘‰ÍšŽĄ, ŕ_ě˜Đ‰î, ’JŒű—F—, ŽOŠp—Sś, ăŒŠ—tŽq, ‰şěPś, —P–؍Ž•F1, ‰Ş–{_–ž (1ŒÄ‹zŠí“ŕ): ‘ć62‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ď (2021/11/28), ‰Ą•l.

723207. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) MET exon 14 skipping—zŤ”x‘BŠŕ‚ɑ΂ľ‚ăJƒvƒ}ƒ`ƒjƒu‚ĹŠÔŽżŤ”x‰Š‚𐜂ś, ‰ü‘PŒăƒeƒ|ƒ`ƒjƒu‚đ“Š—^‚ľ‚˝ˆę—á. ŽR–{_‹M1, ‹´Œű…—t, ˛“Ą@’1, ŕ_粌’‘˝, áÁ糉p–ž1, ˆÉ“ĄO‹I1, ‰Ás~Žq, ‰–ŒŠ“N–ç (1ŒÄ‹zŠí“ŕ): ‘ć62‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ď (2021/11/27), ‰Ą•l.

723208. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) FGF9‚É‚ć‚é”x‘BŠŕ‚̏Ź×–EŠŕ‰ť‚ÉŠÖ‚ˇ‚錟“˘. Î‰ŞG‘ž, ˆŔ“c_”V, •l–{ƒŽq, Ž›ˆäGŽ÷, rˆä‘ĺ•ă, î–ěŒ\Žq, ’J@“N•v, ‘ŕVŒ[‘ž, ^“çˆŰŽu, ŽÂč‘ž˜Y, ŒőÎ•jŽj, ŒÓ’JrŽ÷, •Ÿ“‡‹M‘ĺ, ’r‘ş’C”V‰î, ě“cˆę˜Y, —P–؍Ž•F1, ‘ĺ’ˁ@’, ŸÇ‘şŽś, •›“‡Œ¤‘˘, •Ÿ‰i‹ťˆë (1‹zŠí“ŕ): ‘ć62‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ď (2021/11/28), ‰Ą•l.

723209. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) A rP2 study comparing Nivo with CBDCA-PEM for EGFRm NSCLC acquired TKI-resistance not due to T790M (WJOG8515L). ’†‘ş@“Ö, —с@G•q, ă‘ş„‘ĺ, Œő‰Ş–ÎŽ÷, ˆÉ“ĄŒ’‘ž˜Y, “ŕ“cƒ“ń, “c‘ş—m•ă, Šâ–{N’j, ‰Ť@š‰p, –k‰€@‘, ’ˇ’JěŠěˆę, ‹v•Űşm, —P–؍Ž•F1, ’r“c@Œd, “n粌i–ž, ç—tNŒh, âˆä˜aŽq, ź”ö˜al, ŽR–{M”V, ’†ě˜a•F (1ŒÄ‹zŠí“ŕ): ‘ć19‰ń“ú–{—Տ°Žîᇊw‰ďŠwpW‰ď (2022/2/17), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723210. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Longitudinal evaluation of prognostic understanding and its associated factors in patients with advanced lung cancer. rˆä‘ĺ•ă, ˛“Ą@’1, ’‡’nˆę˜Y, “ĄŕV‘ĺ•ă, ’|“ŕ–ƒ—˘, ˛“Ą‘׌›, ě“cˆę˜Y, ˆŔ“c_”V, ’r‘ş’C”V‰î, Ž›ˆäGŽ÷, ˆäă@‘ě, ’†‘şŽç’j, ŹŽR“c‹gF, Ž›“ˆ@‹B, ˛ŽRGˆę, âV“ĄŽj•, âŠŞ•ś—Y, —P–؍Ž•F1, •Ÿ‰i‹ťˆë, •›“‡Œ¤‘˘ (1ŒÄ‹zŠí“ŕ): ‘ć19‰ń“ú–{—Տ°Žîᇊw‰ďŠwpW‰ď (2022/2/19), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723211. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Change in plasma level of damage-associated molecular patterns due to chemoradiotherapy in locally advanced NSCLC. ’†Œ´‘P˜N1, Ö“Ąt—m, g˜I@‘ń, •XŽşG’m, —P–؍Ž•F1, ů“c“N˜N (1ŒÄ‹zŠí“ŕ): ‘ć19‰ń“ú–{—Տ°Žîᇊw‰ďŠwpW‰ď (2022/2/17-19), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733062. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒyƒ“ƒuƒƒŠƒYƒ}ƒu‚É‚ć‚é‘ĺ’°‰Š‚ɑ΂ľ‚ăCƒ“ƒtƒŠƒLƒVƒ}ƒu‚Ě“Š—^‚Ş—LŒř‚Ĺ‚ ‚Á‚˝1—á. ŽR“cŒO—œ1, Ź–ě‘ו˝1, ‘q“c‘ń“l1, ’†–ě^śl1, ÔŕV—IŠó1, ‹T“c–ƒĘŽŔ1, ŠÔ’†”Ž–ç1, ‘]Ş‰p”V1, ×’J^Ži1, ŹŕV‹M—T1, “팴­ˆę˜Y1, Š}“‡^Žu1, Š|ě–˘ŠóŽq1, ’†Œ´‘P˜N1, ˛“Ą@’1, ˆäě@‘1, ˆäě@‘1, ŽO“Ą@‹v2, ˛X–ŘŽĄˆę˜Y1,3, ‹v•Ű“cŸ4, —P–؍Ž•F1 (1ŒÄ‹zŠí“ŕ, 2ŠĹŒěŠw•”, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4ˆă—ÉqśŠw•”): ‘ć190‰ń“ú–{”xŠŕŠw‰ďŠÖ“ŒŽx•”ŠwpW‰ď (2021/7/3), WebŠJĂ.

733063. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) TrousseauÇŒóŒQ‚𔺂¤ALK—zŤ”xG•˝ă”çŠŕ‚ɃAƒŒƒNƒ`ƒjƒu‚Ş’ˇŠú‚É‘tŒř‚ľ‚˝1—á. ‘q“c‘ń“l1, ’†Œ´‘P˜N1, ’†–ě^śl1, ÔŕV—IŠó1, ‹T“c–ƒĘŽŔ1, ŽR“cŒO—œ1, ŹŒI–žl1, áÁ粉p–ž1, ”ޏă—L—˘1, ŽR–{_‹M1, ˆÉ“ĄO‹I1, ŠÔ’†”Ž–ç1, ŠL’ːéŽ÷1, ‘]Ş‰p”V1, ×’J^Ži1, Ź–ě‘ו˝1, ŹŕV‹M—T1, Œ´“c^–ç2, “팴­ˆę˜Y1, Š}“‡^Žu1, Š|ě–˘ŠóŽq1, ˛“Ą@’1, ˆäě@‘1, ‰Ąęł“T3, ŽO“Ą@‹v4, ˛X–؍_ˆę˜Y1,5, ‹v•Ű“cŸ3, •Đ‹Ë^l3, ŽOŽ}@M6, —P–؍Ž•F1 (1ŒÄ‹zŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ÉqśŠw•”, 4ŠĹŒěŠw•”, 5V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 6•a—): ‘ć190‰ń“ú–{”xŠŕŠw‰ďŠÖ“ŒŽx•”ŠwpW‰ď (2021/7/3), WebŠJĂ.

733064. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Ź×–E”xŠŕ‚Ö‚Ě“]‰ť‚đ”F‚ß, ÄśŒŸ‚đŒJ‚č•Ô‚ľŽĄ—Ð헪‚𗧂Ă鎖‚Ĺ’ˇŠúś‘ś‚đ“ž‚˝EGFR—zŤ”x‘BŠŕ‚Ěˆę—á. ÔŕV—IŠó1, ’†Œ´‘P˜N1, ’†–ě^śl1, ‘q“c‘ń“l1, ‹T“c–ƒĘŽŔ1, ŽR“cŒO—œ1, ŹŒI–žl1, áÁ粉p–ž1, ”ޏă—L—˘1, ŽR–{_‹M1, ˆÉ“ĄO‹I1, ŠÔ’†”Ž–ç1, ŠL’ːéŽ÷1, ‘]Ş‰p”V1, ×’J^Ži1, Ź–ě‘ו˝1, ŹŕV‹M—T1, Œ´“c^–ç2, “팴­ˆę˜Y1, Š}“‡^Žu1, Š|ě–˘ŠóŽq1, ˛“Ą@’1, ˆäě@‘1, ‰Ąęł“T3, ŽO“Ą@‹v4, ˛X–ŘŽĄˆę˜Y1,5, ‹v•Ű“cŸ3, •Đ‹Ë^l3, —P–؍Ž•F1, ŽOŽ}@M6 (1ŒÄ‹zŠí“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ÉqśŠw•”, 4ŠĹŒěŠw•”, 5V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 6•a—): ‘ć247‰ń“ú–{ŒÄ‹zŠíŠw‰ďŠÖ“Œ’n•ű‰ď (2021/11/6), H—tŒ´ (ƒnƒCƒuƒŠƒbƒhŠJĂ).


“ŕ•Ş”ĺ‘ăŽÓ“ŕ‰ČŠw

[Šwp˜_•ś]

110236. [Œ´’˜] The effectiveness of growth hormone replacement on energy expenditure and body composition in patients with adult growth hormone deficiency. Momozono A1, Hayashi A1, Takano K1, Shichiri M1: Endocr J 2021/4; 68 (4): 469-75. (“‰€@–ž1, —с@“N”Í1, ‚–ěK˜H1, Žľ—˘áÁ‹`1: 1“ŕ•Ş”ĺ‘ăŽÓ“ŕ)

110237. [Œ´’˜] Circulating prorenin: its molecular forms and plasma concentrations. Fujimoto K1, Kawamura S1, Bando S2, Kamata Y1, Kodera Y, Shichiri M1: Hypertension Research 2021/6; 44 (6): 674-84. (“Ą–{˜aŽŔ1, ě‘şš—FŠó1, â“Œ@Œd2, Š™“c—T“ń1, Žľ—˘áÁ‹`1: 1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110238. [Œ´’˜] Effects of luseogliflozin on the secretion of islet hormones and incretins in patients with type 2 diabetes. Bando S1, Ichikawa R2, Taguchi T2, Fujimoto K2, Motomiya T, Taguchi M, Takano K2, Shichiri M2, Miyatsuka T2: Endocr J 2022/6; 69 (6): 681-7. (â“Œ@Œd1, Žsě—‹Žt2, “cŒű@•ü2, “Ą–{˜aŽŔ2, ‚–ěK˜H2, Žľ—˘áÁ‹`2, ‹{’ˁ@Œ’2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2“ŕ•Ş”ĺ‘ăŽÓ“ŕ)

110239. [Œ´’˜] Hemodialysis-Related Glycemic Disarray Proven by Continuous Glucose Monitoring; Glycemic Markers and Hypoglycemia. Hayashi A1, Shimizu N1, Suzuki A1, Matoba K1, Momozono A1, Masaki T1, Ogawa A1, Moriguchi I, Takano K1, Kobayashi N, Shichiri M1: Diabetes Care 2021/7; 44 (7): 1647-56. (—с@“N”Í1, ´…‡–ç1, —é–Řă–ź1, “IęŒ’‘ž1, “‰€@–ž1, ł–ŘŽkl1, ŹěŒ°Žj1, ‚–ěK˜H1, Žľ—˘áÁ‹`1: 1“ŕ•Ş”ĺ‘ăŽÓ“ŕ)

110240. [Œ´’˜] GIP_HUMAN[22-51] is a new proatherogenic peptide identified by native plasma peptidomics. Masaki T1, Kodera Y, Terasaki M, Fujimoto K1, Hirano T, Shichiri M1: Sci Rep 2021/7; 11 (1): 14470. (ł–ŘŽkl1, “Ą–{˜aŽŔ1, Žľ—˘áÁ‹`1: 1“ŕ•Ş”ĺ‘ăŽÓ“ŕ)

110241. [Œ´’˜] Pill Counting in the Determination of Factors Affecting Medication Adherence in Patients with Type 2 Diabetes: A Retrospective Observational Study. Shiomi M, Kurobuchi M, Tanaka Y, Takada T1, Otori K: Diabetes Ther 2021/7; 12 (7): 1993-2005. (‚“c“NG1: 1“ŕ•Ş”ĺ‘ăŽÓ“ŕ)

110242. [Œ´’˜] Increased glycated albumin levels in patients with acromegaly related to glucose fluctuation caused by growth hormone excess but not albumin metabolism. Taguchi T1, Suzuki A1, Takano K1: Endocr J 2022/3; 69 (3): 225-33. (“cŒű@•ü1, —é–Řă–ź1, ‚–ěK˜H1: 1“ŕ•Ş”ĺ‘ăŽÓ“ŕ)

310023. [Ç—á•ń] Improved AcroQoL scores in acromegaly after sagittal split ramus osteotomy with Le Fort I osteotomy. Taguchi T1, Kimizuka S2, Takano K1: Endocrinol Diabetes Metab Case Rep 2021/4; 2021: 21-0001. (“cŒű@•ü1, ŒN’ˍKŽq2, ‚–ěK˜H1: 1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2Œ`ŹE”üŠO)

310024. [Ç—á•ń] A case of adrenocortical adenoma harboring venous thrombus mimicking adrenal malignancy. Suzuki A1, Kamata Y1, Taguchi T1, Takano K1, Yamazaki Y, Sasano H, Shichiri M1: Endocr J 2021/7; 68 (7): 857-63. (—é–Řă–ź1, Š™“c—T“ń1, “cŒű@•ü1, ‚–ěK˜H1, Žľ—˘áÁ‹`1: 1“ŕ•Ş”ĺ‘ăŽÓ“ŕ)

522056. [uŔ]y˘ŠE‚ĚˆăŠwŽ‚Š‚çz2Œ^“œ”A•aŠłŽŇ‚Ö‚ĚT1‰ńƒCƒ“ƒXƒŠƒ“ťÜŒŒ“œ~‰şě—p‚ĆˆŔ‘SŤ‚Í1“ú1‰ń‚Ć“Ż“™. —с@“N”Í (“ŕ•Ş”ĺ‘ăŽÓ“ŕ): The Mainichi Medical Journal 2021; 17 (2): 50.

[’˜@‘]

620069. [Šwp‘ (•Ş’SŽˇ•M)]y•a‹C‚Ć‚­‚ˇ‚č2021 Šî‘b‚ĆŽŔ‘H Expert's Guide (–ň‹Ç2021”N‘Š§Vol.72 No.4)z7 ‘ăŽÓ“ŕ•Ş”ĺŒn‚Ě•a‹C‚Ć‚­‚ˇ‚č@A ‘ăŽÓŒnŽžŠł@“œ”A•a (‡•šÇ‚đŠÜ‚Ţ), p.902-17. —с@“N”Í1, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ), “ěŽR“°, “Œ‹ž, 2021/4”­s.

620070. [Šwp‘ (•Ş’SŽˇ•M)]y”D•w‚Ě“œ‘ăŽÓˆŮí f—ÁEŠÇ—ƒ}ƒjƒ…ƒAƒ‹ ‘ć3”ŁzII ”DP’†‚ĚŠÇ—@11. ŒŒ“œŽŠŒČ‘Ş’č (SMBG) ‚Ƃ͉˝‚Ĺ‚ˇ‚Š?, p.94-7. 12. ŒŒ“œŽŠŒČ‘Ş’č (SMBG) ‚Ě‚Ć‚Ť, ‹C‚đ•t‚Ż‚é‚ą‚Ć‚Í?, p.98-100. Žsě—‹Žt (“ŕ•Ş”ĺ‘ăŽÓ“ŕ), •Ň: “ú–{“œ”A•aE”DPŠw‰ď, ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, “Œ‹ž, 2021/12”­s.

620071. [Šwp‘ (•Ş’SŽˇ•M)]y‚¨–ň—§‚żBOOK2022@‰đ–Uś—E•a‘Ԑś—‚Š‚ç–ňŠwŠÇ—‚Ö (–ň‹Ç2022”N‘Š§Vol. 73 No.4)zĄ‘ăŽÓŒn, “ŕ•Ş”厞Šł@30. “œ”A•a (1Œ^“œ”A•a, 2Œ^“œ”A•a, ”DP“œ”A•a, ‡•šÇ), p.547-61. —с@“N”Í (“ŕ•Ş”ĺ‘ăŽÓ“ŕ), “ěŽR“°, “Œ‹ž, 2022/3”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

723212. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚Őf’fEŽĄ—Ă‚ľ‚˝bó‘BƒNƒŠ[ƒ[‚Ě—Ő°“I“Á’Ľ. ŻŽRˆťŽq1, Š™“c—T“ń1, ´…‡–ç1, —é–؍V–ź1, “Ą“ˆ@—ŕ1, “cŒű@•ü1, —é–Ř—z•F1, ł–ŘŽkl1, ‚–ěK˜H1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć94‰ń“ú–{“ŕ•Ş”ĺŠw‰ďŠwp‘‰ď (2021/4/22), WebŠJĂ.

723213. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒqƒgŒŒŸ÷ƒyƒvƒ`ƒhƒ~ƒNƒX‚É‚ć‚éƒXƒvƒ‰ƒoƒVƒ“—R—ˆV‹Kś—ŠˆŤƒyƒvƒ`ƒh‚Ě“Ż’č. “cŒű@•ü1, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć94‰ń“ú–{“ŕ•Ş”ĺŠw‰ďŠwp‘‰ď (2021/4/22-24), WebŠJĂ, “ú–{“ŕ•Ş”ĺŠw‰ďŽGŽ, 2021/4; 97 (1): 229.

723214. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Basal-BolusŽĄ—Ă’†2Œ^“œ”A•aŒŒ‰t“§ÍŠłŽŇ‚É‚¨‚Ż‚铧ÍŠÖ˜A’ጌ“œƒŠƒXƒN‚ĚŒŸ“˘. —с@“N”Í1, ´…‡–ç1, “IęŒ’‘ž1, XŒű‚˘‚Ô‚Ť, ‚–ěK˜H1, Ź—Ń’ź”V, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć64‰ń“ú–{“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (2021/5/20-22), WebŠJĂ, “œ”A•a 2021/4; 64 (Suppl): S-241.

723215. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚éƒRƒƒi‰Đ‚Ĺ‚Ě“œ”A•a‹Ů‹}“ü‰@ŠłŽŇ‚ĚŒŸ“˘. “Ą“ˆ@—ŕ1, —с@“N”Í1, ’ҁ@@˜_1, ˆę“‡—R‰ÁŽq1, ‘ş“cH•ä, —é–Ř—z•F1, ź‰Y—˘]2, Š™“c—T“ń1, ‚–ěK˜H1, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2‘‡f—Ă): ‘ć64‰ń“ú–{“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (2021/5/20-22), WebŠJĂ, “œ”A•a 2021/4; 64 (Suppl): S-258.

723216. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Sensor Augmented Pump (SAP) —Ă–@’†‚Ě1Œ^“œ”A•aŠłŽŇ‚É‚¨‚Ż‚éVŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´őÇ (COVID-19) —Źs‚̉e‹ż. —é–؍V–ź1, —с@“N”Í1, –Ř‘ş—˘1, Źă–ž—˘ŠG2, •ě’mŽq1, ”’ě—‰i1, Žsě—‹Žt1, ‚–ěK˜H1, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2‘‡f—Ă): ‘ć64‰ń“ú–{“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (2021/5/20-22), WebŠJĂ, “œ”A•a 2021/4; 64 (Suppl): S-285.

723217. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŒŒ‰t“§ÍŠłŽŇ‚ĚTIR‚ÍHbA1c, ƒOƒŠƒRƒAƒ‹ƒuƒ~ƒ“‚Ć‘ŠŠÖ‚ˇ‚é‚Ě‚Š. ´…‡–ç1, —с@“N”Í1, œAŁłr1, Ź“c@Œd1, “yŠň‘ě–ç2, ŹěŒ°Žj1, XŒű‚˘‚Ô‚Ť, Ź—Ń’ź”V, ‚–ěK˜H1, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2‘‡f—Ă): ‘ć64‰ń“ú–{“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (2021/5/20-22), WebŠJĂ, “œ”A•a 2021/4; 64 (Suppl): S-320.

723218. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŒŒ‰t“§ÍŠłŽŇ‚É‚¨‚Ż‚éCGM‚ĆFGM‚Ĺ‚Ý‚˝TIR‚̍ˇ‚ĚŒŸ“˘. “IęŒ’‘ž1, —с@“N”Í1, ł–ŘŽkl1, ě‘şš—FŠó1, â“Œ@Œd2, XŒű‚˘‚Ô‚Ť, Ź—Ń’ź”V, ‚–ěK˜H1, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć64‰ń“ú–{“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (2021/5/20-22), WebŠJĂ, “œ”A•a 2021/4; 64 (Suppl): S-321.

723219. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “œ”A•aŤtÇ‹łŽşŽóuŽŇ‚É‚¨‚Ż‚錌‰t“§Í“ą“ü‚ÉŽŠ‚éÇ—á‚Ě“Á’Ľ. —é–Ř—z•F1, —с@“N”Í2, Žç‰Ž’B”ü3 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2—ŐŒŸŠw, 3Œ’NŠÇ—ƒZ): ‘ć64‰ń“ú–{“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (2021/5/20-22), WebŠJĂ.

723220. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) CGM‚É‚ć‚é2Œ^“œ”A•aŒŒ‰t“§ÍŠłŽŇ‚ĚŒŒ“œ“Ž‘Ԃ̉đ–ž: “§ÍŠÖ˜A’ጌ“œ‚Ě•p“x‚Ć‚ť‚Ě—Ő°“I“Á’Ľ‚Ć‚Í? —с@“N”Í1, ´…‡–ç1, —é–؍V–ź1, “IęŒ’‘ž1, “‰€@–ž1, ł–ŘŽkl1, ŹěŒ°Žj1, XŒű‚˘‚Ô‚Ť, ‚–ěK˜H1, Ź—Ń’ź”V, Žľ—˘áÁ‹`1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć36‰ń“ú–{“œ”A•a‡•šÇŠw‰ďE‘ć27‰ń“ú–{“œ”A•aŠáŠw‰ď‘‰ď (2021/10/8-9), Ž ‰ę (ƒnƒCƒuƒŠƒbƒhŠJĂ), “œ”A•a‡•šÇ 2021/9; 35 (Suppl): 232.

723221. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚Őf’fEŽĄ—Ă‚ľ‚˝bó‘BƒNƒŠ[ƒ[‚Ě—Ő°“I“Á’Ľ. ŻŽRˆťŽq1, Š™“c—T“ń1, ´…‡–ç1, —é–؍V–ź1, “Ą“ˆ@—ŕ1, “cŒű@•ü1, —é–Ř—z•F1, ł–ŘŽkl1, Žsě—‹Žt1, ‚–ěK˜H1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć64‰ń“ú–{bó‘BŠw‰ďŠwpW‰ď (2021/11/18-20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{“ŕ•Ş”ĺŠw‰ďŽGŽ 2021; 97 (5): 1132.

723222. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) RIA–@‚ĆCLEIA–@‚É‚¨‚Ż‚錌Ÿ÷ƒAƒ‹ƒhƒXƒeƒƒ“”Z“x‚Ě‘ŠŠÖŤ‚ĚŒŸ“˘. Ź“c@Œd1, “cŒű@•ü1, ŻŽRˆťŽq1, —é–Ř—z•F1, ł–ŘŽkl1, Žsě—‹Žt1, Š™“c—T“ń1, ‚–ěK˜H1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć31‰ń—Տ°“ŕ•Ş”ĺ‘ăŽÓUpdate (2021/11/26-27), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{“ŕ•Ş”ĺŠw‰ďŽGŽ 2021; 97 (2): 537.

723223. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •Đ‘¤•›t“Eo‚đs‚Á‚˝ACTH”ńˆË‘śŤ‘ĺŒ‹ßŤ•›t”玿‰ßŒ`Ź‚Ě1—á. ‘唊NG1, ‚“c“NG1, –Ř‘ş—˘1, ˆę“‡—R‰ÁŽq1, ’ҁ@@—@1, “Ą“c“N•v2 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2”ĺ”AŠí): ‘ć31‰ń—Տ°“ŕ•Ş”ĺ‘ăŽÓUpdate (2021/11/26-27), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723224. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ć’[‹°•|Ç‚Ě‚˝‚ßSMBG‚đ—p‚˘‚˝ŒŒ“œŠÇ—‚Ş‚Ĺ‚Ť‚¸ŽŠ‘î”A“œ‘Ş’č‚ĹŠÇ—‚ľ‚˝GDM‚Ěˆę—á. ˆÉ“Œ‚ľ‚¨‚č1, Žsě—‹Žt1, Â–؁@’ó1, Ź“c@Œd1, ‚–ěK˜H1, ‹{’ˁ@Œ’1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć37‰ń“ú–{“œ”A•aE”DPŠw‰ď”NŽŸŠwpW‰ď (2021/11/27-28), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ), “œ”A•a‚Ć”DP 2021; 21 (3): 92.

723225. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) isCGM (ŠÔŸ[ƒXƒLƒƒƒ“ŽŽŽ‘ąŒŒ“œ‘Ş’č) ‚ƐHŽ–ŠÇ—ƒAƒvƒŠ‚đ—p‚˘‚˝”DP“œ”A•aŠÇ—. —с@“N”Í (“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć37‰ń“ú–{“œ”A•aE”DPŠw‰ď”NŽŸŠwpW‰ď (2021/11/27-28), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ), “œ”A•a‚Ć”DP 2021; 21 (3): 95.

723226. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) isCGM (ŠÔŸ[ƒXƒLƒƒƒ“ŽŽŽ‘ąŒŒ“œ‘Ş’č) ‚ƐHŽ–ŠÇ—ƒAƒvƒŠ‚É‚ć‚é”DP“œ”A•a‚ĚŒÂ•Ę‰ť‰h—{Žw“ą. —с@“N”Í1, ŽRŕV—IŽq2, lŒŠ–ƒ”üŽq2, ´…‡–ç1, “Ą“ˆ@—ŕ1, —é–؍V–ź1, “IęŒ’‘ž1, —é–Ř—z•F1, Žç‰Ž’B”ü3, ‹{’ˁ@Œ’1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2‰h—{•”, 3Œ’NŠÇ—ƒZ): ‘ć24‰ńE‘ć25‰ń“ú–{•a‘Ô‰h—{Šw‰ď”NŽŸŠwpW‰ď (2022/1/28-30), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{•a‘Ô‰h—{Šw‰ďŽ 2022; 24/25 (Suppl): S-32.

723227. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “œ”A•aŤtÇ‚ĚŒŒ‰t“§Í“ą“ü’x‰„‚ɑ΂ˇ‚é‘˝EŽíƒ`[ƒ€ˆă—Ă‚Ş‚ć‚čŒř‰Ę‚đ”­Šö‚ˇ‚é‚˝‚߂̐EŽí‚Ě‘g‚ݍ‡‚í‚š. —é–Ř—z•F1, —с@“N”Í1, lŒŠ–ƒ”üŽq2, ‹{’ˁ@Œ’1, Žç‰Ž’B”ü3 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2‰h—{•”, 3Œ’NŠÇ—ƒZ): ‘ć24‰ńE‘ć25‰ń“ú–{•a‘Ô‰h—{Šw‰ď”NŽŸŠwpW‰ď (2022/1/28-30), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{•a‘Ô‰h—{Šw‰ďŽ 2022; 24/25 (Suppl): S-36.

723228. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) 2Œ^“œ”A•aŠłŽŇ‚É‚¨‚Ż‚鐜‘Ě“d‹CƒCƒ“ƒs[ƒ_ƒ“ƒX–@‚É‚ć‚é‘Ě‘gŹ‚ĚŒŸ“˘. ‰–ŒŠ‚ß‚Ž‚Ý, źŽRŕY”ü, X@^Šó, ‚“c“NG1, ”ö’šŸ–ç (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ): “ú–{–ňŠw‰ď‘ć142”N‰ď (2022/3/25), WebŠJĂ.

733065. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‰şŠ{‘O“Ë‚đ—L‚ˇ‚éć’[‹‘ĺÇŠłŽŇ‚ɑ΂ľ‚Ä, ă‰şŠ{œœŘ‚čp‚đs‚˘AcroQoLƒXƒRƒA‚މü‘P‚ľ‚˝ˆę—á. ”‹Œ´@˜j1, “cŒű@•ü1, ŻŽRˆťŽq1, —é–Ř—z•F1, ł–ŘŽkl1, Žsě—‹Žt1, Š™“c—T“ń1, ŒN’ˍKŽq2, ‚–ěK˜H1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2Œ`ŹE”üŠO): ‘ć22‰ń“ú–{“ŕ•Ş”ĺŠw‰ďŠÖ“ŒbM‰zŽx•”ŠwpW‰ď (2021/9/24-25), WebŠJĂ, “ú–{“ŕ•Ş”ĺŠw‰ďŽGŽ, 2021; 97 (4): 779.

733066. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) 2Œ^“œ”A•a“§ÍŠłŽŇ‚É‚¨‚˘‚Ätime in range‚͉˝‚đŽŚ‚ˇ‚Ě‚Š? —с@“N”Í1, ´…‡–ç1, —é–؍V–ź1, “Ą“ˆ@—ŕ1, “IęŒ’‘ž1, XŒű‚˘‚Ô‚Ť, Ź—Ń’ź”V, ‚–ěK˜H1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć20‰ń“ú–{ći“œ”A•aŽĄ—ĂŒ¤‹†‰ďE‘ć18‰ń1Œ^“œ”A•aŒ¤‹†‰ď (2021/11/6-7), ’ˇč (ƒnƒCƒuƒŠƒbƒhŠJĂ), ‘ć20‰ń“ú–{ći“œ”A•aŽĄ—ĂŒ¤‹†‰ďE‘ć18‰ń1Œ^“œ”A•aŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2021; p.58.

733067. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) 2Œ^“œ”A•a“§ÍŠłŽŇ‚É‚¨‚Ż‚éTime In Range‚ĚˆÓ‹`. —с@“N”Í1, ´…‡–ç1, —é–؍V–ź1, “Ą“ˆ@—ŕ1, “IęŒ’‘ž1, XŒű‚˘‚Ô‚Ť, ‚–ěK˜H1, Ź—Ń’ź”V, Žë–ě—Lě2, ‹{’ˁ@Œ’1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 2—ŐŒŸŠw): ‘ć32‰ń“ú–{“œ”A•aŤtÇŒ¤‹†‰ď (2021/12/4-5), WebŠJĂ, ‘ć32‰ń“ú–{“œ”A•aŤtÇŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2021; p.42.

733068. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒAƒxƒ‹ƒ}ƒu‚É‚ć‚č—U”­‚ł‚ę‚˝Œ€Ç1Œ^“œ”A•a‚Ě1—á. Ź“c@Œd1, ´…‡–ç1, ˆę“‡—R‰ÁŽq1, –Ř‘ş—˘1, ‰şčmG‘1, œAŁłr1, ‚–ěK˜H1, ‹{’ˁ@Œ’1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć59‰ń“ú–{“œ”A•aŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2022/1/22), WebŠJĂ.

733069. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒŠƒuƒŒLink‚đ—p‚˘‚ăCƒ“ƒXƒŠƒ““ą“ü‹y‚ŃŒŒ“œŠÇ—‚đs‚Á‚˝”DP’†‚Ě–ž‚ç‚Š‚Č“œ”A•a‚Ě1—á. ”‹Œ´@˜j1, “IęŒ’‘ž1, Â–؁@’ó1, —с@“N”Í1, ‚–ěK˜H1, ‹{’ˁ@Œ’1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć59‰ń“ú–{“œ”A•aŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2022/1/22), WebŠJĂ.

733070. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) –ňÜŤ‚ŕ‹^‚í‚ę‚é“œ”A•aŤƒPƒgƒAƒVƒh[ƒVƒX‚Ěˆę—á. ’ҁ@@—@1, ˆę“‡—R‰ÁŽq1, –Ř‘ş—˘1, ‘唊NL1, ‚“c“NG1 (1“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć59‰ń“ú–{“œ”A•aŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2022/1/22), WebŠJĂ.p


t‘Ÿ“ŕ‰ČŠw

[Šwp˜_•ś]

110243. [Œ´’˜] Oral/oesophageal candidiasis is a risk factor for severe infection after kidney transplantation. Abe T1, Futamura K, Goto N, Ohara K, Ogasa T, Tomosugi T, Okada M, Hiramitsu T, Narumi S, Watarai Y: Nephrology (Carlton) 2022/1; 27 (1): 97-103. (ˆ˘•”“N–ç1: 1t‘Ÿ“ŕ)

110244. [Œ´’˜] Endothelial ganglioside GM3 regulates angiogenesis in solid tumors. Suzuki M, Nagane M, Kato K, Yamauchi A, Shimizu T, Yamashita H, Aihara N, Kamiie J, Nagako Kawashima N1, Naito S1, Yamashita T: Biochem Biophys Res Commun 2021/9; 569: 10-6. (ě“‡‰iŽq1, “ŕ“Ął‹g1: 1t‘Ÿ“ŕ)

110245. [Œ´’˜] The relationship between podocytopathy and periglomerular fibrosis. Kamata F1, Naito S2, Kawashima N2, Takeuchi Y2: Kitasato Med J 2022/3; 52 (2): 1-11. (Š™“c•‡”ü1, “ŕ“Ął‹g2, ě“‡‰iŽq2, ’|“ŕN—Y2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2t‘Ÿ“ŕ)

310025. [Ç—á•ń] Long-term clinical course of immunotactoid glomerulopathy complicated with diffuse large B-cell lymphoma. Takahashi H1, Sano T1, Kawamura S1, Sano K1, Miyasaka R1, Yamazaki T1, Sakakibara M1, Abe T1, Hashimoto K1, Nagaoka M1, Kamata M1, Naito S1, Aoyama T1, Moriya R2, Takeuchi Y1: CEN Case Rep 2022/5; 11 (2): 184-90. doi: 10.1007/s13730-021-00648-0. Epub 2021 Sep 26. (‚‹´@—y1, ˛–ě@—˛1, ě‘şš—R”ü1, ˛–ěŒiŽq1, ‹{â—ł”n1, ŽRč‘ń–ç1, ĺŒ´–ƒ—FŽq1, ˆ˘•”“N–ç1, ‹´–{ŒbŽq1, ‰i‰Ş–˘—ˆ1, Š™“c^—Žq1, “ŕ“Ął‹g1, ÂŽR“ŒŒÜ1, Žç’J—˜‰Ŕ2, ’|“ŕN—Y1: 1t‘Ÿ“ŕ, 2ˆăŠw‹łˆç)

522057. uuŔ]yĹć’[ˆă—Ă‚ĚĄzƒ|ƒhƒTƒCƒg×–E–Œ•ŞŽq‚É’…–Ú‚ľ‚˝ŽĄ—Ă–ň‘no‚ÖŒü‚Ż‚Ä . “ŕ“Ął‹g1, ě“‡‰iŽq1 (1t‘Ÿ“ŕ): Medical Science Digest 2022/2; 48 (2): 94-5.

540024. [‚ť‚Ě‘ź (Œ¤‹†•ń‘)] “œŽ‰ŽżGM3‚ĚƒlƒtƒŠƒ“EƒŠƒ“Ž_‰ť§Œä‹@\‚đ—˜—p‚ľ‚˝‘ƒóŽ…‹…‘̍d‰ťÇ‚ĚŽĄ—Ă–@‚ĚŠm—§. ě“‡‰iŽq1, “ŕ“Ął‹g1, ‚–ě—E‘ž2, ’‡ŽRŒŤˆę3 (1t‘Ÿ“ŕ, 2–kŠC“š‘ĺŠw“dŽq‰ČŠwŒ¤‹†Š, 3ŽY‹Ć‹Zp‘‡Œ¤‹†Š): ‰ČŠwŒ¤‹†”ď•ŹŽ–‹Ćƒf[ƒ^ƒx[ƒX (“ú–{ŠwpU‹ť‰ď) 2022/3.

[Šw‰ďEŒ¤‹†‰ď“™]

722086. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) –k—˘‘ĺŠw•a‰@‚É‚¨‚Ż‚éŒŁt‘Ň‹@ŠłŽŇ‚ĚŒťó‚Ć–â‘č“_`ˆÚA“ŕ‰Čˆă‚ĚŽ‹“_‚Š‚ç`. ˆ˘•”“N–ç1, Îˆä‘ĺ•ă2, ‹g“cˆęŹ2,3, ’|“ŕN—Y1 (1t‘Ÿ“ŕ, 2”ĺ”AŠí, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć66‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2021/6/4), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{“§ÍˆăŠw‰ďŽGŽ 2021/5; 54 (Suppl 1): 234.

723229. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) COVID-19‚đ”­Ç‚ľ‚˝“œ”A•a‡•š‚—îˆŰŽ“§ÍŠłŽŇ‚Ě1—á. “ŕ“Ął‹g1, ě‘şš—R”ü1, ˜a“c’B•F2, ŽRč‘ń–ç1, ‹{â—ł”n1, ˛–ěŒiŽq1, ĺŒ´–ƒ—FŽq1, ‚‹´@—É1, ‰i‰Ş–˘—ˆ1, ÂŽR“ŒŒÜ1, ˛–ě@—˛1, ‚ŽR—zŽq3, ’|“ŕN—Y1 (1t‘Ÿ“ŕ, 2äPŒ´•aEŠ´ő“ŕ, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć66‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2021/6/3), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723230. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) tˆÚAŒăŒűo/H“šƒJƒ“ƒWƒ_Ç‚͏dÇŠ´őÇ‚Ě—\‘ވöŽq‚Ĺ‚ ‚é. ˆ˘•”“N–ç1, ‘ĺŒ´Šó‘ă”ü, “ń‘şŒ’‘ž, ŹŠ}‘ĺ‹N, —F™r‰p, ‰Ş“c@Šw, •˝Œő‚‹v, Œă“ĄŒ›•F, –ŠCrŽĄ, “nˆäŽŠ•F (1t‘Ÿ“ŕ): ‘ć66‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2021/6/3), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723231. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚R‘̉żANCAŠÖ˜AŒŒŠÇ‰Š (AAV) ‚ɑ΂ľ‘I‘đ“IŒŒŸ÷ŒđŠˇ (Selective PE) ‚đŽ{s‚ľ‚˝ˆę—á. “‡“c–F—˛1,2, ’ˇę@‘×1,2, ]Œ´‚Š‚¨‚č1,2, ’|“ŕN—Y2 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2t‘Ÿ“ŕ): ‘ć66‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2021/6/4), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{“§ÍˆăŠw‰ďŽGŽ 2021/5; 54 (Suppl 1): 486.

723232. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) MPO-ANCA‚ƍRGBMR‘Ě“ŻŽž—zŤRPGN‚ɑ΂ľ‘I‘đ“IŒŒŸ÷ŒđŠˇ‚đs‚¤‚ŕˆŰŽ“§Í‚Ć‚Č‚Á‚˝ˆę—á. ]Œ´‚Š‚¨‚č1,2, “‡“c–F—˛1,2, ’ˇę@‘×1,2, ]Œ´M”V‰î1, –ěXŒű”ŽŽj1, ’|“ŕN—Y2 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2t‘Ÿ“ŕ): ‘ć66‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2021/6/4), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{“§ÍˆăŠw‰ďŽGŽ 2021/5; 54 (Suppl 1): 520.

723233. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Alb’uŠˇ—Ę‘—Ę‚Ĺ‘tŒ÷‚ľ‚˝‘I‘đ“IŒŒŸ÷ŒđŠˇ‚Ě1—á. ]Œ´M”V‰î1, VˆäŽŔ‰„1, ‚‹´”Ž‹v1, ]Œ´‚Š‚¨‚č1,2, “‡“c–F—˛1,2, ’ˇę@‘×1,2 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2t‘Ÿ“ŕ): ‘ć66‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2021/6/4), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{“§ÍˆăŠw‰ďŽGŽ 2021/5; 54 (Suppl 1): 487.

723234. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒ_ƒCƒI[ƒh‚đ—p‚˘‚˝‰şŽˆ‚ĚƒcƒŒ‚ɑ΂ˇ‚é—\–h–@: 3Ç—á‚Ě•ń. ‚‹´”Ž‹v1, VˆäŽŔ‰„1, ]Œ´M”V‰î1, ]Œ´‚Š‚¨‚č1,2, “‡“c–F—˛1,2, ’ˇę@‘×1,2, ‰–č‹v–ç1 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2t‘Ÿ“ŕ): ‘ć66‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2021/6/4), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{“§ÍˆăŠw‰ďŽGŽ 2021/5; 54 (Suppl 1): 440.

723235. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”A“ŏǐŤ‹š–Œ‰Š‚Ɛf’f‚ľƒXƒeƒƒCƒhŽĄ—Ă‚đs‚Á‚˝4Ç—á. ĺŒ´–ƒ—FŽq1, ‚‹´@—É1, ě‘şš—R”ü1, ˛–ěŒiŽq1, ‹{â—ł”n1, ŽRč‘ń–ç1, ‹´–{ŒbŽq1, ‰i‰Ş–˘—ˆ1, “ŕ“Ął‹g1, ÂŽR“ŒŒÜ1, ˛–ě@—˛1, ’|“ŕN—Y1 (1t‘Ÿ“ŕ): ‘ć66‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2021/6/4-6), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723236. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŒŒ‰t“§ÍŠłŽŇ‚ɍ‡•š‚ľ‚˝Tumoral Calcinosis‚ɑ΂ľ‚Ä•›bó‘B“Eop‚Ş‘tŒř‚ľ‚˝ˆę—á. ě‘şš—R”ü1, ‚‹´@—É1, ˛–ěŒiŽq1, ‹{â—ł”n1, ŽRč‘ń–ç1, ĺŒ´–ƒ—FŽq1, ‹´–{ŒbŽq1, ‰i‰Ş–˘—ˆ1, “ŕ“Ął‹g1, ÂŽR“ŒŒÜ1, ˛–ě@—˛1, ’|“ŕN—Y1 (1t‘Ÿ“ŕ): ‘ć66‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2021/6/4-6), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723237. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —ź‘¤‚É”A“ŏǐŤ‹š–Œ‰Š‚đ”­Ç‚ľ, ƒXƒeƒƒCƒhŽĄ—Ă‚đs‚Á‚˝ŒŒ‰t“§ÍŠłŽŇ‚Ě1—á. ŽŸ“c“މ›1, ‚‹´@—É1, ě‘şš—R”ü1, ˛–ěŒiŽq1, ‹{â—ł”n1, ŽRč‘ń–ç1, ĺŒ´–ƒ—FŽq1, ‹´–{ŒbŽq1, ‰i‰Ş–˘—ˆ1, “ŕ“Ął‹g1, ÂŽR“ŒŒÜ1, ˛–ě@—˛1, ’|“ŕN—Y1 (1t‘Ÿ“ŕ): ‘ć66‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2021/6/4-6), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723238. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “§Í“ą“üŠú‚ÉŒ°Ý‰ť‚ľ‚˝ˆÝŘœŒă‹zŽű•s—ǏnjóŒQ‚Ěˆę—á. ˛–ěŒiŽq1, ˛–ě@—˛1, ě‘şš—R”ü1, ĺŒ´–ƒ—FŽq1, ‹{â—ł”n1, ŽRč‘ń–ç1, ‹´–{ŒbŽq1, ‰i‰Ş–˘—ˆ1, ‚‹´@—É1, “ŕ“Ął‹g1, ÂŽR“ŒŒÜ1, ’|“ŕN—Y1 (1t‘Ÿ“ŕ): ‘ć66‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2021/6/4-6), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723239. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒqƒgtśŒŸŒŸ‘Ě‚đ—p‚˘‚˝“œŽ‰ŽżGM3”­Œť‚ĚŒŸ“˘. “ŕ“Ął‹g1, ě“‡‰iŽq1, ÎŠ_’źŽq, ’|“ŕN—Y1 (1t‘Ÿ“ŕ): ‘ć64‰ń“ú–{t‘ŸŠw‰ďŠwp‘‰ď (2021/6/18-20), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{t‘ŸŠw‰ďŽ 2022/6; 63 (4): 446.

723240. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ˆÚAt‹CŽîŤtṐt‰Š‚đ”­Ç‚ľ‚˝‚ވڐAt‹@”\‰ˇ‘ś‚Ĺ‚Ť‚˝1—á. ˆ˘•”“N–ç1, ’|“ŕN—Y1, –k“‡˜aŽ÷2, Îˆä‘ĺ•ă2, ‹g“cˆęŹ2,3, ‘ĺŒ´Šó‘ă”ü, “ń‘şŒ’‘ž, ŹŠ}‘ĺ‹N, —F™r‰p, ‰Ş“c@Šw, •˝Œő‚‹v, Œă“ĄŒ›•F, –ŠCrŽĄ, “nˆäŽŠ•F (1t‘Ÿ“ŕ, 2”ĺ”AŠí, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć57‰ń“ú–{ˆÚAŠw‰ď‘‰ď (2021/9/20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733071. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒTƒ‹ƒRƒCƒh[ƒVƒX‚É”ş‚¤‹}Ť”A×ŠÇŠÔŽżŤt‰Š‚É‚ć‚č‹}Ťt•s‘S‚đ’ć‚ľ, ƒXƒeƒƒCƒhŽĄ—Ă‚Ş‘tŒř‚ľ‚˝ˆę—á. ]Œ´‚Š‚¨‚č1,2, “‡“c–F—˛1,2, ’ˇę@‘×1,2, “‡“c@”Ł1, –ěXŒű”ŽŽj1, ’|“ŕN—Y2 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2t‘Ÿ“ŕ): ‘ć51‰ń“ú–{t‘ŸŠw‰ď“Œ•”Šwp‘ĺ‰ď (2021/9/25), WebŠJĂ, “ú–{t‘ŸŠw‰ďŽ 2021/9; 63 (6E): 728.

733072. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) tŽŔŽżZ‚̐f’f‚ŞŽĄ—Ă•űj‚đŒˆ’č‚ľ‚˝ßŤ•Ó‰‘ŃB×–EƒŠƒ“ƒpŽî‚Ěˆę—á. ‹{â—ł”n1, ‚‹´@—É1, ŸN—с@r1, ź“c—F—1, ŽRč‘ń–ç1, ĺŒ´–ƒ—FŽq1, ˆ˘•”“N–ç1, ‰i‰Ş–˘—ˆ1, Š™“c^—Žq1, ˛–ě@—˛1, “ŕ“Ął‹g1, ÂŽR“ŒŒÜ1, ’|“ŕN—Y1 (1t‘Ÿ“ŕ): ‘ć51‰ń“ú–{t‘ŸŠw‰ď“Œ•”Šwp‘ĺ‰ď (2021/9/25-26), WebŠJĂ.

733073. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒ‹[ƒvƒXt‰ŠVŒ^‚ސćs‚ľRGBMt‰Š‚đ‡•š‚ľ‚˝1—á. ŽRč‘ń–ç1, ‚‹´@—É1, ŸN—с@r1, ‹{â—ł”n1, ĺŒ´–ƒ—FŽq1, ˆ˘•”“N–ç1, ‰i‰Ş–˘—ˆ1, Š™“c^—Žq1, ˛–ě@—˛1, “ŕ“Ął‹g1, ÂŽR“ŒŒÜ1, ’|“ŕN—Y1 (1t‘Ÿ“ŕ): ‘ć51‰ń“ú–{t‘ŸŠw‰ď“Œ•”Šwp‘ĺ‰ď (2021/9/25-26), WebŠJĂ.

733074. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒqƒgƒpƒ‹ƒ{ƒEƒCƒ‹ƒXB19Š´őŠÖ˜AC3tÇ‚Ş‹^‚í‚ę‚˝1—á. ĺŒ´–ƒ—FŽq1, ‚‹´@—É1, ŸN—с@r1, ‹{â—ł”n1, ŽRč‘ń–ç1, ˆ˘•”“N–ç1, ‰i‰Ş–˘—ˆ1, Š™“c^—Žq1, ˛–ě@—˛1, “ŕ“Ął‹g1, ÂŽR“ŒŒÜ1, ’|“ŕN—Y1 (1t‘Ÿ“ŕ): ‘ć51‰ń“ú–{t‘ŸŠw‰ď“Œ•”Šwp‘ĺ‰ď (2021/9/25-26), WebŠJĂ.

733075. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚鐏l”­ÇIgAŒŒŠÇ‰Š‚Ě—Ő°Œo‰ß‚ɂ‚˘‚Ä. ‹´–{ŒbŽq1, ˛–ě@—˛1, ě‘şš—R”ü1, ĺŒ´–ƒ—FŽq1, ‹{â—ł”n1, ŽRč‘ń–ç1, ‚‹´@—É1, ‰i‰Ş–˘—ˆ1, “ŕ“Ął‹g1, ÂŽR“ŒŒÜ1, ’|“ŕN—Y1 (1t‘Ÿ“ŕ): ‘ć51‰ń“ú–{t‘ŸŠw‰ď“Œ•”Šwp‘ĺ‰ď (2021/9/25-26), WebŠJĂ.

733076. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) V‹K–Ťt‘Ÿ•aƒ‚ƒfƒ‹“Ž•¨‚̉đÍ. ŽRŒű˜a‰Ô, ě“‡‰iŽq1, ŽR‰ş@‹§, “ŕ“Ął‹g1 (1t‘Ÿ“ŕ): 2021”N“x–ƒ•z‘ĺŠwbˆăŠw•”bˆăŠw‰Č‘˛‹ĆŒ¤‹†”­•\‰ď (2021/11), ‘Š–ÍŒ´.

733077. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) WŠw“IŽĄ—Ă‚É‚ć‚č‹~–˝‚ľ“ž‚˝Aeromonas hydrophila‚É‚ć‚é‰óŽ€Ť‹Ř–Œ‰Š‚Ě1—á. ]Œ´‚Š‚¨‚č1,2, “‡“c–F—˛1,2, ‘ĺŠÖ—ş‰î3, ”nęŽq1,3, ’ˇę@‘×1,2 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2t‘Ÿ“ŕ, 3Œ`ŹE”üŠO): “ú–{“ŕ‰ČŠw‰ď‘ć676‰ńŠÖ“Œ’n•ű‰ď (2022/3/19), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-320001. [Ç—á•ń] tˆÚAŒă–Ɖu—}§–ňŒp‘ą’†‚É‚ŕS‚í‚炸de novo’×ᇐŤ‘ĺ’°‰Š‚đ”­Ç‚ľ‚˝1—á. ˆ˘•”“N–ç1, ’|“ŕŒb”üŽq2, –k“‡˜aŽ÷3, Îˆä‘ĺ•ă3, ‹g“cˆęŹ3,4, ˛“c”ü˜a5, ŽRč‘ń–ç1, ’|“ŕN—Y1 (1t‘Ÿ“ŕ, 2–Ɖu, 3”ĺ”AŠí, 4V˘‹Iˆă—ÁEć’[ˆă—Ă, 5Á‰ťŠí“ŕ): “ú–{—Տ°tˆÚAŠw‰ďŽGŽ 2020/12; 8 (2): 270-2.

[Šw‰ďEŒ¤‹†‰ď“™]

'20-733009. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒlƒtƒ[ƒ[ÇŒóŒQ‚Ĺ”­Ç‚ľƒpƒ‹ƒ{ƒEƒCƒ‹ƒXB19 IgM—zŤ‚𔺂Á‚˝ŠÇ“ŕ‘BŤt‰Š‚Ěˆę—á. ĺŒ´–ƒ—FŽq1, ‚‹´@—É1, ě‘şš—R”ü1, ˛–ěŒiŽq1, ŽRč‘ń–ç1, ‹{â—ł”n1, ‰i‰Ş–˘—ˆ1, “ŕ“Ął‹g1, ÂŽR“ŒŒÜ1, ˛–ě@—˛1, ’|“ŕN—Y1, é@ŒŞ•ă, ŽRŒű@—T (1t‘Ÿ“ŕ): ‘ć75‰ń_“ސět‰ŠŒ¤‹†‰ď (2021/2/20), ‰Ą•l, t‰ŠÇ—ጤ‹† 2021; 38: 17-31.


äPŒ´•aEŠ´ő“ŕ‰ČŠw

[Šwp˜_•ś]

110246. [Œ´’˜] Analysis of the Time-To-Onset and Factors Affecting Clinical Outcomes of Immune Reconstitution Inflammatory Syndrome in People Living with HIV Using Data from the Japanese Spontaneous Reporting Database. Tanaka H, Wada T1, Ohyama K, Ishii T: J Pharm Pharm Sci 2021; 24: 153-60. (˜a“c’B•F1: 1äPŒ´•aĽŠ´ő“ŕ)

[Šw‰ďEŒ¤‹†‰ď“™]

723241. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@äPŒ´•a—Ěˆć‚É‚¨‚Ż‚éƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXŠ´ő‚ĚŒťó. ŻŽR—˛s1, ’ˇ’Jě–ő_2, ‘şź@ 2, “Œ–ěr—m1, ŽR‰Ş–MG1, ‚ŽR—zŽq3 (1äPŒ´•aĽŠ´ő“ŕ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć66‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2021/6/4-6), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).


“ű‘BEbó‘BŠO‰ČŠw

[Šwp˜_•ś]

110247. [Œ´’˜] Prospective cohort study of febrile neutropenia in breast cancer patients administered with neoadjuvant and adjuvant chemotherapies: CSPOR-BC FN study. Ishikawa T, Sakamaki K, Narui K, Nishimura H, Sangai T1, Tamaki K, Hasegawa Y, Watanabe K, Suganuma N, Michishita S, Sugae S, Aihara T, Tsugawa K, Kaise H, Taira N, Mukai H, for Comprehensive Support Project for Oncological Research of Breast Cancer: Breast 2021/4; 56: 70-7. (ŽOŠK‹MŽj1: 1“ű‘BEbó‘BŠO)

110248. [Œ´’˜] Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19). Aogi K, Watanabe K, Kitada M, Sangai T1, Ohtani S, Aruga T, Kawaguchi H, Fujisawa T, Maeda S, Morimoto T, Sato N, Takao S, Morita S, Masuda N, Toi M, Ohno S: Int J Clin Oncol 2021/7; 26 (7): 1229-36. (ŽOŠK‹MŽj1: 1“ű‘BEbó‘BŠO)

110249. [Œ´’˜] Prognostic values of L-type amino acid transporter 1 and CD98hc expression in breast cancer. Ichinoe M, Mikami T, Yanagisawa N, Yoshida T, Hana K, Endou H, Okayasu I, Sengoku N1, Ogata H, Saegusa M2, Shibuya K, Murakumo Y2: J Clin Pathol 2021/9; 74 (9): 589-95. (ĺÎ‹I•F1, ŽOŽ}@M2, ‘ş‰_–FŽ÷2: 1“ű‘BEbó‘BŠO, 2•a—)

110250. [Œ´’˜] Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens. Dai MS, Feng YH, Chen SW, Masuda N, Yau T, Chen ST, Lu YS, Yap YS, Ang PCS, Chu SC, Kwong A, Lee KS, Ow S, Kim SB, Lin J, Chung HC, Ngan R, Kok VC, Rau KM, Sangai T1, Ng TY, Tseng LM, Bryce R, Bebchuk J, Chen MC, Hou MF: Breast Cancer Res Treat 2021/10; 189 (3): 665-76. (ŽOŠK‹MŽj1: 1“ű‘BEbó‘BŠO)

522058. [uŔ]y“ÁWI: œ‘—R—ˆ—}§×–Ez‚Ş‚ńŽĄ—Ă•W“I‚Ć‚ľ‚Ä‚Ěœ‘—R—ˆ–Ɖu—}§×–E (MDSC). ‰Á“Ą@O (“ű‘BEbó‘BŠO): —Տ°–ƉuEƒAƒŒƒ‹ƒM[‰Č 2021/7; 75 (6): 636-43.

[Šw‰ďEŒ¤‹†‰ď“™]

722087. [Šw‰ď (‘S‘)] (ƒfƒBƒx[ƒgƒZƒbƒVƒ‡ƒ“) Žčp‰Â”\‚Čluminal“űŠŕ‚ɑ΂ľ‚Ä‚ÍŽčp‚đćs‚ˇ‚ׂŤ‚Ĺ‚ ‚é. ŽOŠK‹MŽj1, Ž›“c‚Š‚¨‚č (1“ű‘BEbó‘BŠO): ‘ć29‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2021/7/1-3), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722088. [Šw‰ď (‘S‘)] (ƒfƒBƒx[ƒgƒZƒbƒVƒ‡ƒ“) ƒgƒŠƒvƒ‹ƒlƒKƒeƒBƒu“űŠŕ‚É‚¨‚Ż‚éZEB1ˆâ“`Žq‚Ě”­Œť. ‹e’r^—Žq1, ‘ĺ–ŘŒcŽq2, “Ą–ěŽjD2, ‰Ą“cŒő‰›1, ź‹{—mŽj1, ‰Á“Ą@O1, ĺÎ‹I•F1, ŽOŠK‹MŽj1 (1“ű‘BEbó‘BŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č):‘ć29‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2021/7/1-3), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722089. [Šw‰ď (‘S‘)] (ƒfƒBƒx[ƒgƒZƒbƒVƒ‡ƒ“) ‹zˆřŽŽśŒŸ‘gD‚É‚¨‚Ż‚郊ƒ“ƒpŠÇNP‚ĚSN“]ˆÚ—\‘ވöŽq‚Ć‚ľ‚Ẳ”\Ť. “c’†—uŽq, ĺU•Ŕ@Ÿ, “Ą–ěŽjD1, ź‹{—mŽj2, ’†‹{‹IŽq, ‰Ş–{@—¤3, “ŕ“Ą‰Â“ŢŽq3, Ź–ě“c“o, ’|‰ş—˜•v, Źâ–ůŒŤ, ŽOŠK‹MŽj2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2“ű‘BEbó‘BŠO, 3ă•”Á‰ťŠÇŠO): ‘ć29‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2021/7/1-3), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722090. [Šw‰ď (‘S‘)] (ƒfƒBƒx[ƒgƒZƒbƒVƒ‡ƒ“) “–‰@‚É‚¨‚Ż‚é“űŠŕpŒăăŽˆƒŠƒ“ƒp•‚Žî”­ÇŠłŽŇ‚Ě”wŒiˆöŽq‚ĚŒŸ “˘. “ŕ“Ą‰Â“ŢŽq1, “Ą–ěŽjD2, “c’†—uŽq, ’†‹{‹IŽq, ź‹{—mŽj3, Źâ–ůŒŤ, ’|‰ş—˜•v, ĺU•Ŕ@Ÿ, ŽOŠK‹MŽj3 (1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3“ű‘BEbó‘BŠO): ‘ć29‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2021/7/1-3), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722091. [Šw‰ď (‘S‘)] (ƒfƒBƒx[ƒgƒZƒbƒVƒ‡ƒ“) ˆâ“`“IƒnƒCƒŠƒXƒNŽŇ‚đ‘ÎŰ‚Ć‚ľ‚˝ƒT[ƒxƒCƒ‰ƒ“ƒXŠO—ˆ|Œť‹ľ‚Ć“W–]|. ’†’Ðě’qŽq, “Ą–{_Ži, |@^ˆę, ŽOŠK‹MŽj1, â“cŽĄl, ‚“c@Œě, ĺŒ´~‘ž, ‹ŃŒŠ‹ąŽq, Ž›’†—ş‘ž˜Y, ŽR–{Š°l, ‰F’Ă–ěŒb”ü, ŠÖŞ, ’ˇ“ˆ@Œ’, ź‰şˆę”V, Žsě’q•F (1“ű‘BEbó‘BŠO): ‘ć29‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2021/7/1-3), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722092. [Šw‰ď (‘S‘)] (ƒfƒBƒx[ƒgƒZƒbƒVƒ‡ƒ“) “–‰@‚É‚¨‚Ż‚é”N—î‘w•ĘMMGŒŸf‚̐ŹŃ. ‰Ş–{—˛‰p, ˆ˘•”@–L, ˆÉ“Œ–ž”ü, “ŕŽR’‰ś, ‰œ–{’‰”V, •Šâ”üŠG, ă“‡’mŽq, š —F˜a‘P, ĺÎ‹I•F1 (1“ű‘BEbó‘BŠO): ‘ć29‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2021/7/1-3), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722093. [Šw‰ď (‘S‘)] (ƒfƒBƒx[ƒgƒZƒbƒVƒ‡ƒ“) ƒAƒxƒ}ƒVƒNƒŠƒu‚Ş‘tŒř‚ľ‚˝Ä”­’jŤ“űŠŕ‚Ě1—á. ĺÎ‹I•F1, “ŕ“Ą‰Â“ŢŽq2, “Ą–ěŽjD3, “c’†—uŽq, ‹e’r^—Žq1, ź‹{—mŽj1, ŽOŠK‹MŽj1 (1“ű‘BEbó‘BŠO, 2ă•”Á‰ťŠÇŠO, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć29‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2021/7/1-3), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722094. [Šw‰ď (‘S‘)] (ƒfƒBƒx[ƒgƒZƒbƒVƒ‡ƒ“) “űŠŕ‚ɔ畆‹Ř‰Š‚đ‡•š‚ľ‚˝1—á. ź‹{—mŽj1, Â–؉ԓŢ, ‘ĺ–ŘŒcŽq2, ‹e’n^—Žq1, Źâ–ůŒŤ, ĺÎ‹I•F1, ŽOŠK‹MŽj1 (1“ű‘BEbó‘BŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć29‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2021/7/1-3), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722095. [Šw‰ď (‘S‘)] (ƒfƒBƒx[ƒgƒZƒbƒVƒ‡ƒ“) “–‰@‚ĹŒoŒą‚ľ‚˝’jŤ“űŠŕ5—á‚Ě•ń. ‰Ş–{@—¤1, “c’†—uŽq, “ŕ“Ą‰Â“ŢŽq1, âف@‹IŽq, ‘ •Ŕ@Ÿ, Źâ–ůŒŤ, ŽOŠK‹MŽj2 (1ă•”Á‰ťŠÇŠO, 2“ű‘BEbó‘BŠO): ‘ć29‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2021/7/1-3), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722096. [Šw‰ď (‘S‘)] (ƒfƒBƒx[ƒgƒZƒbƒVƒ‡ƒ“) p‘Of’f‚ĹFA‚Ɛf’f‚ľpŒă•a—‚Ĺ“űŠŕ‚Ɛf’f‚ł‚ę‚˝Žá”NŤ (17Ë) “űŠŕ‚Ě1—á. —с@‹žŽq1, ˜m’J”ü“Ţ1, ‰HœAŒ’m, Ź›¸Œc‘ž2, ĺÎ‹I•F1, Œ˘Ž”@‰~3, ŽOŠK‹MŽj1 (1“ű‘BEbó‘BŠO, 2‰ş•”Á‰ťŠÇŠO, 3”]ŠO) :‘ć29‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2021/7/1-3), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722097. [Šw‰ď (‘S‘)] (ƒfƒBƒx[ƒgƒZƒbƒVƒ‡ƒ“) “–‰@‚É‚¨‚Ż‚éBRACAnalysis‚ĚŒŸ“˘. ˜m’J”ü“Ţ1, Ź›¸Œc‘ž2, ‰HœAŒ’m, —с@‹žŽq1 (1“ű‘BEbó‘BŠO, 2‰ş•”Á‰ťŠÇŠO): ‘ć29‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2021/7/1-3), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722098. [Šw‰ď (‘S‘)] (ƒfƒBƒx[ƒgƒZƒbƒVƒ‡ƒ“) “ű‘B‘B—lůN–EŠŕ‚Ě2—á. ”Ń’Ë”ü, –x“cˆťŽq, âV“Ąś˜N, ‹e’r^—Žq1, ĺÎ‹I•F1 (1“ű‘BEbó‘BŠO): ‘ć29‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2021/7/1-3), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722099. [Šw‰ď (‘S‘)] (ƒfƒBƒx[ƒgƒZƒbƒVƒ‡ƒ“) COVID-19”x‰ŠŠŽŽĄŒă‚É“űŠŕŽčp‚đŽ{s‚ľ‚˝1—á. Â–؉ԓŢ, ‹e’r^—Žq1, ĺÎ‹I•F1, ‰Ą“cŒő‰›1, ź‹{—mŽj1, ‰Á“Ą@O1, ŽOŠK‹MŽj1 (1“ű‘BEbó‘BŠO): ‘ć29‰ń“ú–{“űŠŕŠw‰ďŠwp‘‰ď (2021/7/1-3), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722100. [Šw‰ď (‘S‘)] (ƒfƒBƒx[ƒgƒZƒbƒVƒ‡ƒ“) Žo–…‚Ĺ“ŻŽžŠú‚É”­Ç‚ľ”D›sŤ‰ˇ‘śŽĄ—Ă‚đ‘I‘đ‚ľ‚˝AYA˘‘ăHBOC‚Ě1‰ĆŒn. ’†’Ðě’qŽq, ‰F–ě’ĂŒb”ü, ŠÖŞ, ŽR–{Š°l, ˛“Ą–ž“ú, ‹g–ě—LŠóŽq, “Ą–{_Ži, ŒŻ@–őŽq, _’ĂŽO‰Ŕ, ŽOŠK‹MŽj1, ź‰şˆę”V, ź‘ş@Šî, ‰H“c@–ž, Žsě’q•F (1“ű‘BEbó‘BŠO): “ú–{l—Ţˆâ“`Šw‰ď‘ć66‰ń‘ĺ‰ď/‘ć28‰ń“ú–{ˆâ“`Žqf—ĂŠw‰ď‘ĺ‰ď (2021/10/13-16), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722101. [Šw‰ď (‘S‘)] (ƒfƒBƒx[ƒgƒZƒbƒVƒ‡ƒ“) HBOCf—Ă‚É‚¨‚Ż‚é‰@“ŕ˜AŒg‚Ć’nˆćˆă—Ă˜AŒg‚̍\’z. r–؏Ž”ü1, ě“c仉Ŕ1, ˜m’J”ü“Ţ1,2, Źâ–ůŒŤ, ‘ •Ŕ@Ÿ, r–ؐł—Y1, Vˆä@“w3, ŽOŠK‹MŽj1,2, ĺÎ‹I•F2, ŒĂěł‹`1,3, ŠâŁtŽq3, ’Ă‘şGN1,4, “c”¨Œ’ˆę4, ‰œ˜e‹ť‰î5, Šâˆä’m‹v5, –Ř“cŒőL5, ‚“cŽj’j1,6 (1•a‰@ˆâ“`f—Ă•”, 2“ű‘BEbó‘BŠO, 3•wl, 4”ĺ”AŠí, 5Á‰ťŠí“ŕ, 6‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): “ú–{l—Ţˆâ“`Šw‰ď‘ć66‰ń‘ĺ‰ď/‘ć28‰ń“ú–{ˆâ“`Žqf—ĂŠw‰ď‘ĺ‰ď (2021/10/13-16), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723242. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒgƒŠƒvƒ‹ƒlƒKƒeƒBƒu“űŠŕ‚É‚¨‚Ż‚éZEB1 ˆâ“`Žq‚ĚˆÓ‹`. ‹e’r^—Žq1, ‘ĺ–ŘŒcŽq2, “Ą–ěŽjD2, ‰Ą“cŒő‰›1, ź‹{—mŽj1, ‰Á“Ą@O1, ĺÎ‹I•F1, ŽR‰şŒpŽj3,4, ŽOŠK‹MŽj1 (1“ű‘BEbó‘BŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4ă•”Á‰ťŠÇŠO): ‘ć121‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/4/8-10), WebŠJĂ.

723243. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹zˆřŽŽśŒŸ‘gD‚É‚¨‚Ż‚郊ƒ“ƒpŠÇNP‚ĚSN“]ˆÚ—\‘ވöŽq‚Ć‚ľ‚Ẳ”\Ť. “c’†—uŽq, ĺU•Ŕ@Ÿ, Źâ–ůŒŤ, “Ą–ěŽjD1, ’†‹{‹IŽq, “ŕ“Ą‰Â“ŢŽq2, Ź–ě“c“o, ’|‰ş—˜•v, ź‹{—mŽj3, ŽOŠK‹MŽj3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ă•”Á‰ťŠÇŠO, 3“ű‘BEbó‘BŠO): ‘ć121‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/4/8-10), WebŠJĂ.

723244. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰ć‘œf’f‚Ĺčň“Ž–ŹNP‚đ‹^‚¤Ç—á‚É‚¨‚Ż‚éneoadjuvant setting‚Ĺ‚ĚLenvatinibŽg—pŒoŒą. ‰Á“Ą@O1, ‰Ą“cŒő‰›1, ‹e’r^—Žq1, ĺÎ‹I•F1, ŽOŠK‹MŽj1 (1“ű‘BEbó‘BŠO): ‘ć33‰ń“ú–{“ŕ•Ş”ĺŠO‰ČŠw‰ď‘‰ď (2021/6/3-4), Œyˆä‘ň.

723245. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) bó‘B“ű“ŞŠŕčň“Ž–ŹZ‚É‚ć‚éčň“Ž–Ź“´ÇŒóŒQ‚đ‚Ť‚˝‚ľ‚˝Ç—á‚É‚¨‚Ż‚éLenvatinibŽg—pŒoŒą. ‰Á“Ą@O1, ‰Ą“cŒő‰›1, ‹e’r^—Žq1, ĺÎ‹I•F1, ŽOŠK‹MŽj1 (1“ű‘BEbó‘BŠO): ‘ć33‰ń“ú–{“ŕ•Ş”ĺŠO‰ČŠw‰ď‘‰ď (2021/6/3-4), Œyˆä‘ň.

723246. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) PRLŽYś‰ş‚‘Ě‘BŽî‚đ‡•š‚ľ‚˝Hyperparathyroidism-jaw tumor (HPT-JT) ÇŒóŒQ‚Ě1—á. “‡’Á@Ť, ě“c仉Ŕ, r–؏Ž”ü, ˆŔ–{—´”n1, ˜m’J”ü“Ţ2, ’Ă‘şGN3, Źâ–ůŒŤ, ‚“cŽj’j4 (1—ŐŒŸ•”, 2“ű‘BEbó‘BŠO, 3”ĺ”AŠí, 4‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): “ú–{l—Ţˆâ“`Šw‰ď‘ć66‰ń/‘ĺ‰ď‘ć28‰ń“ú–{ˆâ“`Žqf—ĂŠw‰ď‘ĺ‰ď‡“ŻŠJĂ (2021/10/14), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

732037. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰) bó‘B”÷Ź“ű“ŞŠŕ‚̐ϋɓIŒo‰ßŠĎŽ@‚ĚŠT—v‚Ć—ŻˆÓ“_. ‰Á“Ą@O (“ű‘BEbó‘BŠO): ‘ć8‰ńŒú–Ř—Ő°ŠO‰Čˆă‰ď (2021/7), Œú–Ř (ƒnƒCƒuƒŠƒbƒhŠJĂ).

732038. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰) bó‘B”÷Ź“ű“ŞŠŕ‚̐ϋɓIŒo‰ßŠĎŽ@‚Ć—ŻˆÓ‚ˇ‚ׂŤƒ|ƒCƒ“ƒg. ‰Á“Ą@O (“ű‘BEbó‘BŠO): ‘ć11‰ńź_“ސě“ŕ•Ş”ĺE‘ăŽÓŽžŠłŒ¤‹†‰ď (2021), ‘Š–ÍŒ´ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

732039. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰) (TKI) —LŠQŽ–Űƒ}ƒlƒWƒƒ“ƒg‚É‚¨‚˘‚Ä‘ĺŘ‚Č‚ą‚Ć. ‰Á“Ą@O (“ű‘BEbó‘BŠO): Thyroid Cancer Meet The Expert in Kanagawa (2022/3), WebŠJĂ.

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-110017. [Œ´’˜] Is total endoscopic parathyroidectomy an acceptable treatment for patients with primary hyperparathyroidism due to a presumed solitary adenoma?|comparison of minimally invasive total endoscopic parathyroidectomy and open minimally invasive parathyroidectomy. Saito Y, Ikeda Y, Katoh H1, Nakao A, Takami H: Gland Surg 2021/1; 10 (1): 83-9. (‰Á“Ą@O1: 1“ű‘BEbó‘BŠO)

'20-310001. [Ç—á•ń] Neoadjuvant use of lenvatinib in locally advanced papillary thyroid carcinoma involving critical vessels. Katoh H1, Kajita S2, Yokota M3, Sengoku N1, Sangai T1: Int J Endocrine Oncol 2021/3; 7 (3): IJE33. doi.org/10.2217/ije-2020-0014. (‰Á“Ą@O1, Š“cç”ü”T2, ‰Ą“cŒő‰›3, ĺÎ‹I•F1, ŽOŠK‹MŽj1: 1“ű‘BEbó‘BŠO, 2•a—, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

[Šw‰ďEŒ¤‹†‰ď“™]

'20-723016. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) bó‘B“ű“ŞŠŕ‚É‚¨‚Ż‚郊ƒ“ƒp‹…-’P‹…”ä (LMR) ‚ĚˆÓ‹`. ‰Á“Ą@O1, ź‹{—mŽj1, ‹e’r^—Žq1, ĺÎ‹I•F1, ŽR‰şŒpŽj2,3, ŽOŠK‹MŽj1 (1“ű‘BEbó‘BŠO, 2ă•”Á‰ťŠÇŠO, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć53‰ń“ú–{“ŕ•Ş”ĺŠO‰ČŠw‰ďŠwp‘ĺ‰ď (2020/11/26), Vh.


ˆę”ʁEŹŽ™EŠĚ’_äXŠO‰ČŠw

[Šwp˜_•ś]

110251. [Œ´’˜] Multicenter Propensity Score-Based Study of Laparoscopic Repeat Liver Resection for Hepatocellular Carcinoma: A Subgroup Analysis of Cases with Tumors Far from Major Vessels. Miyama A, Morise Z, Aldrighetti L, Belli G, Ratti F, Cheung TT, Lo CM, Tanaka S, Kubo S, Okamura Y, Uesaka K, Monden K, Sadamori H, Hashida K, Kawamoto K, Gotohda N, Chen K, Kanazawa A, Takeda Y, Ohmura Y, Ueno M, Ogura T, Suh KS, Kato Y, Sugioka A, Belli A, Nitta H, Yasunaga M, Cherqui D, Halim NA, Laurent A, Kaneko H, Otsuka Y, Kim KH, Cho HD, Lin CCW, Ome Y, Seyama Y, Troisi RI, Berardi G, Rotellar F, Wilson GC, Geller DA, Soubrane O, Yoh T, Kaizu T1, Kumamoto Y1, Han HS, Ekmekcigil E, Dagher I, Fuks D, Gayet B, Buell JF, Ciria R, Briceno J, O'Rourke N, Lewin J, Edwin B, Shinoda M, Abe Y, Hilal MA, Alzoubi M, Tanabe M, Wakabayashi G: Cancers (Basel) 2021/6; 13 (13): 3187. (ŠC’Ă‹MŽj1, ŒGŒł—Y‰î1: 1ˆę”ʁEŹŽ™EŠĚ’_äXŠO)

110252. [Œ´’˜] Surgical Outcomes of Pancreatectomy with Resection of the Portal Vein and/or Superior Mesenteric Vein and Jejunal Vein for Pancreatic Head Cancer: A Multicenter Study. Nagakawa Y, Jang JY, Kawai M, Kim SC, Inoue Y, Yabushita Y, Heo JS, Honda M, Sugiura T, Kagawa S, Hayasaki A, Kwon W, Uemura K, Han HS, Sugimoto M, Ando Y, Nakamura M, Wada K, Kumamoto Y1, Osakae H, Tsuchida A, Yoon YS, Park JS, Yamaue H, Endo I: Ann Surg 2021/12. doi: 10.1097/SLA.0000000000005330. Online ahead of print. (ŒGŒł—Y‰î1: 1ˆę”ʁEŹŽ™EŠĚ’_äXŠO)

120007. [Œ´’˜] ”­Ç‚Š‚ç15”NˆČăŒo‰ß‚ľ‚Ä‚ŕ’ʉ@‚Ş•K—v‚Č’Z’°ÇŒóŒQ‚Ě’ˇŠú—\Œă‚ĚŒŸ“˘. o‰Ć‹œˆę1, “c’†@Œ‰1,2, “n•”–ő˜Y1, ŹěËŽq1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ŹŽ™ŠO‰Č 2022/3; 54 (3): 241-6.

320002. [Ç—á•ń] –ƉuőF‚ĹƒOƒ‹ƒJƒSƒ“•”•Ş—zŤ‚đŽŚ‚ľ‚˝ƒOƒ‹ƒJƒSƒm[ƒ}‚Ě1—á. ćс@—T—ş1, źŕVL‹ą2, “c“‡@O2, “Ą”örˆň2, ‰Ş–{Œő‹FŽq2, ‹v•Ű”CŽj2, ‘ŕV^ŽŔŽq3, ŠC’Ă‹MŽj2, ‘ş‰_–FŽ÷4, ŒGŒł—Y‰î2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 3”畆, 4•a—): “ú–{ŠO‰ČŒn˜A‡Šw‰ďŽ 2021/12; 46 (6): 709-16.

522059. [uŔ]y“ÁW: ă•”Á‰ťŠÇŽčp‚É‚¨‚Ż‚éƒgƒ‰ƒuƒ‹ƒVƒ…[ƒeƒBƒ“ƒO|˘“ďÇ—áE‹ô”­Ç‚Ö‚Ě‘ÎôzŠĚś—tŽö“Ž’E“]Žž‚̉ĄŠu–Œ’ź‰ş‰ş‘ĺ“Ž–Ź—Ź“ü•”‚É‚¨‚Ż‚éŠĚĂ–Ź‘š‚ɑ΂ˇ‚é‘Ώˆ ŒGŒł—Y‰î1, ŠC’Ă‹MŽj1, “c“‡@O1, źŕVL‹ą1, ‹v•Ű”CŽj1, ”äŠé’źŽ÷2 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2ă•”Á‰ťŠÇŠO): Žčp 2021/6; 75 (7): 1205-9.

522060. [uŔ]y“ÁW: ŹlˆÚsŽx‰‡‚Ě“ń–ʐŤz[Še˜_] Ź’ˇ‚ɍ‡‚í‚š‚˝ŽŠ—§EŽŠ—ĽŽx‰‡@ę–ĺ—Ěˆć‚ĚŽŠ—§Žx‰‡@ŹŽ™ŠO‰ČŽžŠł. ”ö‰Ô˜aŽq, “c•—TŽq, “c’†@Œ‰1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ŹŽ™“ŕ‰Č 2021/8; 53 (8): 1265-70.

522061. [uŔ]y“ÁW: ŹŽ™ŠO‰ČŽžŠł‚̉Ƒ°“ŕ”­śzäX’_ŠÇ‡—ŹˆŮíÇ. “c’†@Œ‰1,2, o‰Ć‹œˆę2, “n•”–ő˜Y2 ŹěËŽq2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ŹŽ™ŠO‰Č 2021/12; 53 (12): 1291-5.

540025. [‚ť‚Ě‘ź]yˆĎˆő‰ď•ńzu“ú–{ŹŽ™ŠO‰ČŠw‰ď”F’čŽ{Ý/‹łˆçŠÖ˜AŽ{Ý‚É‚¨‚Ż‚éƒgƒ‰ƒ“ƒWƒVƒ‡ƒ“ŽŔ‘Ô’˛¸v•ń. “ú–{ŹŽ™ŠO‰ČŠw‰ďƒgƒ‰ƒ“ƒWƒVƒ‡ƒ“ŒŸ“˘ˆĎˆő‰ď (“c’†@Œ‰1,2: 1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO): “ú–{ŹŽ™ŠO‰ČŠw‰ďŽGŽ 2021/6; 57 (4): 773-81.

[’˜@‘]

620072. [Šwp‘ (•Ş’SŽˇ•M)]y•W€ŹŽ™ŠO‰ČŠw@‘ć8”Łz‘ć20Í • •ÇEä`‚¨‚ć‚Ń‘lŒa•”@ä`‘Ńƒwƒ‹ƒjƒA, • •Ç”j—ô, ä`ƒwƒ‹ƒjƒA, ä`’°ŠÇˆâŽc, —‘‰Š’°ŠÇˆâŽc, ”A–ŒŠÇˆâŽc,ć“VŤ• •Ç‹ŘŒ`Ź•s‘S (prune belly ÇŒóŒQ), p.272-9. “c’†@Œ‰1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO), ŠÄC: ă–ě@Ž , •Ň: m”öł‹L, ‰œŽRGb, “cK’B˜Y, ˆăŠw‘‰@, “Œ‹ž, 2022/3”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

722102. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) • o‹ž‰şŒn““IŠĚŘœ‚É‚¨‚Ż‚éˆŔ‘SŤ‚đl—ś‚ľ‚˝ŽčpŽč‹Z. ŠC’Ă‹MŽj1, “c“‡@O1, źŕVL‹ą1, ‹v•Ű”CŽj1, ‰Ş–{Œő‹FŽq, “ĄŽR–FŽ÷2, ćс@—T—ş2, ŽO‰YŒ[šć3, ˛“Ą•˜Y3, ×“c@Œj4, ĺÎ‹I•F5, ‰Á“Ą@O5, “c’†@Œ‰1,6, ŽR‰şŒpŽj4,7, ŽOŠK‹MŽj5, ”äŠé’źŽ÷4, “ŕ“Ą@„3, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‰ş•”Á‰ťŠÇŠO, 4ă•”Á‰ťŠÇŠO, 5“ű‘BEbó‘BŠO, 6V˘‹Iˆă—ÁEć’[ˆă—Ă, 7V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć121‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/4/8-10), WebŠJĂ.

722103. [Šw‰ď (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) “ú–{ŹŽ™ŠO‰ČŠw‰ď”F’čŽ{Ý/‹łˆçŠÖ˜AŽ{Ý‚É‚¨‚Ż‚éƒgƒ‰ƒ“ƒWƒVƒ‡ƒ“ŽŔ‘Ô’˛¸. “c•—TŽq, ‘ĺ‹´L‰î, “cˆä’†‹M‹v, ŒĂě‘׎O, Ö“Ą@•, ‰ÁŽĄ@Œš, ›Ŕ—], –]ŒŽ‹żŽq, ”ö‰Ô˜aŽq, “c’†@Œ‰1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć58‰ń“ú–{ŹŽ™ŠO‰ČŠw‰ďŠwpW‰ď (2021/4/29), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722104. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Coping with hemorrhage in laparoscopic pancreatic resection. “c“‡@O1, ŠC’Ă‹MŽj1, źŕVL‹ą1, ‰Ş–{Œő‹FŽq, ćс@—T—ş2, “ĄŽR–FŽ÷2, ‹v•Ű”CŽj1, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć33‰ń“ú–{ŠĚ’_äXŠO‰ČŠw‰ďŠwpW‰ď (2021/6/3), WebŠJĂ.

722105. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Standardization and safety of laparoscopic right posterior sectionectomy. ŠC’Ă‹MŽj1, “c“‡@O1, źŕVL‹ą1, ‹v•Ű”CŽj1, ‰Ş–{Œő‹FŽq, “ĄŽR–FŽ÷2, ćс@—T—ş2, ”äŠé’źŽ÷3, “ŕ“Ą@„4, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ă•”Á‰ťŠÇŠO, 4‰ş•”Á‰ťŠÇŠO): ‘ć76‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2021/7/9), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722106. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‹‘ĺä`‘Ńƒwƒ‹ƒjƒA‚Ě•Ű‘ś‰Á—Ă’†‚É—\‘zŠO‚ĚŒo‰ß‚đ’H‚Á‚˝‚ŕ‚̂̔畆‚Ŕ핢‚ľ“ž‚˝ˆę—á. o‰Ć‹œˆę1, “c’†@Œ‰1,2, “n•”–ő˜Y1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć37‰ń“ú–{ŹŽ™ŠO‰ČŠw‰ďH‹GƒVƒ“ƒ|ƒWƒEƒ€ (2021/10/30), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722107. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Řœ‰Â”\äXŠŕ‚ɑ΂ˇ‚ép‘OƒQƒ€ƒVƒ^ƒrƒ“‰–Ž_‰–+S-1 (GS) •š—p—Ă–@‚Ě—Ő°“IˆÓ‹`. źŕVL‹ą1, ŒGŒł—Y‰î1, “c“‡@O1, ŒÜ\—’ˆę°1, ‹v•Ű”CŽj1, ŠC’Ă‹MŽj1, VŒ´ł‘ĺ2, ×“c@Œj2, ŽO‰YŒ[šć3, ˛“Ą•˜Y3, ‰Á“Ą@O4, ŽOŠK‹MŽj4, “ŕ“Ą@„3, ”äŠé’źŽ÷2 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2ă•”Á‰ťŠÇŠO, 3‰ş•”Á‰ťŠÇŠO, 4“ű‘BEbó‘BŠO): ‘ć83‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2021/11/19), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723247. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) äXŠŕ‚ɑ΂ˇ‚é• o‹ž‰ş”ö‘¤äXŘœp‚ĚŽčpŽč‹Z‚Ć’ZŠúŹŃ. źŕVL‹ą1, “c“‡@O1, ćс@—T—ş2, ‰Ş–{Œő‹FŽq, ‹v•Ű”CŽj1, ŽO‰YŒ[šć3, ‰Á“Ą@O4, ŠC’Ă‹MŽj1, ĺÎ‹I•F4, ×“c@Œj5, ”äŠé’źŽ÷5, ˛“Ą•˜Y3, ŽOŠK‹MŽj4, “ŕ“Ą@„3, “c’†@Œ‰1,6, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‰ş•”Á‰ťŠÇŠO, 4“ű‘BEbó‘BŠO, 5ă•”Á‰ťŠÇŠO, 6V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć121‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/4/8-10), WebŠJĂ.

723248. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) • o‹ž‰şäX“ޏ\“ńŽw’°Řœp‚̐ŹŃ‚ƍH•v. “c“‡@O1, ŠC’Ă‹MŽj1, źŕVL‹ą1, ‰Ş–{Œő‹FŽq, ćс@—T—ş2, “ĄŽR–FŽ÷2, ‹v•Ű”CŽj1, ŽO‰YŒ[šć3, ‰Á“Ą@O4, ĺÎ‹I•F4, ×“c@Œj5, ˛“Ą•˜Y3, ŽR‰şŒpŽj5,6, “c’†@Œ‰1,7, ”äŠé’źŽ÷5, “ŕ“Ą@„3, ŽOŠK‹MŽj4, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‰ş•”Á‰ťŠÇŠO, 4“ű‘BEbó‘BŠO, 5ă•”Á‰ťŠÇŠO, 6V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 7V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć121‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/4/8-10), WebŠJĂ.

723249. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”j—ôŠĚ×–EŠŕ‚ɑ΂ˇ‚é• o‹ž‰şŠĚŘœ. ‰Ş–{Œő‹FŽq, ŠC’Ă‹MŽj1, “c“‡@O1,źŕVL‹ą1, ‹v•Ű”CŽj1, “ĄŽR–FŽ÷2, ćс@—T—ş2, ŽO‰YŒ[šć3, ˛“Ą•˜Y3, ×“c@Œj4, ĺÎ‹I•F5, ‰Á“Ą@O5, “c’†@Œ‰1,6, ŽR‰şŒpŽj4,7, ŽOŠK‹MŽj5, ”äŠé’źŽ÷4, “ŕ“Ą@„3, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‰ş•”Á‰ťŠÇŠO, 4ă•”Á‰ťŠÇŠO, 5“ű‘BEbó‘BŠO, 6V˘‹Iˆă—ÁEć’[ˆă—Ă, 7V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć121‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/4/8-10), WebŠJĂ.

723250. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) IPMN‘Űf—ĂƒKƒCƒhƒ‰ƒCƒ“‚É‚¨‚Ż‚éEUSŒ‹ßŒa‚Ć•a—Šw“IˆŮŒ^“x‚ĚŒŸ“˘. “ĄŽR–FŽ÷1, źŕVL‹ą2, ‰Ş–{Œő‹FŽq, ćс@—T—ş1, ’†–{CŽi2, ‹v•Ű”CŽj2, “c“‡@O2, ŠC’Ă‹MŽj2, ŒGŒł—Y‰î2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć121‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/4/10), WebŠJĂ.

723251. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ĺŠw•a‰@‚É‚¨‚Ż‚é16ÎˆČă‚ĚŽčpÇ—á‚ĚŒŸ“˘. “n•”–ő˜Y1, “c’†@Œ‰1,2, o‰Ć‹œˆę1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć58‰ń“ú–{ŹŽ™ŠO‰ČŠw‰ďŠwpW‰ď (2021/4/28-30), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723252. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) The laparoscopic lens cleaning device reduces surgeon's stress in hepatobiliary-pancreatic laparoscopic surgery. źŕVL‹ą1, ŠC’Ă‹MŽj1, “c“‡@O1, ‰Ş–{Œő‹FŽq, ćс@—T—ş2, “ĄŽR–FŽ÷2, ‹v•Ű”CŽj1, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć33‰ń“ú–{ŠĚ’_äXŠO‰ČŠw‰ďŠwpW‰ď (2021/6/2), WebŠJĂ.

723253. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Intrahepatic Glissonian approach for S7 segmentectomy -Parenchymal transection- rst with direct dorsal approach under IOUS guidance. ŠC’Ă‹MŽj1, “c“‡@O1, źŕVL‹ą1, ‹v•Ű”CŽj1, ‰Ş–{Œő‹FŽq, “ĄŽR–FŽ÷2, ćс@—T—ş2, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć33‰ń“ú–{ŠĚ’_äXŠO‰ČŠw‰ďŠwpW‰ď (2021/6/2), WebŠJĂ.

723254. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) VśŽ™Šú‚ÉŽčp—đ‚Ě‚ ‚é—cŽ™Šú‚É”­Ç‚ľ‚˝’°ŠÇ‹CŽîÇ‚Ě2—á. “n•”–ő˜Y1, “c’†@Œ‰1,2, o‰Ć‹œˆę1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć34‰ń“ú–{ŹŽ™‹~‹}ˆăŠw‰ďŠwpW‰ď (2021/6/18-20), “Ţ—Ç (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723255. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’â—Ż¸‘ƒŽčpŽž‚É”F‚ß‚˝—V—Ł‘Ě‚Ě2—á. “n•”–ő˜Y1, “c’†@Œ‰1,2, o‰Ć‹œˆę1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć30‰ń“ú–{ŹŽ™”ĺ”AŠí‰ČŠw‰ď‘‰ďEŠwpW‰ď (2021/7/2), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723256. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒXƒg[ƒ}‚đ•Ű—L‚ˇ‚鏬Ž™‚âŠÔŒ‡“ą”A‚đ•K—v‚Ć‚ˇ‚鏬Ž™‚̏A‰€EAŠw‚Ě‚˝‚߂̕׋­‰ďŽ‘—ż‚̍쐬. •ŰŠ L‘ă, ‰œ“c—T”ü, ˆ˘•”@ŒO, Š™“c’źŽq, ‚ŒŠŕVŽ , “ŒŠÔ–˘—ˆ, ź–ě‘ĺ•ă, “c’†@Œ‰1,2 (1V˘‹Iˆă—ÁEć’[’f“Iˆă—Ă, 2ˆę”ʁEŹŽ™EŠĚ’_äX): ‘ć30‰ń“ú–{‘nEƒIƒXƒgƒ~[EŽ¸‹ÖŠÇ—Šw‰ďŠwpW‰ď (2021/7/3-5), WebŠJĂ.

723257. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚éPNEN‚ĚŽĄ—ÐŹŃ. ćс@—T—ş1, źŕVL‹ą2, “c“‡@O2, ‰Ş–{Œő‹FŽq, ‹v•Ű”CŽj2, ŠC’Ă‹MŽj2, ŽOŠK‹MŽj3, “ŕ“Ą@„4, ”äŠé’źŽ÷5, ŒGŒł—Y‰î2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 3“ű‘BEbó‘BŠO, 4‰ş•”Á‰ťŠÇŠO, 5ă•”Á‰ťŠÇŠO): ‘ć76‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2021/7/7), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723258. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) • o‹ž‰şäXŘœp‚É‚¨‚Ż‚ép’†‹ô”­Ç‚Ö‚Ě‘Îˆ–@. “c“‡@O1, ŠC’Ă‹MŽj1, źŕVL‹ą1, ‰Ş–{Œő‹FŽq, ćс@—T—ş2, “ĄŽR–FŽ÷2, ‹v•Ű”CŽj1, ”äŠé’źŽ÷3, “ŕ“Ą@„4, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ă•”Á‰ťŠÇŠO, 4‰ş•”Á‰ťŠÇŠO): ‘ć76‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2021/7/8), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723259. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) äX‰t˜R‚đĹŹŒŔ‚É—}‚Ś‚éŠ`“cŽŽäX‹ó’°•Ť‡‚ƏŹ—tŠÔäXŘ—Ł‚Ě’ńˆÄ. źŕVL‹ą1, ŒGŒł—Y‰î1, ‰Ş–{Œő‹FŽq, ćс@—T—ş2, “ĄŽR–FŽ÷2, “c“‡@O1, ‹v•Ű”CŽj1, ŠC’Ă‹MŽj1, “ŕ“Ą@„3, ”äŠé’źŽ÷4 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‰ş•”Á‰ťŠÇŠO, 4ă•”Á‰ťŠÇŠO): ‘ć76‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2021/7/9), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723260. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚éÁ‰ťŠÇ’Ę‰ßáŠQ‚Ě‚Č‚˘‘ٕ֐Ť• –Œ‰Š‚ĚŒŸ“˘. o‰Ć‹œˆę1, “c’†@Œ‰1,2 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć57‰ń“ú–{ŽüŽYŠúEVśŽ™ˆăŠw‰ďŠwpW‰ď (2021/7/11), ‹{č (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723261. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “ŕŽ‹‹ž‰şĚŽćŒŸ‘Ě‚É‚¨‚Ż‚éCDO1ˆâ“`ŽqDNAƒƒ`ƒ‹‰ť‚Ě—Ő°“IˆÓ‹`. źŕVL‹ą1, “ĄŽR–FŽ÷2, ćс@—T—ş2, ŒÜ\—’ˆę°1, “c“‡@O1, ‹v•Ű”CŽj1, ŠC’Ă‹MŽj1, ‰œ˜e‹ť‰î3, Šâˆä’m‹v3, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3Á‰ťŠí“ŕ): ‘ć52‰ń“ú–{äX‘ŸŠw‰ď‘ĺ‰ď (2021/9/22), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723262. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’_“šŠŕ‚ɑ΂ˇ‚é• o‹ž‰şäX“ޏ\“ńŽw’°Řœ‚Ě“ą“ü. “c“‡@O1, ŠC’Ă‹MŽj1, źŕVL‹ą1, ŒÜ\—’ˆę°1, ‹v•Ű”CŽj1, ‰œ˜e‹ť‰î2, Šâˆä’m‹v2, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2Á‰ťŠí“ŕ): ‘ć57‰ń“ú–{’_“šŠw‰ďŠwpW‰ď (2021/10/7), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723263. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) äXŠŕ‚ɑ΂ˇ‚é• o‹ž‰şäX‘Ě”ö•”Řœp‚̏p–ě“WŠJ‚̍H•v. “c“‡@O1, ŠC’Ă‹MŽj1, źŕVL‹ą1, ‰Ş–{Œő‹FŽq, ćс@—T—ş2, ŒÜ\—’ˆę°1, ‹v•Ű”CŽj1, ŽR‰şŒpŽj3,4, ˛“Ą•˜Y5, “c’†@Œ‰1,6, ”äŠé’źŽ÷4, “ŕ“Ą@„5, ŽOŠK‹MŽj7, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4ă•”Á‰ťŠÇŠO, 5‰ş•”Á‰ťŠÇŠO, 6V˘‹Iˆă—ÁEć’[ˆă—Ă, 7“ű‘BEbó‘BŠO): ‘ć83‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2021/11/18), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723264. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) • o‹ž‰şäX“ޏ\“ńŽw’°Řœp‚̍H•v. “c“‡@O1, ŠC’Ă‹MŽj1, źŕVL‹ą1, ‰Ş–{Œő‹FŽq, ćс@—T—ş2, ŒÜ\—’ˆę°1, ‹v•Ű”CŽj1, ˛“Ą•˜Y3, “c’†@Œ‰1,4, ”äŠé’źŽ÷5, “ŕ“Ą@„3, ŽOŠK‹MŽj6, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‰ş•”Á‰ťŠÇŠO, 4V˘‹Iˆă—ÁEć’[ˆă—Ă, 5ă•”Á‰ťŠÇŠO, 6“ű‘BEbó‘BŠO): ‘ć83‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2021/11/18), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723265. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) äB‘Ÿ‚̉ˇ‘ś‚މ”\‚Ĺ‚ ‚Á‚˝“Á”­Ť‚̐VśŽ™äB‘Ÿ‘š‚Ěˆę—á. ‰şŒ`Ť‰›1, “c’†@Œ‰2,3, o‰Ć‹œˆę3, “n•”–ő˜Y3 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć83‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2021/11/18), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723267. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Oncologic emergency‚đ’ć‚ľ‚˝“űŽ_ƒAƒVƒh[ƒVƒX‡•šVśŽ™•›tŒ´”­_Œo‰čŽî‚Ěˆę—á. o‰Ć‹œˆę1, “c’†@Œ‰1,2, “n•”–ő˜Y1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć63‰ń“ú–{ŹŽ™ŒŒ‰tE‚Ş‚ńŠw‰ďŠwpW‰ď (2021/11/25), WebŠJĂ.

723268. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”ńí‚É‹H‚Č‹‘ĺ• •ÇŽîᇂ̈ę—á. “n•”–ő˜Y1, “c’†@Œ‰1,2, o‰Ć‹œˆę1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć63‰ń“ú–{ŹŽ™ŒŒ‰tE‚Ş‚ńŠw‰ďŠwpW‰ď (2021/11/25), WebŠJĂ.

723269. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) • o‹ž‰şŠĚŘœ‚É‚¨‚Ż‚éoŒŒE’_`˜R‘΍ô. ŒGŒł—Y‰î1, ŠC’Ă‹MŽj1, “c“‡@O1, źŕVL‹ą1, ‹v•Ű”CŽj1, ŒÜ\—’ˆę°1, ‰Ş–{Œő‹FŽq, ćс@—T—ş2, “ŕ“Ą@„3, ”äŠé’źŽ÷4, ×“c@Œj4, ˛“Ą•˜Y3, ŽR—œ‚L3, ŽO‰YŒ[šć3, VŒ´ł‘ĺ4, ŽOŠK‹MŽj5 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‰ş•”Á‰ťŠÇŠO, 4ă•”Á‰ťŠÇŠO, 5“ű‘BEbó‘BŠO): ‘ć34‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2021/12/2), _ŒË.

723270. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) • o‹ž‰ş’_ŠÇ‹ó’°•Ť‡‚Ě’čŒ^‰ť‚Ć’ZŠúŹŃ. “c“‡@O1, ŠC’Ă‹MŽj1, źŕVL‹ą1, ‰Ş–{Œő‹FŽq, ćс@—T—ş2, ŒÜ\—’ˆę°1, ‹v•Ű”CŽj1, ŽR—œ‚L3, ×“c@Œj4, ŽR‰şŒpŽj4,5, ˛“Ą•˜Y3, “c’†@Œ‰1,6, ”äŠé’źŽ÷4, “ŕ“Ą@„3, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‰ş•”Á‰ťŠÇŠO, 4ă•”Á‰ťŠÇŠO, 5V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 6V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć34‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2021/12/2), _ŒË.

723271. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) • o‹ž‰şŒn““IŠĚŘœ‚̍H•v‚¨‚ć‚Ń‚ť‚ĚŽčpŹŃ. ŠC’Ă‹MŽj1, ŒÜ\—’ˆę°1, źŕVL‹ą1, “c“‡@O1, ‹v•Ű”CŽj1, VŒ´ł‘ĺ2, ŽO‰YŒ[šć3, ŽR—œ‚L3, ‰Á“Ą@O4, ×“c@Œj2, ˛“Ą•˜Y3, ”äŠé’źŽ÷2, “ŕ“Ą@„3, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2ă•”Á‰ťŠÇŠO, 3‰ş•”Á‰ťŠÇŠO, 4“ű‘BEbó‘BŠO): ‘ć34‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2021/12/3), _ŒË.

723272. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) • o‹ž‰ş‰E—tŒnŒn““IŠĚŘœ‚Ě’čŒ^‰ť‚É”ş‚¤ŽĄ—ÐŹŃ‚Ě•Ď‘J. ŒÜ\—’ˆę°1, ŠC’Ă‹MŽj1, źŕVL‹ą1, “c“‡@O1, ‹v•Ű”CŽj1, o‰Ć‹œˆę1, VŒ´ł‘ĺ2, ŽR—œ‚L3, ×“c@Œj2, ˛“Ą•˜Y3, “c’†@Œ‰1,4, ”äŠé’źŽ÷2, “ŕ“Ą@„3, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2ă•”Á‰ťŠÇŠO, 3‰ş•”Á‰ťŠÇŠO, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć34‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2021/12/4), _ŒË.

732040. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) äXŠŕ‚ɑ΂ˇ‚é• o‹ž‰ş”ö‘¤äXŘœ‚ĚƒŠƒ“ƒpßŠs´‚É‚¨‚Ż‚é‰đ–UŠw“Iƒ‰ƒ“ƒhƒ}[ƒN. źŕVL‹ą1, “c“‡@O1, ŒÜ\—’ˆę°1, ‹v•Ű”CŽj1, ŠC’Ă‹MŽj1, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć15‰ńŠĚ‘Ÿ“ŕŽ‹‹žŠO‰ČŒ¤‹†‰ďE‘ć13‰ńäX‘Ÿ“ŕŽ‹‹žŠO‰ČŒ¤‹†‰ď (2021/11/17), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

732041. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) • o‹ž‰şäXŘœ‚Ĺ‚Ěp–ě“WŠJ‚̍H•v. “c“‡@O1, ŠC’Ă‹MŽj1, źŕVL‹ą1, ‰Ş–{Œő‹FŽq, ćс@—T—ş2, ŒÜ\—’ˆę°1, ‹v•Ű”CŽj1, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć15‰ńŠĚ‘Ÿ“ŕŽ‹‹žŠO‰ČŒ¤‹†‰ďE‘ć13‰ńäX‘Ÿ“ŕŽ‹‹žŠO‰ČŒ¤‹†‰ď (2021/11/17), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

732042. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) • o‹ž‰ş”ö‘¤äXŘœ‚É‚¨‚Ż‚éreduced port surgery (needlescopic surgery) ‚ĚŽĄ—ÐŹŃ. źŕVL‹ą1, “c“‡@O1, ŠC’Ă‹MŽj1, ŒÜ\—’ˆę°1, ‹v•Ű”CŽj1, ×“c@Œj2, ˛“Ą•˜Y3, “ŕ“Ą@„3, ”äŠé’źŽ÷2, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2ă•”Á‰ťŠÇŠO, 3‰ş•”Á‰ťŠÇŠO): 9th Reduced Port Surgery Forum in Okinawa (2022/2/16), WebŠJĂ.

733078. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‘ŮŽ™Šú‚Éä`‘ŃůN–E‚đŽw“E‚ł‚ę”A–ŒŠÇᑂƐf’f‚ł‚ę‚˝2—á. “n•”–ő˜Y1, “c’†@Œ‰1,2, o‰Ć‹œˆę1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć7‰ń“ú–{ŹŽ™‚Ö‚ťŒ¤‹†‰ď (2021/4/9), WebŠJĂ.

733079. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ”­Ç‚Š‚ç15”NˆČăŒo‰ß‚ľ‚Ä‚ŕ’ʉ@‚Ş•K—v‚Č’Z’°ÇŒóŒQÇ—á‚Ě’ˇŠú—\Œă‚ĚŒŸ“˘. o‰Ć‹œˆę1, “c’†@Œ‰1,2, “n•”–ő˜Y1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć118‰ń“Œ‹žŹŽ™ŠO‰ČŒ¤‹†‰ď (2021/6/1), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733080. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) lHăč–ĺÄ‘˘Ý‚đ•K—v‚Ć‚ľ‚˝\“ńŽw’°•Â˝Ç‡•š‚ˆĘ˝ăč‚Ě1—á. “n•”–ő˜Y1, “c’†@Œ‰1,2, o‰Ć‹œˆę1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć55‰ń“ú–{ŹŽ™ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/10/2), WebŠJĂ.

733081. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) äB‰ˇ‘ś‚މ”\‚Ĺ‚ ‚Á‚˝“Á”­Ť‚̐VśŽ™äB‘Ÿ‘š‚Ě1—á. ‰şŒ`Ť‰›1, “c’†@Œ‰2,3, o‰Ć‹œˆę3, “n•”–ő˜Y3 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć55‰ń“ú–{ŹŽ™ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/10/2), WebŠJĂ.

733082. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) –Ó’°ŒeŽş‚ɑ΂ľ‚Ä• o‹ž‰şŒeŽşŘœp‚đŽ{s‚ľ‚˝1—á. “n•”–ő˜Y1, “c’†@Œ‰1,2, o‰Ć‹œˆę1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć40‰ń“ú–{ŹŽ™“ŕŽ‹‹žŠO‰ČEŽčpŽč‹ZŒ¤‹†‰ď (2021/10/28), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733083. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Žĺ—v–ŹŠÇ‚ć‚č‹——Ł‚Ş‚ ‚éÄ”­ŠĚ×–EŠŕ‚ɑ΂ˇ‚é• o‹ž‰şŠĚÄŘœ: ‘Ű‘˝Ž{Ý‹¤“ŻŒă‚ëŒü‚ŤŒ¤‹†ƒTƒuƒOƒ‹[ƒv‰đÍ. ŽçŁ‘Pˆę, Aldrighetti Luca, Belli Giulio, “c糁@–Ť, Žá—с@„, ILLS-Tokyo Collaborator group (ŒGŒł—Y‰î1, ‘ź) (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć15‰ńŠĚ‘Ÿ“ŕŽ‹‹žŠO‰ČŒ¤‹†‰ďE‘ć13‰ńäX‘Ÿ“ŕŽ‹‹žŠO‰ČŒ¤‹†‰ď (2021/11/17), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733084. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) • o‹ž‰şŠĚŘœ‚É‚¨‚Ż‚éoŒŒE’_`˜R‘΍ô‚¨‚ć‚Ń‘ĺ’°“ŻŽžŘœŠÖ˜A‡•šÇ‘΍ô. ŠC’Ă‹MŽj1, “c“‡@O1, źŕVL‹ą1, ŒÜ\—’ˆę°1, ‹v•Ű”CŽj1, ŽR—œ‚L2, ×“c@Œj3, ˛“Ą•˜Y2, ”äŠé’źŽ÷3, “ŕ“Ą@„2, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‰ş•”Á‰ťŠÇŠO, 3ă•”Á‰ťŠÇŠO): ‘ć15‰ńŠĚ‘Ÿ“ŕŽ‹‹žŠO‰ČŒ¤‹†‰ďE‘ć13‰ńäX‘Ÿ“ŕŽ‹‹žŠO‰ČŒ¤‹†‰ď (2021/11/17), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733085. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) • o‹ž‰şŒn““IŠĚŘœ‚Ě’čŒ^‰ť‚̍H•v‚¨‚ć‚ŃŽĄ—ÐŹŃ‚Ě•Ď‘J. ŒÜ\—’ˆę°1, ŠC’Ă‹MŽj1, ‰Ş–{Œő‹FŽq, ćс@—T—ş2, źŕVL‹ą1, “c“‡@O1, ‹v•Ű”CŽj1, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć15‰ńŠĚ‘Ÿ“ŕŽ‹‹žŠO‰ČŒ¤‹†‰ďE‘ć13‰ńäX‘Ÿ“ŕŽ‹‹žŠO‰ČŒ¤‹†‰ď (2021/11/17), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733086. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “–‰Č‚É‚¨‚Ż‚é‘lŒa•”ŘŠJ–@‚É‚ć‚鏬Ž™‘lŒaƒwƒ‹ƒjƒAŽčp. “c’†@Œ‰1,2, o‰Ć‹œˆę2, “n•”–ő˜Y2, ŹěËŽq2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć12‰ń_“ސěƒwƒ‹ƒjƒAŒ¤‹†‰ď (2021/12/4), WebŠJĂ.

'20”N“xˆČ‘O•Ş

[Šw‰ďEŒ¤‹†‰ď“™]

'20-722002. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Technique and outcomes of laparoscopic distal pancreatectomy for pancreatic cancer. źŕVL‹ą1, “c“‡@O1, ‹v•Ű”CŽj1, ŠC’Ă‹MŽj1, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć33‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (JSES 2020) (2021/3/12), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-723017. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Difficulty assessment of HBP surgery Validation of an Index-based IWATE Criteria for Laparoscopic Liver Resection: A Multicenter Analysis by the Endoscopic Liver Surgery Study Group in Japan. Shogo T, Kawaguchi Y, Kubo S, Kanazawa A, Takeda Y, Hirokawa F, Nitta H, Nakajima T, ŠC’Ă‹MŽj1, Kaibori M, Kojima T, Otsuka Y, Fuks David, Hasegawa K, Kokudo N, Kaneko H, Gayet Brice, Wakabayashi G (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć32‰ń“ú–{ŠĚ’_äXŠO‰ČŠw‰ďŠwpW‰ď (2021/2/24), WebŠJĂ.

'20-723018. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒXƒg[ƒ}‚đ•Ű—L‚ˇ‚鏬Ž™‚̏A‰€EAŠw‚É‚¨‚Ż‚é‰Ű‘č‚Ě–žŠm‰ť|ˆă—ĂŽŇ‚ĚŒoŒą‚ÉŠî‚Ă‚­ŽŔ‘Ô’˛¸|. •ŰŠ L‘ă, ˆ˘•”@ŒO, ‰œ“c—T”ü, Š™“c’źŽq, ‚ŒŠŕVŽ , “ŒŠÔ–˘—ˆ, ź–ě‘ĺ•ă, “c’†@Œ‰1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć38‰ń“ú–{ƒXƒg[ƒ}E”rŸ•ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ď‘‰ď (JSSCR) (2021/2/26-27), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-723019. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠÔŒ‡“ą”A‚đ•K—v‚Ć‚ˇ‚鏬Ž™‚̏A‰€EAŠw‚É‚¨‚Ż‚é‰Ű‘č‚Ě–žŠm‰ť|ˆă—ĂŽŇ‚ĚŒoŒą‚ÉŠî‚Ă‚­ŽŔ‘Ô’˛¸|. Š™“c’źŽq, •ŰŠ L‘ă, ˆ˘•”@ŒO, ‰œ“c—T”ü, ‚ŒŠŕVŽ , “ŒŠÔ–˘—ˆ, ź–ě‘ĺ•ă, “c’†@Œ‰1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć38‰ń“ú–{ƒXƒg[ƒ}E”rŸ•ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ď‘‰ď (JSSCR) (2021/2/26-27), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-723020. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) The advantages of laparoscopic approach in anatomical liver resection; a single center experience. ŠC’Ă‹MŽj1, “c“‡@O1, źŕVL‹ą1, ‹v•Ű”CŽj1, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć33‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (JSES 2020) (2021/3/11), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-723021. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Impact of upper abdominal surgical history on short-term outcomes in laparoscopic liver resection. ŒGŒł—Y‰î1, ŠC’Ă‹MŽj1, “c“‡@O1, ‹v•Ű”CŽj1, źŕVL‹ą1, ‰Ş–{Œő‹FŽq1, “ĄŽR–FŽ÷2, ćс@—T—ş2 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć33‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (JSES 2020) (2021/3/11), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-723022. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Pancreatic transection procedure for laparoscopic distal pancreatectomy. “c“‡@O1, źŕVL‹ą1, ‹v•Ű”CŽj1, ŠC’Ă‹MŽj1, ŒGŒł—Y‰î1 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć33‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (JSES 2020) (2021/3/11), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-733010. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŹŽ™‚“ď“x“ŕŽ‹‹žŽčp‚Ě‹ZpK“ž‚Ě‚˝‚߂Ɂ`VśŽ™H“š•Â˝Çƒ‚ƒfƒ‹‚ĚŠJ”­‚ĆƒgƒŒ[ƒjƒ“ƒOŒř‰Ę‚ĚŒŸŘ`. o‰Ć‹œˆę1, “ŕ“cL•v, ÎŠŰ“N–ç, “n•”–ő˜Y1, “c’†@Œ‰1,2 (1ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć23‰ńKSOA (2021/2/27), WebŠJĂ.


ă•”Á‰ťŠÇŠO‰ČŠw

[Šwp˜_•ś]

110253. [Œ´’˜] Prospective study to validate the clinical utility of DNA diagnosis of peritoneal fluid cytology test in gastric cancer. Harada H1, Soeno T2, Nishizawa N3, Washio M1, Sakuraya M1, Ushiku H1, Niihara M1, Hosoda K1, Kumamoto Y3, Naitoh T4, Sangai T5, Hiki N1, Yamashita K1,6: Cancer Sci 2021/4; 112 (4): 1644-54. (Œ´“cG‹P1, “Y–ěF•ś2, źŕVL‹ą3, ˜h”ö^—ˆ¤1, ŸN’J”ü‹MŽq1, ‹‹vGŽ÷1, VŒ´ł‘ĺ1, ×“c@Œj1, ŒGŒł—Y‰î3, “ŕ“Ą@„4, ŽOŠK‹MŽj5, ”äŠé’źŽ÷1, ŽR‰şŒpŽj1,6: 1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4‰ş•”Á‰ťŠÇŠO, 5“ű‘BEbó‘BŠO, 6V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

110254. [Œ´’˜] Intraoperative conversion from laparoscopic gastrectomy to an open procedure: a decade of experience in a Japanese high-volume center. Kumagai K, Hiki N1, Nunobe S, Jiang X, Makuuchi R. Ida S, Ohashi M Yamaguchi T, Sano T: Surg Endosc 2021/4; 35 (4): 1834-42. (”äŠé’źŽ÷1: 1ă•”Á‰ťŠÇŠO)

110255. [Œ´’˜] Comparison of effects of six main gastrectomy procedures on patients' quality of life assessed by Postgastrectomy Syndrome Assessment Scale-45. Nakada K, Kawashima Y, Kinami S, Fukushima R, Yabusaki H, Seshimo A, Hiki N1, Koeda K, Kano M, Uenosono Y, Oshio A, Kodera Y: Gastrointest Surg. 2021/5; 13 (5): 461_75. (”äŠé’źŽ÷1: 1ă•”Á‰ťŠÇŠO)

110256. [Œ´’˜] Preoperative chemotherapy could modify recurrence patterns through postoperative complications in patients with gastric cancer. Hosoda K1, Ushiku H1, Katada C2, Ishido K2, Niihara M1, Sakuraya M1, Araki I1, Washio M1, Harada H1, Yamashita K1,3, Hiki N1: Langenbecks Arch Surg 2021/6; 406 (4): 1045-55. (×“c@Œj1, ‹‹vGŽ÷1, Œ˜“ce—˜2, ÎŒËŒŞŽŸ2, VŒ´ł‘ĺ1, ŸN’J”ü‹MŽq1, r–Řˆę•˝‘ž1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, ŽR‰şŒpŽj1,3, ”äŠé’źŽ÷1: 1ă•”Á‰ťŠÇŠO, 2Á‰ťŠí“ŕ, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

110257. [Œ´’˜] Esophageal cancer patients' survival after complete response to definitive chemoradiotherapy: a retrospective analysis. Mori K, Sugawara K, Aikou S, Yamashita H, Yamashita K1,2, Ogura M, Chin K, Watanabe M , Matsubara H, Toh Y, Kakeji Y, Seto Y: Esophagus 2021/7; 18 (3): 629-37. (ŽR‰şŒpŽj1,2: 1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2ă•”Á‰ťŠÇŠO)

110258. [Œ´’˜] Features of the complications for intracorporeal Billroth-I and Roux-en-Y reconstruction after laparoscopic distal gastrectomy for gastric cancer. Shoji Y, Kumagai K, Ida S, Ohashi M, Hiki N1, Sano T, Nunobe S: Langenbecks Arch Surg 2021/8; 406 (5): 1425-32. (”äŠé’źŽ÷1: 1ă•”Á‰ťŠÇŠO)

110259. [Œ´’˜] Therapeutic value of splenectomy to dissect splenic hilar lymph nodes for type 4 gastric cancer involving the greater curvature, compared with other types. Kano Y, Ohashi M, Ida S, Kumagai K, Makuuchi R, Sano T, Hiki N1, Nunobe S: Gastric Cancer 2020/9; 23 (5): 927-36. (”äŠé’źŽ÷1: 1ă•”Á‰ťŠÇŠO)

110260. [Œ´’˜] Comparison of Postoperative Quality of Life among Three Different Reconstruction Methods After Proximal Gastrectomy: Insights From the PGSAS Study. Yabusaki H, Kodera Y, Fukushima N, Hiki N1, Kinami S, Yoshida M, Aoyagi K, Ota S, Hata H, Noro H, Oshio A, Nakada K: World J Surg 2020/10; 44 (10): 3433-40. (”äŠé’źŽ÷1: 1ă•”Á‰ťŠÇŠO)

110261. [Œ´’˜] Facilitated completion of 1-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer by medical oncologists. Kano Y, Ohashi M, Hiki N1, Takahari D, Chin K, Yamaguchi K, Ida, S, Kumagai K, Sano T, Nunobe S: Surg Today 2020/10; 50 (10): 1197-205. (”äŠé’źŽ÷1: 1ă•”Á‰ťŠÇŠO)

110262. [Œ´’˜] Clinical outcomes of radical gastrectomy following trastuzumab-based chemotherapy for stage IV HER2-positive gastric or gastroesophageal junction cancer. Takahashi R, Nunobe S, Osumi H, Takahari D, Yamamoto N, Ida S, Kumagai K, Ohashi M, Sano T, Hiki N1: Surg Today 2020/10; 50 (10): 1240-8. (”äŠé’źŽ÷1: 1ă•”Á‰ťŠÇŠO)

110029. [Œ´’˜] Activation of iNKT Cells Facilitates Liver Repair After Hepatic Ischemia Reperfusion Injury Through Acceleration of Macrophage Polarization. Goto T1, Ito Y2, Satoh M3, Nakamoto S4, Nishizawa N4, Hosono K2, Naitoh T5, Eshima K3, Iwabuchi K3, Hiki N6, Amano H2: Front Immunol 2021/10; 12: 754106. (Œă“Ą‘ě–ç1, ˆÉ“Ą‹`–ç2, ˛“Ą@‰ë3, ’†–{CŽi4, źŕVL‹ą4, ×–ě‰Á“ŢŽq2, “ŕ“Ą@„5, ]“‡k“ń3, ŠâŸş˜a–ç3, ”äŠé’źŽ÷6, “V–ě‰pŽ÷2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3–Ɖu, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 5‰ş•”Á‰ťŠÇŠO, 6ă•”Á‰ťŠÇŠO)

110263. [Œ´’˜] Haploinsufficiency by minute MutL homolog 1 promoter DNA methylation may represent unique phenotypes of microsatellite instability-gastric carcinogenesis. Harada H1, Nie Y2, Araki I, Soeno T2, Chuman M1, Washio M1, Sakuraya M1, Ushiku H1, Niihara M1, Hosoda K1, Kumamoto Y3, Naitoh T4, Sangai T5, Hiki N1, Yamashita K1,6: PLoS One 2021/12; 16 (12): e0260303. (Œ´“cG‹P1, ćс@—T—ş2, “Y–ěF•ś2, ’†”nŠî”Ž1, ˜h”ö^—ˆ¤1, ŸN’J”ü‹MŽq1, ‹‹vGŽ÷1, VŒ´ł‘ĺ1, ×“c@Œj1, ŒGŒł—Y‰î3, “ŕ“Ą@„4, ŽOŠK‹MŽj5, ”äŠé’źŽ÷1, ŽR‰şŒpŽj1,6: 1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4‰ş•”Á‰ťŠÇŠO, 5“ű‘BEbó‘BŠO, 6V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

110264. [Œ´’˜] Improved anastomotic technique for esophagojejunal anastomosis using circular stapler. Niihara M1, Hiki N1, Hosoda K1, Sakuraya M1, Washio M1, Chuman M1, Yamashita K1,2: Langenbecks Arch Surg 2022/2; 407 (1): 353-6. (VŒ´ł‘ĺ1, ”äŠé’źŽ÷1, ×“c@Œj1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, ’†”nŠî”Ž1, ŽR‰şŒpŽj1,2: 1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

110265. [Œ´’˜] Indocyanine green fluorescence imaging for evaluating blood flow in the reconstructed conduit after esophageal cancer surgery. Koyanagi K, Ozawa S, Ninomiya Y, Yatabe K, Higuchi T1, Yamamoto M, Kanamori K, Tajima K: Surg Today 2022/3; 52 (3): 369-76. (”óŒű@Ši1: 1ă•”Á‰ťŠÇŠO)

110266. [Œ´’˜] Preliminary Clinical Surgical Experience with Temporary Simultaneous Use of an Endoscope during Exoscopic Neurosurgery: An Observational Study. Murai Y, Shirokane K, Sato S, Higuchi T1, Kubota A, Ozeki T, Matano F, Sasakai K, Yamaguchi F, Morita A: J Clin Med 2022/3; 11 (7): 1753. (”óŒű@Ši1: 1ă•”Á‰ťŠÇŠO)

120008. [Œ´’˜] Řœ•s”\isˆÝŠŕ‚ɑ΂ˇ‚éconversionŽčpÇ—á‚Ě—\ŒăˆöŽq‚Ě“Ż’č. Œ´“cG‹P1, ŽR‰şŒpŽj1,2, “c糁@‘3,4, ÎŒËŒŞŽŸ4, ˜a“c‘ń–ç4, ˜h”ö^—ˆ¤2, ŸN’J”ü‹MŽq2, ‹‹vGŽ÷2, VŒ´ł‘ĺ2, ×“c@Œj2, ”äŠé’źŽ÷2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2ă•”Á‰ťŠÇŠO, 3V˘‹Iˆă—ÁEć’[ˆă—Ă, 4Á‰ťŠí“ŕ): “ú–{Á‰ťŠíŠO‰ČŠw‰ďŽGŽ 2022/3; 55 (3): 147-55.

310026. [Ç—á•ń] Laparoscopic and endoscopic cooperative surgery for advanced gastric cancer as palliative surgery in elderly patients: a case report. Washio M1, Hiki N1, Hosoda K1, Niihara M1, Chuman M1, Sakuraya M1, Wada T2, Harada H1, Sato T3, Tanaka K4,5, Naitoh T6, Kumamoto Y5, Sangai T7, Tanabe S2,4, Yamashita K1,8: Surg Case Rep 2021/11; 7 (1): 241. (˜h”ö^—ˆ¤1, ”äŠé’źŽ÷1, ×“c@Œj1, VŒ´ł‘ĺ1, ’†”nŠî”Ž1, ŸN’J”ü‹MŽq1, ˜a“c‘ń–ç2, Œ´“cG‹P1, ˛“Ą•˜Y3, “c’†@Œ‰4,5, “ŕ“Ą@„6, ŒGŒł—Y‰î5, ŽOŠK‹MŽj7, “c糁@‘2,4, ŽR‰şŒpŽj1,8: 1ă•”Á‰ťŠÇŠO, 2Á‰ťŠí“ŕ, 3ˆă—Ă‹Zp‹łˆç, 4V˘‹Iˆă—ÁEć’[ˆă—Ă, 5ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 6‰ş•”Á‰ťŠÇŠO, 7“ű‘BEbó‘BŠO, 8V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

510016. [‘ŕ] Robot-assisted minimally invasive esophagectomy for esophageal cancer: Meticulous surgery minimizing postoperative complications. Hosoda K1, Niihara M1, Harada H1, Yamashita K1,2, Hiki N1: Ann Gastroenterol Surg 2020/8; 4 (6): 608-17. (×“c@Œj1, VŒ´ł‘ĺ1, Œ´“cG‹P1, ŽR‰şŒpŽj1,2, ”äŠé’źŽ÷1: 1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

510017. [‘ŕ] Postoperative pancreatic fistula after gastrectomy for gastric cancer. Washio M1, Yamashita K1,2, Niihara M1, Hosoda K1, Hiki N1: Ann Gastroenterol Surg 2020/9; 4 (6): 618-27. (˜h”ö^—ˆ¤1, ŽR‰şŒpŽj1,2, VŒ´ł‘ĺ1, ×“c@Œj1, ”äŠé’źŽ÷1: 1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

522062. [uŔ]y“ÁW: ‚Í‚ś‚߂ăi[ƒX‚Ö‘Ą‚é‚ç‚­‚ç‚­•a“ƒPƒAƒKƒCƒh!@Á‰ťŠí‰đ–UEŽžŠłEŽĄ—Ă‚Ě‚Š‚ń‚Ř‚Ťƒ}ƒbƒvz2 ˆÝ‚̉đ–UEŽžŠłEŽĄ—ÁEƒPƒA. ŸN’J”ü‹MŽq (ă•”Á‰ťŠÇŠO): Á‰ťŠíƒi[ƒVƒ“ƒO 2021/4; 26 (4): 16-26.

522063. [uŔ)]yÁ‰ťŠíŠŕ; f’f‚ĆŽĄ—Ă‚Ě‚ˇ‚ׂāzIII —Տ°Çó‚Š‚ç‚ĚŠŕf’fƒvƒƒZƒX@3. HŽv•sUE‚邢‘‰. VŒ´ł‘ĺ1, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO): Á‰ťŠíŠO‰Č 2021/5; 44 (6): 1031-3.

522064. [uŔ]y“ÁW: ŽĄ—Ă‚ĚŽż‚đ‚‚ß‚é! ăŽč‚ȉh—{ťÜ‚Ě‘I‚Ń•űEŽg‚˘•ű; Ç—á‚Š‚çl‚Ś‚é‰h—{ťÜ‚ĚŽg‚˘•űzˆÝ‚Ş‚ń (ŽüpŠú, pŒă‚đŠÜ‚Ţ). ŸN’J”ü‹MŽq1, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO): –ňŽ– 2021/6; 63 (8): 1575-8.

522065. [uŔ]y“ÁW: • o‹žE“ŕŽ‹‹ž‡“ŻŽčp (LECS) ‚ĚŒťó‚Ć“W–]zI. ‘˜_@1) LECS: ŠJ”­‚Ě—đŽj. ˜h”ö^—ˆ¤1, ”äŠé’źŽ÷1, ’†”nŠî”Ž1, ŸN’J”ü‹MŽq1, VŒ´ł‘ĺ1, ×“c@Œj1 (1ă•”Á‰ťŠÇŠO): Žčp 2021/10; 75 (11): 1625-9.

522066. [uŔ]y“ÁW: ‚Ş‚ńˆŤ‰tŽż‚ĚŽĄ—Á|ƒOƒŒƒŠƒ“—lě—p–ňƒAƒiƒ‚ƒŒƒŠƒ“‰–Ž_‰–‚Ě“oę|z1. ‚Ş‚ńƒTƒ|[ƒeƒBƒuƒPƒA‚Ć‚Ş‚ńˆŤ‰tŽż‚ĚŽĄ—Á@6) ‚Ş‚ńˆŤ‰tŽż‚̉h—{—Ă–@. VŒ´ł‘ĺ1, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO): Progress in Medicine 2021/11; 41 (11): 1087-90.

522067. [uŔ]yÁ‰ťŠÇ“ŕŽ‹‹žŽĄ—Á|Šî–{‚Š‚獂“ď“x‚܂ŁzIII. ”S–Œ‰ş‘wE‹Ř‘wE‘S‘wŘœ, ‹Ř‘wŘŠJ@Classical LECS‚Š‚ç‚̍‚“ď“xLECS‚ւ̐i‰ť. ˜h”ö^—ˆ¤1, ”äŠé’źŽ÷1, ×“c@Œj1, VŒ´ł‘ĺ1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, ˜a“c‘ń–ç2, Œ´“cG‹P1, ŽR‰şŒpŽj1,3, “c粁@‘2,4 (1ă•”Á‰ťŠÇŠO, 2Á‰ťŠí“ŕ, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): Á‰ťŠí“ŕŽ‹‹ž 2021/11; 33 (‘Š§†): 248-52.

522068. [uŔ]y“ÁW: ‚Č‚Š‚Č‚ŠŠw‚ׂȂ˘ —ǐŤă•”Á‰ťŠÇŽžŠł‚Ě’áNPŽčpz5. ˆÝŽîᇂɑ΂ˇ‚éLECS. ˜h”ö^—ˆ¤1, ”äŠé’źŽ÷1, ×“c@Œj1, VŒ´ł‘ĺ1, ŸN’J”ü‹MŽq1, ˜a“c‘ń–ç2, ’†”nŠî”Ž1, ŽR‰şŒpŽj1,3, ‘–ě@‰›2, “c粁@‘2,4 (1ă•”Á‰ťŠÇŠO, 2Á‰ťŠí“ŕ, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4V˘‹Iˆă—ÁEć’[ˆă—Ă) Á‰ťŠíŠO‰Č 2022/1; 45 (1): 53-60.

522069. [uŔ]yŠO‰Čˆă‚Ş’m‚Á‚Ä‚¨‚­‚ׂŤ sĹV”Łt ‰h—{—Ă–@zĄŠe˜_@ˆÝŠO‰Č‚É‚¨‚Ż‚é‰h—{—Ă–@. VŒ´ł‘ĺ1, ŸN’J”ü‹MŽq1, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO): —Տ°ŠO‰Č 2022/1; 77 (1): 57-60.

522070. [uŔ]y“ÁW: ă•”Á‰ťŠÇ—ĚˆćÄŒšŽč‹Z|Ĺ‹ß‚ĚƒgƒsƒbƒNzICGŒŒ—Ź•]‰ż‚đ—p‚˘‚˝ˆÝŠÇěťEÄŒš. Ź–ö˜a•v, É–ě‹Ĺl, ’J“c•”Œ’‘ž˜Y, ”óŒű@Ši1, ‹ŕX_•˝, “c“‡N•˝ (1•”Á‰ťŠÇŠO): Žčp 2022/2; 76 (2): 125-30.

522071. [uŔ]y—Տ°ˆÝŠŕŠw|Šî‘bE—Տ°‚̍ŐV“ŽŒü| zˆÝV. Šŕ‚ĚŽĄ—Á@4. ˆÝŠŕŽĄ—Ïă‚̉h—{ŠÇ—@(2) pŒă‘ŠúŒo’°‰h—{. ŸN’J”ü‹MŽq1, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO): “ú–{—Őଠ2022/3; 80 (‘Š§†3): 355-7.

[’˜@‘]

620073. [Šwp‘ (•Ş’SŽˇ•M)]y“ú–{—Տ°‰h—{‘ăŽÓ‰h—{Šw‰ď JSPENƒeƒLƒXƒgƒuƒbƒNză•”Á‰ťŠÇ‚Ş‚ńpŒă‡•šÇ‚ɑ΂ˇ‚é‰h—{ŠÇ—, p.453-6. VŒ´ł‘ĺ1, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO), •Ň: “ú–{—Տ°‰h—{‘ăŽÓŠw‰ď, “ě]“°, “Œ‹ž, 2021/4”­s.

620074. [Šwp‘ (•Ş’SŽˇ•M)]yV—Տ°Žîᇊw ‰ü’č‘ć6”Ĺ) ‚Ş‚ń–ň•¨—Ă–@ę–ĺˆă‚Ě‚˝‚߂ɁzIII —Տ°Žîᇊw‚ĚŽŔ‘H@49 •›ě—p‘΍ô‚ĆŽxŽ—Ă–@@6. ‰h—{ƒTƒ|[ƒg, p.698-702. VŒ´ł‘ĺ1, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO), •Ň: “ú–{—Տ°Žîᇊw‰ď, “ě]“°, “Œ‹ž, 2021/5”­s.

620075. [Šwp‘ (•Ş’SŽˇ•M)]y“ŕŽ‹‹žŠO‰ČÁ‰ťŠíÄŒšp‚Ě‚ˇ‚ׂā@Žčp—Í‚Ş•K‚¸Œüă‚ˇ‚ézƒGƒlƒ‹ƒM[ƒfƒoƒCƒX‚ĚŽí—Ţ‚ĆŽg—p–@, p.8-13. Œ´“cG‹P1, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO), •Ň: ˆ˘•”“WŽŸ, ă–쐳‹I, ]Œ´ˆęŽ, ’|­ˆÉ’m˜N, ’†‘şŒct, ŠwŒ¤ƒƒfƒBƒJƒ‹GŽĐ, “Œ‹ž, 2021/9”­s.

620076. [Šwp‘ (•Ş’SŽˇ•M)]y•ŞŽqŽîᇃ}[ƒJ[ŽĄ—ĂƒKƒCƒhƒ‰ƒCƒ“ ‘ć2”Łz‘ŕ4@RAS/BRAF, p,19-27. “c’†r“š1, ŽR‰şŒpŽj1,2 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă), •Ň: “ú–{•ŞŽqŽîᇃ}[ƒJ[Œ¤‹†‰ď, ‹ŕŒ´o”Ĺ, “Œ‹ž, 2021/9”­s.

620077. [Šwp‘ (•Ş’SŽˇ•M)]y•ŞŽqŽîᇃ}[ƒJ[ŽĄ—ĂƒKƒCƒhƒ‰ƒCƒ“ ‘ć2”ŁzŠe˜_7@‘ĺ’°Šŕ, p.85-98. ‰ĄˆäŒ\Œĺ1, ŽR‰şŒpŽj1,2, “ŕ“Ą@„3 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‰ş•”Á‰ťŠÇŠO), •Ň: “ú–{•ŞŽqŽîᇃ}[ƒJ[Œ¤‹†‰ď, ‹ŕŒ´o”Ĺ, “Œ‹ž, 2021/9”­s.

620078. [Šwp‘ (•Ş’SŽˇ•M)]y• o‹ž‰şˆÝŘœpŒöŽŽƒeƒLƒXƒgz‘ćIIÍ • o‹ž‰şˆÝ‘S“E , p.112-9. ”äŠé’źŽ÷ (ă•”Á‰ťŠÇŠO), ŠÄC: •Ň: Ź“ˆˆęK, “ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‹łˆçˆĎˆő‰ď, “ě]“°, “Œ‹ž, 2022/3”­s.

620079. [Šwp‘ (•Ş’SŽˇ•M)]yÁ‰ťŠí“ŕŽ‹‹žŠO‰ČŽčp@‡•šÇ‰ń”đ‚ĚABC|‡•šÇ‚đ‰ČŠw‚ˇ‚é|z• o‹žE“ŕŽ‹‹ž‡“ŻŽčp (laparoscopy andendoscopy cooperative surgery: LECS) pŒăoŒŒ‚âˆÝ“ŕ—e”ro’x‰„‰ń”đŽč‹Z‚ĚABC, p.76-86. ˜h”ö^—ˆ¤1, ”äŠé’źŽ÷1 (1•”Á‰ťŠÇŠO), •Ň: ”’ÎŒ›’j, ă“c‹MˆĐ, ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, “Œ‹ž, 2022/3”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

722108. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) H“šˆÝÚ‡•”Šŕ‚ɑ΂ˇ‚郊ƒ“ƒpßŠs´Œř‰Ę‚ĆŽŠ“KpŽŽ‚ĚŒŸ“˘. Œ´“cG‹P1, “Y–ěF•ś2, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, VŒ´ł‘ĺ1, ×“c@Œj1, ŽR‰şŒpŽj1,3, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć121‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/4/9), WebŠJĂ.

722109. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ă•”Á‰ťŠÇpŒă‚ĚƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ˆăŠw‚Ě•űŒüŤ‚Ɖۑč. VŒ´ł‘ĺ1, ×“c@Œj1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, ŽR‰şŒpŽj1,2, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć58‰ń“ú–{ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ˆăŠw‰ďŠwpW‰ď (2021/6/10-13), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722110. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒƒ{ƒbƒgŽx‰‡‹šo‹ž‰şH“šŘœp‚ĚˆĘ’u‚Ă‚Ż. VŒ´ł‘ĺ1, ×“c@Œj1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, ŽR‰şŒpŽj1,2, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć46‰ń“ú–{ŠO‰ČŒn˜A‡Šw‰ďŠwpW‰ď (2021/6/19), WebŠJĂ.

722111. [Šw‰ď (‘S‘)] (‹łˆçu‰‰) ‚Ş‚ńŽĄ—Ă‚É‚¨‚Ż‚é‰h—{‚Ě–đŠ„. ”äŠé’źŽ÷ (ă•”Á‰ťŠÇŠO): ‘ć8‰ń“ú–{Ý‘î‰h—{ŠÇ—Šw‰ďŠwpW‰ď (2021/9/18-10/4), WebŠJĂ.

722112. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) H“šˆÝÚ‡•”Šŕ‚ɑ΂ˇ‚é• o‹ž‰ş‰ş•”H“š•Ź–呤ˆÝŘœ, ‹šo‹ž‰şŠĎ‰šŠJ‚Ť–@ÄŒš. ×“c@Œj1, VŒ´ł‘ĺ1, ‹‹vGŽ÷1, Œ´“cG‹P1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, ŽR‰şŒpŽj1,2, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć75‰ń“ú–{H“šŠw‰ďŠwpW‰ď (2021/9/23), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722113. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Řœ‰Â”\‹ÇŠisH“šˆÝÚ‡•”Šŕ‚ɑ΂ˇ‚ép‘ODOS‰ťŠw—Ă–@‚Ě’ZŠú’ˇŠúŹŃ. ×“c@Œj1, VŒ´ł‘ĺ1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, ’†”nŠî”Ž1, ˛“Ą•˜Y2, “c’†@Œ‰3,4, “ŕ“Ą „2, ŒGŒł—Y‰î4, ŽOŠK‹MŽj5, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2‰ş•”Á‰ťŠÇŠO, 3V˘‹Iˆă—ÁEć’[ˆă—Ă, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 5“ű‘BEbó‘BŠO): ‘ć83‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2021/11/18), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722114. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Emerging novel concept of haplo-insufcient MSI positive gastric cancer. ŽR‰şŒpŽj1,2, Œ´“cG‹P2, ’†”nŠî”Ž2, ŸN’J”ü‹MŽq2, ˜h”ö^—ˆ¤2, VŒ´ł‘ĺ2, ×“c@Œj2, ”äŠé’źŽ÷2 (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2ă•”Á‰ťŠÇŠO): ‘ć94‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2022/3/3), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722115. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Neoadjuvant Chemotherapy with DOS for Siewert Type 2 Esophagogastric Junction Cancer. ×“c@Œj1, VŒ´ł‘ĺ1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, ’†”nŠî”Ž1, Œ˜“ce—˜2, ÎŒËŒŞŽŸ2, ŽR‰şŒpŽj1,3, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2Á‰ťŠí“ŕ, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć94‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2022/3/4), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723273. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒPƒ‚ƒZƒŒƒNƒVƒ‡ƒ“ŽĄ—Ð헪‚É‚¨‚Ż‚éisH“šŠŕŠO‰Č“IŘœŒă‚ĚÄ”­‚ĚŒŸ“˘. VŒ´ł‘ĺ1, ŽR‰şŒpŽj1,2, ×“c@Œj1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć121‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/4/9), WebŠJĂ.

723274. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆÝŠŕ‚ĚCT‚É‚ć‚é—Ěˆć•Ę[’B“xf•]‰ż‚ɂ‚˘‚Ä‚ĚŒŸ“˘. ‰œ–ěW‘ž1, Œ´“cG‹P1, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, VŒ´ł‘ĺ1, ×“c@Œj1, ŽR‰şŒpŽj1,2, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć121‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/4/9), WebŠJĂ.

723275. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚é”ń•ÂÇŤ’°ŠÔ–Œ‹•ŒŒ (NOMI) Žčp—á‚ĚŒŸ“˘. ‰şŒ`Ť‰›1, ‹‹vGŽ÷1, Œ´“cG‹P1, ˜h”ö^—ˆ¤1, ŸN’J”ü‹MŽq1, VŒ´ł‘ĺ1, ×“c@Œj1, ŽR‰şŒpŽj1,2, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć121‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/4/9), WebŠJĂ.

723276. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) H“šŠŕ‚É‚¨‚Ż‚鎥—Ă‘OC-reactive protein’l‚ĚŒŸ“˘. Œă“Ą‘ě–ç1, ŽR‰şŒpŽj2,3, ”äŠé’źŽ÷3, ×“c@Œj3, VŒ´ł‘ĺ3, ˜h”ö^—ˆ¤3, ‹‹vGŽ÷3, ŸN’J”ü‹MŽq3, Œ´“cG‹P3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3ă•”Á‰ťŠÇŠO): ‘ć121‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/4/8-10), WebŠJĂ.

723277. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Stage IˆÝŠŕpŒă‚É‚¨‚Ż‚é‘ź•aŽ€—\‘ވöŽq‚Ě“Ż’č. ŸN’J”ü‹MŽq1, ŽR‰şŒpŽj1,2, “Y–ěF•ś3, Œ´“cG‹P1, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, VŒ´ł‘ĺ1, ×“c@Œj1, ”äŠé’źŽ÷1, ˛“Ą•˜Y4, “c“‡@O5, ŠC’Ă‹MŽj5, ‰Á“Ą@O6, ĺÎ‹I•F6, “c’†@Œ‰5,7, “ŕ“Ą@„4, ŒGŒł—Y‰î5, ŽOŠK‹MŽj6 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4‰ş•”Á‰ťŠÇŠO, 5ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 6“ű‘BEbó‘BŠO, 7V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć121‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/4/8-10), WebŠJĂ.

723278. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —ŤŠO‰Čˆă‚ɑ΂ľ‚Ä, ˆă‹Çˆő‚Í‚Ç‚¤l‚Ś‚Ä‚˘‚é‚Š?|—ŤŠO‰ČˆăƒŠ[ƒ_[’aś‚Ě‚˝‚ß‚ĚlŽ@|. ˜h”ö^—ˆ¤1, ”äŠé’źŽ÷1, ×“c@Œj1, VŒ´ł‘ĺ1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, Œ´“cG‹P1, ˛“Ą•˜Y2, “c“‡@O3, ŠC’Ă‹MŽj3, ‰Á“Ą@O4, ĺÎ‹I•F4, “c’†@Œ‰3,5, “ŕ“Ą@„2, ŒGŒł—Y‰î3, ŽOŠK‹MŽj4, ŽR‰şŒpŽj1,6 (1ă•”Á‰ťŠÇŠO, 2‰ş•”Á‰ťŠÇŠO, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4“ű‘BEbó‘BŠO, 5V˘‹Iˆă—ÁEć’[ˆă—Ă, 6V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć121‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/4/8-10), WebŠJĂ.

723279. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒOƒŒƒŠƒ“‚ĚˆÝ“ŕ•Ş•z‚ĆˆÝˆŸ‘S“Ep‚ĚŽč‹Z‚̍H•v. ‹‹vGŽ÷1, Œă“Ą‘ě–ç2, ×“c@Œj1, VŒ´ł‘ĺ1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, “Y–ěF•ś2, “ŕ“Ą@„3, ŒGŒł—Y‰î4, ŽOŠK‹MŽj5, ŽR‰şŒpŽj1,6, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‰ş•”Á‰ťŠÇŠO, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 5“ű‘BEbó‘BŠO, 6V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć121‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/4/8-10), WebŠJĂ.

723280. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) p‘O‰ťŠw—Ă–@‚͈݊ŕpŒă‡•šÇ‚ĚÄ”­‚ɑ΂ˇ‚éˆŤ‰e‹ż‚đC‘U‚ˇ‚é‚Š? ×“c@Œj1, ‹‹vGŽ÷1, VŒ´ł‘ĺ1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, “ŕ“Ą@„2, ŒGŒł—Y‰î3, ŽOŠK‹MŽj4, ŽR‰şŒpŽj1,5, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2‰ş•”Á‰ťŠÇŠO, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4“ű‘BEbó‘BŠO, 5V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć46‰ń“ú–{ŠO‰ČŒn˜A‡Šw‰ďŠwpW‰ď (2021/6/18), WebŠJĂ.

723281. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚—îŽŇˆÝŠŕŠłŽŇ‚ɑ΂ˇ‚éoptional LECS. ˜h”ö^—ˆ¤1, ”äŠé’źŽ÷1, Œ´“cG‹P1, ŸN’J”ü‹MŽq1, ‹‹vGŽ÷1, VŒ´ł‘ĺ1, ×“c@Œj1, “ŕ“Ą@„2, ŒGŒł—Y‰î3, ŽR‰şŒpŽj1,4 (1ă•”Á‰ťŠÇŠO, 2‰ş•”Á‰ťŠÇŠO, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć76‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2021/7/7), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723282. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) H“šG•˝ă”çŠŕ‚Ě3q OncCassette‚ĚˆÓ‹`. “Y–ěF•ś1, Œ´“cG‹P2, ŸN’J”ü‹MŽq2, ‹‹vGŽ÷2, ˜h”ö^—ˆ¤2, VŒ´ł‘ĺ2, ×“c@Œj2, ”äŠé’źŽ÷2, ŽR‰şŒpŽj2,3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ă•”Á‰ťŠÇŠO, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć76‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2021/7/7), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723283. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) • …ôň×–Ef‹^—zŤˆÝŠŕ‚ɂ‚˘‚Ä‚Ě—\ŒăˆöŽq‚ĚŒŸ“˘. •“c@—I1, Œ´“cG‹P1, ‹‹vGŽ÷1, “Y–ěF•ś2, ˜h”ö^—ˆ¤1, ŸN’J”ü‹MŽq1, VŒ´ł‘ĺ1, ×“c@Œj1, ŽR‰şŒpŽj1,3, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć76‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2021/7/7), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723284. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Siewert type II‚̐H“šˆÝÚ‡•”‘BŠŕ‚ɑ΂ˇ‚éŽčp‘O‰ťŠw—Ă–@. ‹‹vGŽ÷1, ×“c@Œj1, VŒ´ł‘ĺ1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, “Y–ěF•ś2, ŽR‰şŒpŽj1,3, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć76‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2021/7/8), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723285. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒƒ{ƒbƒgŽx‰‡ˆÝŘœp‚̏]—ˆŒ^• o‹ž‰şˆÝŘœp‚ɑ΂ˇ‚é—˜“_ ‚Ć–â‘č“_. ×“c@Œj1, VŒ´ł‘ĺ1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, “ŕ“Ą@„2, ŒGŒł—Y‰î3, ŽR‰şŒpŽj1,4, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2‰ş•”Á‰ťŠÇŠO, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć76‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2021/7/8), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723286. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) LECS‚É‚¨‚Ż‚鋐‘ĺˆÝ•ÇŒ‡‘š•”‚ĚŽÎŽ˛•Â˝Žč‹Z. ‰œ–ěW‘ž1, ˜h”ö^—ˆ¤1, ŸN’J”ü‹MŽq1, ‹‹vGŽ÷1, VŒ´ł‘ĺ1, ×“c@Œj1, ŽR‰ş ŒpŽj1,2, ”äŠé’źŽ÷1, ŒGŒł—Y‰î3, “ŕ“Ą@„4 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4‰ş•”Á‰ťŠÇŠO): ‘ć76‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2021/7/8), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723287. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) cStage IVˆÝŠŕ‚ɑ΂ˇ‚éconversionŽčpÇ—á‚Ě—\ŒăˆöŽq‚ĚŒŸ“˘. Œ´“cG‹P1, “Y–ěF•ś2, ˜h”ö^—ˆ¤1, ŸN’J”ü‹MŽq1, ‹‹vGŽ÷1, VŒ´ł‘ĺ1, ×“c@Œj1, ŽR‰şŒpŽj1,3, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć76‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2021/7/8), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723288. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚郍ƒ{ƒbƒgŽx‰‡‹šo‹ž‰şH“šŘœp‚ĚŒťó‚Ɖۑč. VŒ´ł‘ĺ1, ×“c@Œj1, ‹‹vGŽ÷1, Œ´“cG‹P1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, ŽR‰şŒpŽj1,2, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć76‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2021/7/9), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723289. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Stage IˆÝŠŕpŒă‚É‚¨‚Ż‚é‘ź•aŽ€—\‘ވöŽq‚Ě“Ż’č`ƒTƒ‹ƒRƒyƒjƒA‚Ć‘ź•aŽ€‚ĚŠÖ˜A‚ɂ‚˘‚ā`. ŸN’J”ü‹MŽq1, ŽR‰şŒpŽj1,2, “Y–ěF•ś3, Œ´“cG‹P1, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, VŒ´ł‘ĺ1, ×“c@Œj1, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć36‰ń“ú–{—Տ°‰h—{‘ăŽÓŠw‰ďŠwpW‰ď (2021/7/21-22), •şŒÉ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723290. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆÝŘœŒăƒ_ƒ“ƒsƒ“ƒOÇó‚̉ü‘P‚ÉŽ‘ąŒŒ“œƒ‚ƒjƒ^ƒŠƒ“ƒO‚Ş—L—p‚Ĺ‚ ‚Á‚˝ˆę—á. VŒ´ł‘ĺ1, ŸN’J”ü‹MŽq1, ×“c@Œj1, ‹‹vGŽ÷1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, “Y–ěF•ś2, ŽR‰şŒpŽj1,3, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć36‰ń“ú–{—Տ°‰h—{‘ăŽÓŠw‰ďŠwpW‰ď (2021/7/21-22), •şŒÉ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723291. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒƒ{ƒbƒgŽx‰‡‹š‹ž‰şH“šŘœ‚Ə]—ˆ‚Ě‹šo‹ž‰şH“šŘœ‚Ć‚Ě’ZŠúŹŃ‚ÉŠÖ‚ˇ‚錟“˘. VŒ´ł‘ĺ1, ×“c@Œj1, ‹‹vGŽ÷1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, Œ´“cG‹P1, ŽR‰şŒpŽj1,2, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć75‰ń“ú–{H“šŠw‰ďŠwpW‰ď (2021/9/23-24), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723292. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) H“šG•˝ă”çŠŕ3q OncCassette‚̏d—vŤ. “Y–ěF•ś1, Œ´“cG‹P2, ŸN’J”ü‹MŽq2, ‹‹vGŽ÷2, ˜h”ö^—ˆ¤2, VŒ´ł‘ĺ2, ×“c@Œj2, ”äŠé’źŽ÷2, ŽR‰şŒpŽj2,3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ă•”Á‰ťŠÇŠO, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć75‰ń“ú–{H“šŠw‰ďŠwpW‰ď (2021/9/23-24), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723293. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) A Clinical Trial Plan; ˆÝŘœpŒă‚Ě‘Šú‰^“Ž—Ă–@‚đ•š—p‚ľ‚˝ƒAƒ~ƒmŽ_E“œEŽ‰–b“űÜŒoĂ–Ź“Š—^‚Ě—LŒřŤ‚ĚŒŸ“˘. ŸN’J”ü‹MŽq1, ”äŠé’źŽ÷1, ’†”nŠî”Ž1, ˜h”ö^—ˆ¤1, VŒ´ł‘ĺ1, ×“c@Œj1, ŽR‰şŒpŽj1,2 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ú–{ŠO‰Č‘ăŽÓ‰h—{Šw‰ď‘ć58‰ńŠwpW‰ď (2021/10/8), •şŒÉ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723294. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Řœ•s”\ˆÝŠŕ‚ɑ΂ˇ‚éSOX—Ă–@Œă‚ĚConversion surgery‚Ö‚ĚˆÚs—Ś‚ĚŒŸ“˘. ’†”nŠî”Ž1, ˜h”ö^—ˆ¤1, ŸN’J”ü‹MŽq1, VŒ´ł‘ĺ1, ×“c@Œj1, ŠC’Ă‹MŽj2, ˛“Ą•˜Y3, ŒGŒł—Y‰î2, “ŕ“Ą@„3, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 3‰ş•”Á‰ťŠÇŠO): ‘ć83‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2021/11/18), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723295. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) H“šŽcˆÝ•Ť‡‚É‚¨‚Ż‚é‹t—ŹÇó‚Š‚ç‚Ý‚˝H“šŽcˆÝ•Ť‡. VŒ´ł‘ĺ1, Œ´“cG‹P1, ×“c@Œj1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, ’†”nŠî”Ž1, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO): ‘ć83‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2021/11/18), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723296. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚—îŽŇˆÝŠŕŠłŽŇ‚ɑ΂ˇ‚éoptional LECS. ˜h”ö^—ˆ¤1, ”äŠé’źŽ÷1, ’†”nŠî”Ž1, ŸN’J”ü‹MŽq1, ˜a“c‘ń–ç2, VŒ´ł‘ĺ1, ×“c@Œj1, “c糁@‘2,3 (1ă•”Á‰ťŠÇŠO, 2Á‰ťŠí“ŕ, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć83‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2021/11/19), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723297. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒƒ{ƒbƒgŽx‰‡‹šo‹ž‰şH“šŘœp‚ĚŽĄ—ÐŹŃ. ×“c@Œj1, VŒ´ł‘ĺ1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, ’†”nŠî”Ž1, ˛“Ą•˜Y2, “c’†@Œ‰3,4, “ŕ“Ą@„2, ŒGŒł—Y‰î4, ŽOŠK‹MŽj5, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2‰ş•”Á‰ťŠÇŠO, 3V˘‹Iˆă—ÁEć’[ˆă—Ă, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 5“ű‘BEbó‘BŠO): ‘ć83‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2021/11/19), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723298. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) H“šŠŕpŒă‚ĚŠÇ—‰h—{Žm‚É‚ć‚éŰŽćƒGƒlƒ‹ƒM[—Ę‚Ě’ŽŽć‚Ć‘Ěd•Ď‰ť‚ĚŒŸ“˘. VŒ´ł‘ĺ1, ‹e’r“Ţ•äŽq2, ×“c@Œj1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, ’†”nŠî”Ž1, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2‰h—{•”): ‘ć83‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2021/11/19), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723299. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚—îŽŇisˆÝŠŕŠłŽŇ‚ɑ΂ˇ‚éŠÉ˜aLECS. ŠÔ’†Œh‰î1, ˜h”ö^—ˆ¤1, ‰œ–ěW‘ž1, ’†”nŠî”Ž1, ˜a“c‘ń–ç2, ŸN’J”ü‹MŽq1, VŒ´ł‘ĺ1, ×“c@Œj1, “c糁@‘2,3, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2Á‰ťŠí“ŕ, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć83‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2021/11/19), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723300. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆŔ‘SŤ‚Š‚ç‚Ý‚˝isˆÝŠŕ‚ɑ΂ˇ‚é• o‹ž‰ş—H–呤ˆÝŘœp‚Ě“K‰žŠî€. ’†”nŠî”Ž1, ˜h”ö^—ˆ¤1, ŸN’J”ü‹MŽq1, VŒ´ł‘ĺ1, ×“c@Œj1, ŠC’Ă‹MŽj2, ˛“Ą•˜Y3, ŒGŒł—Y‰î2, “ŕ“Ą@„3, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 3‰ş•”Á‰ťŠÇŠO): ‘ć83‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2021/11/20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723301. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) A Clinical Trial PlanˆÝŘœpŒă‚Ě‘Šú‰^“Ž—Ă–@‚đ•š—p‚ľ‚˝ƒAƒ~ƒmŽ_E“œEŽ‰–b“űÜŒoĂ–Ź“Š—^‚Ě—LŒřŤ‚ĚŒŸ“˘. ŸN’J”ü‹MŽq1, ”äŠé’źŽ÷1, ’†”nŠî”Ž1, ˜h”ö^—ˆ¤1, VŒ´ł‘ĺ1, ×“c@Œj1 (1ă•”Á‰ťŠÇŠO): ‘ć83‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2021/11/20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723302. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) p‘OGNRI‚͍‚—îˆÝŠŕŠłŽŇ‚̏pŒă‡•šÇ”­Ç‚Ě—\‘ވöŽq‚Ć‚Č‚č“ž‚é‚Š? ŸN’J”ü‹MŽq1, ”äŠé’źŽ÷1, ’†”nŠî”Ž1, ˜h”ö^—ˆ¤1, VŒ´ł‘ĺ1, ×“c@Œj1 (1ă•”Á‰ťŠÇŠO): ‘ć83‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2021/11/18-20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723303. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹‘ĺˆÝŽ‰–bŠÖ˜AŽîᇂɑ΂ľ—H–呤ˆÝŘœ‚đŽ{s‚ľ‚˝ˆę—á. ’r‘ş‹ž”V‰î1, ˜h”ö^—ˆ¤1, ‰œ–ěW‘ž1, ’†”nŠî”Ž1, ŸN’J”ü‹MŽq1, VŒ´ł‘ĺ1, ×“c@Œj1, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO): ‘ć83‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2021/11/18-20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723304. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆÝ‹ÇŠŘœ (LECS) Œă‚É‹@”\‚đ’D‚í‚Č‚˘ˆÝ•Ç•Â˝–@‚̍H•v. ŸN’J”ü‹MŽq1, ”äŠé’źŽ÷1, ’†”nŠî”Ž1, ˜h”ö^—ˆ¤1, VŒ´ł‘ĺ1, ×“c@Œj1, ŽR‰şŒpŽj1,2 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć34‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2021/12/2), •şŒÉ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723305. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) \“ńŽw’°dĎÇ‚đ—ˆ‚ľ‚˝Brunner‘B‰ßŒ`Ź‚ɑ΂ľ• o‹ž•â•‰ş‚ɐ؏œ‚ľ“ž‚˝1—á. ‰Á“Ą’q”V1, ŒÜ\—’ˆę°2, ŠC’Ă‹MŽj2, źŕVL‹ą2, “c“‡@O2, o‰Ć‹œˆę2, VŒ´ł‘ĺ1, ŽR—œ‚L3, ×“c@Œj1, ŽR‰şŒpŽj1,4, ˛“Ą•˜Y3, “c’†@Œ‰2,5, ”äŠé’źŽ÷1, “ŕ“Ą@„3, ŒGŒł—Y‰î2 (1ă•”Á‰ťŠÇŠO, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 3‰ş•”Á‰ťŠÇŠO, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 5V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć34‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2021/12/3), •şŒÉ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723306. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) H“šŠŕ‚ɑ΂ˇ‚郍ƒ{ƒbƒgŽx‰‡‹šo‹ž‰şH“šŘœp‚Ě’ZŠúŹŃ. ×“c@Œj1, VŒ´ł‘ĺ1, ’†”nŠî”Ž1, ˜h”ö^—ˆ¤1, ŸN’J”ü‹MŽq1, ŽR‰şŒpŽj1,2, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć34‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2021/12/3), •şŒÉ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723307. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) • o‹ž‰şˆÝ‘S“EŒăOver lapÄŒšŽč‹Z‚Ěƒ|ƒCƒ“ƒg. ˜h”ö^—ˆ¤1, ”äŠé’źŽ÷1, ‰œ–ěW‘ž1, ’†”nŠî”Ž1, ŸN’J”ü‹MŽq1, VŒ´ł‘ĺ1, ×“c@Œj1, ˛“Ą•˜Y2, ŠC’Ă‹MŽj3, “ŕ“Ą@„2, ŒGŒł—Y‰î3, ŽR‰şŒpŽj1,4 (1ă•”Á‰ťŠÇŠO, 2‰ş•”Á‰ťŠÇŠO, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć34‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2021/12/3), •şŒÉ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723308. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) isˆÝŠŕ‚ɑ΂ˇ‚é• o‹ž‰ş—H–呤ˆÝŘœp‚É‚¨‚Ż‚é#6ƒŠƒ“ƒpß‚ĚŽĄ—Ă“IŠs´Žč‹Z. ’†”nŠî”Ž1, ˜h”ö^—ˆ¤1, ŸN’J”ü‹MŽq1, VŒ´ł‘ĺ1, ŠC’Ă‹MŽj2, ×“c@Œj1, ˛“Ą•˜Y3, ŽR‰şŒpŽj1,4, “ŕ“Ą@„3, ŒGŒł—Y‰î2, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 3‰ş•”Á‰ťŠÇŠO, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć34‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2021/12/3), •şŒÉ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723309. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) isˆÝŠŕ‚ɑ΂ˇ‚é• o‹ž‰ş—H–呤ˆÝŘœp‚ĚˆŔ‘SŤ‚ĆŞŽĄŤ‚ÉŠÖ‚ˇ‚éRCT (JLSSG0901): Žĺ‰đÍŒ‹‰Ę•ń. ‰q“Ą@„, ŸN–{Mˆę, ’ҁ@•qŽ, —›@‘Š—Y, ‹g“c˜aO, ”ě“cŒ\‰î, ”äŠé’źŽ÷1, š čŽĺĹ, “ż‰ił‘Ľ, ‘ĺ’؁@‘ĺ, ‚‹ŕ–ž“T, ŽOŕVˆęŹ, –؉şŒhO, ’ˇ@°•F, “yŠň—Sˆę˜Y, •z•”‘n–ç, ‘ĺŽR“NŽi, ”’ÎŒ›’j, –k–쐳„ (1ă•”Á‰ťŠÇŠO): ‘ć94‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2022/3/2), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723310. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) V‚ľ‚˘ˆÝŠŕŽćˆľ‚˘‹K–ń: V‚ľ‚˘‹K–ńô’č‚ÉŒü‚Ż‚˝Žć‚č‘g‚݁@isˆÝŠŕ‚ɑ΂ˇ‚é• o‹ž‰ş—H–呤ˆÝŘœp‚ĚˆŔ‘SŤ‚ĆŞŽĄŤ‚ÉŠÖ‚ˇ‚éRCT (JLSSG0901) Žĺ‰đÍŒ‹‰Ę•ń. ‰q“Ą@„, ŸN–{Mˆę, ’ҁ@•qŽ, —›@‘Š—Y, ‹g“c˜aO, ”ě“cŒ\‰î, ”äŠé’źŽ÷1, š čŽĺĹ, “ż‰ił‘Ľ, ‘ĺ’؁@‘ĺ, ‚‹ŕ–ž“T, ŽOŕVˆęŹ, –؉şŒhO, ’ˇ@°•F, “yŠň—Sˆę˜Y, •z•”‘n–ç, ‘ĺŽR“NŽi, ”’ÎŒ›’j, –k–쐳„ (1ă•”Á‰ťŠÇŠO): ‘ć94‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2022/3/2), ‰Ą•l, “ú–{ˆÝŠŕŠw‰ď‘‰ď‹LŽ– 2022/3; 94: 149.

723311. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Which reconstruction should be optimal after gastrectomy for the upper gastric body cancer? ”äŠé’źŽ÷ (ă•”Á‰ťŠÇŠO): ‘ć94‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2022/3/3), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723312. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) LECS with esophageal reconstruction for tumors around the EGJ. ˜h”ö^—ˆ¤1, ”äŠé’źŽ÷1, ×“c@Œj1, VŒ´ł‘ĺ1, ŸN’J”ü‹MŽq1, ˜a“c‘ń–ç2, ’†”nŠî”Ž1, ‘–ě@‰›2, “c糁@‘2,3, ŽR‰şŒpŽj1,4 (1ă•”Á‰ťŠÇŠO, 2Á‰ťŠí“ŕ, 3V˘‹Iˆă—ÁEć’[ˆă—Ă, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć94‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2022/3/3), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723313. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆÝŠŕ‚É‚¨‚Ż‚ép‘O[’B“x‚Ě•”ˆĘ•Ęf’f. ‰œ–ěW‘ž1, ”äŠé’źŽ÷1, ’†”nŠî”Ž1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, VŒ´ł‘ĺ1, ×“c@Œj1, ŽR‰şŒpŽj1,2 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć94‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2022/3/3), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723314. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Laparoscopic distal gastrectomy for advanced gastric cancer-technique of N0.6 lymph node dissection-. ŸN’J”ü‹MŽq1, ”äŠé’źŽ÷1, ×“c@Œj1, VŒ´ł‘ĺ1, ˜h”ö^—ˆ¤1, ’†”nŠî”Ž1, ŽR‰şŒpŽj1,2 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć94‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2022/3/4), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723315. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆÝŠŕpŒăáŠQ‚Ě•]‰ż–@‚ĆŽĄ—Ă‚Ö‚ĚŠˆ—p: ˆÝŘœŒă‚Ěƒ_ƒ“ƒsƒ“ƒO‚đ—}§‚ˇ‚éŒÂ•Ę‰ť‰h—{—Ă–@‚̉î“ü. ’†”nŠî”Ž1, ‹‹vGŽ÷1, ‰œ–ěW‘ž1, ˜h”ö^—ˆ¤1, ŸN’J”ü‹MŽq1, VŒ´ł‘ĺ1, ×“c@Œj1, ŽR‰şŒpŽj1,2, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć94‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2022/3/4), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723316. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆÝŠŕ–ň•¨—Ă–@Ž{sŽž‚É‚¨‚Ż‚é‰h—{•â•—Ă–@‚Ě—L—pŤ. ÂŽR@“O, ‹gě‹MŒČ, ˆä“c@’q, ’ˇ@°•F, âŠŞŒ°‘ž˜Y, ˆÉ“Ą—Fˆę, “Ą’J˜ał, ‘ęŒűL_, ě“‡‹g”V, źě˜aG, •z•”‘n–ç, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO): ‘ć94‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2022/3/4), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723317. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠÉ˜a–Ú“I‚ĹƒAƒiƒ‚ƒŒƒŠƒ“‚đ“Š—^‚ľ‚˝ˆÝŠŕpŒăœ“]ˆÚÄ”­‚Ě1—á. “c’†Š°l1, ŸN’J”ü‹MŽq1, ‰œ–ěW‘ž1, ’†”nŠî”Ž1, ˜h”ö^—ˆ¤1, VŒ´ł‘ĺ1, ×“c@Œj1, ŽR‰şŒpŽj1,2, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć94‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2022/3/2-4), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723318. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Šŕ/¸‘ƒRŒ´KK-LC-1‚͈ݑgD‚Ě‘OŠŕŽw•W‚Ć‚ľ‚Ä—L—p‚Ĺ‚ ‚é. “Y–ěF•ś1, •ŸŽR@—˛, “ń“nM], Žs—ˆ‰ĂL, ‘ĺ’ˏr˜a2, ç–ěTˆę˜Y3, “Ą”örˆň4, ŠŰŽRł—T3, ’†‘ş˜a“ż4, ‹ß“ĄNŽj5, ‚‹´’ől4, ’r‰i@˝5, Ź—ŃŒ›’‰, ŽRč@“™6, ź@”ŞŽk, ”äŠé’źŽ÷7 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2Á‰ťŠí“ŕ, 3‰ş•”Á‰ťŠÇŠO, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 5“ű‘BEbó‘BŠO, 6•a—, 7ă•”Á‰ťŠÇŠO): ‘ć94‰ń“ú–{ˆÝŠŕŠw‰ď‘‰ď (2022/3/2-4), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

731006. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ˆÝ‚Ş‚ń‚ɑ΂ˇ‚éŠÉ˜aLECS‚ĚKey note lecture: ˆÝ‚Ş‚ń‚ɑ΂ˇ‚éLECS‚ĚŒťó|LECSŒ¤‹†‰ďƒAƒ“ƒP[ƒg’˛¸‚̂܂Ƃ߁|. ˜h”ö^—ˆ¤1, ×“c@Œj1, VŒ´ł‘ĺ1, ŸN’J”ü‹MŽq1, ˜a“c‘ń–ç2, ’†”nŠî”Ž1, ‘–ě@‰›2, ŽR‰şŒpŽj1,3, “c糁@‘2,4, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2Á‰ťŠí“ŕ, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć23‰ń• o‹ž“ŕŽ‹‹ž‡“ŻŒ¤‹†‰ď (2022/3/4), WebŠJĂ.

732043. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰) —ߘa‚ɂ͂΂˝‚­LECS‚Ě‚ą‚ę‚Š‚ç. ”äŠé’źŽ÷ (ă•”Á‰ťŠÇŠO): “ú–{Á‰ťŠí•aŠw‰ď–k—¤Žx•”‘ć44‰ń‹łˆçu‰‰‰ď (2021/6/6), •xŽR, “ú–{Á‰ťŠí•aŠw‰ď–k—¤Žx•”—á‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2021/6; 131: 4.

732044. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) âu⃕”Řœ‚É’…–Ú‚ľ‚˝ˆÝŘœ–@•Ę‘̏dEœŠi‹Ř—ĘŒ¸­—Ś‚ĚŒŸ“˘. ŸN’J”ü‹MŽq1, ”äŠé’źŽ÷1, ’†”nŠî”Ž1, ˜h”ö^—ˆ¤1, VŒ´ł‘ĺ1, ×“c@Œj1, ŽR‰şŒpŽj1,2 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć43‰ń“ú–{‰h—{ƒAƒZƒXƒƒ“ƒgŒ¤‹†‰ď (2021/6/26), WebŠJĂ.

732045. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰) ‚Ş‚ńŽĄ—Ă‚ÉŠÖ‚ˇ‚é‰h—{áŠQE‘ŸŠíáŠQ‘Ήžy’á‰h—{z. ”äŠé’źŽ÷ (ă•”Á‰ťŠÇŠO): 2022”N‘ć1‰ńNSTę–ĺ—Ă–@ŽmXV•K{ƒZƒ~ƒi[ (2022/3/6), ‹ž“s.

732046. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰) ŽüpŠúŠÇ— (‘˜_). ”äŠé’źŽ÷ (ă•”Á‰ťŠÇŠO): 2022”N‘ć1‰ńNSTę–ĺ—Ă–@ŽmXV•K{ƒZƒ~ƒi[ (2022/3/6), ‹ž“s.

733087. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) LECS‚É‚¨‚Ż‚鋐‘ĺˆÝ•ÇŒ‡‘š•”‚ĚŽÎŽ˛•Â˝Žč‹Z. ‰œ–ěW‘ž1, ˜h”ö^—ˆ¤1, ŸN’J”ü‹MŽq1, ‹‹vGŽ÷1, VŒ´ł‘ĺ1, ×“c@Œj1, ŽR‰şŒpŽj1,2, ”äŠé’źŽ÷1, ŒGŒł—Y‰î3, “ŕ“Ą@„4 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4‰ş•”Á‰ťŠÇŠO): ‘ć75‰ńŽčpŽč‹ZŒ¤‹†‰ď (2021/5/14-15), Ă‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733088. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚郍ƒ{ƒbƒgŽx‰‡‹šo‹ž‰şH“šŘœp‚ĚŒťó. VŒ´ł‘ĺ1, ×“c@Œj1, ‹‹vGŽ÷1, Œ´“cG‹P1, ŸN’J”ü‹MŽq1, ˜h”ö^—ˆ¤1, ŽR‰şŒpŽj1,2, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć75‰ńŽčpŽč‹ZŒ¤‹†‰ď (2021/5/14-15), Ă‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733089. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “–‰Č‚É‚¨‚Ż‚éă•”ˆÝŠŕ, ‚—îŽŇˆÝŠŕ‚Ö‚ĚŽĄ—Ð헪`‘ă‘ÖŽĄ—Ă‚Ć‚ľ‚Ä‚ĚLECS‚đŠÜ‚ß‚Ä. ˜h”ö^—ˆ¤1, ”äŠé’źŽ÷1, Œ´“cG‹P1, ˜a“c‘ń–ç2, ŸN’J”ü‹MŽq1, ‹‹vGŽ÷1, VŒ´ł‘ĺ1, ×“c@Œj1, ŽR‰şŒpŽj1,3, “c糁@‘2,4 (1ă•”Á‰ťŠÇŠO, 2Á‰ťŠí“ŕ, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć43‰ń“ú–{Šŕ‹ÇŠ—Ă–@Œ¤‹†‰ď (2021/5/21), WebŠJĂ.

733090. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) p‘OœŠi‹Ř—ĘŒ¸­‚Í‘ź•aŽ€—\‘ވöŽq‚Ć‚Č‚č“ž‚é‚Š?` Stage I ˆÝŠŕ‚ĚŒŸ“˘`. ŸN’J”ü‹MŽq1, ŽR‰şŒpŽj1,2, “Y–ěF•ś3, Œ´“cG‹P1, ˜h”ö^—ˆ¤1, ‹‹vGŽ÷1, VŒ´ł‘ĺ1, ×“c@Œj1, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć43‰ń“ú–{Šŕ‹ÇŠ—Ă–@Œ¤‹†‰ď (2021/5/21), WebŠJĂ.

733091. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒnƒCƒŠƒXƒN•š‘śŽžŠł‚đŽ‚ÂˆÝŠŕ‚ɑ΂ľLECS‚đŽ{s‚ľ‚˝ˆę—á. ’r‘ş‹ž”V‰î1, ˜h”ö^—ˆ¤1, ‰œ–ěW‘ž1, ’†”nŠî”Ž1, ˜a“c‘ń–ç2, ŸN’J”ü‹MŽq1, VŒ´ł‘ĺ1, ×“c@Œj1, ŽR‰şŒpŽj1,3, “c糁@‘2,4, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2Á‰ťŠí“ŕ, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć860‰ńŠO‰ČW’k‰ď (2021/6/26), WebŠJĂ.

733092. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) o‹ž‰ş‚ɏC•œ‚ľ‚˝Petersenƒwƒ‹ƒjƒA›Ć“Ú‚Ě1—á. H‰i˝Žu˜Y, “c’†Š°l1, ‰œ–ěW‘ž1, ’†”nŠî”Ž1, ˜h”ö^—ˆ¤1, ŸN’J”ü‹MŽq1, VŒ´ł‘ĺ1, ×“c@Œj1, ŽR‰şŒpŽj1,2, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć861‰ńŠO‰ČW’k‰ď (2021/9/11), WebŠJĂ.

733093. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‚—îŽŇˆÝŠŕŠłŽŇ‚ɑ΂ˇ‚éoptional LECS. ˜h”ö^—ˆ¤1, ”äŠé’źŽ÷1, ’†”nŠî”Ž1, ˜a“c‘ń–ç2, ŸN’J”ü‹MŽq1, VŒ´ł‘ĺ1, ×“c@Œj1, ŽR‰şŒpŽj1,3, “c糁@‘2,4 (1ă•”Á‰ťŠÇŠO, 2Á‰ťŠí“ŕ, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć53‰ń_“ŢěŒ§Á‰ťŠí•aˆăŠw‰ď‘‰ď (2021/10/30), WebŠJĂ.

733094. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‚—îŽŇ‚Ě10 cmˆČă‚ĚˆÝŠŕˆÝ‚Ş‚ń‚ɑ΂ˇ‚éLECS‚Ěˆę—á. ˜h”ö^—ˆ¤1, ”äŠé’źŽ÷1, ×“c@Œj1, VŒ´ł‘ĺ1, ŸN’J”ü‹MŽq1, ˜a“c‘ń–ç2, ’†”nŠî”Ž1, ‘–ě@‰›2, “c糁@‘2,3, ŽR‰şŒpŽj1,4 (1ă•”Á‰ťŠÇŠO, 2Á‰ťŠí“ŕ, 3V˘‹Iˆă—ÁEć’[ˆă—Ă, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć14‰ńći“ŕŽ‹‹žŽĄ—ĂŒ¤‹†‰ď (J-CASE) (2021/11/6), WebŠJĂ.

733095. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Ž‹ŠoƒAƒiƒƒOƒXƒP[ƒ‹‚đ—p‚˘‚˝—H–呤ˆÝŘœŒă‚Ěƒ_ƒ“ƒsƒ“ƒOÇŒóŒQ‚ÉŠÖ‚ˇ‚錟“˘. ’†”nŠî”Ž1, ˜h”ö^—ˆ¤1, ŸN’J”ü‹MŽq1, VŒ´ł‘ĺ1, ×“c@Œj1, ŽR‰şŒpŽj1,2, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć51‰ńˆÝŠO‰ČEpŒăáŠQŒ¤‹†‰ď (2021/11/11), WebŠJĂ.

733096. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) H“šÄŒš‚đŠÜ‚Ţ•Ź–ĺ’ź‰ş‚ĚLECS‚ĚŒ‡‘šE–D‡‚ĚƒRƒc. ˜h”ö^—ˆ¤1, ”äŠé’źŽ÷1, ˜a“c‘ń–ç2, VŒ´ł‘ĺ1, “c糁@‘2,3 (1ă•”Á‰ťŠÇŠO, 2Á‰ťŠí“ŕ, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć113‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2021/12/4), WebŠJĂ.

733097. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŽcˆÝ‘BŽîESDŒăúE‚É‚ć‚é’_`ŤŒă• –Œ‰Š‚ɑ΂ľ‚ÄŠO‰ČŽĄ—Ă‚É‚Ä‹~–˝‚ľ“ž‚˝ˆę—á. ŹŕVŒ‹‰Ô1, ’†”nŠî”Ž1, •“c@—I1, ˜h”ö^—ˆ¤1, ŸN’J”ü‹MŽq1, VŒ´ł‘ĺ1, ×“c@Œj1, ŽR‰şŒpŽj1,2, ”äŠé’źŽ÷1 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć862‰ńŠO‰ČW’k‰ď (2021/12/8), WebŠJĂ.

733098. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ”DP16T‚Ĺ”­ś‚ľ‚˝•›äB”P“]‚ɑ΂ľ• o‹ž‚Ő؏œ‚ľ“ž‚˝ˆę—á. ‰şŒ`Ť‰›1, źŕVL‹ą2, ŠÔ’†Œh‰î1, ’r‘ş‹ž”V‰î1, ‰œ–ěW‘ž1, •l–ěˆč”ü, ’†ě䝗S3, ƒEƒbƒhƒnƒ€ƒX—ćŽq4, ŽOŠK‹MŽj5, “ŕ“Ą@„6, ”äŠé’źŽ÷1, ŒGŒł—Y‰î2 (1ă•”Á‰ťŠÇŠO, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4•úŽËü (‰ć‘œ), 5“ű‘BEbó‘BŠO, 6‰ş•”Á‰ťŠÇŠO): ‘ć863‰ńŠO‰ČW’k‰ď (2022/3/12), WebŠJĂ.

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-110018. [Œ´’˜] Size-dependent differences in the proximal remnant stomach: how much does a small remnant stomach after subtotal gastrectomy work? Yasufuku I, Ohashi M, Eto K, Ida S, Kumagai K, Nunobe S, Sano T, Hiki N1: Surg Endosc 2020/12; 34 (12): 5540-9. (”äŠé’źŽ÷1: 1ă•”Á‰ťŠÇŠO)

[Šw‰ďEŒ¤‹†‰ď“™]

'20-723023. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒrƒbƒNƒf[ƒ^‚Š‚ç“ž‚˝“ŕŽ‹‹žŠO‰Č‚ĚƒGƒrƒfƒ“ƒX: NCD‚É‚ć‚éReal Worldƒf[ƒ^‚ŞˆÝŠŕ‚É‚¨‚Ż‚éŽčpŽč‹Z‚đ•Ď‚Ś‚é‰Â”\Ť. ”äŠé’źŽ÷1, ‹g“c˜aO, –{‘˝’ʍF, ‰q“Ą@„, ˆä“c@’q, ŒGŠŰ@‘ń, ŹŽ›‘׍O, Š|’n‹gO, Ą–ěO”V, ‹{“c—TÍ, ŁŒË‘×”V, ‹‹vGŽ÷1, VŒ´ł‘ĺ1, ×“c@Œj1, ŽR‰şŒpŽj1,2 (1ă•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć33‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (JSES 2020) (2021/3/13), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).


‰ş•”Á‰ťŠÇŠO‰ČŠw

[Šwp˜_•ś]

110267. [Œ´’˜] Current status of laparoscopic bariatric/metabolic surgery in Japan: The sixth nationwide survey by the Japan Consortium of Obesity and Metabolic Surgery. Ohta M, Kasama K, Sasaki A, Naitoh T1, Seki Y, Inamine S, Oshiro T, Doki Y, Seto Y, Hayashi H, Uyama I, Takiguchi S, Kojima K, Mori T, Inomata M, Kitagawa Y, Kitano S, Japan Consortium of Obesity and Metabolic Surgery (JCOMS): Asian J Endosc Surg 2021/4; 14 (2): 170-7. (“ŕ“Ą@„1: 1‰ş•”Á‰ťŠÇŠO)

110268. [Œ´’˜] Prediction of Long-Term Diabetes Remission After Metabolic Surgery in Obese East Asian Patients: a Comparison Between ABCD and IMS Scores. Ohta M, Seki Y, Ohyama T, Bai R, Kim SH, Oshiro T, Jiang T, Sasaki A, Naitoh T1, Yamaguchi T, Inamine S, Miyazaki Y, Ahn SM, Heo Y, Liang H, Choi SH, Yang W, Yao Q, Inoue K, Yamamoto H, Lee HJ, Park YS, Ha TK, Ryu SW, Wang C, Park S, Kasama K: Obes Surg 2021/4; 31 (4): 1485-95. (“ŕ“Ą@„1: 1‰ş•”Á‰ťŠÇŠO)

110269. [Œ´’˜] Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases. Takadate T, Morikawa T, Ishida M, Aoki S, Hata T, Iseki M, Miura T, Ariake K, Maeda S, Kawaguchi K, Masuda K, Ohtsuka H, Mizuma M, Hayashi H, Nakagawa K, Motoi F, Kamei T, Naitoh T1, Unno M: Surg Today 2021/5; 51 (5): 686-94. (“ŕ“Ą@„1: 1‰ş•”Á‰ťŠÇŠO)

110270. [Œ´’˜] Usefulness of laparoscopic surgery and preoperative examinations for chronic recurrent small bowel obstruction. Yahagi M1, Ishii Y1,2, Ochiai H1, Sako H1, Maeda H1, Takemura Y1, Oka T1, Soutome K1, Kamiya N1,3, Watanabe M1: Surg Today 2021/5; 51 (5): 807-13. (–îě‰ëŽj1, Îˆä—ǍK1,2, —Ž‡‘ĺŽ÷1, ”—@—T”V1, ‘O“c“úŘŽq1, ’|‘ş—T‰î1, ‰Ş@‘׏B1, ŒÜŒŽ—Œbˆę1, _’J‹I‹P1,3, “n粏š•F1: 1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‰ş•”Á‰ťŠÇŠO, 3ŒÄ‹zŠíŠO)

110271. [Œ´’˜] The role of bilio-pancreatic limb in nonalcoholic steatohepatitis improvement after duodenal-jejunal bypass in rats. Ichikawa H, Imoto H, Tanaka N, Fujishima F, Tsuchiya T, Watanabe K, Aoki T, Kohyama A, Morikawa T, Ohnuma S, Naitoh T1, Kamei T, Unno M: Surgery 2021/10; 170 (4): 1006-13. (“ŕ“Ą@„1: 1‰ş•”Á‰ťŠÇŠO)

110029. [Œ´’˜] Activation of iNKT Cells Facilitates Liver Repair After Hepatic Ischemia Reperfusion Injury Through Acceleration of Macrophage Polarization. Goto T1, Ito Y2, Satoh M3, Nakamoto S4, Nishizawa N4, Hosono K2, Naitoh T5, Eshima K3, Iwabuchi K3, Hiki N6, Amano H2: Front Immunol 2021/10; 12: 754106. (Œă“Ą‘ě–ç1, ˆÉ“Ą‹`–ç2, ˛“Ą@‰ë3, ’†–{CŽi4, źŕVL‹ą4, ×–ě‰Á“ŢŽq2, “ŕ“Ą@„5, ]“‡k“ń3, ŠâŸş˜a–ç3, ”äŠé’źŽ÷6, “V–ě‰pŽ÷2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3–Ɖu, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 5‰ş•”Á‰ťŠÇŠO, 6ă•”Á‰ťŠÇŠO)

110272. [Œ´’˜] Comprehensive Analysis of microRNA Profiles in Organoids Derived from Human Colorectal Adenoma and Cancer. Nagai H, Kuroha M, Handa T, Karasawa H, Ohnuma S, Naito T, Moroi R, Kanazawa Y, Shiga H, Hamada S, Kakuta Y, Naitoh T1, Kinouchi Y, Shimosegawa T, Masamune A: Digestion 2021/11; 102 (6): 860-9. (“ŕ“Ą@„1: 1‰ş•”Á‰ťŠÇŠO)

110273. [Œ´’˜] A Phenylfurocoumarin Derivative Reverses ABCG2-Mediated Multidrug Resistance In Vitro and In Vivo. Kokubo S, Ohnuma S, Murakami M, Kikuchi H, Funayama S, Suzuki H, Kajiwara T, Yamamura A, Karasawa H, Sugisawa N, Ohsawa K, Kano K, Aoki J, Doi T, Naitoh T1, Ambudkar SV, Unno M: Int J Mol Sci 2021/11; 22 (22): 12502. (“ŕ“Ą@„1: 1‰ş•”Á‰ťŠÇŠO)

320003. [Ç—á•ń] Žá”N—Ť‚̐üˆŰ‘BŽî“ŕ‚É”F‚ß‚ç‚ę‚˝”ńZŤ“űŠÇŠŕ‚Ě1—á. ‘O“c“úŘŽq1, ‘O“cˆę˜Y1,2, –öŕV‹MŽq1, ŒÜŒŽ—Œbˆę1, óŔŽjŽ÷1, –î“ŕŒ´‹v1, ’r“c@ł1, Îˆä—ǍK1,3 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2•a—, 3‰ş•”Á‰ťŠÇŠO): “űŠŕ‚Ě—Ő° 2021/7; 36 (3): 249-57.

520008. [‘ŕ] ‹ÇŠis’ź’°Šŕ‚ɑ΂ˇ‚鉝Šw•úŽËü—Ă–@‚ĚŒťó. ˛“Ą•˜Y1,2 (1ˆă—Ă‹Zp‹łˆç, 2‰ş•”Á‰ťŠÇŠO): –k—˘ˆăŠw 2021/6; 51 (1): 1-5.

522072. [uŔ]y“ÁW: • o‹ž‰şŽčp‚ĚŠî–{z1. • o‹ž‰şŽčp‚Ě“Á’Ľ. “ŕ“Ą@„1, ˛“Ą•˜Y1,2, ŽR—œ‚L1, ŽO‰YŒ[šć1, ŒĂé@Œ›1, “c’†r“š1, ‰ĄˆäŒ\Œĺ1, ×“c@Œj1, ŽR‰şŒpŽj3,4, ŒGŒł—Y‰î5, ”äŠé’źŽ÷4 (1‰ş•”Á‰ťŠÇŠO, 2ˆă—Ă‹Zp‹łˆç, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4ă•”Á‰ťŠÇŠO, 5ˆę”ʁEŹŽ™EŠĚ’_äXŠO): Á‰ťŠíŠO‰Č 2021/4; 44 (4): 385-90.

522073. [uŔ]y˜AÚ: Ž„‚ĚŽĄ—Áz’°•ÂÇ (ƒCƒŒƒEƒX). —Ž‡‘ĺŽ÷1, Îˆä—ǍK1,2, “n粏š•F1 (1–k—˘Œ¤‹†Š•a‰@, 2‰ş•”Á‰ťŠÇŠO): “ú–{ˆăŽ–V•ń 2021/4; 5061: 37-8.

522074. [uŔ]y“ÁW: ’ź’°‚Ş‚ń‚ĚŽčp‚đ‚ß‚Ž‚éŠĹŒě`H‚ׂéE”rŸ•‚ˇ‚éE“Ž‚­v‚đƒTƒ|[ƒg‚ˇ‚é`zƒf[ƒ^‚Ĺ‚Ý‚é’ź’°‚Ş‚ń‚Ě“Á’Ľ. ˛“Ą•˜Y1,2, ŽR—œ‚L2, “ŕ“Ą@„2 (1ˆă—Ă‹Zp‹łˆç, 2‰ş•”Á‰ťŠÇŠO): ‚Ş‚ńŠĹŒě 2021/9-10; 26 (7): 575-7.

522075. [uŔ]y“ÁW: ƒXƒRƒsƒXƒg‚đ‹É‚ß‚ézĄŠe˜_@• o‹ž‰ş‚róŒ‹’°Řœ‚Ĺ‚ĚƒXƒRƒsƒXƒg‚ĚƒeƒNƒjƒbƒN‚ĆƒRƒc. “c’†r“š1, ‰ĄˆäŒ\Œĺ1, ŒĂé@Œ›1, ŽO‰YŒ[šć1, ŽR—œ‚L1, ˛“Ą•˜Y1,2, “ŕ“Ą@„1 (1‰ş•”Á‰ťŠÇŠO, 2ˆă—Ă‹Zp‹łˆç): —Տ°ŠO‰Č 2021/10; 76 (10): 1240-5.

530009. [‚ť‚Ě‘ź (joint consensus statement)] Metabolic surgery in treatment of obese Japanese patients with type 2 diabetes: a joint consensus statement from the Japanese Society for Treatment of Obesity, the Japan Diabetes Society, and the Japan Society for the Study of Obesity. Sasaki A, Yokote K, Naitoh T1, Fujikura J, Hayashi K, Hirota Y, Inagaki N, Ishigaki Y, Kasama K, Kikkawa E, Koyama H, Masuzaki H, Miyatsuka T, Nozaki T, Ogawa W, Ohta M, Okazumi S, Shimabukuro M, Shimomura I, Nishizawa H, Saiki A, Seki Y, Shojima N, Tsujino M, Ugi S, Watada H, Yamauchi T, Yamaguchi T, Ueki K, Kadowaki T, Tatsuno I; Joint Committee in the Japanese Society for Treatment of Obesity, the Japan Diabetes Society, Joint Committee in the Japanese Society for Treatment of Obesity, the Japan Diabetes Society, the Japan Society for the Study of Obesity: Diabetol Int 2021/11; 13 (1): 1-30. (“ŕ“Ą@„1: 1‰ş•”Á‰ťŠÇŠO)

540026. [‚ť‚Ě‘ź (ˆĎˆő‰ď•ń)] “ú–{l‚̔얞2Œ^“œ”A•aŠłŽŇ‚ɑ΂ˇ‚錸—ʁE‘ăŽÓ‰ü‘PŽčp‚ÉŠÖ‚ˇ‚éƒRƒ“ƒZƒ“ƒTƒXƒXƒe[ƒgƒƒ“ƒg ˛X–؏Í1, “ŕ“Ą@„1,2, ‰ĄŽčK‘ž˜Y1, ˆîŠ_’¨–ç1, ‰vč—TÍ1, –Č“c—TF1, Źě@Â1, ‰ş‘şˆÉˆę˜Y1, ŽR“ŕ•qł1, ÎŠ_@‘×1, Š}ŠÔ˜a“T1, –ěč„O1, “‡‘܏[ś1, “Ą‘qƒ“ń1, ‹{’ˁ@Œ’1,3, Ż“ˆL_1, źŕV@‹Ď1, œA“c—EŽm1, ‰K–؁@’q1, ‘ž“cł”V1, ‰ŞZTˆę1, ‹gěŠG—œ1, ŹŽR‰p‘Ľ1, âV–ŘŒúl1, ŠÖ@—m‰î1, ’Ň–ěŒłË1, —с@‰Ę—Ń1, ŽRŒű@’1, —´–ěˆę˜Y1, A–؍_“ń˜Y1, –ĺ˜e@F1 (1“ú–{l‚̔얞2Œ^“œ”A•aŠłŽŇ‚ɑ΂ˇ‚錸—ʁE‘ăŽÓ‰ü‘PŽčp‚Ě“K‰žŠî€‚ÉŠÖ‚ˇ‚é3Šw‰ď‡“ŻˆĎˆő‰ď, “ú–{”ě–žÇŽĄ—ĂŠw‰ď, “ú–{“œ”A•aŠw‰ď, “ú–{”ě–žŠw‰ď, 2‰ş•”Á‰ťŠÇŠO, 3“ŕ•Ş”ĺ‘ăŽÓ“ŕ): “œ”A•a 2022/3; 65 (3): 109-77.

[’˜@‘]

620080. [Šwp‘ (•Ş’SŽˇ•M)]yŒˆ’č”Ĺ!}‰đ‚Ĺ‚ŕ‚ę‚Č‚­‚Ý‚Ś‚éE‚í‚Š‚é@‚܂邲‚ƏÁ‰ťŠíƒhƒŒ[ƒ“Eƒ`ƒ…[ƒuŠÇ— (Á‰ťŠíƒi[ƒVƒ“ƒO2021”Nt‹G‘Š§)zĄ6ÍƒhƒŒ[ƒ“Eƒ`ƒ…[ƒu‚ɂ܂‚í‚éƒPƒA‚ĚQ&A@3 ‚ť‚Ě‚Ů‚Š‚ĚƒPƒA, p.233-8. ‰ĄˆäŒ\Œĺ1, “ŕ“Ą@„1 (1‰ş•”Á‰ťŠÇŠO), ŠÄC: ŒŃ“c Œ’ˆę, ƒƒfƒBƒJo”Ĺ ‘ĺă, 2021/4”­s.

620081. [Šwp‘ (•Ş’SŽˇ•M)]yę–ĺˆă•KŒg VŠO‰ČŽčp‘ V‚ľ‚˘ŽčpŽč‹Z‚ĚƒGƒbƒZƒ“ƒX (—Տ°ŽGŽŠO‰Č2021”N4ŒŽ‘Š§†)zIII. Ź’°@3. –ü’…Ť’°•ÂÇ‚ɑ΂ˇ‚é• o‹ž‰şŽčp‚ĚŽčpŽč‹Z, p.477-81. ŽO‰YŒ[šć1, “c’†r“š1, ‰ĄˆäŒ\Œĺ1, ŒĂé@Œ›1, ŽR—œ‚L1, ŠC’Ă‹MŽj1, ×“c@Œj, ˛“Ą•˜Y1,2, ŽR‰şŒpŽj3,4, ŒGŒł—Y‰î5, ”äŠé’źŽ÷4, “ŕ“Ą@„1 (1‰ş•”Á‰ťŠÇŠO, 2ˆă—Ă‹Zp‹łˆç, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4ă•”Á‰ťŠÇŠO, 5ˆę”ʁEŹŽ™EŠĚ’_äXŠO), “ě]“°, 2021/4”­s.

620082. [Šwp‘ (•Ş’SŽˇ•M)]yę–ĺˆă‚Ě‚˝‚ß‚ĚÁ‰ťŠí•aŠw ‘ć3”ŁzIII Ź’°E‘ĺ’°@Še˜_@Á‰ťŠÇŠÔŽżŽîᇠ(GIST), p.286-8. “c’†r“š1, “ŕ“Ą@„1 (1‰ş•”Á‰ťŠÇŠO), ŠÄC: ‰şŁě“O, “n•Ó@Žç, •Ň: –؉ş–Fˆę, ‹ŕŽqŽüˆę, Š~“c”ŽŽj, ‘şă˜aŹ, ˆŔ“Ą@˜N, Ž…ˆä—˛•v, ˆăŠw‘‰@, “Œ‹ž, 2021/11”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713040. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Contribution of neoadjuvant chemoradiotherapy with S-1/ Irinotecan to minimally invasive treatment for advanced rectal cancer. Kojo K1, Naitoh T1, Sato T1, Yamanashi T1, Miura H1, Yokoi K1, Tanaka T1: 2021 Scientific Session of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) (2021/8/31-9/3), Las Vegas, USA. (ŒĂé@Œ›1, “ŕ“Ą@„1, ˛“Ą•˜Y1, ŽR—œ‚L1, ŽO‰YŒ[šć1, ‰ĄˆäŒ\Œĺ1, “c’†r“š1: 1‰ş•”Á‰ťŠÇŠO)

722116. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Á‰ťŠÇƒoƒCƒpƒXp‚Ě“œ”A•a‰ü‘PŒř‰Ę‚Ě”­Œť‹@˜. “ŕ“Ą@„1, “c’†’źŽ÷, ˆä–{”Ž•ś, ’†”nŠî”Ž2, ×“c@Œj2, ŠC–ě—Ď–ž, ˛“Ą•˜Y1, ŽR‰şŒpŽj2,3, ŒGŒł—Y‰î4, ”äŠé’źŽ÷2 (1‰ş•”Á‰ťŠÇŠO, 2ă•”Á‰ťŠÇŠO, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć34‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2021/12/3), •şŒÉ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722117. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŽáŽčˆăŽt‚É‚ć‚é’ź’°Šŕƒƒ{ƒbƒgŽx‰‡‰şŽčp‚Ě‹łˆç‚ɂ‚˘‚Ä‚ĚŒŸ“˘. “c’†r“š1, ŽR—œ‚L1, ŽO‰YŒ[šć1, “n•”WŽq2, Œă“Ą‘ě–ç2, ‰ĄˆäŒ\Œĺ1, ŒĂé@Œ›1, ˛“Ą•˜Y1, ×“c@Œj3, ŠC’Ă‹MŽj4, ŽR‰şŒpŽj3,5, ŒGŒł—Y‰î4, ”äŠé’źŽ÷3, “ŕ“Ą@„1 (1‰ş•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ă•”Á‰ťŠÇŠO, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 5V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć34‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2021/12/3), •şŒÉ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722118. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Šî‘bE—Տ°Œ¤‹†‚Š‚ç‚Ý‚˝Á‰ťŠÇƒoƒCƒpƒXp“ą“ü‚Ě•K—vŤ. “ŕ“Ą@„1, “c’†’źŽ÷, ˆä–{”Ž•ś, ’†”nŠî”Ž2, ×“c@Œj2, ŠC–ě—Ď–ž, ˛“Ą•˜Y1, ŽR‰şŒpŽj2,3, ŒGŒł—Y‰î4, ”äŠé’źŽ÷2 (1‰ş•”Á‰ťŠÇŠO, 2ă•”Á‰ťŠÇŠO, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć34‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2021/12/3), •şŒÉ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722119. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‘˝EŽí˜AŒg‚É‚ć‚éƒ`[ƒ€ˆă—Ă‚Ć‚ľ‚Ä‚ĚpŒăŠÇ—|‘މ@‚Ü‚Ĺ‚Ě‡’˛‚Č‘Šú‰ń•œ‚Ě‚˝‚߂Ɂ|Œ¸—ʁE‘ăŽÓ‰ü‘PŽčp‚É‚¨‚Ż‚é‘˝EŽí˜AŒg‚ĚŽć‚č‘g‚Ý. “ŕ“Ą@„1, ’†”nŠî”Ž2, Žsě—‹Žt3, ‹{’ˁ@Œ’3, ”äŠé’źŽ÷2 (1‰ş•”Á‰ťŠÇŠO, 2ă•”Á‰ťŠÇŠO, 3“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć43‰ń“ú–{ŽčpˆăŠw‰ď‘‰ď (2022/1/29), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722120. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “–‰Č‚É‚¨‚Ż‚é‘ĺ’°Šŕ‚ɑ΂ˇ‚éreduced port surgery. Îˆä—ǍK1,2, —Ž‡‘ĺŽ÷1, ”—@—T”V1, ’|‘ş—Y‰î1, •l–ěˆč”ü1, ‰€“cŒ[‘ž1, ‘O“c“úŘŽq1, ŒÜŒŽ—Œbˆę1, _’J‹I‹P1,3, “n粏š•F1 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‰ş•”Á‰ťŠÇŠO‰Č, 3ŒÄ‹zŠíŠO): 9th Reduced Port Surgery Forum in Okinawa (2022/2/16-3/31), WebŠJĂ, 9th Reduced Port Surgery Forum in Okinawa ƒvƒƒOƒ‰ƒ€E´˜^W 2022/2; p.44.

722121. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) 3Šw‰ď‡“ŻƒXƒe[ƒgƒƒ“ƒgŠ§sŒă‚ĚŒ¸—ʁE‘ăŽÓ‰ü‘PŽčp‚ĚŒťó‚Ć“W–]. “ŕ“Ą@„1, ’†”nŠî”Ž2, ”äŠé’źŽ÷2 (1‰ş•”Á‰ťŠÇŠO, 2ă•”Á‰ťŠÇŠO): ‘ć42‰ń“ú–{”ě–žŠw‰ďE‘ć39‰ń“ú–{”ě–žÇŽĄ—ĂŠw‰ďŠwpW‰ď (2022/3/27), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723319. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘˝Ž{Ý‹¤“ŻŠĎŽ@Œ¤‹†‚Ě—L—pŤ`‘ĺ‹K–ÍŽčpŒ¤‹†Ž––ą‹Ç12”N‚ĚŒoŒą‚Š‚ç`. ”ě“cŒň–î, ‰Ş‘ş—ş•ă, źé‘ĺ•ă, Zˆä“Ö•F, ‹ŕé—m‰î, âˆä‹`ŽĄ, “n粏š•F1, “ŕ“Ą@„2 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‰ş•”Á‰ťŠÇŠO‰Č): ‘ć121‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/4/8), WebŠJĂ.

723320. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) \“ńŽw’°‹ó’°ƒoƒCƒpƒXp‚Ě”ńƒAƒ‹ƒR[ƒ‹ŤŽ‰–bŠĚ‰Š‰ü‘PŒř‰Ę‚É‚¨‚Ż‚é’_äX˜H‚Ě–đŠ„. Žsě‰pF, “c’†’źŽ÷, ˆä–{”Ž•ś, _ŽR“ÄŽj, Â–؁@‹, “n•Ó˜aG, ‘ĺŔ@”E, “Ą“‡ŽjŠě, “ŕ“Ą@„1, Î“cFé, ‹Tˆä@Ž, ŠC–ě—Ď–ž (1‰ş•”Á‰ťŠÇŠO): ‘ć121‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/4/8), WebŠJĂ.

723321. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) pŒă–ü’…Ť’°•ÂÇ‚ɑ΂ˇ‚é• o‹ž‰şŽčp‚ĚŒťó: ‚í‚ę‚í‚ę‚̍H•v‚ĆŽĄ—ÐŹŃ. —Ž‡‘ĺŽ÷1, Îˆä—ǍK1,2, ”—@—T”V1, ’|‘ş—T‰î1, ‘O“c“úŘŽq1, ŒÜŒŽ—Œcˆę1, _’J‹I‹P1,3, ‰Ş@‘׏B1, “n粏š•F1 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‰ş•”Á‰ťŠÇŠO‰Č, 3ŒÄ‹zŠíŠO): ‘ć121‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/4/8-10), WebŠJĂ.

723322. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) p‘O CT ‚đ—p‚˘‚˝œŠi‹Ř‘gŹ•]‰ż‚ÍStage III‘ĺ’°Šŕ‚Ě’ˇŠú—\Œă‚đ—\‘Ş‚ˇ‚é. ‰ĄˆäŒ\Œĺ1, “c’†r“š1, ŒĂé@Œ›1, ŽO‰YŒ[šć1, ŽR—œ‚L1, ˛“Ą•˜Y1, ×“c@Œj2, “c“‡@O3, ŠC’Ă‹MŽj3, ‰Á“Ą@O4, ĺÎ‹I•F4, ”äŠé’źŽ÷2, ŒGŒł—Y‰î3, ŽOŠK‹MŽj4, “c’†@Œ‰3,5, ŽR‰şŒpŽj2,6, “ŕ“Ą@„1 (1‰ş•”Á‰ťŠÇŠO, 2ă•”Á‰ťŠÇŠO, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4“ű‘BEbó‘BŠO, 5V˘‹Iˆă—ÁEć’[ˆă—Ă, 6V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć121‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/4/8-10), WebŠJĂ.

723323. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚é‘ĺ’°_Œo“ŕ•Ş”ĺŠŕ‚ĚŽĄ—ÐŹŃ. “c’†r“š1, ˛“Ą•˜Y1, b”ă“c•Žu2, Œă“Ą‘ě–ç2, ‰ĄˆäŒ\Œĺ1, ŒĂé@Œ›1, ŽO‰YŒ[šć1, ×“c@Œj3, ŠC’Ă‹MŽj4, ‰Á“Ą@O5, ĺÎ‹I•F5, ŽR‰şŒpŽj3,6, ŒGŒł—Y‰î4, ŽOŠK‹MŽj5, “c’†@Œ‰4,7, ”äŠé’źŽ÷3, “ŕ“Ą@„1 (1‰ş•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ă•”Á‰ťŠÇŠO, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 5“ű‘BEbó‘BŠO, 6V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 7V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć121‰ń“ú–{ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/4/8-10), WebŠJĂ.

723324. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) bó‘B‘S“Ep‚đŽ{s‚ľ‚˝‹´–{•a‹}Ť‘ˆŤ‚Ě1—á. ŒÜŒŽ—Œbˆę1, ‘O“c“úŘŽq1, –öŕV‹MŽq1, ‰Ş@‘׏B1, ’|‘ş—T‰î1, ”—@—T”V1, —Ž‡‘ĺŽ÷1, ‘ĺěš‹`1, _’J‹I‹P1,2, Îˆä—ǍK1,3, ‘O“cˆę˜Y1,4, ’r“c@ł1, “n粏š•F1 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2ŒÄ‹zŠíŠO, 3‰ş•”Á‰ťŠÇŠO, 4•a—): ‘ć33‰ń“ú–{“ŕ•Ş”ĺŠO‰ČŠw‰ď‘‰ď (2021/6/3-4), Œyˆä‘ň (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{“ŕ•Ş”ĺŠO‰ČŠw‰ďŽGŽ 2021/5; 38 (Suppl 1): S109.

723325. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œ‹’°Šŕ‚É‚¨‚Ż‚éCD44ƒoƒŠƒAƒ“ƒg’č—ĘŒn‚ĚŠm—§‚Ć—Ő°•a—Šw“IˆÓ‹`‚ɂ‚˘‚Ä‚ĚŒŸ“˘. b”ă“c•Žu1, Œă“Ą‘ě–ç1, “c’†r“š2, ‰ĄˆäŒ\Œĺ2, ŒĂé@Œ›2, ŽO‰YŒ[šć2, ŽR—œ‚L2, ˛“Ą•˜Y2, ŽR‰şŒpŽj3,4, “ŕ“Ą@„2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‰ş•”Á‰ťŠÇŠO, 3ă•”Á‰ťŠÇŠO, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć76‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2021/7/7), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723326. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) is‰ĄsŒ‹’°Šŕ‚ɑ΂ˇ‚鎊“KßŠs´”ÍˆÍ‚ĚŒŸ“˘. ŽO‰YŒ[šć1, ˛“Ą•˜Y1, ‰ĄˆäŒ\Œĺ1, “c’†r“š1, ŒĂé@Œ›1, ŽR—œ‚L1, ŽR‰şŒpŽj2,3, ŒGŒł—Y‰î4, ”äŠé’źŽ÷3, “ŕ“Ą@„1 (1‰ş•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3ă•”Á‰ťŠÇŠO, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć76‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2021/7/7), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723327. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) p‘OCT‚đ—p‚˘‚˝œŠi‹Ř’č—Ę‚ĚStage III‘ĺ’°Šŕ‚É‚¨‚Ż‚é—Տ°“IˆÓ‹`‚Ě’j—ˇ‚ɂ‚˘‚Ä‚ĚŒŸ“˘. ‰ĄˆäŒ\Œĺ1, “c’†r“š1, ŒĂé@Œ›1, ŽO‰YŒ[šć1, ŽR—œ‚L1, ˛“Ą•˜Y1, ŽR‰şŒpŽj2,3, ”äŠé’źŽ÷3, ŒGŒł—Y‰î4, “ŕ“Ą@„1 (1‰ş•”Á‰ťŠÇŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3ă•”Á‰ťŠÇŠO, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć76‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2021/7/7), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723034. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠĚ‹•ŒŒÄŸó—ŹáŠQŒă‚̩̏C•œ‚É‚¨‚Ż‚éiNKT×–E‚Ě–đŠ„. Œă“Ą‘ě–ç1, ˆÉ“Ą‹`–ç2, ˛“Ą@‰ë3, ’†–{CŽi4, ×–ě‰Á“ŢŽq2, ”¨’†@Œö2, ”n“ˆł—˛2, “V–ě‰pŽ÷2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3–Ɖu, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć42‰ń“ú–{‰ŠÇĽÄśˆăŠw‰ď (2021/7/7), WebŠJĂ.

723328. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒIƒ“ƒRƒpƒlƒ‹ŒŸ¸‚ÉŠî‚Ă‚­ƒQƒmƒ€ˆă—Ă‚É‚ć‚Á‚ÄŠŽ‘S‘tŒ÷‚Ş“ž‚ç‚ę‚˝isÄ”­ăč–ĺŠÇŠŕ‚Ě1—á. “c’†r“š1, b”ă“c•Žu2, Œă“Ą‘ě–ç2, ‰ĄˆäŒ\Œĺ1, ŒĂé@Œ›1, ŽO‰YŒ[šć1, ŽR—œ‚L1, ˛“Ą•˜Y1, ”äŠé’źŽ÷3, “ŕ“Ą@„1 (1‰ş•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ă•”Á‰ťŠÇŠO): ‘ć76‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2021/7/8), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723329. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŒŔ‹Ç‚ˇ‚éŠĚ“ŕ’_ŠÇŠg’Ł‚Ĺ”­ŒŠ‚ł‚ę‚˝SóŒ‹’°ŠŕpŒăŠĚ“]ˆÚ‚Ě1—á. â–{—FŒŠŽq, ‰Ą“c˜aŽq1, ŠřŽč˜a•F, ‹ŕŕVG‹I, ‹ŕ“cŒĺ˜Y, –x“cˆťŽq, Ö“Ąś˜N, ŠC’Ă‹MŽj2, ŒGŒł—Y‰î2 (1‰ş•”Á‰ťŠÇŠO, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć76‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2021/7/8), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723330. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹žŽ‹‰şŽčpŽž‘ă‚É‚¨‚Ż‚é“–‰@‚Ě‹}Ť’Ž‚‰Š‚ɑ΂ˇ‚é‹Ů‹}Žčp‚Ć‘Ň‹@Žčp‚̐ŹŃ‚ĚŒŸ“˘. ’|‘ş—T‰î1, Îˆä—ǍK1,2, ‰Ş@‘׏B1, ‘O“c“úŘŽq1, ”—@—T”V1, —Ž‡‘ĺŽ÷1, ŒÜŒŽ—Œbˆę1, _’J‹I‹P1,3, “n粏š•F1 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‰ş•”Á‰ťŠÇŠO, 3ŒÄ‹zŠíŠO): ‘ć76‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2021/7/7-9), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď76‰ńƒvƒƒOƒ‰ƒ€ 2021/7; p.P293-6.

723331. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆÝŘœŒă‚̍œŠi‹Ř—ʂ̕ωť‚Ć—\Œă‚ւ̉e‹ż. ”—@—T”V1, ‰Ş@‘׏B1, ’|‘ş—T‰î1, ‘O“c“úŘŽq1, —Ž‡‘ĺŽ÷1, ŒÜŒŽ—Œbˆę1, _’J‹I‹P1,2, Îˆä—ǍK1,3, “n粏š•F1 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2ŒÄ‹zŠíŠO, 3‰ş•”Á‰ťŠÇŠO): ‘ć76‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď (2021/7/7-9), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{Á‰ťŠíŠO‰ČŠw‰ď‘‰ď76‰ńƒvƒƒOƒ‰ƒ€ 2021/7; p.P022-1.

723332. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒIƒ“ƒRƒpƒlƒ‹ŒŸ¸‚ÉŠî‚Ă‚­‚Ş‚ńƒQƒmƒ€ˆă—Ă‚ĹŠŽ‘S‘tŒ÷‚đ“ž‚˝isÄ”­ăč–ĺŠÇŠŕ‚Ě1—á. “c’†r“š1, b”ă“c•Žu1, Œă“Ą‘ě–ç2, ‰ĄˆäŒ\Œĺ1, ŒĂé@Œ›1, ŽO‰YŒ[šć1, ŽR—œ‚L1, ˛“Ą•˜Y1, “ŕ“Ą@„1, ˛X–ŘŽĄˆę˜Y3 (1‰ş•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć59‰ń“ú–{ŠŕŽĄ—ĂŠw‰ďŠwpW‰ď (2021/10/21-23), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723333. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) bó‘BŽžŠłpŒă, ”˝‰ń_Œo•s‘S–ƒáƒ‚ĚŒŸ“˘. ŒÜŒŽ—Œbˆę1, ‘O“c“úŘŽq1, –öŕV‹MŽq1, ‰€“cŒ[‘ž1, ’|‘ş—T‰î1, •l–ěˆč”ü1, ”—@—T”V1, —Ž‡‘ĺŽ÷1, _’J‹I‹P1,2, Îˆä—ǍK1,3, “n粏š•F1, ’r“c@ł1 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2ŒÄ‹zŠíŠO, 3‰ş•”Á‰ťŠÇŠO): ‘ć54‰ń“ú–{“ŕ•Ş”ĺŠO‰ČŠw‰ďŠwp‘ĺ‰ď (2021/10/28-29), WebŠJĂ, “ú–{“ŕ•Ş”ĺŠO‰ČŠw‰ďŽGŽ 2021/10; 38 (Suppl 2): S255.

723334. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆÝŘœp‚É‚¨‚Ż‚é“ŕ‘ŸŽ‰–b‚̉e‹ż. ”—@—T”V1, ‰Ş@‘׏B1, ’|‘ş—T‰î1, ‘O“c“úŘŽq1, —Ž‡‘ĺŽ÷1, ŒÜŒŽ—Œbˆę1, _’J‹I‹P1,2, Îˆä—ǍK1,3, “n粏š•F1 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2ŒÄ‹zŠíŠO, 3‰ş•”Á‰ťŠÇŠO): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (‘ć19‰ń“ú–{Á‰ťŠíŠO‰ČŠw‰ď‘ĺ‰ď) (2021/11/4-7), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723335. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) SóŒ‹’°ŠŕpŒă‚ÉŽ¤á‘“]ˆÚ‚đ—ˆ‚ľ‚˝1—á. ŠŰŽRł—T1, “ŕ“Ął‹K, ç–ěTˆę˜Y1, –Ľ‰YG”V1, “Ą”ör[2, “Y–ěF•ś3, ’†”nŠî”Ž4, ’†‘ş˜a“ż2, ‹ß“ĄNŽj5, ‚‹´’ől2, “ŕ“Ą@„1 (1‰ş•”Á‰ťŠÇŠO, 2ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4ă•”Á‰ťŠÇŠO, 5“ű‘BEbó‘BŠO): ‘ć76‰ń“ú–{‘ĺ’°ăč–ĺ•aŠw‰ďŠwpW‰ď (2021/11/13), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723336. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’ź’°Šŕ‚ɑ΂ˇ‚郍ƒ{ƒbƒgŽčp‚Ć• o‹ž‰şŽčp‚Ě”äŠrŒŸ“˘. ŽO‰YŒ[šć1, ŽR—œ‚L1, ‰ĄˆäŒ\Œĺ1, “c’†r“š1, ŒĂé@Œ›1, ˛“Ą•˜Y1, “ŕ“Ą@„1 (1‰ş•”Á‰ťŠÇŠO): ‘ć76‰ń“ú–{‘ĺ’°ăč–ĺ•aŠw‰ďŠwpW‰ď (2021/11/12-13), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723337. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) isÄ”­ăč–ĺŠÇŠŕ‚ɑ΂ľ‚ăIƒ“ƒRƒpƒlƒ‹ŒŸ¸‚ÉŠî‚Ă‚˘‚˝‚Ş‚ńƒQƒmƒ€ˆă—Ă‚Ş‘tŒ÷‚ľ‚˝1—á. “c’†r“š1, “n•”WŽq2, Œă“Ą‘ě–ç2, ‰ĄˆäŒ\Œĺ1, ŒĂé@Œ›1, ŽO‰YŒ[šć1, ŽR—œ‚L1, ˛“Ą•˜Y1, “ŕ“Ą@„1 (1‰ş•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć76‰ń“ú–{‘ĺ’°ăč–ĺ•aŠw‰ďŠwpW‰ď (2021/11/12-13), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723338. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) p‘OCT‚đ—p‚˘‚˝œŠi‹Ř’č—ʂƉŠÇƒ}[ƒJ[‚ĚStage III‘ĺ’°Šŕ‚É‚¨‚Ż‚é—Տ°“IˆÓ‹`‚ɂ‚˘‚Ä‚ĚŒŸ“˘. ‰ĄˆäŒ\Œĺ1, “c’†r“š1, ŒĂé@Œ›1, ŽO‰YŒ[šć1, ŽR—œ‚L1, ˛“Ą•˜Y1, “ŕ“Ą@„1 (1‰ş•”Á‰ťŠÇŠO): ‘ć76‰ń“ú–{‘ĺ’°ăč–ĺ•aŠw‰ďŠwpW‰ď (2021/11/12-13), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723339. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Stage III‘ĺ’°Šŕ‚É‚¨‚Ż‚ép‘OpŒăCT‚đ—p‚˘‚˝œŠi‹Ř‘gŹ•]‰ż‚ƉŠÇƒ}[ƒJ[‚Ě‘ŠŠÖ. ‰ĄˆäŒ\Œĺ1, “c’†r“š1, ŒĂé@Œ›1, ŽO‰YŒ[šć1, ŽR—œ‚L1, ×“c@Œj2, ŠC’Ă‹MŽj3, ˛“Ą•˜Y1, ŒGŒł—Y‰î3, ”äŠé’źŽ÷2, “ŕ“Ą@„1 (1‰ş•”Á‰ťŠÇŠO, 2ă•”Á‰ťŠÇŠO, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć83‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2021/11/18-20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723340. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠO‰Č“IŽĄ—Éî“ü‚đ‚ľ‚˝‘ĺ’°NET (neuroendocrine tumor) 15—á‚ɂ‚˘‚Ä‚ĚŒŸ“˘. Œă“Ą‘ě–ç1, “c’†r“š2, ‰ĄˆäŒ\Œĺ2, ŒĂé@Œ›2, ŽO‰YŒ[šć2, ŽR—œ‚L2, ×“c@Œj3, ŠC’Ă‹MŽj4, ˛“Ą•˜Y2, ŒGŒł—Y‰î4, ”äŠé’źŽ÷3, “ŕ“Ą@„2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‰ş•”Á‰ťŠÇŠO, 3ă•”Á‰ťŠÇŠO, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć83‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2021/11/18-20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723341. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘BŠŕ‚𔺂¤’ź’°_Œo“ŕ•Ş”ĺŠŕ‚ɑ΂ľ‚ÄŒoăč–ĺ“I“ŕŽ‹‹ž‰ş’áNPŽčp‚đŽ{s‚ľ‚˝1—á. ‰€“cŒ[‘ž1, —Ž‡‘ĺŽ÷1, Îˆä—ǍK1,2, ŒÜŒŽ—Œbˆę1, _’J‹I‹P1,3, ”—@—T”V1, •l–ěˆč”ü1, ’|‘ş—T‰î1, “n糏š•F1 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‰ş•”Á‰ťŠÇŠO‰Č, 3ŒÄ‹zŠíŠO): ‘ć83‰ń“ú–{—Տ°ŠO‰ČŠw‰ď‘‰ď (2021/11/18-20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723342. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰ĄsŒ‹’°Šŕ‚ɑ΂ˇ‚é• o‹ž‰şŽčp‚ĚŽĄ—ÐŹŃ. ŽO‰YŒ[šć1, “c’†r“š1, ‰ĄˆäŒ\Œĺ1, ŒĂé@Œ›1, ŽR—œ‚L1, “n•”WŽq2, Œă“Ą‘ě–ç2, ˛“Ą•˜Y1, ×“c@Œj3, ŠC’Ă‹MŽj4, ŽR‰şŒpŽj3,5, ŒGŒł—Y‰î4, ”äŠé’źŽ÷3, “ŕ“Ą@„1 (1‰ş•”Á‰ťŠÇŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ă•”Á‰ťŠÇŠO, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 5V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć34‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2021/12/3), •şŒÉ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723343. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) p‘OCT‚đ—p‚˘‚˝œŠi‹Ř’č—Ę‚Ě‘ĺ’°Šŕ‚É‚¨‚Ż‚é—Տ°“IˆÓ‹`‚ƉŠÇƒ}[ƒJ[‚Ě‘ŠŠÖ. ‰ĄˆäŒ\Œĺ1, “c’†r“š1, ŒĂé@Œ›1, ŽO‰YŒ[šć1, ŽR—œ‚L1, ×“c@Œj2, ŠC’Ă‹MŽj3, ŽR‰şŒpŽj2,4, ˛“Ą•˜Y1, ”äŠé’źŽ÷2, ŒGŒł—Y‰î3, “ŕ“Ą@„1 (1‰ş•”Á‰ťŠÇŠO, 2ă•”Á‰ťŠÇŠO, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć34‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2021/12/3), •şŒÉ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723344. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) is’ź’°Šŕ‚ɑ΂ˇ‚鉝Šw•úŽËüŽĄ—ĂŒă‚Ě‹žŽ‹‰ş‘¤•űƒŠƒ“ƒpßŠs´‚ĚŽĄ—ÐŹŃ. ŒĂé@Œ›1, ˛“Ą•˜Y1, ŽR—œ‚L1, ŽO‰YŒ[šć1, ‰ĄˆäŒ\Œĺ1, “c’†r“š1, ×“c@Œj2, ŠC’Ă‹MŽj3, ŽR‰şŒpŽj2,4, ”äŠé’źŽ÷2, ŒGŒł—Y‰î3, “ŕ“Ą@„1 (1‰ş•”Á‰ťŠÇŠO, 2ă•”Á‰ťŠÇŠO, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć34‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2021/12/4), •şŒÉ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723345. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) pŒă–ü’…Ť’°•ÂÇ‚ɑ΂ˇ‚é• o‹ž‰şŽčp‚É‚¨‚Ż‚éƒtƒ@[ƒXƒgƒ|[ƒg‘}“ü‚̍H•v. —Ž‡‘ĺŽ÷1, Îˆä—ǍK1,2, ”—@—T”V1, •l–ěˆč”ü1, ’|‘ş—Y‰î1, ‰€“cŒ[‘ž1, _’J‹I‹P1,3, “n粏š•F1 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‰ş•”Á‰ťŠÇŠO, 3ŒÄ‹zŠíŠO): ‘ć34‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2021/12/2-4), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{“ŕŽ‹‹žŠO‰ČŠw‰ďŽGŽ 2021/12; 26 (7): MO169-1.

723346. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •Ą”‰ń‚Ě• •”Žčp—đ‚Ş‚ ‚é–ü’…Ť’°•ÂÇ‚ɑ΂ľ‚Ä• o‹ž‰şŽčp‚đŽ{s‚ľ‚˝1—á. ‰€“cŒ[‘ž1, —Ž‡‘ĺŽ÷1, Îˆä—ǍK1,2, _’J‹I‹P1,3, ”—@—T”V1, •l–ěˆč”ü1, ’|‘ş—Y‰î1, “n粏š•F1 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‰ş•”Á‰ťŠÇŠO, 3ŒÄ‹zŠíŠO): ‘ć34‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2021/12/2-4), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{“ŕŽ‹‹žŠO‰ČŠw‰ďŽGŽ 2021/12; 26 (7): MO198-2.

723347. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —ǐŤcŠuŽîᇓEop‚É‚¨‚Ż‚éˆŔ‘S‚ČŽčpŽč‹Z‚ĚŒŸ“˘. _’J‹I‹P1,2, ‰€“cŒ[‘ž1, ’|‘ş—T‰î1, •l–ěˆč”ü1, ”—@—T”V1, —Ž‡‘ĺŽ÷1, Îˆä—ǍK1,3 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2ŒÄ‹zŠíŠO, 3‰ş•”Á‰ťŠÇŠO): ‘ć34‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (2021/12/2-4), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{“ŕŽ‹‹žŠO‰ČŠw‰ďŽGŽ 2021/12; 26 (7): MO059-4.

723348. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) QOLŒüă‚đ–ÚŽw‚ľ‚˝IBDƒZƒ“ƒ^[“ŕ‰Čˆă‚Ć‘ĺ’°ŠO‰Čˆă‚Ć‚ĚƒRƒ‰ƒ{ƒŒ[ƒVƒ‡ƒ“. —Ž‡‘ĺŽ÷1, Îˆä—ǍK1,2, Ź—с@‘ń1,3 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‰ş•”Á‰ťŠÇŠO, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć18‰ń“ú–{Á‰ťŠÇŠw‰ď‘‰ďŠwpW‰ď (GI Week 2022) (2022/2/11-12), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733099. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) p‘Of’f‰Â”\‚Ĺ‚ ‚Á‚˝‰ń’°NET‚ɑ΂ľ“ŕŽ‹‹ž“IŽĄ—Ă‚¨‚ć‚Ń• o‹ž‰şŞŽĄŘœ‚đŽ{s‚ľ‚˝1—á. ‰i‰Şä—˜“Ţ1, —Ž‡‘ĺŽ÷1, Îˆä—ǍK1,2, ź‘ş@ŒŤ1,3, ”—@—T”V1, ’|‘ş—T‰î1, _’J‹I‹P1,4, ‘ĺěš‹`1, ’†–ě@‰ë1, “n粏š•F1 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‰ş•”Á‰ťŠÇŠO, 3Á‰ťŠí“ŕ, 4ŒÄ‹zŠíŠO): ‘ć112‰ń“ú–{Á‰ťŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”—á‰ď (2021/6/12-13), WebŠJĂ, Progress of Digestive Endoscopy 2021/6; 99 (suppl): S128.

733100. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ’ź’°Šŕ‚ɑ΂ˇ‚郍ƒ{ƒbƒgŽčp‚Ć• o‹ž‰şŽčp‚Ě”äŠrŒŸ“˘. ŽO‰YŒ[šć1, ŽR—œ‚L1, ‰ĄˆäŒ\Œĺ1, “c’†r“š1, ŒĂé@Œ›1, ˛“Ą•˜Y1, “ŕ“Ą@„1 (1‰ş•”Á‰ťŠÇŠO): ‘ć95‰ń‘ĺ’°ŠŕŒ¤‹†‰ď (2021/7/2), ˆŽě (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733101. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚鍂—îŽŇ‚Ě‘ĺ’°Šŕ•â•‰ťŠw—Ă–@Ž{sŽŔ‘Ԃɂ‚˘‚Ä‚ĚŒŸ“˘. ‰ĄˆäŒ\Œĺ1, “c’†r“š1, ŒĂé@Œ›1, ŽO‰YŒ[šć1, ŽR—œ‚L1, ˛“Ą•˜Y1, “ŕ“Ą@„1 (1‰ş•”Á‰ťŠÇŠO): ‘ć95‰ń‘ĺ’°ŠŕŒ¤‹†‰ď (2021/7/2), ˆŽě (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733102. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ˆÝ”S–Œ‰ş‚É“ÁˆŮ‚ČŒ`‘Ô‚Ě‘˝–[Ť”^ᇂđŒ`Ź‚ľ, \“ńŽw’°’×ᇂ̐ú”j‚Ş‹^‚í‚ę‚˝1—á. ‹vŒ´ÍO1, ˛ăW‘ž˜Y1, •l–ěˆč”ü1, h“‡@—É1, –kžŠ@–ä1, ‹{’J˜Đ—C1, “ú”ä‹I•ś1,2, ‰€“cŒ[‘ž1, ’|‘ş—T‰î1, ”—@—T”V1, —Ž‡‘ĺŽ÷1, Îˆä—ǍK1,3, ź‘ş@ŒŤ1,4, Ź—с@‘ń1,2, ’†–ě@‰ë1 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3‰ş•”Á‰ťŠÇŠO, 4Á‰ťŠí“ŕ): “ú–{Á‰ťŠí•aŠw‰ďŠÖ“ŒŽx•”‘ć366‰ń—á‰ď (2021/9/18), WebŠJĂ, “ú–{Á‰ťŠí•aŠw‰ďŠÖ“ŒŽx•”—á‰ďƒvƒƒOƒ‰ƒ€E´˜^W366‰ń 2021/9; ´˜^W366‰ń: 45.

733010. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Role of IFN-ƒÁ produced by iNKT cells in liver repair after hepatic ischemiareperfusion injury in mice. Œă“Ą‘ě–ç1, ˆÉ“Ą‹`–ç2, ˛“Ą@‰ë3, ’†–{CŽi4, ×–ě‰Á“ŢŽq2, ”¨’†@Œö2, “V–ě‰pŽ÷2, ”n“ˆł—˛2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ň—, 3–Ɖu, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO): ‘ć145‰ń“ú–{–ň—Šw‰ďŠÖ“Œ•”‰ď (2021/10/9), WebŠJĂ.

733103. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Stage II‘ĺ’°Šŕ‚ĚÄ”­ƒŠƒXƒNˆöŽq‚ĚŒŸ“˘. “n•”WŽq1, ŒĂé@Œ›2, Œă“Ą‘ě–ç1, “c’†r“š2, ‰ĄˆäŒ\Œĺ2, ŽO‰YŒ[šć2, ŽR—œ‚L2, ˛“Ą•˜Y2, “ŕ“Ą@„2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‰ş•”Á‰ťŠÇŠO): ‘ć96‰ń‘ĺ’°ŠŕŒ¤‹†‰ď (2022/1/21), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733104. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) –TƒXƒg[ƒ}ƒwƒ‹ƒjƒA‚ĆƒXƒg[ƒ}’E‚đ‡•š‚ľ, ’°ŠÇ‰óŽ€‚đ—ˆ‚ľ‚˝1—á. Žž”C’‘1, ˛“Ą•˜Y2, “c’†r“š2, ‰ĄˆäŒ\Œĺ2, ŒĂé@Œ›2, ŽO‰YŒ[šć2, ŽR—œ‚L2, ŽR‰şŒpŽj3,4, ŒGŒł—Y‰î5, ”äŠé’źŽ÷4, “ŕ“Ą@„2 (1“ű‘BEbó‘BŠO, 2‰ş•”Á‰ťŠÇŠO, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4ă•”Á‰ťŠÇŠO, 5ˆę”ʁEŹŽ™EŠĚ’_äXŠO) ‘ć863‰ńŠO‰ČW’k‰ď (2022/3/12), WebŠJĂ.

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-110019. [Œ´’˜] Background characteristics and diabetes remission after laparoscopic sleeve gastrectomy in Japanese patients with type 2 diabetes stratified by BMI: subgroup analysis of J-SMART. Saiki A, Yamaguchi T, Sasaki A, Naitoh T1, Matsubara H, Yokote K, Okazumi S, Ugi S, Yamamoto H, Ohta M, Ishigaki Y, Kasama K, Seki Y, Tsujino M, Shirai K, Miyazaki Y, Masaki T, Nagayama D, Tatsuno I: Diabetol Int 2021/1; 12 (3): 303-12. (“ŕ“Ą@„1: 1‰ş•”Á‰ťŠÇŠO)

'20-310002. [Ç—á•ń] Efficacy of laparoscopic sleeve gastrectomy for patient with morbid obesity and type 1 diabetes mellitus: a case report. Ichikawa H, Imoto H, Tanaka N, Musha H, Sawada S, Naitoh T1, Kamei T, Unno M: Surg Case Rep 2021/1; 7 (1): 7. (“ŕ“Ą@„1: 1‰ş•”Á‰ťŠÇŠO)

[Šw‰ďEŒ¤‹†‰ď“™]

'20-722003. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Metabolic surgery‚Ě‘ăŽÓ‰ü‘PŒř‰Ę‚É‚¨‚Ż‚é’_`Ž_‚ĚˆÓ‹`: \“ńŽw’°E‹ó’°ƒoƒCƒpƒXƒ‚ƒfƒ‹‚Š‚ç‚ĚŒŸŘ. “c’†’źŽ÷, ˆä–{”Ž•ś, ‹{’n’q—m, “y‰ŽęŸ—T, ˆÉ¨ˆę˜N, ă–ě’męŸ, Žsě‰pF, “n•Ó˜aG, Â–؁@‹, _ŽR“ÄŽj, “ŕ“Ą@„1, ‘ĺŔ@”E, ‹Tˆä@Ž, ŠC–ě—Ď–ž (1‰ş•”Á‰ťŠÇŠO): ‘ć41‰ń“ú–{”ě–žŠw‰ďE‘ć38‰ń“ú–{”ě–žÇŽĄ—ĂŠw‰ďŠwpW‰ď (2021/3/21), WebŠJĂ.

'20-723024. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’˜–ž‚Č’_ůNŸ÷–Œ‰ş•‚Žî‘œ‚đ’ć‚ľ‚˝úEŤ’_ůN‰Š‚Ěˆę—á. ’|‘ş—T‰î1, ”—@—T”V1, —Ž‡‘ĺŽ÷1, _’J‹I‹P1,2, Îˆä—ǍK1,3, “n粏š•F1 (1–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 2ŒÄ‹zŠíŠO, 3‰ş•”Á‰ťŠÇŠO): ‘ć33‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (JSES 2020) (2021/3/10-13), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{“ŕŽ‹‹žŠO‰ČŠw‰ďŽGŽ 2021/3; 25 (7): DP82-7.

'20-723025. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Postoperative outcomes of minimally-invasive surgery for congenital choledochoal dilatation. Morikawa T, Takadate T, Ishida M, Ohtsuka H, Miura T, Iseki M, Kawaguchi K, Masuda K, Mizuma M, Hayashi H, Nakagawa K, Kamei T, “ŕ“Ą@„1, Unno M (1‰ş•”Á‰ťŠÇŠO): ‘ć33‰ń“ú–{“ŕŽ‹‹žŠO‰ČŠw‰ď‘‰ď (JSES 2020) (2021/3/13), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-723026. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) \“ńŽw’°‹ó’°ƒoƒCƒpƒXp‚Ě”ńƒAƒ‹ƒR[ƒ‹ŤŽ‰–bŠĚ‰Š‰ü‘PŒř‰Ę‚É‚¨‚Ż‚éBilio-Pancreatic Limb ‚̏d—vŤ Žsě‰pF, “c’†’źŽ÷, ˆä–{”Ž•ś, _ŽR“ÄŽj, Â–؁@‹, “n•Ó˜aG, ‘ĺŔ@”E, “ŕ“Ą@„1, ‹Tˆä@Ž, ŠC–ě—Ď–ž (1‰ş•”Á‰ťŠÇŠO): ‘ć41‰ń“ú–{”ě–žŠw‰ďE‘ć38‰ń“ú–{”ě–žÇŽĄ—ĂŠw‰ďŠwpW‰ď (2021/3/21), WebŠJĂ.


S‘ŸŒŒŠÇŠO‰ČŠw

[Šwp˜_•ś]

110274. [Œ´’˜] Neutrophil-to-lymphocyte ratio is prognostic factor of prolonged pleural effusion after pediatric cardiac surgery. Yakuwa K1, Miyaji K1, Kitamura T1, Miyamoto T1, Ono M, Kaneko Y: JRSM Cardiovasc Dis 2021/4; 10: 20480040211009438. (”ŞŒLˆę‹M1, ‹{’n@ŠÓ1, –k‘ş@—Ľ1, ‹{–{—˛Ži1: 1S‘ŸŒŒŠÇŠO)

110275. [Œ´’˜] Regional oxygen saturation change rate for detection of leg ischemia in minimally invasive cardiac surgery. Shikata F1, Nakamura Y, Okuzono Y, Uchigasaki Y, Yamauchi N: Perfusion 2021/5; 36 (4): 382-7. (Ž­“c•śş1: 1S‘ŸŒŒŠÇŠO)

110276. [Œ´’˜] Low skeletal muscle density combined with muscle dysfunction predicts adverse events after adult cardiovascular surgery. Yamashita M1, Kamiya K2, Matsunaga A2, Kitamura T3, Hamazaki N4 Nozaki K4, Ichikawa T4, Maekawa E5, Meguro K5, Yamaoka-Tojo M2, Ako J5, Miyaji K3: Nutr Metab Cardiovasc Dis 2021/6; 31 (6): 1782-90. (ŽR‰ş^Ži1, _’JŒ’‘ž˜Y2, ź‰i“Ä•F2, –k‘ş@—Ľ3, ŕ_čL–ž4, –ěčN•˝4, Žsě‹M•ś4, ‘OěŒb”ü5, –ڍ•Œ’‘ž˜Y5, “ŒžŠ”ü“ŢŽq2, ˆ˘ŒĂĆ5, ‹{’n@ŠÓ3: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3S‘ŸŒŒŠÇŠO, 4ƒŠƒnƒrƒŠ•”, 5zŠÂŠí“ŕ)

110277. [Œ´’˜] Outcomes after Rivaroxaban Treatment of Extensive Deep Vein Thrombosis. Fujioka S1, Kitamura T1, Shikata F1, Mishima T1, Onishi Y1, Araki H1, Goto H1, Sasahara A1, Fukuzumi M1, Torii S1,2, Miyaji K1: Ann Vasc Surg 2022/9; 85: 246-52. (“Ą‰Şrˆę˜Y1, –k‘ş@—Ľ1, Ž­“c•śş1, ”ü“‡—˜ş1, ‘吟‹`•F1, r‹Lt“Ţ1, Œă“Ą”ŽŽu1, ůŒ´‘–L1, •Ÿ‹÷łb1, ’šˆäWŽO1,2, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—ĂŠw‹łˆç)

110278. [Œ´’˜] Near-infrared spectroscopy device selection affects intervention management for cerebral desaturation during cardiopulmonary bypass surgery. Kobayashi K1, Kitamura T1, Kohira S2, Inoue N1, Fukunishi T1, Miyaji K1: Gen Thorac Cardiovasc Surg 2022/1; 70 (1): 11-5. (Ź—ŃŒ’‰î1, –k‘ş@—Ľ1, Ź•˝@‘2, ˆäăMK1, •Ÿź‘ô^1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO, 2ˆă—ÉqśŠw•”)

110279. [Œ´’˜] Unique Angiogenesis From Cardiac Arterioles During Pericardial Adhesion Formation. Namiguchi K, Sakaue T, Okazaki M, Kanno K, Komoda Y, Shikata F1, Kurata M, Ota N, Kubota Y, Kurobe H, Nishimura T, Masumoto J, Higashiyama S, Izutani H: Front Cardiovasc Med 2022/2; 8: 761591. (Ž­“c•śş1: 1S‘ŸŒŒŠÇŠO)

310027. [Ç—á•ń] Coarctation of the aorta with total anomalous pulmonary venous connection: a case report Hayashi H1, Sughimoto K, Oka N1, Tsuchida Y1, Miyaji K1: AME Case Rep 2021/4; 5: 11. (—с@GŒ›1, ‰Ş@“ż•F1, “y“c—E‘ž1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO)

310028. [Ç—á•ń] Aortic Valvuloplasty for Cusp Perforation Caused by Kawasaki Disease. Yamada Y, Shikata F1, Yamamoto R, Numata R, Yasukochi S, Takeuchi T: Indian J Pediatr 2021/4; 88 (4): 405. (Ž­“c•śş1: 1S‘ŸŒŒŠÇŠO)

310029. [Ç—á•ń] Emergency pericardial drainage without aortic repair for type A intramural haematoma complicated by cardiac tamponade. Kitamura T1, Miyaji K1: Interact Cardiovasc Thorac Surg 2021/5; 32 (6): 953-5. (–k‘ş@—Ľ1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO)

310030. [Ç—á•ń] A case of mitral valve repair complicated by acquired factor V deficiency. Nakashima K1, Hari Y1, Takagi H, Okazaki T, Kitamura T1, Miyaji K1: Gen Thorac Cardiovasc Surg 2021/5; 69 (5): 874-6. (’†“‡Œő‹M1, ”g—˘—z‰î1, –k‘ş@—Ľ1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO)

310031. [Ç—á•ń] AA case of mitral valve repair complicated by acquired factor V deficiency. Nakashima K, Hari Y, Takagi H, Okazaki T, Kitamura T1, Miyaji K1: Gen Thorac Cardiovasc Surg 2021/5; 69 (5): 874-6. (–k‘ş@—Ľ1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO)

310032. [Ç—á•ń] Treatment of Complete Displacement of the Bilateral Legs into an Aortic Aneurysm Using an Iliac Branch Device. Murai Y1, Tamura Y1, Tanaka Y1, Nakashima K1, Miyaji K1: J Endovasc Ther 2022/2; 29 (1): 143-9. (‘şˆä—C‘ž1, “c‘şK•ä1, “c’†—C‹M1, ’†“‡Œő‹M1, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO)

[Šw‰ďEŒ¤‹†‰ď“™]

713041. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Optimal High Flow Regional Cerebral Perfusion in Aortic Arch Reconstruction from the Perspective of Postoperative Renal Function. Shikata F1, Miyaji K1, Kohira S2, Goto H1, Torii S3, Kitamura T1, Mishima T1, Fukuzumi M1, Fujioka S1, Sasahara A1, Araki H1, Hataoka T1: The 58th Annual Meeting of Society of Thoracic Surgeons (STS) (2022/1/29-30), WebŠJĂ. (Ž­“c•śş1, ‹{’n@ŠÓ1, ŒĂ•˝@‘2, Œă“Ą”ŽŽu1, ’šˆäWŽO3, –k‘ş@—Ľ1, ”ü“‡—˜ş1, •Ÿ‹÷łb1, “Ą‰Şrˆę˜Y1, ůŒ´‘–L1, r‹Lt“Ţ1, ”¨‰Ş@“w1: 1S‘ŸŒŒŠÇŠO, 2ˆă—ÉqśŠw•”, 3’nˆćˆă—Ă‹łˆç)

713042. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Samurai Cannulation (Direct True Lumen Cannulation) for Acute Stanford Type A Aortic Dissection:Experience with Initial 127 Patients. Sasahara A1, Kitamura T1, Hataoka T1, Goto H1, Araki H1, Fujioka S1, Fukuzumi M1, Shikata F1, Mishima T1, Torii S2, Miyaji K1: The 58th Annual Meeting of Society of Thoracic Surgeons (STS) (2022/1/29-30), WebŠJĂ. (ůŒ´‘–L1, –k‘ş@—Ľ1, ”¨‰Ş@“w1, Œă“Ą”ŽŽu1, r‹Lt“Ţ1, “Ą‰Şrˆę˜Y1, •Ÿ‹÷łb1, Ž­“c•śş1, ”ü“‡—˜ş1, ’šˆäWŽO2, ‹{’n@ŠÓ1: 1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—Ă‹łˆç)

723349. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) DOAC‹­‰ť—Ă–@‚ĚˆŔ‘SŤ‚ĆŒř‰Ę‚ĚŒŸ“˘. “Ą‰Şrˆę˜Y1, ”ü“‡—˜ş1, r‹Lt“Ţ1, –k‘ş@—Ľ1, ’šˆäWŽO2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—Ă‹łˆç): ‘ć49‰ń“ú–{ŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď (2021/5/19-21), WebŠJĂ, “ú–{ŒŒŠÇŠO‰ČŠw‰ďŽGŽ 2021/5; 30 (Suppl): PR14-1.

723350. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) EVARpŒă, —ź‘¤‹r‚Ě‘ĺ“Ž–ŹáŽ“ŕˆí’E‚ɑ΂ľ‚Änative‚ĚTerminal Aorta‚đŒo—R‚ľ‚ÄPull through wire‚đŒ`Ź‚ľ, IBE‚đ—Ż’u‚ľ‚˝ˆę—á. ‘şˆä—C‘ž1, “c‘şK•ä1, “c’†—C‹M1, ’†“‡Œő‹M1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO): ‘ć49‰ń“ú–{ŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď (2021/5/19-21), WebŠJĂ, “ú–{ŒŒŠÇŠO‰ČŠw‰ďŽGŽ 2021/5; 30 (Suppl): O38-3.

723351. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “ü‰@‰Á—Ă‚đ—v‚ˇ‚é‘ĺŒŒŠÇŽžŠłŠłŽŇ‚É‚¨‚Ż‚é‹}ŤŠúŽĄ—ĂŽŔŽ{‘OŒă‚Ĺ‚Ě• •”œŠi‹Ř–§“x‚̕ωť. ŽR‰ş^Ži, _’JŒ’‘ž˜Y1, –k‘ş@—Ľ2, ŕ_čL–ž3, –ěčN•˝3, ‘OěŒb”ü4, “ŒžŠ”ü“ŢŽq1, ź‰i“Ä•F1, ˆ˘ŒĂĆ4, ‹{’n@ŠÓ2 (1ˆă—ÉqśŠw•”, 2S‘ŸŒŒŠÇŠO, 3ƒŠƒnƒrƒŠ•”, 4zŠÂŠí“ŕ): ‘ć57‰ń“ú–{zŠÂŠí•a—\–hŠw‰ďŠwpW‰ď (2021/5/28-6/15), WebŠJĂ, “ú–{zŠÂŠí•a—\–hŠw‰ďŽ 2021/5; 56 (2): 176.

723352. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Š´őŤS“ŕ–Œ‰Š‚ɑ΂ˇ‚é‘m–X•ŮŒ`Źp|•Ůë””ç‚ĆŽŠŒČS–ŒÄŒš‚ĚƒeƒNƒjƒbƒN|. –k‘ş@—Ľ1, ’šˆäWŽO2, ”ü“‡—˜ş1, “Ą‰Şrˆę˜Y1, ůŒ´‘–L1, Œă“Ą”ŽŽu1, r‹Lt“Ţ1, ’†‘ş—D”ň1, Î“°”ŽŒh1, ”¨‰Ş@“w1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—Ă‹łˆç): ‘ć74‰ń“ú–{‹š•”ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/10/31-11/3), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{‹š•”ŠO‰ČŠw‰ďŽGŽ 2021/10; 69 (suppl): 315.

723353. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽŠŒČS–Œƒpƒbƒ`‚đ—p‚˘‚˝‘m–X•ŮŒ`Źp‚̏pŒăŹŃ|lH•Ů—ÖƒTƒCƒU[‚đ—p‚˘‚˝ƒe[ƒ‰ƒŠƒ“ƒOƒeƒNƒjƒbƒN|. –k‘ş@—Ľ1, ’šˆäWŽO2, ”ü“‡—˜ş1, “Ą‰Şrˆę˜Y1, ůŒ´‘–L1, Œă“Ą”ŽŽu1, r‹Lt“Ţ1, ’†‘ş—D”ň1, Î“°”ŽŒh1, ”¨‰Ş@“w1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—Ă‹łˆç): ‘ć74‰ń“ú–{‹š•”ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/10/31-11/3), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{‹š•”ŠO‰ČŠw‰ďŽGŽ 2021/10; 69 (suppl): 415.

723354. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹}Ť‘ĺ“Ž–Ź‰đ—ŁAŒ^‚ɑ΂ˇ‚éFrozen Elephant Trunk‚đ—p‚˘‚˝‘S‹|•”’uŠˇpŒă‚Ě‘ĺ“Ž–ŹƒŠƒ‚ƒfƒŠƒ“ƒO‚ĚŒŸ“˘. “Ą‰Şrˆę˜Y1, “c‘ş‰Ŕ”ü1, r‹Lt“Ţ1, ”ŞŒLˆę‹M, ‰Ş‘ş@’B1, ”ü“‡—˜ş1, –k‘ş@—Ľ1, ’šˆäWŽO2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—Ă‹łˆç): ‘ć74‰ń“ú–{‹š•”ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/10/31-11/3), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{‹š•”ŠO‰ČŠw‰ďŽGŽ 2021/10; 69 (suppl): 1092.

723355. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –Ť‘ĺ“Ž–Ź‰đ—Ł‚ɑ΂ˇ‚éŠO‰Č“IŽĄ—Ð헪. ”¨‰Ş@“w1, “Ą‰Şrˆę˜Y1, Î“°”ŽŒh1, ’†‘ş—D”ň1, r‹Lt“Ţ1, Œă“Ą”ŽŽu1, ůŒ´‘–L1, ”ü“‡—˜ş1, –k‘ş@—Ľ1, ’šˆäWŽO2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—Ă‹łˆç): ‘ć74‰ń“ú–{‹š•”ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/10/31-11/3), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{‹š•”ŠO‰ČŠw‰ďŽGŽ 2021/10; 69 (suppl): 1122.

723356. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) 60Î–˘–žŠłŽŇ‚É‚¨‚Ż‚é‘ĺ“Ž–Ź•Ů‚̐lH•Ů‘I‘đ. ’†‘ş—D”ň1, –k‘ş@—Ľ1, ’šˆäWŽO2, ”ü“‡—˜ş1, “Ą‰Şrˆę˜Y1, ůŒ´‘–L1, r‹Lt“Ţ1, Œă“Ą”ŽŽu1, Î“°”ŽŒh1, ”¨‰Ş@“w1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—Ă‹łˆç): ‘ć74‰ń“ú–{‹š•”ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/10/31-11/3), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{‹š•”ŠO‰ČŠw‰ďŽGŽ 2021/10; 69 (suppl): 1164.

723357. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŹŽ™•â•zŠÂ‚É‚¨‚Ż‚é–ŒŒ^lH”x‚Š‚ç‚̐…•Ş‘rŽ¸‚ÉŠÖ‚ˇ‚éŠî‘b“IŒ¤‹†. ŒĂ•˝@‘1, ŠC˜VŞ’q‘ă1, ‹{’n@ŠÓ2, ’šˆäWŽO3, –k‘ş@—Ľ2, “Ą‰Şrˆę˜Y2, ůŒ´‘–L2, Œă“Ą”ŽŽu2, r‹Lt“Ţ2, ’†‘ş—D”ň2, ”¨‰Ş@“w2 (1ˆă—ÉqśŠw•”, 2S‘ŸŒŒŠÇŠO, 3’nˆćˆă—Ă‹łˆç): ‘ć74‰ń“ú–{‹š•”ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/10/31-11/3), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{‹š•”ŠO‰ČŠw‰ďŽGŽ 2021/10; 69 (suppl): 1239.

723358. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚é‘ĺ“Ž–Źkó/—Ł’f•Ą‡‚ɑ΂ˇ‚é‘ĺ“Ž–ŹÄŒšp‚Ě’†Šú‰“ŠuŹŃ. Œă“Ą”ŽŽu1, ‹{’n@ŠÓ1, Ž­“c•śş1, ’šˆäWŽO2, –k‘ş@—Ľ1, “Ą‰Şrˆę˜Y1, ůŒ´‘–L1, r‹Lt“Ţ1, ’†‘ş—D”ň1, ”¨‰Ş@“w1 (1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—Ă‹łˆç): ‘ć74‰ń“ú–{‹š•”ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/10/31-11/3), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{‹š•”ŠO‰ČŠw‰ďŽGŽ 2021/10; 69 (suppl): 1263.

723359. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) śS‹@”\•]‰ż‚É‚ć‚éƒtƒ@ƒ[Žl’ĽÇpŒă”x“Ž–Ź•Ů’uŠˇp‚ĚŽŠ“KŽžŠú‚ĚŒŸ“˘. Œă“Ą”ŽŽu1, ‹{’n@ŠÓ1, Ž­“c•śş1, ’šˆäWŽO2, –k‘ş@—Ľ1, “Ą‰Şrˆę˜Y1, ůŒ´‘–L1, r‹Lt“Ţ1, ’†‘ş—D”ň1, ”¨‰Ş@“w1 (1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—Ă‹łˆç): ‘ć74‰ń“ú–{‹š•”ŠO‰ČŠw‰ď’čŠúŠwpW‰ď (2021/10/31-11/3), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{‹š•”ŠO‰ČŠw‰ďŽGŽ 2021/10; 69 (suppl): 1282.

723360. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Â”NŠú‚É‚¨‚Ż‚éƒtƒ@ƒ[Žl’ĽÇpŒă”x“Ž–Źś‘Ě•Ů’uŠˇp‚Ě’†Šú‰“ŠuŹŃ. Ž­“c•śş1, ‹{’n@ŠÓ1, Œă“Ą”ŽŽu1, ”¨‰Ş@“w1, ’šˆäWŽO2, –k‘ş@—Ľ1, •Ÿ‹÷łb1, “Ą‰Şrˆę˜Y1, ůŒ´‘–L1, r‹Lt“Ţ1, Ź”‹´r”ü3, ŒSŽRŒbŽq4, “Ą“c“S•˝3 (1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—Ă‹łˆç, 3zŠÂŠí“ŕ, 4‘‡f—Ă): ‘ć23‰ń“ú–{Źlć“VŤSŽžŠłŠw‰ď‘‰ďEŠwpW‰ď (2022/1/7-9), •Ÿ‰Ş.

723361. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Routine Fenestrated FontanŽčp‚̉“ŠuŹŃ. Ž­“c•śş1, ‹{’n@ŠÓ1, ”¨‰Ş@“w1, ’šˆäWŽO2, –k‘ş@—Ľ1, ”ü“‡—˜ş1, •Ÿ‹÷łb1, “Ą‰Şrˆę˜Y1, ůŒ´‘–L1, Œă“Ą”ŽŽu1, r‹Lt“Ţ1 (1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—Ă‹łˆç): ‘ć52‰ń“ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď (2022/3/3-5), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď´˜^W 2022/3; 52: 163.

723362. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) SŠOŒ^TAPVC‚ɑ΂ˇ‚鑍”xĂ–ŹŠ˛\ś–[’źÚ•Ť‡–@‚Ě’†Šú‰“ŠuŹŃ. ‹{’n@ŠÓ1, Ž­“c•śş1, ”¨‰Ş@“w1, ’šˆäWŽO2, –k‘ş@—Ľ1, ”ü“‡—˜ş1, “Ą‰Şrˆę˜Y1, ůŒ´‘–L1, r‹Lt“Ţ1, Œă“Ą”ŽŽu1 (1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—Ă‹łˆç): ‘ć52‰ń“ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď (2022/3/3-5), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď´˜^W 2022/3; 52: 167.

723363. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚—Ź—Ę”]ŠŇ—Ź‰ş‚ōs‚Á‚˝‘ĺ“Ž–Ź‹|C•œ‚̏pŒăt‹@”\‚ĚŠĎ“_‚Š‚ç“ąo‚ł‚ę‚˝ŽŠ“KŠŇ—Ź—Ę. Ž­“c•śş1, ‹{’n@ŠÓ1, ŒĂ•˝@‘2, ”¨‰Ş@“w1, ’šˆäWŽO3, –k‘ş@—Ľ1, ”ü“‡—˜ş1, •Ÿ‹÷łb1, “Ą‰Şrˆę˜Y1, ůŒ´‘–L1, Œă“Ą”ŽŽu1, r‹Lt“Ţ1 (1S‘ŸŒŒŠÇŠO, 2ˆă—ÉqśŠw•”, 3’nˆćˆă—Ă‹łˆç): ‘ć52‰ń“ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď (2022/3/3-5), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď´˜^W 2022/3; 52: 171.

723364. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŹlŠJSpŽüpŠúNO‹z“ü—Ă–@‚ĚŒř‰Ę|ƒAƒCƒmƒtƒ[85—á‚ĚŒoŒą‚Š‚ç|. ůŒ´‘–L1, –k‘ş@—Ľ1, ”¨‰Ş@“w1, Œă“Ą”ŽŽu1, r‹Lt“Ţ1, “Ą‰Şrˆę˜Y1, •Ÿ‹÷łb1, Ž­“c•śş1, ”ü“‡—˜ş1, ’šˆäWŽO2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—Ă‹łˆç): ‘ć52‰ń“ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď (2022/3/3-5), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď´˜^W 2022/3; 52: 207.

723365. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ăsŒaŁ50 mm, ’É‚ÝŁ3/10, ăsULP (-) ‚ĚAŒ^IMH, ăs‹Uo•ÂÇ‰đ—Ł‚̏‰Šú•Ű‘ś—Ă–@. –k‘ş@—Ľ1, ’šˆäWŽO2, ”ü“‡—˜ş1, Ž­“c•śş1, •Ÿ‹÷łb1, “Ą‰Şrˆę˜Y1, ůŒ´‘–L1, r‹Lt“Ţ1, Œă“Ą”ŽŽu1, ”¨‰Ş@“w1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—Ă‹łˆç): ‘ć52‰ń“ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď (2022/3/3-5), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď´˜^W 2022/3; 52: 216.

723366. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œo”çƒAƒvƒ[ƒ`‚Ĺ‚ĚƒXƒeƒ“ƒgƒOƒ‰ƒtƒg“ŕ‘}p‚É‚¨‚Ż‚鍇•šÇ—\–h‚̍H•v. “Ą‰Şrˆę˜Y1, ”ü“‡—˜ş1, ”¨‰Ş@“w1, r‹Lt“Ţ1, Œă“Ą”ŽŽu1, ůŒ´‘–L1, Ž­“c•ś–ž1, •Ÿ‹÷łb1, –k‘ş@—Ľ1, ’šˆäWŽO2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—Ă‹łˆç): ‘ć52‰ń“ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď (2022/3/3-5), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď´˜^W 2022/3; 52: 335.

723367. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹}Ť‘ĺ“Ž–Ź‰đ—Ł‚É‚¨‚Ż‚éƒTƒ€ƒ‰ƒCƒJƒjƒ…ƒŒ[ƒVƒ‡ƒ“-127—á‚ĚŒoŒą. ůŒ´‘–L1, –k‘ş@—Ľ1, ”¨‰Ş@“w1, Œă“Ą”ŽŽu1, r‹Lt“Ţ1, “Ą‰Şrˆę˜Y1, •Ÿ‹÷łb1, Ž­“c•śş1, ”ü“‡—˜ş1, ’šˆäWŽO2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—Ă‹łˆç): ‘ć52‰ń“ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď (2022/3/3-5), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď´˜^W 2022/3; 52: 412.

723368. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) NorwoodŽčpEDKS•Ť‡Œă‚̐V‘ĺ“Ž–Ź•Ů—ÖŒa‚ĚŠg‘ĺ‚Ć‹t—Ź‚ĚŒŸ“˘. ”¨‰Ş@“w1, Ž­“c•śş1, ’šˆäWŽO2, –k‘ş@—Ľ1, ”ü“‡—˜ş1, •Ÿ‹÷łb1, “Ą‰Şrˆę˜Y1, ůŒ´‘–L1, r‹Lt“Ţ1, Œă“Ą”ŽŽu1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—Ă‹łˆç): ‘ć52‰ń“ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď (2022/3/3-5), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď´˜^W 2022/3; 52: 421.

733105. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ”sŒŒÇ¸¸’†‚É”­ŒŠ‚ł‚ę‚˝‘ĺ“Ž–Ź•Ůă‹ˇó‚𔺂¤WilliamsÇŒóŒQŠłŽ™‚Ě‘ĺ“Ž–Ź‰đ—Ł‚ɑ΂ˇ‚éŽčpŒoŒą. ź‰iŒc—ő1, ‰Ş‘ş@’B1, ’šˆäWŽO2, –k‘ş@—Ľ1, ”ü“‡—˜ş1, “Ą‰Şrˆę˜Y1, ”ŞŒLˆę‹M, r‹Lt“Ţ1, “c‘ş‰Ŕ”ü1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—Ă‹łˆç): ‘ć186‰ń“ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/6/5), WebŠJĂ, “ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď—vŽ|W 2021/5; 186: 21.

733106. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ””N‚ĚŒo‰ß‚Ĺ‹}‘Ź‚É‘‘ĺ‚ľ‚˝‹‘卶–[”S‰tŽî‚Ě1—á. ”¨‰Ş@“w1, r‹Lt“Ţ1, –k‘ş@—Ľ1, ’šˆäWŽO2, ”ü“‡—˜ş1, “Ą‰Şrˆę˜Y1, ůŒ´‘–L1, Œă“Ą”ŽŽu1, ’†‘ş—D”ň1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—Ă‹łˆç): ‘ć186‰ń“ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/6/5), WebŠJĂ, “ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď—vŽ|W 2021/5; 186: 30.

733107. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŠOŤŽOë•Ů•Â˝•s‘SÇ‚ɑ΂ľ‚Ä‹šo‹ž‰şŽOë•ŮŒ`Źp‚đŽ{s‚ľ‚˝1—á. ”¨‰Ş@“w1, ůŒ´‘–L1, –k‘ş@—Ľ1, ’šˆäWŽO2, ”ü“‡—˜ş1, •Ÿ‹÷łb1, Ž­“c•śş1, “Ą‰Şrˆę˜Y1, r‹Lt“Ţ1, Œă“Ą”ŽŽu1, ’†‘ş—D”ň1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—Ă‹łˆç): ‘ć187‰ń“ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/11/6), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď—vŽ|W 2021/11; 187: 10.

733108. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Ă–ŹŠŇ—ŹˆŮí‚𔺂¤‘˝äBÇ, ŠŽ‘SŒ^–[Žş’†ŠuŒ‡‘š, ‰EŽş’áŒ`Ź‚ɑ΂ľ‚Ä, “ńSŽşC•œ‚đs‚Á‚˝ˆę—á. Œă“Ą”ŽŽu1, Ž­“c•śş1, ’šˆäWŽO2, –k‘ş@—Ľ1, ”ü“‡—˜ş1, “Ą‰Şrˆę˜Y1, ůŒ´‘–L1, r‹Lt“Ţ1, ’†‘ş—D”ň1, ”¨‰Ş@“w1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—Ă‹łˆç): ‘ć187‰ń“ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/11/6), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď—vŽ|W 2021/11; 187: 13.

733109. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‹}ŤS‹Ř[ÇŒă‚̐SŽş’†ŠuúE‚ɑ΂ľ‚蜎şŘŠJƒAƒvƒ[ƒ`‚ŏC•œ‚đs‚Á‚˝1—á. –L“c^Žő1, ŽÄ“c@u1, “c‘ş‰Ŕ”ü1, ŹŒ´–M‹`, ćс@łŠî, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO): ‘ć187‰ń“ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/11/6), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď—vŽ|W 2021/11; 187: 17.

733110. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “űŽ™ŠúVSD‚ɑ΂ˇ‚é”x“Ž–ŹiNpŒă47”N‚ÉVSD•Â˝, ”x“Ž–ŹŒ`Ź, ‰EŽş—Źo˜HŒ`Ź‚đŽ{s‚ľ‚˝Ç—á. Œă“Ą”ŽŽu1, Ž­“c•śş1, ‘吟‹`•F1, r‹Lt“Ţ1, ůŒ´‘–L1, “Ą‰Şrˆę˜Y1, •Ÿ‹÷łb1, ”ü“‡—˜ş1, –k‘ş@—Ľ1, ’šˆäWŽO2, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—Ă‹łˆç): ‘ć188‰ń“ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2022/3/19), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď—vŽ|W 2022/3; 188: 35.

733111. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‘ĺ“Ž–Ź•Ů’uŠˇŒă1”N‚Ĺ•ŮŔ‚Ě“Ž—h‚đ”F‚ß‚˝ƒx[ƒ`ƒFƒbƒgÇ—á. ˛“Ąr˜Y, –k‘ş@—Ľ1, ’šˆäWŽO2, ”ü“‡—˜ş1, Ž­“c•śş1, •Ÿ‹÷łb1, “Ą‰Şrˆę˜Y1, ůŒ´‘–L1, r‹Lt“Ţ1, Œă“Ą”ŽŽu1, ‘吟‹`•F1, ‹{’n@ŠÓ1 (1S‘ŸŒŒŠÇŠO, 2’nˆćˆă—Ă‹łˆç): ‘ć188‰ń“ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű (2022/3/19), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).


ŒÄ‹zŠíŠO‰ČŠw

[Šwp˜_•ś]

110280. [Œ´’˜] Comparison of local therapy in patients with lung oligo-recurrence of non-small-cell lung cancer. Sonoda D1, Matsuura Y, Kondo Y1, Ichinose J, Nakao M, Ninomiya H, Nishio M, Okumura S, Satoh Y1, Mun M: J Surg Oncol 2021/5; 123 (8): 1828-35. (‰€“c@‘ĺ1, ‹ß“Ą‘אl1, ˛“Ą”Vr1: 1ŒÄ‹zŠíŠO)

110281. [Œ´’˜] Clinicopathologic Significance of False-Positive Lymph Node Status on FDG-PET in Lung Cancer. Endo H, Yamamoto R, Ichikawa A, Shiozawa S, Nishizawa N, Satoh Y1, Oriuchi N: Clin Lung Cancer 2021/5; 22 (3): 218-24. (˛“Ą”Vr1: 1ŒÄ‹zŠíŠO)

110282. [Œ´’˜] Validation of the Japanese National Clinical Database Risk calculator for lung cancer surgery focused on postoperative morbidity. Kondo Y, Matsuura Y, Kawaguchi Y, Ichinose J, Nakao M, Okumura S, Satoh Y1, Mun M: Gen Thorac Cardiovasc Surg 2021/8; 69 (8): 1222-9. (˛“Ą”Vr1: 1ŒÄ‹zŠíŠO)

110283. [Œ´’˜] Factors associated with lymph node metastasis upstage after resection for patients with micropapillary lung adenocarcinoma. Matsushima K1, Sonoda D1, Mitsui A1, Tamagawa S1, Hayashi S1, Naito M1, Matsui Y1, Shiomi K1, Satoh Y1: Thorac Cancer 2022/1; 13 (1): 48-53. (ź“‡Œ\Œá1, ‰€“c@‘ĺ1, ŽOˆä@ˆ¤1, ‹Ęě@’B1, —с@ËŽq1, “ŕ“Ą‰ëm1, źˆäŒ[•v1, ‰–ŒŠ@˜a1, ˛“Ą”Vr1: 1ŒÄ‹zŠíŠO)

110284. [Œ´’˜] A Reasonable Definition of Oligo-Recurrence in Non-Small-Cell Lung Cancer. Sonoda D1, Matsuura Y, Kondo Y1, Ichinose J, Nakao M, Ninomiya H, Nishio M, Okumura S, Satoh Y1, Mun M: Clin Lung Cancer 2022/1; 23 (1): 82-90. (‰€“c@‘ĺ1, ‹ß“Ą‘אl1, ˛“Ą”Vr1: 1ŒÄ‹zŠíŠO)

110285. [Œ´’˜] Characterization of morphological alterations in micropapillary adenocarcinoma of the lung using an established cell line. Sonoda D1, Kamizaki K, Matsuo Y1, Aruga K, Mikubo M1, Yamashita K2, Nishita M, Minami Y, Satoh Y1: Oncol Rep 2022/1; 47 (1): 19. (‰€“c@‘ĺ1, ź”ö—R‹IŽq1, ŽOŒEŤŽj1, ŽR‰şŒpŽj2, ˛“Ą”Vr1: 1ŒÄ‹zŠíŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

110286. [Œ´’˜] Selection of preoperative stress electrocardiography test for appropriate patients with non-small cell lung cancer. Tamagawa S1, Sonoda D1, Mitsui A1, Matsushima K1, Hayashi S1, Naito M1, Matsui Y1, Shiomi K1, Satoh Y1: Gen Thorac Cardiovasc Surg 2022/2; 70 (2): 139-43. (‹Ęě@’B1, ‰€“c@‘ĺ1, ŽOˆä@ˆ¤1, ź“‡Œ\Œá1, —с@ËŽq1, “ŕ“Ą‰ëm1, źˆäŒ[•v1, ‰–ŒŠ@˜a1, ˛“Ą”Vr1: 1ŒÄ‹zŠíŠO)

110287. [Œ´’˜] Cytology Reporting System for Lung Cancer from the Japan Lung Cancer Society and the Japanese Society of Clinical Cytology: An Extensive Study Containing More Benign Lesions. Yoshizawa A, Hiroshima K, Takenaka A, Hba R, Kawahara K, Minami Y, Kakinuma H, Shibuki Y, Miyake S, Kajio K, Kiyonaga K, Nagatomo M, Nishimura S, Mano M, Matsubayashi J, Motoi N, Nagao T, Nakatsuka S, Yoshida T1,2, Satoh Y3: Acta Cytol 2022/3; 66 (2): 124-33. (‹g“c@Œ÷1,2, ˛“Ą”Vr3: 1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2•a—, 3ŒÄ‹zŠíŠO)

310033. [Ç—á•ń] Two Cases of Lower Lobe Pneumatoceles Following Upper Lobectomy. Kondo Y1, Nakao M, Hashimoto K, Ichinose J, Matsuura Y, Ninomiya H, Okumura S, Satoh Y1, Mun M: Ann Thorac Surg 2021/12; 112 (6): e403-6. (‹ß“Ą‘אl1, ˛“Ą”Vr1: 1ŒÄ‹zŠíŠO)

320004. [Ç—á•ń] –Ť”^‹š‚ɑ΂ˇ‚é‹šo“ŕôňŒă‚ĚŠĽ“Ž–Ź‹ó‹CÇđ‚ɐS‘ŸƒJƒe[ƒeƒ‹ŽĄ—Ă‚Ş‘tŒ÷‚ľ‚˝1—á. •Đ‹Ë@”E, ‰““ĄG‹I, ‹k@ŒŤœA, źŕV‰„G, ˛“Ą”Vr1, ŽR–{—ş•˝ (1ŒÄ‹zŠíŠO): “úŒÄŠO‰ďŽ 2021/5; 35 (4): 337-43.

510018. [‘ŕ] Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy. Mikubo M1, Inoue Y, Liu G, Tsao MS: J Thorac Oncol 2021/11; 16 (11): 1798-809. (ŽOŒEŤŽj1: 1ŒÄ‹zŠíŠO)

540027. [‚ť‚Ě‘ź (´˜^)] ”xŠŕ‚Ě×–Ef. ˛“Ą”Vr (ŒÄ‹zŠíŠO): ”xŠŕ 2021/11; 61 (supple): 869-871.

[’˜@‘]

621001. [Šwp‘ (•ŇW)]yŒÄ‹zŠíŠO‰ČƒeƒLƒXƒg ‰ü’ů‘ć2”Łz˛“Ą”Vr1,2 (1•ŇWˆĎˆő’ˇ, 2ŒÄ‹zŠíŠO), •Ň: “ú–{ŒÄ‹zŠíŠO‰ČŠw‰ď, ŒÄ‹zŠíŠO‰Čę–ĺˆă‡“ŻˆĎˆő‰ď, “ě]“°, “Œ‹ž, 2021/4”­s.

621002. [Šwp‘ (•ŇW)]y”xŠŕŠłŽŇ‚É‚¨‚Ż‚éALK—Z‡ˆâ“`ŽqŒŸ¸‚ĚŽčˆř‚Ť (‘ć4”Ĺ)zŽOŒEŤŽj1,2 (1“ú–{”xŠŕŠw‰ďƒoƒCƒIƒ}[ƒJ[ˆĎˆő‰ď, 2ŒÄ‹zŠíŠO), “ú–{”xŠŕŠw‰ď, “Œ‹ž, 2021/10”­s.

621003. [Šwp‘ (•ŇW)]y”xŠŕŠłŽŇ‚É‚¨‚Ż‚é ŽŸ˘‘ăƒV[ƒNƒGƒ“ƒT[‚đ—p‚˘‚˝ˆâ“`Žqƒpƒlƒ‹ŒŸ¸‚ĚŽčˆř‚Ť (‘ć2”Ĺ)zŽOŒEŤŽj1,2 (1“ú–{”xŠŕŠw‰ďƒoƒCƒIƒ}[ƒJ[ˆĎˆő‰ď, 2ŒÄ‹zŠíŠO), “ú–{”xŠŕŠw‰ď, “Œ‹ž, 2021/10”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713043. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Combination of EGFR mutation and presence of high-grade subtype predicts recurrence in resected stage I lung adenocarcinoma. Ichinose J, Kondo Y1, Ninomiya H, Yamamichi T, Omura K, Hashimoto K, Matsuura Y, Nakao M, Ishikawa Y, Okumura S, Satoh Y1, Mun M: IASLC 2021 World Conference on Lung Cancer (2021/9/8-14), WebŠJĂ. (‹ß“Ą‘אl1, ˛“Ą”Vr1: 1ŒÄ‹zŠíŠO)

713044. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Molecular and cellular dynamics of drug-tolerant persister (DTP) cells during osimertinib therapy in EGFR mutant lung adenocarcinoma. Mikubo M1, Li Q, Filho S, Inoue Y, Pham N, Moghal N, Tsao M: IASLC 2021 World Conference on Lung Cancer (2021/9/8-14), WebŠJĂ. (ŽOŒEŤŽj1: 1ŒÄ‹zŠíŠO)

713045. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) A new cytology reporting system for lung cancer from Japan Lung Cancer Society and Japanese Society of Clinical Cytology. Minami Y, Satoh Y1: Europian Congress of Cytology 2021 (2021/10/3), Wroc_aw, Poland. (˛“Ą”Vr1: 1ŒÄ‹zŠíŠO)

721011. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) V‚ľ‚˘ŒÄ‹zŠí×–Ef‚Ě•ń—lŽŽ. ŕF–؍N—Y, Š`ŔœA–M, ‰ÍŒ´–MŒő, ’|’†–ž”ü, ‰Hę—玟, œA“‡Œ’ŽO, “ě@—DŽq, ŽO‘î^Ži, ‹gŕV–ž•F, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO): ‘ć62‰ń“ú–{—Տ°×–EŠw‰ď‘‰ďtŠú‘ĺ‰ď (2021/6/5), ç—t (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722122. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŒÄ‹zŠí×–Ef‚̐V‚ľ‚˘•ń—lŽŽ‚Ě–â‘č“_. Š`ŔœA–M, ‰ÍŒ´–MŒő, ŕF–؍N—Y, ’|’†–ž”ü, ‰Hę—玟, œA“‡Œ’ŽO, “ě@—DŽq, ŽO‘î^Ži, ‹gŕV–ž•F, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO): ‘ć60‰ń“ú–{—Տ°×–EŠw‰ďHŠú‘ĺ‰ď (2021/11/20), •ÄŽq.

722123. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) V”xŠŕ×–Ef”ť’č•ń—lŽŽ‚É‚¨‚Ż‚égatypical cellsh‚ɂ‚˘‚Ä. ‰ÍŒ´–MŒő, œA“‡Œ’ŽO, ’|’†–ž”ü, ‰Hę—玟, ‹gŕV–ž•F, “ě@—DŽq, ŕF–؍N—Y, Š`ŔœA–M, ŽO‘î^Ži, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO): ‘ć60‰ń“ú–{—Տ°×–EŠw‰ďHŠú‘ĺ‰ď (2021/11/20), •ÄŽq.

722124. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŒÄ‹zŠí×–Ef‚̐V‚ľ‚˘•ń—lŽŽ: ×–Ef”ť’č‹ć•Ş‚ĚŠĎŽ@ŽŇŠÔ‚Ěˆę’v. œA“‡Œ’ŽO, ‹gŕV–ž•F, ’|’†–ž”ü, ‰Hę—玟, ‰ÍŒ´–MŒő, “ě@—DŽq, Š`ŔœA–M, ŕF–؍N—Y, ŽO‘î^Ži, Š”öŒ’‘ž, ´‰i‰ÁŘ, ’ˇ—F@–G, ź‘ş‘ŘŽq, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO): ‘ć60‰ń“ú–{—Տ°×–EŠw‰ďHŠú‘ĺ‰ď (2021/11/20), •ÄŽq.

722125. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŒÄ‹zŠí×–Ef‚̐V‚ľ‚˘•ń—lŽŽ: —ǐŤ•a•Ď‚ɑ΂ˇ‚éJLCC-JSCC•Ş—Ţ‚Ě—L—pŤ. ‹gŕV–ž•F, œA“‡Œ’ŽO, ’|’†–ž”ü, ‰Hę—玟, ‰ÍŒ´–MŒő, “ě@—DŽq, Š`ŔœA–M, ŕF–؍N—Y, ŽO‘îMŽi, ´‰i‰ÁŘ, Š”öŒ’‘ž, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO): ‘ć60‰ń“ú–{—Տ°×–EŠw‰ďHŠú‘ĺ‰ď (2021/11/20), •ÄŽq.

722126. [Šw‰ď (‘S‘)] (‹łˆçu‰‰) ”xŠŕ‚Ě×–Ef. ˛“Ą”Vr (ŒÄ‹zŠíŠO): ‘ć62‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ď (2021/11/27), ‰Ą•l.

723369. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”x‘BŠŕ×–EŠ”‚̉tó‰ťŒŸ‘Ě×–Ef (LBC) ŒŸ‘Ě‚Š‚ç’Šo‚ľ‚˝ƒQƒmƒ€DNA•iŽż‚Ě•ŰŽ•ű–@. ź”ö—R‹IŽq1, ŽR‰ş˜a–ç2, ‹g“c@Œ÷3, ˛“Ą”Vr4 (1•a‘ԁEf—ĂŒn, 2•a—•”, 3•a—, 4ŒÄ‹zŠíŠO): ‘ć110‰ń“ú–{•a—Šw‰ď‘‰ď (2021/4/22-24), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723370. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆŤŤ•FŽî‚Ě”x“]ˆÚ‚đŘœ‚ľ‚˝4Ç—á‚ĚŒŸ“˘. —с@ËŽq1, ŽOˆä@ˆ¤2, ‹Ęě@’B2, ź“‡Œ\Œá2, “ŕ“Ą‰ëm2, źˆäŒ[•v2, ‰–ŒŠ@˜a2, ˛“Ą”Vr2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŒÄ‹zŠíŠO): ‘ć38‰ń“ú–{ŒÄ‹zŠíŠO‰ČŠw‰ďŠwpW‰ď (2021/5/20), ’ˇč (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723371. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Characterization of morphological and invasive alterations in lung micropapillary adenocarcinoma using a cell line. ‰€“c@‘ĺ1, ˛“Ą”Vr2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŒÄ‹zŠíŠO): ‘ć80‰ń“ú–{ŠŕŠw‰ďŠwp‘‰ď (2021/10/1), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723372. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œ´”­Ť”xŠŕpŒă‚É’áNaŒŒÇ‚đ—ˆ‚ľ‚˝8—á‚ĚŒŸ“˘. ‹ß“Ą‘אl1, ŽO‹´r‰î1, ŠŰŽR—ˆ‹P1, —с@ËŽq2, ‰€“c@‘ĺ2, ŽOŒEŤŽj1, źˆäŒ[•v1, ‰–ŒŠ@˜a1, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć62‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ď (2021/11/26), ‰Ą•l.

723373. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”xG•˝ă”çŠŕ‚É‚¨‚Ż‚éŽîᇐZ, CD8—zŤ×–E”‚ƏpŒăÄ”­‚ĚŠÖ˜AŤ‚ĚŒŸ“˘. ‰–ŒŠ@˜a1, ˆęŒËš–ž2, —с@ËŽq3, ŽOŒEŤŽj1, ‰€“c@‘ĺ3, ‹ß“Ą‘אl1, ŠŰŽR—ˆ‹P1, źˆäŒ[•v1, Ó@˘ˆŽ, ‘ş‰_–FŽ÷2, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO, 2•a—, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć62‰ń“ú–{”xŠŕŠw‰ďŠwpW‰ď (2021/11/27), ‰Ą•l.

731007. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ”xŠŕf—Ă‚ĆŒÄ‹zŠí×–Ef‚Ě“W–]. ˛“Ą”Vr (ŒÄ‹zŠíŠO): ‘ć39‰ńÂXŒ§—Տ°×–EŠw‰ď‘‰ď•Ŕ‚Ń‚ÉŠwpW‰ď (2022/3/5), O‘O.

733112. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‘˝”­”x“ŕ”X–EŤƒŠƒ“ƒpŠÇŽî‚Ěˆę—á. ŽO‹´r‰î1, ŠŰŽR—ˆ‹P1, ŽOˆä@ˆ¤1, ‹ß“Ą‘אl1, ‹Ęě@’B1, ź“‡Œ\Œá1, —с@ËŽq2, “ŕ“Ą‰ëm1, ŽOŒEŤŽj1, źˆäŒ[•v1, ‰–ŒŠ@˜a1, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć186‰ń“ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2021/6/5), “Œ‹ž.

733113. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‘ą”­Ť‹C‹š‚đ’ć‚ľ‚˝“ޔ猴”­ŒŒŠÇ“÷Žî”x“]ˆÚ‚Ě2—á. ŠŰŽR—ˆ‹P1, ŽO‹´r‰î1, ‹ß“Ą‘אl1, ŽOŒEŤŽj1, źˆäŒ[•v1, ‰–ŒŠ@˜a1, ‘ŕV^ŽŔŽq2, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO, 2”畆): ‘ć177‰ń“ú–{ŒÄ‹zŠí“ŕŽ‹‹žŠw‰ďŠÖ“ŒŽx•”‰ď (2021/6/19), WebŠJĂ.

733114. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‹š‘B”S•\”çŠŕŽčp‚Š‚ç21”NŒă‚É‹š–Œ”dŽíÄ”­‚đ‚Ť‚˝‚ľ‚˝1—á. —с@ËŽq1, ŽO‹´r‰î2, ŠŰŽR—ˆ‹P2, ‹ß“Ą‘אl2, ŽOŒEŤŽj2, źˆäŒ[•v2, ‰–ŒŠ@˜a2, “Č–{šF3, ˆęŒËš–ž3, ˛“Ą”Vr2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŒÄ‹zŠíŠO, 3•a—): ‘ć41‰ń“ú–{‹š‘BŒ¤‹†‰ď (2022/2/11), WebŠJĂ.

733115. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) S–Œ’†”çŽî‚Ě1—á. ŽO‹´r‰î1, ŠŰŽR—ˆ‹P1, ‹ß“Ą‘אl1, —с@ËŽq2, ‰€“c@‘ĺ2, ŽOŒEŤŽj1, źˆäŒ[•v1, ‰–ŒŠ@˜a1, ˛“Ą”Vr1, Ż–쏺–F3, ‘ş‰_–FŽ÷3 (1ŒÄ‹zŠíŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3•a—): ‘ć192‰ń“ú–{”xŠŕŠw‰ďŠÖ“ŒŽx•”ŠwpW‰ď (2022/3/5), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733116. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒJƒeƒRƒ‰ƒ~ƒ“—U”­ŤSŽş•p”‚ɑ΂ľ‚Ä—ź‘¤‹šo‹ž‰ş‹š•”ŒđŠ´_ŒoŽŐ’fp‚đŽ{s‚ľ‚˝1—á. ŠŰŽR—ˆ‹P1, ŽO‹´r‰î1, ‹ß“Ą‘אl1, ŽOŒEŤŽj1, źˆäŒ[•v1, ‰–ŒŠ@˜a1, ˛“Ą”Vr1 (1ŒÄ‹zŠíŠO): ‘ć188‰ń“ú–{‹š•”ŠO‰ČŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2022/3/19), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).


”]_ŒoŠO‰ČŠw

[Šwp˜_•ś]

110288. [Œ´’˜] Long-term follow-up after BCNU wafer implantation in patients with newly diagnosed glioblastoma. Shibahara I1, Miyasaka K1, Sekiguchi A2, Ishiyama H2, Inukai M1, Yaui Y3, Watanabe T, Sato S1, Hide T1, Kumabe T1: J Clin Neurosci 2021/4; 86: 202-10. (ŽÄŒ´ˆę—z1, ‹{â˜aO1, ŠÖŒűˆŠˆß2, ÎŽR”ŽžŠ2, Œ˘Ž”@‰~1, ˆŔˆä”ü]3, ˛“ĄŸl1, G‘ńˆę˜Y1, ŒG•”rG1: 1”]ŠO, 2•úŽËü (Žîá‡), 3Œ`‘ÔŒn)

110289. [Œ´’˜] Postcentral gyrus resection of opercular gliomas is a risk factor for motor deficits caused by damaging the radiologically invisible arteries supplying the descending motor pathway. Shibahara I1, Sato S1, Hide T1, Saito R, Kanamori M, Sonoda Y, Tominaga T, Kumabe T1: Acta Neurochir (Wien) 2021/5; 163 (5): 1269-78. (ŽÄŒ´ˆę—z1, ˛“ĄŸl1, G‘ńˆę˜Y1, ŒG•”rG1: 1”]ŠO)

110290. [Œ´’˜] Necessity for craniospinal irradiation of germinoma with positive cytology without spinal lesion on MR imaging-A controversy. Kanamori M, Takami H, Suzuki T, Tominaga T, Kurihara J, Tanaka S, Hatazaki S, Nagane M, Matsuda M, Yoshino A, Natsumeda M, Yamaoka M, Kagawa N, Akiyama Y, Fukai J, Negoto T, Shibahara I1, Tanaka K, Inoue A, Mase M, Tomita T, Kuga D, Kijima N, Fukami T, Nakahara Y, Natsume A, Yoshimoto K, Keino D, Tokuyama T, Asano K, Ujifuku K, Abe H, Nakada M, Matsuda K, Arakawa Y, Ikeda N, Narita Y, Shinojima N, Kambe A, Nonaka M, Izumoto S, Kawanishi Y, Kanaya K, Nomura S, Nakajima K, Yamamoto S, Terashima K, Ichimura K, Nishikawa R: Neurooncol Adv 2021/6; 3 (1): vdab086. (ŽÄŒ´ˆę—z1: 1”]ŠO)

110291. [Œ´’˜] Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma. Osada Y, Saito R, Miyata S, Shoji T, Shibahara I1, Kanamori M, Sonoda Y, Kumabe T1, Watanabe M, Tominaga T: Brain Tumor Pathol 2021/7; 38 (3): 218-27. (ŽÄŒ´ˆę—z1, ŒG•”rG1: 1”]ŠO)

110292. [Œ´’˜] Low tumor cell content predicts favorable prognosis in germinoma patients. Takami H, Satomi K, Fukuoka K, Fukushima S, Matsushita Y, Yamasaki K, Nakamura T, Tanaka S, Mukasa A, Saito N, Suzuki T, Yanagisawa T, Nakamura H, Sugiyama K, Tamura K, Maehara T, Nakada M, Nonaka M, Asai A, Yokogami K, Takeshima H, Iuchi T, Kanemura Y, Kobayashi K, Nagane M, Kurozumi K, Yoshimoto K, Matsuda M, Matsumura A, Hirose Y, Tokuyama T, Kumabe T1, Narita Y, Shibui S, Nakazato Y, Nishikawa R, Matsutani M, Ichimura K: Neurooncol Adv 2021/8; 3 (1): vdab110. (ŒG•”rG1: 1”]ŠO)

110293. [Œ´’˜] Ventricular opening and cerebrospinal fluid circulation accelerate the biodegradation process of carmustine wafers suggesting their immunomodulation potential in the human brain. Shibahara I1, Shibahara Y2, Hagiwara H, Watanabe T, Orihashi Y, Handa H1, Inukai M1, Hide T1, Yasui Y, Kumabe T1: J Neurooncol 2022/9; 159 (2): 425-35. (ŽÄŒ´ˆę—z1, ŽÄŒ´—T‹IŽq2, ”ź“c@”Ł1, Œ˘Ž”@‰~1, G‘ńˆę˜Y1, ŒG•”rG1: 1”]ŠO, 2•a—)

110294. [Œ´’˜] Role of the parietooccipital fissure and its implications in the pathophysiology of posterior medial temporal gliomas. Shibahara I1, Saito R, Kanamori M, Sonoda Y, Sato S1, Hide T1, Tominaga T, Kumabe T1: J Neurosurg 2021/12; 137 (2): 505-14. (ŽÄŒ´ˆę—z1, ˛“ĄŸl1, G‘ńˆę˜Y1, ŒG•”rG1: 1”]ŠO)

110295. [Œ´’˜] Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial. Narita Y, Muragaki Y, Kagawa N, Asai K, Nagane M, Matsuda M, Ueki K, Kuroda J, Date I, Kobayashi H, Kumabe T1, Beppu T, Kanamori M, Kasai S, Nishimura Y, Xiong H, Ocampo C, Yamada M, Mishima K: Cancer Sci 2021/12; 112 (12): 5020-33. (ŒG•”rG1: 1”]ŠO)

110296. [Œ´’˜] Long-term effectiveness of Gliadel implant for malignant glioma and prognostic factors for survival: 3-year results of a postmarketing surveillance in Japan. Iuchi T, Inoue A, Hirose Y, Morioka M, Horiguchi K, Natsume A, Arakawa Y, Iwasaki K, Fujiki M, Kumabe T1, Sakata Y: Neurooncol Adv 2022/1; 4 (1): vdab189. (ŒG•”rG1: 1”]ŠO)

110297. [Œ´’˜] Influence of hospital capabilities and prehospital time on outcomes of thrombectomy for stroke in Japan from 2013 to 2016. Kurogi A, Onozuka D, Hagihara A, Nishimura K, Kada A, Hasegawa M, Higashi T, Kitazono T, Ohta T, Sakai N, Arai H, Miyamoto S, Sakamoto T, Iihara K, J-ASPECT Study Collaborators (Kumabe T1, etc):Sci Rep 2022/2; 12 (1): 3252. (ŒG•”rG1: 1”]ŠO)

120009. [Œ´’˜] ‚ˆĘ˜’Ĺ (L1/2, L2/3) ’ĹŠÔ”Âƒwƒ‹ƒjƒA‚Ě—Ő°‘œ‚ĆŽĄ—Ă–@‚ĚŒŸ“˘. ‰Ž“c˜a‹MŽq1, ‰Ô–k‡Ć, ŒG•”rG1, “ě@@Šw, Œ“ź@—´, “‡“ੰ–ç, ‘ĺ’Ë—ş‘ž˜N, ‚‹´•qs: ”]_ŒoŠO‰ČƒWƒƒ[ƒiƒ‹ 2022/5; 31 (5): 324-32.

220002. [€Œ´’˜] ŠÔ”]‰ş‚‘ĚŽîᇂ̌o•@“ŕŽ‹‹žŽčp‚É‚¨‚Ż‚éICG“ŕŽ‹‹ž‚Ě—L—pŤ. G‘ńˆę˜Y1, ŽÄŒ´ˆę—z1, dŽ}—Č‘ž1, ŽR–{‘ĺ•ă1, ŹňŠ°”V1, Š™“c—T“ń2, –Ř‘ş—˘2, ˆÉ“Œ‚ľ‚¨‚č2, ‚–ěK˜H2, ŒG•”rG1 (1”]ŠO, 2“ŕ•Ş”ĺ‘ăŽÓ“ŕ): “ú–{“ŕ•Ş”ĺŠw‰ďŽGŽƒTƒvƒŠƒƒ“ƒg 2021/9; 97 (S.HPT): 19-22.

310034. [Ç—á•ń] Leber's hereditary optic neuropathy with diffuse white matter changes mimicking gliomatosis cerebri: illustrative case. Saruta W1, Shibahara I1, Handa H1, Inukai M1, Kanayama S2, Yasumoto R3, Sakurai K3, Akiyama H, Ishikawa H4, Sato S1, Hide T1, Kumabe T1: J Neurosurg Case Lessons 2021/6; 1 (26): CASE21161. (‰Ž“c˜a‹MŽq1, ŽÄŒ´ˆę—z1, ”ź“c@”Ł1, Œ˘Ž”@‰~1, ‹ŕŽRr‰î2, ˆŔ–{—´”n3, ŸNˆäŒc‘˘3, Îě@‹Ď4, ˛“ĄŸl1, G‘ńˆę˜Y1, ŒG•”rG1: 1”]ŠO, 2Šá‰Č, 3—ŐŒŸ•”, 4ˆă—ÉqśŠw•”)

310035. [Ç—á•ń] Cortical Neural Damage Associated with Cerebral Hyperperfusion after Reperfusion Therapy for Acute Ischemic Stroke: 123I-iomazenil Single-photon Emission Computed Tomography Findings. Kuroda H1, Yamamoto D1, Koizumi H1, Shimizu S1, Kumabe T1: NMC Case Rep J 2021/7; 8 (1): 367-30. (•“c”Ž‹I1, ŽR–{‘ĺ•ă1, ŹňŠ°”V1, ´…@ú1, ŒG•”rG1: 1”]ŠO)

310036. [Ç—á•ń] Transdural reduction of a bone fragment protruding into the spinal canal during surgical treatment of lumbar burst fracture: A case report. Saruta W1, Takahashi T, Kumabe T1, Minami M, Kanematsu R, Shimauchi-Ohtaki H, Otsuka R, Hanakita J: Surg Neurol Int 2021/8; 12: 406. (‰Ž“c˜a‹MŽq1, ŒG•”rG1: 1”]ŠO)

310037. [Ç—á•ń] A Case of Synchronous Occurrence of Intracranial Germinoma and Systemic Sarcoidosis. Hyakutake Y1, Shibahara I1, Inukai M1, Koizumi H1, Hide T1, Morota N1, Yoshida T2, Sasaki J2, Kumabe T1: NMC Case Rep J 2021/9; 8 (1): 645-50. (•S•—C—1, ŽÄŒ´ˆę—z1, Œ˘Ž”@‰~1, ŹňŠ°”V1, G‘ńˆę˜Y1, Žt“cMl1, ‹g“c@Œ÷2, ˛X–ŘŽĄˆę˜Y2, ŒG•”rG1: 1”]ŠO, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

310038. [Ç—á•ń] Aneurysms Arising from Persistent Arteries in the Vertebrobasilar Paramedian Longitudinal Axis: Two Case Reports. Shimizu S1, Mochizuki T, Inukai M1, Osawa S, Kuroda H1, Amari K, Nakai Y, Kumabe T1: NMC Case Rep J 2021/10; 8 (1): 665-71. (´…@ú1, Œ˘Ž”@‰~1, •“c”Ž‹I1, ŒG•”rG1: 1”]ŠO)

310039. [Ç—á•ń] Long-term survival of a patient with diffuse midline glioma in the pineal region: A case report and literature review. Ono T, Kuwashige H, Adachi J, Takahashi M, Oda M, Kumabe T1, Shimizu H: Surg Neurol Int 2021/12; 12: 612. (ŒG•”rG1: 1”]ŠO)

310040. [Ç—á•ń] Strategic neuronavigation-guided emergent endoscopic evacuation of the hematoma caused by ruptured brain arteriovenous malformation: Technical note and retrospective case series. Koizumi H1, Yamamoto D1, Hide T1, Asari Y2, Kumabe T1: J Clin Neurosci 2022/2; 96: 61-7. (ŹňŠ°”V1, ŽR–{‘ĺ•ă1, G‘ńˆę˜Y1, ó—˜@–ő2, ŒG•”rG1: 1”]ŠO, 2‹~–˝)

310041. [Ç—á•ń] Coexistence of anterior cranial fossa dural arteriovenous fistula and arteriovenous malformation with the same drainage system: illustrative case. Yamamoto D1, Shibahara I1, Inukai M1, Koizumi H1, Hyakutake Y1, Ishima D2, Usui R2, Kimura A2, Hide T1, Kumabe T1: J Neurosurg Case Lessons 2022/3; 3 (13): CASE2222. (ŽR–{‘ĺ•ă1, ŽÄŒ´ˆę—z1, Œ˘Ž”@‰~1, ŹňŠ°”V1, •S•—C—1, m–؁@~1, ˆä“‡‘ĺ•ă2, ‰Oˆä@—É2, –Ř‘ş•śŤ2, G‘ńˆę˜Y1, ŒG•”rG1: 1”]ŠO, 2”]_Œo“ŕ)

522076. [uŔ]yę–ĺˆă‚É‹‚ß‚ç‚ę‚éĹV‚Ě’mŽŻz[”]Žîá‡] ”]—Ŕi“W‚ľ‚Ä‚˘‚é_ŒoäPŽî‚ɑ΂ˇ‚é“Eop. ŽÄŒ´ˆę—z1, ŒG•”rG1 (”]ŠO): ”]_ŒoŠO‰Č‘Ź•ń 2021/7; 31 (4): 700-9.

[Šw‰ďEŒ¤‹†‰ď“™]

722127. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) 75ÎˆČă‚̍‚—îŽŇäP‰čŽî‚ɑ΂ˇ‚éƒxƒoƒVƒYƒ}ƒu—Ă–@‚É‚ć‚鎥—ĂŒř‰Ę. ŽÄŒ´ˆę—z1, ”ź“c@”Ł1, –L“c䝗œŽq1, •S•—C—1, Œ˘Ž”@‰~1, ˛“ĄŸl1, G‘ńˆę˜Y1, ŒG•”rG1 (1”]ŠO): ‘ć34‰ń“ú–{˜V”N”]_ŒoŠO‰ČŠw‰ď (2021/4/17), WebŠJĂ.

722128. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) 90ÎˆČă‚Ě’´‚—îŽŇ‹}ŤŠú”][ÇŠłŽŇ‚ɑ΂ˇ‚é‹@ŠB“IŒŒđ‰ńŽű—Ă–@Œă‚ĚŽĄ—Ă“]‹A. ŽR–{‘ĺ•ă1, ŹňŠ°”V1,2, m–؁@~1, ŽÄŒ´ˆę—z1, ‹{â˜aO1, ˆä“‡‘ĺ•ă3, ‰Oˆä@—É3, –Ř‘ş•śŤ3, źŽR˜a—˜3, ŒG•”rG1 (1”]ŠO, 2‹~–˝, 3”]_Œo“ŕ): ‘ć34‰ń“ú–{˜V”N”]_ŒoŠO‰ČŠw‰ď (2021/4/17), WebŠJĂ.

722129. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒoƒCƒpƒXp–ě‚đó‚­‚ľ‚Ü‚Á‚ˇ‚Ž‚Ě“š‹ď‚đŽg—p‚ˇ‚éH•v. ‹v{”ü^—1, ‰Ş@GG1, ‹ß“ĄGŽĄ1, ˆŇ‘şŒöˆč1, ŒG•”rG1 (1”]ŠO): ‘ć30‰ń”]_ŒoŠO‰ČŽčp‚Ć‹@ŠíŠw‰ď (CNTT2021) (2021/4/23), WebŠJĂ.

722130. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Dural scoring: ŠJ“ޏp‚É‚¨‚Ż‚éd–ŒˆęŽŸ•Â˝‚Ě•â•Žč‹Z. ´…@ú1, –]ŒŽ’O, •“c”Ž‹I1, ŠÖŒű•üŽq1, ŹňŠ°”V1,2, ŒG•”rG1 (1”]ŠO, 2‹~–˝): ‘ć14‰ń“ú–{Ž—e”]_ŒoŠO‰ČŠw‰ď (JSAN2021) (2021/4/24), WebŠJĂ.

722131. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‘O“Ş‘¤“ŞŠJ“ŞŽž‚Ě“Ş”Żü‚𖳎‹‚ľ‚˝•K—vĹ’áŒŔ‚Ě”çŘ•ű–@‚ĚŒŸ“˘. ŽÄŒ´ˆę—z1, ”ź“c@”Ł1, –L“c䝗œŽq1, ˛“ĄŸl1, G‘ńˆę˜Y1, ŒG•”rG1 (1”]ŠO): ‘ć14‰ń“ú–{Ž—e”]_ŒoŠO‰ČŠw‰ď (JSAN2021) (2021/4/24), WebŠJĂ.

722132. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) Œo•@“ŕŽ‹‹žŽčp‚É‚¨‚Ż‚éICG“ŕŽ‹‹ž‚̍ĄŒă‚Ě“WŠJ. G‘ńˆę˜Y1, ŒG•”rG1 (1”]ŠO): ‘ć41‰ń“ú–{”]_ŒoŠO‰ČƒRƒ“ƒOƒŒƒX‘‰ď (2021/5/15), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722133. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ‘ĺŒűŒa‹zˆřƒJƒe[ƒeƒ‹‚Ěí‘Žž‘ă` SOFIA‚đŽg‚˘‚ą‚Č‚š!`. ŽR–{‘ĺ•ă1, ŹňŠ°”V1,2, m–؁@~1, ŽÄŒ´ˆę—z1, ‹{â˜aO1, ˆä“‡‘ĺ•ă3, ‰Oˆä@—É3, –Ř‘ş•śŤ3, źŽR˜a—˜3, ŒG•”rG1 (1”]ŠO, 2‹~–˝, 3”]_Œo“ŕ): ‘ć41‰ń“ú–{”]_ŒoŠO‰ČƒRƒ“ƒOƒŒƒX‘‰ď (2021/5/16), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722134. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒŠƒ{ƒ][ƒ€‚ÍäP‰čŽî×–E‚ÉŠ˛×–EŤ‚đ—U“ą‚ˇ‚é. G‘ńˆę˜Y1, ”’ě—T‹M, é–씎Žj, ŽÄŒ´ˆę—z1, Œ˘Ž”@‰~1, ŽÂ“‡’źŽ÷, •Š}Wä, ŒG•”rG1 (1”]ŠO): ‘ć39‰ń“ú–{”]Žîᇕa—Šw‰ďŠwpW‰ď (2021/5/21), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722135. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ICG“ŕŽ‹‹ž‚đŽg—p‚ľ‚˝‹žŽ‹‰şŽčp‚ĚŒťó‚Ć“W–]. G‘ńˆę˜Y1, dŽ}—Č‘ž1, ŽÄŒ´ˆę—z1, ŽR–{‘ĺ•ă1, ŹňŠ°”V1,2, ŒG•”rG1 (1”]ŠO, 2‹~–˝): ‘ć26‰ń“ú–{”]Žîᇂ̊O‰ČŠw‰ď (2021/9/9), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722136. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “Ş’¸Œă“ލa‚É‹K’č‚ł‚ę‚鑤“Ş—t“ŕ‘¤Œă•ű_ŒoäPŽî‚̐i“W—lŽŽ‚Ć‚ť‚ę‚đŠÓ‚Ý‚˝Žčpí—Ş. ŽÄŒ´ˆę—z1, ˛“ĄŸl1, G‘ńˆę˜Y1, âV“Ą—ł‘ž, ‹ŕX­”V, ‰€“c‡•F, •y‰i’î“ń, ŒG•”rG1 (1”]ŠO): ‘ć26‰ń“ú–{”]Žîᇂ̊O‰ČŠw‰ď (2021/9/10), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722137. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Œă“ŞŠWâ|Žîᇋy‚Ń”]“ŽĂ–ŹŠďŒ`‚ɑ΂ˇ‚éŒă“ŞŠWâ|EŒă“ŞŠJ“Ş•š—p‚É‚ć‚é“Eop. ŒG•”rG1, ŽÄŒ´ˆę—z1, ŽR–{‘ĺ•ă1, ŹňŠ°”V1,2, G‘ńˆę˜Y1 (1”]ŠO, 2‹~–˝): ‘ć26‰ń“ú–{”]Žîᇂ̊O‰ČŠw‰ď (2021/9/10), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722138. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) äP‰čŽî‚ĚŠO‰ČŽĄ—Ă. ŒG•”rG1, ŽÄŒ´ˆę—z1 (1”]ŠO): ‘ć80‰ń“ú–{”]_ŒoŠO‰ČŠw‰ď‘‰ď (2021/10/27), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722139. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŹŽ™”]Žîá‡•ŞŽqf’fƒlƒbƒgƒ[ƒN‚̍\’z‚Ɖž—p. ‹ŕ‘ş•Ä”Ž, łŽD’qŽq, ‹g‰ŞŠG–ƒ, Žs‘şKˆę, ’†–ě‰ĂŽq, •˝ŒËƒŽq, ˛X–Ř“Ő, ‹`‰ŞFŽq, ŽRč‰ÄˆŰ, Œ´@ƒˆę, ŒG•”rG1, ˆÉ’B@ŒM, ‰iŞŠî—Y, źě@—ş (1”]ŠO): ‘ć80‰ń“ú–{”]_ŒoŠO‰ČŠw‰ď‘‰ď (2021/10/27), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722140. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ăóŽî‚É‚¨‚Ż‚é’ˇŠú‹@”\—\Œă. ‹ŕX­”V, ‰ş“c—R‹P, âV“Ą—ł‘ž, ‰€“c‡•F, ŒG•”rG1, ”ž‘qrŽi, —é–Ř‹§Žq, •y‰i’î“ń (1”]ŠO): ‘ć80‰ń“ú–{”]_ŒoŠO‰ČŠw‰ď‘‰ď (2021/10/27), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722141. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Ä”­‰ş‚‘Ě‘BŽî“Eo‚ĚŽčpŽč‹Z. ‹v{”ü^—1, ‰Ş@GG1, ‹ß“ĄGŽĄ1, ˆŇ‘şŒöˆč1, ŒG•”rG1 (1”]ŠO): ‘ć28‰ńˆę”ĘŽĐ’c–@l“ú–{_Œo“ŕŽ‹‹žŠw‰ď (2021/11/18), –źŒĂ‰Ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722142. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‹}ŤŠúŹloŒŒŒ^‚ŕ‚â‚ŕ‚â•aÇ—á‚ɑ΂ˇ‚é“ŕŽ‹‹ž‰şŒŒŽîœ‹Žp‚Ě—L—pŤ‚Ć–â‘č“_. ŹňŠ°”V1,2, ŽR–{‘ĺ•ă2, G‘ńˆę˜Y2, ‰Ž“c˜a‹MŽq2, •S•—C—2, ó—˜@–ő1, ŒG•”rG2 (1‹~–˝, 2”]ŠO): ‘ć28‰ńˆę”ĘŽĐ’c–@l“ú–{_Œo“ŕŽ‹‹žŠw‰ď (2021/11/18), –źŒĂ‰Ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722143. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ICG“ŕŽ‹‹ž‚đŽčp‚ÉŠˆ‚Š‚ˇ`ƒŠƒAƒ‹ƒ^ƒCƒ€‚É“ž‚ç‚ę‚éî•ń`. G‘ńˆę˜Y1, ŒG•”rG1 (1”]ŠO): ‘ć28‰ńˆę”ĘŽĐ’c–@l“ú–{_Œo“ŕŽ‹‹žŠw‰ď (2021/11/19), –źŒĂ‰Ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722144. [Šw‰ď (‘S‘)] (‹łˆçƒZƒbƒVƒ‡ƒ“) ăˆßŽî‚ĚŽĄ—Ă‚Ć–â‘č“_: ăˆßŽî‚ĚŽčp‚Ƃ͉˝‚Č‚Ě‚Š? ŒG•”rG (”]ŠO): ‘ć63‰ń“ú–{ŹŽ™ŒŒ‰tE‚Ş‚ńŠw‰ďŠwpW‰ď (2021/11/25), WebŠJĂ.

722145. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŠďŒ`ŽîŹ•Ş‚đŠÜ‚Ţăó×–EŽî‚ɑ΂ˇ‚é•úŽËüE‰ťŠw—Ă–@‚Ě•K—vŤ. ‹ŕX­”V, ‰ş“c—R‹P, ŽÄŒ´ˆę—z1, âV“Ą—ł‘ž, ‰€“c‡•F, ŒG•”rG1, •y‰i’î“ń (1”]ŠO): ‘ć39‰ń“ú–{”]Žîᇊw‰ďŠwpW‰ď (2021/12/5), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722146. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) _ŒoäPŽî‚̉đ–UŠw“Ii“W—lŽŽ‰đÍ: “Ş’¸Œă“ލa‚É’–Ú‚ľ‚˝‘¤“Ş—t“ŕ‘¤Œă•ű_ŒoäPŽî‚ĚŒŸ“˘. ŽÄŒ´ˆę—z1, ˛“ĄŸl1, G‘ńˆę˜Y1, âV“Ą—ł‘ž, ‹ŕX­”V, ‰€“c‡•F, •y‰i’î“ń, ŒG•”rG1 (1”]ŠO): ‘ć39‰ń“ú–{”]Žîᇊw‰ďŠwpW‰ď (2021/12/6), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722147. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “Eo“x‚đ“KŠiŠî€‚Ć‚ľ‚ďp’†ƒ‰ƒ“ƒ_ƒ€‰ť‚đs‚¤äP‰čŽî‚ɑ΂ˇ‚é”äŠr—Տ°ŽŽŒą. âV“Ą—ł‘ž, –؉ş@Šw, ŽRč•ś”V, Šp”ü“ŢŽq, ˆäŠ_@_, a’J@˝, ˛X–Ř“Ő, ŹX—˛Ži, rě–F‹P, Ź“c‘PF, źě@—ş, ŠÖ–ě—Y‘ž, ˛X–ŘŒ[‘ž, ŒG•”rG1 (1”]ŠO): ‘ć39‰ń“ú–{”]Žîᇊw‰ďŠwpW‰ď (2021/12/6), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722148. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) 4K ICG“ŕŽ‹‹ž‚Ö‚ĚˆÚs‚ƏpŒă‰ş‚‘Ě‹@”\. G‘ńˆę˜Y1, dŽ}—Č‘ž1, ŽÄŒ´ˆę—z1, ŹňŠ°”V1,2, ŒG•”rG1 (1”]ŠO, 2‹~–˝): ‘ć32‰ńˆę”ĘŽĐ’c–@l“ú–{ŠÔ”]‰ş‚‘ĚŽîᇊw‰ď (2022/2/18), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722149. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‚ˆĘŒz•”“ŕčň“Ž–Ź‹ˇóÇ‚ɑ΂ˇ‚éCEA‚É‚¨‚Ż‚éˆŔ‘S‚Č“ž’BŒŔŠE‚Ɖ“ˆĘƒVƒƒƒ“ƒg‘}“ü˘“‚Ě‘Îˆ–@. ‹v{”ü^—1, ‰Ş@GG1, ‹ß“ĄGŽĄ1 (1”]ŠO): STROKE 2022 (2022/3/19), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723374. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “ŕŽ‹‹ž“I‘ćŽO”]Žş’ęŠJ‘‹p‚Ş’˜Œř‚ľ‚˝”ӐŹŤ’†”]…“š‹ˇóÇ‚Ě2—á|•a‘Ô“IlŽ@|. ˛“ĄŸl1, ŹňŠ°”V1,2, ”ź“c@”Ł1, ˆäă’q•v, ŠÖŒű•üŽq1, Žt“cMl, G‘ńˆę˜Y1, ŒG•”rG1 (1”]ŠO, 2‹~–˝): ‘ć62‰ń“ú–{_ŒoŠw‰ďŠwp‘ĺ‰ď (2021/5/21), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723375. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”ń“TŒ^“I‰ć‘œŠŒŠ‚đŽŚ‚ˇŒ´”­Ť’†•_ŒoŒnˆŤŤƒŠƒ“ƒpŽî‚Ě•a—‘gDŠw“I“Á’Ľ. Œ˘Ž”@‰~1, ŽÄŒ´ˆę—z1, ”ź“c@”Ł1, ‰Ž“c˜a‹MŽq1, ˛“ĄŸl1, G‘ńˆę˜Y1, ŒG•”rG1 (1”]ŠO): ‘ć39‰ń“ú–{”]Žîᇕa—Šw‰ďŠwpW‰ď (2021/5/21), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723376. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “ŞŠW“ŕăóŽî‚É‚¨‚Ż‚é”]Ň‘‰t‚đ—p‚˘‚˝ˆâ“`Žqf’f. –L“c䝗œŽq1, ŽÄŒ´ˆę—z1, •S•—C—1, ”ź“c@”Ł1, “Ą’J˜aŽq2, Œ˘Ž”@‰~1, ŹňŠ°”V1,3, Žt“cMl, G‘ńˆę˜Y1, ŒG•”rG1 (1”]ŠO, 2DNAŽŔŒąƒZ, 3‹~–˝): ‘ć39‰ń“ú–{”]Žîᇕa—Šw‰ďŠwpW‰ď (2021/5/22), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723377. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Gliomatosis cerebri—l‚Ě”]”’Žż•a•Ď‚đ’ć‚ľ‚˝Leberˆâ“`ŤŽ‹_ŒoÇ‚Ěˆę—á. ‰Ž“c˜a‹MŽq1, ŽÄŒ´ˆę—z1, Œ˘Ž”@‰~1, ‹ŕŽRr‰î2, HŽR‹vŽ, Îě@‹Ď3, ˛“ĄŸl1, G‘ńˆę˜Y1, ŒG•”rG1 (1”]ŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ÉqśŠw•”): ‘ć39‰ń“ú–{”]Žîᇕa—Šw‰ďŠwpW‰ď (2021/5/22), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723378. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “ŞŠW“ŕgerminoma‚É‘SgŤsarcoidosis‚đ‡•š‚ľ‚˝ˆę—á. •S•—C—1, ŽÄŒ´ˆę—z1, ŹňŠ°”V1,2, Žt“cMl, G‘ńˆę˜Y1, ‹g“c@Œ÷3, ˛X–ŘŽĄˆę˜Y4, ŒG•”rG1 (1”]ŠO, 2‹~–˝, 3•a—, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć39‰ń“ú–{”]Žîᇕa—Šw‰ďŠwpW‰ď (2021/5/22), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723379. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’†”]ŽŔŽż“ŕ”w‘¤•”Žîᇂɑ΂ˇ‚éoccipital transtentorial approach‚É‚ć‚é“Eop. ŒG•”rG1, ŽÄŒ´ˆę—z1, ”ź“c@”Ł1, ˆî‘ş˛‹I, űŒ´Œől, ŽR–{‘ĺ•ă1, Œ˘Ž”@‰~1, ˛“ĄŸl1, G‘ńˆę˜Y1 (1”]ŠO): ‘ć49‰ń“ú–{ŹŽ™_ŒoŠO‰ČŠw‰ď (2021/6/5), •Ÿ“‡ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723380. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘¤”]Žş‰şŠp‚É‘śÝ‚ˇ‚é–Ź—‘pŽîᇂɑ΂ˇ‚铇‰ş‹ŤŠEa‚đ‰î‚ľ‚˝“Eop. ŽÄŒ´ˆę—z1, •S•—C—1, –L“c䝗œŽq1, ”ź“c@”Ł1, ‰Ž“c˜a‹MŽq1, Œ˘Ž”@‰~1, ˛“ĄŸl1, G‘ńˆę˜Y1, âV“Ą—ł‘ž, ‹ŕX­”V, ‰€“c‡•F, •y‰i’î“ń, ŒG•”rG1 (1”]ŠO): ‘ć49‰ń“ú–{ŹŽ™_ŒoŠO‰ČŠw‰ď (2021/6/5), •Ÿ“‡ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723381. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “ŞŠW“ŕgerminoma‚É‘SgŤsarcoidosis‚đ‡•š‚ľ‚˝ˆę—á. •S•—C—1, ŽÄŒ´ˆę—z1, ŹňŠ°”V1,2, Žt“cMl, G‘ńˆę˜Y1, ‹g“c@Œ÷3, ˛X–ŘŽĄˆę˜Y4, ŒG•”rG1 (1”]ŠO, 2‹~–˝, 3•a—, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć49‰ń“ú–{ŹŽ™_ŒoŠO‰ČŠw‰ď (2021/6/5), •Ÿ“‡ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723382. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”]Žş\‹šoƒVƒƒƒ“ƒgp‚đŒoŒą‚ľ‚˝…“ŞÇ‚Ěˆę—á. –L“c䝗œŽq1, Žt“cMl, _–쐒ś, ”ź“c@”Ł1, •S•—C—1, ŒG•”rG1 (1”]ŠO): ‘ć49‰ń“ú–{ŹŽ™_ŒoŠO‰ČŠw‰ď (2021/6/5), •Ÿ“‡ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723373. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “Á”­ŤŇ‘ƒwƒ‹ƒjƒA‚̏C•œpŒă‚Édouble-barreled dural theca‚𐜂ś‚˝1—á. ´…@ú1, Ź—Ń—m‰î, Â“c—mˆę, ŒG•”rG1 (1”]ŠO): ‘ć28‰ń“ú–{Ň’ŁEŇ‘_ŒoŽčpŽč‹ZŠw‰ďŠwpW‰ď (2021/9/3), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723384. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “ŞŠW’ęŽčp‚É‚¨‚Ż‚éICG“ŕŽ‹‹ž‚ĚŒťó‚Ć–˘—ˆ. G‘ńˆę˜Y1, ”ź“c@”Ł1, ŽÄŒ´ˆę—z1, ˆäă’q•v, ŹňŠ°”V1,2, ŒG•”rG1 (1”]ŠO, 2‹~–˝): ‘ć32‰ń“ú–{“ŞŠW’ęŠO‰ČŠw‰ď (2021/10/26), •Ÿ“‡.

723385. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚—îŽŇ‚Ě–˘”j—ô”]“Ž–ŹáŽŒo‰ßŠĎŽ@’†‚É”­Ç‚ľ‚˝‚­‚ŕ–Œ‰şoŒŒÇ—á‚ĚŒă•űŽ‹“IŒŸ“˘: ”j—ôƒŠƒXƒNƒXƒRƒA‚É‚ć‚鎥—Éî“ü‚Ě‘Ă“–Ť•]‰ż. ŹňŠ°”V1,2, ŽR–{‘ĺ•ă2, ”ź“c@”Ł2, ‰Ž“c˜a‹MŽq2, ŽÄŒ´ˆę—z2, ‹{â˜aO2, •S•—C—2, –L“c䝗œŽq2, ˛“ĄŸl2, G‘ńˆę˜Y2, ó—˜@–ő1, ŒG•”rG2 (1‹~–˝, 2”]ŠO): ‘ć80‰ń“ú–{”]_ŒoŠO‰ČŠw‰ď‘‰ď (2021/10/27), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723386. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ĺŒ^‰ş‚‘Ě‘BŽî“Eo‚ĚŽčpŽč‹Z: ‰”­‚ĆÄ”­‚É‚¨‚Ż‚éŠeX‚ĚƒRƒc‚ɂ‚˘‚Ä. ‹v{”ü^—1, ‰Ş@GG1, ‹ß“ĄGŽĄ1, ˆŇ‘şŒöˆč1, ŒG•”rG1 (1”]ŠO): ‘ć80‰ń“ú–{”]_ŒoŠO‰ČŠw‰ď‘‰ď (2021/10/27), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723387. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹ô”­“I‚É”­ŒŠ‚ł‚ę‚˝‘ćŽl”]Žş“ŕ_ŒoäPŽî3Ç—á‚ĚŒŸ“˘. –L“c䝗œŽq1, ŽÄŒ´ˆę—z1, Œ˘Ž”@‰~1, ‰Ž“c˜a‹MŽq1, ”ź“c@”Ł1, •S•—C—1, ‹îˆä‰pl1, ˛“ĄŸl1, G‘ńˆę˜Y1, ŒG•”rG1 (1”]ŠO): ‘ć80‰ń“ú–{”]_ŒoŠO‰ČŠw‰ď‘‰ď (2021/10/27), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723388. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “ŞŠW“ŕăóŽîŽĄ—ĂŒă‚É‚Ä‚ń‚Š‚ń‚đ”­Ç‚ľ‚˝Ç—áŒQ‚ĚŒŸ“˘. ‰ş“c—R‹P, ‹ŕX­”V, ‘ĺ‘ňLˆę˜Y, âV“Ą—ł‘ž, ‰€“c‡•F, ŒG•”rG1, ’†—˘M˜a, •y‰i’î“ń (1”]ŠO): ‘ć80‰ń“ú–{”]_ŒoŠO‰ČŠw‰ď‘‰ď (2021/10/27), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723389. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “Ş’¸Œă“ލa‚É‹K’č‚ł‚ę‚鑤“Ş—t“ŕ‘¤Œă•ű_ŒoäPŽî‚̐i“W—lŽŽ‚Ć‚ť‚ĚŽčpí—Ş. ŽÄŒ´ˆę—z1, ˛“ĄŸl1, G‘ńˆę˜Y1, âV“Ą—ł‘ž, ‹ŕX­”V, ‰€“c‡•F, •y‰i’î“ń, ŒG•”rG1 (1”]ŠO): ‘ć80‰ń“ú–{”]_ŒoŠO‰ČŠw‰ď‘‰ď (2021/10/27), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723390. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) _ŒoüˆŰŽîÇIŒ^‚ɍ‡•š‚ľ‚˝–Ń—l×–EŒ`‘Ô‚đ—L‚ˇ‚鏬”]‘ŢŒ`ŹŤŻ×–EŽî‚Ě1—á. ’†“‡Ę‰Ř, ŽÄŒ´ˆę—z1, Œ˘Ž”@‰~1, G‘ńˆę˜Y1, ŒG•”rG1 (1”]ŠO): ‘ć80‰ń“ú–{”]_ŒoŠO‰ČŠw‰ď‘‰ď (2021/10/27), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723391. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ICG“ŕŽ‹‹žŽž‘ă‚ĚŠÔ”]‰ş‚‘ĚŽîᇂ̎čpí—Ş. G‘ńˆę˜Y1, dŽ}—Č‘ž1, ŽÄŒ´ˆę—z1, ŽR–{‘ĺ•ă1, ŹňŠ°”V1,2, ŒG•”rG1 (1”]ŠO, 2‹~–˝): ‘ć80‰ń“ú–{”]_ŒoŠO‰ČŠw‰ď‘‰ď (2021/10/28), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723392. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) 90ÎˆČă‚Ě’´‚—îŽŇ‚ɑ΂ˇ‚錌đ‰ńŽű—Ă–@Œă‚ĚŽĄ—Ă“]‹A. ŽR–{‘ĺ•ă1, ŹňŠ°”V1,2, m–؁@~1, ŽÄŒ´ˆę—z1, dŽ}—Č‘ž1, ‹{â˜aO1, ‰Ž“c˜a‹MŽq1, ”ź“c@”Ł1, •S•—C—1, –L“c䝗œŽq1, ‹îˆä‰pl1, ˆä“‡‘ĺ•ă3, ‰Oˆä@—É3, –Ř‘ş•śŤ3, źŽR˜a—˜3, ŒG•”rG1 (1”]ŠO, 2‹~–˝, 3”]_Œo“ŕ): ‘ć80‰ń“ú–{”]_ŒoŠO‰ČŠw‰ď‘‰ď (2021/10/29), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723393. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”]Žş‹šoƒVƒƒƒ“ƒgp‚ĚŒoŒą‚Ć—L—pŤ. ˆŇ‘şŒöˆč1, ‹v{”ü^—1, ‹ß“ĄGŽĄ1, ‰Ş@GG1, ŒG•”rG1 (1”]ŠO): ‘ć80‰ń“ú–{”]_ŒoŠO‰ČŠw‰ď‘‰ď (2021/10/29), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723394. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ĺ”]Š™•”‘–ŒŽîŽčp‚É‚¨‚Ż‚é4K ICG“ŕŽ‹‹ž•š—p‚Ě—L—pŤ. dŽ}—Č‘ž1, G‘ńˆę˜Y1, ŹňŠ°”V1, ŽR–{‘ĺ•ă1, •S•—C—1, ŒG•”rG1 (1”]ŠO): ‘ć28‰ńˆę”ĘŽĐ’c–@l“ú–{_Œo“ŕŽ‹‹žŠw‰ď (2021/11/19), –źŒĂ‰Ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723395. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “ŞŠW“ŕăóŽî‚É‚¨‚Ż‚é”]Ň‘‰t‚đ—p‚˘‚˝ˆâ“`Žqf’f. –L“c䝗œŽq1, ŽÄŒ´ˆę—z1, •S•—C—1, ”ź“c@”Ł1, “Ą’J˜aŽq2, Œ˘Ž”@‰~1, ŹňŠ°”V1,3, Žt“cMl, G‘ńˆę˜Y1, ŒG•”rG1 (1”]ŠO, 2DNAŽŔŒąƒZ, 3‹~–˝): ‘ć39‰ń“ú–{”]Žîᇊw‰ďŠwpW‰ď (2021/12/5), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723396. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) äP‰čŽîpŒăŽc‘śT2‚M†ˆć‚ĆÄ”­. ‰ş“c—R‹P, ‹ŕX­”V, âV“Ą—ł‘ž, ‰€“c‡•F, ŒG•”rG1, ”ž‘qrŽi (1”]ŠO): ‘ć39‰ń“ú–{”]Žîᇊw‰ďŠwpW‰ď (2021/12/5), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723397. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Gliomatosis cerebri—l‚Ě”]”’Žż•a•Ď‚đ’ć‚ľ‚˝Leberˆâ“`ŤŽ‹_ŒoÇ‚Ěˆę—á. ‰Ž“c˜a‹MŽq1, ŽÄŒ´ˆę—z1, Œ˘Ž”@‰~1, ‹ŕŽRr‰î2, HŽR‹vŽ, Îě@‹Ď3, ˛“ĄŸl1, G‘ńˆę˜Y1, ŒG•”rG1 (1”]ŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ÉqśŠw•”): ‘ć39‰ń“ú–{”]Žîᇊw‰ďŠwpW‰ď (2021/12/6), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723398. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹@”\“IŒăŞŘ’fp (functional posterior rhizotomy: FPR) ‚É‚¨‚Ż‚ép’†F”g‚̕ωť‚ĆÄŒťŤ. ‹îˆä‰pl1, ˛“ĄŸl1, Œ˘Ž”@‰~1, ‰Ÿ“cD”ü2, Ź–ěŕV—T–ç, Žt“cMl, ŒG•”rG1 (1”]ŠO, 2—ŐŒŸ•”): ‘ć51‰ń“ú–{—Տ°_Œoś—Šw‰ďŠwp‘ĺ‰ďE‘ć58‰ń“ú–{—Տ°_Œoś—Šw‰ď‹ZpuK‰ď (2021/12/16), ĺ‘ä (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723399. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •Đ‘¤Šç–Ę‚Ż‚˘‚ę‚ń‚ɑ΂ˇ‚é“KŘ‚Činfrafloccular approach. ‹v{”ü^—1, ‰Ş@GG1, ˆŇ‘şŒöˆč1, ‹ß“ĄGŽĄ1, ŒG•”rG1 (1”]ŠO): ‘ć24‰ń“ú–{”]_ŒoŒ¸ˆłpŠw‰ď (2022/1/27), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723400. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) VŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´őÇ‚đ‡•š‚ľŽĄ—Ă‚Ş’x‚ę‚˝“Ş•”ŠO‚Ě1—á. •S•—C—1, ŹňŠ°”V1,2, ŽR–{‘ĺ•ă1, G‘ńˆę˜Y1, ó—˜@–ő2, ŒG•”rG1 (1”]ŠO, 2‹~–˝): ‘ć45‰ń“ú–{”]_ŒoŠOŠw‰ď (2022/2/25), “Ţ—Ç (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723401. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”ń‘˘‰eMRI/CT fusion‰ć‘œ‚đ—p‚˘‚˝CEAp‘O•]‰ż. •“c”Ž‹I1, ’†‹N“W, ŽO‘î–Αž, ´…@ú1, ŒG•”rG1 (1”]ŠO): STROKE 2022 (‘ć47‰ń“ú–{”]‘˛’†Šw‰ďŠwpW‰ď) (2022/3/17), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723402. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “Ş”çĂ–Ź‚𓪔瓎–Ź‚ĆŒë”F‚ľƒ}[ƒLƒ“ƒO‚ľ‚˝‚˝‚߂ɃoƒCƒpƒXp‚Ş•ĄŽG‰ť‚ľ‚˝2Ç—á. ´…@ú1, •“c”Ž‹I1, ŽO‘î–Αž, –]ŒŽ’O, ’†‹N“W, ŒG•”rG1 (1”]ŠO): STROKE 2022 (‘ć47‰ń“ú–{”]‘˛’†Šw‰ďŠwpW‰ď) (2022/3/17), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

731008. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) Occipital & transtentorial approach‚É‚ć‚éŽîᇓEop: pŒă‚Ě‚Ä‚ń‚Š‚ń”­ě‚đŠÜ‚ß‚˝‡•šÇ‰ń”đ. ŒG•”rG (”]ŠO): Neuro-oncology in Hiroshima 2021 (2021/9/3), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

731009. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) Choroidal arteries anatomy & surgery related complications. ŒG•”rG (”]ŠO): ’ß•‘”]Žîá‡webƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2021/9/16), WebŠJĂ.

732047. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‚‚܂¸‚˘‚Ä‚ŕ—§‚żă‚Ş‚ę!`ŒŒđ‰ńŽű‚É‚¨‚Ż‚éÄŠJ’ʍ˘“ďEŠëŒŻÇ—á‚ĚŒXŒü‚Ć‘Îô`. ŽR–{‘ĺ•ă1, ŹňŠ°”V1,2, ŽÄŒ´ˆę—z1, m–؁@~1, ‹{â˜aO1, ˆä“‡‘ĺ•ă3, ‰Oˆä@—É3, ŒG•”rG1 (1”]ŠO, 2‹~–˝, 3”]_Œo“ŕ): ‘ć20‰ńNPO–@l“ú–{”]_ŒoŒŒŠÇ“஡—ĂŠw‰ďŠÖ“Œ’n•ű‰ďŠwpW‰ď (2021/8/21), “Œ‹ž.

732048. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŒŒđ‰ńŽű`‹zˆřƒJƒe[ƒeƒ‹‚ĚŽg—p–@`. ŽR–{‘ĺ•ă1, ˆä“‡‘ĺ•ă2, ‰Oˆä@—É2, –Ř‘ş•śŤ2, ŹňŠ°”V1,3, ŽÄŒ´ˆę—z1, m–؁@~1, ‹{â˜aO1, źŽR˜a—˜2, ŒG•”rG1 (1”]ŠO, 2”]_Œo“ŕ, 3‹~–˝): ‘ć1‰ń“Œ‹ž”]_ŒoŒŒŠÇ“஡—Ă‹łˆçƒZƒ~ƒi[ (2021/9/24), ‰Ą•l.

732049. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) äP‰čŽî‚ĚŽčp“Eo: Äl. ŒG•”rG (”]ŠO): ‘ć87‰ń“ú–{”]_ŒoŠO‰ČŠw‰ď–kŠC“šŽx•”‰ď (2022/3/26), ŽD–y (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733117. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Bevacizumab“Š—^Œă‚É“Eop‚đs‚Á‚˝‘¤“Ş—t“ŕ‘¤‚ÉŽĺŔ‚đ—L‚ˇ‚éÄ”­äP‰čŽî“Eop. ŽÄŒ´ˆę—z1, •S•—C—1, Œ˘Ž”@‰~1, ˛“ĄŸl1, G‘ńˆę˜Y1, ŒG•”rG1 (1”]ŠO): ‘ć144‰ńˆę”ĘŽĐ’c–@l“ú–{”]_ŒoŠO‰ČŠw‰ďŠÖ“ŒŽx•”ŠwpW‰ď (2021/4/3), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733118. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) 8ŒÂ‚Ě”]“Ž–ŹáŽ‚đ—L‚ˇ‚é’†‚ŏ‰‰ńƒRƒCƒ‹Çđp‚đs‚Á‚˝‰“ˆĘŒă‘ĺ”]“Ž–ŹáŽ‚Š‚ç7”NŒă‚ɍďoŒŒ‚𐜂ś‚˝1—á. •S•—C—1, ŽR–{‘ĺ•ă1, _–쐒ś, m–؁@~1, ˆä“‡‘ĺ•ă2, ‰Oˆä@—É2, –Ř‘ş•śŤ2, ‰Pˆäk‘ž˜Y2, ŹňŠ°”V1,3, ŒG•”rG1 (1”]ŠO, 2”]_Œo“ŕ, 3‹~–˝): ‘ć144‰ńˆę”ĘŽĐ’c–@l“ú–{”]_ŒoŠO‰ČŠw‰ďŠÖ“ŒŽx•”ŠwpW‰ď (2021/4/3), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733119. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Gliomatosis cerebri—l‚Ě”]”’Žż•a•Ď‚đ’ć‚ľ‚˝Leberˆâ“`ŤŽ‹_ŒoÇ‚Ěˆę—á. ‰Ž“c˜a‹MŽq1, ŽÄŒ´ˆę—z1, Œ˘Ž”@‰~1, ‹ŕŽRr‰î2, HŽR‹vŽ, Îě@‹Ď3, ˛“ĄŸl1, G‘ńˆę˜Y1, ŒG•”rG1 (1”]ŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ÉqśŠw•”): ‘ć40‰ń“Œ‹ž”]ŽîᇎĄ—ͧ˜b‰ď (2021/6/18), WebŠJĂ.

733120. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ˆę”N‚ĚŒo‰ß‚ĹˆŤŤ‘–ŒŽî‚Ö‚Ć“]‰ť‚ľ‹~‚Ś‚Č‚Š‚Á‚˝ˆę—á. G‘ńˆę˜Y1, Œ˘Ž”@‰~1, –L“c䝗œŽq1, dŽ}—Č‘ž1, ”ź“c@”Ł1, ŽÄŒ´ˆę—z1, ŒG•”rG1 (1”]ŠO): ‘ć39‰ń_“ސě”]ŽîᇃtƒH[ƒ‰ƒ€ (2021/6/18), ěč.

733121. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‹@”\“IŒăŞŘ’fp (functional posterior rhizotomy: FPR) ‚É‚¨‚Ż‚ép’†F”g‚̕ωť‚ĆÄŒťŤ. ‹îˆä‰pl1, ˛“ĄŸl1, Œ˘Ž”@‰~1, •S•—C—1, –L“c䝗œŽq1, ”ź“c@”Ł1, ‰Ž“c˜a‹MŽq1, dŽ}—Č‘ž1, ‰Ÿ“cD”ü2, Ź–ěŕV—T–ç2, Žt“cMl, ŒG•”rG1 (1”]ŠO, 2—ŐŒŸ•”): ‘ć145‰ńˆę”ĘŽĐ’c–@l“ú–{”]_ŒoŠO‰ČŠw‰ďŠÖ“ŒŽx•”ŠwpW‰ď (2021/9/4), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20”N“xˆČ‘O•Ş

[Šw‰ďEŒ¤‹†‰ď“™]

'20-731001. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ŽáŽč”]ŒŒŠÇ“஡—Ăˆă‚É’m‚Á‚Ä‚Ů‚ľ‚˘!`–k—˘‘ĺŠwŽŽEŒŒđ‰ńŽű—Ă–@ŹŒ÷‚Ě‚˝‚ß‚Ě’mŽŻ‚Ć‹Zp`. ŽR–{‘ĺ•ă1, ŹňŠ°”V1,2, ŽÄŒ´ˆę—z1, m–؁@~1, ‹{â˜aO1, ˆä“‡‘ĺ•ă3, ‰Oˆä@—É3, –Ř‘ş•śŤ3, źŽR˜a—˜3, ŒG•”rG1 (1”]ŠO, 2‹~–˝, 3”]_Œo“ŕ): ‘ć19‰ńNPO–@l“ú–{”]_ŒoŒŒŠÇ“஡—ĂŠw‰ďŠÖ“Œ’n•ű‰ďŠwpW‰ď (2021/2/20), WebŠJĂ.


ŹŽ™‰ČŠw

[Šwp˜_•ś]

110298. [Œ´’˜] Perinatal factors contributing to chronic kidney disease in a cohort of Japanese children with very low birth weight. Uemura O, Ishikura K1, Kaneko T, Hirano D, Hamasaki Y, Ogura M, Mikami N, Gotoh Y, Sahashi T, Fujita N, Yamamoto M, Hibino S, Nakano M, Wakano Y, Honda M: Pediatr Nephrol 2021/5; 36 (4): 953-60. (Î‘qŒ’Ži1: 1ŹŽ™)

110299. [Œ´’˜] Inhibition of Glucose-6-Phosphate Dehydrogenase Activity Attenuates Right Ventricle Pressure and Hypertrophy Elicited by VEGFR Inhibitor + Hypoxia. Kitagawa A1, Jacob C, Jordan A, Waddell I, McMurtry IF, Gupte SA: J Pharmacol Exp Ther 2021/5; 377 (2): 284-92. (–kě“ÄŽj1: 1ŹŽ™)

110300. [Œ´’˜] Live attenuated vaccines under immunosuppressive agents or biological agents: survey and clinical data from Japan. Kamei K, Miyairi I, Shoji K, Arai K, Kawai T, Ogura M, Ishikura K1, Sako M, Nakamura H: Eur J Pediatr 2021/6; 180 (6): 1847-54. (Î‘qŒ’Ži1: 1ŹŽ™)

110301. [Œ´’˜] Dietary Potassium Intake and Mortality in a Prospective Hemodialysis Cohort. Narasaki Y, Okuda Y1, Kalantar SS, You AS, Novoa A, Nguyen T, Streja E, Nakata T, Colman S, Kalantar-Zadeh K, Nguyen DV, Rhee CM: J Ren Nutr 2021/7; 31 (4): 411-20. (‰œ“c—Y‰î1: 1ŹŽ™)

110302. [Œ´’˜] Study on the Causes, Types, and Mechanisms of Childhood Injuries-Age and Disease Specificity. Matsuura N, Nishida Y, Harada S, Takahashi K, Koshikawa K, Konn S1, Hosoda N, Deguchi K, Hotta U, Oka T: JMA J 2021/7; 4 (3): 246-53. (Š@L–ç1: 1ŹŽ™)

110303. [Œ´’˜] Dietary protein intake, kidney function, and survival in a nationally representative cohort. Narasaki Y, Okuda Y1, Moore LW, You AS, Tantisattamo E, Inrig JK, Miyagi T, Nakata T, Kovesdy CP, Nguyen DV, Kalantar-Zadeh K, Rhee CM: Am J Clin Nutr 2021/7; 114 (1): 303-13. (‰œ“c—Y‰î1: 1ŹŽ™)

110304. [Œ´’˜] Association Between Eosinophilia and Late-onset Circulatory Collapse in Preterm Infants: A case-Control Study, Okamura T, Washio Y, Watanabe H, Nakanishi H1,2, Uchiyama A, Tsukahara H, Kusuda S: Acta Med Okayama 2021/8; 75 (4): 505-9. (’†źG•F1,2: 1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™)

110305. [Œ´’˜] Glucocorticoid discontinuation in pediatric-onset systemic lupus erythematosus: a single-center experience. Nishi K, Ogura M, Ishiwa S, Kanamori T, Okutsu M, Yokota S, Nada T, Sato M, Kamei K, Ishikura K1, Ito S: Pediatr Nephrol 2022/9; 37 (9): 2131-9. (Î‘qŒ’Ži1: 1ŹŽ™)

110306. [Œ´’˜] Mean of creatinine clearance and urea clearance examined over 1 h estimates glomerular filtration rate accurately and precisely in children. Okuda Y1, Hamada R, Uemura O, Sakai T, Sawai T, Harada R, Hamasaki Y, Ishikura K1, Hataya H, Honda M: Nephrology (Carlton) 2021/10; 26 (10): 763-71. (‰œ“c—Y‰î1, Î‘qŒ’Ži1: 1ŹŽ™)

110307. [Œ´’˜] Ultrasonography as a Diagnostic Support Tool for Childhood Takayasu Arteritis Referred to as Fever of Unknown Origin: Case Series and Literature Review. Nozawa H, Ogura M, Miyasaka M, Suzuki H, Ishikura K1, Ishiguro A, Ito S: JMA J 2021/10; 4 (4): 358-66. (Î‘qŒ’Ži1: 1ŹŽ™)

110308. [Œ´’˜] Risk factors for post-nephrectomy hypotension in pediatric patients. Nishi K, Kamei K, Ogura M, Sato M, Ishiwa S, Shioda Y, Kiyotani C, Matsumoto K, Nozu K, Ishikura K1, Ito S: Pediatr Nephrol 2021/11; 36 (11): 3699-709. (Î‘qŒ’Ži1: 1ŹŽ™)

110309. [Œ´’˜] Influenza virus vaccination in pediatric nephrotic syndrome significantly reduces rate of relapse and influenza virus infection as assessed in a nationwide survey. Ishimori S, Ando T, Kikunaga K, Terano C, Sato M, Komaki F, Hamada R, Hamasaki Y, Araki Y, Gotoh Y, Nakanishi K, Nakazato H, Matsuyama T, Iijima K, Yoshikawa N, Ito S, Honda M, Ishikura K1: Sci Rep 2021/12; 11 (1): 23305. (Î‘qŒ’Ži1: 1ŹŽ™)

110310. [Œ´’˜] Evaluation of postoperative complications for patent ductus arteriosus in extremely-low-birthweight infants. Ishida S1, Yamaguchi A1, Ooka M1, Kenmochi M1, Nakanishi H1,2: Pediatr Int 2022/1; 64 (1): e14759. (Î“c@Ži1, ŽRŒűˆť”T1, ‘剪–ƒ—1, ™›Ž@Šw1, ’†źG•F1,2: 1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă)

110311. [Œ´’˜] Dysregulation of the Intestinal Microbiome in Patients With Haploinsufficiency of A20. Toyofuku E, Takeshita K, Ohnishi H, Kiridoshi Y, Masuoka H, Kadowaki T, Nishikomori R, Nishimura K, Kobayashi C, Ebato T1, Shigemura T, Inoue Y, Suda W, Hattori M, Morio T, Honda K, Kanegane H: Front Cell Infect Microbiol 2022/1; 11: 787667. (]”gŒËF•ă1: 1ŹŽ™)

110312. [Œ´’˜] Medical, welfare, and educational challenges and psychological distress in parents caring for an individual with 22q11.2 deletion syndrome: A cross-sectional survey in Japan. Morishima R, Kumakura Y, Usami S, Kanehara A, Tanaka M, Okochi N, Nakajima N, Hamada J, Ogawa T, Ando S, Tamune H, Nakahara M, Jinde S, Kano Y, Tanaka K, Hirata Y1, Oka A, Kasai K: Am J Med Genet A 2022/1; 188 (1): 37-45. (•˝“c—zˆę˜Y1: 1ŹŽ™)

110313. [Œ´’˜] Comparison of inulin clearance with 2-h creatinine clearance in Japanese pediatric patients with renal disease: open-label phase 3 study of inulin. Uemura O, Ishikura K1, Kamei K, Hamada R, Yamamoto M, Gotoh Y, Fujita N, Sakai T, Sano T, Fushimi M, Iijima K: Clin Exp Nephrol 2022/2; 26 (2): 132-9. (Î‘qŒ’Ži1: 1ŹŽ™)

110314. [Œ´’˜] Respiratory management for extremely premature infants born at 22 to 23 weeks of gestation in proactive centers in Sweden, Japan, and USA. Sindelar R, Nakanishi H1,2, Stanford AH, Colaizy TT, Klein JM: Semin Perinatol 2022/2; 46 (1): 151540. (’†źG•F1,2: 1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™)

110315. [Œ´’˜] Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome. Iijima K, Sako M, Oba M, Tanaka S, Hamada R, Sakai T, Ohwada Y, Ninchoji T, Yamamura T, Machida H, Shima Y, Tanaka R, Kaito H, Araki Y, Morohashi T, Kumagai N, Gotoh Y, Ikezumi Y, Kubota T, Kamei K, Fujita N, Ohtsuka Y, Okamoto T, Yamada T, Tanaka E, Shimizu M, Horinouchi T, Konishi A, Omori T, Nakanishi K, Ishikura K1, Ito S, Nakamura H, Nozu K, Japanese Study Group of Kidney Disease in Children: J Am Soc Nephrol 2022/2; 33 (2): 401-19. (Î‘qŒ’Ži1: 1ŹŽ™)

110316. [Œ´’˜] Interventions for Shiga toxin-producing Escherichia coli gastroenteritis and risk of hemolytic uremic syndrome: A population-based matched case control study. Myojin S, Pak K, Sako M, Kobayashi T, Takahashi T, Sunagawa T, Tsuboi N, Ishikura K1, Kubota M, Kubota M, Igarashi T, Morioka I, Miyairi I: PLoS One 2022/2; 17 (2): e0263349. (Î‘qŒ’Ži1: 1ŹŽ™)

110317. [Œ´’˜] Comparison of inulin clearance with 2-h creatinine clearance in Japanese pediatric patients with renal disease: open-label phase 3 study of inulin. Uemura O, Ishikura K1, Kamei K, Hamada R, Yamamoto M, Gotoh Y, Fujita N, Sakai T, Sano T, Fushimi M, Iijima K: Clin Exp Nephrol 2022/2; 26 (2): 132-9. (Î‘qŒ’Ži1: 1ŹŽ™)

110318. [Œ´’˜] Incidence of malignancy after pediatric kidney transplantation: a single-center experience over the past three decades in Japan. Aoki Y, Satoh H, Hamasaki Y, Hamada R, Harada R, Hataya H, Ishikura K1, Muramatsu M, Shishido S, Sakai K: Clin Exp Nephrol 2022/3; 26 (3): 294-302. (Î‘qŒ’Ži1: 1ŹŽ™)

110319. [Œ´’˜] Validation of the estimated glomerular filtration rate equation for Japanese children younger than 2 years. Gotoh Y, Uemura O, Fujita N, Hamasaki Y, Honda M, Ishikura K1, Pediatric CKD Study Group in Japan in conjunction with the Committee of Measures for Pediatric CKD of the Japanese Society of Pediatric Nephrology: Clin Exp Nephrol 2022/3; 26 (3): 266-71. (Î‘qŒ’Ži1: 1ŹŽ™)

110320. [Œ´’˜] Efficacy of a Transitional Support Program Among Adolescent Patients With Childhood-Onset Chronic Diseases: A Randomized Controlled Trial. Morisaki-Nakamura M, Suzuki S, Kobayashi A, Kita S, Sato I, Iwasaki M, Hirata Y1, Sato A, Oka A, Kamibeppu K: Front Pediatr 2022/3; 10: 829602. (•˝“c—zˆę˜Y1: 1ŹŽ™)

110321. [Œ´’˜] Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study. Chan EYH, Yu ELM, Angeletti A, Arslan Z, Basu B, Boyer O, Chan CY, Colucci M, Dorval G, Dossier C, Drovandi S, Ghiggeri GM, Gipson DS, Hamada R, Hogan J, Ishikura K1, Kamei K, Kemper MJ, Ma ALT, Parekh R, Radhakrishnan S, Saini P, Shen Q, Sinha R, Subun C, Teo S, Vivarelli M, Webb H, Xu H, Kim H, Yap HK, Tullus K: J Am Soc Nephrol 2022/6; 33 (6): 1193-207. doi: 10.1681/ASN.2021111472. Epub 2022 Mar 30. (Î‘qŒ’Ži1: 1ŹŽ™)

110322. [Œ´’˜] Risks and renal outcomes of severe acute kidney injury in children with steroid-resistant nephrotic syndrome. Ishiwa S, Sato M, Kamei K, Nishi K, Kanamori T, Okutsu M, Ogura M, Sako M, Ito S, Orihashi Y, Ishikura K1: Clin Exp Nephrol 2022/7; 26 (7): 700-8. doi: 10.1007/s10157-022-02198-w. Epub 2022 Mar 7. (Î‘qŒ’Ži1: 1ŹŽ™)

110323. [Œ´’˜] Glucose-6-phosphate dehydrogenase and MEG3 controls hypoxia-induced expression of serum response factor (SRF) and SRF-dependent genes in pulmonary smooth muscle cell. Kitagawa A1, Jacob C, Gupte SA: J Smooth Muscle Res 2022; 58 (0): 34-49. Published online: April 29, 2022; doi: 10.1540/jsmr.58.34 (–kě“ÄŽj1: 1ŹŽ™)

120010. [Œ´’˜] Šw“śŠú‚É“ž’B‚ľ‚˝’´‘ŽYŽ™‚̏AŠwó‹ľE‡•šÇ‚ɂ‚˘‚Ä‚ĚƒAƒ“ƒP[ƒg’˛¸Œ‹‰Ę. çݎ@Šw1, ‘剪–ƒ—1, Î“c@Ži1, ŽRŒűˆť”T1, Źă—T‰ŔŽq1, ‰ĄŠÖ—Sˆę˜Y1,–ě“nł•F, ’†źG•F1,2, Î‘qŒ’Ži1 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): “ú–{ŽüŽYŠúEVśŽ™ˆăŠw‰ďŽGŽ 2021/5; 57 (1): 66-72.

120011. [Œ´’˜] Ý‘Ů26T–˘–ž‚ĚŽ™‚Ĺ‚ĚŽĄ—Éî“ü‚É‚ć‚é“Ž–ŹŠÇ•Â˝‘OŒă‚̏zŠÂ“Ž‘Ԃ̕ωť. Î“c@Ži1, ’†źG•F1,2, ŽRŒűˆť”T1, ‘剪–ƒ—1, çݎ@Šw1 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): “ú–{ŽüŽYŠúEVśŽ™ˆăŠw‰ďŽGŽ 2021/9; 57 (2): 269-74.

310042. [Ç—á•ń] Tocilizumab for juvenile Takayasu arteritis complicated with acute heart failure at onset. Kanamori K, Ogura M, Ishikura K1, Ishiguro A, Ito S: Mod Rheumatol Case Rep 2022/6; 6 (2): 226-9. (Î‘qŒ’Ži1: 1ŹŽ™)

310043. [Ç—á•ń] Contradiction between genetic analysis and diuretic loading test in type I Bartter syndrome: a case report. Kuroda J, Harada R, Hamada R, Okuda Y, Yoshida Y, Hataya H, Nozu K, Iijima K, Honda M, Ishikura K1: BMC Nephrol 2021/8; 22 (1): 295. (Î‘qŒ’Ži1: 1ŹŽ™)

310044. [Ç—á•ń] Venous Properties in a Fontan Patient with Successful Remission of Protein-Losing Enteropathy. Kuwata S, Saiki H, Takanashi M1, Fukunishi T2, Miyaji K2, Senzaki H: Int Heart J 2021; 62 (3): 710-4. (‚—œ@Šw1, •Ÿź‘ô^2, ‹{’n@ŠÓ2: 1ŹŽ™, 2S‘ŸŒŒŠÇŠO)

510019. [‘ŕ] Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies. Harada R, Hamasaki Y, Okuda Y1, Hamada R, Ishikura K1: Pediatr Nephrol 2022/6; 37 (6): 1215-29. (‰œ“c—Y‰î1, Î‘qŒ’Ži1: 1ŹŽ™)

522077. [uŔ]yƒVƒ“ƒ|ƒWƒEƒ€12: VśŽ™—Ěˆć‚ĚNO‹z“ü—Ă–@zŔ’ˇ‚Ě‚Ü‚Ć‚ß. ’†źG•F1,2, –F–{˝Ži (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): “ú–{ŽüŽYŠúVśŽ™ˆăŠw‰ďŽGŽ 2021/4; 57 (4): 708-9.

522078. [uŔ]yƒVƒ“ƒ|ƒWƒEƒ€12: VśŽ™—Ěˆć‚ĚNO‹z“ü—Ă–@zVśŽ™—Ěˆć‚É‚¨‚Ż‚éNO‹z“ü—Ă–@‚ĚŠú‘Ň‚ł‚ę‚éŒř‰Ę (Šî‘b“IƒAƒvƒ[ƒ`). ’†źG•F1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): “ú–{ŽüŽYŠúVśŽ™ˆăŠw‰ďŽGŽ 2021/4; 57 (4): 718-21.

522079. [uŔ]y“ÁW: “ű—cŽ™Œ’fŽŔ‘HƒKƒCƒhzę–ĺ‰Ć‚Š‚ç‚ĚƒAƒhƒoƒCƒX`—Ěˆć•Ę‚Ɂ`@zŠÂŠí. –kě“ÄŽj1, •˝“c—zˆę˜Y1 (1ŹŽ™): ŹŽ™‰Čf—Ă 2021/4; 84 (5): 663-7.

522080. [uŔ]y“ÁW: NEO SpecialityzwithƒRƒƒiŽž‘ă‚ɍčl‚ˇ‚é@Œťę‚ĹŽg‚Ś‚é!NICU‚Ĺ‚ĚŠ´ő‘΍ôQ&A@‘˜_ •W€—\–hô‚ĆŠ´őŒo˜H•Ę—\–hô. ’†źG•F1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): with NEO 2021/6; 34 (3): 408-11.

522081. [uŔ]y“ÁW: NEO SpecialityzwithƒRƒƒiŽž‘ă‚ɍčl‚ˇ‚é@Œťę‚ĹŽg‚Ś‚é! NICU‚Ĺ‚ĚŠ´ő‘΍ôQ&A@Ž{Ý•ĘƒRƒƒiƒEƒCƒ‹ƒXŠ´ő‘΍ôQ&A@‘ź‚ĚŽ{Ý‚Í‚Ç‚¤‚ľ‚Ä‚é? (–k—˘‘ĺŠw•a‰@‚Ěę‡). ‘剪–ƒ— (ŹŽ™): with NEO 2021/6; 34 (3): 427-38.

522082. [uŔ]y“ÁW: ”­śŠw‚Š‚çl‚Ś‚Ă݂悤! ŹŽ™‚̐ć“VŽžŠłzII. Še˜_@ć“VŤt”A˜HˆŮí, ůN–EŤtŽžŠł. źŒ’‘ž˜N, Î‘qŒ’Ži1 (1ŹŽ™): ŹŽ™‰Čf—Ă 2021/7; 84 (8): 1089-96.

522083. [uŔ]y“ÁW: ŹlˆÚsŽx‰‡‚Ě“ń–ʐŤz[Še˜_] Źlˆă—Ă‚Ć‚Ě˜AŒg‚̏ę@ŹŽ™‰Č‚ƐŹlf—Ă‰Č‚Ć‚Ě˜AŒg@‘‡•a‰@“ŕ‚Ĺ‚Ě˜AŒg|‰@“ŕĐ‰î‚ĚŰ‚É•K—v‚ȁuŽŠ—§Žx‰‡v‚Ć‚Í. •˝“c—zˆę˜Y (ŹŽ™): ŹŽ™“ŕ‰Č 2022/8; 53 (8): 1271-4.

522084. [uŔ]y“ÁW: tŽžŠł‚ĚˆÚsŠúˆă—ÁzˆÚsŠúˆă—Â̐i‚ß•ű. Š@L–ç1, ‘ĺ’ˁ@2, •˝“c—zˆę˜Y1, –ěX“c–L1, ‰œ“c—Y‰î1, ’|“ŕN—Y3, Î‘qŒ’Ži1 (1ŹŽ™, 2ŠĹŒě•”, 3t‘Ÿ“ŕ): t‘Ÿ“ŕ‰Č 2021/8; 14 (2): 132-7.

522085. [uŔ]y“ÁW: Ý‘Ů22`23T‚Ě’´‘ŽY‚đ‚ß‚Ž‚é‰Ű‘č‚Ć“W–]zNICU“ü‰@’†‚̍‡•šÇ‚Ć—\–hí—ށ@‡•šÇ‚̑Ήž‚Ć—\–hí—ށ@”ÓŠúzŠÂ•s‘S. ’†źG•F1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): ŽüŽYŠúˆăŠw 2021/8; 51 (8): 1140-5.

522086. [uŔ]yŽ•a‚Ş‚ ‚鎙“ś‚Ö‚ĚŠwZˆă‚̑ΉžzŠwZˆă‚É‹‚ß‚ç‚ę‚鏬Ž™zŠÂŠíŽžŠł‚ɑ΂ˇ‚闝‰đ‚ƑΉž. –kě“ÄŽj1, •˝“c—zˆę˜Y1 (1ŹŽ™): ’nˆćˆăŠw 2022/1; 36 (1): 20-6.

522087. [uŔ]y“ÁW: ŽüŽYŠú‚ĚƒXƒeƒƒCƒhz—Տ°•Ň: VśŽ™@”ÓŠúzŠÂ•s‘S‚ɑ΂ˇ‚éƒXƒeƒƒCƒh—Ă–@. ’†źG•F1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): ŽüŽYŠúˆăŠw 2022/1; 52 (1): 92-6.

522088. [uŔ]yOnco-nephrology: ˆŤŤŽîᇎĄ—ÂƐt‹@”\áŠQz[‘˜_] ŹŽ™CKDŠłŽŇ‚É‚¨‚Ż‚é‚Ş‚ń”­ś‚̉uŠw‚Ć“Á’Ľ. ‰œ“c—Y‰î1, ˆę‰Ş‘Žq, Î‘qŒ’Ži1 (1ŹŽ™): t‚Ć“§Í 2022/3; 92 (3): 529-32.

530010. [‚ť‚Ě‘ź (Comment)] Outcomes of infants born at periviable gestations in Japan. Kono Y, Rysavy MA, Nakanishi H1, Kusuda S: Acta Paediatr 2021/5; 110 (5): 1694-5. (’†źG•F1,2: 1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™)

540028. [‚ť‚Ě‘ź (Œ¤‹†•ń‘)]yŹŽ™–Ťt‘Ÿ•aŠłŽŇ‚Ě‚˝‚ß‚ĚˆÚsŠúˆă—ĂŽx‰‡ƒc[ƒ‹uŒúś˜J“­s­„i’˛¸”ď•â•‹ŕ (tŽžŠł­ôŒ¤‹†Ž–‹Ć)vz‚¨‚ľ‚Á‚ą (”A) ‚Ɛt‘Ÿ‚Ě•sŽv‹c. ”Œ´’źŽ÷1, •ž•”ŒłŽj1, Î‘qŒ’Ži1,2, _“cËˆę˜Y1, Ž›–ěçŽq1, ’ˇ‰Ş—RC1, ŽO‰YŒ’ˆę˜Y1, –öŒ´@„1, ‹ŕŽqšO1, ‹e‰i‰ŔD1,2, Ź—ŃŒőˆę1, Š@L–ç1,2 (1utŽžŠł‘΍ôŒŸ“˘‰ď•ń‘‚ÉŠî‚Ă‚­‘΍ô‚̐i’ťŠÇ—‚¨‚ć‚ѐV‚˝‚Č‘Îô‚Ě’ńŒž‚É‚ľ‚ˇ‚éƒGƒrƒfƒ“ƒX\’zv”Ç, 2ŹŽ™), ŹŽ™–Ťt‘Ÿ•aŠłŽŇ‚Ě‚˝‚ß‚ĚˆÚsŠúˆă—ĂŽx‰‡ƒc[ƒ‹uŒúś˜J“­s­„i’˛¸”ď•â•‹ŕ (tŽžŠł­ôŒ¤‹†Ž–‹Ć)vŒ¤‹†•ń‘, 2021/9.

[’˜@‘]

610001. [Šwp‘ (•Ş’SŽˇ•M)]yPediatric dialysis, third editionzOutcome of Chronic Dialysis@Long-Term Outcome of Chronic Dialysis in Children, p.745-83. Honda M, Terano C, Inoguchi T, Kikunaga K1, Harada R, Groothof JW, Editors: Warady BA, Alexander SR, Schaefer F, SpringerSwitzerland AG, 2021. (‹e‰i‰ŔD1: 1ŹŽ™)

620083. [Šwp‘ (•Ş’SŽˇ•M)]yŽŔ‘H?ŹŽ™‚Ě—A‰t (ŹŽ™“ŕ‰Č4ŒŽ‘‘ĺ†)z[Še•a‘Ô‚É‚¨‚Ż‚é—A‰t‚̍l‚Ś•ű] zŠÂŠíŽžŠł@–ŤS•s‘S, p.574-7. •˝“c—zˆę˜Y (ŹŽ™), “Œ‹žˆăŠwŽĐ, “Œ‹ž, 2022/4”­s.

620084. [Šwp‘ (•Ş’SŽˇ•M)]y`ƒGƒLƒXƒp[ƒg‚ĚŒoŒą‚ÉŠw‚ԁ`ŹŽ™‰ČDecision Making (ŹŽ™‰Čf—ĂVol.84‘Š§†)z15. ƒzƒ‹ƒ‚ƒ“E‘ăŽÓE“d‰đŽż‚ÉŠÖ‚ˇ‚é•a‘ԁ@’áƒiƒgƒŠƒEƒ€ŒŒÇ, ‚ƒiƒgƒŠƒEƒ€ŒŒÇ, p.393-7. ‰œ“c—Y‰î1, Š@L–ç1, Î‘qŒ’Ži1 (1ŹŽ™), f’f‚ĆŽĄ—ĂŽĐ, “Œ‹ž, 2021/4”­s.

620085. [Šwp‘ (•Ş’SŽˇ•M)]yt‘Ÿ•af—ĂQ&A@AKI`CKD`t“ď•a‚܂Łz5) ŽĄ—Á@ŹŽ™CKD@ŠłŽŇ‚̐HŽ–—Ă–@‚đ‹ł‚Ś‚Ä‚­‚ž‚ł‚˘, p.115-6. ‰œ“c—Y‰î1, Š@L–ç1, Î‘qŒ’Ži1 (1ŹŽ™), ŠÄC: ŽRăp–MO, •Ň: ‰Pˆääˆę, Ö“Ą’m‰h, “Œ‹žˆăŠwŽĐ, “Œ‹ž, 2021/6”­s.

620086. [Šwp‘ (•Ş’SŽˇ•M)]yŹŽ™RSƒEƒCƒ‹ƒXŒÄ‹zŠíŠ´őÇf—ĂƒKƒCƒhƒ‰ƒCƒ“2021zClinical Question CQ1@‘ŽYŽ™‚ĚRSƒEƒCƒ‹ƒX×‹CŠÇŽx‰Š‚Ě—\–h‚ɃpƒŠƒrƒYƒ}ƒu‚Í—LŒř‚Š?, p.2-5. ’†źG•F1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™), ŠÄC: ‹gŒ´d”ü, X‰Şˆę˜N, ‰Ş“c–M”V, ŒËÎŒĺŽi, ěŹ: “ú–{ŹŽ™ŒÄ‹zŠíŠw‰ď, “ú–{VśŽ™ŹˆçˆăŠw‰ď, ‹Ś˜aŠé‰ć, “Œ‹ž, 2021/6”­s.

620087. [Šwp‘ (•Ş’SŽˇ•M)]y•W€“Iˆă—Ăŕ–ž@ƒCƒ“ƒtƒH[ƒ€ƒhEƒRƒ“ƒZƒ“ƒg‚ĚĹ‘OüzŹŽ™ŽžŠł@dÇć“VŤŽžŠł‚̐f—Ă (‘ŽYŽ™‚𒆐S‚É), p.255-7. ’†źG•F1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™), •Ň: ˆę”ĘŽĐ’c–@l “ŕ‰ČŒnŠw‰ďŽĐ‰ď•ŰŒŻ˜A‡, ˆăŠw‘‰@, “Œ‹ž, 2021/8”­s.

620088. [Šwp‘ (•Ş’SŽˇ•M)]y•W€“Iˆă—Ăŕ–ž@ƒCƒ“ƒtƒH[ƒ€ƒhEƒRƒ“ƒZƒ“ƒg‚ĚĹ‘OüzŹŽ™ŽžŠł@ŹŽ™ƒlƒtƒ[ƒ[ÇŒóŒQ‚ÉŠÖ‚ˇ‚é–Ɖu—}§–ň (ƒVƒNƒƒXƒ|ƒŠƒ“) ‚ĚŽg—p, p.258-9. Î‘qŒ’Ži (ŹŽ™), •Ň: ˆę”ĘŽĐ’c–@l “ŕ‰ČŒnŠw‰ďŽĐ‰ď•ŰŒŻ˜A‡, ˆăŠw‘‰@, “Œ‹ž, 2021/8”­s.

620089. [Šwp‘ (•Ş’SŽˇ•M)]yVśŽ™‚ĚŒÄ‹zEzŠÂ@”ť’f—́EŽŔ‘H—ÍUP‚Ě‚˝‚ß‚ĚƒP[ƒX71 (with NEO (2021”NH‹G‘Š§)z •Ň’˜: ç—t—m•v, ’†źG•F1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™), ƒƒfƒBƒJo”Ĺ, “Œ‹ž, 2021/9”­s.

620090. [Šwp‘ (•Ş’SŽˇ•M)]yĄ“ú‚ĚŽĄ—ĂŽwj`Ž„‚Í‚ą‚¤ŽĄ—Ă‚ľ‚Ä‚˘‚é`2022”N”Łz22 VśŽ™ŽžŠł@”]Žş“ŕoŒŒ, ”]ŽşŽüˆÍ”’Žż“Ç, 1430-1. ’†źG•F1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™), ‘•ŇW: •ŸˆäŽŸ–î, ‚–؁@˝, ŹŽş ˆęŹ, ˆăŠw‘‰@, “Œ‹ž, 2022/1”­s.

620091. [Šwp‘ (•Ş’SŽˇ•M)]yŽüŽYŠúˆăŠw•KC’mŽŻ ‘ć9”Ĺ (ŽüŽYŠúˆăŠw51ŠŞ‘Š§†)zŽ‘—ż“ŒvE—pŒę•Ň@VII Ž‘—ż“ŒvE—pŒę@375 •ęŽq•ŰŒ’“Œv, p.1312-9. ’†źG•F1,2 (1˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™), “Œ‹žˆăŠwŽĐ, “Œ‹ž, 2022/1”­s.

620092. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ń‚Č‚Ć‚Ť‚Ç‚¤‚ˇ‚é?‘ź‰Č‚Ć‚ĚƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“ƒKƒCƒh (ŽY‰Č‚Ć•wl‰Č2022”NVol.89 No.‘Š§†)z‘ć1Í VśŽ™‰ČEŹŽ™‰ČEVśŽ™ŠO‰Č@11. ‚Č‚ń‚Ć‚Č‚­Œł‹C‚Ě‚Č‚˘VśŽ™, p.63-6. ’†źG•F1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™), f’f‚ĆŽĄ—ĂŽĐ, “Œ‹ž, 2022/3”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

712008. [Šw‰ď (‘Ű)] (‹łˆçu‰‰) CKD in children (CME Cat A 1 point). Ishikura K1 Hong Kong Paediatric Nephrology Society (2021/8/2), WebŠJĂ. (Î‘qŒ’Ži1: 1ŹŽ™)

713044. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Nephronophthisis: case report of an adolescent girl and up-to-date results of a national survey in Japanese children. Okuda Y1, Hamasaki Y, Sugimoto K, Okutsu M, Kon S1,2, Hamada R, Kaneko T, Ishikura K1 The 18th Japan-Korea-China Pediatric Nephrology Seminar 2021 (2021/4/25), WebŠJĂ. (‰œ“c—Y‰î1, Š@L–ç1,2, Î‘qŒ’Ži1: 1ŹŽ™, 2‹~–˝)

722150. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‚ą‚ę‚Š‚ç‚̐ŹlˆÚsŽx‰‡. •˝“c—zˆę1, ˛“Ą~Žu, ‰Ş@@–ž, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć124‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2021/4/17), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722151. [Šw‰ď (‘S‘)] (ƒpƒlƒXƒfƒBƒXƒJƒbƒVƒ‡ƒ“) CAKUT: ŹŽ™t‘Ÿ“ŕ‰Čˆă‚ĚŠÇ—. Î‘qŒ’Ži (ŹŽ™): ‘ć58‰ń“ú–{ŹŽ™ŠO‰ČŠw‰ďŠwpW‰ď (2021/4/29), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ),

722152. [Šw‰ď (‘S‘)] (‹łˆçu‰‰) V‚ľ‚˘ŽĄ—Ă•W“I‚Ć‚ľ‚Ä‚ĚƒOƒ‹ƒR[ƒX-6-ƒŠƒ“Ž_’E…‘fy‘f‚̉”\Ť. –kě“ÄŽj1, Sachin Gupte, ‚—œ@Šw1, –{“c@’1, •˝“c—zˆę˜Y1, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć6‰ń“ú–{”x‚ŒŒˆłE”xzŠÂŠw‰ďŠwpW‰ď (2021/5/6-8), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722153. [Šw‰ď (‘S‘)] (‹łˆçu‰‰) ‹}ŤŠú‚Š‚çŽn‚ß‚éHFOVŠÇ—`22-24TŽ™‚ĚŒÄ‹zŽĄ—Ð헪`. ’†źG•F1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): ‘ć65‰ń“ú–{VśŽ™ŹˆçˆăŠw‰ďEŠwpW‰ď (2021/5/7), WebŠJĂ.

722154. [Šw‰ď (‘S‘)] (‹łˆçu‰‰) ’Bl‚Š‚çŠw‚Ô, Œ¤‹†‚ĚŽŔŰ‚Ć˜_•ś‚̏‘‚Ť•ű. ’†źG•F1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): ‘ć65‰ń“ú–{VśŽ™ŹˆçˆăŠw‰ďEŠwpW‰ď (2021/5/7), WebŠJĂ.

722155. [Šw‰ď (‘S‘)] (‹łˆçu‰‰) VśŽ™—Ěˆć‚É‚¨‚Ż‚éNO‹z“ü—Ă–@‚ĚŠú‘Ň‚ł‚ę‚éŒř‰Ę (Šî‘b“IƒAƒvƒ[ƒ`). ’†źG•F1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): ‘ć57‰ń“ú–{ŽüŽYŠúEVśŽ™ˆăŠw‰ďŠwpW‰ď (2021/7/12), ‹{č (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722156. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ś”x“Ž–Ź“ŕŒŒđŒ`Ź‚É‚ć‚é‹}Œƒ‚ȏǏóis‚đ”F‚ß‚˝VśŽ™“Ž–ŹŠÇᎂ̈ę—á. ˆî–؏G‰p1, ’†źG•F1,2, Źă—T‰ŔŽq1, ŽRŒűˆť”T1, Î“c@Ži1, ‘剪–ƒ—1, ‹{’n@ŠÓ3 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[“Iˆă—Ă, 3S‘ŸŒŒŠÇŠO): ‘ć57‰ń“ú–{ŽüŽYŠúEVśŽ™ˆăŠw‰ďŠwpW‰ď (2021/7/11-13), ‹{č (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722157. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Medication Withdrawal in JIAu‘SgŒ^EŽá”NŤ“Á”­ŤŠÖß‰ŠvŽĄ—Ă–ňŒ¸—Ę‚ÉŠÖ‚ˇ‚é‘S‘ŹŽ™ƒŠƒEƒ}ƒ`ˆă’˛¸. ]”gŒËF•ă (ŹŽ™): ‘ć30‰ń“ú–{ŹŽ™ƒŠƒEƒ}ƒ`Šw‰ďŠwpW‰ď (2021/10/16), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723403. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Œă“VŤTTP”­ÇŒă‚ÉSLE‚Ɛf’f‚ł‚ę‚˝13Î’jŽ™—á. “n糗ڔü1, ]”gŒËF•ă1, ‹ŕŽq‰ë‹I1, ‰œ“c—Y‰î1, Š@L–ç1,2, •˝“c—zˆę˜Y1, Î‘qŒ’Ži1 (1ŹŽ™, 2‹~–˝): ‘ć124‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2021/4/16-18), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723404. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) _“ŢěŒ§‘Š–ÍŒ´’nˆć‚É‚¨‚Ż‚鏬Ž™COVID-19f—Ă˜AŒg‚ĚŽŽ‚Ý. –{“c@’1, ˆÉ“ĄŽŽu1, ˆŔ“Ą@Žő1, ˆžśk‘ž, ˆÉ“Ą@—ş, ĄˆäƒD1, –ĺˆäL‹Ĺ, ˛“Ą‰Á‘ăŽq1, ”’ˆäGK, ť‰Ÿ@Â, ’†‘şM–ç, –ě‘ş‰ëŠ°, –ö“c‹I”V, ŽRč‰ë•F, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć124‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2021/4/16-18), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723405. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŽîᇓEo‚É‚ć‚čd“Ä‚Č“űŽ_ƒAƒVƒh[ƒVƒX‚̉ü‘P‚đ“ž‚˝VśŽ™_Œo‰čŽî‚Ěˆę—á. ’†‘ş^‹I1, Î“c@Ži1, Źă—T‰ŔŽq1, ŽRŒűˆť”T1, ‘剪–ƒ—1, çݎ@Šw1, ’†źG•F1,2, •˝“c—zˆę˜Y1, Î‘qŒ’Ži1 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[“Iˆă—Ă): ‘ć124‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2021/4/16-18), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723406. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) TTP‚đ‡•š‚ľ‚˝‰”­SLE‚Ě1—á. “n糗ڔü1, ‹ŕŽq‰ë‹I1, ]”gŒËF•ă1, ‰œ“c—Y‰î1, Š@L–ç1,2, •˝“c—zˆę˜Y1, Î‘qŒ’Ži1 (1ŹŽ™, 2‹~–˝): ‘ć124‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2021/4/16-18), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723407. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒlƒtƒ[ƒ[ÇŒóŒQÄ”­’†‚É–łÇŒóŤ‚Ě”xŒŒđÇđÇ‚đ”­Ç‚ľ‚˝ŽvtŠú’jŽq—á. “ú‰ş•”ˆÇŽŃŒ\, Š@L–ç1,2, ŠÖ’J—˘‰Ŕ2, ‰œ“c—Y‰î2, •˝“c—zˆę˜Y2, Î‘qŒ’Ži2 (1‹~–˝, 2ŹŽ™): ‘ć124‰ń“ú–{ŹŽ™‰ČŠw‰ďŠwpW‰ď (2021/4/16-18), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723408. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Microgeodic disease‚Ɛf’f‚ľ‚˝6Ç—á‚Ě—Ő°“I“Á’Ľ. ]”gŒËF•ă (ŹŽ™): ‘ć65‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď‘‰ďEŠwpW‰ď (2021/4/26-28), WebŠJĂ.

723409. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒXƒeƒƒCƒh—Ă–@‚Ě‚Ý‚Ĺ—ÇD‚ČŒo‰ß‚đ’H‚Á‚˝RMDA5R‘Ě—zŤŽá”NŤ”畆‹Ř‰Š‚Ě1—á. ‘ĺ“ˆ@–ž, ]”gŒËF•ă1 (1ŹŽ™): ‘ć65‰ń“ú–{ƒŠƒEƒ}ƒ`Šw‰ď‘‰ďEŠwpW‰ď (2021/4/26-28), WebŠJĂ.

723410. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ’´‘ŽYŽ™E‹šo‹ž‰ş“Ž–ŹŠÇ•Â˝p (VATS-PDA) ‚Ě’ˇŠú—\Œă@AŠwŽ™‚ĚƒAƒ“ƒP[ƒg’˛¸‚Ĺ‚í‚Š‚Á‚˝‚ą‚Ć. çݎ@Šw1, ‘剪–ƒ—1, Î“c@Ži1, ŽRŒűˆť”T1, ‰ĄŠÖ—Sˆę˜Y1, ’†źG•F1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[“Iˆă—Ă): ‘ć65‰ń“ú–{VśŽ™ŹˆçˆăŠw‰ďEŠwpW‰ď (2021/5/7-9), WebŠJĂ.

723411. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŹŽ™ƒlƒtƒƒ“ᔂɂ¨‚Ż‚é––Šút•s‘Sis‚Ö‚ĚƒŠƒXƒNˆöŽq. ‰œ“c—Y‰î1, ŕ_č—SŽq, ™–{Œ\‘Š, ‰œ’Ă”ü‰Ä, ŕ_“c@—¤, ‹ŕŽq“OŽĄ, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć64‰ń“ú–{t‘ŸŠw‰ďŠwp‘‰ď (2021/6/18-20), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723412. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Clinical characteristics of nephronophthisis in Japanese children: a national survey. ‰œ“c—Y‰î1, ŕ_č—SŽq, ™–{Œ\‘Š, ‰œ’Ă”ü‰Ä, ŕ_“c@—¤, ‹ŕŽq“OŽĄ, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć56‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2021/7/9), ‚’m.

723413. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŹŽ™“Á”­Ťƒlƒtƒ[ƒ[ÇŒóŒQ‘S‘‰uŠw’˛¸ (JP-SHINE study) ƒCƒ“ƒtƒ‹ƒGƒ“ƒUƒEƒCƒ‹ƒXƒƒNƒ`ƒ“‚Ě—LŒřŤ‚Ćƒlƒtƒ[ƒ[Ä”­‚ւ̉e‹ż. ÎX^Œá, ˆŔ“Ą‚Žu, ‹e‰i‰ŔD1, Ž›–ěçŽq, ˛“Ą@•‘, ŕ_č—SŽq, ˆÉ“ĄGˆę, –{“c‰ëŒh, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć56‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2021/7/10), ‚’m, “ú–{ŹŽ™t‘Ÿ•aŠw‰ďŽGŽ 2021/5; 34 (1 Suppl): 93.

723414. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) LoweÇŒóŒQ‚̐t‹@”\‚Ć—Ő°ˆâ“`Šw“IŠŒŠ‚Ć‚ĚŠÖ˜AŤ‚ĚŒŸ“˘. ˆŔ“Ą‘ž˜Y, ŽO‰YŒ’ˆę˜Y, Î’ˊ쐢L, –÷“ŕ’q˜N, Î˜a@ăÄ, ’Ł“c@–L, _“cËˆę˜Y, ˛“Ą“ÖŽj, ˆé“‡@‹, ŕ_“c@—¤, Î‘qŒ’Ži1, ŒÜ\—’—˛, •ž•”ŒłŽj (1ŹŽ™): ‘ć56‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2021/7/10), ‚’m, “ú–{ŹŽ™t‘Ÿ•aŠw‰ďŽGŽ 2021/5; 34 (1 Suppl): 94.

723415. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) •p‰ńÄ”­Œ^/ƒXƒeƒƒCƒhˆË‘śŤƒlƒtƒ[ƒ[ÇŒóŒQ‚ɑ΂ˇ‚éƒVƒNƒƒtƒHƒXƒtƒ@ƒ~ƒh‚ĆƒVƒNƒƒXƒ|ƒŠƒ“‚Ě•p‰ńÄ”­‰ť‘jŽ~Œř‰Ę‚ɍˇ‚Í‚Č‚˘. Ž›–ěçŽq, ŕ_“c@—¤, Ź–q•ś‘ă, ‰eŽR‚ ‚łŽq, ăp@ˆęŽu, –{“c@‹Ä, •yŠ~—El, ´…•ŕ”ü, Ô•ôŒhŽĄ, Œ´“c—ÁŽq, ŕ_č—SŽq, –{“c‰ëŒh, ”Ś’J_Žj, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć56‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2021/7/10), ‚’m, “ú–{ŹŽ™t‘Ÿ•aŠw‰ďŽGŽ 2021/5; 34 (1 Suppl): 94.

723416. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŹŽ™Šú”­Ç“Ť“Á”­Ťƒlƒtƒ[ƒ[ÇŒóŒQ (INS) ‚É‚¨‚Ż‚郊ƒcƒLƒVƒ}ƒu (RTX) “Š—^Œă‘J‰„Ť’áIgGŒŒÇ‚ĚƒŠƒXƒNˆöŽq‚ĚŒŸ“˘. –{“c@‹Ä, ŕ_“c@—¤, ăp@ˆęŽu, ‰eŽR‚ ‚łŽq, •yŠ~—El, ´…•ŕ”ü, ˆäŒű’q—m, ŽOă’ź˜N, Ô•ôŒhŽĄ, Ž›–ěçŽq, Œ´“c—ÁŽq, ŕ_č—SŽq, Î‘qŒ’Ži1, –{“c‰ëŒh, ”Ś’J_Žj (1ŹŽ™): ‘ć56‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2021/7/10), ‚’m, “ú–{ŹŽ™t‘Ÿ•aŠw‰ďŽGŽ 2021/5; 34 (1 Suppl): 105.

723417. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŹŽ™ƒXƒeƒƒCƒh’ďRŤƒlƒtƒ[ƒ[ÇŒóŒQ‚Ě•sŠŽ‘SŠ°‰đÇ—á‚É‚¨‚Ż‚é’ˇŠú—\Œă‚ĚŒŸ“˘. ‰eŽR‚ ‚łŽq, ŕ_“c@—¤, ˆî—t@Ę, ăp@ˆęŽu, ´…•ŕ”ü, •yŠ~—El, –{“c@‹Ä, Ô•ôŒhŽĄ, Ž›–ěçŽq, Œ´“c—ÁŽq, ŕ_č—SŽq, Î‘qŒ’Ži1, –{“c‰ëŒh, ”Ś’J_Žj (1ŹŽ™): ‘ć56‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2021/7/10), ‚’m, “ú–{ŹŽ™t‘Ÿ•aŠw‰ďŽGŽ 2021/5; 34 (1 Suppl): 107.

723418. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”A×ŠÇŠÔŽżŤt‰Š‚̉ü‘P‚Ü‚Ĺ‚ĚŒo‰ß‚Ć”A×ŠÇƒ}[ƒJ[‚̐„ˆÚ. ˆęŁ^”ü, Œ´“c—ÁŽq, ŕ_“c@—¤, •yŠ~—El, –{“c@‹Ä, ăp@ˆęŽu, ‰eŽR‚ ‚łŽq, ´…•ŕ”ü, Ô•ôŒhŽĄ, Ž›–ěçŽq, ŕ_č—SŽq, Î‘qŒ’Ži1, –{“c‰ëŒh, ”Ś’J_Žj (1ŹŽ™): ‘ć56‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2021/7/10), ‚’m, “ú–{ŹŽ™t‘Ÿ•aŠw‰ďŽGŽ 2021/5; 34 (1 Suppl): 119.

723419. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒlƒtƒƒ“ᔂɂ¨‚Ż‚étŠOÇó‚̍‡•š•p“x‚Č‚ç‚Ń‚ÉŽžŠú‚ĚŒŸ“˘. •yŠ~—El, ŕ_“c@—¤, ˆŔ”[‚ ‚‚ą, ăp@ˆęŽu, ‰eŽR‚ ‚łŽq, ´…•ŕ”ü, –{“c@‹Ä, Ô•ôŒhŽĄ, Ž›–ěçŽq, Œ´“c—ÁŽq, ŕ_č—SŽq, Î‘qŒ’Ži1, –{“c‰ëŒh, ”Ś’J_Žj (1ŹŽ™): ‘ć56‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2021/7/10), ‚’m, “ú–{ŹŽ™t‘Ÿ•aŠw‰ďŽGŽ 2021/5; 34 (1 Suppl): 126.

723420. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒGƒvƒXƒ^ƒCƒ“ÇŒóŒQ‚̐tśŒŸŠŒŠ‚Ć—Ő°Œo‰ß. ŽO‰YŒ’ˆę˜Y, ”’ˆä—zŽq, ‘ĺ’ˑ׎j, ‘ĺ˜a“c—tŽq, ‹g“c@W, “Œ@‹`l, źŽR@Œc, ŸŒł—˛—Y, ”‹´@ŠÂ, ŕ_“c@—¤, Î‘qŒ’Ži1, •ž•”ŒłŽj (1ŹŽ™): ‘ć56‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2021/7/10), ‚’m, “ú–{ŹŽ™t‘Ÿ•aŠw‰ďŽGŽ 2021/5; 34 (1 Suppl): 127.

723421. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) tˆÚAŒăÄ”­‚đ”F‚ß‚˝‘ƒó•ŞßŤŽ…‹…‘̍d‰ťÇ (FSGS) Ç—á‚ĚÄ”­ŽĄ—Ă”˝‰ž‚Ć’ˇŠút—\Œă‚ĚŒŸ“˘. ăp@ˆęŽu, ŕ_“c@—¤, ˛“Ą—T”V, Ž›–ěçŽq, Œ´“c—ÁŽq, Â–Ř—TŽŸ˜Y, ŕ_č—SŽq, Î‘qŒ’Ži1, ŽłŒË´ˆę˜Y, –{“c‰ëŒh, ”Ś’J_Žj (1ŹŽ™): ‘ć56‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2021/7/10), ‚’m, “ú–{ŹŽ™t‘Ÿ•aŠw‰ďŽGŽ 2021/5; 34 (1 Suppl): 131.

723422. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒlƒtƒ[ƒ[ÇŒóŒQ‚ɍ‡•š‚ľ‚˝”xŒŒđÇđÇ‚Ě’źÚŒoŒűR‹ĂŒĹ–ň (DOAC) ‚É‚ć‚鎥—Ð헪. Š@L–ç1,2, ˛“ĄL—m1, ‰Ą“ŕ‹ĹŽq2, ‰œ“c—Y‰î2, Šâ”g’ź”ü, ‘ĺŒF_], Žç‰Žr‰î, ’†‘şM–ç, ‰Íź‹Iş, Î‘qŒ’Ži2 (1‹~–˝, 2ŹŽ™): ‘ć56‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2021/7/10), ‚’m, “ú–{ŹŽ™t‘Ÿ•aŠw‰ďŽGŽ 2021/5; 34 (1 Suppl): 144.

723423. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ěč•aƒVƒ‡ƒbƒNÇŒóŒQœëŠłŒă‚ɐt‹@”\’ቺ‘Ź“x‚Ş2.8”{‚ɉÁ‘Ź‚ľ‚˝ć“VŤt”A˜HˆŮí‚Ě’jŽ™—á. •yŠ~—El, Œ´“c—ÁŽq, ŕ_“c@—¤, ăp@ˆęŽu, ‰eŽR‚ ‚łŽq, ´…•ŕ”ü, –{“c@‹Ä, Ô•ôŒhŽĄ, Ž›–ěçŽq, –{“c‰ëŒh, Î‘qŒ’Ži1, ”Ś’J_Žj (1ŹŽ™): ‘ć56‰ń“ú–{ŹŽ™t‘Ÿ•aŠw‰ďŠwpW‰ď (2021/7/10), ‚’m, “ú–{ŹŽ™t‘Ÿ•aŠw‰ďŽGŽ 2021/5; 34 (1 Suppl): 169.

723424. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) FontanpŒă‚̓Ť’`”’˜RoŤˆÝ’°Ç‚ւ̐V‚˝‚ČŽĄ—Ð헪: ƒVƒƒXƒ^ƒ][ƒ‹‚É‚ć‚éS–[’˛—Ľ‚ւ̉î“ü. “n糗ڔü1, –{“c@’1, ‚—œ@Šw1, –kě“ÄŽj1, –Ř‘şƒl1, •˝“c—zˆę˜Y1, ‹{’n@ŠÓ2, Î‘qŒ’Ži1 (1ŹŽ™, 2S‘ŸŒŒŠÇŠO): ‘ć57‰ń“ú–{ŹŽ™zŠÂŠíŠw‰ď‘‰ďEŠwpW‰ď (2021/7/9-11), “Ţ—Ç (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{ŹŽ™zŠÂŠíŠw‰ď‘‰ďEŠwpW‰ď´˜^W 2021/7; 57: OR24-2.

723425. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹}‘Ź‚É‘‘ĺ‚ľ‚˝ŒŒđ‚É‚ć‚č‹Ů‹}Žčp‚ÉŽŠ‚Á‚˝“Ž–ŹŠÇᎂ̐VśŽ™—á. ˆî–؏G‰p1, –kě“ÄŽj1, –{“c@’1, ‰Ş–{@’B1, •˝“c—zˆę˜Y1, ’†ź‰p•F1,2, ‹{’n@ŠÓ3, Î‘qŒ’Ži1 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[“Iˆă—Ă, 3S‘ŸŒŒŠÇŠO): ‘ć57‰ń“ú–{ŹŽ™zŠÂŠíŠw‰ď‘‰ďEŠwpW‰ď (2021/7/9-11), “Ţ—Ç (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{ŹŽ™zŠÂŠíŠw‰ď‘‰ďEŠwpW‰ď´˜^W 2021/7; 57: P1-3.

723426. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽOë•ŮäFő’f—ô‚đ‡•š‚ľ‚˝“űŽ™“Á”­Ť‘m–X•ŮäFő’f—ô—á‚Ě•a‘ԍlŽ@. ‚—œ@Šw1, i“Ąl—m, ‚ŒŠŕVKˆę, ŹŕV—Rˆß, —с@‘×—C, ŽOč‘׎u, ‹ŕŽqK—T, Ź–ě@”Ž, ‰ę“Ą@‹Ď (1ŹŽ™): ‘ć57‰ń“ú–{ŹŽ™zŠÂŠíŠw‰ď‘‰ďEŠwpW‰ď (2021/7/9-11), “Ţ—Ç (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723427. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‰ß‹Ž8”NŠÔ‚̐_“ŢěŒ§Œ§‰›–k‘Š’nˆć“ŕ‚É‚¨‚Ż‚éVśŽ™”Ŕ‘—‚Ě‚Ü‚Ć‚ß. ‘剪–ƒ—1, ’†źG•F1,2, Źă—T‰ŔŽq1, ŽRŒűˆť”T1, Î“c@Ži1, ‰ĄŠÖ—Sˆę˜Y1, çݎ@Šw1 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[“Iˆă—Ă): ‘ć57‰ń“ú–{ŽüŽYŠúEVśŽ™ˆăŠw‰ďŠwpW‰ď (2021/7/11-13), ‹{č (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723428. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Šw“śŠú‚É’B‚ľ‚˝’´‘ŽYŽ™‚̏AŠwó‹ľE‡•šÇ‚ɂ‚˘‚Ä‚ĚƒAƒ“ƒP[ƒgŒ‹‰Ę. çݎ@Šw1, ‘剪–ƒ—1, Î“c@Ži1, ŽRŒűˆť”T1, Źă—T‰ŔŽq1, ‰ĄŠÖ—Sˆę˜Y1, –ě“nł•F, ’†źG•F1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[“Iˆă—Ă): ‘ć57‰ń“ú–{ŽüŽYŠúEVśŽ™ˆăŠw‰ďŠwpW‰ď (2021/7/11-13), ‹{č (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723429. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) “űŽ™ŒŒŠÇŽî‚ɑ΂ľ‚ďCł34T‚Ĺƒvƒƒvƒ‰ƒmƒ[ƒ‹‚đŽg—p‚ľ‚˝’´‘ŽYŽ™—á. “ú‰ş•”ˆÇŽŃŒ\, ’†źG•F1,2, Źă—T‰ŔŽq2, ŽRŒűˆť”T2, Î“c@Ži2, ‘剪–ƒ—2, çݎ@Šw2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): ‘ć57‰ń“ú–{ŽüŽYŠúEVśŽ™ˆăŠw‰ďŠwpW‰ď (2021/7/11-13), ‹{č (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723430. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) śŒă72ŽžŠÔˆČ~‚É”­Ç‚ľ‚˝‹É’áoś‘̏dŽ™‚Ě”]Žş“ŕoŒŒ‚ɂ‚˘‚Ä72ŽžŠÔ–˘–ž”­Ç—á‚Ć‚Ě”äŠr. ŽRŒűˆť”T1, ’†źG•F1,2, Źă—T‰ŔŽq1, Î“c@Ži1, ‘剪–ƒ—1, ‰ĄŠÖ—Sˆę˜Y1, çݎ@Šw1 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[“Iˆă—Ă): ‘ć57‰ń“ú–{ŽüŽYŠúEVśŽ™ˆăŠw‰ďŠwpW‰ď (2021/7/11-13), ‹{č (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723431. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Ý‘Ů26T–˘–ž‚Ě’´‘ŽYŽ™‚Ě“Ž–ŹŠÇ•Â˝‘OŒă‚̏zŠÂ“Ž‘Ԃ̕ωť. Î“c@Ži1, Źă—T‰ŔŽq1, ŽRŒűˆť”T1, ‘剪–ƒ—1, çݎ@Šw1, ’†źG•F1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[“Iˆă—Ă): ‘ć57‰ń“ú–{ŽüŽYŠúEVśŽ™ˆăŠw‰ďŠwpW‰ď (2021/7/11-13), ‹{č (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723432. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) “–‰@‚É‚¨‚Ż‚éVśŽ™Ž€–SÇ—á‚ÉŠÖ‚ˇ‚錟“˘@_“ŢěŒ§VśŽ™Ž€–S“o˜^Ž–‹Ć‚ĚŠJŽn‚ÉŒü‚Ż‚˝Žć‚č‘g‚Ý. Źă—T‰ŔŽq1, ŽRŒűˆť”T1, Î“c@Ži1, ‘剪–ƒ—1, çݎ@Šw1, ’†źG•F1,2 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[“Iˆă—Ă): ‘ć57‰ń“ú–{ŽüŽYŠúEVśŽ™ˆăŠw‰ďŠwpW‰ď (2021/7/11-13), ‹{č (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723433. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‘˝Ę‚ȏǏó‚đ’ć‚ľ, f’f‚É“ďa‚ľ‚˝ƒVƒF[ƒOƒŒƒ“ÇŒóŒQ‚Ě14Î‚̏—Ž™—á. ]”gŒËF•ă (ŹŽ™): ‘ć30‰ń“ú–{ŹŽ™ƒŠƒEƒ}ƒ`Šw‰ďŠwpW‰ď (2021/10/15), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723434. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œă“VŤTTP‚đ‰”­Çó‚Ć‚ľ‚˝SLE‚Ě2Ç—á. ‹ŕŽq‰ë‹I1, ]”gŒËF•ă1, ‰œ“c—Y‰î1, Š@L–ç1,2, â“Œ—R‹I1, Î‘qŒ’Ži1 (1ŹŽ™, 2‹~–˝): ‘ć30‰ń“ú–{ŹŽ™ƒŠƒEƒ}ƒ`Šw‰ďŠwpW‰ď (2021/10/15-17), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723435. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) EIEE44: UBA5•ĎˆŮ‚É‚ć‚éíőF‘Ě—ňŤˆâ“`Ť‚Ä‚ń‚Š‚ńŤ”]Ç‚ĚŽo–…—á. ”’ˆäG’ź1, “yŠň@•˝1, –ěX“c–L1, –x‚ ‚ˇ‚Š2, ‰E“c‰¤‰î, `Œ’ˆę˜Y, Î‘qŒ’Ži1, ‚“cŽj’j2 (1ŹŽ™, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): “ú–{l—Ţˆâ“`Šw‰ď‘ć66‰ń‘ĺ‰ď/‘ć28‰ń“ú–{ˆâ“`Žqf—ĂŠw‰ď‘ĺ‰ď‡“ŻŠJĂ (2021/10/13-16), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723436. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”ľ‹š‚ƉşŽˆSk‚É‚ć‚č”rႃhƒŒƒi[ƒW‚É“ďa‚ľ‚˝1Ç—á. ‘ĺ‹ČłŽ÷, “ě–ě‰1 (1ŹŽ™): ‘ć53‰ń“ú–{ŹŽ™ŒÄ‹zŠíŠw‰ď (2021/10/22-23), WebŠJĂ.

723437. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚éć“VŤ’†•Ť–łŒÄ‹zÇŒóŒQÇ—á‚ɑ΂ˇ‚éCCHSŒÄ‹zƒ~ƒjƒhƒbƒN. “ě–ě‰ (ŹŽ™): ‘ć53‰ń“ú–{ŹŽ™ŒÄ‹zŠíŠw‰ď (2021/10/22-23), WebŠJĂ.

723438. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ECMO“ą“üŽžƒKƒCƒhƒƒCƒ„‚Ş–Ŕ“ü‚ľ‘Ň‹@“I‚ɏœ‹Ž‚đs‚Á‚˝‹}ŤS‹Ř‰Š1—Ž™—á. “c‘ş—C•˝1, ź‘şŘ•ä, ŠC˜VŒ´’źŽ÷, ’Ůˆä”Œ•F, “Ą–ě–ž_, ’†ě@‘ (1ŹŽ™): ‘ć49‰ń“ú–{‹~‹}ˆăŠw‰ď‘‰ďEŠwpW‰ď (2021/11/21-23), “Œ‹ž.

723439. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –{–M‚É‚¨‚Ż‚é‰ß‹Ž10”NŠÔ‚̏ŹŽ™“§ÍV‹K“ą“ü—Ś‚Ć—L•a—Ś|•Ä‘, ‰˘B, ƒIƒZƒAƒjƒA‚Ć‚Ě”äŠr|. ‰œ“c—Y‰î1, Œ´“c—ÁŽq, ŕ_“c@—¤, ŕ_č—SŽq, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć42‰ń“ú–{ŹŽ™t•s‘SŠw‰ďŠwpW‰ď (2021/12/9-10), WebŠJĂ.

723440. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) FontanzŠÂ‚É‚¨‚Ż‚é‘ĺ“Ž–Ź•Ů•Â˝•s‘S‚̏zŠÂ“Ž‘Ô‚É—^‚Ś‚é‰e‹ż. –kě“ÄŽj1, •˝“c—zˆę˜Y1, ‚—œ@Šw1, –{“c@’1, ‹{’n@ŠÓ2, Î‘qŒ’Ži1 (1ŹŽ™, 2S‘ŸŒŒŠÇŠO): ‘ć23‰ń“ú–{Źlć“VŤSŽžŠłŠw‰ď‘‰ďEŠwpW‰ď (2022/1/7-9), •Ÿ‰Ş.

723441. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽĄ—Ă‚É“ďa‚ľ‚Ä‚˘‚éHA20‚ɑ΂ˇ‚éJAK‘jŠQ–ň‚ĚŽg—pŒoŒą. ]”gŒËF•ă (ŹŽ™): ‘ć5‰ń“ú–{–Ɖu•s‘SEŽŠŒČ‰ŠÇŠw‰ď‘‰ďEŠwpW‰ď (2022/2/12), WebŠJĂ.

723442. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ŮŽ™Šú‚̏™–Ź‚đŒ_‹@‚É”­ŒŠ‚ł‚ę‚˝ƒ~ƒgƒRƒ“ƒhƒŠƒAS‹ŘÇ‚Ě1—á. “n糗ڔü1, –{“c@’1, •˝“c—zˆę˜Y1 (1ŹŽ™): ˆę”ĘŽĐ’c–@l“ú–{‘ŮŽ™S‘Ÿ•aŠw‰ď‘ć28‰ńŠwpW‰ď (2022/2/18-19), ź–{ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723443. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŹŽ™S‘ŸpŒă‚É‚¨‚Ż‚é• –Œ“§Í‚ĆPICUƒAƒEƒgƒJƒ€‚ĚŠÖ˜A. •ô”öŒb—œ1, ‰œ“c—Y‰î1, ˆŔ“Ą@Žő1, •˝“c—zˆę˜Y1, ‹{’n@ŠÓ2, Î‘qŒ’Ži1 (1ŹŽ™, 2S‘ŸŒŒŠÇŠO): ‘ć49‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ďŠwpW‰ď (2021/3/18), WebŠJĂ.

731010. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ˆÚsŠúŽx‰‡‚ĚŒťó‚Ɖۑč2021`ƒRƒƒi‰Đ‚đ’´‚Ś‚ā`. •˝“c—zˆę˜Y (ŹŽ™): ‘ć12‰ńěčŹŽ™zŠÂŠíƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2021/6/4), WebŠJĂ.

731011. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ŹŽ™zŠÂŠí“ŕ‰Č‚Ć‚ŕ‹¤—L‚ľ‚˝‚˘`VśŽ™f—ĂUp to Date`. ’†źG•F1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): ‘ć25‰ńă_ŹŽ™zŠÂŠíŽžŠłŒ¤‹†‰ď (2021/9/11), WebŠJĂ.

731012. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) –{–MŹŽ™CKD‚ĚŽŔ‘́|tˆÚA‚ŕŠÜ‚߂ā|. Î‘qŒ’Ži (ŹŽ™): ‘ć122‰ń–k—˘zŠÂŠíƒZƒ~ƒi[ (2021/10/21), WebŠJĂ.

732050. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰) ŒŠ“Ś‚ľ‚Ä‚Í‚˘‚Ż‚Č‚˘ŹŽ™‚̐_Œo‹ŘŽžŠł. –ěX“c–L (ŹŽ™): ‘ć449‰ń‘Š–ÍŒ´ŽsŹŽ™‰Čˆă‰ďŒŽ—፧˜b‰ď (2021/6/16), ‘Š–ÍŒ´.

732051. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰) SARS-CoV-2—Źs‰ş‚É‚¨‚Ż‚éRSƒEƒCƒ‹ƒX‚đŠÜ‚ŢNICUŠ´ő‘΍ô‚Ě•Ď‘J|“–‰@‚ĚŽć‚č‘g‚݁|. ’†źG•F1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): ƒAƒXƒgƒ‰ƒ[ƒlƒJŽĺĂPediatric TV Symposium (2021/10/26), “Œ‹ž.

732052. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (Žs–ŻŒöŠJuŔ) —c’t‰€EŠwZ‚Č‚Ç‚É‚¨‚Ż‚é‚Ä‚ń‚Š‚ń”­ě‚̑Ήž. –ěX“c–L (ŹŽ™): _“ŢěŒ§‚Ä‚ń‚Š‚ńˆă—ÁEŽĐ‰ď˜AŒg‹Ś‹c‰ď‚Ä‚ń‚Š‚ń‚ĚŒ¤C‰ď (2021/11/7), WebŠJĂ.

732053. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) ěč•a. ]”gŒËF•ă (ŹŽ™): ŠâŽčˆă‰Č‘ĺŠw•a‰@ŹŽ™‰Č‚ɂĐěč•a‚̍u‰‰ (2021/11/9), WebŠJĂ.

732054. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰) Œo’°‰h—{ŠÇ—’†‚ɈŸ‰”Œ‡–RÇ‚đ’ć‚ľ‚˝dÇSgáŠQŽ™ŽŇ‚Ěˆę—á. “n糖œ—t1, “yŠň@•˝1, ‹k“cˆę‹P1, “Ą•‹`ˆę, –ěX“c–L1, •˝“c—zˆę˜Y1, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć451‰ń‘Š–ÍŒ´ŽsˆăŽt‰ďŹŽ™‰Čˆă‰ďŒŽ—፧˜b‰ď (2021/11/10), ‘Š–ÍŒ´, Web.

732055. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰) ŹŽ™‚Ěƒlƒtƒ[ƒ[ÇŒóŒQ‚̐f—Á|ĹV‚ĚƒKƒCƒhƒ‰ƒCƒ“‚ÉŠî‚Ă‚˘‚ā|. Î‘qŒ’Ži (ŹŽ™): ‘ć46‰ń“Œ“ú–{ŹŽ™‰ČŠw‰ď (2021/11/23), WebŠJĂ.

732056. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łŽöA”Cu‰‰) ŹŽ™“Á”­Ťƒlƒtƒ[ƒ[ÇŒóŒQ: –{–M‚É‚¨‚Ż‚鎥—ĂŠJ”­Œ¤‹†‚ĆRegistry. Î‘qŒ’Ži (ŹŽ™): ‘ć47‰ń–k—˘ˆăŠw‰ď‘‰ď (2021/11/26), WebŠJĂ.

732057. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰) ‘S”Ę‚Ä‚ń‚Š‚ń‚ɂ‚˘‚Ä. “yŠň@•˝1, –ěX“c–L1, Î‘qŒ’Ži1 (1ŹŽ™): _“ސě‚Ä‚ń‚Š‚ńf—Ăƒlƒbƒgƒ[ƒN (2021/12/3), ‰Ą•l.

732058. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰) NICU Webinar PIƒJƒe[ƒeƒ‹Ç—á•ń‰ď. ’†źG•F1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): CardinalHealthŽĺĂ NICU Webinar PIƒJƒe[ƒeƒ‹Ç—á•ń‰ď (2021/12/4), WebŠJĂ.

732059. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰) “–‰@NICU‚É‚¨‚Ż‚éPIƒJƒe[ƒeƒ‹•ÂÇ‚ɂ‚˘‚Ä: ‹É’áoś‘̏dŽ™‚Ĺ‚ĚŒŸ“˘. ŽRŒűˆť”T1, ’†źG•F1,2, Źă—T‰ŔŽq1, Î“c@Ži1, ‘剪–ƒ—1 (1ŹŽ™, 2V˘‹Iˆă—ÁEć’[“Iˆă—Ă): CardinalHealthŽĺĂ NICU Webinar PIƒJƒe[ƒeƒ‹Ç—á•ń‰ď (2021/12/4), WebŠJĂ.

732060. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰) Neuromyelitis optca spectrum disorder (NMOSD) ŹŽ™—á‚ɑ΂ˇ‚éƒTƒgƒ‰ƒŠƒYƒ}ƒu‚ĚŽg—pŒoŒą. –ěX“c–L1, “yŠň@•˝1, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć63‰ń_“ސ쏬Ž™_Œo§˜b‰ď (2021/12/11), ěč.

732061. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) –{–MŹŽ™CKD ˘ŠE‚Ć‚Ě”äŠr‚ĹŒŠ‚Ś‚Ä‚Ť‚˝‰Ű‘č. Î‘qŒ’Ži (ŹŽ™): ‘ć5‰ń‰Ť“ꏬŽ™tEäPŒ´•aŒ¤‹†‰ď (2022/2/17), WebŠJĂ.

732062. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰) –ƉuŽžŠł‚̍l‚Ś•ű. ]”gŒËF•ă (ŹŽ™): “ú–{V–ňŽĺĂŽĐ“ŕ•×‹­‰ď (2022/3/1), WebŠJĂ.

732063. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰) ŹŽ™–ƉuŽžŠł‚đl‚Ś‚é‰ďin KANAGAWA. ]”gŒËF•ă (ŹŽ™): abbie‡“Ż‰ďŽĐŽĺĂJIA‚̐f’fEŽĄ—Ă (2022/3/22), WebŠJĂ.

732064. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒpƒlƒXƒfƒBƒXƒJƒbƒVƒ‡ƒ“) _“ŢěŒ§‚Ě“ď•aˆă—Ă˜AŒg‹’“_•a‰@‚ĚŒťó‚ĆŽó‚Ż“ü‚ę‘̐§. Î‘qŒ’Ži (ŹŽ™): ˆÚsŠúˆă—ĂŒ¤C‰ď (‚Š‚Č‚Ş‚íˆÚsŠúˆă—ĂŽx‰‡ƒZƒ“ƒ^[ŽĺĂ) (2022/3/23), WebŠJĂ.

733122. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ‹UŤ’áƒAƒ‹ƒhƒXƒeƒƒ“Ç‚Ş‹^‚í‚ę‚˝1‘ŽYŽ™—á. ź“cŽŽj (ŹŽ™): ‘ć448‰ń‘Š–ÍŒ´ŽsŹŽ™‰Čˆă‰ďŒŽ—፧˜b‰ď (2021/5/19), WebŠJĂ.

733123. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŽOë•ŮäFő’f—ô‚đ‡•š‚ľ‚˝“űŽ™“Á”­Ť‘m–X•ŮäFő’f—ô—á‚Ě•a‘ԍlŽ@. –{“c@’1, –kě“ÄŽj1, –Ř‘şƒl1, •˝“c—zˆę˜Y1, Ź–ě@”Ž, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć12‰ńěčŹŽ™zŠÂŠíƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2021/6/4), WebŠJĂ.

733124. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‹Ö‰Œ‚𐄐i‚ľ‚Ä‚˘‚éŒť‘ă‚É‚¨‚Ż‚éƒ^ƒoƒRŒëˆůÇ—á‚ĚŒťó. Ä“ĄŒł‹K, “ě–ě‰1 (1ŹŽ™): ‘ć152‰ń“ú–{ŹŽ™‰ČŠw‰ďĂ‰Ş’n•ű‰ď (2021/6/6), Ă‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733125. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ’×ᇐŤ‘ĺ’°‰Š‚ĚÄ”R‚ĆŠÓ•Ę‚đ—v‚ľ‚˝‹U–ŒŤ’°‰Š‚Ě13Î—Ž™—á. ˆî–؏G‰p1, ]”gŒËF•ă1 (1ŹŽ™): ‘ć365‰ń“ú–{ŹŽ™‰ČŠw‰ď_“ŢěŒ§’n•ű‰ď (2021/6/12), WebŠJĂ.

733126. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) BartterÇŒóŒQ. ‰œ“c—Y‰î (ŹŽ™): ‘ć56‰ńŹŽ™t‘Ÿ•aƒZƒ~ƒi[ (2021/7/9-10), ‚’m.

733127. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‹‘吅áv‚đŒ`Ź‚ľ‚˝”ń“TŒ^“I‘˝Œ`ŸřoŤg”Á‚Ě1—á. ‰Y“c‰č‹v”ü1,2, ˆî–؏G‰p1, ˛”Œ•q—ş2, â“Œ—R‹I1,2 (1ŹŽ™, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć184‰ń“ú–{ŹŽ™‰ČŠwé‹Ę’n•ű‰ďŠwpW‰ď (2021/9/12), WebŠJĂ.

733128. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) 1ƒ–ŒŽŒ’fŽž‚Ě‘hśŽ–Ű‚đŒ_‹@‚ɐf’f‚ł‚ę‚˝‘”xĂ–ŹŠŇ—ŹˆŮíÇ‚Ě1—á. “n糗ڔü1, –{“c@’1, •˝“c—zˆę˜Y1 (1ŹŽ™): ‘ć366‰ń“ú–{ŹŽ™‰ČŠw‰ď_“ŢěŒ§’n•ű‰ď (2021/9/18), WebŠJĂ.

733129. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “ú—î28–Ť”xŽžŠł‚đ‡•š‚ľ‚˝’´‘ŽYŽ™‚É‚¨‚Ż‚é‹}ŤŠúˆČ~‚ĚˆęŽ_‰ť’‚‘f‹z“ü—Ă–@‚ĚŒř‰Ę: 2003-2016”N‚É‚¨‚Ż‚éŽüŽYŠúVśŽ™ƒlƒbƒgƒ[ƒNƒf[ƒ^ƒx[ƒX‚đ—p‚˘‚˝Œă•űŽ‹“IƒRƒz[ƒgŒ¤‹†. ’†źG•F1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2ŹŽ™): ‘ć33‰ń“ú–{VśŽ™–Ť”xŽžŠłŒ¤‹†‰ď (2021/10/9), WebŠJĂ.

733130. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‰đ–UŠw“IC•œŽčp‚đŽ{s‚ľ‚˝Cł‘ĺŒŒŠÇ“]ˆĘ‚Ě2—á. –kě“ÄŽj1, ‚—œ@Šw1, –{“c@’1, Ž­“c•śş1, •˝“c—zˆę˜Y1, ‹{’n@ŠÓ2, Î‘qŒ’Ži1 (1ŹŽ™, 2S‘ŸŒŒŠÇŠO): ‘ć17‰ń_“ސ쏬Ž™zŠÂŠíŒ¤‹†‰ď (2021/11/6), ‰Ą•l.

733131. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŠwZŒ’f‚đ‚Ť‚Á‚Š‚Ż‚ɉƑ°ŤŽá”N”­Ç“œ”A•a5Œ^ (MODY5) ‚đ‹^‚Á‚˝1—á. ěŒű—SŽk, ‰œ“c—Y‰î1, ‹k“cˆę‹P1, Š@L–ç1,2, •˝“c—zˆę˜Y1, Î‘qŒ’Ži1 (1ŹŽ™, 2‹~–˝): ‘ć367‰ń“ú–{ŹŽ™‰ČŠw‰ď_“ސě’n•ű‰ď (2021/11/20), WebŠJĂ.

733132. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ƒlƒtƒƒ“á”. ‰œ“c—Y‰î (ŹŽ™): ŹŽ™t‘Ÿ•aƒZƒ~ƒi[ (2021/12/4), •lź.

733133. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Œă“VŤTTP‚Ĺ”­Ç‚ľ‚˝SLE—Žq‚Ěˆę—á. ‘ž“c‚Ü‚č1, ]”gŒËF•ă1 (1ŹŽ™): “Œ‹ž_“ސ쏬Ž™tƒZƒ“ƒ^[‚̉ď (2022/1/6), WebŠJĂ.

733134. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ŹŽ™t—Ěˆć‚̩󏭁E“ŤŽžŠłŒQ‚̐f—ÁEŒ¤‹†‘̐§‚Ě”­“W. Î‘qŒ’Ži (ŹŽ™): —ߘa3”N“xJSNŒö“IŒ¤‹†”ÇŒ¤‹†Ź‰Ę‡“Ż”­•\‰ď (2022/1/30), WebŠJĂ.

733135. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒWƒAƒmƒbƒeƒBÇŒóŒQ‚ĆŠÓ•Ę‚É“ďa‚ľ‚˝ěč•a‚Ě1’jŽ™—á. ’ź‹{‹ż•˝1, ]”gŒËF•ă1 (1ŹŽ™): ‘ć17‰ń_“ސěěč•aŒ¤‹†‰ď (2022/2/5), WebŠJĂ.

733136. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “]‘—”Ŕ‘—Žó‚Ż“ü‚ę‚É‚¨‚Ż‚éˆŔ‘SŠÇ—. “n糖œ—t1, •ô”öŒb—œ1, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć368‰ń“ú–{ŹŽ™Šw‰ď_“ސě’n•ű‰ď (2022/2/19), WebŠJĂ.

733137. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “űŽ™Šú‚É‘Ěd‘‰Á•s—Ç‚Š‚çf’f‚ł‚ę‚˝Lesh-NyhanÇŒóŒQ‚Ěˆę’jŽ™—á. ’ź‹{‹ż•˝1, ‹k“cˆę‹P1, –Ř‘şƒl1, ’†‘ş^‹I1, Ž–ě@Žő1, “Ą–{‚Ü‚ä1, ™›Ž@Šw1 (1ŹŽ™): ‘ć369‰ń“ú–{ŹŽ™‰ČŠw‰ď_“ŢěŒ§’n•ű‰ď (2022/3/12), WebŠJĂ.

733138. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ‘̏d‘‰Á•s—Ç‚Š‚ç”­ŒŠ‚ł‚ę‚˝Lesch-NyhanÇŒóŒQ‚Ěˆę—á. ’ź‹{‹ż•˝1, ‹k“cˆę‹P1, –Ř‘şƒl1, ’†‘ş^‹I1, Ž–ě@Žő1, “Ą–{‚Ü‚ä1, çݎ@Šw1 (1ŹŽ™): ‘ć369‰ń“ú–{ŹŽ™‰ČŠw‰ď_“ŢěŒ§’n•ű‰ď (2022/3/12), ‰Ą•l.

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'18-530001. [‚ť‚Ě‘ź (Correction)] Correction to: Validation of estimated glomerular filtration rate equations for Japanese children. Gotoh Y, Uemura O, Ishikura K1, Sakai T, Hamasaki Y, Araki Y, Hamada R, Honda M, Pediatric CKD Study Group in Japan in conjunction with the Committee of Measures for Pediatric CKD of the Japanese Society of Pediatric Nephrology: Clin Exp Nephrol 2018/12; 22 (6): 1477. (Î‘qŒ’Ži1: 1ŹŽ™)

'20-320002. [Ç—á•ń] ŹŽ™Šú‚É”­Ç‚ľ‚˝microgeodric disease‚Ě2Ç—á. ]”gŒËF•ă (ŹŽ™): ”畆•af—Ă 2021/3; 43 (3): 260-3.

[Šw‰ďEŒ¤‹†‰ď“™]

'20-723027. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‚š‚ń–ςɑ΂ľ‚Ä“Ž•¨‰îÝ—Ă–@‚đŠˆ—p‚ľ‚˝ˆę—á. Îŕ_’q“Ţ”ü1, ŽR–{G–ž1, ‹Ŕ’돎Žq1, ă@•ä1, ŒKŒ´Œc‘ž1, ‘ĺŠŃ–ƒ”ü1, â“Œ—R‹I1,2 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2ŹŽ™): ‘ć40‰ń“ú–{ŽĐ‰ď¸_ˆăŠw‰ď (2021/3/4-5), WebŠJĂ, “ú–{ŽĐ‰ď¸_ˆăŠw‰ďŽGŽ 2021; 30 (3): 295.

'20-732004. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰) RAISE study‚ÉŠî‚Ă‚˘‚˝PSL“ą“üŒă‚ɓśŒo‰ß‚đ‚˝‚Ç‚Á‚˝ěč•a‚ւ̉î“ü. ‹ŕŽq‰ë‹I1, ]”gŒËF•ă1 (1ŹŽ™): ‘ć16‰ń_“ŢěŒ§ěč•aŒ¤‹†‰ď (2021/2/13), ’Ź“c.

'20-733011. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “]‘—”Ŕ‘—Žó‚Ż“ü‚ę‚É‚¨‚Ż‚éˆŔ‘SŠÇ—. “n糖œ—t1, •ô”öŒb—œ1, Î‘qŒ’Ži1 (1ŹŽ™): ‘ć368‰ń“ú–{ŹŽ™Šw‰ď_“ސě’n•ű‰ď (2021/2/19), WebŠJĂ.


ŽY‰ČŠw

[Šwp˜_•ś]

120012. [Œ´’˜] ’oŠÉoŒŒÇ—á‚É‚¨‚Ż‚é‘ĺ—Ę—AŒŒ‚Ě—\‘ވöŽq‚ÉŠÖ‚ˇ‚錟“˘. ’†‹ŕ˜NŽq1, –]ŒŽƒŽq1, ‘吟—fŽq1, •ž•”‹żŽq1, ‹g‘ş‰ĂL1, ŠÖŒű˜aŠé1, ‹ŕˆä—Y“ń1, ŠC–ěM–ç1 (1ŽY‰Č): “ú–{ŽüŽYŠúEVśŽ™ˆăŠw‰ďŽGŽ 2021/5; 57 (1): 19-25.

522522. [uŔ]y“ÁW: Ç—á‚Ƀ}ƒbƒ`‚ˇ‚é•Ş•Ř—U”­ƒAƒvƒ[ƒ`z8. –ł’ÉŒv‰ć•Ş•Ř‚É‚¨‚Ż‚é•Ş•Ř—U”­‚Ě—ŻˆÓ“_. ‹ŕˆä—Y“ń (ŽY‰Č): ŽY•wl‰Č‚ĚŽŔŰ 2021/4; 70 (4): 407-13.

522523. [uŔ]y“ÁWNEO Speciality: withƒRƒƒiŽž‘ă‚ɍčl‚ˇ‚é@Œťę‚ĹŽg‚Ś‚é! NICU‚Ĺ‚ĚŠ´ő‘΍ôQ•Az1. ƒRƒƒiƒEƒCƒ‹ƒXĹV‚ĚƒGƒrƒfƒ“ƒXQ&A: ŽY‰Č•Ň. •ž•”‹żŽq (ŽY‰Č): with NEO 2021/6; 34 (3): 412-9.

522524. [uŔ]y“ÁW: ŽY•wl‰Č? “­‚Ť•ű‰üŠv‚Ö‚Ěƒ[ƒhƒ}ƒbƒvzuˆă—ÉüŠvˆĎˆő‰ďv‚Ć‚ľ‚ÄŒŠ‚Ä‚Ť‚˝‚ą‚Ć. ŠC–ěM–ç (ŽY‰Č): ŽY•wl‰Č‚ĚŽŔŰ 2022/1; 71 (1): 9-2.

[’˜@‘]

620093. [Šwp‘ (•Ş’SŽˇ•M)]yŽüŽYŠúˆăŠw•KC’mŽŻ ‘ć9”Ĺ (ŽüŽYŠúˆăŠw2021”N51ŠŞ‘Š§†)zIII •Ş•ŘEŽYĺń@[ŽY‰ČˆŮíEŽžŠł]@096 œ”ŐˆĘ, p.325-7. ‹ŕˆä—Y“ń (ŽY‰Č), “Œ‹žˆăŠwŽĐ, “Œ‹ž, 2022/1”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

721012. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) VŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´őÇ‚đ“Ľ‚Ü‚Ś‚˝ĐŠQ‘Ήž. ŠC–ěM–ç (ŽY‰Č): ‘ć73‰ń“ú–{ŽY‰Č•wl‰ČŠw‰ďŠwpu‰‰‰ď (2021/4/22-25), VŠƒ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

721013. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) –ł’É•Ş•Ř‚ĚˆŔ‘SŤŒüă‚Ě‚˝‚ß‚É-–ł’É•Ş•ŘŠÖŒWŠw‰ďE’c‘Ě˜A—‹Ś‹c‰ď (JALA) ‚ĚŠˆ“Ž•ń (2021”N“x)-. ŠC–ěM–ç (ŽY‰Č): ‘ć125‰ń“ú–{ŽY‰Č–ƒŒŠw‰ďŠwpW‰ď (2021/12/4), –źŒĂ‰Ž (ƒnƒCƒuƒŠƒbƒgŠJĂ).

722158. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yŽY‰Č‹~‹}WGŠé‰ćzŽY‰ČŠë‹@“IoŒŒ‚ɑ΂ˇ‚鎥—Ð헪‚ĚˆÓŽvŒˆ’č‚Ć‚ť‚ĚŽŔ‘H. ‘吟—fŽq1, ŽRč@—D1, ‹g‘ş‰ĂL1, ŠÖŒű˜aŠé1, ‹ŕˆä—Y“ń1, ŠC–ěM–ç1 (1ŽY‰Č): ‘ć125‰ń“ú–{ŽY‰Č–ƒŒŠw‰ďŠwpW‰ď (2021/12/4), –źŒĂ‰Ž (ƒnƒCƒuƒŠƒbƒgŠJĂ).

723444. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) TAFROÇŒóŒQœëŠłŒă‚ÉŽŠ‘R”DP‚ľ‚˝1—á. ŽRč@—D1, ‘吟—fŽq1, ‹g‘ş‰ĂL1, •ž•”‹żŽq1, ’†‹ŕ˜NŽq1, ŠÖŒű˜aŠé1, Îě—˛ŽO1, ‹ŕˆä—Y“ń1, –]ŒŽƒŽq, ŠC–ěM–ç1 (1ŽY‰Č): ‘ć73‰ń“ú–{ŽY‰Č•wl‰ČŠw‰ďŠwpu‰‰‰ď (2021/4/22-25), VŠƒ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723445. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Žq‹{“ŕ–ŒÇ‚É‚¨‚Ż‚郊ƒ“ƒpŠÇVś‚đ§Œä‚ˇ‚éVEGFR1ƒVƒOƒiƒ‹‚Ě–đŠ„. •ž•”‹żŽq1, ˆÉ“Ą‹`–ç2, –{“c‰ëŽq3, ŠÖŒű˜aŠé1, ŠC–ěM–ç1 (1ŽY‰Č, 2–ň—, 3•wl): ‘ć73‰ń“ú–{ŽY‰Č•wl‰ČŠw‰ďŠwpu‰‰‰ď (2021/4/22-25), VŠƒ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723446. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “–Ž{Ý‚É‚¨‚Ż‚鑁ŽYVśŽ™‚Ě—\Œă (The prognosis of preterm infants at our institution). ŒÜ“‡—T”V1, –]ŒŽƒŽq, źŕVW‘ă1, źŽRD1, VˆäłG2, –]ŒŽˆ¤˜Y, ‹gŒ´@ˆę, ŠC–ěM–ç1 (1ŽY‰Č, 2•wl): ‘ć73‰ń“ú–{ŽY‰Č•wl‰ČŠw‰ďŠwpu‰‰‰ď (2021/4/22-25), VŠƒ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723447. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ”DP’†‚É”­Ç‚ľ‚˝‹}Ť”’ŒŒ•a‚Ě3—á. ŽRč@—D1, ŠÖŒű˜aŠé1, ‹g‘ş‰ĂL1, •ž•”‹żŽq1, ’†‹ŕ˜NŽq1, ‘吟—fŽq1, Îě—˛ŽO1, ‹ŕˆä—Y“ń1, ŠC–ěM–ç1 (1ŽY‰Č): ‘ć57‰ń“ú–{ŽüŽYŠúEVśŽ™ˆăŠw‰ďŠwpW‰ď (2021/7/11-13), ‹{č (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723448. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) oś‘̏d‚ɉe‹ż‚đ—^‚Ś‚é•ę‘Ě—vˆö‚ĚŒŸ“˘. źŽRD1, ‹gŒ´@ˆę, ŒÜ“‡—T”V1, ŽRč@—D1, źŕVW‘ă1, –]ŒŽƒŽq, ŠC–ěM–ç1 (1ŽY‰Č): ‘ć57‰ń“ú–{ŽüŽYŠúEVśŽ™ˆăŠw‰ďŠwpW‰ď (2021/7/11-13), ‹{č (ƒnƒCƒuƒŠƒbƒhŠJĂ).

731013. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) –k—˘‘ĺŠw‚Ĺ‚Ě17”NŠÔ‚ĹŠw‚ń‚ž‚ą‚Ć. ŠC–ěM–ç (ŽY‰Č): ‘Š–ÍŒ´ŽsŽY•wl‰Čˆă‰ďEŽq‹{‚Ş‚ńŒŸf•”‰ď‡“ŻŒ¤C‰ď (2022/2/15), WebŠJĂ.

732065. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (uK‰ďŽĺĂ) J-CIMELSŒö”FuK‰ďB. •ž•”‹żŽq (ŽY‰Č): J-CIMELSŒö”FuK‰ďB (2021/11/7), ‘Š–ÍŒ´.

732066. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒXƒ|ƒ“ƒT-ƒhƒZƒ~ƒi[) Œv‰ć•Ş•Ř, –ł’É•Ş•Ř, ’鉤ŘŠJp-ćl‚Ě’mŒb‚ĆŒť‘ă‹Zp‚Ě—Z‡-. ‹ŕˆä—Y“ń (ŽY‰Č): ‘ć142‰ńŠÖ“Œ˜A‡ŽY‰Č•wl‰ČŠw‰ď‘‰ďEŠwpW‰ď (2021/11/21), ‰Ą•l.

733139. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) VŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´ő‚É‚¨‚Ż‚é”DŽY•w‚ւ̑Ήžó‹ľ‚ɂ‚˘‚Ä. •ž•”‹żŽq (ŽY‰Č): Œ§‰›–k‘ŠƒuƒƒbƒN‘ć106‰ńŽüŽYŠú‹~‹}˜A—‰ď (2021/6/10), WebŠJĂ.

733140. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŽY‰Č‹~‹}”Ŕ‘—Ç—á•ń. ŒÜ“‡—T”V (ŽY‰Č): Œ§‰›E–k‘Š’n‹ćŽüŽYŠú‹~‹}ŒŸ“˘‰ď (2021/6/17), WebŠJĂ.

733141. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) VŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´ő”D•w‚ւ̑Ήž‚ĚŒťó‚ɂ‚˘‚Ä. ŠC–ěM–ç (ŽY‰Č): Œ§‰›E–k‘Š’n‹ćŽüŽYŠú‹~‹}ŒŸ“˘‰ď (2021/6/17), WebŠJĂ.

733142. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “–‰@‚Ĺ‚ĚCOVID-19”D•w‚ւ̑Ήž. Žž”CňŒÎ1, •ž•”‹żŽq1, ŒÜ“Ą—T”V1, ŽRč@—D1, ’†‹ŕ˜NŽq1, ŠÖŒű˜aŠé1, Îě—˛ŽO1, ‘吟—fŽq1, ‹ŕˆä—Y“ń1, ŠC–ěM–ç1 (1ŽY‰Č): ‘ć384‰ńŽl…‰ď (2021/6/23), WebŠJĂ.

733143. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) —ŹŽYŠú‚Š‚ç‚Ě‘OŠú”j…‚ŐśŽ™‚đ“ž‚˝ˆę—á. ‰Şč‰Ŕ“ŢŽq, ŽRč@—D1, ŒÜ“‡—T”V1, •ž•”‹żŽq1, ’†‹ŕ˜NŽq1, ŠÖŒű˜aŠé1, Îě—˛ŽO1, ‘吟—fŽq1, ‹ŕˆä—Y“ń1, ŠC–ěM–ç1 (1ŽY‰Č): ‘ć433‰ń_“ސěŽY‰Č•wl‰ČŠw‰ď‘‰ďŠwpu‰‰‰ď (2021/7/3-9), WebŠJĂ.

733144. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‘}ŠÇŠÇ—‘O‚É•Řo‚đl—ś‚ľ‚˝”DP26T‚Ěˆę—á. ŕ_“c“Ţ”ü1, ‘吟—fŽq1, ˆ˘•”@‰1, ŠÖŒű˜aŠé1, ‹ŕˆä—Y“ń1, ŠC–ěM–ç1 (1ŽY‰Č): ‘ć385‰ńŽl…‰ď (2021/11/17), WebŠJĂ.

733145. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ”DP26T‚É‹CŠÇ‘}ŠÇŠÇ—‚Ć‚Č‚č, “Ż“ú‚ɒ鉤ŘŠJ‚đŽ{s‚ľ‚˝COVID-19dÇ—á. ŠÖŒű˜aŠé (ŽY‰Č): ‘ć107‰ń_“ŢěŒ§ŽüŽYŠú‹~‹}˜A—‰ď (2021/11/18), WebŠJĂ.

733146. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) RMDA5R‘Ě—zŤ”畆‹Ř‰Š‡•š”DP‚Ěˆę—á. ŒÜ“‡—T”V1, ŽRč@—D1, •ž•”‹żŽq1, ’†‹ŕ˜NŽq1, ŠÖŒű˜aŠé1, Îě—˛ŽO1, ‘吟—fŽq1, ‹ŕˆä—Y“ń1, ŠC–ěM–ç1 (1ŽY‰Č): ‘ć142‰ńŠÖ“Œ˜A‡ŽY‰Č•wl‰ČŠw‰ď‘‰ďEŠwpW‰ď (2021/11/20), ‰Ą•l.

733147. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ’ág’ˇ”D•w‚͒鉤ŘŠJ‚É‚Č‚é‚ą‚Ć‚Ş‘˝‚˘‚Ě‚Š? •˝“cŠxŽj1, –]ŒŽƒŽq, ‹g‘ş‰ĂL1, źŕVW‘ă1, źŽRD1, –]ŒŽˆ¤˜Y, ‘ĺ–ě@•×, VˆäłG2, ă–V•qŽq, ‹gŒ´@ˆę, ŠC–ěM–ç1 (1ŽY‰Č, 2•wl): ‘ć142‰ńŠÖ“Œ˜A‡ŽY‰Č•wl‰ČŠw‰ď‘‰ďEŠwpW‰ď (2021/11/20), ‰Ą•l.


•wl‰ČŠw

[Šwp˜_•ś]

110324. [Œ´’˜] A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis. Ishikawa M, Shibata T, Iwata T, Nishio S, Takada T1, Suzuki S, Horie K, Kudaka W, Kagabu M, Tanikawa M, Kitagawa R, Takekuma M, Kobayashi H, Yaegashi N, Japan Clinical Oncology Group: Gynecol Oncol 2021/8; 162 (2): 292-8. (‚“c‹ąb1: 1•wl)

320005. [Ç—á•ń] —‘‘ƒŠŕÄ”­‰ťŠw—Ă–@’†‚É”­Ç‚ľ‚˝ƒjƒ…[ƒ‚ƒVƒXƒ`ƒX”x‰Š‚Ěˆę—á. Žž”CňŒÎ1, ŠâŁtŽq1, ’†‘şŠîŠ°1, ‰““Ą^ˆę1, ŒĂěł‹`1, ‘吟ŒŤl1, “cŽG—L‹I1, ‚“c‹ąb1, VˆäłG1, ‹g–ě@C1, ‰ś“c‹MŽu1 (1•wl): “ú–{•wl‰ČŽîᇊw‰ďŽGŽ 2021/4; 39 (2): 549-56.

320006. [Ç—á•ń] äNă÷ŒeŽş‚Ě‚˝‚ß’Ęí‚Ć‚ÍˆŮ‚Č‚éˆĘ’u‚Ě”AŠÇ‚ɏ\•Ş‚Č’ˆÓ‚đ•Ľ‚Á‚ÄŠŽ‹‚Ĺ‚Ť‚˝• o‹ž‰şŽq‹{‘S“Ep (TLH) ‚Ě1—á. ’J@‘ě–ç1,2, “‡‰Ş‹ś1,2, ‰iˆä@’1, ‹g“cW‘ĺ1, ˆÉ“ĄŽŔ1,3, Šâ’[r•ă1,3, ‹v“ˆ‘Ľs1, ŽO–Ř–ž“ż1,2 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2ŽY‰Č, 3•wl): é‹ĘŽY‰Č•wl‰ČŠw‰ďŽGŽ 2022; 52 (1): 1-7.

521004. [‰đŕ] —‘‘ƒŠŕE—‘ŠÇŠŕE• –ŒŠŕ‚ĚŽčp‚ÉŠÖ‚ˇ‚éĹ‹ß‚ĚƒGƒrƒfƒ“ƒX. ŠâŁtŽq (•wl): “ú–{•wl‰ČŽîᇊw‰ďŽGŽ 2021/10; 39 (4): 723-33.

522525. [uŔ]y“ÁW: ­Žq‰ťŽž‘ă‚É‚¨‚Ż‚éA˜J—Ť‚Ě•s”DŽĄ—Áz3. A˜J—Ť‚Ěˆę”Ę•s”DŒŸ¸EŽĄ—ĂƒXƒPƒWƒ…[ƒ‹. ‰Ź–ě‹|ŠóŽq, Šâ’[r•ă1, ‹g–ě@C1,2 (1•wl, 2ŽY‰Č): ŽY‰Č‚Ć•wl‰Č 2021/12; 88 (12): 1407-14.

[Šw‰ďEŒ¤‹†‰ď“™]

723449. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Distinct functions of uterine epithelial and stromal STAT3 orchestrate uterine receptivity and embryo attachment. •˝‰Ş‹B‘ĺ1, Hirota Y, Fukui Y, Hirata T, Akaeda S, Matsuo M, ŠâŁtŽq1, ‹g–ě@C1,2, ŠC–ěM–ç2, Fujii T, Osuga Y (1•wl, 2ŽY‰Č): ‘ć73‰ń“ú–{ŽY‰Č•wl‰ČŠw‰ďŠwpu‰‰‰ď (2021/4/22-25), VŠƒ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723450. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Žq‹{“ŕ–ŒÇŤ”X–E‚ĚŠÓ•Ę‚É‚¨‚Ż‚éMRI IDEAL IQ‚Ě—L—pś‚ɂ‚˘‚Ä‚ĚŒŸ“˘. ŒĂ]–žŽq1, •˝“c‹B‘ĺ1, –{“c‰ëŽq1, Šâ’[r•ă1, ‹g–ě@C1,2, ŠâŁtŽq1, ŠC–ěM–ç2 (1•wl, 2ŽY‰Č): ‘ć73‰ń“ú–{ŽY‰Č•wl‰ČŠw‰ďŠwpu‰‰‰ď (2021/4/22-25), VŠƒ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723451. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) RAMP1Žó—e‘ĚƒVƒOƒiƒ‹‚É‚ć‚éŽq‹{“ŕ–ŒÇi“W§Œä‹@\. –{“c‰ëŽq1, ˆÉ“Ą‹`–ç2, •ž•”‹żŽq3, ŠÖŒű˜aŠé3, ‹g–ě@C1,3, ŠâŁtŽq1, ŠC–ěM–ç3 (1•wl, 2–ň—, 3ŽY‰Č): ‘ć73‰ń“ú–{ŽY‰Č•wl‰ČŠw‰ďŠwpu‰‰‰ď (2021/4/22-25), VŠƒ (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723452. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) pŒă‚ɍĔ­’†ƒŠƒXƒNŒQ‚Ć•]‰ż‚ł‚ę‚˝Žq‹{čňŠŕÇ—á‚Ě—Ő°“IŒŸ“˘. ŒĂěł‹`1, ’†‘şŠîŠ°1, ‰““Ą^ˆę1, ‘吟ŒŤl1, “cŽG—L‹I1, ‚“c‹ąb1, ‹g–ě@C1,2, ŠâŁtŽq1 (1•wl, 2ŽY‰Č): ‘ć63‰ń“ú–{•wl‰ČŽîᇊw‰ďŠwpu‰‰‰ď (2021/7/16-18), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723453. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚ĹOlaparib‚đ“Š—^‚ľ‚˝ƒvƒ‰ƒ`ƒiŠ´ŽóŤÄ”­—‘‘ƒŠŕŠłŽŇ‚Ě—LŠQŽ–Ű‚ĚŒŸ“˘. ’†‘şŠîŠ°1, ‚“c‹ąb1, ’J@‘ě–ç1, ‰““Ą^ˆę1, ŒĂěł‹`1, ‘吟ŒŤl1, “cŽG—L‹I1, ‹g–ě@C1,2, ŠâŁtŽq1 (1•wl, 2ŽY‰Č): ‘ć63‰ń“ú–{•wl‰ČŽîᇊw‰ďŠwpu‰‰‰ď (2021/7/16-18), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723454. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚̍‚—î•wl‰ČŽîᇊłŽŇ‚ɑ΂ˇ‚鍂—îŽŇ‹@”\•]‰ż‚Ě“ą“ü. ‰““Ą^ˆę1, ’†‘şŠîŠ°1, ŒĂěł‹`1, ‘吟ŒŤl1, “cŽG—L‹I1, ‚“c‹ąb1, ‹g–ě@C1,2, ŠâŁtŽq1 (1•wl, 2ŽY‰Č): ‘ć63‰ń“ú–{•wl‰ČŽîᇊw‰ďŠwpu‰‰‰ď (2021/7/16-18), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723455. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚Ěƒƒ{ƒbƒgŽx‰‡‰şŽq‹{‘ĚŠŕŽčp“ą“ü‰Šú10Ç—á‚É‚¨‚Ż‚éˆŔ‘SŤ‚Ě•]‰ż. ŠâŁtŽq1, ‘吟ŒŤl1, ’†‘şŠîŠ°1, ‰““Ą^ˆę1, ŒĂěł‹`1, ‚“c‹ąb1, ‹g–ě@C1,2, ‰Á“ĄˆęŠě1 (1•wl, 2ŽY‰Č): ‘ć14‰ń“ú–{ƒƒ{ƒbƒgŠO‰ČŠw‰ďŠwpW‰ď (2022/2/26-27), WebŠJĂ.

723456. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚é•wl‰Č—ǐŤŽžŠł‚ɑ΂ˇ‚郍ƒ{ƒbƒgŽx‰‡‰şŽčp‚Ě“ą“ü. ŒĂěł‹`1, ŠâŁtŽq1, ’†‘şŠîŠ°1, ‰““Ą^ˆę1, ‘吟ŒŤl1, ‚“c‹ąb1, ‹g–ě@C1,2, ‰Á“ĄˆęŠě1 (1•wl, 2ŽY‰Č): ‘ć14‰ń“ú–{ƒƒ{ƒbƒgŠO‰ČŠw‰ďŠwpW‰ď (2022/2/26-27), WebŠJĂ.

731014. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) •wl‰Č‚Ş‚ńŽĄ—Ă‚ĚĄŒă‚Ě“WŠJ. ‰Á“ĄˆęŠě (•wl): ‘Š–ÍŒ´ŽsŽY•wl‰Čˆă‰ďŠwpu‰‰‰ď (2021/9/16), WebŠJĂ.

731015. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) •wl‰Č—LjŤŤŽîᇂɑ΂ˇ‚é‹žŽ‹‰şŽčp‚Ě“W–]. ‰Á“ĄˆęŠě (•wl): ‘Š–ÍŒ´ŽsŽY•wl‰Čˆă‰ďŠwpu‰‰‰ď (2021/12/9), WebŠJĂ.

731016. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) —ߘa2”N“x”­ŒŠŽq‹{‚Ş‚ńÇ—á. ‰Á“ĄˆęŠě (•wl): ‘Š–ÍŒ´ŽsŽY•wl‰Čˆă‰ďEŽq‹{‚Ş‚ńŒŸf•”‰ď‡“ŻŒ¤C‰ď (2022/2/15), WebŠJĂ.

733148. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) Žq‹{“ŕ–Œäɔ–‚ɑ΂ľPRP (Platelet Rich Plasma‘˝ŒŒŹ”ÂŒŒŸ÷) —Ă–@‚đs‚˘”DPŒp‘ą‚Ĺ‚Ť‚˝2Ç—á. ‰ş“c—˛m (•wl): ‘ć62‰ńé‹ĘŒ§ŽY•wl‰Čˆă‰ďƒzƒ‹ƒ‚ƒ“‚ƐśBˆăŠwŒ¤‹†‰ď (2021/7/10), é‹Ę.

733149. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‚“x‚ɐΊD‰ť‚ľ‚˝Ÿ÷–Œ‰ş‹ŘŽî‚ŞŒ´ˆö‚ƍl‚Ś‚ç‚ę‚˝Žq‹{”P“]‚Ě1—á. ŕ_“c“Ţ”ü1, ŒĂěł‹`1, ”ö•űšŒŽ1, ˆ˘•”@‰1, ’†‘şŠîŠ°1, ‰““Ą^ˆę1, ŠâŁtŽq1, ‰Á“ĄˆęŠě1 (1•wl): ‘ć142‰ńŠÖ“Œ˜A‡ŽY‰Č•wl‰ČŠw‰ď‘‰ďEŠwpW‰ď (2021/11/20), ‰Ą•l.

733150. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŞŽĄp‚Š‚ç6ƒ•ŒŽŒă‚É• –Œ”dŽíÄ”­‚đ—ˆ‚ľ‚˝Žq‹{čň•”G•˝ă”çŠŕIB1Šú‚Ě1—á. ˆÉ“Ą‘ĺ‹B1, ‰““Ą^ˆę1, Ź“‡@ˆč1, ŒÜ\”¨mŽu1, ˆ˘•”@‰1, ’†‘şŠîŠ°1, ŒĂěł‹`1, ŠâŁtŽq1, ‰Á“ĄˆęŠě1 (1•wl): ‘ć434‰ń_“ސěŽY‰Č•wl‰ČŠw‰ďŠwpu‰‰‰ď (2021/10/9-10/15), WebŠJĂ.

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-120001. [Œ´’˜] “űŠŕ“ńŽŸŒŸf‚ł̐úŽh‹zˆř×–Ef (FNA) ‚̐¸“xŒüă‚ÉŒü‚Ż‚ā|“–‹Ś‰ďŽ{Ý‚Ĺ‚Ě5”NŠÔ‚ĚŒŸŘ (‘ć2•ń)|. ›Œ´@—˛, â–ě‚Ý‚Ç‚č, –x^{Žq, ‰Á“Ą‚ż‚Ă‘ă, ‹{ě@, ™–{’źŽq, ‹g“c@–ž, —´@”üŽŃ, ĺU–{”Žs1 (1–k—˘‘ĺŠw–ź—_‹łŽö): _“ŢěŒ§—\–hˆăŠw‹Ś‰ďŽ–‹Ć”N•ń —ߘaŒł”N“x”Ĺ 2021/1; p.118-24.

'20-120002. [Œ´’˜] —ߘaŒł”N“x_“ސěŽY‰Č•wl‰Čˆă‰ď•wl‰ČˆŤŤŽîᇓo˜^WŒv•ń. ˆéč‘žˆę, Ŕč—ߎq, Vˆä@“w1, ƒ‹ƒCƒY‰Ą“c“Ţ•ü, ‹g“c@_, ™‰Y@ŒŤ, ‘ĺŒ´@Ž÷, ‚“c‹ąb1, –Ř”ŇvŽœ, ˛X–؍N, •ÄŽR„ˆę, —с@NŽq, •˝ŕV@–Ň, ”Ş‘ă—•Žq, “y‰Ž@‘, ’†“c‚ł‚­‚ç, X‰Ş@Š˛, ŽOăŠ˛’j, ‰Á“Ą‹vˇ, ’†–ěáÁ˛’j, ‹{é‰xŽq, ‚‹´P’j (1•wl): “ú–{ŽY‰Č•wl‰ČŠw‰ď_“ސě’n•ű•”‰ď‰ďŽ 2021/3; 57 (2): 129-36.


ŽŒ`ŠO‰ČŠw

[Šwp˜_•ś]

110325. [Œ´’˜] Gender-specific analysis for the association between trunk muscle mass and spinal pathologies. Hori Y, Hoshino M, Inage K, Miyagi M1, Takahashi S, Ohyama S, Suzuki A, Tsujio T, Terai H, Dohzono S, Sasaoka R, Toyoda H, Kato M, Matsumura A, Namikawa T, Seki M, Yamada K, Habibi H, Salimi H, Yamashita M, Yamauchi T, Furuya T, Orita S, Maki S, Shiga Y, Inoue M, Inoue G1, Fujimaki H, Murata K2, Kawakubo A1, Kabata D, Shintani A, Ohtori S, Takaso M1, Nakamura H: Sci Rep 2021/4; 11 (1): 7816. (ˆäă@Œş1, ‘ş“cK—C2, ě‹v•Ű•ŕ1, ‚‘ŠťŽm1: 1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110326. [Œ´’˜] Efficacy and safety of arthroscopic treatment for native acute septic arthritis of the hip joint in adult patients. Fukushima K1, Uekusa Y, Koyama T2, Ohashi Y2, Uchiyama K1,3, Takahira N4, Takaso M1: BMC Musculoskelet Disord 2021/4; 22 (1): 318. (•Ÿ“‡Œ’‰î1, ŹŽR’q‹v2, ‘ĺ‹´Œc‹v2, “ŕŽRŸ•ś1,3, ‚•˝ŽL4, ‚‘ŠťŽm1: 1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ĂˆŔ‘SEŠÇ—, 4ˆă—ÉqśŠw•”)

110327. [Œ´’˜] Relationships Between Spinal Alignment and Muscle Mass in Osteoporosis Patients Over 75 Years of Age Who Were Independent and Maintained Their Activities of Daily Living. Kawakubo A1, Miyagi M1, Fujimaki H, Inoue G1, Nakazawa T1, Imura T1, Saito W1, Uchida K1, Ohtori S, Takaso M1: Cureus 2021/5; 13 (5): e15130. (ě‹v•Ű•ŕ1, ‹{éłs1, ˆäă@Œş1, ’†ŕVr”V1, ˆä‘ş‹M”V1, âV“Ą@˜j1, “ŕ“cŒ’‘ž˜Y1, ‚‘ŠťŽm1: 1ŽŠO)

110328. [Œ´’˜] Risk Factor for Poor Patient Satisfaction After Lumbar Spine Surgery in Elderly Patients Aged Over 80 years. Hikata T, Ishii K, Matsumoto M, Kobayashi K, Imagama S, Ando K, Ishiguro N, Yamashita M, Seki S, Terai H, Suzuki A, Tamai K, Aramomi M, Ishikawa T, Kimura A, Inoue H, Inoue G1, Miyagi M1, Saito W1, Yamada K, Hongo M, Endo K, Suzuki H, Nakano A, Watanabe K, Ohya J, Chikuda H, Aoki Y, Shimizu M, Futatsugi T, Mukaiyama K, Hasegawa M, Kiyasu K, Iizuka H, Kobayashi R, Iizuka Y, Nishida K, Kakutani K, Nakajima H, Murakami H, Demura S, Kato S, Yoshioka K, Namikawa T, Watanabe K, Nakanishi K, Nakagawa Y, Yoshimoto M, Fujiwara H, Nishida N, Imajo Y, Yamazaki M, Abe T, Fujii K, Kaito T, Eguchi Y, Furuya T, Orita S, Ohtori S: Clin Spine Surg 2021/5; 34 (4): E223-8. (ˆäă@Œş1, ‹{éłs1, âV“Ą@˜j1: 1ŽŠO)

110329. [Œ´’˜] Prevalence and Characteristics of Spinal Sagittal Malalignment in Patients with Osteoporosis. Matsunaga T1, Miyagi M1, Nakazawa T1, Murata K1, Kawakubo A1, Fujimaki H, Koyama T2, Kuroda A2, Yokozeki Y, Mimura Y1, Shirasawa E1, Saito W1, Imura T1, Uchida K1, Nanri Y3, Inage K, Akazawa T, Ohtori S, Takaso M1, Inoue G1: J Clin Med 2021/6; 10 (13): 2827. (ź‰iV”V1, ‹{éłs1, ’†ŕVr”V1, ‘ş“cK—C1, ě‹v•Ű•ŕ1, ŹŽR’q‹v2, •“cW‹`2, ŽO‘ş—I—S1, ”’ŕV‰hŽ÷1, âV“Ą@˜j1, ˆä‘ş‹M”V1, “ŕ“cŒ’‘ž˜Y1, “ě—˘—C‘ž3, ‚‘ŠťŽm1, ˆäă@Œş1: 1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ƒŠƒnƒrƒŠ•”)

110330. [Œ´’˜] Neurological improvement is associated with neck pain attenuation after surgery for cervical ossification of the posterior longitudinal ligament. Koda M, Yoshii T, Egawa S, Sakai K, Kusano K, Nakagawa Y, Hirai T, Wada K, Katsumi K, Kimura A, Furuya T, Maki S, Nagoshi N, Watanabe K, Kanchiku T, Nagamoto Y, Oshima Y, Ando K, Nakashima H, Takahata M, Mori K, Nakajima H, Murata K, Matsunaga S, Kaito T, Yamada K, Kobayashi S, Kato S, Ohba T, Inami S, Fujibayashi S, Katoh H, Kanno H, Takahashi H, Fujii K, Miyagi M1, Inoue G1, Takaso M1, Imagama S, Kawaguchi Y, Takeshita K, Nakamura M, Matsumoto M, Okawa A, Yamazaki M: Sci Rep 2021/6; 11 (1): 11910. (‹{éłs1, ˆäă@Œş1, ‚‘ŠťŽm1: 1ŽŠO)

110331. [Œ´’˜] Automated detection of cervical ossification of the posterior longitudinal ligament in plain lateral radiographs of the cervical spine using a convolutional neural network. Miura M, Maki S, Miura K, Takahashi H, Miyagi M1, Inoue G1, Murata K, Konishi T, Furuya T, Koda M, Takaso M1, Endo K, Ohtori S, Yamazaki M: Sci Rep 2021/6; 11 (1): 12702. (‹{éłs1, ˆäă@Œş1, ‚‘ŠťŽm1: 1ŽŠO)

110332. [Œ´’˜] Differential Synovial CGRP/RAMP1 Expression in Men and Women With Knee Osteoarthritis. Uchida K1, Takano S1, Takata K, Mukai M2, Koyama T2, Ohashi Y2, Saito H2, Takaso M1, Miyagi M1, Inoue G1: Cureus 2021/6; 13 (6): e15483. (“ŕ“cŒ’‘ž˜Y1, ‚–쏸‘ž˜Y1, Œ}@@Šw2, ŹŽR’q‹v2, ‘ĺ‹´Œc‹v2, âV“ĄLŽ÷2, ‚‘ŠťŽm1, ‹{éłs1, ˆäă@Œş1: 1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110333. [Œ´’˜] The Mechanical Strength of Side-to-Side Tendon Repair Using a Modified Krackow Technique. Ueno K, Suzuki T, Matsuura Y, Sukegawa K1, Ohtori S, Kuniyoshi K: J Hand Surg Asian Pac Vol 2021/6; 26 (2): 188-193. (•ě_Žm1,2: 1—Տ°‰đ–U‹łˆçŒ¤, 2ŽŠO)

110334. [Œ´’˜] Somnolence and Dizziness During Mirogabalin Treatment in Patients With Neuropathic Pain Related to Lumbar Disease Who Switched From Pregabalin: A Retrospective Study. Akazawa T, Inoue G1, Tanaka M, Umehara T, Nagai T, Oshita Y, Imura T1, Miyagi M1, Saito W1, Sako K, Nomura S, Hiyama A, Katoh H, Sakai D, Sato M, Yoshida A, Iinuma M, Niki H, Takaso M1, Watanabe M: Global Spine J 2021/7; 21925682211031185. (ˆäă@Œş1, ˆä‘ş‹M”V1, ‹{éłs1, âV“Ą@˜j1, ‚‘ŠťŽm1: 1ŽŠO)

110335. [Œ´’˜] Possible Regulation of bFGF Expression by Mast Cells in Osteoarthritis Patients with Obesity: A Cross-Sectional Study. Takata K, Uchida K1, Takano S1, Muaki M2, Inoue G1, Sekiguchi H1, Aikawa J1, Miyagi M1, Iwase D1, Takaso M1: Diabetes Metab Syndr Obes 2021/7; 14: 3291-7. (“ŕ“cŒ’‘ž˜Y1, ‚–쏸‘ž˜Y1, Œ}@@Šw2, ˆäă@Œş1, ŠÖŒű—T”V1, ‘Šě@~1, ‹{éłs1, ŠâŁ@‘ĺ1, ‚‘ŠťŽm1: 1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110336. [Œ´’˜] TGF-ƒŔ regulates nerve growth factor expression in a mouse intervertebral disc injury model. Yokozeki Y1, Uchida K2, Kawakubo A2, Nakawaki M2, Okubo T3, Miyagi M2, Inoue G2, Itakura M4, Sekiguchi H2, Takaso M2: BMC Musculoskelet Disord 2021/7; 22 (1): 634. (‰ĄŠÖ—YŽi1, “ŕ“cŒ’‘ž˜Y2, ě‹v•Ű•ŕ2, ’†˜e[Í2, ‘ĺ‹v•Ű’ź3, ‹{éłs2, ˆäă@Œş2, ”‘q@˝4, ŠÖŒű—T”V2, ‚‘ŠťŽm2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO, 3ŽŔ“Ž, 4ś‰ť)

110337. [Œ´’˜] Reduced TGF-ƒŔ Expression and CD206-Positive Resident Macrophages in the Intervertebral Discs of Aged Mice. Yokozeki Y1, Kawakubo A2, Miyagi M2, Kuroda A1, Sekiguchi H2, Inoue G2, Takaso M2, Uchida K2: Biomed Res Int 2021/7; 2021: 7988320. (‰ĄŠÖ—YŽi1, ě‹v•Ű•ŕ2, ‹{éłs2, •“cW‹`1, ŠÖŒű—T”V2, ˆäă@Œş2, ‚‘ŠťŽm2, “ŕ“cŒ’‘ž˜Y2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO)

110338. [Œ´’˜] Regulation of Tumor Necrosis Factor-ƒż by Peptide Lv in Bone Marrow Macrophages and Synovium. Mukai M1, Uchida K2, Okubo T3, Takano S2, Matsumoto T4, Satoh M5, Inoue G2, Takaso M2: Front Med (Lausanne) 2021/7; 8: 702126. (Œ}@@Šw1, “ŕ“cŒ’‘ž˜Y2, ‘ĺ‹v•Ű’ź3, ‚–쏸‘ž˜Y2, ź–{r‰p4, ˛“Ą@‰ë5, ˆäă@Œş2, ‚‘ŠťŽm2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO, 3ŽŔ“Ž, 4ˆă—ÉqśŠw•”, 5–Ɖu)

110339. [Œ´’˜] Influence of different energy patterns on efficacy of radial shock wave therapy. Kenmoku T1, Iwakura N, Ochiai N, Saisu T, Ohtori S, Takahashi K, Nakazawa T1, Fukuda M2, Takaso M1: J Orthop Sci 2021/7; 26 (4): 698-703. (ŒŠ–Ú’q‹I1, ’†ŕVr”V1, •Ÿ“c—Ď–ç2, ‚‘ŠťŽm1: 1ŽŠO, 2ˆă—ÉqśŠw•”)

110340. [Œ´’˜] Investigating interest in orthopedic surgery within an entire medical faculty: A cross-sectional study. Kenmoku T, Sho S, Suzuki T, Suzuki A, Suzuki R, Sakaguchi K, Saito A, Kohata A, Takaso M1: J Orthop Sci 2021/7; 26 (4): 704-8. (ŒŠ–Ú’q‹I1, ‚‘ŠťŽm1: 1ŽŠO)

110341. [Œ´’˜] Increasing transforming growth factor-beta concentrations with age decrease apelin in the rat rotator cuff. Tazawa R1, Uchida K1, Kenmoku T1, Nakawaki M1, Muneshige K2, Ishii D2, Inoue G1, Takaso M1: J Orthop Surg Res 2021/8; 16 (1): 539. (“cŕV@—Č1, “ŕ“cŒ’‘ž˜Y1, ŒŠ–Ú’q‹I1, ’†˜eˆňÍ1, @d‹żŽq2, Îˆä‘ĺ•ă2, ˆäă@Œş1, ‚‘ŠťŽm1: 1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110342. [Œ´’˜] Role of CD14-positive cells in inflammatory cytokine and pain-related molecule expression in human degenerated intervertebral discs. Miyagi M1, Uchida K1, Takano S1, Nakawaki M1, Sekiguchi H1, Nakazawa T1, Imura T1, Saito W1, Shirasawa E1, Kawakubo A1, Akazawa T, Inoue G1, Takaso M1: J Orthop Res 2021/8; 39 (8): 1755-62. (‹{éłs1, “ŕ“cŒ’‘ž˜Y1, ‚–쏸‘ž˜Y1, ’†˜eˆňÍ1, ŠÖŒű—T”V1, ’†ŕVr”V1, ˆä‘ş‹M”V1, âV“Ą@˜j1, ”’ŕV‰hŽ÷1, ě‹v•Ű•ŕ1, ˆäă@Œş1, ‚‘ŠťŽm1: 1ŽŠO)

110343. [Œ´’˜] Incidences of deep vein thrombosis and major bleeding under the administration of fondaparinux for thromboprophylaxis after periacetabular osteotomy: a retrospective observational study. Fukushima K1, Saito H2, Koyama T2, Ohashi, Y2, Uchiyama K1,3, Takahira N4, TakasoM1: J Hip Preserv Surg 2021/8; 8 (3): 293-7. (•Ÿ“‡Œ’‰î1, âV“ĄLŽ÷2, ŹŽR’q‹v2, ‘ĺ‹´Œc‹v2, “ŕŽRŸ•ś1,3, ‚•˝ŽL4, ‚‘ŠťŽm1: 1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ĂˆŔ‘SEŠÇ—, 4ˆă—ÉqśŠw•”)

110344. [Œ´’˜] NGF Expression and Elevation in Hip Osteoarthritis Patients with Pain and Central Sensitization. Ohashi Y1, Uchida K2, Fukushima K2, Satoh M3, Koyama T1, Tsuchiya M1, Saito H1, Takahira N4, Inoue G2, Takaso M2: Biomed Res Int 2021/9; 2021: 9212585. (‘ĺ‹´Œc‹v1, “ŕ“cŒ’‘ž˜Y2, •Ÿ“‡Œ’‰î2, ˛“Ą@‰ë3, ŹŽR’q‹v1, “y‰Ž^•ä1, âV“ĄLŽ÷1, ‚•˝ŽL4, ˆäă@Œş2, ‚‘ŠťŽm2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO, 3–Ɖu, 4ˆă—ÉqśŠw•”)

110345. [Œ´’˜] Factors Significantly Associated with Postoperative Neck Pain Deterioration after Surgery for Cervical Ossification of the Posterior Longitudinal Ligament: Study of a Cohort Using a Prospective Registry. Koda M, Yoshii T, Egawa S, Sakai K, Kusano K, Nakagawa Y, Hirai T, Wada K, Katsumi K, Kimura A, Furuya T, Maki S, Nagoshi N, Watanabe K, Kanchiku T, Nagamoto Y, Oshima Y, Ando K, Nakashima H, Takahata M, Mori K, Nakajima H, Murata K, Matsunaga S, Kaito T, Yamada K, Kobayashi S, Kato S, Ohba T, Inami S, Fujibayashi S, Katoh H, Kanno H, Takahashi H, Fujii K, Miyagi M1, Inoue G1, Takaso M1, Imagama S, Kawaguchi Y, Takeshita K, Nakamura M, Matsumoto M, Okawa A, Yamazaki M: J Clin Med 2021/10; 10 (21): 5026. (‹{éłs1, ˆäă@Œş1, ‚‘ŠťŽm1: 1ŽŠO)

110346. [Œ´’˜] Prevalence and location of endplate fracture and subsidence after oblique lumbar interbody fusion for adult spinal deformity. Inoue G1, Saito W1, Miyagi M1, Imura 1, Shirasawa E1, Ikeda S1, Mimura Y1, Kuroda A2, Yokozeki Y2, Inoue S2, Akazawa T, Nakazawa T1, Uchida K1, Takaso M1: BMC Musculoskelet Disord 2021/10; 22 (1): 880. (ˆäă@Œş1, âV“Ą@˜j1, ‹{éłs1, ˆä‘ş‹M”V1, ”’ŕV‰hŽ÷1, ’r“cM‰î1, ‘ş“cK—C1, •“cW‹`2, ‰ĄŠÖ—YŽi2, ˆäă@ăÄ2, ’†ŕVr”V1, “ŕ“cŒ’‘ž˜Y1, ‚‘ŠťŽm1: 1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110347. [Œ´’˜] Adverse Effects of Higher Preoperative Pain at Rest, a Central Sensitization-Related Symptom, on Outcomes After Total Hip Arthroplasty in Patients with Osteoarthritis. Ohashi Y1, Fukushima K2, Uchida K2, Koyama T1, Tsuchiya M1, Saito H1, Uchiyama K2,3, Takahira N4, Inoue G2, Takaso M2: J Pain Res 2021/20; 14: 3345-52. (‘ĺ‹´Œc‹v1, •Ÿ“‡Œ’‰î2, “ŕ“cŒ’‘ž˜Y2, ŹŽR’q‹v1, “y‰Ž^•ä1, âV“ĄLŽ÷1, “ŕŽRŸ•ś2,3, ‚•˝ŽL4, ˆäă@Œş2, ‚‘ŠťŽm2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO, 3ˆă—ĂˆŔ‘SEŠÇ—, 4ˆă—ÉqśŠw•”)

110348. [Œ´’˜] Increased nerve growth factor expression in the synovial tissues of patients with rotator cuff tears. Tazawa R1, Kenmoku T1, Uchida K1, Arendt-Nielsen L, Nagura N, Nakawaki M1, Matsumoto T2, Inoue G1, Takeuchi H3, Jimbo T3, Nakazawa T1, Fukuda M2, Takaso M1: Mol Pain 2021/1-12; 17: 17448069211021252. (“cŕV@—Č1, ŒŠ–Ú’q‹I1, “ŕ“cŒ’‘ž˜Y1, ’†˜eˆňÍ1, ź–{r‰p2, ˆäă@Œş1, ’|“ੰl3, _•Ű•‘Ľ3, ’†ŕVr”V1, •Ÿ“c—Ď–ç2, ‚‘ŠťŽm1: 1ŽŠO, 2ˆă—ÉqśŠw•”, 3ƒŠƒnƒrƒŠ•”)

110349. [Œ´’˜] Factors associated with pain-related disorders and gait disturbance scores from the Japanese orthopedic association back pain evaluation questionnaire and Oswestry Disability Index in patients with osteoporosis. Miyagi M1, Inoue G1, Murata K1, Koyama T2, Kuroda A2, Kawakubo A1, Yokozeki Y2, Mimura Y1, Nannri Y3, Inage K, Akazawa T, Ohtori S, Uchida K1, Takaso M1: Arch Osteoporos 2021/12; 17 (1): 1. (‹{éłs1, ˆäă@Œş1, ‘ş“cK—C1, ŹŽR’q‹v2, •“cW‹`2, ě‹v•Ű•ŕ1, ‰ĄŠÖ—YŽi2, ŽO‘ş—I—S1, “ě—˘—C‘ž3, “ŕ“cŒ’‘ž˜Y1, ‚‘ŠťŽm1: 1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ƒŠƒnƒrƒŠ•”)

110350. [Œ´’˜] Elevated macrophage-inducible C-type lectin expression in the synovial tissue of patients with rheumatoid arthritis. Takata K, Takano S1, Miyagi M1, Mukai M2, Iwase D1, Aikawa J1, Ohashi Y2, Inoue G1, Takaso M1, Uchida K1: Cent Eur J Immunol 2021/12; 46 (4): 470-3. (‚–쏸‘ž˜Y1, ‹{éłs1, Œ}@@Šw2, ŠâŁ@‘ĺ1, ‘Šě@~1, ‘ĺ‹´Œc‹v2, ˆäă@Œş1, ‚‘ŠťŽm1, “ŕ“cŒ’‘ž˜Y1: 1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110351. [Œ´’˜] Management of regional bone bank during declaration of a state of emergency concerning the COVID-19 in Japan. Uchida K1, Mukai M2, Miyagi M1, Fukushima K1, Uchiyama K1,3, Nakayama A, Matsumoto M, Takahira N4, Urabe K1, Takaso M1, Inoue G1: Cell Tissue Bank 2021/12; 22 (4): 703-9. (“ŕ“cŒ’‘ž˜Y1, Œ}@@Šw2, ‹{éłs1, •Ÿ“‡Œ’‰î1, “ŕŽRŸ•ś1,3, ‚•˝ŽL4, č•”@Œ›1, ‚‘ŠťŽm1, ˆäă@Œş1: 1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ĂˆŔ‘SEŠÇ—, 4ˆă—ÉqśŠw•”)

110352. [Œ´’˜] Femoral varus derotational osteotomy without pelvic osteotomy in nonambulatory children with cerebral palsy: Minimum 5 years follow-up. Iwase D1, Fukushima K1, Kusumoto Y, Metoki Y2, Aikawa J1, Kenmoku T1, Minato S1, Takaso M1: Medicine (Baltimore) 2022/1; 101 (3): e28604. (ŠâŁ@‘ĺ1, •Ÿ“‡Œ’‰î1, –ÚŽž—LŠóŒb2, ‘Šě@~1, ŒŠ–Ú’q‹I1, –Š˛‘ăŽq1, ‚‘ŠťŽm1: 1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110353. [Œ´’˜] Long-term antibacterial activity of vancomycin from calcium phosphate cement in vivo. Mukai M1, Uchida K2, Sugo K, Nakasu M, Nakajima T, Takata K, Takaso M2, Urabe K2: Biomed Mater Eng 2022; 33 (1): 41-50. (Œ}@@Šw1, “ŕ“cŒ’‘ž˜Y2, ‚‘ŠťŽm2, č•”@Œ›2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO)

120013. [Œ´’˜] ‚—‘e頏NJłŽŇ‚É‚¨‚Ż‚éˆÝH“š‹t—ŹÇ‚̏Ǐó‚ƐҒŒ–îó–ĘƒAƒ‰ƒCƒƒ“ƒg. ”’ŕV‰hŽ÷1, •ˆäłˆę˜Y1, ź–{ŒőŒ\1, ‹{éłs1, ˆäă@Œş1, ‚‘ŠťŽm1 (1ŽŠO): “Œ“ú–{ŽŒ`ĐŠQŠO‰ČŠw‰ďŽGŽ 2021/5; 33 (1): 1-6.

120014. [Œ´’˜] ƒTƒ‹ƒRƒyƒjƒA‚đ‡•š‚ľ‚˝Œ´”­Ťœ‘e頏NJłŽŇ‚Ě“Á’Ľ. –î–씎”V1, ‹{éłs1, ‘ş“cK—C1, ‘ĺ’š¸Ži1, ˆäă@Œş1, ‚‘ŠťŽm1 (1ŽŠO): “Œ“ú–{ŽŒ`ĐŠQŠO‰ČŠw‰ďŽGŽ 2021/5; 33 (1): 22-7.

120015. [Œ´’˜] ‚ƒGƒlƒ‹ƒM[ŠO‚É”ş‚¤ĺœ•sˆŔ’čŒ^œÜ‚ɑ΂ˇ‚é’áNPŒă•űŒĹ’čp‚ĚŽĄ—ÐŹŃ‚ĚŒŸ“˘. ’†ŕVr”V1, ‹{éłs1, ”’ŕV‰hŽ÷1, ˆä‘ş‹M”V1, âV“Ą@˜j1, “Ą–쏯‘ž˜Y1, ˆäă@Œş1, ‚‘ŠťŽm1 (1ŽŠO): –k—˘ˆăŠw 2021/6; 51 (1): 17-23.

120016. [Œ´’˜] Š°œ‰P”핢“x‚ރZƒƒ“ƒgƒŒƒXŠ°œ‰PƒVƒFƒ‹‚̏‰ŠúŒĹ’č—Í‚Ö—^‚Ś‚é‰e‹ż. ‹g“c˜aO1, •Ÿ“‡Œ’‰î2, Žđˆä—˜“Ţ1, “ŕŽRŸ•ś2,3, ‚•˝ŽL1, Ž•˝­L1 (1ˆă—ÉqśŠw•”, 2ŽŠO, 3ˆă—ĂˆŔ‘SEŠÇ—): —Տ°ƒoƒCƒIƒƒJƒjƒNƒX 2021/10; 42: 137-44.

310045. [Ç—á•ń] Hip Dislocation After Correction for Scoliosis in an Adolescent with Angelman Syndrome: A Case Report. Metoki Y1, Iwase D1, Fukushima K1, Uchiyama K1,2, Saito W1, Takao M1: JBJS Case Connect 2021/4; 11 (2). doi: 10.2106/JBJS.CC.20.00959. (–ÚŽž—LŠóŒb1, ŠâŁ@‘ĺ1, •Ÿ“‡Œ’‰î1, “ŕŽRŸ•ś1,2, âV“Ą@˜j1, ‚‘ŠťŽm1: 1ŽŠO, 2ˆă—ĂˆŔ‘SEŠÇ—)

310046. [Ç—á•ń] Disseminated nocardiosis complicated by multiple abscesses of the brain and lower limbs diagnosed by the melting temperature mapping method: A case report. Ikeda S1, Uchiyama K1,2, Moriya M, Sakurai K3, Nihonyanagi S3,4, Niimi H, Takaso M1: J Orthop Sci 2021/8; S0949-2658 (21) 00232-3. (’r“cM‰î1, “ŕŽRŸ•ś1,2, ŸNˆäŒc‘˘3, “ń–{–öL3,4, ‚‘ŠťŽm1: 1ŽŠO, 2ˆă—ĂˆŔ‘SEŠÇ—, 3—ŐŒŸ•”, 4Š´őŠÇ—Žş)

320007. [Ç—á•ń] III. ŠOEŠO‡•šÇ@•IŠÖßŒăŠO‘¤‰ńů•sˆŔ’čÇ‚𔺂Á‚˝ŹŽ™ă˜rœŠO‘¤č÷sleeveœÜ‚Ě1—á. Ą–ě—Y‘ž1, •ě_Žm1,2, ŹŔŒŤŽĄ1, ‘ĺ’|—IĆ1, ‚‘ŠťŽm1 (1ŽŠO, 2—Տ°‰đ–U‹łˆçŒ¤): “ú–{•IŠÖßŠw‰ďŽGŽ 2021/11; 28 (2): 7-10.

320008. [Ç—á•ń] VII. ‰ŠÇEŠ´ő@“ŻŽíœ‚đŽg—p‚ľ‚˝Impaction bone grafting–@‚É‚ć‚élH•IŠÖßÄ’uŠˇp‚đŽ{s‚ľ‚˝ŠÖßƒŠƒEƒ}ƒ`‚Ě1—á. ‚‰Şƒˆę1, ŹŔŒŤŽĄ1, •ě_Žm1,2, ‘ĺ’|—IĆ1, ‚‘ŠťŽm1 (1ŽŠO, 2—Տ°‰đ–U‹łˆçŒ¤): “ú–{•IŠÖßŠw‰ďŽGŽ 2021/11; 28 (2): 163-6.

521005. [‰đŕ] TKAŒă‚Ě•GŠÖß‚Á‚Ä‘O\Žšx‘Ń‹@”\•s‘S•G‚ś‚á‚Č‚˘‚Ě? ‚ť‚ę‚Ĺ‚˘‚˘‚Ě? č•”@Œ› (ŽŠO): é‹ĘŒ§ˆăŽt‰ďŽ 2021/6; (855): 46-50.

521006. [‰đŕ]y˜AÚ: “`‚í‚ç‚Č‚˘ƒRƒgƒo‚˝‚ż (‘ć2‰ń)zDDH‚ĆCDH. •Ÿ“‡Œ’‰î (ŽŠO): ŠÖßŠO‰Č 2022/1; 41 (1): 95.

521007. [‰đŕ]y˜AÚ: “`‚í‚ç‚Č‚˘ƒRƒgƒo‚˝‚ż (‘ć3‰ń)z‰^“ŽŠí•sˆŔ’čÇ‚ĆƒƒRƒ‚ƒeƒBƒuƒVƒ“ƒhƒ[ƒ€, ƒtƒŒƒCƒ‹. •Ÿ“‡Œ’‰î (ŽŠO): ŠÖßŠO‰Č 2022/3; 41 (3): 312-3.

522526. [uŔ]y‘ć93‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠwp‘‰ďƒVƒ“ƒ|ƒWƒEƒ€u˜’É‚Ě•a‘Ô‰đ–ž‚ÉŒü‚Ż‚˝V‚ľ‚˘ƒAƒvƒ[ƒ`vz˜’É‚Ě•a‘Ô‰đ–ž‚ÉŒü‚Ż‚˝V‚ľ‚˘ƒAƒvƒ[ƒ`|œ‘e頏NJłŽŇ‚̍˜’É‚Ć•ŕs‹@”\áŠQ@Ň’Œ–îó–ĘƒAƒ‰ƒCƒƒ“ƒgˆŮí‚Ć‘ĚŠ˛‹Ř—ʒቺ‚Ş‹y‚Ú‚ˇ‰e‹ż|. ‚‘ŠťŽm1, ‹{éłs1 (1ŽŠO): “ú–{ŽŒ`ŠO‰ČŠw‰ďŽ 2021/4; 95 (4): 224-8.

522527. [uŔ]yDebatez•ęŽwCMŠÖßÇ|ŠÖßŒĹ’čp vs. ŠÖßŒ`Źp. •ě_Žm1,2, ăŒ´_‰î (1—Տ°‰đ–U‹łˆç, 2ŽŠO): —Տ°ŽŒ`ŠO‰Č 2021/4; 56 (4): 393-6.

522528. [uŔ]y“ÁW: œ‘e頏ǐŤ’Ĺ‘ĚœÜ|“—á‚̐f’fEŽĄ—Â𒆐S‚Ɂ|zœ‘e頏ǐŤ’Ĺ‘ĚœÜ‚É‚¨‚Ż‚éŒăœ]•ĎŒ`|“—á‚̐f’fEŽĄ—Â𒆐S‚Ɂ|. ‹{éłs1, ’†ŕVr”V1, ˆä‘ş‹M”V1, âV“Ą@˜j1, ”’ŕV‰hŽ÷1, ˆäă@Œş1, ‚‘ŠťŽm1 (1ŽŠO): ŠÖßŠO‰Č 2021/5; 40 (5): 514-20.

522529. [uŔ]yŽŒ`ƒgƒsƒbƒNƒXzŠÖßƒŠƒEƒ}ƒ`ŠłŽŇ‚ĚŠŠ–Œƒ}ƒNƒƒtƒ@[ƒW‚É‚¨‚˘‚Ę´i‚đ”F‚ß‚éCŒ^ƒŒƒNƒ`ƒ“Žó—e‘Ě (macrophage inducible C-type lectin) ‚Ě”­Œť. X’JŒőr1, “ŕ“cŒ’‘ž˜Y1, ‚‘ŠťŽm1 (1ŽŠO): ŽŒ`ŠO‰Č 2021/5; 72 (5): 462.

522530. [uŔ]y“ÁW: FAI’†ŠúŹŃ‚̍lŽ@‚Ć“W–]zFAI‚̉uŠw. •Ÿ“‡Œ’‰î1, ‚•˝ŽL2, ‚‘ŠťŽm1 (1ŽŠO, 2ˆă—ÉqśŠw•”): Monthly Book Ortrhopaedics 2021/12; 34 (13): 1-5.

522531. [uŔ]y“ÁW: ƒRƒ“ƒo[ƒWƒ‡ƒ“THA ‚Ě‚ˇ‚ׂā|“ďˆŐ“x‚̍‚‚˘primary THA|z‘ĺ‘ڍœŠO”˝œŘ‚čpŒă‚ĚTHA. •Ÿ“‡Œ’‰î1, ‚•˝ŽL2, “ŕŽRŸ•ś1,3, ‚‘ŠťŽm1 (1ŽŠO, 2ˆă—ÉqśŠw•”, 3ˆă—ĂˆŔ‘SEŠÇ—): ŠÖßŠO‰Č 2022/2; 41 (2): 66-72.

522532. [uŔ]y“ÁW: f’fEŽĄ—Ă‚É“ďa‚ľ‚˝Periprosthetic Joint Infection‚ւ̑ΉžzĄŽĄ—Õҁ@‹‘ĺœŒ‡‘š‚𔺂¤Ç—á‚ւ̑Ήž. “ŕŽRŸ•ś1,2, •Ÿ“‡Œ’‰î2, X’JŒőr2, ŹŽR’q‹v3, ‘ĺ‹´Œc‹v3, ‚•˝ŽL4, ‚‘ŠťŽm2 (1ˆă—ĂˆŔ‘SEŠÇ—, 2ŽŠO, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4ˆă—ÉqśŠw•”): —Տ°ŽŒ`ŠO‰Č 2022/3; 57 (3): 241-8.

[’˜@‘]

620094. [Šwp‘ (•Ş’SŽˇ•M)]yƒXƒyƒVƒƒƒŠƒXƒg‚Ş‚ˇ‚ˇ‚ß‚élHŠÖßŽčp‡•šÇ‘΍ôz‘˜_@‘ćIIÍ lHŠÖßŽüˆÍŠ´ő@3 ‚ƒŠƒXƒNÇ—á‚ɑ΂ˇ‚éŽüpŠúŠÇ—. 4 p‘O´@EÁ“Ĺ‚Ě•ű–@‚Ćƒ^ƒCƒ~ƒ“ƒO, p.35-8. “ŕŽRŸ•ś1,2 (1ˆă—ĂˆŔ‘SEŠÇ—Šw, 2ŽŠO), •Ň: ŽR–{ŒŞŒá, “ě]“°, “Œ‹ž, 2021/4”­s.

620095. [Šwp‘ (•Ş’SŽˇ•M)]yƒCƒ“ƒvƒ‰ƒ“ƒgŽüˆÍŠ´ő‚Ě‘Îˆ–@|lHŠÖßEŇ’ŁEœÜ| (ŠÖßŠO‰Č2021”N4ŒŽ‘Š§†)zII. Še˜_@’x”­ŤlHœ“ށElHŒŇŠÖßŽüˆÍŠ´ő‚Ě‘Îˆ–@, p.88-94. “ŕŽRŸ•ś1,2, •Ÿ“‡Œ’‰î2, X’JŒőr2, ŹŽR’q‹v3, ‘ĺ‹´Œc‹v3, ‚•˝ŽL4, ‚‘ŠťŽm2 (1ˆă—ĂˆŔ‘SEŠÇ—, 2ŽŠO, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4ˆă—ÉqśŠw•”): •Ň: “c’†Nm, ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, “Œ‹ž, 2021/4”­s.

620096. [Šwp‘ (•Ş’SŽˇ•M)]y•GŠÖßŠO‰ČŠwzII Še˜_ @3 ‰ŠÇ@D Ň’Ŋ֐߉Š, p.415-26. č•”@Œ› (ŽŠO), •Ň: ’Ă‘ş@O, ŽO‰Y—Tł, ź“cGˆę, ‰Şč@ŒŤ, “ě]“°, “Œ‹ž, 2021/8”­s.

620097. [Šwp‘ (•Ş’SŽˇ•M)]ySave the Athlete ŒŇŠÖßƒXƒ|[ƒc‘šzII ŒŇŠÖßEœ”Ő‚ĚƒXƒ|[ƒc‘š@B. ‘ÎŰ•Ň@5 ƒgƒbƒvƒAƒXƒŠ[ƒg: –ě‹…‚ĆŒŇŠÖß‚ĚŠÖ˜AŤ, p.185-8 ŒŠ–Ú’q‹I1, •Ÿ“‡Œ’‰î1 (1ŽŠO), •Ň: ‚•˝ŽL, ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, “Œ‹ž, 2020/10”­s.

620098. [Šwp‘ (•Ş’SŽˇ•M)]y“ü‰@‚Š‚ç‘މ@‚Ü‚Ĺ‚Ěƒ`ƒƒ[ƒg‚ĹŠw‚ԁ@ŽŒ`ŠO‰Č•a“‚̏pŽŽ•ĘƒPƒAƒ}ƒjƒ…ƒAƒ‹ (ŽŒ`ŠO‰ČŠĹŒě2021”NH‹G‘Š§)z‘ć3Í ăŽˆ@žôœ‰“ˆĘ’[œÜ, p.109-18. ŽÚœ_ŒoˆÚsp, p.119-26. ŽčŽwœÜ‚̐Ž•œŒĹ’čp, p.127-33. _Œo‘š‚ɑ΂ˇ‚é_Œo–D‡p, p.134-41. •ě_Žm1,2 (1—Տ°‰đ–U‹łˆç, 2ŽŠO), •Ň: ‚•˝ŽL, ƒƒfƒBƒJo”Ĺ, 2021/11”­s.

621004. [Šwp‘ (•ŇW)]yŽŒ`ŠO‰Čˆă‚Ě‚˝‚ß‚ĚŒŇŠÖßƒXƒ|[ƒcf—Ă‚Ě‚ˇ‚ׂāz•Ň: •Ÿ“‡Œ’‰î, “ú–{ˆăŽ–V•ńŽĐ, “Œ‹ž, 2021/12”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

712009. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Surgical treatment for neuromuscular disease patients with severe scoliosis whose Cobb angle was over 100 degrees. Miyagi M1, Saito W1, Mimura Y1, Inoue G1, Nakazawa T1, Imura T1, Shirasawa E1, Ikeda S1, Kuroda A2, Yokozeki Y2, Takaso M1: 13th Combined Meeting of Asia Pacific Spine Society and Asia Pacific Paediatric Orthopaedic Society (2021/6/9-12), Kobe, Japan. (‹{éłs1, âV“Ą@˜j1, ŽO‘ş—I—S1, ˆäă@Œş1, ’†ŕVr”V1, ˆä‘ş‹M”V1, ”’ŕV‰hŽ÷1, ’r“cM‰î1, •“cW‹`2, ‰ĄŠÖ—YŽi2, ‚‘ŠťŽm1: 1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

712010. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Residual neuropathic pain in postoperative patients for cervical ossification of posterior longitudinal ligament. Miyagi M1, Yoshii T, Koda M, Furuya T, Kimura A, Nagoshi N, Nakashima H, Sakai K, Ikeda S1, Inoue G1, Imagama S, Takeshita K, Matsumoto M1, Okawa A, Yamazaki M, Takaso M1: Spine Across the Sea 2021 (2021/7/5-8), Hawaii, USA. (‹{éłs1, ’r“cM‰î1, ˆäă@Œş1, ź–{ŒőŒ\1, ‚‘ŠťŽm1: 1ŽŠO)

722159. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŒŇŠÖßPJIŽĄ—Ă‚ĚŒťó‚Ć–˘—ˆ. “ŕŽRŸ•ś1,2, ’r“cM‰î2, •Ÿ“‡Œ’‰î2, ŹŽR’q‹v3, ‘ĺ‹´Œc‹v3, X’JŒőr2, ‚•˝ŽL4, ‚‘ŠťŽm2 (1ˆă—ĂˆŔ‘SEŠÇ—, 2ŽŠO, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4ˆă—ÉqśŠw•”): ‘ć94‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠwp‘‰ď (2021/5/20-21), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722160. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰“™) FAI‚ɑ΂ˇ‚éŒŇŠÖß‹žŽĄ—Ă‚ĚŒťó. •Ÿ“‡Œ’‰î1, ‘ĺ‹´Œc‹v2, ŹŽR’q‹v2, “ŕŽRŸ•ś1,3, ‚•˝ŽL4, ‚‘ŠťŽm1 (1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ĂˆŔ‘SEŠÇ—, 4ˆă—ÉqśŠw•”): ‘ć94‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠwp‘‰ď (2021/5/21), “Œ‹ž.

722161. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŒŇŠÖß‹žŽ‹‰şŽčp‚É‚¨‚Ż‚é, ŠŠ–Œ‰Š‚¨‚ć‚ŃŠŠ–Œ“ŕ‰ŠÇŤƒTƒCƒgƒJƒCƒ“”­Œť‚̉e‹ż. •Ÿ“‡Œ’‰î1, ˆäă@Œş1, “ŕ“cŒ’‘ž˜Y1, ‘ĺ‹´Œc‹v2, ŹŽR’q‹v2, “ŕŽRŸ•ś3, ‚•˝ŽL4, ‚‘ŠťŽm1 (1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ĂˆŔ‘SEŠÇ—, 4ˆă—ÉqśŠw•”): JOSKAS/JOSSM meeting 2021 (2021/6/18), WebŠJĂ.

722162. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Žčp•”ˆĘŠ´ő‚Ě–o–Ĺ‚đ–ÚŽw‚ľ‚ā|THAŽüˆÍŠ´ő‚ɑ΂ˇ‚é“ńŠú“IÄ’uŠˇp‚̍H•v|. “ŕŽRŸ•ś1,2, •Ÿ“‡Œ’‰î2, X’JŒőr2, ŹŽR’q‹v3, ‘ĺ‹´Œc‹v3, ’r“cM‰î2, ‚•˝ŽL4, ‚‘ŠťŽm2 (1ˆă—ĂˆŔ‘SEŠÇ—, 2ŽŠO, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4ˆă—ÉqśŠw•”): ‘ć44‰ń“ú–{œEŠÖßŠ´őÇŠw‰ď (2021/6/25), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722163. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “–‰@‚ł̐lHŒŇŠÖßŽüˆÍŠ´ő‚ĚŽĄ—Ă‘S”ʁ|ƒXƒy[ƒT[EÄ’uŠˇER‹Ű–ň|. “ŕŽRŸ•ś1,2, •Ÿ“‡Œ’‰î2, ’r“cM‰î2, ŹŽR’q‹v3, ‘ĺ‹´Œc‹v3, X’JŒőr2, ‚•˝ŽL4, ‚‘ŠťŽm2 (1ˆă—ĂˆŔ‘SEŠÇ—, 2ŽŠO, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4ˆă—ÉqśŠw•”): ‘ć51‰ń“ú–{lHŠÖßŠw‰ď (2021/7/8), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), ´˜^W p.244.

722164. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) •s—ǏǗႊ‚çŠw‚ń‚žŒŇŠÖß‹žŽ‹‰şŽčp‚Ě“K‰ž‚ĆŽč‹Z‚Ě•Ď‘J. •Ÿ“‡Œ’‰î1, ‘ĺ‹´Œc‹v2, ŹŽR’q‹v2, âV“ĄLŽ÷2, “y‰Ž^•ä2, “ŕŽRŸ•ś3, ‚•˝ŽL4, ‚‘ŠťŽm1 (1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ĂˆŔ‘SEŠÇ—, 4ˆă—ÉqśŠw•”): ‘ć48‰ń“ú–{ŒŇŠÖßŠw‰ďŠwpW‰ď (2021/10/22), “Ţ—Ç (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722165. [Šw‰ď (‘S‘)] (‹łˆçŒ¤Cu‰‰) ‘ĺ‘ڍœ‹ßˆĘœŘ‚čp‚Ě“K‰ž‚ĆŒŔŠE. “ŕŽRŸ•ś1,2 (1ˆă—ĂˆŔ‘SEŠÇ—, 2ŽŠO): ‘ć48‰ń“ú–{ŒŇŠÖßŠw‰ďŠwpW‰ď (2021/10/22-23), “Ţ—Ç (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722166. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Avenir Complete stem (Zimmer-BiometŽĐ). •Ÿ“‡Œ’‰î1, ŹŽR’q‹v2, ‘ĺ‹´Œc‹v2, âV“ĄLŽ÷2, “y‰Ž^•ä2, “ŕŽRŸ•ś3, ‚•˝ŽL4, ‚‘ŠťŽm1 (1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ĂˆŔ‘SEŠÇ—, 4ˆă—ÉqśŠw•”): ‘ć48‰ń“ú–{ŒŇŠÖßŠw‰ďŠwpW‰ď (2021/10/23), “Ţ—Ç (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722167. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) lHŒŇŠÖßŽüˆÍŠ´ő‚ɑ΂ˇ‚鎥—Ă‚ĚŠî–{. “ŕŽRŸ•ś1,2, •Ÿ“‡Œ’‰î2, ’r“cM‰î2, ŹŽR’q‹v3, ‘ĺ‹´Œc‹v3, X’JŒőr2, ‚ŽR—zŽq4, ŻŽR—˛s5, ˜a“c’B•F5, ’†‘şłŽ÷6, ‚•˝ŽL6, ‚‘ŠťŽm2, mˆäŒŠ‰pŽ÷7, ‰Ô–؏G–ž8 (1ˆă—ĂˆŔ‘SEŠÇ—, 2ŽŠO, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 5äPŒ´•aEŠ´ő“ŕ, 6ˆă—ÉqśŠw•”, 7•xŽR‘ĺŠw, 8–k—˘ś–˝‰ČŠwŒ¤‹†Š): ‘ć70‰ń“ú–{Š´őÇŠw‰ď“Œ“ú–{’n•ű‰ďŠwpW‰ď/‘ć68‰ń“ú–{‰ťŠw—Ă–@Šw‰ď“Œ“ú–{Žx•”‘‰ď ‡“ŻŠw‰ď (2021/10/27), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722168. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ’ōœ“Ž–Ź‘š. ‹{éłs1, ˆä‘ş‹M”V1, ”’ŕV‰hŽ÷1, ŽO‘ş—I—S1, ’r“cM‰î1, ’†ŕVr”V1, ˆäă@Œş1, ‚‘ŠťŽm1 (1ŽŠO): ‘ć11‰ńĹŹNPŇ’ĹŽĄ—ĂŠw‰ď (2021/10/29-30), “Œ‹ž.

722169. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) •úŽËü”픘’ጸƒfƒoƒCƒX“ą“üŠg‘ĺ‚đ–ÚŽw‚ľ‚˝s­‚Ö‚ĚƒAƒvƒ[ƒ`ŠT—v. ‹{éłs1, ‘ĺ’š¸Ži, ‰““ĄŒ’Ži, ŽíŽs@—m (1ŽŠO): ‘ć11‰ńĹŹNPŇ’ĹŽĄ—ĂŠw‰ď (2021/10/29-30), “Œ‹ž.

722170. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) _Œo‹ŘŤŇ’Œ‘¤œ]Ç‚ɑ΂ˇ‚éŽčpŽĄ—Ă. ‹{éłs1, âV“Ą@˜j1, ŽO‘ş—I—S1, ˆäă@Œş1, ’†ŕVr”V1, ˆä‘ş‹M”V1, ”’ŕV‰hŽ÷1, ’r“cM‰î1, ‚‘ŠťŽm1 (1ŽŠO): ‘ć55‰ń“ú–{‘¤œ]ÇŠw‰ďŠwpW‰ď (2021/11/5-6), •lź (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722171. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) lHŒŇŠÖßŽüˆÍŠ´ő‚ɑ΂ˇ‚鎝‘ą“I‹ÇŠR‹Ű–ňŸó—Ź (CLAP). “ŕŽRŸ•ś1,2, •Ÿ“‡Œ’‰î2, X’JŒőr2, ŹŽR’q‹v3, ‘ĺ‹´Œc‹v3, ‚•˝ŽL4, ‚‘ŠťŽm2 (1ˆă—ĂˆŔ‘SEŠÇ—, 2ŽŠO, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4ˆă—ÉqśŠw•”): ‘ć34‰ń“ú–{ŠO‰ČŠ´őÇŠw‰ď‘‰ďŠwpW‰ď (2021/12/17), WebŠJĂ.

723457. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚é•ęŽwCMŠÖßÇ‚ɑ΂ˇ‚é‘•‹ď—Ă–@‚ĆŽčp—Ă–@. ŹŔŒŤŽĄ1, ˛X–؏Gˆę2, •ě_Žm1, ‘ĺ’|—IĆ1, ‚‘ŠťŽm1 (1ŽŠO, 2ƒŠƒnƒrƒŠ•”): ‘ć64‰ń“ú–{ŽčŠO‰ČŠw‰ďŠwpW‰ď (2021/4/23), ’ˇč (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723458. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŹŽ™EÂ”NŠú‚É‚¨‚Ż‚é•sˆŔ’čŒ^•IŠÖß’E‰PœÜ‚ĚŽĄ—ĂŒoŒą. •ě_Žm1,2, ŹŔŒŤŽĄ2, ‘ĺ’|—IĆ2, ’Ź“cŽü•˝2, Ą–ě—Y‘ž2, ‚‘ŠťŽm2 (1—Տ°‰đ–U‹łˆç, 2ŽŠO): ‘ć64‰ń“ú–{ŽčŠO‰ČŠw‰ďŠwpW‰ď (2021/4/23), ’ˇč (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723459. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) X—F•Ş—ŢType 1-B3MóœœÜ‚ɑ΂ˇ‚é”w‘¤i“ü‚É‚ć‚鉓ˆĘœ•Đ‚Š‚ç‹ßˆĘœ•Đ‚ÉŒü‚Ż‚ăXƒNƒŠƒ…[‚đ‘}“ü‚ˇ‚鍜Ü•”ŒĹ’č–@. ŹŔŒŤŽĄ1, ‘˝“c‘ń–î1, •ě_Žm1,2, ‘ĺ’|—IĆ1, ‚‘ŠťŽm1 (1ŽŠO, 2—Տ°‰đ–U‹łˆç): ‘ć64‰ń“ú–{ŽčŠO‰ČŠw‰ďŠwpW‰ď (2021/4/23), ’ˇč (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723460. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒS[ƒ‹ƒL[ƒp[‚ރ{[ƒ‹‚đŽčś•”‚ĹƒZ[ƒu‚ľ‚˝Ű‚Ɏ󏝂ľ‚˝‚ƍl‚Ś‚ç‚ę‚˝MóœœÜ‚Ě2—á. ‘˝“c‘ń–î1, ŹŔŒŤŽĄ1, •ě_Žm1,2, ‘ĺ’|—IĆ1, ŒŠ–Ú’q‹I1, ‚‘ŠťŽm1 (1ŽŠO, 2—Տ°‰đ–U‹łˆç): ‘ć94‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠwp‘‰ď (2021/5/20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723461. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŹŽ™EÂ”NŠú‚É‚¨‚Ż‚é•sˆŔ’čŒ^•IŠÖß’E‰PœÜ. •ě_Žm1,2, ŹŔŒŤŽĄ2, ‘ĺ’|—IĆ2, Ą–ě—Y‘ž2, –ÚŽž—LŠóŒb2, ’Ź“cŽü•˝2, ŒŠ–Ú’q‹I2, ‚‘ŠťŽm2 (1—Տ°‰đ–U‹łˆç, 2ŽŠO): ‘ć94‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠwp‘‰ď (2021/5/20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723462. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) COVID-19ƒpƒ“ƒfƒ~ƒbƒN‰ş‚É‚¨‚Ż‚é“–‰@ŽOŽŸ‹~‹}‚É”Ŕ‘—‚ł‚ę‚˝ŠOŠłŽŇ‚¨‚ć‚ѐŽŒ`ŠOŽčp”‚̐„ˆÚ‚ĚŒŸ“˘. ‰Í‘ş@’ź1, ź‰YWł2, ŻŽi^‘ž˜Y1, •ôŒ´Gš, ‚‘ŠťŽm1 (1ŽŠO, 2‹~–˝): ‘ć47‰ń“ú–{œÜŽĄ—ĂŠw‰ďŠwpW‰ď (2021/7/3), _ŒË.

723463. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •ĎŒ`ŤŒŇŠÖßÇ‚É‚¨‚Ż‚é’†•ŤŠ´ěŠÖ˜A’ɂސlHŒŇŠÖß’uŠˇpŒă‚É‹y‚Ú‚ˇ‰e‹ż. ‘ĺ‹´Œc‹v1, •Ÿ“‡Œ’‰î2, “ŕ“cŒ’‘ž˜Y2, ŹŽR’q‹v1, “y‰Ž^•ä1, âV“ĄLŽ÷1, “ŕŽRŸ•ś2,3, ‚•˝ŽL4, ˆäă@Œş2, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO, 3ˆă—ĂˆŔ‘SEŠÇ—, 4ˆă—ÉqśŠw•”): ‘ć51‰ń“ú–{lHŠÖßŠw‰ď (2021/7/7), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), ´˜^W p.339.

723464. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Ž‰Žż‘ăŽÓˆŮí‚É”ş‚¤‹Řƒ^ƒCƒv’˛ßˆöŽq‚̕ωť. ŹŽR’q‹v1, “ŕ“cŒ’‘ž˜Y2, “cŕV@—Č2, œAŕV’ź–ç, ‘ĺ‹´Œc‹v1, •Ÿ“‡Œ’‰î2, ŠÖŒű—T”V2, ‹{éłs2, ˆäă@Œş2, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO): ‘ć36‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/14-15), ŽOd.

723465. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹Ů‹}Ž–‘Ԑ錞‚É”ş‚¤œ‘e頏NJłŽŇ‚ĚŠˆ“ŽŤ’ቺ‚ލœ–§“x, œ‘ăŽÓƒ}[ƒJ[‚É‹y‚Ú‚ˇ‰e‹ż‚ɂ‚˘‚Ä. ‰ĄŠÖ—YŽi1, “ŕ“cŒ’‘ž˜Y2, ě‹v•Ű•ŕ2, •“cW‹`1, ŹŽR’q‹v1, ‘ş“cK—C1, ‹{éłs2, ˆäă@Œş2, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO): ‘ć36‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/14-15), ŽOd.

723466. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’ĹŠÔ”ÂŠQŒă‚ĚApelin‚¨‚ć‚Ń‚ť‚ĚŽó—e‘ĚAPJ‚Ě”­Œť“Ž‘Ô‚ÉŠÖ‚ˇ‚錟“˘. •“cW‹`1, “ŕ“cŒ’‘ž˜Y2, ‹{éłs2, ’†˜e[Í2, ě‹v•Ű•ŕ2, ˆäă@Œş2, ŠÖŒű—T”V2, âV“Ą@˜j2, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO): ‘ć36‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/14-15), ŽOd.

723467. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”ě–ž•ĎŒ`Ť•GŠÖßÇŠłŽŇ‚ĚŠŠ–Œ‘gD‚É‚¨‚Ż‚鉖ŠîŤüˆŰ‰č×–E‘BˆöŽqbFGF”­Œť‘‰Á‹@\‚ĚŒŸ“˘. ‚“c@Œ¤1, “ŕ“cŒ’‘ž˜Y2, Œ}@@Šw1, ‘Šě@~2, ŠâŁ@‘ĺ2, ‹{éłs2, ˆäă@Œş2, ‘ĺŠŃ—TŽq3, ŠÖŒű—T”V2, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO, 3•a‘ԁEf—ĂŒn): ‘ć36‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/14-15), ŽOd.

723468. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”ě–ž•ĎŒ`Ť•GŠÖßÇŠłŽŇ‚ĚŠŠ–Œ‘gD‚É‚¨‚˘‚Ä‘‰Á‚ˇ‚é”ě–ž×–E‚Ě•\ŒťŒ^‚ĚŒŸ“˘‚ƉŠÇŤƒTƒCƒgƒJƒCƒ“ŽYś‚Ö‚ĚŠÖ—^‚ĚŒŸ“˘. ‚“c@Œ¤1, “ŕ“cŒ’‘ž˜Y2, ‘Šě@~2, ŠâŁ@‘ĺ2, Œ}@@Šw1, ‹{éłs2, ˆäă@Œş2, ŠÖŒű—T”V2, ‘ĺŠŃ—TŽq3, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO, 3•a‘ԁEf—ĂŒn): ‘ć36‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/14-15), ŽOd.

723469. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒqƒAƒ‹ƒƒ“Ž_d‰ťƒQƒ‹‚đ—p‚˘‚ÄBMP-2‚đ“ą“ü‚ľ‚˝lHœ‚ĚŒă‘¤•űŒĹ’čp‚É‚¨‚Ż‚鍜Œ`Ź‘ŁiŒř‰Ę‚ĚŒŸ“˘. •“cW‹`1, “ŕ“cŒ’‘ž˜Y2, ŻŽi^‘ž˜Y2, ‰ĄŠÖ—YŽi1, ‹{éłs2, âV“Ą@˜j2, ˆäă@Œş2, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO): ‘ć36‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/14-15), ŽOd.

723470. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •ĎŒ`ŤŠÖßÇ‚ĚŠŠ–Œ‘gD‚É‚¨‚Ż‚é”ě–ž×–E—R—ˆ_Œoƒyƒvƒ`ƒh‚ĚŒŸ“˘. ‚“c@Œ¤1, “ŕ“cŒ’‘ž˜Y2, Œ}@@Šw1, ‘Šě@~2, ŠâŁ@‘ĺ2, ‹{éłs2, ˆäă@Œş2, ŠÖŒű—T”V2, ‘ĺŠŃ—TŽq3, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO, 3•a‘ԁEf—ĂŒn): ‘ć36‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/14-15), ŽOd.

723471. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œ´”­Ťœ‘e頏ǃ‚ƒfƒ‹‚Ě‹Ř‘gD‚É‚¨‚Ż‚éUCP2‚Ě”­Œť’ቺ‚Ć‚ť‚̒ቺƒƒJƒjƒYƒ€‚ĚŒŸ“˘. ŹŽR’q‹v1, “ŕ“cŒ’‘ž˜Y2, ‹{éłs2, “cŕV@—Č2, ˆäă@Œş2, “ĄŠŞŽőŽq, ‘ĺ‹´Œc‹v1, ŠÖŒű—T”V2, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO): ‘ć36‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/14-15), ŽOd.

723472. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) BMP-2ŠÜ—L‹ÇŠd‰ťƒqƒAƒ‹ƒƒ“Ž_ƒQƒ‹‚đ—p‚˘‚˝L”͈͍œŒ‡‘šC•œ–@‚Ě—L—pŤ. ŻŽi^‘ž˜Y1, “ŕ“cŒ’‘ž˜Y1, “cŕV@—Č1, ŠÖŒű—T”V1, ˆäă@Œş1, âV“Ą@˜j1, ‹{éłs1, •“cW‹`2, ‚‘ŠťŽm1 (1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć36‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/14-15), ŽOd.

723473. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒ}ƒEƒX‘ĺ‘ڍœ“ŤœÜƒ‚ƒfƒ‹‚É‚¨‚Ż‚éBMP-2ŠÜ—L‚”Z“xPoly (POG) nƒQƒ‹‚̍œŒ`Ź‘ŁiŒř‰Ę‚ĚŒŸ“˘. •“cW‹`1, “ŕ“cŒ’‘ž˜Y2, ŻŽi^‘ž˜Y2, ŠÖŒű—T”V2, ‹{éłs2, âV“Ą@˜j2, ‘ş“cK—C1, ‰ĄŠÖ—YŽi1, ŹŽR’q‹v1, ˆäă@Œş2, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO): ‘ć36‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/14-15), ŽOd.

723474. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰Á—î‚É”ş‚¤TGF-ƒŔ‚Ě”­ŒťŒ¸­‚ĆCD206—zŤ’ŊԔ“ŕÝŤƒ}ƒNƒƒtƒ@[ƒW‚ĚŒ¸­‚Ć‚ĚŠÖ˜AŤ‚ĚŒŸ“˘. “ŕ“cŒ’‘ž˜Y1, ě‹v•Ű•ŕ1, ‰ĄŠÖ—YŽi2, ‹{éłs1, •“cW‹`2, ˆäă@Œş1, âV“Ą@˜j1, ŠÖŒű—T”V1, ‚‘ŠťŽm1 (1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć36‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/14-15), ŽOd.

723475. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) TGF-ƒŔ‚đ‰î‚ľ‚˝’ŊԔ‘gD“ŕ_ŒoŹ’ˇˆöŽq‚Ě”­Œťă¸‹@\‚ĚŒŸ“˘. ‰ĄŠÖ—YŽi1, “ŕ“cŒ’‘ž˜Y2, ě‹v•Ű•ŕ2, ‹{éłs2, •“cW‹`1, ˆäă@Œş2, âV“Ą@˜j2, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO): ‘ć36‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/14-15), ŽOd.

723476. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) M2ƒ}ƒNƒƒtƒ@[ƒW•Ş‰ť‚É‚¨‚Ż‚éTGF-ƒŔ‚Ě–đŠ„‚ĚŒŸ“˘. •“cW‹`1, “ŕ“cŒ’‘ž˜Y2, ě‹v•Ű•ŕ2, ‹{éłs2, ˆäă@Œş2, ‰ĄŠÖ—YŽi1, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO): ‘ć36‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/14-15), ŽOd.

723477. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠÖßO‘šŠłŽŇ‚ĚŠŠ–Œ‘gD‚É‚¨‚Ż‚鉊ÇŤƒTƒCƒgƒJƒCƒ“‚Ě”­Œťă¸: ––Šú•ĎŒ`ŤŒŇŠÖßÇ‚Ć‚Ě”äŠr. ŹŽR’q‹v1, “ŕ“cŒ’‘ž˜Y2, •Ÿ“‡Œ’‰î2, ‘ĺ‹´Œc‹v1, “ŕŽRŸ•ś3, ˆäă@Œş2, ‘ĺŠŃ—TŽq4, ‚•˝ŽL5, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO, 3ˆă—ĂˆŔ‘SEŠÇ—, 4•a‘ԁEf—ĂŒn, 5ˆă—ÉqśŠw•”): ‘ć36‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/14-15), ŽOd.

723478. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —ź‘¤‰şŽˆCT‰ć‘œ‚đ—p‚˘‚˝•ĎŒ`Ť•GŠÖßÇ‚É‚¨‚Ż‚é•Đ‘¤Ť‚̋ؗʕωť‚Ƌ͕ؗωť‚Ć‚ĚŠÖ˜AŤ‚ĚŒŸ“˘. Œ}@@Šw1, “ŕ“cŒ’‘ž˜Y2, ’Ë“cˆŸ—T”ü2, ‘Šě@~2, ŠâŁ@‘ĺ2, ‚–쏸‘ž˜Y2, ‹{éłs2, ŠÖŒű—T”V2, ˆäă@Œş2, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO): ‘ć36‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/14-15), ŽOd.

723479. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •›bó‘Bƒzƒ‹ƒ‚ƒ“‚É‚ć‚鉊ÇŤƒTƒCƒgƒTƒCƒgƒJƒCƒ“, _ŒoŹ’ˇˆöŽq—}§Œř‰Ę‚ĚŒŸ“˘|’P‰ń“Š—^‚Ć”˝•œ“Š—^‚̍ě—p”äŠr|. ‘ş“cK—C1, “ŕ“cŒ’‘ž˜Y2, ‹{éłs2, “cŕV@—Č2, ˆäă@Œş2, ŹŽR’q‹v1, ě‹v•Ű•ŕ2, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO): ‘ć36‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/14-15), ŽOd.

723480. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “űŠŕ‹ÇŠœ“]ˆÚƒ‚ƒfƒ‹‚ɑ΂ˇ‚éacridine orangeŒŒŠÇ“ŕ“Š—^‚Ćbisphosphonate‚ĚŒř‰Ę. “ŒŠC—Ń—Č, ‹{˜Ž‹v, –{‹˝“šś, ””ě—YŽi, ‰iŕV”ŽK, “y]”ŽK, “ŕ“cŒ’‘ž˜Y1, ‘Šě@~1, “‡“c—mˆę (1ŽŠO): ‘ć36‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/14-15), ŽOd.

723481. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒ‰ƒbƒg_Œo‘šƒ‚ƒfƒ‹‚ɑ΂ˇ‚éƒgƒƒ“ƒrƒ““Y‰Á, ”ń“Y‰Áplatelet-rich plasma‚Ě’ÉŠo‰ß•q—}§Œř‰Ę‚Ě”äŠr. Œüˆä–ąW, “ŕ“cŒ’‘ž˜Y1, œAŕV’ź–ç, Žu‰ęN_, ˆî–ŃˆęG, Ü“cƒ‹v, ]Œű@˜a, ź‰Y—C‰î, ˆäă@Œş1, ‚‘ŠťŽm1, ‘ĺ’š¸Ži (1ŽŠO): ‘ć36‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/14-15), ŽOd.

723482. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ––˝_ŒoáŠQ‚É‚¨‚Ż‚éV-set and transmembrane domain containing 4‚Ě–đŠ„‚ĚŒŸ“˘. ‰ĄŠÖ—YŽi1, “ŕ“cŒ’‘ž˜Y2, Œüˆä–ąW, Œ}@@Šw1, ˆäă@Œş2, ‹{éłs2, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO): ‘ć36‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/14-15), ŽOd.

723483. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) V-set and transmembrane domain containing 4‚É‚ć‚éƒ}ƒNƒƒtƒ@[ƒWŠˆŤ§Œä‹@\‚ĆŠŠ–Œ‰Š‚Ö‚ĚŠÖ—^‚ĚŒŸ“˘. Œ}@@Šw1, “ŕ“cŒ’‘ž˜Y2, ‘ĺ‹v•Ű’ź3, ź–{r‰p4, ‚–쏸‘ž˜Y2, ‚“c@Œ¤1, ŠâŁ@‘ĺ2, ‘Šě@~2, ˆäă@Œş2, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO, 3ŽŔ“Ž, 4ˆă—ÉqśŠw•”): ‘ć36‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/14-15), ŽOd.

723484. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œ¨ŠÖß•sˆŔ’čÇŠłŽŇ‚ĚŒ¨bă˜rŠÖßŠŠ–Œ‘gD‚ł͉ŠÇŤƒTƒCƒgƒJƒCƒ“, ƒ}ƒNƒƒtƒ@[ƒWƒ}[ƒJ[‚Ě”­Œť‚ޘ´i‚ľ‚Ä‚˘‚é. @d‹żŽq1, ŒŠ–Ú’q‹I2, “ŕ“cŒ’‘ž˜Y2, “cŕV@—Č2, ’†˜e[Í2, Îˆä‘ĺ•ă1, ˛“Ą@‰ë3, ˆäă@Œş2, ‚‘ŠťŽm2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO, 3–Ɖu): ‘ć36‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/14-15), ŽOd.

723485. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰Á—î‚É”ş‚¤äF”ÂTGF-ƒŔŽYśă¸‚͍RŽ_‰ťŠÖ˜Aˆâ“`Žq‚Ě”­Œť‚đ’ቺ‚ł‚š‚é. “cŕV@—Č1, “ŕ“cŒ’‘ž˜Y1, ŒŠ–Ú’q‹I1, ’†˜e[Í1, @d‹żŽq2, Îˆä‘ĺ•ă2, ‘ĺŠŃ—TŽq3, ˆäă@Œş1, ‚‘ŠťŽm1 (1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3•a‘ԁEf—ĂŒn): ‘ć36‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/14-15), ŽOd.

723486. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) äF”Â’f—ôŠłŽŇ‚ĚŠŠ–Œ‘gD‚É‚¨‚Ż‚éNGF”­Œť‚Ćáu’É‚ĚŠÖ˜AŤ. “cŕV@—Č1, ŒŠ–Ú’q‹I1, “ŕ“cŒ’‘ž˜Y1, –ź‘q’źd, ’†˜e[Í1, @d‹żŽq2, Îˆä‘ĺ•ă2, ‘ĺŠŃ—TŽq3, ˆäă@Œş1, ‚‘ŠťŽm1 (1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3•a‘ԁEf—ĂŒn): ‘ć36‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/14-15), ŽOd.

731017. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) Avenir Complete stem‚Ě’ZŠú—Տ°ŒoŒą‚ĆŽčpŽč‹Z‚Ěƒ|ƒCƒ“ƒg. •Ÿ“‡Œ’‰î (ŽŠO): Zimmer Biomet Webinar (2021/4/8), WebŠJĂ.

731018. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) Femoroacetabular impingement (FAI) ‚̐f’f‚ĆŽĄ—Ă. •Ÿ“‡Œ’‰î (ŽŠO): ‘ć29‰ń‘Š–ÍŒ´œ‘e頏nj¤‹†‰ď (2021/6/5), WebŠJĂ.

731019. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ‰ť”^ŤŒŇŠÖß‰Š‚ɑ΂ˇ‚éŒŇŠÖß‹žŽ‹‰şŽčp. •Ÿ“‡Œ’‰î (ŽŠO): ‘ć36‰ń_“ސ쐎Œ`ŽčpŽč‹ZŒ¤‹†‰ď (2021/7/9), WebŠJĂ.

731020. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) Full HA coated Corail stem‚ĚƒRƒ“ƒZƒvƒg‚ĆŽg—p‚É‚¨‚Ż‚钍ˆÓ“_. •Ÿ“‡Œ’‰î (ŽŠO): ‘ć28‰ńHip Forum (2021/7/30), •lź.

731021. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) Avenir stem‚Ć‚Ěˆá‚˘. •Ÿ“‡Œ’‰î (ŽŠO): Salon de Corail (2021/7/31), WebŠJĂ.

731022. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ŽŒ`ŠO‰Č‚É‚¨‚Ż‚éMRSAŠ´őÇŽĄ—Ă-ŒŇŠÖßŠO‰Č‚ĚŽŔŰ. “ŕŽRŸ•ś1,2 (1ˆă—ĂˆŔ‘SEŠÇ—, 2ŽŠO): Š´őÇ Virtual Meeting (2021/9/16), WebŠJĂ.

731023. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ŽŒ`ŠO‰Č‚É‚¨‚Ż‚éSSI‘΍ô‘S”ʁ|ASTŠˆ“Ž‚Š‚çŽčpŽş‚܂Ł|. “ŕŽRŸ•ś1,2 (1ˆă—ĂˆŔ‘SEŠÇ—, 2ŽŠO): ‘ć2‰ń“ú–{ŠO‰ČŠ´őÇŠw‰ď“Á•ĘƒZƒ~ƒi[ (2021/9/28), WebŠJĂ.

731024. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) Š°œ‰PÄ’uŠˇ‚ĚŽĄ—Ð헪. “ŕŽRŸ•ś1,2 (1ˆă—ĂˆŔ‘SEŠÇ—, 2ŽŠO): Zimmer Biomet RTCD THA ‚¨‚Ż‚é Dual Mobility (2021/10/12), WebŠJĂ.

731025. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ‰ń•œŠúƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“•a‰@‚É‚¨‚Ż‚鍜‘e頏ǐf—Ă. •Ÿ“‡Œ’‰î (ŽŠO): ˆŽ‰ťŹƒtƒ@[ƒ}Šé‹Ć“ŕŒ¤C (2022/1/20), WebŠJĂ.

731026. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ƒZƒ‰ƒsƒXƒg‚É“`‚Ś‚˝‚˘|ŒŇŠÖßŽžŠł‚̐f’f‚ĆŽĄ—Á|•a‘Ô‰đŽß‚Š‚ç’m‚Á‚Ä‚¨‚­‚ׂŤŽčp‚܂Ł|. •Ÿ“‡Œ’‰î (ŽŠO): Professional Therapy Seminars (2022/2/5), WebŠJĂ.

731027. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ’´‰š”g‚É‚ć‚鍜ÜŽĄ—Ă‚ĚŠî‘b‚Ć—Ő°. č•”@Œ› (ŽŠO): ‘ć159‰ńˇ‰Ş—Տ°ŽŒ`ŠO‰Čˆă‰ď (2022/3/10), WebŠJĂ.

731028. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) Ň’Ĺ•ĎŒ`‚ɑ΂ˇ‚鎥—Ð헪|áu’É‚Ö‚Ě‘Îˆ‚đŠÜ‚߂ā|. ˆäă@Œş (ŽŠO): Pain Expert Meeting (2022/3/22), WebŠJĂ.

732067. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) Ň’ĹŽčp‚É‚¨‚Ż‚éŽčp•”ˆĘŠ´őƒŠƒXƒN‚Ě—\‘ރc[ƒ‹. ’r“cM‰î1, ˆäă@Œş1, ‹{éłs1, ’†ŕVr”V1, ˆä‘ş‹M”V1, ”’ŕV‰hŽ÷1, ŽO‘ş—I—S1, ‚‘ŠťŽm1, “ď”gF“ż (1ŽŠO): ‘ć172‰ń_“ސ쐎Œ`ĐŠQŠO‰ČŒ¤‹†‰ď (2021/7/10), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

732068. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŒŇŠÖß‹ž‚ĆTHA. •Ÿ“‡Œ’‰î1, ŹŽR’q‹v1, ‘ĺ‹´Œc‹v2, “y‰Ž^•ä2, âV“ĄLŽ÷2, “ŕŽRŸ•ś3, ‚•˝ŽL4, ‚‘ŠťŽm1 (1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ĂˆŔ‘SEŠÇ—, 4ˆă—ÉqśŠw•”): ‘ć16‰ń“ú–{ŒŇŠÖß‹žŒ¤‹†‰ď (2021/9/4), WebŠJĂ.

732069. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‚“xœŒ‡‘š‚đ—L‚ˇ‚élHŒŇŠÖßÄ’uŠˇp‚ĚŽĄ—Ð헪: “ŻŽíœ‚đ—p‚˘‚˝‘Ήž. •Ÿ“‡Œ’‰î1, “ŕŽRŸ•ś2, ‚•˝ŽL3, ˆäă@Œş1, ‚‘ŠťŽm1 (1ŽŠO, 2ˆă—ĂˆŔ‘SEŠÇ—, 3ˆă—ÉqśŠw•”): ‘ć70‰ń“Œ“ú–{ŽŒ`ĐŠQŠO‰ČŠw‰ď (2021/9/18), ŠâŽč (ƒnƒCƒuƒŠƒbƒhŠJĂ).

732070. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) Źlă˜rœ‰“ˆĘ•”œÜ‚ĚŽĄ—Ă: •IŠÖßŽüˆÍœÜpŒă‚ɍ‡•š‚ľ‚˝ŠOŤ•IŠÖßSk‚ĚŽĄ—ĂŒoŒą. •ě_Žm1,2, ŹŔŒŤŽĄ2, ‘ĺ’|—IĆ2, ’Ź“cŽü•˝2, ‚‘ŠťŽm2 (1—Տ°‰đ–U‹łˆç, 2ŽŠO): 173‰ń_“ސ쐎Œ`ĐŠQŠO‰ČŒ¤‹†‰ď (2021/11/20), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

732071. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) Avenir Complete stem‚đŽg—p‚ľ‚˝ˆóŰ („‚ľƒ|ƒCƒ“ƒg). •Ÿ“‡Œ’‰î (ŽŠO): ‘ć6‰ńHITŒ¤‹†‰ď (2022/2/26), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733151. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‘ĺ‘ڍœ•Ą‡œÜ‚É‚¨‚Ż‚éŽOdœÜ‚Ě2—á ‘ĺč—T“l1, ŻŽi^‘ž˜Y1, ź‰YWł2, ‰Í‘ş@’ź1, ŽO‘ş—I—S1, •ôŒ´Gš, ‚‘ŠťŽm1 (1ŽŠO, 2‹~–˝): ‘ć172‰ń_“ސ쐎Œ`ĐŠQŠO‰ČŒ¤‹†‰ď (2021/7/10), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733152. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ăřœäCœœŠ˛•”œÜpŒă‚É‘ŤŠÖß‰Ę•”œÜPER stage 4‚̍‡•š‚Ş”ť–ž‚ľ‚˝1—á. źŒ´Žj•ü1, ź‰YWł2, ‰Í‘ş@’ź1, ŻŽi^‘ž˜Y1, •ôŒ´Gš, ‚‘ŠťŽm1 (1ŽŠO, 2‹~–˝): ‘ć70‰ń“Œ“ú–{ŽŒ`ĐŠQŠO‰ČŠw‰ď (2021/9/17), ˇ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733153. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “ŻŽíœ‚đ—p‚˘‚˝Impaction bone grafting–@‚É‚ÄCoonrad-MorreyŒ^lH•IŠÖß‚ĚÄ’uŠˇp‚đŽ{s‚ľ‚˝ŠÖßƒŠƒEƒ}ƒ`‚Ě1—á. ‚‰Şƒˆę1, ŹŔŒŤŽĄ1, “ŕŽRŸ•ś1,2, •ě_Žm1,3, ‘ĺ’|—IĆ1, ‚‘ŠťŽm1 (1ŽŠO, 2ˆă—ĂˆŔ‘SEŠÇ—, 3—Տ°‰đ–U‹łˆç): ‘ć27‰ń_“ސěăŽˆŠO‰ČŒ¤‹†‰ď (2021/10/23), WebŠJĂ.

733154. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ”­Ç‹@˜‚ĚˆŮ‚Č‚é“¤óŽOŠpœŠÖßÇ‚ĚŽĄ—ĂŒoŒą. ‘ĺ’|—IĆ1, •ě_Žm1,2, ŹŔŒŤŽĄ1, ŒŠ–Ú’q‹I1, ‚‘ŠťŽm1 (1ŽŠO, 2—Տ°‰đ–U‹łˆç): ‘ć27‰ń_“ސěăŽˆŒ¤‹†‰ď (2021/10/23), WebŠJĂ.

733155. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŹŽ™EÂ”NŠú‚É‚¨‚Ż‚é•sˆŔ’čŒ^•IŠÖß’E‰PœÜ‚ĚŽĄ—ĂŒoŒą. •ě_Žm1,2, ŹŔŒŤŽĄ2, ‘ĺ’|—IĆ2, ’Ź“cŽü•˝2, ŒŠ–Ú’q‹I2, ‚‘ŠťŽm2 (1—Տ°‰đ–U‹łˆç, 2ŽŠO): ‘ć27‰ń_“ސěăŽˆŒ¤‹†‰ď (2021/10/23), WebŠJĂ.

733156. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) pŒă‘Šú‚É—\‘zŠO‚̍œ”˝‰ž‚đŽŚ‚ľ‚˝Full HA stem‚Ě1—á. •Ÿ“‡Œ’‰î1, ŹŽR’q‹v2, ‘ĺ‹´Œc‹v2, âV“ĄLŽ÷2, “y‰Ž^•ä2, “ŕŽRŸ•ś3, ‚•˝ŽL4, ‚‘ŠťŽm1 (1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ĂˆŔ‘SEŠÇ—, 4ˆă—ÉqśŠw•”): ‘ć56‰ńŠÖ“ŒŒŇŠÖß§˜b‰ď (2022/3/5), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733157. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Šî‘bŽžŠł‚Ě‚Č‚˘Źl‚É”­ś‚ľ‚˝—ź‘¤’†Žw[Žw‹ü‹ŘäF”牺’f—ô‚Ě1—á. –î–씎”V1, ŹŔŒŤŽĄ1, •ě_Žm1, ‘ĺ’|—IĆ1, ŒŠ–Ú’q‹I1, ˆäă@Œş1, ‚‘ŠťŽm1 (1ŽŠO): ‘ć62‰ńŠÖ“ŒŽŒ`ĐŠQŠO‰ČŠw‰ď (2022/3/12), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-110020. [Œ´’˜] Acceleration of bone formation using in situ-formed hyaluronan-hydrogel containing bone morphogenetic protein-2 in a mouse critical size bone defect model. Shoji S1, Uchida K1, Tazawa R1, Saito W1, Kuroda A2, Sekiguchi H1, Ishii D2, Inoue S2, Inoue G1, Takaso M1: Biomed Mater Eng 2021/1; 32 (4): 207-15. (ŻŽi^‘ž˜Y1, “ŕ“cŒ’‘ž˜Y1, “cŕV@—Č1, âV“Ą@˜j1, •“cW‹`2, ŠÖŒű—T”V1, Îˆä‘ĺ•ă2, ˆäă@ăÄ2, ˆäă@Œş1, ‚‘ŠťŽm1: 1ŽŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

'20-110021. [Œ´’˜] Limitation of the external glenohumeral joint rotation is associated with subacromial impingement syndrome, especially pain. Ishi D1, Kenmoku T2, Tazawa R2, Nakawaki M2, Nagura N, Muneshige K1, Saito K, Takaso M2: JSES Int 2021/3; 5 (3): 430-8. (Îˆä‘ĺ•ă1, ŒŠ–Ú’q‹I2, “cŕV@—Č2 ’†˜eˆňÍ2, @d‹żŽq1, ‚‘ŠťŽm2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŽŠO)

'20-310003. [Ç—á•ń] Polymicrobial Extensor Tenosynovitis Including Mycobacterium chelonae Caused by a Dog Bite: A Case Report. Minato S1, Sukegawa K2,3, Onuma K3, Otake Y1, Iida R, Takaso M3: JBJS Case Connect 2021/2; 11 (1): e20.00608. (–Š˛‘ăŽq1, •ě_Žm2,3, ŹŔŒŤŽĄ3, ‘ĺ’|—IĆ1, ‚‘ŠťŽm3: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2—Տ°‰đ–U‹łˆçŒ¤, 3ŽŠO)

'20-310004. [Ç—á•ń] Displaced Isolated Coronal Shearing Fracture of theDisplaced isolated coronal shearing fracture of the trapezoid: a case report. Otake Y1, Sukegawa K1,2, Onuma K1, Machida S1, Iida R, Takaso M1: Case Reports Plast Surg Hand Surg 2021/3; 8 (1): 50-5. (‘ĺ’|—IĆ1, •ě_Žm1,2, ŹŔŒŤŽĄ1, ’Ź“cŽü•˝1, ‚‘ŠťŽm1: 1ŽŠO, 2—Տ°‰đ–U‹łˆçŒ¤)

'20-320003. [Ç—á•ń] ŠÖßƒŠƒEƒ}ƒ`‚ĚŠÓ•Ę‚É‚¨‚­‚ׂŤ”ńŒ‹ŠjŤRŽ_‹ŰÇ|ŽĄ—ĂŠJŽn‚Ü‚ĹŠúŠÔ‚đ—v‚ľ‚˝‹łˆç“I‚Č2Ç—á|. ‘ĺ’|—IĆ1, •ě_Žm1,2, ‘˝“c‘ń–î1, ŹŔŒŤŽĄ1, ‚‘ŠťŽm1 (1ŽŠO, 2—Տ°‰đ–U‹łˆçŒ¤): “ú–{ŽčŠO‰ČŠw‰ďŽGŽ 2020/9; 37 (5): 743-7.

'20-522004. [uŔ]y“ÁW: œÜ‚ɑ΂ˇ‚éĎ‹É“I•Ű‘ś—Ă–@zĄŠî‘b•Ň@‰–ŠîŤüˆŰ‰č×–E‘BˆöŽq‚̍œÜŽĄ–ü‰ß’ö‚ւ̉e‹ż. “ŕ“cŒ’‘ž˜Y (ŽŠO): —Տ°ŽŒ`ŠO‰Č 20213/; 56 (3): 247-51.

[’˜@‘]

'15-620001. [Šwp‘ (•Ş’SŽˇ•M)]yŽĺ—vŽžŠłE‘Sg–Ô—…! ‘Ě‘€—Ă–@ƒI[ƒ‹ƒuƒbƒN ‚Đ‚Ć‚ß‚Ĺ‚í‚Š‚éŒř‰Ę“I‚Č‹Ř‚ĚŽg‚˘•űz3Í ŽŔ‘H ‚˘‚´‘Ě‘€‚ĚŽw“ą|ŽžŠłEÇó‚É‚ ‚í‚š‚˝‘Ě‘€|@02 Œ¨‚ą‚čEŒ¨’ɁE•I’É‚Ě‘Ě‘€, p.50-7. ŒŠ–Ú’q‹I (ŽŠO), •Ň: ‚•˝ŽL, ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, “Œ‹ž, 2016/3”­s.

'19-620001. [Šwp‘ (•Ş’SŽˇ•M)]yŽŒ`ŠO‰ČŽžŠł‚ĚƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Ĺ‘Oü (Journal of Clinical Rehabilitation 28ŠŞ—ŐŽž‘Š§†)zŒ¨ŠÖßŽüˆÍ‰Š, p.613-620. ŒŠ–Ú’q‹I (ŽŠO), ˆăŽ•–ňo”Ĺ, “Œ‹ž, 2019/6”­s.

'19-620002. [Šwp‘ (•Ş’SŽˇ•M)]yĄ“ú‚ĚŽžŠłŽŤ“T Current Decision SupportzäF’f—ô (Žč•”). •ě_Žm1,2 (1—Տ°‰đ–U‹łˆç, 2ŽŠO), ƒvƒŒƒVƒWƒ‡ƒ“, 2019”­s.

'19-620003. [Šwp‘ (•Ş’SŽˇ•M)]yĄ“ú‚ĚŽžŠłŽŤ“T Current Decision Supportz’E‰P‚ĆˆŸ’E‰P (Žč•”). •ě_Žm1,2 (1—Տ°‰đ–U‹łˆç, 2ŽŠO), ƒvƒŒƒVƒWƒ‡ƒ“, 2019”­s.

'20-620002. [Šwp‘ (•Ş’SŽˇ•M)]yĄ“ú‚ĚŽĄ—ĂŽwj 2021z18. ŽŒ`ŠO‰ČŽžŠł@•IŠÖß•sˆŔ’čÇ, p.1142-3. ŒŠ–Ú’q‹I (ŽŠO), ‘•ŇW: •ŸˆäŽŸ–î, ‚–؁@˝, ŹŽşˆęŹ, ˆăŠw‘‰@, “Œ‹ž, 2021/1”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

'20-723028. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •IŠÖßŒăŠO‘¤‰ńů•sˆŔ’萍‚đ—L‚ľ‚˝ŹŽ™ă˜rœŠO‘¤č÷sleeveœÜ‚Ě1—á. Ą–ě—Y‘ž1, •ě_Žm1,2, ŹŔŒŤŽĄ1, ‘ĺ’|—IĆ1, ’Ź“cŽü•˝1, ŒŠ–Ú’q‹I1, ‚‘ŠťŽm1 (1ŽŠO, 2—Տ°‰đ–U‹łˆç): ‘ć33‰ń“ú–{•IŠÖßŠw‰ďŠwpW‰ď (2021/2/12), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-733012. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) óŽw‹ü‹ŘäF”牺’f—ô‚đ‡•š‚ľ‚˝Type 5aŹŽw[Žw‹ü‹ŘäF—ô—Ł‘š‚Ě1—á|•sˆŔ’č‚Č––ßœ‰ĄœÜ‚Ć—ô—ŁœÜ‚ɑ΂ˇ‚éhook plate–@|. ”Ń“c仗^, •ě_Žm1,2, ŹŔŒŤŽĄ2, ‘ĺ’|—IĆ2, ‚‘ŠťŽm2 (1—Տ°‰đ–U‹łˆç, 2ŽŠO): ‘ć35‰ń“Œ“ú–{ŽčŠO‰ČŒ¤‹†‰ď (2021/1/30), ‰F“s‹{.

'20-733013. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Œ˘™ůŒă‚É”­Ç‚ľ‚˝Mycobacterium chelonae‚É‚ć‚éŽč•”L‹ŘäFäFâŠŠ–Œ‰Š‚Ě1—á. –Š˛‘ăŽq2, •ě_Žm1,2, ŹŔŒŤŽĄ2, ‘ĺ’|—IĆ2, ’Ź“cŽü•˝2, ŒŠ–Ú’q‹I2, ‚‘ŠťŽm2 (1ŽŠO, 2—Տ°‰đ–U‹łˆç): ‘ć35‰ń“Œ“ú–{ŽčŠO‰ČŒ¤‹†‰ď (2021/1/30), ‰F“s‹{.

'20-733014. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Ž•œŒă‚Ě•sˆŔ’萍‚ɑ΂ľAPTUS Hand ‚É‚ć‚éˆęŠú“I‘n“ŕŒĹ’č‚đs‚Á‚˝’‹ŒŤŒŽóœŽüˆÍ’E‰P‚Ěˆę—á. ”ě—ŻěP•˝2, ‘ĺ’|—IĆ2, •ě_Žm1,2, ŹŔŒŤŽĄ2, ‚‘ŠťŽm2 (1ŽŠO, 2—Տ°‰đ–U‹łˆç): ‘ć26‰ń–k—˘E“Ą‚Ş‹u‰^“ŽŠíŽžŠłƒtƒH[ƒ‰ƒ€ (2021/3/7), ‘Š–ÍŒ´.

'20-733015. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) f’fEŽĄ—Ă‚É“ďa‚ľ‚˝ŽčŠO‰Č—Ěˆć‚¨‚Ż‚é”ńŒ‹ŠjŤRŽ_‹ŰÇ|3—á•ń|. Ą–ě—Y‘ž2, •ě_Žm1,2, ŹŔŒŤŽĄ2, ‘ĺ’|—IĆ2, –Š˛‘ăŽq2, ‰ĄŠÖ—YŽi3, ‚‘ŠťŽm2 (1ŽŠO, 2—Տ°‰đ–U‹łˆç, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć26‰ń–k—˘E“Ą‚Ş‹u‰^“ŽŠíŽžŠłƒtƒH[ƒ‰ƒ€ (2021/3/7), ‘Š–ÍŒ´.


Œ`ŹŠO‰ČE”ü—eŠO‰ČŠw

[Šwp˜_•ś]

110354. [Œ´’˜] Evaluation of elastin fibres in young and aged eyelids and abdominal skin using computational 3D structural analysis. Tohgasaki T, Kondo S, Nishizawa S, Ishiwatari S, Sakurai T, Ishikawa S1, Takeda A1: Skin Health Dis 2021/6; 1 (4): e58. (ÎěS‰î1, •“c@Œ[1: 1Œ`ŹE”üŠO)

110355. [Œ´’˜] Differentiation and proliferation potencies of human bone tissue-derived mesenchymal stromal cells (hBT-MSCs) after long-term cryopreservation |Comparison among cells stored for 1, 5, 10, 15, and 20 years. Sugimoto Y1, Yamazaki Y1, Moriyama K1, Sugimoto T1, Kumazawa K2, Baba K1,3, Sone Y4, Takeda A1: Regen Ther 2021/9; 18: 363-71. (™–{‰Ŕ1, ŽRčˆŔ°1, XŽR˜a‚Ě1, ™–{F”V1, ŒFŕVŒ›ˆę2, ”nęŽq1,3, ‘]Ş—R”üŽq4, •“c@Œ[1: 1Œ`ŹE”üŠO, 2‹~–˝, 3–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 4f—ÁE•a‘ÔŒn)

110356. [Œ´’˜] Elastin microfibril interface-located protein 1 and its catabolic enzyme, cathepsin K, regulate the age-related structure of elastic fibers in the skin. Kondo S, Tohgasaki T, Shiga S, Nishizawa S, Ishiwatari S, Ishikawa S1, Takeda A1, Sakurai T: J Cosmet Dermatol 2022/10; 21 (10): 4796-804. doi: 10.1111/jocd.14789. Epub 2022 Feb 1. (ÎěS‰î1, •“c@Œ[1: 1Œ`ŹE”üŠO)

120017. [Œ´’˜] ƒƒfƒBƒJƒ‹ƒ\ƒƒ“ƒGƒXƒeƒeƒBƒbƒN‚Ě–đŠ„‚Ć‚ť‚Ě—LŒřŤ‚ɂ‚˘‚ā|–k—˘‘ĺŠwŒ`ŹŠO‰ČE”ü—eŠO‰Č‚Ĺ‚ĚŽć‚č‘g‚݁|. ™–{‰Ŕ1, “‡‘qNl1, ‚ŽR“ÖŽq, ™–{F”V1, “‡ă˜a‘Ľ, ŠÚ“ŕŒNŽ}, ˆŔ‘ƒ~Žq, •“c@Œ[1 (1Œ`ŹE”üŠO): “ú”üŠO•ń 2021/9; 43 (3): 107-19.

310047. [Ç—á•ń] Clinical pitfall with Chievitz's organ: A case report of tongue cancer patient. Kimizuka S1, Fijihara H, Ito Y, Takeda A1, Yamada H, Hamada Y: J Oral Maxillofac Surg, Med, Pathol 2021/5; 33 (3): 272-5. (ŒN’ˍKŽq1, •“c@Œ[1: 1Œ`ŹE”üŠO)

310048. [Ç—á•ń] A patient with macrodystrophia lipomatosa bilaterally affecting the entire upper extremity: reporting of a rare case and literature review. Baba K1,2, Kashiwagi S2, Nemoto M2, Takeda A2, Fukumoto K, Uchinuma E: Case Reports Plast Surg Hand Surg 2021/6; 8 (1): 1-7. (”nęŽq1,2, ”–ؐT–ç2, Ş–{@[2, •“c@Œ[2: 1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`ŹE”üŠO)

310049. [Ç—á•ń] A Histological Evaluation of Artificial Dermal Scaffold Used in Micrograft Treatment: A Case Study of Micrograft and NPWT Performed on a Postoperative Ulcer Formation after Tumor Resection. Niimi Y1, Baba K1,2, Tsuchida M1, Takeda A1: Medicina (Kaunas) 2022/1; 58 (1): 73. (V”ü—Y‘ĺ1, ”nęŽq1,2, “y“c—Žq1, •“c@Œ[1: 1Œ`ŹE”üŠO, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[)

310050. [Ç—á•ń] Devised coronoidectomy with zygomaplasty for coronoid process hyperplasia of the mandible. Kimizuka S1, Fijihara H, Takeda A1, Hamada Y: Oral Maxillofac Surg 2022/1-3; 5: 100233. (ŒN’ˍKŽq1, •“c@Œ[1: 1Œ`ŹE”üŠO)

320009. [Ç—á•ń] ‰şŠ{ˆŸ‘S“EŒă‚ɃJƒXƒ^ƒ€ƒƒCƒhƒ`ƒ^ƒ“ƒgƒŒ[‚ĆPCBM‚É‚ć‚鉺Š{œÄŒš‚ĆŽ•‰ČƒCƒ“ƒvƒ‰ƒ“ƒg‚É‚ć‚é™ů‡ÄŒš‚đs‚Á‚˝1—á. –kžŠGŽ÷, ’†‰Şˆę•q, ŒN’ˍKŽq1, ŽR“cG“T, ’ˇ’J•”[•F, Î’Ë’‰—˜, ěŒű_Ži, ŕ_“c—ÇŽ÷ (1Œ`ŹE”üŠO): “ú–{Š{Šç–ĘƒCƒ“ƒvƒ‰ƒ“ƒgŠw‰ďŽ 2021/4; 20 (1): 45-50.

320010. [Ç—á•ń] Van der WondeÇŒóŒQ‚Ě4—á. ‰F‰ę_Š”ü1, ™–{F”V1, H–{•ôŽ, ™–{‰Ŕ1, ŒN’ˍKŽq1, •“c@Œ[1 (1Œ`ŹE”üŠO): Œ`ŹŠO‰Č 2021/5; 64 (5): 583-9.

320011. [Ç—á•ń] • –Œ“§ÍƒJƒe[ƒeƒ‹”牺ƒgƒ“ƒlƒ‹Š´ő‚ɑ΂ľƒJƒe[ƒeƒ‹‚đ‰ˇ‘ś‚ľ‚Ś‚˝1—á|• ’ź‹ŘE‹Ř–Œ•Ů‚ĆŽüŠú“IŽ‘ąŸó—Ź•š—p‹ÇŠ‰Aˆł•Â˝—Ă–@‚đ—p‚˘‚˝V‚˝‚ČŽĄ—Ă–@|. “c’†Šó1,2, ”nęŽq1,2 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`ŹE”üŠO): “ú–{E‹ĆEĐŠQˆăŠw‰ďŽ 2021/11; 69 (6): 285-9.

320012. [Ç—á•ń] ’E—Ž‚ľ‚˝ŠĽ“Ž–ŹƒXƒeƒ“ƒg‚Şžôœ“Ž–Ź•Ç‚ɐú’Ę‚ľŽc—Ż‚ľ‚˝Ç—á‚ɑ΂ˇ‚éŠO‰Č“IŽĄ—ĂŒoŒą. “y“c—Žq1, V”ü—Y‘ĺ1, ”nęŽq1, ˛“Ą”Vr2 (1Œ`ŹE”üŠO, 2ŒÄ‹zŠíŠO): é‹ĘŒ§ˆăŠw‰ďŽGŽ 2022/3; 56 (2): 471-5.

522533. [uŔ]y“ÁW: ƒyƒbƒg™ů‘n‚Ö‚Ě‰ŠúŽĄ—Ă‚Ć‹@”\EŽ—e‚̉ü‘P [3]|Šç–Ę‚Ě‘gDŒ‡‘š‚𔺂¤ƒCƒk™ů‘n (2) ŒűOˆČŠO|z•@—ƒŒ‡‘š‚𔺂¤ƒCƒk™ů‘n‚ɑ΂ľ‚Ä•@Oa”ç•Ů‚É‚ć‚éÄŒš‚đs‚Á‚˝1—á. ăŒ´—Œb1, Ş–{@[1, ŁčWˆę˜N1, ”nęŽq1, é‰ş@W1, •“c@Œ[1 (1Œ`ŹE”üŠO): Œ`ŹŠO‰Č 2021/4; 64 (4): 403-8.

[Šw‰ďEŒ¤‹†‰ď“™]

713045. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Effectiveness of W-plasty scar revision after self-harm scars of arms. Takeda A1, Suzuki T, Sakata Y1, Sukegawa H1: The 2nd World Congress of Global Scar Society with Scar Academy and Japan Scar Workshop (2021/12/19), Yokohama, Japan. (•“c@Œ[1, â“c–F—m1, •ě—T˜a1: 1Œ`ŹE”üŠO)

722172. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) •Ą”ŽčŽw‘š‚ɑ΂ˇ‚é’ljÁŽĄ—Ă‚ĚŒř‰Ę‚ĆŒŔŠE. Ş–{@[1, ŒFŕVŒ›ˆę1, ”–ؐT–ç1, ˜a“‚ƒ•˝1, Šâě‚ł‚¨‚č2, •“c@Œ[1 (1Œ`ŹE”üŠO, 2‹~–˝): ‘ć64‰ń“ú–{Œ`ŹŠO‰ČŠw‰ď‘‰ďEŠwpW‰ď (2021/4/14), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722173. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Á–ĹŽč‚É‚¨‚Ż‚é‘Η§‹@”\áŠQ‚Ć2ŽŸŽčp. Ş–{@[1, ŒFŕVŒ›ˆę1, ”–ؐT–ç1, •ě—T˜a1, â“c–F—m1, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć64‰ń“ú–{ŽčŠO‰ČŠw‰ďŠwpW‰ď (2021/4/23), ’ˇč (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722174. [Šw‰ď (‘S‘)] (ƒpƒlƒ‹) p’†’˛Ž‚É‚ć‚épŒăŠJáوʒu‚̐„’č‚ĆŽŔŰ. ‘ĺŽœ–í—T”V, ‚–ؐ˝Ži, ŒĂŽR“o—˛, •“c@Œ[1 (1Œ`ŹE”üŠO): “ú–{”ü—eŠO‰ČŠw‰ď (JSAPS) ‘ć141‰ńŠwpW‰ď (2021/7/3), _ŒË.

723487. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒƒfƒBƒJƒ‹ƒ\ƒƒ“ƒGƒXƒeƒeƒBƒbƒNŠO—ˆ‚ĚŽć‚č‘g‚݂ɂ‚˘‚Ä. ™–{‰Ŕ1, “‡‘qNl1, ‚ŽR“ÖŽq, ™–{F”V1, “‡ă˜a‘Ľ, ŠÚ“ŕŒNŽ}, ˆŔ‘ƒ~Žq, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć64‰ń“ú–{Œ`ŹŠO‰ČŠw‰ď‘‰ďEŠwpW‰ď (2021/4/14), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723488. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘˝”­Šç–ʍœœÜ‚É‚¨‚Ż‚é‘Ň‹@“I—֏óbóŠÔ–ŒŘŠJ‚Ě—L—pŤ. ŒN’ˍKŽq1, ŒFŕVŒ›ˆę1, Šâě‚ł‚¨‚č2, ™–{F”V1, ™–{‰Ŕ1, •“c@Œ[1 (1Œ`ŹE”üŠO, 2‹~–˝): ‘ć64‰ń“ú–{Œ`ŹŠO‰ČŠw‰ď‘‰ďEŠwpW‰ď (2021/4/14), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723489. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚éŠç–Ę‘˝”­œÜ‚ĚŽĄ—Ð헪|f—Ñ̐§EŽčp•ű–@‚ĚŒťó|. ŒFŕVŒ›ˆę1, ˜a“‚ƒ•˝1, Šâě‚ł‚¨‚č2, ™–{F”V1, ™–{‰Ŕ1, ŒN’ˍKŽq1, •“c@Œ[1 (1Œ`ŹE”üŠO, 2‹~–˝): ‘ć64‰ń“ú–{Œ`ŹŠO‰ČŠw‰ď‘‰ďEŠwpW‰ď (2021/4/14), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723490. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ś‰ş‘Ú‚É”­Ç‚ľ‚˝ˆŤŤ“î•”ŽîᇂĚ1—á. ˆęŽr˘, ŽR“c’źl1, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć64‰ń“ú–{Œ`ŹŠO‰ČŠw‰ď‘‰ďEŠwpW‰ď (2021/4/14), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723491. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “Ť’×ᇂɑ΂ˇ‚émicrograft‚ĚŽĄ—ĂŒoŒą|13—á‚ĚŒŸ“˘. ”nęŽq1,2, “y“c—Žq2, V”ü—Y‘ĺ2, Ş–{@[2, Î•‹§Žj, •“c@Œ[2 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`ŹE”üŠO): ‘ć64‰ń“ú–{Œ`ŹŠO‰ČŠw‰ď‘‰ďEŠwpW‰ď (2021/4/14), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723492. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Œo”ç“IŠĽ“Ž–ŹƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Œăžôœ“Ž–ŹˆŮ•¨Žc‘śÇ—á‚Ö‚ĚŠO‰Č“IŽĄ—Éî“ü‚ĚŒoŒą. “y“c—Žq1, V”ü—Y‘ĺ1, ”nęŽq1,2, Ş–{@[1, •“c@Œ[1 (1Œ`ŹE”üŠO, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć64‰ń“ú–{Œ`ŹŠO‰ČŠw‰ď‘‰ďEŠwpW‰ď (2021/4/14), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723493. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽčŽw”畆“î•”‘gDŒ‡‘š‚ɑ΂ˇ‚éŒăăřœ“Ž–Ź‚đŒŒŠÇŒs‚Ć‚ˇ‚é—V—Ł”ç•Ů‚Ě—L—pŤ. ŒFŕVŒ›ˆę1, –űˆä˛ŒbŽq1, V”ü—T‘ĺ1, •ě—T˜a1, ŽÂč’qŒö, ”–ؐT–ç1, Ş–{@[1, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć64‰ń“ú–{ŽčŠO‰ČŠw‰ďŠwpW‰ď (2021/4/23), ’ˇč (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723494. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –k—˘‘ĺŠwŒ`ŹŠO‰ČE”ü—eŠO‰Č‚̐OŠ{ŒűŠW—ôV‹KŠłŽŇ‚Ě—Ő°“Œv“IŒŸ“˘, ć“VˆŮí‚̍‡•š‚ÉŠÖ‚ľ‚Ä. â“c–F—m1, ™–{F”V1, ™–{‰Ŕ1, ŒN’ˍKŽq1, Î“n–ő•v, ‚‹´ˆę˝, ŁčWˆę˜Y1, ŽRčˆŔ°, •ě—T˜a1, “y“c—Žq1, –űˆä˛ŒbŽq1, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć45‰ń“ú–{ŒűŠW—ôŠw‰ď‘‰ďEŠwpW‰ď (2021/5/20), WebŠJĂ.

723495. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –k—˘‘ĺŠwŒ`ŹŠO‰ČE”ü—eŠO‰Č‚̐OŠ{ŒűŠW—ôV‹KŠłŽŇ10”NŠÔ‚Ě“ŽŒü. ™–{F”V1, ™–{‰Ŕ1, ŒN’ˍKŽq1, Î“n–ő•v, ‚‹´ˆę˝, ŁčWˆę˜Y1, ŽRčˆŔ°1, â“c–F—m1, •ě—T˜a1, “y“c—Žq1, –űˆä˛ŒbŽq1, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć45‰ń“ú–{ŒűŠW—ôŠw‰ď‘‰ďEŠwpW‰ď (2021/5/20), WebŠJĂ.

723496. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –k—˘‘ĺŠwŒ`ŹŠO‰ČE”ü—eŠO‰Č‚É‚¨‚Ż‚é‰ß‹Ž1”NŠÔ‚ĚŒűO—ôEŒűŠW—ôŠłŽŇ‚Ě’˛¸. ŒN’ˍKŽq1, ™–{F”V1, ™–{‰Ŕ1, â“c–F—m1, •ě—T˜a1, “y“c—Žq1, –űˆä˛ŒbŽq1, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć45‰ń“ú–{ŒűŠW—ôŠw‰ď‘‰ďEŠwpW‰ď (2021/5/20), WebŠJĂ.

723497. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —ź‘¤Œ˘Ž•‚ĚŠJ‘‹ŒĄˆř‚đs‚Á‚˝ś‘¤OŠ{ŒűŠW—ôÇ—á. Î“n–ő•v, ‚‹´ˆę˝, ŒN’ˍKŽq1, ŽRčˆŔ°1, ™–{‰Ŕ1, ™–{F”V1, •“c@Œ[1, ŁčWˆę˜Y1 (1Œ`ŹE”üŠO): ‘ć45‰ń“ú–{ŒűŠW—ôŠw‰ďEŠwpW‰ď (2021/5/20), WebŠJĂ.

723498. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) •Đ‘¤ŤOŠ{ŒűŠW—ôŠłŽŇ‚ÉŠ{‹¸łŽčp‚đs‚Á‚˝1—á. ŒN’ˍKŽq1, ™–{F”V1, Î“n–ő•v, ‚‹´ˆę˝, ™–{‰Ŕ1, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć31‰ń“ú–{Š{•ĎŒ`ÇŠw‰ď‘‰ďEŠwp‘ĺ‰ď (2021/6/11), ĺ‘ä (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723499. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Cloud based telemedicine and telementorning using extended reality in orthognathic surgery. •x“c‘ĺ‰î, ˛ŒËěç”ż, –ě’†Ę‰Á, ŒN’ˍKŽq1, ‹{č–M•v, ›Œ´—ł—C, ’†–ě—Ú”ü, “y‰Ž“–ž, •x“c—R”üŽq, ŽR–{’O, ™–{^Ž÷ (1Œ`ŹE”üŠO): ‘ć31‰ń“ú–{Š{•ĎŒ`ÇŠw‰ď‘‰ďEŠwp‘ĺ‰ď (2021/6/11), ĺ‘ä (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723500. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒRƒ‰[ƒQƒ“CüƒŠƒ|ƒ\[ƒ€ŠÜ—L”畆‰ťĎ—ż‚Ě‘n“™ŽĄ—ĂŒă”§‰ń•œ•â•Œř‰Ę‚É‚ć‚é–łěˆ×‰ťƒvƒ‰ƒZƒ{‘ÎĆ“ńd–ÓŒŸƒn[ƒtƒTƒCƒh”äŠrŽŽŒą. ™–{‰Ŕ1, ™–{F”V1, Ź—ѐł_, ˆäă‰i‰î, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć21‰ń“ú–{R‰Á—îˆăŠw‰ď‘‰ď (2021/6/25), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723501. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Š{œ—R—ˆ‚¨‚ć‚Ń’°œ—R—ˆŠÔ—tŒn×–E‚Ě‘˝•Ş‰ť”\‚̍ˇˆŮ‚ɂ‚˘‚Ä. XŽR˜a‚Ě1, ŽRčˆŔ°1, ‘]Ş—R”üŽq2, ™–{‰Ŕ1, ™–{F”V1, ŒFŕVŒ›ˆę1, ”nęŽq1,3, •“c@Œ[1 (1Œ`ŹE”üŠO, 2•a‘ԁEf—ĂŒn, 3–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć30‰ń“ú–{Œ`ŹŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/7), Vh (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723502. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ä`‘Ń—R—ˆŠÔ—tŒn×–E‚Ě‘gDŒ`Ź”\‚ĚŒŸ“˘|“–‹łŽş‚É‚¨‚Ż‚é‰ß‹Ž10”NŠÔ‚Ě‘Š‡|. ”nęŽq1,2, ŽRčˆŔ°2, ‘]Ş—R”üŽq3, ™–{‰Ŕ2, XŽR˜a‚Ě2, ™–{F”V2, ŒFŕVŒ›ˆę2, •“c@Œ[2 (1–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 2Œ`ŹE”üŠO, 3•a‘ԁEf—ĂŒn): ‘ć30‰ń“ú–{Œ`ŹŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/8), Vh (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723503. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰Č‚É‚¨‚Ż‚é“Ť’×ᇂɑ΂ˇ‚émicro graft‚ĚŽĄ—ĂŒoŒą|25Ç—á‚Ě•ń|. –űˆä˛ŒbŽq1, V”ü—Y‘ĺ1, ”nęŽq1 (1Œ`ŹE”üŠO): ‘ć30‰ń“ú–{Œ`ŹŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/7-8), “Œ‹ž.

723504. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) L”ÍˆÍ‚ČăŠ{œŒ‡‘š‚ɑ΂ľ‚Ä, ’°œƒuƒƒbƒNˆÚA‚ĆƒCƒ“ƒvƒ‰ƒ“ƒg‚É‚ć‚éŠ{œ™ů‡ÄŒš‚đs‚Á‚˝1—á. ŒN’ˍKŽq1, ™–{F”V1, ŒFŕVŒ›ˆę1, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć39‰ń“ú–{“ŞŠWŠ{Šç–ĘŠO‰ČŠw‰ďŠwpW‰ď (2021/11/11), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723505. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Swinging Eyelid Approach‚ĆŒo—Ü‹uŘŠJ‚É‚ć‚éŠáâ|ŽüˆÍœÜŽčp‚Ě—L—pŤ. ŒFŕVŒ›ˆę1, •ě—T˜a1, â“c–F—m1, V”ü—Y‘ĺ1, ™–{‰Ŕ1, ™–{F”V1, ŒN’ˍKŽq1, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć39‰ń“ú–{“ŞŠWŠ{Šç–ĘŠO‰ČŠw‰ďŠwpW‰ď (2021/11/11), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723506. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –k—˘‘ĺŠw•a‰@Œ`ŹŠO‰ČE”ü—eŠO‰Č‚É‚¨‚Ż‚é‰ß‹Ž1”NŠÔ‚ĚŒűO—ôEŒűŠW—ôŠłŽŇ‚Ě’˛¸. ŒN’ˍKŽq1, ŒFŕVŒ›ˆę1 (1Œ`ŹE”üŠO): ‘ć66‰ńŒö‰vŽĐ’c–@l“ú–{ŒűoŠO‰ČŠw‰ď‘‰ďEŠwp‘ĺ‰ď (2021/11/12), ç—t (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723507. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) œ‰„’ˇŠí‚đ—p‚˘‚˝Šç–Ę‘˝”­œÜÇ—á‚ĚŽĄ—ĂŒoŒą. ŒN’ˍKŽq1, ŒFŕVŒ›ˆę1 (1Œ`ŹE”üŠO): ‘ć66‰ńŒö‰vŽĐ’c–@l“ú–{ŒűoŠO‰ČŠw‰ď‘‰ďEŠwp‘ĺ‰ď (2021/11/12), ç—t (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723508. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œ´”­Ťăüâ|‘˝ŠžÇ‚ɑ΂ˇ‚éƒ\ƒtƒsƒƒjƒEƒ€L‰ť•¨ŠO—pÜ‚ĚŽg—pŒoŒą. ”nęŽq1, –űˆä˛ŒbŽq1, “c’†Šó1 (1Œ`ŹE”üŠO): ‘ć69‰ń“ú–{E‹ĆEĐŠQˆăŠw‰ďŠwp‘ĺ‰ď (2021/11/27-28), WebŠJĂ.

723509. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) micrograft‚đ—p‚˘‚˝‰şŽˆ“Ť’×ᇂ̎Ą—ĂŒoŒą. –űˆä˛ŒbŽq1, “c’†Šó1, ”nęŽq1 (1Œ`ŹE”üŠO): ‘ć69‰ń“ú–{E‹ĆEĐŠQˆăŠw‰ďŠwp‘ĺ‰ď (2021/11/27-28), WebŠJĂ.

733158. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Œ‹’°úE• •Çú”j‚É‚ć‚萜‚ś‚˝• •Ç”^ᇂ̎Ą—ĂŒoŒą|NPWTid‚Ćmicrograft‚đ—p‚˘‚ÄŽĄ–ü‚ľ‚Ś‚˝1—á|. –űˆä˛ŒbŽq1, V”ü—Y‘ĺ1, ”nęŽq1 (1Œ`ŹE”üŠO): ŠÖ“ŒŒ`ŹŠO‰ČŠw‰ď‘ć300‰ń“Œ‹ž’n•ű‰ď (2021/7/3), WebŠJĂ.

733159. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Šç–Ę”ń‘ÎĚÇ—á‚ɑ΂ľ‚Ä—ÖŠsŒ`‘Ô‚đl—ś‚ľ‚ÄŠ{‹¸łŽčp‚đs‚Á‚˝1—á. ŒN’ˍKŽq (Œ`ŹE”üŠO): ‘ć24‰ń–k—˘Œ`ŹŠO‰ČƒtƒH[ƒ‰ƒ€ (2021/7/17), ‘Š–ÍŒ´.

733160. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Dingman–@‚Ć—ÖŠsŒ`Ź‚đ•šjaw surgery‚Ĺ—ÇD‚ČŒ‹‰Ę‚Ş“ž‚ç‚ę‚˝d“x‰şŠ{”ě‘ĺ‚ĚÇ—á. ’†–kMş, ŽRčˆŔ°, •ş“Ş“O–ç, ŒĂŽR“o—˛, ŒN’ˍKŽq1, ™–{F”V1, •“c@Œ[1, •ŸŽR‰pŽĄ (1Œ`ŹE”üŠO): ‘ć24‰ń–k—˘Œ`ŹŠO‰ČƒtƒH[ƒ‰ƒ€ (2021/7/17), ‘Š–ÍŒ´.

733161. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) f’f‚É‹ę—ś‚ľ‚˝ŠOŤăŠáâ|—ôÇŒóŒQ1—á. ‚@U‰Ć, Šâě‚ł‚¨‚č1, V”ü—Y‘ĺ2, ŒFŕVŒ›ˆę2, •“c@Œ[2 (1‹~–˝, 2Œ`ŹE”üŠO): ‘ć24‰ń–k—˘Œ`ŹŠO‰ČƒtƒH[ƒ‰ƒ€ (2021/7/17), ‘Š–ÍŒ´.

733162. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) –Ú‚ŕ‚Ć‚ĚƒGƒCƒWƒ“ƒO‚Ö‚ĚƒAƒvƒ[ƒ`. •“c@Œ[ (Œ`ŹE”üŠO): ‘ć14‰ń_“ސěƒNƒƒXƒI[ƒo[ƒVƒ“ƒ|ƒWƒEƒ€ (2022/2/5), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733163. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‹}Ť”Ä”­Ť• –Œ‰ŠpŒă‘nŠ´ő (SSI) ‚Őś‚ś‚˝’×ᇂɑ΂ˇ‚émicrograft‚ĚŽĄ—ĂŒoŒą. Ą‘ş@x1, –űˆä˛ŒbŽq1, –Ľ‰YG”V2, ”nęŽq1, ‚‹´’ől3, ˛“Ą”Vr4 (1Œ`ŹE”üŠO, 2‰ş•”Á‰ťŠÇŠO, 3ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 4ŒÄ‹zŠíŠO): ‘ć59‰ńé‹ĘŒ§ˆăŠw‰ď‘‰ď (2022/2/27), WebŠJĂ.

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-110022. [Œ´’˜] RNA-sequencing reveals positional memory of multipotent mesenchymal stromal cells from oral and maxillofacial tissue transcriptomes. Onizuka S, Yamazaki Y1, Park SJ, Sugimoto T1, Sone Y2, Sjšqvist S, Usui M, Takeda A1, Nakai K, Nakashima K, Iwata T: BMC Genomics 2020/6; 21 (1): 417. (ŽRčˆŔ°1, ™–{F”V1, ‘]Ş—R”üŽq2, •“c@Œ[1: 1Œ`ŹE”üŠO, 2•a‘ԁEf—ĂŒn)

'20-320004. [Ç—á•ń] Šç–Ę”ń‘ÎĚÇ—á‚ɑ΂ľ‚Ä—ÖŠsŒ`‘Ô‚đl—ś‚ľ‚ÄŠ{‹¸łŽčp‚đs‚Á‚˝1—á. ŒN’ˍKŽq1, ’†–kMş, ŽRčˆŔ°1, •{ěr•F, ™–{‰Ŕ1, ™–{F”V1, •“c@Œ[1 (1Œ`ŹE”üŠO): “ú”üŠO•ń 2021/3; 43 (1): 12-9.

[Šw‰ďEŒ¤‹†‰ď“™]

'20-722004. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)–Ń”Ż‚̐Ž—eŤ‚ɂ‚˘‚Ä: Œ`ŹŠO‰Čˆă‚Ě—§ę‚Š‚ç. •“c@Œ[1, ™–{F”V1 (1Œ`ŹE”üŠO): ‘ć13‰ń“ú–{Ž—e”]_ŒoŠO‰ČŠw‰ď (JSAN2020) (2020/9/30), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-722005. [Šw‰ď (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ’jŤŒ^’E–ŃÇ‚ĚŽĄ—ĂŒŔŠE‚đÄśˆă—Ă‹Zp‚Ĺ’§í‚ˇ‚é. ˛“Ą–ž’j, –öŕVł”V, “‡‘qNl1, ÎěS‰î1, XŽR˜a‚Ě1, ‰Á“Ą’B–ç, ‹MŽu˜aś, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć38‰ń“ú–{“ŞŠWŠ{Šç–ĘŠO‰ČŠw‰ďŠwpW‰ď (2020/11/12-13), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20-722006. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Šáâ|Ž‰–bŘœ‚đ•š—p‚ľ‚˝–„–vŽŽdáُp‚Ě—L—pŤ‚ĚŒŸ“˘. Žđˆä’ź•F, –î‘ňŒcŽj, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć43‰ń“ú–{”ü—eŠO‰ČŠw‰ď‘‰ď (2021/2/25), –k‹ăB.

'20-723029. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰A•”“ű–[ŠOPaget•apŒă‚É”­ś‚ľ‚˝•úŽËü—U”­“÷Žî‚Ě1—á. ŽÂč’qŒö, ”–ؐT–ç1, •“c@Œ[1 (1Œ`ŹE”üŠO): ‘ć53‰ń“ú–{ŽŒ`ŠO‰ČŠw‰ďœE“î•”ŽîᇊwpW‰ď (2020/9/11), WebŠJĂ.

'20-733016. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‹šŠsoŒűÇŒóŒQ—lÇó‚đ’ć‚ľ‚˝ś‘ć1˜]œć“VˆŮí‚Ě1—á. Ş–{@[ (Œ`ŹE”üŠO): ‘ć17‰ńŠÖ“ŒăŽˆć“VˆŮíÇ—ጟ“˘‰ď (2021/1/21), WebŠJĂ.


”畆‰ČŠw

[Šwp˜_•ś]

110357. [Œ´’˜] Hair-Follicle-Associated Pluripotent (HAP) Stem Cells Can Extensively Differentiate to Tyrosine-Hydroxylase-Expressing Dopamine-Secreting Neurons. Yamane M, Takaoka N1, Obara K1, Shirai K1, Aki R1, Hamada Y2, Arakawa N, Hoffman RM, Amoh Y1: Cells 2021/4; 10 (4): 864. (‚‰Ş“ޓߎq1, ŹŒ´GĆ1, ”’ˆä‹ž”ü1, ˆŔĺY—Lję1, •l“c—SŽq2, “V‰HN”V1: 1”畆, 2•a‘ԁEf—ĂŒn)

120018. [Œ´’˜] “Ş•”ŒŒŠÇ“÷Žî‹ÇŠÄ”­—á‚ɑ΂ˇ‚éƒhƒLƒ\ƒ‹ƒrƒVƒ“’P“Ć—Ă–@. Ž”ŔŽŔ—D1, ‘ŕV^ŽŔŽq1, ‚‰Ş“ޓߎq1, ”’ˆä‹ž”ü1, ‘“c@Ši2, –öŕVGl, “V‰HN”V1 (1”畆, 2•úŽËü (Žîá‡)): “ú–{”畆‰ČŠw‰ďŽGŽ 2021/11; 131 (12): 2589-93.

210002. [€Œ´’˜] Successful treatment of non-AIDS Kaposi's sarcoma with eribulin. Masuzawa M1, Yamashita K2, Horigome Y3, Amoh Y1: J Dermatol 2021/7; 48 (7): e345-6. (‘ŕV^ŽŔŽq1, ŽR‰ş˜a–ç2, –x•Ä—Cˆę3, “V‰HN”V1: 1”畆, 2•a—•”, 3ŒŒ‰t“ŕ)

320013. [Ç—á•ń]y“ÁW: ă”çŒnŽîᇁzHPV16Œ^‚ŞŒŸo‚ł‚ę‚˝QueyratgF”ěŒúÇ‚Ě1—á. ŠFě‘ĺ•ă1, ŹŒ´GĆ1, ”’ˆä‹ž”ü1, “c•ÓŒ’ˆę1, “V‰HN”V1 (1”畆): ”畆‰Č‚Ě—Ő° 2021/4; 63 (4): 445-8.

522534. [uŔ]y“ÁW: ŒŒŠÇŤŽîᇁz“Ş•”ŒŒŠÇ“÷Žî”x“]ˆÚ‚É‚ć‚éÄ”­Ť‹C‹š‚ĚŽĄ—Ð헪|ƒpƒ]ƒpƒjƒu‚Ć‹šo‹ž‰ş”x•”•ŞŘœp‚Ş‘tŒř‚ľ‚˝Ç—á|. ‘ŕV^ŽŔŽq1, ŽOˆä@ˆ¤2, —с@ËŽq2, ‰–ŒŠ@˜a2, ‘“c’qŹ3, “V‰HN”V1 (1”畆, 2ŒÄ‹zŠíŠO, 3‹~–˝): ”畆•af—Ă 2021/4; 43 (4): 348-51.

530011. [‚ť‚Ě‘ź (LETTER TO THE EDITOR)] Successful treatment of non-AIDS Kaposi's sarcoma with eribulin. Masuzawa M1, Yamashita K2, Horigome Y3, Amoh Y1: J Dermatol 2021;48 (7): e345-6. (‘ŕV^”üŽq1, ŽR‰ş˜a–ç2, –xž—Cˆę3, “V‰HN”V1: 1”畆, 2•a—•”, 3ŒŒ‰t“ŕ)

[Šw‰ďEŒ¤‹†‰ď“™]

722175. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‘Ήž‚ɍ˘‚éÚG”畆‰Š: ‚ť‚̐f’f‚Ć‘Îô|ƒŒƒWƒ“ƒAƒŒƒ‹ƒM[‚Ć‚ť‚̑Ήž|. ‘ŕV^ŽŔŽq (”畆): ‘ć51‰ń“ú–{”畆–ƉuƒAƒŒƒ‹ƒM[Šw‰ď‘‰ďŠwp‘ĺ‰ď (2021/11/26), “Œ‹ž.

723510. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Šá‹…Œ‹–Œ[ŒŒ‚ĆŒűo“ŕ”S–Œ]‚𔺂Á‚˝Œă“VŤ•\”琅ávÇ‚Ě1—á. ”ä—ŻŠÔ‰Ŕ“Ţ1, ”’ˆä‹ž”ü1, âV“Ą‹ąŽq1, ‹ŕ•Ł—DŽ÷1, ˛X–Řˆ˛1, ’r‘ş—LŠŽ2, “Ş@‹B, Îˆä•śl, ŒĂ‰ę_Žk, “V‰HN”V1 (1”畆, 2Šá‰Č): ‘ć120‰ń“ú–{”畆‰ČŠw‰ď‘‰ď (2021/6/10-13), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723511. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ăŽÓˆŮíÇ‚É”ş‚¤”畆•a•Ď: “d‰đŽżˆŮí, ƒrƒ^ƒ~ƒ“Œ‡–R, “ŕ•Ş”ĺŒnŽžŠł‚É”ş‚¤”畆Çó“™. ”’ˆä‹ž”ü (”畆): ‘ć120‰ń“ú–{”畆‰ČŠw‰ď‘‰ď (2021/6/10-13), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723512. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) The potencial of hair-follicle-associated pluripotennt (HAP) stem cells for heart regeneration. ‚‰Ş“ޓߎq, ŽRŞ”ü’qŽq1, ŹŒ´GĆ2, ”’ˆä‹ž”ü2, •l“c—SŽq3, rěMŽq3, ˆŔĺY—Lję2, Robert M Hoffman, “V‰HN”V2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2”畆, 3•a‘ԁEf—ĂŒn): “ú–{Œ¤‹†”畆‰ČŠw‰ď‘ć46‰ń”NŽŸŠwp‘ĺ‰ďE‘‰ď (2021/12/3-5), WebŠJĂ.

733164. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) …ávŤƒGƒŠƒeƒ}ƒg[ƒfƒX‚Ěˆę—á. ’ˇ’JěĘŒŠ, Œj@—F—1, ‚–ě“N˜Y1, ”’ˆä‹ž”ü1, —LŔ—ǍK2, ŒĂ‰ę_Žk3, Îˆä•śl3, “V‰HN”V1 (1”畆, 2äPŒ´•aEŠ´ő“ŕ, 3‹v—Ż•Ä‘ĺ): “ú–{”畆‰ČŠw‰ď‘ć897‰ń“Œ‹ž’n•ű‰ď (2021/7/17), _“ސě.

733165. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‰E‘O˜r–Iâ|D‰ŠŽĄ—Ă’†‚É”­ś‚ľ‚˝ƒZƒtƒFƒsƒ€”]Ç. ‹ŕŽR‚Ü‚č‚Š1, ‹ŕ•Ł—DŽ÷1, •ÄŽRŽőŽq1, ”’ˆä‹ž”ü1, “ż“c@ăÄ2, “V‰HN”V1 (1”畆, 2”]_Œo“ŕ): “ú–{”畆‰ČŠw‰ď‘ć897‰ń“Œ‹ž’n•ű‰ď (2021/7/17), _“ސě.

733166. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒyƒ€ƒuƒƒŠƒYƒ}ƒu‚É‚ć‚éirAE‚ƍl‚Ś‚˝DŽ_‹…Ť‹Ř–Œ‰Š‚Ěˆę—á. ˛X–Řˆ˛1, ‘ŕV^ŽŔŽq1, •ÄŽRŽőŽq1, ”’ˆä‹ž”ü1, “V‰HN”V1 (1”畆): ‘ć85‰ń“ú–{”畆‰ČŠw‰ď“Œ‹žŽx•”Šwp‘ĺ‰ď (2021/11/13-14), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733167. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) č÷—ą‹…‹z’…—Ă–@‚Ş‘tŒ÷‚ľ‚˝IL-36RNˆâ“`Žq•ĎˆŮ‚đ—L‚ˇ‚é”Ä”­Ť”^ávŤŠŁá‚Ě1—á. …Œű—ł”V‰î1, ”’ˆä‹ž”ü1, ˆŔĺY—Lję1, ˛X–Řˆ˛1, ě‘şš—R”ü2, ‰Ş“‡Œő–ç, “V‰HN”V1 (1”畆, 2t‘Ÿ“ŕ): ‘ć85‰ń“ú–{”畆‰ČŠw‰ď“Œ‹žŽx•”Šwp‘ĺ‰ď (2021/11/13-14), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733168. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) —\Œă•s—Ç‚ČŒo‰ß‚đ‚˝‚Ç‚Á‚˝ƒGƒbƒNƒŠƒ“ŠžEŠŕ‚Ě1—á ‹ĘˆäˆťŽq1, •ÄŽRŽőŽq1, ”–ˆä—˜‘ĺ1, ŹŒ´GĆ1, ”’ˆä‹ž”ü1, ‹e’r•üŽq, “V‰HN”V1 (1”畆): “ú–{”畆‰ČŠw‰ď‘ć899‰ń“Œ‹ž’n•ű‰ď (2021/12/18), WebŠJĂ.

733169. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‘˝”­”]“]ˆÚ‚đ‚Ť‚˝‚ľ‚˝“Ş•”ŒŒŠÇ“÷Žî‚Ě1—á ‰zŒăŠŃŒd1, ‘ŕV^ŽŔŽq1, ”–ˆä—˜‘ĺ1, •ÄŽRŽőŽq1, ”’ˆä‹ž”ü1, “ż“c@ăÄ2, ŠŰŽR—ˆ‹P3, “V‰HN”V1 (1”畆, 2”]_Œo“ŕ, 3ŒÄ‹zŠíŠO): “ú–{”畆‰ČŠw‰ď‘ć899‰ń“Œ‹ž’n•ű‰ď (2021/12/18), WebŠJĂ.

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-110023. [Œ´’˜] Gray-edged line sign of scabies burrow. Ueda T, Katsura Y, Sasaki A, Minagawa D, Amoh Y1, Shirai K1: J Dermatol 2021/2; 48 (2): 190-8. (“V‰HN”V1, ”’ˆä‹ž”ü1: 1”畆)

'20-320005. [Ç—á•ń] NUDT15ˆâ“`Žq‘˝Œ^‚Ě‚˝‚߃AƒUƒ`ƒIƒvƒŠƒ“‚É‚ć‚éÄś•s—ǐŤ•nŒŒ‚đ‚Ť‚˝‚ľ‚˝…ávŤ—Ţ“VáváŒ. Ž”ŔŽŔ—D1, ”’ˆä‹ž”ü1, “cŽ›”͍s2, “V‰HN”V1 (1”畆, 2ŒŒ‰t“ŕ): ”畆‰Č‚Ě—Ő° 2021/3; 63 (3): 356-9.

'20-540002. [‚ť‚Ě‘ź (ƒKƒCƒhƒ‰ƒCƒ“)] ”畆ˆŤŤŽîᇐf—ĂƒKƒCƒhƒ‰ƒCƒ“‘ć3”Ł@”畆ŒŒŠÇ“÷Žîf—ĂƒKƒCƒhƒ‰ƒCƒ“2021. “ĄŕVNO, ó‰zŒ’ŽĄ, ‘ŕV^ŽŔŽq1, ‘ĺ’Ë“ÄŽi, “ŕ@”ŽŽj, ź‰ş–ΐl, `@—m˜Y, ‘ě˜ad, ŒĂ‰ęOŽu, ›’J@˝ (1”畆): “ú–{”畆‰ČŠw‰ďŽGŽ 2021/2; 131 (2): 245-77.

'20”N“xˆČ‘O•Ş

[Šw‰ďEŒ¤‹†‰ď“™]

'20-723030. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) IL36RNˆâ“`Žq•ĎˆŮ‚đ”F‚ß‚˝Ä”­ŤŠÂóg”Á—lŠŁá‚Ě1—á. ‹ŕ•Ł—DŽ÷1, ‘ŕV^ŽŔŽq1, •l“c—SŽq2, ˆŔĺY—Lję1, “V‰HN”V1 (1”畆, 2•a‘ԁEf—ĂŒn): ‘ć84‰ń“ú–{”畆‰ČŠw‰ď“Œ‹žŽx•”Šwp‘ĺ‰ď (2020/11/21), WebŠJĂ.

'20-733017. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Œă“VŤŒŒ—F•a‚đ‡•š‚ľ‚˝…ávŤ—Ţ“VávጂĚ1—á. a’J—ş‘ž1, ˛X–Řˆ˛1, ”’ˆä‹ž”ü1, ‰ĄŽR^Šě2, “ż‰içt3, “V‰HN”V1 (1”畆, 2ŒŒ‰t“ŕ, 3˜aŽs—§•a‰@): “ú–{”畆‰ČŠw‰ď‘ć895‰ń“Œ‹ž’n•ű‰ď (2021/2/20), “Œ‹ž.

'20-733018. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Žü•Ó•”Šp–Œ’×á‡‚đ‡•š‚ľ‚˝DŽ_‹…Ť‘˝”­ŒŒŠÇ‰ŠŤ“÷‰čŽî‚Ě1—á. …Œű—ł”V‰î1, ”’ˆä‹ž”ü1, ˆŔĺY—Lję1, •ÄŽRŽőŽq1, ‹ŕ•Ł—DŽ÷1, “c’†’mŽ÷2, ‰Í–ě—Y—ş3, –Ř‘şŽé—˘4, “V‰HN”V1 (1”畆, 2äPŒ´•aEŠ´ő“ŕ, 3Šá‰Č, 4Ž¨•@ˆôAE“ŞčňŠO): “ú–{”畆‰ČŠw‰ď‘ć895‰ń“Œ‹ž’n•ű‰ď (2021/2/20), “Œ‹ž.


”ĺ”AŠí‰ČŠw

[Šwp˜_•ś]

110358. [Œ´’˜] Prognostic Impact of AHNAK2 Expression in Patients Treated with Radical Cystectomy. Koguchi D1, Matsumoto K1, Shimizu Y, Kobayashi M1, Hirano S1, Ikeda M1, Sato Y, Iwamura M1: Cancers (Basel) 2021/4; 13 (8): 1748. (‚Œű@‘ĺ1, ź–{˜aŤ1, Ź—Ń“Žq1, •˝–ěC•˝1, ’r“cŸb1, Šâ‘şłŽk1: 1”ĺ”AŠí)

110359. [Œ´’˜] Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial. Yokomizo A, Koga H, Ito K, Takezawa Y, Komiyama M, Nishimura K, Yonese J, Hashine K, Masumori N, Arai G, Saito S, Shinohara M, Shimizu N, Yamauchi A, Satoh T1, Tochigi T, Kobayashi M, Fujimoto H, Kakimoto K, Fukui I, Tsukamoto T, Nozaki M, Karasawa K, Hasumi M, Ohtani M, Ishiyama H2, Kuwahara M, Harada M, Ohashi Y, Kotake T, Kakizoe T, Suzuki K, Naito S, Yamanaka H, National Research Project on Endocrine-Radiation Combination Therapy for Locally Advanced Prostate Cancer investigators: Cancer Med 2021/5; 10 (10): 3240-8. (˛“ĄˆĐ•ś1, ÎŽR”ŽžŠ2: 1”ĺ”AŠí, 2•úŽËü (Žîá‡))

110360. [Œ´’˜] Correcting anemia and native vitamin D supplementation in kidney transplant recipients: a multicenter, 2 ~ 2 factorial, open-label, randomized clinical trial. Obi Y, Ichimaru N, Sakaguchi Y, Iwadoh K, Ishii D1, Sakai K, Iwami D, Harada H, Sumida K, Sekine A, Masutani K, Akutsu N, Inoue T, Nishihira M, Yoneda T, Ito S, Araki M, Kaimori J, Yoshida K, Satoh S, Ubara Y, Isaka Y, Yoshida K1,2, Tsubakihara Y, Takahara S, Hamano T, CANDLE-KIT Trial Investigators: Transpl Int 2021/7; 34 (7): 1212-25. (Îˆä‘ĺ•ă1, ‹g“cˆęŹ1,2: 1”ĺ”AŠí, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

110361. [Œ´’˜] Cytopathic effects and local immune responses in repeated neoadjuvant HSV- tk + ganciclovir gene therapy for prostate cancer. Yanagisawa N, Satoh T1, Tabata K1, Tsumura H1, Nasu Y, Watanabe M, Thompson TC, Okayasu I2, Murakumo Y2, Baba S1, Iwamura M1: Asian J Urol 2021/7; 8 (3): 280-8. (˛“ĄˆĐ•ś1, “c”¨Œ’ˆę1, ’Ă‘şGN1, ‰ŞˆŔ@ŒM2, ‘ş‰_–FŽ÷2, ”nęŽu˜Y1, Šâ‘şłŽk1: 1”ĺ”AŠí, 2•a—)

110362. [Œ´’˜] A novel prognostic model for Japanese patients with newly diagnosed bone-metastatic hormone-na_ve prostate cancer. Miyoshi Y, Yasui M, Yoneyama S, Kawahara T, Nakagami Y, Ohno Y, Iizuka J, Tanabe K, Hashimoto Y, Tsumura H1, Tabata K1, Iwamura M1, Yano A, Kawakami S, Uemura H: BJUI Compass 2020/9; 2 (2): 105-14. (’Ă‘şGN1, “c”¨Œ’ˆę1, Šâ‘şłŽk1: 1”ĺ”AŠí)

110363. [Œ´’˜] Serum Epiplakin Might Be a Potential Serodiagnostic Biomarker for Bladder Cancer. Shimura S1, Matsumoto K1, Shimizu Y, Mochizuki K1, Shiono Y1, Hirano S1, Koguchi D1, Ikeda M1, Sato Y, Iwamura M1: Cancers (Basel) 2021/10; 13 (20): 5150. (Žu‘ş‘sˆę˜N1, ź–{˜aŤ1, –]ŒŽN•˝1, ‰––ě@—T1, •˝–ěC•˝1, ‚Œű@‘ĺ1, ’r“cŸb1, Šâ‘şłŽk1: 1”ĺ”AŠí)

110364. [Œ´’˜] Nationwide surveillance of the antimicrobial susceptibility of Chlamydia trachomatis from male urethritis in Japan: Comparison with the first surveillance report. Takahashi S, Yasuda M, Wada K, Matsumoto M, Hayami H, Kobayashi K, Miyazaki J, Kiyota H, Matsumoto T, Yotsuyanagi H, Tateda K, Sato J, Hanaki H, Masumori N, Hiyama Y, Egawa S, Yamada H, Matsumoto K1, Ishikawa K, Yamamoto S, Togo Y, Tanaka K, Shigemura K, Uehara S, Kitano H, Kiyoshima K, Hamasuna R, Ito K, Hirayama H, Kawai S, Shiono Y, Maruyama T, Ito S, Yoh M, Ito M, Hatano K, Ihara H, Uno S, Monden K, Yokoyama T, Takayama K, Sumii T, Kadena H, Kawahara M, Hosobe T, Izumitani M, Kano M, Nishimura H, Fujita R, Kaji S, Hayashi K, Tojo T, Matumura M: J Infect Chemother 2022/1; 28 (1): 1-5. (ź–{˜aŤ1: 1”ĺ”AŠí)

120019. [Œ´’˜] “–‰Č‚É‚¨‚Ż‚郍ƒ{ƒbƒgŽx‰‡t᱌`Źp‚̏‰ŠúŹŃ‚Ć• o‹ž‰şt᱌`Źp‚Ć‚Ě”äŠrŒŸ“˘. X@˜j•˝1, ź@ˇG1, •˝–ěC•˝1, –k“‡˜aŽ÷1, ’r“cŸb1, Îˆä‘ĺ•ă1, Šâ‘şłŽk1 (1”ĺ”AŠí): Japanese Journal of Endourology and ESWL 2021/12; 34 (2): 323-7.

120020. [Œ´’˜] 35Î–˘–ž‚É”­ś‚ľ‚˝äNă÷Šŕ‚Ě—Ő°“I“Á’Ľ‚ĚŒŸ“˘. •˝–ěC•˝1, ź–{˜aŤ1, ‰––ě@—T1, ’†‘ş^—˜]1, Ÿ–”—mŽ÷1, Ź—Ń“Žq1, ’r“cŸb1, ’Ă‘şGN1, Šâ‘şłŽk1 (1”ĺ”AŠí): ”ĺ”AŠí‰Č‹I—v 2021/6; 67 (6): 221-4.

310051. [Ç—á•ń] Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report. Koguchi D1, Tabata K1, Tsumura H1, Mori K1, Koh H, Iwamura M1: Urol Case Rep 2021/5; 38: 101712. (‚Œű@‘ĺ1, “c”¨Œ’ˆę1, ’Ă‘şGN1, X@˜j•˝1, Šâ‘şłŽk1: 1”ĺ”AŠí)

520009. [‘ŕ] COVID-19‚ƐtˆÚAˆă—Ă. ŽR‰iŹ”ü, ‹gě”üŠěŽq, ‘ –ž@ŒO, “ú”ä‘ב˘, ‘ĺŕV—ljî, •gŽq—m‰î, Ź–ě@–Ť, \ě@”Ž, –źŽć—mˆę˜Y, –î–쐰”ü, –Fě–LŽj, ‹g“cˆęŹ1,2, Źě’źŽq, Œ•Ž@Œh, “’‘ňŒŤŽĄ, ]ě—Tl (1V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 2”ĺ”AŠí): “ú–{—Տ°tˆÚAŠw‰ďŽGŽ 2021/7; 9 (1): 62-72.

522535. [uŔ]y“ÁW: ‘O—§‘BŠŕ‚ĚŠO‰ČŽĄ—Áz15. “]ˆÚ‚Ě‚ ‚éÇ—á‚ɑ΂ˇ‚é‘O—§‘B‘S“E‚ĚˆÓ‹`. “c”¨Œ’ˆę (”ĺ”AŠí): Prostate Journal 2021/4; 8 (1): 88-93.

522536. [uŔ]y“ÁW: i‰ť‚ˇ‚é‹Ž¨’ďRŤ‘O—§‘B‚Ş‚ń‚̐f’f‚ĆŽĄ—Ă‚ĚĹV’mŒŠzmCRPC‚̉ťŠw—Ă–@|ƒ^ƒLƒTƒ“ŒnR‚Ş‚ńÜ‚ĚƒGƒrƒfƒ“ƒX‚ĆŽg—p•ű–@|. “c”¨Œ’ˆę (”ĺ”AŠí): ”ĺ”AŠíŠO‰Č 2021/8; 34 (8): 945-50.

522537. [uŔ]y‘ŸŠí’ń‹ŸE‘ŸŠíˆÚA‚Ě‘S‘Ě‘œz‘ŸŠíˆÚA‚ĚŠT—v‚Ć“K‰ž, Ç—ᐔ, ŹŃ. ‹g“cˆęŹ1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí): ‹~‹}ˆăŠw 2021/9; 45 (10): 1236-46.

[’˜@‘]

620099. [Šwp‘ (•Ş’SŽˇ•M)]yŒŒ‰t“§Íf—ĂŽwjz“§ÍŠÖ˜AŽčpEŽč‹Z‚ĆŠÇ—@ŽüpŠúŠÇ—, p.349-52. ‹g“cˆęŹ1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí), ŠÄC: ‰Ş“cˆę‹`, •Ň: ‰Ş“cˆę‹`, ˆäă•üŽq, “c‘ă@Šw, …Œű@, “Œ‹žˆăŠwŽĐ, “Œ‹ž, 2021/6”­s.

620100. [Šwp‘ (•Ş’SŽˇ•M)]ytŽžŠłŽĄ—Ă–ňupdate (t‚Ć“§Í2021”N91ŠŞ‘Š§†)z‘ć3Í ”ĺ”AŠí‰ČŽžŠł@2. tˆÚA‚ÉŽg‚í‚ę‚Ä‚˘‚é–Ɖu—}§–ň@‘ăŽÓhR–ň@ƒ~ƒ]ƒŠƒrƒ“, p.606-8. ‹g“cˆęŹ1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí), “Œ‹žˆăŠwŽĐ “Œ‹ž, 2021/8”­s.

620101. [Šwp‘ (•Ş’SŽˇ•M)]ytŽžŠłŽĄ—Ă–ňupdate (t‚Ć“§Í2021”N91ŠŞ‘Š§†)z‘ć3Í ”ĺ”AŠí‰ČŽžŠł@2. tˆÚA‚ÉŽg‚í‚ę‚Ä‚˘‚é–Ɖu—}§–ň@‘ăŽÓhR–ň@ƒ~ƒ]ƒŠƒrƒ“, p.606-8. ‹g“cˆęŹ1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí): “Œ‹žˆăŠwŽĐ, “Œ‹ž, 2021/9”­s.

620102. [Šwp‘ (•Ş’SŽˇ•M)]y‚¨–ň—§‚żBOOK 2022@‰đ–Uś—E•a‘Ԑś—‚Š‚ç–ňŠwŠÇ—‚Ö (–ň‹Ç2022”N‘Š§Vol. 73 No.4)zĄ‚Ş‚ńEŽxŽ—Ă–@@66 ‘O—§‘BŠŕ, p.927-32. ’r“cŸb1, “ü]@Œ[ (1”ĺ”AŠí) “ěŽR“°, “Œ‹ž, 2022/3”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

721014. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) tˆÚA‚É‚¨‚Ż‚éƒ`[ƒ€ˆă—ĂƒXƒ^ƒbƒt`tˆÚAˆă—Ă‚ĚŽż‚ĚŒüă‚đŽx‚Ś‚éƒXƒ^ƒbƒt’B`. ‹g“cˆęŹ1,2, –ěŒű•ś”T2, Îˆä‘ĺ•ă2, ˆä‘ş—[•P3 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí, 3ŠĹŒě•”): ‘ć25‰ń“ú–{“§ÍƒAƒNƒZƒXˆăŠw‰ďŠwpW‰ďE‘‰ď (2021/11/28), WebŠJĂ.

722176. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ”Ä—pe-learningƒVƒXƒeƒ€‚ĆAI‰šş‡ŹƒVƒXƒeƒ€‚đŠˆ—p‚ľ‚˝Ý‘‰t“§ÍŒ¤C—pƒc[ƒ‹‚̍쐬. ˆ˘•”“Ţ’Ă”ü, Žáˆä—zŠó, •ş“Ą@“§, ‹g“cˆęŹ1,2 (1V˘‹Iˆă—ÁEć’[’f“Iˆă—Ă, 2”ĺ”AŠí): ‘ć66‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2021/6/4), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722177. [Šw‰ď (‘S‘)] (‹łˆçu‰‰) “§ÍŠłŽŇ‚Ĺ‚Ě”ĺ”AŠí‰ČŽčp‚Ć‚ť‚ĚŠÇ—. ‹g“cˆęŹ1,2, Îˆä‘ĺ•ă2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí): ‘ć66‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2021/6/6), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722178. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) tˆÚAˆă—Ă‚Ĺ“­‚­RTC`ŠF‚Ĺ‚ą‚ę‚Š‚ç‚Ě10”N‚đ•Ď‚Ś‚é‚˝‚߂Ɂ`. –ěŒű•ś”T1, ’‡‹{—DŽq, ‰Í–ě@Œb, Îˆä‘ĺ•ă1, Šâ‘şłŽk1, ‹g“cˆęŹ1,2 (1”ĺ”AŠí, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć57‰ń“ú–{ˆÚAŠw‰ď‘‰ď (2021/9/20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722179. [Šw‰ď (‘S‘)] (ƒfƒBƒx[ƒgƒZƒbƒVƒ‡ƒ“) ƒyƒ“ƒuƒƒŠƒYƒ}ƒu‚ɑ΂ˇ‚éƒ}ƒCƒNƒƒTƒeƒ‰ƒCƒg•sˆŔ’萍ŒŸ¸‚Ć‚ť‚Ě—zŤŽŇ‚ɑ΂ˇ‚éˆâ“`ƒJƒEƒ“ƒZƒŠƒ“ƒO‚ĚŽŔ‘Ô’˛¸. ’Ă‘şGN1,2, Žu‘ş‘sˆę˜N1, “‡’Á@Ť2, Źâ–ůŒŤ, ”’ˆäG’ź2,3, ˜m’J”ü“Ţ2,4, –x“ŕŒb”üŽq, ě“c仉Ŕ2, r–؏Ž”ü2, r–ؐł—Y2, ŽOŠK‹MŽj2,4, ‚“cŽj’j2,5 (1”ĺ”AŠí, 2•a‰@ˆâ“`f—Ă•”, 3ŹŽ™, 4“ű‘BEbó‘BŠO, 5‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): “ú–{l—Ţˆâ“`Šw‰ď‘ć66‰ń‘ĺ‰ď/‘ć28‰ń“ú–{ˆâ“`Žqf—ĂŠw‰ď‘ĺ‰ď (2021/10/13-16), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722180. [Šw‰ď (‘S‘)] (Žs–ŻŒöŠJuŔ) ‘O—§‘B‚Ş‚ń‚Ě•úŽËü—Ă–@. ’Ă‘şGN (”ĺ”AŠí): “ú–{”ĺ”AŠíŽîᇊw‰ď‘ć7‰ńŠwpW‰ď (2021/10/23), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722181. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) RLPP`•‹y‚Ě‚˝‚ß‚É•K—v‚Č‚ą‚Ɓ`Pros and Cons: LPP‚ĚŒoŒą‚Í•K—v‚Č‚˘. X@˜j•˝1, •˝–ěC•˝1, –k“‡˜aŽ÷1, ’r“cŸb1, Îˆä‘ĺ•ă1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć35‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2021/11/11), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722182. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŽáŽč—Ť”ĺ”AŠí‰Čˆă‚Ě—§ę‚Š‚çEndourology‹Zp‚̏K“ž‚ĆˆŰŽ. ‚“cŽĄŽq1, •˝ˆäËŽi, ‰œ–ě‹I•F, ‰Š@‰p–Î, “ü]@Œ[, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć35‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2021/11/12), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722183. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‘O—§‘B‚Ě‘ĺ‚Ť‚ł‚âŒ`ó‚É‚ć‚鍂“ď“xÇ—á‚ɑ΂ˇ‚éRARPŽč‹Z. “c”¨Œ’ˆę1, ’Ă‘şGN1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć35‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2021/11/13), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722184. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‹ÇŠisEƒIƒŠƒS“]ˆÚ‚đ—L‚ˇ‚éV‹Kf’f‘O—§‘B‚Ş‚ń‚ɑ΂ˇ‚éHDRƒuƒ‰ƒLƒZƒ‰ƒs[‚Ě—DˆĘŤ. ’Ă‘şGN1, “c”¨Œ’ˆę1, ’r“cŸb1, •˝–ěC•˝1, Îˆä‘ĺ•ă1, ź–{˜aŤ1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć35‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2021/11/13), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722185. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒiƒrƒQ[ƒVƒ‡ƒ“ƒVƒXƒeƒ€‚Ě“ą“ü‚ÉŒü‚Ż‚˝ƒAƒvƒ[ƒ`. ’r“cŸb (”ĺ”AŠí): ‘ć35‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2021/11/11-13), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722186. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) tˆÚA‚ĚŒťó‚Ć–â‘č“_`ƒŒƒVƒR‚͉˝‚đ‚ˇ‚él‚ź!?`. –ěŒű•ś”T1, ˆä‘ş—[•P2, ˆ˘•”“N–ç3, –k“‡˜aŽ÷1, Îˆä‘ĺ•ă1, Šâ‘şłŽk1, ‹g“cˆęŹ1,4 (1”ĺ”AŠí, 2ŠĹŒě•”, 3t‘Ÿ“ŕ, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć30‰ń“ú–{t•s‘SŠO‰ČŒ¤‹†‰ďŠwpW‰ď (2021/12/4), ‰Ť“ę (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722187. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ˆÚA‚ސŹ—§‚ľ‚Č‚˘ę‡‚ĚRTC‚Ě–đŠ„. –ěŒű•ś”T1, ˆä‘ş—[•P2, ˆ˘•”“N–ç3, Îˆä‘ĺ•ă1, Šâ‘şłŽk1, ‹g“cˆęŹ1,4 (1”ĺ”AŠí, 2ŠĹŒě•”, 3t‘Ÿ“ŕ, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć32‰ń“ú–{ƒTƒCƒRƒlƒtƒƒƒW[Šw‰ďŠwpW‰ďE‘‰ď (2021/12/12), WebŠJĂ.

723513. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “ú–{ŽY•wl‰Čˆă‰ďć“VˆŮíƒ‚ƒjƒ^ƒŠƒ“ƒO‚É‚¨‚Ż‚éć“VˆŮíƒf[ƒ^ƒx[ƒX‚đŠî‚É‚ľ‚˝ŹŽ™”ĺ”AŠíŠÖ˜Ać“VˆŮí”­ś“ŽŒü‚ĚŒŸ“˘. X@˜j•˝ (”ĺ”AŠí): ‘ć30‰ń“ú–{ŹŽ™”ĺ”AŠí‰ČŠw‰ď‘‰ďEŠwpW‰ď (2021/7/2), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723514. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚̐ćs“ItˆÚA‚ɂ‚˘‚Ä‚ĚŒŸ“˘. Îˆä‘ĺ•ă1, ‰––ě@—T1, ’†‘ş^—˜]1, ź–{˜aŤ1, Šâ‘şłŽk1, –ěŒű•ś”T1, ˆä‘ş—[•P2, ˆ˘•”“N–ç3, ’|“ŕN—Y3, ‹g“cˆęŹ1,4 (1”ĺ”AŠí, 2ŠĹŒě•”, 3t‘Ÿ“ŕ, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć57‰ń“ú–{ˆÚAŠw‰ď‘‰ď (2021/9/20), “Œ‹ž.

723515. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) tˆÚAŒăÄ”­‘ƒóŽ…‹…‘̍d‰ťÇ‚ɑ΂ˇ‚錌Ÿ÷ŒđŠˇ—Ă–@‚ĚŽĄ—ĂŒř‰Ę‚ĚŒŸ“˘. –k“‡˜aŽ÷1, ŠCăk•˝, ÎˆäG‘ž, ‘ĺ–Ř—˘‰ÔŽq, “ĄŒ´—T–ç, —с@ç—T, –Ş“c@—ş, ”Ş–ŘŕV—˛Žj, _ŕV‘žˆę, ”ö–{˜a–ç, “y’J@Œ’, Î“c‰pŽ÷, “c粈ꐏ, ‚–Ř•q’j (1”ĺ”AŠí): ‘ć57‰ń“ú–{ˆÚAŠw‰ď‘‰ď (2021/9/20), “Œ‹ž.

723516. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒyƒ“ƒuƒƒŠƒYƒ}ƒu‚ɑ΂ˇ‚éƒ}ƒCƒNƒƒTƒeƒ‰ƒCƒg•sˆŔ’萍ŒŸ¸‚Ć‚ť‚Ě—zŤŽŇ‚ɑ΂ˇ‚éˆâ“`ƒJƒEƒ“ƒZƒŠƒ“ƒO‚ĚŽŔ‘Ô’˛¸. ’Ă‘şGN1, Žu‘ş‘sˆę˜N1, “‡’Á@Ť, Źâ–ůŒŤ, ”’ˆäG’ź2, ˜m’J”ü“Ţ3, –x“ŕŒb”üŽq, ě“c仉Ŕ, r–؏Ž”ü, r–ؐł—Y, ŽOŠK‹MŽj3, ‚“cŽj’j4 (1”ĺ”AŠí, 2ŹŽ™, 3“ű‘BEbó‘BŠO, 4‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): “ú–{l—Ţˆâ“`Šw‰ď‘ć66‰ń/‘ĺ‰ď‘ć28‰ń“ú–{ˆâ“`Žqf—ĂŠw‰ď‘ĺ‰ď‡“ŻŠJĂ (2021/10/15), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723517. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) äNă÷Šŕ‚É‚¨‚Ż‚錌´‚¨‚ć‚Ń•a—‘gD‚Ĺ‚ĚEpiplakin”­Œť‚ĚŒŸ“˘. Žu‘ş‘sˆę˜N1, ź–{˜aŤ1, “V–ě“”V2, ´…ƒ†ƒŠŽq, •˝–ěC•˝1, “c”¨Œ’ˆę1, ˛“Ą—Yˆę3, Šâ‘şłŽk1 (1”ĺ”AŠí, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ÉqśŠw•”): “ú–{”ĺ”AŠíŽîᇊw‰ď‘ć7‰ńŠwpW‰ď (2021/10/23), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723518. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “Ť¸‘ƒŽîᇂɑ΂ˇ‚éTIP—Ă–@‚ĚÄ“Š—^‚Ş’˜Œř‚ľ‚˝1—á. Žu‘ş‘sˆę˜N1, “c”¨Œ’ˆę1, ŸNˆä@—v1, ‰––ě@—T1, “V–ě“”V2, ’r“cŸb1, Šâ‘şłŽk1 (1”ĺ”AŠí, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): “ú–{”ĺ”AŠíŽîᇊw‰ď‘ć7‰ńŠwpW‰ď (2021/10/23), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723519. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ÚGŽŽƒŒ[ƒU[‘O—§‘BöŽUp (CVP) ‚̏‰ŠúŽĄ—ĂŒoŒą. aŒűG”V, {ŽRˆę•ä, Žu‘ş@“N, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć35‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2021/11/11), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723520. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒƒ{ƒbƒgŽx‰‡• o‹ž‰şŞŽĄ“IäNă÷“Eœp‚Ć‘źpŽŽ‚̐§ŠŕŒř‰Ę‚ɂ‚˘‚Ä‚Ě”äŠrŒŸ“˘. ź–{˜aŤ1, ’r“cŸb1, •˝ŽR‹M”Ž1, ‘şă‘א´1, •˝–ěC•˝1, ’Ă‘şGN1, “c”¨Œ’ˆę1, Îˆä‘ĺ•ă1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć35‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2021/11/11), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723521. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) BPH‚ɑ΂ˇ‚éŒo”A“š“I‘O—§‘BŽčpŒă‚ĚŽc‘ś‰ßŠˆ“ŽäNă÷Çó‚ÉŠÖ˜A‚ˇ‚éˆöŽq‚ĚŒŸ“˘. ‘şă‘א´1, •˝ŽR‹M”Ž1, ‰œ“c’mŽj1, “ü]@Œ[, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć35‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2021/11/11), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723522. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) 3”NŠÔ•ú’u‚ł‚ę‚˝”AŠÇƒXƒeƒ“ƒg, ”A˜HŒ‹Î‚ɑ΂ˇ‚é”jÓŽĄ—Ă‚Ě1—á. ”‹Œ´ł”Ž1, ‘ĺXŽé˜a”T1, –L“cš”ü1, Ÿ–”—mŽ÷2, ˆŔ“Ą–š”ü1, ‰œ–ě‹I•F, ŠŰ@“T•v, Šâ‘şłŽk1 (1”ĺ”AŠí, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć35‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2021/11/11), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723523. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚É‚¨‚Ż‚éHoLEPp‘O‚Ě‘O—§‘BMRIŒŸ¸‚ɂ‚˘‚Ä‚ĚŒŸ“˘. •˝–ěC•˝1, ź‰şˆęŽ÷1, Ź—Ń“Žq1, Žu‘ş‘sˆę˜N1, ’r“cŸb1, •˝ŽR‹M”Ž1, Îˆä‘ĺ•ă1, ź–{˜aŤ1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć35‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2021/11/11), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723524. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒƒ{ƒbƒgŽx‰‡‰şŞŽĄ“IäNă÷‘S“Ep‚Ě“ą“üŠúŽĄ—ÐŹŃ. ’r“cŸb1, ź–{˜aŤ1, •˝ŽR‹M”Ž1, •˝–ěC•˝1, ‘şă‘א´1, ’†‘ş^—˜]1, Ź—Ń“Žq1, –k“‡˜aŽ÷1, Îˆä‘ĺ•ă1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć35‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2021/11/11), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723525. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚É‚¨‚Ż‚郍ƒ{ƒbƒgŽx‰‡‰şt•”•ŞŘœpŒă‚ĚÄ”­“]ˆÚÇ—á‚ɑ΂ˇ‚錟“˘. ‰––ě@—T1, Îˆä‘ĺ•ă1, ’†‘ş^—˜]1, Ź—Ń“Žq1, •˝–ěC•˝1, –k“‡˜aŽ÷1, “Ą“c“N•v1, ź–{˜aŤ1, ‹g“cˆęŹ1,2, Šâ‘şłŽk1 (1”ĺ”AŠí, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć35‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2021/11/11), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723526. [Šw‰ď (‘S‘)] (‘‰ďÜƒ|ƒXƒ^[) • o‹ž‰ş_Œo‰ˇ‘śŞŽĄ“I‘O—§‘B‘S“Eœp‚ŞŘœ’f’[‚É—^‚Ś‚é‰e‹ż‚ÉŠÖ‚ˇ‚錟“˘. Œ´–ě‹MO1, “c”¨Œ’ˆę1, Îě—T˜a1, ź‰şˆęŽ÷1, ‹{ŕV–žŽq1, Ź—Ń“Žq1, Žu‘ş‘sˆę˜N1, ’Ă‘şGN1, ź–{˜aŤ1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć35‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2021/11/11), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723527. [Šw‰ď (‘S‘)] (‘‰ďÜƒ|ƒXƒ^[) ś”AŠÇŠŕ‚ɑ΂ľ‚ăcƒŠƒEƒ€ƒŒ[ƒU[öŽUŘœp‚đŽ{s‚ľ‚˝ˆę—á. –L“cš”ü1, Ÿ–”—mŽ÷2, ‰œ–ě‹I•F, Šâ‘şłŽk1 (1”ĺ”AŠí, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć35‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2021/11/11), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723528. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ś‘̐tˆÚAŒă‚ĚˆÚAt”AŠÇŒ‹Î‚ɑ΂ľ‚Ä, Œo”A“š“IŒ‹Î”jÓp‚đŽ{s‚ľ‚˝ˆę—á. ‘ĺXŽé˜a”T1, ŠŰ@“T•v, ”‹Œ´ł”Ž1, ˆŔ“Ą–š”ü1, Îˆä‘ĺ•ă1, ‹g“cˆęŹ1,2, Šâ‘şłŽk1 (1”ĺ”AŠí, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć35‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2021/11/11), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723529. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚郍ƒ{ƒbƒgŽx‰‡t᱌`Źp‚̏‰ŠúŹŃ‚Ć• o‹ž‰şt᱌`Źp‚Ć‚Ě”äŠrŒŸ“˘. X@˜j•˝1, •˝–ěC•˝1, –k“‡˜aŽ÷1, ’r“cŸb1, ź@ˇG, Îˆä‘ĺ•ă1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć35‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2021/11/11), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723530. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[)“–‰Č‚É‚¨‚Ż‚é• o‹ž‰ş”A–ŒŠÇ“Eœp‚ĚŒoŒą. ź‰şˆęŽ÷1, •˝–ěC•˝1, ’†‘ş^—˜]1, Ź—Ń“Žq1, –k“‡˜aŽ÷1, ’r“cŸb1, Îˆä‘ĺ•ă1, ź–{˜aŤ1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć35‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2021/11/11-13), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723531. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Glenn-Anderson–@‚É‚ć‚é‹CäNă÷‰şäNă÷”AŠÇ‹t—ŹÇŽčp‚Ě1—á. Îě—T˜a1, X@˜j•˝1, ź@ˇG, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć35‰ń“ú–{”ĺ”AŠí“ŕŽ‹‹žŠw‰ď‘‰ď (2021/11/11-13), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723532. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽĄ—Ă‚É“ďa‚ľ‚˝tˆÚAŒă• –Œ“§ÍÄ“ą“üŠłŽŇ‚ĚƒJƒe[ƒeƒ‹ƒgƒ“ƒlƒ‹Š´ő‚Ěˆę—á. ‘ĺXŽé˜a”T1, Îˆä‘ĺ•ă1, Œ´–ě‹MO1, ‰––ě@—T1, ’†‘ş^—˜]1, –k“‡˜aŽ÷1, –ěŒű•ś”T1, Šâ‘şłŽk1, ‹g“cˆęŹ1,2 (1”ĺ”AŠí, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć30‰ń“ú–{t•s‘SŠO‰ČŒ¤‹†‰ďŠwpW‰ď (2021/12/4), ‰Ť“ę (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723533. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) äNă÷ŠŕŠłŽŇ‚É‚¨‚Ż‚éDJ-1”­Œť‚Ě•a—‘gDŠw“IŒŸ“˘. •˝–ěC•˝1, ź–{˜aŤ1, ’†‘ş^—˜]1, Ź—Ń“Žq1, –k“‡˜aŽ÷1, ’r“cŸb1, “c”¨Œ’ˆę1, ˛“Ą—Yˆę2, Šâ‘şłŽk1 (1”ĺ”AŠí, 2ˆă—ÉqśŠw•”): ‘ć109‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (JUA2021) (2021/12/7), ‰Ą•l.

723534. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “]ˆÚŤtŠŕ‚ɑ΂ˇ‚錴”­‘ƒ“Eœ‚Ě—LŒřŤ‚ĚŒŸ“˘. –k“‡˜aŽ÷1, Îˆä‘ĺ•ă1, “Ą“c“N•v1, Ÿ–”—mŽ÷2, Ź—Ń“Žq1, ’†‘ş^—˜]1, ‰––ě@—T1, •˝–ěC•˝1, ’r“cŸb1, ‹g“cˆęŹ1,3, ź–{˜aŤ1, Šâ‘şłŽk1 (1”ĺ”AŠí, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć109‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (JUA2021) (2021/12/7), ‰Ą•l.

723535. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) äNă÷Šŕ‚É‚¨‚Ż‚錌´‚¨‚ć‚Ń•a—‘gD‚Ĺ‚ĚEpiplakin”­Œť‚ĚŒŸ“˘. Žu‘ş‘sˆę˜N1, ź–{˜aŤ1, ´…ƒ†ƒŠŽq, –]ŒŽN•˝1, –k“‡˜aŽ÷1, “c”¨Œ’ˆę1, ‹g“cˆęŹ1,2, Šâ‘şłŽk1 (1”ĺ”AŠí, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć109‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (JUA2021) (2021/12/7), ‰Ą•l.

723536. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ă•””A˜Hă”çŠŕpŒăäNă÷Ä”­‚ɑ΂ˇ‚éBCGäNă÷“ŕ’“ü—Ă–@‚ĚŽĄ—ÐŹŃ. ‘OŽR—Ç‘ž1, ’r“cŸb1, Žu‘ş‘sˆę˜N1, “V–ě“”V2, ‘şă‘א´1, ŽR“c‘׎j1, ‚Œű@‘ĺ1, —§‰Ô‹MŽj1, ě‘ş•ä1, â“c—S‰î1, ”‹Œ´ł”Ž1, ź–{˜aŤ1, Šâ‘şłŽk1 (1”ĺ”AŠí, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć109‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (JUA2021) (2021/12/8), ‰Ą•l.

723537. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹Ř‘w”ńZŤäNă÷Šŕ‚ɑ΂ˇ‚é’á—p—ĘBCGäNă÷“ŕ’“ü—Ă–@‚ĚŽĄ—ÐŹŃ. —§‰Ô‹MŽj1, ’r“cŸb1, Žu‘ş‘sˆę˜N1, “V–ě“”V2, ‘şă‘א´1, ŽR“c‘׎j1, ‚Œű@‘ĺ1, ‘OŽR—Ç‘ž1, ě‘ş•ä1, â“c—S‰î1, ”‹Œ´ł”Ž1, ź–{˜aŤ1, Šâ‘şłŽk1 (1”ĺ”AŠí, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć109‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (JUA2021) (2021/12/8), ‰Ą•l.

723538. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) äNă÷‘S“EœpÇ—á‚É‚¨‚Ż‚éAHNAK2”­Œť‚Ć—\Œă‚ÉŠÖ‚ˇ‚錟“˘. ‚Œű@‘ĺ1, ź–{˜aŤ1, Žu‘ş‘sˆę˜Y1, ´…ƒ†ƒŠŽq, X@˜j•˝1, ’Ă‘şGN1, ‰Š@‰p–Î, ‹g“cˆęŹ1,2, ˛“Ą—Yˆę3, Šâ‘şłŽk1 (1”ĺ”AŠí, 2V˘‹Iˆă—ÁEć’[ˆă—Ă, 3ˆă—ÉqśŠw•”): ‘ć109‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (JUA2021) (2021/12/9), ‰Ą•l.

723539. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ’†ŠÔƒŠƒXƒNŒQ‚É‚¨‚Ż‚郈ƒE‘f125–§••ŹüŒš—Ă–@’P“Ć‚ĆŠOĆŽË•š—p–§••ŹüŒš—Ă–@‚Ě”äŠr. ’Ă‘şGN1, “c’†é“š2, ŹŒű’q•F3, ”ö’Ł‘ń–ç2,4, ’†ˆä@–ő2, óě—E—Y2, ”Ń“‡˜a–F3, ‰Á“Ą°˜N3, ‹´“c@ŠŢ3, “c”¨Œ’ˆę1, ˛“ĄˆĐ•ś1, ÎŽR”ŽžŠ5, Šâ‘şłŽk1 (1”ĺ”AŠí, 2“Ţ—ÇŒ§—§ˆă‰Č‘ĺŠw, 3’ˇ–ěŽs–Ż•a‰@, 4‘ĺ˜a‚“cŽs—§•a‰@, 5•úŽËü (Žîá‡)): ‘ć109‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď (JUA2021) (2021/12/7-10), _“ސě, “ú–{”ĺ”AŠí‰ČŠw‰ď‘‰ď 2021/12; 109: OP82-05.

723540. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “Ť¸‘ƒŽîᇂɑ΂ľTIP—Ă–@‚ĚÄ“Š—^‚Ş’˜Œř‚ľ‚˝ˆę—á. Žu‘ş‘sˆę˜N1, “c”¨Œ’ˆę1, ’r“cŸb1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć19‰ń“ú–{—Տ°Žîᇊw‰ďŠwpW‰ď (2022/2/17), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

731029. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) mCRPC‚ĚŒÂ•Ę‰ťŽĄ—Ă‚ĆƒŠƒ€ƒp[ƒU‚ĚŽg—pŒoŒą. “c”¨Œ’ˆę (”ĺ”AŠí): CRPC Precision Medicine Expert meeting _“ސě–kź•” (2021/4/9), WebŠJĂ.

731030. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ‘O—§‘B‚Ş‚ńf—Â̐V‚˝‚Č‚é’Ş—Ź. “c”¨Œ’ˆę (”ĺ”AŠí): mCRPCƒvƒŒƒVƒWƒ‡ƒ“ƒƒfƒBƒVƒ“u‰‰‰ď (2021/4/23), WebŠJĂ.

731031. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) mHSPC‚ĚƒxƒXƒgƒvƒ‰ƒNƒeƒBƒX‚đl‚Ś‚é. “c”¨Œ’ˆę (”ĺ”AŠí): ‘O—§‘BŠŕŽĄ—ͧ˜b‰ď (2021/6/4), WebŠJĂ.

731032. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) mHSPC‚ĚƒxƒXƒgƒvƒ‰ƒNƒeƒBƒX‚đl‚Ś‚é. “c”¨Œ’ˆę (”ĺ”AŠí): ŽRŒűŒ§‰›’n‹ć‘O—§‘BŠŕƒZƒ~ƒi[ (2021/6/10), WebŠJĂ.

731033. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) mCRPC‚ĚŒÂ•Ę‰ťŽĄ—Ă‚ĆƒŠƒ€ƒp[ƒU‚ĚŽg—pŒoŒą. “c”¨Œ’ˆę (”ĺ”AŠí): Tokyo West Prostate Cancer Seminar (2021/6/11), WebŠJĂ.

731034. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) mCRPC‚ĚŒÂ•Ę‰ťŽĄ—Ă‚ĆƒŠƒ€ƒp[ƒU‚ĚƒCƒ“ƒpƒNƒg. “c”¨Œ’ˆę (”ĺ”AŠí): ‘Š–ÍŒ´CRPC Seminar–ž“ú‚Š‚犈‚Š‚š‚é‘O—§‘B‚Ş‚ń‚ĚŒÂ•Ę‰ťŽĄ—Ă (2021/6/17), WebŠJĂ.

731035. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) •Ş‚Š‚č‚₡‚˘! ‘O—§‘B‚Ş‚ń‚ĚƒQƒmƒ€f—Á|—Տ°‚Ŗ𗧂Šî‘b’mŽŻ|. ’Ă‘şGN (”ĺ”AŠí): ‘Š–ÍŒ´CRPC Seminar–ž“ú‚Š‚犈‚Š‚š‚é‘O—§‘B‚Ş‚ń‚ĚŒÂ•Ę‰ťŽĄ—Ă (2021/6/17), WebŠJĂ.

731036. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ”r”AŽŠ—§ƒTƒ|[ƒg‚ɑ΂ˇ‚é–k—˘‘ĺŠw•a‰@‚ĚŽć‚č‘g‚Ý. •˝ŽR‹M”Ž (”ĺ”AŠí): K-NUC Kanagawa Network of Urination Care (2021/6/18), WebŠJĂ.

731037. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) mCRPC‚ĚŒÂ•Ę‰ťŽĄ—Ă‚ĆƒŠƒ€ƒp[ƒU‚ĚŽg—pŒoŒą. “c”¨Œ’ˆę (”ĺ”AŠí): ‘ć317‰ń‰ŞŽR”ĺ”AŠí‰ČƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2021/6/22), WebŠJĂ.

731038. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) —\Œă‰ü‘P‚đ–ÚŽw‚ľ‚˝‘O—§‘BŠŕ‚É‚¨‚Ż‚é•úŽËüŽĄ—Á`–§••ŹüŒš—Ă–@‚Ć“]ˆÚ‘ƒĆŽË‚đ—p‚˘‚˝ŽĄ—Ð헪`. ’Ă‘şGN (”ĺ”AŠí): Prostate Cancer Expert Meeting (2021/6/29), WebŠJĂ.

731039. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ”ĺ”AŠí‰Č—Ěˆć‚Ěƒƒ{ƒbƒgŽčpŠÖ˜A. Šâ‘şłŽk (”ĺ”AŠí): “Œ‹ž_“ސ쏬Ž™tƒZƒ“ƒ^[‚̉ď (2021/7/1), WebŠJĂ.

731040. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) mHSPCŽĄ—Ă‚ĚĹV’Ş—Ź -‚ż‚傤‚Ç—Ç‚˘ŽĄ—Ă‚đ’T‚é-. “c”¨Œ’ˆę (”ĺ”AŠí): –ž“ú‚Ě‘O—§‘B‚Ş‚ń‚đl‚Ś‚é‰ď (2021/7/3), WebŠJĂ.

731041. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) M1‘O—§‘BŠŕ‚ĚƒGƒrƒfƒ“ƒX|–{–M‚Ĺ‚Ě‚ż‚傤‚Ç—Ç‚˘ŽĄ—Ă‚đ’T‚é|. “c”¨Œ’ˆę (”ĺ”AŠí): Both Surgery and Drug therapy conference for young urologist at HYOGO (2021/7/12), WebŠJĂ.

731042. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) mHSPCŽĄ—Ă‚Ěƒpƒ‰ƒ_ƒCƒ€ƒVƒtƒg|‚ż‚傤‚Ç—Ç‚˘ŽĄ—Ă‚đ‹‚ß‚Ä|. “c”¨Œ’ˆę (”ĺ”AŠí): Prostate Cancer Consensus Conference (2021/7/21), WebŠJĂ.

731043. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) mCRPC‚É‚¨‚Ż‚éŒÂ•Ę‰ťŽĄ—Ẩ”\Ť‚ĆƒŠƒ€ƒp[ƒU‚ĚŽg—pŒoŒą. “c”¨Œ’ˆę (”ĺ”AŠí): ‘ĺ“c‹ć‘O—§‘BŠŕƒQƒmƒ€u‰‰‰ď (2021/7/30), WebŠJĂ.

731044. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) |upfront‚ĆƒQƒmƒ€ˆă—Ă‚ĚŽž‘ă|CRPC‚É‚¨‚Ż‚éƒAƒrƒ‰ƒeƒƒ“‚đÄl‚ˇ‚é|. ’Ă‘şGN (”ĺ”AŠí): “]ˆÚŤ‘O—§‘B‚Ş‚ńŽĄ—Ð헪‚đl‚Ś‚é‘O—§‘B‚Ş‚ńWebƒZƒ~ƒi[ (2021/8/30), WebŠJĂ.

731045. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ƒRƒƒi‰Đ‚Ĺ‚Ě‘O—§‘BŠŕ–ň•¨—Ă–@‚đl‚Ś‚é. ’Ă‘şGN (”ĺ”AŠí): ‘O—§‘BŠŕWebƒZƒ~ƒi[ (2021/9/7), WebŠJĂ.

731046. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) mHSPCŽĄ—Ă‚Ěƒpƒ‰ƒ_ƒCƒ€ƒVƒtƒg; ‚ż‚傤‚Ç—Ç‚˘ŽĄ—Ă‚đl‚Ś‚é. “c”¨Œ’ˆę (”ĺ”AŠí): é‹Ę”ĺ”AŠíˆŤŤŽîᇍu‰‰‰ď (2021/9/10), WebŠJĂ.

731047. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ‘O—§‘B‚Ş‚ń‚É‚¨‚Ż‚é–ň•¨—Ă–@‚Ć•úŽËüŽĄ—Ă-‚ą‚̐””N‚É‚¨‚Ż‚鎥—Ă‘I‘đŽˆ‚Ě•Ď‘J-. ’Ă‘şGN (”ĺ”AŠí): ”ĺ”AŠíŽžŠł˜AŒgƒZƒ~ƒi[ (2021/9/17), WebŠJĂ.

731048. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) mHSPCŽĄ—Ă‚É‚¨‚Ż‚éƒxƒXƒgƒvƒ‰ƒNƒeƒBƒX‚Ć‚Í? “c”¨Œ’ˆę (”ĺ”AŠí): ‘ć5‰ńŽáŽčˆăŽt Prostate Cancer Forum (2021/9/30), WebŠJĂ.

731049. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) isŤ‘O—§‘BŠŕŽĄ—ÂɉťŠw—Ă–@‚͍vŒŁ‚ľ‚Ä‚˘‚é‚Ě‚Š?`ƒGƒrƒfƒ“ƒX‚Š‚ç•R‰đ‚­`mHSPC‚É‚¨‚Ż‚鉝Šw—Ă–@‚Ě–đŠ„. “c”¨Œ’ˆę (”ĺ”AŠí): JEVTANA WEBƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2021/10/13), WebŠJĂ.

731050. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) M0CRPC‚ɃCƒ“ƒeƒ“ƒVƒu‚ČŽĄ—Ă‚Í•K—v‚Š? “c”¨Œ’ˆę (”ĺ”AŠí): ƒjƒ…ƒxƒNƒI”­”„1Žü”N&ƒ][ƒtƒBƒS”­”„5Žü”N‹L”Ou‰‰‰ď in ‰Ą{‰ę (2021/10/28), WebŠJĂ.

731051. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ”ĺ”AŠí• o‹žŽčp‚Ě–˘—ˆ: ƒƒ{ƒbƒg‚̏oŒť‚͐ElŒ|‚đIŕ‚É“ą‚­‚Š? Šâ‘şłŽk (”ĺ”AŠí): ‹{č”ĺ”AŠí‰Čˆă‰ďƒTƒeƒ‰ƒCƒgƒZƒ~ƒi[ 5 (2021/11/6), WebŠJĂ.

731052. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ‘O—§‘BŠŕ–ň•¨—Ă–@ŠÖ˜A‚˛‰‰‘č. “c”¨Œ’ˆę (”ĺ”AŠí): ”ĺ”AŠí‚Ş‚ńMeet the Expert in KANAGAWA (ˆÄ) (2021/12/3), WebŠJĂ.

732072. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŒÂ•Ę‰ťf—Ă‚ĚŽć‚č‘g‚Ý‚ĆŽŔŰ. “c”¨Œ’ˆę (”ĺ”AŠí): CRPC Precision Medicine Expert meeting _“ސě–kź•” (2021/4/9), WebŠJĂ.

732073. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ŽQ‰ÁŒ^ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) Œƒ˜_!BRCAˆâ“`Žq•ĎˆŮŒŸ¸`ŽĺŽĄˆă‚Ć‚ľ‚ĉ˝‚đ‚Ç‚¤‚ˇ‚ׂŤ? ‹^–â‚𐰂炡ŒoŒą‹Ÿ——`. “c”¨Œ’ˆę (”ĺ”AŠí): Japan REAL Experience Symposium `WŒ‹, BRCAˆâ“`Žq•ĎˆŮŒŸ¸‚ĚŽŔ‘H` (2021/5/26), WebŠJĂ.

732074. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) tˆÚA‚É‚¨‚Ż‚éƒAƒNƒZƒX, ‹Zp‚Ě“`ł. Îˆä‘ĺ•ă1, –k“‡˜aŽ÷1, ‹g“cˆęŹ1,2 (1”ĺ”AŠí, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć36‰ńtˆÚAEŒŒŠÇŠO‰ČŒ¤‹†‰ď (2021/6/11), WebŠJĂ.

732075. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒoƒxƒ“ƒ`ƒIˆŰŽ—Ă–@‚ĚŽg‚˘‚Ç‚ą‚ë‚đl‚Ś‚é. •âáÁ“ń (”ĺ”AŠí): UC Internet Symposium DUAL in Sagamihara (2021/8/3), WebŠJĂ.

732076. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒoƒxƒ“ƒ`ƒIˆŰŽ—Ă–@‚ĚŽg‚˘‚Ç‚ą‚ë‚đl‚Ś‚é. ’r“cŸb (”ĺ”AŠí): UC Internet Symposium DUAL in Sagamihara (2021/8/3), WebŠJĂ.

732077. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) mHSPC‚ɑ΂ˇ‚é‘O—§‘B‹ÇŠ•úŽËüŽĄ—Ă‚Ć“]ˆÚ‘ƒĆŽË‚É‚ć‚é—\Œă‰ü‘P‚đ–ÚŽw‚ľ‚˝ŽĄ—Ð헪. ’Ă‘şGN1, “c”¨Œ’ˆę1, ’†‘ş^—˜]1, Ź—Ń“Žq1, Žu‘ş‘sˆę˜N1, “V–ě“”V2, ’r“cŸb1, ź–{˜aŤ1, ˛“ĄˆĐ•ś, ÎŽR”ŽžŠ3, Šâ‘şłŽk1 (1”ĺ”AŠí, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3•úŽËü (Žîá‡)): ‘ć86‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď“Œ•”‘‰ď (2021/9/4), WebŠJĂ.

732078. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒRƒƒi‰Đ‚É‚¨‚Ż‚é‘O—§‘BŠŕ‰ťŠw—Ă–@‚Ć•›ě—p‘΍ô. •âáÁ“ń (”ĺ”AŠí): ‘O—§‘BŠŕWebƒZƒ~ƒi[ (2021/9/7), WebŠJĂ.

732079. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‰ťŠw—Ă–@: ƒVƒXƒvƒ‰ƒ`ƒ“Žg—p‚ĚŽŔŰ. ź–{˜aŤ (”ĺ”AŠí): Hybrid Internet Symposium in _“ŢěŒ§‰›/Œ§ź (2021/9/16), WebŠJĂ.

732080. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (Žs–ŻŒöŠJuŔ) ‘O—§‘B‚Ş‚ń‚ɑ΂ˇ‚é•úŽËüŽĄ—Ă. ’Ă‘şGN (”ĺ”AŠí): ‚ą‚ą‚Ü‚Ĺ‚Ť‚˝! ‘O—§‘B‚Ş‚ń•úŽËüŽĄ—Á`ƒRƒƒi‰Đ‚ĚŒť‹ľ‚ŕ“Ľ‚Ü‚Ś‚ā` (2021/10/3), WebŠJĂ.

732081. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçƒZƒ~ƒi[) Pros and Cons‚ōl‚Ś‚émHSPCŽĄ—Ă‚É‚¨‚Ż‚éARATs. “c”¨Œ’ˆę (”ĺ”AŠí): ‘ć71‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď’†•”‘‰ď (2021/10/7), –źŒĂ‰Ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

732082. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) mCSPC‚ĚŠĎ“_‚ć‚č. “c”¨Œ’ˆę (”ĺ”AŠí): —Տ°”ĺ”AŠíƒZƒ~ƒi[ (2021/10/20), WebŠJĂ.

732083. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) tˆÚB‚ĚŒť‹ľ‚Ć–â‘č“_|tˆÚA‚É‚¨‚Ż‚éƒ`[ƒ€ˆă—Ă‚Ěd—vŤ|. ‹g“cˆęŹ1,2, Îˆä‘ĺ•ă2, –ěŒű•ś”T3, –k“‡˜aŽ÷2, ˆ˘•”“N–ç4, ˆä‘ş—[•P3 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2”ĺ”AŠí, 3ŠĹŒě•”, 4t‘Ÿ“ŕ): ‘ć30‰ń“ú–{t•s‘SŠO‰ČŒ¤‹†‰ďŠwpW‰ď (2021/12/4-5), ‰Ť“ę (ƒnƒCƒuƒŠƒbƒhŠJĂ)

733170. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‘ƒóŽ…‹…‘̍d‰ťÇ‚đŒ´ŽžŠł‚Ć‚ˇ‚郌ƒVƒsƒGƒ“ƒg16—á‚ĚŒŸ“˘. ‰––ě@—T1, –k“‡˜aŽ÷1, Îˆä‘ĺ•ă1, ˆ˘•”“N–ç2, –ěŒű•ś”T1, ˆä‘ş—[•P3, ’|“ŕN—Y2, ‹g“cˆęŹ1,4, Šâ‘şłŽk1 (1”ĺ”AŠí, 2t‘Ÿ“ŕ, 3ŠĹŒě•”, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć100‰ń_“ސětŒ¤‹†‰ď‘‰ďEŒ¤‹†W‰ď (2021/5/29), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733171. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) pŒă‚ɈڐA”AŠÇ-äNă÷V•Ť‡‚đ—v‚ľ‚˝ŒŁtˆÚA‚Ě1—á. –k“‡˜aŽ÷1, Îˆä‘ĺ•ă1, ‰œ“c’mŽj1, Ÿ–”—mŽ÷2, Žu‘ş‘sˆę˜N1, ˆ˘•”“N–ç3, Š@L–ç4, Šâ‘şłŽk1, ‹g“cˆęŹ1,5 (1”ĺ”AŠí, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3t‘Ÿ“ŕ, 4‹~–˝, 5V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć36‰ńtˆÚAEŒŒŠÇŠO‰ČŒ¤‹†‰ď (2021/6/11), WebŠJĂ.

733172. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Ä—Ă–@‘I‘đ. Îˆä‘ĺ•ă (”ĺ”AŠí): ‘ć4‰ńt•s‘Sƒ`[ƒ€ˆă—Ă‹Ś‹c‰ďŠwp‘ĺ‰ď (2021/8/22), WebŠJĂ.

733173. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ|ƒXƒ^[) äNă÷Šŕ‚Ĺ‚ĚHNRNPA3”­Œť‚¨‚ć‚Ń—\Œă‚ÉŠÖ‚ˇ‚錟“˘. “V–ě“”V1, ź–{˜aŤ2, ´…ƒ†ƒŠŽq, –k“‡˜aŽ÷2, ’r“cŸb2, “c”¨Œ’ˆę2, ‹g“cˆęŹ2,3, ˛“Ą—Yˆę, Šâ‘şłŽk2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2”ĺ”AŠí, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć86‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď“Œ•”‘‰ď (2021/9/3), WebŠJĂ.

733174. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ|ƒXƒ^[) BCGäNă÷“ŕ’“ü—Ă–@‚Ěă•””A˜Hă”çŠŕŠů‰‚Ě—L–ł‚É‚¨‚Ż‚鎥—ÐŹŃ. ‘OŽR—Ç‘ž1, ’r“cŸb1, Žu‘ş‘sˆę˜N1, “V–ě“”V2, ‘şă‘א´1, ŽR“c‘׎j1, ‚Œű@‘ĺ1, —§‰Ô‹MŽj1, ě‘ş•ä1, â“c—T‰î1, ”‹Œ´ł”Ž1, ź“c‘ĺ‰î1, ź–{˜aŤ1, Šâ‘şłŽk1 (1”ĺ”AŠí, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć86‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď“Œ•”‘‰ď (2021/9/3), WebŠJĂ.

733175. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ|ƒXƒ^[) t᱔AŠÇ‹žŒŸ¸‚ސt”AŠÇ‘S“Ep‚É‹y‚Ú‚ˇ‰e‹ż‚ɂ‚˘‚Ä‚ĚŒŸ“˘. –]ŒŽN•˝1, â“c—T‰î1, Îˆä~ˆę˜Y (1”ĺ”AŠí): ‘ć86‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď“Œ•”‘‰ď (2021/9/3), WebŠJĂ.

733176. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) äNă÷ŠŕŠłŽŇ‚É‚¨‚Ż‚錌´’†DJ-1ƒ^ƒ“ƒpƒNŽż”­ŒťƒŒƒxƒ‹‚ĚŒŸ“˘. •˝–ěC•˝1, ź–{˜aŤ1, “V–ě“”V2, ‰––ě@—T1, ’†‘ş^—˜]1, Ź—Ń“Žq1, Žu‘ş‘sˆę˜N1, ˛“Ą—Yˆę3, Šâ‘şłŽk1 (1”ĺ”AŠí, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ÉqśŠw•”): ‘ć86‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď“Œ•”‘‰ď (2021/9/3), WebŠJĂ.

733177. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ|ƒXƒ^[) “–‰@‚É‚¨‚Ż‚é‹Ž¨’ďRŤ‘O—§‘BŠŕ (CRPC), œ“]ˆÚÇ—á‚ɑ΂ˇ‚é223Ra (ƒ][ƒtƒBƒS) ‚Ě—LŒřŤ‚ɂ‚˘‚Ä‚ĚŒŸ“˘. Ÿ–”—mŽ÷1, –L“cš”ü2, Œ´–ě‹MO2, Žá“c•”—zŽi, –k–ě‰ëŽj, ‰œ–ě‹I•F, Šâ‘şłŽk2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2”ĺ”AŠí): ‘ć86‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď“Œ•”‘‰ď (2021/9/3), WebŠJĂ.

733178. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ|ƒXƒ^[) ‹Ž¨’ďRŤ‘O—§‘BŠŕ‚ɑ΂ˇ‚éCabazitaxel—Ă–@: “Š—^—Ę•Ę‚ĚƒNƒŠƒjƒJƒ‹ƒAƒEƒgƒJƒ€. ‰––ě@—T1, “c”¨Œ’ˆę1, ’Ă‘şGN1, ’†‘ş^—˜]1, Ź—Ń“Žq1, Œ´–ě‹MO1, ‘ş–Ř•q˜Y1, ŸNˆä@—v1, ‹{ŕV–žŽq1, Îě—T˜a1, ź‰şˆęŽ÷1, ź–{˜aŤ1, Šâ‘şłŽk1 (1”ĺ”AŠí): ‘ć86‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď“Œ•”‘‰ď (2021/9/3), WebŠJĂ.

733179. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ|ƒXƒ^[) ƒƒ{ƒbƒgŽx‰‡• o‹ž‰şt•”•ŞŘœp147—á‚É‚¨‚Ż‚épŒăŠł‘¤t‹@”\‚ĚŒŸ“˘. –k“‡˜aŽ÷1, Îˆä‘ĺ•ă1, “Ą“c“N•v1, ’r“cŸb1, •˝–ěC•˝1, ź–{˜aŤ1, ‹g“cˆęŹ1,2, Šâ‘şłŽk1 (1”ĺ”AŠí, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć86‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď“Œ•”‘‰ď (2021/9/3), WebŠJĂ.

733180. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ|ƒXƒ^[) äNă÷‘S“Eœp•W–{‚đ—p‚˘‚˝Epiplakin”­Œť‚ĚŒŸ“˘. Žu‘ş‘sˆę˜N1, ź–{˜aŤ1, ´…ƒ†ƒŠŽq1, X@˜j•˝1, •˝–ěC•˝1, ’r“cŸb1, ˛“Ą—Yˆę2, Šâ‘şłŽk1 (1”ĺ”AŠí, 2ˆă—ÉqśŠw•”): ‘ć86‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď“Œ•”‘‰ď (2021/9/3), WebŠJĂ.

733181. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŞŽĄ“IäNă÷Šŕ‘S“Eœp•W–{‚É‚¨‚Ż‚éƒ|ƒŠƒIƒEƒCƒ‹ƒXŽó—e‘Ě (CD155) ”­Œť‚ĚŒŸ“˘. X@˜j•˝1, ź–{˜aŤ1, “V–ě“”V2, ´…ƒ†ƒŠŽq, ”‹Œ´ł”Ž1, ’Ă‘şGN1, Îˆä‘ĺ•ă1, ˛“Ą—Yˆę3, Šâ‘şłŽk1 (1”ĺ”AŠí, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ÉqśŠw•”): ‘ć86‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď“Œ•”‘‰ď (2021/9/4), WebŠJĂ.

733182. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) —Տ°f’f‚É‹ę—ś‚ľ‚˝‘lŒa•”Žîᎂ̈ę—á. –L“cš”ü1, Ÿ–”—mŽ÷2, –x“cˆťŽq, âV“Ąś˜N, ‰œ–ě‹I•F, Šâ‘şłŽk1 (1”ĺ”AŠí, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć63‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď_“ސě’n•ű‰ď (2021/9/16), WebŠJĂ.

733183. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “Ť¸‘ƒŽîᇂɑ΂ľTIP—Ă–@‚ĚÄ“Š—^‚Ş’˜Œř‚ľ‚˝ˆę—á. Îě—T˜a1, Žu‘ş‘sˆę˜N1, ‰––ě@—T1, Ź—Ń“Žq1, “V–ě“”V2, ’r“cŸb1, “c”¨Œ’ˆę1, ź–{˜aŤ1, ‹g“cˆęŹ1,3, Šâ‘şłŽk1 (1”ĺ”AŠí, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć63‰ń“ú–{”ĺ”AŠí‰ČŠw‰ď_“ސě’n•ű‰ď (2021/9/16), WebŠJĂ.

733184. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒƒ{ƒbƒgŽx‰‡• o‹ž‰şt᱌`Źp`–ž“ú‚Š‚ç‚Ě—Ő°‚ÉŒü‚Ż‚ā`. Îˆä‘ĺ•ă (”ĺ”AŠí): ”ĺ”AŠíŽîᇎŔ‘Hm in Žń“sŒ—`–ž“ú‚Š‚ç‚Ě—Ő°‚ÉŒü‚Ż‚ā` (2021/10/13), WebŠJĂ.

733185. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “]ˆÚŤ‘O—§‘BŠŕŽĄ—Ă‚ĚĹ‘Oü`low volume mCSPC‚ĚŽĄ—Ă‚Í‚Ç‚¤•Ď‚í‚é‚Š`. ”ŠŽR^Œá, “c”¨Œ’ˆę1 (1”ĺ”AŠí): ‘O—§‘B‚Ş‚ńWebƒZƒ~ƒi[ (2021/10/18), WebŠJĂ.

733186. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‘O—§‘B‚Ş‚ńŽĄ—Ð헪‚ɂ‚˘‚Ä. Žu‘ş‘sˆę˜N1, äoŔ’ź—˜, ”~–{’BĆ, A‘şŒöˆę (1”ĺ”AŠí): SKYT 2021 Extend meeting (2021/11/24), WebŠJĂ.

733187. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) mHSPC‚̐f’fEŽĄ—Âɂ‚˘‚Ä (‰ź). “c”¨Œ’ˆę (”ĺ”AŠí): “ŒŠ‹–k•” Prostate Cancer WEB Forum (2021/11/26), WebŠJĂ.

733188. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “]ˆÚŤ‘O—§‘BŠŕ‚̍ŐVŽĄ—Âɂ‚˘‚Ä (‰ź). “c”¨Œ’ˆę (”ĺ”AŠí): Metropolitan Oncology Seminar (2021/12/2), WebŠJĂ.

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-110024. [Œ´’˜] Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort. Ito K, Kobayashi T, Kojima T, Hikami K, Yamada T, Ogawa K, Nakamura K, Sassa N, Yokomizo A, Abe T, Tsuchihashi K, Tatarano S, Inokuchi J, Tomida R, Fujiwara M, Takahashi A, Matsumoto K1, Shimizu K, Araki H, Kurahashi R, Osaki Y, Tashiro Y, Uegaki M, Ogawa O 4, KitamuraH, Nishiyama H: Cancer Med 2021/3; 10 (10): 3188-96. (ź–{˜aŤ1: 1”ĺ”AŠí)


Šá‰ČŠw

[Šwp˜_•ś]

110365. [Œ´’˜] Clinical Features of Crowded Orbital Syndrome on Magnetic Resonance Imaging. Iwasa M, Wakakura M, Kohmoto H, Tatsui S1, Ishikawa H2: Neuroophthalmology 2021; 45 (2): 87-91. (—´ˆä‰‘Žq1, Îě@‹Ď2: 1Šá‰Č, 2ˆă—ÉqśŠw•”)

110366. [Œ´’˜] Factors Influencing Contrast Sensitivity Function in Eyes with Mild Cataract. Kamiya K1, Fujimura F1, Kawamorita T1, Ando W2, Iida Y2, Shoji N2: J Clin Med 2021/4; 10 (7): 1506. (_’J˜aF1, “Ą‘ş•‡ŽŃŽq1, ěŽç“c‘ńŽu1, ˆŔ“Ą˜a‰ĚŽq2, ”Ń“c‰Ă•F2, ŻŽiMs2: 1ˆă—ÉqśŠw•”, 2Šá‰Č)

110367. [Œ´’˜] Clinical outcomes of simultaneous phototherapeutic keratectomy and photoastigmatic keratectomy. Kamiya K1, Yazaki K2, Ando W2, Takahashi M2, Shoji N2: Sci Rep 2021/5; 11 (1) :9504. (_’J˜aF1, –îčŘ2, ˆŔ“Ą˜a‰ĚŽq2, _‹´ł‰p2, ŻŽiMs2: 1ˆă—ÉqśŠw•”, 2Šá‰Č)

110368. [Œ´’˜] Comparison of Mean and Centroid of Surgically Induced Astigmatism After Standard Cataract Surgery. Kamiya K1, Iijima K2, Ando W2 , Shoji N2: Front Med (Lausanne) 2021/6; 8: 670337. (_’J˜aF1, ”Ń“‡@Œh2, ˆŔ“Ą˜a‰ĚŽq2, ŻŽiMs2: 1ˆă—ÉqśŠw•”, 2Šá‰Č)

110369. [Œ´’˜] Prediction of Phakic Intraocular Lens Vault Using Machine Learning of Anterior Segment Optical Coherence Tomography Metrics. Kamiya K1, Ando W2, Shoji N2: Am J Ophthalmol 2021/6; 226: 90-9. (_’J˜aF1, ˆŔ“Ą˜a‰ĚŽq2, ŻŽiMs2: 1ˆă—ÉqśŠw•”, 2Šá‰Č)

110370. [Œ´’˜] Fovea-Sparing as Opposed to Total Peeling of Internal Limiting Membrane for Myopic Foveoschisis: A Systematic Review and Meta-analysis. Azuma K, Hirasawa K1, Araki F, Shiraya T, Yashiro S, Kato S, Nagahara M, Ueta T: Ophthalmol Retina 2021/7; 5 (7): 670-9. (•˝ŕVˆę–@1: 1Šá‰Č)

110371. [Œ´’˜] Sagging eye syndrome. Goseki T1,2: Jpn J Ophthalmol 2021/7; 65 (4): 448-53. (ŒăŠÖ—˜–ž1,2: 1Šá‰Č, 2‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@)

110372. [Œ´’˜] Prediction of keratoconus progression using deep learning of anterior segment optical coherence tomography maps. Kamiya K1, Ayatsuka Y, Kato Y, Shoji N2, Miyai T, Ishii H, Mori Y, Miyata K: Ann Transl Med 2021/8; 9 (16): 1287. (_’J˜aF1, ŻŽiMs2: 1ˆă—ÉqśŠw•”, 2Šá‰Č)

110373. [Œ´’˜] High Visibility Conditions in a Sunset Environment. Iizuka T1, Kawamorita T2, Handa T2, Ishikawa H2: Appl Sci 2021/8; 11 (16): 7229; (”Ń’Ë’B–ç1, ěŽç“c‘ńŽu2, ”ź“c’m–ç2, Îě@‹Ď2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”)

110374. [Œ´’˜] Clinical evaluation of flat peripheral curve design with aspherical-curve and multi-curve hard contact lenses for keratoconus. Kumanomido T1, Kamiya K2, Takahashi M1, Tsujisawa T1, Hayakawa H1, Ando W1, Utsumi Y1, Shoji N1: PLoS One 2022/8; 17 (2): e0263506. (ŒF”WŒä“°—˛1, _’J˜aF2, ‚‹´ł‰p1, ’Ň‘ň’C•F1, ‘ěG‹P1, ˆŔ“Ą˜a‰ĚŽq1, ‰F’ĂŒŠ‹`ˆę1, ŻŽiMs1: 1Šá‰Č, 2ˆă—ÉqśŠw•”)

110375. [Œ´’˜] Comparison of magnitude and summated vector mean of surgically induced astigmatism vector according to incision site after phakic intraocular lens implantation. Kamiya K1, Ando W2, Takahashi M2, Shoji N2: Eye Vis (Lond) 2021/9; 8 (1): 32. (_’J˜aF1, ˆŔ“Ą˜a‰ĚŽq2, ‚‹´ł‰p2, ŻŽiMs2: 1ˆă—ÉqśŠw•”, 2Šá‰Č)

110376. [Œ´’˜] Diagnosability of Keratoconus Using Deep Learning With Placido Disk-Based Corneal Topography. Kamiya K1, Ayatsuka Y, Kato Y, Shoji N2, Mori Y, Miyata K: Front Med (Lausanne) 2021/10; 8: 724902. (_’J˜aF1, ŻŽiMs2: 1ˆă—ÉqśŠw•”, 2Šá‰Č)

110377. [Œ´’˜] Effect of Platelet-Rich Plasma on Corneal Epithelial Healing after Phototherapeutic Keratectomy: An Intraindividual Contralateral Randomized Study. Kamiya K1, Takahashi M2, Shoji N2: Biomed Res Int 2021/11; 2021: 5752248. (_’J˜aF1, ‚‹´ł‰p2, ŻŽiMs2: 1ˆă—ÉqśŠw•”, 2Šá‰Č)

110378. [Œ´’˜] Eight-Year Outcomes of Implantation of Posterior Chamber Phakic Intraocular Lens With a Central Port for Moderate to High Ametropia. Kamiya K1, Shimizu K, Takahashi M2, Ando W2, Hayakawa H2, Shoji N2: Front Med (Lausanne) 2021/12; 8: 799078. (_’J˜aF1, ‚‹´ł‰p2, ˆŔ“Ą˜a‰ĚŽq2, ‘ěG‹P2, ŻŽiMs2: 1ˆă—ÉqśŠw•”, 2Šá‰Č)

110379. [Œ´’˜] Effect of Trabeculectomy on Mean and Centroid Surgically Induced Astigmatism. Ando W1, Kamiya K2, Kasahara M1, Shoji N1: J Clin Med 2022/1; 11 (1): 240. (ˆŔ“Ą˜a‰ĚŽq1, _’J˜aF2, Š}Œ´łs1, ŻŽiMs1: 1Šá‰Č, 2ˆă—ÉqśŠw•”)

110380. [Œ´’˜] Characteristics of glaucoma patients with intraocular pressure elevation early after trabectome surgery. Kono Y1, Kasahara M1, Hirasawa K1, Matsumura K1,2, Morita T1,3, Shoji N1: Graefes Arch Clin Exp Ophthalmol 2022/2; 260 (2): 537-43. (‰Í–ě—Y—ş1, Š}Œ´łs1, •˝ŕVˆę–@1, ź‘şˆęO1,2, X“c“N–ç1,3, ŻŽiMs1: 1Šá‰Č, 2’Ź“c‚܂‚ނçŠá‰Č, 3X“cƒAƒCƒNƒŠƒjƒbƒN)

110381. [Œ´’˜] New device for taking nine-directional ocular photographs: ""9Gaze"" application. Toshiaki Goseki T1,2, Kunimi K1,2: J Eye Mov Res 2022/3; 15 (1): 10.16910/jemr.15.1.5. (ŒăŠÖ—˜–ž1,2, š ŒŠŒhŽq1,2: 1Šá‰Č, 2‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@)

110382. [Œ´’˜] Hyperopia-Correcting Phototherapeutic Keratectomy and Its Comparison With Conventional Phototherapeutic Keratectomy. Hayakawa H1, Kamiya K2, Tsujisawa T1, Takahashi M1, Shoji N1: Front Med (Lausanne) 2022/3; 9: 708188. (‘ěGŠö1, _’J˜aF2, ’Ň‘ň’C•F1, ‚‹´ł‰p1, ŻŽiMs1: 1Šá‰Č, 2ˆă—ÉqśŠw•”)

120021. [Œ´’˜] ‰~Šp–ŒŠá‚É‚¨‚Ż‚éIOLMaster700‚Ě2Ží—Ţ‚ĚŠp–Œ‹üÜ—Í‚đ—p‚˘‚˝—\‘Ş‹üÜŒëˇ‚Ě”äŠr. óˆä—D“Ţ1, Ź“‡—˛Ži2, ‹Ę’u–ž–ě1, ‹´’Ü—Ç‘ž1, ŽđˆäKO3, ‰Á‰ę’BŽu1,4, Žsěˆę•v3,4 (1’†‹ž•a‰@, 2Œc‰ž‹`m‘ĺŠw, 3’†‹žŠá‰Č, 4Šá‰Č): ‚ ‚˝‚ç‚ľ‚˘Šá‰Č 2021/4; 38 (4): 459-63.

120022. [Œ´’˜] ”]Ň‘‰tŒ¸­ÇÇ—á‚ĚŠáÇó‚ĚŒŸ“˘. ŽRă–žŽq1,2, Šâ˛^‹|1, ˆäăŒŤŽĄ1, Žá‘q‰ë“o1, —´ˆä‰‘Žq2, Îě@‹Ď3, ‚‹´_ˆę4 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č, 3ˆă—ÉqśŠw•”, 4ŽR‰¤•a‰@”]_ŒoŠO‰Č): _ŒoŠá‰Č 2021/6; 38 (2): 162-71.

120023. [Œ´’˜]y‘ć74‰ń“ú–{—Տ°Šá‰ČŠw‰ďu‰‰W [7] u‰‰40-5zƒqƒg…ť‘̂̐ԓš•”ˆĘ’u‚𐜑̊á‚É‚¨‚˘‚ÄŒŸo‚ˇ‚éV‚ľ‚˘‰đÍ–@. ”n“ˆ´”@1, Žsě@Œc2, ŽđˆäKO2, •Đ‰Ş“”Ž3, ˆé’JŽ‹P3, ’†‘ş—Fş3, ‹Ę’u–ž–ě4, Žsěˆę•v2,5 (1Šá‰Č–žŠá‰@, 2’†‹žŠá‰Č, 3–źŒĂ‰ŽƒAƒCƒNƒŠƒjƒbƒN, 4JCHO’†‹ž•a‰@Šá‰Č, 5Šá‰Č): —Տ°Šá‰Č 2021/9; 75 (9): 1190-8.

120024. [Œ´’˜] Šp–Œƒgƒ|ƒOƒ‰ƒtƒB‚Ć‘OŠá•”OCT‚ĚˆŮ‚Č‚éŠp–ŒŒ`ó‰đÍ‘•’u‚É‚ć‚éŠp–Œ—Ž‹—Ę‚Ě”äŠr. ‰Á“ĄKm1, Ź“‡—˛Ži2, ‹Ę’u–ž–ě3, ŽđˆäKO1, Žsěˆę•v1,4 (1’†‹žŠá‰Č, 2Œcœä‹`m‘ĺŠw, 3’†‹ž•a‰@, 4Šá‰Č): ‚ ‚˝‚ç‚ľ‚˘Šá‰Č 2021/10; 38 (10): 1207-11.

120025. [Œ´’˜] ŠOŽÎŽ‹‚𔺂¤ŠłŽŇ‚Ě”’“ŕáŽčp‘OŒă‚ĚŠáˆĘ•Ď‰ť. ÔÎ‘ň’q”ż1, Šąě—˘ŠG2, ”Ń“c‰Ă•F1, Îě@‹Ď2, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): “ú–{Ž‹”\ŒP—űŽm‹Ś‰ďŽ 2021/12; 50: 123-8.

120026. [Œ´’˜]y‘ć60‰ń“ú–{Ž‹”\‹¸łŠw‰ďˆę”ʍu‰‰zƒŒ[ƒU[ƒXƒyƒbƒNƒ‹ƒtƒ[ƒOƒ‰ƒtƒB[‚É‚¨‚Ż‚鎋_Œo“ű“ŞŒŒ—Ź‚ĚÄŒťŤ‚¨‚ć‚Ńˆę’v§. Źě仓Ţ1, Ö“Ą@Ę1, ]•—Ft2, ‰i–ěKˆę1, ŽRŒű@ƒ1, ŻŽiMs1 (1Šá‰Č, 2ŽOƒc‹ŤŠá‰Č): “ú–{Ž‹”\ŒP—űŽm‹Ś‰ďŽ 2021/12; 50: 129-34.

120027. [Œ´’˜] ƒIƒ~ƒfƒlƒpƒOEƒCƒ\ƒvƒƒsƒ‹“_Šá‰t0.002%‚ĚŠáˆł‰ş~Œř‰Ę‚¨‚ć‚ŃˆŔ‘SŤ‚ĚŒă•ű“IŒŸ“˘. ‚–ŘŒ˜‘ž˜Y1, Š}Œ´łs1, •˝ŕVˆę–@1, ‰Í–ě—Y—ş1, •ÄŽR@—Č1, ’Ň‘ň’C•F1, ŻŽiMs1 (1Šá‰Č): “ú–{Šá‰ČŠw‰ďŽGŽ 2022/1; 126 (1): 19-26.

120028. [Œ´’˜ (Šw‰ďŒ´’˜)]y‘ć77‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ďzź“c–@‚Ş’˜Œř‚ľ‚˝DuaneÇŒóŒQ…ŸŒ^‚Ě3—á. ’r“cNm1, ÎěŒb—˘1, ‚‹´T–ç1, “c’†—Tˆę˜N1, Ź‘ň’‰•F1, ŒăŠÖ—˜–ž1,2,3 (1Ź‘ňŠá‰Č“ŕ‰Č•a‰@, 2‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 3Šá‰Č): Šá‰Č—Տ°‹I—v 2022/1; 15 (1): 56-9.

120029. [Œ´’˜] Œ’NŹl‚đ‘ÎŰ‚Ć‚ľ‚˝ƒrƒ‹ƒxƒŠ[/źŽ÷”ç’Šo•¨”z‡H•iÚŽí‚É‚ć‚éŠáˆł‚ւ̉e‹ż‚ĚŒŸ“˘. ‚–Ř‘×F1, “‡“c‹vś1, ‰Ťă—T”ü1, ŻŽiMs2 (1ŽQ“Vť–ň, 2Šá‰Č): ‚ ‚˝‚ç‚ľ‚˘Šá‰Č 2022/2; 39 (2): 251-7.

120030. [Œ´’˜ (Šw‰ďŒ´’˜)]y‘ć77‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ďzƒfƒWƒ^ƒ‹ƒfƒoƒCƒX‚ŞŒ´ˆö‚ĆŽv‚í‚ę‚éŒă“V‹¤“ŻŤ“ŕŽÎŽ‹‚ĚŽĄ—ĂŒo‰ß. ˆŔ“Ą—F‹I1, ŒăŠÖ—˜–ž1,2,3, ŒË’˘aŽq1, ŒN“‡^ƒ1, Š—ś^—˘1, ŸNˆä—•Žq1,2, Žs糋`Í1,2 (1_“ސ쎕‰Č‘ĺŠw•‘Ž‰Ą•lƒNƒŠƒjƒbƒN, 2Šá‰Č, 3‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@): Šá‰Č—Տ°‹I—v 2022/2; 15 (2): 110-6.

120031. [Œ´’˜ (Šw‰ďŒ´’˜)]y‘ć77‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ďzśŽY”N—î‚đ‘ÎŰ‚Ć‚ľ‚˝ŠáˆĘ‚Ć‹üÜ“x”‚ĚŠÖŒW. ‚‹´T–ç1, ŒăŠÖ—˜–ž1,2,3, –ě“cMŒá1, ’ˇ’Jěx1, ÎěŒb—˘1, “c’†—Tˆę˜N1, Ź‘ň’‰•F1 (1Ź‘ňŠá‰Č“ŕ‰Č•a‰@, 2‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 3Šá‰Č): Šá‰Č—Տ°‹I—v 2022/2; 15 (2): 122-6.

120032. [Œ´’˜] ’´‰š”gś‘ĚŒ°”÷‹ž‚Ć‘OŠá•”ŒőŠąÂ’f‘wŒv‚ĹŽB‰e‚ľ‚˝…ť‘̐ԓš•”ˆĘ’u‚Ě”äŠr. ”n“ˆ´”@1, Žsě@Œc2, ŽđˆäKO2, •Đ‰Ş“”Ž3, ˆé’JŽ‹P3, ’†‘ş—Fş3, ‹Ę’u–ž–ě4, Žsěˆę•v2,5 (1Šá‰Č–žŠá‰@, 2’†‹žŠá‰Č, 3–źŒĂ‰ŽƒAƒCƒNƒŠƒjƒbƒN, 4JCHO’†‹ž•a‰@Šá‰Č, 5Šá‰Č): IOL&RS 2022/3; 36 (1): 77-85.

320014. [Ç—á•ń] ƒrƒmƒŒƒ‹ƒrƒ““Š—^’†‚ÉŽ‹_ŒoÇ‚đ”­Ç‚ľ‚˝ˆę—á. ě_ŠG—œŽq1, Źź—eŽq1, Šâ˛^‹|1, ŽRă–žŽq1,2, ˆäăŒŤŽĄ1, Žá‘q‰ë“o1 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č): _ŒoŠá‰Č 2021/9; 38 (3): 298-303.

320015. [Ç—á•ń] ƒQ[ƒ€‚Ě‰ßčŽg—p‚ÉŠÖ˜A‚ľ‚Ä”­Ç‚ľ‚˝‚ƍl‚Ś‚ç‚ę‚éŠw“śŠú‚Ě‹}Ť“ŕŽÎŽ‹2Ç—á‚Ě—Ő°“I“Á’Ľ. ]’ËĘ‰č1, Œ´@’źl1,2,3, ‰Ş–ě^‹|2, X@Œ\‰î1, Vˆä“cF—T1,2,3 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw•a‰@Šá‰Č, 2‘Űˆă—Ă•ŸŽƒ‘ĺŠw•ŰŒ’ˆă—ĂŠw•”Ž‹‹@”\—Ă–@Šw‰Č, 3Šá‰Č): Šá‰Č 2021/11; 63 (11): 1107-12.

320016. [Ç—á•ń] ‘ŠúŽĄ—Ă‚É‚ć‚莋‹@”\‚ŞˆŰŽ‚Ĺ‚Ť‚˝d–Œ“ŽĂ–Źá‘‚É‚ć‚é—ź‘¤Ž‹_Œo“ű“ŞŽî’Ż‚Ě1—á. ’ß“cŘ“E1, Žs糋`Í1,4, Œ´@’źl1,2,4, ŒN“‡^ƒ1, Š—ś^—˘1, ŒË’˘aŽq1, Œü–ě˜a—Y1,4, ŠÔ’†@_3 (1_“ސ쎕‰Č‘ĺŠw•‘Ž‰Ą•lƒNƒŠƒjƒbƒN, 2‘Űˆă—Ă•ŸŽƒ‘ĺŠw•ŰŒ’ˆă—ĂŠw•”, 3‰Ą•lŽs—§‘ĺŠw•‘ŽŽs–Ż‘‡ˆă—ĂƒZƒ“ƒ^[”]_ŒoŠO‰Č, 4Šá‰Č): _ŒoŠá‰Č 2021/12; 38 (4): 366-72.

320017. [Ç—á•ń] ‚¤‚ÁŒŒ‚đ‚Ť‚˝‚ľ‚˝Camurati-Engelmann•a‚Ě1—á. ‘ĺ]ˆ˘Žq1, ŒăŠÖ—˜–ž1,2, —´ˆä‰‘Žq1, Îě@‹Ď3, ŻŽiMs1 (1Šá‰Č, 2‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 3ˆă—ÉqśŠw•”): _ŒoŠá‰Č 2021/12; 38 (4): 387-93.

320018. [Ç—á•ń] ƒŒ[ƒU[ƒXƒyƒbƒNƒ‹ƒtƒ[ƒOƒ‰ƒtƒB[‚đ—p‚˘‚˝Ž‹_Œo‰Š‹^‚˘Ç—á‚É‚¨‚Ż‚éUhthoff’ĽŒóoŒť‘OŒă‚ĚŠáŒŒ—Ź‘Ş’č. ŕ_“ޏŽq1,2, ź–{@’ź2, •x“c‹§•F2, Œ÷“—tŽq2, ‰Á“ĄŒjŽq2, –x@—Tˆę2, Îě@‹Ď3 (1“Œ‹ž•iě•a‰@, 2“Œ–M‘ĺŠwˆă—ĂƒZƒ“ƒ^[‘ĺX•a‰@, 3ˆă—ÉqśŠw•”) _ŒoŠá‰Č 2022/3; 39 (1): 34-9.

320019. [Ç—á•ń] bó‘BŠáÇ‚ƏdÇ‹Ř–ł—ÍÇ‚ĚŽĄ—Ă‚đ“ŻŽž‚É—v‚ľ‚˝1—á. ŽRč”ü1, ŽRă–žŽq1.3, Šâ˛^‹|1, ˆäăŒŤŽĄ1, Žá‘q‰ë“o1, Ž­“‡@Œĺ2, áÁ–Ř“ń—t3 (1ˆäăŠá‰Č•a‰@, 2šƒ}ƒŠƒAƒ“ƒiˆă‰Č‘ĺŠw”]_Œo“ŕ‰Č, 3Šá‰Č): _ŒoŠá‰Č 2022/3; 39 (1): 53-8.

420001. [—Տ°•ń] ”’“ŕápŒă‚Ě•ĄŽ‹‚Ě”­ś•p“x‚Ć‚ť‚Ě“Á’Ľ. –îčŘ1, ŒăŠÖ—˜–ž1,2, ŒË’ˁ@Œĺ1, —´ˆä‰‘Žq1, ŻŽiMs1 (1Šá‰Č, 2‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@): —Տ°Šá‰Č 2021/4; 75 (4): 479-84.

420002. [—Տ°•ń] Ž‹_Œo“ű“ŞŽî’Ż‚Ć“ű“ŞŽüˆÍ‚̐üóoŒŒ‚đ”F‚ß‚˝Weber-Christian•a‚Ě1—á. ‘şăš•ä1, “n粓VăÄ2, Î“c­O3, řw–ě‰ĂO4, ě–k“N–ç1, Ą‘ş@—T1,2 (1–k—˘‘ĺŠwŒ¤‹†Š, 2’é‹ž‘ĺŠwˆăŠw•”•‘ŽaŒű•a‰@Šá‰Č, 3“Œ–M‘ĺŠwˆă—ĂƒZƒ“ƒ^[‘ĺ‹´•a‰@, 4’é‹ž‘ĺŠwˆăŠw•”•‘ŽaŒű•a‰@”畆‰Č): —Տ°Šá‰Č 2021/6; 75 (6): 753-60.

510020. [‘ŕ] Sagging eye syndrome. Goseki T1,2: Jpn J Ophthalmol 2021/7; 65 (4): 448-53. (ŒăŠÖ—˜–ž1,2: 1Šá‰Č, 2‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@)

520010. [‘ŕ] ‘ŕ@’†‹žƒOƒ‹[ƒv‚ĚŠCŠOˆă—ÍvŒŁ Žsěˆę•v1,2,3 (1JSCRS—Ž–’ˇ, 2’†‹žƒOƒ‹[ƒv‰ď’ˇ, 3Šá‰Č): IOL&RS 2021/6; 35 (2): 247-52.

520011. [‘ŕ] Œ´ˆö‚Ě‚ć‚­‚í‚Š‚ç‚Č‚˘ăľ–ž‚̍l‚Ś•ű. ŽRă–žŽq1,2 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č): Šá‰Č 2021/7; 63 (7): 645-9.

520012. [‘ŕ] 2021 JSCRS Clinical Survey. ˛“ĄłŽ÷1, _’J˜aF1,2, Ź“‡—˛Ži1, Œă“ĄŒ›m1, “c•ŁmŽu1, ‰â“Ţ’ĂŽq1, —с@@Œ¤1 (1JSCRSƒf[ƒ^‰đÍˆĎˆő‰ď, 2ˆă—ÉqśŠw•”): IOL&RS 2021/9; 35 (3): 427-48.

520013. [‘ŕ] Šáâ|pulley‚Ć‚ť‚ĚˆŮí. š ŒŠŒhŽq1, ŒăŠÖ—˜–ž1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č): Šá‰Č 2021/12; 63 (12): 1179-83.

520014. [‘ŕ] ”’“ŕáp‘Oś‘ĚŒv‘ރf[ƒ^EĹ“KŠá“ŕƒŒƒ“ƒY“x”ŒvŽZŽŽ‚Ě‘źŽ{Ý”äŠrŒ¤‹†. _’J˜aF1,2, —с@@Œ¤2, ˛“ĄłŽ÷2, Ź“‡—˛Ži2, Œă“ĄŒ›m2, ‰â“Ţ’ĂŽq2, “c糐^ś3, “c•ŁmŽu2, Žsěˆę•v2,4 (1ˆă—ÉqśŠw•”, 2JSCRSƒf[ƒ^‰đÍˆĎˆő‰ď, 3ƒcƒJƒUƒL•a‰@, 4Šá‰Č): IOL&RS 2022/3; 36 (1): 51-6.

521008. [‰đŕ]yŠá‰Čˆă‚ĚŽčˆř<982>zAI‚đ—p‚˘‚˝‰~Šp–Œ‚̐f’f. _’J˜aF (ˆă—ÉqśŠw•”): “ú–{‚ĚŠá‰Č 2021/4; 92 (4): 46-7.

521009. [‰đŕ]y‹üÜ‹¸łŽčpƒZƒ~ƒi[zƒXƒLƒ‹ƒAƒbƒvuŔ|˜AÚ252: ƒJƒXƒ^ƒ€Šp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO. _’J˜aF (ˆă—ÉqśŠw•”): ‚ ‚˝‚ç‚ľ‚˘Šá‰Č 2021/5; 38 (5): 547-8.

521010. [‰đŕ]yˆă‰ďPick UpzŹŽ™‚̏ˆ•űⳂȂľ‚Ĺ‚ĚŠá‹žěŹ‚Ě–â‘č“_. ‹{“ŕ@C1, ˛–ěŒ¤“ń2, ‰F’ĂŒŠ‹`ˆę3,4, V“c‘ě–ç5, —é–ŘŒ’Žj6, ‰Ź–ěŒöŽk7, —FŠńLŽm8, ‹{‘şšF9, ‹{–{—TŽq10, •˝ź–M•v11, •M‡Žq12, ăŽ}G˜a13, “ń‹{@Œł14, o…˝“ń15 (1‚݂₤‚żŠá‰Č, 2‚ ‚ˇ‚Ý‚Ş‹u˛–ěŠá‰Č, 3‰F’ĂŒŠŠá‰Čˆă‰@, 4Šá‰Č, 5‰ń–ž“°Šá‰ČEŽ•‰Č, 6—é–ŘŠá‰Čˆă‰@, 7‰Ź–ěŠá‰Čˆă‰@, 8‚Ć‚ŕ‚ć‚čŠá‰Č, 9źă‹{‘şŠá‰Č, 10ƒAƒCƒAƒCŠá‰Čˆă‰@, 11•˝źŠá‰Čˆă‰@, 12•MŠá‰Č, 13‚¤‚Ś‚žŠá‰Č, 14‹›’ŹŠá‰Čf—ÏŠ, 15o…Šá‰Č): “ú–{‚ĚŠá‰Č 2021/5; 92 (5): 535-40.

521011. [‰đŕ]yƒRƒ“ƒTƒ‹ƒe[ƒVƒ‡ƒ“ƒR[ƒi[: ƒGƒLƒXƒp[ƒg‚É•ˇ‚­z‰ń“š4. ”Ń“c‰Ă•F (Šá‰Č): IOL&RS 2021/9; 35 (3): 526-7.

521012. [‰đŕ]yŽčpŽč‹Z‚ĚƒRƒczMIGSŒă‚ĚMIGSÄŽčp. Š}Œ´łs1, ŻŽiMs1 (1Šá‰Č): Šá‰ČŽčp 2021/10; 34 (4): 581-5.

521013. [‰đŕ]yƒGƒLƒXƒp[ƒg‚ÉŠw‚Ô: Šá‰ČŽčp‚ĚŽż–â” 19zQ”’“ŕáŽčp’†‚ÉZinnŹ‘ѐƎăE’f—ô‚𐜂ś‚˝Ű‚ɂǂ̂悤‚ȑΉž‚âŠá“ŕƒŒƒ“ƒY‚đ‘I‘đ‚ˇ‚×‚Ť‚Ĺ‚ˇ‚Š. ”Ń“c‰Ă•F (Šá‰Č): Šá‰ČŽčp 2021/10; 34 (4): 608-9.

521014. [‰đŕ]y”’“ŕáE‹üÜŽčp‚Ě˜_“_zLASIKŒăŠá‚ɑ΂ˇ‚éIOL‘I‘đ (’PĹ“_IOL). ”Ń“c‰Ă•F (Šá‰Č): IOL&RS 2021/12; 35 (4): 651-4.

521015. [‰đŕ]yŽčpŠí‹ďzZepto҂đ—p‚˘‚˝precision pulse capsulotomy‚ɂ‚˘‚Ä. Žsě@Œc1, Žsěˆę•v2,3 (1‘‡ÂŽR•a‰@, 2’†‹žŠá‰Č, 3Šá‰Č): IOL&RS 2021/12; 35 (4): 659-64.

521016. [‰đŕ]y‹üÜ‹¸łŽčpƒZƒ~ƒi[zƒXƒLƒ‹ƒAƒbƒvuŔ|˜AÚ259: ”’“ŕápŒă‹üÜŒëˇ‚ĚŽŔŰ. _’J˜aF (ˆă—ÉqśŠw•”): ‚ ‚˝‚ç‚ľ‚˘Šá‰Č 2021/12; 38 (12): 1479-80.

521017. [‰đŕ]y‹üÜ‹¸łŽčpƒZƒ~ƒi[zƒXƒLƒ‹ƒAƒbƒvuŔ|˜AÚ262: ICL‚É‚¨‚Ż‚闐Ž‹‹¸ł. ŒÜ\—’ÍŽj1,2 (1ƒXƒJƒCƒrƒ‹Šá‰Č, 2Šá‰Č): ‚ ‚˝‚ç‚ľ‚˘Šá‰Č 2022/3; 39 (3): 325-6.

522538. [uŔ]yƒƒCƒ““ÁW: ŠłŽŇ–ž‘Ť“x‚đ‚‚ß‚é! Šá“ŕƒŒƒ“ƒYŠÖ˜A’mŽŻƒAƒbƒvƒf[ƒgz1. ĹV‚Ě”’“ŕáŽčp‚Ě–ž‘Ť“x‚ɉe‹ż‚đ‚ ‚˝‚Ś‚éˆöŽq. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): Šá‰ČƒOƒ‰ƒtƒBƒbƒN 2021/4; 10 (2): 134-41.

522539. [uŔ]yƒƒCƒ““ÁW: ŠłŽŇ–ž‘Ť“x‚đ‚‚ß‚é! Šá“ŕƒŒƒ“ƒYŠÖ˜A’mŽŻƒAƒbƒvƒf[ƒgz2. ĹV‚ĚŠá“ŕƒŒƒ“ƒY“x”ŒvŽZ. _’J˜aF (ˆă—ÉqśŠw•”): Šá‰ČƒOƒ‰ƒtƒBƒbƒN 2021/4; 10 (2): 142-6.

522540. [uŔ]y“ÁW: ICL‚Ě‚ą‚ą‚Ş’m‚č‚˝‚˘|Šî–{‚Š‚ç—Տ°‚܂Ł|zHole ICL‚ĚŠJ”­‚Ć’†SE‚Ě–đŠ„. ´…Œö–ç1,2 (1ŽR‰¤•a‰@, 2Šá‰Č): OCULISTA 2021/4; 97: 1-9.

522541. [uŔ]y“ÁW: ICL‚Ě‚ą‚ą‚Ş’m‚č‚˝‚˘|Šî–{‚Š‚ç—Տ°‚܂Ł|z‘OŠá•”OCT‚đ—p‚˘‚˝ICL‚ĚƒTƒCƒYŒˆ’č•ű–@|KSŽŽ|. ŒÜ\—’ÍŽj1,2 (1ŽR‰¤•a‰@, 2Šá‰Č): OCULISTA 2021/4; 97: 31-6.

522542. [uŔ]y“ÁW: ICL‚Ě‚ą‚ą‚Ş’m‚č‚˝‚˘|Šî–{‚Š‚ç—Տ°‚܂Ł|zICLŽčp‚ĚŽŔŰ‚Əp’†ƒgƒ‰ƒuƒ‹‚Ě‘Îˆ•ű–@. Žsěˆę•v1,2 (1’†‹žŠá‰Č, 2Šá‰Č): OCULISTA 2021/4; 97: 37-43.

522543. [uŔ]y“ÁW: ICL‚Ě‚ą‚ą‚Ş’m‚č‚˝‚˘|Šî–{‚Š‚ç—Տ°‚܂Ł|zICL‚Ě—Ő°‰ž—p|”’“ŕápŒă‚â‰~Šp–Œ‚ւ̉ž—p|. _’J˜aF (ˆă—ÉqśŠw•”): OCULISTA 2021/4; 97: 61-6.

522544. [uŔ]y“ÁW: ŽÎŽ‹‚ĚƒƒWƒbƒNŒn““IfŽ@–@zIII. Še˜_@Šá‹…‰^“ŽáŠQ‚ĚŽž‚ɍl‚Ś‚é‚ׂŤŽžŠł‚ĆŒŸ¸. ŒăŠÖ—˜–ž1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č): OCULISTA 2021/6; 99: 56-9.

522545. [uŔ]y“ÁW: —ΓŕáŽĄ—Ă‚ĚŒťó‚Ć‹ß–˘—ˆz‹ß–˘—ˆ‚̗ΓŕáŽĄ—Á@‹ß–˘—ˆ‚̗ΓŕáŽčp. ŻŽiMs (Šá‰Č): ‚ ‚˝‚ç‚ľ‚˘Šá‰Č 2021/6; 38 (6): 663-70.

522546. [uŔ]y‚í‚Š‚č‚₡‚˘—Տ°uŔzŹl‚ĚŠj‰şŤŠá‹…‰^“ŽáŠQ. ‚‹´—m•˝1, Îě@‹Ď2 (1“Œ‹ž—Žqˆă‰Č‘ĺŠw”ސç‘ăˆă—ĂƒZƒ“ƒ^[, 2ˆă—ÉqśŠw•”): “ú–{‚ĚŠá‰Č 2021/6; 92 (6): 665-70.

522547. [uŔ]y“ÁW: —Ž‹‹¸ł‚đ‚Ť‚í‚ß‚ézƒg[ƒŠƒbƒN—L…ť‘ĚŠá“ŕƒŒƒ“ƒY‚É‚ć‚闐Ž‹‹¸ł. _’J˜aF (ˆă—ÉqśŠw•”): Šá‰ČŽčp 2021/7; 34 (3): 328-33.

522548. [uŔ]y“ÁW: …ť‘Ě’E‰PE•ÎˆĘ‚Ć“řĘŒ‡‘šƒgƒ‰ƒuƒ‹z…ť‘Ě’E‰PE•ÎˆĘ‚ĚŽĄ—Ă…D|i‰ť‚ˇ‚é–D’…p, Ž„‚Ě‚ą‚ž‚í‚č|. ”Ń“c‰Ă•F (Šá‰Č): OCULISTA 2021/9; 102: 43-51

522549. [uŔ]y“ÁW: Œă“V“ŕŽÎŽ‹‚Ɛ_ŒoŠá‰Čz˜˜_|Še—pŒę‚Ěˆá‚˘‚ɂ‚˘‚ā|. ŒăŠÖ—˜–ž1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č): _ŒoŠá‰Č 2021/9; 38 (3): 239-40.

522550. [uŔ]y“ÁW: Œă“V“ŕŽÎŽ‹‚Ɛ_ŒoŠá‰ČzSagging eye syndrome‚Ć—ŢŽ—ŽžŠł. ‰Í‡ˆ¤ŽŔ (‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): _ŒoŠá‰Č 2021/9; 38 (3): 263-8.

522551. [uŔ]y“ÁW: Œă“V“ŕŽÎŽ‹‚Ɛ_ŒoŠá‰ČzŠáâ|‹‡‹üÇŒóŒQ. Šâ˛^‹|1,2 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č): _ŒoŠá‰Č 2021/9; 38 (3): 269-75.

522552. [uŔ]y“ÁW: —ΓŕáŠáˆł”ńˆË‘śˆöŽqƒAƒbƒvƒf[ƒgzŠáŒŒ—Ź‘Ş’č. ŻŽiMs (Šá‰Č): NANO OPHTHALMOLOGY 2021/9; 59: 5-11.

522553. [uŔ]y“ÁW: Šá‰Čˆă‚Ě‚˝‚ß‚ĚŠwZ•ŰŒ’ƒKƒCƒh|Ĺ‹ß‚Ě“ŽŒü|zŠwZ‚Ĺ‚ĚICTŠˆ—p‚ĆŠá‚ɂ‚˘‚Ä. ‰F’ĂŒŠ‹`ˆę1,2 (1‰F’ĂŒŠŠá‰Čˆă‰@, 2Šá‰Č): OCULISTA 2021/10; 103: 33-44.

522554. [uŔ]y“ÁW: –ňÜ‚̉ˇŒĚ’mVzŠá‚É•›ě—p‚𐜂ś‚₡‚˘RŽîᇖň. ”–؍LĆ1,2 (1Ă‰ŞŒ§—§Ă‰Ş‚Ş‚ńƒZƒ“ƒ^[, 2Šá‰Č): ‚ ‚˝‚ç‚ľ‚˘Šá‰Č 2021/11; 38 (11): 1291-19.

522555. [uŔ]y“ÁW: ‰~Šp–ŒŽĄ—Ă‚ĚĹ‘Oüz3. Šp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO. ‚‹´ł‰p1,2 (1Šá‰Č, 2ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[): Šá‰Č 2021/12; 63 (12): 1155-64.

522556. [uŔ]y“ÁW: ‚ ‚˝‚ç‚ľ‚˘—ΓŕáŽčp|‚Ç‚¤‚˘‚¤ŠłŽŇ‚đĐ‰î‚ˇ‚é?z1. ‘I‘đ“IƒŒ[ƒU[‘@ˆŰ’Œ‘ŃŒ`Źp (SLT). ‰Í–ě—Y—ş1, Š}Œ´łs1 (1Šá‰Č): Šá‰Č 2022/1; 64 (1): 3-10.

522557. [uŔ]y‚í‚Š‚č‚₡‚˘—Տ°uŔ@_ŒoŠá‰Č‚Š‚ç‚Ý‚˝Šá’ɁE㵖ž‚̊ӕʐf’f‚ĆŽĄ—Ă, ŽRă–žŽq1,2 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č): “ú–{‚ĚŠá‰Č 2022/1; 93 (1): 42-6.

522558. [uŔ]yˆă‰ďPick Up <“ú–{Šá‰ČŽĐ‰ď•ŰŒŻ‰ď‹cƒVƒ“ƒ|ƒWƒEƒ€•ń>: ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď@“ú–{Šá‰ČŽĐ‰ď•ŰŒŻ‰ď‹cƒVƒ“ƒ|ƒWƒEƒ€zf—Ă•ńV‰ü’čƒqƒAƒŠƒ“ƒO‚đ“Ľ‚Ü‚Ś‚Ä: 4. “ú–{—ΓŕáŠw‰ď‚Š‚ç‚Ě—v–]. ŻŽiMs (Šá‰Č): “ú–{‚ĚŠá‰Č 2022/2; 93 (2): 208-13.

522559. [uŔ]y“ÁW: ”]ˆł‚̕ωť‚ĆŽ‹‹@”\áŠQz”]Ň‘‰tŒ¸­‚É‚ć‚鎋‹@”\ˆŮí. ŽRă–žŽq1,2 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č): _ŒoŠá‰Č 2022/3; 39 (1): 26-33.

522560. [uŔ]y“ÁWzAI‚É‚ć‚éŒvŽZŽŽ. ”Ń“‡@Œh (Šá‰Č): IOL&RS 2022/3; 36 (1): 19-25.

540029. [‚ť‚Ě‘ź (ƒZƒ~ƒi[ƒŠƒ|[ƒg)]yACUVUE@SeminarReportz‘ć124‰ń“ú–{Šá‰ČŠw‰ď‘‰ďƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[3:gŒŠ‚Ś‚éh‚đ’Ç‹‚ˇ‚é. _’J˜aF1, ěŽç“c‘ńŽu1 (1ˆă—ÉqśŠw•”): ƒWƒ‡ƒ“ƒ\ƒ“EƒGƒ“ƒhEƒWƒ‡ƒ“ƒ\ƒ“SeminarReport 2021/6/1.

540030. [‚ť‚Ě‘ź (V•ˇ‹LŽ–)] ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY@AQŽž‚É‘•’…‚ľŽ‹—Í‹¸ł (ƒIƒ‹ƒ\K). ‰F’ĂŒŠ‹`ˆę1,2 (1‰F’ĂŒŠŠá‰Čˆă‰@, 2Šá‰Č): “Ç”„V•ˇ 2021/6/22; P.16.

540031. [‚ť‚Ě‘ź (ŠŞ“ŞŒž)]yŠŞ“ŞŒžzAIŒ¤‹†‚Ć˜_—“IŽvl. _’J˜aF (ˆă—ÉqśŠw•”): IOL&RS 2021/6; 35 (2): 191.
540032. [‚ť‚Ě‘ź (ƒgƒsƒbƒNƒX)]yƒgƒsƒbƒNƒXzƒJƒXƒ^ƒ}ƒCƒYƒhŠp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO. _’J˜aF (ˆă—ÉqśŠw•”): IOL&RS 2021/6; 35 (2): 253-8.

540033. [‚ť‚Ě‘ź] ‚ą‚̐l‚É’–Ú. ”Ń“‡@Œh (Šá‰Č): IOL&RS 2021/6; 35 (2): 328-33.

540034. [‚ť‚Ě‘ź (˜˜_)]y“ÁW: Ž‹_ŒoŽžŠł‚ƗΓŕáŤŽ‹_ŒoÇ‚̊ӕʁz˜˜_. Îě@‹Ď (ˆă—ÉqśŠw•”): Šá‰Č 2021/7; 63 (7): 613.

540035. [‚ť‚Ě‘ź (ĄŒŽ‚Ě•\Ž†)]yĄŒŽ‚Ě•\Ž†zŠp–ŒƒCƒ“ƒŒ[KAMRATM. ‰i–ěKˆę1, ˆäăKŽŸ2 (1Šá‰Č, 2’šŽć‘ĺŠw): —Տ°Šá‰Č 2021/9; 75 (9): 1140.

540036. [‚ť‚Ě‘ź] Ž„‚Ć”’“ŕáŽčp|ć”y‚Š‚ç‚ĚƒƒbƒZ[ƒW|. Žsěˆę•v1,2 (1’†‹žŠá‰Č, 2Šá‰Č): IOL&RS 2021/9; 35 (3): 528-33.

540037. [‚ť‚Ě‘ź] –@l‚Š‚ç‚Ě‚¨’m‚ç‚š: ƒRƒƒi‰Đ‚ÉŽv‚¤‚ą‚Ć. Žsěˆę•v1,2,3 (1JSCRS—Ž–’ˇ, 2’†‹žŠá‰Č, 3Šá‰Č): IOL&RS 2021/9; 35 (3): 538.

540038. [‚ť‚Ě‘ź]yCLƒoƒgƒ‹ƒƒCƒ„ƒ‹ƒT[ƒhƒXƒe[ƒW‘ć66‰ńz˜VŽ‹‚ɑ΂ˇ‚é‘Ήž: CL‚ĆIOL. _’J˜aF (ˆă—ÉqśŠw•”): “ú–{ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYŠw‰ďŽ 2021/9; 63 (4): 148-55.

540039. [‚ť‚Ě‘ź (V•ˇ‹LŽ–)] Šá‹ž‚ɃTƒˆƒiƒ‰@‹ßŽ‹‚ÉICL, ƒŒ[ƒVƒbƒN‚Ć‚Ěˆá‚˘‚́uí‚ç‚Č‚˘v. _’J˜aF (ˆă—ÉqśŠw•”): ’Š“úV•ˇDIGITAL 2021/10/3.

540040. [‚ť‚Ě‘ź (ŠO‘Ž—v——)] ‘OŠá•”ŒőŠąÂ’f‘wŒv‚ĚƒoƒCƒIƒƒgƒŠ[‚đ—p‚˘‚˝‹@ŠBŠwK‚É‚ć‚é—L…ť‘ĚŠá“ŕƒŒƒ“ƒY‚Ěvault —\‘Ş. _’J˜aF1, Ik Hee Ryu2,3, Tae Keun Yoo2,3,4, Jung Sub Kim2,3, In Sik Lee2,3, Jin Kook Kim2,3, ˆŔ“Ą˜a‰ĚŽq3, ŻŽiMs3, ŽR“ŕ’m–[5, “c•ŁmŽu5 (1ˆă—ÉqśŠw•”, 2B & VIIT Eye Center, 3Šá‰Č, 4Aerospace Medical Center, 5ŽĐ‰ďˆă—Ă–@lŽO‰h‰ďƒcƒJƒUƒL•a‰@Šá‰Č): “ú–{Šá‰ČŠw‰ďŽGŽ 2021/10; 125 (10): 971-5.

540041. [‚ť‚Ě‘ź (ŠŞ“ŞŒž)] ŠŞ“ŞŒž|ƒRƒƒi‰Đ‚Ş‚ŕ‚˝‚ç‚ľ‚˝‚ŕ‚́|. ”Ń“c‰Ă•F (Šá‰Č): Šá‰ČŽčp 2021/10; 34 (4): 477-8.

540042. [‚ť‚Ě‘ź (Žčp‘Š’kŽş)]yŽčp‘Š’kŽşzÇ—á’ńŽŚ: pŒă•Ą”‰ńƒŒƒ“ƒY‰ń“]‚ˇ‚étoric ICLÇ—á. ŒÜ\—’ÍŽj1,2 (1ŽR‰¤•a‰@, 2Šá‰Č): Šá‰ČŽčp 2021/10; 34 (4): 601-6.

540043. [‚ť‚Ě‘ź (ˆóŰ‹L)] ŽÎŽ‹‚Ć•ĄŽ‹, ƒƒWƒbƒN‚ĆƒA[ƒg. ŒăŠÖ—˜–ž1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č): “ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‰ď•ń 2021/10; 57 (1): 69-70.

540044. [‚ť‚Ě‘ź (˜˜_)] “ÁW: ˜˜_. –Ń’Ë„Ži1,2, Îě@‹Ď3 (1–Ń’ËŠá‰Č•a‰@, 2“Œ‹žˆă‰Č‘ĺŠw, 3ˆă—ÉqśŠw•”): _ŒoŠá‰Č 2021/12; 38 (4): 339.

540045. [‚ť‚Ě‘ź] –@l‚Š‚ç‚Ě‚¨’m‚ç‚š: ŽčpŠw‰ď‚ĚŽű˜^‚đI‚Ś‚Ä. Žsěˆę•v1,2,3 (1JSCRS—Ž–’ˇ, 2’†‹žŠá‰Č, 3Šá‰Č): IOL&RS 2021/12; 35 (4): 173.

540046. [‚ť‚Ě‘ź] “ÁW‚É‚ ‚˝‚Á‚Ä. _’J˜aF1, •Ÿ‰Ş˛’mŽq2 (1ˆă—ÉqśŠw•”, 2‚Ó‚­‚¨‚ŠŠá‰ČƒNƒŠƒjƒbƒN’†–ě): IOL&RS 2021/12; 35 (4): 577.

540047. [‚ť‚Ě‘ź] ‚ą‚̐l‚É’–Ú: Ĺ—DGŔ’ˇÜŽóÜŽŇ. ăŽR@•– (Šá‰Č): IOL&RS 2021/12; 35 (4): 691-2.

540048. [‚ť‚Ě‘ź] Ž„‚Ć”’“ŕáŽčp|ć”y‚Š‚ç‚ĚƒƒbƒZ[ƒW|. ´…Œö–ç1,2,3 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2‘Űˆă—Ă•ŸŽƒ‘ĺŠw, 3Šá‰Č): IOL&RS 2021/12; 35 (4): 708-12.

[’˜@‘]

620103. [Šwp‘ (•Ş’SŽˇ•M)]y‘ŽŽ115‰đŕ‘ (‘ć115‰ńˆăŽt‘‰ĆŽŽŒą–â‘č‰đŕ‘)zA-31 ‰Á—”Á•ĎŤ‚̐f’f, p.42-3. A-67 “ľE“ŕˆŮí‚Ş‚Ý‚ç‚ę‚鎞Šł, p.105-6. A-70 VśŒŒŠÇ—Γŕá‚đ‚Ť‚˝‚ˇŽžŠł, p.110-1. C-39 ‰ß”M”’“ŕá, …ť‘Ě—Z‰đŤ‚Ô‚Ç‚¤–Œ‰Š‚ĚŽĄ—Ă, p.219-20. D-3 Šá‰Č‹~‹}ŽžŠł‚Ə‰Šú‘Ήž‚Ě‘g‡‚š, p.276-7. D-19 –Ô–ŒĂ–Ź•ŞŠň•ÂÇÇ‚É‚ć‚鉊”Á•‚Žî‚ɍs‚¤ŽĄ—Ă, p.292-4. ŒăŠÖ—˜–ž1,2, Žs粋`Í2,3 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č, 3_“ސ쎕‰Č‘ĺŠw•‘Ž‰Ą•lƒNƒŠƒjƒbƒN), •Ň: ˆăŽt‘‰ĆŽŽŒą–â‘č‰đŕ‘•ŇWˆĎˆő‰ď, ƒeƒRƒ€, “Œ‹ž, 2021/4”­s.

620104. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ĚÇ—á‚̂܂܂Őf‚Ä‚˘‚Ä‘ĺä•v?@•af˜AŒg‚É‚ŕ‚Ć‚Ă‚­ŽžŠł•ĘŠá‰Čf—ĂƒKƒCƒh (—Տ°Šá‰Č2021”N‘Š§†z5 —Γŕá@”’“ŕá‡•š‚̗Γŕá, p.174-9. ŻŽiMs (Šá‰Č), ˆăŠw‘‰@, “Œ‹ž, 2021/10”­s.

620105. [Šwp‘ (•Ş’SŽˇ•M)]yŠá‰ČŽčpQ&A (‚ ‚˝‚ç‚ľ‚˘Šá‰Č—ŐŽž‘Š§†)zII Šp–Œ@Q2 ‹üÜ‚Ě’ö“x‚âŠá‚̏ó‘Ô‚É‚ć‚Á‚Ä‘I‘đ‚ˇ‚×‚Ť‹üÜŽčp‚Ć‚ť‚Ě‹ď‘Ě“I•ű–@‚ɂ‚˘‚Ä‹ł‚Ś‚Ä‚­‚ž‚ł‚˘, p.41-6. _’J˜aF (ˆă—ÉqśŠw•”), ƒƒfƒBƒJƒ‹ˆ¨o”Ĺ, “Œ‹ž, 2021/12”­s.

620106. [Šwp‘ (•Ş’SŽˇ•M)]yŠá‰ČŽčpQ&A (‚ ‚˝‚ç‚ľ‚˘Šá‰Č—ŐŽž‘Š§†)zIV —Γŕá@Q6 ‚ł‚Ü‚´‚Ü‚ČMIGSƒfƒoƒCƒX‚ŞŠJ”­‚ł‚ę‚Ä‚˘‚Ü‚ˇ‚Ş, ĄŒă‚í‚Ş‘‚Ö‚Ě“ą“ü‚ŞŠú‘Ň‚ł‚ę‚éƒfƒoƒCƒX‚ɂ‚˘‚Ä‹ł‚Ś‚Ä‚­‚ž‚ł‚˘, p.163-7. ŻŽiMs (Šá‰Č), ƒƒfƒBƒJƒ‹ˆ¨o”Ĺ, “Œ‹ž, 2021/12”­s.

620107. [Šwp‘ (•Ş’SŽˇ•M)]yŠo‚Ś‚Ä‚¨‚Ť‚˝‚˘_ŒoŠá‰ČŽžŠł (2021”N12ŒŽ—ŐŽž‘Š§†)zI. Ž‹_ŒoŽžŠł@11. –ňÜŤŽ‹_ŒoÇ, 1311-7. ‚ˆäNs1, ŽRă–žŽq1,2 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č), ‹ŕŒ´o”Ĺ, “Œ‹ž, 2021/12, ”­s.

620108. [Šwp‘ (•Ş’SŽˇ•M)]yŠo‚Ś‚Ä‚¨‚Ť‚˝‚˘_ŒoŠá‰ČŽžŠł (2021”N12ŒŽ—ŐŽž‘Š§†)zIII. ŽÎŽ‹EŠáU@3. Sagging eye syndrome, p.1419-24. š ŒŠŒhŽq1, ŒăŠÖ—˜–ž1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č), ‹ŕŒ´o”Ĺ, “Œ‹ž, 2021/12, ”­s.

620109. [Šwp‘ (•Ş’SŽˇ•M)]yŠo‚Ś‚Ä‚¨‚Ť‚˝‚˘_ŒoŠá‰ČŽžŠł (2021”N12ŒŽ—ŐŽž‘Š§†)zIV. “ľEˆŮí@2. “ľE‹Ů’ŁÇEAdieÇŒóŒQ, p.1443-5. Îě@‹Ď (ˆă—ÉqśŠw•”), ‹ŕŒ´o”Ĺ, “Œ‹ž, 2021/12, ”­s.

620110. [Šwp‘ (•Ş’SŽˇ•M)]yŽ‹”\Šw ‘ć3”Łz[1] Šî‘bˆăŠw‘ĺ—v@I. Ž‹Ší‚̍\‘˘‚Ć‹@”\@D. Šá‚ĚŽŠ—Ľ_Œo/“ľEE’˛ßEçt–Š, p.39-45. Îě@‹Ď (ˆă—ÉqśŠw•”), •Ň: Ź—Ń‹`ŽĄ, ź‰Ş‹v”üŽq, ‰Pˆäçœ¨, ‰Ş^—R”ü, •śŒő“°, “Œ‹ž, 2022/1, ”­s.

620111. [Šwp‘ (•Ş’SŽˇ•M)]yŽ‹”\Šw ‘ć3”Łz[1] Šî‘bˆăŠw‘ĺ—v@I. Ž‹Ší‚̍\‘˘‚Ć‹@”\@E. ŠáˆłE–[…, p.46-8. ŻŽiMs (Šá‰Č), •Ň: Ź—Ń‹`ŽĄ, ź‰Ş‹v”üŽq, ‰Pˆäçœ¨, ‰Ş^—R”ü, •śŒő“°, “Œ‹ž, 2022/1, ”­s.

620112. [Šwp‘ (•Ş’SŽˇ•M)]yŽ‹”\Šw ‘ć3”Łz[2] Šî‘bŽ‹”\‹¸łŠw@I. Ž‹Šoś—Šw@E. FŠo, p.76-85. Žsěˆę•v1,2 (1’†‹žŠá‰Č, 2Šá‰Č), •Ň: Ź—Ń‹`ŽĄ, ź‰Ş‹v”üŽq, ‰Pˆäçœ¨, ‰Ş^—R”ü, •śŒő“°, “Œ‹ž, 2022/1, ”­s.

620113. [Šwp‘ (•Ş’SŽˇ•M)]yŽ‹”\Šw ‘ć3”Łz[2] Šî‘bŽ‹”\‹¸łŠw@I. Ž‹Šoś—Šw@G. “d‹Cś—Šw, p.90-105. Vˆä“cF—T1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw, 2Šá‰Č), •Ň: Ź—Ń‹`ŽĄ, ź‰Ş‹v”üŽq, ‰Pˆäçœ¨, ‰Ş^—R”ü, •śŒő“°, “Œ‹ž, 2022/1, ”­s.

620114. [Šwp‘ (•Ş’SŽˇ•M)]yŽ‹”\Šw ‘ć3”Łz[4] Ž‹”\áŠQŠw@II. _ŒoŠá‰ČŠw@B. ŠjăŤŠá‹…‰^“ŽˆŮí, p.301-8. Œü–ě˜a—Y (Šá‰Č), •Ň: Ź—Ń‹`ŽĄ, ź‰Ş‹v”üŽq, ‰Pˆäçœ¨, ‰Ş^—R”ü, •śŒő“°, “Œ‹ž, 2022/1, ”­s.

620115. [Šwp‘ (•Ş’SŽˇ•M)]yŠá‰ČŽžŠłĹV‚ĚŽĄ—Ă2022-2024z[ŠŞ“ރgƒsƒbƒNƒX] 8 ‹üÜ‹¸łŽčpƒKƒCƒhƒ‰ƒCƒ“ (‘掾ŽŸ“š\), p.29-31. _’J˜aF (ˆă—ÉqśŠw•”), •Ň: ‘şă@ť, ”’Î@“Ö ’Ґ얞F, “ě]“°, “Œ‹ž, 2022/1”­s.

620116. [Šwp‘ (•Ş’SŽˇ•M)]yŠá‰ČŽžŠłĹV‚ĚŽĄ—Ă2022-2024zIV ‚ť‚Ě‘ź‚ĚŽžŠł@…BŽÎŽ‹, ŽăŽ‹@4 ć“VăŽÎ‹Ř–ƒáƒ, p.302. ŒăŠÖ—˜–ž1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č), •Ň: ‘şă@ť, ”’Î@“Ö ’Ґ얞F, “ě]“°, “Œ‹ž, 2022/1”­s.

620117. [Šwp‘ (•Ş’SŽˇ•M)]yŠá‰ČŒŸ¸ƒKƒCƒh ‘ć3”Łz2. ‹üÜŒŸ¸@1) ‘źŠo“I‹üÜŒŸ¸@…@ƒI[ƒgƒŒƒtƒ‰ƒNƒg (ƒPƒ‰ƒg) ƒ[ƒ^, …Aƒ|[ƒ^ƒuƒ‹ƒI[ƒgƒŒƒtƒ‰ƒNƒg (ƒPƒ‰ƒg) ƒ[ƒ^, p.52-9. ěŽç“c‘ńŽu1, ”ź“c’m–ç1 (1ˆă—ÉqśŠw•”), ŠÄC: Ş–؁@ş, •Ň: ”Ń“c’mO, ‹ß“Ą•ôś, ’†‘ş@˝, ŽR“cš˜a, •śŒő“°, “Œ‹ž, 2022/2, ”­s.

620118. [Šwp‘ (•Ş’SŽˇ•M)]yŠá‰ČŒŸ¸ƒKƒCƒh ‘ć3”Łz5. ŠáˆĘEŠá‹…“ˏoEŠá‹…‰^“ŽŒŸ¸@7) ‘źŠo“IŽ‹‹@”\ŒŸ¸, p.182-3. ”ź“c’m–ç (ˆă—ÉqśŠw•”), ŠÄC: Ş–؁@ş, •Ň: ”Ń“c’mO, ‹ß“Ą•ôś, ’†‘ş@˝, ŽR“cš˜a, •śŒő“°, “Œ‹ž, 2022/2, ”­s.

620119. [Šwp‘ (•Ş’SŽˇ•M)]yŠá‰ČŒŸ¸ƒKƒCƒh ‘ć3”Łz8. FŠoŒŸ¸@5) ƒAƒmƒ}ƒƒXƒR[ƒv, p.230-5. “c’†–FŽ÷, Žsěˆę•v1,2 (1’†‹žŠá‰Č, 2Šá‰Č), ŠÄC: Ş–؁@ş, •Ň: ”Ń“c’mO, ‹ß“Ą•ôś, ’†‘ş@˝, ŽR“cš˜a, •śŒő“°, “Œ‹ž, 2022/2, ”­s.

620120. [Šwp‘ (•Ş’SŽˇ•M)]yŠá‰ČŒŸ¸ƒKƒCƒh ‘ć3”Łz9. Ž‹–ěŒŸ¸@2) ŽŠ“ŽŽ‹–ěŒv (Ă“IŽ‹–ěŒŸ¸)@…AOctopusŽ‹–ěŒv (PulsarŽ‹–ě), p.253-61. •˝ŕVˆę–@1, ŻŽiMs1 (1Šá‰Č), ŠÄC: Ş–؁@ş, •Ň: ”Ń“c’mO, ‹ß“Ą•ôś, ’†‘ş@˝, ŽR“cš˜a, •śŒő“°, “Œ‹ž, 2022/2, ”­s.

620121. [Šwp‘ (•Ş’SŽˇ•M)]yŠá‰ČŒŸ¸ƒKƒCƒh ‘ć3”Łz10. ŠááٌŸ¸@3) ƒAƒCƒXƒpƒbƒNƒeƒXƒg, ƒeƒ“ƒVƒƒ“ƒeƒXƒg (_ŒoE‹Ř•‰‰×ƒeƒXƒg), p.334-5. ŒăŠÖ—˜–ž1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č), ŠÄC: Ş–؁@ş, •Ň: ”Ń“c’mO, ‹ß“Ą•ôś, ’†‘ş@˝, ŽR“cš˜a, •śŒő“°, “Œ‹ž, 2022/2, ”­s.

620122. [Šwp‘ (•Ş’SŽˇ•M)]yŠá‰ČŒŸ¸ƒKƒCƒh ‘ć3”Łz12. Šp–ŒEŒ‹–ŒE…ť‘ĚŒŸ¸@11) Šp–ŒƒqƒXƒeƒŠƒVƒX‘Ş’č, p402-3. _’J˜aF (ˆă—ÉqśŠw•”), ŠÄC: Ş–؁@ş, •Ň: ”Ń“c’mO, ‹ß“Ą•ôś, ’†‘ş@˝, ŽR“cš˜a, •śŒő“°, “Œ‹ž, 2022/2, ”­s.

620123. [Šwp‘ (•Ş’SŽˇ•M)]yŠá‰ČŒŸ¸ƒKƒCƒh ‘ć3”Łz13. “ľEŒŸ¸@1) “ľEŒaŒv‘Ş, 2) “ľE”˝‰žŒŸ¸, 3) “_ŠáŽŽŒą (“ľE–ň•¨•‰‰×ƒeƒXƒg), 4) ÔŠOü“ľEŒv, p.404-20. óě@ŒŤ1, Îě@‹Ď1 (1ˆă—ÉqśŠw•”), ŠÄC: Ş–؁@ş, •Ň: ”Ń“c’mO, ‹ß“Ą•ôś, ’†‘ş@˝, ŽR“cš˜a, •śŒő“°, “Œ‹ž, 2022/2, ”­s.

620124. [Šwp‘ (•Ş’SŽˇ•M)]yŠá‰ČŒŸ¸ƒKƒCƒh ‘ć3”Łz14. Šá“ŕƒŒƒ“ƒY“x”Œv‘ށ@1) Šá“ŕƒŒƒ“ƒY“x”Œˆ’č‚Ě—˜_, 2) ’´‰š”gAƒ‚[ƒhŠáŽ˛’ˇŒv‘Ş, 3) ŒőŠwŽŽŠáŽ˛’ˇŒv‘Ş, p.421-30. _’J˜aF (ˆă—ÉqśŠw•”), ŠÄC: Ş–؁@ş, •Ň: ”Ń“c’mO, ‹ß“Ą•ôś, ’†‘ş@˝, ŽR“cš˜a, •śŒő“°, “Œ‹ž, 2022/2, ”­s.

620125. [Šwp‘ (•Ş’SŽˇ•M)]yŠá‰ČŒŸ¸ƒKƒCƒh ‘ć3”Łz21. “d‹Cś—ŒŸ¸@2) _ŒoŠá‰ČŽžŠł‚Ě“d‹Cś—Šw“IŒŸ¸@…B‘˝‹ÇŠEMG, p.674-5. Vˆä“cF—T1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw, 2Šá‰Č), ŠÄC: Ş–؁@ş, •Ň: ”Ń“c’mO, ‹ß“Ą•ôś, ’†‘ş@˝, ŽR“cš˜a, •śŒő“°, “Œ‹ž, 2022/2, ”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713046. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) THREE-MONTH RESULTS OF OMIDENEPAG ISOPROPYL OPHTHALMIC SOLUTION 0.002%. Kasahara M1, Hirasawa K1, Kono Y1, Yoneyama R1, Shoji N1: 9th World Glaucoma Congress (2021/6/30), WebŠJĂ. (Š}Œ´łs1, •˝ŕVˆę–@1, ‰Í–ě—Y—ş1, •ÄŽR@—Č1, ŻŽiMs1: 1Šá‰Č)

713047. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) CHARACTERISTICS OF GLAUCOMA PATIENTS WITH INTRAOCULAR PRESSURE ELEVATION EARLY AFTER TRABECTOME SURGERY. Kono Y1, Kasahara M1, Hirasawa K1, Yoneyama R1, Ito A1, Ueyama K1, Shoji N1: 9th World Glaucoma Congress (2021/6/30), WebŠJĂ. (‰Í–ě—Y—ş1, Š}Œ´łs1, •˝ŕVˆę–@1, •ÄŽR@—Č1, ˆÉ“ĄŽé—1, ăŽR@•–1, ŻŽiMs1: 1Šá‰Č)

713048. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) EFFECT OF TRABECULECTOMY ON MEAN SURGICAL INDUCED@ASTIGMATISM AND CENTROID VALUE. Ando W1, Kamiya K2, Iida Y1, Iijima K1, Tsujisawa T1, Fujimura F2, Kawamorita T2, Hoshikawa R2, Kasahara M1, Shoji N1: 9th World Glaucoma Congress (2021/6/30), WebŠJĂ. (ˆŔ“Ą˜a‰ĚŽq1, _’J˜aF2, ”Ń“c‰Ă•F1, ”Ń“‡@Œh1, ’Ň‘ň’C•F1, “Ą‘ş•‡ŽŃŽq2, ěŽç“c‘ńŽu2, Šąě—˘ŠG2, Š}Œ´łs1, ŻŽiMs1: 1Šá‰Č, 2ˆă—ÉqśŠw•”)

713049. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) TWO YEAR RESULTS OF TRABECTOME SURGERY FOR CASES WITH PREOPERATIVE INTRAOCULAR PRESSURE OF LESS THAN 20 MMHG. Yoneyama R1, Kasahara M1, Hirasawa K1, Kono Y1, Shoji N1: 9th World Glaucoma Congress (2021/6/30), WebŠJĂ. (•ÄŽR@—Č1, Š}Œ´łs1, •˝ŕVˆę–@1, ‰Í–ě—Y—ş1, ŻŽiMs1: 1Šá‰Č)

713050. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Comparison between the time required to take nine-direction ocular photographs using conventional method and a novel convenient application. Kunimi K1,2, Goseki T1,2, Shioya N1, Iijima Y1, Sebe M1, Fukaya K1, Hosoya K1: AAPOS2022 (2022/3/23), WebŠJĂ. (š ŒŠŒhŽq1,2, ŒăŠÖ—˜–ž1,2: 1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č)

721015. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰)yŔ’ˇzThe Light Adjustable Lens: Implications for Patients and Doctors. Žsěˆę•v1,2 (1’†‹žŠá‰Č, 2Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/25), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

721016. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰)yŔ’ˇz”’“ŕáŽčpŽžŠú‚̗ΓŕáŠÇ—. Žsěˆę•v1,2 (1’†‹žŠá‰Č, 2Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

721017. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰)yŔ’ˇz“Á•Ęu‰‰. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć60‰ń“ú–{”’“ŕáŠw‰ď‘‰ďE‘ć47‰ń…ť‘ĚŒ¤‹†‰ď (2021/11/27), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

721018. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ‘˝Ĺ“_Šá“ŕƒŒƒ“ƒY‚Ć‚Ě•t‚Ť‡‚˘•ű. ´…Œö–ç1,2 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2‘Űˆă—Ă•ŸŽƒ‘ĺŠw): ‘ć60‰ń“ú–{”’“ŕáŠw‰ď‘‰ďE‘ć47‰ń…ť‘ĚŒ¤‹†‰ď (2021/11/27), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722188. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ’iŠK“I‚’ź’ź‹ŘŘäFpGVRT (graded vertical rectus tenotomy). ŒăŠÖ—˜–ž1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/8), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722189. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‚Ô‚Ç‚¤–ŒˆŤŤ•FŽî‚Ě—Ő°Œo‰ß‚ĆƒQƒmƒ€‰đÍ (Clinical course and genomic analysis findings of uveal melanoma). ”–؍LĆ1,2, Œ´@Ë•v1, ‹gěŽü˛1, ‘ĺ’ːłŽ÷1, ˆÉ“ĄˆČ’m˜Y1, “n粗íŽq1, Œă“ĄŒ[‰î1, ’Š‘qOˆč1, …Œű–‚ŒČ1, ‰YăŒ¤ˆę1, HŽR–ől1, ŽRŒű@Œš1 (1Ă‰ŞŒ§—§Ă‰Ş‚Ş‚ńƒZƒ“ƒ^[, 2Šá‰Č): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/8), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722190. [Šw‰ď (‘S‘)] (‹łˆçƒZƒ~ƒi[)yŔ’ˇz‹łˆçƒZƒ~ƒi[1‚ŽŸŽűˇ‚Ɗ᎞Šł. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/9), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722191. [Šw‰ď (‘S‘)] (‹łˆçƒZƒ~ƒi[) …ť‘̂̉Á—î•Ď‰ťE”’“ŕá‚ƍ‚ŽŸŽűˇ Age-related changes in crystalline lens, cataracts and higher order aberrations. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/9), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722192. [Šw‰ď (‘S‘)] (‹łˆçƒZƒ~ƒi[) Šp–ŒŽžŠł‚É‚¨‚Ż‚éŽčp“K‰ž‚̍l‚Ś•ű How to determine surgical indication for corneal diseases. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/9), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722193. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)yŔ’ˇzƒXƒyƒVƒƒƒŠƒXƒg‚ĚŠá“ŕƒŒƒ“ƒY `‚ą‚ž‚í‚č‚ĚŠî€‚ĆIOL‘I‘đ`. ŻŽiMs (Šá‰Č): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/9), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722194. [Šw‰ď (‘S‘)] (ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[)yŔ’ˇzŠáˆł“ú“ŕ•Ď“Ž‚đ–ž‚ç‚Š‚É‚ˇ‚é `V‚ľ‚˘ŒŸ¸‹@Ší‚đŽg‚˘‚ą‚Č‚ť‚¤!`. ŻŽiMs (Šá‰Č): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/10), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722195. [Šw‰ď (‘S‘)] (ƒTƒuƒXƒyƒVƒƒƒŠƒeƒBƒTƒ“ƒf[) ”]Ň‘‰tŒ¸­‚É‚ć‚鎋‹@”\áŠQ (Visual disturbance of cerebrospinal fluid leakage). ŽRă–žŽq1,2 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/11), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722196. [Šw‰ď (‘S‘)] (ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[) —Ž‹‹¸ł‚ĚˆÓ‹``łŠm‚Č—Ž‹‹¸ł‚ŞŠ‚Ś‚é‚ŕ‚́`. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/11), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722197. [Šw‰ď (‘S‘)] (ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[) —Ž‹‹¸ł‚ĚˆÓ‹``łŠm‚Č—Ž‹‹¸ł‚ŞŠ‚Ś‚é‚ŕ‚́`. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/11), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722198. [Šw‰ď (‘S‘)] (uK‰ď) ‹üÜ‹¸łŽčpE‘“ŕŠO‚ĚŒťó‚ƍĄŒă‚Ě“W–]. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (“ú–{Šá‰ČŠw‰ď‹üÜ‹¸łŽčpuK‰ď) (2021/4/26), WebŠJĂ.

722199. [Šw‰ď (‘S‘)] (uK‰ď) ŽÎŽ‹f—Ă‚ĚƒsƒbƒgƒtƒH[ƒ‹. ŒăŠÖ—˜–ž1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (“ú–{Šá‰ČŠw‰ďę–ĺˆă§“x‘ć73‰ńuK‰ďƒvƒƒOƒ‰ƒ€) (2021/4/26), WebŠJĂ.

722200. [Šw‰ď (‘S‘)] (JIPSƒR[ƒ`ƒ“ƒOƒZƒ~ƒi[)yŔ’ˇz–ž“ú‚Š‚ç–𗧂Ž‹–ěŒŸ¸: Œťę‚ĚƒmƒEƒnƒE. ŻŽiMs (Šá‰Č): ‘ć10‰ń“ú–{Ž‹–ě‰ć‘œŠw‰ďŠwpW‰ď (2021/4/25), WebŠJĂ.

722201. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)yŔ’ˇz—ΓŕáŠłŽŇ‚ł‚ń‚Ě–˘—ˆ‚ւ̉˂Ż‹´. ŻŽiMs (Šá‰Č): ‘ć10‰ń“ú–{Ž‹–ě‰ć‘œŠw‰ďŠwpW‰ď (2021/4/25), WebŠJĂ.

722202. [Šw‰ď (‘S‘)] (‰ď’ˇŠé‰ć) 3DƒrƒWƒ…ƒAƒ‹ƒVƒXƒeƒ€‚Ě—L—pŤ‚ɂ‚˘‚Ä. Žsěˆę•v1,2 (1’†‹žŠá‰Č, 2Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/25), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722203. [Šw‰ď (‘S‘)] (“Á•Ę•ń) ƒg[ƒŠƒbƒNŠá“ŕƒŒƒ“ƒY‚đŽg‚Á‚˝—Ž‹§Œä”’“ŕáŽčp. Žsěˆę•v1,2, Žsě@Œc1, ŽđˆäKO1, ‰Á“ĄKm1, “´ˆä—˘ŠG1, í”ՐšŽi1, Ź“‡—˛Ži3, ‹Ę’u–ž–ě4 (1’†‹žŠá‰Č, 2Šá‰Č, 3Œcœä‘ĺ, 4JCHO’†‹ž•a‰@): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/25), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722204. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “ľE‚Ć—Ž‹. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/25), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722205. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yŔ’ˇz”’“ŕáŽčp`‹†‹É‚ĚŽ‹‹@”\‚đ–ÚŽw‚ľ‚ā`. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/25), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722206. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “ÁŽęÇ—á (‹üÜ‹¸łŽčpŒă, ‰~Šp–Œ, ƒsƒM[ƒoƒbƒO) ‚đ‹É‚ß‚é. ”Ń“‡@Œh1, _’J˜aF2, ”Ń“c‰Ă•F1, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/25), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722207. [Šw‰ď (‘S‘)] (‹łˆçƒZƒ~ƒi[) ‘OŠá•”ŒőŠąÂ’f‘wŒv‚Ě‰ć‘œ‚Š‚琅ť‘̂̐ԓš•”ˆĘ’u‚đ—\‘Ş‚ˇ‚éV‚ľ‚˘‰đÍ–@. ”n“ˆ´”@1, Žsě@Œc2, ŽđˆäKO2, •Đ‰Ş“”Ž3, ˆé’JŽ‹P3, ’†‘ş—Fş3, ‹Ę’u–ž–ě4, Žsěˆę•v2,5 (1Šá‰Č–žŠá‰@, 2’†‹žŠá‰Č, 3–źŒĂ‰ŽƒAƒCƒNƒŠƒjƒbƒN, 4JCHO’†‹ž•a‰@, 5Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/25), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722208. [Šw‰ď (‘S‘)] (‹łˆçƒZƒ~ƒi[) ICL. ŒÜ\—’ÍŽj (ŽR‰¤•a‰@): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/25), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722209. [Šw‰ď (‘S‘)] (‹łˆçƒZƒ~ƒi[) isŤ‰~Šp–Œ‚ɑ΂ˇ‚éCustomizedŠp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO. ‚‹´ł‰p1,2 (1Šá‰Č, 2ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/25), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722210. [Šw‰ď (‘S‘)] (‹łˆçƒZƒ~ƒi[) —Ž‹‚ĚŒŸ¸‚Ć‹¸ł–@. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/25), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722211. [Šw‰ď (‘S‘)] (ƒP[ƒXƒŠƒ|[ƒg) IC-8?‘}“üŠá‚ɐś‚ś‚˝–Ô–Œ”—Ł‚É‚¨‚˘‚Ä, Šá“ŕŽ‹‹ž•š—pÉŽq‘ĚŽčp‚Ĺ–Ô–Œ•œˆĘ‚đ“ž‚˝ˆę—á. ‹g‰Ş˜aŽ÷1, ‰Á‰ę’BŽu1,3, ‰ĄŽR@ăÄ1, ź“c‘וă1, Ź“‡—˛Ži2, Žsěˆę•v2,3 (1JCHO’†‹ž•a‰@, 2’†‹žŠá‰Č, 3Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/25), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722212. [Šw‰ď (‘S‘)] (ƒP[ƒXƒŠƒ|[ƒg) ƒ}ƒ‹ƒtƒ@ƒ“ÇŒóŒQ‚É‚ć‚鐅ť‘Ě•ÎˆĘ‚É‚Ä’á”N—‚ÉŽčp‚đŽ{s‚ľ‚˝Ç—á. ‰ĄŽR‹g”ü1, ‰Á‰ę’BŽu1,3, Žsěˆę•v2,3 (1JCHO’†‹ž•a‰@, 2’†‹žŠá‰Č, 3Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/25), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722213. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)yŔ’ˇzƒXƒyƒVƒƒƒŠƒXƒg‚ĚćŒŠ”V–ž`”’“ŕáŽčp‚ĆAMDŽĄ—Á`. Žsěˆę•v1,2 (1’†‹žŠá‰Č, 2Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/25), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722214. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) Ž„‚Í‚ą‚ą‚đŒŠ‰ß‚˛‚ł‚Č‚˘!`p‘OŒŸ¸‚ĆƒŒƒ“ƒY‘I‘đ`. ”Ń“c‰Ă•F (Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/25), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722215. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)yŔ’ˇz”’“ŕá‹üÜ‹¸łŽčp‚É‚¨‚Ż‚éCASIA2‚Ě—L—pŤ. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/25), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722216. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ATA‚đ—p‚˘‚˝ICLƒTƒCƒY—\‘ŞŽŽ (KSŽŽ). ŒÜ\—’ÍŽj (ŽR‰¤•a‰@): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/25), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722217. [Šw‰ď (‘S‘)] (‰ď’ˇŠé‰ć) ‹­–ŒŒĹ’čp‚É“K‚ľ‚˝Šá“ŕƒŒƒ“ƒY. ‹g“c‘Ľ•F1, Žsěˆę•v2,3 (1Šň•ŒÔ\Žš•a‰@, 2’†‹žŠá‰Č, 3Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722218. [Šw‰ď (‘S‘)] (“Á•Ę•ń) ”’“ŕáp‘Oś‘ĚŒv‘ރf[ƒ^EĹ“KŠá“ŕƒŒƒ“ƒY“x”ŒvŽZŽŽ‚Ě‘˝Ž{Ý”äŠrŒ¤‹†. _’J˜aF1, —с@@Œ¤2, ˛“ĄłŽ÷3, Ź“‡—˛Ži4, Œă“ĄŒ›m5, ‰â“Ţ’ĂŽq6, “c糐^ś7, “c•ŁmŽu7 (1ˆă—ÉqśŠw•”, 2—ŃŠá‰Č•a‰@, 3ƒTƒgƒEŠá‰Č, 4Œc‰ž‘ĺ, 5ŒË“c‚˛‚Ć‚¤Šá‰Č, 6‹ŕ‘ňˆă‘ĺ, 7ƒcƒJƒUƒL•a‰@): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722219. [Šw‰ď (‘S‘)] (“Á•Ę•ń) Šá“ŕƒŒƒ“ƒY•ÎˆĘE—Ž‰ş‚Ě‘˝Ž{Ý‹¤“ŻŒ¤‹† (’†ŠÔ•ń). Œă“ĄŒ›m1, _’J˜aF2, Ź“‡—˛Ži3, ˛“ĄłŽ÷4, “c•ŁmŽu5,6, ‰â“Ţ’ĂŽq7, —с@@Œ¤8 (1ŒË“c‚˛‚Ć‚¤Šá‰Č, 2ˆă—ÉqśŠw•”, 3Œc‰ž‘ĺ, 4ƒTƒgƒEŠá‰Č, 5L“‡‘ĺEŠń•uŔDT2M, 6ƒcƒJƒUƒL•a‰@, 7‹ŕ‘ňˆă‘ĺ, 8—ŃŠá‰Č•a‰@): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722220. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yŔ’ˇz‘˝Ĺ“_IOL‚̉A‚Ě‘Îô. Žsěˆę•v1,2 (1’†‹žŠá‰Č, 2Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722221. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‹­“x‹ßŽ‹Šá‚Ě—Ž‹‹¸ł. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722222. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) —L…ť‘ĚŠá“ŕƒŒƒ“ƒY‚ĚŒťó‚ƍĄŒă. ´…Œö–ç1,2 (1ŽR‰¤•a‰@, 2Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722223. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ICL‚Ě–˘—ˆ (˜VŽ‹‘ΉžICL‚Č‚Ç). ŒÜ\—’ÍŽj1,2 (1ŽR‰¤•a‰@, 2Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722224. [Šw‰ď (‘S‘)] (‹łˆçƒZƒ~ƒi[)yŔ’ˇzŽ‹‹@”\E‘OŠá•”•]‰żƒAƒbƒvƒf[ƒg. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722225. [Šw‰ď (‘S‘)] (‹łˆçƒZƒ~ƒi[) ‘OŠá•”‰ć‘œ‰đÍ. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722226. [Šw‰ď (‘S‘)] (‹łˆçƒZƒ~ƒi[) ‘˝Ĺ“_Šá“ŕƒŒƒ“ƒY‚Ě“KłŽg—p. Žsěˆę•v1,2 (1’†‹žŠá‰Č, 2Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722227. [Šw‰ď (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX)yƒI[ƒKƒiƒCƒU[z˘ŠE‚̍ŐVƒgƒŒƒ“ƒh‚đ’m‚낤!gWhat's New in 2021h. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722228. [Šw‰ď (‘S‘)] (ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[) TECNISƒvƒ‰ƒbƒgƒtƒH[ƒ€‚ĆTECNIS Simplicity‚ĚŽg—pŒoŒą. ”Ń“c‰Ă•F (Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722229. [Šw‰ď (‘S‘)] (ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[)yŔ’ˇz‚ą‚ę‚Š‚ç‚Ě”’“ŕáŽčp‚Í‚ą‚ę‚ĹŒˆ‚Ü‚č! Žsěˆę•v1,2 (1’†‹žŠá‰Č, 2Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722230. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)yŔ’ˇzZEISS Cataract Solution Part‡U. Žsěˆę•v1,2 (1’†‹žŠá‰Č, 2Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722231. [Šw‰ď (‘S‘)] (ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[)yŔ’ˇzpŒăQOVEQOLŒüă‚Ě‚˝‚ß‚ĚŽć‚č‘g‚Ý. Žsěˆę•v1,2 (1’†‹žŠá‰Č, 2Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722232. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yŔ’ˇz‘˝Ĺ“_Šá“ŕƒŒƒ“ƒY‘}“üŠá‚ĚŽ‹‹@”\‚ւ̉e‹żˆöŽq. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/27), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722233. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Šá“ŕƒŒƒ“ƒY•ÎˆĘ‚ĆƒÉŠp‚̉e‹ż. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/27), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722234. [Šw‰ď (‘S‘)] (ƒP[ƒXƒŠƒ|[ƒg) Ĺ“_[“xŠg’ŁŒ^—L…ť‘ĚŒă–[ƒŒƒ“ƒY‚đ—p‚˘‚˝ƒnƒCƒuƒŠƒbƒhƒ‚ƒmƒrƒWƒ‡ƒ“. ŒÜ\—’ÍŽj1,2, ´…Œö–ç1,2, íœAr‘ž˜Y1,2 (1ŽR‰¤•a‰@, 2Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/27), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722235. [Šw‰ď (‘S‘)] (ƒP[ƒXƒŠƒ|[ƒg) ŠŃ’ʍE•t‚Ť—L…ť‘ĚŒă–[ƒŒƒ“ƒY‘}“üpŒă‚É‹}Ť—Γŕá”­ě‚đ—ˆ‚ľ‚˝1—á. ÎěŒb—˘1, ŒÜ\—’ÍŽj2,3, ]”gŒË”ü˜a1, “c’†—Sˆę˜N1, ŹŕV’‰•F1 (1Ź‘ňŠá‰Č“ŕ‰Č•a‰@, 2ŽR‰¤•a‰@, 3Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/27), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722236. [Šw‰ď (‘S‘)] (ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[)yŔ’ˇzIntense Pulsed Light (IPL) ŽĄ—Á|pŒăŹŃ•–ž‘Ť“xŒüă‚̐V‚˝‚ČŽč’i|. Žsěˆę•v1,2 (1’†‹žŠá‰Č, 2Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/27), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722237. [Šw‰ď (‘S‘)] (ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[) AŒ^ƒ{ƒcƒŠƒkƒX“Ĺ‘fťÜƒ{ƒgƒbƒNƒX?@uKEŽŔ‹ZƒZƒ~ƒi[uŽÎŽ‹vŽžŠł•Ň. ŒăŠÖ—˜–ž1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č): ‘ć77‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ď (2021/7/2), _“ސě (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722238. [Šw‰ď (‘S‘)] (uK‰ď)yŔ’ˇzŽăŽ‹‚Ć•ĄŽ‹, ƒƒWƒbƒN‚ĆƒA[ƒg. ŒăŠÖ—˜–ž1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č): ‘ć77‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ď (‘ć37‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ďuK‰ď) (2021/7/3), _“ސě (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722239. [Šw‰ď (‘S‘)] (ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[) —Ž‹‹¸ł‚́uŽżv‚đ‰ČŠw‚ˇ‚é. ”ź“c’m–ç (ˆă—ÉqśŠw•”): ƒtƒH[ƒTƒ€2021ĺ‘ä (2021/7/24), ĺ‘ä (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722240. [Šw‰ď (‘S‘)] (‹L”Ou‰‰)yŔ’ˇzŠwp§—ăÜŽóÜ‹L”Ou‰‰. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć57‰ń“ú–{ŠáŒőŠwŠw‰ď‘‰ď (2021/9/4), WebŠJĂ.

722241. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ˆę•bŽ‹—Í. ŒÜ\—’ÍŽj1,2 (1ŽR‰¤•a‰@, 2Šá‰Č): ‘ć57‰ń“ú–{ŠáŒőŠwŠw‰ď‘‰ď (2021/9/4), WebŠJĂ.

722242. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yŔ’ˇz‹üÜ‚đÄl‚ˇ‚é. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć57‰ń“ú–{ŠáŒőŠwŠw‰ď‘‰ď (2021/9/4), WebŠJĂ.

722243. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “ú–{l–ÍŒ^Šá‚̏d—vŤ. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): ‘ć57‰ń“ú–{ŠáŒőŠwŠw‰ď‘‰ď (2021/9/4), WebŠJĂ.

722244. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) Šá“ŕƒŒƒ“ƒY‚𐜗“I‚ɍl‚Ś‚é. Žsěˆę•v1,2 (1’†‹žŠá‰Č, 2Šá‰Č): ‘ć57‰ń“ú–{ŠáŒőŠwŠw‰ď‘‰ď (2021/9/4), WebŠJĂ.

722245. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) ˆ•űŹŒ÷—Ś94%‚đŽx‚Ś‚鉓‹ßCL‚ĚŒőŠw“ÁŤ. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): ‘ć57‰ń“ú–{ŠáŒőŠwŠw‰ď‘‰ď (2021/9/5), WebŠJĂ.

722246. [Šw‰ď (‘S‘)] (ƒf[ƒ^‰đÍˆĎˆő‰ď“Á•ĘƒZƒbƒVƒ‡ƒ“) Report from Glaucoma Blood Flow Research Group —ΓŕáŒŒ—ŹŒ¤‹†”Ç•ń. ŻŽiMs (Šá‰Č): ‘ć32‰ń“ú–{—ΓŕáŠw‰ď (2021/9/10), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722247. [Šw‰ď (‘S‘)] (JGS special session) Current Status and Issues of MIGS MIGS‚ĚŒťó‚Ɖۑč. ŻŽiMs (Šá‰Č): ‘ć32‰ń“ú–{—ΓŕáŠw‰ď (2021/9/11), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722248. [Šw‰ď (‘S‘)] (Œ¤CˆăEƒRƒƒfƒBƒJƒ‹ƒvƒƒOƒ‰ƒ€) How to use the kinetic perimetry in glaucoma diagnosis —Γŕáf’f‚É‚¨‚Ż‚é“Ž“IŽ‹–ěŒv‚Ěƒ|ƒCƒ“ƒg. “Ą‘ş•‡ŽŃŽq (ˆă—ÉqśŠw•”): ‘ć32‰ń“ú–{—ΓŕáŠw‰ď (2021/9/11), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722249. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)yŔ’ˇzŽĺ—Źo˜H‚đ‹†‚ß‚é. ŻŽiMs (Šá‰Č): ‘ć32‰ń“ú–{—ΓŕáŠw‰ď (2021/9/11), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722250. [Šw‰ď (‘S‘)] ({“c‹L”Ou‰‰) To protect visual acuity in glaucoma surgery —ΓŕáŽčp‚ĹŽ‹—Í‚đŽç‚é‚˝‚ß‚É. ŻŽiMs (Šá‰Č): ‘ć32‰ń“ú–{—ΓŕáŠw‰ď (2021/9/12), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722251. [Šw‰ď (‘S‘)] (‹łˆçƒZƒ~ƒi[)yŔ’ˇz—Γŕá‚Ć•´‚ç‚í‚ľ‚˘ŽžŠł. ŻŽiMs (Šá‰Č): ‘ć32‰ń“ú–{—ΓŕáŠw‰ď (2021/9/12), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722252. [Šw‰ď (‘S‘)] (‹łˆçƒZƒ~ƒi[) Optic nerve disease confusing with glaucoma —Γŕá‚Ć‚Ü‚Ź‚ç‚í‚ľ‚˘Ž‹_ŒoŽžŠł. ŽRă–žŽq1,2 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č): ‘ć32‰ń“ú–{—ΓŕáŠw‰ď (2021/9/12), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722253. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰“™)yƒ‚ƒfƒŒ[ƒ^[z”’“ŕáŽčp‚É‚¨‚Ż‚é˜VŽ‹‹¸ł‚ĚĹ‘Oü. _’J˜aF1, ěŽç“c‘ńŽu1 (1ˆă—ÉqśŠw•”): The 24th IRSJ (2021)/‘ć20‰ńŠá‰Č—Տ°‹@ŠíŒ¤‹†‰ď (2021/10/16), WebŠJĂ.

722254. [Šw‰ď (‘S‘)] (Šî’˛u‰‰) “dŽq‹üÜ—͉•ϊዞTouchFocus? ”Ń“‡@Œh (Šá‰Č): The 24th IRSJ (2021)/‘ć20‰ńŠá‰Č—Տ°‹@ŠíŒ¤‹†‰ď (2021/10/16), WebŠJĂ.

722255. [Šw‰ď (‘S‘)] (ƒAƒtƒ^ƒk[ƒ“ƒZƒ~ƒi[)yŔ’ˇz—Γŕá–ň•¨ŽĄ—ĂƒAƒbƒvƒf[ƒg. ŻŽiMs (Šá‰Č): The 24th IRSJ (2021)/‘ć20‰ńŠá‰Č—Տ°‹@ŠíŒ¤‹†‰ď (2021/10/16), WebŠJĂ.

722256. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰“™)yƒ‚ƒfƒŒ[ƒ^[zu‰‰‡T‘OŠá•”OCT: ƒAƒ“ƒeƒŠƒIƒ“. Š}Œ´łs (Šá‰Č): The 24th IRSJ (2021)/‘ć20‰ńŠá‰Č—Տ°‹@ŠíŒ¤‹†‰ď (2021/10/16), WebŠJĂ.

722257. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰“™) —ΓŕáŠá‚ɑ΂ˇ‚éƒAƒ“ƒeƒŠƒIƒ“‚̉ž—p. •ÄŽR@—Č (Šá‰Č): The 24th IRSJ (2021)/‘ć20‰ńŠá‰Č—Տ°‹@ŠíŒ¤‹†‰ď (2021/10/16), WebŠJĂ.

722258. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰“™)yƒ‚ƒfƒŒ[ƒ^[zu‰‰II ZEISS ARTEVO 800. –ö“c’q•F (Šá‰Č): The 24th IRSJ (2021)/‘ć20‰ńŠá‰Č—Տ°‹@ŠíŒ¤‹†‰ď (2021/10/16), WebŠJĂ.

722259. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰“™) ZEISS ARTEVO 800‚ĚŽg—pŒoŒą. ‰Í–ě—Y—ş (Šá‰Č): The 24th IRSJ (2021)/‘ć20‰ńŠá‰Č—Տ°‹@ŠíŒ¤‹†‰ď (2021/10/16), WebŠJĂ.

722260. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰“™)yƒ‚ƒfƒŒ[ƒ^[zu‰‰III ƒtƒFƒCƒRƒ}ƒV[ƒ“Ĺ‘Oü. ”Ń“c‰Ă•F (Šá‰Č): The 24th IRSJ (2021)/‘ć20‰ńŠá‰Č—Տ°‹@ŠíŒ¤‹†‰ď (2021/10/16), WebŠJĂ.

722261. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) –Ú‚Ě’É‚Ý‚ĚƒTƒCƒGƒ“ƒX: New Insight of Ocular Pain. ŽRă–žŽq1,2 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/28), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722262. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Šá•”ˆŤŤŽîᇎĄ—Â̐V‚˝‚Č’Ş—Ź (New trend of treatment for ocular malignant tumors). ”–؍LĆ1,2 (1Œ§—§Ă‰Ş‚Ş‚ńƒZƒ“ƒ^[, 2Šá‰Č): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/28), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722263. [Šw‰ď (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX) ŽÎŽ‹Žčp‚ĚƒOƒ[ƒoƒ‹ƒXƒ^ƒ“ƒ_[ƒh‚đl‚Ś‚é@‚ť‚Ě3. ’ˇ’J•”‘1, ŒăŠÖ—˜–ž2,3, –č’îŽi4, —с@F—Y5, ŞŠÝ‹MŽu6 (1ěčˆă‘ĺ, 2‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 3Šá‰Č, 4Šá‰Č‚â‚Ş‚ł‚Ťˆă‰@, 5’é‹ž‘ĺˆă—Ă‹Zp, 6‡“V‘ĺ): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/28), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722264. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yƒI[ƒKƒiƒCƒU[zĹV‚ĚŒő”g’ˇ‚̍l‚Ś•ű (Eye-opening Perspectives on Light Wavelengths). Žsěˆę•v1,2 (1’†‹žŠá‰Č, 2Šá‰Č): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/29), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722265. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) —‘z‚ĚŠá“ŕƒŒƒ“ƒY•ŞŒő“§‰ß“ÁŤ. Žsěˆę•v1,2 (1’†‹žŠá‰Č, 2Šá‰Č): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/29), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722266. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) •sł—Ž‹Šá‚ɑ΂ˇ‚闐Ž‹‹¸ł‚ɃtƒH[ƒJƒX! _’J˜aF (ˆă—ÉqśŠw•”): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/29), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722267. [Šw‰ď (‘S‘)] (ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[)yŔ’ˇzĘ‚č‚ä‚˝‚Š‚ōK‚š‚Č–˘—ˆ‚đ–ÚŽw‚ľ‚ā`–Ô–Œ•ŇŹŽĄ—Ă‚ĚĹ‘Oü‚ƐFĘS—Šw`. ŒÜ\—’ÍŽj1,2 (1ŽR‰¤•a‰@, 2Šá‰Č): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/29), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722268. [Šw‰ď (‘S‘)] (ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[) ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[@ƒNƒ[ƒWƒ“ƒOƒŠƒ}[ƒNƒX. ´…Œö–ç1,2 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰Č): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/29), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722269. [Šw‰ď (‘S‘)] (ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[) AŒ^ƒ{ƒcƒŠƒkƒX“Ĺ‘fťÜƒ{ƒgƒbƒNƒXuKEŽŔ‹ZƒZƒ~ƒi[uŠááŮázš/•Đ‘¤Šç–ĘázšvŽžŠł•Ň. ŒăŠÖ—˜–ž1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/29), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722270. [Šw‰ď (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX) FŠoˆŮí‚̐f’f‚ĆŽw“ą. Žsěˆę•v1,2, ’†‘ş‰pŽ÷3, Šâ˛^‹I4, –Ű–ě‹v”üŽq5, ’†‘ş‚Š‚¨‚é6, ‘ş–Ř‘•c7, ”ˆä^—Žq8 (1’†‹žŠá‰Č, 2Šá‰Č, 3–ź“ŒŠá‰Č, 4Ž ‰ęˆă‘ĺ, 5Š ’J–L“c‘‡•a‰@, 6—Žqˆă‘ĺ, 7‚Ţ‚ç‚ŤŠá‰Č, 8Šá‰Č”ˆäˆă‰@): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/30), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722271. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[) “ľEˆŮíŠá‚Ě”’“ŕáŽčp@“ľE‚ĆŽ‹‹@”\, ‘˝Ĺ“_IOL‚̉e‹ż. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/30), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722272. [Šw‰ď (‘S‘)] (ƒAƒtƒ^ƒk[ƒ“ƒZƒ~ƒi[) ”’“ŕáŽčp‚É‹‚ß‚ç‚ę‚é3A`ˆŔSEˆŔ‘SEˆŔ’č`ŠáŽ˛’ˇ‘Ş’čŠí‚Ş‚ŕ‚˝‚炡ˆŔSEˆŔ‘SEˆŔ’č. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/30), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722273. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “ú–{—ΓŕáŠw‰ď‚Š‚ç‚Ě—v–]. ŻŽiMs (Šá‰Č): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/30), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722274. [Šw‰ď (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX) CTEMRI‚Ĺ‚ŕ‚Á‚Ć‚í‚Š‚é!@ŽÎŽ‹‚Ě•a‘Ô‚ĆŽĄ—Ă. ŞŠÝ‹MŽu1, ˛“Ą”ü•Ű2, ™ŽR”\Žq3, •F’J–žŽq3, ź‘şŸ4,5, ŒăŠÖ—˜–ž6,7, _‘O‚ ‚˘8 (1‡“V‘ĺ, 2•lźˆă‘ĺ, 3‹ŕ‘ň‘ĺ, 4ă–ěŠá‰Č, 5š—ę•lź•a‰@, 6‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 7Šá‰Č, 8ƒIƒŠƒ“ƒsƒAŠá‰Č): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/11/22), ƒIƒ“ƒfƒ}ƒ“ƒh”zM.

722275. [Šw‰ď (‘S‘)] (ƒCƒ“ƒXƒgƒ‰ƒNƒVƒ‡ƒ“ƒR[ƒX) ŽŔ‘H‚Š‚çŠw‚Ô—L…ť‘ĚŠá“ŕƒŒƒ“ƒY. ´…Œö–ç1,2, _’J˜aF3, Žsěˆę•v2,4, ’†‘ş—Fş5, –kŕV˘Žu”Ž6, ‚‹´ł‰p1,4, `˝ˆę˜Y7 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰Č, 3ˆă—ÉqśŠw•”, 4’†‹žŠá‰Č, 5–źŒĂ‰ŽƒAƒCƒNƒŠƒjƒbƒN, 6ƒTƒsƒAƒ^ƒ[ƒAƒCƒNƒŠƒjƒbƒN“Œ‹ž, 7ƒXƒJƒCƒrƒ‹Šá‰Čˆă‰@): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/11/22), ƒIƒ“ƒfƒ}ƒ“ƒh”zM.

722276. [Šw‰ď (‘S‘)] (uK‰ď) uĹ‹ß‚̐i•ŕƒVƒŠ[ƒY43vIOL (“K‰žEpŽŽE‡•šÇE’ˇŠú—\Œă) “K‰ž‚Əp‘OŒŸ¸. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (“ú–{Šá‰ČŠw‰ďę–ĺˆă§“x‘ć74‰ńuK‰ď) (2021/11/22), ƒIƒ“ƒfƒ}ƒ“ƒh”zM.

722277. [Šw‰ď (‘S‘)] (uK‰ď) ‹üÜ‹¸łŽčpE‘“ŕŠO‚ĚŒťó‚ƍĄŒă‚Ě“W–]. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (“ú–{Šá‰ČŠw‰ď‹üÜ‹¸łŽčpuK‰ď) (2021/11/22), ƒIƒ“ƒfƒ}ƒ“ƒh”zM.

722278. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‘˛‘R‹łˆç‚Ě—§ę‚Š‚ç. Vˆä“cF—T1,2,3 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw, 2‘S‘Ž‹”\ŒP—űŽmŠwZ‹Ś‰ď‰ď’ˇ, 3Šá‰Č): ‘ć62‰ń“ú–{Ž‹”\‹¸łŠw‰ď (2021/11/20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722279. [Šw‰ď (‘S‘)] (ƒIƒ“ƒfƒ}ƒ“ƒhƒZƒ~ƒi[) 3ÎŽ™Œ’f‚É‚¨‚Ż‚鎋ŠoŒŸ¸‚ĚŽŔŰ. “Ą‘ş•‡ŽŃŽq (ˆă—ÉqśŠw•”): ‘ć62‰ń“ú–{Ž‹”\‹¸łŠw‰ď (2021/12/3), ƒIƒ“ƒfƒ}ƒ“ƒh”zM.

722280. [Šw‰ď (‘S‘)] (‰ď’ˇˆĽŽA) ‰ď’ˇˆĽŽA. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć60‰ń“ú–{”’“ŕáŠw‰ď‘‰ďE‘ć47‰ń…ť‘ĚŒ¤‹†‰ď (2021/11/26), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722281. [Šw‰ď (‘S‘)] (ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[)yŔ’ˇzƒOƒŒ[ƒhƒAƒbƒv!@pŒăŠÇ— —Γŕá‚Ş‚ç‚Ý‚ĚpŒăŠÇ—‚đƒOƒŒ[ƒhƒAƒbƒv! ŻŽiMs (Šá‰Č): ‘ć60‰ń“ú–{”’“ŕáŠw‰ď‘‰ďE‘ć47‰ń…ť‘ĚŒ¤‹†‰ď (2021/11/26), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722282. [Šw‰ď (‘S‘)] (ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[)yŔ’ˇzƒOƒŒ[ƒhƒAƒbƒv!@pŒăŠÇ—@”’“ŕápŒăŠÇ—‚Ěƒ|ƒCƒ“ƒg. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć60‰ń“ú–{”’“ŕáŠw‰ď‘‰ďE‘ć47‰ń…ť‘ĚŒ¤‹†‰ď (2021/11/26), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722283. [Šw‰ď (‘S‘)] (ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[)yŔ’ˇzpŒăŽ‹‹@”\‚đ’Ç‹‚ˇ‚é”’“ŕáŽĄ—Ă. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć60‰ń“ú–{”’“ŕáŠw‰ď‘‰ďE‘ć47‰ń…ť‘ĚŒ¤‹†‰ď (2021/11/27), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722284. [Šw‰ď (‘S‘)] (ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[) ‚ŽŸ”ń‹…–ĘŒ`ó‚đ—L‚ˇ‚éV‚ľ‚˘’PĹ“_Šá“ŕƒŒƒ“ƒYgTECNIS Eyhanceh‚ĚŒőŠw“ÁŤ. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): ‘ć60‰ń“ú–{”’“ŕáŠw‰ď‘‰ďE‘ć47‰ń…ť‘ĚŒ¤‹†‰ď (2021/11/27), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722285. [Šw‰ď (‘S‘)] (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)yŔ’ˇzŽčpƒŠƒXƒN‚Ć”’“ŕáŽčpí—Ş. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć60‰ń“ú–{”’“ŕáŠw‰ď‘‰ďE‘ć47‰ń…ť‘ĚŒ¤‹†‰ď (2021/11/27), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722286. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€)yŔ’ˇz‰F’ˆˆăŠw‚Ɛ_ŒoŠá‰Č. Îě@‹Ď (ˆă—ÉqśŠw•”): ‘ć59‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2021/12/17), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722287. [Šw‰ď (‘S‘)] (‹¤ĂƒZƒ~ƒi[)yŔ’ˇz“úíf—Ă‚Şƒƒ“ƒ‰ƒ“ƒNƒAƒbƒv‚ˇ‚é_ŒoŠá‰ČŒűŔ. Îě@‹Ď (ˆă—ÉqśŠw•”): ‘ć59‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2021/12/17), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722288. [Šw‰ď (‘S‘)] (‹¤ĂƒZƒ~ƒi[) ŽÎŽ‹f—Á`–˘’m‚Č‚é—Ěˆć‚ց`. ŒăŠÖ—˜–ž1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č): ‘ć59‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2021/12/17), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722289. [Šw‰ď (‘S‘)] (‹¤ĂƒZƒ~ƒi[) Ž‹_Œo‰Š‚Ě‹}ŤŠúŽĄ—Ă‚ľ‚Ä‚˘‚Ü‚ˇ‚Š?@Before NMO‚Š‚çwith NMO‚Ö. ŒăŠÖ—˜–ž1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č): ‘ć59‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2021/12/17), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722290. [Šw‰ď (‘S‘)] (Ž‹”\ŒP—űŽmƒZƒ~ƒi[) “ľEŒŸ¸. óě@ŒŤ (ˆă—ÉqśŠw•”): ‘ć59‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2021/12/18), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722291. [Šw‰ď (‘S‘)] (‘Š’kÇ—á) Hysterical hemianopia—l•Đ‘¤Ž¨‘¤”ź–Ó‚đ’ć‚ľ‚˝“Á”­ŤŽ‹_Œo‰Š‚đ‹^‚¤1—á. ‰~’JN—C1, —´ˆä‰‘Žq1, ‹ŕŽRr‰î1, ‚‹´—m•˝1, ŻŽiMs1, Îě@‹Ď2 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć59‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2021/12/18), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722292. [Šw‰ď (‘S‘)] (‘Š’kÇ—á) ˆę‰ßŤ‚ÉŽ‹—͒ቺ‚đ—ˆ‚ľ‚˝ŹŽ™‚Ě‹U“ű“Ş•‚Žî‚Ěˆę—á. łˆä’qŽq1, Šâ˛^‹|1,2, ŽRă–žŽq1,2, Žá‘q‰ë“o1 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č): ‘ć59‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2021/12/18), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722293. [Šw‰ď (‘S‘)] (‘Š’kÇ—á) Œ´ˆö•s–ž‚Ě—źŠáŤŽ‹_ŒoˆĎk‚Ě1—á. ÂŽR—S—˘1, ŕV‘ş—Tł1, ŽRă–žŽq2,3, ‘ŠŒ´@ˆę1 (1“Œ‘ĺ•a‰@, 2ˆäăŠá‰Č•a‰@, 3Šá‰Č): ‘ć59‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2021/12/18), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722294. [Šw‰ď (‘S‘)] (‹¤ĂƒZƒ~ƒi[)yŔ’ˇzŽ‹_ŒoŇ‘‰Š‚ĆIL-6`”]_Œo“ŕ‰Čˆă‚ĚŽ‹“_, ƒTƒgƒ‰ƒŠƒYƒ}ƒu‚𒆐S‚Ɂ`. Îě@‹Ď (ˆă—ÉqśŠw•”): ‘ć59‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2021/12/18), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723541. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”’“ŕáŽčp‚É‚¨‚Ż‚é•˝‹ĎŽä‹N—Ž‹—Ę‚ĆƒZƒ“ƒgƒƒCƒh’l‚Ě”äŠr (Comparison of mean induced astigmatism and centroid value after cataract surgery). _’J˜aF1, ”Ń“‡@Œh2, ˆŔ“Ą˜a‰ĚŽq2, ‘ěG‹P2, ‚‹´ł‰p2, ŻŽiMs2 (1ˆă—ÉqśŠw•”, 2Šá‰Č): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/8), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723542. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Waterclefts‚ĚƒTƒCƒYE‹ÇÝ‚ĆŽ‹‹@”\|ŒőŠwƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“‚É‚ć‚é‰đÍ|(Impact of Waterclefts on visual function by optical simulation). ŠÖ@—S‰î1, ěŽç“c‘ńŽu2, ŽO“c“N‘ĺ1, ŽRč@•‘1, ‹v•Ű]—1, ˛X–Ř—m1 (1‹ŕ‘ňˆă‘ĺ, 2ˆă—ÉqśŠw•”): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/8), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723543. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰)yŔ’ˇz_ŒoŠá‰Č. ŽRă–žŽq1,2 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/8), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723544. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒŒ[ƒxƒ‹ˆâ“`ŤŽ‹_ŒoÇ‚̉ń•œ—á‚ĚŒŸ“˘ (Clinical feature of visual recovery cases in Leber hereditary optic neuropathy). •Ÿ“c–ƒ“Ţ1, ŽRă–žŽq1,2, ‰–ě”üŘŽq1, Šâ˛^‹|1, ˆäăŒŤŽĄ1, Žá‘q‰ë“o1, Îě@‹Ď3, ˆŔ–{—´”n4, ŸNˆäŒc‘˘4 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č, 3ˆă—ÉqśŠw•”, 4—ŐŒŸ•”): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/8), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723545. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) ‘OŠá•”ŒőŠąÂ’f‘wŒv‚ĹŽB‰e‚ł‚ę‚˝‰ć‘œ‚đŽg—p‚ľ‚˝V‚ľ‚˘ƒqƒg”’“ŕá…ť‘ĚŠj‚Ě•Ş—Ţ (Classification as to the opacification of nucleus of human cataractous lens). ”n“ˆ´”@1, Žsě@Œc2, ‰Á“ĄKm2, ŽđˆäKO2, ‹Ę’u–ž–ě3, Žsěˆę•v2,4 (1Šá‰Č–žŠá‰@, 2’†‹žŠá‰Č, 3JCHO’†‹ž•a‰@, 4Šá‰Č): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/8), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723546. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) ŒőŠwŽŽŠáŽ˛’ˇ‘Ş’č‘•’u‚É‚¨‚Ż‚é‹}Ť‹÷Šp•ÂÇÇ‚ÉŠÖ˜A‚ˇ‚éˆöŽq (Factors related to acute primary angle closure in IOLmasterŇ700). ‰Í–ě—Y—ş1, Š}Œ´łs1, ’Ň‘ň’C•F1, •ÄŽR@—Č1, •˝ŕVˆę–@1, ŻŽiMs1 (1Šá‰Č): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/8), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723547. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) Šá“ŕƒŒƒ“ƒY•ÎˆĘ‚𔺂킸‚ɐ…ť‘ĚŒă•űˆöŽq‚É‚ć‚Á‚Đś‚ś‚˝‘ą”­‹÷Šp•ÂÇ‚Ě1—á (A case of angle closure by retrolenticular mechanism without IOL dislocation). ‘ěG‹P1, –ö“c’q•F1, ŻŽiMs1 (1Šá‰Č): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/8), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723548. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) 0.002%ƒIƒ~ƒfƒlƒpƒOƒCƒ\ƒvƒƒsƒ‹“_Šá‰t‚Ě’ZŠúŹŃ (Short-term results of Omidenepag Isopropyl Ophthalmic Solution 0.002%). Š}Œ´łs (Šá‰Č): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/8), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723549. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Hill-RBF–@Version 2.0‚ĆBeta Version 3.0‚Ě—\‘ސŤ‚Ě”äŠr (Comparison of Predictability of the Hill-RBF method Version 2.0 and 3.0). ”Ń“‡@Œh1, _’J˜aF2, ”Ń“c‰Ă•F1, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/9), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723550. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’´‰š”gƒ`ƒbƒvć’[‚̍ޮż‚Ěˆá‚˘‚É‚ć‚é”j”XƒŠƒXƒN‚Ě•]‰ż (Evaluation of capsule rupture risk by difference of material of ultrasonic tip). Žsě@Œc1,2, “c’†–FŽ÷2, í”ՐšŽi2, “ŕ“Ąˆ¤—2, Žsě—ćŽq2, Žsěˆę•v2,3 (1‘‡ÂŽR•a‰@, 2’†‹žŠá‰Č, 3Šá‰Č): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/9), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723551. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰)yŔ’ˇz—L…ť‘ĚŠá“ŕƒŒƒ“ƒY. Žsěˆę•v1,2 (1’†‹žŠá‰Č, 2Šá‰Č): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/10), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723552. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠŃ’ʍE•t‚ŤŒă–[Œ^—L…ť‘ĚŠá“ŕƒŒƒ“ƒY‚Ě’ˇŠú—Տ°ŹŃ (Long-term clinical results of posterior-chamber phakic lens with central hole). ‚‹´ł‰p1, _’J˜aF2, ‘ěG‹P1, ˆŔ“Ą˜a‰ĚŽq1, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/10), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723553. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —L…ť‘ĚŠá“ŕƒŒƒ“ƒYŽčp‚¨‚Ż‚éŘŠJ•”ˆĘ•Ę‚ĚŽä‹N—Ž‹‚Ě”äŠr (Comparison of surgical induced astigmatism after phakic intraocular lens surgery). ˆŔ“Ą˜a‰ĚŽq1, _’J˜aF2, ‚‹´ł‰p1, ‘ěG‹P1, ŒÜ\—’ÍŽj1,3, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”, 3ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/10), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723554. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) łíŠá‚É‚¨‚Ż‚éFŽ‹—͂̉Á—•Ď‰ť Aging change of color visual acuity in normal eyes. ‰ĄŽR@ăÄ1, “c’†–FŽ÷2, “´ˆä—˘ŠG2, Ź‘ ‘ńŠC3, ’†‘ş‰pŽ÷4, “c’†@´3, Žsěˆę•v2,5 (1JCHO’†‹ž•a‰@, 2’†‹žŠá‰Č, 3MB‘ĺ, 4–ź“ŒŠá‰Č, 5Šá‰Č): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/10), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723555. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒGƒsƒiƒXƒ`ƒ“‰–Ž_‰–0.1%‚Ě“ľE‚ɑ΂ˇ‚éě—p Effect of epinastine hydrochloride 0.1% eye-drops on pupil diameter. —´ˆä‰‘Žq1, •˝ŕVˆę–@1, óě@ŒŤ2, Îě@‹Ď2, ‹g•yŒ’Žu3, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”, 3•Ÿ‰Ş‘Űˆă—Ă•ŸŽƒ‘ĺ): ‘ć125‰ń“ú–{Šá‰ČŠw‰ď‘‰ď (2021/4/10), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723556. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒgƒ‰ƒxƒNƒg[ƒ€Žčp‘OŒă‚ĚŽ‹–ě•Ď‰ť. Š}Œ´łs1, ‰Í–ě—Y—ş1, •˝ŕVˆę–@1, •ÄŽR@—Č1, ŻŽiMs1 (1Šá‰Č): ‘ć10‰ń“ú–{Ž‹–ě‰ć‘œŠw‰ďŠwpW‰ď (2021/4/24), WebŠJĂ.

723557. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Ć–žÝŒv‰đÍƒ\ƒtƒg‚đ—p‚˘‚˝Šá“ŕƒŒƒ“ƒYŽ˛ŠO“üŽËŒő‚Ě–ŔŒő‰đÍ. ěŽç“c‘ńŽu1, ”ź“c’m–ç1, ŻŽiMs2 (1ˆă—ÉqśŠw•”, 2Šá‰Č): ‘ć10‰ń“ú–{Ž‹–ě‰ć‘œŠw‰ďŠwpW‰ď (2021/4/24), WebŠJĂ.

723558. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”]ŽžŠł‚É‚¨‚Ż‚éƒwƒbƒhƒ}ƒEƒ“ƒgŒ^Ž‹–ěŒvuƒAƒCƒ‚v‚Ćƒnƒ“ƒtƒŠ[Ž‹–ěŒv‚ĚŽ‹–ě‚Ěˆę’vŤ‚ĚŒŸ“˘. â–{–ƒ—˘1, ŕV‘ş—Tł2, ‘ŠŒ´@ˆę2, ŒăŠÖ—˜–ž3,4, ’r“c“N–ç5, Îě@‹Ď6, ’†‘ş@˝1 (1_ŒË‘ĺ, 2“Œ‹ž‘ĺ, 3Šá‰Č, 4‘Űˆă—Ă•ŸŽƒ‘ĺE”MŠC, 5ŽR‰¤•a‰@, 6ˆă—ÉqśŠw•”): ‘ć10‰ń“ú–{Ž‹–ě‰ć‘œŠw‰ďŠwpW‰ď (2021/4/24), WebŠJĂ.

723559. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒCƒ[ƒWƒKƒCƒhƒVƒXƒeƒ€‚đ—p‚˘‚˝ƒg[ƒŠƒbƒNŠá“ŕƒŒƒ“ƒY355TpŒăŹŃ. ŽđˆäKO1, Ź“‡—˛Ži2, ‹Ę’u–ž–ě3, ŕV–ŘˆťŽq3, ‰F‘ÉŒbŽq1, “´ˆä—˘ŠG1, ‰Í–ěúuL1, Žsěˆę•v1,4 (1’†‹žŠá‰Č, 2Œcœä‘ĺ, 3JCHO’†‹ž•a‰@, 4Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/25), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723560. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Žá”N‘w‚̋ߎ‹Šá‚É‚¨‚Ż‚é—‡ŠáŽ‹—Í‚Ć‹üÜ“x”‚ĚŠÖŒW. ăŽR@•–1, _’J˜aF2, Šąě—˘ŠG2, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/25), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723561. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’PĹ“_Šá“ŕƒŒƒ“ƒY‘}“üŠá‚̉“’†‹ß‹——Ł—‡ŠáŽ‹—Í‚ĚŒŸ“˘. ‰Á“ĄKm1, Ź“‡—˛Ži2, ‹Ę’u–ž–ě3, “c’†–FŽ÷1, ŽO“c‘ş–ƒ—˘1,4, Žsěˆę•v1,5 (1’†‹žŠá‰Č, 2Œcœä‘ĺ, 3JCHO’†‹ž•a‰@, 4Šň•ŒÔ\Žš•a‰@, 5Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/25), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723562. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) MiLoop‚đŽg—p‚ľ‚˝”’“ŕáŽčp‚̏‰ŠúŽčpŽg—pŽž‚Ě•]‰ż. Žsě@Œc1,2, Ź“‡—˛Ži3, ŽđˆäKO2, í”ՐšŽi2, Žsě—ćŽq2, Žsěˆę•v2,4 (1‘‡ÂŽR•a‰@, 2’†‹žŠá‰Č, 3Œc‰ž‘ĺ, 4Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/25), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723563. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) üˆŰ’Œ‘ѐ؏œp‚Ş•˝‹ĎŽä‹N—Ž‹‚âdS’l‚É‹y‚Ú‚ˇ‰e‹ż. ˆŔ“Ą˜a‰ĚŽq1, _’J˜aF2, ”Ń“c‰Ă•F1, ”Ń“‡@Œh1, ’Ň‘ň’C•F1, “Ą‘ş•‡˛Žq2, Šąě—˘ŠG2, Š}Œ´łs1, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/25), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723564. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ZeptoҎŠ“Ž‘OůNŘŠJ‘•’u‚đ—p‚˘‚˝Šá‰ČęUˆă‚É‚ć‚é”’“ŕáŽčp‚Ě’ZŠúŹŃ. Žu‰ę@—D1, Ź“‡—˛Ži2, Žsě@Œc3, ŽO“c‘ş–ƒ—˘3, “c’†–FŽ÷3, ‹g“c‘Ľ•F1, Žsěˆę•v3,4 (1Šň•ŒÔ\Žš•a‰@, 2Œcœä‘ĺ, 3’†‹žŠá‰Č, 4Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723565. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”’“ŕáŽčp‚É‚¨‚Ż‚éACTIVE CENTRY?ƒnƒ“ƒhƒs[ƒX‚ĚŽg—p‚É‚ć‚é‰e‹ż‚ĚŒŸ“˘. ŕV–ŘˆťŽq1, Ź“‡—˛Ži2,3, “ŕ“Ąˆ¤—3, “´ˆä—˘ŠG3, Žsěˆę•v3,4 (1JCHO’†‹ž•a‰@, 2Œcœä‘ĺ, 3’†‹žŠá‰Č, 4Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723566. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠOŤŽU“ľ‹y‚Ń“řĘˆĎk‚ɑ΂ľ‚ăVƒŠƒRƒ“ťlŒű“řĘˆÚAp‚đŽ{s‚ľ‚˝2—á. –ěŒűŠ@“l1, ŕV–ŘˆťŽq1, “´ˆä—˘ŠG2, Ź“‡—˛Ži2,3, Žsěˆę•v2,4 (1JCHO’†‹ž•a‰@, 2’†‹žŠá‰Č, 3Œcœä‘ĺ, 4Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723567. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”’“ŕáŽčp’†‚É—p‚˘‚˝ˆŮ‚Č‚é“ľEŠg’ŁƒfƒoƒCƒX‚É‚ć‚épŒăŹŃ‚ĚŒŸ“˘. ŽO“c‘ş–ƒ—˘1,2, Ź“‡—˛Ži1,3, ‰F‘ÉŒbŽq1, ‹´’Ü—Ç‘ž4, ŕV–ŘˆťŽq4, Žsě@Œc5, Žsěˆę•v1,6 (1’†‹žŠá‰Č, 2Šň•ŒÔ\Žš•a‰@, 3Œcœä‘ĺ, 4JCHO’†‹ž•a‰@, 5‘‡ÂŽR•a‰@, 6Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723568. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œ’íŠá‚É‚¨‚Ż‚éAngle-to-Angle‚ĚŒŸ“˘. ‰iŁx‹K1, ˆÉ“Ą”üšŠG1, ’r“c“N–ç1, ´…Œö–ç1,2 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723569. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰~Šp–Œ—pKaneŽŽ‚đŽg—p‚ľ‚˝”’“ŕápŒă‹üÜŒëˇ‚Ě‘˝Ž{ÝŒ¤‹†. ‰Í–ěéL1, Ź“‡—˛Ži2, ‹Ę’u–ž–ě3, ‰Á“ĄKm1, ŽđˆäKO1, “´ˆä—˘ŠG1, “c’†–FŽ÷1, Žsěˆę•v1,4 (1’†‹žŠá‰Č, 2Œcœä‘ĺ, 3JCHO’†‹ž•a‰@, 4Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723570. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹ć•Ş‹üÜ—Ś‚đ—p‚˘‚˝’ˇE’ZŠáŽ˛’ˇŠá‚Ě”’“ŕápŒă—\‘Ş‹üÜŒëˇ‚ÉŠÖ‚ˇ‚錟“˘. ‹Ę’u–ž–ě1, Ź“‡—˛Ži2, ˛“Ą—T–ç3, —ŻŽç—Ç‘ž4, “n粌hŽO5, ’ˇ’JěˆŸ—˘1, ŕV–ŘˆťŽq1, ‰Á‰ę’BŽu1,7, Žsě@Œc6, Žsěˆę•v6,7 (1JCHO’†‹ž•a‰@, 2Œcœä‘ĺ, 3˛“Ą—T–çŠá‰Č, 4ƒgƒƒ‚ƒŠŠá‰ČEŒ`ŹŠO‰Č, 5“ě‘ĺăƒAƒCƒNƒŠƒjƒbƒN, 6’†‹ž•a‰@, 7Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723571. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) isŤ‰~Šp–Œ‚ɑ΂ˇ‚鍂‘ŹŠp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO‚̏pŒă4”NŠÔ‚̐ŹŃ. ’ˇ’JěˆŸ—˘1,2, Ź“‡—˛Ži1,2,3, ź“c’m–ç2, ’†‘ş—Fş2, ‰Á‰ę’BŽu1,5, Žsěˆę•v4,5 (1JCHO’†‹ž•a‰@, 2–źŒĂ‰ŽƒAƒCƒNƒŠƒjƒbƒN, 3Œcœä‘ĺ, 4’†‹žŠá‰Č, 5Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/26), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723572. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ICL‚ĚƒTƒCƒY•ĎXŒă‚ĚVault‚̕ωť—Ę. ’†‘ş—Fş1, ‹g“c—zŽq1, …–ě‘׎q1, ˆé’JŽ‹P1, ź“c’m–ç1, Ź“‡—˛Ži1,2, Žsěˆę•v3,4 (1–źŒĂ‰ŽƒAƒCƒNƒŠƒjƒbƒN, 2Œcœä‘ĺ, 3’†‹žŠá‰Č, 4Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/27), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723573. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Implantable collamer lensŽčp‘OŒŸ¸‚É‚¨‚Ż‚é‹üÜŒŸ¸‚ɂ‚˘‚Ä‚ĚŒŸ“˘. “´ˆä—˘ŠG1, ź“c’m–ç2, Ź“‡—˛Ži3, ’†‘ş—Fş2, Žsěˆę•v1,4 (1’†‹žŠá‰Č, 2–źŒĂ‰ŽƒAƒCƒNƒŠƒjƒbƒN, 3Œcœä‘ĺ, 4Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/27), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723574. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰~Šp–ŒŠłŽŇ‚É‚¨‚Ż‚é“úíśŠˆKŠľƒAƒ“ƒP[ƒg’˛¸Œ‹‰Ę. Ź“‡—˛Ži1, ź“c’m–ç2, —é–ؓމ›2, ’†‘ş—Fş2, ”’ˆä—D‘ž3, “n•”@ŠÂ3, ˛“Ą—T–ç3, Žsěˆę•v4,5 (1Œc‰ž‘ĺ, 2–źŒĂ‰ŽƒAƒCƒNƒŠƒjƒbƒN, 3˛“Ą—T–çŠá‰Čˆă‰@, 4’†‹žŠá‰Č, 5Šá‰Č): ‘ć36‰ńJSCRSŠwp‘‰ď (2021/6/27), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723575. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒIƒ“ƒ‰ƒCƒ“Žö‹Ć‚É‚ć‚é‹ßŒŠ”˝‰ž‚̕ωť‚ĆŠáÇóEg‘Ě”ć˜J‚ĚŒŸ“˘. Œ´@’źl1, Š™“c‘׏˛1, Žs–Ń—˘•ŕ1, ˛“Ą•‘–í1, ťŒ´‰i—˘Žq1, ‘ę“cžxŘ1, í”Ő—B1, ”ň“cç—T1, Ş–{’m“T1, –ČŠŃ仍Ř1, Vˆä“cF—T1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw•ŰŒ’ˆă—ĂŠw•”, 2Šá‰Č): ‘ć77‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ď (2021/7/2), _“ސě (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723576. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ź“c–@‚Ş’˜Œř‚ľ‚˝DuaneÇŒóŒQ1Œ^‚Ě3—á. ’r“cNm1, ŒăŠÖ—˜–ž2,3, ÎěŒb—˘1, “c’†—Tˆę˜N1, Ź‘ň’‰•F1 (1Ź‘ňŠá‰Č“ŕ‰Č•a‰@, 2‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 3Šá‰Č): ‘ć77‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ď (2021/7/2), _“ސě (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723577. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒfƒWƒ^ƒ‹ƒfƒoƒCƒX‚ŞŒ´ˆö‚ĆŽv‚í‚ę‚éŒă“V‹¤“ŻŤ“ŕŽÎŽ‹‚ĚŽĄ—ĂŒo‰ß. ˆŔ“Ą—F‹I1, ŒăŠÖ—˜–ž1,2,3, ŒN“‡^ƒ1, Š—ś^—˘1, ’ß“cŘ“E1, ŒË’˘aŽq1, ŸNˆä—•Žq1,2, Žs糋`Í1,2 (1_“ސ쎕‘ĺE‰Ą•l, 2Šá‰Č, 3‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@): ‘ć77‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ď (2021/7/2), _“ސě (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723578. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) śŽY”N—î‚đ‘ÎŰ‚Ć‚ľ‚˝ŠáˆĘ‚Ć‹üÜˆŮí‚ĚŠÖŒW. ‚‹´T–ç1, ŒăŠÖ—˜–ž2,3, –ě“cMŒá1, ’ˇ’Jěx1, ÎěŒb—˘1, “c’†—Tˆę˜N1, Ź‘ň’‰•F1 (1Ź‘ňŠá‰Č“ŕ‰Č•a‰@, 2‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 3Šá‰Č): ‘ć77‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ď (2021/7/2), _“ސě (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723579. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰“•űŽ‹, ‹ß•űŽ‹‚Ĺ“ŕŽÎŽ‹‚đ’悡‚éDistance-independent esotropia‚ĚŠáâ|MRI‰ć‘œ‚Ě“Á’Ľ. ‰Í‡ˆ¤ŽŔ1,2, ŒăŠÖ—˜–ž2,3, Îě@‹Ď1,4, —´ˆä‰‘Žq2, —›@g—z5, •‚F—´‘ž˜Y6, ŻŽiMs1,2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2Šá‰Č, 3‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 4ˆă—ÉqśŠw•”, 5Žń“sˆă‰Č‘ĺ–k‹ž—F‹bˆă‰@, 6•úŽËü (‰ć‘œ)): ‘ć77‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ď (2021/7/2), _“ސě (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723580. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) “ŞˆĘˆŮí‚ŞSpot vision Screener‚Ě‘Ş’čŒ‹‰Ę‚É—^‚Ś‚é‰e‹ż. Ł•”ˆ¤”ü1, ŒăŠÖ—˜–ž1,2, ‰–’J’źŽq1, Ż@ŒŞŹ3 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č, 3‘Űˆă—Ă•ŸŽƒ‘ĺŠwŹ“c•a‰@): ‘ć77‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ď (2021/7/2), _“ސě (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723581. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) ‰đ—ŁŤ”]“Ž–ŹáŽ‚ŞŒ´ˆö‚Ĺ”­Ç‚ľ‚˝Œă“VŤŠŠŽÔ_Œo–ƒáƒ‚Ěˆę—á. ‘ĺXçš1,2, ŒăŠÖ—˜–ž1,3, “n•Óˆę˜Y1, ’ˇ’Jě‰p–Ť1,2, ‘PĎ“N–ç4 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2’ˇ’JěŠá‰Č, 3Šá‰Č, 4‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@”]_ŒoŠO‰Č): ‘ć77‰ń“ú–{ŽăŽ‹ŽÎŽ‹Šw‰ď‘‰ď (2021/7/3), _“ސě (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723582. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒNƒƒXƒŠƒ“ƒLƒ“ƒOŽ{sŒăƒn[ƒhƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‚đ‘•—p‚ľ‚˝‰~Šp–Œ‚ĚŠp–ŒŒ`ó. ŒF”WŒä“°—˛1, ˆÉ“ĄŽé—1, ‚‹´ł‰p1, ‹ŕŽRr‰î1, ˆŔ“Ą˜a‰ĚŽq1, ‰F’ĂŒŠ‹`ˆę1, _’J˜aF2, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ƒtƒH[ƒTƒ€2021 (‘ć63‰ń“ú–{ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYŠw‰ď‘‰ď) (2021/7/24), ĺ‘ä (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723583. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’PĹ“_Šá“ŕƒŒƒ“ƒYpŒă‚Ě‘˝Ĺ“_ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒY‚Ć‘˝Ĺ“_Šá“ŕƒŒƒ“ƒY‚ĚŽ‹‹@”\”äŠr. _’J˜aF1, X@—mÄ2, ‹{“c˜a“T2, •˝‰ŞF_3 (1ˆă—ÉqśŠw•”, 2‹{“cŠá‰Č, 3’}”g‘ĺ): ƒtƒH[ƒTƒ€2021 (‘ć63‰ń“ú–{ƒRƒ“ƒ^ƒNƒgƒŒƒ“ƒYŠw‰ď‘‰ď) (2021/7/24), ĺ‘ä (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723584. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”––ž‰ş‚É‚¨‚Ż‚é‹üÜ‹y‚ŃŽ‹‹@”\•Ď‰ť. ”Ń’Ë’B–ç1, ěŽç“c‘ńŽu2, ”ź“c’m–ç2, Îě@‹Ď2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”): ‘ć57‰ń“ú–{ŠáŒőŠwŠw‰ď‘‰ď (2021/9/4), WebŠJĂ.

723585. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œő”g’ˇ§ŒäƒŒƒ“ƒY‚đ—p‚˘‚˝ŽăŽ‹Šá‚ĚƒRƒ“ƒgƒ‰ƒXƒgŠ´“xŒüăŒř‰Ę‚ĚŒŸ“˘. ’†’ˏGŽi1, ”ź“c’m–ç2, ˆÉ“Ą”Ž—˛1, “n粒ql1, –Ű–ě‹v”üŽq1 (1Š ’J–L“c‘‡•a‰@, 2ˆă—ÉqśŠw•”): ‘ć57‰ń“ú–{ŠáŒőŠwŠw‰ď‘‰ď (2021/9/5), WebŠJĂ.

723586. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰)yŔ’ˇzŠázŠÂ. ŻŽiMs (Šá‰Č): ‘ć32‰ń“ú–{—ΓŕáŠw‰ď (2021/9/10), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723587. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) •Ď•Ş‹ßŽ—ƒxƒCƒYüŒ`‰ń‹A‚đ—p‚˘‚˝2‚‚̐V‚ľ‚˘Ž‹–ě‘Ş’čƒAƒ‹ƒSƒŠƒYƒ€‚ĆSITA-Fast‚Ě”äŠr (Comparing new algorithms based on the variational Bayes linear regression and SITA-Fast). ŔŕV—E‹P1, ‘ş“c”ŽŽj2, ’Š‰Ş@—ş3,4, •˝ŕVˆę–@1, ź–ě–Gˆß1, “‡“c@ŒŤ, ŻŽiMs1 (1Šá‰Č, 2“Œ‹ž‘ĺ, 3š—ę•lź•a‰@, 4š—ęƒNƒŠƒXƒgƒtƒ@[‘ĺ): ‘ć32‰ń“ú–{—ΓŕáŠw‰ď (2021/9/10), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723588. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒgƒ‰ƒxƒNƒƒgƒ~[Šá“ŕ–@‚É‚¨‚Ż‚ép’†–[…Ă–Ź“Ž‘ԕʂ̐ŹŃ (Evaluation of the effectiveness of ab internotrabeculotomy by aqueous humor outflow). •ÄŽR@—Č1, Š}Œ´łs1, ‰Í–ě—Y—ş1, ŻŽiMs1 (1Šá‰Č): ‘ć32‰ń“ú–{—ΓŕáŠw‰ď (2021/9/11), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723589. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Trabectome‚ĆMicrohooküˆŰ’Œ‘ѐ؊JppŒăŹŃ‚đ”äŠr‚ˇ‚é‘˝Ž{ÝŒă‚ëŒü‚ŤŠĎŽ@Œ¤‹† (Trabectome vs. Microhook Trabeculotomy Comparative Study; TramTrac Study). ˇ’‘ž˜N1, ŻŽiMs2, ’JŒËłŽ÷3, ‰ĄŽR@—I4, ‹T“c—˛”Í5, ŻŽi‘ń•˝6, aăŽu˜N7, âV“Ą—Y‘ž8, Î“c‹ąŽq9,10, A“cr•F11, ’†‘ş@˝1 (1_ŒË‘ĺ, 2Šá‰Č, 3“‡Ş‘ĺ, 4“Œ–k‘ĺ, 5‹ž“s‘ĺ, 6é‹Ęˆă‘ĺ, 7ˆ¤•Q‘ĺ, 8ş˜a‘ĺ, 9ˆäăŠá‰Č•a‰@, 10“Œ–M‘ĺE‘ĺ‹´, 11“ń–{źŠá‰Č•a‰@): ‘ć32‰ń“ú–{—ΓŕáŠw‰ď (2021/9/11), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723590. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) —ΓŕáŠłŽŇ‚É‚¨‚Ż‚é㵖ž‚ւ̉e‹żˆöŽq‚ĚŒŸ“˘ (Factors affecting photophobia in glaucoma patients). ÔÎ‘ň’q”ż1, “Ą‘ş•‡˛Žq2, ŠFě—FŒ›1, ˛“ĄM”V1, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć32‰ń“ú–{—ΓŕáŠw‰ď (2021/9/11), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723591. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) RŒŒđ–ň•ž—p‚Ě—L–ł‚É‚ć‚éƒgƒ‰ƒxƒNƒg[ƒ€Žčp‚̐ŹŃ (The effect of antithrombotic therapy in trabectome surgery). ‰Í–ě—Y—ş1, Š}Œ´łs1, •˝ŕVˆę–@1, •ÄŽR@—Č1, ŻŽiMs1 (1Šá‰Č): ‘ć32‰ń“ú–{—ΓŕáŠw‰ď (2021/9/12), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723592. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰)yŔ’ˇzŕh‰ßŽčp2@Filtration surgery 2. ŻŽiMs (Šá‰Č): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/28), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723593. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰)yŔ’ˇz‰~Šp–Œ/Šg’ŁÇ 1 Keratoconus/ectasia. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/28), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723594. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) isŤƒyƒ‹[ƒVƒhŠp–Œ•Ó‰•ĎŤ‚ɑ΂ˇ‚éƒJƒXƒ^ƒ}ƒCƒYƒhŠp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO‚Ě—Ő°ŹŃ. ‚‹´ł‰p1,2, _’J˜aF3, ‘ěG‹P2, ’Ň‘ň’C•F2, ˆŔ“Ą˜a‰ĚŽq2, ŻŽiMs2 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰Č, 3ˆă—ÉqśŠw•”): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/28), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723595. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —ΓŕáŤ’†SŽ‹–ěáŠQ‚đ‡•š‚ľŽ‹_Œo‰Š‚Ć‚ĚŠÓ•Ę‚É‹ę—ś‚ľ‚˝Leberˆâ“`ŤŽ‹_ŒoÇ—á. ÂŽR—S—˘1, ŽRă–žŽq2,3, ‘ŠŒ´@ˆę1, ŕV‘ş—Tł1 (1“Œ‹ž‘ĺ, 2ˆäăŠá‰Č•a‰@, 3Šá‰Č): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/28), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723596. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘“ŕ‘˝Ž{Ý‹¤“ŻŒ¤‹†‚É‚ć‚é—Ž‹űÇŒóŒQ‚É‚¨‚Ż‚é”’“ŕáŽčp‚ĚŒŸ“˘ (‘ć1•ń: ŠłŽŇ”wŒi). _’J˜aF1, ‹˝‰E‹ß”ŽN2, X@—mÄ3, ‹{“c˜a“T3, ŽÄ@‘ô–ç4, Ź“‡—˛Ži5 (1ˆă—ÉqśŠw•”, 2Šá‰Č, 3‹{“cŠá‰Č, 4˜Z–{–ŘŽÄ•a‰@, 5Œc‰ž‘ĺ): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/28), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723597. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘“ŕ‘˝Ž{Ý‹¤“ŻŒ¤‹†‚É‚ć‚é—Ž‹űÇŒóŒQ‚Ě”’“ŕáŽčp‚ĚŒŸ“˘ (‘ć2•ń: ŽčpƒAƒEƒgƒJƒ€). X@—mÄ1, _’J˜aF2, ‹˝‰E‹ß”ŽN3, Ź“‡—˛Ži4, ŽÄ@‘ô–ç5, ‹{“c˜a“T1 (1‹{“cŠá‰Č•a‰@, 2ˆă—ÉqśŠw•”, 3Šá‰Č, 4Œcœä‘ĺ, 5˜Z–{–ŘŽÄŠá‰Č): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/28), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723598. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘OŠá•”ŒőŠąÂ’f‘wŽB‰e‚É‚ć‚éŒă–[Œ^—L…ť‘ĚŠá“ŕƒŒƒ“ƒYƒTƒCƒY—\‘ŞŽŽ (KSŽŽver.4). ŒÜ\—’ÍŽj1,2, ‰Á“ĄŽŃ–1, ‰iŁx‹K1, ´…Œö–ç1,2 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰Č): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/28), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723599. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Photorefractive Intrastromal Corneal Collagen Cross-Linking (PiXL) ‚Ě—Ő°ŹŃ. Ź“‡—˛Ži1,2, •Đ‰Ş“”Ž1, ź“c’m–ç1, ˆé’JŽ‹P1, ‹g“c—zŽq1, ’†‘ş—Fş1, Žsěˆę•v3,4 (1–źŒĂ‰ŽƒAƒCƒNƒŠƒjƒbƒN, 2Œcœä‘ĺ, 3’†‹žŠá‰Č, 4Šá‰Č): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/28), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723600. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’á‰Á“ü“x”•ŞßŒ^Šá“ŕƒŒƒ“ƒY‘}“üŠá‚ĚƒŒƒ“ƒYˆĘ’u‚ƏpŒăŽ‹‹@”\. —`…@Šw1,2, ´…Œö–ç1,2, ‰iŁx‹K1, ŒÜ\—’ÍŽj1,2 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2Šá‰Č): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/28), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723601. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”N—î•Ę‚Ě‘źŠo“I‰ńů•ÎˆĘ“x‚ĚŒŸ“˘. ‚‹´T–ç1, ŒăŠÖ—˜–ž2,3, –ě“cMŒá1, ’ˇ’J•”x1, ě–ě•Ó“O1, źč‘ń–ç1, ’r“c—őm1, ÎěŒb—˘1, “c’†—Tˆę˜N1, Ź‘ň’‰•F1 (1Ź‘ňŠá‰Č“ŕ‰Č•a‰@, 2‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 3Šá‰Č): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/29), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723602. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹ŕ‘ŽƒAƒŒƒ‹ƒM[ŠłŽŇ‚ɏɎq‘ĚŽčp‚đs‚Á‚˝2Ç—á. ŠFě—FŒ›1, –ö“c’q•F1, t–ؐ’G1, ˛“ĄM”V1, ŻŽiMs1 (1Šá‰Č): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/30), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723603. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠÔŒ‡ŤŠOŽÎŽ‹‚ɑ΂ˇ‚é“ŕ’ź‹ŘplicationpŒă‚Ě‹üÜ•Ď‰ť. ŸNˆä—•Žq1,2, ŒăŠÖ—˜–ž1,2,3, ŒN“‡^ƒ1, Žs糋`Í1,2, ŻŽiMs2 (1_“ސ쎕‘剥•lƒNƒŠƒjƒbƒN, 2Šá‰Č, 3‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/30), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723604. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒXƒeƒB[ƒvŠp–ŒŠá‚ɑ΂ˇ‚éŠá“ŕƒŒƒ“ƒY“x”ŒvŽZŽŽ‚Ě—\‘ސŤ‚Ě”äŠr. ”Ń“‡@Œh1, _’J˜aF2, ”Ń“c‰Ă•F1, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/31), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723605. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹ßŽ‹LASIKŒă‚ĚŠá“ŕƒŒƒ“ƒY“x”ŒvŽZŽŽ‚Ě”äŠr. íœAr‘ž˜Y1,2,3, ´…Œö–ç1,2, ˛“Ą@Ži2, ’r“c“N–ç1,2,3, ŒÜ\—’ÍŽj1,2, —`…@Šw1,2,3 (1ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[, 2‘Űˆă—Ă•ŸŽƒ‘ĺ, 3Šá‰Č): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/10/31), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723606. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) ƒ}ƒCƒNƒƒpƒ‹ƒX–Ń—l‘ĚŒő‹ĂŒĹp, ‚¨‚ć‚ђljÁ—ΓŕáŽčp‚̐ŹŃ. ’Ň‘ň’C•F1, ŻŽiMs1, Š}Œ´łs1, ‰Í–ě—Y—ş1 (1Šá‰Č): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/11/22), ƒIƒ“ƒfƒ}ƒ“ƒh”zM.

723607. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) Œă–[Œ^—L…ť‘ĚŠá“ŕƒŒƒ“ƒY‚’źŒĹ’č‚É‚¨‚Ż‚évault‚ĚŒoŽž•Ď‰ť‚Ć‹üÜ‚ւ̉e‹ż. ˆŔ“Ą˜a‰ĚŽq1, _’J˜aF2, ‘ěG‹P1, ’Ň‘ň’C•F1, ‚‹´ł‰p1,3, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”, 3ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/11/22), ƒIƒ“ƒfƒ}ƒ“ƒh”zM.

723608. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) ‰“Ž‹—}§ŽĄ—Ă“IŠp–ŒŘœp (HC-PTK) ‚Ə]—ˆPTK‚ĚŽ‹—́E‹üÜ•Ď‰ť‚Ě”äŠr. ‘ěG‹P1, _’J˜aF2, ˆŔ“Ą˜a‰ĚŽq1, ’Ň‘ň’C•F1, ‚‹´ł‰p1,3, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”, 3ŽR‰¤•a‰@ƒAƒCƒZƒ“ƒ^[): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/11/22), ƒIƒ“ƒfƒ}ƒ“ƒh”zM.

723609. [Šw‰ď (‘S‘)] (Šwp“WŽŚ) Soemmering—ւ𔺂¤–Ń—l‘ĚƒuƒƒbƒN‚É‚ć‚é‘ą”­•ÂÇ‹÷Šp‚Ě1—á. ’r‘ş—LŠŽ1, ”Ń“c‰Ă•F1, ‚–ŘŒ˜‘ž˜Y1, –ö“c’q•F1, ŻŽiMs1 (1Šá‰Č): ‘ć75‰ń“ú–{—Տ°Šá‰ČŠw‰ď (2021/11/22), ƒIƒ“ƒfƒ}ƒ“ƒh”zM.

723610. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹ßŽ‹‚̉ߋ¸łŠá‹ž‘•—p‰ş‚Ĺ‚ĚƒXƒ}[ƒgƒtƒHƒ“‚ĚŽg—p‚Ş“ŕŽÎŽ‹‚Ě—Uˆö‚Ć‚Č‚Á‚˝1Ç—á. •D“cŘ‰›1, –î–ě@—˛1, ‘ŠŕV‘ĺ•ă2,3, _ŽR‚Ć‚ć‚Ý2,3 (1ŠC˜V–źƒvƒ‰ƒU, 2ŠC˜V–ź‘‡•a‰@, 3Šá‰Č): ‘ć62‰ń“ú–{Ž‹”\‹¸łŠw‰ď (2021/11/20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723611. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Total Keratometry‚đ—p‚˘‚˝LASIKŒăŠá‚É‚¨‚Ż‚é”’“ŕápŒă‹üÜŒëˇ‚ĚŒŸ“˘. ź‘ş‚ ‚Š‚Ë1, Ź“‡—˛Ži2, ‹Ę’u–ž–ě3, ŽđˆäKO1, Žsěˆę•v1,4 (1’†‹žŠá‰Č, 2Œc‰ž‹`m‘ĺŠw, 3JHCO’†‹ž•a‰@, 4Šá‰Č): ‘ć62‰ń“ú–{Ž‹”\‹¸łŠw‰ď (2021/11/20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723612. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ”N’ˇŽ™‚É‚¨‚Ż‚é“Ç‚Ý”\—Í‚ĆŽ‹‹@”\ˆŮí‚Ć‚ĚŠÖŒW. ‰Ş–ě^‹|1, ‚‹´—RŽk1, ˛“Ą@Ži1, Ž˝Œ´”üŠó1, “ŕě‹`˜a1, Vˆä“cF—T1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺEŽ‹‹@”\—Ă–@, 2Šá‰Č): ‘ć62‰ń“ú–{Ž‹”\‹¸łŠw‰ď (2021/11/20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723613. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Ă“I—§ˆĘŽž‚É‚¨‚Ż‚銊“ŽŤ’Ǐ]Šá‹…‰^“Ž•‰‰×Žž‚̏dS“Ž—h‚ĚŽü”g”“ÁŤ‚ɂ‚˘‚Ä‚ĚŒŸ“˘. “ŕě‹`˜a1, rˆä”ü•ä1, •ěˆ¤–í”T1, ˛“Ą‰~1, Ž›ŽR”ü•ä1, ś“c–Ú”üŠC1, “n糁@‘ĺ1, ‰Ş–ě^‹|1, ‚‹´—RŽk1, Vˆä“cF—T1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺEŽ‹‹@”\—Ă–@, 2Šá‰Č): ‘ć62‰ń“ú–{Ž‹”\‹¸łŠw‰ď (2021/11/20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723614. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ’ˇŠáŽ˛Šá‚É‚¨‚Ż‚éŠáŽ˛’ˇ‘Ş’čŽž‚ĚŒĹŽ‹ó‘Ô‚Ć‹üÜŒëˇ‚ĚŠÖ˜AŤ‚ĚŒŸ“˘. ‰F‘ÉŒbŽq1, Ź“‡—˛Ži2, “´ˆä—˘ŠG1, ‰ĄŽR@ăÄ3, “c’†–FŽ÷1, ŽđˆäKO1, —]“cçŒb1, ‹Ę’u–ž–ě3, Žsěˆę•v1,4 (1’†‹žŠá‰Č, 2Œc‰ž‹`m‘ĺŠw, 3JHCO’†‹ž•a‰@, 4Šá‰Č): ‘ć62‰ń“ú–{Ž‹”\‹¸łŠw‰ď (2021/11/20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723615. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ŠááŮázšŠłŽŇ‚Ö‚ĚŽŐŒőŠá‹žˆ•ű. ’†‘şH•ä1, “yŽt‚Š‚ł‚Ë1, ŽÄ“c‘ń–ç2, ˆÉ“Ą—T”ü3, ˆîˆä—˛‘ž4, Îˆä—SŽq1, “ě‰_@Š˛1, ŽRă–žŽq1,5, ˆäăŒŤŽĄ1 (1ˆäăŠá‰Č•a‰@, 2źŠ‹źEˆäăŠá‰Č•a‰@, 3‘ĺ‹{EˆäăŠá‰ČƒNƒŠƒjƒbƒN, 4ŽD–yEˆäăŠá‰ČƒNƒŠƒjƒbƒN, 5Šá‰Č): ‘ć62‰ń“ú–{Ž‹”\‹¸łŠw‰ď (2021/11/20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723616. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Šá‰ČŒŸ¸Œ‹‰Ę‚Ě•\‹L•ű–@‚ÉŠÖ‚ˇ‚éƒAƒ“ƒP[ƒg’˛¸. •Ä“c@„1,2, ‰Ą“c•qŽq2,3, “c–ěă‹ąŽq2,4, ‹›Z˜a‘ă2,5, Vˆä“cF—T2,6,7 (1ěčˆă•Ÿ‘ĺ, 2‘S‘Ž‹”\ŒP—űŽmŠwZ‹Ś‰ď, 3‘ĺăˆă•ž, 4‘ĺ•ŞŽ‹”\ę, 5ź‹łˆă, 6‘Űˆă•Ÿ‘ĺ, 7Šá‰Č) ‘ć62‰ń“ú–{Ž‹”\‹¸łŠw‰ď (2021/11/20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723617. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ˆŮ‚Č‚é‘OŠá•”OCT‚ĚICLƒTƒCƒYŒˆ’č‚ÉŠÖ—^‚ˇ‚éƒpƒ‰ƒ[ƒ^‚Ě”äŠr. “c‘şŒŤś1, Ź“‡—˛Ži2, ‹Ę’u–ž–ě3, ‰Á“ĄKm1, “´ˆä—˘ŠG1, Žsě@Œc4, Žsěˆę•v1,5 (1’†‹žŠá‰Č, 2Œc‰ž‘ĺ, 3JCHO’†‹ž•a‰@, 4‘‡ÂŽR•a‰@, 5Šá‰Č): ‘ć62‰ń“ú–{Ž‹”\‹¸łŠw‰ď (2021/11/20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723618. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) 9•űŒüŠáˆĘŽĘ^‚ĚŽB‰e•ű–@‚Ěˆá‚˘‚É‚ć‚鏊—vŽžŠÔ‚Ě”äŠr. ‰–’J’źŽq1, ŒăŠÖ—˜–ž1,2, ”Ń“‡—R‰Ŕ1, Ł•”ˆ¤”ü1, [’J@‹ž1, ×’J‰Ô—Ô1 (1‘Űˆă—Ă•ŸŽƒ‘ĺ”MŠC, 2Šá‰Č): ‘ć62‰ń“ú–{Ž‹”\‹¸łŠw‰ď (2021/11/20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723619. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Ž‹Šo—U”­“dˆĘ‚đ—p‚˘‚˝ƒ‚ƒmƒrƒWƒ‡ƒ“‚É‚¨‚Ż‚é—źŠá‰Ád‚Ě•]‰ż. Ž˝Œ´”üŠó1, ˛“Ą@Ži1, Vˆä“cF—T1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺ, 2Šá‰Č): ‘ć62‰ń“ú–{Ž‹”\‹¸łŠw‰ď (2021/11/21), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723620. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘źŠo“IŽ‹‹@”\ŒŸ¸‘•’uORTeEYENAC‚đ—p‚˘‚˝AIŽŠ“Ž”ť’č•â•‚ĚŽŽ‚Ý. ˆÉ“ĄŽé—1, ŒË’ˁ@Œĺ1, ”ź“c’m–ç2, Îě@‹Ď2, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć62‰ń“ú–{Ž‹”\‹¸łŠw‰ď (2021/11/21), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723621. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —Ž‹űÇŒóŒQ‚Ě”’“ŕáŽčp‘OŒă‚É‚¨‚Ż‚鐅ť‘Ě‚ĆŠá“ŕƒŒƒ“ƒY‚̕ΐS‚ĆŒXŽÎ‚Ě’č—Ę“IŒŸ“˘. ‹˝‰E‹ß”ŽN1, _’J˜aF2, ”Ń“c‰Ă•F1, ”Ń“‡@Œh1, ‰ĄŠÖ—S‰ŔŽq1, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć60‰ń“ú–{”’“ŕáŠw‰ď‘‰ďE‘ć47‰ń…ť‘ĚŒ¤‹†‰ď (2021/11/26), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723622. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”’“ŕáp‘Oś‘ĚŒv‘Ş‘•’uANTERION‚ĆIOL Master700‚Ě”äŠr. Źě仓Ţ1, _’J˜aF2, ˆŔ“Ą˜a‰ĚŽq1, ÔÎ‘ň’q”ż1, ”Ń“‡@Œh1, ”Ń“c‰Ă•F1, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć60‰ń“ú–{”’“ŕáŠw‰ď‘‰ďE‘ć47‰ń…ť‘ĚŒ¤‹†‰ď (2021/11/26), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723623. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) IOLMaster700‚ĆOA-2000‚É‚ć‚鐜‘ĚŒv‘Ş’l‚Ć”’“ŕápŒă‚Ě‹üÜŒëˇ‚Ě”äŠr. ź–ě–Gˆß1, _’J˜aF2, “Ą‘ş•‡ŽŃŽq2, ”Ń“‡@Œh1, ”Ń“c‰Ă•F1, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć60‰ń“ú–{”’“ŕáŠw‰ď‘‰ďE‘ć47‰ń…ť‘ĚŒ¤‹†‰ď (2021/11/26), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723624. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Waterclefts‚ĚŒ`ó‚ŞŽ‹‹@”\‚É‹y‚Ú‚ˇ‰e‹ż|ŒőŠwƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“‚É‚ć‚é‰đÍ|. ŠÖ@—S‰î1, ěŽç“c‘ńŽu2, ‰LŽ”—S‹P1, ŽO“c“N‘ĺ1, ŽRč@•‘1, ‹v•Ű]—˘1, ˛X–Ř—m1 (1‹ŕ‘ňˆă‘ĺ, 2ˆă—ÉqśŠw•”): ‘ć60‰ń“ú–{”’“ŕáŠw‰ď‘‰ďE‘ć47‰ń…ť‘ĚŒ¤‹†‰ď (2021/11/26), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723625. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰)yŔ’ˇzŽčpƒAƒEƒgƒJƒ€. Žsěˆę•v1,2 (1’†‹žŠá‰Č, 2Šá‰Č): ‘ć60‰ń“ú–{”’“ŕáŠw‰ď‘‰ďE‘ć47‰ń…ť‘ĚŒ¤‹†‰ď (2021/11/26), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723626. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’´ŠáŽ˛’ˇŠá‚ɑ΂ˇ‚é’á“x”Šá“ŕƒŒƒ“ƒY‚Ě—\‘ސŤ‚ĚŒŸ“˘. ”Ń“‡@Œh1, _’J˜aF2, ”Ń“c‰Ă•F1, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć60‰ń“ú–{”’“ŕáŠw‰ď‘‰ďE‘ć47‰ń…ť‘ĚŒ¤‹†‰ď (2021/11/26), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723627. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘˝Ž{Ý‚ĹƒCƒ[ƒWƒKƒCƒhƒVƒXƒeƒ€‚đŽg—p‚ľ‚˝ƒg[ƒŠƒbƒNŠá“ŕƒŒƒ“ƒY‚̏pŒă‘ŠúŹŃ. Žsě@Œc1,2, Ź“‡—˛Ži3, ˛“Ą—T”V4, ‹g“c‘Ľ•F5, ŽđˆäKO2, “´ˆä—˘ŠG2, Œă“Ą@C1, Žsě—ćŽq2, Žsěˆę•v2,6 (1‘‡ÂŽR•a‰@, 2’†‹žŠá‰Č, 3Œcœä‘ĺ, 4˛“Ą—T–çŠá‰Č, 5Šň•ŒÔ\Žš•a‰@, 6Šá‰Č): ‘ć60‰ń“ú–{”’“ŕáŠw‰ď‘‰ďE‘ć47‰ń…ť‘ĚŒ¤‹†‰ď (2021/11/26), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723628. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) 2019”N‚ĚƒŒ[ƒxƒ‹ˆâ“`ŤŽ‹_ŒoÇ‚̐V‹K”­ÇŽŇ”‚ÉŠÖ‚ˇ‚é‰uŠw’˛¸. ‚–ěŽjś1, ă“cD1, ŽRă–žŽq2,3, Îě—Tl4, ’†”nGŽ÷5, Îě@‹Ď6, ’r“cN”Ž5, ’†‘ş@˝1 (1_ŒË‘ĺŠw, 2ˆäăŠá‰Č•a‰@, 3Šá‰Č, 4•şŒÉˆă‰Č‘ĺŠw•a‰@, 5‹{č‘ĺŠw, 6ˆă—ÉqśŠw•”): ‘ć59‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2021/12/17), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723629. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) m.12811T>Cƒ~ƒgƒRƒ“ƒhƒŠƒAˆâ“`Žq•ĎˆŮ‚đ”F‚ß‚˝ŽĄ—Ă’ďRŤŽ‹_Œo‰Š‚Ěˆę—á. ‚‹´—m•˝1,2, Îě@‹Ď3, —´ˆä‰‘Žq2, ‹ŕŽRr‰î2, ˆŔ–{—´”n4, ÷ˆäŒc‘˘4, ŻŽiMs2 (1“Œ‹ž—Žqˆă‰Č‘ĺŠw”ސç‘ăˆă—ĂƒZƒ“ƒ^[, 2Šá‰Č, 3ˆă—ÉqśŠw•”, 4—ŐŒŸ•”): ‘ć59‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2021/12/17), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723630. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŒŒ‰tň‰ť—Ă–@Œă‚ɃŒ[ƒxƒ‹•a‚Ɛf’f‚ł‚ę‚˝3—á. ‹{’J—SŽ÷1, Šâ˛^‹|1,2, ŽRă–žŽq1,2, ˆäăŒŤŽĄ1, Žá‘q‰ë“o1, Îě@‹Ď3, ˆŔ–{—´”n4, ÷ˆäŒc‘˘4 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č, 3ˆă—ÉqśŠw•”, 4—ŐŒŸ•”): ‘ć59‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2021/12/17), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723631. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰)yŔ’ˇzŽ‹_Œo‡V. ŽRă–žŽq1,2 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č): ‘ć59‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2021/12/18), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723632. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) –k—˘‘ĺŠw‚É‚¨‚Ż‚鎋_ŒoŽžŠł‚Ě—Ő°“I“Á’Ľ. ‹ŕŽRr‰î1,2, Îě@‹Ď3, —´ˆä‰‘Žq2, ‰Í‡ˆ¤ŽŔ1,2, ‚‹´—m•˝2,4, ŻŽiMs2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2Šá‰Č, 3ˆă—ÉqśŠw•”, 4“Œ‹ž—Žqˆă‰Č‘ĺŠw”ސç‘ăˆă—ĂƒZƒ“ƒ^[): ‘ć59‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2021/12/18), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723633. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) COVID-19‚ĚmRNAƒƒNƒ`ƒ“ÚŽíŒă‚É”­Ç‚ľ‚˝—źŠáŤŽ‹_Œo‰Š‚Ěˆę—á. ŽRč”ü1, Šâ˛^‹|1,2, ŽRă–žŽq1, ‰–ě”üŘŽq1, ˆäăŒŤŽĄ1, Žá‘q‰ë“o1 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č): ‘ć59‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2021/12/18), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723634. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) •p”É‚Čˆę‰ßŤ•ĐŠáŤŽ‹ŠoáŠQ‚đ—ˆ‚ˇŽá”N‚Ě’ŠŠçÇŒóŒQ‚Ěˆę—á. Šâ˛^‹|1,2, ŽRă–žŽq1,2, ˆäăŒŤŽĄ1, Žá‘q‰ë“o1 (1ˆäăŠá‰Č•a‰@, 2Šá‰Č): ‘ć59‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2021/12/18), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723635. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‘Sg–ƒŒ‚É‚ć‚é‘źŠo“I‹üÜ’l‚ւ̉e‹ż. ‰Í‡ˆ¤ŽŔ1,2, Îě@‹Ď3, —´ˆä‰‘Žq2, ‹ŕŽRr‰î1,2, ’†ŕVˆť”T4, ź“cO”ü4, ‰Ş–{_Žk4, ŻŽiMs2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2Šá‰Č, 3ˆă—ÉqśŠw•”, 4–ƒŒ): ‘ć59‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2021/12/18), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723636. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) —ΓŕáŠłŽŇ‚É‚¨‚Ż‚éÔŠOü“ľEŒv‚đ—p‚˘‚˝‘ÎŒő”˝ŽË‚ĚŒŸ“˘. ”Ń’Ë’B–ç1, Îě@‹Ď2, ŔŕV—E‹P3, óě@ŒŤ2, ŻŽiMs3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3Šá‰Č): ‘ć59‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2021/12/18), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723637. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰)yŔ’ˇzŠáâ|. ”–؍LĆ1,2 (1Ă‰ŞŒ§—§Ă‰Ş‚Ş‚ńƒZƒ“ƒ^[, 2Šá‰Č): ‘ć59‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2021/12/18), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723638. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ˆł”—ŤŽ‹_ŒoÇ‚Ĺ”­ŒŠ‚ł‚ę‚˝šk_Œo‰č×–EŽî‚ĚŽá”N—Ť—á. ŠFě—FŒ›1, Îě@‹Ď2, —´ˆä‰‘Žq1, ‹ŕŽRr‰î1, ‚‹´—m•˝1, ’†ě䝗S3, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”, 3•a—): ‘ć59‰ń“ú–{_ŒoŠá‰ČŠw‰ď‘‰ď (2021/12/18), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

731053. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) MIGS‚ĚŒťó‚ĆŠú‘Ň. ŻŽiMs (Šá‰Č): —ߘa3”N“xĂ‰ŞŒ§“Œ•”Šá‰ČƒtƒH[ƒ‰ƒ€ (2021/5/27), WebŠJĂ.

731054. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ‘ŹU—‰đEĹV‚ĚŽ‹_Œo‰Š. Îě@‹Ď (ˆă—ÉqśŠw•”): ‘ć12‰ń“ŒŠC“šŠá‰ČŒ¤‹†‰ď (2021/6/19), WebŠJĂ.

731055. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) —ΓŕáŽčp‚ĆŽ‹‹@”\. ŻŽiMs (Šá‰Č): ‘ć152‰ńL“‡Œ§Šá‰Čˆă‰ďuK‰ď (2021/10/3), WebŠJĂ.

731056. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰)yŔ’ˇz“Á•Ęu‰‰. ŻŽiMs (Šá‰Č): ‘ć57‰ń–k—˘‘ĺŠwE_“ŢěŒ§Šá‰Čˆă‰ď‡“ŻƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2021/10/7), WebŠJĂ.

731057. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) —ΓŕáŽčp‚ĆŽ‹‹@”\. ŻŽiMs (Šá‰Č): ‘ć2‰ńYokohama Ophthalmic Meeting (2021/11/2), WebŠJĂ.

731058. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰)y‰đŕzSagging Eye Syndrome. ŒăŠÖ—˜–ž1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č): O‘OŠáŽžŠłƒtƒH[ƒ‰ƒ€2021 (2021/11/6), ÂX (ƒnƒCƒuƒŠƒbƒhŠJĂ).

731059. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) —ΓŕáŽčp‚ĆŽčp. ŻŽiMs (Šá‰Č): Ž‹Šo‚đŒě‚éEŽć‚č–ß‚ˇ2021 (2021/11/14), ‹{é (ƒnƒCƒuƒŠƒbƒhŠJĂ).

731060. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ‚ą‚ą‚Ü‚Ĺ•Ď‚í‚Á‚˝!@‰~Šp–Œ‚̍ŐVŽĄ—Á`CuRV, PiXL‚Š‚çAIf’f‚܂Ł`. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć41‰ń‹ŕ‘ňˆă‰Č‘ĺŠwŠá‰ČŒ¤‹†‰ď (2021/11/14), WebŠJĂ.

731061. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) —ΓŕáŽčp‚Ěƒ^ƒCƒ~ƒ“ƒO‚đl‚Ś‚é. ŻŽiMs (Šá‰Č): ‘ć42‰ń‚ł‚´‚Č‚ÝŠá‰ČŒ¤‹†‰ď (2021/11/20), Ž ‰ę.

731062. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰)yŔ’ˇz“Á•Ęu‰‰2. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć18‰ńĂ“ěŠá‰Č‹äŠy•” (2022/1/13), Š™‘q.

731063. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰)yŔ’ˇz“Á•Ęu‰‰. ŻŽiMs (Šá‰Č): ‘ć19‰ń–k—˘Šá‰Č•af˜AŒg‰ď (2022/1/20), WebŠJĂ.

731064. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ƒgƒ‰ƒxƒNƒŒƒNƒgƒ~[Œă‚ĚŽ‹‹@”\. Š}Œ´łs (Šá‰Č): ‘ć19‰ń–k—˘Šá‰Č•af˜AŒg‰ď (2022/1/20), WebŠJĂ.

731065. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) Ç—á‚Š‚çŠw‚ń‚žŽ„‚̐_ŒoŠá‰Č|‰ä”]— ‚ɍ‚Ü‚ę‚ľÇ—á|. Îě@‹Ď (ˆă—ÉqśŠw•”): ‘ć6‰ń‚Đ‚Ć‚Ýƒlƒbƒg‚̉ď (2022/1/22), –źŒĂ‰Ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

731066. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰)yŔ’ˇz“Á•Ęu‰‰. ŻŽiMs (Šá‰Č): ‘ć14‰ń_“ސěƒNƒƒXƒI[ƒo[ƒVƒ“ƒ|ƒWƒEƒ€ (2022/2/5), WebŠJĂ.

731067. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) _ŒoŠá‰ČŒŸ¸‚Ě—Ž‚Ć‚ľŒŠ‚Ć‘ĺŘ‚Č‚ą‚Ć. óě@ŒŤ (ˆă—ÉqśŠw•”): ‚Ý‚â‚ŹŽ‹”\ŒP—űŽm‚̉ď (2022/2/13), WebŠJĂ.

731068. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) Ž„‚̐_ŒoŠá‰Č-”]— ‚ɍ‚Ü‚ę‚˝–Y‚ę‚ç‚ę‚Č‚˘Ç—á‚Ć‚ť‚ą‚Š‚çŠw‚ń‚ž‚ŕ‚Ě. Îě@‹Ď (ˆă—ÉqśŠw•”): YOKOHAMA RETINA NIGHT season6 (2022/2/17), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

731069. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰)yŔ’ˇz“Á•Ęu‰‰. ŻŽiMs (Šá‰Č): ‘ĺ’˗ΓŕáWEBƒZƒ~ƒi[ (2022/2/25), WebŠJĂ.

731070. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰)yŔ’ˇz“Á•Ęu‰‰‡T. ŻŽiMs (Šá‰Č): ‘ć3‰ńSENJU Glaucoma Seminar (2022/3/9), WebŠJĂ.

731071. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) —Γŕá‚ĚŽ‹‹@”\‚đl‚Ś‚é. ŻŽiMs (Šá‰Č): ‘ć4‰ńVisual Function Seminar in Saitama (2022/3/11), WebŠJĂ.

731072. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ‘ć“ń‚Ě˜VŠá`ƒTƒMƒ“ƒOƒAƒCÇŒóŒQ`. ŒăŠÖ—˜–ž1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č): ‘ć115‰ń•xŽR‘ĺŠwŠá‰Č—Տ°ƒJƒ“ƒtƒ@ƒŒƒ“ƒX 44632 WebŠJĂ.

732084. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) —Źo˜HÄŒšpŒă‚̍‡•šÇŠÇ—‚Ć–ň•¨ŠÇ—`Ĺ‹ß‚ĚƒOƒ‰ƒiƒeƒbƒN‚Ě˜b‘č‚ŕŠÜ‚߂ā`. Š}Œ´łs (Šá‰Č): Kowa Web Conference (2021/4/20), WebŠJĂ.

732085. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™)yŔ’ˇzu‰‰2. ŻŽiMs (Šá‰Č): ‘ć15‰ń‚ł‚Ş‚ÝŠá‰ČŒ¤‹†‰ď (2021/6/17), WebŠJĂ.

732086. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) —ΓŕáŽĄ—Ă‚ĚƒAƒbƒvƒf[ƒg. Š}Œ´łs (Šá‰Č): ‘ć15‰ń‚ł‚Ş‚ÝŠá‰ČŒ¤‹†‰ď (2021/6/17), WebŠJĂ.

732087. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) ŠłŽŇ‚ł‚ń‚Ě‚˝‚߂Ɂg’m‚Á‚Ä‚¨‚­‚ׂŤ‚ť‚Ě’mŽŻh‚Ɓg‚ť‚̏€”őh`ƒŒƒ“ƒY‚̐Ť”\, “Á’Ľ‚Š‚çl‚Ś‚Ä‚˘‚­`. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): ŽQ“Vť–ňWEBu‰‰‰ď (2021/7/15), WebŠJĂ.

732088. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (Šî’˛u‰‰)yŔ’ˇzŠî’˛u‰‰1. –ö“c’q•F (Šá‰Č): ‘ć3‰ń–k—˘‘ĺŠwŠá‰Č’ƒ˜b‰ď (2021/7/17), WebŠJĂ.

732089. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (Šî’˛u‰‰) Šá‰Čˆă11”N–Ú, ŹŽ™ˆă—Ă‚ĆŠááَčp. —´ˆä‰‘Žq (Šá‰Č): ‘ć3‰ń–k—˘‘ĺŠwŠá‰Č’ƒ˜b‰ď (2021/7/17), WebŠJĂ.

732090. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (Šî’˛u‰‰)yŔ’ˇzŠî’˛u‰‰2. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć3‰ń–k—˘‘ĺŠwŠá‰Č’ƒ˜b‰ď (2021/7/17), WebŠJĂ.

732091. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (Šî’˛u‰‰) —r–ŒˆÚA‚Ě—đŽj‚ƍĄŒă‚Ě“W–]. ě–k“N–ç (Šá‰Č): ‘ć3‰ń–k—˘‘ĺŠwŠá‰Č’ƒ˜b‰ď (2021/7/17), WebŠJĂ.

732092. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (”F’čuK‰ď) ŠááŮázš@f’f‚ĆŽĄ—Ă. ŒăŠÖ—˜–ž1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠwŠá‰Č, 2Šá‰Č): ‘ć36‰ń^’߃Zƒ~ƒi[ (2021/8/21), WebŠJĂ.

732093. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒAƒhƒoƒCƒU[) —Γŕá–ň•¨ŽĄ—Âɂ‚˘‚Ä. Š}Œ´łs1, ‰Í–ě—Y—ş1 (1Šá‰Č): ƒAƒhƒoƒCƒU[Dr.ľăيé‰ć (çŽő) (2021/9/16), _“ސě.

732094. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™)y‰đŕzSagging Eye Syndrome. ŒăŠÖ—˜–ž1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠwŠá‰Č, 2Šá‰Č): ‘ĺăˆă‰Č–ň‰Č‘ĺŠwŠá‰ČƒI[ƒvƒ“ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2021/9/16), WebŠJĂ.

732095. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ŽĐ“ŕŒ¤C‰ď) ÉŽq‘ĚŽčp. –ö“c’q•F (Šá‰Č): ŽQ“Vť–ňŽĐ“ŕŒ¤C‰ď (2021/9/22), WebŠJĂ.

732096. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) ŒŒŠÇVś—Γŕá‚ĚŽčpŹŃ. Š}Œ´łs (Šá‰Č): Ă“ěFRONTIER TODAY`–ž“ú‚Š‚çŽg‚Ś‚éŠá‰ČŽĄ—Ă‚đƒAƒbƒvƒf[ƒg` (2021/9/28), WebŠJĂ.

732097. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) JCHO‘Š–Í–ě•a‰@@Šá‰Č‚ĚĐ‰î. t“úˆähŽq1,2 (1‘Š–Í–ě•a‰@, 2Šá‰Č): ĂźŠá‰ČuK‰ď (2021/10/2), WebŠJĂ.

732098. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) •Ş‚Š‚č‚₡‚˘ŠáŒőŠw`—Տ°‚Ĺ‚ĚŽ‹—́E‹üÜ‚ÉŠÖ‚ˇ‚é‹^–â‚ɂ‚˘‚čl‚Ś‚é`. ěŽç“c‘ńŽu (ˆă—ÉqśŠw•”): ĂźŠá‰ČuK‰ď (2021/10/2), WebŠJĂ.

732099. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™)y‰đŕzSagging Eye Syndrome. ŒăŠÖ—˜–ž1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠwŠá‰Č, 2Šá‰Č): é‹ĘŒ§Šá‰Č‹łˆçu‰‰‰ď (2021/10/3), WebŠJĂ.

732100. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (Ç—á”­•\)yŔ’ˇzƒgƒ‰ƒxƒNƒŒƒNƒgƒ~[‚ĚŠe‘ĺŠw‚ĚŽč‹Z‚Ěƒ|ƒCƒ“ƒg‚ɂ‚˘‚Ä. ŻŽiMs (Šá‰Č): ‘ć37‰ńNG‰ď (2021/10/5), WebŠJĂ.

732101. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰)yŔ’ˇz‹łˆçu‰‰. –ö“c’q•F (Šá‰Č): ‘ć57‰ń–k—˘‘ĺŠwE_“ŢěŒ§Šá‰Čˆă‰ď‡“ŻƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2021/10/7), WebŠJĂ.

732102. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰) ÉŽq‘ĚŽčp‚Ě“K‰ž‚ĆŽĄ—Ă. ŠFě—FŒ› (Šá‰Č): ‘ć57‰ń–k—˘‘ĺŠwE_“ŢěŒ§Šá‰Čˆă‰ď‡“ŻƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2021/10/7), WebŠJĂ.

732103. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™)yŔ’ˇzŽčpÇ—á‚̍lŽ@. ”Ń“c‰Ă•F (Šá‰Č): ‘ć13‰ńƒRƒ‹ƒjƒAƒtƒFƒCƒRƒZƒ~ƒi[ (2021/10/21), WebŠJĂ.

732104. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) MarfanÇŒóŒQ‚̐…ť‘Ě•ÎˆĘ‚É‘Î‚ľ, …ť‘ĚůNŠg’ŁƒŠƒ“ƒO•š—pSulcus-Subcapsular fixation‚đŽ{s‚ľ‚˝1—á. ‰ĄŠÖ—S‰ŔŽq (Šá‰Č): ‘ć13‰ńƒRƒ‹ƒjƒAƒtƒFƒCƒRƒZƒ~ƒi[ (2021/10/21), WebŠJĂ.

732105. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™)yŔ’ˇzRVO‚ĚŠá’ęƒCƒ[ƒWƒ“ƒO‚ĆŽĄ—Ð헪. –ö“c’q•F (Šá‰Č): ‘ć12‰ńĂźŠá‰ČƒAƒJƒfƒ~[ (2021/11/11), WebŠJĂ.

732106. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™)yŔ’ˇzŠáŽîᇂɑ΂ˇ‚éŠO‰Č“IŽĄ—Ă‚ĚŽŔŰ. Îě@‹Ď (ˆă—ÉqśŠw•”): ‘ć12‰ńĂźŠá‰ČƒAƒJƒfƒ~[ (2021/11/11), WebŠJĂ.

732107. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) Ç—á‚Š‚çŠw‚ÔŽ‹_Œo‰Š|Ž‹_Œo‰Š”­ě—\–hś•¨ťÜ2020|. Îě@‹Ď (ˆă—ÉqśŠw•”): ‘ć1‰ńŽ‹_ŒoŇ‘‰ŠWebƒZƒ~ƒi[ (2021/11/29), WebŠJĂ.

732108. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (‹łˆçu‰‰)yŔ’ˇz‹łˆçu‰‰. ŒăŠÖ—˜–ž1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č): ‘ć31‰ńŹŽ™Šá‰Č (ŽÎŽ‹EŽăŽ‹) Ç—ጟ“˘‰ďE•×‹­‰ď (2021/12/9), WebŠJĂ.

732109. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (Ç—ጟ“˘)yŔ’ˇzÇ—ጟ“˘. Îě@‹Ď (ˆă—ÉqśŠw•”): ‘ć31‰ńŹŽ™Šá‰Č (ŽÎŽ‹EŽăŽ‹) Ç—ጟ“˘‰ďE•×‹­‰ď (2021/12/9), WebŠJĂ.

732110. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (Ç—ጟ“˘) —L…ť‘ĚŠá“ŕƒŒƒ“ƒY‘}“üŒă“ŕŽÎŽ‹‚Ć’˛ßázš‚đ”­Ç‚ľ‚˝1—á. ÔÎ‘ň’q”ż (Šá‰Č): ‘ć31‰ńŹŽ™Šá‰Č (ŽÎŽ‹EŽăŽ‹) Ç—ጟ“˘‰ďE•×‹­‰ď (2021/12/9), WebŠJĂ.

732111. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) ŠOŠá‹Ř‹y‚ŃŠOŠá‹ŘŽxŽ‘gD‚ĚˆŮí‚ĆƒXƒ|[ƒcŽ‹Šo. ŒăŠÖ—˜–ž1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č): ‘ć12‰ń“ú–{ƒXƒ|[ƒcŽ‹ŠoŒ¤‹†‰ď (2021/12/12), WebŠJĂ.

732112. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™)yŔ’ˇzu‰‰1. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć67‰ńĂźŠá‰Č—Տ°ƒtƒH[ƒ‰ƒ€ (2021/12/16), ’Ź“c (ƒnƒCƒuƒŠƒbƒhŠJĂ).

732113. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™)yŔ’ˇzu‰‰2. ŻŽiMs (Šá‰Č): ‘ć67‰ńĂźŠá‰Č—Տ°ƒtƒH[ƒ‰ƒ€ (2021/12/16), ’Ź“c (ƒnƒCƒuƒŠƒbƒhŠJĂ).

732114. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ŽĐ“ŕŒ¤C‰ď) ‚—îŽŇ‚Ě•ĄŽ‹|Sagging Eye Syndrome‚đ—‰đ‚ˇ‚é|. ŒăŠÖ—˜–ž1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č): çŽőť–ňŽĐ“ŕu‰‰‰ď (2022/1/7), Ă‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

732115. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) “œ”A•a‚É‚ć‚é, –Ô–ŒÇˆČŠO‚ĚŠá‡•šÇ‚ɂ‚˘‚Ä. –ö“c’q•F (Šá‰Č): ‘ć97‰ń‚ł‚Ş‚Ý“œ”A•aƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2022/1/21), WebŠJĂ.

732116. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒfƒBƒXƒJƒbƒVƒ‡ƒ“)yŽi‰ďzƒfƒBƒXƒJƒbƒVƒ‡ƒ“. Îě@‹Ď (ˆă—ÉqśŠw•”): NMOSD‡“ŻƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2022/1/26), WebŠJĂ.

732117. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) NMOSD‚̐f—Ă‰Č˜AŒg‚Ć‚ť‚ę‚ź‚ę‚ĚŽ‹“_‹¤—L@ƒfƒBƒXƒJƒbƒTƒ“ƒg. ŒăŠÖ—˜–ž11,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č): NMOSD‡“ŻƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2022/1/26), WebŠJĂ.

732118. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (Ç—á•ń) Šáâ|“ŕ‘¤•ÇœÜŒă‚ÉŠJŽU–ƒáƒ—l‚Ě“ŕŽÎŽ‹‚đ‚Ť‚˝‚ľ‚˝1—á. Î“c@‹Ĺ1,2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 2Šá‰Č): ‘ć14‰ń_“ސěƒNƒƒXƒI[ƒo[ƒVƒ“ƒ|ƒWƒEƒ€ (2022/2/5), WebŠJĂ.

732119. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (Ç—á’ńŽŚ) —Î‚ĚƒLƒYƒi…B“Ť—Γŕá‚̑Ήž. ŻŽiMs (Šá‰Č): —΂ĚăJ2022 (2022/2/15), WebŠJĂ.

732120. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™)yŔ’ˇzŽŸ˘‘ă‚ĚŽ‹–ěŒŸ¸ƒAƒ‹ƒSƒŠƒYƒ€. ŻŽiMs (Šá‰Č): AP-7700WebƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2022/2/18), WebŠJĂ.

732121. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) Ŕ’ˇ. ŻŽiMs (Šá‰Č): ‘ć7‰ńŽ‹Šoś—ŠwŠî‘bƒZƒ~ƒi[ (2022/2/20), WebŠJĂ.

732122. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™)yŔ’ˇzu‰‰1. ŻŽiMs (Šá‰Č): ‘ć68‰ńĂźŠá‰Č—Տ°ƒtƒH[ƒ‰ƒ€ (2022/3/3), WebŠJĂ.

732123. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™)yŔ’ˇzu‰‰2. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć68‰ńĂźŠá‰Č—Տ°ƒtƒH[ƒ‰ƒ€ (2022/3/3), WebŠJĂ.

732124. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (Ç—ጟ“˘)yŔ’ˇzÇ—ጟ“˘. ě–k“N–ç (Šá‰Č): ‘ć21‰ń‚ß‚´‚š!ƒRƒ‹ƒlƒA‚Ě“Sl (2022/3/4), “Œ‹ž.

732125. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (Ç—ጟ“˘) isŤ‰~Šp–Œ‚ɑ΂ˇ‚éCustomizedŠp–ŒƒNƒƒXƒŠƒ“ƒLƒ“ƒO‚Ě”N—î•ĘpŒăŽ‹‹@”\E–ž‘Ť“x‚ĚŒŸ“˘. Œă“Ą“c“NŽj1,2 (1Šá‰Č, 2“Œ–M‘ĺŠwˆă—ĂƒZƒ“ƒ^[‘ĺX•a‰@): ‘ć21‰ń‚ß‚´‚š!ƒRƒ‹ƒlƒA‚Ě“Sl (2022/3/4), “Œ‹ž.

732126. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) ‹üÜ‹¸łŽčp‚Ě“K‰ž‚Ć‘I‘đ. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć20‰ńŠá‰Čf—ĂƒAƒbƒvƒf[ƒgƒZƒ~ƒi[ 2022 in Kyoto (2022/3/13), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

732127. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) ‹üÜ‹¸łŽčpƒAƒbƒvƒf[ƒg2022. _’J˜aF (ˆă—ÉqśŠw•”): ‘ć31‰ń–ś“‡Šá‰ČŒ¤čr‰ď (2022/3/19), WebŠJĂ.

733189. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) ‹s‘Ň‚É‚ć‚é“ű—cŽ™“Ş•”ŠO (AHT=Abusive Head Trauma in Infants and Children) ‚Š‚ç–Ô–ŒoŒŒ‚đ”F‚ß‚˝1—á. ‰~’JN—C1,2, ŽO‘îr”V1,2, ’r“c“N–ç1,2,3, ź–{_”V1,2, ŻŽiMs1 (1Šá‰Č, 2‰Ą{‰ęŽs—§‚¤‚í‚Ü‚ż•a‰@, 3ŽR‰¤•a‰@): ‘ć13‰ń_“ސěŠá‰ČŠw‰ďE‘ć134‰ń_“ŢěŒ§Šá‰ČW’k‰ď (2021/5/30), WebŠJĂ.

733190. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) ‚¤‚ÁŒŒ“ű“Ş‚ĚŽĄ—Ă‚É‹ę—ś‚ľ‚˝isŤœŠ˛ˆŮŒ`ŹÇ‚Ě1—á. ‘ĺ]ˆ˘Žq1,2, ŒăŠÖ—˜–ž1,3, —´ˆä‰‘Žq1, Îě@‹Ď4, ŻŽiMs1 (1Šá‰Č, 2ŠC˜V–ź‘‡•a‰@, 3‘Űˆă—Ă•ŸŽƒ‘ĺŠw”MŠC•a‰@, 4ˆă—ÉqśŠw•”): ‘ć13‰ń_“ސěŠá‰ČŠw‰ďE‘ć134‰ń_“ŢěŒ§Šá‰ČW’k‰ď (2021/5/30), WebŠJĂ.

733191. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) Vogt-Ź–ö-Œ´“c•a‚ɑ΂ˇ‚éƒXƒeƒƒCƒhƒpƒ‹ƒX—Ă–@7”NŒă‚É•ĐŠáÄ”­‚đ‚Ť‚˝‚ľ‚˝1—á. ŸNˆä—•Žq1, ˛“ĄM”V1, –ö“c’q•F1, t–ؐ’G1, ŠFě—FŒ›1, ŻŽiMs1 (1Šá‰Č): ‘ć13‰ń_“ސěŠá‰ČŠw‰ďE‘ć134‰ń_“ŢěŒ§Šá‰ČW’k‰ď (2021/5/30), WebŠJĂ.

733192. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) Hill-RBF–@Version3.0‚Ě—\‘ސŤ‚ĆBarrett Universal IIŽŽESRK/TŽŽ‚Ć‚Ě”äŠr. ”Ń“‡@Œh1, _’J˜aF2, ”Ń“c‰Ă•F1, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”): ‘ć13‰ń_“ސěŠá‰ČŠw‰ďE‘ć134‰ń_“ŢěŒ§Šá‰ČW’k‰ď (2021/5/30), WebŠJĂ.

733193. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) •p”É‚Čˆę‰ßŤŽ‹ŠoáŠQ‚đ‹N‚ą‚ľ‚˝’ŠŠçÇŒóŒQ‚Ěˆę—á. Šâ˛^‹|1,2 (1ˆäăŠá‰Č, 2Šá‰Č): ‘ć36‰ń^’߃Zƒ~ƒi[ (2021/8/21), WebŠJĂ.

733194. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) ˆł”—ŤŽ‹_ŒoÇ‚Ĺ”­ŒŠ‚ł‚ę‚˝šk_Œo‰č×–EŽî‚ĚŽá”N—Ť—á. ŠFě—FŒ›1, Îě@‹Ď2, —´ˆä‰‘Žq1, ‹ŕŽRr‰î1,3, ‚‹´—m•˝1, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć36‰ń^’߃Zƒ~ƒi[ (2021/8/21), WebŠJĂ.

733195. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) Hysterical hemianopia—l•Đ‘¤Ž¨‘¤”ź–Ó‚đ’ć‚ľ‚˝“Á”­ŤŽ‹_Œo‰Š‚đ‹^‚¤1—á. ‰~’JN—C (Šá‰Č): ‘ć36‰ń^’߃Zƒ~ƒi[ (2021/8/21), WebŠJĂ.

733196. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) Ž‹_Œo‰Š? ‹•ŒŒŤŽ‹_ŒoÇ? ŽRă–žŽq1,2 (1ˆäăŠá‰Č, 2Šá‰Č): ‘ć36‰ń^’߃Zƒ~ƒi[ (2021/8/21), WebŠJĂ.

733197. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č)yŔ’ˇzˆę”ʉ‰‘č. Š}Œ´łs (Šá‰Č): ‘ć57‰ń–k—˘‘ĺŠwE_“ŢěŒ§Šá‰Čˆă‰ď‡“ŻƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2021/10/7), WebŠJĂ.

733198. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) —ź‘¤Šááَ‚đ’ć‚ľ‚˝’´‚—îŽŇ‚ĚŠáâ|ƒAƒ~ƒƒCƒh[ƒVƒX‚Ěˆę—á. ‘ĺ‰ęT•˝1, Îě@‹Ď2, —´ˆä‰‘Žq1, ‹ŕŽRr‰î1,3, ‰ĄŠÖ—S‰ŔŽq1, Ż–쏺–F4, ™–{‰Ŕ5, ŻŽiMs1 (1Šá‰Č, 2ˆă—ÉqśŠw•”, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4•a—, 5Œ`ŹE”üŠO): ‘ć57‰ń–k—˘‘ĺŠwE_“ŢěŒ§Šá‰Čˆă‰ď‡“ŻƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2021/10/7), WebŠJĂ.

733199. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) ƒuƒŠƒ‚ƒjƒWƒ“^ƒuƒŠƒ“ƒ]ƒ‰ƒ~ƒh”z‡“_Šá–ň‚ĚŽĄ—ÐŹŃ. ‰~’JN—C1, Š}Œ´łs1, ‰Í–ě—Y—ş1, •ÄŽR@—Č1, ˆäŒ´ä“ß”ü1, ŻŽiMs1 (1Šá‰Č): ‘ć57‰ń–k—˘‘ĺŠwE_“ŢěŒ§Šá‰Čˆă‰ď‡“ŻƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2021/10/7), WebŠJĂ.

733200. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) “Ý“IŠOŒă‚ɐ…ť‘ĚŒăůN‚Ş”j—ô‚ľ…ť‘ĚŠj‚Ş’E‰P‚ľ‚˝1—á. ’r‘ş—LŠŽ1, ŠFě—FŒ›1, ˛“ĄM”V1, –ö“c’q•F1, ŻŽiMs1 (1Šá‰Č): ‘ć57‰ń–k—˘‘ĺŠwE_“ŢěŒ§Šá‰Čˆă‰ď‡“ŻƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2021/10/7), WebŠJĂ.

733201. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) ‰~Šp–Œ‚ɑ΂ˇ‚éŠp–Œ“ŕƒŠƒ“ƒO‚Ş—źŠá‚Ć‚ŕ‚ÉŽŠ‘R’Eo‚ľ‚˝1—á. Œă“Ą“c“NŽj1,2, ‚‹´ł‰p1, ‘ěG‹P1, _’J˜aF3, ŻŽiMs1 (1Šá‰Č, 2“Œ–M‘ĺŠwˆă—ĂƒZƒ“ƒ^[‘ĺX•a‰@, 3ˆă—ÉqśŠw•”): ‘ć57‰ń–k—˘‘ĺŠwE_“ŢěŒ§Šá‰Čˆă‰ď‡“ŻƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2021/10/7), WebŠJĂ.

733202. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) MarfanÇŒóŒQ‚̐…ť‘Ě•ÎˆĘ‚É‘Î‚ľ, …ť‘ĚůNŠg’ŁƒŠƒ“ƒO•š—pSulcus-Subcapsular fixation‚đŽ{s‚ľ‚˝1—á. ‰ĄŠÖ—S‰ŔŽq1, ”Ń“c‰Ă•F1, ”Ń“‡@Œh1, ’r‘ş—LŠŽ1, ‘ĺ‰ęT•˝1, ŻŽiMs1 (1Šá‰Č): ‘ć57‰ń–k—˘‘ĺŠwE_“ŢěŒ§Šá‰Čˆă‰ď‡“ŻƒŠƒT[ƒ`ƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2021/10/7), WebŠJĂ.

733203. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č)yŔ’ˇzˆę”ʉ‰‘č. Îě@‹Ď (ˆă—ÉqśŠw•”): ‘ć19‰ń–k—˘Šá‰Č•af˜AŒg‰ď (2022/1/20), WebŠJĂ.

733204. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) –k—˘‘ĺŠw•a‰@Šá‰Čę–ĺŠO—ˆ‚ĚĐ‰î@Šp–ŒE‹üÜ‹¸ł”Ç. ‘ěG‹P (Šá‰Č): ‘ć19‰ń–k—˘Šá‰Č•af˜AŒg‰ď (2022/1/20), WebŠJĂ.

733205. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) –k—˘‘ĺŠw•a‰@Šá‰Čę–ĺŠO—ˆ‚ĚĐ‰î@ŽÎŽ‹E_Œo”Ç. —´ˆä‰‘Žq (Šá‰Č): ‘ć19‰ń–k—˘Šá‰Č•af˜AŒg‰ď (2022/1/20), WebŠJĂ.

733206. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) –k—˘‘ĺŠw•a‰@Šá‰Čę–ĺŠO—ˆ‚ĚĐ‰î@–Ô–ŒÉŽq‘Ě”Ç. –ö“c’q•F (Šá‰Č): ‘ć19‰ń–k—˘Šá‰Č•af˜AŒg‰ď (2022/1/20), WebŠJĂ.

733207. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) –k—˘‘ĺŠw•a‰@Šá‰Čę–ĺŠO—ˆ‚ĚĐ‰î@”’“ŕá”Ç. ”Ń“c‰Ă•F (Šá‰Č): ‘ć19‰ń–k—˘Šá‰Č•af˜AŒg‰ď (2022/1/20), WebŠJĂ.

733208. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č)yŔ’ˇzˆę”ʍu‰‰. ŻŽiMs (Šá‰Č): ‘ĺ’˗ΓŕáWEBƒZƒ~ƒi[ (2022/2/25), WebŠJĂ.

733209. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʉ‰‘č) –k—˘‘ĺŠw‚É‚¨‚Ż‚éƒ~ƒPƒ‹ƒiҎĄ—ÐŹŃ‚Š‚ç‚̍lŽ@. ‰Í–ě—Y—ş (Šá‰Č): ‘ĺ’˗ΓŕáWEBƒZƒ~ƒi[ (2022/2/25), WebŠJĂ.

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-110025. [Œ´’˜] Visual performance and patient satisfaction of multifocal contact lenses in eyes undergoing monofocal intraocular Lens implantation. Kamiya K1, Fujimura F1, Ando W2, Iijima K2, Shoji N2: Cont Lens Anterior Eye 2020/6; 43 (3): 218-21. (_’J˜aF1, “Ą‘ş•‡˛Žq1, ˆŔ“Ą˜a‰ĚŽq2, ”Ń“‡@Œh2, ŻŽiMs2: 1ˆă—ÉqśŠw•”, 2Šá‰Č)

'20-110026. [Œ´’˜] The Relationship Between Corneal Hysteresis and Progression of Glaucoma After Trabeculectomy. FujinoY, Murata H, Matsuura M, Nakakura S, Shoji N1, Nakao Y, Kiuchi Y, Asaoka R: J Glaucoma 2020/10; 29 (10): 912-7. (ŻŽiMs1: 1Šá‰Č)

'20-110027. [Œ´’˜] Regional comparison of preoperative biometry for cataract surgery between two domestic institutions. Kamiya K1, Fujimura F1, Iijima K2, Shoji N2, Mori Y, Miyata K: Int Ophthalmol 2020/11; 40 (11): 2923-30. (_’J˜aF1, “Ą‘ş•‡˛Žq1, ”Ń“‡@Œh2, ŻŽiMs2: 1ˆă—ÉqśŠw•”, 2Šá‰Č)

'20-110028. [Œ´’˜] Characterization of laser speckle flowgraphy pulse waveform parameters for the evaluation of the optic nerve head and retinal circulation. Enomoto N, Anraku A, Tomita G, Iwase A, Sato T, Shoji N1, Shiba T, Nakazawa T, Sugiyama K, Nitta K, Araie M: Sci Rep 2021/3; 11 (1): 6847. (ŻŽiMs1: 1Šá‰Č)


Ž¨•@ˆôA‰ČE“Şčň•”ŠO‰ČŠw

[Šwp˜_•ś]


110383. [Œ´’˜] Evaluation of the usefulness of upper gastrointestinal endoscopy and the Valsamouth_ by an otolaryngologist in patients with Hypopharyngeal cancer. Hosono H1, Katada C2, Kano K1, Kimura A1, Tsutsumi S3, Miyamoto S1, Ichinoe M4, Furue Y2, Tanabe S2,5, Koizumi W2, Yamashita T1: Auris Nasus Larynx 2021/4; 48 (2): 265-73. (×–ě_Žj1, Œ˜“ce—˜2, ‰Á”[Fˆę1, –Ř‘şŽé—˘1, ’ç@ăĕ˝3, ‹{–{r•ă1, ˆęŒËš–ž4, ŒĂ]N–ž2, “c糁@‘2,5, Źň˜aŽO˜Y2, ŽR‰ş@‘ń1: 1Ž¨•@ˆôAE“ŞčňŠO, 2Á‰ťŠí“ŕ, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4•a—, 5V˘‹Iˆă—ÁEć’[ˆă—Ă)

110384. [Œ´’˜] Resection of Parapharyngeal Space Tumors Located in the Prestyloid Compartment: Efficacy of the Cervical Approach. Matsuki T1, Okamoto I, Tada Y, Masubuchi T, Fushimi C, Kamata S, Miyamoto S1, Yamashita T1, Miura K: Ann Surg Oncol 2021/6; 28 (6): 3066-72. (ź–؁@’1, ‹{–{r•ă1, ŽR‰ş@‘ń1: 1Ž¨•@ˆôAE“ŞčňŠO)

110385. [Œ´’˜] The effect of laryngeal elevation training on swallowing function in patients with dysphagia. Sugaya N, Goto F, Seino Y1, Nishiyama K, Okami K: J Laryngol Otol 2021/7; 135 (7): 574-8. (´–ě—R”y1: 1Ž¨•@ˆôAE“ŞčňŠO)

110386. [Œ´’˜] A report on patients with vertigo seen at a specialized vertigo outpatient clinic Ochiai A1: Kitasato Med J 2021/9; 51 (2): 102-8. (—Ž‡@“Ö1: 1Ž¨•@ˆôAE“ŞčňŠO)

110387. [Œ´’˜] Characteristics that predict penetration - aspiration in elderly patients following supracricoid laryngectomy with cricohyoidoepiglottopexy - a videofluoroscopic study. Seino Y1, Miyamoto S1, Nakayama M, Yamashita T1, Miles A, Allen JE: J Laryngol Otol 2021/11; 1-24. (´–ě—R”y1, ‹{–{r•ă1, ŽR‰ş@‘ń1: 1Ž¨•@ˆôAE“ŞčňŠO)

110388. [Œ´’˜] The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy. Saigusa N, Hirai H, Tada Y, Kawakita D, Nakaguro M, Tsukahara K, Kano S, Ozawa H, Kondo T, Okami K, Togashi T, Sato Y, Urano M, Kajiwara M, Shimura T, Fushimi C, Shimizu A, Okamoto I, Okada T, Suzuki T, Imanishi Y, Watanabe Y, Sakai A, Ebisumoto K, Sato Y, Honma Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Takahashi H, Ando M, Kohsaka S, Matsuki T1, Nagao T: Front Oncol 2022/2; 11: 779882. (ź–؁@’1: 1Ž¨•@ˆôAE“ŞčňŠO)

110389. [Œ´’˜] Postoperative Complications and Swallowing Function after Jejunal and Skin Flap Reconstruction for Hypopharyngeal Carcinoma-A Multicenter Retrospective Study. Tokashiki K, Okamoto I, Okada T, Sato H, Yamashita T1, Matsuki T1, Kondo T, Fushimi C, Masubuchi T, Miura K, Omura G, Tsukahara K: J Clin Med 2022/3; 11 (5): 1464. (ŽR‰ş@‘ń1, ź–؁@’1: 1Ž¨•@ˆôAE“ŞčňŠO)

110390. [Œ´’˜] Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma. Okada T, Fushimi C, Matsuki T1, Okamoto I, Sato H, Kondo T, Tokashiki K, Kishida T, Ito T, Yamashita G, Aihara Y, Hanyu K, Kushihashi Y, Masubuchi T, Tada Y, Miura K, Harada Y1, Momiyama K1, Yamashita T1, Omura G, Takahashi H, Oridate N, Tsukahara K: Anticancer Res 2022/3; 42 (3): 1607-13. (ź–؁@’1, Œ´“c—YŠî1, –ŕŽR•Ű1, ŽR‰ş@‘ń1: 1Ž¨•@ˆôAE“ŞčňŠO)

120033. [Œ´’˜] ‘SgŤƒGƒŠƒeƒ}ƒg[ƒfƒX (SLE) ‚̐_ŒoŽ¨‰ČŠw“IŒŸ“˘. —Ž‡@“Ö (Ž¨•@ˆôAE“ŞčňŠO): Ž¨•@ˆôA‰ČE“Şčň•”ŠO‰Č 2021/4; 93 (4): 367-72.

120034. [Œ´’˜] “Şčň•”ŠO‰Čˆă‚ŞŽ{s‚ľ‚˝—V—Ł‘gD‚É‚ć‚éÄŒšŽčp‚ĚŒŸ“˘. ź–؁@’1, ‹{–{r•ă1, ‰Á”[Fˆę1, ’ç@ăĕ˝2, ŒĂ–ŘˆťŽq1, –ŕŽR•Ű1, Œ´“c—YŠî1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): “ú–{“Şčň•”ŠŕŠw‰ďŽ 2021/6; 47 (1): 15-20.

120035. [Œ´’˜] ‘Šúš‹‰şƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‰î“ü‚É‚ć‚éA“ވŸ‘S“Eop‚ĚŽĄ—ĂŠúŠÔ’Zk‚ĚŽŽ‚Ý. ‹{–{r•ă1, ź–؁@’1, ‰Á”[Fˆę1, ’ç@ăĕ˝2, ŒĂ–ŘˆťŽq1, –ŕŽR•Ű1, Œ´“c—YŠî1, ´–ě—R”y1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): “ú–{“Şčň•”ŠŕŠw‰ďŽ 2021/6; 47 (1): 65-70.

310052. [Ç—á•ń] Endolymphatic sac tumor followed as Meniere's disease Ochiai A1, Seino Y1: International Journal of Clinical and Medical Case Reports 2021; OPEN ACCESS. DOI: 10.46998/UCMCR.2021.14.000334. (—Ž‡@“Ö1, ´–ě—R”y1: 1Ž¨•@ˆôAE“ŞčňŠO)

310053. [Ç—á•ń] Removal of a Giant Parapharyngeal Space Oncocytoma Without Osteotomy. Matsuki T1, Tsutsumi S2, Miyamoto S1, Kano K1, Momiyama K1, Asako Y1, Yamashita T1:
Ear Nose Throat J 2021/10; 1455613211048973. (ź–؁@’1, ’ç@ăĕ˝2, ‹{–{r•ă1, ‰Á”[Fˆę1, –ŕŽR•Ű1, óŒĂ—R‹IŽq1, ŽR‰ş@‘ń1: 1Ž¨•@ˆôAE“ŞčňŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

320020. [Ç—á•ń] Š{ŠÖß–ł‹ŰŤ”^ᇂđćs”­Ç‚ľ‚˝‰ŠÇŤŽžŠł‚Ě1—á. óŒĂ—L‹IŽq1, ‹{–{r•ă1, “Ąě’ź–ç1, ŒĂ–ŘČŒá1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): “ú–{Ž¨•@ˆôA‰ČŠw‰ď‰ď•ń 2021/6; 124 (6): 897-902.

320021. [Ç—á•ń] ‘¤čň•”‚ɐś‚ś‚˝‹‘ĺ–aŽŒ`×–EŽ‰–bŽî—á. “c‘şš–ç1, ź–؁@’1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): Ž¨•@—Տ° 2021/10; 114 (10): 771-6.

[Šw‰ďEŒ¤‹†‰ď“™]

723639. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Supracricoid Laryngectomy‚É‚¨‚Ż‚éVş–勡ó‚Ě•p“x‚Ć—\‘ވöŽq. ‹{–{r•ă1, ź–؁@’1, ‰Á”[Fˆę1, ’ç@ăĕ˝2, –ŕŽR•Ű1, Œ´“c—YŠî1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć45‰ń“ú–{“Şčň•”ŠŕŠw‰ď (2021/6/17), ç—t (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723640. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŞŽĄ“IĆŽËŒă‚Ě‹ÇŠˆâŽcÄ”­‚ɑ΂ˇ‚éELPS. ‰Á”[Fˆę1, Œ˜“ce—˜2, ˆęŒËš–ž3, Œ´“c—YŠî1, ŒĂ]N–ž2, ‹{–{r•ă1, ź–؁@’1, ’ç@ăĕ˝4, –ŕŽR•Ű1, “c糁@‘2,5, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO, 2Á‰ťŠí“ŕ, 3•a—, 4‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 5V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć45‰ń“ú–{“Şčň•”ŠŕŠw‰ď (2021/6/18), ç—t (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723641. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) TS-1Ň‚Ş’ˇŠú‚Ě—LŒřŤ‚đŽŚ‚ľ‚˝Žčp‹‘”ېisŒűo’ęŠŕ‚Ěˆę—á. –ŕŽR•Ű1, ź–؁@’1, ‹{–{r•ă1, ‰Á”[Fˆę1, ’ç@ăĕ˝2, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć45‰ń“ú–{“Şčň•”ŠŕŠw‰ď (2021/6/18), ç—t (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723642. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) A“Ş“EoŒă‚Ě–Ť•Ö”éÇ‚ÉŠÖ‚ˇ‚é—Տ°Œ¤‹†. Œ´“c—YŠî1, ź–؁@’1, ‹{–{r•ă1, ‰Á”[Fˆę1, ’ç@ăĕ˝2, –ŕŽR•Ű1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć45‰ń“ú–{“Şčň•”ŠŕŠw‰ď (2021/6/18), ç—t (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723643. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Nivolumab‚đ“Š—^‚ľ‚˝Ä”­“]ˆÚ“Şčň•”G•˝ă”çŠŕ88—á‚É‚¨‚Ż‚éReal-world‚Ě’ˇŠúŹŃ|‘˝Ž{Ý‹¤“ŻŒ¤‹†|. ź–؁@’1, ‰Ş–{ˆÉě, •šŒŠç’ˆ, ‚‹´G‘, ‰Ş“c‘ń˜N, ‹ß“Ą‹Mm, ˛“ĄGŽ÷, ˆÉ“Ą’BĆ, “n‰Ă•~–M•F, ’ËŒ´´˛, ‰HśŒ’ŽĄ, ‘•Ł’B•v, ‘˝“c—Yˆę˜Y, ŽO‰YO‹K, Ź‘ş@‹, ŕV•”@—Ď, ě–k‘ĺ‰î, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć45‰ń“ú–{“Şčň•”ŠŕŠw‰ď (2021/6/17), ç—t (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723644. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒƒjƒG[ƒ‹•a‚Ě—ź‘¤’Ž—Í‚É‚¨‚Ż‚é“Ż’˛Ť‚ɂ‚˘‚Ä‚ĚŒŸ“˘|‘ć3•ń|. V“c‹`—m1, ’ˇŔ‰p–ž1,2 (1Ž¨•@ˆôAE“ŞčňŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć80‰ń“ú–{‚ß‚Ü‚˘•˝tˆăŠw‰ď‘‰ďEŠwpu‰‰‰ď (2021/11/11), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), —\eW: Equilibrium Res 2021; 80 (5): p.447.

723645. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚ß‚Ü‚˘”­ě‚ĚŠł‘¤‚Ě”ť’č‚Ş˘“ď‚Ĺ‚ ‚Á‚˝—ź‘¤ƒƒjƒG[ƒ‹•a‚Ě1Ç—á. ’†ě‹M”V1, —Ž‡@“Ö1, ’ˇŔ‰p–ž1,2 (1Ž¨•@ˆôAE“ŞčňŠO, 2V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć80‰ń“ú–{‚ß‚Ü‚˘•˝tˆăŠw‰ď‘‰ďEŠwpu‰‰‰ď (2021/11/11), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), —\eW: Equilibrium Res 2021; 80 (5): p.449.

723646. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‰Á—•˝táŠQ‚ɑ΂ˇ‚éW’c‚Ĺ‚Ě•˝t‹Ř—̓gƒŒ[ƒjƒ“ƒO. —Ž‡@“Ö (Ž¨•@ˆôAE“ŞčňŠO): ‘ć80‰ń“ú–{‚ß‚Ü‚˘•˝tˆăŠw‰ď‘‰ďEŠwpu‰‰‰ď (2021/11/12), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723647. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŒoŒű“Iƒƒ{ƒbƒgŽx‰‡‰şŽčp“ą“ü‰Šú‚É‚ ‚˝‚Á‚Ä‚Ě“–‰Č‚ĚŽć‚č‘g‚Ý. ŽR‰ş@‘ń1, ‹{–{r•ă1 (1Ž¨•@ˆôAE“ŞčňŠO): ‘ć31‰ń“ú–{“Şčň•”ŠO‰ČŠw‰ď‘‰ď‚Č‚ç‚Ń‚ÉŠwpu‰‰‰ď (2022/3/3), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723648. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ăŠ{“´‚ɐś‚ś‚˝intravascular papillary endothelial hyperplasia‚Ě1—á. Œ´“c—YŠî1, ‹{–{r•ă1, ŽR–{ŒŤŒá1, ŽR‰ş@‘ń1, ‘ĺ–ŘŠ˛•ś2 (1Ž¨•@ˆôAE“ŞčňŠO, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): ‘ć31‰ń“ú–{“Şčň•”ŠO‰ČŠw‰ď‘‰ď‚Č‚ç‚Ń‚ÉŠwpu‰‰‰ď (2022/3/3), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723649. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚—î“Şčň•”ŠŕŠłŽŇ‚Ě”F’m‹@”\‚ƏpŒă‚š‚ń–Ď‚ĚŠÖŒW‚ĚŒŸ“˘. –ŕŽR•Ű1, ‹{–{r•ă1, ź–؁@’1, ‰Á”[Fˆę1, ’ç@ăĕ˝2, Œ´“c—YŠî1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć31‰ń“ú–{“Şčň•”ŠO‰ČŠw‰ď‘‰ď‚Č‚ç‚Ń‚ÉŠwpu‰‰‰ď (2022/3/3), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723650. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —\–h“Ičň•”Šs´‚ލA“ވŸ‘S“E‚É‹y‚Ú‚ˇ‰e‹ż. ‹{–{r•ă1, ź–؁@’1, ‰Á”[Fˆę1, ’ç@ăĕ˝2, –ŕŽR•Ű1, Œ´“c—YŠî1, ŽR‰ş@‘ń1 (1Ž¨•@ˆôAE“ŞčňŠO, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć31‰ń“ú–{“Şčň•”ŠO‰ČŠw‰ď‘‰ď‚Č‚ç‚Ń‚ÉŠwpu‰‰‰ď (2022/3/4), ‘ĺă (ƒnƒCƒuƒŠƒbƒhŠJĂ).


¸_‰ČŠw

[Šwp˜_•ś]

110391. Œ´’˜ Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study. Numata S, Nakataki M, Hasegawa N, Takaesu Y, Takeshima M, Onitsuka T, Nakamura T, Edagawa R, Edo H, Miura K, Matsumoto J, Yasui]Furukori N, Kishimoto T, Hori H, Tsuboi T, Yasuda Y, Furihata R, Muraoka H, Ochi S, Nagasawa T, Kyou Y1, Murata A, Katsumoto E, Ohi K, Hishimoto A, Inada K1, Watanabe K, Hashimoto R: Neuropsychopharmacol Rep 2021/6; 41 (2): 199-206. (›I@‘P‹M1, ˆî“c@Œ’1: 1¸_)

110392. [Œ´’˜] Factors associated with blood carnitine levels in adult epilepsy patients with chronic valproic acid therapy. Saito M1, Takizawa T1, Miyaoka H1: Epilepsy Research 2021/9; 175: 106697. (âV“Ął”Í1, ‘ęŕV‹B–î1, ‹{‰Ş@“™1: 1¸_)

110393. [Œ´’˜] Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project. Hashimoto N, Yasui-Furukori N, Hasegawa N, Ishikawa S, Numata S, Horie H, Iida H, Ichihashi K, Furihata R, Murata A, Tsuboi T, Takeshima M, Kyou Y1, Komatsu H, Kubota C, Ochi S, Takaesu Y, Usami M, Nagasawa T, Hishimoto A, Miura K, Matsumoto J, Ohi K, Yamada H, Inada K1, Watanabe K, Shimoda K, Hashimoto R: Asian Journal of Psychiatry 2021/9; 63: 102744. (›I@‘P‹M1, ˆî“c@Œ’1: 1¸_)

320022. [Ç—á•ń] ‹}ŤŠúŽĄ—ĂŒă3”NŠÔ”F’m‹@”\‚̐„ˆÚ‚đ’ǐՂľ‚˝_Œo”~“Ĺ‚Ěˆę—á. ‹g‘ş—LŠó1, ›I@‘P‹M1, •űŒcŽO˜Y2, ‘ęŕV‹B–î1, ‘ĺÎ@’q1, ‹{‰Ş@“™1 (1¸_, 2—Տ°S—Žş): ¸_‰ČŽĄ—ĂŠw 2021/4; 36 (4): 461-6.

320023. [Ç—á•ń] Ť“Iˆí’Esˆ×‚đŒJ‚č•Ô‚ľ‚˝”F’m‹@”\áŠQ‚𔺂¤‚—îŽŇ‚Ěˆę—á. Ź–ě@„1, ›I@‘P‹M1, –Ř‘ş—F•F1, ’†—˘—F1, o…—ć“Ţ1, ‘ęŕV‹B–î1, ‘ĺÎ@’q1, ‹{‰Ş@“™1 (1¸_): ¸_‰ČŽĄ—ĂŠw 2021/7; 36 (7): 841-7.

320024. [Ç—á•ń] ’YŽ_ƒŠƒ`ƒEƒ€‚ĹŽĄ—Ă’†‚É’†•Ť”A•öÇ‚đ”­Ç‚ľƒŠƒ“ƒp‹…Ť˜R“l‰ş‚‘ĚŒă—t‰Š‚Ş‹^‚í‚ę‚˝1—á. –Ř‘ş—F•F1, ‹´–{@Ž÷1, Vˆä‹v–Ť1, Ź–ě@„1, o…—ć“Ţ1, ‘ĺÎ@’q1, âV“Ął”Í1, ‹{‰Ş@“™1 (1¸_): “Œ‹ž¸_ˆăŠw‰ďŽ 2021/7; 35: 44752.

522561. [uŔ]y“ÁW: ¸_‰Č‚É‚¨‚Ż‚éƒAƒEƒgƒŠ[ƒ`‚ĚŠŠ‚߁z‘ĺŠw•a‰@‚É‚¨‚Ż‚é‘˝EŽíƒAƒEƒgƒŠ[ƒ`ƒ`[ƒ€‚ĚƒXƒXƒ. Î“c‹§G1, Ż–ěŠT”O1 (1¸_): ¸_‰ČŽĄ—ĂŠw 2021/4; 36 (4): 419-24.

522562. [uŔ]y“ÁWI: ƒXƒ|[ƒc‚Ɛ¸_ˆăŠwzƒAƒXƒŠ[ƒg‚É‚¨‚Ż‚鐇–°áŠQ. ŽR–{G–ž (¸_): ¸_‰Č 2021/4; 38 (4): 401-7.

522563. [uŔ]y“ÁW: ˆË‘śÇ ƒŒƒWƒfƒ“ƒg‚Ş’m‚Á‚Ä‚¨‚Ť‚˝‚˘f’f‚⎥—Ă‚ĚƒRƒc! “ÁW‚É‚ ‚˝‚Á‚āzS—EŽĐ‰ď“IŽĄ—Ă <•¨ŽżŠÖ˜AáŠQŒQƒAƒ‹ƒR[ƒ‹ˆË‘śE–ň•¨ˆË‘śS—EŽĐ‰ď“IŽĄ—Ă. ‘şŁ‰ŘŽq1, ’Š‘q’•ś2 (1ˆă—ÉqśŠw•”, 2¸_): ¸_‰ČResident 2021/4; 2 (2): 96-8.

522564. [uŔ]y“Á•ĘŠé‰ć: ŽvtŠú‚Ě‚ą‚ą‚ë‚Ć‚Š‚ç‚žzĽŽvtŠú‚Ě‚ą‚ą‚ë‚Ć‚Š‚ç‚ž‚đf‚é@‹N—§Ť’˛ßáŠQ‚Ć•s“oZ|Ž™“ś¸_‰Čˆă‚Š‚ç“`‚Ś‚˝‚˘‚ą‚Ć. ˆäăŸ•v (¸_): ‚ą‚ą‚ë‚̉Ȋw 2021/5; 217: 67-72.

522565. [uŔ]y“ÁW: ‚—îŽŇ‚Ě•é‚ç‚ľE‚ą‚ą‚ëE‹ęŠz‚—î‚̐l‚Ě‚ą‚ą‚ë‚ɕωť‚ސś‚Ü‚ę‚鎞. ‘ĺÎ@’q (¸_): ‚ą‚ą‚ë‚̉Ȋw 2021/7; 218: 18-22.

522566. [uŔ]y“ÁW: ‚—îŽŇ‚Ě•é‚ç‚ľE‚ą‚ą‚ëE‹ęŠz‚—î‚̐l‚Ö‚ĚŽx‰‡‚Ć–K–âf—Ă. Ż–ěŠT”O (¸_): ‚ą‚ą‚ë‚̉Ȋw 2021/7; 218: 59-64.

522567. [uŔ]y“ÁW: VŒ^ƒRƒƒiƒEƒCƒ‹ƒX1”N‚đU‚č•Ô‚Á‚āzCOVID-19‚ą‚ą‚ë‚ĚƒPƒA. ‘ĺÎ@’q (¸_): —Տ°‚ĆƒEƒCƒ‹ƒX 2021/8; 49 (3): 106-11.

522568. [uŔ]y“ÁW: Ž„‚Ě‚ą‚ŕ‚č•űz”ޏ䓇‚ĚŽv‚˘o‚ĆYouTube. Ż–ěŠT”O (¸_): “‡Ž¸’˛Ç‚Ě‚Đ‚ë‚Î 2021/9; 18: 49-54.

522569. [uŔ]y“ÁW: ”F’mÇ‚ĚŽžŠłŠT”O‚ɂ‚˘‚čl‚Ś‚é;—đŽj“IŽ–€‚Š‚珫—ˆ‚܂Łz”F’mÇ‚̍s“ŽES—Çó(BPSD)ŠT”O‚ĚŒ÷ß. ‘ĺÎ@’q (¸_): ˜V”N¸_ˆăŠwŽGŽ 2021/10; 32 (10): 1046-50.

530012. [‚ť‚Ě‘ź (Letter to the Editor)] Mental health services at the Tokyo 2020 Olympic and Paralympic Games during the COVID-19 pandemic. Nishida M, Takagi S, Yamaguchi T, Yamamoto H1, Yoshino S, Yagishita K, Akama T: Sports Psychiatry 2022/2; 1 (2): 36-8. (ŽR–{G–ž1: 1¸_)

530013. [‚ť‚Ě‘ź (Letter to the Editor)] Administration of a small dose of perampanel improves walking ability in a case of Lance-Adams Syndrome. Saita D1, Oishi S1, Saito M1: Psychiatry Clin Neurosci 2022/3; 76 (3): 89. (×“c‘厥1, ‘ĺÎ@’q1, âV“Ął”Í1: 1¸_)

540049. [‚ť‚Ě‘ź (ŽGŽ“ÁW•ŇW)]y“ÁW: ‚—îŽŇ‚Ě•é‚ç‚ľE‚ą‚ą‚ëE‹ęŠz‘ĺÎ@’q (¸_): ‚ą‚ą‚ë‚̉Ȋw 2021/7; 218.

540050. [‚ť‚Ě‘ź (´˜^)] ‹~–˝‹~‹}ƒZƒ“ƒ^[‚É”Ŕ‘—‚ł‚ę‚鎊ŽEŠé}ŽŇ‚ɑ΂ˇ‚鐸_‰Čˆă‚Ě–đŠ„@ŽŠŽEŠé}‚Ĺ”Ŕ‘—‚ł‚ę‚é‹}Ť–ň•¨’†“ĹŠłŽŇ‚ĚĹ‹ß‚ĚŒXŒü‚ƑΉž. Vˆä‹v–Ť1, Ż–ěr–í1, Î“c‹§G1, ‹{‰Ş@“™1 (1¸_): ¸__ŒoŠwŽGŽ 2021/9; “Á•Ę†: S411.

540051. [‚ť‚Ě‘ź (ŽGŽ“ÁW•ŇW)]y“Á•ĘŠé‰ć: ’N‚Š‚đƒPƒA‚ˇ‚él‚ĚƒPƒA|Žx‰‡ŽŇŽx‰‡‚đl‚Ś‚éz‘ĺÎ@’q (¸_): ‚ą‚ą‚ë‚̉Ȋw 2022/3; 222.

[’˜@‘]

620126. [Šwp‘ (’P’˜)]y‹łˆő‚Ěƒƒ“ƒ^ƒ‹ƒwƒ‹ƒX : ćś‚Ě‚ą‚ą‚ë‚Ş‰ó‚ę‚Č‚˘‚˝‚ß‚Ěƒqƒ“ƒgz‘ĺÎ@’q (¸_), ‘ĺCŠŮ‘“X, “Œ‹ž, 2021/5”­s.

620127. [Šwp‘ (•Ş’SŽˇ•M)]y‚â‚Á‚Ä‚Ý‚˝‚­‚Č‚éƒAƒfƒBƒNƒVƒ‡ƒ“f—ÁEŽx‰‡ƒKƒCƒh@ƒAƒ‹ƒR[ƒ‹E–ň•¨EƒMƒƒƒ“ƒuƒ‹‚Š‚çƒQ[ƒ€ˆË‘ś‚܂ŁzŠ—ś—TŽi (¸_), •Ň: ź–{r•F, ˛‹vŠÔŠ°”V, Š—ś—TŽi, •śŒő“°, “Œ‹ž, 2021/9”­s.

620128. [Šwp‘ (•Ş’SŽˇ•M)]yuSv‚Ě‚¨ŽdŽ–@Ą“ú‚ŕ’N‚Š‚Ě‚ť‚΂ɗ§‚Â24l‚Ě•¨ŒęzChapter 1 gS‚Ě‚¨ˆăŽŇ‚ł‚ńh‚Á‚ĉ˝‚đ‚ľ‚Ä‚˘‚é‚Ě?@‚Ž‚é‚Ž‚é‚ľ‚Č‚Ş‚çS‚Ć‚Š‚Š‚í‚é, p.54-64. Ż–ěŠT”O (¸_), •Ň: ‰Ío‘–[VŽĐ, ‰Ío‘–[VŽĐ, “Œ‹ž, 2021/10”­s.

620129. [Šwp‘ (•Ş’SŽˇ•M)]y“Ś‚°‚Č‚˘“ŕ‰Čf—Á@uę–ĺŠO‚Ȃ̂Łcv‚Š‚çu‘Sg‚đf‚é!v‚ցz—Ěˆć…L ‚ť‚Ě‘ź@ƒAƒ‹ƒR[ƒ‹ˆË‘śÇ`‘ĺŘ‚Č‚Ě‚Í–â‘č‚Ě‹¤—L‚Ć‚ť‚Ě‰đŒˆô‚đˆę‚ɍl‚Ś‚é‚ą‚Ć, p.331-5. ’Š‘q’•ś (¸_), •Ň: Ôˆä–őG, “Œ@Œő‹v, ”Ş“c@, —é–؁@‘, źŽR‘ĺ’n, Œ´@Ť”V, —r“yŽĐ, “Œ‹ž, 2021/10”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

722295. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰“™) u‡–°Eś‘ĚƒŠƒYƒ€‚ĆƒXƒ|[ƒcvƒI[ƒo[ƒgƒŒ[ƒjƒ“ƒOÇŒóŒQ‚Ɛ‡–°. ŽR–{G–ž (¸_): ‘ć32‰ń“ú–{—Տ°ƒXƒ|[ƒcˆăŠw‰ďŠwpW‰ď (2021/11/14), WebŠJĂ, “ú–{—Տ°ƒXƒ|[ƒcˆăŠw‰ďŽ 2021/10; 29 (4): S91.

722296. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰“™) ”F’mÇ‚Ě‚ ‚él‚Ş, –{“–‚É’nˆć‚Őś‚Ťś‚Ť‚Ć•é‚ç‚ľ‚Ä‚˘‚­‚˝‚ß‚É‚Ĺ‚Ť‚é‚ą‚ƂƂ́`ƒNƒŠƒjƒJƒ‹ƒpƒX‚ĚŽ‹“_‚Š‚ç`. ›I@‘P‹M1, ‰ş‘ş—TŒŠŽq2, ŽOŒ´”üá3, ‘ĺÎ@’q1, •xŠ~ç‘ă”ü4, ’†‘şŒőŹ5, ‰Á“Ą’‰‘Š6 (1¸_, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3Ż“ŕ“ě•”’nˆć˜AŒgƒpƒX‹Ś‹c‰ď, 4’ß‰ŞŽs—§‘‘“ŕ•a‰@, 5źŒ´ƒNƒŠƒjƒbƒN, 6(Š”) ‚ ‚¨‚˘‚Ż‚ ): ‘ć21‰ń“ú–{ƒNƒŠƒjƒJƒ‹ƒpƒXŠw‰ďŠwpW‰ď (2021/11/27), ŽRŒ` (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722297. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰“™) “d‹C‚Ż‚˘‚ę‚ń—Ă–@ (ECT) ‚Ě”­ě‚Ş100%‚ŏ\•Ş—U”­‚Ĺ‚Ť‚Č‚˘‚Ć‚Ť`”­ě臒l‚đƒRƒ“ƒgƒ[ƒ‹‚ˇ‚é`. ŕVŽRŒb”g (¸_): ‘ć34‰ń“ú–{‘‡•a‰@¸_ˆăŠw‰ď‘‰ď (2021/12/7-31), WebŠJĂ.

722298. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ”­ě臒l‚đƒRƒ“ƒgƒ[ƒ‹‚ˇ‚é. ŕVŽRŒb”g (¸_): ‘ć34‰ń“ú–{‘‡•a‰@¸_ˆăŠw‰ď‘‰ď (2021/12/7-31), WebŠJĂ.

723651. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —ŤƒAƒXƒŠ[ƒg”ŐېHáŠQƒXƒNƒŠ[ƒjƒ“ƒOƒeƒXƒg (TA-EDQ) ‚ĆSCOFF‚Ć‚Ě”äŠr. ŠÖŒű–MŽq, ‘Œ’J”ü—Ľ, ‰F’Ă–ěĘ, ’†‘şŠ°], Ź´…FŽq, ç—t—zŽq, ]“cD, ŽR–{G–ž1, ŽRŒű’B–ç, ”\Ł‚ł‚â‚Š (1¸_): ‘ć32‰ń“ú–{—Տ°ƒXƒ|[ƒcˆăŠw‰ďŠwpW‰ď (2021/11/13-12/6), WebŠJĂ, “ú–{—Տ°ƒXƒ|[ƒcˆăŠw‰ďŽ 2021/10; 29 (4): S220.

723652. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘‡•a“ŕ‚Š‚ç“WŠJ‚ˇ‚é—lX‚ČˆË‘śÇŽĄ—Ă. ’Š‘q’•ś1, ”’â’m•F, Žč’ˍK—Y, “Ąě–žŠó, í‰Şrş (1¸_): ‘ć34‰ń“ú–{‘‡•a‰@¸_ˆăŠw‰ď‘‰ď (2021/12/7-31), WebŠJĂ.

723653. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “d‹C‚Ż‚˘‚ę‚ń—Ă–@‚É‚¨‚Ż‚é‹Ř’oŠÉ–ňƒƒNƒƒjƒEƒ€‚ĚŽg—p‚ÉŠÖ‚ˇ‚éŒă•űŽ‹“I’˛¸. “y“cš‘ž1, ŕVŽRŒb”g1, “‡–ě•ü–ç1, V”ü—T‘ž1, ‘ĺÎ@’q1, ’|˜Q–Ż]2, âV“Ął”Í1 (1¸_, 2–ƒŒ): ‘ć34‰ń“ú–{‘‡•a‰@¸_ˆăŠw‰ď‘‰ď (2021/12/7-31), WebŠJĂ.

731073. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) Ž™“ś¸_‰Čˆă‚Š‚ç‚Š‚Š‚č‚‚ŻŹŽ™‰Čˆă‚Ö“`‚Ś‚˝‚˘‚ą‚Ć. ˆäăŸ•v (¸_): ‘ć23‰ńuŽq‚Ç‚ŕ‚̐SvŒ¤C‰ď (2021/5/9), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733210. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‰đ—ŁŤáŠQ‚̐f’f‚ʼnÁ—Ă’†‚ÉŽî᎗l‘˝”­Ťd‰ťÇ‚đ”­Ç‚ľ‚˝1—á. o…—ć“Ţ1, Vˆä‹v–Ť1, ‹´–{@Ž÷1, –Ř‘ş—F•F1, Ź–ě@„1, ł–؍—Ń1, ‘ĺÎ@’q1, âV“Ął”Í1, ‹{‰Ş@“™1 (1¸_): “Œ‹ž¸_ˆăŠw‰ď‘ć122‰ńŠwp‘‰ď (2021/7/3), “Œ‹ž.

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-110029. [Œ´’˜] A reliable method to reduce electrode impedances during electroconvulsive therapy. Shimano T1, Sawayama E, Oishi S1, Natsuyama T1, Takizawa T1, Saito M1, Tanaka K2, Miyaoka H1: Kitasato Med J 2021/3; 51 (1): 19-23. (“‡–ě•ü–ç1, ŕVŽRŒb”g1, ‘ĺÎ@’q1, ‰ÄŽR@‘ě1, ‘ęŕV‹B–î1, âV“Ął”Í1, “c’†Žr2, ‹{‰Ş@“™1: 1¸_, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

'20-110030. [Œ´’˜] A comparative study of the outcomes of individual psychotherapy alone and that in conjunction with group psychotherapy for gambling disorder. Asakura T1, Oishi S1, Ogata K2, Takizawa T1, Kyou Y1, Demizu R1, Imayuki H1, Gamo Y1: Kitasato Med J 2021/3; 51 (1): 49-55. (’Š‘q’•ś1, ‘ĺÎ@’q1, •űŒcŽO˜Y2, ‘ęŕV‹B–î1, ›I@‘P‹M1, o…—ć“Ţ1, ĄáG’1, Š—ś—TŽi1: 1¸_, 2—Տ°S—Žş)

'20-120003. [Œ´’˜] ”F’mÇ‚Ě‚ ‚él‚̉Ƒ°‰îŒěŽŇ‚ɑ΂ˇ‚éS—‹łˆçƒvƒƒOƒ‰ƒ€‚Ě—LŒřŤ‚ĚŒŸ“˘. ›I@‘P‹M1, ‘ĺÎ@’q1, ‘ęŕV‹B–î1, ‹{‰Ş@“™1 (1¸_): ¸_‰ČŽĄ—ĂŠw 2021/3; 36 (3): 357-62.


•úŽËü‰ČŠw (‰ć‘œf’fŠw)

[Šwp˜_•ś]

110394. [Œ´’˜] Effects of negativity bias on amygdala and anterior cingulate cortex activity in short and long emotional stimulation paradigms. Yoshida N, Kotani Y, Ohgami Y, Kunimatsu A, Inoue Y1, Kiryu S, Okada Y: Neuroreport 2021/4; 32 (6): 531-9. (ˆäă—D‰î1: 1•úŽËü (‰ć‘œ))

110395. [Œ´’˜] Childhood trauma affects autobiographical memory deficits through basal cortisol and prefrontal-extrastriate functional connectivity. Hakamata Y, Mizukami S1, Izawa S, Moriguchi Y, Hori H, Matsumoto N, Hanakawa T, Inoue Y2, Tagaya H1: Psychoneuroendocrinology 2021/5; 127: 105172. (…ăT–ç1, ˆäă—D‰î2, “cƒ–’J_–M1: 1ˆă—ÉqśŠw•”, 2•úŽËü (‰ć‘œ))

110396. [Œ´’˜] The membrane-linked adaptor FRS2ƒŔ fashions a cytokine-rich inflammatory microenvironment that promotes breast cancer carcinogenesis. Takeuchi Y, Kimura N, Murayama T, Machida Y, Iejima D, Nishimura T, Terashima M, Wang Y, Li M, Sakamoto R, Yamamoto M, Itano N, Inoue Y1, Ito M, Yoshida N, Inoue J, Akashi K, Saya H, Fujita K, Kuroda M, Kitabayashi I, Voon D, Suzuki T, Tojo A, Gotoh N: Proc Natl Acad Sci U S A 2021/10; 118 (43): e2103658118. (ˆäă—D‰î1: 1•úŽËü (‰ć‘œ))

110397. [Œ´’˜] Effects of Gadolinium Deposition in the Brain on Motor or Behavioral Function: A Mouse Model. Akai H, Miyagawa K, Takahashi K, Mochida-Saito A, Kurokawa K, Takeda H, Tsuji M, Sugawara H, Yasaka K, Kunimatsu A, Inoue Y1, Abe O, Ohtomo K, Kiryu S: Radiology 2021/11; 301 (2): 409-16. (ˆäă—D‰î1: 1•úŽËü (‰ć‘œ))

110398. [Œ´’˜] Conversion from dose-length product to effective dose in computed tomography venography of the lower extremities. Inoue Y1, Yonekura Y1, Nagahara K2, Uehara A2, Ikuma H2: J Radiol Prot 2022/1; 42 (1). doi: 10.1088/1361-6498/ac49d6. (ˆäă—D‰î1, •Ä‘q—R‰Ŕ1, ‰iŒ´˜aŒ›2, ăŒ´•ŕ‰Ä2, ˆÉŒFG‹L2: 1•úŽËü (‰ć‘œ), 2•úŽËü•”)

110399. [Œ´’˜] Implicit and explicit emotional memory recall in anxiety and depression: Role of basolateral amygdala and cortisol-norepinephrine interaction. Hakamata Y, Mizukami S, Izawa S, Okamura H, Mihara K, Marusak H, Moriguchi Y, Hori H, Hanakawa T, Inoue Y1, Tagaya H2: Psychoneuroendocrinology 2022/2; 136: 105598. (ˆäă—D‰î1, “cƒ–’J_–M2: 1•úŽËü (‰ć‘œ), 2ˆă—ÉqśŠw•”)

110400. [Œ´’˜] Association of childhood maltreatment history with salivary interleukin-6 diurnal patterns and C-reactive protein in healthy adults. Hori H, Izawa S, Yoshida F, Kunugi H, Kim Y, Mizukami S1, Inoue Y2, Tagaya H, Hakamata Y: Brain Behav Immun 2022/3; 101: 377-82. (…ăT–ç1, ˆäă—D‰î2: 1ˆă—ÉqśŠw•”, 2•úŽËü (‰ć‘œ))

310054. [Ç—á•ń] A case of solid-type pancreatic hamartoma presenting high apparent diffusion coefficient value: histopathological correlation and literature review. Woo J, Haradome H1,2, Adachi K3, Iwai T4, Nishizawa N5, Murakumo Y6, Kusano C4, Kumamoto Y5, Inoue Y2, Ojiri H: Abdom Radiol (NY) 2022/6; 47 (6): 1939-47. (Œ´—ŻOŽ÷1,2, ˆŔ’B@‰ő3 Šâˆä’m‹v4, źŕVL‹ą5, ‘ş‰_–FŽ÷6, ‘–ě@‰›4, ŒGŒł—Y‰î5, ˆäă—D‰î2: 1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2•úŽËü (‰ć‘œ), 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4Á‰ťŠí“ŕ, 5ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 6•a—)

510021. [‘ŕ] Radiation Dose Modulation of Computed Tomography Component in Positron Emission Tomography/Computed Tomography. Inoue Y1: Semin Nucl Med 2022/3; 52 (2): 157-66. (ˆäă—D‰î1: 1•úŽËü (‰ć‘œ))

520015. [‘ŕ]yRefresher Coursezf—Ă—p•úŽËü‚Ě‚˝‚ß‚ĚˆŔ‘SŠÇ—@1. ‰üł–@—ß‚ÉŠî‚Ă‚­f—Ă—p•úŽËü‚ĚˆŔ‘SŠÇ—‘̐§. ˆäă—D‰î (•úŽËü (‰ć‘œ)): ‰ć‘œf’f 2021/4; 41 (5): 512-6.

522570. [uŔ] ě•i”­•\1: Šáâ|‰ş•Ç‚̐‚Ť”˛‚ŻœÜ‚đ—‰đ‚ˇ‚é‚˝‚ß‚Ě2–‡‚ĚƒCƒ‰ƒXƒg. •‚F—´‘ž˜Y (•úŽËü (‰ć‘œ): “ú–{ƒƒfƒBƒJƒ‹ƒCƒ‰ƒXƒgƒŒ[ƒVƒ‡ƒ“Šw‰ďŽGŽ 2021/9; 3 (1): 81-3.

522571. [uŔ]y“ÁW: f’f‚ĚŒˆ‚ߎč‚Ć‚Č‚Á‚˝‰ć‘œEŠŒŠII|Á‰ťŠí|zŠĚ’_“š|‚Ń‚Ü‚ńŤŠĚŽžŠł. Œ´—ŻOŽ÷1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2•úŽËü (‰ć‘œ)): —Տ°•úŽËü 2021/11; 66 (12): 1391-413.

530014. [‚ť‚Ě‘ź (Published Erratum)] Correction to: Predictive factors of truncation artifacts in the arterial phase of Gd-EOB-DTPA-enhanced MRI: a nationwide multicenter study. Tsurusaki M, Sofue K, Onishi H, Goshima S, Higaki A, Isoda H, Haradome H1,2, Ishii K, Murakami T: Jpn J Radiol 2021/4; 39 (4): 405. (Œ´—ŻOŽ÷1,2: 1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2•úŽËü (‰ć‘œ))

540052. [‚ť‚Ě‘ź (ƒKƒCƒhƒ‰ƒCƒ“)]y“ú–{IVRŠw‰ďƒKƒCƒhƒ‰ƒCƒ“zCTƒKƒCƒh‰ş”xśŒŸ‚ĚŽč‹Z‚ÉŠÖ‚ˇ‚éƒKƒCƒhƒ‰ƒCƒ“2020. “ú–{IVRŠw‰ď (ƒEƒbƒhƒnƒ€ƒX—ćŽq1, ‘ź) (1•úŽËü (‰ć‘œ)): “ú–{ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒiƒ‹ƒ‰ƒWƒIƒƒW[Šw‰ďŽGŽ 2021/9; 36 (1): 82-98.

[’˜@‘]

620130. [Šwp‘ (•Ş’SŽˇ•M)]y“ŞŒz•”’PƒCT‚ą‚ĆŽn‚߁|ŽŸ‚ĚƒXƒeƒbƒv‚܂ł‚Ȃ°‚悤| (‰ć‘œf’f2021”N‘Š§†)zIVÍ “ŞŠWŠO‚Ě’PƒCT@1. “ŞŠW’ę‰đ–U, A166-77. •‚F—´‘ž˜Y (•úŽËü (‰ć‘œ), •Ň: Â–Ř–ÎŽ÷, ź–؁@[, X@@¤, Gakken, “Œ‹ž, 2021/8”­s.

620131. [Šwp‘ (•Ş’SŽˇ•M)]y‘Śí—͂ސg‚ɂ‚­“Şčň•”‚Ě‰ć‘œf’fzŽŔ—͕ҁ@Ç—áL2-32 ,10Î‘ä’jŤ, ‘Oˆă‚ĹŽvtŠú’x”­‚đŽw“E, p.265-7. Ç—áL2-44, 40Î‘䏗Ť, ‚ŕ‚Ć‚ŕ‚ƍśŠá‚͎㎋‚Ĺ’ág’ˇ, Œ’f‚ʼnEŠá‚ĚŽ‹–ěáŠQ‚đŽw“E‚ł‚ę‚˝, p.309-11. Ç—áL2-60, 70Î‘ä’jŤ, ‘OˆăŽ¨•@‰Č‚É‚Ä, ăˆô“ŞŽîᎂđŽw“E‚ł‚ę‚˝, p.362-4. ’§í•Ň@Ç—áL3-1, 30Î‘䏗Ť, –ń3”N‘O‚Š‚çš‹‰ş˘“, 10‚ŠŒŽ‘O‚Š‚çšmş‚𮩩o, p.366-9. ’§í•Ň@Ç—áL3-24, 60Î‘䏗Ť, Œ´ŽžŠł‚ɑ΂ľŽĄ—Ă’†, p439-42. Žë–ě—m•ă, •‚F—´‘ž˜Y1 (1•úŽËü (‰ć‘œ)), •Ň: ”öK”Ž–ç, ‰Á“Ą”ŽŠî, ‹v–씎•ś, ƒƒfƒBƒJƒ‹ƒTƒCƒGƒ“ƒXƒCƒ“ƒ^[ƒiƒVƒ‡ƒiƒ‹, “Œ‹ž, 2021/9”­s.

620132. [Šwp‘ (•Ş’SŽˇ•M)]y‰ć‘œf’fƒKƒCƒhƒ‰ƒCƒ“ 2021”N”Ł@‘ć3”Łz2 “Şčň•”, p.70-97. •‚F—´‘ž˜Y (•úŽËü (‰ć‘œ)), •Ň: “ú–{ˆăŠw•úŽËüŠw‰ď, ‹ŕŒ´o”Ĺ, “Œ‹ž, 2021/9”­s.

620133. [Šwp‘ (•Ş’SŽˇ•M)]yƒJƒ“ƒQƒL‚ˇ‚é‚Ů‚Ç‚í‚Š‚é“Şčň•”ŠÔŒ„‚Ě‰ć‘œf’fzII ŠÔŒ„‚đ“ǂށ@ăœăčň•”‚É‚ ‚éŠÔŒ„@Ž¨‰ş‘BŠÔŒ„, p.118-29. •‚F—´‘ž˜Y (•úŽËü (‰ć‘œ)), •Ň: âV“ĄŽŽq, ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, “Œ‹ž, 2021/10”­s.

620134. [Šwp‘ (•Ş’SŽˇ•M)]yƒJƒ“ƒQƒL‚ˇ‚é‚Ů‚Ç‚í‚Š‚é“Şčň•”ŠÔŒ„‚Ě‰ć‘œf’fzII ŠÔŒ„‚đ“ǂށ@ăœ‰şčň•”‚É‚ ‚éŠÔŒ„@‘ŸŠíŠÔŒ„, p.192-204. Žë–ě—m•ă, •‚F—´‘ž˜Y1 (1•úŽËü (‰ć‘œ)), •Ň: âV“ĄŽŽq, ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, “Œ‹ž, 2021/10”­s.

620135. [Šwp‘ (•Ş’SŽˇ•M)]yŠĚŠŕf—ĂƒKƒCƒhƒ‰ƒCƒ“2021”N“x”Ĺ ‘ć5”ŁzŠĚŠŕf—ĂƒKƒCƒhƒ‰ƒCƒ“2021”N“x”Ĺ‚ĚŠO•”•]‰ż, p.286-92. ˛–ěŒ\“ń, ˆÉ˛ŽR_’Ę, š •Ş–ΔŽ, âŠŞŒ°‘ž˜Y, ™Œ´Œ’ˆę, Œ´—ŻOŽ÷1,2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2•úŽËü (‰ć‘œ)), •Ň: “ú–{ŠĚ‘ŸŠw‰ď, ‹ŕŒ´o”Ĺ, “Œ‹ž, 2021/10”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

712010. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Stimulus modality and contents differently affect SPN cortical distributions and components, Symposium (Functional correlates of the stimulus-preceding negativity). Kotani Y, Ohgami Y, Yoshida N, Kunimatsu A, Kiryu S, Inoue Y1: 2021 Virtual Annual Meeting of Society for Psychophysiological Research (2021/10/10-18), WebŠJĂ, Psychophysiology 2021; 58 (Suppl 1): S13. (ˆäă—D‰î1: 1•úŽËü (‰ć‘œ))

712011. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Principal Component Analysis of Subtracted SPN before auditory stimuli. Ohgami Y, Kotani Y, Yoshida N, Akai H, Kunimatsu A, Kiryu S, Inoue Y1: 2021 Virtual Annual Meeting of Society for Psychophysiological Research (2021/10/10-18), WebŠJĂ, Psychophysiology 2021; 58 (Suppl 1): S47. (ˆäă—D‰î1: 1•úŽËü (‰ć‘œ))

712012. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Radiation safety issues in clinical practice in Japan. In Radiation monitoring with patients and in medicine. Inoue Y1: IAEA Technical Meeting (2021/11/10), WebŠJĂ. (ˆäă—D‰î1: 1•úŽËü (‰ć‘œ))

713051. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Hemifield Auditory Stimulation and the Right Hemisphere Dominance of Stimulus-Preceding Negativity. Kotani Y, Ohgami Y, Yoshida N, Kunimatsu A, Kiryu S, Inoue Y1: Annual Meeting of the Organization of Human Brain Mapping (OHBM) 2021 The 27th Annual Meeting (2021/6/21-25), WebŠJĂ, Abstract Book 2021; p.22. (ˆäă—D‰î1: 1•úŽËü (‰ć‘œ))

713052. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) The Two-component Structure of Cortical Slow Waves in Anticipation of Auditory Stimuli. Ohgami Y, Kotani Y, Yoshida N, Kunimatsu A, Kiryu S, Inoue Y1: Annual Meeting of the Organization of Human Brain Mapping (OHBM) 2021 The 27th Annual Meeting (2021/6/21-25), WebŠJĂ, Abstract Book 2021; p. 23. (ˆäă—D‰î1: 1•úŽËü (‰ć‘œ))

722299. [Šw‰ď (‘S‘)] (“Á•ĘŠé‰ć) ŽY‰ČŠë‹@“IoŒŒ‚ɑ΂ˇ‚éIVR: Ž~ŒŒŹŒ÷‚Ě‚˝‚ß‚ĚƒKƒCƒhƒ‰ƒCƒ“‚ÉŠî‚Ă‚˘‚˝Žč‹Z‚Ć‚ť‚̉ž—p. ƒEƒbƒhƒnƒ€ƒX—ćŽq1, “Ąˆä@Š]1, ‹ŕˆä—Y“ń2, ˆäă—D‰î1 (1•úŽËü (‰ć‘œ), 2ŽY‰Č): ‘ć50‰ń“ú–{IVRŠw‰ď‘‰ď (2021/5/21), WebŠJĂ, “ú–{ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒiƒ‹ƒ‰ƒWƒIƒƒW[Šw‰ďŽGŽ 2021; 36 (Suppl): 100.

722300. [Šw‰ď (‘S‘)] (Œ¤CˆăEˆăŠwśƒZƒ~ƒi[) bó‘BE•›bó‘BŽžŠł‚Ě‰ć‘œf’f. •‚F—´‘ž˜Y (•úŽËü (‰ć‘œ)): ‘ć57‰ń“ú–{ˆăŠw•úŽËüŠw‰ďH‹G—Տ°‘ĺ‰ď (2021/10/4-31), WebŠJĂ, ‘ć57‰ń“ú–{ˆăŠw•úŽËüŠw‰ďH‹G—Տ°‘ĺ‰ď´˜^W 2021; p.384.

722301. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰) ‹}Ť• Ç‚ĚŽĄ—Ð헪|—ǐŤ’°ŽžŠł‚̐f’f‚ĆŽĄ—Á|. ƒEƒbƒhƒnƒ€ƒX—ćŽq (•úŽËü (‰ć‘œ): ‘ć58‰ń“ú–{• •”‹~‹}ˆăŠw‰ď‘‰ď (2022/3/24-25), “Œ‹ž.

723654. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‚ADC’l‚đŽŚ‚ľ‚˝äX‰ßŒëŽî‚Ě1—á. âZ@@, Œ´—ŻOŽ÷1,2, Šâˆä’m‹v3, źŕVL‹ą4, ˆŔ’B@‰ő5, ˆäă—D‰î2 (1V˘‹Iˆă—ÁEć’[ˆă—Ă, 2•úŽËü (‰ć‘œ), 3Á‰ťŠí“ŕ, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 5‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć34‰ń“ú–{• •”•úŽËüŠw‰ď (2021/6/19), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723655. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‘SgPET/CT‚É‚¨‚Ż‚éü—Ę’ˇ‚łĎ‚Š‚çŽŔŒřü—Ę‚Ö‚Ě•ĎŠˇ. ‘ĺ‹v•Ű—I1, ˆäă—D‰î1, ‰iŒ´˜aŒ›2, ăŒ´•ŕ‰Ä2, ‚–쐽l2, ‹{•”ä˜CŽ÷2 (1•úŽËü (‰ć‘œ), 2•úŽËü•”): ‘ć61‰ń“ú–{ŠjˆăŠw‰ďŠwp‘‰ď (2021/11/4-6), –źŒĂ‰Ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), ŠjˆăŠw 2021; 58 (Suppl): S222.

731074. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ˆă—Ă”í‚΂­‚Ě“Kł‰ť‚ÉŒü‚Ż‚ā|f—Ă—p•úŽËü‚ĚˆŔ‘SŠÇ—‚Ě–@§‰ť|. ˆäă—D‰î (•úŽËü (‰ć‘œ)): “ú–{ŠwpU‹ť‰ďu•úŽËü‚Ě—˜—p‚Ɛś‘̉e‹żv‘ć195ˆĎˆő‰ď (2021/7/17), WebŠJĂ.

731075. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) f—Ă—p•úŽËü‚ĚˆŔ‘S—˜—p‚Ě‚˝‚ß‚ĚŒ¤C‚ĚŽŔŽ{|“ú–{ˆăŠw•úŽËüŠw‰ď‚ĚŽć‚č‘g‚݁|. ˆäă—D‰î (•úŽËü (‰ć‘œ)): —ߘa3”N“xuˆă—Ă•úŽËüˆŔ‘SŠÇ—uK‰ďv (2021/10/24), WebŠJĂ.

731076. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) f—Ă—p•úŽËü‚ĚˆŔ‘S—˜—p‚ĆˆŔ‘SŠÇ—|ˆă—Ă–@Ž{s‹K‘Ľ‚ւ̑Ήž|. ˆäă—D‰î (•úŽËü (‰ć‘œ)): ‘Š–ÍŒ´ŽsˆăŽt‰ďˆă—ĂˆŔ‘SuK‰ď (2021/10/25), ‘Š–ÍŒ´.

731077. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) f—Ă—p•úŽËü‚ĚˆŔ‘SŠÇ—: ˆă—Ă–@Ž{s‹K‘Ľ‰üłŒă‚Ěˆă—ĂŒťę‚É‚¨‚Ż‚é‘Ήž‚ĚŽŔŰ. ˆäă—D‰î (•úŽËü (‰ć‘œ)): Ž­Ž™“‡Žs—§•a‰@f—Ă•úŽËüˆŔ‘SŠÇ—Œ¤C‰ď (2021/11/2), WebŠJĂ.

731078. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) f—Ă—p•úŽËü‚ĚˆŔ‘S—˜—p‚Ě‚˝‚ß‚ĚŒ¤C‚Ćˆă—Ă‹@ŠÖ‚Ĺ‚ĚCOVID-19‘Ήž. ˆäă—D‰î (•úŽËü (‰ć‘œ)): ‘—§•ŰŒ’ˆă—ÉȊw‰@ —ߘa3”N“x’ZŠúŒ¤C ˆă—Ă•úŽËü‚Ě“KłŠÇ—‚ÉŠÖ‚ˇ‚錤C (2021/11/24), WebŠJĂ.

731079. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) •úŽËüˆŔ‘SŠÇ—‚ÉŠÖ‚ˇ‚é–k—˘‘ĺŠw‚ĚŽć‚č‘g‚Ý. ˆäă—D‰î (•úŽËü (‰ć‘œ)): ‘ć10‰ń‘Š–ÍŒ´‹@”\‰ć‘œƒZƒ~ƒi[ (2021/11/25), WebŠJĂ.

733211. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) śdŒűŠWŒ´”­‚ƍl‚Ś‚ç‚ę‚˝‚Ń‚Ü‚ńŤ‘ĺ×–EŒ^B×–EƒŠƒ“ƒpŽî. •Ä‘q—R‰Ŕ1, •‚F—´‘ž˜Y1, ˆäă—D‰î1, ŒĂ–ŘˆťŽq2, ŽR‰ş@‘ń2, Ż–쏺–F3 (1•úŽËü (‰ć‘œ), 2Ž¨•@ˆôAE“Şčň•”ŠO, 3•a—): ‘ć34‰ń“Şčň•”•úŽËüŒ¤‹†‰ď (2021/9/18), WebŠJĂ, ‘ć57‰ń“ú–{ˆăŠw•úŽËüŠw‰ďH‹G—Տ°‘ĺ‰ď´˜^W 2021; p. S454.

733212. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) •@•ÂŠ´‚đŒ_‹@‚É”­ŒŠ‚ł‚ę‚˝ glomangiopericytoma. —´“c‚ŕ‚ŕ‚ą1, •‚F—´‘ž˜Y1, ˆäă—D‰î1, ‹{–{r•ă2, ŽR‰ş@‘ń2, áÁŽR@“ž3, “Č–{šF4 (1•úŽËü (‰ć‘œ), 2Ž¨•@ˆôAE“Şčň•”ŠO, 3•a—, 4‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć34‰ń“Şčň•”•úŽËüŒ¤‹†‰ď (2021/9/18), WebŠJĂ, ‘ć57‰ń“ú–{ˆăŠw•úŽËüŠw‰ďH‹G—Տ°‘ĺ‰ď´˜^W 2021; p. S455-6.

733213. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ƒCƒ[ƒWƒCƒ“ƒ^[ƒvƒŠƒe[ƒVƒ‡ƒ“ƒZƒbƒVƒ‡ƒ“@Session…@1 [‰ń“š]. •Ä‘q—R‰Ŕ1, •‚F—´‘ž˜Y1, ˆäă—D‰î1, ŒĂ–ŘˆťŽq2, ŽR‰ş@‘ń2, Ż–쏺–F3 (1•úŽËü (‰ć‘œ), 2Ž¨•@ˆôAE“Şčň•”ŠO, 3•a—): ‘ć34‰ń“Şčň•”•úŽËüŒ¤‹†‰ď (2021/9/18), WebŠJĂ.

733214. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒCƒ[ƒWƒCƒ“ƒ^[ƒvƒŠƒe[ƒVƒ‡ƒ“ƒZƒbƒVƒ‡ƒ“@Session…@2 [o‘č].
—´“c‚ŕ‚ŕ‚ą1, •‚F—´‘ž˜Y1, ˆäă—D‰î1, ‹{–{r•ă2, ŽR‰ş@‘ń2, áÁŽR@“ž3, “Č–Řšl4 (1•úŽËü (‰ć‘œ), 2Ž¨•@ˆôAE“Şčň•”ŠO, 3•a—, 4‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć34‰ń“Şčň•”•úŽËüŒ¤‹†‰ď (2021/9/18), WebŠJĂ.

733215. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) •@•ÂŠ´‹y‚Ń•@oŒŒ‚đŽĺ‘i‚É”­ŒŠ‚ł‚ę‚˝t×–EŠŕ. ˆŔ’B‚Ý‚¸‚Ů1, •‚F—´‘ž˜Y1, ˆäă—D‰î1, ´–ě—R”y2, ‹{–{r‰î2, ”g‘˝–ě‰l‘ž2, ŽR‰ş@‘ń2, áÁŽR@“ž3 (1•úŽËü (‰ć‘œ), 2Ž¨•@ˆôAE“Şčň•”ŠO, 3•a—): 2021”N“x_“ŢěŒ§•úŽËüˆă‰ď‘‰ď‹y‚Ń‘ć61‰ń—á‰ď (2021/10/30), WebŠJĂ, 2021”N“x_“ŢěŒ§•úŽËüˆă‰ď‘‰ďE‘ć61‰ń—á‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2021; p. 10.

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-110031. [Œ´’˜] Predictive factors of truncation artifacts in the arterial phase of Gd-EOB-DTPA-enhanced MRI: a nationwide multicenter study. Tsurusaki M, Sofue K, Onishi H, Goshima S, Higaki A, Isoda H, Haradome H1,2, Ishii K, Murakami T: Jpn J Radiol 2021/2; 39 (2): 165-77. (Œ´—ŻOŽ÷1,2: 1V˘‹Iˆă—ÁEć’[ˆă—Ă, 1•úŽËü (‰ć‘œ))

'20-310005. [Ç—á•ń] Pulmonary Artery-Bronchus Fistula Treated with a Combination of Bare Metal Stent, Metallic Coil, and N-Butyl Cyanoacrylate. Woodhams R1, Fujii K1, Takigawa M, Inoue Y1: J Vasc Interv Radiol 2021/1; 32 (1): 152-5. (ƒEƒbƒhƒnƒ€ƒX—ćŽq1, “Ąˆä@Š]1, ˆäă—D‰î1: 1•úŽËü (‰ć‘œ))

'20-520001. [‘ŕ] ˆă—Ă–@Ž{s‹K‘Ľ‰üłŒă‚Ěˆă—ĂŒťę‚É‚¨‚Ż‚é‘Ήž‚ĚŽŔŰ. ˆäă—D‰î (•úŽËü (‰ć‘œ)): ˆă—Ă•úŽËü–hŒěNewsletter 2021/3; 84: 5-18.

'20-540003. [‚ť‚Ě‘ź (ƒKƒCƒhƒ‰ƒCƒ“)]y“ú–{IVRŠw‰ďƒKƒCƒhƒ‰ƒCƒ“zŇ’Ĺ“]ˆÚ‚ĚŒo”ç“I’Ĺ‘ĚŒ`Źp (PVP) ƒKƒCƒhƒ‰ƒCƒ“2019. “ú–{IVRŠw‰ď (ƒEƒbƒhƒnƒ€ƒX—ćŽq1, ‘ź) (1•úŽËü (‰ć‘œ)): “ú–{ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒiƒ‹ƒ‰ƒWƒIƒƒW[Šw‰ďŽGŽ 2021/2; 35 (3): 290-309.


•úŽËü‰ČŠw (•úŽËüŽîᇊw)

[Šwp˜_•ś]

110401. [Œ´’˜] Multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for Japanese prostate cancer patients. Ishiyama H1, Tsumura H2, Nagano H, Watanabe M, Mizuno E, Taka M, Kobayashi H, Eriguchi T, Imada H, Inaba K, Nakamura K: Sci Rep 2021/6; 11 (1): 13194. (ÎŽR”ŽžŠ1, ’Ă‘şGN2: 1•úŽËü (Žîá‡), 2”ĺ”AŠí)

110402. [Œ´’˜] Protective Effects of Amino Acids on Plasmid DNA Damage Induced by Therapeutic Carbon Ions. Yogo K, Murayama C, Hirayama R, Matsumoto K, Nakanishi I, Ishiyama H1, Yasuda H: Radiat Res 2021/8; 196 (2): 197-203. (ÎŽR”ŽžŠ1: 1•úŽËü (Žîá‡))

110403. [Œ´’˜] Three-dimensional dose-distribution measurement of therapeutic carbon-ion beams using a ZnS scintillator sheet. Yogo K, Tsuneda M, Horita R, Souda H , Matsumura A, Ishiyama H1, Hayakawa K, Kanai T, SYamamoto S: J Radiat Res 2021/9; 62 (5): 825-32. (ÎŽR”ŽžŠ1: 1•úŽËü (Žîá‡))

110404. [Œ´’˜] Quality of life score as a prognosticator for pharyngeal cancer patients treated with radiotherapy. Ishiyama H1, Kawakami S1, Sekiguchi A1, Kainuma T1, Miyamoto S2, Yamashita T2, Nakano M1: Sci Rep 2022/2; 12 (1): 2387. (ÎŽR”ŽžŠ1, ěăłŒĺ1, ŠÖŒűˆŠˆß1, Ž”Ŕ‘ě˜N1, ‹{–{r•ă2, ŽR‰ş@‘ń2, ’†–쐳Š°1: 1•úŽËü (Žîá‡), 2Ž¨•@ˆôAE“ŞčňŠO)

110405. [Œ´’˜] Radiosensitization Effect of Gold Nanoparticles on Plasmid DNA Damage Induced by Therapeutic MV X-rays. Yogo K, Misawa M, Shimizu H, Kitagawa T, Hirayama R, Ishiyama H1, Yasuda H, Kametaka S, Takami S: Nanomaterials (Basel) 2022/2; 12 (5): 771. (ÎŽR”ŽžŠ1: 1•úŽËü (Žîá‡))

[Šw‰ďEŒ¤‹†‰ď“™]

723656. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ’´‰đ‘œ‹Zp‚đ—p‚˘‚˝[‘wŠwK‚É‚ć‚é‘ŸŠíŽŠ“Ž’ŠoƒVƒXƒeƒ€‚ĚŠJ”­. ŸN’댒‘ž˜N1, ‹{“ŕ@‹P2, “c’†—Iˆę2, ’†–쐳Š°3, ÎŽR”ŽžŠ3, ’ˇ’Jě’q”V2, ‹´–{Ź˘2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3•úŽËü (Žîá‡)): ‘ć77‰ń“ú–{•úŽËü‹ZpŠw‰ď‘‰ďŠwp‘ĺ‰ď (2021/4/15-18), _“ސě, “ú–{•úŽËü‹ZpŠw‰ďŽGŽ 2021/9; 77 (9): 1115.


–ƒŒ‰ČŠw

[Šwp˜_•ś]

110406. [Œ´’˜] The characteristics, types of intervention, and outcomes of postoperative patients who required rapid response system intervention: a nationwide database analysis. Sento Y, Arai M1,2, Yamamori Y, Fujiwara S, Tamashiro M, Kawamoto E, Naito T, Atagi K, Fujitani S, Osaga S, Sobue K; In-Hospital Emergency Study Group: J Anesth 2021/4; 35 (2): 222-31. (VˆäłN1,2: 1V˘‹Iˆă—ĂŠJE‰Ą’f“Iˆă—Ă, 2–ƒŒ)

110407. [Œ´’˜] Incidence of accidental events during anesthesia from 2012 to 2016: survey on anesthesia-related events by the Japanese Society of Anesthesiologists. Morimatsu H; Accidental Event (Pulmonary Embolism) Working Group, Safety Committee of the Japanese Society of Anesthesiologists (Collaborators: Hirota K, Hagihira S, Masui K, Yokota M, Sawa T, Yamauchi M, Kuroiwa M1): J Anesth 2021/4; 35 (2): 206-12. (•Šâ­”V1: 1–ƒŒ)

110026. [Œ´’˜] Roles of Thromboxane Receptor Signaling in Enhancement of Lipopolysaccharide-Induced Lymphangiogenesis and Lymphatic Drainage Function in Diaphragm. Matsuda H1, Ito Y2, Hosono K2, Tsuru S1, Inoue T3, Nakamoto S4, Kurashige C1, Hirashima M, Narumiya S, Okamoto H1, Majima M2: Arterioscler Thromb Vasc Biol 2021/4; 41 (4): 1390-407. (ź“cO”ü1, ˆÉ“Ą‹`–ç2, ×–ě‰Á“ŢŽq2, ’Ă—Ż˘—˘1, ˆäă’qm3, ’†–{CŽi4, ĺUdçŠG1, ”n“ˆł—˛2: 1–ƒŒ, 2–ň—, 3Á‰ťŠí“ŕ, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO)

110408. [Œ´’˜] Validation of National Early Warning Score for predicting 30-day mortality after rapid response system activation in Japan. Naito T, Hayashi K, Hsu HC, Aoki K, Nagata K, Arai M1,2, Nakada T, Suzaki S, Hayashi Y, Fujitani S; In]Hospital Emergency Study Group: Acute Med Surg 2021/5; 8 (1): e666. (VˆäłN1,2: 1V˘‹Iˆă—ĂŠJE‰Ą’f“Iˆă—Ă, 2–ƒŒ)

110409. [Œ´’˜] Use of electrical muscle stimulation body massager (EMS-BMs) improves deep venous blood flow. Sakai M1, Otsuka T1, Sugimura K1, Nishizawa Y1, Nagai A1, Yamamoto S1, Okamoto H1, Kuroiwa M1: Med Eng Phys 2021/6; 92: 110-4. (ăˆä䝗LŽq1, ‘ĺ’Ë’q‹v1, ™‘şŒ›—ş1, źŕV‹`”V1, ‰iˆäˆŸˆË1, ŽR–{^–ç1, ‰Ş–{_Žk1, •Šâ­”V1: 1–ƒŒ)

110410. [Œ´’˜] Prevalence and predictors of direct discharge home following hospitalization of patients with serious adverse events managed by the rapid response system in Japan: a multicenter, retrospective, observational study. Hongo T, Naito H, Fujiwara T, Naito T, Homma Y, Fujimoto Y, Takaya M, Yamamori Y, Nakada T, Nojima T, Nakao A, Fujitani S; In]Hospital Emergency Study Group (Arai M1,2, et al): Acute Med Surg 2021/8; 8 (1): e690. (VˆäłN1,2: 1V˘‹Iˆă—ĂŠJE‰Ą’f“Iˆă—Ă, 2–ƒŒ)

110411. [Œ´’˜] Six-Minute Walk Test Predicts Postoperative Delirium After Transcatheter Aortic Valve Replacement. Yamashita A1 ,Suzuki S2, Otsuka T2, Matsuda H2, Ando H2, Sugimura K2, Maekawa E3, Meguro K3, Ako J3, Okamoto H2: J Cardiothorac Vasc Anesth 2021/9; 35 (9): 2613-7. (ŽR‰ş@“Ö1, —é–Ř›’Žk2, ‘ĺ’Ë’q‹v2, ź“cO”ü2, ˆŔ“ĄŽőŒb2, ™‘şŒ›—ş2, ‘OěŒb”ü3, –ڍ•Œ’‘ž˜Y3, ˆ˘ŒĂĆ3, ‰Ş–{_Žk2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ƒŒ, 3zŠÂŠí“ŕ)

110412. [Œ´’˜] Effectiveness of anti-slip dots on the soles of elastic compression stockings. Kuroiwa M1, Sakai M1, Otsuka T1, Nishizawa Y1, Sugimura K1, Nagai A1, Yamamoto S1: Kitasato Med J 2021/9; 51 (2): 97-101. (•Šâ­”V1, ăˆä䝗LŽq1, ‘ĺ’Ë’q‹v1, źŕV‹`”V1, ™‘şŒ›—ş1, ‰iˆäˆŸˆË1, ŽR–{^–ç1: 1–ƒŒ)

110007. [Œ´’˜] Cytohesin-2 mediates group I metabotropic glutamate receptor-dependent mechanical allodynia through the activation of ADP ribosylation factor 6 in the spinal cord. Ito A1, Fukaya M2, Sugawara T2, Hara Y2, Okamoto H1, Yamauchi J, Sakagami H2: Neurobiol Dis 2021/11; 159: 105466. (ˆÉ“Ą—@Žq1, [’JšO2, ›Œ´Œ’”V2, Œ´@–FL2, ‰Ş–{_Žk1, ăă—ms2: 1–ƒŒ, 2‰đ–U)

320025. [Ç—á•ń] ‰ťŠw—Ă–@—U”­Ť––˝_ŒoáŠQ’ɂɑ΂ˇ‚éƒtƒFƒ“ƒ^ƒjƒ‹Ă’ŽŽŒą‚Ć‹­ƒIƒsƒIƒCƒh’Á’É–ň‚Ě—L—pŤ‚ĚŒŸ“˘. r@Ť’q1, —с@Œol1, ‰Í‘ş’źŽ÷, ‹ŕˆäş•ś1,2 (1–ƒŒ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ƒyƒCƒ“ƒNƒŠƒjƒbƒN 2021/5; 42 (5): 641-5.

522572. [uŔ]y“ÁW: Š´őÇ‚¨‚ć‚щŠÇŤŽžŠł‚đ—L‚ˇ‚銳ŽŇ‚Ě–ƒŒŠÇ—zS‹Ř‰Š‚¨‚ć‚ŃŠ´őŤS“ŕ–Œ‰Š‚Ć–ƒŒŠÇ—. ˆŔ“ĄŽőŒb1, ”öč@‰ˇ1, ‰Ş–{_Žk1 (1–ƒŒ): –ƒŒ 2021/5; 70 (5): 512-6.

[’˜@‘]

620136. [Šwp‘ (•Ş’SŽˇ•M)]y‚—îŽŇ–ƒŒ‚Ěƒ|ƒCƒ“ƒg50zQ40. ’ˇŠú‰ç°ŠłŽŇ‚ĚŽüpŠú”xÇđÇ‚Ě—\–h‚ɂ‚˘‚Ä‹ł‚Ś‚Ä‚­‚ž‚ł‚˘, p.155-8. •Šâ­”V (–ƒŒ), ŠÄC: Ź”‹´rĆ, •Ň: ěŒűš•F, ěŒŇ’m”V, Ž˝“°o”Ĺ, “Œ‹ž, 2021/5”­s.

620137. [Šwp‘ (•Ş’SŽˇ•M)]y–ƒŒ‰Čˆă‚Č‚ç’m‚Á‚Ä‚¨‚Ť‚˝‚˘ŒŒđÇEÇđÇ (LiSA 2021”N•ĘűH†)zPART 4 Ă–ŹŤŒŒđ@23 ŽüpŠú”xŒŒđÇđÇ, p.171-8. ’†ŕVˆş”T, •Šâ­”V1 (1–ƒŒ), Ó”C•ŇW: ’ؐěP‹v, ƒƒfƒBƒJƒ‹EƒTƒCƒGƒ“ƒXEƒCƒ“ƒ^[ƒiƒVƒ‡ƒiƒ‹, “Œ‹ž, 2021/9”­s.

620138. [Šwp‘ (•Ş’SŽˇ•M)]y–ƒŒ‰Čˆă‚Č‚ç’m‚Á‚Ä‚¨‚Ť‚˝‚˘ ŒŒđÇEÇđÇ (LiSA 2021”N•ĘűH†)zPART 5 ‚ť‚Ě‘ź‚̍ǐđÇ@‹Ű‰ňÇđ, ŽîᇉňÇđ, p.221-5. ˆŔ“ĄŽőŒb1, ‰Ş–{_Žk1 (1–ƒŒ), •Ň: ’ؐěP‹v, ƒƒfƒBƒJƒ‹ƒTƒCƒGƒ“ƒX, “Œ‹ž, 2021/9”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

722302. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) S‘ŸŒŒŠÇ–ƒŒ—Ěˆć‚ĹŒq‚ނ낤. ‰Ş–{_Žk (–ƒŒ): “ú–{–ƒŒ‰ČŠw‰ď‘ć68‰ńŠwpW‰ď (2021/6/4), WebŠJĂ.

722303. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) S‘ŸŽčp‚É‚¨‚Ż‚é”x“Ž–ŹƒJƒe[ƒeƒ‹‚Ě“K‰ž‚ĆˆŔ‘S‚Č‘}“ü‚ĆŽg—p–@[–ƒŒ‰Čˆă‚Ě—§ę‚Š‚ç. ‰Ş–{_Žk (–ƒŒ): ‘ć52‰ń“ú–{S‘ŸŒŒŠÇŠO‰ČŠw‰ďŠwp‘‰ď (2022/3/4), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723657. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) A“ŞŠŕ‚ɑ΂ˇ‚éŒoŒű“I“ŕŽ‹‹žŽčp‚̏p’†pŒă‚É—\Šú‚š‚¸‹Ů‹}‹CŠÇŘŠJ‚đ—v‚ľ‚˝16Ç—á‚ĚŒŸ“˘. ŽR˜H—TO1, ăˆä䝗LŽq1, ’|˜Q–Ż]1, ‰Ş–{_Žk1 (1–ƒŒ): “ú–{–ƒŒ‰ČŠw‰ď‘ć68‰ńŠwpW‰ď (2021/6/3), WebŠJĂ.

723658. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) COVID19Š´ő—\–h‘΍ô‚Ć‚ľ‚Ä‚Ě”˛ŠÇŒăƒT[ƒWƒJƒ‹ƒ}ƒXƒN‘•’…‚Ş—^‚Ś‚é‰e‹ż‚ɂ‚˘‚Ä. ’Ă—Ż˘—˘1, ŹâN°1, ˛“ĄŽ•F1, ‰ĄŽR—F, –xš—F‰Ä1, ‰Ş–{_Žk1 (1–ƒŒ): “ú–{–ƒŒ‰ČŠw‰ď‘ć68‰ńŠwpW‰ď (2021/6/3), WebŠJĂ.

723659. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒoƒNƒƒtƒFƒ“‚­‚ŕ–Œ‰şo“Š—^‚Ě‘gDŠw“IˆŔ‘SŤ‚ĚŒŸ“˘. ’|˜Q–Ż]1, “ޗljŔ—m, ‘ĺ‹v•Ű’ŠŽq, ŽR‰ş@ăÄ1, ˆÉ“ĄŒbˆČ1, ‰Ş–{_Žk1 (1–ƒŒ): “ú–{–ƒŒ‰ČŠw‰ď‘ć68‰ńŠwpW‰ď (2021/6/3), WebŠJĂ.

723660. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŹŽ™_Œo‹ŘŽžŠł‚É‚ć‚éÇŒóŤ‘¤œ^Ç‚ɑ΂ˇ‚éŒă•űŒĹ’čp‚ĚŽüpŠúŒÄ‹zŠí‡•šÇ‚ĚŒŸ“˘. ŽR‰ş^–ç, ŽR‰ş@“Ö1, ź“cO”ü2, ’†ŕVˆş”T, ŽR‰ş@ăÄ2, ‰Ş–{_Žk2 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2–ƒŒ): “ú–{–ƒŒ‰ČŠw‰ď‘ć68‰ńŠwpW‰ď (2021/6/3), WebŠJĂ.

723661. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ĺ—ĘƒIƒsƒIƒCƒhŽg—p’†‚Ě‚Ş‚ńáu’ÉŠłŽŇ‚É‚¨‚Ż‚é“d—Ź’mŠo臒l‚Ě’˛¸. ”öč@‰ˇ1, ‹ŕˆäş•ś1,2, ‰Ş–{_Žk1 (1–ƒŒ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ú–{–ƒŒ‰ČŠw‰ď‘ć68‰ńŠwpW‰ď (2021/6/3), WebŠJĂ.

723662. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’áNPS‘ŸŽčp‚É‚¨‚Ż‚鉺ŽˆŸó—Ź‚ĚŽw•W‚Ć‚ľ‚Ă̋ߐԊOü•ŞŒő–@‚Ě—L—pŤ. ŽR‰ş@ăÄ1, ˆŔ“ĄŽőŒb1, ˆÉ“ĄŒbˆČ1, –{“c’h1, ‰Ş–{_Žk1 (1–ƒŒ): “ú–{–ƒŒ‰ČŠw‰ď‘ć68‰ńŠwpW‰ď (2021/6/3), WebŠJĂ.

723663. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŹŽ™‚ĚŽÎŽ‹Žčp‚É‚¨‚Ż‚éŠá“îp“h•z‚É‚ć‚éŠp–Œ’É–hŽ~Œř‰Ę‚ĚŒŸ“˘. ˆÉ“ĄŒbˆČ1, ź“cO”ü1, ’†ŕVˆş”T1, ŽR‰ş@ăÄ1, ‰Ş–{_Žk1 (1–ƒŒ): “ú–{–ƒŒ‰ČŠw‰ď‘ć68‰ńŠwpW‰ď (2021/6/3), WebŠJĂ.

723664. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒƒNƒƒjƒEƒ€‚É‚ć‚éƒAƒiƒtƒBƒ‰ƒLƒV[‚ĚŠů‰‚Ě‚ ‚銳ŽŇ‚ɑ΂ľ, Œă“ú‘Sg–ƒŒ‰ş‚É• •”Žčp‚đŽ{s‚ľ‚˝ˆę—á. ‰i‰Â“ŢŽq1, ‰Ş–{_Žk1 (1–ƒŒ): “ú–{—Տ°–ƒŒŠw‰ď‘ć41‰ń‘ĺ‰ď (2021/11/5), ŽD–y (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723665. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) DHAEEPAŠÜ—LƒTƒvƒŠƒƒ“ƒgŰŽć’†‚Ě”D•w‚Ö‚Ě‹ćˆć–ƒŒŽ{sÇ—á‚ĚŒŸ“˘. “Ą“c“ߌb1, ‹ß“ĄOW1, “úŒür•ă1, ŠÖŞš—R”ü1, ‰œ•xr”V1, ‰Ş–{_Žk1 (1–ƒŒ): ‘ć125‰ń“ú–{ŽY‰Č–ƒŒŠw‰ďŠwpW‰ď (2021/12/4), –źŒĂ‰Ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733216. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) i-gelґ}“üŽž‚É–˘f’f‚ĚƒAƒfƒmƒCƒh‘š‚É‚ć‚éˆô“ޏoŒŒ‚đ‚Ť‚˝‚ľ‚˝ˆę—á. ‰i‰Â“ŢŽq1, ŽR˜H—TO1, ˆÉ“Ą—@Žq1, ź“cO”üź1, ‰Ş–{_Žk1 (1–ƒŒ): “ú–{–ƒŒ‰ČŠw‰ď2021”N“xŽx•”ŠwpW‰ď (ŠÖ“ŒbM‰zE“Œ‹žŽx•”‘ć61‰ń‡“ŻŠwpW‰ď) (2021/9/4), WebŠJĂ.

733217. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ăs‘ĺ“Ž–Ź’uŠˇpŒă‚ĚARDS‚ɑ΂ľ‚Ä• ‰çˆĘ—Ă–@‚Ş’˜Œř‚ľ‚˝1—á. –xŽŃ—F‰Ä1, źŕV‹`”V1, •Šâ­”V1, VˆäłN1,2, ‰Ş–{_Žk1 (1–ƒŒ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ú–{–ƒŒ‰ČŠw‰ď2021”N“xŽx•”ŠwpW‰ď (ŠÖ“ŒbM‰zE“Œ‹žŽx•”‘ć61‰ń‡“ŻŠwpW‰ď) (2021/9/4), WebŠJĂ.

733218. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) • o‹ž‰şŠĚ•”•ŞŘœp‚Ě”˛ŠÇŒă, —\Šú‚š‚Ę”x…Žî‚đ—ˆ‚˝‚ľ‚˝1—á. ŽR‰ş@ăÄ1, ŠÖ“cş•F1, źŕV‹`”V1, ’|˜Q–Ż]1, •Šâ­”V1, ‰Ş–{_Žk1 (1–ƒŒ): “ú–{–ƒŒ‰ČŠw‰ď2021”N“xŽx•”ŠwpW‰ď (ŠÖ“ŒbM‰zE“Œ‹žŽx•”‘ć61‰ń‡“ŻŠwpW‰ď) (2021/9/4), WebŠJĂ.

733219. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‰EˆÝ‘ĺ–Ô“Ž–Ź‚đ—p‚˘‚˝ŠĽ“Ž–ŹƒoƒCƒpƒXpŒă‚Ě‘ŠúˆÝŠŕ‚ɑ΂ľ, • o‹ž‰şˆÝ‘S“Ep‚đŽ{s‚ľ‚˝1—á. ŽđˆäˆŸŠóŽq1, ŠÖ“cş•F1, z–Kç—˘, ˆŔ“ĄŽőŒb1, ’ˇ“céŽq1, ‰Ş–{_Žk1 (1–ƒŒ): “ú–{–ƒŒ‰ČŠw‰ď2021”N“xŽx•”ŠwpW‰ď (ŠÖ“ŒbM‰zE“Œ‹žŽx•”‘ć61‰ń‡“ŻŠwpW‰ď) (2021/9/4), WebŠJĂ.

733220. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ć“VŤ‹Ř–ł—͏njóŒQ‚̐Ғő¤œ^ÇŽčp‚ĚŽüpŠúŒÄ‹zŠÇ—. ‘şź—I‰Ř1, ŽR‰ş@“Ö2, ź“cO”ü1, Ź–ěçq1, –xŽŃ—F‰Ä1, ‰Ş–{_Žk1 (1–ƒŒ, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): “ú–{–ƒŒ‰ČŠw‰ď2021”N“xŽx•”ŠwpW‰ď (ŠÖ“ŒbM‰zE“Œ‹žŽx•”‘ć61‰ń‡“ŻŠwpW‰ď) (2021/9/4), WebŠJĂ.

733221. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Œ°”÷‹ž“I‘˝”­ŒŒŠÇ‰Š‚É”ş‚¤‹•ŒŒ’ɂɑ΂ľ‚Ä, ‹­ƒIƒsƒIƒCƒh’Á’É–ň‚đ—p‚˘‚é‚ą‚Ć‚Ĺ—ÇD‚Č’Á’ÉŠÇ—‚މ”\‚Ć‚Č‚Á‚˝1—á. Ź–ěçq1, r@Ť’q1, ‚‹´—Cˆę˜N1, ‘şź—I‰Ř1, ‹ŕˆäş•ś1,2, ‰Ş–{_Žk1 (1–ƒŒ, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ú–{–ƒŒ‰ČŠw‰ď2021”N“xŽx•”ŠwpW‰ď (ŠÖ“ŒbM‰zE“Œ‹žŽx•”‘ć61‰ń‡“ŻŠwpW‰ď) (2021/9/4), WebŠJĂ.

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-110032. [Œ´’˜] Rapid response system in Japanese outpatient departments based on online registry: Multicentre observational study. Aoyama T, Tsuneyoshi I, Otake T, Ouchi K, Kawase Y, Arai M1,2, Shibata N, Fujiwara S, Fujitani S; In-Hospital Emergency Registry in Japan collaborators: Resusc Plus 2021/1; 5: 100065. (VˆäłN1,2: 1V˘‹Iˆă—ĂŠJE‰Ą’f“Iˆă—Ă, 2–ƒŒ)

[Šw‰ďEŒ¤‹†‰ď“™]

'20-723031. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) VŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´őÇ (COVID-19) ‚đ‡•š‚ľ‚˝”D•w‚̍‘“ŕ‰oŽY—á‚ĚŽüpŠúŠÇ—. ˆŔ“ĄŽőŒb1, “úŒür•ă1, ˆŔ’B^—œŽq, –{“c’h1, ŒË“c‰ë–ç1, ‰Ş–{_Žk1, ‰œ•xr”V1 (1–ƒŒ): “ú–{—Տ°–ƒŒŠw‰ď‘ć40‰ń‘ĺ‰ď (2020/11/6), WebŠJĂ.


—Տ°ŒŸ¸f’fŠw

[Šwp˜_•ś]

110413. [Œ´’˜] Bone marrow ring sideroblasts in hematological diseases: an analysis of consecutive 1300 samples in a single institution. Hayama K1, Abe Y2, Kamata H3, Okina S3, Murakami Y, Kanoh Y4, Suzuki T3: Int J Hematol 2022/4; 115 (4): 508-14. doi: 10.1007/s12185-021-03278-5. Epub 2022 Jan 22. (‰HŽRŒdˆČ1, ˆ˘•”—L2, Š™“c_–Ť3, ‰Ľ@‘c˝3, Žë–ě—Lě4, —é–Ř—˛_3: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2—ŐŒŸ•”, 3ŒŒ‰t“ŕ, 4—ŐŒŸŠw)

120036. [Œ´’˜] –k—˘‘ĺŠw•a‰@‚É‚¨‚Ż‚éƒJƒ‹ƒoƒyƒlƒ€‘ϐŤ’°“ŕ×‹Ű–Ú×‹Ű‚ĚŒŸoó‹ľ‚ɂ‚˘‚Ä‚Ě’PŽ{ÝŒă•űŽ‹“IŒ¤‹†. “ń–{–öL1, ‚ŽR—zŽq2, ŁŒË—Ç‹ł1, ˆŔ’B@÷3, ŹŠŃ’q˘3, ˛“Ą—h—S1, •ŰâŠGäť1, ‹{čI‰î1, ˛X–ŘŒ°Žq1, ‚–Ř—R”üŽq1, ŻŽR—˛s4, ’†‘şłŽ÷5, —с@“N”Í6, Žë–ě—Lě6 (1Š´őŠÇ—Žş, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3—ŐŒŸ•”, 4äPŒ´•aEŠ´ő“ŕ, 5ˆă—ÉqśŠw•”, 6—ŐŒŸŠw): –k—˘ˆăŠw 2021/12; 51 (2): 83-94.

220003. [€Œ´’˜] CŒ^ŠĚ‰Š–o–Ĺ‚ÉŒü‚Ż‚˝—Տ°ŒŸ¸•”‚ĚŽć‚č‘g‚݁`–k—˘‘ĺŠw•a‰@‚É‚¨‚Ż‚éŠĚ‰Š‘΍ô‚É‚¨‚Ż‚éf—Ă•”–ĺ‚Ć‚Ě˜AŒg‘̐§` Žë–ě—Lě (—ŐŒŸŠw): “Œ‹ž“sˆăŠwŒŸ¸ 2022/1; 50 (1): 53-5.

[’˜@‘]

620139. [Šwp‘ (•Ş’SŽˇ•M)]yĹV ŒŸ¸E‰ć‘œf’fŽ–“T 2022-23”N”Łzƒ|ƒ‹ƒtƒBƒŠƒ“ÇƒXƒNƒŠ[ƒjƒ“ƒOƒeƒXƒg, p.10. Žë–ě—Lě (—ŐŒŸŠw), •Ň: “ú–{—Տ°ŒŸ¸ˆăŠw‰ď, ˆăŠw’ʐMŽĐ, “Œ‹ž, 2021/5”­s.

620140. [Šwp‘ (•Ş’SŽˇ•M)]yĹV ŒŸ¸E‰ć‘œf’fŽ–“T 2022-23”N”ŁzN-ƒAƒZƒ`ƒ‹ƒOƒ‹ƒRƒTƒ~ƒVƒ^[ƒ[ (NAG), p.10-1. Žë–ě—Lě (—ŐŒŸŠw), •Ň: “ú–{—Տ°ŒŸ¸ˆăŠw‰ď, ˆăŠw’ʐMŽĐ, “Œ‹ž, 2021/5”­s.

620141. [Šwp‘ (•Ş’SŽˇ•M)]yĹV ŒŸ¸E‰ć‘œf’fŽ–“T 2022-23”N”ŁzIVŒ^ƒRƒ‰[ƒQƒ“’č—ʐ¸–§‘Ş’č, p.13. Žë–ě—Lě (—ŐŒŸŠw), •Ň: “ú–{—Տ°ŒŸ¸ˆăŠw‰ď, ˆăŠw’ʐMŽĐ, “Œ‹ž, 2021/5”­s.

620142. [Šwp‘ (•Ş’SŽˇ•M)]yĹV ŒŸ¸E‰ć‘œf’fŽ–“T 2022-23”N”ŁzƒVƒ…ƒEŽ_ (”A), p.13. Žë–ě—Lě (—ŐŒŸŠw), •Ň: “ú–{—Տ°ŒŸ¸ˆăŠw‰ď, ˆăŠw’ʐMŽĐ, “Œ‹ž, 2021/5”­s.

620143. [Šwp‘ (•Ş’SŽˇ•M)]yĹV ŒŸ¸E‰ć‘œf’fŽ–“T 2022-23”N”Łzƒtƒ[ƒTƒCƒgƒƒgƒŠ[–@‚É‚ć‚é”A’†—LŒ`Ź•Ş’č—Ę‘Ş’č, p.15. Žë–ě—Lě (—ŐŒŸŠw), •Ň: “ú–{—Տ°ŒŸ¸ˆăŠw‰ď, ˆăŠw’ʐMŽĐ, “Œ‹ž, 2021/5”­s.

620144. [Šwp‘ (•Ş’SŽˇ•M)]yĹV ŒŸ¸E‰ć‘œf’fŽ–“T 2022-23”N”Łzƒ~ƒGƒŠƒ“‰–Ž_Ť’`”’ (MPB), p.21. Žë–ě—Lě (—ŐŒŸŠw), •Ň: “ú–{—Տ°ŒŸ¸ˆăŠw‰ď, ˆăŠw’ʐMŽĐ, “Œ‹ž, 2021/5”­s.

620145. [Šwp‘ (•Ş’SŽˇ•M)]yĹV ŒŸ¸E‰ć‘œf’fŽ–“T 2022-23”N”ŁzƒtƒBƒVƒ…ƒo[ƒOŽŽŒą, p.246. Žë–ě—Lě (—ŐŒŸŠw), •Ň: “ú–{—Տ°ŒŸ¸ˆăŠw‰ď, ˆăŠw’ʐMŽĐ, “Œ‹ž, 2021/5”­s.

620146. [Šwp‘ (•Ş’SŽˇ•M)]yĹV ŒŸ¸E‰ć‘œf’fŽ–“T 2022-23”N”ŁzƒAƒWƒXƒJƒEƒ“ƒg (addis”A’žŸÔ’č—ĘŒŸ¸), p.305. Žë–ě—Lě (—ŐŒŸŠw), •Ň: “ú–{—Տ°ŒŸ¸ˆăŠw‰ď, ˆăŠw’ʐMŽĐ, “Œ‹ž, 2021/5”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

723666. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “–‰@“œ”A•aŠłŽŇ‚É‚¨‚Ż‚éĹ‘ĺ“ŕ–Œ’†–Œ•Ą‡‘ĚŒú‚Ě4”N•Ď‰ť‚Ć‚ť‚̉e‹żˆöŽq‚ĚŒŸ“˘. ä@G”ü, “n‹ď’m–ƒˆßŽq, ŽR‰şŽD, ‘ş‰Ş“Ţ”ü, ‰Á“Ą–ƒ—SŽq, źŒű•Žu, —с@“N”Í1, ‘Ť—§”Ž‹I (1—ŐŒŸŠw): ‘ć64‰ń“ú–{“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (2021/5/20-22), WebŠJĂ.

723667. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “§Í’†‚Ě2Œ^“œ”A•aŠłŽŇ‚É‚¨‚Ż‚éŠÔŸ[ƒXƒLƒƒƒ“Ž‘ąŒŒ“œ‘Ş’čŠí‚̐¸“x•]‰ż‚ÉŠÖ‚ˇ‚錤‹† (AIDT2HŒ¤‹†). –L“c‰ë•v, ‘ş“c@Œh, ꎓĄm’Ę, –Ř‘şŽçŽŸ, Î“c’źl, –k‘ş@^, ”ň“c”ü•ä, —с@“N”Í1, XŒű‚˘‚Ô‚Ť, Ź—Ń’ź”V, ’Ţ’J‘ĺ•ă, â”öKr, ź‰ş—˛Ć, ˆÉ“ĄáŠG, —é–ŘÂ‘ž, Š}ŠÔ@Žü, Š}Œ´ł“o, ŽRě@ł, X@Žm, •“c‹Ĺś, ŽO‰Y‡”V•, œA“c—EŽm, ˆ˘•”‰ë‹I, [ě‰ëŽj, âŞ’źŽ÷, ×“cŒö‘Ľ (1—ŐŒŸŠw): ‘ć64‰ń“ú–{“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (2021/5/20-22), WebŠJĂ.

723668. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”ě–ž‡•š2Œ^“œ”A•aŒŒ‰t“§Í (DMHD) ŠłŽŇ2—á‚É‚¨‚Ż‚éƒZƒ}ƒOƒ‹ƒ`ƒh‚ĚŽg—pŒoŒą. XŒű‚˘‚Ô‚Ť, —с@“N”Í1, Ź—Ń’ź”V, ’|’†@˝, ‘ĺ‹v•Ű[l, Žç‰Ž—˜‰Ŕ2, Žç‰Ž’B”ü3, ’|“ŕN—Y4 (1—ŐŒŸŠw, 2ˆăŠw‹łˆç, 3Œ’NŠÇ—ƒZ, 4t‘Ÿ“ŕ): ‘ć66‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2021/6/4-6), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723669. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –k—˘‘ĺŠw•a‰@‚Ĺ•Ş—Ł‚ł‚ę‚˝MRSA‹ŰŠ”‚É‚¨‚Ż‚éRMRSA–ňŠ´ŽóŤŒXŒü‚ÉŠÖ‚ˇ‚錟“˘. ’†‘şłŽ÷1, ˆŔ’B@÷2, “ń–{–öL2,3, —с@“N”Í1, “IęŒ’‘ž1, Žë–ě—Lě1, –k—˘‰p˜Y4 (1—ŐŒŸŠw, 2—ŐŒŸ•”, 3Š´őŠÇ—Žş, 4ˆă—ÉqśŠw•”): ‘ć68‰ń“ú–{—Տ°ŒŸ¸ˆăŠw‰ďŠwpW‰ď (2021/11/11-14), •xŽR (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723670. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –k—˘‘ĺŠw•a‰@‚É‚¨‚Ż‚郊ƒuƒŒView‰^—p‚ĚŽć‚č‘g‚Ý‚Ć—Ő°ŒŸ¸‹ZŽt‚Ě–đŠ„. —с@“N”Í1, “IęŒ’‘ž1, “y•M’qť2, ŽO‰Y–F“T2, ’†‘şłŽ÷1, Žë–ě—Lě1 (1—ŐŒŸŠw, 2—ŐŒŸ•”): ‘ć68‰ń“ú–{—Տ°ŒŸ¸ˆăŠw‰ďŠwpW‰ď (2021/11/11-14), •xŽR (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{—Տ°ŒŸ¸ˆăŠw‰ďŽ 2021/10; 69: 112.

723671. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠÔŸ[ƒXƒLƒƒƒ“ŽŽŽ‘ąŒŒ“œ‘Ş’č (isCGM) ‚đ—p‚˘‚˝E‚ÉŠÖ‚ˇ‚é—Ă—{Žw“ą‚Ş—LŒř‚Ĺ‚ ‚Á‚˝1Œ^“œ”A•a‚Ě1—á. “n糎”żäť, ŽR–{‰p—˘, —с@“N”Í1, ‘Ť—§”Ž‹I (1—ŐŒŸŠw): ‘ć24‰ńE‘ć25‰ń“ú–{•a‘Ô‰h—{Šw‰ď”NŽŸŠwpW‰ď (2022/1/28-30), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

731080. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) CŒ^ŠĚ‰Š–o–Ĺ‚ÉŒü‚Ż‚˝—Տ°ŒŸ¸•”‚ĚŽć‚荾‚݁`–k—˘‘ĺŠw•a‰@‚̊̉Š‘΍ô‚É‚¨‚Ż‚éf—Ă•”–ĺ‚Ć‚Ě˜AŒg`. Žë–ě—Lě (—ŐŒŸŠw): “Œ‹ž“s—Տ°ŒŸ¸‹ZŽt‰ď‘ć3‰ń–ƉuŒŒ´ŒŸ¸Œ¤‹†”ÇŒ¤C‰ď (2021/11/18), “Œ‹ž.

733222. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “–‰@‚É‚¨‚Ż‚錌“œƒRƒ“ƒgƒ[ƒ‹•s’˛ŠłŽŇ‚Ö‚Ě—Ă—{Žw“ą‚ĚŽć‚č‘g‚݂ɂ‚˘‚Ä. Ź—Ń—F—˘, “n糎”żäť, ŽR–{‰p—˘, ŠâŁ^‹I, ‚–Ř—œ‰Ô, ‰Á“Ą–ƒ—SŽq, ‘şˆäˆ¤–], —с@“N”Í1, ‘Ť—§”Ž‹I (1—ŐŒŸŠw): ‘ć59‰ń“ú–{“œ”A•aŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2022/1/22), WebŠJĂ.

733223. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “–‰@ŠÇ—‰h—{Žm‚ƍs­•ŰŒ’Žt‚Ć‚Ě˜AŒg‚ŞŒŒ“œƒRƒ“ƒgƒ[ƒ‹‚É‘tŒ÷‚ľ‚˝ˆę—á. ‚–Ř—œ‰Ô, “n糎”żäť, —с@“N”Í1, ‘Ť—§”Ž‹I (1—ŐŒŸŠw): ‘ć59‰ń“ú–{“œ”A•aŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2022/1/22), WebŠJĂ.

733224. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŒŒ“œ’l‚Ěă‚Ş‚č‚É‚­‚˘˜a‰ŮŽquˆ¤ě‚‚‚śé\“ށv‚ĚŒŒ“œă¸—}§Œř‰Ę‚ĚŒŸ“˘. ŠâŁ^‹I, ‘Ť—§”Ž‹I, —с@“N”Í1, “n糎”żäť, ŽR–{‰p—˘, ź˜eˆ¤–], Ź—Ń—F—˘, ‚–Ř—œ‰Ô (1—ŐŒŸŠw): ‘ć59‰ń“ú–{“œ”A•aŠw‰ďŠÖ“ŒbM‰z’n•ű‰ď (2022/1/22), WebŠJĂ.


—AŒŒE×–EˆÚAŠw

[Šwp˜_•ś]

110414. [Œ´’˜] Nonconditioned ADA-SCID gene therapy reveals ADA requirement in the hematopoietic system and clonal dominance of vector-marked clones. Uchiyama T, Takahashi S, Nakabayashi K, Okamura K, Edasawa K, Yamada M, Watanabe N, Mochizuki E, Yasuda T, Miura A, Kato M, Tomizawa D, Otsu M1, Ariga T, Onodera M: Mol Ther Methods Clin Dev 2021/10; 23: 424-33. (‘ĺ’Á@^1: 1—AŒŒE×–EˆÚA)

110415. [Œ´’˜] Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma. Nakazato T, Hagihara M, Sahara N, Tamai Y, Ishii R, Tamaki S, Wake A, Tajika K, Sakai R, Kobayashi T, Hua J, Inoue M, Aisa Y, Fujisawa S, Miyazaki K1, Irie S, Tanaka E, Higashihara M2: Ann Hematol 2021/11; 100 (11): 2745-54. (‹{ř“_“ń1, “ŒŒ´ł–ž2: 1—AŒŒE×–EˆÚA, 2ŒŒ‰t“ŕ)

522573. [uŔ]y“ÁW: Ą’m‚Á‚Ä‚¨‚Ť‚˝‚˘@ƒQƒmƒ€ˆă—Ă‚Ćˆâ“`ŽqŽĄ—Á|Šî‘b‚Š‚ç—Տ°‚܂Łz[‘˜_] ŒťÝł”F‚ł‚ę‚Ä‚˘‚éˆâ“`ŽqŽĄ—Ă–ň|‚í‚Ş‘‚ĆŠCŠO. ‘ĺ’Á@^ (—AŒŒE×–EˆÚA): ŹŽ™“ŕ‰Č 2022/2; 54 (2): 288-93.

[Šw‰ďEŒ¤‹†‰ď“™]

722304. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) •a‰@î•ńƒVƒXƒeƒ€8”NŠÔ‚Ě•ŕ‚Ý. ‘ĺ’JTˆę (—AŒŒE×–EˆÚA): ‘ć69‰ń“ú–{—AŒŒE×–EŽĄ—ĂŠw‰ďŠwp‘‰ď (2021/6/5), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-110033. [Œ´’˜] EffEfficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study. Jang JH, Tomiyama Y, Miyazaki K1, Nagafuji K, Usuki K, Uoshima N, Fujisaki T, Kosugi H, Matsumura I, Sasaki K, Kizaki M, Sawa M, Hidaka M, Kobayashi N, Ichikawa S, Yonemura Y, Enokitani K, Matsuda A, Ozawa K, Mitani K, Lee JW, Nakao S: Br J Haematol 2021/1; 192 (1): 190-9. (‹{ř“_“ń1: 1—AŒŒE×–EˆÚA)

[Šw‰ďEŒ¤‹†‰ď“™]

'20-722007. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŒŒŹ”ÂŒ¸­Ç‚̊ӕʐf’f‚ĆŒŒŹ”ƒpƒ‰ƒ[ƒ^. ‹{ř“_“ń (—AŒŒE×–EˆÚA): ‘ć15‰ń“ú–{ŒŒđŽ~ŒŒŠw‰ďŠwp•W€‰ťˆĎˆő‰ď (SSC) 2021ƒVƒ“ƒ|ƒWƒEƒ€ (2021/2/27), WebŠJĂ.


‹~–˝‹~‹}ˆăŠw

[Šwp˜_•ś]

120037. [Œ´’˜] Possible ƒhƒi[‚Š‚ç‘ŸŠí’ń‹Ÿ‚̉”\Ť‚ŞŽ¸‚í‚ę‚é—vˆö‚ĆŽŔ‘Ô: ’PŽ{ÝŒă•űŽ‹“IŒ¤‹†. “c‘ş@’q1, ‚‹´@Œb2,3, ă‘ş—RŽ—3, ŠÖ@ˆę”n2,3, ˛ě”ü—˘3, ’Ö”ü’q”Ž4, ‹g“cˆęŹ5, •ž•”@1, •Đ‰Ş—Sˆę1, ó—˜@–ő1 (1‹~–˝, 2ˆÚAˆă—ĂŽx‰‡Žş, 3ŠĹŒě•”, 4ŠĹŒěŠw•”, 5V˘‹Iˆă—ÁEć’[ˆă—Ă): ˆÚA 2021/11; 56 (4): 397-403.

310055. [Ç—á•ń] Detection of Rectal Artery Supply to Vaginal Postpartum Hemorrhage Using CO2. Kurihara Y1, Woodhams R2, Fujii K2, Mitsui K2, Maruhashi T1, Asari Y1, Inoue Y2: J Vasc Interv Radiol 2022/2; 33 (2): 207-9. (ŒIŒ´—S‘ž˜N1, ƒEƒbƒhƒnƒ€ƒX—ćŽq2, “Ąˆä@Š]2, ŽOˆäN•˝2, ŠŰ‹´Fş1, ó—˜@–ő1, ˆäă—D‰î2: 1‹~–˝, 2•úŽËü (‰ć‘œ))

522574. [uŔ]y“ÁW: ƒuƒ‰ƒCƒ“ƒhúŽhEŽč‹Zz8. ‘ĺ‘Ú“Ž–ŹúŽh‚ĆREBOAƒJƒe[ƒeƒ‹‘}“ü. ŒIŒ´—S‘ž˜N1, ŠŰ‹´Fş1 (1‹~–˝): ‹~‹}ˆăŠw 2021/6; 45 (6): 658-65.

[’˜@‘]

620147. [Šwp‘ (•Ş’SŽˇ•M)]yJRC‘hśƒKƒCƒhƒ‰ƒCƒ“2020z‘ć2Í Źl‚Ě“ńŽŸ‹~–˝ˆ’u (ALS), p.47-150. ‰Á“ĄłĆ, Ö“ĄLs, Ž›â—E—ş, ŠŰ‹´Fş1, ‹{•”_“š (1‹~–˝): ŠÄC: “ú–{‘hś‹Ś‹c‰ď, ˆăŠw‘‰@, “Œ‹ž, 2021/6”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713053. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Direct Oral Anticoagulant is Associated with a Lower Prevalence of Thin-Cap Fibroatheroma in Patients with Coronary Artery Disease. Kinoshita D1, Minami Y2, Kakizaki R2, Ishida K2, Fujiyoshi K2, Sato T2, Kato A3, Nagata T3, Asakura K3, Katamine M3, Katsura A2, Ako J2: American Heart Association (AHA) 2021 Scientific Session (2021/11/13-15), WebŠJĂ. (–؉ş‘厑1, “ě@ŽŒŤ2, Š`č—Ç‘ž2, Î“cO‹B2, “Ą‹g˜a”Ž2, ˛“Ąr[2, ‰Á“ĄĘ”ü3, ‰i“c‹MŽq3, ’Š‘q´Žj3, •Đ•ôłáŠ3, Œj@—L’q2, ˆ˘ŒĂĆ2: 1‹~–˝, 2zŠÂŠí“ŕ, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

723672. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŽY‰ČoŒŒ‚É‚¨‚Ż‚銈“ŽŤoŒŒ‚ĚŒŸo‚ɑ΂ˇ‚é’YŽ_ƒKƒX‘˘‰e‚Ě—L—pŤ‚ĚŒŸ“˘. ŒIŒ´—S‘ž˜N1, ƒEƒbƒhƒnƒ€ƒX—ćŽq2, ź‰iŒh“ń2, “Ąˆä@Š]2, ŽOˆäN•˝2, ŠŰ‹´Fş1, “c‘ş@’q1, ˆäă—D‰î2, ó—˜@–ő1 (1‹~–˝, 2•úŽËü (‰ć‘œ)): ‘ć50‰ń“ú–{IVRŠw‰ď‘‰ď (2021/5/20), WebŠJĂ, “ú–{ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒiƒ‹ƒ‰ƒWƒIƒƒW[Šw‰ďŽGŽ 2021; 36 (Suppl): 146.

723673. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‘ŤŠÖß‰Ę•”œÜ‚𔺂¤ăřœœŠ˛•”œÜ‚ĚŽĄ—ÏŹŒoŒą. ź‰YWł1, ‰Í‘ş@’ź2, ŻŽi^‘ž˜Y2, •ôŒ´Gš, ‚‘ŠťŽm2 (1‹~–˝, 2ŽŠO): ‘ć47‰ń“ú–{œÜŽĄ—ĂŠw‰ďŠwpW‰ď (2021/7/3), _ŒË.

723674. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) possible donor‚Š‚ç‘ŸŠí’ń‹Ÿ‚̉”\Ť‚ŞŽ¸‚í‚ę‚é—vˆö‚ĆŽŔ‘Ô. “c‘ş@’q1, ‚‹´@Œb2, ŠÖ@ˆę”n2, ă‘ş—RŽ—2, ˛ě”ü—˘2, ‹g“cˆęŹ3,4, •Đ‰Ş—Sˆę1, ó—˜@–ő1 (1‹~–˝, 2ŠĹŒě•”, 3V˘‹Iˆă—ÁEć’[ˆă—Ă, 4”ĺ”AŠí): ‘ć57‰ń“ú–{ˆÚAŠw‰ď‘‰ď (2021/9/20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), ˆÚA 2021/9; 56 (‘‰ď—ŐŽž): O22-4.

732128. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) “–‰@‚É‚¨‚Ż‚é“]ˆÚŤ‘ĺ‘ڍœœŽîᇂɑ΂ˇ‚鎥—Ă‚ĚŒťó. ź‰YWł1, ‰Í‘ş@’ź2, ŻŽi^‘ž˜Y2, ‚‘ŠťŽm2 (1‹~–˝, 2ŽŠO): ‘ć174‰ń_“ސ쐎Œ`ĐŠQŠO‰ČŒ¤‹†‰ď (2022/1/29), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733161. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) f’f‚É‹ę—ś‚ľ‚˝ŠOŤăŠáâ|—ôÇŒóŒQ1—á. ‚@U‰Ć, Šâě‚ł‚¨‚č1, V”ü—Y‘ĺ2, ŒFŕVŒ›ˆę2, •“c@Œ[2 (1‹~–˝, 2Œ`ŹE”üŠO): ‘ć24‰ń–k—˘Œ`ŹŠO‰ČƒtƒH[ƒ‰ƒ€ (2021/7/17), ‘Š–ÍŒ´.


‘‡f—ĂˆăŠw

[Šwp˜_•ś]

521018. [‰đŕ] ‹š•”•s‰őŠ´‚ĚÇó“™‚đŠm”F‚ˇ‚é‹`–ą‚đ‘Ó‚č, ‹}ŤŠĽÇŒóŒQ‚ĚŠÓ•Ę‚đ‘Ó‚Á‚˝‚˝‚ß, ŠłŽŇ‚É—‚“úS”j—ô‚ސś‚ś‚ÄŽ€–S‚ľ‚˝‚Ć‚ľ‚Ä‘šŠQ”…ž‚đ‹‚ß‚˝Ž–—á. ÂŽR’ź‘P (‘‡f—Ă): ˆă—Ă”ť—á‰đŕ 2021/10; 94: 122-4.


ˆăŠw•”•‘ŽˆăŠw‹łˆçŒ¤‹†ŠJ”­ƒZƒ“ƒ^[

ˆăŠw‹łˆçŒ¤‹†•”–ĺ

[Šwp˜_•ś]

220004. [€Œ´’˜] ‘Ήž˘“ď‚ČŠłŽŇ‚đ‘z’č‚ľ‚˝–Í‹[ŠłŽŇ‚Ć‚Ěˆă—Öʐډ‰K‚ÉŠÖ‚ˇ‚éŽŔ‘H•ń. Žs‘q‰Á“ŢŽq1, Žç‰Ž—˜‰Ŕ2, ç—tG‹B, ˆäă˛b, “‡’Ă–žl, ’ç@–žƒ3 (1ˆă—ÉqśŠw•”, 2ˆăŠw‹łˆç, 3ŒöO‰qś): “ú–{ƒwƒ‹ƒXƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“Šw‰ďŽGŽ 2021/4; 12 (1): 51-5.

220005. [€Œ´’˜] [‹łŢEƒVƒiƒŠƒI] ˆă—ĂŒn‚ĚŠwśŠÔƒ[ƒ‹EƒvƒŒƒC‰‰K‚𑣐i‚ˇ‚éĎ‹É“IŒX’ŽŠwK‚ÉŠÖ‚ˇ‚é“Ž‰ć‹łŢ‚ĚŠJ”­. ç—tG‹B1, ˆäă˛b, Žç‰Ž—˜‰Ŕ1, “‡’Ă–žl, Žs‘q‰Á“ŢŽq2, ’ç@–žƒ3 (1ˆăŠw‹łˆç, 2ˆă—ÉqśŠw•”, 3ŒöO‰qś): “ú–{ƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“ˆă—Ă‹łˆçŠw‰ďŽGŽ 2021/10; 9: 64-71.

[’˜@‘]

620148. [Šwp‘ (•Ş’SŽˇ•M)]y”ń‚Ş‚ńŽžŠł‚ĚƒGƒ“ƒhƒIƒuƒ‰ƒCƒtEƒPƒA (EOLC) ‚ÉŠÖ‚ˇ‚éƒKƒCƒhƒ‰ƒCƒ“z[d—v—Տ°‰Ű‘č9] ƒAƒhƒoƒ“ƒXEƒPƒAEƒvƒ‰ƒ“ƒjƒ“ƒO (ACP)@CQ21, p77-9. ç—tG‹B1, ŽO‰Y‹vK, źě–ž‘Ľ, ŽRŒű‘׍O, Šˆä•śŽq (1ˆăŠw‹łˆç), •Ň: “úŒoƒƒfƒBƒJƒ‹, “úŒoBP, “Œ‹ž, 2021/9”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

723675. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒIƒ“ƒ‰ƒCƒ“u‹`Œ^Žö‹Ć‚É‚¨‚Ż‚éƒJƒEƒ“ƒZƒŠƒ“ƒO“Ž‰ć‚đŠˆ—p‚ľ‚˝ƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“‰‰K‚ĚŽŔŽ{‰Â”\Ť‚¨‚ć‚Ń—L—pŤ. Žs‘q‰Á“ŢŽq1, Žç‰Ž—˜‰Ŕ2, ç—tG‹B2, ˆäă˛b, “n•Ó˜aL3, rˆä—L”ü4, “‡’Ă–žl, [Ł—TŽq1, ‘şŁ‰ŘŽq1, “cƒ–’J_–M1, ’ç@–žƒ3 (1ˆă—ÉqśŠw•”, 2ˆăŠw‹łˆç, 3ŒöO‰qś, 4ˆă—Ă‚ĚŽżEˆŔ‘S„iŽş): ƒwƒ‹ƒXƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“ƒEƒB[ƒN2021`L“‡` (2021/10/2), WebŠJĂ.

723676. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒGƒ“ƒhEƒIƒuEƒ‰ƒCƒtƒPƒA‚ÉŠÖ‚í‚éę–ĺE‚đ‘ÎŰ‚Ć‚ľ‚˝ƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“Œ¤C‘OŒă‚̉ď˜b•Ď‰ť‚ĆŠłŽŇ•]‰ż‚ÉŠÖ‚ˇ‚錤‹†. ç—tG‹B1, Žç‰Ž—˜‰Ŕ1, ”öŒ`—Ď–ž, ‚˝‚çŕV–M’j, X’JAŒc, ‘ž“cˆęŽ÷ (1ˆăŠw‹łˆç): ƒwƒ‹ƒXƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“ƒEƒB[ƒN2021`L“‡` (2021/10/2), L“‡ (ƒnƒCƒuƒŠƒbƒhŠJĂ).


ˆăŠwŒ´˜_Œ¤‹†•”–ĺ

[Šwp˜_•ś]

521019. [‰đŕ]y˜AÚ: —DśŽv‘z‚É—§‚żŒü‚Š‚¤s27tzgŒhˆÓ‚𔺂¤hŠ°—e‚Ě‚˝‚ß‚É. âV“Ą—L‹IŽq (ˆăŠwŒ´˜_): ‚ˇ‚ׂĂ̐l‚̎Љď 2021/10; 41 (7): 8-9.

[Šw‰ďEŒ¤‹†‰ď“™]

723677. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”D•w‚ĚŒŒ‰t‚É‚ć‚éoś‘OŒŸ¸`ƒKƒCƒhƒ‰ƒCƒ“‚đěŹ‚ˇ‚éę–ĺE‚Ě—Ď—`. âV“Ą—L‹IŽq (ˆăŠwŒ´˜_): ‘ć11‰ń“ú–{ˆâ“`Žqf—ĂŠw‰ďˆâ“`Žqf’fEŒŸ¸‹Zp„iƒtƒH[ƒ‰ƒ€ (2021/12/2), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

733225. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ”]_Œo“ŕ‰Čˆă‚É‹‚ß‚ç‚ę‚éˆâ“`Žqf’fŒŸ¸‚É‚¨‚Ż‚é—Ď—“IE–@“I”z—ś. âV“Ą—L‹IŽq (ˆăŠwŒ´˜_): —ߘa3”N“x_Œo•ĎŤŽžŠł—Ăˆç‚ĚŠî”Ő“I’˛¸Œ¤‹†”ǃ[ƒNƒVƒ‡ƒbƒv (2021/7/9), WebŠJĂ.

733226. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) oś‘Of’f‚Ć—Ď—. âV“Ą—L‹IŽq (ˆăŠwŒ´˜_): “ú–{‰Ć‘°Œv‰ć‹Ś‰ďˆâ“`‚ĚŠî‘bƒIƒ“ƒ‰ƒCƒ“uŔ (2021/11/22), WebŠJĂ.

733227. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “ú–{¸_‰qś‰ď‚Ć—Dś•ŰŒě–@’˛¸•ń. âV“Ą—L‹IŽq (ˆăŠwŒ´˜_): “ú–{¸_‰qś‰ď (2021/12/16), WebŠJĂ.

733228. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) oś‘OE’…°‘OŒŸ¸‚Ş‚ŕ‚˝‚炡—Ť‚Ö‚ĚƒXƒeƒBƒOƒ}. âV“Ą—L‹IŽq (ˆăŠwŒ´˜_): ƒQƒmƒ€–â‘čŒŸ“˘‰ď‹c (2022/1/16), WebŠJĂ.

733229. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Ť“IDVEŤ–\—Í‚Ć”DP’†â. âV“Ą—L‹IŽq (ˆăŠwŒ´˜_): #‚ŕ‚Á‚ĆˆŔ‘S‚Č’†â‚đƒAƒNƒVƒ‡ƒ“ (2022/1/28), WebŠJĂ.

733230. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) oś‘OE’…°‘OŒŸ¸‚ĆDSDs. âV“Ą—L‹IŽq (ˆăŠwŒ´˜_): –žŽĄŠw‰@‘ĺŠwŽĐ‰ďŠw•”•t‘ŽŒ¤‹†Šˆę”ĘƒvƒƒWƒFƒNƒg (2022/3/16), WebŠJĂ.

733231. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‚Ť‚傤‚ž‚˘‚ĚŽ‹“_‚Š‚ç‚Ý‚˝oś‘OŒŸ¸. âV“Ą—L‹IŽq (ˆăŠwŒ´˜_): –žŽĄŠw‰@‘ĺŠwŽĐ‰ďŠw•”•t‘ŽŒ¤‹†Šˆę”ĘƒvƒƒWƒFƒNƒg (2022/3/16), WebŠJĂ.


ˆă—ĂˆŔ‘SEŠÇ—ŠwŒ¤‹†•”–ĺ

ŚuŽŒ`ŠO‰ČŠwv‚đŽQĆ


ˆă—Ă‹Zp‹łˆçŒ¤‹†•”–ĺ

Śut‘Ÿ“ŕ‰ČŠwv‚đŽQĆ


ŠwKŽx‰‡Œ¤‹†•”–ĺ


ˆă—Ïî•ń‹łˆçŒ¤‹†•”–ĺ

[Šw‰ďEŒ¤‹†‰ď“™]

713054. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Multi-state structure determination and dynamics analysis reveals a new ubiquitin-recognition mechanism in yeast ubiquitin C-terminal hydrolase. Ikeya T, Okada M, Tateishi Y, Nojiri E, Mikawa T, Rajesh Sundaresan, Ogasa H, Ueda T, Yagi H, Kohno T1, Kigawa T, Shimada I, Guntert Peter, Ito Y ISMAR-APNMR-NMRSJ-SEST 2021 (2021/8/23), Osaka, Japan. (‰Í–ěr”V1: 1ˆă—Ïî•ń‹łˆç)

713055. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Successful Analysis of the Interaction between a GPCR Peptide Fragment Having High Aggregating Tendency with a Modulator Protein of the GPCR. Kuzunuki E, Busujima I, Kurokawa Y, Sakamoto T, Kohno T1, Hosoda K, Terawaki S, Wakamatsu K ISMAR-APNMR-NMRSJ-SEST 2021 (2022/8/23), Osaka, Japan. (‰Í–ěr”V1: 1ˆă—Ïî•ń‹łˆç)


“Œ—mˆăŠw‹łˆçŒ¤‹†•”–ĺ

[Šwp˜_•ś]

110416. [Œ´’˜] The Relationship between ""Shofuku-Fujin"" (Abnormality of Abdominal Examination in Japanese Kampo Medicine) and Body Composition by Bioelectrical Impedance Analysis: A Cross-Sectional Study. Ishige T1, Odaguchi H1,2, Hanawa T1: Evid Based Complement Alternat Med 2021/4; 2021: 6610593. (Ź“cŒű_1,2: 1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç)

110417. [Œ´’˜] Prevention and Recovery of COVID-19 Patients With Kampo Medicine: Review of Case Reports and Ongoing Clinical Trials. Takayama S, Namiki T, Odaguchi H1,2, Arita R, Hisanaga A, Mitani K, Takashi Ito T: Front Pharmacol 2021/6; 12: 656246. (Ź“cŒű_1,2: 1“Œ—mˆăŠw‹łˆç, 2“Œ—mˆăŠw‘‡Œ¤‹†Š)

110418. [Œ´’˜] Preventive effect of a Kampo medicine, kososan, on recurrent depression in a mouse model of repeated social defeat stress. Ito N1, Sasaki K, Hirose E, Nagai T1, Isoda H, Odaguchi H1,2: Gene 2022/1; 806: 145920. (Ź“cŒű_1,2: 1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç)

110419. [Œ´’˜] Kampo formulas alleviate aging-related emotional disturbances and neuroinflammation in male senescence-accelerated mouse prone 8 mice. Ito N1, Maruko A, Oshima K, Yoshida M, Honma K, Sugiyama C, Nagai T1, Kobayashi Y1, Odaguchi H1,2, Okada N: Aging (Albany NY) 2022/1; 14 (1): 109-42. (Ź“cŒű_1,2: 1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç)

120038. [Œ´’˜] ‘ŰŽž•a•Ş—Ţ‘ć11‰ń‰ü’ů”Ĺ (ICD-11) “`“ˆăŠwÍVÝ‚ĚˆÓ‹`. ˆÉ“Ą@—˛, “n@ŽO‰Ŕ, Ä“Ą@‘Ľ, Ż–ě‘ě”V1,2, ‰Ą–x—RŠěŽq, –î‹v•ŰCŽk, ŽáŽRˆç˜Y (1“Œ—mˆăŠw‹łˆç, 2“Œ—mˆăŠw‘‡Œ¤‹†Š): “ú–{“Œ—mˆăŠwŽGŽ 2021/10; 72 (4): 461-72.

320026. [Ç—á•ń] •sˆŔ_ŒoÇ‚̏”Çó‚É—čŒjŠĂžĽ“’‰Ág‰Ô‚Ş—LŒř‚Ĺ‚ ‚Á‚˝1Ç—á. ’†”öŒjŽq1, Ż–ě‘ě”V1,2, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): Šż•ű‚Ě—Ő° 2021/5; 68 (5): 632-6.

320027. [Ç—á•ń] čI‹„‚ĆŠż•ű‚Ě•š—p‚Ş‘tŒř‚ľ‚˝‡–°áŠQ‚Ě1—á. ˆä“c„l1, ˆÉ“ŒGŒ›1, —é–Ř–M•F1, ˆÉ“Ą@„1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): Šż•ű‚Ě—Ő° 2022/1; 69 (1): 95-100.

522575. [uŔ]y“ÁW: ƒWƒFƒlƒ‰ƒŠƒXƒgEŠż•ű|‚Ć‚Á‚Ä‚¨‚Ť‚ĚŠż•űŠˆ—ppzĄ—Ěˆć•Ę‚¨‚ˇ‚ˇ‚ߊż•űŽĄ—Á@Á‰ťŠí“ŕ‰Č…@@H—~•sU, ‹@”\ŤƒfƒBƒXƒyƒvƒVƒA, ‹t—ŹŤH“š‰Š. Ż–ě‘ě”V1,2 (1“Œ—mˆăŠw‹łˆç, 2“Œ—mˆăŠw‘‡Œ¤‹†Š): medicina 2021/7; 58 (8): 1140-3.

522576. [uŔ]y“ÁW: ƒWƒFƒlƒ‰ƒŠƒXƒgEŠż•ű|‚Ć‚Á‚Ä‚¨‚Ť‚ĚŠż•űŠˆ—ppzĄ—Ěˆć•Ę‚¨‚ˇ‚ˇ‚ߊż•űŽĄ—Á@ŽY•wl‰Č@ŒŽŒo‘OÇŒóŒQCX”NŠúáŠQ. X@‰lŽq1, Ź“cŒű_2,3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2“Œ—mˆăŠw‹łˆç, 3“Œ—mˆăŠw‘‡Œ¤‹†Š): medicina 2021/7; 58 (8): 1202-6.

[’˜@‘]

620149. [Šwp‘ (•ŇWEŠÄC)]yę–ĺ‰Ć‚ĚƒRƒ“ƒZƒ“ƒTƒX‚ÉŠî‚Ă‚­ƒ|ƒPƒbƒgŠż•ű–ňƒKƒCƒh34 1”ŁzVˆä@M, Ź“cŒű_1,2, ŽÄŒ´’ź—˜, “ˆ“c@–L, •Ŕ–Ř—˛—Y, ‰Ô—Öšć•F2, ŽOŕk’‰“š, ‘şźTˆę, ŠÖŞ–ƒ—Žq, Žá™ˆŔŠó”T (1“Œ—mˆăŠw‹łˆç, 2“Œ—mˆăŠw‘‡Œ¤‹†Š), ’˜: ƒ|ƒPƒbƒgŠż•ű–ňƒKƒCƒh•ŇWˆĎˆő‰ď, “ěŽR“°, “Œ‹ž, 2021/8”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

722305. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) Šż•űˆ•ű‚ĚŒÄ‹zŠíƒEƒCƒ‹ƒXŠ´őÇ‚ɑ΂ˇ‚éŒř‰Ę: •â’†‰v‹C“’, ŽÄŠ‹‰đ”§“’, Š‹Ş“’‚ƏŹŽÄŒÓ“’‰Á‹j[Îp‡Ü‚ĚŠî‘bŒ¤‹†. ‰iˆä—˛”V1, Ź“cŒű_1,2, ´Œ´Š°Í1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć38‰ń˜aŠżˆă–ňŠw‰ďŠwp‘ĺ‰ď (2021/9/5), WebŠJĂ.

722306. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ˆăŽtŽĺ“ąŽĄŒągŠ´ő‰Šú‚ĚCOVID-19ŠłŽŇ‚ɑ΂ˇ‚éEFE‚Ě—LŒřŤ‹y‚ŃˆŔ‘SŤ‚đŒŸ“˘‚ˇ‚é’Tő“IŽŽŒąh‚Ě’†ŠÔ•ń. Ź“cŒű_1,2 (1“Œ—mˆăŠw‹łˆç, 2“Œ—mˆăŠw‘‡Œ¤‹†Š): “ú–{–ňŠw‰ď‘ć142”N‰ď (2022/3/26), WebŠJĂ.

723678. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “Ť‚Ě“ű‚Ş‚ńŘœŒăáu’ɏnjóŒQ‚ÉčI‹„ŽĄ—Ă‚Ş—LŒř‚Ĺ‚ ‚Á‚˝ˆęÇ—á. •Šâ“ށXŽq1, ˆÉ“ŒGŒ›1, ˆÉ“Ą@„1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć70‰ń (ŒöŽĐ) ‘S“ú–{čI‹„Šw‰ďŠwp‘ĺ‰ď (2021/6/4), WebŠJĂ.

723679. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ćů•”‚̒ɂ݂ɑ΂ľ‚ÄŒo—ŽĄ—Ă‚Ć“§”M‹„‚Ş‘tŒř‚ľ‚˝1Ç—á. “Œě—剛1, ˆÉ“ŒGŒ›1, ˆÉ“Ą@„1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć70‰ń (ŒöŽĐ) ‘S“ú–{čI‹„Šw‰ďŠwp‘ĺ‰ď (2021/6/4), WebŠJĂ.

723680. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ánć҂ɑ΂ľ‚ÄčI‹„CŠż•űŽĄ—Ă‚Ş—LŒř‚ĆŽv‚í‚ę‚˝2Ç—á. ˆÉ“ŒGŒ›1, ˆÉ“Ą@„1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć70‰ń (ŒöŽĐ) ‘S“ú–{čI‹„Šw‰ďŠwp‘ĺ‰ď (2021/6/5), WebŠJĂ.

723681. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŠááŮázš‚ÉčI‹„ŽĄ—Ă‚Ş—LŒř‚Ĺ‚ ‚Á‚˝1Ç—á. ˆä“c„l1, ˆÉ“ŒGŒ›1, ˆÉ“Ą@„1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć70‰ń (ŒöŽĐ) ‘S“ú–{čI‹„Šw‰ďŠwp‘ĺ‰ď (2021/6/5), WebŠJĂ.

723682. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ICD-11“`“ˆăŠw‚ĚÍ‚Ě‘“ŕ“K—p\—pŒę‹y‚Ń•a–ź•Ş—ŢˆĎˆő‰ďŠˆ“Ž•ń. Ż–ě‘ě”V1,2 (1“Œ—mˆăŠw‹łˆç, 2“Œ—mˆăŠw‘‡Œ¤‹†Š): ‘ć71‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2021/8/13), WebŠJĂ.

723683. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”ě–ž‚đD‘i‚Ć‚ľ‚˝ŽófŠłŽŇ‚ĚŠż•űˆ•ű‚ɂ‚˘‚Ä‚ĚŒă‚ëŒü‚ŤŠĎŽ@‚ĚŒŸ“˘. ˆÉ“ŒGŒ›1, ‰Ô—Öšć•F1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć71‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2021/8/13), WebŠJĂ.

723684. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) AI‚É‚ć‚鍏‚ݐś–ň‚Ě‰ć‘œ”ť•Ę‚ĚŽŽ‚݁|[‘wŠwKƒjƒ…[ƒ‰ƒ‹ƒlƒbƒgƒ[ƒN‚É‚ć‚锝•Ę¸“x‚ĚŒŸŘ|. ˆÉ“Ą—Yˆę1, ˆÉ“ŒGŒ›1, ˆÉ“Ą@„1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć71‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2021/8/13), WebŠJĂ.

723685. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Šá‚Ě•s’čD‘i‚Éž‰Žq””ç“’‚Ş’˜Œř‚ľ‚˝1—á. X—T‹IŽq1, •—ŒË—zŽq1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć71‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2021/8/14), WebŠJĂ.

723686. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “ű–[ÄŒšpŒă‚ĚŒ¨ŠÖßSk‚ÉŒo‹ŘŽĄ—Ă‚đŠÜ‚ŢčIŽĄ—Ă‚Ş—LŒř‚ž‚Á‚˝ˆęÇ—á. ‹ß“ĄˆŸš1, ˆÉ“ŒGŒ›1, ˆÉ“Ą@„1, ‰Ô—Öšć•F1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć71‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2021/8/14), WebŠJĂ.

723687. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Šż•űŘŽĄ—Ă‚É‚ć‚čă‘Ű (•ŠŒF) ‚̕ωť‚đ”F‚ß‚˝ˆę—á. ě“çˆÉW1, ‰Ô—Öšć•F1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć71‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2021/8/14), WebŠJĂ.

723688. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆó“xŽÖ–؉Á–Ą•ű‚ō~ˆłŒř‰Ę‚Ş”F‚ß‚ç‚ę‚˝‚ŒŒˆłÇ‚Ě3—á. Ź“cŒű_1,2 (1“Œ—mˆăŠw‹łˆç, 2“Œ—mˆăŠw‘‡Œ¤‹†Š): ‘ć71‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2021/8/14), WebŠJĂ.

723689. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —Տ°Œ¤‹†ƒR[ƒfƒBƒl[ƒ^[ (CRC) ‚Š‚ç‚Ý‚é—Տ°Œ¤‹†‚Ě“ŽŒü`‰ß‹Ž10”NŠÔ‚Ě“ŽŒü`‰ß‹Ž10”NŠÔ‚Ě–{Šw‰ďŠwp‘‰ď‚̍u‰‰—vŽ|W‚đ‚ŕ‚ƂɁ`. ŠÖŞ–ƒ—Žq1, Žá™ˆŔŠó”T1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć71‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2021/8/15), WebŠJĂ.

723690. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –k—˘‘ĺŠwˆăŠw•”‚É‚¨‚Ż‚é“Œ—mˆăŠwŽŔK‚ĚŠT—v‚¨‚ć‚ŃŠwś‚É‚ć‚é•]‰ż. Žá™ˆŔŠó”T1, ŠÖŞ–ƒ—Žq1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć71‰ń“ú–{“Œ—mˆăŠw‰ďŠwp‘‰ď (2021/8/15), WebŠJĂ.

723691. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”ě–žÇ‚Ü‚˝‚̓ƒ^ƒ{ƒŠƒbƒNÇŒóŒQŠłŽŇ‚ɑ΂ˇ‚銿•ű–ň‚Ě—LŒřŤ‚¨‚ć‚ŃˆŔ‘SŤ‚ɂ‚˘‚Ä‚ĚŒă•űŽ‹“IŒ¤‹†. ˆÉ“ŒGŒ›1, ‰Ô—Öšć•F1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć38‰ń˜aŠżˆă–ňŠw‰ďŠwp‘ĺ‰ď (2021/9/4), WebŠJĂ.

723692. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”’žQ”z‡•â’†‰v‹C“’‚̖Ɖuƒ`ƒFƒbƒNƒ|ƒCƒ“ƒg‘jŠQÜ‚É‚ć‚é•›ě—p”­Œť—\–h‚ւ̉ž—p‚̉”\Ť‚ĚŒŸ“˘. ŽRŒű˜a‹P1, ‰““Ą^—1, ´Œ´Š°Í1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć38‰ń˜aŠżˆă–ňŠw‰ďŠwp‘ĺ‰ď (2021/9/4), WebŠJĂ.

723693. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) SAMP8ƒ}ƒEƒX‚đ—p‚˘‚˝Šż•ű–ň‚Ě–˘•a§ŒäƒƒJƒjƒYƒ€‚̉đÍ. ˆÉ“Ą’źŽ÷1, –{ŠÔŒ’Œĺ1, ™ŽRç‰Ŕ1, ’čŒő—S‰Ŕ1, ’ˇ’Jěˆť“ß1, ‰iˆä—˛”V1, ´Œ´Š°Í1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć38‰ń˜aŠżˆă–ňŠw‰ďŠwp‘ĺ‰ď (2021/9/4), WebŠJĂ.

723694. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –˘•aƒ‚ƒfƒ‹ƒ}ƒEƒX‚ɑ΂ˇ‚é•Ÿ—ˆ (ƒtƒNƒŒ) ƒ~ƒJƒ“‰Ę”çŰŽć‚Ě—LŒřŤ‚̉đÍ. ’čŒő—S‰Ŕ1, ˆÉ“Ą’źŽ÷1, –{ŠÔŒ’Œĺ1, ™ŽRç‰Ŕ1, –L“c@~1, ˆäă‰hˆę1, Ź“cŒű_1,2, ´Œ´Š°Í1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć38‰ń˜aŠżˆă–ňŠw‰ďŠwp‘ĺ‰ď (2021/9/4), WebŠJĂ.

723695. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) LPS—U”­sickness behaviorƒ‚ƒfƒ‹ƒ}ƒEƒX‚ɑ΂ˇ‚銿•ű–ň‚̍ě—p‚̉đÍ. –{ŠÔŒ’Œĺ1, ’čŒő—S‰Ŕ1, ™ŽRç‰Ŕ1, ˆÉ“Ą’źŽ÷1, Ź“cŒű_1,2, ´Œ´Š°Í1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć38‰ń˜aŠżˆă–ňŠw‰ďŠwp‘ĺ‰ď (2021/9/4), WebŠJĂ.

723696. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) WăË-”’žQ”z‡•â’†‰v‹C“’‚ĚTƒŠƒ“ƒp‹…‰îÝŤŹ’°”S–Œ‰ŠÇ‰ü‘Pě—p‚Ě‹@˜‚Ć—LŒřŹ•Ş‚̉đ–ž. ‰““Ą^—1, ´Œ´Š°Í1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć38‰ń˜aŠżˆă–ňŠw‰ďŠwp‘ĺ‰ď (2021/9/4), WebŠJĂ.

723697. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) –ƒˆÇ@ŠĂ“’‚Ě’Á’ɍě—p‚ÉŠÖ‚í‚é\Źś–ň‚̉đ–ž. ’|“ŕ@ƒ1, ’†Xr•ă1, “úŒü{”üŽq2, ‹{“ˆ’ź‹I1, “ŕŽR“Ţ•äŽq, “úŒüšŽi, “V‘q‹gÍ, ŒŃ’ˍ‚Žu, ‡“cKL, Ź“cŒű_2,3, ‰Ô—Öšć•F2, Ź—Ń‹`“T1 (1–ňŠw•”, 2“Œ—mˆăŠw‘‡Œ¤‹†Š, 3“Œ—mˆăŠw‹łˆç): ‘ć38‰ń˜aŠżˆă–ňŠw‰ďŠwp‘ĺ‰ď (2021/9/4), WebŠJĂ.

723698. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒ}ƒEƒXƒRƒƒiƒEƒCƒ‹ƒXMurine hepatitis virusŠ´őƒ}ƒEƒX‚ɑ΂ˇ‚éEFE‚ĚŒř‰Ę. ź@–ž‹I1, “úŒü{”üŽq1, “úŒüšŽi, ăŠÔ@‹§, “ŕŽR“Ţ•äŽq, aŒű˜ab, Ź“cŒű_1,2 ‡“cKL (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć38‰ń˜aŠżˆă–ňŠw‰ďŠwp‘ĺ‰ď (2021/9/4), WebŠJĂ.

723699. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) VeroE6/TMPRSS2×–E‚đ—p‚˘‚˝EFE‚̍RSARS-CoV-2ě—p‚̉đÍ. ăŠÔ@‹§, “úŒüšŽi, “úŒü{”üŽq1, “V‘q‹gÍ, “ŕŽR“Ţ•äŽq, aŒű˜ab, ’Š‘q@G, Ź“cŒű_1,2, ‡“cKL (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć38‰ń˜aŠżˆă–ňŠw‰ďŠwp‘ĺ‰ď (2021/9/4), WebŠJĂ.

723700. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒGƒtƒFƒhƒŠƒ“ƒAƒ‹ƒJƒƒCƒhœ‹Ž–ƒ‰ŠƒGƒLƒX (EFE) ‚̍RVŒ^ƒRƒƒiƒEƒCƒ‹ƒXě—p‚É‚¨‚Ż‚é•ŞŽq‹@\. “úŒüšŽi, “úŒü{”üŽq1, “V‘q‹gÍ, ăŠÔ@‹§, “ŕŽR“Ţ•äŽq, aŒű˜ab, Ź“cŒű_1,2, ‡“cKL (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć38‰ń˜aŠżˆă–ňŠw‰ďŠwp‘ĺ‰ď (2021/9/4), WebŠJĂ.

723701. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Paclitaxel—U”­––˝_ŒoáŠQŤáu’ɂɑ΂ˇ‚é–ƒ‰ŠƒGƒLƒX‚ĆƒGƒtƒFƒhƒŠƒ“ƒAƒ‹ƒJƒƒCƒhœ‹Ž–ƒ‰ŠƒGƒLƒX‚Ě’Á’ɍě—p. ‰Š@á’O1,2, “úŒü{”üŽq2, —k@‹ŕˆÜ, “ŕŽR“Ţ•äŽq, “úŒüšŽi, “V‘q‹gÍ, ŒŃ’ˍ‚Žu, ‡“cKL, Ź“cŒű_2,3, ‰Ô—Öšć•F2, Ź—Ń‹`“T1 (1–ňŠw•”, 2“Œ—mˆăŠw‘‡Œ¤‹†Š, 3“Œ—mˆăŠw‹łˆç): ‘ć38‰ń˜aŠżˆă–ňŠw‰ďŠwp‘ĺ‰ď (2021/9/4), WebŠJĂ.

723702. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŒŸőŒę‚̋ߐړx‚đŒŔ’č‚Ĺ‚Ť‚銿•űƒeƒLƒXƒg•Ą‡ŒŸőƒf[ƒ^ƒx[ƒX‚̍\’z. Ż–ě‘ě”V1,2, Žü–hˆę•˝2, ‰Á”¨‘Žq2, Ź“cŒű_1,2, ‰Ô—Öšć•F2 (1“Œ—mˆăŠw‹łˆç, 2“Œ—mˆăŠw‘‡Œ¤‹†Š): ‘ć122‰ń“ú–{ˆăŽjŠw‰ď‘‰ďEŠwp‘ĺ‰ď (2021/9/18), WebŠJĂ.

723703. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˆäăŒb—‚Ě–Źf‚ɂ‚˘‚Ä. Žü–hˆę•˝1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć122‰ń“ú–{ˆăŽjŠw‰ď‘‰ďEŠwp‘ĺ‰ď (2021/9/18), WebŠJĂ.

723704. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Vo‚̐ź‘ş—Źw‰Ć“`čI‹„”é˜^x‚ɂ‚˘‚Ä. ‰Á”¨‘Žq1, Ż–ě‘ě”V1,2, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć122‰ń“ú–{ˆăŽjŠw‰ď‘‰ďEŠwp‘ĺ‰ď (2021/9/18), WebŠJĂ.

723705. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ”ź‰ÄŒú–p“’‚̏pŒă’°ŠÇ–ƒáƒƒ‚ƒfƒ‹ƒ}ƒEƒX‚ɑ΂ˇ‚éR‰ŠÇě—p‚̉đÍ. ‰““Ą^—1, ´Œ´Š°Í1, –x@ł•q, ‹yě“N˜Y1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć23‰ń“ú–{_ŒoÁ‰ťŠí•aŠw‰ď (2021/10/8), WebŠJĂ.

723706. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ˜V‰ť‘Łiƒ‚ƒfƒ‹“Ž•¨‚đ—p‚˘‚˝Šż•ű–ň‚Ě–˘•a§ŒäŒ¤‹†`‰Á—‚¤‚‚ɑ΂ˇ‚é—LŒřŤ`. ˆÉ“Ą’źŽ÷1, –{ŠÔŒ’Œĺ1, ’čŒő—S‰Ŕ1, ‰iˆä—˛”V1, ‰Ô—Öšć•F1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): “ú–{–ňŠw‰ď‘ć142”N‰ď (2022/3/27), WebŠJĂ.

723707. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Paclitaxel—U”­––˝_ŒoáŠQŤáu’ɂɑ΂ˇ‚éƒGƒtƒFƒhƒŠƒ“ƒAƒ‹ƒJƒƒCƒhœ‹Ž–ƒ‰ŠƒGƒLƒX‚ĚŽĄ—Ă‹y‚Ń—\–hŒř‰Ę. ÎěKŽu1, HŠÔ”ü‹v1, ‰Š@á’O1,2, “úŒü{”üŽq2, —k@‹ŕˆÜ, “ŕŽR“Ţ•äŽq, “úŒüšŽi, “V‘q‹gÍ, ŒŃ’ˍ‚Žu, ‡“cKL, Ź“cŒű_2,3, ‰Ô—Öšć•F2, Ź—Ń‹`“T2 (1–ňŠw•”, 2“Œ—mˆăŠw‘‡Œ¤‹†Š, 3“Œ—mˆăŠw‹łˆç): “ú–{–ňŠw‰ď‘ć142”N‰ď (2022/3/27), WebŠJĂ.

723708. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) 1HNMRƒƒ^ƒ{ƒŠƒbƒNƒvƒƒtƒ@ƒCƒŠƒ“ƒO‚đ—p‚˘‚˝Šż•ű–ňu–ƒˆÇ@ŠĂ“’v‚̐Ź•Ş‘gŹ‰đÍ. ă“c’q–ç1, ”’”¨’C–í1, ’†Xr•ă1, “úŒü{”üŽq2, ’|“ŕ@ƒ1, “ŕŽR“Ţ•äŽq, “úŒüšŽi, “V‘q‹gÍ, ŒŃ’ˍ‚Žu, ‡“cKL, Ź“cŒű_2,3, ‰Ô—Öšć•F2, Ź—Ń‹`“T2 (1–ňŠw•”, 2“Œ—mˆăŠw‘‡Œ¤‹†Š, 3“Œ—mˆăŠw‹łˆç): “ú–{–ňŠw‰ď‘ć142”N‰ď (2022/3/27), WebŠJĂ.

723709. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Formalin—U”­áu’ɂɑ΂ˇ‚é–ƒ‰ŠƒGƒLƒX‹y‚ŃƒGƒtƒFƒhƒŠƒ“ƒAƒ‹ƒJƒƒCƒh‚Ě‘ŚŒřŤ‚Ě’Á’ɍě—p‚ĚƒƒJƒjƒYƒ€. ˆäo—˘‰Ŕ1, ‰Š@á’O1,2, “úŒü{”üŽq2, ’†Xr•ă1, “ŕŽR“Ţ•äŽq, “úŒüšŽi, “V‘q‹gÍ, ŒŃ’ˍ‚Žu, ‡“cKL, Ź“cŒű_2,3, ‰Ô—Öšć•F2, Ź—Ń‹`“T2 (1–ňŠw•”, 2“Œ—mˆăŠw‘‡Œ¤‹†Š, 3“Œ—mˆăŠw‹łˆç): “ú–{–ňŠw‰ď‘ć142”N‰ď (2022/3/27), WebŠJĂ.

733232. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) čI‹„‚ĆŠż•ű‚Ě•š—p‚Ş‘tŒř‚ľ‚˝‡–°áŠQ‚Ě1—á. ˆä“c„l1, ÎŒ´@•1, ˆÉ“ŒGŒ›1, —é–Ř–M•F1,2, ˆÉ“Ą@„1, Ź“cŒű_1,2 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć31‰ńŠż•űŽĄ—ĂŒ¤‹†‰ď (2021/9/26), WebŠJĂ.

733233. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “–Ž{Ý‚É‚¨‚Ż‚é”]‘˛’†ŒăˆâÇŠłŽŇ‚ɑ΂ˇ‚銿•űŽĄ—Ă‚ĚŽŔ‘Ô’˛¸. ’†”öŒjŽq1, Î–Ń’B–ç1, Ź“cŒű_1,2, ‰Ô—Öšć•F1 (1“Œ—mˆăŠw‘‡Œ¤‹†Š, 2“Œ—mˆăŠw‹łˆç): ‘ć77‰ń“ú–{“Œ—mˆăŠw‰ďŠÖ“ŒbM‰zŽx•”‘‰ď (2021/10/24), WebŠJĂ.


•a‰@˜AŒg‹łˆçŒ¤‹†•”–ĺ

Śu‰ş•”Á‰ťŠÇŠO‰ČŠwv‚đŽQĆ


—Տ°‰đ–U‹łˆç‹†•”–ĺ

Śu‰đ–UŠwiŹě’PˆĘjv‚đŽQĆ


’nˆćˆă—ĂŠw‹łˆçŒ¤‹†•”–ĺ

ŚuS‘ŸŒŒŠÇŠO‰ČŠwv‚đŽQĆ


ˆăŠw•”•‘Ž—Տ°Œ¤‹†ƒZƒ“ƒ^[

Šé‰ćŠJ”­•”–ĺ

[Šwp˜_•ś]

110417. [Œ´’˜] How Community Pharmacists Perceive Ethics in Clinical Research: A Qualitative Study. Ogura M, Takehira R, Watanabe T1, Arita E: Healthcare (Basel) 2021/11; 9(11): 1496. (“n糒B–ç1: 1—Տ°Œ¤‹†EŠé‰ć)

110418. [Œ´’˜] Status survey on research ethics education for physicians: toward proper clinical research. Watanabe T1, Arita E, Ogura M, Takehira R: Kitasato Med J 2022/3; 52 (1): 12-9. (“n糒B–ç1: 1—Տ°Œ¤‹†EŠé‰ć)

522577. [uŔ]yƒVƒ“ƒ|ƒWƒEƒ€8: CRCEŽ––ą‹ÇƒXƒ^ƒbƒt‹łˆç‚ĚŒťó‚Ć‚ą‚ę‚Š‚ç|–{Žż‚Ě—‰đ‚É‚Â‚Č‚Ş‚é‚Š‚Š‚í‚č‚Ć‚Í?|z“ú–{•a‰@–ňÜŽt‰ď‚É‚ć‚éCRCEŽ––ą‹ÇƒXƒ^ƒbƒt‚Ě‹łˆçŒ¤C‚ɂ‚˘‚Ä. Žđˆä—˛_, ‹ß“Ą’źŽ÷, –Ř–“”ü’Ă•v, Ž›Œł@„, ˜V–{–ź’ĂŽq, •“c@’q, “n糒B–ç1, …ˆä‹MŽŒ, ’ߊۉëŽq, “cč‰Ăˆę (1—Տ°Œ¤‹†EŠé‰ć): –ň—‚ĆŽĄ—Ă 2021/8; 49 (8): 1219-22.

522578. [uŔ]yƒtƒH[ƒ‰ƒ€z—Ď—ˆĎˆő‰ď‚Í‹K§ŠO‘Ώ۩OŒ¤‹†‚ɂǂ̂悤‚ɑΉž‚ľ‚Ä‚˘‚é‚Š. “°šœr•F, “n糒B–ç1, ’†“cˆŸŠóŽq, ŽŒ´@~, —L“c‰xŽq (1—Տ°Œ¤‹†EŠé‰ć): —Տ°–ň— 2021/9; 52 (5): 127-33.

[Šw‰ďEŒ¤‹†‰ď“™]

722307. [Šw‰ď (‘S‘)] (ˆă—Ă—Ď—ƒZƒ~ƒi[) Œ¤‹†—Ď—‚Ć–@‹K§`V‚ľ‚˘ˆăŠwŒnŽwj‚̉đŕ`. “n糒B–ç (—Տ°Œ¤‹†EŠé‰ć): ‘ć60‰ń“ú–{—Տ°×–EŠw‰ďHŠú‘ĺ‰ď (2021/11/21), ’šŽć (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723710. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) —Ď—ˆĎˆő‰ď‚Í‹K§‘Ώ۩O‚ĚŒ¤‹†‚ɂǂ̂悤‚ɑΉž‚ľ‚Ä‚˘‚é‚Š. “°šœr•F, “n糒B–ç1, ’†“cˆŸŠóŽq, ŽŒ´@~2, —L“c‰xŽq3 (1—Տ°Œ¤‹†EŠé‰ć, 2–k—˘Œ¤‹†Š•a‰@, 3–ňŠw•”): ‘ć33‰ń“ú–{ś–˝—Ď—Šw‰ď”NŽŸ‘ĺ‰ď (2021/11/28), WebŠJĂ.


ƒvƒƒWƒFƒNƒgŽŔŽ{•”–ĺ

[Šwp˜_•ś]

110419. [Œ´’˜] Concentration-QTc analysis for single arm studies. Orihashi Y, Ohwada S, Kumagai Y1: J Pharmacokinet Pharmacodyn 2021/4; 48 (2): 203-11. (ŒF’J—YŽĄ1: 1—Տ°Œ¤‹†EƒvƒƒWƒFƒNƒg)

110420. [Œ´’˜] Real-world evidence of population differences in allopurinol-related severe cutaneous adverse reactions in East Asians: A population-based cohort study. Sato T, Cheng CL, Park HW, Yang YHK, Yang MS, Fujita M, Kumagai Y1, Tohkin M, Saito Y, Sai K: Clin Transl Sci 2021/5; 14 (3): 1002-14. (ŒF’J—YŽĄ1: 1—Տ°Œ¤‹†EƒvƒƒWƒFƒNƒg)

110421. [Œ´’˜] Concentration-QTc analysis with two or more correlated baselines. Orihashi Y, Kumagai Y1: J Pharmacokinet Pharmacodyn 2021/10; 48 (5): 615-22. (ŒF’J—YŽĄ1: 1—Տ°Œ¤‹†EƒvƒƒWƒFƒNƒg)

110422. [Œ´’˜] The necessary conduct: Exploratory multiregional clinical trials in East Asia. Jeon I, Kim YK, Song I, Yoon DY, Huh KY, Jin X, Yu KS, Lee SH, Kumagai Y1, Jang IJ: Clin Transl Sci 2021/11; 14 (6): 2399-407. (ŒF’J—YŽĄ1: 1—Տ°Œ¤‹†EƒvƒƒWƒFƒNƒg)

[’˜@‘]

620150. [Šwp‘ (•Ş’SŽˇ•M)]y–ňÜ‰uŠw‚ĚŠî‘b‚ĆŽŔ‘H (‰ü’ů‘ć3”Ĺ)z6Í ”Ě”„ł”F‘O‚Ě—Ő°ŽŽŒą (ŽĄŒą) ‚ĆŽs”ĚŒă‚Ě’˛¸EŽŽŒą@2 ‘Ű‹¤“ŻŽŽŒą‚ĆƒuƒŠƒbƒWƒ“ƒOƒRƒ“ƒZƒvƒg, p.300-5. ŒiŽR@–Î, ŒF’J—YŽĄ1, ‰FŽR‰Ŕ–ž, Î•’qŒbŽq (1—Տ°Œ¤‹†EƒvƒƒWƒFƒNƒg), •Ň: ŒiŽR@–Î, ‹v•Ű“cŒ‰, ƒ‰ƒCƒtƒTƒCƒGƒ“ƒXo”Ĺ, “Œ‹ž, 2021/7”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

712013. [Šw‰ď (‘Ű)] (ƒVƒ“ƒ|ƒWƒEƒ€) Recent development of clinical pharmacology in Japan. Kumagai Y1: Summit Forum on Innovative R&D Services 2021 CIFTIS (2021/9/4), Beijing, China. (ŒF’J—YŽĄ1: 1—Տ°Œ¤‹†EƒvƒƒWƒFƒNƒg)

722308. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‹’“_‚É‚ć‚郍[ƒJƒ‹ƒlƒbƒgƒ[ƒN‚Ö‚ĚŠú‘Ň. ŒF’J—YŽĄ (—Տ°Œ¤‹†EƒvƒƒWƒFƒNƒg): ARO‹Ś‹c‰ď‘ć8‰ńŠwpW‰ď (2021/9/11), WebŠJĂ.

722309. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ƒAƒWƒA‚É‚¨‚Ż‚鎥Œą‚ĚŽŔŽ{ŠÂ‹Ť. ŒF’J—YŽĄ (—Տ°Œ¤‹†EƒvƒƒWƒFƒNƒg): ‘ć42‰ń“ú–{—Տ°–ň—Šw‰ďŠwp‘‰ď (2021/12/11), ĺ‘ä (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723711. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’×ᇐŤ‘ĺ’°‰ŠŽĄ—Ă–ňcarotegrast methyl‚Ěthorough QT/QTc (TQT) ŽŽŒą: ICH E14 Q&A‚ÉŠî‚Ă‚­‘˝–Ę“I‰đÍ. _—Ń—˛ˆę, Œă“Ą@ˆ¤, ’†ŁŒĂ (ň) Š°Žq, •ˆä‹`‘Ľ, ź–{–ž˜Y, ě‡áÁˆę, ŒF’J—YŽĄ1, ™ŽR@“Ä (1—Տ°Œ¤‹†EƒvƒƒWƒFƒNƒg): ‘ć42‰ń“ú–{—Տ°–ň—Šw‰ďŠwp‘‰ď (2021/12/9), ĺ‘ä (ƒnƒCƒuƒŠƒbƒhŠJĂ).


ƒoƒCƒIƒGƒVƒbƒNƒX•”–ĺ


‘n–ňƒV[ƒYŒ¤‹†ŠJ”­•”–ĺ


ˆăŠw•”•‘ŽV˘‹Iˆă—ĂŠJ”­ƒZƒ“ƒ^[

ć’[ˆă—Ă—ĚˆćŠJ”­•”–ĺ

(‹g“cˆęŹ)
Śu”ĺ”AŠí‰ČŠwv‚đŽQĆ

(“c糁@‘)
ŚuÁ‰ťŠí“ŕ‰ČŠwv‚đŽQĆ

(’ˇŔ‰p–ž)
ŚuŽ¨•@ˆôA‰ČE“Şčň•”ŠO‰ČŠwv‚đŽQĆ

(“c’†@Œ‰)
Śuˆę”ʁEŹŽ™EŠĚ’_äXŠO‰ČŠwv‚đŽQĆ

(Œ´—ŻOŽ÷)
Śu•úŽËü‰ČŠwi‰ć‘œf’fŠwjv‚đŽQĆ

(ćčG–ž)
ŚuŹŽ™‰ČŠwv‚đŽQĆ

(’†źG•F)
ŚuŹŽ™‰ČŠwv‚đŽQĆ


‰Ą’f“Iˆă—Ă—ĚˆćŠJ”­•”–ĺ

(‹ŕˆäş•ś)
Śu–ƒŒ‰ČŠwv‚đŽQĆ

(ŽR‰şŒpŽj)
Śuă•”Á‰ťŠÇŠO‰ČŠwv‚đŽQĆ

(VˆäłN)
Śu–ƒŒ‰ČŠwv‚đŽQĆ

(˛X–ŘŽĄˆę˜Y)
ŚuŒÄ‹zŠí“ŕ‰ČŠwv‚đŽQĆ

(Ź—ѐ´“T)
ŚuÁ‰ťŠí“ŕ‰ČŠwv‚đŽQĆ

(‚ŽR—zŽq)
Śu–k—˘‘ĺŠw•a‰@Š´őŠÇ—Žşv‚ŕŽQĆ

[Šw‰ďEŒ¤‹†‰ď“™]

722310. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “–‰@‚É‚¨‚Ż‚éSARS-CoV-2Š´ő‘΍ô`_“Ţěƒ‚ƒfƒ‹ ‚“xˆă—Ă‹@ŠÖEd“_ˆă—Ă‹@ŠÖ‚Ć‚ľ‚ā`. ‚ŽR—zŽq (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć30‰ń“ú–{Œ`ŹŠO‰ČŠw‰ďŠî‘bŠwpW‰ď (2021/10/8), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

731081. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) VŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´őÇ`•Ş‚Š‚Á‚˝‚ą‚Ć‚Ć•Ş‚Š‚Á‚Ä‚˘‚Č‚˘‚ą‚Ɓ`. ‚ŽR—zŽq (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć19‰ń–k—˘‘ĺŠwˆăŠw•”“Ż‘‹‰ďŽs–ŻŒöŠJuŔu’m‚Á‚Ė𗧂VŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´őÇ‚̍ŐVî•ńv(2021/10/9), WebŠJĂ.

732129. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) –k—˘‘ĺŠw•a‰@‚É‚¨‚Ż‚銴ő‘΍ô`_“Ţěƒ‚ƒfƒ‹ ‚“xˆă—Ă‹@ŠÖEd“_ˆă—Ă‹@ŠÖ‚Ć‚ľ‚ā`. ‚ŽR—zŽq (V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć34‰ńƒoƒCƒIƒTƒCƒGƒ“ƒXƒtƒH[ƒ‰ƒ€E‘ć23‰ń”÷ś•¨ƒAƒJƒfƒ~[Œ¤‹†W‰ď (2021/8/18), WebŠJĂ.


ˆăŠw•”‹łˆçŒn‹ZpEˆő

Œ`‘ÔŒn


ś•¨•¨—Œn


•a‘ԁEf—ĂŒn

[Šw‰ďEŒ¤‹†‰ď“™]

722311. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‰tó‰ťŒŸ‘Ě×–Ef•Ű‘ś‰t‚ĹŒĹ’č‚ľ‚˝”xŠŕ×–E‚Š‚ç’Šo‚ľ‚˝DNA‚ĚˆŔ’萍‚ɂ‚˘‚Ä. ź”ö—R‹IŽq1, ‹g“c@Œ÷2, ŽR‰ş˜a–ç3, ‘ş‰_–FŽ÷2, ˛“Ą”Vr4 (1•a‘ԁEf—ĂŒn, 2•a—, 3•a—•”, 4ŒÄ‹zŠíŠO): ‘ć62‰ń“ú–{—Տ°×–EŠw‰ď‘‰ďtŠú‘ĺ‰ď (2021/6/5), ç—t (ƒnƒCƒuƒŠƒbƒhŠJĂ).


—\–hˆăŠwŒn


•ŞŽqˆă‰ČŠwE§ŒäŒn


“Œ•a‰@Œ¤‹†Œn


‘gD”|—{ƒZƒ“ƒ^[


DNAŽŔŒąƒZƒ“ƒ^[


ƒoƒCƒIƒCƒ[ƒWƒ“ƒOŒ¤‹†ƒZƒ“ƒ^[


ˆâ“`Žq‚ŽŸ‹@”\‰đÍƒZƒ“ƒ^[


Œ’NŠÇ—ƒZƒ“ƒ^[

[Šwp˜_•ś]

110423. [Œ´’˜] Arteriolar hyalinosis is related to rapid GFR decline and long-standing GFR changes observed on renal biopsies in normo-microalbuminuric type 2 diabetic patients. Moriya T1, Yamagishi T, Yoshida Y1, Matsubara M1, Ouchi M: J Diabetes and its Complications 2021/8; 35 (4): 107847. (Žç‰Ž’B”ü1, ‹g“c—F‹I1, źŒ´‚Ü‚Ç‚Š1: 1Œ’NŠÇ—ƒZ)

110424. [Œ´’˜] Glucose control, diabetic retinopathy, and hemodialysis induction in subjects with normo-microalbuminuric type 2 diabetic patients with normal renal function followed for 15 years. Moriya M1, Hayashi A2, Matsubara M1, Suzuki A2, Ouchi M: J Diabetes and its Complications 2022/1; 36 (1): 108080. (Žç‰Ž’B”ü1, —с@“N”Í2, źŒ´‚Ü‚Ç‚Š1, —é–Ř—z•F2: 1Œ’NŠÇ—ƒZ, 2“ŕ•Ş”ĺ‘ăŽÓ“ŕ)

[’˜@‘]

620151. [Šwp‘ (•Ş’SŽˇ•M)]yuŔ@¸_ŽžŠł‚Ě—Ő°@4. g‘Ě“I‹ę’ɏnjQ@‰đ—ŁÇŒQ@SgÇ@Hs“ŽÇ‚Ü‚˝‚͐ېHÇŒQz1Í g‘Ě“I‹ę’ɏnjQ‚Ü‚˝‚͐g‘Ě“I‘ĚŒąÇŒQ@g‘Ě“I‹ę’ÉÇ‚Ć–Ťáu’Ɂ@Topics Ž•‰Č—Ěˆć‚̐g‘Ě“I‹ę’ɏÇ, p.37-42. ‹{’n‰p—Y (Œ’NŠÇ—ƒZ), ŠÄC: ź‰şł–ž, •ŇWŽĺŠ˛: _’ëdM, ’S“–•ŇW: ‹vZˆę˜Y, ’†ŽR‘“X, “Œ‹ž, 2021/7”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713056. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Arteriolar Hyalinosis Is Associated with the Rate of eGFR Decline and Predicts the Onset of Macroalbuminuria and eGFR. Moriya T1, Hayashi A2, Suzuki A2, Matsubara M1, Ouchi M: American Diabetes Association 81th Scientific Sessions (2021/6/25-29), WebŠJĂ, Diabetes 2021/6; 70 (Suppl 1): 409-P. (Žç‰Ž’B”ü1, —с@“N”Í2, —é–Ř—z•F2, źŒ´‚Ü‚Ç‚Š1: 1Œ’NŠÇ—ƒZ, 2“ŕ•Ş”ĺ‘ăŽÓ“ŕ)

713057. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Sodium Intake and Incidence of Diabetes Retinopathy in Elderly Patients with Type 2 Diabetes: Analysis of Data from the Japanese Elderly Diabetes Intervention Study (J-EDIT). Horikawa C, Aida R, Tanaka S, Kamada C, Tanaka S, Yoshimura Y, Kodera R, Fujihara K, Kawasaki R, Moriya T1, Yamashita H, Ito H, Sone H, Araki A: The American Diabetes Association's 81st Scientific Sessions (2021/6/25-29), WebŠJĂ, Diabetes 2021/6; 70 (Suppl 1): 432-P. (Žç‰Ž’B”ü1: 1Œ’NŠÇ—ƒZ)

723712. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ×“Ž–ŹÉŽq‰ť‚͐łí`”÷—ĘƒAƒ‹ƒuƒ~ƒ“”AŠú2Œ^“œ”A•a‚Ě‹}Œƒ‚Ȑt‹@”\’ቺ‚đ—\‘Ş‚ˇ‚éŽw•W‚Ĺ‚ ‚é. Žç‰Ž’B”ü1, —с@“N”Í2, źŒ´‚Ü‚Ç‚Š1, —é–Ř—z•F2, ‘ĺ“ŕŠîŽi (1Œ’NŠÇ—ƒZ, 2“ŕ•Ş”ĺ‘ăŽÓ“ŕ): ‘ć64‰ń“ú–{“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (2021/5/20-22), WebŠJĂ, “œ”A•a 2021/4; 64 (Suppl): S-233.

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-110034. [Œ´’˜] Sodium Intake and Incidence of Diabetes Complications in Elderly Patients with Type 2 Diabetes-Analysis of Data from the Japanese Elderly Diabetes Intervention Study (J-EDIT). Horikawa C, Aida R, Tanaka S, Kamada C, Tanaka S, Yoshimura Y, Kodera R, Fujihara K, Kawasaki R, Moriya T1, Yamashita H, Ito H, Sone H, Araki A: Nutrients 2021/2; 13 (2): 689. (Žç‰Ž’B”ü1: 1Œ’NŠÇ—ƒZ)


–k—˘‘ĺŠw•a‰@

ŠĹŒě•”

[Šwp˜_•ś]

110425. [Œ´’˜] Evaluation of the usefulness of a nurse-centered delirium care program. Shirai N1, Nagata M1, Takubo M, Iwamitsu Y2: Jpn J Gen Hosp Psychiatry 2022/1; 33 (1): 44-56. (”’ˆä‹łŽq1, ’ˇ“c^—R”ü1, ŠâŸŢ—D”ü2: 1ŠĹŒě•”, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

120039. [Œ´’˜] ‰Ć‘°Žx‰‡ę–ĺŠĹŒěŽt‚É‚ć‚é‰Ć‘°ŠĹŒěŽŔ‘H‚ĚŠT”O‰ť‚ÉŠÖ‚ˇ‚錤‹†. ˆäă—ćŽq1, ŸNˆä‘ĺ•ă1, —é–Ř˜aŽq2, ˆŔ•@ˆť3, źâ—R—˘4, ‚ŒŠ‹IŽq5, ŽOŽ}^—6, ŹňDŠG1, ‰€ě—Y“ń6, ˆÉ“ŕ‚ł‚ä‚č6 (1“ŒŠC‘ĺŠwˆăŠw•”ŠĹŒěŠw‰Č, 2Ă“ěƒŠƒT[ƒ`ƒZƒ“ƒ^[, 3ŒF–{‘ĺŠwˆăŠw•”•ŰŒ’Šw‰Č, 4_“ŢěŒ§—§•ŰŒ’•ŸŽƒ‘ĺŠw, 5ŠĹŒě•”, 6“ŒŠC‘ĺŠwˆăŠw•”•t‘Ž•a‰@): –Ř‘şŠĹŒě‹łˆçU‹ťŕ’cŠĹŒěŒ¤‹†W˜^ 2021/7; 28†: 1-17.

120040. [Œ´’˜] ŹŽ™W’†ŽĄ—Ă‚ÉŒg‚í‚鏬Ž™‰ČˆăŽt‚Ş‚Ć‚ç‚Ś‚˝End-of-Life‚đŒ}‚Ś‚銳Ž™‰Ć‘°‚Ć‚Ě‘ŠŒÝě—p‚ĚƒvƒƒZƒX. ‚‹´@Œb1, Ź“‡‚Đ‚ĹŽq2 (1ŠĹŒě•”, 2ŠĹŒěŠw•”): “ú–{ŹŽ™ŠĹŒěŠw‰ďŽ 2021/12; 30: 115-21.

220006. [€Œ´’˜] ŽŠ‘î‘މ@1ƒ–ŒŽŒă‚Ě“Ć‹‚—îŽŇ‚̐śŠˆ‘ĚŒą. ‘ĺ‰i—˘”ü1, ŹŽRK‘ă2 (1ŠĹŒě•”, 2Ă“슙‘qˆă—Ă‘ĺŠwŠĹŒěŠw•”): ˜V”NŠĹŒěŠw 2021/7; 26 (1): 114-22.

320028. [Ç—á•ń] VŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´őÇŠłŽŇ‚ĚƒŠƒ‚[ƒg–ʉď‚É‚ć‚éI––ŠúŠĹŒě: ƒP[ƒXƒŒƒ|[ƒg. ‰Hś“c—I1, ’Ö”ü’q”Ž2, ’–Žë—ÉŽq1, X@‘ń–ç1, ‰Ąaˆç”ü1 (1ŠĹŒě•”, 2ŠĹŒěŠw•”): ƒOƒŠ[ƒt•ƒrƒŠ[ƒuƒƒ“ƒgŒ¤‹† 2021/12; 2†: 87-93.

522579. [uŔ]y“ÁW: ""with NEO"" Update NCPR2020@oś’źŒă‚̐VśŽ™‚ĚƒPƒA@ƒKƒCƒhƒ‰ƒCƒ“‰ü’ůƒ|ƒCƒ“ƒg11z10. ƒ|ƒWƒVƒ‡ƒjƒ“ƒO@ó‘Ԃ𐎂Ś‚éƒPƒA. ›–ě‚ł‚â‚Š (ŠĹŒě•”): with NEO 2021/4; 34 (2): 242-8.

522580. [uŔ]y“ÁW: dÇ‚ČŽq‚Ç‚ŕ‚ĚƒxƒbƒhƒTƒCƒhƒPƒAz[Žĺ‚ČŽĄ—Ă‚ĆŠĹŒě‚Ě—v“_]@‡A”ńNP“I—zˆłŠˇ‹C—Ă–@ (NPPV) ‚ƍ‚—Ź—Ę•@ƒJƒjƒ…ƒ‰Ž_‘f—Ă–@ (HFNC). ěă‘ĺ•ă1, ‘ĺ‹v•Ű‘t”ü1 (1ŠĹŒě•”): ŹŽ™ŠĹŒě 2021/5; 44 (5): 535-43.

522581. [uŔ]y“ÁW: ƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“Œ¸­‚É‚ć‚éS‚̔敞‚Š‚çƒXƒ^ƒbƒt‚đŽç‚é@ŽáŽčŠĹŒěŽt‚Ö‚Ěƒƒ“ƒ^ƒ‹ƒtƒHƒ[pzƒRƒƒi‰Đ‚ĹŽć‚č‘g‚Ü‚ę‚˝ŽáŽčŠĹŒěŽt‚Ěƒƒ“ƒ^ƒ‹ƒwƒ‹ƒXŽx‰‡@ƒRƒƒi‰Đ‚É‚¨‚Ż‚éVlŠĹŒěEˆő‚Ěƒ\[ƒVƒƒƒ‹ƒTƒ|[ƒg|W‡Œ¤CEƒLƒƒƒŠƒAƒJƒEƒ“ƒZƒŠƒ“ƒO‚đŠˆ—p‚ľ‚˝ƒƒ“ƒ^ƒ‹ƒtƒHƒ[|. ’JŒű—zŽq (ŠĹŒě•”): ŠĹŒě“W–] 2021/7; 46 (8): 724-7.

522582. [uŔ]y“ÁW: WithƒRƒƒi‚É‚¨‚Ż‚éŽčpˆăŠwzVŒ^ƒRƒƒiƒEƒBƒ‹ƒXŠ´őÇŠłŽŇŽó‚Ż“ü‚ę‚đŒoŒą‚ľ‚Ä. ‰Ąa@Žq (ŠĹŒě•”): “ú–{ŽčpˆăŠw‰ďŽ 2021/7; 42 (2): 156-60.

522583. [uŔ]y“ÁW: ‚Ş‚ńŠłŽŇ‚ĚƒXƒLƒ“ƒgƒ‰ƒuƒ‹@Ž–—á‚Ĺ‚í‚Š‚éƒAƒZƒXƒƒ“ƒg‚ĆƒPƒAzPart4 ‚Ş‚ńI––ŠúŠłŽŇ‚̔畆áŠQƒPƒA@•‚Žî‚ĆƒŠƒ“ƒp˜R‚ĚƒAƒZƒXƒƒ“ƒg‚ĆƒPƒA. ŁŒË–qŽq (ŠĹŒě•”): ƒi[ƒVƒ“ƒO 2021/7; 41 (9): 88-95.

522584. [uŔ]y“ÁW1: ˆă—ĂˆŔ‘S‚Ěƒ[ƒLƒ“ƒOƒOƒ‹[ƒvŠˆ“Ž‚𐄐i‚ľ‚悤Iz“]“|“]—Ž–hŽ~ƒ[ƒLƒ“ƒOƒOƒ‹[ƒvŠˆ“Ž‚ĚŽŔŰ‚Ɖ~ŠŠ‚Ȑ„i‚Ěƒ|ƒCƒ“ƒg. ” “c”ü’mŒb (ŠĹŒě•”): •a‰@ˆŔ‘S‹łˆç 2021/10; 9 (2): 34-9.

522585. [uŔ]y“ÁW: dÇ“x•ĘCOVID-19zdÇ‰ť‚đ–h‚ŽƒPƒA‚Ěƒ|ƒCƒ“ƒg. XˆŔŒbŽŔ1, ˛X–ŘŒ°Žq2 (1ŠĹŒě•”, 2Š´őŠÇ—Žş): Expert Nurse 2021/11; 37 (13): 18-23.

522586. [uŔ]y“ÁW: ƒXƒgƒ‰ƒeƒWƒbƒNEƒVƒ“ƒLƒ“ƒO@uí—Ş“IŽvlv‚ÉŠî‚Ă‚Ť, ^‚̉ۑč‚É”—‚éƒvƒƒZƒXz[Ž„‚̐헪‚đU‚č•Ô‚é@^‚̉ۑč‰đŒˆ‚ÉŒü‚Ż‚˝ŠÇ—ŽŔ‘H]@ŠĹŒě•â˛‚Ěƒ|ƒeƒ“ƒVƒƒƒ‹‚đŠˆ‚Š‚ľ‚˝ŠĹŒěŠÇ—. •Ę•{çŒb (ŠĹŒě•”): ŠĹŒěŠÇ— 2021/12; 31 (12): 1090-3.

522587. [uŔ]y“ÁW: ‘Θb‚ƐM—Š@‰Ű‘č‚đ‹¤—L‚ľ, •Ď‰ť‚É‹­‚˘‘gD‚đ‚‚­‚ézƒRƒƒi‰Đ‚É‚¨‚Ż‚éŠĹŒěŒW’ˇEŽĺ”C‰ď‚ĚƒIƒ“ƒ‰ƒCƒ“‚É‚ć‚é‘gD‰ü‘PŠˆ“Ž. ꎓĄŒ\Žq1, ´…›’“1, ’JŒű—zŽq1 (1ŠĹŒě•”): ŠĹŒěŠÇ— 2022/1; 32 (1): 18-23.

522588. [uŔ]y“ÁW: Ą‚ł‚畡‚Ż‚Č‚˘ŠĹŒě‚ĚŞ‹’@Žq‚Ç‚ŕ‚É‚ć‚­‚ ‚é•a‹C‚ĆŠî–{ƒPƒAz[Žq‚Ç‚ŕ‚É‚ć‚­‚ ‚é•a‹Cu“ŕ‰ČŒnŽžŠłv]@…@ŒÄ‹zŠíŽžŠł (RSƒEƒCƒ‹ƒXŠ´őÇ, ‹CŠÇŽxšb‘§). –Ř‘ş‚ä‚ÝŽq (ŠĹŒě•”): ŹŽ™ŠĹŒě 2022/2; 45 (2): 163-9.

522589. [uŔ]y[‚ß‚é“ÁW: –°‚ç‚Č‚˘! –°‚ę‚Č‚˘! ‚Ç‚¤‚ľ‚Ä? •s–°ŠłŽŇ‚ł‚ń‚Ö‚ĚƒxƒXƒg‘Ήžz5. Ç—á:] p‘OEpŒă‚Ě•s–°‚ĆŠĹŒěŽŔ‘H. ”’’š—FŠî (ŠĹŒě•”): ŽŒ`ŠO‰ČŠĹŒě 2022/2; 27 (2): 201-2.

[’˜@‘]

620152. [Šwp‘ (•Ş’SŽˇ•M)]yŽžŠúEó‹ľEó‘Ô•ĘƒXƒg[ƒ}‘˘ÝŠłŽŇ‚Ö‚ĚƒPƒA‚ĆŽw“ąE‹łˆç‚Ěƒ|ƒCƒ“ƒg (ŒŽŠÔƒi[ƒVƒ“ƒO2021”N10ŒŽ‘Š§†)z2. pŒă‚Š‚ç‘މ@‚Ü‚Ĺ‚ĚŠłŽŇ|ƒPƒA‚ĚŽŔŰ‚Ć‘•‹ď‘I‘đ‚𒆐S‚Ɂ@ƒZƒ‹ƒtƒPƒA‚ɏÁ‹É“I‚ČŠłŽŇ, p.77-81. “n•ÓšD (ŠĹŒě•”), ŠwŒ¤ƒƒfƒBƒJƒ‹GŽĐ, “Œ‹ž, 2021/10”­s.

620153. [Šwp‘ (•Ş’SŽˇ•M)]yŽžŠúEó‹ľEó‘Ô•ĘƒXƒg[ƒ}‘˘ÝŠłŽŇ‚Ö‚ĚƒPƒA‚ĆŽw“ąE‹łˆç‚Ěƒ|ƒCƒ“ƒg (ŒŽŠÔƒi[ƒVƒ“ƒO2021”N10ŒŽ‘Š§†)z2. pŒă‚Š‚ç‘މ@‚Ü‚Ĺ‚ĚŠłŽŇ|ƒPƒA‚ĚŽŔŰ‚Ć‘•‹ď‘I‘đ‚𒆐S‚Ɂ@ŽčŽw‚̍IăkŤ‚Ş’á‰ş‚ľ‚Ä‚˘‚銳ŽŇ, p.82-86. “n•ÓšD (ŠĹŒě•”), ŠwŒ¤ƒƒfƒBƒJƒ‹GŽĐ, “Œ‹ž, 2021/10”­s.

620154. [Šwp‘ (•Ş’SŽˇ•M)]yŠĹŒěf’f‚Ě‚˝‚ß‚Ě‚ć‚­‚í‚Š‚é’†”͈͗˜_ ‘ć3”Łz‘ć4Í î“Ž“I’†”͈͗˜_@Ž€‚ĚŽó—e‰ß’ö—˜_@Ž–—á•Ň, p.342-54. ŹňƒŽq1, Źˆä”ü•ä2 (1ŒË“c’†‰›‘‡•a‰@ŠĹŒě•”, 2ŠĹŒě•”), ŠÄC: •“c—TŽq, ŠwŒ¤ƒƒfƒBƒJƒ‹GŽĐ, “Œ‹ž, 2021/10”­s.

620155. [Šwp‘ (•Ş’SŽˇ•M)]yŒŠ‚é‚ą‚ƁE‚â‚é‚ą‚Ć‚Ş‚í‚Š‚é! “ü‰@‚Š‚ç‘މ@‚Ü‚Ĺ‚Ěƒ`ƒƒ[ƒg‚ĹŠw‚ԁ@ŽŒ`ŠO‰Č•a“‚̏pŽŽ•ĘƒPƒAƒ}ƒjƒ…ƒAƒ‹ (ŽŒ`ŠO‰ČŠĹŒě2021”NH‹G‘Š§)z[1Í] ‘˜_@A. ŽŒ`ŠO‰Č‚ĚŽčp‚Ě“Á’Ľ, p.10-1. ˛“Ąˆş‰Ä1, ‰Ş“‡–ƒˆß1 (1ŠĹŒě•”), •Ň: ‚•˝ŽL2 (2ˆă—ÉqśŠw•”), ƒƒfƒBƒJo”Ĺ, ‘ĺă, 2021/11”­s.

620156. [Šwp‘ (•Ş’SŽˇ•M)]yŒŠ‚é‚ą‚ƁE‚â‚é‚ą‚Ć‚Ş‚í‚Š‚é! “ü‰@‚Š‚ç‘މ@‚Ü‚Ĺ‚Ěƒ`ƒƒ[ƒg‚ĹŠw‚ԁ@ŽŒ`ŠO‰Č•a“‚̏pŽŽ•ĘƒPƒAƒ}ƒjƒ…ƒAƒ‹ (ŽŒ`ŠO‰ČŠĹŒě2021”NH‹G‘Š§)z[1Í] ‘˜_@C. ŽŒ`ŠO‰Č‚Ě‹C‚đ‚‚Ż‚˝‚˘p‘OEpŒăƒPƒAp.16-22. ˛“Ąˆş‰Ä1, ‰Ş“‡–ƒˆß1 (1ŠĹŒě•”), •Ň: ‚•˝ŽL2 (2ˆă—ÉqśŠw•”), ƒƒfƒBƒJo”Ĺ, ‘ĺă, 2021/11”­s.

620157. [Šwp‘ (•Ş’SŽˇ•M)]yŒŠ‚é‚ą‚ƁE‚â‚é‚ą‚Ć‚Ş‚í‚Š‚é! “ü‰@‚Š‚ç‘މ@‚Ü‚Ĺ‚Ěƒ`ƒƒ[ƒg‚ĹŠw‚ԁ@ŽŒ`ŠO‰Č•a“‚̏pŽŽ•ĘƒPƒAƒ}ƒjƒ…ƒAƒ‹ (ŽŒ`ŠO‰ČŠĹŒě2021”NH‹G‘Š§)z[1Í] ‘˜_@D. ŽŒ`ŠO‰Č‚Ě‹C‚đ‚‚Ż‚˝‚˘Žĺ‚ȏpŒă‡•šÇp.23-5. ˛“Ąˆş‰Ä1, ‰Ş“‡–ƒˆß1 (1ŠĹŒě•”), •Ň: ‚•˝ŽL2 (2ˆă—ÉqśŠw•”), ƒƒfƒBƒJo”Ĺ, ‘ĺă, 2021/11”­s.

620158. [Šwp‘ (•Ş’SŽˇ•M)]yŠĹŒěŠwƒeƒLƒXƒgNICE@¸_ŠĹŒěŠwI@‚ą‚ą‚ë‚ĚŒ’N‚Ć’nˆć•ďŠ‡ƒPƒA (‰ü’ů‘ć3”Ĺ)z‘ćIVÍ ˆę”Ę•a°‚É‚¨‚Ż‚鐸_ŠĹŒě@1. Ž–—á‚Š‚çŠw‚Ôˆę”Ę•a°‚ł̐¸_ŠĹŒě@1-1. g‘̏ǏóÇ, •a‹C•sˆŔÇ, p.176-9. ”’ˆä‹łŽq (ŠĹŒě•”), •Ň: ŠžŠÔ^”ü, ˆîŠ_@’†, “ě]“°, “Œ‹ž, 2022/1”­s.

620159. [Šwp‘ (•Ş’SŽˇ•M)]yŠĹŒěŠwƒeƒLƒXƒgNICE@¸_ŠĹŒěŠwI@‚ą‚ą‚ë‚ĚŒ’N‚Ć’nˆć•ďŠ‡ƒPƒA (‰ü’ů‘ć3”Ĺ)z‘ćIVÍ ˆę”Ę•a°‚É‚¨‚Ż‚鐸_ŠĹŒě@1. Ž–—á‚Š‚çŠw‚Ôˆę”Ę•a°‚ł̐¸_ŠĹŒě@1-3. •sˆŔ, p.185-9. ”’ˆä‹łŽq (ŠĹŒě•”), •Ň: ŠžŠÔ^”ü, ˆîŠ_@’†, “ě]“°, “Œ‹ž, 2022/1”­s.

620160. [Šwp‘ (•Ş’SŽˇ•M)]yŠĹŒěŠwƒeƒLƒXƒgNICE@¸_ŠĹŒěŠwI@‚ą‚ą‚ë‚ĚŒ’N‚Ć’nˆć•ďŠ‡ƒPƒA (‰ü’ů‘ć3”Ĺ)z‘ćIVÍ ˆę”Ę•a°‚É‚¨‚Ż‚鐸_ŠĹŒě@‚Q. ƒŠƒGƒ]ƒ“¸_ŠĹŒě‚Ć‚Í, p.226-32. ”’ˆä‹łŽq (ŠĹŒě•”), •Ň: ŠžŠÔ^”ü, ˆîŠ_@’†, “ě]“°, “Œ‹ž, 2022/1”­s.

620161. [Šwp‘ (•Ş’SŽˇ•M)]yŠĹŒě‚ĚŠë‹@ŠÇ—@ƒRƒƒi‰Đ‚ĚŒoŒą‚𐜂Š‚ľ‚Ä (ŠĹŒě2022”N3ŒŽ—ŐŽž‘Š§†)z2Í •ń@ƒRƒƒi‰Đ‚É‚¨‚Ż‚éŠĹŒě‚ĚŠë‹@ŠÇ—@2-11. –k—˘‘ĺŠw•a‰@@ƒRƒƒi‰Đ‚É‚¨‚Ż‚銈“Ž‚ĆŠë‹@ŠÇ—‚É‚¨‚Ż‚éuS—“IˆŔ‘SŤv‚ĚŠm•Ű, p.116-22. “y‰ŽŽu•Ű (ŠĹŒě•”), “ú–{ŠĹŒě‹Ś‰ďo”ʼnď, “Œ‹ž, 2022/3”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

721019. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) ŠĹŒěŽt‚Ěƒƒ“ƒ^ƒ‹ƒwƒ‹ƒX@COVID-19‰Đ‚É‚¨‚Ż‚郁ƒ“ƒ^ƒ‹ƒwƒ‹ƒXŽx‰‡F ƒŠƒGƒ]ƒ“ƒi[ƒXC‚ą‚ą‚ë‚ĚƒPƒAƒ`[ƒ€‚ĚŽć‚č‘g‚Ý. ”’ˆä‹łŽq (ŠĹŒě•”): ‘ć37‰ń“ú–{ƒXƒgƒŒƒXŠw‰ďŠwp‘‰ď (2021/10/30), WebŠJĂ, ƒXƒgƒŒƒX‰ČŠw 2021/10; 36 (2): 87.

722312. [Šw‰ď (‘S‘)] (‹łˆçu‰‰) COVID-19—Źs‰ş‚Ĺ‚ĚŠĹŒěŽtˆçŹ-ƒpƒ“ƒfƒ~ƒbƒN‚ĚŒoŒą‚đŠĹŒěŽtˆçŹ‚Ě”­“W‚É‚˘‚Š‚ˇ-. •Ę•{çŒb (ŠĹŒě•”): ‘ć21‰ń“ú–{Š´őŠĹŒěŠw‰ďŠwpW‰ď (2021/9/4), ‰Ť“ę (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{Š´őŠĹŒěŠw‰ďŠwpW‰ďu‰‰W 2021/9; 21: 12.

722313. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) COVID-19ƒpƒ“ƒfƒ~ƒbƒN‚É‚ć‚éŠë‹@‚ĆŠĹŒěE‚̑Ήž u•a‰@‚Ĺ‚ĚCOVID|19ŠłŽŇŽó‚Ż“ü‚ę‘̐§‚̐Ž”őv. ŠŽR˜a”ü (ŠĹŒě•”): ˆę”ĘŽĐ’c–@l“ú–{ĐŠQŠĹŒěŠw‰ď‘ć23‰ń”NŽŸ‘ĺ‰ď (2021/9/4-30), WebŠJĂ.

722314. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) COVID-19—ŹsŠúC‚ť‚ĚŒă‚Ě‘ŸŠí’ń‹ŸEˆÚA@ƒRƒƒi‰Đ‚É‚¨‚Ż‚é‘ŸŠí’ń‹Ÿ‹@‰ď‚Ě‘šŽ¸‚ɂ‚˘‚Ä. ŠÖ@ˆę”n1, ‚‹´@Œb1, ă‘ş—RŽ—1, ˛ě”ü—˘1, “c‘ş@’q2, •Đ‰Ş—Sˆę2, ‹g“cˆęŹ3,4 (1ŠĹŒě•”, 2‹~–˝, 3V˘‹Iˆă—ÁEć’[ˆă—Ă, 4”ĺ”AŠí): ‘ć57‰ń“ú–{ˆÚAŠw‰ď‘‰ď (2021/9/20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), ˆÚA 2021/9; 56 (‘‰ď—ŐŽž): CSY1-6.

722315. [Šw‰ď (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ACP‚ĚŒťó‚Ć‚ą‚ę‚Š‚ç@zŠÂŠíAdvance Care Planning (ACP) ƒJƒ“ƒtƒ@ƒŒƒ“ƒX„iƒvƒƒZƒX‚Ěƒ|ƒCƒ“ƒg|ƒ`[ƒ€‚̏řŹ‚Ć•a“ŠĹŒěŽt‚ĚˆçŹ|. 傖ź—R‰Á—˘1, ŽRčˆč”ü1, Žç‰ŽŽľŠC1, ŒI“c‹MŽuŽq1, ŽR’†‰f—˘“Ţ1 (1ŠĹŒě•”): ‘ć18‰ń“ú–{zŠÂŠíŠĹŒěŠw‰ďŠwpW‰ď (2021/10/10), WebŠJĂ, ‘ć18‰ń“ú–{zŠÂŠíŠĹŒěŠw‰ďŠwpW‰ď´˜^ 2021/10; p.26.

722316. [Šw‰ď (‘S‘)] (ƒ[ƒNƒVƒ‡ƒbƒv) VADŽĄ—Ă‚É‚¨‚Ż‚é‹@ŠíƒgƒŒ[ƒjƒ“ƒO, ‘މ@Žw“ą‚Ě•W€‰ť@”ńS‘ŸˆÚAŽŔŽ{Ž{Ý‚É‚¨‚Ż‚éAžŒ^VADŠłŽŇ‚Ě‹łˆç‚ÉŒü‚Ż‚˝Žć‚č‘g‚Ý. –ö“cŒ’–ž1, ’†“‡ßŽq1, —ŃˆŸŠóŽq1, “‡–ě‰Ř“Ţ1, •“cÍ”2, –k‘ş@—Ľ3, Îˆär•ă4, ‘“cł˜a1 (1ŠĹŒě•”, 2ME•”, 3S‘ŸŒŒŠÇŠO, 4zŠÂŠí“ŕ): ‘ć59‰ń“ú–{lH‘ŸŠíŠw‰ď‘ĺ‰ď (2021/11/26), ç—t, lH‘ŸŠí 2021/10; 50 (2): S-62.

722317. [Šw‰ď (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) W’†ŽĄ—Ă‚É‚¨‚Ż‚éƒGƒ“ƒhEƒIƒuEƒ‰ƒCƒtEƒPƒA-ŠłŽŇE‰Ć‘°‚Ć‚ĚŒü‚Ť‡‚˘•ű@ŠłŽŇE‰Ć‘°‚Ć‚ĚƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“. žŇź‹v”üŽq (ŠĹŒě•”): ‘ć49‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ďŠwpW‰ď (2022/3/19), WebŠJĂ, ‘ć49‰ń“ú–{W’†ŽĄ—ĂˆăŠw‰ďŠwpW‰ďWEB´˜^ 2022/3; p.PD14-3.

723713. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) EXIT‚É‚¨‚Ż‚éƒ`[ƒ€ˆă—Ă‚ĚŽŔ‘H`NICUŠĹŒěŽt‚Ě—§ę‚Š‚ç`. ›–ě‚ł‚â‚Š1, —é–؉p—“Ţ1, ŽRŠÝ”ü•Ű1 (1ŠĹŒě•”): ‘ć30‰ń“ú–{VśŽ™ŠĹŒěŠw‰ďŠwpW‰ď (2021/5/8-9), WebŠJĂ, “ú–{VśŽ™ŠĹŒěŠw‰ďu‰‰W 2021/5; 30: 71.

723714. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) “œ”A•a—Ă—{Žw“ąŽx‰‡ƒ`[ƒ€—§‚żă‚°‚Ɖî“ü‚Š‚猊‚Ś‚˝‚ą‚Ɓ`“œ”A•a‚đ•ř‚Ś‚é“ü‰@ŠłŽŇ‚ŞŽŠ‘î‚Ĺ“œ”A•aŠÇ—‚đ‰~ŠŠ‚ɍs‚¤‚˝‚ß‚ĚŽć‚č‘g‚݁`. â–{”~Žq1, Š™“c—T“ń2, “y•M’qť3, ˆî–ě@Š°4, ŽRŕV—IŽq5, ŽÂŒ´—ş‘ž3, ‰Oˆä—D—1, Žľ—˘áÁ‹`2 (1ŠĹŒě•”, 2“ŕ•Ş”ĺ‘ăŽÓ“ŕ, 3—ŐŒŸ•”, 4–ňÜ•”, 5‰h—{•”): ‘ć64‰ń“ú–{“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (2021/5/20), WebŠJĂ, “œ”A•a 2021/5; 64 (Suppl 1): I-59-5.

723715. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) COVID-19ŽĄ—ʋŤ‚É‚¨‚Ż‚é‚š‚ń–ĎƒPƒA@ƒiƒ‰ƒeƒBƒuƒAƒvƒ[ƒ`‚É‚ć‚葁Šú‰ü‘P‚đ”F‚ß‚˝1—á. “ĄŽ}@K1, ”’ˆä‹łŽq1, ˛“Ą˛“s”ü1, ‘ĺÎ@’q2 (1ŠĹŒě•”, 2¸_): ‘ć22‰ń“ú–{”F’mÇƒPƒAŠw‰ď‘ĺ‰ď (2021/6/5-10/5), WebŠJĂ, “ú–{”F’mÇƒPƒAŠw‰ďŽ 2021/4; 20 (1): 141.

723716. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‚Ş‚ńŠłŽŇ‚đe‚É‚ŕ‚ÂŽq‚Ç‚ŕ‚Ö‚ĚŹE’†ŠwZ’S”C‹łˆő‚Ě‚Š‚Š‚í‚č. Ź“‡‚Đ‚ĹŽq1, ’ҍ˛ŒbŽq1, ˆÉ“ĄT–ç1, Žs–ѐłm2, —Ž‡‰ę’ĂŽq2, –ű’J˜aŽq3, ‚ŒŠ‹IŽq4, ‚‹´@Œb4, —Ń”ü“ŢŽq5 (1ŠĹŒěŠw•”, 2‹łEƒZƒ“ƒ^[, 3ŒłŠĹŒě•”, 4ŠĹŒě•”, 5Œł–Ú”’‘ĺŠwŠĹŒěŠw•”): ‘ć26‰ń“ú–{ŠÉ˜aˆă—ĂŠw‰ďŠwp‘ĺ‰ď (2021/6/18-19), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), Palliative Care Research 2021/6; 16 (Suppl): S365.

723717. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‚Ş‚ńŠłŽŇ‚đe‚É‚ŕ‚ÂŽq‚Ç‚ŕ‚É‚Š‚Š‚í‚鏬E’†ŠwZ’S”C‹łˆő‚Ěˆă—ĂŽŇ‚Ć‚Ě˜AŒg‚ɑ΂ˇ‚éƒj[ƒY|ŠÖ“ŒŒ—“ŕŹE’†ŠwZ‚ĚŽŔ‘Ô’˛¸|. ’ҍ˛ŒbŽq1, Ź“‡‚Đ‚ĹŽq1, ˆÉ“ĄT–ç1, Žs–ѐłm2, —Ž‡‰ę’ĂŽq2, –ű’J˜aŽq3, ‚ŒŠ‹IŽq4, ‚‹´@Œb4, —Ń”ü“ŢŽq5 (1ŠĹŒěŠw•”, 2‹łEƒZƒ“ƒ^[, 3ŒłŠĹŒě•”, 4ŠĹŒě•”, 5Œł–Ú”’‘ĺŠwŠĹŒěŠw•”): ‘ć26‰ń“ú–{ŠÉ˜aˆă—ĂŠw‰ďŠwp‘ĺ‰ď (2021/6/18-19), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), Palliative Care Research 2021/6; 16 (Suppl): S365.

723718. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) BCP‚đˆÓŽŻ‚ľ‚˝‘ĺ‹K–͍ЩQ‘z’čƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“‚ĚŒoŒą`ĐŠQ‹’“_•a‰@‚̏ŹŽ™•a“EPICU‚Š‚ç‚Ě•ń`. Źł]—˘“Ţ1, ŸŽR”ü—˘2, •˝—Ń“Ţ•c1, ěă‘ĺ•ă1, ‘şă”üŒb1, •ô”öŒb—œ3, ˆŔ“Ą@Žő3 (1ŠĹŒě•”, 2ŒłŠĹŒě•”, 3ŹŽ™): ‘ć34‰ń“ú–{ŹŽ™‹~‹}ˆăŠw‰ďŠwpW‰ď (2021/6/18-20), “Ţ—Ç (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{ŹŽ™‹~‹}ˆăŠw‰ďŽGŽ 2021/5; 20 (2): 353.

723719. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ŠłŽŇ‚ĚˆÓŽv‚đ‘¸d‚ľ‚˝End of Life Care: ƒNƒŠƒeƒBƒJƒ‹ƒPƒA—Ěˆć‚ĚŠĹŒěŽt‚ŞŒę‚č‡‚¤‚ą‚Ć‚đ’Ę‚ľ‚Ä. ’J@Kˆę1,2 (1ŠĹŒě•”, 2ˆă—Ă‚ĚŽżEˆŔ‘S„iŽş): ‘ć17‰ń“ú–{ƒNƒŠƒeƒBƒJƒ‹ƒPƒAŠĹŒěŠw‰ďŠwpW‰ď (2021/7/1-31), WebŠJĂ.

723720. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) dÇ‹~‹}ŠłŽŇ‚É‚¨‚Ż‚é‰h—{ó‘ԂƔ畆ƒgƒ‰ƒuƒ‹”­ś‚ĚŠÖ˜AŤ. ‘ž“c]—œ‰Ô1, Î‘q@ˆ¤1, ‹yě‚ ‚¸‚ł2, ‰““ĄŹŽq3, ‰Ąaˆç”ü1, “c‘ş@’q4, •Đ‰Ş—Sˆę4 (1ŠĹŒě•”, 2‰h—{•”, 3—ŐŒŸ•”, 4‹~–˝): ‘ć36‰ń“ú–{—Տ°‰h—{‘ăŽÓŠw‰ďŠwpW‰ď (2021/7/21-22), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ), Šw‰ďŽJSPEN 2021/10; 3 (Suppl 1): 751.

723721. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒRƒƒi‰Đ‚Łu“Ż‚śŒ`v‚Ĺ‚Í‚Č‚­u“Ż‚ś‰ż’lv‚đ’Ç‹‚ˇ‚é‘gDŠˆ“Ž|–k—˘‘ĺŠw•a‰@‚ĚƒIƒ“ƒ‰ƒCƒ“ŽŠŽĺŠé‰ć‚đ‘čŢ‚Ɂ|. ’JŒű—zŽq1, ‚‹´N‰î1, ´…›’“1, –x]çœ¨Žq1, ‹g•”Œb—Žq1, ꎓĄŒ\Žq1, ‘ĺ’JŽ–ç1 (1ŠĹŒě•”): ‘ć25‰ń“ú–{ŠĹŒěŠÇ—Šw‰ďŠwpW‰ď (2021/8/29), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), ‘ć25‰ń“ú–{ŠĹŒěŠÇ—Šw‰ďŠwpW‰ď´˜^W 2021/7; p.201.

723722. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “Ž‰ćŽ‹’Ž‚É‚ć‚éS—‹łˆç“I‰î“ü‚ɑ΂ˇ‚é“ű‚Ş‚ńŠłŽŇ‚ĚƒXƒgƒŒƒXŒyŒ¸‚ɂ‚˘‚Ä. ˛“Ą–ŤŽq1, ŁŒË–qŽq2, ŽOŠK‹MŽj3,, ĺÎ‹I•F3, ź‹{—mŽj3,4, ‹e’r^—Žq3,, ´…ˆş1, ŽRčŒb”ü1, Šâ–ž—D”ü1 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ŠĹŒě•”, 3,“ű‘BEbó‘BŠO, 4‘Š–ÍŒ´‹Ś“Ż•a‰@): ‘ć34‰ń“ú–{ƒTƒCƒRƒIƒ“ƒRƒƒW[Šw‰ď‘‰ď (2021/9/18-19), WebŠJĂ, “ú–{ƒTƒCƒRƒIƒ“ƒRƒƒW[Šw‰ď‘‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2021; 34th: 201.

723723. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ”]Ž€‰ş‘ŸŠí’ń‹Ÿ‚É‚¨‚Ż‚éƒhƒi[‰Ć‘°‚Ö‚ĚƒPƒA‚ĚŒŸ“˘@‰Ć‘°‚Ć‚Ć‚ŕ‚É’ń‹Ÿ‚Š‚ç1”N‚đU‚č•Ô‚é. ˛ě”ü—˘1, “c‘ş@’q2, ‚‹´@Œb1, ŠÖ@ˆę”n1, ă‘ş—RŽ—1, •Đ‰Ş—Sˆę2, ‹g“cˆęŹ3,4 (1ŠĹŒě•”, 2‹~–˝, 3V˘‹Iˆă—ÁEć’[ˆă—Ă, 4”ĺ”AŠí): ‘ć57‰ń“ú–{ˆÚAŠw‰ď‘‰ď (2021/9/20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), ˆÚA 2021/9; 56 (‘‰ď—ŐŽž): O22-2.

723724. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒRƒƒi‰Đ‚Ĺ‚ĚI––ŠúˆÓŽvŒˆ’č‚ĚŽŔ‘ԂƉƑ°Žx‰‡•ű–@‚̍č\’z‚Ě•K—vŤ. ‚‹´@Œb1, “c‘ş@’q2, ŠÖ@ˆę”n1, ă‘ş—RŽ—1, ˛ě”ü—˘1, •Đ‰Ş—Sˆę2, ‹g“cˆęŹ3,4 (1ŠĹŒě•”, 2‹~–˝, 3V˘‹Iˆă—ÁEć’[ˆă—Ă, 4”ĺ”AŠí): ‘ć57‰ń“ú–{ˆÚAŠw‰ď‘‰ď (2021/9/20), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), ˆÚA 2021/9; 56 (‘‰ď—ŐŽž): O25-4.

723725. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) “–‰@‚Ě‹}•Ď‘ΉžŒ¤C‚Ě‹łˆçŒř‰Ę (‘ć2•ń). ’J@Kˆę1,2, “c‘ş@’q3, ” “c”ü’mŒb1,2, –x]çŒbŽq1, _@ˆę–˛2, ‰iˆäD1, ‹e’nO”ü2, rˆä—L”ü1,2, “ŕŽRŸ•ś2,4 (1ŠĹŒě•”, 2ˆă—Ă‚ĚŽżEˆŔ‘S„iŽş, 3‹~–˝, 4ˆă—ĂˆŔ‘SEŠÇ—): ‘ć16‰ńˆă—Ă‚ĚŽżEˆŔ‘SŠw‰ďŠwpW‰ď (2021/11/27-28), WebŠJĂ, ˆă—Ă‚ĚŽżEˆŔ‘SŠw‰ďŽ 2021/11; 16 (Suppl): 235.

723726. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) “–‰@‚É‚¨‚Ż‚銳ŽŇŒë”F–hŽ~‘΍ô‚ĚŒř‰Ę‚ƍĄŒă‚̉ۑč (‘ć2•ń) `Eˆő‚ĚŠłŽŇŠm”FŽč‡‚̏…Žçó‹ľ’˛¸‚ĆŠłŽŇ‹Ś—Í‚ĚŒÄ‚Ń‚Š‚Ż‚đŽŔŽ{‚ľ‚ā`. ” “c”ü’mŒb1,2, rˆä—L”ü1,2, ’J@Kˆę1,2, _@ˆę–˛2, Žá—Ń—Ç—Y2, â‘q’qŽq2,3, ‹e’nO”ü2, ŽRŒű•‘‰Ô2, “ŕŽRŸ•ś2,4 (1ŠĹŒě•”, 2ˆă—Ă‚ĚŽżEˆŔ‘S„iŽş, 3–ňÜ•”, 4ˆă—ĂˆŔ‘SEŠÇ—): ‘ć16‰ńˆă—Ă‚ĚŽżEˆŔ‘SŠw‰ďŠwpW‰ď (2021/11/27-28), WebŠJĂ, ˆă—Ă‚ĚŽżEˆŔ‘SŠw‰ďŽ 2021/11; 16 (Suppl): 254.

723727. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‘ĺŠw•a‰@‚É‚¨‚Ż‚鎊ŽE–hŽ~‘΍ôƒvƒƒWƒFƒNƒg‚ĚŽć‚č‘g‚Ý (‘ć2•ń). ” “c”ü’mŒb1,2, rˆä—L”ü1,2, Vˆä‹v–Ť3, Ż–ěr–í4, ”’ˆä‹łŽq1, ŒFâ^—R”ü1, “ŕŽRŸ•ś2,5 (1ŠĹŒě•”, 2ˆă—Ă‚ĚŽżEˆŔ‘S„iŽş, 3é‹Ęˆă‰Č‘ĺŠw¸__Œo‰Č, 4¸_, 5ˆă—ĂˆŔ‘SEŠÇ—): ‘ć16‰ńˆă—Ă‚ĚŽżEˆŔ‘SŠw‰ďŠwpW‰ď (2021/11/27-28), WebŠJĂ, ˆă—Ă‚ĚŽżEˆŔ‘SŠw‰ďŽ 2021/11; 16 (Suppl): 255.

723728. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ˆŤŤ”]ŽîᇊłŽŇ‚ĚˆÓŽvŒˆ’čŽx‰‡‚É‚¨‚Ż‚éŠĹŒě‚ĚŽŔŰ`‰Ć‘°‚ĆŠĹŒěŽt‚ĚŠÖ‚í‚č`. ŽR–{@–r1, ‚ŒŠ‹IŽq1 (1ŠĹŒě•”): ‘ć36‰ń“ú–{‚Ş‚ńŠĹŒěŠw‰ďŠwpW‰ď (2022/2/19), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ) ‘ć36‰ń“ú–{‚Ş‚ńŠĹŒěŠw‰ďŠwpW‰ď´˜^ (ƒIƒ“ƒ‰ƒCƒ“) 2022/2; p.P42-246.

723729. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ’ʉ@ŽĄ—ĂŽş‚Ĺ‚ĚR‚Ş‚ń–ň“Š—^ŠÇ—‚É‚¨‚Ż‚é•Â˝ŽŽ–ň•¨ˆÚ‘—ƒVƒXƒeƒ€“ą“ü‘OŒă‚Ě”˜˜IŒťó’˛¸`ŠÂ‹Ť’˛¸‚ƐEˆő‚Ě‘Á‰t”Z“x‘Ş’č‚ć‚č`. ”Ş–öçt1, ‚‹´‚Š‚¨‚é1, ’ˇ“c^—R”ü1, ˆî–ě@Š°2, ˛X–ŘŽőŽq2, “c‘ş˜aŒh2, ˛X–ŘŽĄˆę˜Y3 (1ŠĹŒě•”, 2–ňÜ•”, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć36‰ń“ú–{‚Ş‚ńŠĹŒěŠw‰ďŠwpW‰ď (2022/2/19), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ) ‘ć36‰ń“ú–{‚Ş‚ńŠĹŒěŠw‰ďŠwpW‰ď´˜^ (ƒIƒ“ƒ‰ƒCƒ“) 2022/2; p.O10-46.

723730. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ’ʉ@ŽĄ—ĂŽş‚Ĺ‚ĚR‚Ş‚ń–ň“Š—^ŠÇ—‚É‚¨‚Ż‚é•Â˝ŽŽ–ň•¨ˆÚ‘—ƒVƒXƒeƒ€“ą“ü‘OŒă‚Ě’˛¸`—A‰tƒ{ƒgƒ‹‚Ě•rj”˛‚Ťˇ‚ľŽž‚ĚŽč‘Ü”˜˜I`. ‚‹´‚Š‚¨‚é1, ”Ş–öçt1, ’ˇ“c^—R”ü1, ˆî–ě@Š°2, ˛X–ŘŽőŽq2, “c‘ş˜aŒh2, ˛X–ŘŽĄˆę˜Y3 (1ŠĹŒě•”, 2–ňÜ•”, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć36‰ń“ú–{‚Ş‚ńŠĹŒěŠw‰ďŠwpW‰ď (2022/2/19), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ) ‘ć36‰ń“ú–{‚Ş‚ńŠĹŒěŠw‰ďŠwpW‰ď´˜^ (ƒIƒ“ƒ‰ƒCƒ“) 2022/2; p.O10-48.

732130. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŠĹŒěE‚̓Rƒƒi‚É‚ć‚é‰Ű‘č‚ɂǂ̂悤‚ɑΉž‚ľ‚˝‚Š|‹łˆç“I‚ČŽ‹“_‚Š‚ç|uƒRƒƒi‰Đ‚ł̐VlŠĹŒěEˆő‚ĚˆçŹv. ’JŒű—zŽq (ŠĹŒě•”): ‘ć20‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2021/12/11-13), WebŠJĂ.

733234. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) VŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´őÇ‚É‚ć‚édÇŒÄ‹z•s‘S‚ĚŽĄ—Ă‚É‚¨‚˘‚ÄŒo’°‰h—{‚̏Ź’°“Š—^‚Ş—L—p‚Ĺ‚ ‚Á‚˝1—á. ‘ž“c]—œ‰Ô1, Î‘qˆ¤1, ‰Ąaˆč”ü1, ‹yě‚ ‚¸‚ł2, ˛“ĄĆŽq2, “c‘ş@’q3, •Đ‰Ş—Sˆę3 (1ŠĹŒě•”, 2‰h—{•”, 3‹~–˝): ‘ć12‰ń“ú–{—Տ°‰h—{‘ăŽÓŠw‰ďŽń“sŒ—Žx•”‰ďŠwpW‰ď (2021/5/15), WebŠJĂ.

733235. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) t‘Ÿ•aSDMƒZƒ~ƒi[ƒx[ƒVƒbƒNƒR[ƒXŽŔ‘H•Ň@Ž–—áĐ‰î. ’ˇ‰Ş@‰~ (ŠĹŒě•”): t‘Ÿ•aSDMƒZƒ~ƒi[ ƒx[ƒVƒbƒNƒR[ƒX`ŽŔ‘H•Ň` (2021/5/30), WebŠJĂ.

733236. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ”ĺ”AŠí‰Čƒ_ƒ”ƒBƒ“ƒ`Žčp‚É‚¨‚Ż‚鎖—ጟ“˘|RALPÇ—á‚É‚¨‚Ż‚é”畆ƒgƒ‰ƒuƒ‹—\–hE‘Ěˆł‚É’…–Ú‚ľ‚ā|. Žu‘ş”ü‰š1, œ}“c´1, ’†“ˆ—R”üŽq1, ’†“ˆO”ü1 (1ŠĹŒě•”): ‘ć32‰ń“ú–{ŽčpŠĹŒěŠw‰ďŠÖ“ŒbM‰z’n‹ćŠw‰ď (2021/6/26) WebŠJĂ, ‘ć32‰ń“ú–{ŽčpŠĹŒěŠw‰ďŠÖ“ŒbM‰z’n‹ćW˜^ 2021/6; p.52.

733237. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ‘‡ŽčpƒZƒ“ƒ^[“ŕ‚Ěĺń጑΍ôƒ`[ƒ€‚ĚŠˆ“Ž‚ɂ‚˘‚ā|‘źEŽí‚Ě‹­‚Ý‚đŠˆ‚Š‚ľ, ˜AŒg‚đs‚¤‚˝‚ß‚Ě“y‘äě‚č|. ‹e’r”š“l1, ’†“ˆ—R”üŽq1, ’†“ˆO”ü1 (1ŠĹŒě•”): ‘ć32‰ń“ú–{ŽčpŠĹŒěŠw‰ďŠÖ“ŒbM‰z’n‹ćŠw‰ď (2021/6/26) WebŠJĂ, ‘ć32‰ń“ú–{ŽčpŠĹŒěŠw‰ďŠÖ“ŒbM‰z’n‹ćW˜^ 2021/6; p.54.

733238. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) dÇCOVID-19ŠłŽŇ‚ɑ΂ˇ‚鏬’°Ž‘ą“Š—^‚É‚ć‚éŒo’°‰h—{ŠÇ—‚Ě—L—pŤ. Ŕ–ěˆäăđž1, Î‘q@ˆ¤1, ‘ž“c]—œ‰Ô1, •Đ‰Ş—Sˆę2 (1ŠĹŒě•”, 2‹~–˝): ‘ć7‰ń_“ސě‹}ŤŠú‰h—{ŠÇ—Œ¤‹†‰ď (2021/7/3), WebŠJĂ, Šw‰ďŽJSPEN 2021/12; 3 (Suppl 2): 22.

733239. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ‹~–˝‹~‹}ĐŠQˆă—ĂƒZƒ“ƒ^[‚É‚¨‚Ż‚éƒOƒŠ[ƒtƒJ[ƒh‚Ě—L—pŤ‚ĚŒŸŘ. ă‘ş—RŽ—1, ‚‹´@Œb1, –î•”hŽu1, ěă‘ĺ•ă1, Â–Ř—”ü1, Žsě‰ęˆę2, ’ÍčS–ç3, •Đ‰Ş—Sˆę4, ó—˜@–ő4 (1ŠĹŒě•”, 2ƒg[ƒ^ƒ‹ƒTƒ|[ƒgƒZ, 3—Տ°S—Žş, 4‹~–˝): –k—˘‘ĺŠw•a‰@EˆőŒ¤‹†”­•\‰ď (2021/7/8), _“ސě.

733240. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ƒXƒg[ƒ}‚ɋߐڂľ‚˝‘nŠÇ—‚É, ‰Aˆł•Â˝—Ă–@‚đ—p‚˘‚˝ˆęŽ–—á. “n•ÓšD (ŠĹŒě•”): ‘ć43‰ń_“ސěƒXƒg[ƒ}Œ¤‹†‰ď (2021/10/2), WebŠJĂ, ‘ć43‰ń_“ŢěŒ¤‹†‰ďƒvƒƒOƒ‰ƒ€´˜^W 2021/10; p.16.

733241. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ƒNƒŠƒjƒJƒ‹ƒ‰ƒ_[I‚Ş–˘C“ž‚Ĺ‚ ‚Á‚˝VlŠĹŒěEˆő‚Ě‚ť‚ĚŒă‚̐Ź’ˇ‚ɂ‚˘‚Ä‚ĚlŽ@. —é–Ř—B‰Ř1, ‰F“cě”ü‹I1, –x]çŒbŽq1, ’JŒű—zŽq1 (1ŠĹŒě•”): ‘ć20‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2021/12/11-13), WebŠJĂ.

733242. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) COVID-19– ‰„‚Ě’†‚ŁCŽŠŒČ‚Ěƒpƒ^[ƒ“‚Ö‚Ě‹C‚Ă‚Ť`MEƒjƒ…[ƒ}ƒ“—˜_‚đ—p‚˘‚ā`. _’J–FŠG1, ‹gŒ´çŒb1, Ž™‹Ę”ü—R‹I1 (1ŠĹŒě•”): ‘ć20‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2021/12/11-13), WebŠJĂ.

733243. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) MRI‚đˆŔ‘S‚ÉŽ{s‚ˇ‚é‚˝‚ß‚ÉŽć‚č‘g‚ń‚ž‹Ć–ą‰ü‘P`ŠĹŒěŽt‚É‚ć‚é‹ŕ‘Ž’T’m‹@“_ŒŸ‚Ě“ą“üE•]‰ż`. —с@Žu”T1, ś’J”ü•ä1, ‘şŽR—F”ü1, ‰Í‡ˆŸ–îŽq1, ‚“c’qŽq1, çř“”ü“oŽq1 (1ŠĹŒě•”): ‘ć20‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2021/12/11-13), WebŠJĂ.

733244. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ˆę”Ę•a“‚É‚¨‚Ż‚éƒCƒ“ƒVƒfƒ“ƒgƒŒƒ|[ƒg•ń‚ĚŒťó‚Ćˆă—ĂˆŔ‘S‘΍ô‚ĚŒŸ“˘. řw“cŒ‹ˆß1, “y‰ŽŽu•Ű1 (1ŠĹŒě•”): ‘ć20‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2021/12/11-13), WebŠJĂ.

733245. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ŠłŽŇ‚Ěƒj[ƒY‚đ‚Ć‚ç‚Ś‚˝“ŕŽ‹‹žŒŸ¸‚ĚŽć‚č‘g‚݁`‹ę’ÉŒyŒ¸‚đ–Ú“I‚Ć‚ľ‚˝’Á’ɍܒP“Ć“Š—^‚̉^—pŠm—§`. ŽÂč–œ—˘Žq1, “Ą“c–ƒ”üŽq1 (1ŠĹŒě•”): ‘ć20‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2021/12/11-13), WebŠJĂ.

733246. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) • –Œ“§Í‚Ěˆă—Ă‚ĚŽżŒüă‚đ–ÚŽw‚ľ‚˝‘̐§‚Ă‚­‚č`• –Œ‰Š‚Ě–hŽ~‚Ö‚ĚŽć‚č‘g‚Ý‚đ’Ę‚ľ‚ā`. Ź‘q—Ú”ü1, ˛X–Řˆź”ü1, “‰€@”E1 (1ŠĹŒě•”): ‘ć20‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2021/12/11-13), WebŠJĂ.

733247. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ŹŽ™_ŒoŽžŠłŠłŽŇ‚̐ŹlˆÚsŠúŽx‰‡‚É‚¨‚Ż‚éŠĹŒě (1)`ŹlˆÚs‚đŽó‚Ż“ü‚ę‚é‚܂ł̉Ƒ°‚ĚˆÓŽvŒˆ’čŽx‰‡`. ‘ĺ’ˁ@1, ‘ĺ’J—ćŽq1 (1ŠĹŒě•”): ‘ć20‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2021/12/11-13), WebŠJĂ.

733248. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ŹŽ™_ŒoŽžŠłŠłŽŇ‚̐ŹlˆÚsŠúŽx‰‡‚É‚¨‚Ż‚éŠĹŒě (2) `ŹlˆÚsˆă—Ẩ~ŠŠ‰ť‚đ}‚é‚˝‚ß‚É—LŒř‚ČŽx‰‡`. ‘ĺ’J—ćŽq1, ‘ĺ’ˁ@1 (1ŠĹŒě•”): ‘ć20‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2021/12/11-13), WebŠJĂ.

733249. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) f—ĂŽžŠÔŠO‚Ě‹~‹}”Ŕ‘—Ç—á‚ĚŽŔ‘Ô‚ĆŒp‘ąŠĹŒě‚̉ۑč. âj•x“ß“Ţ1, ’–Žë—ÉŽq1, Â–Ř—”ü1 (1ŠĹŒě•”): ‘ć20‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2021/12/11-13), WebŠJĂ.

733250. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) dÇSgáŠQŽ™‚đŽ‚Âe‚ĚˆÓŽvŒˆ’č‚Ö‚ĚŠĹŒě‰î“ü. ꎓĄ‘Žq1, “ŕ“Ą–΍K1 (1ŠĹŒě•”): ‘ć20‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2021/12/11-13), WebŠJĂ.

733251. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ˆŤŤ”]ŽîᇊłŽŇ‚ĚˆÓŽvŒˆ’čŽx‰‡‚É‚¨‚Ż‚éŠĹŒěŽt‚ĚŠÖ‚í‚č. ŽR–{@–r1, ‚ŒŠ‹IŽq1 (1ŠĹŒě•”): ‘ć20‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2021/12/11-13), WebŠJĂ.

733252. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ‚Ş‚ńƒTƒoƒCƒo[ƒVƒbƒv‹}ŤŠú‚̐ś‘ś‚ĚŽžŠú‚É‚ ‚éŽüpŠúŠłŽŇ‚Ö‚ĚŠÖ‚í‚č`ŠÉ˜aƒPƒAƒXƒNƒŠ[ƒjƒ“ƒO‚ĚŒ‹‰Ę‚Š‚çŠĹŒěŠî€‚đ•]‰ż`. Šě‰Ž•śK1, ‰Oˆä@Œ’1, oŕV”ü—˘1, •Đ–ě–ƒäťŘ1, ě’[–[ŠG1 (1ŠĹŒě•”): ‘ć20‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2021/12/11-13), WebŠJĂ.

733253. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ŽŠ‘î‚Ĺ‚Ě—Ă—{‚đŠó–]‚ľ‚˝’ő̒ŊԔ‰ŠŠłŽŇ‚ĚˆÓŽvŒˆ’čŽx‰‡. ‹{–{‚ß‚Ž‚Ý1, ˛X–Ř—œ1, Źˆä”ü•ä1, ‰ĄŽR—˜1 (1ŠĹŒě•”): ‘ć20‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2021/12/11-13), WebŠJĂ.

733254. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ŠłŽŇ‚ĚˆÓŽv‚đ‘¸d‚ľ‚˝End of Life Care`ƒNƒŠƒeƒBƒJƒ‹ƒPƒA—Ěˆć‚ĚŠĹŒěŽt‚ŞŒę‚č‡‚¤‚ą‚Ć‚đ’Ę‚ľ‚ā`. ’J@Kˆę1,2 (1ŠĹŒě•”, 2ˆă—Ă‚ĚŽżEˆŔ‘S„iŽş): ‘ć20‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2021/12/11-13), WebŠJĂ.

733255. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) A•a“‚É‚¨‚Ż‚ég‘̍S‘ŠĹŹ‰ť‚ÉŒü‚Ż‚˝Žć‚č‘g‚݁`g‘̍S‘ŠŽOŒ´‘Ľ‚ɉˆ‚Á‚˝ƒJƒ“ƒtƒ@ƒŒƒ“ƒX‚̐„i`. ˛X–Ř—œ1, ‹{–{‚ß‚Ž‚Ý1, Źˆä”ü•ä1, ‰ĄŽR—˜1 (1ŠĹŒě•”): ‘ć20‰ń–k—˘ŠĹŒěŒ¤‹†‰ď (2021/12/11-13), WebŠJĂ.

733256. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) VŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´őÇŠłŽŇ‚ɃŠƒ‚[ƒg–ʉď‚đ—p‚˘‚˝I––ŠúƒPƒA. ‰Hś“c—I1, ’Ö”ü’q”Ž1, ’–Žë—ÉŽq1, X@‘ń–ç1, ‰Ąaˆç”ü1 (1ŠĹŒě•”): ‘ć72‰ń“ú–{‹~‹}ˆăŠw‰ďŠÖ“Œ’n•ű‰ďŠwpW‰ď (2022/2/26), WebŠJĂ.

733257. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) COVID-19ŒyÇ`’†“™Ç‘Ήž•a“‚É‚¨‚Ż‚é”F’mÇŠłŽŇ‚ւ̑Ήž‚ĹŠĹŒěŽt‚ŞŠ´‚ś‚˝˘“ď‚ĆŠ‹“Ą. ˜ď‰ŽčˆťŠó1, ‘ž“ěˆŸ‹I1, “Ąˆä”ü‰Ä1, ˛–ě@–Ś1, ˛“Ą˛“s”ü1 (1ŠĹŒě•”): “ú–{ˆă—Ăƒ}ƒlƒWƒƒ“ƒgŠw‰ď‘ć21‰ń_“ŢěŒ§Žx•”ŠwpW‰ď (2022/3/12), _“ސě, “ú–{ˆă—Ăƒ}ƒlƒWƒƒ“ƒgŠw‰ď‘ć21‰ń_“ŢěŒ§Žx•”ŠwpW‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2022/3; p.O1-4.

733258. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) COVID-19ŠłŽŇ‚̑̂ƐS‚̂‚炳‚ɂ‚˘‚ā|ŠÉ˜aƒPƒA‹ę’ɃXƒNƒŠ[ƒjƒ“ƒOŽż–â•[‚Š‚猊‚Ś‚Ä‚­‚é‚ŕ‚́|. ‘ž“c˛’mŽq1, Îě”üá1, ˛“Ą@—Î1, ˛“Ą˛“s”ü1 (1ŠĹŒě•”): “ú–{ˆă—Ăƒ}ƒlƒWƒƒ“ƒgŠw‰ď‘ć21‰ń_“ŢěŒ§Žx•”ŠwpW‰ď (2022/3/12), _“ސě, “ú–{ˆă—Ăƒ}ƒlƒWƒƒ“ƒgŠw‰ď‘ć21‰ń_“ŢěŒ§Žx•”ŠwpW‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2022/3; p.O1-7.

733259. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) COVID-19•a“‚É‚¨‚Ż‚鍡Œă‚̉ۑč|‹CŽ‚ż‚̂‚炳‚É’…–Ú‚ľ‚ā|. ˛“Ą@—Î1, Îě”üá1, ‘ž“c˛’mŽq1, ˛“Ą˛“s”ü1 (1ŠĹŒě•”): “ú–{ˆă—Ăƒ}ƒlƒWƒƒ“ƒgŠw‰ď‘ć21‰ń_“ŢěŒ§Žx•”ŠwpW‰ď (2022/3/12), _“ސě, “ú–{ˆă—Ăƒ}ƒlƒWƒƒ“ƒgŠw‰ď‘ć21‰ń_“ŢěŒ§Žx•”ŠwpW‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2022/3; p.O2-2.

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-120004. [Œ´’˜] ‚Ş‚ńˆă—Ă‚ÉŒg‚í‚éS—E‚̐S—“IƒXƒgƒŒƒX‚Ć‚ť‚ĚŠÖ˜A—vˆö‚ÉŠÖ‚ˇ‚錟“˘. ŽRč—˘ŽŃ1, ‘şăŽ”ü2, ’†“‡Ÿ3, ”’ˆä‹łŽq4, ŠâŸŢ—D”ü2 (1‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[‚Ş‚ń‘΍ôî•ńƒZƒ“ƒ^[‚Ş‚ńˆă—ĂŽx‰‡•”, 2‘ĺŠw‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3“ŒŠC‘ĺŠw•ś‰ťŽĐ‰ď•”S—EŽĐ‰ďŠw‰Č, 4ŠĹŒě•”): –k—˘‘ĺŠw•t‘Ž—Տ°S—‘Š’kƒZƒ“ƒ^[‹I—v 2021/3; ‘ć9†: 1-11.


—Տ°ŒŸ¸•”

[Šwp˜_•ś]

120041. [Œ´’˜] LHON“ď•a”F’čŠî€‚̐f’f‹ć•Ş‚É‚ć‚éƒ~ƒgƒRƒ“ƒhƒŠƒAˆâ“`ŽqŒŸ¸‚ÉŠÖ‚ˇ‚錟“˘. ŸNˆäŒc‘˘1, ˆŔ–{—´”n1, Š}ˆäˆÇŽq1, Îě@‹Ď2, ŽRă–žŽq3, Žá‘q‰ë“o3, Žë–ě—Lě4 (1—ŐŒŸ•”, 2ˆă—ÉqśŠw•”, 3Žá‘qŠá‰Č•a‰@, 4—ŐŒŸŠw): ˆăŠwŒŸ¸ 2021/10; 70 (4): 676-84.

120042. [Œ´’˜] –k—˘‘ĺŠw•a‰@‚É‚¨‚Ż‚éƒzƒ‹ƒ^[S“d}‚ĚƒpƒjƒbƒN’l•ń‚ĚŠT—v‚¨‚ć‚Ń‘Šúf’fEŽĄ—Ă‚ÉvŒŁ‚Ĺ‚Ť‚˝1Ç—á‚ɂ‚˘‚Ä. ŠFě@•ŕ1, Ź–ěŽRŽuD1, ˛‹´‹v”üŽq1, ‹{“ŕ˜a”ü1, ‰FŽĄ‹´‘PŸ1, “•űLˆę1, Žë–ě—Lě1,2 (1—ŐŒŸ•”, 2—ŐŒŸŠw): _“ŢěŒ§—Տ°ŒŸ¸‹ZŽt‰ďŽGŽ 2021/12; 56 (173): 12-8.

220007. [€Œ´’˜] lHŠÖßŠ´őÇ‚É‚¨‚Ż‚éTm mapping–@‚đ—p‚˘‚˝×‹Űˆâ“`ŽqŒŸ¸‚Ě—L—pŤ‚ɂ‚˘‚Ä. ŸNˆäŒc‘˘1, ˆŔ–{—´”n1, Š}ˆäˆÇŽq1, “ŕŽRŸ•ś2, Žë–ě—Lě3 (1—ŐŒŸ•”, 2ŽŠO, 3—ŐŒŸŠw): _“ŢěŒ§—Տ°ŒŸ¸‹ZŽt‰ďŽGŽ 2021/12; 56 (173): 7.

522590. [uŔ]y“ÁW: ‚˘‚Ü‚ł‚畡‚Ż‚Č‚˘—Տ°‰ťŠwŒŸ¸‚́uíŽŻvz2. ‚˘‚Ü‚ł‚畡‚Ż‚Č‚˘ŒŸ‘Ě•s”őƒf[ƒ^‚Ě“Á’Ľ@…BR‹ĂŒĹÜ‚â—A‰t‚̍Ź“ü. “Ą‘ş‘Ps (—Տ°ŒŸ¸•”): Medical Technology 2021/6; 48 (6): 560-3.

[Šw‰ďEŒ¤‹†‰ď“™]

721020. [Šw‰ď (‘S‘)] (“Á•Ęu‰‰) BNPƒRƒ“ƒgƒ[ƒ‹@ƒVƒIƒmƒM‚ĚŠî‘b“IŤ”\•]‰ż‚¨‚ć‚ѐ¸“xŠÇ—‚É‚¨‚Ż‚é—L—pŤ‚ɂ‚˘‚Ä. ŽÂŒ´—ş‘ž (—ŐŒŸ•”): “ú–{ˆă—ĂŒŸ¸‰ČŠw‰ď‘ć53‰ń‘ĺ‰ď (2021/10/8), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), ˆă—ĂŒŸ¸‚ĆŽŠ“Ž‰ť “ú–{ˆă—ĂŒŸ¸‰ČŠw‰ď‘ć53‰ń‘ĺ‰ď´˜^W 2021/8; 46: 40.

722318. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ˆę”ĘŒŸ¸—Ěˆć‚É‚¨‚Ż‚éƒsƒbƒgƒtƒH[ƒ‹|”A’萍ŒŸ¸|. “y•M’qť (—ŐŒŸ•”): ‘ć61‰ń“ú–{—Տ°‰ťŠw‰ď”NŽŸŠwpW‰ď (2021/11/7), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ), —Տ°‰ťŠw 2021/10; 50 (suppl 1): 147.

722319. [Šw‰ď (‘S‘)] (ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“) ’°ŠÇ—R—ˆŒŸ‘Ě‚Ĺ•ń‚Ş•K—v‚Č×‹Ű. ˆŔ’B@÷ (—ŐŒŸ•”): ‘ć33‰ń“ú–{—Տ°”÷ś•¨Šw‰ď‘‰ďEŠwpW‰ď (2022/1/28-30), ĺ‘ä, “ú–{—Տ°”÷ś•¨Šw‰ďŽGŽ 2021/12; 32 (suppi 1): 176.

723731. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŒŒ‰tŒ^‚ĚˆŮ‚Č‚éŽž“_‚Ĺ‚Ě“ńdƒ`ƒFƒbƒN‚đ“O’ꂡ‚éŽć‚č‘g‚Ý. Ź–{”ü“Ţ1, ŽR–{–ž—˘“Ţ1, —L”n˜a“Ţ1, “ŕŽRˆÇ“Ţ1, “c•”—T“ń1, ŠâŘ•śŽq1, ŽR•Ó°”ü1, ‰““Ą@—m1, ‘ĺ’JTˆę2, ‹{ř“_“ń2 (1—ŐŒŸ•”, 2—AŒŒE×–EˆÚA): ‘ć69‰ń“ú–{—AŒŒE×–EŽĄ—ĂŠw‰ďŠwp‘‰ď (2021/6/4-6), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{—AŒŒ×–EŽĄ—ĂŠw‰ďŽ 2021/6; 67 (2): 353.

723732. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œ`‘Ԑf’f‚Ě‚˝‚ß‚ĚƒP[ƒXƒJƒ“ƒtƒ@ƒŒƒ“ƒX. ’†ź@ŒO (—ŐŒŸ•”): ‘ć22‰ń“ú–{ŒŸ¸ŒŒ‰tŠw‰ďŠwpW‰ď (2021/9/12), WebŠJĂ, “ú–{ŒŸ¸ŒŒ‰tŠw‰ďŽGŽ 2021/8; 22: S100.

723733. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ŒŒ´ALP‚͈Ÿ‰”Œ‡–RƒXƒNƒŠ[ƒjƒ“ƒO‚É—L—p‚Š. “y•M’qť1, ŽÂŒ´—ş‘ž1, ‹ß“Ą—Ż”üŽq2, Žç‰Ž’B”ü3, Žë–ě—Lě1,4 (1—ŐŒŸ•”, 2–ňÜ•”, 3Œ’NŠÇ—ƒZ, 4—ŐŒŸŠw): ‘ć61‰ń“ú–{—Տ°‰ťŠw‰ď”NŽŸŠwpW‰ď (2021/11/6), •Ÿ‰Ş (ƒnƒCƒuƒŠƒbƒhŠJĂ), —Տ°‰ťŠw 2021/10; 50 (suppl 1): 215.

723734. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒqƒgŒŒŸ÷‚đƒx[ƒX‚Ć‚ľ‚˝uBNPƒRƒ“ƒgƒ[ƒ‹ƒVƒIƒmƒMv‚Ě—L—pŤ‚ÉŠÖ‚ˇ‚錟“˘. ŽÂŒ´—ş‘ž1, “y•M’qť1, “Ą‘ş‘Ps1, ’†čLŽq1, “ŕ“cˆęO1, “•űLˆę1, Žë–ě—Lě1,2 (1—ŐŒŸ•”, 2—ŐŒŸŠw): “ú–{ˆă—ĂŒŸ¸‰ČŠw‰ď‘ć53‰ń‘ĺ‰ď (2021/11/8-10), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), ˆă—ĂŒŸ¸‚ĆŽŠ“Ž‰ť 2021/8; 46 (4): 440.

723735. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Ž‰–bŽ_Œ‹‡ƒAƒ‹ƒuƒ~ƒ“‚ÍPKCŠˆŤ‰ť‚đ‰î‚ľ‚Ä‹ßˆĘ”A×ŠÇă”ç×–E‚Ě×–E‘B‚¨‚ć‚Ń×–E˜V‰ť‚đ—U“ą‚ˇ‚é. •čËŽj1, “y•M’qť2, —é–؉p–ž3, Žsě‘¸•ś1, •Đ‹Ë^l1, Îˆä’źm1 (1ˆă—ÉqśŠw•”, 2—ŐŒŸ•”, 3•Ÿ“‡Œ§—§ˆă‰Č‘ĺŠw): ‘ć68‰ń“ú–{—Տ°ŒŸ¸ˆăŠw‰ďŠwpW‰ď (2021/11/11-14), •xŽR (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{—Տ°ŒŸ¸ˆăŠw‰ďŽ 2021/10; 69: 111.

731082. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ‘ć4‰ńƒƒ“ƒiƒbƒvƒZƒ~ƒi[: y‘f. ŽÂŒ´—ş‘ž (—ŐŒŸ•”): _“ŢěŒ§ś•¨‰ťŠw•ŞÍŒŸ¸Œ¤‹†”Ç (‘ć4‰ńƒƒ“ƒiƒbƒvƒZƒ~ƒi[) (2022/2/19), WebŠJĂ, _“ŢěŒ§—Տ°ŒŸ¸‹ZŽt‰ďHP -

732131. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) ƒRƒ“ƒsƒ…[ƒ^ƒNƒƒXƒ}ƒbƒ`‚̉^—p‚ɂ‚˘‚ā`24ŽžŠÔˆŔ‘S‚ĹŒř—Ś“I‚Č—AŒŒ€”ő`. Ź–{”ü“Ţ (—ŐŒŸ•”): ‘ć152‰ń“ú–{—AŒŒE×–EŽĄ—ĂŠw‰ďŠÖ“ŒbM‰zŽx•”—á‰ď (2021/9/11), WebŠJĂ, “ú–{—AŒŒ×–EŽĄ—ĂŠw‰ďŽ 2021/12; 67 (6): 637.

733260. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) Žż—Ę•ŞÍ‘•’u‚É‚ć‚č“Ż’č‰Â”\‚Ĺ‚ ‚Á‚˝Candida auris‚É‚ć‚閝Ť’†Ž¨‰Š‚Ěˆę—á. ˆÉŕVh‹P1, ˆŔ’B@÷1, ‹ŕ–؁@—y1, ’†čM•F1, “•űLˆę1, Žë–ě—Lě1,2 (1—ŐŒŸ•”, 2—ŐŒŸŠw): ‘ć70‰ń_“ŢěŒ§ˆăŠwŒŸ¸Šw‰ď (2021/12/28-2022/1/10), WebŠJĂ, ‘ć70‰ń_“ŢěŒ§ˆăŠwŒŸ¸Šw‰ďƒvƒƒOƒ‰ƒ€W 2021/12; p.13.

733261. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒRƒƒi‰Đ‚É‚¨‚Ż‚錌‰tŒŸ¸Žş‚Ĺ‚ĚŠwśŽŔK‚ĚÝ‚č•ű. “ŕŽR—Y“l1, ‰Ą“c—R‰Ŕ—1, ’†ź@ŒO1, ˆ˘•”—L1, “ŕ“cˆęO1, “•űLˆę1, Žë–ě—Lě1,2 (1—ŐŒŸ•”, 2—ŐŒŸŠw): ‘ć70‰ń_“ŢěŒ§ˆăŠwŒŸ¸Šw‰ď (2021/12/28-2022/1/10), WebŠJĂ, ‘ć70‰ń_“ŢěŒ§ˆăŠwŒŸ¸Šw‰ďƒvƒƒOƒ‰ƒ€W 2021/12; p.14.


•úŽËü•”

[Šwp˜_•ś]

110426. [Œ´’˜] Clinical Evaluation of Left Ventricular Diastolic Function Using Phase-contrast Cine Cardiovascular Magnetic Resonance Imaging: A Comparison With Steady-state Free Precession Cine Cardiovascular Magnetic Resonance Imaging and Echocardiography. Komi S1, Inoue Y2, Hata H1, Miyatake H1: J Comput Assist Tomogr 2022/1-2; 46 (1): 56-63. (ŹŒŠł‘ž˜Y1, ˆäă—D‰î2, `@”Ž•ś1, ‹{•”ä˜CŽ÷1: 1•úŽËü•”, 2•úŽËü (‰ć‘œ))

[Šw‰ďEŒ¤‹†‰ď“™]

722320. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) MR conditionalƒfƒoƒCƒX‚đŽg—p‚ľ‚Ä‚˘‚銳ŽŇ‚ĚMRI: GEŽĐMRI‘•’u‚đ—p‚˘‚˝“Ş•”‚¨‚ć‚Ń• •”‚ĚŒŸ¸‚ɂ‚˘‚Ä. ŹŒŠł‘ž˜Y1, `@”Ž•ś1 (1•úŽËü•”): JSMRM2021EASMRM2021‡“Ż‘ĺ‰ďi‘ć49‰ń“ú–{ŽĽ‹C‹¤–ˆăŠw‰ď‘ĺ‰ď) (2021/9/12), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{ŽĽ‹C‹¤–ˆăŠw‰ďŽGŽ 2021/9; 46: 136.

723736. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Image non-uniformity correction in 3T EOB-MRI: Comparison of quantitative indices of liver parenchymal enhancement among different software versions. ’†“ˆ@—•1, `@”Ž•ś1, ˆäă—D‰î2, ‚“Ą—D‹P1 (1•úŽËü•”, 2•úŽËü (‰ć‘œ)): JSMRM2021EASMRM2021‡“Ż‘ĺ‰ďi‘ć49‰ń“ú–{ŽĽ‹C‹¤–ˆăŠw‰ď‘ĺ‰ď) (2021/9/10-12), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{ŽĽ‹C‹¤–ˆăŠw‰ďŽGŽ 2021/9; 46: 254.

733262. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) “Żˆęƒxƒ“ƒ_[‚ĚˆŮ‚Č‚éCT‘•’uŠÔ‚É‚¨‚Ż‚éCT Automatic Exposure Control‚Ě‹““Ž‚Ě”äŠr. ˆ­”ü—F‹I1, ––œA’źŽ÷1, ˆÉ“ĄŠ°‘×1, `@”Ž•ś1, ”ˇ@G“T1 (1•úŽËü•”): “ú–{•úŽËü‹ZpŠw‰ď‘ć68‰ńŠÖ“ŒŽx•”Œ¤‹†”­•\‘ĺ‰ď (2021/11/27), ‰Ą{‰ę (ƒnƒCƒuƒŠƒbƒhŠJĂ), ‘ć68‰ńŠÖ“Œ•”‰ďŒ¤‹†”­•\‘ĺ‰ď´˜^W 2021; p.57.

733263. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) Cone Beam CTŽž‚ĚƒRƒŠƒ[ƒVƒ‡ƒ“‚É‚ć‚éŽU—ü’ጸŒř‰Ę‚ĚŒŸŘ. ‰Žˆä—Y‰î1, ’†“ˆ‹K—e1, ŽÂŒ´‰ÄŠC1, ŽR‰ş—ş—C1 (1•úŽËü•”): “ú–{•úŽËü‹ZpŠw‰ď‘ć68‰ńŠÖ“ŒŽx•”Œ¤‹†”­•\‘ĺ‰ď (2021/11/27), ‰Ą{‰ę (ƒnƒCƒuƒŠƒbƒhŠJĂ), ‘ć68‰ńŠÖ“Œ•”‰ďŒ¤‹†”­•\‘ĺ‰ď´˜^W 2021; p.72.

733264. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ‰ć‘œ‰đÍƒ\ƒtƒgƒEƒFƒA‚đ—p‚˘‚˝SPECT‰ć‘œÄ\ŹŽž‚É‚¨‚Ż‚éButterworthƒtƒBƒ‹ƒ^‚ĚŠî‘b“IŒŸ“˘. ˛X—ş•ă1, ‹{•”ä˜CŽ÷1, ‚‹´Œc‘ž1, “că_ˆę1, _‹{ŽiŒö“ń1 (1•úŽËü•”): “ú–{•úŽËü‹ZpŠw‰ď‘ć68‰ńŠÖ“ŒŽx•”Œ¤‹†”­•\‘ĺ‰ď (2021/11/27), ‰Ą{‰ę (ƒnƒCƒuƒŠƒbƒhŠJĂ), ‘ć68‰ńŠÖ“Œ•”‰ďŒ¤‹†”­•\‘ĺ‰ď´˜^W 2021; p.74-5.

733265. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) •W“I‚đ”z’u‚ľ‚˝3ŽŸŒłƒ|ƒŠƒ}[ƒQƒ‹ü—ĘŒv‚ĚŠî‘bŒŸ“˘. ]Œű@V1, —´–؉Á“ß1, ˆäăŠ˛‘ž2, …ăT–ç3, ‘OŽR‘ńĆ4, “n糗S‰î3 (1•úŽËü•”, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ÉqśŠw•”, 4—Šw•”): “ú–{•úŽËü‹ZpŠw‰ď‘ć68‰ńŠÖ“ŒŽx•”Œ¤‹†”­•\‘ĺ‰ď (2021/11/27), ‰Ą{‰ę (ƒnƒCƒuƒŠƒbƒhŠJĂ), ‘ć68‰ńŠÖ“Œ•”‰ďŒ¤‹†”­•\‘ĺ‰ď´˜^W 2021; p.82.

733266. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ‹óŠÔ–O˜aƒpƒ‹ƒX‚Ě“ÁŤ‚ÉŠÖ‚ˇ‚éŠî‘b“IŒŸ“˘. ‹´–{“N–ç1, ŹŒŠł‘ž˜Y1, `@”Ž•ś1 (1•úŽËü•”): “ú–{•úŽËü‹ZpŠw‰ď‘ć68‰ńŠÖ“ŒŽx•”Œ¤‹†”­•\‘ĺ‰ď (2021/11/28), ‰Ą{‰ę (ƒnƒCƒuƒŠƒbƒhŠJĂ), ‘ć68‰ńŠÖ“ŒŽx•”Œ¤‹†”­•\‘ĺ‰ď´˜^W 2021; p.112-3.

733267. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ‘•’uƒ[ƒJ‚¨‚ć‚ѐÎĽę‹­“x‚Ěˆá‚˘‚É‚¨‚Ż‚é‹óŠÔ–O˜aƒpƒ‹ƒX‚Ě“ÁŤ‚ÉŠÖ‚ˇ‚錟“˘. ‹´–{“N–ç1, ŹŒŠł‘ž˜Y1, `@”Ž•ś1 (1•úŽËü•”): “ú–{•úŽËü‹ZpŠw‰ď‘ć68‰ńŠÖ“ŒŽx•”Œ¤‹†”­•\‘ĺ‰ď (2021/11/28), ‰Ą{‰ę (ƒnƒCƒuƒŠƒbƒhŠJĂ), ‘ć68‰ńŠÖ“ŒŽx•”Œ¤‹†”­•\‘ĺ‰ď´˜^W 2021; p.113.

733268. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) MVCTĆ‡‚É‚¨‚Ż‚éŽB‰eđŒ‚ĆŽŠ“ŽĆ‡¸“x‚Ć‚ĚŠÖŒW. ‹î‘ş‘ž‹O1, Îă@–Ť1, ŒĂ‰ę—_Žj1, ‚“Ą—D‹P1, ‘ĺ–쐳’q1, ˆî“c—´Ži1 (1•úŽËü•”): “ú–{•úŽËü‹ZpŠw‰ď‘ć68‰ńŠÖ“ŒŽx•”Œ¤‹†”­•\‘ĺ‰ď (2021/11/28), ‰Ą{‰ę (ƒnƒCƒuƒŠƒbƒhŠJĂ), ‘ć68‰ńŠÖ“Œ•”‰ďŒ¤‹†”­•\‘ĺ‰ď´˜^W 2021; p.114.

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-522005. [uŔ]y“ÁW2: MRIŽş‚Ěƒqƒ„ƒŠEƒnƒbƒg‚đ‚‚Ԃš!zMRIŽB‰eŽş‚Ö‚Ě‘ĺŒ^‹­ŽĽŤ‘Ě‚ĚŽ‚żž‚Ý‚đ–h‚Ž‚˝‚ß‚É. `@”Ž•ś1, ˆäă —D‰î2 (1•úŽËü•”, 2•úŽËü (‰ć‘œ)): —Տ°‰ć‘œ 2021/3; 37 (3): 380-4.


–ňÜ•”

[Šwp˜_•ś]

110427. [Œ´’˜] Impact of overlapping risks of type 2 diabetes and obesity on coronavirus disease severity in the United States. Ando W1, Horii T1, Uematsu T2, Hanaki H3, Atsuda K1,4, Otori K1,2: Sci Rep 2021/9; 11 (1): 17968. (ˆŔ“Ą@q1, –xˆä„Žj1, Aź’”V2, ‰Ô–؏G–ž3, Œú“cKˆę˜Y1,4, ”ö’šŸ–ç1,2: 1–ňŠw•”, 2–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, 3–k—˘‘ĺŠw‘ĺ‘ş’q‹L”OŒ¤‹†Š, 4–ňÜ•”)

110428. [Œ´’˜] Development and validation of an equation to predict the incidence of coronary heart disease in patients with type 2 diabetes in Japan. Yamashita Y1, Inoue G1, Nozaki Y1, Kitajima R1, Matsubara K1,2, Horii T1, Mohri J1, Atsuda K1,3, Matsubara H1: BMC Res Notes 2021/11; 14 (1): 426. (ŽR‰şN–ç1, ˆäă@Šx1, –쓇_K1, –k“‡—˘“Ţ1, źŒ´@š1,2, –xˆä„Žj1, –Ń—˜‡ˆę1, Œú“cKˆę˜Y1,3, źŒ´@”Ł1: 1–ňŠw•”, 2AdvanceSoft Corporation, 3–ňÜ•”)

110429. [Œ´’˜] Acute kidney injury in Japanese type 2 diabetes patients receiving sodium-glucose cotransporter 2 inhibitors: A nationwide cohort study. Horii T1, Oikawa Y2, Kunisada N1, Shimada A2, Atsuda K1,3: J Diabetes Investig 2022/1; 13 (1): 42-6. (–xˆä„Žj1, ‹yě—mˆę2, ‘’ĺ‚Č‚é‚Ý1, “‡“c@˜N2, Œú“cKˆę˜Y1,3: 1–ňŠw•”, 2é‹Ęˆă‰Č‘ĺŠw“ŕ•Ş”ĺ“ŕ‰ČE“œ”A•a“ŕ‰Č, 3–ňÜ•”)

110430. [Œ´’˜] Venous thromboembolism risk factors and usefulness of a risk scoring system in lower limb orthopedic surgery: A case-control study in Japan. Akamine A1,2, Takahira N2,3, Kuroiwa M4, Tomizawa A1, Atsuda K1,5: Medicine (Baltimore) 2022/1; 101 (4): e28622. (Ô—䑏•F1,2, ‚•˝ŽL2,3, •Šâ­”V4, •yŕV@~1, Œú“cKˆę˜Y1,5: 1–ňÜ•”, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ÉqśŠw•”, 4–ƒŒ, 5–ňŠw•”)

110431. [Œ´’˜] Initial trough concentration may be beneficial in preventing linezolid-induced thrombocytopenia. Komatsu T1, Nakamura M1, Uchiyama K2,3, Inoue G3, Sakanoue K1, Kawamura A1, Hiratsuka K1, Takayama Y4, Takaso M3, Atsuda K1,5: J Chemother 2022/2; 1-6. doi: 10.1080/1120009X.2022.2043538. Online ahead of print. (Źź•q˛1, ’†‘ş”ü•ä1, “ŕŽRŸ•ś2,3, ˆäă@Œş3, â”Vă˜aŽŔ1, ě‘ş[Žj1, •˝’ËŒöŒČ1, ‚ŽR—zŽq4, ‚‘ŠťŽm3, Œú“cKˆę˜Y1,5: 1–ňÜ•”, 2ˆă—ĂˆŔ‘SEŠÇ—, 3ŽŠO, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 5–ňŠw•”)

110432. [Œ´’˜] Population Pharmacokinetic-Pharmacodynamic Target Attainment Analysis of Flomoxef in the Serum and Liver Tissue of Patients Undergoing Hepatic Resection. Komatsu T1, Tsumuraya S2, Takayama Y3, Kaizu T4, Okamoto M4, Tajima H4, Nishizawa N4, Kubo H4, Kumamoto Y4, Okamoto H5, Hanaki H6, Atsuda K1,2: Antimicrob Agents Chemother 2022/4; 66 (4): e0230321. doi: 10.1128/aac.02303-21. Epub 2022 Mar 21. (Źź•q˛1, š˘’J’q”ü2, ‚ŽR—zŽq3, ŠC’Ă‹MŽj4, ‰Ş–{ŒőŠóŽq4, “c“‡@O4, źŕVL‹ą4, ‹v•Ű”CŽj4, ŒGŒł—Y‰î4, ‰Ş–{_Žk5, ‰Ô–؏G–ž6, Œú“cKˆę˜Y1,2: 1–ňÜ•”, 2–ňŠw•”, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4ˆę”ʁEŹŽ™EŠĚ’_äXŠO, 5–ƒŒ, 6–k—˘‘ĺŠw‘ĺ‘ş’q‹L”OŒ¤‹†Š)

110433. [Œ´’˜] Evaluation of a carbapenem antimicrobial stewardship program and clinical outcomes in a Japanese hospital. Komatsu T1, Inagaki R2, Azuma S1, Mochida S1, Sato Y1, Seto Y1, Nihonyanagi S3, Hoshiyama T4, Wada T4, Takayama Y5, Atsuda K1,2: J Infect Chemother 2022/7; 28 (7): 884-9. doi: 10.1016/j.jiac.2022.03.006. Epub 2022 Mar 21. (Źź•q˛1, ˆîŠ_—ş—S2, “ŒM‘ž˜N1, Ž“cr–ç1, ˛“Ą—y—S1, ŁŒË—Ç‹ł1, “ń–{–öL3, ŻŽR—˛s4, ˜a“c’B•F4, ‚ŽR—zŽq5, Œú“cKˆę˜Y1,2: 1–ňÜ•”, 2–ňŠw•”, 3Š´őŠÇ—Žş, 4äPŒ´•aEŠ´ő“ŕ, 5V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)

120043. [Œ´’˜] ‘ĺ‹K–̓ŒƒZƒvƒgƒf[ƒ^ƒx[ƒX‚đ—p‚˘‚˝2Œ^“œ”A•aŠłŽŇ‚É‚¨‚Ż‚éSGLT2‘jŠQ–ň‚̐Ź•Ş•Ę‚É‚Ý‚˝—LŠQŽ–Ű”­ÇƒŠƒXƒN‚ĚŒŸ“˘. –xˆä„Žj1, š ’ĺ‚Č‚é‚Ý1, Œú“cKˆę˜Y1,2 (1–ňŠw•”, 2–ňÜ•”): ‚­‚ˇ‚č‚Ć“œ”A•a 2021/12; 10 (2): 197-208.

120044. [Œ´’˜] lH’m”\ (AI) ‚Ě‹@ŠBŠwK‚đŽg—p‚ľ‚˝ŒŒ’†–ň•¨”Z“x‚Ě—\‘ސŤ|NONMEMƒTƒ“ƒvƒ‹ƒf[ƒ^‚đ—p‚˘‚˝ƒpƒCƒƒbƒgƒXƒ^ƒfƒB|. Ź—яšG1, —F“c‹g‘Ľ1 (1–ňŠw•”): TDMŒ¤‹† 2021/12; 38 (4): 85-91.

220008. [€Œ´’˜]u‚“x–ňŠwŠÇ—‹@”\‚đ”­Šö‚ˇ‚é‚˝‚ß‚Ě–ň‹Ç–ňÜŽtŒ¤CƒvƒƒOƒ‰ƒ€ (‚Ş‚ń—Ěˆć)vŒ¤C“ú•ń‚ɑ΂ˇ‚éƒeƒLƒXƒgƒ}ƒCƒjƒ“ƒO•ŞÍ‚ĚŽŽ‚Ý. •wě‹M”Ž1, –Ń—˜‡ˆę1, â‘q’qŽq2, “ŒŽR—ĎŽq1, ˆî–ě@Š°2, •yŕV@~2, –{ŠÔ‰ëŽm2, Œú“cKˆę˜Y1,2 (1–ňŠw•”, 2–ňÜ•”): “ú–{–ňÜŽt‰ďŽGŽ 2021/4; 73 (4): 365-70.

220009. [€Œ´’˜] •a‰@–ňÜŽt‚ĚƒgƒŒ[ƒVƒ“ƒOƒŒƒ|[ƒgŠˆ—p‚ÉŠÖ‚ˇ‚éˆÓŽŻ’˛¸|ƒgƒŒ[ƒVƒ“ƒOƒŒƒ|[ƒg‚ĚŠˆ—p„i‚ÉŒü‚Ż‚ā|. •wě‹M”Ž1, •yŕV@~2, ’Ł@@’2, ˛X–Ř‘PM2, Vˆä–œ—Žq2, ‹g“cŽ”ü3, źŒ´@”Ł3, ‰Ą“cŒP’j4, ”ö’šŸ–ç2, Œú“cKˆę˜Y1,2 (1–ňŠw•”, 2–ňÜ•”, 3–k—˘‘ĺŠw–k—˘Œ¤‹†Š•a‰@, 4–k—˘‘ĺŠwƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[): “ú–{–ňÜŽt‰ďŽGŽ 2021/5; 73 (8): 837-41.

320029. [Ç—á•ń] ƒCƒgƒ‰ƒRƒiƒ][ƒ‹•ž—p‰ş‚ĹƒVƒNƒƒXƒ|ƒŠƒ“‚ĆDPP-4‘jŠQ–ň‚Ć‚Ě‘ŠŒÝě—p‚đŒoŒą‚ľ‚˝1Ç—á. ‹{“‡—ĽŽq1, “š‰ş—Y‰î2, ‰Ľ@‘c˝2, —é–Ř—˛_2, Œú“cKˆę˜Y1,3 (1–ňÜ•”, 2ŒŒ‰t“ŕ, 3–ňŠw•”): “ú–{•a‰@–ňÜŽt‰ďŽGŽ 2022/3; 58 (3): 313-7.

522591. [uŔ]y“ÁW: ƒ`[ƒ€ˆă—Ă‚É‚ć‚é“œ”A•aŠłŽŇ‚ĚŽx‰‡`‚ą‚ę‚Ü‚Ĺ‚Ć‚ą‚ę‚Š‚ç`zII ę–ĺE‚Ě—§ę‚Š‚ç@4. –ňÜŽt. ˆî–ě@Š°1, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”): ŒŽŠ§“œ”A•a 2021/4; 13 (4): 33-9.

522592. [uŔ]y“ÁW: 1Œ^“œ”A•aƒAƒbƒvƒf[ƒg`‚ť‚̐Źˆö‚Š‚玥—Â܂Ł`z12. 1Œ^“œ”A•a‚É‚¨‚Ż‚éƒCƒ“ƒXƒŠƒ“—Ă–@‚Ö‚ĚSGLT2‘jŠQ–ň•š—p‚ĚˆÓ‹`‚ĆŽŔŰ. –xˆä„Žj (–ňŠw•”): ŒŽŠ§“œ”A•a 2021/6; 13 (6): 75-80.

522593. [uŔ]ySymposium [Ŕ’k‰ď]zCRC‚̉ߋŽEŒťÝE–˘—ˆ@Vol.2:uCRC‚ ‚č•ű‰ď‹cv‚Ě‚ą‚ę‚܂ł𒆐S‚É. ’†–ěds1, —é–Řçœ¨Žq2, ˆŔ“ĄKŽq3, ‘ĺ–쏹”ü4, ‘O“cŽŔ‰Ô5 (1‘ĺ•Ş‘ĺŠw, 2•lźˆă‰Č‘ĺŠwˆăŠw•”•‘Ž•a‰@—Տ°Œ¤‹†ƒZƒ“ƒ^[, 3(Š”) ƒ~ƒjƒ}ƒ‹—Տ°Œ¤‹†Žx‰‡•”, 4ƒVƒ~ƒbƒNƒwƒ‹ƒXƒPƒAEƒCƒ“ƒXƒeƒBƒeƒ…[ƒg (Š”), 5–ňÜ•”): Clinical Research Professionals 2021/11; 85: 14-27.

522594. [uŔ]y“ÁW: –ňŠw“IŠÇ—‚ÉŠˆ‚Š‚ˇ! —Տ°–ň—UPDATE 2022z2Œ^“œ”A•aŽĄ—Ă–ň (ƒCƒƒOƒŠƒ~ƒ“). ˆî–ě@Š° (–ňÜ•”): ’˛Ü‚Əî•ń 2022/1; 28 (1): 16-21.

540053. [‚ť‚Ě‘ź (ƒKƒCƒhƒ‰ƒCƒ“)] R‹Ű–ňTDM—Տ°ŽŔ‘HƒKƒCƒhƒ‰ƒCƒ“2022 ’|–––Fś, –Ř‘ş—˜”ü, źŒłˆę–ž, –ÎŒŠˆŠ—˘, “Y“c@”Ž, ‚‹´‰ŔŽq, ’ҁ@‘׍O, ’†”n^K, ’O‰H@—˛, ‰Ôˆä—Y‹M, “Ą‹@ŒŤ, ^‹|r•F, ŻŽiŒ’‰î, ě‘ş‰pŽ÷, ”ö“cˆę‹M, ‘“c’qć, ’r“cŒŤ“ń, ŽR“c’q”V, ‰Á“Ą—˛Ž™, ŽR–{•l, ’–ě˜a˜N, Ź—яšG1, •l“cKG, Ž›“c’q—S (1–ňŠw•”): “ú–{‰ťŠw—Ă–@Šw‰ďŽGŽ 2022/1; 70 (1): 1-72.

540054. [‚ť‚Ě‘ź (ƒKƒCƒhƒ‰ƒCƒ“)] R‹Ű–ňTDM—Տ°ŽŔ‘HƒKƒCƒhƒ‰ƒCƒ“2022. ’|–––Fś, –Ř‘ş—˜”ü, źŒłˆę–ž, –ÎŒŠˆŠ—˘, “Y“c@”Ž, ‚‹´‰ŔŽq, ’ҁ@‘׍O, ’†”n^K, ’O‰H@—˛, ‰Ôˆä—Y‹M, A“Ą‹@ŒŤ, ^‹|r•F, ŻŽiŒ’‰î, ě‘ş‰pŽ÷, ”ö“cˆę‹M, ‘“c’qć, ’r“cŒŤ“ń, ŽR“c’q”V, ‰Á“Ą—˛Ž™,ŽR–{•l, ’–ě˜a˜N, Ź—яšG1, •l“cKG, Ž›“c’q—S (1–ňŠw•”): TDMŒ¤‹† 2022/3; 39 (1): 35-106.

[’˜@‘]

620162. [Šwp‘ (•Ş’SŽˇ•M)]yŒťę‚ĹŽg‚Ś‚é‚­‚ˇ‚č‚Ě’mŽŻ (ƒGƒLƒXƒp[ƒgƒi[ƒX‘Š§†)z“Š—^Žž‚ĚŠĎŽ@‚Ćƒ^ƒCƒ~ƒ“ƒO@ƒIƒsƒIƒCƒh’Á’É–ň (‚Ş‚ńŤáu’É), p.54-71. •˝ŽR•Ži1,2, ě–ěçq1,2 (1–ňÜ•”, 2–ňŠw•”), Ć—ŃŽĐ, “Œ‹ž, 2021/4”­s.

620163. [Šwp‘ (•Ş’SŽˇ•M)]y•a‹C‚Ć‚­‚ˇ‚č2021@Šî‘b‚ĆŽŔ‘H Expert's Guide (–ň‹Ç2021”N‘Š§ Vol.72 No.4)z1 ¸_E_ŒoŒn‚Ě•a‹C‚Ć‚­‚ˇ‚č@B ’†•ŒnŽžŠł@E•s–°, •s–°Ç|ŽĄ—Ă–ň‚Ě–ň—‚Ć–ňŠwŠÇ—ă‚Ě’ˆÓ“_|, p.614-34. Ô—ä‚ż‚Š]1, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”), “ěŽR“°, “Œ‹ž, 2021/4”­s.

620164. [Šwp‘ (•Ş’SŽˇ•M)]y•a‹C‚Ć‚­‚ˇ‚č2021@Šî‘b‚ĆŽŔ‘H Expert's Guide (–ň‹Ç2021”N‘Š§ Vol.72 No.4)z7 ‘ăŽÓ“ŕ•Ş”ĺŒn‚Ě•a‹C‚Ć‚­‚ˇ‚č@A ‘ăŽÓŒnŽžŠł@“œ”A•a (‡•šÇ‚đŠÜ‚Ţ)|ŽĄ—Ă–ň‚Ě–ň—‚Ć–ňŠwŠÇ—ă‚Ě’ˆÓ“_|, p.918-33. Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”), “ěŽR“°, “Œ‹ž, 2021/4”­s.

620165. [Šwp‘ (•Ş’SŽˇ•M)]yVˆá‚˘‚Ş‚í‚Š‚é! “ŻŽíE“ŻŒř–ň (ăŠŞ)zChapter 08 ‡–°–ň, p.107-21. Ô—ä‚ż‚Š]1, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”), •ŇWF•ŽR­ˆę, ‘ĺ’J“š‹P, “ě]“°, “Œ‹ž, 2021/7”­s.

620166. [Šwp‘ (•Ş’SŽˇ•M)]yVˆá‚˘‚Ş‚í‚Š‚é! “ŻŽíE“ŻŒř–ň (ăŠŞ)zChapter 10 R‚¤‚–ň, p.137-49. ”ň“c—[‹I (–ňÜ•”), •ŇWF•ŽR­ˆę, ‘ĺ’J“š‹P, “ě]“°, “Œ‹ž, 2021/7”­s.

620167. [Šwp‘ (•Ş’SŽˇ•M)]yVˆá‚˘‚Ş‚í‚Š‚é! “ŻŽíE“ŻŒř–ň (‰şŠŞ)zChapter 19 ƒp[ƒLƒ“ƒ\ƒ“•aŽĄ—Ă–ň, p.65-77. ź‰Ş—zŽq1, •˝ŽR•Ži1,2 (1–ňÜ•”, 2–ňŠw•”), •ŇWF•ŽR­ˆę, ‘ĺ’J“š‹P, “ě]“°, “Œ‹ž, 2021/7”­s.

620168. [Šwp‘ (•Ş’SŽˇ•M)]yVˆá‚˘‚Ş‚í‚Š‚é! “ŻŽíE“ŻŒř–ň (‰şŠŞ)zChapter 20 R”F’mÇ–ň, p.78-87. ”ň“c—[‹I1, •˝ŽR•Ži1,2 (1–ňÜ•”, 2–ňŠw•”), •ŇWF•ŽR­ˆę, ‘ĺ’J“š‹P, “ě]“°, “Œ‹ž, 2021/7”­s.

620169. [Šwp‘ (•Ş’SŽˇ•M)]y“ď‚ľ‚˘”ŽŽ‚ŕ, TDM‚ŕ‚í‚Š‚ç‚Č‚˘!uƒjƒKƒe‚ł‚ńv‚Ě‚˝‚ß‚Ě–ň•¨“Ž‘Ô (’˛Ü‚Əî•ń2021”N7ŒŽ‘Š§)z‘ć4Í ŠłŽŇ”wŒi‚É‚ć‚éADME‚̕ωť‚É’–Ú‚Ĺ‚Ť‚é!@”ě–žŠłŽŇE‚邢‘‰ŠłŽŇ‚Ě–ň•¨“Ž‘Ô, p.79-87. Ź—яšG (–ňŠw•”), •Ň: ŽR–{•l, ‚ś‚Ů‚¤, “Œ‹ž, 2021/7”­s.

620170. [Šwp‘ (•Ş’SŽˇ•M)]y–ň‚Ě“Á’ĽEˆ•ű‚Ěƒ|ƒCƒ“ƒgEƒCƒ“ƒXƒŠƒ“ƒ|ƒ“ƒv—Ă–@‚Ş‚í‚Š‚é!I@“œ”A•a‚Ě‚­‚ˇ‚č “O’ęƒiƒrƒQ[ƒgBOOK (“œ”A•aƒPƒA2021”NH‹G‘Š§)z‘ć2Í ƒCƒ“ƒXƒŠƒ“ťÜ@6 ’†ŠÔŒ^ƒCƒ“ƒXƒŠƒ“ťÜ‚ĚŽg‚˘‚Š‚˝, p.114-8. Ÿ˜C”ü1, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”), •Ň: •“Ą’B–ç, ƒƒfƒBƒJo”Ĺ, ‘ĺă, 2021/9”­s.

620171. [Šwp‘ (•Ş’SŽˇ•M)]y–ň‚Ě“Á’ĽEˆ•ű‚Ěƒ|ƒCƒ“ƒgEƒCƒ“ƒXƒŠƒ“ƒ|ƒ“ƒv—Ă–@‚Ş‚í‚Š‚é!!@“œ”A•a‚Ě‚­‚ˇ‚č “O’ęƒiƒrƒQ[ƒgBOOK (“œ”A•aƒPƒA2021”NH‹G‘Š§)z‘ć2Í ƒCƒ“ƒXƒŠƒ“ťÜ@8 Ź‡Œ^ƒCƒ“ƒXƒŠƒ“ťÜ‚ĚŽg‚˘‚Š‚˝, p.124-9. Ÿ˜C”ü1, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”), •Ň: •“Ą’B–ç, ƒƒfƒBƒJo”Ĺ, ‘ĺă, 2021/9”­s.

620172. [Šwp‘ (•Ş’SŽˇ•M)]y‚ą‚ę‚ŞŽ„‚Ě–ňÜŽtƒ‰ƒCƒt`6”Nś‘˛50l‚ރLƒƒƒŠƒA‚đŒę‚é` (“úŒoDIƒLƒƒƒŠƒA)z•a‹C‚ĚŽq‚Ç‚ŕ‚ƉƑ°‚̏Ωç‚Ě‚˝‚ߏŹŽ™–ň•¨—Ă–@‚̐ę–名ś‚Š‚ľ“úXƒ`ƒƒƒŒƒ“ƒW. Źě—˛O (–ňÜ•”), “úŒoHR, “Œ‹ž, 2021/9WEBŒfÚ.

620173. [Šwp‘ (•Ş’SŽˇ•M)]y“ü‰@‚Š‚ç‘މ@‚Ü‚Ĺ‚Ěƒ`ƒƒ[ƒg‚ĹŠw‚ԁ@ŽŒ`ŠO‰Č•a“‚̏pŽŽ•ĘƒPƒAƒ}ƒjƒ…ƒAƒ‹ (ŽŒ`ŠO‰ČŠĹŒě2021”NH‹G‘Š§)z[1Í] ‘˜_@B ŽŒ`ŠO‰ČŠłŽŇ‚Ě‹C‚đ‚‚Ż‚˝‚˘ŽŽQ–ň, p.12-5. Ô—䑏•F (–ňÜ•”), •Ň: ‚•˝ŽL (ˆă—ÉqśŠw•”), ƒƒfƒBƒJo”Ĺ, “Œ‹ž, 2021/10”­s.

620174. [Šwp‘ (•Ş’SŽˇ•M)]yĄ“ú‚ĚŽĄ—ĂŽwj2022”N”Łz‘˜_@11 ‘ăŽÓŽžŠł, p.738, 744, 758. Œú“cKˆę˜Y1,2 (1–ňŠw•”, 2–ňÜ•”), ‘•ŇW: •ŸˆäŽŸ–î, ‚–؁@˝, ŹŽşˆęŹ, ˆăŠw‘‰@, “Œ‹ž, 2022/1”­s.

620175. [Šwp‘ (•Ş’SŽˇ•M)]yŽĄ—Ă–ňƒnƒ“ƒhƒuƒbƒN2022z–ňÜƒŠƒXƒg•Ň, p.648-79. Œú“cKˆę˜Y1,2 (1–ňŠw•”, 2–ňÜ•”), ŠÄC: ‚‹vŽj–›, •Ň: –xł“ń, ›–ěŒ’‘ž˜Y, –ĺ˜e@F, ŠŁ@ŒŤˆę, —с@š—m, ‚ś‚Ů‚¤, “Œ‹ž, 2022/1”­s.

620176. [Šwp‘ (•Ş’SŽˇ•M)]yŽĄ—Ă–ňƒnƒ“ƒhƒuƒbƒN2022z–ň•¨“Ž‘Ô”äŠr•\, p.23-5, p.50, p.80, p.107, p.140, p.156, p.198, p.326, p.377-80, p.464-5, p.489, p.536-7, p.647, p.686, p.768, p.806, p.820, p.924-5, p.1145, p.1160, p.1191-2, p.1244, p.1298. •˝ŽR•Ži1, ”ň“c—[‹I2, ě–ěçq2, •ŽR­ˆę3 (1–ňŠw•”, 2–ňÜ•”, 3Œł“Œ•a‰@–ňÜ•”), ŠÄC: ‚‹vŽj–›, •Ň: –xł“ń, ›–ěŒ’‘ž˜Y, –ĺ˜e@F, ŠŁ@ŒŤˆę, —с@š—m, ‚ś‚Ů‚¤, “Œ‹ž, 2022/1”­s.

620177. [Šwp‘ (•Ş’SŽˇ•M)]yƒi[ƒVƒ“ƒOƒOƒ‰ƒtƒBƒJ@Žž•a‚̐Ź‚č—§‚ż@—Տ°–ň—Šwz4 ”]E’†•_ŒoŒnŽžŠł‚ĹŽg—p‚ˇ‚é–ň, p.94-129. _@ˆę–˛ (–ňÜ•”), •Ň: ŒĂě—T”V, ÔŁ’qŽq, —ѐłŒ’“ń, ‘吟O‚, ƒƒfƒBƒJo”Ĺ, “Œ‹ž, 2022/1”­s.

620178. [Šwp‘ (•Ş’SŽˇ•M)]yPocket Drugs 2022zŠŕŽĄ—ĂŠÖ˜A–ň@64 ‘ăŽÓhR–ň, p.504-18. ‰Ş–{Œb”üŽq1, Źň˜aŽO˜Y2 (1–ňÜ•”, 2–k—˘‘ĺŠw–ź—_‹łŽö), ŠÄC: •ŸˆäŽŸ–î, •Ň: ŹźNG, “n糗TŽi, ˆăŠw‘‰@, “Œ‹ž, 2022/1”­s.

620179. [Šwp‘ (•Ş’SŽˇ•M)]yŽw“ąƒ|ƒCƒ“ƒg‚𑨂Ś‚˝–ňŠwś•a‰@ŽŔ–ąŽŔKŽw“ą‘ 2018‰ü’ů”Łz‘ć8Í ‚Ş‚ń‰ťŠw—Ă–@, p.225-42. –Ń—˜‡ˆę1,2 (1–ňŠw•”, 2–ňÜ•”), •Ň: ‹ŕ“cŒőł, “n粁@“O, –ňŽ–“ú•ńŽĐ, “Œ‹ž, 2022/2”­s.

620180. [Šwp‘ (•Ş’SŽˇ•M)]y—Տ°Žx‰‡ƒAƒvƒŠHOKUTOz‰ťŠw—Ă–@ƒŒƒWƒƒ“ (ŒŒ‰t“ŕ‰Č). ‹{“‡—ĽŽq (–ňÜ•”), ŠÄC: î‰Ž‘ĺ•ă, HOKUTO, “Œ‹ž, 2021/8-2022/1ŒfÚ.

620181. [Šwp‘ (•Ş’SŽˇ•M)]y‚¨–ň—§‚żBOOK2022@‰đ–Uś—E•a‘Ԑś—‚Š‚ç–ňŠwŠÇ—‚Ö (–ň‹Ç2022”N‘Š§ Vol.73 No.4)zĄ‘ăŽÓŒn, “ŕ•Ş”厞Šł@30 “œ”A•a (1Œ^“œ”A•a, 2Œ^“œ”A•a, ”DP“œ”A•a, ‡•šÇ), p.547-74. ˆî–ě@Š°1, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”), ŠÄC: —é–ŘŠ˛‘ž, •Ň: ‘şˆäŒb”ü, “ěŽR“°, “Œ‹ž, 2022/3”­s.

620182. [Šwp‘ (•Ş’SŽˇ•M)]y‚¨–ň—§‚żBOOK2022@‰đ–Uś—E•a‘Ԑś—‚Š‚ç–ňŠwŠÇ—‚Ö (–ň‹Ç2022”N‘Š§ Vol.73 No.4)zĄ‚Ş‚ńEŽxŽ—Ă–@@66 ‘O—§‘BŠŕ, p.932-5. ŽR–{—IŽ÷1, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”), ŠÄC: —é–ŘŠ˛‘ž, •Ň: ‘şˆäŒb”ü, “ěŽR“°, “Œ‹ž, 2022/3”­s.

620183. [Šwp‘ (•Ş’SŽˇ•M)]y—Տ°HŠw‹ZŽm•W€ƒeƒLƒXƒg ‘ć4”Łz‘ć1•Ň ę–ĺŠî‘b‰Č–ځ@I. ˆăŠwŠT˜_@E. –ň—Šw, p.69-84. â‘q’qŽq (–ňÜ•”), •Ň: Ź–ě“NÍ, –xě@”V, •ô“‡ŽOç’j, ‹g–ěG˜N, ‹ŕŒ´o”Ĺ, “Œ‹ž, 2022/3”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713058. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Risk Factor for COVID-19 Infection-Related Hospitalization in Patients with Type 2 Diabetes. Horii T1, Oikawa Y2, Shimada A2, Atsuda K1,3: ADA 81h Scientific Session (2021/6/25-29), WebŠJĂ. (–xˆä„Žj1, ‹yě—mˆę2, “‡“c@˜N2, Œú“cKˆę˜Y1,3: 1–ňŠw•”, 2é‹Ęˆă‰Č‘ĺŠw“ŕ•Ş”ĺ“ŕ‰ČE“œ”A•a“ŕ‰Č, 3–ňÜ•”)

713059. [Šw‰ď (‘Ű)] (ƒ|ƒXƒ^[) Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 4, with combined neurokinin-1 receptor antagonist, palonosetron, and olanzapine in patients receiving cisplatin-containing highly emetogenic chemotherapy: SPARED Trial. Shimomura K, Minatogawa H, Mashiko T, Arioka H, Iihara H, Sugawara M1,2, Hida N, Akiyama K, Nawata S, Tsuboya A, Mishima K, Izawa N, Miyaji T, Honda K, Inada Y, Ohno Y, Katada C3, Morita H, Yamaguchi T, Nakajima TE: ESMO congress 2021 (2021/9/17), WebŠJĂ. (›Œ´[L1,2, Œ˜“ce—˜3: 1–ňÜ•”, 2–ňŠw•”, 3Á‰ťŠí“ŕ)

722321. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “ú–{ŠO‰ČŠ´őÇŠw‰ďÁ‰ťŠíŠO‰ČSSI—\–h‚Ě‚˝‚ß‚ĚŽüpŠúŠÇ—ƒKƒCƒhƒ‰ƒCƒ“ěŹ‰ß’ö. ^‹|r•F1, ‘ĺ–эGŠě1, “ŕ–ě@Šî1, –kě—Yˆę1, Ź—яšG1,2, Ź—с@‹1, â–{Žjˆß1, ´…ŽO1, —é–؍Ž“T1, “yŽt˝“ń1, …Œű@“O1, –Ń—˜–ő•F1, ŽR‰şç’ß1, ‹g“c‰ë”Ž1, ‘’nM–ç1 (1“ú–{ŠO‰ČŠ´őÇŠw‰ďÁ‰ťŠíŠO‰ČSSI—\–h‚Ě‚˝‚ß‚ĚŽüpŠúŠÇ—ƒKƒCƒhƒ‰ƒCƒ“ěŹƒ[ƒLƒ“ƒOƒOƒ‹[ƒv, 2–ňŠw•”): ‘ć46‰ń“ú–{ŠO‰ČŒn˜A‡Šw‰ďŠwpW‰ď (2021/6/18), WebŠJĂ, “ú–{ŠO‰ČŒn˜A‡Šw‰ďŽ 2021/5; 46 (3): 321.

722322. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) –ň•¨“Ž‘Ô‰đÍƒ\ƒtƒgƒEƒFƒA‚Ě“Á’Ľ‚ĆŠˆ—p‚ÉŠÖ‚ˇ‚郊ƒeƒ‰ƒV[. Ź—яšG (–ňŠw•”): ˆă—Ă–ňŠwƒtƒH[ƒ‰ƒ€2021/‘ć29‰ńƒNƒŠƒjƒJƒ‹ƒtƒ@[ƒ}ƒV[ƒVƒ“ƒ|ƒWƒEƒ€ (2021/7/24), WebŠJĂ, ˆă—Ă–ňŠwƒtƒH[ƒ‰ƒ€u‰‰—vŽ|W 2021/7; 29th: 120.

722323. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “œ”A•aŠłŽŇ‚É‚¨‚Ż‚éƒ|ƒŠƒtƒ@[ƒ}ƒV[‰đÁ‚ĚŽŔ‘H|—vˆö‰đÍ‚đ—p‚˘‚˝‰î“üŽč–@‚đ—p‚˘‚ā|. –xˆä„Žj (–ňŠw•”): ‘ć9‰ń“ú–{‚­‚ˇ‚č‚Ć“œ”A•aŠw‰ďŠwpW‰ď (2021/9/11-12), WebŠJĂ.

722324. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ‘ĺ‹K–͈ă—Ăƒf[ƒ^‚đŠˆ—p‚ľ‚˝“œ”A•aƒKƒCƒhƒ‰ƒCƒ“‚ĚŒŸŘ. –xˆä„Žj (–ňŠw•”): ‘ć31‰ń“ú–{ˆă—Ă–ňŠw‰ď”N‰ď (2021/10/9-10), WebŠJĂ.

722325. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) —Տ°ŒŸ¸’l‚ÉŠî‚Ă‚­“œ”A•aŽĄ—Ă–ň‚Ě“KłŽg—p. –xˆä„Žj (–ňŠw•”): ‘ć31‰ń“ú–{ˆă—Ă–ňŠw‰ď”N‰ď (2021/10/9-10), WebŠJĂ.

722326. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) –k—˘‘ĺŠw•a‰@‚É‚¨‚Ż‚é–ňÜŽtƒŒƒWƒfƒ“ƒg‹łˆç‚Ö‚ĚŽć‚č‘g‚Ý. â‘q’qŽq (–ňÜ•”): ‘ć11‰ń“ú–{–ňÜŽtƒŒƒWƒfƒ“ƒgƒtƒH[ƒ‰ƒ€ (2021/11/6), WebŠJĂ.

722327. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) tˆÚA‚ĚŒťó –Ɖu—}§–ň‚É‚ć‚éŠÇ—. Ź—яšG (–ňŠw•”): ‘ć30‰ń“ú–{t•s‘SŠO‰ČŒ¤‹†‰ďŠwpW‰ď (2021/12/4), “ß”e (ƒnƒCƒuƒŠƒbƒhŠJĂ), ‘ć30‰ń“ú–{t•s‘SŠO‰ČŒ¤‹†‰ďŠwpW‰ď—vŽ|W 2021/12; 30th: Web.

723737. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) MRSA‚ɑ΂ˇ‚錌’†”Z“xƒVƒ~ƒ…ƒŒ[ƒ^[‚đ—p‚˘‚˝ST‡ÜƒŠƒtƒ@ƒ“ƒsƒVƒ“•š—p—Ă–@‚ĚŒŸ“˘. ’†‘şłŽ÷1, —F“c‹g‘Ľ2, Ź—яšG2, ‰Ô–؏G–ž3, –k—˘‰p˜Y1 (1ˆă—ÉqśŠw•”, 2–ňŠw•”, 3–k—˘‘ĺŠw‘ĺ‘ş‹L”OŒ¤‹†ŠŠ´ő§ŒäŒ¤‹†ƒZƒ“ƒ^[): ‘ć95‰ń“ú–{Š´őÇŠw‰ďŠwpu‰‰‰ď^‘ć69‰ń“ú–{‰ťŠw—Ă–@Šw‰ď‘‰ď‡“ŻŠw‰ď (2021/5/7-9), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{‰ťŠw—Ă–@Šw‰ďŽGŽ 2021/4; 69 (Suppl): 232.

723738. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ƒvƒŒƒKƒoƒŠƒ“‚Š‚çƒ~ƒƒKƒoƒŠƒ“‚ւ̐؂č‘Ö‚ŚÇ—á‚É‚¨‚Ż‚é’†•_ŒoŒnŠÖ˜A—LŠQŽ–Ű‚ÉŠÖ‚ˇ‚錟“˘. •“š—Á•˝1, –{ŠÔ‰ëŽm1, •˝’ËŒöŒČ1, ‘ž“c’q”Ž1, •˝ŽR•Ži1,2, —с@Œol3, ‹ŕˆäş•ś3,4, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”, 3–ƒŒ, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): ‘ć14‰ń“ú–{ŠÉ˜aˆă—Ă–ňŠw‰ď”N‰ď (2021/5/13-16), WebŠJĂ.

723739. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‘ĺ‹K–̓ŒƒZƒvƒgƒf[ƒ^ƒx[ƒX‚đ—p‚˘‚˝SGLT2‘jŠQ–ň‚đV‹K“Š—^‚ľ‚˝‚—î2Œ^“œ”A•aŠłŽŇ‚É‚¨‚Ż‚édÇ’ጌ“œ”­ÇƒŠƒXƒN‚ĚŒŸ“˘. –xˆä„Žj1, Œú“cKˆę˜Y1,2 (1–ňŠw•”, 2–ňÜ•”): ‘ć64‰ń“ú–{“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (2021/5/20-22), WebŠJĂ.

723740. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‘ĺ‹K–̓ŒƒZƒvƒgƒf[ƒ^ƒx[ƒX‚É‚ć‚éSGLT2‘jŠQ–ň‚Ş“Š—^‚ł‚ę‚˝“œ”A•aŠłŽŇ‚É‚¨‚Ż‚é“œ”A•aƒPƒgƒAƒVƒh[ƒVƒX”­ÇƒŠƒXƒN‚ĚŒŸ“˘. –xˆä„Žj1, Œú“cKˆę˜Y1,2 (1–ňŠw•”, 2–ňÜ•”): ‘ć9‰ń“ú–{‚­‚ˇ‚č‚Ć“œ”A•aŠw‰ďŠwpW‰ď (2021/9/11-12), WebŠJĂ.

723741. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) Evaluation of bendamustine-induced CINV and efficacy of aprepitant. ‹{“‡—ĽŽq1, Š™“c_–Ť2, —é–Ř—˛_2, Œú“cKˆę˜Y1,3 (1–ňÜ•”, 2ŒŒ‰t“ŕ, 3–ňŠw•”): ‘ć83‰ń“ú–{ŒŒ‰tŠw‰ďŠwpW‰ď (2021/9/23-25), WebŠJĂ.

723742. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‰ş•”Á‰ťŠÇŽčp‚É‚¨‚Ż‚éƒZƒtƒƒ^ƒ][ƒ‹‚ĚŒŒ’†”Z“x‚Ć’°ŠÇŽ‰–b”Z“x‚Ć‚ĚŠÖŒWŤ`•”ˆĘ“ÁˆŮ“I PK-PD ‰đÍ‚đ“Ľ‚Ü‚Ś‚ā`. Źź•q˛1, X“c”Ü“ěŽq2, ‚ŽR—zŽq3,4, ‰Ä–Ú—Sˆß5, —F“c‹g‘Ľ2, ’†‘ş—˛r6, ‰Ô–؏G–ž7, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”, 3Š´őŠÇ—Žş, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 5“Œ‹žˆă‰ČŽ•‰Č‘ĺŠwˆăŠw•”•‘Ž•a‰@–ňÜ•”, 6ŕՋŚˆă‰Č‘ĺŠw‘ćˆęŠO‰Č, 7–k—˘ś–˝‰ČŠwŒ¤‹†Š): ‘ć31‰ń“ú–{ˆă—Ă–ňŠw‰ď”N‰ď (2021/10/9-10), WebŠJĂ.

723743. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) •a‰@–ňÜŽtEˆő‹łˆçƒVƒXƒeƒ€‚̍\’z (‘ć2•ń)|–ňÜŽt”ĹƒNƒŠƒjƒJƒ‹ƒ‰ƒ_[ěŹ‚É‚¨‚Ż‚éƒnƒCƒp[ƒtƒH[ƒ}[‘œ‚ĚŒŸ“˘|. ŹŽRˆč”ü1, ˆî–ě@Š°1, •wě‹M”Ž2, â‘q’qŽq1, ‹ß“Ą—Ż”üŽq1, ’JŒű—zŽq3, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”, 3ŠĹŒě•”): ‘ć31‰ń“ú–{ˆă—Ă–ňŠw‰ď”N‰ď (2021/10/9-10), WebŠJĂ.

723744. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) 2Œ^“œ”A•aŠłŽŇ‚ĚŠĽ“Ž–ŹŤSŽžŠł”­Ç—Ś—\‘ŞŽŽ‚ĚŠJ”­‚¨‚ć‚ŃŒŸŘ. ŽR‰şN–ç1, ˆäă@Šx1, –쓇_K1, –k“‡—˘“Ţ1, źŒ´@š2, –xˆä„Žj1, –Ń—˜‡ˆę1,3, Œú“cKˆę˜Y1,3, źŒ´@”Ł1 (1–ňŠw•”, 2AdvanceSoft Corporation, 3–ňÜ•”): ‘ć31‰ń“ú–{ˆă—Ă–ňŠw‰ď”N‰ď (2021/10/9-10), WebŠJĂ.

723745. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) –ň“Ĺ•¨‚Ě•¨—‰ťŠw“IŤŽż‚ÉŠî‚Ă‚­ŠˆŤ’Y‚Ě“K‰ž—\‘Ş. —F“c‹g‘Ľ1, Ź—яšG1 (1–ňŠw•”): ‘ć43‰ń“ú–{’†“ĹŠw‰ď‘‰ďEŠwpW‰ď (2021/10/15), ŽăŠJĂ, ’†“ĹŒ¤‹† 2021/1; 34 (3): 221.

723746. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Řœ•s”\‚ČŠĚ×–EŠŕ‚ĚLenvatinib—Ă–@‚ɑ΂ˇ‚éˆęŽ_‰ť’‚‘f‡Źy‘fŠˆŤ‚̉e‹ż. ě‘ş[Žj1, ‹›“ˆ°‹I2, ’†”n@˝3 (1–ňÜ•”, 2Á‰ťŠí“ŕ, 3‰Ą•lŽs—§‘ĺŠw•t‘ŽŽs–Ż‘‡ˆă—ĂƒZƒ“ƒ^[): ‘ć29‰ń“ú–{Á‰ťŠíŠÖ˜AŠw‰ďTŠÔ (JDDW 2021 KOBE) (2021/11/4-7), _ŒË (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723747. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒIƒ“ƒ‰ƒCƒ“‚đŠˆ—p‚ľ‚˝‘ŰŒđ—ŹƒvƒƒOƒ‰ƒ€‚ĚŽŽ‚Ý. ˆî–ě@Š°1, ŽR–{—IŽ÷1, ŹŽRˆč”ü1, •wě‹M”Ž2, –Ń—˜‡ˆę1,2, ŠâŕV^‹IŽq2, â‘q’qŽq1, ‹ß“Ą—Ż”üŽq1, éŒË˜a•F3, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”, 3ƒEƒGƒXƒgƒo[ƒWƒjƒA‘ĺŠw–ňŠw•”): ‘ć11‰ń“ú–{–ňÜŽtƒŒƒWƒfƒ“ƒgƒtƒH[ƒ‰ƒ€ (2021/11/6), WebŠJĂ.

723748. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) –k—˘‘ĺŠw•a‰@‚É‚¨‚Ż‚éˆă—Ă—p–ƒ–ň‚Ě”pŠüó‹ľ‚ĆÄ—˜—p‚É‚ć‚éŒoĎŒř‰Ę‚ĚŒŸŘ. ŹŒ´Ř”ü1, â”Vă˜aŽŔ1, ‹{â—Dl1, ˆî–ě@Š°1, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”): ‘ć11‰ń“ú–{–ňÜŽtƒŒƒWƒfƒ“ƒgƒtƒH[ƒ‰ƒ€ (2021/11/6), WebŠJĂ.

723749. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ‚¤‚•aŠłŽŇ‚É‚¨‚Ż‚éƒxƒ“ƒ]ƒWƒAƒ[ƒsƒ“Œn–ňÜ‚ĚŒ¸–ňEŒ¸—Ę‚ľ‚˝Ç—á‚ɂ‚˘‚Ä. MŒŠ•S‘ă1, Ÿ“c‹ą•˝1, ‹ß“Ą—Ż”üŽq1, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”): ‘ć11‰ń“ú–{–ňÜŽtƒŒƒWƒfƒ“ƒgƒtƒH[ƒ‰ƒ€ (2021/11/6), WebŠJĂ.

723750. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) ”A˜Hă”çŠŕŠłŽŇ‚É‚¨‚Ż‚éGN—Ă–@‚ĚNedaplatin—p—Ę‘Ă“–Ť‚Ě•]‰ż. ŽR–{—IŽ÷1, ˆî–ě@Š°1, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”): ‘ć15‰ń“ú–{t‘Ÿ•a–ň•¨—Ă–@Šw‰ďŠwpW‰ďE‘‰ď2021 (2021/11/6-7), WebŠJĂ.

723751. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) p‘O‹x–ň‚ĚˆŔ‘S‚ȉ^—p‚ÉŒü‚Ż‚˝Žć‚č‘g‚Ý (‘ć2•ń)|Patient Flow Management (PFM) ‚Ö‚Ě–{‰^—p‚Ě‘g‚ݍž‚݁|. _@ˆę–˛1, ’Ă‘şGN2, ‰ş•lF˜Y3, Źň–ƒ”ü4, •yŕV@~5, rˆä—L”ü1, “ŕŽRŸ•ś1,6, ˆ˘ŒĂĆ3 (1ˆă—Ă‚ĚŽżEˆŔ‘S„iŽş, 2”ĺ”AŠí, 3zŠÂŠí“ŕ, 4f—Ïî•ńŠÇ—Žş, 5–ňÜ•”, 6ˆă—ĂˆŔ‘SEŠÇ—): ‘ć16‰ńˆă—Ă‚ĚŽżEˆŔ‘SŠw‰ďŠwpW‰ď (2021/11/27-28), WebŠJĂ, ˆă—Ă‚ĚŽżEˆŔ‘SŠw‰ďŽ 2021/11; 16 (Suppl): 262.

723752. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) –k—˘‘ĺŠw•a‰@‚É‚¨‚Ż‚é—Տ°Œ¤‹†ŠÇ—‘̐§‚̍\’z: ‘ź‹@ŠÖ‚Ě”F’č—Տ°Œ¤‹†R¸ˆĎˆő‰ď/—Ď—R¸ˆĎˆő‰ď‚Ĺ ł”F‚đŽó‚Ż‚˝Œ¤‹†‚ĚŽŔŽ{‹–‰Â‘̐§‚ĚŒŸ“˘‚đ’Ę‚ľ‚Ä. ŠÖŞ’q”ü1,2, ‘O“cŽŔ‰Ô1,2,3, Žu‘ş‘L1, ÎěrL1, Œú“cKˆę˜Y2,3, Î‘qŒ’Ži1,4, ‚‘ŠťŽm5 (1–k—˘‘ĺŠw•a‰@HRP (Human Research Protections) Žş, 2–ňÜ•”, 3–ňŠw•”, 4ŹŽ™, 5ŽŠO): ‘ć42‰ń“ú–{—Տ°–ň—Šw‰ďŠwp‘‰ď (2021/12/11), ĺ‘ä (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{—Տ°–ň—Šw‰ďŠwpW‰ď´˜^W (J-STAGE‚Ě‚Ý) 2021; 42: Web.

723753. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Phase III study comparing DEX on day 1 to days 1-4 with combined NK-1-RA PALO and OLZ in CDDP-based chemotherapy: SPARED Trial. –öŒ´•Žj1, ‰ĄaˆťŽq2, ěŒű@’3, ‰ş‘şˆęŒi4, ”ŃŒ´‘ĺ–Ť5, ›Œ´[L6,7, ŽOˆä–ž—˘“Ţ8, Îě@Š°9, “ę“cCˆę10, ’Ř’JˆťŽq11, ŽO“‡Œ\‰î12, Xě@Œc2, ŹŽR“c”š—C13, –{‘˝˜a“T4, “’ě—TŽq1, ‘ĺ–ě@N5, Œ˜“ce—˜14, žw“c’ź–ç8, ŽRŒű‘ń—m15, ’†“‡‹MŽq16 (1‰Ą•l˜JĐ•a‰@, 2šƒ}ƒŠƒAƒ“ƒiˆă‰Č‘ĺŠw•a‰@, 3“Œ‹ž–ň‰Č‘ĺŠw, 4ˆ¤’mŒ§‚Ş‚ńƒZƒ“ƒ^[, 5Šň•Œ‘ĺŠw•a‰@, 6–ňŠw•”, 7–ňÜ•”, 8šƒ}ƒŠƒAƒ“ƒiˆă‰Č‘ĺŠw‰Ą•lŽsź•”•a‰@, 9Ă‰ŞŒ§—§Ă‰Ş‚Ş‚ńƒZƒ“ƒ^[, 10ş˜a‘ĺŠw‰Ą•lŽs–k•”•a‰@, 11ěčŽs—§‘˝–€•a‰@, 12“ú–{ˆă‰Č‘ĺŠw•‘ Ź™•a‰@, 13NPO–@lJORTCƒf[ƒ^ƒZƒ“ƒ^[, 14Á‰ťŠí“ŕ, 15“Œ–k‘ĺŠw‘ĺŠw‰@, 16‹ž“s‘ĺŠw‘ĺŠw‰@): ‘ć19‰ń“ú–{—Տ°Žîᇊw‰ďŠwpW‰ď (2022/2/17-19), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723754. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) H“šŠŕp‘OE“ą“üDCF—Ă–@‚É‚¨‚Ż‚é•›ě—p”­Œť‚ލRŠŕÜ“Š—^—Ę‚É‹y‚Ú‚ˇ‰e‹ż. “ŒŽR—ĎŽq1,2, –Ń—˜‡ˆę1,2, VŠpˆč•ŕ1, ›Œ´[L1,2, Œ˜“ce—˜3, •˝ŽR•Ži1,2, Œú“cKˆę˜Y1,2 (1–ňŠw•”, 2–ňÜ•”, 3Á‰ťŠí“ŕ): “ú–{—Տ°ŽîᇖňŠw‰ďŠwp‘ĺ‰ď2022 (JASPO2022) (2022/3/12-13), ĺ‘ä (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723755. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒAƒuƒ‰ƒLƒTƒ“Ň“_“HĂ’—p‚É‚¨‚Ż‚édrug vial optimization‚ÉŠÖ‚ˇ‚éŽć‚č‘g‚݂ƐŹ‰Ę. ŹŒ´@—I1, ‘ž“c’q”Ž1, ˆäă仍1, “c‘ş˜aŒh1, ˛X–ŘŽőŽq1, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”): “ú–{—Տ°ŽîᇖňŠw‰ďŠwp‘ĺ‰ď2022 (JASPO2022) (2022/3/12-13), ĺ‘ä (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723756. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒ^ƒyƒ“ƒ^ƒh[ƒ‹ŒoŒű“Š—^Žž‚Ě–ň•¨“Ž‘Ô‚Ö‰e‹ż‚đ‹y‚Ú‚ˇˆöŽq‚ÉŠÖ‚ˇ‚錤‹†. –{ŠÔ‰ëŽm1, ‘•ŞG–ç2, •˝ŽR•Ži1,3, ‰œ˜e‹ť‰î4, Œ˜“ce—˜4, —с@Œol5,6, ‹ŕˆäş•ś6,7, Œú“cKˆę˜Y1,3 (1–ňÜ•”, 2“Œ‹ž–ň‰Č‘ĺŠw–ňŠw•”–ňŠwŽŔ–ąŽŔK‹łˆçƒZƒ“ƒ^[, 3–ňŠw•”, 4Á‰ťŠí“ŕ, 5‘Š–ÍŒ´‹Ś“Ż•a‰@ŠÉ˜aƒPƒA‰Č, 6–ƒŒ, 7V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): “ú–{—Տ°ŽîᇖňŠw‰ďŠwp‘ĺ‰ď2022 (JASPO2022) (2022/3/12-13), ĺ‘ä (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723757. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) Clostridioides dfficileŠ´őÇ (CDI) ‚ĚŒŸ¸‚ĆŽĄ—Ă‚đŽx‰‡‚ˇ‚éAI chatbot‚ĚŠJ”­. Ź—яšG1, ‰ĄŽR“ށX1 (1–ňŠw•”): “ú–{–ňŠw‰ď‘ć142”N‰ď (2022/3/25-28), WebŠJĂ, “ú–{–ňŠw‰ď”N‰ď‘ć142”N‰ď—vŽ|W (Web) 2022/3; 142th: Web.

723758. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ŠČˆŐŒœ‘÷–@‚đ—p‚˘‚˝Œ‹Šj•W€ŽĄ—Ă‚É‚¨‚Ż‚郊ƒtƒ@ƒ“ƒsƒVƒ“‚ĚˆŔ’萍. ‰ĄŽR“ށX1, Ź—яšG1, —F“c‹g‘Ľ1 (1–ňŠw•”): “ú–{–ňŠw‰ď‘ć142”N‰ď (2022/3/25-28), WebŠJĂ, “ú–{–ňŠw‰ď”N‰ď‘ć142”N‰ď—vŽ|W (Web) 2022/3; 142th: Web.

723759. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ‹}ŤƒAƒZƒgƒAƒ~ƒmƒtƒFƒ“’†“Ĺ‚É‚¨‚Ż‚éN-ƒAƒZƒ`ƒ‹ƒVƒXƒeƒCƒ“‚Ě“K‰ž”ť’f‚đŽx‰‡‚ˇ‚éAI chatbot‚ĚŠJ”­. —F“c‹g‘Ľ1, ”Ń“‡‘ż‰ë1, H“Ą‘ĺŽ÷1, Ź—яšG1 (1–ňŠw•”): “ú–{–ňŠw‰ď‘ć142”N‰ď (2022/3/25-28), WebŠJĂ, “ú–{–ňŠw‰ď”N‰ď‘ć142”N‰ď—vŽ|W (Web) 2022/3; 142th: Web.

723760. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒoƒ“ƒRƒ}ƒCƒVƒ“‚̏‰Šú“Š—^ÝŒv‚Ě‚˝‚ß‚ĚAI Chatbot‚ĚŠJ”­|Tomson–@‚Ě“K—p|. ”Ń“‡‘ż‰ë1, H“Ą‘ĺŽ÷1, Ź—яšG1, —F“c‹g‘Ľ1 (1–ňŠw•”): “ú–{–ňŠw‰ď‘ć142”N‰ď (2022/3/25-28), WebŠJĂ, “ú–{–ňŠw‰ď”N‰ď‘ć142”N‰ď—vŽ|W (Web) 2022/3; 142th: Web.

723761. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒoƒ“ƒRƒ}ƒCƒVƒ“‰Šú“Š—^ÝŒv‚Ě‚˝‚ß‚ĚAI Chatbot‚ĚŠJ”­|WinterŽŽ‚Ě“K—p|. H“Ą‘ĺŽ÷1, ”Ń“‡‘ż‰ë1, Ź—яšG1, —F“c‹g‘Ľ1 (1–ňŠw•”): “ú–{–ňŠw‰ď‘ć142”N‰ď (2022/3/25-28), WebŠJĂ, “ú–{–ňŠw‰ď”N‰ď‘ć142”N‰ď—vŽ|W (Web) 2022/3; 142th: Web.

723762. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ƒRƒƒi‰Đ‚É‚¨‚Ż‚éˆă–ň•iî•ńŠwu‹`‚Ĺ‚ĚŽŽ‚Ý‚Š‚猊‚Ś‚˝‰“ŠuŽö‹Ć‚Ě—LŒřŤ‚Ɖۑč. ŠâŕV^‹IŽq1, Œú“cKˆę˜Y1,2 (1–ňŠw•”, 2–ňÜ•”): “ú–{–ňŠw‰ď‘ć142”N‰ď (2022/3/25-28), WebŠJĂ, “ú–{–ňŠw‰ď”N‰ď‘ć142”N‰ď—vŽ|W (Web) 2022/3; 142th: Web.

733269. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ|ƒXƒ^[) –k—˘‘ĺŠw•a‰@“ü‰@ŠłŽŇ‚É‚¨‚Ż‚éƒ{ƒmƒvƒ‰ƒUƒ“ƒtƒ}ƒ‹Ž_‰–ů‚ĚŽg—pŽŔ‘Ô’˛¸. ”Ń“c^—R1, ›Œ´[L1,2, ŠâŕV^‹IŽq1, ŁŒË—Ç‹ł2, ŽÂŒ´—SŽq2, ŹŒ´”ü]2, •ÄŽR‘ĺŽu2, •˝ŽR•Ži1,2, Œú“cKˆę˜Y1,2 (1–ňÜ•”, 2–ňŠw•”): “ú–{•a‰@–ňÜŽt‰ďŠÖ“ŒƒuƒƒbƒN‘ć51‰ńŠwp‘ĺ‰ď (2021/8/28-9/5), WebŠJĂ.

733270. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ|ƒXƒ^[) _ŒoŽ¨‰ČƒƒjƒG[ƒ‹•a“ü‰@ŠłŽŇ‚đ‘ÎŰ‚Ć‚ľ‚˝–ňÜŽt‚É‚ć‚éW’cŽw“ą‚ĚŒř‰Ę‚ÉŠÖ‚ˇ‚é’˛¸. ň’J‘‹I1, ě–ěçq1,2, •˝ŽR•Ži1,2, ’ˇŔ‰p–ž3,4, Œú“cKˆę˜Y1,2 (1–ňŠw•”, 2–ňÜ•”, 3Ž¨•@ˆôAE“ŞčňŠO, 4V˘‹Iˆă—ÁEć’[ˆă—Ă): “ú–{•a‰@–ňÜŽt‰ďŠÖ“ŒƒuƒƒbƒN‘ć51‰ńŠwp‘ĺ‰ď (2021/8/28-9/5), WebŠJĂ.

733271. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) ƒIƒ“ƒ‰ƒCƒ“‚Ĺ‚ĚKJ–@‚đ—p‚˘‚˝ƒ[ƒNƒVƒ‡ƒbƒv‚ĚŽŔŽ{•ń. {“c“NŽj1, •wě‹M”Ž1,2, ŒIŒ´‡ˆę1, •ĐŽRŽü–ç1, Îě‹|Žq1, ă“c’mO1, “ú‰ş•”‹g’j1, Î•“N•v1, ‹´–{^–ç1, âăˆíF3, ”’ˆä—T“ń3, –ĺ“c‰ŔŽq3, ‹îˆäŒł•F3, •˝–Č—mŽq3, “n粁@“O3 (1Œö‰vŽĐ’c–@l_“ŢěŒ§–ňÜŽt‰ďŽŔ–ąŽŔKˆĎˆő‰ď, 2–ňŠw•”, 3Œö‰vŽĐ’c–@l_“ŢěŒ§•a‰@–ňÜŽt‰ď–ňŠwś•a‰@ŽŔKŒŸ“˘ˆĎˆő‰ď): ‘ć19‰ń‚Š‚Č‚Ş‚í–ňÜŽtŠwp‘ĺ‰ď (2021/11/21), WebŠJĂ, –ňšâ 2022/3; 4ŒŽ†: p.38.

733272. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) –ň—p’Y–łŒř•¨Žż‚ɑ΂ˇ‚é’´ŠˆŤ’Y‚Ě—L—pŤ‚ĚŒŸ“˘. —F“c‹g‘Ľ (–ňŠw•”): ‘ć35‰ń“ú–{’†“ĹŠw‰ď“Œ“ú–{’n•ű‰ď (2022/1/22), WebŠJĂ, ’†“ĹŒ¤‹† 2022/3; 35 (1): 73.


ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“•”

[Šwp˜_•ś]

110434. [Œ´’˜] Prognostic utility of dynapenia in patients with cardiovascular disease. Uchida S1, Kamiya K2, Hamazaki N3, Nozaki K3, Ichikawa T3, Nakamura T1, Yamashita M1, Maekawa E4, Reed JL Yamaoka-Tojo M2, Matsunaga A2, Ako J4: Clin Nutr 2021/4; 40 (4): 2210-8. (“ŕ“căđž1, _’JŒ’‘ž˜Y2, ŕ_čL–ž3, –ěčN•˝3, Žsě‹M•ś3, ’†‘şŠxŽj1, ŽR‰ş^Ži1, ‘OěŒb”ü4, “ŒžŠ”ü“ŢŽq2, ź‰i“Ä•F2, ˆ˘ŒĂĆ4: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3ƒŠƒnƒrƒŠ•”, 4zŠÂŠí“ŕ)

110435. [Œ´’˜] Clinical usefulness of oxygen uptake during usual gait in patients with cardiovascular disease. Hamazaki N1, Kamiya K2, Nozak K1, Yanagi N3, Ichikawa T1, Matsuzawa R, Nakamura T3, Yamashita M3, Uchida S3, Saito T, Maekawa E4, Meguro K4, Yamaoka-Tojo M2, Matsunaga A2, Ako J4: Int J Cardiol 2021/7; 335: 118-22. (ŕ_čL–ž1, _’JŒ’‘ž˜Y2, –ěčN•˝1, –ö@Ž–í3, Žsě‹M•ś1, ’†‘şŠxŽj3, ŽR‰ş^Ži3, “ŕ“căđž3, ‘OěŒb”ü4, –ڍ•Œ’‘ž˜Y4, “ŒžŠ”ü“ŢŽq2, ź‰i“Ä•F2, ˆ˘ŒĂĆ4: 1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4zŠÂŠí“ŕ)

110436. [Œ´’˜] Modified Creatinine Index and Clinical Outcomes of Hemodialysis Patients: An Indicator of Sarcopenia? Yamamoto S1, Matsuzawa R, Hoshi K2, Suzuki Y1, Harada M, Watanabe T, Isobe Y, Imamura K1, Osada S, Yoshida A, Kamiya K3, Matsunaga A3: J Ren Nutr 2021/7; 31 (4): 370-9. (ŽR–{Ž•˝1, Ż@‰Ŕ–F2, —é–Ř—T‘ž1, Ą‘şŒcŒá1, _’JŒ’‘ž˜Y3, ź‰i“Ä•F3: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‰qś, 3ˆă—ÉqśŠw•”)

110437. [Œ´’˜] Impact of Physical Activity on Dialysis and Nondialysis Days and Clinical Outcomes Among Patients on Hemodialysis. Yamamoto S1, Matsuzawa R, Hoshi K2, Harada M, Watanabe T, Suzuki Y1, Isobe Y, Imamura K1, Osada S, Yoshida A, Kamiya K3, Matsunaga A3: J Ren Nutr 2021/7; 31 (4): 380-8. (ŽR–{Ž•˝1, Ż@‰Ŕ–F2, —é–Ř—T‘ž1, Ą‘şŒcŒá1, _’JŒ’‘ž˜Y3, ź‰i“Ä•F3: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‰qś, 3ˆă—ÉqśŠw•”)

110438. [Œ´’˜] Low skeletal muscle density combined with muscle dysfunction predicts adverse events after adult cardiovascular surgery. Yamashita M1, Kamiya K2, Matsunaga A2, Kitamura T3, Hamazaki N4, Nozaki K4, Ichikawa T4, Maekawa E5, Meguro K5, Yamaoka-Tojo M2, Ako J5, Miyaji K3: Nutr Metab Cardiovasc Dis 2021/7; 31 (6): 1782-90. (ŽR‰ş^Ži1, _’JŒ’‘ž˜Y2, ź‰i“Ä•F2, –k‘ş@—Ľ3, ŕ_čL–ž4, –ěčN•˝4, Žsě‹M•ś4, ‘OěŒb”ü5, –ڍ•Œ’‘ž˜Y5, “ŒžŠ”ü“ŢŽq2, ˆ˘ŒĂĆ5, ‹{’n@ŠÓ3: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3S‘ŸŒŒŠÇŠO, 4ƒŠƒnƒrƒŠ•”, 5zŠÂŠí“ŕ)

110439. [Œ´’˜] Validity and Utility of the Questionnaire-based FRAIL Scale in Older Patients with Heart Failure: Findings from the FRAGILE-HF. Nozaki K1, Kamiya K2, Hamazaki N1, Saito H, Saito K, Ogasahara Y, Maekawa E3, Konishi M, Kitai T, Iwata K, Jujo K, Wada H, Kasai T, Nagamatsu H, Ozawa T, Izawa K, Yamamoto S, Aizawa N, Makino A, Oka K, Momomura S, Kagiyama N, Matsue Y: J Am Med Dir Assoc 2021/8; 22 (8): 1621-6.e2. (–ěčN•˝1, _’JŒ’‘ž˜Y2, ŕ_čL–ž1, ‘OěŒb”ü3: 1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”, 3zŠÂŠí“ŕ)

110440. [Œ´’˜] Standardized gait speed ratio in elderly patients with heart failure. Ozawa T, Yamashita M1, Seino S, Kamiya K2, Kagiyama N, Konishi M, Saito H, Saito K, Ogasahara Y, Maekawa E3, Kitai T, Iwata K, Jujo K, Wada H, Kasai T, Momomura S, Hamazaki N4, Nozaki K4, Kim H, Obuchi S, Kawai H, Kitamura A, Shinkai S, Matsue Y: ESC Heart Fail 2021/10; 8 (5): 3557-65. (ŽR‰ş^Ži1, _’JŒ’‘ž˜Y2, ‘OěŒb”ü3, ŕ_čL–ž4, –ěčN•˝4: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č 2ˆă—ÉqśŠw•”, 3zŠÂŠí“ŕ, 4ƒŠƒnƒrƒŠ•”)

110441. [Œ´’˜] Increased medial laxity of the elbow in preadolescent baseball players with or without medial elbow apophysitis. Watanabe H1, Masuma H2, Kenmoku T3, Kudo H, Saito K, Nagami T, Sekita J, Matsunaga A1: JSES Int 2021/9; 5 (6): 1119-24. (“n粗T”V1, ‘ŠÔOË2, ŒŠ–Ú’q‹I3, ź‰i“Ä•F1: 1ˆă—ÉqśŠw•”, 2ƒŠƒnƒrƒŠ•”, 3ŽŠO)

110442. [Œ´’˜] Effect of atrial fibrillation on response to exercise-based cardiac rehabilitation in older individuals with heart failure. Hamazaki N1, Kamiya K2, Fukaya H3, Nozaki K1, Ichikawa T1, Matsuzawa R, Yamashita M4, Uchida S4, Maekawa E3, Meguro K3, Yamaoka-Tojo M2, Matsunaga A2, Ako J3: Ann Phys Rehabil Med 2021/11; 64 (6): 101466. (ŕ_čL–ž1, _’JŒ’‘ž˜Y2, [’J‰p•˝3, –ěčN•˝1, Žsě‹M•ś1, ŽR‰ş^Ži4, “ŕ“căđž4, ‘OěŒb”ü3, –ڍ•Œ’‘ž˜Y3, “ŒžŠ”ü“ŢŽq2, ź‰i“Ä•F2, ˆ˘ŒĂĆ3: 1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”, 3zŠÂŠí“ŕ, 4‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č)

110443. [Œ´’˜] Relationship between high-sensitivity cardiac troponin T, B-type natriuretic peptide, and physical function in patients with heart failure. Ueno K1, Kamiya K2, Hamazaki N3, Nozaki K3, Ichikawa T3, Yamashita M1, Uchida S1, Yanagi N1, Maekawa E4, Yamaoka-Tojo M2, Matsunaga A2, Ako J4: ESC Heart Fail 2021/12; 8 (6): 5092-101. (ă–ěŒ“•ă1, _’JŒ’‘ž˜Y2, ŕ_čL–ž3, –ěčN•˝3, Žsě‹M•ś3, ŽR‰ş^Ži1, “ŕ“căđž1, –ö@Ž–í1, ‘OěŒb”ü4, “ŒžŠ”ü“ŢŽq2, ź‰i“Ä•F2, ˆ˘ŒĂĆ4: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3ƒŠƒnƒrƒŠ•”, 4zŠÂŠí“ŕ)

110444. [Œ´’˜] Preoperative malnutrition is a risk factor for delayed recovery of mobilization after total hip arthroplasty. Nanri Y1, Shibuya M1, Fukushima K2, Uchiyama K2,3, Takahira N4, Takaso M2: PM R 2021/12; 13 (12): 1331-9. (“ě—˘—C‘ž1, ŕF’J^1, •Ÿ“‡Œ’‰î2, “ŕŽRŸ•ś2,3, ‚•˝ŽL4, ‚‘ŠťŽm2: 1ƒŠƒnƒrƒŠ•”, 2ŽŠO, 3ˆă—ĂˆŔ‘SEŠÇ—, 4ˆă—ÉqśŠw•”)

110445. [Œ´’˜] Physical activity and its trajectory over time and clinical outcomes in hemodialysis patients. Suzuki Y1, Matsuzawa R, Hoshi K2, Koh YM, Harada M, Yamamoto S1, Imamura K1, Kamiya K3, Matsunaga A3: Int Urol Nephrol 2022/1. doi: 10.1007/s11255-021-03098-w. Online ahead of print. (—é–Ř—T‘ž1, Ż@‰Ŕ–F2, ŽR–{Ž•˝1, Ą‘şŒcŒá1, _’JŒ’‘ž˜Y3, ź‰i“Ä•F3: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2‰qś, 3ˆă—ÉqśŠw•”)

110446. [Œ´’˜] Gait speed and 6-minute walking distance are useful for identifying difficulties in activities of daily living in patients with cardiovascular disease. Sato A, Kamiya K1, Hamazaki N2, Nozaki K2, Ichikawa T2, Yamashita M3, Uchida S3, Maekawa E4, Yamaoka-Tojo M1, Matsunaga A1, Ako J4: Heart Lung 2022/1-2; 51: 46-51. (_’JŒ’‘ž˜Y1, ŕ_čL–ž2, –ěčN•˝2, Žsě‹M•ś2, ŽR‰ş^Ži3, “ŕ“căđž3, ‘OěŒb”ü4, “ŒžŠ”ü“ŢŽq1, ź‰i“Ä•F1, ˆ˘ŒĂĆ4: 1ˆă—ÉqśŠw•”, 2ƒŠƒnƒrƒŠ•”, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4zŠÂŠí“ŕ)

110447. [Œ´’˜] Features of trunk muscle wasting during acute care and physical function recovery with aortic disease. Yamashita M1, Kamiya K2, Matsunaga A2, Kitamura T3, Hamazaki N4, Ichikawa T4, Uchida S1, Noda T1, Yanagi N1, Maekawa E5, Yamaoka-Tojo M2, Ako J5, Miyaji K3: J Cachexia Sarcopenia Muscle 2022/4; 13 (2): 1054-63. doi: 10.1002/jcsm.12935. Epub 2022 Feb 17. (ŽR‰ş^Ži1, _’JŒ’‘ž˜Y2, ź‰i“Ä•F2, –k‘ş@—Ľ3, ŕ_čL–ž4, Žsě‹M•ś4, “ŕ“căđž1, –ě“c@ 1, –ö@Ž–í1, ‘OěŒb”ü5, “ŒžŠ”ü“ŢŽq2, ˆ˘ŒĂĆ5, ‹{’n@ŠÓ3: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3S‘ŸŒŒŠÇŠO, 4ƒŠƒnƒrƒŠ•”, 5zŠÂŠí“ŕ)

110448. [Œ´’˜] Associations between kidney function and outcomes of comprehensive cardiac rehabilitation in patients with heart failure. Hamazaki N1, Kamiya K2, Yamamoto S3, Nozak K1, Ichikawa T1, Matsuzawa R, Yamashita M3, Uchida S3, Maekawa E4, Meguro K4, Yamaoka-Tojo M2, Matsunaga A2, Ako J4: Clin Res Cardiol 2022/3; 111 (3): 253-63. (ŕ_čL–ž1, _’JŒ’‘ž˜Y2, ŽR–{Ž•˝3, –ěčN•˝1, Žsě‹M•ś1, ŽR‰ş^Ži3, “ŕ“căđž3, ‘OěŒb”ü4, –ڍ•Œ’‘ž˜Y4, “ŒžŠ”ü“ŢŽq2, ź‰i“Ä•F2, ˆ˘ŒĂĆ4: 1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4zŠÂŠí“ŕ)

110449. [Œ´’˜] Work status before admission relates to prognosis in older patients with heart failure partly through social frailty. Yamashita M1, Kamiya K2, Hamazaki N3, Nozaki K3, Saito H, Saito K, Ogasahara Y, Maekawa E4, Konishi M, Kitai T, Iwata K, Jujo K, Wada H, Kasai T, Nagamatsu H, Ozawa T, Izawa K, Shuhei Yamamoto Y, Aizawa N, Wakaume K, Oka K, Momomura S, Kagiyama N, Matsue Y: J Cardiol 2022/3; 79 (3): 439-45. (ŽR‰ş^Ži1, _’JŒ’‘ž˜Y2, ŕ_čL–ž3, –ěčN•˝3, ‘OěŒb”ü4: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3ƒŠƒnƒrƒŠ•”, 4zŠÂŠí“ŕ)

110450. [Œ´’˜] Usefulness of physical function sub-item of SF-36 survey to predict exercise intolerance in patients with heart failure. Ueno K1, Kamiya K2, Hamazaki N3, Nozaki K3, Ichikawa T3, Yamashita M1, Uchida S1, Kawabata M2, Maekawa E4, Yamaoka-Tojo M2, Matsunaga A2, Ako J4: Eur J Cardiovasc Nurs 2022/3; 21 (2): 174-7. (ă–ěŒ“•ă1, _’JŒ’‘ž˜Y2, ŕ_čL–ž3, –ěčN•˝3, Žsě‹M•ś3, ŽR‰ş^Ži1, “ŕ“căđž1, ‰Í’[ŤŽi2, ‘OěŒb”ü4, “ŒžŠ”ü“ŢŽq2, ź‰i“Ä•F2, ˆ˘ŒĂĆ4: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3ƒŠƒnƒrƒŠ•”, 4zŠÂŠí“ŕ)

110451. [Œ´’˜] Acute-Phase Initiation of Cardiac Rehabilitation for Short-Term Improvement in Activities of Daily Living in Patients Hospitalized for Acute Heart Failure. Ueno K1, Kamiya K2, Kaneko H, Okada A, Itoh H, Fujiu K, Takeda N, Morita H, Michihata N, Jo T, Yasunaga H, Komuro I: J Cardiovasc Dev Dis 2022/3; 9 (4): 97. (ă–ěŒ“•ă1, _’JŒ’‘ž˜Y2: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”)

110452. [Œ´’˜] The Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease and Its Association with Physical Function and Prognosis in Patients with Acute Coronary Syndrome. Noda T1, Kamiya K2, Hamazaki N3, Nozaki K3, Ichikawa T3, Yamashita M1, Uchida S1, Maekawa E4, Terada T, Reed JR, Yamaoka-Tojo M2, Matsunaga A2, Ako J4: J Clin Med 2022/3; 11 (7): 1847. (–ě“c@ 1, _’JŒ’‘ž˜Y2, ŕ_čL–ž3, –ěčN•˝3, Žsě‹M•ś3, ŽR‰ş^Ži1, “ŕ“căđž1, ‘OěŒb”ü4, “ŒžŠ”ü“ŢŽq2, ź‰i“Ä•F2, ˆ˘ŒĂĆ4: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3ƒŠƒnƒrƒŠ•”, 4zŠÂŠí“ŕ)

110453. [Œ´’˜] Pulmonary Rehabilitation for Patients After COPD Exacerbation. Shibuya M1, Yamamoto S, Kobayashi S1, Nishie K, Yamaga T, Kawachi S, Matsunaga A2: Respir Care 2022/3; 67 (3): 360-9. (ŕF’J^1, Ź—ŃŽĺŒŁ1, ź‰i“Ä•F2: 1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”)

110454. [Œ´’˜] Cross-sectional area of erector spinae muscles is associated with activities of daily living at discharge in middle- to older-aged patients with coronavirus disease 2019. Yamashita M1, Koike T, Hamazaki N2, Ueno K1, Uchida S1, Noda T1, Ogura K1, Nagumo D1, Miki T1, Shakuta S1, Wada T3, Kamiya K4: Exp Gerontol 2022/6; 163: 111774. doi: 10.1016/j.exger.2022.111774. Epub 2022 Mar 25. (ŽR‰ş^Ži1, ŕ_čL–ž2, ă–ěŒ“•ă1, “ŕ“căđž1, –ě“c@ 1, Ź‘q@Œ’1, “ě‰_’é“ß1, ŽO–Ř—˛Žj1, ŽÚ“cç‹G1, ˜a“c’B•F3, _’JŒ’‘ž˜Y4: 1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ƒŠƒnƒrƒŠ•”, 3äPŒ´•aEŠ´ő“ŕ, 4ˆă—ÉqśŠw•”)

310056. [Ç—á•ń] Hemodynamic Changes During Neuromuscular Electrical Stimulation and Mobility Therapy for an Advanced Heart Failure Patient with Impella 5.0 Device. Nozaki K1, Hamazaki N1, Ikeda Y2, Nihei M1, Kobayashi S1, Kamiya K3, Maekawa E2, Matsunaga A3, Yamaoka-Tojo M3, Ako J2: Int Heart J 2021/5; 62 (3): 695-9. (–ěčN•˝1, ŕ_čL–ž1, ’r“c—S‹B2, “ń•rˆ¤ŽŔ1, Ź—ŃŽĺŒŁ1, _’JŒ’‘ž˜Y3, ‘OěŒb”ü2, ź‰i“Ä•F3, “ŒžŠ”ü“ŢŽq3, ˆ˘ŒĂĆ2: 1ƒŠƒnƒrƒŠ•”, 2zŠÂŠí“ŕ, 3ˆă—ÉqśŠw•”)

522595. [uŔ]y“ÁW: ‰^“Ž‘Ď—e”\‚đl‚Ś‚ézŠČ•Ö‚ɉ^“Ž‘Ď—e”\‚đ•]‰ż‚ˇ‚é. ŕ_čL–ž1, _’JŒ’‘ž˜Y2, ź‰i“Ä•F2 (1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”): The Japanese Journal of Rehabilitation Medicine 2022/1; 59 (1): 4-11.

530015. [‚ť‚Ě‘ź (Research Letters)] Impact of Preoperative Muscle Strength on Walking Independence After Total Hip Arthroplasty. Nozaki K1, Nanri Y1, Yamamoto S2, Hamazaki N1, Noda T2, Yamashita M2, Shirota T1, Uchiyama K3, Fukushima K4, Kamiya K5, Takahira N5, Takaso M4: J Am Med Dir Assoc 2022/4; 23 (4): 695-7. doi: 10.1016/j.jamda.2021.11.006. Epub 2021 Dec 6. (–ěčN•˝1, “ě—˘—C‘ž1, ŽR–{Ž•˝2, ŕ_čL–ž1, –ě“c@ 2, ŽR‰ş^Ži2, ‘ă“c•‘ĺ1, “ŕŽRŸ•ś3, •Ÿ“‡Œ’‰î4, _’JŒ’‘ž˜Y5, ‚•˝ŽL5, ‚‘ŠťŽm4: 1ƒŠƒnƒrƒŠ•”, 2‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 3ˆă—ĂˆŔ‘SEŠÇ—, 4ŽŠO, 5ˆă—ÉqśŠw•”)

540055. [‚ť‚Ě‘ź (Šw‰ď´˜^)] “ü‰@‰Á—Ă‚đ—v‚ˇ‚é‘ĺŒŒŠÇŽžŠłŠłŽŇ‚É‚¨‚Ż‚é‹}ŤŠúŽĄ—ĂŽŔŽ{‘OŒă‚Ĺ‚Ě• •”œŠi‹Ř–§“x‚̕ωť. ŽR‰ş^Ži1, _’JŒ’‘ž˜Y2, –k‘ş@—Ľ3, ŕ_čL–ž4, –ěčN•˝4, ‘OěŒb”ü5, “ŒžŠ”ü“ŢŽq2, ź‰i“Ä•F2, ˆ˘ŒĂĆ5, ‹{’n@ŠÓ3 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3S‘ŸŒŒŠÇŠO, 4ƒŠƒnƒrƒŠ•”, 5zŠÂŠí“ŕ) “ú–{zŠÂŠí•a—\–hŠw‰ďŽ 2021/5; 56 (2): 176.

540056. [‚ť‚Ě‘ź (Šw‰ď´˜^)] ‹Ů‹}Ž–‘Ԑ錞‚ŞŠO—ˆS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ŽQ‰ÁŽŇ‚̐g‘ĚŠˆ“Ž‚É—^‚Ś‚˝‰e‹ż`’PŽ{Ý‘OŒü‚ŤŠĎŽ@Œ¤‹†`. ŕ_čL–ž1, _’JŒ’‘ž˜Y2, –ěčN•˝1, Žsě‹M•ś1, ŽR‰ş^Ži3, “ŕ“căđž3, –ě“c@ 3, ‘OěŒb”ü4, ˆ˘ŒĂĆ4 (1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4zŠÂŠí“ŕ): “ú–{zŠÂŠí•a—\–hŠw‰ďŽ 2021/5; 56 (2): 182.

[’˜@‘]

620184. [Šwp‘ (•Ş’SŽˇ•M)]yPTEOT ƒrƒWƒ…ƒAƒ‹ƒeƒLƒXƒg ADL (‘ć2”Ĺ)z‰î••ű–@‚Ć—űKŽw“ą (”]‘˛’†Ň‘|‘šˆČŠO‚ĚŽžŠł)@…@ƒp[ƒLƒ“ƒ\ƒ“•a, p.178-84. …A_Œo“ď•aŽžŠł, p.191-200. …–ěŒö•ă (ƒŠƒnƒrƒŠ•”), •Ň: ŽÄ@Šě’, ‰ş“cM–ž, —r“yŽĐ, “Œ‹ž, 2021/10”­s.

620185. [Šwp‘ (•Ş’SŽˇ•M)]y—Šw—Ă–@ƒKƒCƒhƒ‰ƒCƒ“ ‘ć2”Łz‘ć3Í _Œo“ď•a@ƒp[ƒLƒ“ƒ\ƒ“•a, p.126-7. …–ěŒö•ă (ƒŠƒnƒrƒŠ•”), ŠÄC: “ú–{—Šw—Ă–@Žm‹Ś‰ď, •Ň: “ú–{—Šw—Ă–@Šw‰ď˜A‡ —Šw—Ă–@•W€‰ťŒŸ“˘ˆĎˆő‰ďƒKƒCƒhƒ‰ƒCƒ“•”‰ď, ˆăŠw‘‰@, “Œ‹ž, 2021/10”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713060. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Associations between kidney function and outcomes following cardiac rehabilitation in patients with heart failure (Nursing and Allied Proffesions Investigator Award Winner ŽóÜ‰‰‘č). Hamazaki N1, Kamiya K2, Nozaki K1, Ichikawa T1, Matsuzawa R, Yamashita M3, Uchida S3, T Noda3, Maekawa E4, Meguro K4, Yamaoka-Tojo M2, Matsunaga A2, Ako J4: ESC Congress 2021 - The Digital Experience (2021/8/30), WebŠJĂ. (ŕ_čL–ž1, _’JŒ’‘ž˜Y2, –ěčN•˝1, Žsě‹M•ś1, ŽR‰ş^Ži3, “ŕ“căđž3, –ě“c@ 3, ‘OěŒb”ü4, –ڍ•Œ’‘ž˜Y4, “ŒžŠ”ü“ŢŽq2, ź‰i“Ä•F2, ˆ˘ŒĂĆ4: 1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4zŠÂŠí“ŕ)

713061. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Validity and Utility of the Qustionnaire-based FRAIL scale in older patients with Heart Failure: Findings from the FRAGILE-HF. Nozaki K1, Kamiya K2, Hamazaki N1, Saito H, Saito K, Ogasahara Y, Maekawa E3, Konishi M, Kitai T, Iwata K, Jujo K, Kagiyama N, Matsue Y: ESC Congress 2021 - The Digital Experience (2021/8/30), WebŠJĂ. (–ěčN•˝1, _’JŒ’‘ž˜Y2, ŕ_čL–ž1, ‘OěŒb”ü3: 1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”, 3zŠÂŠí“ŕ)

713062. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Standing balance is superior to gait parameters for motor impairment risk assesment in preterm and very-low-birth-weight toddlers. Nomura Y1, Sato H, Kariya H1, Kamide K, Ooka M2, Kemmochi M2: 75th American Academy for Cerebral Palsy and Developmental Medicine (2021/10/6-7), WebŠJĂ, Dev Med Child Neurol 2021/10; 63 (Suppl 3): 76-7. (–ě‘ş—DŽq1, ŠĄ’J‰p‹I1, ‘剪–ƒ—2, çݎ@Šw2: 1ƒŠƒnƒrƒŠ•”, 2ŹŽ™)

722328. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) ŒÄ‹z‹ŘƒgƒŒ[ƒjƒ“ƒO‚ĚƒGƒrƒfƒ“ƒX‚ĆŽŔ‘H. ŕ_čL–ž (ƒŠƒnƒrƒŠ•”): ‘ć27‰ń“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ďŠwpW‰ď (2021/6/19), ç—t (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722329. [Šw‰ď (‘S‘)] (ƒWƒ‡ƒCƒ“ƒgƒVƒ“ƒ|ƒWƒEƒ€) ƒRƒƒi‰Đ‚Ĺ“ž‚˝ŒoŒą‚đS‘ŸEt‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚ÉŠˆ‚Š‚ˇ. ŕ_čL–ž (ƒŠƒnƒrƒŠ•”): ‘ć27‰ń“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ďŠwpW‰ď (2021/6/19), ç—t (ƒnƒCƒuƒŠƒbƒhŠJĂ).

722330. [Šw‰ď (‘S‘)] (ƒWƒ‡ƒCƒ“ƒgƒVƒ“ƒ|ƒWƒEƒ€) d•ĄáŠQ‚ĚƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“. ŕ_čL–ž (ƒŠƒnƒrƒŠ•”): ‘ć12‰ń“ú–{t‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ďŠwpW‰ď (2022/3/26), ‰ŞŽR (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723763. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹Ů‹}Ž–‘Ԑ錞‚ŞŠO—ˆS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ŽQ‰ÁŽŇ‚̐g‘ĚŠˆ“Ž‚É—^‚Ś‚˝‰e‹ż`’PŽ{Ý‘OŒü‚ŤŠĎŽ@Œ¤‹†`. ŕ_čL–ž1, _’JŒ’‘ž˜Y2, –ěčN•˝1, Žsě‹M•ś1, ŽR‰ş^Ži3, “ŕ“căđž3, –ě“c@ 3, ‘OěŒb”ü4, ˆ˘ŒĂĆ4, ź‰i“Ä•F2 (1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 4zŠÂŠí“ŕ): ‘ć57‰ń“ú–{zŠÂŠí•a—\–hŠw‰ďŠwpW‰ď (2021/6/6), WebŠJĂ.

723764. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) lHŒŇŠÖß‘S’uŠˇp‚É‚¨‚Ż‚ép‘O‰h—{ó‘Ô‚ĆpŒă14“úˆČ“ŕ‚ĚŽŠ‘î‘މ@‰Â”Ű‹y‚яpŒăÝ‰@“ú”‚Ć‚ĚŠÖ˜A. “ě—˘—C‘ž1, •Ÿ“‡Œ’‰î2, “ŕŽRŸ•ś2,3, ‚•˝ŽL4 (1ƒŠƒnƒrƒŠ•”, 2ŽŠO, 3ˆă—ĂˆŔ‘SEŠÇ—, 4ˆă—ÉqśŠw•”): ‘ć58‰ń“ú–{ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ˆăŠw‰ďŠwpW‰ď (2021/6/10), ‹ž“s (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723765. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) IMPELLA 5.0‘}“üŠłŽŇ‚ɑ΂ˇ‚郊ƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ƌؗ́EŠˆ“Ž“x‚̉ü‘P|Ç—á•ń|. –ěčN•˝1, ŕ_čL–ž1, ’r“c—C‹B2, “ń•rˆ¤ŽŔ1, Ź—ŃŽĺŒŁ1, _’JŒ’‘ž˜Y3, ‘OěŒb”ü4, ź‰i“Ä•F3, “ŒžŠ”ü“ŢŽq3, ˆ˘ŒĂĆ4 (1ƒŠƒnƒrƒŠ•”, 2‹~–˝, 3ˆă—ÉqśŠw•”, 4zŠÂŠí“ŕ): ‘ć27‰ń“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ďŠwpW‰ď (2021/6/19-20), ç—t (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723766. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹}Ť‹@”\‘˛’†ŠłŽŇ‚Ě“ü‰@‰Šú‚É‚¨‚Ż‚钍ˆÓ‹@”\•]‰żTMT-J Part A‚ĆŽŠ‘î‘މ@‰Â”Ű‚Ć‚ĚŠÖ˜A. ç—tŽü•˝1, ˛X–؏Gˆę1, “cŒű°‹M1, Œy•”“ÖŽq1, •Ÿ“c—Ď–ç2 (1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”): ‘ć55‰ń“ú–{ě‹Ć—Ă–@Šw‰ď (2021/9/10-11), WebŠJĂ.

723767. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Œ’íŹl‚É‚¨‚Ż‚éŽčŽwŠÖß‰Â“Žˆć‘Ş’č‚ĚŒŸŽŇ“ŕM—ŠŤ‚¨‚ć‚ŃŒŸŽŇŠÔM—ŠŤ‚ĚŒŸ“˘. ’†ˆä‘ôĆ1, ‚‹´‘ăŽq2, ‘ş”öç‰ŘŽq1, “cŒű°‹M1, _•Ű•‘Ľ1 (1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”): ‘ć55‰ń“ú–{ě‹Ć—Ă–@Šw‰ď (2021/9/10-11), WebŠJĂ.

723768. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹}ŤŠú‚É‚¨‚Ż‚é”][ÇŒŒđ‰ńŽű—Ă–@ŽŇ‚Ě“V‹C•ĘTMT-J partA‚̐„ˆÚ. “cŒű°‹M1, ˛X–؏Gˆę1, ç—tŽü•˝1, ’†‰€“NŽĄ1, Œy•”“ÖŽq1 (1ƒŠƒnƒrƒŠ•”): ‘ć55‰ń“ú–{ě‹Ć—Ă–@Šw‰ď (2021/9/10-11), WebŠJĂ.

723769. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’´’áoś‘̏dŽ™‚̏Cł1Î”ź‚¨‚ć‚Ń3ÎŽž“_‚Ĺ‚ĚŠ´Šoˆ—”\—Í‚Ě“Á’Ľ. źˆäˆŸš”ü1,2, ‚‹´‘ăŽq3, ’|“ੰl2, ‘剪^—4, ’†źG•F4,5 (1‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č, 2ƒŠƒnƒrƒŠ•”, 3ˆă—ÉqśŠw•”, 4ŹŽ™, 5V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć55‰ń“ú–{ě‹Ć—Ă–@Šw‰ď (2021/9/10-11), WebŠJĂ.

723770. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹žŽ‹‰şäF”C•œp6ƒ–ŒŽ‚ĚŠłŽŇ—§‹rŒ^Shoulder36‚Ě‹Ř—Í€–Ú‚ÉŠÖ˜A‚ˇ‚éˆöŽq‚ĚŒŸ“˘. ˛X–؏Gˆę1, ŒŠ–Ú’q‹I2, ’|“ੰl1, _•Ű•‘Ľ1, –ź‘q’źd, ’†˜e[Í2, “cŕV@—Č2, @d‹żŽq3, Îˆä‘ĺ•ă3, ‚‘ŠťŽm2 (1ƒŠƒnƒrƒŠ•”, 2ŽŠO, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć48‰ń“ú–{Œ¨ŠÖßŠw‰ďŠwpW‰ďE‘ć18‰ń“ú–{Œ¨‚̉^“Ž‹@”\Œ¤‹†‰ďŠwpW‰ď (2021/10/29-30), –źŒĂ‰Ž.

723771. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) p‘OŒă‚Ě‹ü‹Č/ŠO“]‹Ř—Í”ä (FE”ä) ‚Ş—Ő°ŠŒŠ‚É—^‚Ś‚é‰e‹ż. ’|“ੰl1, ˛X–؏Gˆę1, ŒŠ–Ú’q‹I2, _•Ű•‘Ľ1, –ź‘q’źd, ’†˜e[Í2, “cŕV@—Č2, @d‹żŽq3, Îˆä‘ĺ•ă3, ‚‘ŠťŽm2 (1ƒŠƒnƒrƒŠ•”, 2ŽŠO, 3‘ĺŠw‰@ˆă—ĂŒnŒ¤‹†‰Č): ‘ć48‰ń“ú–{Œ¨ŠÖßŠw‰ďŠwpW‰ďE‘ć18‰ń“ú–{Œ¨‚̉^“Ž‹@”\Œ¤‹†‰ďŠwpW‰ď (2021/10/29-30), –źŒĂ‰Ž.

723772. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ’´’áoś‘̏dŽ™‚É‚¨‚Ż‚é”­’BŒo‰ß‚Ě•]‰ż‚Ć‚ľ‚Ä‚ĚƒAƒ‹ƒo[ƒ^“ű—cŽ™‰^“Ž”­’BŒŸ¸–@‚Ě—L—pŤ. –ě‘ş—DŽq1, …–ěŒö•ă1, ŠĄ’J‰p‹I1, ŕ_čL–ž1, —é–Ř—Ç˜a1, ’†‰€“NŽĄ1, ‹ť’Ă—˘•ŕ1, ź“c—˛Žq1, ‘剪–ƒ—2, çݎ@Šw2, •Ÿ“c—Ď–ç3 (1ƒŠƒnƒrƒŠ•”, 2ŹŽ™, 3ˆă—ÉqśŠw•”): ‘ć8‰ń“ú–{ŹŽ™—Šw—Ă–@Šw‰ďŠwp‘ĺ‰ď (2021/11/27-28), WebŠJĂ.

723773. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ‹}ŤŠú”][ÇŠłŽŇ‚É‚¨‚Ż‚鉺ŽˆFugl Meyer assessment‚Í“]‹AŽž“_‚Ě•ŕsŽŠ—§‚Ě—\‘Ş‚É—L—p‚Ĺ‚ ‚é. ’†‰€“NŽĄ1, _’JŒ’‘ž˜Y2, ŠĄ’J‰p‹I1, —é–Ř—Ç˜a1, …–ěŒö•ă1, –ě‘ş—DŽq1, ‹ť’Ă—˘•ŕ1, ź“c—˛Žq1, Î’JŠó1, ‘Ĺ–î‹MŽq1, ě’[—ÇŽĄ1, t“ú”ü•Ű1, •Ÿ“c—Ď–ç2 (1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”): ‘ć19‰ń“ú–{_Œo—Šw—Ă–@Šw‰ďŠwp‘ĺ‰ď in ‚˘‚í‚Ä (2021/12/18-19), WebŠJĂ.

732132. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) —Šw—Ă–@‚Ě•W€“I‚ȏî•ńŽűW: ŽĄ—ÕҁuŠeŽíƒfƒoƒCƒXv. ŕ_čL–ž (ƒŠƒnƒrƒŠ•”): ‘ć2‰ń“ú–{zŠÂŠí—Šw—Ă–@Šw‰ďS•s‘SÇ—ጟ“˘ƒTƒeƒ‰ƒCƒgƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2021/12/5), WebŠJĂ.

732133. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) —Šw—Ă–@‚ĚŽŔŰ: —Šw—Ă–@‚Ě•W€‰ť‚ÉŒü‚Ż‚āu‰ˇ“x”‚Ȃǁv. ŕ_čL–ž (ƒŠƒnƒrƒŠ•”): ‘ć2‰ń“ú–{zŠÂŠí—Šw—Ă–@Šw‰ďS•s‘SÇ—ጟ“˘ƒTƒeƒ‰ƒCƒgƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2021/12/5), WebŠJĂ.

732134. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) —Šw—Ă–@‚ĚŽŔŰ: —Šw—Ă–@‚Ě•W€‰ť‚ÉŒü‚Ż‚āu‰^“Ž—Ă–@E‹}ŤŠúv. ŕ_čL–ž (ƒŠƒnƒrƒŠ•”): ‘ć2‰ń“ú–{zŠÂŠí—Šw—Ă–@Šw‰ďS•s‘SÇ—ጟ“˘ƒTƒeƒ‰ƒCƒgƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2021/12/5), WebŠJĂ.

732135. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) •œE‚ɐŹŒ÷‚ľ‚˝’´‚—î‹}ŤS•s‘S‚Ěˆę—á. –ěčN•˝ (ƒŠƒnƒrƒŠ•”): ‘ć1‰ńzŠÂŠí—Šw—Ă–@ƒgƒsƒbƒNƒX Ç—ጟ“˘ƒTƒeƒ‰ƒCƒgƒJƒ“ƒtƒ@ƒŒƒ“ƒX (2021/12/15), WebŠJĂ.

733273. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) •œEŠó–]‚̐_ŒoäP‰čŽîŠłŽŇ‚ɑ΂ľADOC‚đ—p‚˘‚ďpŒă‘Šú‚Š‚çOBP‚đs‚Á‚˝Ž–—á. •č@‹ó1, ˛X–؏Gˆę1, “cŒű°‹M1, Œy•”“ÖŽq1, _•Ű•‘Ľ1 (1ƒŠƒnƒrƒŠ•”): ‘ć18‰ń_“ŢěŒ§ě‹Ć—Ă–@Šw‰ď (2021/12/4-5), WebŠJĂ.

733274. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ƒ`ƒƒƒŒƒ“ƒW”­•\) ‹}ŤŠú‚É‚¨‚Ż‚é“]ˆÚŤ”]ŽîᇊłŽŇ‚ɑ΂ˇ‚é‘މ@Žx‰‡‚đŽŔ‘H‚ľ‚˝1Ç—á. ŽR‰ş˜a‰ĚŽq1, “cŒű°‹M1, ˛X–؏Gˆę1, •č@‹ó1, _•Ű•‘Ľ1 (1ƒŠƒnƒrƒŠ•”): ‘ć18‰ń_“ŢěŒ§ě‹Ć—Ă–@Šw‰ď (2021/12/4-5), WebŠJĂ.

733275. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‹}ŤŠú•a‰@‚ɂĈӎv“`’B‘•’u‚đ“ą“ü‚ľ‰Ć‘°‚Ć‚ĚƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“‚đŒp‘ą‚Ĺ‚Ť‚˝ALSÇ—á. •Ÿ“c@–G1, ˛X–؏Gˆę1, Œy•”“ÖŽq1, ‚‹´‘ăŽq2, _•Ű•‘Ľ1 (1ƒŠƒnƒrƒŠ•”, 2ˆă—ÉqśŠw•”): ‘ć18‰ń_“ŢěŒ§ě‹Ć—Ă–@Šw‰ď (2021/12/4-5), WebŠJĂ.

733276. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ‹}ŤŠú‚É‚¨‚Ż‚éRNMDAŽó—e‘Ě”]‰ŠŠłŽŇ‚ɑ΂ľ‚Ä, MTDLP‚đ—p‚˘‚Ä’˛—“Žě‚đŠl“ž‚ľ‚˝ˆęÇ—á. ŹŒ´—R‹M1, ç—tŽü•˝1, ˛X–؏Gˆę1, ’|“ੰl1, _•Ű•‘Ľ1 (1ƒŠƒnƒrƒŠ•”): ‘ć18‰ń_“ŢěŒ§ě‹Ć—Ă–@Šw‰ď (2021/12/4-5), WebŠJĂ.

733277. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ŠÖßƒŠƒEƒ}ƒ`ŽÚ‘¤•ÎˆĘ‚̐lHŽwŠÖß’uŠˇpŒă—Ă–@‚ÉŽg—p‚ˇ‚éV‚˝‚Č‘•‹ď‚ĚŽŽ‚݁|”M‰Â‘YŤƒjƒbƒg‘fŢ‚ĆƒlƒIƒvƒŒƒ“‚ō쐻‚ľ‚˝ƒXƒvƒŠƒ“ƒg|. ˛X–؏Gˆę1, ŹŔŒŤŽĄ2, •ě_Žm2, ‘ĺ’|—IĆ2, ’|“ੰl1, _•Ű•‘Ľ1, ŒŠ–Ú’q‹I2, ‚•˝ŽL3 (1ƒŠƒnƒrƒŠ•”, 2ŽŠO, 3ˆă—ÉqśŠw•”): ‘ć22‰ń_“ŢěƒŠƒEƒ}ƒ`‚ĚƒŠƒnEƒPƒAŒ¤‹†‰ď (2022/1/22), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ).

'20”N“xˆČ‘O•Ş

[Šwp˜_•ś]

'20-110035. [Œ´’˜] Prognostic value of cardio-hepatic-skeletal muscle syndrome in patients with heart failure. Noda T1, Kamiya K2, Hamazaki N3, Nozaki K3, Ichikawa T3, Nakamura T1, Yamashita M1, Uchida S1, Maekawa E4, Reed JL, Yamaoka-Tojo M2, Matsunaga A2, Ako J4: Sci Rep 2021/2; 11 (1):3715. (–ě“c@ 1, _’JŒ’‘ž˜Y2, ŕ_čL–ž3, –ěčN•˝3, Žsě‹M•ś3, ’†‘şŠxŽj1, ŽR‰ş^Ži1, “ŕ“căđž1, ‘OěŒb”ü4, “ŒžŠ”ü“ŢŽq2, ź‰i“Ä•F2, ˆ˘ŒĂĆ4: 1‘ĺŠw‰@ˆă—ĂŒ¤‹†‰Č, 2ˆă—ÉqśŠw•”, 3ƒŠƒnƒrƒŠ•”, 4zŠÂŠí“ŕ)

'20-110036. [Œ´’˜] Post-intensive care syndrome as a predictor of mortality in patients with critical illness: A cohort study. Yanagi N, Kamiya K1, Hamazaki N2, Matsuzawa R, Nozaki K2, Ichikawa T2, Valley TS, Nakamura T3, Yamashita M3, Maekawa E4, Koike T5, Yamaoka-Tojo M1, Arai M6, Matsunaga A1, Ako J4: PLoS One 2021/3; 16 (3): e0244564. (_’JŒ’‘ž˜Y1, ŕ_čL–ž2, –ěčN•˝2, Žsě‹M•ś2, ’†‘şŠxŽj3, ŽR‰ş^Ži3, ‘OěŒb”ü4, Ź’r•üF5, “ŒžŠ”ü“ŢŽq1, VˆäłN6, ź‰i“Ä•F1, ˆ˘ŒĂĆ4: 1ˆă—ÉqśŠw•”, 2ƒŠƒnƒrƒŠ•”, 3‘ĺŠw‰@ˆă—ĂŒ¤‹†‰Č, 4zŠÂŠí“ŕ, 5ME•”, 6V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă)


‰h—{•”

[Šwp˜_•ś]

110455. [Œ´’˜] Prospective study for an independent predictor of prognosis in liver cirrhosis based on the new sarcopenia criteria produced by the Japan Society of Hepatology. Kikuchi N1, Uojima H2, Hidaka H2, Iwasaki S2, Wada N2, Kubota K2, Nakazawa T2, Shibuya A3, Fujikawa T, Kako M, Sato T1, Koizumi W2: Hepatol Res 2021/9; 51 (9): 968-78. (‹e’r“Ţ•äŽq1, ‹›“ˆ°‹I2, “ú‚@‰›2, ŠâčGˆę˜Y2, ˜a“cŽ‹v2, ŒE“cK‰î2, ’†ŕV‹MG2, a’J–ž—˛3, ˛“ĄĆŽq1, Źň˜aŽO˜Y2 (1‰h—{•”, 2Á‰ťŠí“ŕ, 3ˆă—ĂˆŔ‘SEŠÇ—)

120045. [Œ´’˜] “œ”A•atÇ•Ű‘śŠú‚Ě‘˝EŽí‰î“ü‚ÍŒŒ‰t“§Í“ą“üŽž‚Ě•a‘Ô‚¨‚ć‚Ń“ą“üŒă‚Ě—\Œă‚đ‰ü‘P‚ˇ‚é. lŒŠ–ƒ”üŽq1, ˛“ĄĆŽq1, ‘ĺŠŃŒbŽq2, â–{”~Žq2, Ÿ˜C”ü3, ŽO‰Y–F“T4, Žç‰Ž’B”ü5 (1‰h—{•”, 2ŠĹŒě•”, 3–ňÜ•”, 4—ŐŒŸ•”, 5Œ’NŠÇ—ƒZ): “œ”A•a 2021/4; 64 (4): 263-8.

520016. [‘ŕ] ƒ`[ƒ€‚ō\’z‚ľ‚˝tˆÚAƒŒƒVƒsƒGƒ“ƒg‚̉h—{ŠÇ—. ‹g“c•üŽq1, Îˆä‘ĺ•ă2, –ěŒű•ś”T2, ˆä‘ş—[•P3, X‰Ş—DŽq1, ˆ˘•”“N–ç4, –k“‡˜aŽ÷2, ’|“ŕN—Y4, ‹g“cˆęŹ2,5 (1‰h—{•”, 2”ĺ”AŠí, 3ŠĹŒě•”, 4t‘Ÿ“ŕ, 5V˘‹Iˆă—ÁEć’[ˆă—Ă): “ú–{—Տ°tˆÚAŠw‰ďŽGŽ 2021/7; 9 (1): 23|9.

522596. [uŔ]y“ÁW: ’m‚Á‚Ä‚¨‚Ť‚˝‚˘! ˆÚAˆă—Ă‚ĚŽŔŰ‚Ɖh—{EHŽ–ŠÇ—ztˆÚA‚ĚŽŔŰ‚Ɖh—{EHŽ–ŠÇ—. ‹g“c•üŽq (‰h—{•”): —Տ°‰h—{ 2021/7; 139 (1): 26-31.

522597. [uŔ]y“ÁW: CKDE“§ÍŠłŽŇ‚̉h—{Žw“ą•ű–@‚ĆŽŔ‘Hz5 ‰h—{Žw“ąŽŔ‘H|tˆÚAŠłŽŇ‚̉h—{Žw“ą. X‰Ş—DŽq, ‹g“c•üŽq1 (1‰h—{•”): —Őଓ§Í 2021/11; 37 (12): 77-82.

522598. [uŔ]y“ÁW: ”DP“œ”A•aE“œ”A•a‡•š”DP‚Ěƒ}ƒlƒWƒƒ“ƒg@ŒŒ“œƒRƒ“ƒg ƒ[ƒ‹‚Ə•ŽYƒPƒAĹVƒKƒCƒhz07 ”DP’†`ŽYŒă‚̉h—{Žw“ą`uŠÇ—‰h—{Žm‚Ć‹Ś—́v‚ľ•ŽYŽt‚É‚ŕ‚Ĺ‚Ť‚é! lŒŠ–ƒ”üŽq (‰h—{•”): ƒyƒŠƒlƒCƒ^ƒ‹ƒPƒA 2021/11; 40 (11): 1100-6.

[’˜@‘]

620186. [Šwp‘ (•Ş’SŽˇ•M)]yt‘Ÿ•a—Ă—{Žw“ąŽm‚Ě‚˝‚ß‚ĚCKDŽw“ąƒKƒCƒhƒuƒbƒNzChapter11 HŽ–—Ă–@@4 t‘ă‘Ö—Ă–@ (RRT) •Ę‚̐HŽ–ŠÇ— ctˆÚA, p.115-7. ‹g“c•üŽq (‰h—{•”), ŠÄC: “ú–{t‘Ÿ•a‹Ś‰ď, •Ň: “ú–{t‘ŸŠw‰ď, “ú–{t•s‘SŠĹŒěŠw‰ď, “ú–{‰h—{Žm‰ď, “ú–{t‘Ÿ•a–ň•¨—Ă–@Šw‰ď, “ú–{t‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ď, “Œ‹žˆăŠwŽĐ, “Œ‹ž, 2021/10”­s.

620187. [Šwp‘ (•Ş’SŽˇ•M)]y”D•w‚Ě“œ‘ăŽÓˆŮí f—ÁEŠÇ—ƒ}ƒjƒ…ƒAƒ‹ ‘ć3”ŁzIV ŽYŒă‚ĚŠÇ—@3. ŽYŒă‚̐HŽ–—Ă–@‚Ć‚ť‚ĚŽx‰‡‚Í‚Ç‚¤‚ľ‚˝‚ç‚悢‚Ĺ‚ˇ‚Š?, p.202-4. lŒŠ–ƒ”üŽq (‰h—{•”). •Ň: “ú–{“œ”A•aE”DPŠw‰ď, ƒƒWƒJƒ‹ƒrƒ…[ŽĐ, “Œ‹ž, 2022/1”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

713063. [Šw‰ď (‘Ű)] (ˆę”ʍu‰‰) Multidisciplinary Predialyis Team Education for patients with Diabetic Nephropathy,Postponed Hemodialysis Induction, and Prolonged Survival After Hemodialysis Induction. Hitomi M1, Sato T1, Moriya T2: ‘ć81‰ń•Ä‘“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (ADA2021) (2021/6/25), WebŠJĂ, HP‚Ě“dŽq”}‘Ě‚Ě‚Ý 2021/6. (lŒŠ–ƒ”üŽq1, ˛“ĄĆŽq1, Žç‰Ž’B”ü2: 1‰h—{•”, 2Œ’NŠÇ—ƒZ)

722331. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) t•s‘SŠłŽŇ‚ɑ΂ˇ‚éŒo’°‰h—{Ü‚ĚŽí—Ţ‚Ć“Á’Ľ. ‹g“c•üŽq1, ÂŽR“ŒŒÜ2, ’|“ŕN—Y2 (1‰h—{•”, 2t‘Ÿ“ŕ): ‘ć66‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2021/6/4), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), ‘ć66‰ń“ú–{“§ÍˆăŠw‰ď´˜^W (ƒAƒvƒŠŒfÚ‚Ě‚Ý) 2021/5. (HP‚Ě“dŽq”}‘Ě‚Ě‚Ý)

722332. [Šw‰ď (‘S‘)] (ƒVƒ“ƒ|ƒWƒEƒ€) “œ‘ăŽÓˆŮí‚đ—L‚ˇ‚é”D•w‚Ě‘ĚdŠÇ—‚ĚŒťó‚Ɖۑč@‰h—{Žw“ą‚ĚŠĎ“_‚Š‚ç. lŒŠ–ƒ”üŽq (‰h—{•”): ‘ć37‰ń“ú–{“œ”A•aE”DPŠw‰ď”NŽŸŠwpW‰ď (2021/11/27), WebŠJĂ, ‘ć37‰ń“ú–{“œ”A•a”DPŠw‰ď´˜^W 2021/11; 21 (3): S-18.

723774. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) “œ”A•atÇ•Ű‘śŠú‚ɑ΂ˇ‚é‘˝EŽí‰î“ü‚ĚŒř‰Ę‚đ‹qŠĎ“I‚ÉŒŸŘ‚ˇ‚é. lŒŠ–ƒ”üŽq1, ˛“ĄĆŽq1, Žç‰Ž’B”ü2 (1‰h—{•”, 2Œ’NŠÇ—ƒZ): ‘ć64‰ń“ú–{“œ”A•aŠw‰ď”NŽŸŠwpW‰ď (2021/5/20), WebŠJĂ, ‘ć64‰ń“ú–{“œ”A•a”NŽŸŠwpW‰ď“œ”A•a 2021; 64 (Suppl): 51.

723775. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) ”ńŒv‰ćŒŒ‰t“§Í“ą“üŠłŽŇ‚ĚADL‚ɉh—{ŠÇ—‚͉e‹ż‚ˇ‚é. ‹g“c•üŽq1, ÂŽR“ŒŒÜ2, X‰Ş—DŽq1, “Ąˆä䝎Ŕ1, ‰i‰Ş–˘—ˆ2, ‚‹´@—É2, “ŕ“Ął‹g2, ˛–ě@—˛2, ’|“ŕN—Y2 (1‰h—{•”, 2t‘Ÿ“ŕ): ‘ć66‰ń“ú–{“§ÍˆăŠw‰ďŠwpW‰ďE‘‰ď (2021/6/5), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), ‘ć66‰ń“ú–{“§ÍˆăŠw‰ď´˜^W (ƒAƒvƒŠŒfÚ‚Ě‚Ý) 2021/5. (HP‚Ě“dŽq”}‘Ě‚Ě‚Ý)

732136. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰“™) CKDŠłŽŇ‚É‚¨‚Ż‚éÄ—Ă–@‘I‘đŽž‚ĚŠÇ—‰h—{Žm‚ĚŠÖ‚í‚č. ‹g“c•üŽq (‰h—{•”): ‘ć4‰ńt•s‘Sƒ`[ƒ€ˆă—Ă‹Ś‹c‰ď (Kicos) Šwp‘ĺ‰ď (2021/8/22), WebŠJĂ, ‘ć4‰ńt•s‘Sƒ`[ƒ€ˆă—Ă‹Ś‹c‰ď (űŽq‚Č‚ľCWEBŒfÚ‚Ě‚Ý) 2021/8. (HP‚Ě“dŽq”}‘Ě‚Ě‚Ý)

732137. [Šw‰ď (Œ¤‹†‰ďE’n•ű‰ď)] (ƒVƒ“ƒ|ƒWƒEƒ€) tˆÚAŒă‚̉h—{ŠÇ—. ‹g“c•üŽq1, X‰Ş—DŽq1, –k“‡˜aŽ÷2, Îˆä‘ĺ•ă2, ‹g“cˆęŹ2,3 (1‰h—{•”, 2”ĺ”AŠí, 3V˘‹Iˆă—ÁEć’[ˆă—Ă): ‘ć30‰ń“ú–{t•s‘SŠO‰ČŒ¤‹†‰ďŠwpW‰ď (2021/12/4), ‰Ť“ę (ƒnƒCƒuƒŠƒbƒhŠJĂ), ‘ć30‰ń“ú–{t•s‘SŠO‰ČŒ¤‹†‰ď´˜^W (űŽq‚Č‚ľ, WEBŒfÚ‚Ě‚Ý) 2021/11. (HP‚Ě“dŽq”}‘Ě‚Ě‚Ý)

733278. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) dÇŠłŽŇ‚É‚¨‚Ż‚éƒ^ƒ“ƒpƒNŽż“Š—^—ʂƐg‘ĚŠˆ“ŽŤ‚ĚŒă•űŽ‹“IŒŸ“˘. [‘ň˛ŒbŽq1,2, •Đ‰Ş—Sˆę3, “c‘ş@’q3, ‹{č“š‹P4, “c‘ş’qŽq5, ‰““ĄŹŽq1, ˛“ĄĆŽq1, ˜hŕVŽG2, Źź•q˜Y2 (1‰h—{•”, 2“Œ‹žˆă—Ă•ŰŒ’‘ĺŠw‘ĺŠw‰@, 3‹~–˝, 4ƒŠƒnƒrƒŠ•”, 5ˆă—ÉqśŠw•”): ‘ć12‰ń“ú–{—Տ°‰h—{‘ăŽÓŠw‰ďŽń“sŒ—Žx•”‰ďŠwpW‰ď (2021/5/15), WebŠJĂ, ‘ć12‰ń“ú–{—Տ°‰h—{‘ăŽÓŠw‰ďŽń“sŒ—Žx•”‰ďŠwpW‰ď´˜^W 2021/5; p.41.

733279. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) ƒ~ƒgƒRƒ“ƒhƒŠƒA•a‚ɍ‡•š‚ľ‚˝ă’°ŠÔ–Œ“Ž–Ź (SMA) ÇŒóŒQ‚đŠÉ‰đ‚É“ą‚˘‚˝‰h—{—Ă–@‚Ěˆę—á. ‹e’r“Ţ•äŽq1, ŸN’J”ü‹MŽq2, VŒ´ł‘ĺ2, ˛“ĄĆŽq1, ”äŠé’źŽ÷2 (1‰h—{•”, 2ă•”Á‰ťŠÇŠO): ‘ć12‰ń“ú–{—Տ°‰h—{‘ăŽÓŠw‰ďŽń“sŒ—Žx•”‰ďŠwpW‰ď (2021/5/15), WebŠJĂ, ‘ć12‰ń“ú–{—Տ°‰h—{‘ăŽÓŠw‰ďŽń“sŒ—Žx•”‰ďŠwpW‰ď´˜^W 2021/5; p.55.

733280. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “ú–{ŠĚ‘ŸŠw‰ď‚ĚƒTƒ‹ƒRƒyƒjƒA”ť’čŠî€‚đ—p‚˘‚˝ŠĚd•Ď‚Ě—\Œă‚ĚŒŸ“˘‚ĆƒTƒ‹ƒRƒyƒjƒA‘΍ô‚É‚¨‚Ż‚é‰h—{HŽ–—Ă–@‚ĚŽŔŰ. ‹e’r“Ţ•äŽq1, ‹›“ˆ°‹I2 (1‰h—{•”, 2Á‰ťŠí“ŕ): ‘ć26‰ńŠĚŽžŠł‚Ɖh—{Œ¤‹†‰ď (2021/7/15), WebŠJĂ.

733281. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ʍu‰‰) “Á’čW’†ŽĄ—ĂŽş‚É‚¨‚Ż‚鑁Šú‰h—{‰î“üŠÇ—‰ÁŽZ‚Ö‚ĚŽć‚č‘g‚Ý‚ĆŒťó. [‘ň˛ŒbŽq1, ‘O“cˆť”T2, ŽOˆä’qD2, “ŕ“ĄˆŸŽ÷2, ‹gŁŠG—3, ŕ_“c–­Žq2, •Šâ­”V4, ˛“ĄĆŽq1 (1‰h—{•”, 2ŠĹŒě•”, 3–ňÜ•”, 4–ƒŒ): ‘ć23‰ń_“ސěNSTƒtƒH[ƒ‰ƒ€ (2021/11/20), WebŠJĂ, ‘ć23‰ń_“ސěNSTƒtƒH|ƒ‰ƒ€´˜^W (űŽq‚Č‚ľ) 2021/11; p.8.


•a‰@•a—•”

[Šwp˜_•ś]

120046. [Œ´’˜] ’…Fƒzƒ‹ƒ}ƒŠƒ“ŒĹ’č‰t‚¨‚ć‚Ń••ăg—eŠí‚É‚ć‚éˆă—ĂŽ–ŒĚ–hŽ~‚Ě’ńˆÄ|ƒzƒ‹ƒ}ƒŠƒ“ŒĹ’č‰t—R—ˆ‚Ěˆă—ĂŽ–ŒĚ•ŞÍ‚Š‚ç|. ŽR‰ş˜a–ç1, ‹vę@Ž÷1, âŒű@”E1, ‹g“c@Œ÷2, ‘ş‰_–FŽ÷3, ŽOŽ}@M3 (1•a—•”, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3•a—Šw): ˆăŠwŒŸ¸ 2021/7; 70 (3): 433-42.

120047. [Œ´’˜] …—nŤƒpƒ‰ƒtƒBƒ“‚đ—p‚˘‚˝ƒuƒƒbƒNƒJƒo[‚Ě—L—pŤ‚ĚŒŸ“˘. ’ˇ’Jě—S“ń1, ŽR‰ş˜a–ç1, ‹g“c@Œ÷2, ‘ş‰_–FŽ÷3, ŽOŽ}@M3 (1•a—•”, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3•a—Šw): ˆăŠwŒŸ¸ 2022/1; 71 (1): 10-9.

320030. [Ç—á•ń] ’†cŠu‚É”­ś‚ľ‚˝’E•Ş‰ťŒ^Ž‰–b“÷Žî‚Ě1—á. ’†ěm”ü1, Š`ŔœA–M1, ŽR‰ş˜a–ç1, ˛“Ą”Vr2, ˆęŒË š–ž3, ‹g“c@Œ÷4, ŽOŽ}@M3 (1•a—•”, 2ŒÄ‹zŠíŠO, 3•a—Šw, 4V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă): _“ŢěŒ§—Տ°×–EŠw‰ďŽ 2022/1; 26 (1): 14-29.

[Šw‰ďEŒ¤‹†‰ď“™]

723776. [Šw‰ď (‘S‘)] (ˆę”ĘŒű‰‰) 2020”N“x“ú—Ő‹Z•a—ŒŸ¸•W€‰ťE¸“xŠÇ—‡“ŻƒAƒ“ƒP[ƒg’˛¸‚Ě•ń (1). —с@—TŽi1, Î“cŽŹ2, —é–؏r‹I3, âŞˆę4, źŒ´^“Ţ”ü5, “Œ@@Šw6, ŽR‰ş˜a–ç7, ŒĂ‰ŽŽüˆę˜Y8 (1Ž ‰ęˆă‰Č‘ĺŠwˆăŠw•”•‘Ž•a‰@, 2L“‡‘ĺŠwˆăŠw•”•t‘Ž•a‰@, 3ŽRŒ`‘ĺŠwˆăŠw•”•t‘Ž•a‰@, 4Ă‰Ş‚ą‚Ç‚ŕ•a‰@, 5“‡ŞŒ§—§’†‰›•a‰@, 6‘—§•a‰@‹@\”ŸŠŮ•a‰@, 7•a—•”, 8’}”g‘ĺŠw•‘Ž•a‰@): ‘ć70‰ń“ú–{ˆăŠwŒŸ¸Šw‰ď (2021/5/15-6/14), WebŠJĂ, ˆăŠwŒŸ¸ 2021/5; 70 (•Ęű): 223.

723777. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) 2020”N“x“ú—Ő‹Z•a—ŒŸ¸•W€‰ťE¸“xŠÇ—‡“ŻƒAƒ“ƒP[ƒg’˛¸‚Ě•ń (2). —с@—TŽi1, Î“cŽŹ2, —é–؏r‹I3, âŞˆę4, źŒ´^“Ţ”ü5, “Œ@@Šw6, ŽR‰ş˜a–ç7, ŒĂ‰ŽŽüˆę˜Y8 (1Ž ‰ęˆă‰Č‘ĺŠwˆăŠw•”•‘Ž•a‰@, 2L“‡‘ĺŠwˆăŠw•”•t‘Ž•a‰@, 3ŽRŒ`‘ĺŠwˆăŠw•”•t‘Ž•a‰@, 4Ă‰Ş‚ą‚Ç‚ŕ•a‰@, 5“‡ŞŒ§—§’†‰›•a‰@, 6‘—§•a‰@‹@\”ŸŠŮ•a‰@, 7•a—•”, 8’}”g‘ĺŠw•‘Ž•a‰@): ‘ć70‰ń“ú–{ˆăŠwŒŸ¸Šw‰ď‘‰ď (2021/5/15-6/14), WebŠJĂ, ˆăŠwŒŸ¸ 2021/5; 70 (•Ęű): 224.

731083. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (“Á•Ęu‰‰) ˆâ“`ŽqŒŸ¸‚ĚŠî‘b (‘gDŒŸ‘ĚŽć‚čˆľ‚˘‚đŠÜ‚ß‚˝). ŽR‰ş˜a–ç (•a—•”): —ߘa3”N“x”F’č•a—ŒŸ¸‹ZŽtŽw’čuK‰ď (2021/8/1-31), WebŠJĂ, Žw’čuK‰ďƒeƒLƒXƒg 2021/8; —ߘa3”N“x”Ĺ.

732138. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ľ‘ҍu‰‰) “űŠŕ•W–{ěť‹Zp‚Ě“_ŒŸ (“űŠŕEˆÝŠŕHER2•a—f’fƒKƒCƒhƒ‰ƒCƒ“‘ć2”Ĺ‚ÉŠw‚Ô). ŽR‰ş˜a–ç (•a—•”): ě•a—ƒZƒ~ƒi[ěŒ§—Տ°×–EŠw‰ď‹¤Ă (2021/10/23), WebŠJĂ.


ME•”

[Šwp˜_•ś]

120048. [Œ´’˜] ECMOŽ{sŽž‚É‚¨‚Ż‚élH”x‚ĚƒKƒXŒđŠˇ”\•s‘Ť‚ɑ΂ˇ‚élH”x•Ŕ—ńÚ‘ą‚Ć’ź—ńÚ‘ą‚Ě”äŠrŒŸ“˘. “ŒžŠŒ\ˆę1, –؉şt“Ţ1, •“cÍ”1, ‘哇O”V1, ‹âě”üš‹I1, ’†‘ş‹ąŽq1, “ĄˆäłŽŔ1 (1ME•”): ‘ĚŠOzŠÂ‹Zp 2022/3; 49 (1): 1-6.

320031. [Ç—á•ń] ƒwƒbƒhƒ‰ƒCƒg‚Ěƒtƒ@ƒCƒo[ƒP[ƒuƒ‹‰ˇ“xă¸‚ĚŠëŒŻŤ‚ɂ‚˘‚Ä. —§–ě@‘1, “ŒžŠŒ\ˆę1, “ĄˆäłŽŔ1, ě“‡Ę‰Ř1 (1ME•”): “ú–{ŽčpˆăŠw‰ď‰ďŽ 2021/10; 42 (3): 281-6.

320032. [Ç—á•ń] COVID-19—zŤ‹^‚˘ŠłŽŇ‚ɑ΂ˇ‚éAž‚ÝŒ^•â•lHS‘Ÿ‘•’…p‚ĚŒoŒą. ‘哇O”V1, “ŒžŠŒ\ˆę1, ŒKŒ´ŽŃˆß1, “c’†—D”ü1, ˆÉ“ŒË‘ž1, ‹{’n@ŠÓ2 (1ME•”, 2S‘ŸŒŒŠÇŠO): ‘ĚŠOzŠÂ‹Zp 2022/3; 49 (1): 11-5.

[’˜@‘]

620188. [Šwp‘ (•Ş’SŽˇ•M)]yƒi[ƒX‚Ě‚˝‚ß‚ĚME‹@Šíƒ}ƒjƒ…ƒAƒ‹ ‘ć2”ŁzII •a‰@“ŕ‚ĹŽg—p‚ˇ‚éME‹@Ší@ŠłŽŇƒ‚ƒjƒ^ƒŠƒ“ƒO‚Ě‚˝‚ß‚Ě‹@Ší@5“dŽq‘̉ˇŒv, p.37-40. 6 ƒpƒ‹ƒXƒIƒLƒVƒ[ƒ^[, p.41-6. 7 ƒJƒEƒmƒ[ƒ^[, p.47-51. 8 Œo”ç.ƒKƒXƒ‚ƒjƒ^, p.52-5. “ŒžŠŒ\ˆę (ME•”), •Ň: ‰Á”[@—˛, œAŁ@–Ť, ˆăŠw‘‰@, “Œ‹ž, 2021/10”­s.

620189. [Šwp‘ (•Ş’SŽˇ•M)]yƒi[ƒX‚Ě‚˝‚ß‚ĚME‹@Šíƒ}ƒjƒ…ƒAƒ‹ ‘ć2”ŁzII •a‰@“ŕ‚ĹŽg—p‚ˇ‚éME‹@Ší@zŠÂ‚đ•‚Ż‚é‹@Ší@18 •â•zŠÂ—pƒ|ƒ“ƒvƒJƒe[ƒeƒ‹ (Impella), p.98-101. ŒÄ‹z‚đ•‚Ż‚é‹@Ší@23 ‰Á‰ˇ‰ÁŽźŠí‚Ćƒlƒvƒ‰ƒCƒU, p.128-31. 24 Ž_‘f—Ź—ĘŒv, p.132-6. 25 Ž_‘f”Z“xŒv, p.137-9. 26 Ž_‘f”ZkŠí, p.140-3. 28 Œo•@‚—Ź—ĘŽ_‘f—Ă–@ (ƒl[ƒUƒ‹ƒnƒCƒtƒ[ƒZƒ‰ƒs[), p.148-51. 29 ‚‹CˆłŽ_‘fŽĄ—Ă‘•’u, p.152-4. –؉şt“Ţ (ME•”), •Ň: ‰Á”[@—˛, œAŁ@–Ť, ˆăŠw‘‰@, “Œ‹ž, 2021/10”­s.

620190. [Šwp‘ (•Ş’SŽˇ•M)]yƒi[ƒX‚Ě‚˝‚ß‚ĚME‹@Šíƒ}ƒjƒ…ƒAƒ‹ ‘ć2”ŁzII •a‰@“ŕ‚ĹŽg—p‚ˇ‚éME‹@Ší@ŒÄ‹z‚đ•‚Ż‚é‹@Ší@31 ‹zˆřŠí, p.160-3. 32 ’áˆłŽ‘ą‹zˆřŠí, p.164-67. 33 ˆă—ĂƒKƒXÝ”ő, p.168-70. 34 Ž_‘fƒ{ƒ“ƒx, p.171-4. “ĄˆäłŽŔ (ME•”), •Ň: ‰Á”[@—˛, œAŁ@–Ť, ˆăŠw‘‰@, “Œ‹ž, 2021/10”­s.

620191. [Šwp‘ (•Ş’SŽˇ•M)]yƒi[ƒX‚Ě‚˝‚ß‚ĚME‹@Šíƒ}ƒjƒ…ƒAƒ‹ ‘ć2”ŁzII •a‰@“ŕ‚ĹŽg—p‚ˇ‚éME‹@Ší@Žčp‚ĹŽg‚í‚ę‚é‹@Ší@41 ’´‰š”gŽčp‘•’u, p.204-6. 42 ƒŒ[ƒU[Žčp‘•’u, p.207-10. 43 –ƒŒŠí, p.211-5. —§–ě@‘ (ME•”), •Ň: ‰Á”[@—˛, œAŁ@–Ť, ˆăŠw‘‰@, “Œ‹ž, 2021/10”­s.

620192. [Šwp‘ (•Ş’SŽˇ•M)]yƒi[ƒX‚Ě‚˝‚ß‚ĚME‹@Šíƒ}ƒjƒ…ƒAƒ‹ ‘ć2”ŁzII •a‰@“ŕ‚ĹŽg—p‚ˇ‚éME‹@Ší@Žčp‚ĹŽg‚í‚ę‚é‹@Ší@44 –ƒŒƒKƒXƒ‚ƒjƒ^, p.216-7. 45 BISƒ‚ƒjƒ^, p.218-21. 46 ŒŒ‰t‰ÁŽźŠí, p.222-6. 47 ’™ŒŒŽŽŽŠŒČŒŒ‰ńŽű‘•’u, p.227-9. 48 ‰ÁŽźE—â‹pƒuƒ‰ƒ“ƒPƒbƒg, ’†SĂ–Ź—Ż’uŒ^Œo”ç“I‘̉ˇ’˛ß‘•’u, p.230-7. ‘哇O”V (ME•”), •Ň: ‰Á”[@—˛, œAŁ@–Ť, ˆăŠw‘‰@, “Œ‹ž, 2021/10”­s.

620193. [Šwp‘ (•Ş’SŽˇ•M)]yƒi[ƒX‚Ě‚˝‚ß‚ĚME‹@Šíƒ}ƒjƒ…ƒAƒ‹ ‘ć2”ŁzII •a‰@“ŕ‚ĹŽg—p‚ˇ‚éME‹@Ší@Ý‘î‚ĹŽg—p‚ˇ‚éME‹@Ší@1 Ý‘îˆă—Ă‚É‚¨‚Ż‚éME‹@Ší‚ĚŽg—p, p.254-61. 2 Ý‘î‚ĹME‹@Ší‚đŽg—p‚ˇ‚éŰ‚Ě‘S”Ę“I‚Čƒ|ƒCƒ“ƒg, p.261. •“cÍ” (ME•”), •Ň: ‰Á”[@—˛, œAŁ@–Ť, ˆăŠw‘‰@, “Œ‹ž, 2021/10”­s.

621005. [Šwp‘ (•ŇW)]y—Տ°HŠw‹Zpƒ”ƒBƒWƒ…ƒAƒ‹ƒVƒŠ[ƒY@“Ž‰ć‚Ǝʐ^‚Ĺ‚Ü‚é‚í‚Š‚č!@lHŒÄ‹zz“ŒžŠŒ\ˆę1, “ĄˆäłŽŔ1, –؉şt“Ţ1, •“cÍ”1, —§–ě@‘1, ‘哇O”V1, ‘ź (1ME•”), ŠÄC: 1ME•”, •Ň: “ŒžŠŒ\ˆę1, Œ¤ƒƒfƒBƒJƒ‹GŽĐ, “Œ‹ž, 2021/9”­s.

[Šw‰ďEŒ¤‹†‰ď“™]

722333. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰) COVID-19—zŤ‹^‚˘ŠłŽŇ‚ɑ΂ˇ‚é‘ĚŠOzŠÂ‚ĚŒoŒą. ‘哇O”V1, “ŒžŠŒ\ˆę1, ŒKŒ´ŽŃˆß1, “c’†—D”ü1, ˆÉ“ŒË‘ž1, ‹{’n@ŠÓ2 (1ME•”, 2S‘ŸŒŒŠÇŠO): ‘ć46‰ń“ú–{‘ĚŠOzŠÂ‹ZpˆăŠw‰ď‘ĺ‰ď (2021/10/17), WebŠJĂ, ‘ĚŠOzŠÂ‹Zp 2021/9; 48 (3): 180.

722334. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰) ˆă—Ă‹@Ší’†‰›ŠÇ—‚É‚¨‚Ż‚銴őŠg‘ĺŠú‚̑Ήž. “ŒžŠŒ\ˆę1, “ĄˆäłŽŔ1, –؉şt“Ţ1, —§–ě@‘1 (1ME•”): ‘ć96‰ń“ú–{ˆă—Ă‹@ŠíŠw‰ď‘ĺ‰ď (2021/12/13-2022/1/12), WebŠJĂ, ˆă—Ă‹@ŠíŠw 2021/4; 91 (2): 137-8.

722335. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰) ƒ`[ƒ€ˆă—Ă‚đ[‰ť‚ł‚š‚é‹łˆç‚ĚŒoŒą. —§–ě@‘1, “ŒžŠŒ\ˆę1, “ĄˆäłŽŔ1, ě“‡Ę‰Ř1, ‰v“c’ź–í1, “V–ě’ź‹P1 (1ME•”): ‘ć43‰ń“ú–{ŽčpˆăŠw‰ď‘‰ď (2022/1/28), WebŠJĂ, “ú–{ŽčpˆăŠw‰ďŽ 2021/12; 42 (Suppl): 74.

723778. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) ƒAƒ“ƒeƒiƒP[ƒuƒ‹‚É‹Nˆö‚ˇ‚éƒZƒ“ƒgƒ‰ƒ‹ƒ‚ƒjƒ^ƒAƒ‰[ƒ€‚ɑ΂ˇ‚錟“˘. ‘‘ŹTŒá1, “ŒžŠŒ\ˆę1, “ĄˆäłŽŔ1, —§–ě@‘1, ‰v“c’ź–í1 (1ME•”): ‘ć31‰ń“ú–{—Տ°HŠw‰ď‚¨‚ć‚Ń—ß˜a3”N“xŒö‰vŽĐ’c–@l“ú–{—Տ°HŠw‹ZŽm‰ď‘‰ď (2021/5/23), ŒF–{, “ú–{—Տ°HŠw‹ZŽm‰ď‰ďŽ 2021/4; 72: 242.

723779. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) Žčp‚É‚¨‚Ż‚é‹@Šíƒgƒ‰ƒuƒ‹‚ĚŠłŽŇ‰e‹ż‚ÉŠÖ‚ˇ‚錟“˘. —§–ě@‘1, “ŒžŠŒ\ˆę1, “ĄˆäłŽŔ1, ě“‡Ę‰Ř1, ‰v“c’ź–í1, “V–ě’ź‹P1, ’†“‡—I•ă1 (1ME•”): ‘ć43‰ń“ú–{ŽčpˆăŠw‰ď‘‰ď (2022/1/28), WebŠJĂ, “ú–{ŽčpˆăŠw‰ďŽ 2021/12; 42 (Suppl): 106.

723780. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) VAVDŽg—pŽž‚Ěƒgƒ‰ƒuƒ‹‚ɑ΂ˇ‚é‹zˆřƒAƒEƒgƒŒƒbƒg•t‚Ťƒ|[ƒ^ƒuƒ‹‹zˆřŒš‚đŽg—p‚ľ‚˝‹Ů‹}‘Ήž‚ĚŽŔŒą“IŒŸ“˘. ‘哇O”V1, “ŒžŠŒ\ˆę1, ŒKŒ´ŽŃˆß1, “c’†—D”ü1, ˆÉ“ŒË‘ž1, ‹{’n@ŠÓ2 (1ME•”, 2S‘ŸŒŒŠÇŠO): ‘ć46‰ń“ú–{‘ĚŠOzŠÂ‹ZpˆăŠw‰ď‘ĺ‰ď (2021/10/16), WebŠJĂ, ‘ĚŠOzŠÂ‹Zp 2021/9; 48 (3): 227.

723781. [Šw‰ď (‘S‘)] (ˆę”ʍu‰‰) COVID-19—zŤŠłŽŇ‚â‹^‚˘ŠłŽŇ‚ɑ΂ľ‚Ä‘ĚŠOzŠÂ’S“–‹ZŽm‚Í‚Ç‚¤‘Ήž‚ľ‚˝‚Š?|‰@“ੴő‚đ–hŽ~‚ˇ‚é‚˝‚ß‚Ě“Ź‚˘|‰@“ੴő‚đ–hŽ~‚ˇ‚é‚˝‚ß‚Ě“Ź‚˘|COVID-19—zŤ‹^‚˘ŠłŽŇ‚ɑ΂ˇ‚é‘ĚŠOzŠÂ‚ĚŒoŒą. ‘哇O”V1, “ŒžŠŒ\ˆę1, ŒKŒ´ŽŃˆß1, “c’†—D”ü1, ˆÉ“ŒË‘ž1, ‹{’n@ŠÓ2 (1ME•”, 2S‘ŸŒŒŠÇŠO): ‘ć46‰ń“ú–{‘ĚŠOzŠÂ‹ZpˆăŠw‰ď‘ĺ‰ď (2021/10/16-17), “Œ‹ž (ƒnƒCƒuƒŠƒbƒhŠJĂ), ‘ĚŠOzŠÂ‹Zp 2021/10; 48 (3): 180.


ˆă—Ă‚ĚŽżEˆŔ‘S„iŽş


Š´őŠÇ—Žş

[Šwp˜_•ś]

120036. [Œ´’˜] –k—˘‘ĺŠw•a‰@‚É‚¨‚Ż‚éƒJƒ‹ƒoƒyƒlƒ€‘ϐŤ’°“ŕ×‹Ű–Ú×‹Ű‚ĚŒŸoó‹ľ‚ɂ‚˘‚Ä‚Ě’PŽ{ÝŒă•űŽ‹“IŒ¤‹†. “ń–{–öL1, ‚ŽR—zŽq2, ŁŒË—Ç‹ł1, ˆŔ’B@÷3, ŹŠŃ’q˘3, ˛“Ą—h—S1, •ŰâŠGäť1, ‹{čI‰î1, ˛X–ŘŒ°Žq1, ‚–Ř—R”üŽq1, ŻŽR—˛s4, ’†‘şłŽ÷5, —с@“N”Í6, Žë–ě—Lě6 (1Š´őŠÇ—Žş, 2V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 3—ŐŒŸ•”, 4äPŒ´•aEŠ´ő“ŕ, 5ˆă—ÉqśŠw•”, 6—ŐŒŸŠw): –k—˘ˆăŠw 2021/12; 51 (2): 83-94.

522599. [uŔ]yAdvanced & Focus“ÁW: VŒ^ƒRƒƒiƒEƒCƒ‹ƒX‚ŕŒŠ“Ś‚ł‚Č‚˘! ŽY‰Č•NICU‚ĚŠ´ő‘΍ô ‚ ‚é‚ ‚éƒ`ƒFƒbƒNƒŠƒXƒgz3. NICU‚É‚¨‚Ż‚銴ő‘΍ô‚Ě‚ ‚é‚ ‚éƒ`ƒFƒbƒNƒŠƒXƒg. â–ؐ°˘1, ˛X–ŘŒ°Žq2 (1‘Űˆă—Ă•ŸŽƒ‘ĺŠw‘ĺŠw‰@ˆă—Ă•ŸŽƒŠwŒ¤‹†‰Č, 2Š´őŠÇ—Žş): INFECTION CONTROL 2022/1; 31 (1): 77-81.

[Šw‰ďEŒ¤‹†‰ď“™]

722336. [Šw‰ď (‘S‘)] (ľ‘ҍu‰‰“™) ˆĎˆő‰ďŠé‰ću(JHAISˆĎˆő‰ď) ‚ ‚‚܂ę@ƒT[ƒxƒCƒ‰ƒ“ƒX‚̐Xv. XŒ“Œ[‘ž1, “Ą“c@—ó2, â–ؐ°˘3, ˛X–ŘŒ°Žq4, Ô–ؐ^ŽĄ5, Žl‹{@‘6, ŒE“cŽu•ä7, ăp’qŽq8 (1ŽRŒ`‘ĺŠwˆăŠw•”•t‘Ž•a‰@, 2‘Űˆă—Ă•ŸŽƒ‘ĺŠw, 3‘Űˆă—Ă•ŸŽƒ‘ĺŠw‘ĺŠw‰@, 4Š´őŠÇ—Žş, 5ƒ}ƒcƒ_•a‰@, 8–Ľ–ĘŽs—§•a‰@, 7‘—§‘Űˆă—ĂŒ¤‹†ƒZƒ“ƒ^[, 9NTT“Œ“ú–{ŠÖ“Œ•a‰@): ‘ć36‰ń“ú–{ŠÂ‹ŤŠ´őŠw‰ď‘‰ďEŠwpW‰ď (2021/9/19), –źŒĂ‰Ž (ƒnƒCƒuƒŠƒbƒhŠJĂ).

723782. [Šw‰ď (‘S‘)] (ƒ|ƒXƒ^[) “–‰@‚É‚¨‚Ż‚éŒoŒűR‹Ű–ň‚ĚŽg—p—ʐ„ˆÚ`AMR‘΍ôƒAƒNƒVƒ‡ƒ“ƒvƒ‰ƒ“‚Ě•]‰ż`. ˛“Ąŕô—S1, ŁŒË—Ç‹ł1, “ń–{–öL1, ŻŽR—˛s1,2, ‚ŽR—zŽq1,3, Œú“cKˆę˜Y4,5 (1Š´őŠÇ—Žş, 2äPŒ´•aEŠ´ő“ŕ, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4–ňÜ•”, 5–ňŠw•”): ‘ć95‰ń“ú–{Š´őÇŠw‰ďŠwpu‰‰‰ď^‘ć69‰ń“ú–{‰ťŠw—Ă–@Šw‰ď‘‰ď‡“ŻŠw‰ď (2021/5/7-9), ‰Ą•l (ƒnƒCƒuƒŠƒbƒhŠJĂ), “ú–{‰ťŠw—Ă–@Šw‰ďŽGŽ 2021/4; 69 (Suppl): 297.

733282. [Šw‰ď (’n•ű‰ďEŒ¤‹†‰ď)] (ˆę”ĘŒű‰‰) –k—˘‘ĺŠw•a‰@‚É‚¨‚Ż‚éŒoŒűR‹Ű–ň‚ĚŽg—p—ʐ„ˆÚ‚¨‚ć‚Ń“Kł‰ť‚ÉŒü‚Ż‚˝‰î“üŒř‰Ę‚ĚŒŸŘ. ˛“Ąŕô—S1, ŁŒË—Ç‹ł1, “ń–{–öL1, ŻŽR—˛s1,2, ‚ŽR—zŽq1,3, Œú“cKˆę˜Y4,5 (1Š´őŠÇ—Žş, 2äPŒ´•aEŠ´ő“ŕ, 3V˘‹Iˆă—ÁE‰Ą’f“Iˆă—Ă, 4–ňÜ•”, 5–ňŠw•”): ‘ć89‰ń_“ŢěŒ§Š´őÇˆăŠw‰ď (2022/1/22), WebŠJĂ, ‘ć89‰ń_“ŢěŒ§Š´őÇˆăŠw‰ďƒvƒƒOƒ‰ƒ€E´˜^W 2022/1; p.10.


f—Ïî•ńŠÇ—Žş


—Տ°S—Žş

[Šwp˜_•ś]

320033. [Ç—á•ń] •Ą”‚Ě‹­”—“I‚ȍs“Ž‚ɑ΂ˇ‚éƒVƒFƒCƒsƒ“ƒO‚đ—p‚˘‚˝‰î“ü|Ç—á•ń|. •űŒcŽO˜Y1, ‘ęŕV‹B–î2, “ŕ“c–ƒˆß2, —é–Ř—´‘ž˜Y2, ŽRŠp@Œ\2, ‘ĺÎ@’q2, ‹{‰Ş@“™2 (1—Տ°S—Žş, 2¸_): ¸_‰ČŽĄ—ĂŠw 2021/8; 36 (8): 963-8.


ƒg[ƒ^ƒ‹ƒTƒ|[ƒgƒZƒ“ƒ^[


ˆÚAˆă—ĂŽx‰‡Žş


—Տ°Œ¤‹†•”—Տ°Œ¤‹†Žx‰‡Žş

[Šwp˜_•ś]

110456. [Œ´’˜] Concentration-QTc analysis with two or more correlated baselines. Orihashi Y1, Kumagai Y2: J Pharmacokinet Pharmacodyn 2021/10; 48 (5): 615-22. (“n‹´@–ő1, ŒF’J—YŽĄ2: 1—Տ°Œ¤‹†•”—Տ°Œ¤‹†Žx‰‡Žş, 2—Տ°Œ¤‹†EƒvƒƒWƒFƒNƒg)


ƒOƒ[ƒoƒ‹—Տ°Œ¤‹†Žx‰‡ƒZƒ“ƒ^[